AUTHENTICATED
U.S. GOVERNMENT
INFORMATION
GPO

Federal Register

7–17–00 Monday
Vol. 65 No. 137 July 17, 2000
Pages 43961–44402

The **FEDERAL REGISTER** is published daily, Monday through Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Committee of the Federal Register (1 CFR Ch. I). The Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition.

The **Federal Register** provides a uniform system for making available to the public regulations and legal notices issued by Federal agencies. These include Presidential proclamations and Executive Orders, Federal agency documents having general applicability and legal effect, documents required to be published by act of Congress, and other Federal agency documents of public interest.

Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, see http://www.nara.gov/fedreg.

The seal of the National Archives and Records Administration authenticates the Federal Register as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1507, the contents of the **Federal Register** shall be judicially noticed.

The **Federal Register** is published in paper and on 24x microfiche. It is also available online at no charge as one of the databases on GPO Access, a service of the U.S. Government Printing Office.

The online edition of the **Federal Register** is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6 a.m. each day the **Federal Register** is published and it includes both text and graphics from Volume 59, Number 1 (January 2, 1994) forward.

GPO Access users can choose to retrieve online **Federal Register** documents as TEXT (ASCII text, graphics omitted), PDF (Adobe Portable Document Format, including full text and all graphics), or SUMMARY (abbreviated text) files. Users should carefully check retrieved material to ensure that documents were properly downloaded.

On the World Wide Web, connect to the **Federal Register** at http://www.access.gpo.gov/nara. Those without World Wide Web access can also connect with a local WAIS client, by Telnet to swais.access.gpo.gov, or by dialing (202) 512-1661 with a computer and modem. When using Telnet or modem, type swais, then log in as guest with no password.

For more information about GPO Access, contact the GPO Access User Support Team by E-mail at gpoaccess@gpo.gov; by fax at (202) 512–1262; or call (202) 512–1530 or 1–888–293–6498 (toll free) between 7 a.m. and 5 p.m. Eastern time, Monday–Friday, except Federal holidays.

The annual subscription price for the **Federal Register** paper edition is $638, or $697 for a combined **Federal Register,** Federal Register Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the **Federal Register** including the Federal Register Index and LSA is $253. Six month subscriptions are available for one-half the annual rate. The charge for individual copies in paper form is $9.00 for each issue, or $9.00 for each group of pages as actually bound; or $2.00 for each issue in microfiche form. All prices include regular domestic postage and handling. International customers please add 25% for foreign handling. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard or Discover. Mail to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250–7954.

There are no restrictions on the republication of material appearing in the **Federal Register.**

How To Cite This Publication: Use the volume number and the page number. Example: 65 FR 12345.

SUBSCRIPTIONS AND COPIES

PUBLIC	
Subscriptions:	
Paper or fiche	**202–512–1800**
Assistance with public subscriptions	**512–1806**
General online information	**202–512–1530; 1–888–293–6498**
Single copies/back copies:	
Paper or fiche	**512–1800**
Assistance with public single copies	**512–1803**
FEDERAL AGENCIES	
Subscriptions:	
Paper or fiche	**523–5243**
Assistance with Federal agency subscriptions	**523–5243**

Printed on recycled paper.

Contents

Federal Register

Vol. 65, No. 137

Monday, July 17, 2000

Administration on Aging
See Aging Administration

Aging Administration
NOTICES
Meetings:
American Indian/Alaska Native Tribal Representatives; tribal consultation on Indian elder issues, 44059

Agricultural Marketing Service
RULES
Blueberry promotion, research, and information order, 43961–43969
NOTICES
Dry whey; standards
Correction, 44024–44025

Agricultural Research Service
NOTICES
Meetings:
Agricultural Biotechnology Advisory Committee, 44025

Agriculture Department
See Agricultural Marketing Service
See Agricultural Research Service
See Forest Service

Arts and Humanities, National Foundation
See National Foundation on the Arts and the Humanities

Centers for Disease Control and Prevention
NOTICES
Agency information collection activities:
Proposed collection; comment request, 44059–44060

Children and Families Administration
NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 44060

Commerce Department
See National Oceanic and Atmospheric Administration
NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 44028–44029

Education Department
NOTICES
Agency information collection activities:
Proposed collection; comment request, 44030–44031
Submission for OMB review; comment request, 44031

Energy Department
See Energy Efficiency and Renewable Energy Office
See Federal Energy Regulatory Commission
See Western Area Power Administration
NOTICES
Meetings:
Environmental Management Site-Specific Advisory Board—
Semi-Annual Chairs, 44031–44032

Energy Efficiency and Renewable Energy Office
NOTICES
Meetings:
State Energy Advisory Board, 44032

Environmental Protection Agency
RULES
Air quality implementation plans; approval and promulgation; various States:
Alabama, 43994–43995
Texas, 43986–43994
NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 44046–44047
Air pollution control; new motor vehicles and engines:
Urban buses (1993 and earlier model years); retrofit/rebuild requirements; equipment certification — Turbodyne Systems, Inc., 44047–44049
Grants and cooperative agreements; availability, etc.:
Brownfields Job Training and Development Demonstration Pilots, 44050
Meetings:
Public participation in permitting programs; reference guide; focus group meeting, 44050–44051
Science Advisory Board, 44051–44053

Equal Employment Opportunity Commission
NOTICES
Meetings; Sunshine Act, 44053

Federal Aviation Administration
PROPOSED RULES
Airworthiness directives:
Empresa Brasileira de Aeronautica S.A., 44013–44015

Federal Communications Commission
RULES
Common carrier services:
Wireless telecommunications services—
Wireless medical telemetry service, 43995–44010
Radio stations; table of assignments:
Alabama, 44011
Montana, 44010
Television stations; table of assignments:
Arizona and Nevada, 44011
PROPOSED RULES
Digital television stations; table of assignments:
Florida, 44017–44018
Texas, 44017
Radio stations; table of assignments:
Wyoming and Utah, 44018
NOTICES
Reports and guidance documents; availability, etc.:
Dial-around and other long-distance services advertising; policy statement, 44053–44059

Federal Energy Regulatory Commission
NOTICES
Electric rate and corporate regulation filings:
Electric Energy, Inc., et al., 44039–44041
El Paso Electric Co. et al., 44035–44039

Energy Department et al., 44041–44043
Tennessee Gas Pipeline Co., 44043
Environmental statements; availability, etc.:
Cameron Gas Electric Co., 44043
Applications, hearings, determinations, etc.:
MidAmerican Energy Co., 44033
National Fuel Gas Supply Corp., 44033
PacifiCorp, 44033
PJM Interconnection, L.L.C., 44033–44034
PNM Electric Gas Services, Inc., et al., 44034
Questar Pipeline Co., 44034
Tennessee Gas Pipeline Co., 44034–44035
Texas Eastern Transmission Corp., 44035
Transcontinental Gas Pipe Line Corp., 44035

Federal Highway Administration
NOTICES
Environmental statements; notice of intent:
Crow Wing and Mille Lacs Counties, MN, 44091
Martin County, FL, 44091–44092

Federal Housing Finance Board
RULES
Federal home loan bank system:
Acquired member assets, core mission activities, and investments and advances, 43969–43986

Federal Trade Commission
NOTICES
Reports and guidance documents; availability, etc.:
Dial-around and other long-distance services advertising; policy statement, 44053–44059

Fish and Wildlife Service
NOTICES
Environmental statements; availability, etc.:
Incidental take permits—
Bastrop County, TX; Houston toad, 44067–44068

Food and Drug Administration
NOTICES
Agency information collection activities:
Proposed collection; comment request, 44061–44062
Reporting and recordkeeping requirements, 44062

Forest Service
NOTICES
Environmental statements; notice of intent:
Idaho Panhandle National Forests, ID, 44025–44026
Santa Fe National Forest, NM, 44027–44028

General Services Administration
NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 44059

Health and Human Services Department
See Aging Administration
See Centers for Disease Control and Prevention
See Children and Families Administration
See Food and Drug Administration
See Health Care Financing Administration
See National Institutes of Health

Health Care Financing Administration
PROPOSED RULES
Medicare:
Physician fee schedule (2001 CY); payment policies, 44175–44358

Housing and Urban Development Department
NOTICES
Agency information collection activities:
Proposed collection; comment request, 44066

Interior Department
See Fish and Wildlife Service
See Land Management Bureau
See National Park Service
See Surface Mining Reclamation and Enforcement Office

Internal Revenue Service
NOTICES
Meetings:
Citizen Advocacy Panels—
Brooklyn District, 44094

International Trade Commission
NOTICES
Import investigations:
Anhydrous sodium sulfate from—
Canada, 44075–44076
Cold-rolled steel products from—
Various countries, 44076
Pure magnesium from—
Russia, 44076–44077

Justice Department
See Prisons Bureau

Land Management Bureau
NOTICES
Oil and gas leases:
Wyoming, 44068–44069
Realty actions; sales, leases, etc.:
Arizona, 44069
Nevada, 44069–44071
Recreation management restrictions, etc.:
California Desert District, AZ; Long-Term Visitor Area Program, 44071–44073
Spokane District, WA; campfires, smoking, and motorized vehicles; prohibitions, 44073
Survey plat filings:
Idaho, 44074
New Mexico, 44075

Merit Systems Protection Board
NOTICES
Organization, functions, and authority delegations:
Headquarters offices relocation, 44077

National Foundation on the Arts and the Humanities
NOTICES
Meetings:
Combined Arts Adviory Panel, 44077

National Highway Traffic Safety Administration
NOTICES
Motor vehicle safety standards; exemption petitions, etc.:
EMB Inc., 44092–44093
Piaggo & c., S.p.A., 44093

National Institutes of Health
NOTICES
Meetings:
National Cancer Institute, 44063
National Human Genome Research Institute, 44063–44064

National Institute of Child Health and Human Development, 44064
National Institute of General Medical Sciences, 44064
Scientific Review Center, 44064–44066

National Oceanic and Atmospheric Administration
RULES
Fishery conservation and management:
Alaska; fisheries of Exclusive Economic Zone—Halibut, 44011–44012
PROPOSED RULES
Fishery conservation and management:
Alaska; fisheries of Exclusive Economic Zone—Western Alaska Community Development Quota Program, 44018–44023
NOTICES
Meetings:
Caribbean Fishery Management Council, 44029
Pacific Fishery Management Council, 44029–44030
Permits:
Marine mammals, 44030

National Park Service
NOTICES
Environmental statements; availability, etc.:
Great Egg Harbor National Scenic and Recreational River, NJ; comprehensive management plan, 44075

National Science Foundation
NOTICES
Meetings:
Geosciences Advisory Committee, 44077–44078
Graduate Education Special Emphasis Panel, 44078

Nuclear Regulatory Commission
PROPOSED RULES
Radioactive material packaging and transportation:
International Atomic Energy Agency transportation safety standards compatibility, etc., 44359–44397
NOTICES
Meetings:
Reactor Safeguards Advisory Committee, 44079–44080
Regulatory guides; issuance, availability, and withdrawal, 44080
Reports and guidance documents; availability, etc.:
Nuclear power reactors—
Operator licensing examination standards, 44080–44081
Applications, hearings, determinations, etc.:
International Uranium (USA) Corp., 44078–44079
Northeast Nuclear Energy Co. et al., 44079

Personnel Management Office
RULES
Allowances and differentials:
Cost-of-living allowances (nonforeign areas)—
Guam and Northern Mariana Islands, 44099–44101
Honolulu, HI, 44100–44102
NOTICES
Allowances and differentials:
Cost-of-living allowances (nonforeign areas)—
1998 surveys; report, 44102–44173

Prisons Bureau
PROPOSED RULES
Inmate control, custody, care, etc.:
Occupational education programs, 44400–44402
Postsecondary education programs, 44399–44401

Public Health Service
See Centers for Disease Control and Prevention
See Food and Drug Administration
See National Institutes of Health

Securities and Exchange Commission
NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 44081–44082
Self-regulatory organizations; proposed rule changes:
National Association of Securities Dealers, Inc., 44082–44088
Options Clearing Corp., 44088–44090

Surface Mining Reclamation and Enforcement Office
PROPOSED RULES
Permanent program and abandoned mine land reclamation plan submissions:
North Dakota, 44015–44017

Tennessee Valley Authority
NOTICES
Meetings; Sunshine Act, 44090

Transportation Department
See Federal Aviation Administration
See Federal Highway Administration
See National Highway Traffic Safety Administration
See Transportation Statistics Bureau
NOTICES
Aviation proceedings:
Hearings, etc.—
Servicios Aereos Profesionales, Inc., 44091

Transportation Statistics Bureau
NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 44093–44094

Treasury Department
See Internal Revenue Service

Veterans Affairs Department
NOTICES
Agency information collection activities:
Proposed collection; comment request, 44094–44097
Privacy Act:
Systems of records, 44097–44098

Western Area Power Administration
NOTICES
Power rate adjustments:
Loveland Area Projects, CO, 44044
Pick-Sloan Missouri Basin Program; Eastern Division, 44045–44046

Separate Parts In This Issue

Part II
Office of Personnel Management, 44099–44173

Part III
Health Care Financing Administration, 44175–44358

Part IV
Nuclear Regulatory Commission, 44359–44397

Part V
Department of Justice, Bureau of Prisons, 44399–44402

Reader Aids
Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, reminders, and notice of recently enacted public laws.

CFR PARTS AFFECTED IN THIS ISSUE

A cumulative list of the parts affected this month can be found in the Reader Aids section at the end of this issue.

5 CFR
591 (2 documents) 44099, 44100

7 CFR
1218.....43961

10 CFR

Proposed Rules:
71.....44360

12 CFR
900.....43969
940.....43969
950.....43969
955.....43969
956.....43969
966.....43969

14 CFR

Proposed Rules:
39.....44013

28 CFR

Proposed Rules:
540.....44400
544.....44400

30 CFR

Proposed Rules:
934.....44015

40 CFR
52 (2 documents) 43986, 43994

42 CFR

Proposed Rules:
410.....44176
414.....44176

47 CFR
1.....43995
2.....43995
15.....43995
73 (3 documents) 44010, 44011
90.....43995
95.....43995

Proposed Rules:
73 (3 documents) 44017, 44018

50 CFR
679.....44011

Proposed Rules:
679.....44018

Rules and Regulations

Federal Register
Vol. 65, No. 137
Monday, July 17, 2000

This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week.

DEPARTMENT OF AGRICULTURE

Agricultural Marketing Service

7 CFR Part 1218

[FV–99–701–FR]

RIN 0581–AB78

Blueberry Promotion, Research, and Information Order

AGENCY: Agricultural Marketing Service, USDA.

ACTION: Final rule.

SUMMARY: This rule establishes a Blueberry Promotion, Research, and Information Order (Order) under the Commodity Promotion, Research, and Information Act of 1996. Under the Order, cultivated blueberry producers and importers will pay an assessment of $12 per ton, which will be paid to the U.S.A. Blueberry Council (USABC). Producers and importers of less than 2,000 pounds of fresh and processed cultivated blueberries annually will be exempt from the assessment. First handlers will remit the assessments to the USABC. The USABC will use the funds collected to conduct a generic program of promotion, research, consumer information, and industry information to maintain and expand markets for cultivated blueberries. The U.S. Department of Agriculture (USDA or the Department) conducted a referendum among eligible producers and importers of cultivated blueberries to determine whether they favor the implementation of the Order. The Order was approved by a majority of those voting who also represented a majority of the pounds of cultivated blueberries represented in the referendum.

EFFECTIVE DATE: August 16, 2000.

FOR FURTHER INFORMATION CONTACT: Oliver L. Flake, Research and Promotion Branch, Fruit and Vegetable Programs, AMS, USDA, Stop 0244, 1400 Independence Avenue, SW, Room 2535–S, Washington, DC 20250–0244; telephone (202) 720–5976, fax (202) 205–2800, or e-mail at oliver.flake@usda.gov.

SUPPLEMENTARY INFORMATION: This Order is issued pursuant to the Commodity Promotion, Research, and Information Act of 1996 (Act) [7 U.S.C. 7401–7425; Public Law 104–127].

Previous documents in this proceeding: Proposed Rule Number 1 (July 1999 proposed rule) on the Order published in the July 22, 1999, issue of the **Federal Register** [64 FR 39790]; a proposed rule on referendum procedures published in the July 22, 1999, issue of the **Federal Register** [64 FR 39803]; Proposed Rule Number 2 (February 2000 proposed rule) on the Order, which included a Referendum Order, published in the February 15, 2000, issue of the **Federal Register** [65 FR 7657]; a final rule on referendum procedures published in the February 15, 2000, issue of the **Federal Register** [65 FR 7652].

Question and Answer Overview

Why Is a Final Rule Being Published?

In a recent referendum, eligible producers and importers of cultivated blueberries voted in favor of implementing the Order. This final rule, which will become effective in 30 days, completes the implementation process.

What Is the Purpose of the Program?

The purpose of the program is to develop and finance an effective and coordinated program of promotion, research, and information to maintain and expand the markets for fresh and processed cultivated blueberries.

Who Is Covered by This Rule?

Cultivated blueberry producers who grow and importers who import 2,000 pounds or more of cultivated blueberries annually will be subject to this rule and pay an assessment.

What Is the Assessment Rate?

The assessment rate is $12 per ton.

When Will the Assessment Be Due?

Domestic assessments for the 2001 crop year will be due by November 30, 2001. Assessments for the subsequent crop years will be due by November 30 of the crop year. The U.S. Customs Service will collect assessments on imports at the time of entry into the United States, starting on January 2, 2001.

Will I Have To Pay the Assessment Forever?

Assessments will be due as long as the Order is in effect. However, every five years, USDA will conduct a referendum to determine whether producers and importers of cultivated blueberries want the program to continue. The program will continue if a majority of the voters in the referendum vote for approval and those voters represent a majority of the pounds of cultivated blueberries produced and imported by the voters in the referendum.

Who Will Administer This Order?

The USABC will administer the Order with supervision from USDA. The USABC members will be appointed by the Secretary of Agriculture (Secretary) from nominations received from the blueberry industry.

Who Will Be on the USABC?

The USABC will consist of 13 members: One producer member from each of four producer regions; one producer member from each of the top five cultivated-blueberry-producing states; one importer; one exporter (a foreign producer who ships cultivated blueberries into the United States from the largest foreign cultivated blueberry production area); one first handler; and one public member. Each member will have an alternate. Currently, the top five states (in descending order) are Michigan, New Jersey, Oregon, Georgia, and North Carolina.

When Will USABC Members Be Appointed?

The nomination process for the producer members and alternates will begin soon after the Order becomes effective. The North American Blueberry Council (NABC) will assist USDA in this process for the initial nominations. Future nominations will be managed by the USABC.

It is expected that the producer members and alternates will be appointed by the Secretary in time for the USABC to hold its organizational meeting in Washington, DC, in late 2000. The USABC will nominate persons to serve as the importer, exporter, handler, and public member

and alternates after it is appointed and has met.

I Am a Producer of Cultivated Blueberries, and I Would Like To Serve on the USABC. How Can I Get Nominated?

The NABC will notify all producers of cultivated blueberries when the nomination process will begin. Voting for nominees will be by mail ballot. In states where there is a state commission or marketing order committee for cultivated blueberries, the commission or committee will have the opportunity to nominate members and alternates to serve on the USABC. The commissions and committees must submit two nominees for each member and two nominees for each alternate. Producers in these states should contact their state commission or committee to express interest in being nominated.

In states where no commission or committee exists, the NABC will seek nominations from the cultivated blueberry producers in those states, place the names on a ballot for each state and region, and send the ballot to the producers in the appropriate states and regions to vote on the nominees of their choice. The person receiving the highest number of votes cast for each seat on the USABC will be the first choice nominee for the member. The person receiving the second highest number of votes cast will be the first choice nominee for the alternate member. The persons with the third and fourth highest number of votes cast will be designated as additional nominees for the member and alternate positions. Each nominee will complete and submit to the NABC a background form. The NABC will then submit the nominees and their background forms to the Secretary for consideration.

Executive Orders 12988 and 12866

This rule has been reviewed under Executive Order (E.O.) 12988, Civil Justice Reform. It is not intended to have retroactive effect. Section 524 of the Act provides that the Act shall not affect or preempt any other Federal or state law authorizing promotion or research relating to an agricultural commodity.

Under Section 519 of the Act, a person subject to the Order may file a petition with the Secretary of Agriculture (Secretary) stating that the Order, any provision of the Order, or any obligation imposed in connection with the Order, is not established in accordance with the law, and requesting a modification of the Order or an exemption from the Order. Any petition filed challenging the Order, any provision of the Order, or any obligation imposed in connection with the Order, shall be filed within two years after the effective date of the Order, provision, or obligation subject to challenge in the petition. The petitioner will have the opportunity for a hearing on the petition. Thereafter, the Secretary will issue a ruling on a petition. The Act provides that the district court of the United States for any district in which the petitioner resides or conducts business shall have the jurisdiction to review a final ruling on the petition, if the petitioner files a complaint for that purpose not later than 20 days after the date of the entry of the Secretary's final ruling.

This rule has been determined ''not significant'' for purposes of E.O. 12866 and therefore has not been reviewed by the Office of Management and Budget (OMB).

Regulatory Flexibility Act and Paperwork Reduction Act

In accordance with the Regulatory Flexibility Act (RFA) [5 U.S.C. 601 *et seq.*], the Agency examined the impact of this rule on small entities and prepared a final regulatory flexibility analysis that was included in the proposed rule published in the **Federal Register** on February 15, 2000. The analysis indicates that the agency minimized the economic impacts of the Order provisions on small entities to the fullest extent reasonably possible while adhering to the program's objectives.

In addition, the Order's provisions were carefully reviewed, and every effort was made to minimize any unnecessary information collection and recordkeeping costs or requirements. In accordance with the OMB regulation [5 CFR Part 1320] which implements the Paperwork Reduction Act of 1995 [44 U.S.C. Chapter 35], the information collection and recordkeeping requirements that are imposed by this Order were submitted to OMB and approved under OMB control numbers 0505–0001 and 0581–0093.

Copies of the final regulatory flexibility analysis and the discussion of the information collection and recordkeeping requirements contained in this rulemaking can be obtained from Oliver Flake at the address listed above or by e-mail at *oliver.flake@usda.gov*.

Background

In December 1998, the North American Blueberry Council, Inc. (proponent or NABC) submitted a proposal for a national promotion, research, and information order for cultivated blueberries pursuant to the Act. The Department published the proponent's proposal, with modifications, for public comment in the July 1999 proposed rule. Eight comments were received by the September 20, 1999, deadline. These comments, and related changes to the Order, were discussed in the February 15, 1999 proposed rule, which included a Referendum Order. A referendum was conducted from March 13 to April 14, 2000. In the referendum, producers and importers of 2,000 pounds of cultivated blueberries voted to implement the program.

Under the program, producers and importers of 2,000 pounds or more of cultivated blueberries will pay an assessment of $12 per ton annually. The producer assessment will be collected by first handlers, and the importer assessment will be collected by the U.S. Customs Service.

The program will be administered by the USABC under USDA supervision. The USABC will have 13 members: one producer member from each of four producer regions; one producer member from each of the top five cultivated-blueberry-producing states; one importer; one exporter (a foreign producer who ships cultivated blueberries into the United States from the largest foreign cultivated blueberry production area); one first handler; and one public member. Each member will have an alternate.

The USABC will conduct a generic program of promotion, research, consumer information, and industry information to maintain and expand markets for cultivated blueberries.

The Order is summarized as follows: Sections 1218.1 through 1218.23 of the Order define certain terms, such as blueberries, producer, and importer, which are used in the Order.

Sections 1218.40 through 1218.48 include provisions relating to the USABC. These provisions cover establishment and membership, nominations and appointments, term of office, vacancies, alternate members, procedures for conducting USABC business, compensation and reimbursement, powers and duties of the USABC, and prohibited activities. The USABC is the governing body authorized to administer the Order through the implementation of programs, plans, projects, budgets, and contracts to promote and disseminate information about blueberries, subject to oversight of the Secretary.

Sections 1218.50 through 1218.56 cover budget review and approval; financial statements; authorize the collection of assessments; specify how assessments will be used, including reimbursement of necessary expenses

incurred by the USABC for the performance of its duties and expenses incurred for USDA's oversight responsibilities; specify who pays the assessment and how; authorize the imposition of a late-payment charge on past-due assessments; outline exemption procedures; address programs, plans, and projects; require the USABC to periodically conduct an independent review of its overall program; and address patents, copyrights, trademarks, information, publications, and product formulations developed through the use of assessment funds.

There will be an assessment rate of $12 per ton for domestic cultivated blueberries and imported fresh and processed cultivated blueberries. The assessment rate may be raised or lowered after the initial continuance referendum which will be conducted after the program has been in operation five years. The assessment rate may be raised or lowered without a referendum.

The federal debt collection procedures referenced above and in § 1218.52(f) include those set forth in 7 CFR §§ 3.1 through 3.36 for all research and promotion programs administered by AMS [60 FR 12533, March 7, 1995].

Sections 1218.60 through 1218.62 concern reporting and recordkeeping requirements for persons subject to the Order and protect the confidentiality of information from such books, records, or reports.

Sections 1218.70 through 1218.78 describe the right of the Secretary; address referenda; authorize the Secretary to suspend or terminate the Order when deemed appropriate; prescribe proceedings after termination; address personal liability, separability, and amendments; and provide OMB control numbers.

General Findings

The Department conducted a referendum among producers and importers of cultivated blueberries from March 13 through April 14, 2000, to determine whether the Order would become effective. The representative period for establishing voter eligibility was from January 1 through December 31, 1999. Producers and importers who produced or imported 2,000 pounds or more of cultivated blueberries during the representative period were eligible to vote.

It is determined that a majority of the eligible producers and importers voting who also represent a majority of the pounds of cultivated blueberries represented in the referendum favored implementation of the Order. After consideration of all relevant material presented, including the initial proposal, comments received, and the referendum results, it is found that the Order is consistent with and effectuates the declared policy and purpose of the Act.

The effective date of this action will be 30 days after publication in the **Federal Register**.

List of Subjects in 7 CFR Part 1218

Administrative practice and procedure, Advertising, Blueberries, Consumer information, Marketing agreements, Reporting and recordkeeping requirements.

For the reasons set forth in the preamble, title 7 of chapter XI of the Code of Federal Regulations is amended as follows:

PART 1218—BLUEBERRY PROMOTION, RESEARCH, AND INFORMATION ORDER

1. The authority citation for part 1218 continues to read as follows:

Authority: 7 U.S.C. 7401–7425.

2. Subpart A is added to part 1218 to read as follows:

Subpart A—Blueberry Promotion, Research, and Information Order

Definitions

Sec.
1218.1 Act.
1218.2 Blueberries.
1218.3 Conflict of interest.
1218.4 Crop year.
1218.5 Department.
1218.6 Exporter.
1218.7 First handler.
1218.8 Fiscal period.
1218.9 Importer.
1218.10 Information.
1218.11 Market or marketing.
1218.12 Order.
1218.13 Part and subpart.
1218.14 Person.
1218.15 Processed blueberries.
1218.16 Producer.
1218.17 Promotion.
1218.18 Research.
1218.19 Secretary.
1218.20 Suspend.
1218.21 Terminate.
1218.22 United States.
1218.23 USABC.

U.S.A. Blueberry Council

1218.40 Establishment and membership.
1218.41 Nominations and appointments.
1218.42 Term of office.
1218.43 Vacancies.
1218.44 Alternate members.
1218.45 Procedure.
1218.46 Compensation and reimbursement.
1218.47 Powers and duties.
1218.48 Prohibited activities.

Expenses and Assessments

1218.50 Budget and expenses.
1218.51 Financial statements.
1218.52 Assessments.
1218.53 Exemption procedures.
1218.54 Programs, plans, and projects.
1218.55 Independent evaluation.
1218.56 Patents, copyrights, trademarks, information, publications, and product formulations.

Reports, Books, and Records

1218.60 Reports.
1218.61 Books and records.
1218.62 Confidential treatment.

Miscellaneous

1218.70 Right of the Secretary.
1218.71 Referenda.
1218.72 Suspension and termination.
1218.73 Proceedings after termination.
1218.74 Effect of termination or amendment.
1218.75 Personal liability.
1218.76 Separability.
1218.77 Amendments.
1218.78 OMB control numbers.

Subpart A—Blueberry Promotion, Research, and Information Order

Definitions

§ 1218.1 Act.

Act means the Commodity Promotion, Research, and Information Act of 1996 (7 U.S.C. 7401–7425; Pub. L. 104–127; 110 Stat. 1029), or any amendments thereto.

§ 1218.2 Blueberries.

Blueberries means cultivated blueberries grown in or imported into the United States of the genus Vaccinium *Corymbosum* and *Ashei,* including the northern highbush, southern highbush, rabbit eye varieties, and any hybrid, and excluding the lowbush (native) blueberry Vaccinium *Angustifolium*.

§ 1218.3 Conflict of interest.

Conflict of interest means a situation in which a member or employee of the U.S.A. Blueberry Council has a direct or indirect financial interest in a person who performs a service for, or enters into a contract with, the USABC for anything of economic value.

§ 1218.4 Crop year.

Crop year means the 12-month period from November 1 through October 31 of the following year or such other period approved by the Secretary.

§ 1218.5 Department.

Department means the U.S. Department of Agriculture.

§ 1218.6 Exporter.

Exporter means a person involved in exporting blueberries from another country to the United States.

§ 1218.7 First handler.

First handler means any person, (excluding a common or contract carrier), receiving blueberries from producers and who as owner, agent, or otherwise ships or causes blueberries to be shipped as specified in the Order. This definition includes those engaged in the business of buying, selling and/or offering for sale; receiving; packing; grading; marketing; or distributing blueberries in commercial quantities. This definition includes a retailer, except a retailer who purchases or acquires from, or handles on behalf of any producer, blueberries. The term first handler includes a producer who handles or markets blueberries of the producer's own production.

§ 1218.8 Fiscal period.

Fiscal period means a calendar year from January 1 through December 31, or such other period as approved by the Secretary.

§ 1218.9 Importer.

Importer means any person who imports fresh or processed blueberries into the United States as a principal or as an agent, broker, or consignee of any person who produces or handles fresh or processed blueberries outside of the United States for sale in the United States, and who is listed in the import records as the importer of record for such blueberries.

§ 1218.10 Information.

Information means information and programs that are designed to increase efficiency in processing and to develop new markets, marketing strategies, increase market efficiency, and activities that are designed to enhance the image of blueberries on a national or international basis. These include:

(a) *Consumer information,* which means any action taken to provide information to, and broaden the understanding of, the general public regarding the consumption, use, nutritional attributes, and care of blueberries; and

(b) *Industry information,* which means information and programs that will lead to the development of new markets, new marketing strategies, or increased efficiency for the blueberry industry, and activities to enhance the image of the blueberry industry.

§ 1218.11 Market or marketing.

(a) *Marketing* means the sale or other disposition of blueberries in any channel of commerce.

(b) To *market* means to sell or otherwise dispose of blueberries in interstate, foreign, or intrastate commerce.

§ 1218.12 Order.

Order means an order issued by the Secretary under section 514 of the Act that provides for a program of generic promotion, research, and information regarding agricultural commodities authorized under the Act.

§ 1218.13 Part and subpart.

Part means the Blueberry Promotion, Research, and Information Order and all rules, regulations, and supplemental orders issued pursuant to the Act and the Order. The Order shall be a *subpart* of such part.

§ 1218.14 Person.

Person means any individual, group of individuals, partnership, corporation, association, cooperative, or any other legal entity.

§ 1218.15 Processed blueberries.

Processed blueberries means blueberries which have been frozen, dried, pureed, or made into juice.

§ 1218.16 Producer.

Producer means any person who grows blueberries in the United States for sale in commerce, or a person who is engaged in the business of producing, or causing to be produced for any market, blueberries beyond the person's own family use and having value at first point of sale.

§ 1218.17 Promotion.

Promotion means any action taken to present a favorable image of blueberries to the general public and the food industry for the purpose of improving the competitive position of blueberries both in the United States and abroad and stimulating the sale of blueberries. This includes paid advertising and public relations.

§ 1218.18 Research.

Research means any type of test, study, or analysis designed to advance the image, desirability, use, marketability, production, product development, or quality of blueberries, including research relating to nutritional value, cost of production, new product development, varietal development, nutritional value, health research, and marketing of blueberries.

§ 1218.19 Secretary.

Secretary means the Secretary of Agriculture of the United States, or any officer or employee of the Department to whom authority has heretofore been delegated, or to whom authority may hereafter be delegated, to act in the Secretary's stead.

§ 1218.20 Suspend.

Suspend means to issue a rule under section 553 of title 5, U.S.C., to temporarily prevent the operation of an order or part thereof during a particular period of time specified in the rule.

§ 1218.21 Terminate.

Terminate means to issue a rule under section 553 of title 5, U.S.C., to cancel permanently the operation of an order or part thereof beginning on a date certain specified in the rule.

§ 1218.22 United States.

United States means collectively the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, and the territories and possessions of the United States.

§ 1218.23 USABC.

USABC, or U.S.A. Blueberry Council, means the administrative body established pursuant to § 1218.40.

U.S.A. Blueberry Council

§ 1218.40 Establishment and membership.

(a) *Establishment of the U.S.A. Blueberry Council.* There is hereby established a U.S.A. Blueberry Council, hereinafter called the USABC, composed of no more than 13 members and alternates, appointed by the Secretary from the nominations as follows:

(1) One producer member and alternate from each of the following regions:

(i) Region #1 Western Region (all states from the Pacific east to the Rockies): Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

(ii) Region #2 Midwest Region (all states east of the Rockies to the Great Lakes and south to the Kansas/Missouri/Kentucky state line): Illinois, Indiana, Iowa, Kansas, Kentucky, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin.

(iii) Region #3 Northeast Region (all states east of the Great Lakes and North of the North Carolina/Tennessee state line): Connecticut, Delaware, New York, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, Pennsylvania, Rhode Island, Virginia, Vermont, Washington, D.C., and West Virginia.

(iv) Region #4 Southern Region (all states south of the Virginia/Kentucky/Missouri/Kansas state line and east of the Rockies): Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, Oklahoma, Puerto Rico, South Carolina, Tennessee, and Texas.

(2) One producer member and alternate from each of the top five blueberry producing states, based upon the average of the total tons produced over the previous three years. Average tonnage will be based upon North American Blueberry Council production figures for the initial election and production and assessment figures generated by the USABC thereafter.

(3) One importer and alternate.

(4) One exporter and alternate shall be filled by foreign blueberry producers currently shipping blueberries into the United States from the largest foreign blueberry production area, based on a three-year average.

(5) One first handler member and alternate shall be filled by a United States based independent or cooperative organization which is a producer/shipper of domestic blueberries.

(6) One public member and alternate.

(b) *Adjustment of membership.* At least once every five years, the USABC will review the geographical distribution of United States production of blueberries and the quantity of imports. The review will be conducted through an audit of state crop production figures and USABC assessment receipts. If warranted, the USABC will recommend to the Secretary that membership on the USABC be altered to reflect any changes in geographical distribution of domestic blueberry production and the quantity of imports. If the level of imports increases, importer members and alternates may be added to the USABC.

§ 1218.41 Nominations and appointments.

(a) Voting for regional and state representatives will be made by mail ballot.

(b) In a case where a state has a state blueberry commission or marketing order in place, the state commission or committee will nominate members and alternates to serve on the USABC. At least two nominees shall be submitted to the Secretary for each member and for each alternate.

(c) Nomination and election of regional, and state representatives where no commission or order is in place will be handled by the USABC, provided that the initial nominations will be handled by the North American Blueberry Council. The USABC will seek nominations for members and alternates from the specific states and/or regions. Nominations will be returned to the USABC and placed on a ballot which will then be sent to producers in the state and/or region for vote. The final nominee for member will have received the highest number of votes cast. The person with the second highest number of votes cast will be the final nominee for alternate. The persons with the third and fourth place highest number of votes cast will be designated as additional nominees for consideration by the Secretary.

(d) Nominations for the importer, exporter, first handler, and public member positions will be made by the USABC. Two nominees for each member and each alternate position will be submitted to the Secretary for consideration.

(e) From the nominations, the Secretary shall select the members of the USABC and alternates for each position on the USABC.

§ 1218.42 Term of office.

USABC members and alternates will serve for a term of three years and be able to serve a maximum of two consecutive terms. A USABC member may serve as an alternate during the years the member is ineligible for a member position. When the USABC is first established, the state representatives, first handler member, and their respected alternates will be assigned initial terms of three years. Regional representatives, the importer member, the exporter member, public member, and their alternates will serve an initial term of two years. Thereafter, each of these positions will carry a full three-year term. USABC nominations and appointments will take place in two out of every three years. Each term of office will end on December 31, with new terms of office beginning on January 1.

§ 1218.43 Vacancies.

(a) In the event that any member of the USABC ceases to be a member of the category of members from which the member was appointed to the USABC, such position shall automatically become vacant.

(b) If a member of the USABC consistently refuses to perform the duties of a member of the USABC, or if a member of the USABC engages in acts of dishonesty or willful misconduct, the USABC may recommend to the Secretary that the member be removed from office. If the Secretary finds the recommendation of the USABC shows adequate cause, the Secretary shall remove such member from office.

(c) Should any member position become vacant, the alternate of that member shall automatically assume the position of said member. Should the positions of both a member and such member's alternate become vacant, successors for the unexpired terms of such member and alternate shall be appointed in the manner specified in § 1218.40 and § 1218.41, except that said nomination and replacement shall not be required if said unexpired terms are less than six months.

§ 1218.44 Alternate members.

An alternate member of the USABC, during the absence of the member for whom the person is the alternate, shall act in the place and stead of such member and perform such duties as assigned. In the event of death, removal, resignation, or disqualification of any member, the alternate for that member shall automatically assume the position of said member. In the event that both a producer member of the USABC and the alternate are unable to attend a meeting, the USABC may not designate any other alternate to serve in such member's or alternate's place and stead for such a meeting.

§ 1218.45 Procedure.

(a) At a USABC meeting, it will be considered a quorum when a minimum of seven members, or their alternates serving in the absence, are present.

(b) At the start of each fiscal period, the USABC will select a chairperson and vice chairperson who will conduct meetings throughout that period.

(c) All USABC members and alternates will receive a minimum of 10 days advance notice of all USABC and committee meetings.

(d) Each member of the USABC will be entitled to one vote on any matter put to the USABC, and the motion will carry if supported by one vote more than 50 percent of the total votes represented by the USABC members present.

(e) It will be considered a quorum at a committee meeting when at least one more than half of those assigned to the committee are present. Alternates may also be assigned to committees as necessary. Committees may also consist of individuals other than USABC members and such individuals may vote in committee meetings. These committee members shall serve without compensation but shall be reimbursed for reasonable travel expenses, as approved by the USABC.

(f) In lieu of voting at a properly convened meeting and, when in the opinion of the chairperson of the USABC such action is considered necessary, the USABC may take action if supported by one vote more than 50 percent of the members by mail, telephone, electronic mail, facsimile, or any other means of communication, and all telephone votes shall be confirmed promptly in writing. In that event, all members must be notified and provided the opportunity to vote. Any action so taken shall have the same force and

effect as though such action had been taken at a properly convened meeting of the USABC. All votes shall be recorded in USABC minutes.

(g) There shall be no voting by proxy.

(h) The chairperson shall be a voting member.

(i) The organization of the USABC and the procedures for the conducting of meetings of the USABC shall be in accordance with its bylaws, which shall be established by the USABC and approved by the Secretary.

§ 1218.46 Compensation and reimbursement.

The members of the USABC, and alternates when acting as members, shall serve without compensation but shall be reimbursed for reasonable travel expenses, as approved by the USABC, incurred by them in the performance of their duties as USABC members.

§ 1218.47 Powers and duties.

The USABC shall have the following powers and duties:

(a) To administer the Order in accordance with its terms and conditions and to collect assessments;

(b) To develop and recommend to the Secretary for approval such bylaws as may be necessary for the functioning of the USABC, and such rules as may be necessary to administer the Order, including activities authorized to be carried out under the Order;

(c) To meet, organize, and select from among the members of the USABC a chairperson, other officers, committees, and subcommittees, as the USABC determines to be appropriate;

(d) To employ persons, other than the members, as the USABC considers necessary to assist the USABC in carrying out its duties and to determine the compensation and specify the duties of such persons;

(e) To develop programs and projects, and enter into contracts or agreements, which must be approved by the Secretary before becoming effective, for the development and carrying out of programs or projects of research, information, or promotion, and the payment of costs thereof with funds collected pursuant to this subpart. Each contract or agreement shall provide that any person who enters into a contract or agreement with the USABC shall develop and submit to the USABC a proposed activity; keep accurate records of all of its transactions relating to the contract or agreement; account for funds received and expended in connection with the contract or agreement; make periodic reports to the USABC of activities conducted under the contract or agreement; and make such other reports available as the USABC or the Secretary considers relevant. Any contract or agreement shall provide that:

(1) The contractor or agreeing party shall develop and submit to the USABC a program, plan, or project together with a budget or budgets that shall show the estimated cost to be incurred for such program, plan, or project;

(2) The contractor or agreeing party shall keep accurate records of all its transactions and make periodic reports to the USABC of activities conducted, submit accounting for funds received and expended, and make such other reports as the Secretary or the USABC may require;

(3) The Secretary may audit the records of the contracting or agreeing party periodically; and

(4) Any subcontractor who enters into a contract with a USABC contractor and who receives or otherwise uses funds allocated by the USABC shall be subject to the same provisions as the contractor.

(f) To prepare and submit for approval of the Secretary fiscal year budgets in accordance with § 1218.50;

(g) To maintain such records and books and prepare and submit such reports and records from time to time to the Secretary as the Secretary may prescribe; to make appropriate accounting with respect to the receipt and disbursement of all funds entrusted to it; and to keep records that accurately reflect the actions and transactions of the USABC;

(h) To cause its books to be audited by a competent auditor at the end of each fiscal year and at such other times as the Secretary may request, and to submit a report of the audit directly to the Secretary;

(i) To give the Secretary the same notice of meetings of the USABC as is given to members in order that the Secretary's representative(s) may attend such meetings, and to keep and report minutes of each meeting of the USABC to the Secretary;

(j) To act as intermediary between the Secretary and any producer, first handler, importer, or exporter;

(k) To furnish to the Secretary any information or records that the Secretary may request;

(l) To receive, investigate, and report to the Secretary complaints of violations of the Order;

(m) To recommend to the Secretary such amendments to the Order as the USABC considers appropriate; and

(n) To work to achieve an effective, continuous, and coordinated program of promotion, research, consumer information, evaluation, and industry information designed to strengthen the blueberry industry's position in the marketplace; maintain and expand existing markets and uses for blueberries; and to carry out programs, plans, and projects designed to provide maximum benefits to the blueberry industry.

§ 1218.48 Prohibited activities.

The USABC may not engage in, and shall prohibit the employees and agents of the USABC from engaging in:

(a) Any action that would be a conflict of interest; and

(b) Using funds collected by the USABC under the Order to undertake any action for the purpose of influencing legislation or governmental action or policy, by local, state, national, and foreign governments, other than recommending to the Secretary amendments to the Order.

Expenses and Assessments

§ 1218.50 Budget and expenses.

(a) At least 60 days prior to the beginning of each fiscal year, and as may be necessary thereafter, the USABC shall prepare and submit to the Secretary a budget for the fiscal year covering its anticipated expenses and disbursements in administering this subpart. Each such budget shall include:

(1) A statement of objectives and strategy for each program, plan, or project;

(2) A summary of anticipated revenue, with comparative data or at least one preceding year (except for the initial budget);

(3) A summary of proposed expenditures for each program, plan, or project; and

(4) Staff and administrative expense breakdowns, with comparative data for at least on preceding year (except for the initial budget).

(b) Each budget shall provide adequate funds to defray its proposed expenditures and to provide for a reserve as set forth in this subpart.

(c) Subject to this section, any amendment or addition to an approved budget must be approved by the Secretary, including shifting funds from one program, plan, or project to another. Shifts of funds which do not cause an increase in the USABC's approved budget and which are consistent with governing bylaws need not have prior approval by the Secretary.

(d) The USABC is authorized to incur such expenses, including provision for a reasonable reserve, as the Secretary finds are reasonable and likely to be incurred by the USABC for its maintenance and functioning, and to enable it to exercise its powers and perform its duties in accordance with the provisions of this subpart. Such

expenses shall be paid from funds received by the USABC.

(e) With approval of the Secretary, the USABC may borrow money for the payment of administrative expenses, subject to the same fiscal, budget, and audit controls as other funds of the USABC. Any funds borrowed by the USABC shall be expended only for startup costs and capital outlays and are limited to the first year of operation of the USABC.

(f) The USABC may accept voluntary contributions, but these shall only be used to pay expenses incurred in the conduct of programs, plans, and projects. Such contributions shall be free from any encumbrance by the donor and the USABC shall retain complete control of their use.

(g) The USABC may also receive funds provided through the Department's Foreign Agricultural Service or from other sources, with the approval of the Secretary, for authorized activities.

(h) The USABC shall reimburse the Secretary for all expenses incurred by the Secretary in the implementation, administration, and supervision of the Order, including all referendum costs in connection with the Order.

(i) The USABC may not expend for administration, maintenance, and functioning of the USABC in any fiscal year an amount that exceeds 15 percent of the assessments and other income received by the USABC for that fiscal year. Reimbursements to the Secretary required under paragraph (h) are excluded from this limitation on spending.

(j) The USABC may establish an operating monetary reserve and may carry over to subsequent fiscal periods excess funds in any reserve so established: *Provided* that the funds in the reserve do not exceed one fiscal period's budget. Subject to approval by the Secretary, such reserve funds may be used to defray any expenses authorized under this part.

§ 1218.51 Financial statements.

(a) As requested by the Secretary, the USABC shall prepare and submit financial statements to the Secretary on a periodic basis. Each such financial statement shall include, but not be limited to, a balance sheet, income statement, and expense budget. The expense budget shall show expenditures during the time period covered by the report, year-to-date expenditures, and the unexpended budget.

(b) Each financial statement shall be submitted to the Secretary within 30 days after the end of the time period to which it applies.

(c) The USABC shall submit annually to the Secretary an annual financial statement within 90 days after the end of the fiscal year to which it applies.

§ 1218.52 Assessments.

(a) The funds to cover the Council's expenses shall be paid from assessments on producers and importers, donations from any person not subject to assessments under this Order, and other funds available to the Board including those collected pursuant to § 1218.56 and subject to the limitations contained therein.

(b) The collection of assessments on domestic blueberries will be the responsibility of the first handler receiving the blueberries. In the case of the producer acting as its own first handler, the producer will be required to collect and remit its individual assessments.

(c) Such assessments shall be levied at a rate of $12 per ton on all blueberries. The assessment rate will be reviewed, and may be modified with the approval of the Secretary, after the first referendum is conducted as stated in § 1218.71(b).

(d) Each importer of fresh and processed blueberries shall pay an assessment to the USABC on blueberries imported for marketing in the United States, through the U.S. Customs Service.

(1) The assessment rate for imported fresh and processed blueberries shall be the same or equivalent to the rate for fresh blueberries produced in the United States.

(2) The import assessment shall be uniformly applied to imported fresh and frozen blueberries that are identified by the numbers 0810.40.0028 and 0811.90.2028, respectively, in the Harmonized Tariff Schedule of the United States or any other numbers used to identify fresh and frozen blueberries. Assessments on other types of imported processed blueberries, such as dried blueberries, puree, and juice, may be added at the recommendation of the USABC with the approval of the Secretary.

(3) The assessments due on imported fresh and processed blueberries shall be paid when they enter or are withdrawn for consumption in the United States.

(e) All assessment payments and reports will be submitted to the office of the USABC. All final payments for a crop year are to be received no later than November 30 of that year. A late payment charge shall be imposed on any handler who fails to remit to the USABC, the total amount for which any such handler is liable on or before the due date established by the USABC. In addition to the late payment charge, an interest charge shall be imposed on the outstanding amount for which the handler is liable. The rate of interest shall be prescribed in regulations issued by the Secretary.

(f) Persons failing to remit total assessments due in a timely manner may also be subject to actions under federal debt collection procedures.

(g) The USABC may authorize other organizations to collect assessments on its behalf with the approval of the Secretary.

§ 1218.53 Exemption procedures.

(a) Any producer who produces less than 2,000 pounds of blueberries annually who desires to claim an exemption from assessments during a fiscal year as provided in § 1218.42 shall apply to the USABC, on a form provided by the USABC, for a certificate of exemption. Such producer shall certify that the producer's production of blueberries shall be less than 2,000 pounds for the fiscal year for which the exemption is claimed. Any importer who imports less than 2,000 pounds of fresh and processed blueberries annually who desires to claim an exemption from assessments during a fiscal year as provided in § 1218.52 shall apply to the USABC, on a form provided by the USABC, for a certificate of exemption. Such importer shall certify that the importer's importation of fresh and processed blueberries shall not exceed 2,000 pounds, for the fiscal year for which the exemption is claimed.

(b) On receipt of an application, the USABC shall determine whether an exemption may be granted. The USABC then will issue, if deemed appropriate, a certificate of exemption to each person who is eligible to receive one. Each producer who is exempt from assessment must provide an exemption number to the first handler in order to be exempt from the collection of an assessment on blueberries. First handlers and importers, except as otherwise authorized by the USABC, shall maintain records showing the exemptee's name and address along with the exemption number assigned by the USABC.

(c) Importers who are exempt from assessment shall be eligible for reimbursement of assessments collected by the U.S. Customs Service and shall apply to the USABC for reimbursement of such assessments paid. No interest will be paid on assessments collected by the U.S. Customs Service. Requests for reimbursement shall be submitted to the USABC within 90 days of the last day of the year the blueberries were actually imported.

(d) Any person who desires an exemption from assessments for a subsequent fiscal year shall reapply to the USABC, on a form provided by the USABC, for a certificate of exemption.

(e) The USABC may require persons receiving an exemption from assessments to provide to the USABC reports on the disposition of exempt blueberries and, in the case of importers, proof of payment of assessments.

§ 1218.54 Programs, plans, and projects.

(a) The USABC shall receive and evaluate, or on its own initiative develop, and submit to the Secretary for approval any program, plan, or project authorized under this subpart. Such programs, plans, or projects shall provide for:

(1) The establishment, issuance, effectuation, and administration of appropriate programs for promotion, research, and information, including producer and consumer information, with respect to fresh and processed blueberries; and

(2) The establishment and conduct of research with respect to the use, nutritional value, sale, distribution, and marketing of fresh and processed blueberries, and the creation of new products thereof, to the end that the marketing and use of blueberries may be encouraged, expanded, improved, or made more acceptable and to advance the image, desirability, or quality of fresh and processed blueberries.

(b) No program, plan, or project shall be implemented prior to its approval by the Secretary. Once a program, plan, or project is so approved, the USABC shall take appropriate steps to implement it.

(c) Each program, plan, or project implemented under this subpart shall be reviewed or evaluated periodically by the USABC to ensure that it contributes to an effective program of promotion, research, or information. If it is found by the USABC that any such program, plan, or project does not contribute to an effective program of promotion, research, or information, then the USABC shall terminate such program, plan, or project.

(d) No program, plan, or project including advertising shall be false or misleading or disparaging another agricultural commodity. Blueberries of all origins shall be treated equally.

§ 1218.55 Independent evaluation.

The USABC shall, not less often than every five years, authorize and fund, from funds otherwise available to the USABC, an independent evaluation of the effectiveness of the Order and other programs conducted by the USABC pursuant to the Act. The USABC shall submit to the Secretary, and make available to the public, the results of each periodic independent evaluation conducted under this paragraph.

§ 1218.56 Patents, copyrights, trademarks, information, publications, and product formulations.

Patents, copyrights, trademarks, information, publications, and product formulations developed through the use of funds received by the USABC under this subpart shall be the property of the U.S. Government as represented by the USABC and shall, along with any rents, royalties, residual payments, or other income from the rental, sales, leasing, franchising, or other uses of such patents, copyrights, trademarks, information, publications, or product formulations, inure to the benefit of the USABC; shall be considered income subject to the same fiscal, budget, and audit controls as other funds of the USABC; and may be licensed subject to approval by the Secretary. Upon termination of this subpart, § 1218.73 shall apply to determine disposition of all such property.

Reports, Books, and Records

§ 1218.60 Reports.

(a) Each first handler subject to this subpart may be required to provide to the USABC periodically such information as may be required by the USABC, with the approval of the Secretary, which may include but not be limited to the following:

(1) Number of pounds handled;

(2) Number of pounds on which an assessment was collected;

(3) Name and address of person from whom the first handler has collected the assessments on each pound handled; and

(4) Date collection was made on each pound handled. All reports are due to the USABC 30 days after the end of the crop year.

(b) Each producer and importer subject to this subpart may be required to provide to the USABC periodically such information as may be required by the USABC, with the approval of the Secretary, which may include but not be limited to the following:

(1) Number of pounds produced;

(2) Number of pounds on which an assessment was paid;

(3) Name and address of the producer;

(4) Date collection was made on each pound produced. All reports are due to the USABC 30 days after the end of the crop year.

§ 1218.61 Books and records.

Each first handler, producer, and importer subject to this subpart shall maintain and make available for inspection by the Secretary such books and records as are necessary to carry out the provisions of this subpart and the regulations issued thereunder, including such records as are necessary to verify any reports required. Such records shall be retained for at least 2 years beyond the fiscal period of their applicability.

§ 1218.62 Confidential treatment.

All information obtained from books, records, or reports under the Act, this subpart, and the regulations issued thereunder shall be kept confidential by all persons, including all employees and former employees of the USABC, all officers and employees and former officers and employees of contracting and subcontracting agencies or agreeing parties having access to such information. Such information shall not be available to USABC members, producers, importers, exporters, or first handlers. Only those persons having a specific need for such information to effectively administer the provisions of this subpart shall have access to such information. Only such information so obtained as the Secretary deems relevant shall be disclosed by them, and then only in a judicial proceeding or administrative hearing brought at the direction, or on the request, of the Secretary, or to which the Secretary or any officer of the United States is a party, and involving this subpart. Nothing in this section shall be deemed to prohibit:

(a) The issuance of general statements based upon the reports of the number of persons subject to this subpart or statistical data collected therefrom, which statements do not identify the information furnished by any person; and

(b) The publication, by direction of the Secretary, of the name of any person who has been adjudged to have violated this subpart, together with a statement of the particular provisions of this subpart violated by such person.

Miscellaneous

§ 1218.70 Right of the Secretary.

All fiscal matters, programs, plans, or projects, rules or regulations, reports, or other substantive actions proposed and prepared by the USABC shall be submitted to the Secretary for approval.

§ 1218.71 Referenda.

(a) *Initial referendum.* The Order shall not become effective unless:

(1) The Secretary determines that the Order is consistent with and will effectuate the purposes of the Act; and

(2) The Order is approved by a majority of producers and importers

voting for approval who also represent a majority of the volume of blueberries represented in the referendum who, during a representative period determined by the Secretary, have been engaged in the production or importation of blueberries.

(b) *Subsequent referenda.* Every five years, the Secretary shall hold a referendum to determine whether blueberry producers and importers favor the continuation of the Order. The Order shall continue if it is favored by a majority of producers and importers voting for approval who also represent a majority of the volume of blueberries represented in the referendum who, during a representative period determined by the Secretary, have been engaged in the production or importation of blueberries. The Secretary will also conduct a referendum if 10 percent or more of all eligible blueberry producers and importers request the Secretary to hold a referendum. In addition, the Secretary may hold a referendum at any time.

§ 1218.72 Suspension and termination.

(a) The Secretary shall suspend or terminate this part or subpart or a provision thereof if the Secretary finds that the subpart or a provision thereof obstructs or does not tend to effectuate the purposes of the Act, or if the Secretary determines that this subpart or a provision thereof is not favored by persons voting in a referendum conducted pursuant to the Act.

(b) The Secretary shall suspend or terminate this subpart at the end of the marketing year whenever the Secretary determines that its suspension or termination is approved or favored by a majority of producers and importers voting for approval who also represent a majority of the volume of blueberries represented in the referendum who, during a representative period determined by the Secretary, have been engaged in the production or importation of blueberries.

(c) If, as a result of a referendum the Secretary determines that this subpart is not approved, the Secretary shall:

(1) Not later than 180 days after making the determination, suspend or terminate, as the case may be, collection of assessments under this subpart; and

(2) As soon as practical, suspend or terminate, as the case may be, activities under this subpart in an orderly manner.

§ 1218.73 Proceedings after termination.

(a) Upon the termination of this subpart, the USABC shall recommend not more than three of its members to the Secretary to serve as trustees for the purpose of liquidating the affairs of the USABC. Such persons, upon designation by the Secretary, shall become trustees of all of the funds and property then in the possession or under control of the USABC, including claims for any funds unpaid or property not delivered, or any other claim existing at the time of such termination.

(b) The said trustees shall:

(1) Continue in such capacity until discharged by the Secretary;

(2) Carry out the obligations of the USABC under any contracts or agreements entered into pursuant to the Order;

(3) From time to time account for all receipts and disbursements and deliver all property on hand, together with all books and records of the USABC and the trustees, to such person or persons as the Secretary may direct; and

(4) Upon request of the Secretary execute such assignments or other instruments necessary and appropriate to vest in such persons title and right to all funds, property and claims vested in the USABC or the trustees pursuant to the Order.

(c) Any person to whom funds, property or claims have been transferred or delivered pursuant to the Order shall be subject to the same obligations imposed upon the USABC and upon the trustees.

(d) Any residual funds not required to defray the necessary expenses of liquidation shall be turned over to the Secretary to be disposed of, to the extent practical, to the blueberry producer organizations in the interest of continuing blueberry promotion, research, and information programs.

§ 1218.74 Effect of termination or amendment.

Unless otherwise expressly provided by the Secretary, the termination of this subpart or of any regulation issued pursuant thereto, or the issuance of any amendment to either thereof, shall not:

(a) Affect or waive any right, duty, obligation or liability which shall have arisen or which may thereafter arise in connection with any provision of this subpart or any regulation issued thereunder; or

(b) Release or extinguish any violation of this subpart or any regulation issued thereunder; or

(c) Affect or impair any rights or remedies of the United States, or of the Secretary or of any other persons, with respect to any such violation.

§ 1218.75 Personal liability.

No member, alternate member, or employee of the USABC shall be held personally responsible, either individually or jointly with others, in any way whatsoever, to any person for errors in judgment, mistakes, or other acts, either of commission or omission, as such member, alternate, or employee, except for acts of dishonesty or willful misconduct.

§ 1218.76 Separability.

If any provision of this subpart is declared invalid or the applicability thereof to any person or circumstances is held invalid, the validity of the remainder of this subpart or the applicability thereof to other persons or circumstances shall not be affected thereby.

§ 1218.77 Amendments.

Amendments to this subpart may be proposed from time to time by the USABC or by any interested person affected by the provisions of the Act, including the Secretary.

§ 1218.78 OMB control numbers.

The control number assigned to the information collection requirements by the Office of Management and Budget pursuant to the Paperwork Reduction Act of 1995, 44 U.S.C. Chapter 35, is OMB control number 0581–0093, except for the USABC nominee background statement form which is assigned OMB control number 0505–001.

Dated: July 11, 2000.

Kathleen A. Merrigan,

Administrator, Agricultural Marketing Service.

[FR Doc. 00–17956 Filed 7–14–00; 8:45 am]

BILLING CODE 3410–02–P

FEDERAL HOUSING FINANCE BOARD

12 CFR Parts 900, 940, 950, 955, 956 and 966

[No. 2000–33]

RIN 3069–AA98

Federal Home Loan Bank Acquired Member Assets, Core Mission Activities, Investments and Advances

AGENCY: Federal Housing Finance Board.

ACTION: Final rule.

SUMMARY: The Federal Housing Finance Board (Finance Board) is adding regulations to authorize the Federal Home Loan Banks (Banks) to hold acquired member assets (AMA) and is amending its regulations to enumerate the types of core mission assets (CMA) that must be addressed in the Banks' strategic business plans. The Finance Board is also making related changes to

its regulations governing the Banks' investment, advances and debt issuance authorities.

DATES: This final rule is effective on July 17, 2000.

FOR FURTHER INFORMATION CONTACT: James L. Bothwell, Director and Chief Economist, (202) 408–2821; Scott L. Smith, Deputy Director, (202) 408–2991; Ellen Hancock, Senior Financial Analyst, (202) 408–2906; Christina K. Muradian, Senior Financial Analyst, (202) 408–2584, Office of Policy, Research and Analysis; or Eric M. Raudenbush, Senior Attorney-Advisor, (202) 408–2932; Office of General Counsel, Federal Housing Finance Board, 1777 F Street, N.W., Washington, D.C. 20006.

SUPPLEMENTARY INFORMATION:

I. Background

On May 3, 2000, the Finance Board published for comment a proposed rule to: (1) Add new provisions in part 940 enumerating the Bank activities that are considered to be CMA; (2) add to the regulations a new part 955 setting forth in regulation the authority and requirements for Banks' AMA programs; (3) revise part 956 of the regulations, governing Bank investments; and (4) amend part 950 of the regulations, governing advances, so that inter-district advances activity would be subject to the same requirements as inter-district AMA activities. *See* 65 FR 25676 (May 3, 2000). The initial 30-day public comment period for the proposed rule was later extended to 43 days, see 65 FR 34127 (May 27, 2000), and closed on June 15, 2000. The Finance Board received a total of 107 comment letters about the proposed rule. Among the comment letters considered in preparing the final rule were 19 that were accepted after the official close of the comment period.

II. Analysis of Comment Letters and Changes Made in the Final Rule

A. Core Mission Activities—Part 940

1. General Commentary

As part of its statutory duty to ensure that the Banks carry out their housing finance mission, the Finance Board recently adopted a regulatory requirement, set forth in § 917.5 of the regulations, that each Bank's board of directors have in effect at all times a strategic business plan that describes how the Bank's business activities will achieve the mission of the Bank consistent with part 940 of the regulations. *See* 65 FR 25267 (May 1, 2000). At the same time, the Finance Board adopted § 940.2 of the regulations, which states the mission of the Banks in its broadest terms and, by way of cross-reference, gives meaning to the strategic business plan requirement of § 917.5. *See id.*

This final rule adds to part 940 a new § 940.3, which enumerates the specific Bank activities that qualify as core mission activities. The intent of this new regulatory provision is to further focus the Banks' strategic business plans on the activities that the Finance Board has determined are most central to the fulfillment of the Banks' statutory mission. In so doing, the Finance Board means to stress the importance that must be placed upon this category of activities as each Bank plans and undertakes its ongoing business activities. Aside from the strategic business plan requirements set forth in § 917.5, there currently are no other regulatory requirements pertaining to CMA.

In the proposed rule, activities that would have qualified as CMA were listed in § 940.3(a). Proposed § 940.3(b) stated that, should the Finance Board impose upon the Banks any future requirement regarding the level of Bank CMA holdings, the requirement would not prevent the Banks from holding to maturity, or funding with the proceeds of consolidated obligations, assets acquired under sections II.B.8 through II.B.11 of the Bank System Financial Management Policy (FMP) (consisting mostly of agency and privately-issued mortgage-backed securities (MBS) and asset-backed securities (ABS)). As discussed in detail below, this provision has been removed in the final rule. Accordingly, the list of activities that qualify as CMA, which appeared as § § 940.3(a)(1) through (9) in the proposed rule, appears as § § 940.3(a) through (i) in the final rule.

Of the comment letters addressing aspects of part 940, support for and opposition to the CMA provisions was about evenly divided. Most of the commenters who generally supported the CMA provisions of the proposed rule agreed with the Finance Board's goal of focusing the Banks on their housing finance and community lending mission, and especially upon extending the reach of the Banks' resources into underserved communities. One commenter (a Bank) agreed with the Finance Board that Bank members will be unable to make intelligent choices about their Banks' new capital plans without understanding the future direction of the Bank System, including the asset categories to be supported by the new capital structure.

Of those opposed to the rule, many stated as the primary reason for their opposition a belief that the Finance Board should wait until after it has promulgated new capital regulations as required by the Federal Home Loan Bank System Modernization Act of 1999 (Modernization Act), Title VI of the Gramm-Leach-Bliley Act, Pub. L. 106–102 (1999), and the Banks have adopted new capital plans under those regulations, before putting into place any further mission regulations. Most of these commenters expressed the opinion that, at a time when Congress has recently made membership in the Bank System completely voluntary and when, as a result, the Banks will need to market ''Class B'' stock to their members in order to establish a base of permanent capital, the Finance Board should not be implementing actual or implied asset requirements that could result in earnings volatility.

Many commenters stressed their belief that the uncertain ability of any Bank to maintain strong earnings and pay an attractive dividend while focusing upon the business activities enumerated in § 940.3 could dissuade members or potential members from purchasing Bank stock. Several commenters noted especially that the reference in proposed § 940.3(b) to possible future requirements regarding Bank CMA, combined with a failure to detail what those requirements could be, raises the possibility that a Bank may in the future be required to divest itself of legally-acquired investments, making the future balance sheet composition of the Banks particularly uncertain for potential investors.

Many of the commenters expressing generally negative reactions to proposed § 940.3 raised concerns that the CMA provisions would limit the Banks' flexibility in managing their balance sheets and, therefore, would adversely impact Bank profits and possibly the safety and soundness of the Banks. Frequently mentioned in this regard was the Finance Board's exclusion of investments in most types of MBS from the list of activities that qualify as CMA. Two commenters (both Banks) specifically requested that the Finance Board continue to permit the Banks to hold MBS in an amount up to three times capital (as is currently the limit under the FMP).

Regarding the exclusion of most MBS from the list of CMA, many commenters expressed a belief that MBS are an important balance sheet management tool for the Banks that may be especially useful in deploying Bank capital prudently during periods of cyclical business downturns. Several commenters stressed the Banks' roles as reliable sources of liquidity for their

members and stated that failure to permit the Banks to continue to invest in MBS could threaten the Banks' abilities to act in this role. Others questioned whether it is appropriate for the Finance Board to restrict Bank investment in assets, like MBS, that are specifically authorized by statute as legal investments for a Bank. Still others argued that MBS do play an important role in helping Banks to carry out their mission in that, as low-risk investments with a reasonable record of return, MBS improve the Bank System's financial strength and help to reduce rates on advances. Some commenters also asserted that MBS are mission-related in that, despite the statements of the Finance Board to the contrary, the Banks' purchase of these securities do result in increased availability of funds for housing and in reduced cost of housing funds.

More generally, several Bank members commented that § 940.3, as proposed, would restrict the Banks' abilities to respond to members' needs with well-priced advances by encouraging the Banks to focus upon ''programs'' required by regulation. Several other commenters expressed the opinion that Congress has adequately addressed the ''mission'' of the Banks in the Federal Home Loan Bank Act (Bank Act) and that, by its failure to impose mission requirements as part of the Modernization Act, Congress expressed its intent that such requirements should not be imposed through regulation. Several also pointed out that the Modernization Act devolved the remaining elements of corporate governance authority to the Banks and claimed that the manner in which the Banks carry out their statutory mission is a matter of corporate governance to be decided upon by the Banks' own boards of directors, subject only to the safety and soundness regulation of the Finance Board.

Finally, one commenter stated that the CMA provisions, as proposed, would violate the spirit of an October 18, 1999 letter from Finance Board Chairman Bruce Morrison to Senator Phil Gramm and Congressman Jim Leach. In that letter, Chairman Morrison stated that, upon the enactment of the Modernization Act, the Finance Board would withdraw its Financial Management and Mission Achievement (FMMA) proposed rulemaking, *see* 64 FR 52163 (1999), and would take no action to promulgate proposed or final regulations limiting Bank assets or advances beyond those regulations currently in effect (except to the extent necessary to protect the safety and soundness of the Banks) until such time as the Finance Board's new capital regulations take effect.

2. The Final Rule—Background

The Bank Act authorizes the Finance Board to supervise the Banks and to promulgate and enforce such regulations and orders as are necessary from time to time to carry out the provisions of the Bank Act. *See* 12 U.S.C. 1422b(a)(1). Among the provisions of the Bank Act are those outlining the duties of the Finance Board, which include the duty to ''ensure'' that the Banks carry out their housing finance mission. *See id.* at 1422a(a)(3)(B)(ii). The use of the word ''ensure'' in section 2A(a)(3)(B)(ii) of the Bank Act makes clear that, consistent with the safe and sound operation of the Banks, the Finance Board has the duty to take active measures to see to it that the Banks carry out their housing finance mission.

Because Congress has not expressly defined the term ''housing finance mission,'' it is the responsibility and the privilege of the Finance Board—as the body charged with the duty to ensure that the Banks fulfill that mission and, more generally, as the supervisory regulator of the Banks and the agency charged with the administration of the Bank Act—to construe the term reasonably in light of the totality of the Act. It is the position of the Finance Board that, when Congress amended the Bank Act in 1989 to require the Banks to offer Affordable Housing Programs (AHP) and Community Investment Programs (CIP) and authorized the Banks to offer Community Investment Cash Advance Programs (CICA), the Banks' ''housing finance mission,'' as referenced in section 2A(a)(3)(B)(ii), came to include support not only for the financing of traditional housing-related activities, but also for those types of community lending that the Banks are authorized by statute to support and that indirectly enhance traditional housing finance by helping to create and sustain thriving and livable communities. *See* 12 U.S.C. 1430(i), (j).

Having earlier set forth its construction of the Banks' mission in § 940.2 of the regulations, *see* 65 FR 25267 (May 1, 2000), the Finance Board is now further fulfilling its duty to ensure that the Banks carry out that mission by requiring that the Banks focus on the CMA listed in new § 940.3 as part of their strategic planning process. Under the Finance Board's regulations, as amended by this final rule, this is the only regulatory requirement regarding CMA.

The material formerly contained in proposed § 940.3(b) was intended to give the Banks and their members some assurance that, if the Finance Board were to promulgate at some point in the future any effective limits on non-CMA Bank activities, MBS and other investments previously made under sections II.B.8 through II.B.11 of the FMP would not adversely affected. However, based on the comments it is apparent that rather than providing reassurance, the effect of including this provision in the proposed rule has been to raise the specter of as-yet-undisclosed future limits on non-CMA activities, while obscuring the fact that no such limits are being contemplated or implemented. Accordingly, the Finance Board has eliminated proposed § 940.3(b) and its reference to possible limits on non-CMA activities from the final rule. Although this declaration of intent has been eliminated from the language of the rule, the Finance Board stresses again that: (1) It has no current plans to impose limits on non-CMA activities; and (2) if any such limits were ever to be imposed, the agency has no current plans to require any Bank to divest itself of otherwise legal and safe investments already held.

Because this rule does not limit Bank assets or activities to a greater extent than the limits to which they are subject under the FMP, the rule does nothing to violate either the spirit, or the literal language, of Chairman Morrison's letter to Senator Gramm and Congressman Leach.

The Finance Board disagrees with comments that the Banks would suffer from lower profits and reduced balance-sheet management flexibility as a result of the Finance Board's failure to characterize MBS as CMA. First and foremost, the rule contains no new restrictions on the Banks' ability to invest in MBS. The only limit on the Banks' authority to invest in MBS is the current FMP ''three times capital'' limit (which will remain in effect until expressly repealed by the Finance Board). Second, the loans and pools of loans a Bank may acquire through AMA programs authorized under part 955 of the final rule (which is discussed in more detail below) would be substantially similar to loans that are normally acquired in securitized form through the purchase of MBS.

Since 1989, the Banks have gained substantial experience in managing the risks associated with MBS. This experience should be transferable to the management of what would essentially be ''self-securitized'' MBS acquired under an AMA program. While the rate of return on AMA could be lower than that on MBS depending upon the price structure of a particular AMA program,

the slight difference in return would inure to the benefit of the selling member, in keeping with the cooperative nature of the Bank System. The purchase of MBS from the capital markets typically does little or nothing to enhance the availability of any reasonably-priced product or service to any member or housing associate.

Finally, the Finance Board rejects the notion that the promulgation of the CMA strategic planning requirement should be postponed until after the Banks have put into effect their new capital plans. As the Banks' mission regulator, the Finance Board has made decisions regarding the broad activities it believes are preferable for the Banks to be pursuing in the context of their housing finance and community lending mission. Having made these decisions, the Finance Board finds it most logical to state those preferences as clearly as possible and as soon as possible prior to the development of the Banks' new capital plans. In doing so, the Finance Board is enabling the Banks to structure their capital plans with specific mission considerations in mind, as opposed to amending the plans after they have already been developed. In addition, members and potential members will be aware in advance of the CMA in which the Banks are encouraged to engage. To do otherwise would serve only to undermine the capital planning process and the expectations of investors in the Bank System, and to no good purpose.

3. Definition of CMA and Government-Insured or -Guaranteed AMA Loans—§ 940.3(b)

Under § 940.3(b) of the final rule, all AMA authorized under new part 955 qualify as CMA, except for certain United States government-insured or guaranteed whole single-family residential mortgage loans acquired under a commitment entered into after April 12, 2000. The latter shall qualify as CMA only in a cumulative dollar amount up to 33 percent of: the cumulative total dollar amount of AMA acquired by a Bank after April 12, 2000, less the cumulative dollar amount of United States government-insured or guaranteed whole single-family residential mortgage loans acquired after April 12, 2000 under commitments entered into on or before April 12, 2000. At the discretion of two or more Banks, this percentage calculation may be made based on aggregate transactions among those Banks.

This provision appeared as § 940.3(a)(2) in the proposed rule. Section 940.3(b) of the final rule differs from the proposal in that the ''33 percent'' calculation regarding government-insured and -guaranteed loans has been made to apply on a cumulative basis, as opposed to a year-to-year basis.

The Finance Board received a total of 20 comments regarding the CMA definition as applied to government-insured or -guaranteed loans. Seventeen commenters were opposed to that aspect of the CMA definition that would result in only a portion of the government-insured or -guaranteed loans acquired by a Bank being considered as CMA. Two commenters supported the definition as proposed, and one noted that the issue required further discussion.

Generally, the commenters opposed to this aspect of the CMA definition noted that the Banks should be provided maximum flexibility in meeting the needs of their members. It was noted that the exclusion of a portion of government-insured or -guaranteed loans from the definition of CMA would have a detrimental effect on the ability of private sector lenders to pass the full benefits of AMA programs on to consumers. It was also noted that the Banks should have unlimited flexibility to acquire government insured or guaranteed loans, similar to the unlimited flexibility afforded Fannie Mae and Freddie Mac. One commenter added that no limitation should exist since there are no safety and soundness or mission reasons to justify such a limitation. Another commenter suggested that the April 12, 2000 date, relating to prior acquisition of government-insured and -guaranteed loans, be either deleted or moved to the date of enactment of the final rule. Yet another commenter requested that the 33 percent limitation should not take effect until 2002.

One of the comments in favor of the proposed definition noted that the Banks should be encouraged to focus on conventional and prime rate mortgages that are made to minorities and low-and moderate-income populations. Another commenter supporting the proposed definition added that the use of mortgage insurance would significantly reduce the need for Banks to purchase government-insured or -guaranteed loans, since such purchases to date have been the result of the recourse capital treatment for members selling conventional loans.

The Finance Board considered the comments received regarding the CMA definition as applied to government-insured and -guaranteed loans and decided that the definition should remain as proposed, although the calculation thereunder should be made on a cumulative, as opposed to a year-to-year, basis. The distribution of the Banks' current mortgage portfolio indicates that a high percentage of government-insured loans have been acquired when compared to the percentage of these loans in the total mortgage market. The final rule encourages the composition of the Banks' mortgage portfolios to more closely reflect the distribution of loans in the marketplace. This provision is intended to reduce the emphasis on government-insured loans that currently exists in the Banks' mortgage portfolios and to provide incentive for Bank acquisition of conventional mortgages.

The parenthetical at the end of § 940.3(b) makes clear that the calculation of the percentage of AMA loans that qualify as CMA may be made based on aggregate transactions between two or more Banks so long as the relevant Banks agree (or, even on a System-wide basis if all Banks agree). This provision is intended to provide flexibility among the Banks such that if one Bank's acquisition of government-insured or guaranteed loans exceeds 33 percent of total AMA in a given year, it may combine its portfolio for purposes of the calculation with another Bank that may not have reached the maximum allowed CMA purchase of such loans.

4. Targeted Investments—§ 940.3(e)

Under § 940.3(e) of the final rule, certain targeted debt and equity investments may qualify as CMA. As stated in § 940.3(e)(1), these include debt or equity investments that primarily benefit households having a targeted income level, or areas targeted for redevelopment by local, state, tribal or Federal government, by providing or supporting: housing; economic development; community services; permanent jobs; or area revitalization or stabilization. The term ''targeted income level'' is defined in § 940.1 by cross-referencing to the first two paragraphs of the definition of the same term under the Finance Board's CICA regulation. *See* 12 CFR 952.3. There, ''targeted income level'' is defined to refer to a household income that is at or below 115 percent of the area median income in rural areas, and at or below 100 percent of the area median income in urban areas. *See* 12 CFR 952.3. Section 940.3(e)(1) also requires that a significant proportion of the households with a targeted income level must have incomes at or below 80 percent of area median income. An example of a housing project that would meet the targeted income requirement would be a project that qualifies for a federal Low Income Housing Tax Credit where either 20 percent of the units are affordable to

households with incomes at or below 50 percent of area median income or 40 percent of the units are affordable to households with incomes at or below 60 percent of area median income.

Section 940.3(e)(2) provides that, if the targeted investment is an MBS or ABS, the acquisition of these securities by the Bank must substantially contribute to expanding liquidity for loans that are not otherwise adequately provided by the private sector and do not have a readily-available or well-established secondary market in order for the investment to qualify as CMA. Whether the investment is an MBS or ABS, or a non-securitized asset, § 940.3(e)(3) requires that the investment must in all cases involve one or more members or housing associates in a manner, financial or otherwise, and to a degree to be determined by the Bank.

Most of the comments addressing the targeted lending provision were generally supportive, although many suggested additions, clarifying language or other modifications. Many of the commenters who praised the provision specifically supported Bank debt and equity investments in Community Development Financial Institutions (CDFIs) and secondary capital in community development credit unions, which, as mentioned in the preamble to the proposed rule, would qualify as CMA under § 940.3(e). Several commenters also stated generally that the Finance Board should make clear that § 940.3(e) is intended to encompass whole loans, whole loan portfolios or participations in whole loans or whole loan portfolios, where these loans meet the requirements of the provision.

As proposed, § 940.3(e)(1) (which appeared at § 940.3(a)(5)(i) of the proposed rule) required that these investments primarily benefit ''low- or moderate-income households,'' which the proposed rule defined as a household with an income that is at or below 115 percent of area median income. With regard to these income targets, several commenters stated that the Finance Board should amend its definition of ''low- or moderate-income households'' to include only those households with incomes up to 80 percent of area median income. The commenters noted that this would correspond with the income targets under the Community Reinvestment Act (CRA) and would enhance the ability of Bank members to meet their CRA requirements by making CRA-related loans and investments.

After considering all of the relevant factors, the Finance Board decided that it was desirable to keep the parameters of ''targeted'' Bank activities like CICA programs and targeted investments consistent. Therefore, in the final rule, the Finance Board as amended the income target provision to cross-reference the CICA regulation.

As indicated, in the realm of targeted lending, the term ''low- or moderate-income households'' refers to households with an income that is at or below 80 percent of the area median income. In order to avoid confusion, the Finance Board has removed the term ''low- or moderate-income households'' and has used instead referred to households having a ''targeted income level,'' a term which is used in the Finance Board's CICA regulation. *See* 12 CFR 952.3. By cross-referencing this definition in the CICA regulation, the agency has effectively modified the income targets that were set forth in proposed § 940.3(a)(5)(i) by tightening the requirement from 115 to 100 percent of area median income for urban households. The target remains at 115 percent of area median income for rural households.

As proposed, only ''non-securitized'' debt and equity investments could have qualified as CMA under § 940.3(e). However, this provision has been revised in the final rule to include targeted MBS and ABS as CMA under this section where the requirements of § 940.3(e)(2) (described above) have been met. In the proposed rule, the Finance Board requested comment on appropriate rule language that might allow for MBS and ABS that substantially contribute to opening an underserved market to qualify as CMA, while continuing to exclude securities that, while they may be backed by loans that could qualify as ''targeted,'' actually trade in a well established and liquid market.

While two commenters provided the Finance Board with suggestions regarding income targets for loans backing securitized targeted CMA investments, these comments did not address the Finance Board's concern regarding the market in which the securities trade. The income requirements for MBS and ABS are the same as those for non-securitized assets.

Upon consideration of the issue, the Finance Board decided that MBS and ABS that are backed by mortgages or other assets that meet the targeting requirements, and the purchase of which would substantially contribute to expanding liquidity for loans that would not otherwise be adequately provided by the private sector and that do not have a readily available or well-established secondary market should be deemed to be CMA. MBS or ABS where less than half of the dollar amount of the assets underlying each of the securities meet the targeting requirements of this provision would not be considered to primarily benefit targeted areas or households with a targeted income level as required under § 940.3(e)(1).

The Banks are encouraged to invest in MBS and ABS backed by assets consisting of whole loans and loan participations that address financially underserved income-targeted households or area-targeted markets identified by a Bank. Currently, there are a number of financing opportunities where the secondary market is not fully developed and the Banks' involvement could facilitate the growth and liquidity of loans provided to underserved markets. There are many such types of MBS and ABS where the majority of the underlying assets are composed of loans for households with targeted incomes or loans in targeted areas, for example: Single-family home purchase mortgages that do not meet the underwriting standards of the secondary market Government Sponsored Enterprises (GSEs); mortgages on owner-occupied two- to four-unit homes; home equity conversion (reverse) mortgages; single-family rehabilitation or combination acquisition/rehabilitation loans; home purchase loans for households with incomes less than 80 percent of area median income in areas where GSE purchases are less than the proportion of loans made to such households in those areas; loans of less than $3 million for the acquisition, construction or rehabilitation of small multifamily buildings; homeowner and rental property loans on tribal lands; community facility and economic development loans in low-income census tracts or rural areas; and economic development and housing loans originated by nonprofit organizations.

Many commenters mentioned specific programs, agencies, non-profit organizations and other projects and investments and requested confirmation by the Finance Board that each was a type of targeted investment that could qualify as CMA under § 940.3(e). The elements to be considered under that section can in some cases be known only with respect to a specific investment. While it is impossible to list every type of investment that might qualify as CMA under § 940.3(e), there are several types of investment that would clearly qualify as CMA in most circumstances, such as investments in: Community Development Venture Capital Funds; SBIC ''fund-of-funds''; and equity investments in governmentally-aided economic

development entities structured similarly to SBICs, where the investment primarily benefits low- or moderate-income individuals or areas.

Section 940.3(e)(3) of the rule (§ 940.3(a)(5)(ii) in the proposed rule) requires that, to qualify as CMA, an otherwise qualifying targeted investment by a Bank must involve one or more members or housing associates in a manner, financial or otherwise, and to a degree to be determined by the Bank. One commenter opposed any requirement that, to qualify as CMA, a targeted investment must have the direct financial involvement of one or more members or housing associates and recommended that the rule permit a range of involvement from sponsorship through financial participation. Section 940.3(e)(3) does not require direct financial participation on the part of the member or housing associate and, in fact, clearly allows the Bank itself to determine the extent and nature of its involvement with its member or housing associate. Accordingly, the Finance Board believes that, as worded, the rule allows for levels of member or housing associate involvement from sponsorship through financial participation.

5. SBIC Investments—§ 940.3(g)

Under § 940.3(g) of the final rule, SBIC debentures, the short-term tranche of SBIC securities and other debentures guaranteed by the Small Business Administration (SBA) under Title III of the Small Business Act of 1958 are considered to be CMA. Under the proposed rule, this provision (which appeared at § 940.3(a)(7)) would have defined only the short-term tranche of SBIC securities as CMA. Two commenters (a Bank and the SBA) asked the Finance Board to broaden the provision to include all securities insured by the SBA under Title III of the Small Business Act, in order to provide needed funding for SBICs and to accommodate new programs that the Bank and the SBA are pursuing. In the final rule, the Finance Board has expanded the provision to encompass the investments that the Bank has proposed to make and other similar SBA-guaranteed debt investments. SBIC-related equity investments would not count as CMA under this provision, but could qualify under § 940.3(f).

B. Acquired Member Assets—Part 955

Part 955 of the final rule addresses AMA—that is, whole loans and certain interests in whole loans that a Bank may acquire from or through its members or housing associates in a transaction that is in purpose and economic substance functionally equivalent to the business of making advances in that: (1) It allows the member or housing associate to use its eligible assets to access liquidity for further mission-related lending; and (2) all, or a material portion of, the credit risk attached to the assets is being borne by the member or housing associate.

1. Three-Part Test—§ 955.2

Section 955.2 of the final rule sets forth a three-part test for determining whether an asset may qualify as AMA. As adopted, it is substantially similar the proposal, except for one change relating to state or local housing finance agency (HFA) bonds. This section provides that AMA must be: (a) Whole loans or certain interests in whole loans; (b) originated or held for a valid business purpose by a member or housing associate, and acquired from a member, housing associate, or another Bank; and (c) structured such that a member or housing associate is responsible for a significant portion of the credit risk of the investment and otherwise in compliance with § 955.3.

Two commenters opposed the requirement of proposed § 955.2(a)(1)(i) prohibiting the purchase of single-family mortgages where the loan amount exceeds the conforming loan limits established for Fannie Mae and Freddie Mac. *See* 12 U.S.C. 1717(b)(2). One commenter noted that this limitation would prevent the Bank from fully serving its mission. The second commenter requested relief from the loan limit specifically for ''Difficult Development Areas,'' where housing costs are a significant burden relative to other areas in the region.

The Finance Board considered these comments and decided to maintain the prohibition on the purchase of single-family mortgages where the loan amount exceeds the conforming loan limit. This provision is intended to prohibit the acquisition of ''jumbo'' loans. Additionally, the Finance Board's intent is to create a level playing field among the Banks, Fannie Mae and Freddie Mac with respect to the types of loans eligible for purchase.

At the request of one commenter, the Finance Board here clarifies that, under § 955.2(a)(1), a Bank may acquire certificates representing interests in whole loans as AMA only if: (1) The certificates are rated by an NRSRO to meet the credit enhancement requirement of § 955.3; (2) the certificates are issued following the execution of, and for the purpose of implementing an agreement between and initiated by the Bank and a Bank System member or housing associate to share risks in compliance with the requirements of § 955.3(b); and (3) the initiating Bank or Banks acquire substantially all of the certificates. It is the Finance Board's view that, in such a case, the use of a third party to securitize the whole loans would merely represent a vehicle to invest in certain types of AMA under more favorable terms and should therefore be permitted under the rule. However, if the certificates have been created as a security initially available to investors generally, they will not be considered to qualify as ''whole loans'' under § 955.2(a)(1).

Three commenters addressed the requirements of § 955.2, as applied to the acquisition of HFA bonds. All of the commenters were opposed to the proposed rule's treatment of HFA bonds to varying degrees. Of primary concern was the ''member or housing associate nexus'' requirement set forth in § 955.2(b). The commenters were generally more concerned with whether HFA bonds could qualify as CMA under § 940.3, than with the status of such bonds under the AMA provisions of part 955.

One commenter stated that HFA bonds should qualify as CMA whether or not the Bank purchased the bond from an housing associate of the Bank, or was granted permission by another Bank to purchase such bonds in its district. The commenter believes that this restriction has the potential to increase interest rates on taxable securities issued by HFAs by decreasing the competition for purchase of such securities. The commenter further noted that some Banks may be unwilling to grant permission to deal with HFAs in their district and, even where Banks are so willing, the cost of crafting a transaction would be onerous and unnecessary.

Another commenter noted that constraining the Banks to acquire HFA bonds from out-of-district housing associates only if the Bank has an agreement with the housing associate's District Bank granting permission to make such an acquisition is inappropriate and could cause transactions with housing associates to take place at non-market-clearing prices. The final commenter noted that costs and time would be reduced and HFAs would be able to access a pool of funds to provide low-interest loans for affordable housing if HFAs could privately place bonds, using the agencies' investment grade stand alone rating. The commenter further stated that it would be helpful if the rule would provide a clear description of the criteria applicable to HFAs to engage in selling bonds to Banks, in joint lending

arrangements, in shared risk and credit enhancement programs for affordable housing properties, and in programs with member banks and through Banks directly.

The Finance Board considered the comments received and has, for HFA bonds only, modified the requirement that the bonds may be acquired from out-of-district housing associates only with the permission of the Bank in whose district the HFA is located (local Bank). Instead the final rule requires that the HFA first give the local Bank a right-of-first-refusal to purchase, or negotiate the terms of, a particular bond issue. If the local Bank refuses, or does not respond within three days, the HFA may then offer the bonds to an out-of-district Bank. This has been done in order to preserve the integrity of the Bank Districts, while at the same time preventing any one Bank from denying an HFA in its District financing that another Bank is willing to provide.

At any rate, under final § § 956.2(f) and 956.3(a)(4)(iii) Banks retain their existing authority to invest in AA-rated HFA bonds regardless of the District in which the issuer is located. However, HFA bonds that are acquired under Part 956 only and that do not meet the AMA requirements of § 955.2 do not qualify as CMA.

2. Required AMA Credit Risk-Sharing Structure—§ 955.3

Section 955.3 elaborates upon the credit risk-sharing requirement that is the third part of the AMA test set forth in § 955.2. The risk-sharing requirements of § 955.3 are based on risk-sharing structures that have evolved during the three-and-one-half years that the AMA pilots have been in operation. Though somewhat detailed, the credit risk-sharing requirements of § 955.3 are intended to produce a simple result: a recourse model for capital markets participation in the mortgage business that overcomes the traditional problems with the capital treatment on recourse transactions for financial institutions and results in a reasonable capital charge for the participating member or housing associate.

Although the credit risk of mortgage loans is typically low, it is still important to find the most economical way to manage that risk. The Finance Board believes that the recourse model, under which the seller of a mortgage retains all or part of the credit risk, is a more economically efficient system for bringing the benefits of the capital markets to the mortgage industry. Under the recourse model, entities that underwrite the loans benefit from good underwriting and therefore are economically disciplined to reduce credit risk. In contrast to the insurance-based secondary market model, under which Fannie Mae and Freddie Mac are paid a premium to insure against credit losses, the recourse model allows an originator to take on more credit risk (so long as that risk is adequately capitalized) and to profit from successful management of that credit risk. Thus, credit risk is dispersed among the many potential originators in the Bank System, and even further dispersed through the permitted insurance and credit derivative structures.

Section 955.3 differs from the proposed rule in several respects. These changes generally provide additional clarification and do not represent a change in the Finance Board's intent regarding AMA activities. In some sections additional requirements have been specified to ensure safe and sound operations.

In general, § 955.3 enables the Bank and the member to take best advantage of their core competencies by: (1) Requiring the member to bear most of the economic cost and the management burden associated with lowering the credit risk of AMA assets to levels comparable with investment grade rates securities; thus (2) leaving the Bank with AMA assets that have a risk profile similar to the securities that have historically been a normal part of Bank operations.

Under § 955.3(a), a Bank is required to determine, for each AMA product, the total credit enhancement needed to enhance an AMA asset or pool of assets to a credit quality that is equivalent to that of an instrument having at least the fourth highest credit rating from an NRSRO, or the credit enhancement associated with such other rating equivalent above the lowest investment grade that the Bank may choose. It further requires that the determination be made using a methodology that is confirmed in writing by an NRSRO to be comparable to a methodology that the NRSRO would use in determining credit enhancement levels when conducting a rating review of the asset or pool of assets in a securitization transaction. In addition, this determination must be made at the earlier of 270 days from the date of the Bank's acquisition of the first loan in a pool, or the date at which the amount of a pool's assets reaches $100 million.

The portion of § 955.3(a) regarding the confirmation by NRSROs combines § § 955.3(a)(1)(ii) and 955.3(a)(2) of the proposed rule. The NRSRO's confirmation of the method used to determine the required credit enhancement ensures that the Bank's estimates of credit ratings are reasonably accurate. However, the Finance Board acknowledges that an NRSRO conducting a formal rating of an asset or pool of assets may take into account qualitative factors that may not be considered by a theoretical model. Hence, the estimate of the credit enhancement requirement by a Bank would not be required to be identical to that determined by an NRSRO, but should produce roughly the equivalent rating, or equivalent ratings on average, to a formal rating review of the assets or pools of assets.

The NRSRO confirmations required by this part help ensure that AMA assets have risk and return characteristics that are more transparent, because of their similarity to rated instruments, than if the Banks simply accepted assets with unspecified levels of credit risk, or with credit risk measures that did not map to publicly available rating categories. Finance Board discussions with NRSROs indicate that it will be possible to obtain confirmations that give the Finance Board reasonable assurance regarding the soundness of the approach used to estimate the credit risk of AMA assets.

By specifying that the credit enhancement requirement be determined at the earlier of 270 days from the date of the Bank's acquisition of the first loan in a pool, or the date at which the amount of a pool's assets reaches $100 million, the rule ensures that large volumes of AMA assets cannot be acquired without a determination of their credit quality. This requirement did not appear in the proposed rule and was added to address the safety and soundness concerns that could arise if the credit enhancement determination were not performed on large pools that were formed over extended periods of time. However, the specified period in which the determination may be made still allows Banks latitude to assemble AMA assets in sufficient quantity to achieve and measure the benefit of diversification.

The rule no longer includes the text of proposed § 955.3(a)(1)(i), which specifically required the Bank to determine, at the time of acquisition of member assets, the expected credit losses on the asset or pool of assets using a method confirmed by a NRSRO. However, this determination likely still must be made to comply with § 955.3(b)(2)(ii), regarding the member's incentive to reduce actual credit losses.

Seven comments were received regarding the impact of geographic concentration and pool size on the calculation of the credit risk

requirement and the resulting impact on small originators. These two diversification factors are taken into account by the NRSROs and the credit rating software that would be used to comply with § 955.3(a). Such software is likely to indicate substantially higher credit enhancement requirements for loan pools provided by smaller originators because the marketplace for such originators does not allow them to produce large numbers of geographically dispersed loans. The commenters proposed that the portion of credit enhancement requirements attributable to the lack of diversification not be included in determining compliance with § 955.3(a) for small members because such members could incur higher capital charges from the significantly higher credit enhancement requirements.

The Finance Board believes that such an approach would be detrimental to the safety and soundness of the acquiring Bank because the credit risk associated with the lack of diversification is a real risk that must be accounted for and managed. However, the Banks are not precluded from proposing a credit enhancement structure that appropriately manages the risk associated with the two diversification factors as confirmed by an NRSRO. In addition, 955.3(b)(1)(iii) of this rule now includes a provision allowing a narrow form of pool insurance, discussed more fully below, as one means for the Banks to address this issue.

A comment was also received advocating that § 955.3(a) should allow the recalculation of the amount of the credit enhancement on AMA pools some period of time after the establishment of the pool for the purpose of reducing the amount if such a reduction were found to be appropriate. The rule does not restrict the Bank from performing such recalculation. However, the timing of recalculations and any actions taken by the Bank to apply such new estimates of credit enhancements must be deemed appropriate, *a priori*, in writing, by an NRSRO.

Under § 955.3(b) of the final rule, the member must provide an enhancement to the credit quality of the prospective AMA asset that is sufficient to raise the credit quality of the asset to be comparable with a rated investment grade instrument. The final rule is similar to the provisions of § 955.3(b)(2) of the proposed rule that address the total amount of the credit enhancement. Under final § 955.3(b), the member must provide and bear the economic cost of the required amount of the credit enhancement. The amount of the credit enhancement must cover losses from the first dollar up to at least the coverage of an equivalent rated investment grade instrument and must be designed to extend for the life of the asset or pool of assets. The requirement that the amount of the credit enhancement extend for the life of the asset or pool of assets is intended to exclude, for example, structures that would comply with the credit rating requirement in the first year, but would then scale back the amount of the member's credit enhancement enough in future years so that the pool no longer meets the credit rating requirement. Furthermore, although the Bank may provide loan loss reserves for AMA assets, unless it can be demonstrated that, in substance, the economic cost of such reserves is borne by the member, such reserves would not be included in the credit enhancement for the purpose of determining compliance with this section. However, Bank reserves can be included in calculating the risk-based capital requirement associated with the asset.

Section 955.3(b) does not specify the form of the credit enhancement, only that it must be provided by the member subject to some limitations. By allowing flexibility in the form of the credit enhancement structure, the Banks can pursue alternative structures that meet member needs while providing the best overall return on the AMA activity.

Specifically, § 955.3(b)(1)(i) has been added to the final rule to authorize an insurance affiliate of the member to hold a portion of the credit enhancement obligation, to accommodate corporate structures common to some members that allow the credit enhancement obligation to be held by an entity that incurs a lower capital charge than the member. Also, § 955.3(b)(1)(ii), which replaces § 955.3(b)(ii)(2)(B)(3) of the proposed rule, allows loan-level insurance as a part of the credit enhancement but requires that the insurer be rated not lower than the second highest rating category. However, both of these insurance provisions are subject to the same limitation, which is contained in both §§ 955.3(b)(1)(i) and 955.3(b)(1)(ii)(B). The limitation requires that any insurance, regardless of the source, only absorb losses that remain after the member has economically absorbed all losses associated with the economic incentives described in § 955.3(b)(2). This limitation was added to ensure that members retain an ongoing economic interest in the actual credit losses of the asset even though much of the overall exposure to credit losses might be covered through an insurance arrangement.

Section 955.3(b)(1)(iii)(A) allows pool-level insurance as part of the credit enhancement subject to two limitations. This provision was added to the rule to permit a member to help offset the very high credit enhancement requirements that may be incurred by members that are unable to produce asset pools with sufficient pool size and geographic diversity. However, pool insurance may be used for the sole purpose of allowing groups of members, that would otherwise have to manage financially impractical credit enhancement requirements arising from a lack of diversification, to offset only that portion of the requirement that arises from a lack of diversification. Section 955.3(b)(1)(iii)(B) further requires that such pool insurance must only cover loss exposure that arises after all other credit support structures have been exhausted.

Section 955.3(b)(1)(iv) incorporates and clarifies § 955.3(b)(2)(ii)(B)(*2*) of the proposed rule by allowing a member to contract with another member or housing associate in the Bank's district or in another Bank's district, pursuant to an arrangement with that Bank, to provide a contractual enhancement or undertaking against losses to the Bank in return for some compensation.

Section 955.3(b)(2) of the final rule has been revised from proposed § 955.3(b)(2)(i) and (ii) regarding the member's incentive to reduce actual credit losses. Taken together, § 955.3(b)(2)(i) and (ii) provide that the member must bear the direct economic consequences of actual credit losses in an amount at least equal to expected losses and positioned in the credit enhancement structure no later than immediately after expected losses (and also before any loan-level or pool insurance, as required by §§ 955.3(b)(1)(ii)(B) and (iii)(B)). This design requirement for the credit enhancement structure is intended to ensure that the member retains an economic incentive to reduce actual losses that is both material in amount and early enough in the structure to be meaningful to the member.

''Expected losses'' are defined in § 955.1 as losses on the underlying assets expected under prevailing economic conditions—*i.e.,* the base loss scenario—as estimated at the time the credit enhancement requirement was determined under § 955.3(a). Expected losses may be calculated as the mean of the losses associated with economic conditions represented by the sixth ratings category (*e.g.* single-B)

determined by computer rating models that map to NRSRO ratings.

Recognizing that advantages exist under each structure, the Finance Board is giving the Banks the flexibility to offer products or programs under either of the structures. However, any combination that removes the incentive to reduce actual credit losses is prohibited.

The economic responsibility of the expected credit losses may be borne by the member or housing associate in a variety of ways. For instance, under the product developed by the Federal Home Loan Bank of Chicago known as MPF 100®, a Bank establishes an account to absorb credit losses. As the Bank incurs losses, it is reimbursed by the member through the reduction of credit enhancement fees paid to the member by the Bank. Essentially, the fees paid to the member are contingent upon the performance of the asset.

The Finance Board has determined that the amount represented by expected credit losses is typically of sufficient size that members or housing associates, when responsible for such losses, have incentive to seek ways to achieve better than expected performance. In the case of acquiring mortgage loans, by requiring that the member or housing associate bear direct economic responsibility for such an amount, position early in the structure, a system of risk and reward is established that is based on the core competencies of the participating institutions. Since member financial institutions are most knowledgeable regarding their local housing markets, this structure allows members the opportunity to benefit from their expertise in underwriting mortgage loans in their communities. The credit risk sharing structure is based on the concept that different institutions have different capacities. The Banks are capital market specialists, with the ability to bear market risks well, while depository institutions are experts in credit risk evaluation since they know their communities best. Therefore, by establishing a structure where the member or housing associate from which the Bank acquired the asset or pool of assets bears economic responsibility for the amount of the expected credit losses, members or housing associates are rewarded for their credit risk management expertise.

Regardless of how credit loss coverage is allocated, the economic cost of expected credit losses must be borne by the member or housing associate from which the Bank acquired the asset or pool of assets. In the case of an FHA-insured loan, the loan would meet the risk-sharing requirements since it is insured by the government; however, the member or housing associate would have to bear the economic responsibility of all unreimbursed servicing expenses, up to the amount of expected losses on the loan or loan pool. In the case of HFA bonds, the Banks are only permitted to purchase bonds that have been assigned a credit rating of at least investment grade, and that rating cannot be achieved unless the housing associate selling the bonds has somehow credit enhanced the underlying loans in an amount sufficient to earn the credit rating. In particular, HFA bonds are usually rated in at least the third highest credit rating category based on the fact that the bonds are backed by FHA-insured, VA-guaranteed or private mortgage insurance (PMI)-insured whole loans. In many cases the bonds are backed by loans securitized by the Government National Mortgage Association (Ginnie Mae), Fannie Mae or Freddie Mac and are rated in the highest credit rating category. Additional bondholder protections frequently include mortgage reserve funds.

Section 955.3(b)(3) of the final rule adds a provision requiring the member's credit enhancement obligation to be fully secured. This provision was added to address the concern that the Bank might be exposed to credit risk if the member were not able to comply with its contractual credit enhancement obligation. This provision requires that the member's credit enhancement obligation must be secured in parallel with the requirement for advances to members under part 950.

Section 955.3(b)(4) requires the Bank to obtain written confirmation from an NRSRO regarding the sufficiency of the credit enhancement. This section generally expands and clarifies § 955.3(b) of the proposed rule. The rule clarifies that the confirmation must be satisfactory to the Finance Board and must be based on the underlying economic terms of the credit enhancement structure as represented by the Bank for each AMA product. This confirmation may be provided in two forms. Section 955.3(b)(4)(i) allows the NRSRO to verify that the level of credit enhancement provided by the member or housing associate is generally sufficient to enhance the asset or pool of assets to a credit quality that is equivalent to that of an instrument having the fourth highest credit rating from an NRSRO, or such higher rating as the Bank may require. In this case the NRSRO is, in essence, describing the value of the credit enhancement structure hypothetically for the purpose of determining a credit rating.

Section 955.3(b)(4)(ii) allows that the NRSRO may confirm that the methodology used by the Bank for estimating the level of credit enhancement provided by the member or housing associate is in accordance with the practices established by the NRSRO. In this approach the NRSRO does not provide the value of the credit enhancement but rather indicates whether the Bank is estimating the value of the credit enhancement structure in a way that is comparable to the methodology used by the NRSRO in determining the sufficiency of credit enhancements.

Section 955.3(c), regarding the timing of NRSRO confirmations, was added to the rule to ensure that the confirmations are received on a timely basis for already-established programs. It requires that ongoing AMA programs shall acquire these confirmations within 90 days of the effective date of this rule. This provision was added because established AMA programs have acquired large portfolios even as of the date of the proposed rule.

Two comments were received advocating that certain mortgage financing instruments, if backed by member loans, should be included within the general definition of AMA assets. One of the comments specifically discussed securitized structures in which the Bank would acquire an investment grade senior portion and the member would retain the credit support tranches necessary to support the investment grade tranches. A Bank would not be in compliance with part 955 if it the transaction were merely a capital markets purchase of senior tranches resulting from securitizations of this type. However, it is expected that such structures would meet the requirements of part 955 if the structure were implemented through a Bank's AMA program using assets that conform with the AMA requirements that were previously held by the member for a valid business purpose. In this regard, the structure contemplated by the comment is similar to a ''sequential'' loan participation program previously approved by the Finance Board. The fact that such a structure might include rated subordinate credit tranches would not constitute non-compliance with part 955 as long as the structure were arranged cooperatively with the Bank and the member bore the risk of holding or selling the credit support tranches.

Six comments were received advocating a provision in part 955 that would give members participating in AMA programs the ability to transfer

credit enhancement obligations and the servicing of AMA loans to other members in the same or other Bank districts. The final rule does not explicitly address, nor does it restrict, such transfers, though they may only be undertaken with the concurrence of the Bank of which the transferee is a member. In addition, such transfers must be accompanied by a similar undertaking by the transferee of the incentive requirements in § 955.3(b)(2). Finally, the credit enhancement obligations must be secured according to the same requirements that apply to advances pursuant to part 950.

3. AMA Reporting Requirements—§ 955.4

A total of 24 comment letters were received regarding the AMA reporting requirements set forth in § 955.4 of the rule, and in appendices A and B to part 955. Eighteen of the comments, while not opposed to reporting requirements in general, were opposed to certain aspects of the requirements. Six commenters supported all of the reporting requirements.

In general, the commenters that stated some opposition to the reporting requirements were most concerned with the burden of requiring data elements in addition to those already required by the Department of Housing and Urban and Development (HUD) and Office of Federal Housing Enterprise Office (OFHEO) of Fannie Mae and Freddie Mac. The commenters noted that any data elements in excess of what was already required of members selling loans to Fannie Mae and Freddie Mac would require expensive computer programming and procedural changes. It was further noted that any such changes required to be made to members' systems would make AMA programs less attractive in the marketplace. Some commenters also objected to the lack of a transition period within which the Banks would be required to begin reporting to the Finance Board.

Some commenters were supportive of the reporting requirements in the proposal. These commenters generally were in favor of collecting of ''prepayment penalty'' data on single-family mortgages, noting that predatory lending is a problem in the U.S. and the collection of prepayment penalty data will help prevent the Banks from engaging in anti-borrower activities. One commenter stated that the data elements submitted by the Banks to the Finance Board should be made publicly available and that the Finance Board should consider mandating reporting requirements on all CMA activities. Another commenter supporting the reporting requirements suggested additional data elements to be collected.

The Finance Board has considered the comments received regarding reporting requirements and has made a number of revisions to the final rule in response. In the proposed rule, the Finance Board based its list of data elements on HUD's and OFHEO's requirements of Fannie Mae and Freddie Mac. In addition to the data elements required by HUD and OFHEO for single-family and multifamily mortgage loans, the Finance Board included a total of ten additional data elements to the two lists. Six of these data elements, ''originating lender institution,'' ''originating lender city'' and ''originating lender state'' for both single-family and multifamily acquisitions, are not regularly reported to Fannie Mae and Freddie Mac by financial institutions selling loans. Given the comments received, the Finance Board has decided it would be too burdensome to require the members to provide this data to the Banks and has eliminated these data elements from both the single-family and multifamily data element lists in the rule (Appendices A and B). The Finance Board's original intent was to use this information to monitor compliance with the valid business purpose requirement set forth in § 955.2(b)(1)(ii). The Finance Board has determined that the cost burden on members and housing associates would exceed the benefits of collecting such data on a System-wide and regular basis.

The additional four items not reported to HUD or OFHEO include, ''front-end ratio,'' ''back-end ratio,'' ''self-employment indicator,'' and ''prepayment penalties.'' Although not reported to either HUD or OFHEO, financial institutions selling loans to Fannie Mae and Freddie Mac currently report front-end ratio, back-end ratio, and self-employment indicator to the GSEs. The prepayment penalties data element is currently reported by Fannie Mae and Freddie Mac to OFHEO for multifamily loans. Although not reported by Fannie Mae and Freddie Mac for single-family loans, prepayment penalties for single-family loans have become more prevalent in the marketplace.

Upon consideration, the Finance Board has determined that the collection of the four above-mentioned data elements does not cause undue burden on members and is necessary to evaluate the risk of the loans acquired under AMA programs. Therefore, these four items will remain on the list of required data elements for reporting purposes.

The Finance Board has added three data elements to the single-family and multifamily lists published in the proposed rules. These items are ''owner-occupied'' on the single-family list and ''construction loan'' and ''total number of units'' on the multifamily list. All three of these data elements are reported by Fannie Mae and Freddie Mac to HUD, but were inadvertently omitted from the proposed rule.

In addition to the changes made to the data elements by the Finance Board, the Finance Board has specified in the final rule the date on which Banks must begin to collect and report information to the Finance Board. The Banks must begin collecting from their members the required information on loans acquired as of January 1, 2001. By allowing this transition period, the Finance Board is providing the Banks ample time to design and implement the systems necessary for this type of data collection. The first mortgage report the Banks must submit to the Finance Board will be due no later than May 31, 2001, which is 60 days after the end of the first quarter.

4. Risk-Based Capital Requirements for AMA—§ 955.6

Section 955.6(a) of the rule sets forth capital requirements for AMA that shall apply until the Finance Board's new capital rule is finalized later in 2000. In the proposed rule, the provision would have required each Bank to hold retained earnings plus specific loan loss reserves as support for the credit risk of all AMA estimated by the Bank to be below the second highest credit rating, in an amount equal to or greater than: the outstanding balance of the assets or pools of assets times a factor associated with the credit rating of the assets or pools of assets as determined by the Finance Board. In the final rule, the reference to specific loan loss has been changed to refer to ''general'' loan loss reserves, as was originally intended and a table has been added setting forth the factors applying to single-family AMA.

The Finance Board received three comments regarding the proposed risk-based capital requirement, all of which were opposed in varying degrees to the provision. One of the comments noted that the proposed rule, because it stated that the amount of retained earnings the Banks would be required to hold would be ''as determined by the Finance Board,'' provided little real guidance and made it difficult for the Banks to comply in an effective manner. Another commenter suggested that the Finance Board's risk-based capital requirements were overly complex since they were included in separate regulations. The

commenter further noted that loan-loss reserves established under GAAP should be deducted from risk-based capital.

After considering the comments, the Finance Board has included in final § 955.6(a) a table stipulating the percentage applicable to the on-balance sheet equivalent value of single-family AMA rated below the second highest rating category. The percentages included in the table for the third through sixth categories take into account the difference, in a sample of AMA assets, between the credit enhancement requirement for these grades and the second highest investment grade with a base requirement of 100 percent for pools below the sixth highest investment grade. The sample of AMA assets used to produce these percentages is thought to be representative of the general level of credit risk in AMA. The percentage in the table for AMA with credit quality below the sixth national grade coincides with the requirement that all AMA have credit quality estimated to be equal to or better than similar investment grade instruments. The Finance Board may adjust this requirement going forward if there is information indicating that higher or lower percentages are necessary.

The percentages in table differ from those set forth in the table for single-family mortgage loans contained in the proposed capital regulation. At this time, while the Bank System is still largely subject to the restrictive safety and soundness parameters of the FMP, the Banks will not be required to hold capital against AMA that have a putative rating (calculated in accordance with the requirements of § 955.3) in the second highest credit rating category or higher. Correspondingly, the factors listed for AMA having a rating below the second highest credit rating category are intended to result in a Bank's entire AMA portfolio having the same risk of uncapitalized loss as an instrument rated in at least the second highest credit rating category. Thus, the interim risk-based capital requirement for AMA has been calibrated to be consistent with the risk management regime now in place under the FMP. Once the Finance Board's new capital regulations are in place, banks will need to hold risk based capital against all assets, including those rated in the second highest category or higher, but in amounts determined on a different basis than that reflected in § 955.6(a).

The Finance Board also modified the provision for risk-based capital requirements for AMA by adding § 955.6(b), which requires that, for risk-based capital purposes, each Bank shall recalculate the estimated credit rating of a pool of AMA if there is evidence that a decline in the credit quality of the may have occurred. This provision was added to ensure that any downgrade in credit status of a pool would be reflected in the risk-based capital charge.

5. Removal of Pilot Status of AMA Programs

A total of 13 comments were received regarding the pilot status of the AMA programs. Eleven commenters were in favor of removing the pilot status and two commenters were opposed.

In general, the commenters in favor of converting the AMA programs from pilot to permanent status noted the success of the current MPF program in terms of Bank and member cooperation, allocation of risk, and safety and soundness. It was noted that the AMA cap of $9 billion needed to be lifted so that AMA programs could provide further benefits to members and consumers. It was also noted that pilot status of the AMA program creates unnecessary concern and uncertainty about the Banks' ability to fulfill its obligations.

Two commenters opposed the removal of the pilot status on AMA programs. One commenter noted that the Finance Board should defer any action on the cap until the changes to the Banks' capital structures mandated by the Modernization Act are put into place. The second commenter noted that the cap on AMA programs should not be removed since the performance of the MPF program has not been fully evaluated.

The Finance Board considered the comments received on the removal of the pilot status of these programs and determined that existing AMA programs had, in their pilots stages, proved to be a safe and sound investment for the Banks, as well as a valuable, alternative means for its members and housing associates to sell loans to the secondary market. Accordingly, the Finance Board finds it appropriate to authorize AMA programs on a permanent basis and to ensure the safety and soundness of these programs through appropriate risk-based capital, collateral and credit-risk sharing requirements, as well as through thorough supervisory examinations.

6. Effect of New Business Activities Requirement of Part 980 on AMA

Section 955.2 of the rule makes all Bank AMA activities subject to the ''new business activity'' requirements of part 980 of the Finance Board's regulations. Part 980 is being finalized as part of the Finance Board's rule on advances collateral, which was approved at the Board of Directors meeting of June 29, 2000. Thereunder, Banks are required to provide 60 days notice to the Finance Board before undertaking any new business activity (defined in § 980.1). To the extent that an AMA transaction involves acquisition of a new class of asset, new types of risk or risk structures, or new types of operations, Banks will need to follow the notice procedures set out in part 980 before proceeding. It is anticipated that new AMA products will almost always be new business activities for purposes of part 980. In addition, new classes of transactions engaged in under existing AMA programs may also be new business activities, and thus subject to part 980, if they expose the Bank to new loans types, risks, or operations.

The Finance Board received eight comments on the 60-day approval period for new business activities. All commenters found the approval period was to be lengthy and thought it would hinder product innovation and development. However, the Finance Board believes that this requirement is most needed as a safety and soundness measure where, as with AMA, the Banks will be taking part in transactions with which they have little past experience.

7. Predatory Lending

On June 20, 2000, HUD and the Department of Treasury released a report entitled ''Curbing Predatory Home Mortgage Lending—A Joint Report'' that describes the damaging impact predatory lending practices have on individuals and whole neighborhoods. Predatory lending practices include loan flipping (refinancing borrowers' loans repeatedly in a short period of time), excessive fees, financing single premium credit life insurance products in the mortgage, lending without regard to the borrower's ability to repay, and outright fraud.

The report included recommendations for actions that the Finance Board, working to assure consistency with any requirements that HUD will impose on Fannie Mae and Freddie Mac, could apply to the Federal Home Loan Banks to help end predatory lending. Specifically, the Finance Board could prohibit purchases of high cost mortgages with excessive fees, prepayment penalties (except in circumstances that benefit the borrower, where the terms are fully disclosed, and alternative options are offered), and prepaid single-premium credit life insurance products, as well as

mortgages from a seller/servicer that fails to document monthly that it is submitting payment information to a credit bureau.

Six commenters to the proposed rule recommended that the Finance Board consider prohibitions on the purchase or funding of predatory loans, or that certain information be added to the reporting requirements for AMA so the Finance Board could determine whether AMA included predatory loans.

On June 26, 2000, the Federal Home Loan Banks of Chicago, Atlanta, Boston, Dallas, Des Moines, Indianapolis, New York, Pittsburgh, and Topeka voluntarily agreed to adopt guidelines pertaining to predatory lending, which will be consistent with the relevant secondary market guidelines. In particular, these guidelines will focus on not purchasing or funding loans through the MPF Program that meet the characteristics of a high cost mortgage under the Home Owners' Equity Protection Act of 1994.

The Finance Board anticipates that in a future rulemaking it, working closely with HUD as it develops regulatory requirements for Fannie Mae and Freddie Mac, will propose for public comment parallel requirements for the AMA and Bank debt investments to assure that they will not include predatory loans or contribute to predatory lending practices.

C. Investments—Part 956

Part 956 of the final rule governs Bank investments. Along with the advances, AMA and standby letter of credit regulations (parts 950, 955 and 961, respectively), part 956 provides the authority necessary for the Banks to carry out several of the core mission activities listed in § 940.3. The final provision remains largely unchanged from the that in the proposed rule. However, three modifications have been made.

First, the investment authorization set forth in § 956.2 has been amended to make explicit that, except for those provisions in the FMP that are directly overridden by this proposed rule, all provisions of the FMP will remain in effect until expressly repealed by the Finance Board. Accordingly, Bank investment in agency and private MBS, CMOs and REMICs and in asset-backed securities secured by manufactured housing or home equity loans would continue to be limited to a total amount equal to 300 percent of a Bank's capital. It is anticipated that the remaining provisions of the FMP will be repealed, or at least codified as regulations, at such time as the Finance Board promulgates a final rule on capital and risk management.

Second, § 956.4(a)(4) has been changed in the final rule so that targeted investments described in § 940.3(e) of the CMA regulation are exempted from the list from the general prohibition on Bank investment in whole loans or interests in loans other than pursuant to the AMA requirements. The omission of this provision from the proposed rule was merely an oversight. Its inclusion ensures that targeted loan purchase programs such as the Federal Home Loan Bank of Atlanta's AMPP will qualify as CMA.

Finally, under proposed § 956.4, the Banks must hold retained earnings plus specific loan loss reserves as support for the credit risk of all investments that are not rated by an NRSRO, or are rated below the second highest credit rating, in an amount equal to or greater than the outstanding balance of the investments times a factor associated with the credit rating of the investments as determined by the Finance Board. The Finance Board has clarified in the final provision that the factor shall be 0.08 for unrated assets. It is expected that this specific § 956.4 will be superceded at the time that a final capital rule is promulgated, to be replaced by specific requirements set forth in the capital regulation relating to each credit rating category.

III. Regulatory Flexibility Act

The final rule applies only to the Banks, which do not come within the meaning of ''small entities,'' as defined in the Regulatory Flexibility Act (RFA). *See* 5 U.S.C. 601(6). Therefore, in accordance with section 605(b) of the RFA, *see id.* at 605(b), the Finance Board hereby certifies that this final rule will not have a significant economic impact on a substantial number of small entities.

IV. Paperwork Reduction Act

In the proposed rule, the Finance Board inadvertently failed to include a notice and request for comment regarding the Paperwork Reduction Act implications of the information collection contained in § 955.4 of the rule, described more fully in part II of the **SUPPLEMENTARY INFORMATION.** That notice and request for comment are being provided here.

The data collected are intended to be used to create a data base and reporting infrastructure for monitoring the Banks' risk management and achievement of the public purpose of the residential mortgage-related AMA programs. Responses are required in order obtain or retain a benefit. The Finance Board will maintain the confidentiality of information obtained from respondents pursuant to the collection of information as required by applicable statute, regulation, and agency policy. Books or records relating to this collection of information must be retained as provided in the regulation.

Likely respondents and/or recordkeepers will be Banks, institutions that are members or housing associates of a Bank and the Finance Board. Potential respondents are not required to respond to the collection of information unless the regulation collecting the information displays a currently valid control number assigned by the OMB. *See* 44 U.S.C. 3512(a).

The estimated annual reporting and recordkeeping hour burden is:

a. Number of respondents: 412.

b. Total annual responses: 1600.

Percentage of these responses collected electronically: 75%.

c. Total annual hours requested: 38,880.

d. Current OMB inventory: n/a.

e. Difference: n/a.

The estimated annual reporting and recordkeeping cost burden is:

a. Total annualized capital/startup costs: $300,000.00.

b. Total annual costs (O&M): 0.

c. Total annualized cost requested: $1,212,297.94.

d. Current OMB inventory: n/a.

e. Difference: n/a.

The Finance Board will accept written comments concerning the accuracy of the burden estimates and suggestions for reducing the burden at the address listed above.

The Finance Board submitted an analysis of the information collection to the Office of Management and Budget (OMB) for review. Subsequent to submitting the analysis to OMB, the Finance Board decided to reduce the level of reporting required in the final rule and, therefore, has reduced the estimated annual reporting and recordkeeping hour and cost burden. OMB assigned a control number, 3069–0058, and temporarily approved the information collection with an expiration date of December 31, 2000. Prior to the expiration of this temporary approval, the Finance Board will again submit the collection of information to OMB for review, with the intent of obtaining a full three-year approval and will publish a final notice regarding the information collection.

Comments regarding the proposed collection of information may be submitted in writing to the Office of Information and Regulatory Affairs of OMB, Attention: Desk Officer for Federal Housing Finance Board,

Washington, D.C. 20503 by September 15, 2000.

List of Subjects in 12 CFR Parts 900, 940, 950, 955 and 956

Community development, Credit, Federal home loan banks, Housing, Reporting and recordkeeping requirements.

Accordingly, the Finance Board hereby amends title 12, chapter IX, Code of Federal Regulations, as follows:

PART 900—GENERAL DEFINITIONS

1. The authority citation for part 900 is revised to read as follows:

Authority: 12 U.S.C. 1422, 1422b(a)(1).

2. Amend § 900.1 by adding, in alphabetical order, definitions of the term ''acquired member assets or AMA'' and ''NRSRO'' to read as follows:

§ 900.1 Definitions applying to all regulations.

* * * * *

Acquired member assets or *AMA* means those assets that may be acquired by a Bank under part 955 of this chapter.

* * * * *

NRSRO means a credit rating organization regarded as a Nationally Recognized Statistical Rating Organization by the Securities and Exchange Commission.

* * * * *

PART 940—CORE MISSION ACTIVITIES

3. The heading for part 940 is revised to read as set forth above.

4. The authority citation for part 940 continues to read as follows:

Authority: 12 U.S.C. 1422a(a)(3), 1422b(a), 1430, 1430b, 1431.

5. In part 940, amend § 940.1 by adding, in alphabetical order, definitions of the terms ''Financial Management Policy (FMP)'', ''low- or moderate-income household'', ''SBIC'', and ''Targeted income level'' to read as follows:

§ 940.1 Definitions.

* * * * *

Financial Management Policy (FMP) has the meaning set forth in § 956.1 of this chapter.

SBIC means a small business investment company formed pursuant to 15 U.S.C. 681(d).

Targeted income level has the meaning set forth in paragraphs (1) and (2) of the definition of ''targeted income level'' in § 952.3 of this chapter.

6. Amend part 940 by adding a new § 940.3, to read as follows:

§ 940.3 Core mission activities.

The following Bank activities qualify as core mission activities:

(a) Advances;

(b) Acquired member assets (AMA), except that United States government-insured or guaranteed whole single-family residential mortgage loans acquired under a commitment entered into after April 12, 2000 shall qualify only in a cumulative dollar amount up to 33 percent of: The cumulative total dollar amount of AMA acquired by a Bank after April 12, 2000, less the cumulative dollar amount of United States government-insured or guaranteed whole single-family residential mortgage loans acquired after April 12, 2000 under commitments entered into on or before April 12, 2000 (which calculation, at the discretion of two or more Banks, may be made based on aggregate transactions among those Banks);

(c) Standby letters of credit;

(d) Intermediary derivative contracts;

(e) Debt or equity investments:

(1) That primarily benefit households having a targeted income level, a significant proportion of which must benefit households with incomes at or below 80 percent of area median income, or areas targeted for redevelopment by local, state, tribal or Federal government (including Federal Empowerment Zones and Enterprise and Champion Communities), by providing or supporting one or more of the following activities:

(i) Housing;

(ii) Economic development;

(iii) Community services;

(iv) Permanent jobs; or

(v) Area revitalization or stabilization;

(2) In the case of mortgage- or asset-backed securities, the acquisition of which would expand liquidity for loans that are not otherwise adequately provided by the private sector and do not have a readily available or well established secondary market; and

(3) That involve one or more members or housing associates in a manner, financial or otherwise, and to a degree to be determined by the Bank;

(f) Investments in SBICs, where one or more members or housing associates of the Bank also make a material investment in the same activity;

(g) SBIC debentures, the short term tranche of SBIC securities, ore other debentures that are guaranteed by the Small Business Administration under title III of the Small Business Investment Act of 1958, as amended (15 U.S.C. 681 *et seq.*);

(h) Section 108 Interim Notes and Participation Certificates guaranteed by the Department of Housing and Urban Development under section 108 of the Housing and Community Development Act of 1974, as amended (42 U.S.C. 5308); and

(i) Investments and obligations issued or guaranteed under the Native American Housing Assistance and Self-Determination Act of 1996 (25 U.S.C. 4101 *et seq.*).

PART 950—ADVANCES

7. The authority citation for part 950 continues to read as follows:

Authority: 12 U.S.C. 1422a(a)(3), 1422b(a)(1), 1426, 1429, 1430, 1430b and 1431.

8. Amend part 950 by adding a new subpart C consisting of § 950.25 to read as follows:

Subpart C—Advances to Out-of-District Members and Housing Associates

§ 950.18 Advances to out-of-district members and housing associates.

(a) *Establishment of creditor/debtor relationship.* Any Bank may become a creditor to a member or housing associate of another Bank through the purchase of an outstanding advance, or a participation interest therein, from the other Bank, or through an arrangement with the other Bank that provides for the establishment of such a creditor/debtor relationship at the time an advance is made.

(b) *Applicability of advances requirements.* Any debtor/creditor relationship established pursuant to paragraph (a) of this section shall be subject to all of the provisions of this part that would apply to an advance made by a Bank to its own members or housing associates.

9. In subchapter G, add a new part 955 to read as follows:

PART 955—ACQUIRED MEMBER ASSETS

Sec.

955.1 Definitions.
955.2 Authorization to hold acquired member assets.
955.3 Required credit-risk sharing structure.
955.4 Reporting requirements for acquired member assets.
955.5 Administrative and investment transactions between Banks.
955.6 Risk-based capital requirement for acquired member assets.
Appendix A to Part 955—Reporting requirements for single-family acquired member assets that are residential mortgages: loan-level data elements

Appendix B to Part 955—Reporting requirements for multi-family acquired member assets that are residential mortgages: loan-level data elements

Authority: 12 U.S.C. 1422a(a)(3), 1422b(a), 1430, 1430b, 1431.

§ 955.1 Definitions.

As used in this section:

Affiliate has the meaning set forth in § 950.1 of this chapter.

Expected losses means the base loss scenario in the methodology of an NRSRO applicable to that type of AMA asset.

Residential real property has the meaning set forth in § 950.1 of this chapter.

State has the meaning set forth in § 925.1 of this chapter.

§ 955.2 Authorization to hold acquired member assets.

Subject to the requirements of part 980 of this chapter, each Bank may hold assets acquired from or through Bank System members or housing associates by means of either a purchase or a funding transaction (AMA), subject to each of the following requirements:

(a) *Loan type requirement.* The assets are either:

(1) Whole loans that are eligible to secure advances under §§ 950.7 (a)(1)(i), (a)(2)(ii), (a)(4), or (b)(1) of this chapter, excluding:

(i) Single-family mortgages where the loan amount exceeds the limits established pursuant to 12 U.S.C. 1717(b)(2); and

(ii) Loans made to an entity, or secured by property, not located in a state;

(2) Whole loans secured by manufactured housing, regardless of whether such housing qualifies as residential real property; or

(3) State and local housing finance agency bonds;

(b) *Member or housing associate nexus requirement.* The assets are:

(1) Either:

(i) Originated or issued by, through, or on behalf of a Bank System member or housing associate, or an affiliate thereof; or

(ii) Held for a valid business purpose by a Bank System member or housing associate, or an affiliate thereof, prior to acquisition by a Bank; and

(2) Acquired either:

(i) From a member or housing associate of the acquiring Bank;

(ii) From a member or housing associate of another Bank, pursuant to an arrangement with that Bank, which, in the case of state and local finance agency bonds only, may be reached in accordance with the following process:

(A) The housing finance agency shall first offer the Bank in whose district the agency is located (local Bank) a right of first refusal to purchase, or negotiate the terms of, its proposed bond offering;

(B) If the local Bank indicates, within a three day period, that it will negotiate in good faith to purchase the bonds, the agency may not offer to sell or negotiate the terms of a purchase with another Bank; and

(C) If the local Bank declines the offer, or has failed to respond within the three day period, the acquiring Bank will be considered to have an arrangement with the local Bank for purposes of this section and may offer to buy or negotiate the terms of a bond sale with the agency;

(iii) From another Bank; and

(c) *Credit risk-sharing requirement.* The transactions through which the Bank acquires the assets either:

(1) Meet the credit risk-sharing requirements of § 955.3 of this part; or

(2) Were authorized by the Finance Board under section II.B.12 of the FMP and are within any total dollar cap established by the Finance Board at the time of such authorization.

§ 955.3 Required credit risk-sharing structure.

(a) *Determination of necessary credit enhancement.* At the earlier of 270 days from the date of the Bank's acquisition of the first loan in a pool, or the date at which the amount of a pool's assets reaches $100 million, a Bank shall determine the total credit enhancement necessary to enhance the asset or pool of assets to a credit quality that is equivalent to that of an instrument having at least the fourth highest credit rating from an NRSRO, or such higher credit rating as the Bank may require. The Bank shall make this determination for each AMA product using a methodology that is confirmed in writing by an NRSRO to be comparable to a methodology that the NRSRO would use in determining credit enhancement levels when conducting a rating review of the asset or pool of assets in a securitization transaction.

(b) *Credit risk-sharing structure.* A Bank acquiring AMA shall implement, and have in place at all times, a credit risk-sharing structure for each AMA product under which a member or housing associate of the Bank or, with the approval of both Banks, a member or housing associate of another Bank, provides a sufficient credit enhancement from the first dollar of credit loss for each asset or pool of assets such that the acquiring Bank's exposure to credit risk for the life of the asset or pool of assets is no greater than that of an asset rated in the fourth highest credit rating category, as determined pursuant to paragraph (a) of this section, or such higher rating as the acquiring Bank may require. This credit enhancement structure shall meet the following requirements:

(1) A portion of the credit enhancement may be provided by:

(i) Contracting with an insurance affiliate of that member or housing associate to provide an enhancement or undertaking against losses to the Bank, but only where such insurance is positioned in the credit enhancement structure so as to cover only losses remaining after the member or housing associate has borne losses as required under paragraph (b)(2) of this section;

(ii) Purchasing loan-level insurance, which may include United States government insurance or guarantee, but only where:

(A) The member or housing associate is legally obligated at all times to maintain such insurance with an insurer rated not lower than the second highest credit rating category; and

(B) Such insurance is positioned in the credit enhancement structure so as to cover only losses remaining after the member or housing associate has borne losses as required under paragraph (b)(2) of this section;

(iii) Purchasing pool-level insurance, but only where such insurance:

(A) Insures that portion of the required credit enhancement attributable to the geographic concentration and size of the pool; and

(B) Is positioned last in the credit enhancement structure so as to cover only those losses remaining after all other elements of the credit enhancement structure have been exhausted; or

(iv) Contracting with another member or housing associate in the Bank's district or in another Bank's district, pursuant to an arrangement with that Bank, to provide an enhancement or undertaking against losses to the Bank in return for some compensation;

(2) The member or housing associate that is providing the credit enhancement required under paragraph (b)(1) of this section shall in all cases bear the direct economic consequences of actual credit losses on the asset or pool of assets:

(i) From the first dollar of loss up to the amount of expected losses; or

(ii) Immediately following expected losses, but in an amount equal to or exceeding the amount of expected losses; and

(3) The portion of the credit enhancement that is an obligation of a

Bank System member or housing associate shall be fully secured;

(4) The Bank shall obtain written verification from an NRSRO that concludes to the satisfaction of the Finance Board, based on the underlying economic terms of the credit enhancement structure as represented by the Bank for each AMA product, that either:

(i) The level of credit enhancement provided by the member or housing associate is generally sufficient to enhance the asset or pool of assets to a credit quality that is equivalent to that of an instrument having the fourth highest credit rating from an NRSRO, or such higher rating as the Bank may require; or

(ii) The methodology used by the Bank for estimating the level of credit enhancement provided by the member or housing associate is in accordance with the practices established by the NRSRO.

(c) *Timing of NRSRO opinions.* For AMA programs already in operation at the time of the effective date of this rule, a Bank shall have 90 days from the effective date of this rule to obtain the NRSRO verifications required under paragraphs (a) and (b)(4) of this section.

§ 955.4 Reporting requirements for acquired member assets.

(a) *Loan-Level Data Elements.* Each Bank that acquires AMA that are residential mortgages shall collect and maintain loan-level data on each mortgage held, as specified in appendix A (for single-family mortgage assets) or appendix B (for multifamily mortgage assets) to this part.

(b) *Quarterly Mortgage Reports.* Beginning with calendar year 2001, within 60 days of the end of every quarter of every calendar year, each Bank that acquires AMA that are residential mortgages shall submit to the Finance Board a Mortgage Report, which shall include:

(1) Aggregations of the loan-level mortgage data compiled by the Bank pursuant to paragraph (a) of this section for year-to-date mortgage acquisitions, in a format specified by the Finance Board;

(2) Year-to-date dollar volume, number of units and number of mortgages on owner-occupied and rental properties relating to AMA acquired by the Bank; and

(3) For the second and fourth quarter Mortgage Reports only, year-to-date loan-level data that:

(i) Comprises the data elements required to be collected and maintained by the Bank under paragraph (a) of this section; and

(ii) Appears in a machine-readable format specified by the Finance Board.

(c) *Additional Reports.* The Finance Board may at any time require a Bank to submit reports in addition to those required under paragraph (b) of this section.

§ 955.5 Administrative and investment transactions between Banks.

(a) *Delegation of administrative duties.* A Bank may delegate the administration of an AMA program to another Bank whose administrative office has been examined and approved by the Finance Board to process AMA transactions. The existence of such a delegation, or the possibility that such a delegation may be made, must be disclosed to any potential participating member or housing associate as part of any AMA-related agreements are signed with that member or housing associate.

(b) *Terminability of Agreements.* Any agreement made between two or more Banks in connection with any AMA program shall be made terminable by either party after a reasonable notice period.

(c) *Delegation of Pricing Authority.* A Bank that has delegated its AMA pricing function to another Bank shall retain a right to refuse to acquire AMA at prices it does not consider appropriate.

§ 955.6 Risk-based capital requirement for acquired member assets.

(a) *General.* Each Bank shall hold retained earnings plus general allowance for losses as support for the credit risk of all AMA estimated by the Bank to represent a credit risk that is greater than that of comparable instruments that have received the second highest credit rating from an NRSRO in an amount equal to or greater than the outstanding balance of the assets or pools of assets times a factor associated with the putative credit rating of the assets or pools of assets as determined by the Finance Board on a case-by-case basis. For single-family mortgage assets, the factors are as set forth in Table 1 of this part.

TABLE 1

Putative rating of single-family mortgage assets	Percentage applicable to on-balance sheet equivalent value of AMA
Third Highest Investment Grade	0.90
Fourth Highest Investment Grade	1.50
If Downgraded to Below Investment Grade After Acquisition By Bank:	
Highest Below Investment Grade	2.25
Second Highest Below Investment Grade	2.60
All Other Below Investment Grade	100.00

(b) *Recalculation of credit enhancement.* For risk-based capital purposes, each Bank shall recalculate the estimated credit rating of a pool of AMA if there is evidence that a decline in the credit quality of that pool may have occurred.

Appendix A to Part 955—Reporting Requirements for Single-Family Acquired Member Assets That Are Residential Mortgages: Loan-Level Data Elements

1. *Bank District Flag*—Two-digit numeric code designating the District Bank that originally acquired the loan.

2. *Participating Bank District Flag*—Two-digit numeric code designating the District Bank that purchased a participation in the loan.

3. *Loan Number*—Unique numeric identifier used by the Banks for each mortgage acquisition.

4. *US Postal State*—Two-digit numeric Federal Information Processing Standard (FIPS) code.

5. *US Postal Zip Code*—Five-digit zip code for the property.

6. *MSA Code*—Four-digit numeric code for the property's metropolitan statistical area (MSA) if the property is located in an MSA.

7. *Place Code*—Five-digit numeric FIPS code.

8. *County*—County, as designated in the most recent decennial census by the Bureau of the Census.

9. *Census Tract/Block Numbering Area (BNA)*—Tract/BNA number as used in the most recent decennial census by the Bureau of the Census.

10. *Census Tract-Percent Minority*—Percentage of a census tract's population that is minority based on the most recent decennial census by the Bureau of the Census.

11. *Census Tract-Median Income*—Median family income for the census tract based on the most recent decennial census.

12. *Local Area Median Income*—Median income for the area based on the most recent decennial census.

13. *Tract Income Ratio*—Ratio of the census tract median income based on the most recent decennial census to that year's local area median income (*i.e.,* loan-level data element number 11 divided by loan-level data element number 12).

14. *Borrower(s) Annual Income*—Combined income of all borrowers.

15. *Area Median Family Income*—Current median family income for a family of four for the area as established by HUD.

16. *Borrower Income Ratio*—Ratio of Borrower(s) annual income to area median family income.

17. *Acquisition Unpaid Principal Balance (UPB)*—UPB in whole dollars of the mortgage when acquired by the Bank.

18. *Loan-to-Value (LTV) Ratio at Origination*—LTV ratio of the mortgage at the time of origination.

19. *Participation Percentage*—Where the mortgage acquisition is a participation, the percentage of the mortgage for each Bank listed in loan-level data element number 2.

20. *Date of Mortgage Note*—Date the mortgage note was created.

21. *Date of Acquisition*—Date the Bank acquired the mortgage.

22. *Purpose of Loan*—Indicates whether the mortgage was a purchase money mortgage, a refinancing, a construction mortgage, or a financing of property rehabilitation.

23. *Cooperative Unit Mortgage*—Indicates whether the mortgage is on a dwelling unit in a cooperative housing building.

24. *Product Type*—Indicates the product type of the mortgage (*i.e.,* fixed rate, adjustable rate mortgage (ARM), balloon, graduated payment mortgage (GPM) or growing equity mortgages (GEM), reverse annuity mortgage, or other).

25. *Federal Guarantee*—Numeric code that indicates whether the mortgage has a Federal guarantee, and from which agency.

26. *Term of Mortgage at Origination*—Term of the mortgage at the time of origination in months.

27. *Amortization Term*—For amortizing mortgages, the amortization term of the mortgage in months.

28. *Acquiring Lender Institution*—Name of the institution from which the Bank acquired the mortgage.

29. *Acquiring Lender City*—City location of the institution from which the Bank acquired the mortgage.

30. *Acquiring Lender State*—State location of the institution from which the Bank acquired the mortgage.

31. *Type of Acquiring Lender Institution*—Type of institution that the Bank acquired the mortgage from (*i.e.,* mortgage company, Savings Association Insurance Fund (SAIF) insured depositary institution, Bank Insurance Fund (BIF) insured depositary institution, National Credit Union Association (NCUA) insured credit union, or other seller).

32. *Number of Borrowers*—Number of borrowers.

33. *First-Time Home Buyer*—Numeric code indicating whether the mortgagor(s) are first-time homebuyers (second mortgages and refinancings are not treated as first-time homebuyers).

34. *Mortgage Purchased under the Banks' Community Investment Cash Advances (CICA) Programs*—Indicates whether the mortgage is on a project funded under an AHP, CIP or other CICA program.

35. *Acquisition Type*—Indicates whether the Bank acquired the mortgage with cash, by swap, with a credit enhancement, a bond or debt purchase, reinsurance, risk-sharing, real estate investment trust (REIT), or a real estate mortgage investment conduit (REMIC), or other.

36. *Bank Real Estate Owned*—Indicates whether the mortgage is on a property that was in the Bank's real estate owned (REO) inventory.

37. *Borrower Race or National Origin*—Numeric code indicating the race or national origin of the borrower.

38. *Co-Borrower Race or National Origin*—Numeric code indicating the race or national origin of the co-borrower.

39. *Borrower Gender*—Numeric code that indicates whether the borrower is male or female.

40. *Co-Borrower Gender*—Numeric code that indicates whether the co-borrower is male or female.

41. *Age of Borrower*—Age of borrower in years.

42. *Age of Co-Borrower*—Age of co-borrower in years.

43. *Occupancy Code*—Indicates whether the mortgaged property is an owner-occupied principal residence, a second home, or a rental investment property.

44. *Number of Units*—Indicates the number of units in the mortgaged property.

45. *Unit—Number of Bedrooms*—Where the property contains non-owner-occupied dwelling units, the number of bedrooms in each of those units.

46. *Unit—Affordable Category*—Where the property contains non-owner-occupied dwelling units, indicates under which, if any, of the special affordable goals the units qualified.

47. *Unit—Reported Rent Level*—Where the property contains non-owner-occupied dwelling units, the rent level for each unit in whole dollars.

48. *Unit—Reported Rent Plus Utilities*—Where the property contains non-owner-occupied dwelling units, the rent level plus the utility cost for each unit in whole dollars.

49. *Unit—Owner Occupied*—Indicates whether each of the units are owner-occupied.

50. *Geographically Targeted Indicator*—Numeric code that indicates loans made in census tracts classified as underserved by HUD.

51. *Interest Rate*—Note rate on the loan.

52. *Loan Amount*—Loan balance at origination.

53. *Front-end Ratio*—Ratio of principal, interest, taxes, and insurance to borrower(s) income.

54. *Back-end Ratio*—Ratio of all debt payments to borrower(s) income.

55. *Borrower FICO Score*—Fair, Isaacs, Co. credit score of borrower.

56. *Co-Borrower FICO Score*—Fair, Isaacs, Co. credit score of co-borrower.

57. *PMI Percent*—Percent of original loan balance covered by private mortgage insurance.

58. *Credit Enhancement*—Numeric code indicating type of credit enhancement.

59. *Self-Employed Indicator*—Numeric indicator for whether the borrower is self-employed.

60. *Property Type*—Numeric indicator for whether the property is single-family detached, condominium, townhouse, PUD, etc.

61. *Default Status*—Numeric indicator for whether the loan is currently in default.

62. *Termination Date*—Date on which the loan terminated.

63. *Termination Type*—Numeric indicator for whether the loan terminated in a prepayment, foreclosure, or other types of termination.

64. *ARM Index*—Index used for the calculation of interest on an ARM.

65. *ARM margin*—Margin added to the index for calculation of the interest on an ARM.

66. *Prepayment Penalty Terms*—Numeric indicator for types of prepayment penalties.

Appendix B to Part 955—Reporting Requirements for Multi-Family Acquired Member Assets That Are Residential Mortgages: Loan-Level Data Elements

1. *Bank District Flag*—Two-digit numeric code designating the District Bank that originally acquired the loan.

2. *Participating Bank District Flag*—Two-digit numeric code designating the District Bank that purchased a participation in the loan.

3. *Loan Number*—Unique numeric identifier used by the Banks for each mortgage acquisition.

4. *US Postal State*—Two-digit numeric Federal Information Processing Standard (FIPS) code.

5. *US Postal Zip Code*—Five-digit zip code for the property.

6. *MSA Code*—Four-digit numeric code for the property's metropolitan statistical area (MSA) if the property is located in an MSA.

7. *Place Code*—Five-digit numeric FIPS code.

8. *County*—County, as designated in the most recent decennial census by the Bureau of the Census.

9. *Census Tract/Block Numbering Area (BNA)*—Tract/BNA number as used in the most recent decennial census by the Bureau of the Census.

10. *Census Tract-Percent Minority*—Percentage of a census tract's population that is minority based on the most recent decennial census by the Bureau of the Census.

11. *Census Tract-Median Income*—Median family income for the census tract based on the most recent decennial census.

12. *Local Area Median Income*—Median income for the area based on the most recent decennial census.

13. *Tract Income Ratio*—Ratio of the census tract median income based on the most recent decennial census to that year's local area median income (*i.e.,* loan-level data element number 11 divided by loan-level data element number 12).

14. *Area Median Family Income*—Current median family income for a family of four for the area as established by HUD.

15. *Affordability Category*—Indicates under which, if any, of the special affordable goals mandated by HUD for Fannie Mae and Freddie Mac, the property would qualify.

16. *Acquisition Unpaid Principal Balance (UPB)*—UPB in whole dollars of the mortgage when purchased by the Bank.

17. *Loan-to-Value (LTV) Ratio at Origination*—LTV ratio of the mortgage at the time of origination.

18. *Participation Percentage*—Where the mortgage acquisition is a participation, the percentage of the mortgage when the note was created for each Bank listed in loan-level data element number 2.

19. *Date of Mortgage Note*—Date the mortgage note was created.

20. *Date of Acquisition*—Date the Bank acquired the mortgage.

21. *Purpose of Loan*—Indicates whether the mortgage was a purchase money mortgage, a refinancing, a construction mortgage, or a financing of property rehabilitation.

22. *Cooperative Project Loan*—Indicates whether the mortgage is a project loan on a cooperative housing building.

23. *Mortgagor Type*—Indicates the type of mortgagor (*i.e.,* an individual, a for-profit entity such as a corporation or partnership, a nonprofit entity such as a corporation or partnership, a public entity, or other type of entity).

24. *Product Type*—Indicates the product type of the mortgage (*i.e.,* fixed rate, adjustable rate mortgage (ARM), balloon, graduated payment mortgage (GPM) or growing equity mortgages (GEM), reverse annuity mortgage, or other).

25. *Construction Loan*—Indicates whether the mortgage is for a construction loan.

26. *Government Insurance*—Indicates whether any part of the mortgage has government insurance.

27. *FHA Risk Share Percent*—The percentage of the risk assumed for the mortgage purchased under a risk-sharing arrangement with FHA.

28. *Mortgage Purchased under the Banks' Community Investment Cash Advances (CICA) Programs*—Indicates whether the mortgage is on a project under an AHP, CIP or other CICA program.

29. *Acquisition Type*—Indicates whether the FHLBank acquired the mortgage with cash, by swap, with a credit enhancement, a bond or debt purchase, reinsurance, risk-sharing, real estate investment trust (REIT), or a real estate mortgage investment conduit (REMIC), or other.

30. *Term of Mortgage at Origination*—Term of the mortgage at the time of origination in months.

31. *Amortization Term*—For amortizing mortgages, the amortization term of the mortgage in months.

32. *Acquiring Lender Institution*—Name of the entity from which the Bank acquired the mortgage.

33. *Acquiring Lender City*—City location of the entity from which the Bank acquired the mortgage.

34. *Acquiring Lender State*—State location of the institution from which the Bank acquired the mortgage.

35. *Type of Acquiring Lender Institution*—Type of institution that the Bank acquired the mortgage from (*i.e.,* mortgage company, Savings Association Insurance Fund (SAIF) insured depositary institution, Bank Insurance Fund (BIF) insured depositary institution, National Credit Union Association (NCUA) insured credit union, or other seller).

36. *Bank Real Estate Owned*—Indicates whether the mortgage is on a property that was in the Bank's real estate owned (REO) inventory.

37. *Number of Units*—Indicates the number of units in the mortgaged property.

38. *Geographically Targeted Indicator*—Numeric code that indicates loans made in census tracts classified as underserved by HUD.

39. *Public Subsidy Program*—Indicates whether the mortgage property is involved in a public subsidy program and which level(s) of government are involved in the subsidy program (*i.e.,* Federal government only, other only, Federal government, etc.).

40. *Unit Class Level*—The following data apply to unit types in a particular mortgaged property. The unit types are defined by the Banks for each property and are differentiated based on the number of bedrooms in the units and on the average contract rent for the units. A unit type must be included for each bedroom size category in the property;

A. Unit Type XX-Number of Bedroom(s)—the number of bedrooms in the unit type;

B. Unit Type XX-Number of Units—the number of units in the property within the unit type;

C. Unite Type XX-Average Reported Rent Level—the average rent level for the unit type in whole dollars; and

D. Unit Type XX-Average Reported Rent Plus Utilities—the average reported rent level plus the utility cost for each unit in whole dollars; and

E. Unit Type XX-Affordability Level—the ratio of the average reported rent plus utilities for the unit type to the adjusted area median income;

F. Unit Type XX-Tenant Income Indicator—indicates whether the tenant's income is less than 60 percent of area median income, greater than or equal to 60 percent but less than 80 percent of area median income, greater than or equal to 80 percent but less than 100 percent of area median income, or greater than or equal to 100 percent of area median income.

41. *Interest Rate*—Note rate on the loan.

42. *Debt Service Coverage Ratio*—Ratio of net operating income to debt service.

43. *Total Number of Units*—Indicates the number of dwelling units in the mortgaged property.

44. *Default Status*—Numeric indicator for whether the loan is currently in default.

45. *Termination Date*—Date on which the loan terminated.

46. *Termination Type*—Numeric indicator for whether the loan terminated in a prepayment, foreclosure, or other types of termination.

47. *ARM Index*—Index used for the calculation of interest on an ARM.

48. *ARM margin*—Margin added to the index for calculation of the interest on an ARM.

49. *Prepayment Penalty Terms*—Numeric indicator for types of prepayment penalties.

10. In subchapter G, revise part 956 to read as follows:

PART 956—FEDERAL HOME LOAN BANK INVESTMENTS

Sec.
956.1 Definitions.
956.2 Authorized investments.
956.3 Prohibited investments and prudential rules.
956.4 Risk-based capital requirement for investments.

Authority: 12 U.S.C. 1422a(a)(3), 1422b(a), 1431, 1436.

§ 956.1 Definitions.

As used in this part:

Deposits in banks or trust companies has the meaning set forth in § 969.3 of this chapter.

Financial Management Policy means the Financial Management Policy For The Federal Home Loan Bank System approved by the Finance Board pursuant to Finance Board Resolution No. 96–45 (July 3, 1996), as amended by Finance Board Resolution No. 96–90 (Dec, 6, 1996), Finance Board Resolution No. 97–05 (Jan. 14, 1997), and Finance Board Resolution No. 97–86 (Dec. 17, 1997).

GAAP means Generally Accepted Accounting Principles.

Investment grade means:

(1) A credit quality rating in one of the four highest credit rating categories by an NRSRO and not below the fourth highest credit rating category by any NRSRO; or

(2) If there is no credit quality rating by an NRSRO, a determination by a Bank that the issuer, asset or instrument is the credit equivalent of investment grade using credit rating standards available from an NRSRO or other similar standards.

NRSRO has the meaning set forth in § 966.1 of this chapter.

§ 956.2 Authorized investments.

In addition to assets enumerated in parts 950 and 955 of this chapter and subject to the applicable limitations set forth in this part, in the Financial Management Policy and in part 980 of this chapter, each Bank may invest in:

(a) Obligations of the United States;

(b) Deposits in banks or trust companies;

(c) Obligations, participations or other instruments of, or issued by, the Federal National Mortgage Association or the Government National Mortgage Association;

(d) Mortgages, obligations, or other securities that are, or ever have been, sold by the Federal Home Loan Mortgage Corporation pursuant to 12 U.S.C. 1454 or 1455;

(e) Stock, obligations, or other securities of any small business investment company formed pursuant to 15 U.S.C. 681(d), to the extent such investment is made for purposes of aiding members of the Bank; and

(f) Instruments that the Bank has determined are permissible investments for fiduciary or trust funds under the laws of the state in which the Bank is located.

§ 956.3 Prohibited investments and prudential rules.

(a) *Prohibited investments.* A Bank may not invest in:

(1) Instruments that provide an ownership interest in an entity, except for investments described in § § 940.3(e) and (f) of this chapter;

(2) Instruments issued by non-United States entities, except United States branches and agency offices of foreign commercial banks;

(3) Debt instruments that are not rated as investment grade, except:

(i) Investments described in § 940.3(e) of this chapter;

(ii) Debt instruments that were downgraded to a below investment grade rating after acquisition by the Bank; or

(4) Whole mortgages or other whole loans, or interests in mortgages or loans, except:

(i) Acquired member assets;

(ii) Investments described in § 940.3(e) of this chapter;

(iii) Marketable direct obligations of state, local, or tribal government units or agencies, having at least the second highest credit rating from a NRSRO, where the purchase of such obligations by the Bank provides to the issuer the customized terms, necessary liquidity, or favorable pricing required to generate needed funding for housing or community lending;

(iv) Mortgage-backed securities, or asset-backed securities collateralized by manufactured housing loans or home equity loans, that meet the definition of the term ''securities'' under 15 U.S.C. 77b(a)(1); and

(v) Loans held or acquired pursuant to section 12(b) of the Act (12 U.S.C. 1432(b)).

(b) *Foreign currency or commodity positions prohibited.* A Bank may not take a position in any commodity or foreign currency. If a Bank participates in consolidated obligations denominated in a currency other than U.S. Dollars or linked to equity or commodity prices, the currency, commodity and equity risks must be hedged.

§ 956.4 Risk-based capital requirement for investments.

Each Bank shall hold retained earnings plus general allowance for losses as support for the credit risk of all investments that are not rated by a NRSRO, or are rated or have a putative rating below the second highest credit rating, in an amount equal to or greater than the outstanding balance of the investments multiplied by:

(a) A factor associated with the credit rating of the investments as determined by the Finance Board on a case-by-case basis for rated assets to be sufficient to raise the credit quality of the asset to the second highest credit rating category; and

(b) 0.08 for assets having neither a putative nor actual rating.

PART 966—CONSOLIDATED OBLIGATIONS

11. The authority citation of part 966 continue to read as follows:

Authority: 12 U.S.C. 1442a, 1422b, and 1431.

12. Amend section 966.1 by removing the definition of the term ''NRSRO''.

Dated: June 29, 2000.

By the Board of Directors of the Federal Housing Finance Board.

Bruce A. Morrison,

Chairman.

[FR Doc. 00–17663 Filed 7–14–00; 8:45 am]

BILLING CODE 6725–01–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[TX–100–7390a; FRL–6735–3]

Approval and Promulgation of Implementation Plans; Texas; Permitting of New and Modified Sources in Nonattainment Areas

AGENCY: Environmental Protection Agency (EPA).

ACTION: Final rule.

SUMMARY: The EPA is approving revisions to the Texas State Implementation Plan (SIP) for the permitting of new major sources and major modifications in areas which do not meet the national ambient air quality standards (NAAQS) promulgated by EPA (nonattainment areas). The EPA is approving these revisions to satisfy the provisions of the Clean Air Act (Act) which relate to the permitting of new and modified sources which are located in nonattainment areas. Today's action approves the recodification of and revisions to the nonattainment permitting regulations. Today's action also approves revisions relating to when nonattainment area permitting requirements apply to emissions of nitrogen oxides (NO_X) as a precursor to ozone in an ozone nonattainment area.

EFFECTIVE DATE: This rule is effective on August 16, 2000.

ADDRESSES: Copies of documents relevant to this action are available for public inspection during normal business hours at the following locations. Anyone wanting to examine these documents should make an appointment with the appropriate office at least two working days in advance.

Environmental Protection Agency, Region 6, Air Permits Section (6PD–R), 1445 Ross Avenue, Dallas, Texas 75202–2733.

Texas Natural Resource Conservation Commission, Office of Air Quality, 12124 Park 35 Circle, Austin, Texas 78753.

FOR FURTHER INFORMATION CONTACT: Stanley M. Spruiell of EPA Region 6 Air Permits Section at (214) 665–7212 at the address above, or at spruiell.stanley@epa.gov.

SUPPLEMENTARY INFORMATION: Throughout this document ''we,'' ''us,'' or ''our'' means EPA.

Table of Contents

I. What action are we taking?
II. What is the background for this action?
III. What did Texas submit?

IV. What are the Federal requirements for permitting major sources and major modifications in nonattainment areas?
V. Summary of Texas' 182(f) NO_X waivers
VI. Why can we approve this request?
VII. Final action
VIII. Administrative requirements

I. What Action Are We Taking?

We are finalizing our approval of the recodification of and revisions to Title 30, Texas Administrative Code (TAC) Chapter 116, ''Control of Air Pollution by Permits for New Construction or Modification,'' as indicated in Table 1 below:

TABLE 1.—REGULATIONS THAT EPA IS APPROVING

Recodified section of 30 TAC chapter 116	Submittal dates of recodified section	Title or description	Former section of 30 TAC chapter 116
Section 116.12	August 31, 1993 July 18, 1996 April 13, 1998 March 16, 1999	Nonattainment Review Definitions	Section 101.1.
Section 116.150	August 31, 1993 November 1, 1995 April 13, 1998 March 16, 1999	New Major Source or Major Modification in Ozone Nonattainment Areas.	Section 116.3(a)(7) and (8).
Section 116.151	August 31, 1993 April 13, 1998	New Major Source or Major Modification in Nonattainment Area Other than Ozone.	Section 116.3(a)(10).
Section 116.170	August 31, 1993	Applicability for Reduction Credits	Section 116.3(c).

This proposal includes portions of revisions submitted by the Governor of Texas to EPA on the following dates:

- August 31, 1993.
- November 1, 1995.
- July 18, 1996.
- April 13, 1998.
- March 16, 1999.

We are taking this rulemaking action under sections 110, 301 and part D of the Act. We are acting only on those parts of these submittals which relate to permitting sources in nonattainment areas.

II. What Is the Background for This Action?

On January 18, 2000, we published a notice of proposed rulemaking (NPR) proposing full approval of the recodification of and revisions to Texas' regulations for the permitting of new major sources and major modifications in nonattainment areas. The Governor submitted revisions to these nonattainment area permitting requirements as described above.

As explained in the NPR, we have determined that Texas' recodification of and revisions to its nonattainment permitting requirements continue to meet the requirements of part D of the Act and 40 CFR 51.165 (Permit Requirements). The NPR provided opportunity for the public to comment on the proposed action. The public comment period for our action ended February 17, 2000. We received no comments on the NPR. As a result, we are finalizing our proposed approval without changes. For more details on these submittals, please refer to the proposed rulemaking.

III. What Did Texas Submit?

Table 2 below summarizes each individual SIP submittal that we are approving in today's action.

TABLE 2.—SUMMARY OF EACH INDIVIDUAL SIP SUBMITTAL

Date adopted by state	Date submitted to EPA	Description of SIP submittal
August 16, 1993	August 31, 1993	Recodification and revisions to SIP relating to permitting under part D of the Act. This includes submittal of the following recodified Sections of Chapter 116: —Section 116.12, —Section 116.150, and —116.151, and —Section 116.170(1) and (3).
October 26, 1995	November 1, 1995	Revisions to Section 116.150 to address nonattainment permitting requirements for NO_X (as an ozone precursor) in the Dallas-Fort Worth, El Paso, Houston-Galveston, and Beaumont-Port Arthur ozone nonattainment areas consistent with waivers approved by EPA pursuant to section 182(f) of the Act.
May 15, 1996	July 18, 1996	Revisions to Table I of Section 116.12 to conform to NO_X waivers approved by EPA pursuant to section 182(f) of the Act.
March 18, 1998	April 13, 1998	Revisions to Sections 116.12, Table I of Section 116.12, and 116.150, and 116.151. Texas revised the SIP to reinstate NO_X as an ozone precursor in the Houston-Galveston and Beaumont-Port Arthur ozone nonattainment areas.
February 24, 1999	March 16, 1999	Revisions to Chapter 116, which reinstate the requirement to review NO_X as an ozone precursor in the Dallas-Fort Worth ozone nonattainment area.

IV. What Are the Federal Requirements for Permitting Major Sources and Major Modifications in Nonattainment Areas?

A. What Are the Statutory Requirements for Permitting Major Sources and Major Modifications in Nonattainment Areas?

The statutory requirements governing permitting in nonattainment areas are in part D of the Act. Specifically, the Act requires that a major source or major modification meet the criteria in Table 3 below.

TABLE 3.—SUMMARY OF REQUIREMENT FOR PERMITTING MAJOR SOURCES AND MAJOR MODIFICATIONS IN NONATTAINMENT AREAS

Requirement of Act	Where specified in the Act	Citation in state regulations
Base emissions offsets on the same emissions baseline used in the demonstration of reasonable further progress..	Section 173(a)(1)(A)	Section 116.150(a)(4), Section 116.151(3).
Apply Lowest Achievable Emission Rate (LAER)	Section 173(a)(2)	Section 116.150(a)(1), Section 116.151(1).
Demonstrate that all other major stationary sources under the same ownership or operation in the State are complying with the Act.	Section 173(a)(3)	Section 116.150(a)(2), Section 116.151(2).
State cannot issue a permit if the EPA Administrator finds that the State is not adequately enforcing the provisions of the applicable implementation plan for the nonattainment area in which the source proposes to construct or modify.	Section 173(a)(4)	The EPA has made no such determination for Texas. If EPA makes this determination in the future, EPA will address this matter with Texas at that time.
• Analyze alternative sites, sizes, production processes, and environmental control techniques for proposed sources. • Demonstrate that the benefits of the proposed source significantly outweigh the environmental and social costs associated with its location, construction, or modification.	Section 173(a)(5)	Section 116.150(a)(4). Section 116.151(4).
Prohibits use of growth allowance included in a SIP prior to the Act Amendments of 1990 in an area which receives notice that such plan is substantially inadequate.	Section 173(b)	Not Applicable.
A sources may obtain offsets in another nonattainment area under the following conditions. • The area in which the offsetting reductions originate has an equal or higher nonattainment classification, and. • The emissions from the nonattainment area where the offsetting reductions originate will contribute to a NAAQS violation in the area in which the source would construct.	Section 173(c)(1)	Section 116.150(a)(3). Section 116.151(3).
A new or modified major stationary source must offset a proposed emissions increase with real reductions in actual emissions.	Section 173(c)(1)	Section 116.150(a)(3). Section 116.151(3). Section 116.12(14)—Definition of ''Offset ratio''.
Must not use emission reductions otherwise required by the Act	Section 173(c)(2)	Section 116.170(1).
A State may allow any existing or modified source that tests rocket engines or motors to use alternative or innovative means to offset emissions increases from firing and related cleaning.	Section 173(e)	Section 116.170(3).

B. Who Is Affected by This Action?

The requirements described in Table 3 above apply to each owner and/or operator who constructs or modifies a stationary source in a nonattainment area in Texas if the stationary source is major for the air pollutant for which the area is nonattainment. A stationary source is major if it emits, or has the potential to emit, the nonattaining pollutant, or precursor thereto, in amounts greater than the major source threshold for the nonattaining pollutant.

C. What Are the Major Source Thresholds for Nonattainment Pollutants?

The major source threshold varies, depending on the pollutant and the classification of the nonattainment area. Any owner or operator who proposes to construct a major stationary source must obtain a permit which complies with the regulations that we are approving herein. Table 4 below lists the major source threshold for each pollutant.

TABLE 4.—MAJOR SOURCE THRESHOLDS

Pollutant: classification	Major source threshold in tons per year (TPY)	Where specified in the Act
Ozone:		
Marginal	100 of volatile organic compounds (VOC) or NO_X	Section 302(j).
Moderate	100 of VOC or NO_X	Section 302(j).
Serious	50 of VOC or NO_X	Section 182(c).
Severe	25 of VOC or NO_X	Section 182(d).

TABLE 4.—MAJOR SOURCE THRESHOLDS—Continued

Pollutant: classification	Major source threshold in tons per year (TPY)	Where specified in the Act
Carbon monoxide (CO):		
Moderate	100	Section 302(j).
Serious	50	Section 187(c)(1).
Particulate matter less than 10 micrometers (PM–10):		
Moderate	100	Section 302(j).
Serious	70	Section 189(b)(3).
Sulfur dioxide (SO_2)	100	Section 302(j).
NO_X	100	Section 302(j).
Lead	100	Section 302(j).

Table 4 above refers to classifications for areas designated nonattainment for ozone, CO, and PM–10. These nonattainment classifications are defined in the Act as follows:

• Section 181(a) defines five area classifications for ozone. These five classifications are marginal, moderate, serious, severe, and extreme. Texas has no extreme ozone nonattainment areas and does not address such areas in its regulations.

• Section 186(a) defines two area classifications for CO. These two classifications are moderate and serious.

• Section 188 defines two area classifications for PM–10. These two classifications are moderate and serious.

A detailed description of the individual area classifications for ozone, CO, and PM–10 nonattainment areas is contained in EPA's General Preamble for the Implementation of Title I of the 1990 Amendments, 57 FR 13498 (April 16, 1992).

D. What Is a Major Modification?

A major modification is any physical change, or change in the method of operating, a major stationary source which significantly increases net emissions of the air pollutant, or precursor, for which the area is nonattainment and for which the source is a major source before the modification.

Any owner or operator who proposes a major modification must obtain a permit that complies with the regulations that we are approving herein. Table 5 below lists the significance level for each pollutant which is used in determining whether a net emissions increase is a major modification.

TABLE 5.—SIGNIFICANCE LEVELS FOR MAJOR MODIFICATIONS

Pollutant: Classification	Significance level in TPY	Where specified in the Act or regulations
Ozone:		
Marginal	40 of VOC or NO_X	40 CFR 51.165(a)(x).
Moderate	40 of VOC or NO_X	40 CFR 51.165(a)(x).
Serious	25 of VOC or NO_X	Section 182(c)(6) of the Act.
Severe	25 of VOC or NO_X	Section 182(c)(6) of the Act.
CO:		
Moderate	100	40 CFR 51.165(a)(x).
Serious	50	a.
PM–10:		
Moderate	15	a.
Serious	15	a.
SO_2	40	40 CFR 51.165(a)(x).
NO_X	40	40 CFR 51.165(a)(x).
Lead	0.6	40 CFR 51.165(a)(x).

a—No significance level is specified in the Act nor in the regulations. The significance levels specified in Table 5 are the significance levels that we approved for Texas on September 27, 1995 (60 FR 49781).

The major source thresholds and significance thresholds in Tables 4 and 5 above are required by Texas in section 116.12—Definition of ''major modification,'' Table I.

E. What Are the Offset Requirements in Ozone Nonattainment Areas?

Section 182 of the Act also specifies the offset ratios that are required for marginal, moderate, serious, severe and extreme ozone nonattainment areas. Table 6 below lists the applicable offset ratio for each type of ozone nonattainment area.

TABLE 6.—OFFSET RATIOS FOR EACH TYPE OF OZONE NONATTAINMENT AREA

Ozone nonattainment classification	Offset ratio	Clean Air Act citation for offset ratio
Marginal	1.10 to 1	Section 182(a)(4).
Moderate	1.15 to 1	Section 182(b)(5).
Serious	1.20 to 1	Section 182(c)(10).
Severe	1.30 to 1	Section 182(d)(2).

The offset ratios in Table 6 above are required by Texas in section 116.12—Definition of ''major modification,'' Table I.

F. Does the Act Have Other Provisions That Apply in Serious and Severe Ozone Nonattainment Areas?

Sections 182(c)(6), (7), and (8) of the Act contain provisions which apply to modifications at major sources located in serious and severe ozone nonattainment areas.

Tables 7 and 8 below summarize the requirements of sections 182(c)(6), (7), and (8) and describe how Texas addresses these requirements in Chapter 116. The reader should refer to the NPR which contains detailed discussions of the Act's requirements and our analysis of how Chapter 116 meets these requirements of the Act.

TABLE 7.—REQUIREMENTS OF THE ACT FOR OZONE NONATTAINMENT AREAS

Section of Act	Summary of Act's requirement	Section of chapter 116 which addresses Act's requirement	Summary of requirement of chapter 116
Section 182(c)(6)—*De minimis rule.*	*Netting Trigger.* The source determines the ''increase in net emissions'' from the proposed modification. The net emissions from the proposed modification (the ''project net'') is the sum of all proposed creditable emissions increases and decreases proposed at the source between: (A) the date of application for the modification and (B) the date the modification begins emitting. An increase or decrease is creditable if it meets the criteria described in 40 CFR 51.165(a)(1)(vi).	Section 116.150	*Netting Trigger.* Proposed project triggers contemporaneous netting unless the proposed project meets at least one of the following conditions: —The proposed increase is less than five TPY without consideration of other decreases at the source, or —The ''project net'' is zero or less. Texas definition of ''project net'' in Section 116.12 is consistent with that term as described in the second column of this Table.
Section 182(c)(6)—*De minimis* rule.	*Contemporaneous Period.* If the project net is an emissions increase, then the source aggregates the project net emissions increase with all other ''net increases in emissions from the source'' over a period of five consecutive calendar years which includes the year in which the source increase occurs (the ''contemporaneous net''). If the contemporaneous net increase is greater than 25 TPY, then the proposed modification is subject to nonattainment new source review (NNSR).	Section 116.12. Definition of ''contemporaneous period''.	*Contemporaneous Period.* As described in Table 8 below.
Section 182(c)(7)—Special rule for modifications of sources emitting less than 100 tons per year.	Project is not a modification subject to NNSR if source elects to internally offset the same pollutant at an offset ratio of at least 1.3 to 1 the proposed increase of VOC or NO_X[a].	Section 116.150(a)(3)(A).	NNSR is not required if the project increases are offset with internal offsets of the same pollutant at a ratio of at least 1.3 to 1.
	Best available control technology (BACT) is substituted for LAER, if a source elects not to use internal offsets.	Section 116.150(a)(1)	If source elects not to use internal offsets, it can substitute BACT for LAER.
Section 182(c)(8)—Special rule for modifications of sources emitting 100 tons per year or more.	The requirements of LAER otherwise required by section 173(a)(2) of the Act do not apply, if the source elects to internally offset the same pollutant at 1.3 to 1 such proposed increase of VOC or NO_X[a].	Section 116.150(a)(3)(B).	Source can substitute BACT for LAER, if the project increases are offset with internal offsets of the same pollutant at a ratio of at least 1.3 to 1.
	A source which elects to avoid LAER by satisfying the provisions of section 182(c)(8) may use the 1.3 to 1 internal offset ratio in lieu of the general offset ratio.	Section 116.150(a)(3)(B).	Internal offsets used as described above can also be applied to satisfy the offset requirement.

[a] Applies to a proposed increase of VOC or NO_X from any discrete operation, unit, or other pollutant emitting activity at the source.

TABLE 8.—DESCRIPTION OF TEXAS' CONTEMPORANEOUS PERIODS

Pollutant	Contemporaneous period begins	Contemporaneous period ends
If source has potential to emit (PTE) less than 250 TPY		
VOC	Five years before commencement of construction	Date that new or modified source begins operation.
NO_X	Latter of ..... —November 15, 1992, or ..... —Five years before commencement of construction	Date that new or modified source begins operation.

TABLE 8.—DESCRIPTION OF TEXAS' CONTEMPORANEOUS PERIODS—Continued

Pollutant	Contemporaneous period begins	Contemporaneous period ends
If source has PTE equal to or greater than 250 TPY		
VOC	The earlier of —Five years before commencement of construction, or —November 15, 1992	Date that new or modified source begins operation.
NO_X	November 15, 1992	Date that new or modified source begins operation.

V. Summary of Texas' 182(f) NO_X Waivers

A. What Does Section 182(f) of the Act Require?

Section 182(f) sets forth the presumption that NO_X is an ozone precursor unless the Administrator makes a finding of nonapplicability or grants a waiver pursuant to criteria contained therein. Specifically, section 182(f) provides that requirements applicable for major stationary sources of VOC shall apply to major stationary sources of NO_X, unless otherwise determined by the Administrator, based upon certain determinations related to the benefits or contribution of NO_X control to air quality, ozone attainment, or ozone air quality.

B. Did We Approve NO_X Waivers in Texas?

We approved petitions submitted by Texas under section 182(f) to waive NO_X provisions in Texas, as follows:

- On November 28, 1994, we conditionally approved two petitions from Texas, each dated June 17, 1994. This action exempted Dallas-Fort Worth (DFW) [1] and El Paso (ELP) [2] ozone nonattainment areas from NO_X control requirements of section 182(f) of the Act. *See* 59 FR 60709.
- On April 19, 1995, we approved a petition from Texas dated August 17, 1994. This action temporarily exempted the Houston-Galveston (HGA) [3] and Beaumont-Port Arthur (BPA) [4] ozone nonattainment areas from the NO_X control requirements of section 182(f) of the Act. These temporary exemptions expired December 31, 1996. *See* 60 FR 19515.
- On May 23, 1997, we approved a petition from Texas dated March 8, 1996, to extend the NO_X waiver in HGA and BPA until December 31, 1997. *See* 62 FR 28344.
- On April 20, 1999, we approved a petition from Texas dated November 13, 1998, to rescind the conditional NO_X exemption for the DFW ozone nonattainment area. Texas petitioned for rescission of the exemption after EPA reclassified DFW from a moderate ozone nonattainment area to a serious ozone nonattainment area. The modeling for this serious ozone nonattainment area SIP shows that control of NO_X sources will help the area to attain the air quality standard for ozone. See 64 FR 19283.

C. What Is the Current Status of Texas NO_X Waivers?

On December 31, 1997, the NO_X waiver in HGA and BPA expired. On February 12, 1998, we published a document in the **Federal Register** concerning Texas' decision not to petition for further extension of the NO_X exemption in the HGA and BPA areas. *See* 63 FR 7071. Since the extension of the temporary exemption expired on December 31, 1997, the State must implement the numerous requirements relating to NO_X in the HGA and BPA areas. Accordingly, any new source review (NSR) permits that Texas had not deemed to be administratively complete prior to January 1, 1998, must comply with the NO_X NSR requirements, consistent with the policy set forth in the EPA's NSR Supplemental Guidance memorandum dated September 3, 1992, from John Seitz, Director, EPA's Office of Air Quality Planning and Standards.

On February 18, 1998, we published our finding that the DFW nonattainment area has not attained the 1-hour ozone NAAQS by the applicable attainment date in the Act for moderate ozone nonattainment areas, November 15, 1996. As a result of this finding, the DFW ozone nonattainment area was reclassified by operation of law as a serious ozone nonattainment area, effective March 20, 1998. Texas was required to submit a new SIP, no later that March 20, 1999, addressing attainment of that standard by November 15, 1999. Texas submitted a revised plan on March 16, 1999, in satisfaction of this requirement.

In its revised plan, Texas again recognizes NO_X as an ozone precursor in the DFW nonattainment area. Texas also forwarded a petition to us on November 13, 1998, requesting that we withdraw the waiver for NO_X that we had approved on November 28, 1994, for the DFW nonattainment area. On April 20, 1999, we approved this petition and reinstated NO_X as an ozone precursor in the DFW nonattainment area.

D. What Rule Changes Did Texas Submit to Accommodate the Section 182(f) NO_X Waivers?

Texas submitted the following SIP revisions indicated in Table 9 below to incorporate the section 182(f) NO_X waivers and subsequent reinstatement for NO_X as an ozone precursor:

TABLE 9.—SUMMARY OF TEXAS SIP SUBMITTALS WHICH INCORPORATE THE SECTION 182(f) NO_X WAIVERS

Date of SIP submittal	Description
November 1, 1995	Texas submitted revisions to Section 116.150 to implement the NO_X waivers approved for the DAL, ELP, HGA, and BPA ozone nonattainment areas.
July 18, 1996	Texas submitted revisions to Table I in Section 116.12 [5] to remove NO_X as an ozone precursor, consistent with EPA's approval of the NO_X waivers.
April 13, 1998	Texas submitted revisions to Sections 116.12 (Table I) and 116.150(c), to reinstate NO_X as an ozone precursor in the HGA and BPA areas following the expiration of the temporary waivers for those areas on December 31, 1997.

[1] Includes the following Texas counties: Collin, Dallas, Denton, and Tarrant Counties in Texas

[2] Includes El Paso County in Texas

[3] Includes the following Texas counties: Brazoria, Chambers, Fort Bend, Galveston, Harris, Liberty, Montgomery, and Waller.

[4] Includes the following Texas counties: Hardin, Jefferson, and Orange Counties.

TABLE 9.—SUMMARY OF TEXAS SIP SUBMITTALS WHICH INCORPORATE THE SECTION 182(f) NO_X WAIVERS—Continued

Date of SIP submittal	Description
March 16, 1999	Texas submitted revisions to Sections 116.12 (definition of ''major modification'' and Table I) and 116.150(b), to again require NO_X to be treated as an ozone precursor in the DFW area.

[5] Table I of section 116.12 specifies the various classifications of nonattainment along with the associated emission levels which designate a major modification for those areas. A detailed discussion of the changes to Table I is included in section of the preamble describing the submitted definition of ''major modification.''

The above described revisions to section 116.150 are discussed in the following paragraphs.

E. What Are Texas' Provisions for Addressing NO_X Waivers in DFW and ELP?

Texas addresses the NO_X waivers for DFW and ELP in section 116.150(b) submitted November 1, 1995. section 116.150(b) is consistent with the NO_X waiver approved by EPA on November 28, 1994. Following the redesignation of DFW to a serious ozone nonattainment area, Texas revised section 116.150(b) to revoke applicability of the NO_X waiver in DFW. As revised, section 116.150(b) now identifies ELP as the only area in Texas where a section 182(f) waiver continues to apply. Texas submitted these revisions to section 116.150(b) on March 16, 1999.

F. What Are Texas' Provisions for Addressing NO_X Waivers in HGA and BPA?

Texas addresses the NO_X waivers for HGA and BPA in section 116.150(c) submitted November 1, 1995. This section temporarily removed the requirements relating to NO_X emissions (as an ozone precursor) in these areas.

Section 116.150(c) exempted NO_X from otherwise applicable nonattainment area permitting requirements [6] (except for NO_X offsets). The requirements for obtaining NO_X offsets continue to apply, and will be included in the source's permit. However, the requirement to obtain such offsets was held in abeyance until January 1, 1998.

Section 116.150(c) further required a source to document any proposed increase of NO_X equal to or greater than 40 TPY and submit documentation of netting calculations associated with the proposed increase, and the source must otherwise comply with the requirements of sections 116.150(a).

Texas submitted further revisions to section 116.150(c) on April 13, 1998. This submittal reinstates the NSR requirements for NO_X in HGA and BPA, effective January 1, 1998. The submittal further provides that sources with NO_X offsets in the HGA and BPA areas held in abeyance should have obtained the required NO_X offsets no later than January 1, 2000.

VI. Why Can We Approve the Requested SIP Revisions?

Consistent with the above discussion and with the NPR we find that the NNSR regulations submitted by Texas meet the requirements of the Act. We therefore approve these regulations as revisions to the Texas SIP.

VII. Final Action

We are approving the revisions to 30 TAC Chapter 116 which relate to the permitting of major sources and major modifications in nonattainment areas. Specifically, for the reasons stated herein, we are approving sections 116.12, 116.150, 116.151, 116.170, and 116.170(1) and (3).

VIII. Administrative Requirements

A. Executive Order 12866

The Office of Management and Budget has exempted this regulatory action from Executive Order 12866, entitled ''Regulatory Planning and Review.''

B. Executive Order 13132

Executive Order 13132, entitled ''Federalism'' (64 FR 43255, August 10, 1999) revokes and replaces Executive Order 12612, ''Federalism,'' and Executive Order 12875, ''Enhancing the Intergovernmental Partnership.'' Executive Order 13132 requires EPA to develop an accountable process to ensure ''meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications.'' ''Policies that have federalism implications'' is defined in the Executive Order to include regulations that have ''substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.'' Under Executive Order 13132, EPA may not issue a regulation that has federalism implications, that imposes substantial direct compliance costs, and that is not required by statute, unless the Federal government provides the funds necessary to pay the direct compliance costs incurred by State and local governments, or EPA consults with State and local officials early in the process of developing the proposed regulation. The EPA also may not issue a regulation that has federalism implications and that preempts State law unless the Agency consults with State and local officials early in the process of developing the proposed regulation.

This final rule will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132, because it merely approves a State rule implementing a Federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Act. Thus, the requirements of section 6 of the Executive Order do not apply to this rule.

C. Executive Order 13045

Executive Order 13045, entitled ''Protection of Children from Environmental Health Risks and Safety Risks'' (62 FR 19885, April 23, 1997), applies to any rule that: (1) is determined to be ''economically significant'' as defined under Executive Order 12866, and (2) concerns an environmental health or safety risk that EPA has reason to believe may have a disproportionate effect on children. If the regulatory action meets both criteria, the Agency must evaluate the environmental health or safety effects of the planned rule on children, and explain why the planned regulation is preferable to other potentially effective and reasonably feasible alternatives considered by the Agency.

The EPA interprets Executive Order 13045 as applying only to those regulatory actions that are based on health or safety risks, such that the analysis required under section 5–501 of

[6] Section 116.150(c) exempts NO_X from the application of lowest achievable emission rate, statewide compliance by all sources under common control with the applicant, and alternate site analysis, which are otherwise required by section 116.150(a)(1), (2), and (4), respectively.

the Order has the potential to influence the regulation. This final rule is not subject to Executive Order 13045 because it approves a State program.

D. Executive Order 13084

Under Executive Order 13084, EPA may not issue a regulation that is not required by statute, that significantly or uniquely affects the communities of Indian tribal governments, and that imposes substantial direct compliance costs on those communities, unless the Federal government provides the funds necessary to pay the direct compliance costs incurred by the tribal governments, or EPA consults with those governments. If EPA complies by consulting, Executive Order 13084 requires EPA to provide to the OMB, in a separately identified section of the preamble to the rule, a description of the extent of EPA's prior consultation with representatives of affected tribal governments, a summary of the nature of their concerns, and a statement supporting the need to issue the regulation. In addition, Executive Order 13084 requires EPA to develop an effective process permitting elected officials and other representatives of Indian tribal governments ''to provide meaningful and timely input in the development of regulatory policies on matters that significantly or uniquely affect their communities.''

Today's rule does not significantly or uniquely affect the communities of Indian tribal governments. This action does not involve or impose any requirements that affect Indian tribes. Accordingly, the requirements of section 3(b) of Executive Order 13084 do not apply to this rule.

E. Regulatory Flexibility Act

The Regulatory Flexibility Act, 5 U.S.C. 600 *et seq.*, generally requires an agency to conduct a regulatory flexibility analysis of any rule subject to notice and comment rulemaking requirements unless the agency certifies that the rule will not have a significant economic impact on a substantial number of small entities. Small entities include small businesses, small not-for-profit enterprises, and small governmental jurisdictions. This final rule will not have a significant impact on a substantial number of small entities because SIP approvals under section 110 and subchapter I, part D of the Act do not create any new requirements but simply approve requirements that the State is already imposing. Therefore, because the Federal SIP approval does not create any new requirements, I certify that this action will not have a significant economic impact on a substantial number of small entities. Moreover, due to the nature of the Federal-State relationship under the Act, preparation of a flexibility analysis would constitute Federal inquiry into the economic reasonableness of state action. The Act forbids EPA to base its actions concerning SIPs on such grounds. *See Union Electric Co.* v. *U.S. EPA*, 427 U.S. 246, 255–66 (1976); 42 U.S.C. 7410(a)(2).

F. Unfunded Mandates

Under section 202 of the Unfunded Mandates Reform Act of 1995, signed into law on March 22, 1995, EPA must prepare a budgetary impact statement to accompany any proposed or final rule that includes a Federal mandate that may result in estimated annual costs to State, local, or tribal governments in the aggregate; or to private sector, of $100 million or more. Under section 205, EPA must select the most cost-effective and least burdensome alternative that achieves the objectives of the rule and is consistent with statutory requirements. Section 203 requires EPA to establish a plan for informing and advising any small governments that may be significantly or uniquely impacted by the rule.

The EPA has determined that the approval action promulgated does not include a Federal mandate that may result in estimated annual costs of $100 million or more to either State, local, or tribal governments in the aggregate, or to the private sector. This Federal action approves pre-existing requirements under State or local law, and imposes no new requirements. Accordingly, no additional costs to State, local, or tribal governments, or to the private sector, result from this action.

G. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. The EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the **Federal Register**. A major rule can not take effect until 60 days after it is published in the **Federal Register**. This action is not a ''major'' rule as defined by 5 U.S.C. 804(2). This rule will be effective August 16, 2000.

H. Petitions for Judicial Review

Under section 307(b)(1) of the Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by September 15, 2000. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action may not be challenged later in proceedings to enforce its requirements. See section 307(b)(2).

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Carbon Monoxide, Hydrocarbons, Incorporation by reference, Intergovernmental relations, Lead, Nitrogen oxides, Ozone, Particulate matter, Reporting and recordkeeping requirements, Sulfur oxides, Volatile organic compounds.

Dated: July 5, 2000.

Jerry Clifford,

Acting Regional Administrator, Region 6.

Part 52, chapter I, title 40 of the Code of Federal Regulations is amended as follows:

PART 52—[AMENDED]

1. The authority citation for part 52 continues to read as follows:

Authority: 42 U.S.C. 7401 *et seq.*

Subpart SS—Texas

2. In § 52.2270(c) the first table is amended by deleting the entry for Section 101.1 Table I (Definitions—Major Source/Major Modification Emission Thresholds), revising the entries for Section 101.1 (Definitions) and for Section 116.03 (Consideration for Granting a Permit to Construct and Operate), and by adding new entries in numeric order to read as follows:

§ 52.2270 Identification of plan.

* * * * *

(c) * * *

EPA APPROVED REGULATIONS IN THE TEXAS SIP

State citation	Title/subject	State approval date	EPA approval date	Explanation
Chapter 101—General Rules				
Section 101.1	Definitions	08/16/93	[07/17/00 and page number]	Ref 52.2299(c)(102) Note: Nonattainment review definitions repealed from 101.1 and added to 116.12.
*	*	*	*	*
Chapter 116 (Reg 6)—Control of Air Pollution by Permits for New Construction or Modification				
*	*	*	*	*
Section 116.03	Consideration for Granting a Permit to Construct and Operate.	08/16/93	[07/17/00 and page number]	Ref 52.2299(c)(102) Note:(a)(7), (8), (9), (10), (11), and (12); (c); (d); and (e) NOT in SIP.
*	*	*	*	*
Subchapter A—Definitions				
*	*	*	*	*
Section 116.12	Nonattainment Review Definitions	02/24/99	[07/17/00 and page number]	Includes Table I, Major Source/Major Modification Emission Thresholds.
*	*	*	*	*
Subchapter B—New Source Review Permits Nonattainment Review				
Section 116.150	New Major Source or Major Modification in Ozone Nonattainment Area.	02/24/99	[07/17/00 and page number]	
Section 116.151	New Major Source or Major Modification in Nonattainment Area Other than Ozone.	03/18/98	[07/17/00 and page number]	
*	*	*	*	*
Subchapter B—New Source Review Permits Emission Reductions: Offsets				
Section 116.170	Applicability for Reduction Credits	08/16/93	[07/17/00 and page number]	Note: 116.170(2) Not in SIP.

[FR Doc. 00–17876 Filed 7–14–00; 8:45 am]
BILLING CODE 6560–50–U

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[AL53–200019(a); FRL–6735–6]

Approval and Promulgation of State Plans—Alabama: Approval of Revisions to the Alabama State Implementation Plan: Transportation Conformity Interagency Memorandum of Agreement; Correction

AGENCY: Environmental Protection Agency (EPA).

ACTION: Direct final rule; correction.

SUMMARY: The United States Environmental Protection Agency (EPA) published in the Federal Register on May 11, 2000, a document approving the transportation conformity rule submitted by the Alabama Department of Environmental Management for the State of Alabama. The rule is being clarified and corrected to remove a sentence that was inadvertently included in the **Federal Register** document.

DATES: This correction is effective on July 17, 2000.

FOR FURTHER INFORMATION CONTACT: Kelly Sheckler at (404) 562–9042, sheckler.kelly@epa.gov.

SUPPLEMENTARY INFORMATION: The May 11, 2000, (65 FR 30358–30362) rulemaking included a statement in the first full paragraph in the first column on page 30360 that reads ''The MOA is enforceable against the parties by their consent in the MOA to allow the Attorney General for the State of Alabama to sue any or all of the agencies for specific performance of other relief on behalf of the citizens of Alabama in parren patrial.'' The Federal requirements for conformity do not require that the Attorney General for a state have this legal authority. Since the State of Alabama's submittal does not contain any such provisions for the Alabama Attorney General, the preamble language is amended to delete this sentence in its entirety.

Section 553 of the Administrative Procedure Act, 5 U.S.C. 553(b)(B), provides that, when an agency for good cause finds that notice and public procedure are impracticable, unnecessary or contrary to the public interest, the agency may issue a rule without providing notice and an opportunity for public comment. We have determined that there is good cause for making today's rule final

without prior proposal and opportunity for comment because we are merely correcting the preamble language in a previous action. Thus, notice and public procedure are unnecessary. We find that this constitutes good cause under 5 U.S.C. 553(b)(B).

Administrative Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a ''significant regulatory action'' and is therefore not subject to review by the Office of Management and Budget. Because the agency has made a ''good cause'' finding that this action is not subject to notice-and-comment requirements under the Administrative Procedure Act or any other statute as indicated in the Supplementary Information section above, it is not subject to the regulatory flexibility provisions of the Regulatory Flexibility Act (5 U.S.C. 601 et seq.), or to sections 202 and 205 of the Unfunded Mandates Reform Act of 1995 (UMRA) (Public Law 104–4). In addition, this action does not significantly or uniquely affect small governments or impose a significant intergovernmental mandate, as described in sections 203 and 204 of UMRA. This rule also does not significantly or uniquely affect the communities of tribal governments, as specified by Executive Order 13084 (63 FR 27655, May 10, 1998). This rule will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of governments, as specified by Executive Order 13132 (64 FR 43255, August 10, 1999). This rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant. This correction action does not involve technical standards; thus the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. The rule also does not involve special consideration of environmental justice related issues as required by Executive Order 12898 (59 FR 7629, February 16, 1994). In issuing this rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct, as required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996). EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1998) by examining the takings implications of the rule in accordance with the ''Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings'' issued under the executive order. This rule does not impose an information collection burden under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.).

The Congressional Review Act (5 U.S.C. 801 et seq.), as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. Section 808 allows the issuing agency to make a rule effective sooner than otherwise provided by the CRA if the agency makes a good cause finding that notice and public procedure is impracticable, unnecessary or contrary to the public interest. This determination must be supported by a brief statement. 5 U.S.C. 808(2). As stated previously, EPA had made such a good cause finding, including the reasons therefore, and established an effective date of July 17, 2000. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the **Federal Register**. This correction to the identification of plan for Alabama is not a ''major rule'' as defined by 5 U.S.C. 804(2).

Dated: June 30, 2000.

A. Stanley Meiburg,

Acting Regional Administrator, Region 4.

[FR Doc. 00–18024 Filed 7–14–00; 8:45 am]

BILLING CODE 6560–50–P

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Parts 1, 2, 15, 90 and 95

[ET Docket No. 99–255; PR Docket No. 92–235; FCC 00–211]

Wireless Medical Telemetry Service

AGENCY: Federal Communications Commission.

ACTION: Final rule.

SUMMARY: This document allocates new spectrum and establishes rules for a Wireless Medical Telemetry Service (WMTS) that allows potentially life-critical equipment to operate on an interference-protected basis. Medical telemetry equipment is used in hospitals and health care facilities to transmit patient measurement data, such as pulse and respiration rates to a nearby receiver, permitting greater patient mobility and increased comfort. This action will increase the reliability of medical telemetry equipment.

DATES EFFECTIVE: October 16, 2000.

FOR FURTHER INFORMATION CONTACT: Hugh Van Tuyl, Office of Engineering and Technology, (202) 418–7506.

SUPPLEMENTARY INFORMATION: This is a summary of the Commission's *Report and Order*, ET Docket 99–255 and PR Docket 92–235, FCC 00–211, adopted June 8, 2000, and released June 12, 2000. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC Reference Information Center, Room CY–A257, 445 12th Street, SW, Washington, DC, and also may be purchased from the Commission's duplication contractor, International Transcription Service, (202) 857–3800, 1231 20th Street, NW, Washington, DC 20036.

Summary of the Report and Order

1. The Report and Order establishes a new Wireless Medical Telemetry Service (WMTS) which will enhance the ability of health care providers to offer high quality and cost-effective care to patients with acute and chronic health care needs. This action addresses consumer concerns that medical telemetry devices are increasingly at risk of harmful interference due to more extensive use of spectrum resources by other applications. The Commission allocates 14 Megahertz (MHz) to WMTS on a primary basis, which will allow potentially life-critical medical telemetry equipment to operate on an interference-protected basis. The Commission also adopts service rules for WMTS that ''license by rule'' to minimize regulatory procedures to facilitate rapid deployment. Medical telemetry equipment is used in hospitals and health care facilities to transmit patient measurement data, such as pulse and respiration rates to a nearby receiver, permitting greater patient mobility and increased comfort. As this service permits remote monitoring of several patients simultaneously it could also potentially decrease health care costs. The Commission's action will improve the reliability of this vital service.

2. In the Notice of Proposed Rule Making (NPRM), 64 FR 41891, August 2, 1999, in this proceeding, we proposed to allocate spectrum where medical telemetry equipment could operate on a primary basis. We also proposed to establish a new Wireless Medical Telemetry Service (WMTS) under part

95 of the rules. The Commission's proposal was based on recommendations provided by the American Hospital Association's (AHA) Medical Telemetry Task Force, which was established in coordination with the FDA, in response to the incidence of interference to medical telemetry equipment from a DTV station.

Spectrum Allocation

3. We are making available 14 MHz of spectrum in three blocks located at 608–614 MHz, 1395–1400 MHz, and 1429–1432 MHz for wireless medical telemetry. In making available 14 MHz of spectrum, we note that these bands each have significant constraints, such that the entire allocation is unlikely to be available in any individual market. The 608–614 MHz band is constrained as a result of radio astronomy quiet zones, including some sites in large markets, and interference from adjacent TV channels. The remaining 8 MHz that we are allocating is constrained by adjacent band interference from high power radars located below 1390 MHz and grandfathered protected Federal sites. However, this allocation ensures that at least 6 MHz is available for WMTS in all locations, consistent with the AHA needs assessment, with at least some additional spectrum available to accommodate long term needs. We note that this is in fact significantly less than the amount of spectrum that is currently available to medical telemetry on an unprotected basis. However, we find that the benefits of a primary allocation dedicated to this service compensates for the reduced availability of spectrum. We wish to underscore that we do not anticipate any further allocations for medical telemetry devices and expect manufacturers and the health care community to ensure that this spectrum is used efficiently to meet long term needs. We also wish to note that this medical telemetry allocation is an exception to the approach we have been taking toward more flexible allocations that are not service specific. A specific allocation is necessary in this case to protect the public safety by providing spectrum where medical telemetry equipment can operate without interference. Further, it will resolve conflicts that have delayed the land mobile refarming and that are affecting the deployment of DTV.

Frequency Bands

4. The Notice proposed the following two options for frequency bands to be allocated to the WMTS:

Option 1	Option 2
608–614 MHz ..... 1395–1400 MHz ..... 1429–1432 MHz.	608–614 MHz 1391–1400 MHz

The 608–614 MHz band corresponds to TV channel 37, which is not used for TV stations and is currently reserved for radio astronomy. It is available for medical telemetry under part 15 of the rules on an unlicensed basis. The other proposed bands are former government bands that were reallocated for non-government use under the Omnibus Budget Reconciliation Act of 1993. Government operations in those bands may continue at certain sites around the country for a number of years.

5. We conclude that it is necessary to allocate spectrum where medical telemetry equipment can operate on a primary basis. Based on the record, we also conclude that WMTS's planned use is best accommodated by making three blocks of spectrum available in the 608–614 MHz, 1395–1400 MHz, and 1429–1432 MHz bands. We will coordinate the frequency allocations with Canadian and Mexican governments as appropriate. Given the low-power nature of this equipment, we do not anticipate any interference issues in border areas.

6. *608–614 MHz.* We find the 608–614 MHz band to be suitable for WMTS because, other than radio astronomy, it is only used for medical telemetry under part 15 of the rules. We also note that no commenters opposed the use of this band. Accordingly, we allocate this band to medical telemetry equipment on a co-primary basis with radio astronomy. Operation of medical telemetry equipment in this band must not cause interference to sensitive radio astronomy operations, and users will be required to coordinate their operation with radio astronomy facilities. We note that medical telemetry service providers operating on 608–614 MHz (television channel 37) currently must accept adjacent channel interference from broadcast television stations operating on channels 36 and 38. With this allocation, we are not requiring television broadcasters to protect WMTS from adjacent band interference. We believe that the multi-band approach that we are adopting provides sufficient flexibility to WMTS. WMTS providers can operate on one of the other bands that we are making available in situations where a hospital is in close proximity to a television station operating on channels 36 or 38. Furthermore, WMTS providers can design equipment to provide sufficient protection from adjacent channel interference as is current practice.

7. *1395–1400 MHz and 1429–1432 MHz.* In addition to the 608–614 MHz band, we are allocating the 1395–1400 MHz and 1429–1432 MHz bands for medical telemetry. Allocating the 1395–1400 MHz band instead of the alternative band we proposed will result in a 4 MHz greater frequency separation between medical telemetry and government radars operating below 1385 MHz, thereby reducing the risk of interference to medical telemetry equipment. We find that the frequency separation between the 1395–1400 MHz and the 1429–1432 MHz bands will give greater flexibility for medical telemetry by making the bands more useful for two-way communications than a single contiguous band at 1391–1400 MHz.

Service Rules

8. We adopt service rules for the new Wireless Medical Telemetry Service (WMTS). These service rules only apply to the WMTS that will operate at 608–614 MHz, 1395–1400 MHz, and 1429–1432 MHz, and not to the current medical telemetry operations permitted under parts 15 and 90. The rules include licensing requirements and technical standards for the equipment, as well as a frequency coordination procedure.

9. *Definition.* In the NPRM, 64 FR 41892, August 2, 1999, we proposed the following definition for medical telemetry:

Wireless medical telemetry is defined as the measurement and recording of physiological parameters and other patient-related information via radiated bi- or unidirectional electromagnetic signals.

10. We agree that allowing bi-directional transmissions could promote the development of more advanced medical telemetry equipment and encourage more efficient use of the spectrum. The split frequency allocation we are adopting in this item was selected in part to facilitate two-way communications. Accordingly, we are adopting a definition of medical telemetry that will allow bi-directional transmissions. We find it unnecessary to exclude voice and video transmissions in the definition for medical telemetry.

11. *Licensing.* There were no comments opposing our proposal that WMTS equipment be ''licensed by rule'', rather than requiring individual operators'' licenses. Individual licensing is generally designed to give a licensee a protected service area, and thus establishes rights among competing entities in the same service. Operators in the WMTS will not be in competition

with each other as are parties in other radio services. The WMTS spectrum will be shared among medical telemetry users, and there will be no mutual exclusivity between users. In addition, ''licensing by rule'' will minimize regulatory procedures and thus facilitate deployment. We are therefore adopting our proposal that the WMTS exist as one of the Citizen's Band services contained in part 95 of the rules and that the equipment used in this service be ''licensed by rule''. The Commission has authority under Section 307(e) of the Communications Act to define the citizen's band radio services and to license them by rule.

12. *Eligibility.* We proposed that only authorized health care providers be eligible to operate transmitters in the WMTS. For the purpose of this service, an ''authorized health care provider'' would be defined as (1) a physician or other individual authorized under state or federal law to provide health care services; (2) a health care facility operated by or employing individuals authorized under state or federal law to provide health care services; or (3) any trained technician under the supervision and control of an individual or health care facility authorized under state or federal law to provide health care services. We proposed to define a ''health care provider facility'' as a hospital or other establishment that offers services, facilities and beds for use beyond a 24 hour period in rendering medical treatment, and organizations regularly engaged in providing medical services through clinics, public health facilities and similar establishments, including government entities and agencies such as Veterans Administration Hospitals. Health care facilities on tribal lands would also be included under our proposed definition. A health care facility would not include an ambulance or other moving vehicle, and this definition would also not allow home use of WMTS equipment. We are adopting these eligibility definitions as proposed.

13. *Frequency coordination.* The comments supported our proposal to designate a frequency coordinator to maintain a database of all WMTS equipment identified by location, operating frequency, emission type and output power. NTIA notes that a frequency coordinator would facilitate band sharing between hospitals and the remaining government operations at protected sites. Accordingly, we are adopting the proposal to designate a frequency coordinator to maintain a database of WMTS equipment. Without a database, there would be no record of WMTS usage because WMTS transmitters will not be individually licensed. The database will provide a record of the frequencies used by each facility or device to assist parties in selecting frequencies to avoid interference. The database will be used by eligible users and manufacturers to plan for specific frequency use within a geographic area, especially where numerous WMTS operations may occur.

14. The frequency coordinator will not be a decision maker as to which frequency should be used. Rather, the coordinator will notify users of potential frequency conflicts, and users should be able to resolve any conflicts among themselves. We expect that there will be few conflicts between users of WMTS equipment due to its low operating power, but the Commission will make the final decision on a case-by-case basis in disputes between users, if necessary. The coordinator must be familiar with the medical telemetry user community, and must make its services available to all parties on a first-come, first-served and non-discriminatory basis. The frequency coordinator must be willing to serve a five-year term, which could be renewed by the Commission. In the event that a frequency coordinator does not wish to continue at the end of its term, it will have to transfer its database to another designated entity.

15. The NPRM, 64 FR 41892, August 2, 1999, asked for comments on the following questions about the frequency coordinator: (1) any other qualifications that a frequency coordinator must have, (2) whether a single entity or multiple entities should be designated as frequency coordinator(s), (3) how the frequency records could be maintained with multiple coordinators, and (4) whether we should limit the fees the frequency coordinator(s) can charge.

16. Several entities expressed an interest in being a frequency coordinator for WMTS. In the past the Commission has tried, where appropriate, to introduce market forces into the frequency coordination process. Therefore, rather than adopt a Commission rule restricting database management of WMTS spectrum to a single coordinator, we will leave the ultimate decision on the number of coordinators up to the Commission's Wireless Telecommunications Bureau (WTB). WTB already has delegated authority to select frequency coordinators in the services it administers. WTB will announce its coordination selection procedures in a Public Notice in the near future. We have not found it necessary to set limits on the fees charged by coordinators in other services, and we have no reason to believe that fee limits will be necessary in the WMTS. Accordingly, we will allow the designated coordinator to set the fee structure as necessary to recoup costs.

17. The NPRM, 64 FR 41892, August 2, 1999, proposed that certain information be submitted to the frequency coordinator for inclusion on the database, including:

(1) Frequency range(s) used
(2) Modulation scheme used
(3) Effective radiated power
(4) Number of transmitters in use at the health care facility at the time of registration
(5) Legal name of the authorized health care provider
(6) Location of transmitter (coordinates, street address, building)
(7) Point of contact for the authorized health care provider.

We find that including the equipment manufacturer and model number in the database could be useful for helping the frequency coordinator and users in determining the interference potential of WMTS equipment. This information could also assist the Commission or the FDA in locating certain devices in the event a question of compliance with the rules arose. Accordingly, we will specify that the equipment manufacturer and model number be submitted to the frequency coordinator for inclusion on the database. Much of the other information (fax numbers, e-mail addresses, assigned frequencies and occupied bandwidth) simply represents a more detailed description of the information we proposed. We agree with these recommendations and are including them in the final rules. We recognize that including the name of the health care provider and point of contact in the database could possibly make that information available to commercial entities. However, we find that this information is necessary to allow the coordinator and parties using the WMTS to contact other users to verify information and resolve potential conflicts. Thus, we will require the name of the health care provider and a point of contact to be included on the database. Including this information should not raise issues of privacy of patient information, because the database will not contain the patient names or other patient identification information.

18. We find that requiring periodic equipment registration renewals from health care providers to be an unnecessary burden. Most hospitals would find it difficult to remember to renew their registrations after five years have passed, and requiring coordinators

to send out periodic renewal notices and process renewal applications could significantly increase their workload. However, we will not preclude coordinators from verifying the continued use of registered equipment on an ''as needed'' basis, such as when the database shows a conflict between a registered user and a new user. Accordingly, we are adopting our proposal that equipment registrations will remain valid until the health care provider requests cancellation. Restricting access to the database to certain parties would be difficult and burdensome for the coordinator because the coordinator would have to verify that each and every party accessing the database has a need for the information that is related to health care. Such restrictions could make it difficult for parties with legitimate needs for information to view the database. We therefore find that the database should be open to all parties.

19. *Permissible communications.* We proposed that the WMTS could be used for all types of communications, except for voice or video transmissions. We proposed to exclude these types of transmissions because we were concerned that video could occupy a significant portion of the spectrum allocated to the WMTS, and that allowing voice transmissions could encourage the equipment to be used as a form of wireless intercom.

20. We find that the transmission of waveform information such as electrocardiograms (ECGs) is within the intended purpose of the WMTS, which is to transmit vital patient data. Accordingly, we will permit the transmission of waveform information in the WMTS. However, allowing the general purpose use of video in the WMTS could potentially result in video occupying a large portion of the available spectrum. This is a greater concern initially because portions of the WMTS spectrum will be unavailable for a number of years in parts of the country due to grandfathered government operations. We are not persuaded that there is currently a need for voice capabilities in telemetry equipment, and we reiterate our concern that allowing such capabilities could encourage use of the equipment for other than its intended purpose of transmitting patient data. Accordingly, we will prohibit voice and video transmissions in the WMTS at this time, but we may revisit the issue at a later date after government operations cease in the WMTS bands.

21. *Technical Standards.* We proposed only minimal technical standards for WMTS equipment to give manufacturers the flexibility to develop different applications for medical telemetry. We did not propose a specific channelization scheme for the 1395–1400 MHz and 1429–1432 MHz bands. However, to prevent users from monopolizing the 608–614 MHz band, we proposed that equipment using broadband technologies, such as spread spectrum, be capable of operating on channels of 1.5 MHz each, up to a maximum of 6 MHz. Such equipment would operate on the minimum number of channels necessary, and must have the capability of being ''throttled back'' so it will occupy as little as one 1.5 MHz channel, if necessary, to allow multiple users to share that band. There were no objections to the proposed requirement on maximum channel usage in the 608–614 MHz band, so we are adopting this requirement which will allow the WMTS spectrum to be used more efficiently.

22. We proposed the following field strength limits for transmitters in the WMTS.

Frequency band	Maximum field strength	Measurement distance	Measurement bandwidth	Detector function
608–614 MHz	200 mV/m	3 meters	120 +/−20 kHz	CISPR QP.
1395–1400 MHz	740 mV/m	3 meters	1 MHz	Average.
1429–1432 MHz	740 mV/m	3 meters	1 MHz	Average.

23. We proposed the same out-of-band field strength limits for transmitters in the WMTS bands that are used for most intentional radiators under part 15 of the rules. We have found those limits to be effective at controlling interference. There were no objections to applying the part 15 out-of-band emission limits to WMTS equipment, and we are adopting them.

24. *Protection of other existing services.* The WMTS must not cause interference to radio astronomy operations, and to certain grandfathered government operations. We are therefore adopting rules requiring the coordination of WMTS operations in the 608–614 MHz band with radio astronomy operations, which are the same as the coordination requirements currently found in part 15. The rules also require operators in the 1395–1400 MHz and 1429–1432 MHz bands to protect certain government operations. Finally, parties using WMTS equipment should be aware that the operation of transmitters in close proximity to medical equipment could cause interference to the operation of the medical equipment. The rules provide a warning to this effect, which is the same warning found in part 15.

25. *RF Safety.* We do not currently require the routine evaluation of medical telemetry equipment for compliance with the radiofrequency (RF) radiation safety guidelines in our rules due to the low power of the equipment. The NPRM, 64 FR 41892, August 2, 1999 did not propose to require RF safety measurements for WMTS equipment because such equipment would also operate at relatively low power levels.

26. Our rules for RF safety classify equipment into two categories: (1) mobile devices, which normally operate with at least a 20 centimeter separation from the radiating element to the body of the user or a nearby person , and (2) portable devices, which normally operate with less than a 20 centimeter separation from the radiating element to the body of the user. Based upon our analysis, we agree that portable WMTS equipment could possibly exceed the RF safety guidelines in our rules. Accordingly, we will require routine environmental evaluation for RF exposure of portable WMTS equipment prior to equipment authorization or use. We expect that the majority of WMTS equipment will be classified as ''portable'' because medical telemetry transmitters are typically worn on the body. However, we realize that there may be some applications where the transmitter is separated from the body by more than 20 centimeters, such as a unit mounted on a bed or incorporated within a separate device. Consistent with the RF safety requirements for other services, mobile WMTS equipment will be categorically excluded from routine environmental evaluation because WMTS equipment complying with the technical requirements we are adopting will operate with an effective radiated power (ERP) of less than 1.5 watts, which is the threshold for the exclusion of equipment operating below 1.5 GHz.

27. *Equipment authorization requirement.* The NPRM, 64 FR 41892,

August 2, 1999 proposed authorizing WMTS transmitters through the Declaration of Conformity (DoC) procedure in part 2 of the rules. DoC is a manufacturer's self-approval procedure where the equipment is tested to ensure it complies with the Commission's technical standards, and may then be marketed without an approval by the Commission.

28. The certification procedure requires the manufacturer to file electronically a test report showing the equipment complies with the rules along with other supporting documentation to the Commission or to a designated Telecommunication Certification Body (TCB). The equipment may not be marketed until an approval has been received from the Commission or a TCB. Upon further consideration, we agree that certification is the appropriate authorization procedure for WMTS equipment. WMTS equipment involves new technologies, and the majority will be subject to routine environmental evaluation for RF safety. Requiring certification is consistent with the actions we have taken in similar cases, such as the Medical Implant Communication Service (MICS) in part 95. However, we note that procedures for making the RF exposure measurements are currently under development. When such procedures are developed, we may consider relaxing the certification requirement for medical telemetry equipment.

Transition Provisions

29. *Equipment authorization.* We proposed that all new medical telemetry equipment that receives an equipment authorization starting two years after the adoption of final rules must operate in the newly authorized frequency bands. Two years is a reasonable timetable for requiring manufacturers to produce equipment to operate in the new bands. Based on the comments received, we are confident that manufacturers will be able to meet this deadline. We decline to allow equipment approved after that deadline to have the capability of operating in the current part 15 and part 90 bands. Our goal in this proceeding is to not only provide spectrum where medical telemetry he Commission has taken, such as the freeze in the 450–470 MHz band and the requirement for DTV stations to notify nearby health care facilities, affect other parties. We therefore wish to encourage medical telemetry users to migrate out of the current frequency bands and into the new frequency bands. Allowing the development of new equipment that can operate in the old bands after the transition date would discourage the eventual migration to the new bands.

30. *Grandfathering.* Requiring the replacement of functional medical telemetry systems that are not subject to interference would be an unnecessary financial burden on hospitals. Accordingly, we will permit medical telemetry equipment that has received an equipment authorization to operate in current part 15 and part 90 bands prior to the two year transition date to be manufactured, imported, marketed and operated without a cutoff date. This action will ensure that manufacturers will be able to make replacement parts for systems operating in the old bands, and that hospitals will be permitted to operate their existing systems as long as possible until replacement is necessary due to age or interference concerns.

31. *Existing equipment registration.* We find it unlikely that a complete database of all part 15 and part 90 medical telemetry transmitters could be developed prior to the transition to the new frequency bands. However, placing even some transmitters in a database could possibly assist parties in avoiding cases of interference. We therefore have no objection to allowing the voluntary registration of existing part 15 and part 90 medical telemetry devices. The rules we are adopting allow frequency coordinators to process voluntary requests to register equipment operating under parts 15 and 90.

450–470 MHz Freeze

32. In 1995, the Commission adopted changes to part 90 of the rules to allow more efficient use of the spectrum for land mobile services. These changes permitted high power operations on channels in the 450–470 MHz band. However, under the new channeling scheme, high-power primary users of the band would be able to operate on the same frequencies used for medical telemetry equipment. This could possibly result in interference to medical telemetry equipment. For this reason, on August 11, 1995, the Commission placed a freeze on the filing of applications for high power operation in the 450–470 MHz band on the 12.5 kHz offset channels.

33. *450–460 MHz band freeze.* On October 20, 1999, the Commission issued a public notice asking parties operating medical telemetry equipment in the 450–460 MHz band to provide certain information to the Commission. We received responses from 25 parties around the country operating in this band. The majority of these users were operating a small number of devices on a limited number of frequencies around 457 and 458 MHz. Based on the limited usage of the 450–460 MHz band for medical telemetry, we find that the freeze on high-power land mobile applications in the 450–460 MHz band can be lifted. Accordingly, the Wireless Telecommunications Bureau will issue a public notice announcing the lifting of the freeze in this band in the near future.

34. *460–470 band freeze.* We find that a five-year transition period is longer than is necessary to prepare for the lifting of the freeze in the 460–470 MHz band. The freeze was announced almost five years ago, so hospitals have been on notice that they may eventually have to change frequencies. Equipment is already available to operate in the 608–614 MHz band we are allocating in this proceeding, and equipment to operate in the other bands allocated in this proceeding should become available over the next two years. Five more years should not be required for hospitals to make the transition. We will therefore lift the freeze on high power land mobile application in the 460–470 MHz band within three years from the effective date of final rules in this proceeding.

35. The NPRM, 64 FR 41892, August 2, 1999, did not propose to preclude medical telemetry equipment from operating in the ISM bands under part 15 because only a small number of devices operate under these provisions. Therefore, there is not the same potential for a large number of cases of interference to medical telemetry equipment in these bands as there is for medical telemetry equipment operating in the TV and PLMR bands. We expect that the majority of medical telemetry equipment manufacturers will design equipment for the new bands allocated in this proceeding, and that only a small number of devices will continue to use the ISM bands. There, we will continue to allow medical telemetry equipment to operate in the ISM bands under part 15. While such operation will be permissible, manufacturers and users are cautioned that equipment operating in these bands has no protection from interference from ISM equipment operating under part 18 of the rules or other low power transmitters operating under part 15 of the rules.

36. Pursuant to sections 4(I), 11, 301, 302, 303(e), 303(f), 303(r) 304, 307 and 332(b) of the Communications Act of 1934, as amended, 47 U.S.C. 154(i), 161, 301, 302, 303(3), 303(f), 303(r), 304, 307 and 332(b).

Final Regulatory Flexibility Analysis

37. As required by the Regulatory Flexibility Act (RFA), [1] an Initial Regulatory Flexibility Analysis (IRFA) was incorporated in the Notice of Proposed Rule Making, Amendment of parts 2 and 95 of the Commission's Rules to Establish a Wireless Medical Telemetry Service. [2] The Commission sought written public comment on the proposals in the Notice, including comment on the IRFA. The comments received are discussed below. This present Final Regulatory Flexibility Analysis (FRFA) conforms to the RFA. [3]

A. Need for, and Objectives of, the Report and Order

38. Medical telemetry equipment currently operates on an unlicensed basis on certain unused TV channels under part 15 of the rules, and on a secondary basis to private land mobile services in the 450–470 MHz band under part 90 of the rules. With the transition to digital TV service, both full power and low-power TV stations may begin operating on some of the vacant channels used by medical telemetry equipment. In addition, the new channelization scheme being implemented in the 450–470 MHz band will allow high-power operation on the channels currently reserved for low-power use where medical telemetry equipment operates. Both of these changes could result in severe interference to medical telemetry equipment. The rules adopted in the Report and Order allocate new frequency bands where medical telemetry equipment can operate on a primary basis without receiving interference.

B. Summary of Significant Issues Raised by Public Comments in Response to the IRFA

39. There were no timely filed comments in response to the IRFA. The Office of Advocacy, U.S. Small Business Administration (SBA) filed ''reply comments'' after the comment deadline, but prior to the reply comment deadline. Because they do not respond to comments on the IRFA, they are in fact untimely filed comments. Nevertheless, we will address the issues raised by the SBA.

40. The SBA claims two deficiencies on the part of the Commission in this proceeding. First, SBA states that the NPRM did not consider the impact of the proposed rules on small businesses. [4] Second, SBA states that the IRFA does not describe the impact of the rules on small businesses and does not provide significant alternatives designed to minimize this impact. [5]

41. We believe SBA is clearly in error on the first point. The RFA only requires agencies to provide an analysis of the impact of the proposed rules on small businesses in the IRFA. [6] There is no requirement in the RFA to provide such an analysis in the NPRM, which would unnecessarily duplicate the analysis in the IRFA. Thus we reject SBA's first claim.

42. We disagree with SBA on the second point as well. The RFA requires the Commission to provide an analysis that discusses significant alternatives such as (1) the establishment of differing compliance or reporting requirements or timetables that take into account the resources available to small entities; (2) the clarification, consolidation, or simplification of compliance and reporting requirements under the rule for such small entities; (3) the use of performance rather than design standards; and (4) an exemption from coverage of the rule, or any part thereof, for such small entities. [7] These are merely examples of the type of information that should be included; this list is not a rigid checklist. The IRFA included with the NPRM in this proceeding did in fact include an analysis of the type required by the RFA. Specifically, it discussed the simplified compliance and reporting requirements we considered to minimize the impact of the rules on small businesses. We considered the effect on small business from the outset and made the rules apply equally to all parties. Thus, we consider the IRFA in this proceeding to be adequate. We further note that no other parties had any objections to the IRFA or considered it to be inadequate.

C. Description and Estimate of the Number of Small Entities To Which the Proposed Rules Will Apply

43. The RFA directs agencies to provide a description of, and, where feasible, an estimate of the number of small entities that may be affected by the proposed rules, if adopted.[8] Under the RFA, small entities may include small organizations, small businesses, and small governmental jurisdictions. 5 U.S.C. 601(6). The RFA, 5 U.S.C. 601(3), generally defines the term ''small business'' as having the same meaning as the term ''small business concern'' under the Small Business Act, 15 U.S.C. 632. A small business concern is one which: (1) Is independently owned and operated; (2) is not dominant in its field of operation; and (3) satisfies any additional criteria established by the SBA. This standard also applies in determining whether an entity is a small business for purposes of the RFA.

44. The Commission has not developed a definition of small entities applicable to RF Equipment Manufacturers. Therefore, the applicable definition of small entity is the definition under the SBA rules applicable to manufacturers of ''Radio and Television Broadcasting and Communications Equipment.'' According to the SBA's regulation, an RF manufacturer must have 750 or fewer employees in order to qualify as a small business.[9] Census Bureau data indicates that there are 858 companies in the United States that manufacture radio and television broadcasting and communications equipment, and that 778 of these firms have fewer than 750 employees and would be classified as small entities.[10] Therefore, we believe that many of the companies that manufacture RF equipment would qualify as small entities.

45. According to the SBA's regulations, nursing homes and hospitals must have annual gross receipts of $5 million or less in order to qualify as a small business concern. 13 CFR 121.201. There are approximately 11,471 nursing care firms in the nation, of which 7,953 have annual gross receipts of $5 million or less.[11] There are approximately 3,856 hospital firms in the nation, of which 294 have gross receipts of $5 million or less. Thus, the approximate number of small confined setting entities to which the Commission's new rules will apply is 8,247.

[1] See *5 U.S.C. 603*. The RFA, see *5 U.S.C. 601* et seq., has been amended by the Contract With America Advancement Act of 1996, *Public Law 104–121*, 110 Stat. 847 (1996) (CWAAA). Title II of the CWAAA is the Small Business Regulatory Enforcement Fairness Act of 1996 (SBREFA).

[2] See *Notice of Proposed Rule Making* in ET Docket 99–255, 64 FR 41891, 41896 (August 2, 1999).

[3] See *5 U.S.C. 604*.

[4] See SBA comments at 1–2.

[5] See SBA comments at 2–3.

[6] See *5 U.S.C. 603*(a).

[7] *See 5 U.S.C. 603*(c).

[8] *See 5 U.S.C. 603*(b)(3).

[9] *See 13 CFR 121.201*, Standard Industrial Classification (SIC) Code 3663.

[10] *See* U.S. Department of Commerce, 1992 Census of Transportation, Communications and Utilities (issued May 1995), SIC category 3663.

[11] *See* Small Business Administration Tabulation File, SBA Size Standards Table 2C, January 23, 1996, SBA, Standard Industrial Code (SIC) categories 8050 (Nursing and Personal Care Facilities) and 8060 (Hospitals). (SBA Tabulation File)

D. Description of Projected Reporting, Recordkeeping, and Other Compliance Requirements

46. WMTS equipment will be authorized through the certification procedure. The certification procedure requires the manufacturer to file electronically a test report showing the equipment complies with the rules along with other supporting documentation to the Commission or to a designated Telecommunication Certification Body (TCB). The equipment may not be marketed or operated until an approval has been received from the Commission or TCB. This is the same process adopted by the Commission for the Medical Implant Communication Service (MICS).[12] We are requiring that all parties including small businesses have their equipment approved though the certification procedure because of concerns over radiofrequency radiation safety.

47. Parties operating the equipment will not be required to obtain an individual operator's license from the Commission, but they will have to register with a frequency coordinator designated by the Commission. The Commission may designate multiple coordinators to provide competition to keep costs at a minimum. The information submitted to the frequency coordinator will be:

(1) Specific frequencies or frequency range(s) used;

(2) Modulation scheme used (including occupied bandwidth);

(3) Effective radiated power;

(4) Number of transmitters in use at the health care facility as of the date of registration (including manufacturer name(s) and model numbers);

(5) Legal name of the authorized health care provider;

(6) Location of transmitter (coordinates, street address, building);

(7) Point of contact for the authorized health care provider (name, title, office, phone number, fax number, e-mail address).

E. Steps Taken to Minimize Significant Economic Impact on Small Entities, and Significant Alternatives Considered.

48. We are not requiring individual operators' licenses for equipment in the WMTS. Instead, the equipment will be ''licensed by rule'', meaning that users are permitted to operate WMTS equipment that complies with rules without the need to apply for a license from the Commission. Licensing by rule benefits small businesses by eliminating the expense and delays that would result if parties were required to obtain individual operators' licenses.

49. New equipment for the WMTS will not have to operate in the newly allocated frequency bands until two years after the effective date of the new rules. This will allow sufficient time for manufacturers to develop equipment for the new bands, thus reducing the development costs for small businesses. We are also allowing equipment in the old frequency bands that has received an equipment authorization before the two year transition date to be manufactured, imported, marketed and operated without a cutoff date. This will ensure that replacement parts are available for existing telemetry systems and that hospitals will be able to use their existing systems as long as possible before replacement is required, thus reducing expenses for small businesses.

50. There is currently a freeze on high-power land mobile operations in the 450–470 MHz band. The freeze was put in effect in 1995 to protect medical telemetry in that band from interference. We are providing a three-year transition period before lifting the freeze in the 460–470 MHz band. This will assist small businesses by providing adequate time for medical telemetry users to begin migration to the new frequency bands, if necessary. The freeze in the 450–460 MHz band will be lifted shortly after release of this Order because we have determined that little medical telemetry equipment operates in this portion of the band. Therefore, there will be little impact on small businesses.

Report to Congress: The Commission will send a copy of the *Report and Order, Amendment of parts 2 and 95 of the Commission's Rules to Establish a Wireless Medical Telemetry Service*, including this FRFA, in a report to be sent to Congress pursuant to the SBREFA, *see* 5 U.S.C. 801(a)(1)(A). In addition, the Commission will send a copy of the *Report and Order*, including FRFA, to the Chief Counsel for Advocacy of the SBA.

List of Subjects

47 CFR Part 1

Reporting and recordkeeping requirements

47 CFR Part 2 and 95

Communications equipment, Reporting and recordkeeping requirement.

47 CFR Part 15

Communications equipment.

47 CFR Part 90

Communications equipment, Emergency medical services.

Federal Communications Commission.

William F. Caton,

Deputy Secretary.

Rules Changes

For the reasons discussed in the preamble, the Federal Communications Commission amends 47 CFR parts 1, 2, 15, 90, and 95 as follows:

PART 1—PRACTICE AND PROCEDURE

1. The authority citation for part 1 continues to read as follows:

Authority: 47 U.S.C. 151, 154(i), 154(j), 155, 225, 303(r), 309 and 325(e).

2. Section 1.1307 is amended by revising paragraph (b)(2) to read as follows:

§ 1.1307 Actions that may have a significant environmental effect, for which Environmental Assessments (EAs) must be prepared.

* * * * *

(b) * * *

(2) Mobile and portable transmitting devices that operate in the Cellular Radiotelephone Service, the Personal Communications Services (PCS), the Satellite Communications Services, the General Wireless Communications Service, the Wireless Communications Service, the Maritime Services (ship earth stations only) and the Specialized Mobile Radio Service authorized under Subpart H of parts 22, 24, 25, 26, 27, 80, and 90 of this chapter are subject to routine environmental evaluation for RF exposure prior to equipment authorization or use, as specified in §§ 2.1091 and 2.1093 of this chapter. Unlicensed PCS, unlicensed NII and millimeter wave devices are also subject to routine environmental evaluation for RF exposure prior to equipment authorization or use, as specified in §§ 15.253(f), 15.255(g), 15.319(i), and 15.407(f) of this chapter. Portable transmitting equipment for use in the Wireless Medical Telemetry Service (WMTS) is subject to routine environment evaluation as specified in §§ 2.1093 and 95.1125 of this chapter. Equipment authorized for use in the Medical Implant Communications Service (MICS) as a medical implant transmitter (as defined in Appendix 1 to Subpart E of part 95 of this chapter) is subject to routine environmental evaluation for RF exposure prior to equipment authorization, as specified in § 2.1093 of this chapter by finite difference time domain computational

[12] *See* para. 53, *supra*.

modeling or laboratory measurement techniques. Where a showing is based on computational modeling, the Commission retains the discretion to request that specific absorption rate measurement data be submitted. All other mobile, portable, and unlicensed transmitting devices are categorically excluded from routine environmental evaluation for RF exposure under §§ 2.1091, 2.1093 of this chapter except as specified in paragraphs (c) and (d) of this section.

* * * * *

PART 2—FREQUENCY ALLOCATIONS AND RADIO TREATY MATTERS; GENERAL RULES AND REGULATIONS

3. The authority citation for part 2 continues to read as follows:

Authority: 47 U.S.C. 154, 302, 303, 307, 336, and 337, unless otherwise noted.

4. Section 2.106 is amended as follows:

a. Revise the entries for the MHz bands of the Table of Frequency Allocations to read as follows.

b. In the United States (US) footnotes, revise footnote US246 and add footnotes US350, US351, and US352.

c. In the Government (G) footnotes, revise footnotes G27, G30, and G114.

The revisions and additions read as follows:

§ 2.106 Table of frequency allocations.

* * * * *

BILLING CODE 6712–01–W

470-849 MHz (UHF) Page 37

International Table			United States Table		FCC Rule Part(s)
Region 1	Region 2	Region 3	Federal Government	Non-Federal Government	
470-790 BROADCASTING	470-512 BROADCASTING Fixed Mobile S5.292 S5.293	470-585 FIXED MOBILE BROADCASTING S5.291 S5.298	470-608	470-512 FIXED BROADCASTING LAND MOBILE NG66 NG114 NG127 NG128 NG149	Public Mobile (22) Broadcast Radio (TV) (73) Auxiliary Broadcasting (74) Private Land Mobile (90)
	512-608 BROADCASTING S5.297	585-610 FIXED MOBILE BROADCASTING RADIONAVIGATION S5.149 S5.305 S5.306 S5.307		512-608 BROADCASTING NG128 NG149	Broadcast Radio (TV) (73) Auxiliary Broadcasting (74)
	608-614 RADIO ASTRONOMY Mobile-satellite except aeronautical mobile-satellite (Earth-to-space)	610-890 FIXED MOBILE BROADCASTING	608-614 LAND MOBILE US350 RADIO ASTRONOMY US74 US246		Personal (95)
	614-806 BROADCASTING Fixed Mobile		614-890	614-698 BROADCASTING NG128 NG149	Broadcast Radio (TV) (73) Auxiliary Broadcast. (74)
				698-746 BROADCASTING NG128 NG149	Broadcast Radio (TV) (73) Auxiliary Broadcast. (74) Note: Band to be reallocated and auction-ed by Sept. 30, 2002.

1300-1350 AERONAUTICAL RADIONAVIGATION S5.337 Radiolocation S5.149		1300-1350 AERONAUTICAL RADIO-NAVIGATION S5.337 Radiolocation G2 S5.149	1300-1350 AERONAUTICAL RADIO-NAVIGATION S5.337 S5.149	Aviation (87)
1350-1400 FIXED MOBILE RADIOLOCATION S5.149 S5.338 S5.339	1350-1400 RADIOLOCATION S5.149 S5.334 S5.339	1350-1390 FIXED MOBILE RADIOLOCATION G2 S5.149 S5.334 S5.339 US311 G27 G114	1350-1390 S5.149 S5.334 S5.339	
		1390-1395 RADIOLOCATION G2 Fixed Mobile S5.149 S5.339 US311 US351 G27 G114	1390-1395 S5.149 S5.339 US351	Note: 1390-1395 MHz became non-Federal Government exclusive spectrum in January 1999
		1395-1400 LAND MOBILE US350 S5.149 US5.339 US311 US351	1395-1400 LAND MOBILE US350 S5.149 US5.339 US311 US351	Personal (95)
1400-1427 EARTH EXPLORATION-SATELLITE (passive) RADIO ASTRONOMY SPACE RESEARCH (passive) S5.340 S5.341		1400-1427 EARTH EXPLORATION-SATELLITE (passive) RADIO ASTRONOMY US74 SPACE RESEARCH (passive) S5.341 US246		
1427-1429 SPACE OPERATION (Earth-to-space) FIXED MOBILE except aeronautical mobile S5.341		1427-1429 SPACE OPERATION (Earth-to-space) FIXED MOBILE except aeronautical mobile S5.341 G30	1427-1429 SPACE OPERATION (Earth-to-space) Fixed (telemetry) Land mobile (telemetry and telecommand) S5.341	Satellite Communications (25) Private Land Mobile (90) Note: 1427-1429 MHz became non-Federal government exclusive spectrum in January 1999

1429-1610 MHz (UHF) Page 43

International Table			United States Table		FCC Rule Part(s)
Region 1	Region 2	Region 3	Federal Government	Non-Federal Government	
1429-1452 FIXED MOBILE except aeronautical mobile S5.341 S5.342	1429-1452 FIXED MOBILE S5.343 S5.341		1429-1432 LAND MOBILE US350 S5.341 US352	1429-1432 LAND MOBILE US350 Fixed (telemetry) Land mobile (telemetry and telecommand) S5.341 US352	Private Land Mobile (90) Personal (95)
			1432-1435 FIXED MOBILE S5.341 G30	1432-1435 Fixed (telemetry) Land mobile (telemetry and telecommand) S5.341	Private Land Mobile (90) Note: 1432-1435 MHz became mixed-use spectrum in January 1999.
1452-1492 FIXED MOBILE except aeronautical mobile BROADCASTING S5.345 S5.347 BROADCASTING-SATELLITE S5.345 S5.347 S5.341 S5.342	1452-1492 FIXED MOBILE S5.343 BROADCASTING S5.345 S5.347 BROADCASTING-SATELLITE S5.345 S5.347 S5.341 S5.344		1435-1525 MOBILE (aeronautical telemetry) S5.341 US78		Aviation (87)
1492-1525 FIXED MOBILE except aeronautical mobile S5.341 S5.342	1492-1525 FIXED MOBILE S5.343 MOBILE-SATELLITE (space-to-Earth) S5.348A S5.341 S5.344 S5.348	1492-1525 FIXED MOBILE S5.341 S5.348A			
1525-1530 SPACE OPERATION (space-to-Earth) FIXED MOBILE-SATELLITE (space-to-Earth) Earth exploration-satellite Mobile except aeronautical mobile S5.349 S5.341 S5.342 S5.350 S5.351 S5.352A S5.354	1525-1530 SPACE OPERATION (space-to-Earth) MOBILE-SATELLITE (space-to-Earth) Earth exploration-satellite Fixed Mobile S5.343 S5.341 S5.351 S5.354	1525-1530 SPACE OPERATION (space-to-Earth) FIXED MOBILE-SATELLITE (space-to-Earth) Earth exploration-satellite Mobile S5.349 S5.341 S5.351 S5.352A S5.354	1525-1530 MOBILE-SATELLITE (space-to-Earth) Mobile (aeronautical telemetry) S5.341 S5.351 US78		Satellite Communications (25) Aviation (87)

1530-1535 SPACE OPERATION (space-to-Earth) MOBILE-SATELLITE (space-to-Earth) S5.353A Earth exploration-satellite Fixed Mobile except aeronautical mobile S5.341 S5.342 S5.351 S5.354	1530-1535 SPACE OPERATION (space-to-Earth) MOBILE-SATELLITE (space-to-Earth) S5.353A Earth exploration-satellite Fixed Mobile S5.343 S5.341 S5.351 S5.354	1530-1535 MOBILE-SATELLITE (space-to-Earth) MARITIME MOBILE-SATELLITE (space-to-Earth) Mobile (aeronautical telemetry) S5.341 S5.351 US78 US315	
1535-1559 MOBILE-SATELLITE (space-to-Earth) S5.341 S5.351 S5.353A S5.354 S5.355 S5.356 S5.357 S5.357A S5.359 S5.362A		1535-1544 MOBILE-SATELLITE (space-to-Earth) MARITIME MOBILE-SATELLITE (space-to-Earth) S5.341 S5.351 US315	Satellite Communications (25) Maritime (80)
		1544-1545 MOBILE-SATELLITE (space-to-Earth) S5.341 S5.356	
		1545-1549.5 AERONAUTICAL MOBILE-SATELLITE (R) (space-to-Earth) Mobile-satellite (space-to-Earth) S5.341 S5.351 US308 US309	Aviation (87)
		1549.5-1558.5 AERONAUTICAL MOBILE-SATELLITE (R) (space-to-Earth) MOBILE-SATELLITE (space-to-Earth) S5.341 S5.351 US308 US309	
		1558.5-1559 AERONAUTICAL MOBILE-SATELLITE (R) (space-to-Earth) S5.341 S5.351 US308 US309	
1559-1610 AERONAUTICAL RADIONAVIGATION RADIONAVIGATION-SATELLITE (space-to-Earth) S5.341 S5.355 S5.359 S5.363		1559-1610 AERONAUTICAL RADIONAVIGATION RADIONAVIGATION-SATELLITE (space-to-Earth) S5.341 US208 US260	Note: The *NTIA Manual* (footnote G126) states that differential GPS stations may be authorized in the 1559-1610 MHz band, but the FCC has not yet addressed this footnote.

BILLING CODE 6712–01–C

* * * * *

United States (US) Footnotes

* * * * *

US246 Except for medical telemetry equipment operating in the band 608–614 MHz, no stations shall be authorized to transmit in the following bands: 608–614 MHz, 1400–1427 MHz, 1660.5–1668.4 MHz, 2690–2700 MHz, 4990–5000 MHz, 10.68–10.70 GHz, 15.35–15.40 GHz, 23.6–24.0 GHz, 31.3–31.8 GHz, 51.4–54.25 GHz, 58.2–59.0 GHz, 64–65 GHz, 86–92 GHz, 100–102 GHz, 105–116 GHz, 164–168 GHz, 182–185 GHz and 217–231 GHz. Medical telemetry equipment shall not cause harmful interference to radio astronomy operations in the band 608–614 MHz and shall be coordinated under the requirements found in 47 CFR 95.1119.

* * * * *

US350 In the bands 608–614 MHz, 1395–1400 MHz, and 1429–1432, the land mobile service is limited to medical telemetry and telecommand operations. Additionally, the band 1429–1432 MHz may be used on secondary basis for non-Government land mobile telemetry and telecommand and fixed telemetry.

US351 In the band 1390–1400 MHz, Government operations, except for medical telemetry operations in the sub-band 1395–1400 MHz, are on a non-interference basis to authorized non-Government operations and shall not hinder implementation of any non-Government operations. However, Government operations authorized as of March 22, 1995 at 17 sites identified below will be continued on a fully protected basis until January 1, 2009.

Sites	Lat/Long	Radius (km)	Sites	Lat/Long	Radius (km)
Eglin AFB, FL	30°28′N/086°31′W	80	Ft. Greely, AK	63°47′N/145°52′W	80
Dugway PG, UT	40°11′N/112°53′W	80	Ft. Rucker, AL	31°13′N/085°49′W	80
China Lake, CA	35°41′N/117°41′W	80	Redstone, AL	34°35′N/086°35′W	80
Ft. Huachuca, AZ	31°33′N/110°18′W	80	Utah Test Range, UT	40°57′N/113°05′W	80
Cherry Point, NC	34°57′N/076°56′W	80	WSM Range, NM	32°10′N/106°21′W	80
Patuxent River, MD	38°17′N/076°25′W	80	Holloman AFB, NM	33°29′N/106°50′W	80
Aberdeen PG, MD	39°29′N/076°08′W	80	Yuma, AZ	32°29′N/114°20′W	80
Wright-Patterson AFB, OH	39°50′N/084°03′W	80	Pacific Missile Range, CA	34°07′N/119°30′W	80
Edwards AFB, CA	34°54′N/117°53′W	80			

US352 In the band 1429–1432 MHz, Government operations, except for medical telemetry operations, are on a non-interference basis to authorized non-Government operations and shall not hinder the implementation of any non-Government operations. However, Government operations authorized as of March 22, 1995 at 14 sites identified below will be continued on a fully protected basis until January 1, 2004.

Sites	Lat/Long	Radius (km)	Sites	Lat/Long	Radius (km)
Patuxent River, MD	38°17′N/076°25′W	70	Mountain Home AFB, ID	43°01′N/115°50′W	160
NAS Oceana, VA	36°49′N/076°02′W	100	NAS Fallon, NV	39°24′N/118°43′W	100
MCAS Cherry Point, NC	34°54′N/076°52′W	100	Nellis AFB, NV	36°14′N/115°02′W	100
Beaufort MCAS, SC	32°26′N/080°40′W	160	NAS Lemore, CA	36°18′N/119°47′W	120
NAS Cecil Field, FL	30°13′N/081°52′W	160	Yuma MCAS, AZ	32°39′N/114°35′W	160
NAS Whidbey IS., WA	48°19′N/122°24′W	70	China Lake, CA	35°29′N/117°16′W	80
Yakima Firing Ctr AAF, WA	46°40′N/120°15′W	70	MCAS Twenty Nine Palms, CA	34°15′N/116°03′W	80

* * * * *

G27 In the bands 225–328.6, 335.4–399.9, and 1350–1395 MHz, the fixed and mobile services are limited to the military services.

G30 In the bands 138–144, 148–149.9, 150.05–150.8, 1427–1429, and 1432–1435 MHz, the fixed and mobile services are limited primarily to operations by the military services.

* * * * *

G114 In the band 1350–1395 MHz, the frequency 1381.05 MHz with emissions limited to ±12 MHz is also allocated to fixed and mobile satellite services (space-to-earth) for the relay of nuclear burst data.

* * * * *

5. Section 2.1093 is amended by revising paragraph (c) to read as follows:

§ 2.1093 Radiofrequency radiation exposure evaluation: portable devices.

* * * * *

(c) Portable devices that operate in the Cellular Radiotelephone Service, the Personal Communications Service (PCS), the Satellite Communications Services, the General Wireless Communications Service, the Wireless Communications Service, the Maritime Services, the Specialized Mobile Radio Service, the Wireless Medical Telemetry Service (WMTS) and the Medical Implant Communications Service (MICS), authorized under subpart H of part 22 of this chapter, part 24 of this chapter, part 25 of this chapter, part 26 of this chapter, part 27 of this chapter, part 80 of this chapter (ship earth station devices only), part 90 of this chapter, subparts H and I of part 95, and unlicensed personal communication service, unlicensed NII devices and millimeter wave devices authorized under subparts D and E, § 15.253 and § 15.255 of part 15 of this chapter are subject to routine environmental evaluation for RF exposure prior to equipment authorization or use. All other portable transmitting devices are categorically excluded from routine environmental evaluation for RF exposure prior to equipment authorization or use, except as specified in §§ 1.1307(c) and 1.1307(d) of this chapter. Applications for equipment authorization of portable transmitting devices subject to routine environmental evaluation must contain a statement confirming compliance with the limits specified in paragraph (d) of this section as part of their application. Technical information showing the basis for this statement must be

submitted to the Commission upon request.

* * * * *

PART 15—RADIO FREQUENCY DEVICES

6. The authority citation for Part 15 continues to read as follows:

Authority: 47 U.S.C. 154, 302, 303, 304, 307 and 544A.

7. Section 15.37 is amended by adding a new paragraph (i).

§ 15.37 Transition provisions for compliance with the rules.

* * * * *

(i) Effective October 16, 2002, an equipment approval may no longer be obtained for medical telemetry equipment operating under the provisions of § 15.241 or § 15.242. The requirements for obtaining an approval for medical telemetry equipment after this date are found in Subpart H of Part 95 of this chapter.

PART 90—PRIVATE LAND MOBILE RADIO SERVICES

8. The authority citation for Part 90 continues to read as follows:

Authority: Sections 4(i), 11, 303(g), 303(r), and 332(c)(7) of the Communications Act of 1934, as amended, 47 U.S.C. 154(i), 161, 303(g), 303(r), 332(c)(7).

9. Section 90.203 is amended by revising paragraph (a)(1) to read as follows:

§ 90.203 Certification required.

(a) * * *

(1) Effective October 16, 2002, an equipment approval may no longer be obtained for in-hospital medical telemetry equipment operating under the provisions of this part. The requirements for obtaining an approval for medical telemetry equipment after this date are found in Subpart H of Part 95 of this chapter.

PART 95—PERSONAL RADIO SERVICES

10. The authority citation for Part 95 continues to read as follows:

Authority: Sections 4, 303, 48 Stat. 1066, 1082, as amended; 47 U.S.C. 154, 303.

11. Section 95.401 is amended by adding a new paragraph (d) to read as follows:

§ 95.401 (CB Rule 1) What are the Citizens Band Radio Services?

* * * * *

(d) The Wireless Medical Telemetry Service (WMTS)—a private, short distance data communication service for the transmission of patient medical information to a central monitoring location in a hospital or other medical facility. Voice and video communications are prohibited. Waveforms such as electrocardiograms (ECGs) are not considered video. The rules for this service are contained in subpart H of this part.

12. Section 95.601 is amended by revising the last sentence of the introductory text to read as follows:

§ 95.601 Basis and purpose.

* * * The Personal Radio Services are the GMRS (General Mobile Radio Service)-subpart A, the Family Radio Service (FRS)-subpart B, the R/C (Radio Control Radio Service)-subpart C, the CB (Citizens Band Radio Service)-subpart D, the Low Power Radio Service (LPRS)-subpart G, the Wireless Medical Telemetry Service (WMTS)-subpart H, and the Medical Implants Communication Service (MICS)-subpart I.

13. Section 95.630 is added to read as follows:

§ 95.630 WMTS transmitter frequencies.

WMTS transmitters may operate in the frequency bands specified below:

608–614 MHz
1395–1400 MHz
1429–1432 MHz

14. Section 95.631 is amended by adding a new paragraph (h) to read as follows:

§ 95.631 Emission types.

* * * * *

(h) A WMTS station may transmit any emission type appropriate for communications in this service, except for video and voice. Waveforms such as electrocardiograms (ECGs) are not considered video.

15. Section 95.639 is amended by adding a new paragraph (f) to read as follows:

§ 95.639 Maximum transmitter power.

* * * * *

(f) The maximum field strength authorized for WMTS stations in the 608–614 MHz band is 200 mV/m, measured at 3 meters. For stations in the 1395–1400 MHz and 1429–1432 MHz bands, the maximum field strength is 740 mV/m, measured at 3 meters.

16. Section 95.649 is revised to read as follows:

§ 95.649 Power capability.

No CB, R/C, LPRS, FRS, MICS or WMTS unit shall incorporate provisions for increasing its transmitter power to any level in excess of the limits specified in § 95.639.

17. Section 95.651 is revised to read as follows:

§ 95.651 Crystal control required.

All transmitters used in the Personal Radio Services must be crystal controlled, except an R/C station that transmits in the 26–27 MHz frequency band, a FRS unit, a LPRS unit, a MICS transmitter, or a WMTS unit.

18. Appendix 1 to Subpart E to Part 95—Glossary of Terms is revised to add the term ''WMTS. Wireless Medical Telemetry Service.'' at the end of the list.

19. A new Subpart H is added to Part 95 to read as follows:

Subpart H—Wireless Medical Telemetry Service (WMTS)

General Provisions

Sec.
95.1101 Scope.
95.1103 Definitions.
95.1105 Eligibility.
95.1107 Authorized locations.
95.1109 Equipment authorization requirement.
95.1111 Frequency coordination.
95.1113 Frequency coordinator.
95.1115 General technical requirements.
95.1117 Types of communications.
95.1119 Specific requirements for wireless medical telemetry devices operating in the 608–614 MHz band.
95.1121 Specific requirements for wireless medical telemetry devices operating in the 1395–1400 MHz and 1429–1432 MHz bands.
95.1123 Protection of medical equipment.
95.1125 RF Safety.
95.1127 Station identification.
95.1129 Station inspection.

* * * * *

Subpart H—Wireless Medical Telemetry Service (WMTS)

General Provisions

§ 95.1101 Scope.

This part sets out the regulations governing the operation of Wireless Medical Telemetry Devices in the 608–614 MHz, 1395–1400 MHz and 1429–1432 MHz frequency bands.

§ 95.1103 Definitions.

(a) Authorized health care provider. A physician or other individual authorized under state or federal law to provide health care services, or any other health care facility operated by or employing individuals authorized under state or federal law to provide health care services, or any trained technician operating under the supervision and control of an individual or health care facility authorized under state or federal law to provide health care services.

(b) Health care facility. A health care facility includes hospitals and other establishments that offer services, facilities and beds for use beyond a 24 hour period in rendering medical treatment, and institutions and organizations regularly engaged in providing medical services through clinics, public health facilities, and similar establishments, including government entities and agencies such as Veterans Administration hospitals; except the term health care facility does not include an ambulance or other moving vehicle.

(c) Wireless medical telemetry. The measurement and recording of physiological parameters and other patient-related information via radiated bi-or unidirectional electromagnetic signals in the 608–614 MHz, 1395–1400 MHz, and 1429–1432 MHz frequency bands.

§ 95.1105 Eligibility.

Authorized health care providers are authorized by rule to operate transmitters in the Wireless Medical Telemetry Service without an individual license issued by the Commission provided the coordination requirements in § 95.1111 have been met. Manufacturers of wireless medical telemetry devices and their representatives are authorized to operated wireless medical telemetry transmitters in this service solely for the purpose of demonstrating such equipment to, or installing and maintaining such equipment for, duly authorized health care providers. No entity that is a foreign government or which is active in the capacity as a representative of a foreign government is eligible to operate a WMTS transmitter.

§ 95.1107 Authorized locations.

The operation of a wireless medical telemetry transmitter under this part is authorized anywhere within a health care facility provided the facility is located anywhere a CB station operation is permitted under § 95.405. This authority does not extend to mobile vehicles, such as ambulances, even if those vehicles are associated with a health care facility.

§ 95.1109 Equipment authorization requirement.

(a) Wireless medical telemetry devices operating under this part must be authorized under the certification procedure prior to marketing or use in accordance with the provisions of Part 2, Subpart J of this chapter.

(b) Each device shall be labeled with the following statement:

Operation of this equipment requires the prior coordination with a frequency coordinator designated by the FCC for the Wireless Medical Telemetry Service.

§ 95.1111 Frequency coordination.

(a) Prior to operation, authorized health care providers who desire to use wireless medical telemetry devices must register all devices with a designated frequency coordinator. The registration must include the following information:

(1) Specific frequencies or frequency range(s) used;

(2) Modulation scheme used (including occupied bandwidth);

(3) Effective radiated power;

(4) Number of transmitters in use at the health care facility as of the date of registration including manufacturer name(s) and model numbers);

(5) Legal name of the authorized health care provider;

(6) Location of transmitter (coordinates, street address, building);

(7) Point of contact for the authorized health care provider (name, title, office, phone number, fax number, e-mail address).

(b) An authorized health care provider shall notify the frequency coordinator whenever a medical telemetry device is permanently taken out of service, unless the device is replaced with another transmitter utilizing the same technical characteristics as those reported on the effective registration. An authorized health care provider shall maintain the information contained in each registration current in all material respects, and shall notify the frequency coordinator when any change is made in the location or operating parameters previously reported which is material.

§ 95.1113 Frequency coordinator.

(a) The Commission will designate a frequency coordinator(s) to manage the usage of the frequency bands for the operation of medical telemetry devices.

(b) The frequency coordinator shall (1) Review and process coordination requests submitted by authorized health care providers as required in § 95.1111; (2) maintain a database of WMTS use; (3) notify users of potential conflicts; and (4) coordinate WMTS operation with radio astronomy observatories and Federal Government radar systems as specified in §§ 95.1119 and 95.1121.

§ 95.1115 General technical requirements.

(a) *Field strength limits.* (1) In the 608–614 MHz band, the maximum allowable field strength is 200 mV/m, as measured at a distance of 3 meters, using measuring instrumentation with a CISPR quasi-peak detector.

(2) In the 1395–1400 MHz and 1429–1432 MHz bands, the maximum allowable field strength is 740 mV/m, as measured at a distance of 3 meters, using measuring equipment with an averaging detector and a 1 MHz measurement bandwidth.

(b) *Undesired emissions.* (1) Out-of-band emissions below 960 MHz are limited to 200 μ/m, as measured at a distance of 3 meters, using measuring instrumentation with a CISPR quasi-peak detector.

(2) Out-of-band emissions above 960 MHz are limited to 500 μm as measured at a distance of 3 meters using measuring equipment with an averaging detector and a 1 MHz measurement bandwidth.

(c) *Emission types.* A wireless medical telemetry device may transmit any emission type appropriate for communications in this service, except for video and voice. Waveforms such as electrocardiograms (ECGs) are not considered video.

(d) *Channel use.* (1) In the 1395–1400 MHz and 1429–1432 MHz bands, no specific channels are specified. Wireless medical telemetry devices may operate on any channel within the bands authorized for wireless medical telemetry use in this part.

(2) In the 608–614 MHz band, wireless medical telemetry devices utilizing broadband technologies such as spread spectrum shall be capable of operating within one or more of the following channels of 1.5 MHz each, up to a maximum of 6 MHz, and shall operate on the minimum number of channels necessary to avoid harmful interference to any other wireless medical telemetry devices.

608.0–609.5 MHz
609.5–611.0 MHz
611.0–612.5 MHz
612.5–614.0 MHz

(3) Channel usage is on a co-primary shared basis only, and channels will not be assigned for the exclusive use of any entity.

(4) Authorized health care providers, in conjunction with the equipment manufacturers, must cooperate in the selection and use of frequencies in order to reduce the potential for interference with other wireless medical telemetry devices, or other co-primary users. Operations in the 608–614 MHz band (television channel 37) are not protected from adjacent band interference from broadcast television operating on channels 36 and 38.

(e) *Frequency stability.* Manufacturers of wireless medical telemetry devices are responsible for ensuring frequency stability such that an emission is maintained within the band of operation under all of the manufacturer's specified conditions.

§ 95.1117 Types of communications.

(a) All types of communications except voice and video are permitted, on both a unidirectional and bidirectional basis, provided that all such communications are related to the provision of medical care. Waveforms such as electrocardiograms (ECGs) are not considered video.

(b) Operations that comply with the requirements of this part may be conducted under manual or automatic control, and on a continuous basis.

§ 95.1119 Specific requirements for wireless medical telemetry devices operating in the 608–614 MHz band.

For a wireless medical telemetry device operating within the frequency range 608–614 MHz and that will be located near the radio astronomy observatories listed below, operation is not permitted until a WMTS frequency coordinator specified in § 95.1113 has coordinated with, and obtain the written concurrence of, the director of the affected radio astronomy observatory before the equipment can be installed or operated

(a) Within 80 kilometers of:

(1) National Astronomy and Ionosphere Center, Arecibo, Puerto Rico: 18°20′38.28″ North Latitude, 66° 45′09.42″ West Longitude.

(2) National Radio Astronomy Observatory, Socorro, New Mexico: 34° 04′43″ North Latitude, 107°37′04″ West Longitude.

(3) National Radio Astronomy Observatory, Green Bank, West Virginia: 38°26′08″ North Latitude, 79°49′42″ West Longitude.

(b) Within 32 kilometers of the National Radio Astronomy Observatory centered on:

Very long baseline array stations	Latitude (north)	Longitude (west)
Pie Town, NM	34° 18′	108° 07′
Kitt Peak, AZ	31° 57′	111° 37′
Los Alamos, NM	35° 47′	106° 15′
Fort Davis, TX	30° 38′	103° 57′
North Liberty, IA	41° 46′	91° 34′
Brewster, WA	48° 08′	119° 41′
Owens Valley, CA	37° 14′	118° 17′
Saint Croix, VI	17° 46′	64° 35′
Mauna Kea, HI	19° 49′	155° 28′
Hancock, NH	42° 56′	71° 59′

The National Science Foundation point of contact for coordination is: Spectrum Manager, Division of Astronomical Sciences, NSF Room 1045, 4201 Wilson Blvd., Arlington, VA 22230, telephone: 703–306–1823.

§ 95.1121 Specific requirements for wireless medical telemetry devices operating in the 1395–1400 MHz and 1429–1432 MHz bands.

Due to the critical nature of communications transmitted under this part, the frequency coordinator in consultation with the National Telecommunications and Information Administration shall determine whether there are any federal government radar systems whose operations could affect, or could be affected by, proposed wireless medical telemetry operations in the 1395–1400 MHz and 1429–1432 MHz bands. The locations of government radar systems in these bands are specified in footnotes US351 and US352 of § 2.106 of this chapter.

§ 95.1123 Protection of medical equipment.

The manufacturers, installers and users of WMTS equipment are cautioned that the operation of this equipment could result in harmful interference to other nearby medical devices.

§ 95.1125 RF safety.

Portable devices as defined in § 2.1093(b) of this chapter operating in the WMTS are subject to radio frequency radiation exposure requirements as specified in §§ 1.1307(b) and 2.1093 of this chapter. Applications for equipment authorization of WMTS devices must contain a statement confirming compliance with these requirements. Technical information showing the basis for this statement must be submitted to the Commission upon request.

§ 95.1127 Station identification.

A WMTS station is not required to transmit a station identification announcement.

§ 95.1129 Station inspection.

All WMTS transmitters must be available for inspection upon request by an authorized FCC representative.

[FR Doc. 00–17970 Filed 7–14–00; 8:45 am]

BILLING CODE 6712–01–U

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA 00–1441; MM Docket No. 99–225; RM–9635]

Radio Broadcasting Services; Saint Regis, MT

AGENCY: Federal Communications Commission.

ACTION: Final rule.

SUMMARY: This document allots Channel 256C2 to Saint Regis, Montana, in response to a petition filed by the Battani Corporation. *See* 64 FR 34753, June 29, 1999. The coordinates for Channel 256C2 at Saint Regis are 47–15–56 NL and 114–51–29 WL. There is a site restriction 18.1 kilometers east of the community. Canadian concurrence has been received for the allotment of Channel 256C2 at Saint Regis. A filing window for Channel 256C2 at Saint Regis will not be opened at this time. Instead, the issue of opening a filing window for this channel will be addressed by the Commission in a subsequent order.

DATES: Effective August 14, 2000.

FOR FURTHER INFORMATION CONTACT: Kathleen Scheuerle, Mass Media Bureau, (202) 418–2180.

SUPPLEMENTARY INFORMATION: This is a summary of the Commission's Report and Order, MM Docket No. 99–225, adopted June 21, 2000, and released June 30, 2000. The full text of this Commission decision is available for inspection and copying during normal business hours in the Commission's Reference Center, 445 12th Street, SW., Washington, DC. The complete text of this decision may also be purchased from the Commission's copy contractors, International Transcription Services, Inc., 1231 20th Street, NW., Washington, DC 20036, (202) 857–3800, facsimile (202) 857–3805.

List of Subjects in 47 CFR Part 73

Radio broadcasting.

Part 73 of title 47 of the Code of Federal Regulations is amended as follows:

PART 73—[AMENDED]

1. The authority citation for part 73 continues to read as follows:

Authority: 47 U.S.C. 154, 303, 334 and 336.

§ 73.202 [Amended]

2. Section 73.202(b), the Table of FM Allotments under Montana, is amended by adding Saint Regis, Channel 256C2.

Federal Communications Commission.

John A. Karousos,

Chief, Allocations Branch, Policy and Rules Division, Mass Media Bureau.

[FR Doc. 00–18054 Filed 7–14–00; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[FCC 00–169; MM Docket No. 94–78; RM–8472 and RM–8525]

Radio Broadcasting Services; Cloverdale, Montgomery, and Warrior, AL

AGENCY: Federal Communications Commission.

ACTION: Final rule; application for review.

SUMMARY: This document denies an application for review filed by William P. Rogers that appeals the *Memorandum Opinion and Order*, 62 FR 9375 (March 3, 1997), in this proceeding insofar as it refused to accept Rogers' counterproposal to allot Channel 254A to Florence, Alabama. Rogers' counterproposal was rejected primarily because it did not provide 100 percent city-grade coverage of Florence, as required by Section 73.315(a) of the Commission's Rules. This document does not deal with Pulaski Broadcasting, Inc.'s proposal to allot FM Channel 254A to Cloverdale, Alabama, which was rejected in a previous order. Nor does this document consider a joint counterproposal filed by former licensees of Stations WBHK(FM), Warrior, Alabama, and Station WBAM–FM, Montgomery, Alabama, which was granted by a previous order.

ADDRESSES: Federal Communications Commission, 445 12th Street, SW, Room TW–A325, Washington, DC 20554.

FOR FURTHER INFORMATION CONTACT: R. Barthen Gorman, Mass Media Bureau, (202) 418–2180.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's *Memorandum Opinion and Order*, MM Docket No. 94–78, adopted May 12, 2000, and released June 14, 2000. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC's Reference Information Center at Portals II, CY–A257, 445 12th Street, SW, Washington, DC. The complete text of this decision may also be purchased from the Commission's copy contractors, International Transcription Service, Inc., (202) 857–3800, 1231 20th Street NW., Washington, DC 20036.

Federal Communications Commission.

William F. Caton,

Deputy Secretary.

[FR Doc. 00–18051 Filed 7–14–00; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA 00–1448; MM Docket No. 99–114; RM–8902]

Television Broadcasting Services, DTV Broadcasting Services; Lake Havasu City, AZ and Laughlin, NV

AGENCY: Federal Communications Commission.

ACTION: Final rule.

SUMMARY: This document reallots NTSC Channel 34+ and paired DTV Channel 32 from Lake Havasu City, Arizona, to Laughlin, Nevada, and modifies the authorization of Mojave Broadcasting Company (formerly Meridian Communications Company) for television Station KMCC, as requested, pursuant to the provisions of Section 1.420(i) of the Commission's Rules. *See* 64 FR 23036, April 29, 1999. The reallotment will provide a first local television transmission and DTV service to Laughlin. Coordinates used for NTSC Channel 34+ and DTV Channel 32 at Laughlin, Nevada, are 35–03–12 NL and 114–37–10 WL. Additionally, as Laughlin is located within 320 kilometers (199 miles) of the Mexico border, concurrence of the Mexican government to the reallotment request was obtained.

DATES: Effective August 14, 2000.

FOR FURTHER INFORMATION CONTACT: Nancy Joyner, Mass Media Bureau, (202) 418–2180.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's Report and Order, MM Docket No. 99–114, adopted June 21, 2000, and released June 30, 2000. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC's Reference Center (Room CY–A257), 445 Twelfth Street, SW., Washington, DC. The complete text of this decision may also be purchased from the Commission's copy contractor, International Transcription Service, Inc., 1231 20th Street, NW., Washington, DC 20036, (202) 857–3800.

List of Subjects in 47 CFR Part 73

Television and DTV broadcasting.

Part 73 of title 47 of the Code of Federal Regulations is amended as follows:

PART 73—[AMENDED]

1. The authority citation for part 73 reads as follows:

Authority: 47 U.S.C. 154, 303, 334, 336.

§ 73.606 [Amended]

2. Section 73.606(b), the Table of TV Allotments under Arizona, is amended by removing Lake Havasu City, Channel 34+.

3. Section 73.606(b), the Table of TV Allotments under Nevada, is amended by adding Laughlin, Channel 34+.

§ 73.622 [Amended]

4. Section 73.622(b), the Table of DTV Allotments under Arizona, is amended by removing Lake Havasu City, Channel 32.

5. Section 73.622(b), the Table of DTV Allotments under Nevada, is amended by adding Laughlin, Channel 32.

Federal Communications Commission.

John A. Karousos,

Chief, Allocations Branch, Policy and Rules Division, Mass Media Bureau.

[FR Doc. 00–18055 Filed 7–14–00; 8:45 am]

BILLING CODE 6712–01–P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 679

[Docket No. 000211040–0040–01; I.D. 051100D]

Fisheries of the Exclusive Economic Zone off Alaska; Halibut Bycatch Mortality Allowance in the Bering Sea and Aleutian Islands Management Area

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Reapportionment of Pacific halibut bycatch mortality allowance specified for the nontrawl fishery categories.

SUMMARY: NMFS issues this amendment to the final 2000 harvest specifications that reapportions the 2000 halibut bycatch mortality allowance specified for the Pacific cod hook-and-line fishery category to the other nontrawl fishery category in the Bering Sea and Aleutian Islands management area (BSAI). This action is necessary to allow the harvest of species constrained by the other nontrawl halibut bycatch mortality allowance, in particular Greenland turbot, while not further restricting the hook-and-line Pacific cod fishery. This action is intended to promote the goals and objectives of the Fishery Management Plan for the Groundfish Fishery of the Bering Sea and Aleutians Islands Area (FMP).

DATES: Effective 1200 hrs, Alaska local time (A.l.t.), July 12, 2000, through 2400 hrs, A.l.t., December 31, 2000.

FOR FURTHER INFORMATION CONTACT: Mary Furuness, 907–586–7228.

SUPPLEMENTARY INFORMATION: NMFS manages the groundfish fishery in the BSAI exclusive economic zone according to the FMP prepared by the North Pacific Fishery Management Council under authority of the Magnuson-Stevens Fishery Conservation and Management Act. Regulations governing fishing by U.S. vessels in accordance with the FMP at subpart H of 50 CFR part 600 and 50 CFR part 679.

The BSAI halibut prohibited species catch (PSC) limit for nontrawl gear is an amount of halibut equivalent to 900 metric tons (mt) of halibut mortality (§ 679.21(e)(2)(i)). The apportionment of the nontrawl halibut PSC limit to bycatch allowances for the Pacific cod hook-and-line fishery, other nontrawl fisheries and prohibited species quota reserve was established by the Final 2000 Harvest Specifications of Groundfish for the BSAI (65 FR 8282, February 18, 2000) as 748 mt, 84 mt, and 67 mt, respectively.

At its April 2000 meeting, the Council requested NMFS to amend the 2000 harvest specifications to reapportion 75 mt of the halibut bycatch mortality allowance specified for the Pacific cod hook-and-line fishery to the other nontrawl fishery category. This proposed amendment to the 2000 harvest specifications was published in the *Federal Register* on May 22, 2000 (65 FR 32070), for public comment and review. No comments were received during the comment period that ended June 6, 2000. In order to provide greater opportunity to harvest the BSAI Greenland turbot total allowable catch (TAC) while not jeopardizing the opportunity to harvest the amount of the Pacific cod TAC allocated to hook-and-line vessels, NMFS increases the halibut bycatch mortality allowance specified for the other nontrawl fishery category by 75 mt and reduces the halibut bycatch mortality allowance specified for the Pacific cod hook-and-line fishery by the same amount.

The halibut bycatch mortality specifications for the 2000 BSAI nontrawl fisheries are listed in Table 7 of the Final 2000 Harvest Specifications for Groundfish (65 FR 8282, February 18, 2000). To accommodate the final action, the 2000 BSAI final harvest specifications are amended by adding the following Table 7A.

TABLE 7A. 2000 BSAI PROHIBITED SPECIES BYCATCH ALLOWANCES FOR THE BSAI NON-TRAWL FISHERIES

Non-trawl fisheries	*Halibut mortality (mt) BSAI*
Pacific cod–Total	673
Jan. 1–April 30	457
May 1–Sept. 1	0
Sept. 1–Dec. 31	216
Other non-trawl–Total	159
May 1–Dec. 31	159
Groundfish pot & jig	exempt
Sablefish hook-and-line	exempt

Classification

This action is authorized under 50 CFR 679.21(e)(4) and is exempt from OMB review under E.O. 12866.

NMFS prepared an environmental assessment (EA) and final regulatory flexibility assessment (FRFA) for the 2000 harvest specifications. These documents are available by contacting: Lori Gravel, Alaska Region, NMFS, P.O. Box 21668, Juneau, AK 99802–1668. The reapportionment of the BSAI nontrawl halibut PSC limit is intended to provide fuller opportunity to conduct the fishing activities considered in the EA/FRFA and is fully within the scope of these analyses.

The need to implement this reapportionment promptly to provide greater opportunity to harvest the BSAI Greenland turbot TAC and to prevent the unnecessary economic hardships to fishermen that would result from a fishery closure constitutes good cause under 5 U.S.C. 553(d) to waive the 30-day effective date and make this reapportionment effective July 12, 2000 through 2400 hrs, A.l.t., December 31, 2000.

Authority: 16 U.S.C. 773 *et seq.*, 1801 *et seq.* and 3631 *et seq.*

Dated: July 11, 2000.

Bruce C. Morehead,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 00–18020 Filed 7–12–00; 2:38 pm]

BILLING CODE 3510–22–F

Proposed Rules

Federal Register
Vol. 65, No. 137
Monday, July 17, 2000

This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2000–NM–130–AD]

RIN 2120–AA64

Airworthiness Directives; Empresa Brasileira de Aeronautica S.A. (EMBRAER) Model EMB–120 Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes the adoption of a new airworthiness directive (AD) that is applicable to certain EMBRAER Model EMB–120 series airplanes. This proposal would require inspections of certain components, and corrective action, if necessary. This action is necessary to prevent deterioration and deformation of the mass-balance weights of the aileron, which could affect the surface balance of the aileron and result in loss of aileron control and consequent reduced controllability of the airplane. This action is intended to address the identified unsafe condition.

DATES: Comments must be received by August 16, 2000.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM–114, Attention: Rules Docket No. 2000–NM–130–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227–1232. Comments may also be sent via the Internet using the following address: 9-anm-nprmcomment@faa.gov. Comments sent via fax or the Internet must contain ''Docket No. 2000–NM–130–AD'' in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 for Windows or ASCII text.

The service information referenced in the proposed rule may be obtained from Empresa Brasileira de Aeronautica S.A. (EMBRAER), P.O. Box 343—CEP 12.225, Sao Jose dos Campos—SP, Brazil. This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington; or at the FAA, Small Airplane Directorate, Atlanta Aircraft Certification Office, One Crown Center, 1895 Phoenix Boulevard, suite 450, Atlanta, Georgia.

FOR FURTHER INFORMATION CONTACT: Satish Lall, Aerospace Engineer, Airframe and Propulsion Branch, ACE–117A, FAA, Small Airplane Directorate, Atlanta Aircraft Certification Office, One Crown Center, 1895 Phoenix Boulevard, suite 450, Atlanta, Georgia 30337–2748; telephone (770) 703–6082; fax (770) 703–6097.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this notice may be changed in light of the comments received.

Submit comments using the following format:

- Organize comments issue-by-issue. For example, discuss a request to change the compliance time and a request to change the service bulletin reference as two separate issues.
- For each issue, state what specific change to the proposed AD is being requested.
- Include justification (*e.g.,* reasons or data) for each request.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this notice must submit a self-addressed, stamped postcard on which the following statement is made: ''Comments to Docket Number 2000–NM–130–AD.'' The postcard will be date stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM–114, Attention: Rules Docket No. 2000–NM–130–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056.

Discussion

The Departmento de Aviacao Civil (DAC), which is the airworthiness authority for Brazil, notified the FAA that an unsafe condition may exist on certain EMBRAER Model EMB–120 series airplanes. The DAC advises that the mass-balance weights of the aileron may deteriorate or become deformed. Such deterioration or deformation could affect the surface balance and lead to chafing between the exposed end of the mass-balance weight and the adjoining aileron hinge attachment. This condition, if not corrected, could result in loss of aileron control and consequent reduced controllability of the airplane.

Explanation of Relevant Service Information

EMBRAER has issued Service Bulletin 120–27–0077, Change No. 01, dated October 24, 1997, which, for certain airplanes, describes procedures for repetitive visual inspections to measure the gap between the mass-balance weights and aileron hinge attachment, and corrective action, if necessary. For all airplanes, the service bulletin describes procedures for performing a one-time detailed visual inspection of the mass-balance weights to detect any cavity, hole, or delamination, and follow-on actions. For affected airplanes, accomplishment of the one-time detailed visual inspection eliminates the need for the repetitive inspections described previously. If no cavity, hole, or delamination is found,

follow-on actions involve visual inspection of the surface of the mass-balance weights to detect white powder, and removal of any detected white powder. If any cavity, hole, or delamination is found, corrective action involves replacement of the mass-balance weights with new, improved parts. Accomplishment of the actions specified in the service bulletin is intended to adequately address the identified unsafe condition. The DAC classified this service bulletin as mandatory and issued Brazilian airworthiness directive 98–01–02, dated January 15, 1998, in order to ensure the continued airworthiness of these airplanes in Brazil.

FAA's Conclusions

This airplane model is manufactured in Brazil and is type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the DAC has kept the FAA informed of the situation described above. The FAA has examined the findings of the DAC, reviewed all available information, and determined that AD action is necessary for products of this type design that are certificated for operation in the United States.

Explanation of Requirements of Proposed Rule

Since an unsafe condition has been identified that is likely to exist or develop on other airplanes of the same type design registered in the United States, the proposed AD would require accomplishment of the actions specified in the service bulletin described previously.

Differences Between DAC's Airworthiness Directive and This Proposed AD

Operators should note that the DAC's airworthiness directive recommends that repetitive measurements of the gap between the mass-balance weights and aileron hinge attachment, and corrective action, if necessary, be accomplished on all airplanes manufactured since March 1, 1995. The FAA finds that it is clearer to refer to the airplanes affected by this AD by serial number rather than by date of manufacture. Therefore, this proposed AD would require these repetitive measurements for airplanes with serial numbers 120–0291, 120–0294, and 120–0296 through 120–0333 inclusive.

In addition, operators should note that, for the one-time detailed visual inspection of the mass-balance weights to detect any cavity, hole, or delamination, the DAC's airworthiness directive specifies separate compliance times depending on whether the airplane was manufactured before or after March 1, 1995. However, this proposed AD would require that this action be accomplished on all airplanes subject to this AD within 2,000 flight hours after the effective date of this AD. In developing an appropriate compliance time for this proposed AD, the FAA considered not only the DAC's recommendation, but the degree of urgency associated with addressing the subject unsafe condition, and the date the DAC's recommendation was issued. In light of these factors, the FAA finds that 2,000 flight hours represents an appropriate interval of time allowable for all affected airplanes to continue to operate without compromising safety.

Cost Impact

The FAA estimates that approximately 28 U.S.-registered airplanes would be affected by the proposed requirement to measure the gap between the mass-balance weights and aileron hinge attachment. It would take approximately 2 work hours per airplane to accomplish the proposed measurement, at an average labor rate of $60 per work hour. Based on these figures, the cost impact of this proposed requirement on U.S. operators is estimated to be $3,360, or $120 per airplane, per inspection cycle.

The FAA estimates that approximately 230 U.S.-registered airplanes would be affected by the proposed detailed visual inspection of the mass-balance weights to detect any cavity, hole, or delamination. It would take approximately 8 work hours per airplane to accomplish this proposed inspection, at an average labor rate of $60 per work hour. Based on these figures, the cost impact of these proposed requirements on U.S. operators is estimated to be $110,400, or $480 per airplane.

The cost impact figures discussed above are based on assumptions that no operator has yet accomplished any of the proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation: (1) Is not a ''significant regulatory action'' under Executive Order 12866; (2) is not a ''significant rule'' under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption **ADDRESSES**.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by adding the following new airworthiness directive:

Empresa Brasileira de Aeronautica S.A. (EMBRAER): Docket 2000–NM–130–AD.

Applicability: Model EMB–120 series airplanes, serial numbers 120–0001 through 120–0333 inclusive; certificated in any category.

Note 1: This AD applies to each airplane identified in the preceding applicability provision, regardless of whether it has been modified, altered, or repaired in the area subject to the requirements of this AD. For airplanes that have been modified, altered, or repaired so that the performance of the requirements of this AD is affected, the owner/operator must request approval for an alternative method of compliance in accordance with paragraph (c) of this AD.

The request should include an assessment of the effect of the modification, alteration, or repair on the unsafe condition addressed by this AD; and, if the unsafe condition has not been eliminated, the request should include specific proposed actions to address it.

Compliance: Required as indicated, unless accomplished previously.

To prevent deterioration and deformation of the mass-balance weights of the aileron, which could affect the surface balance of the aileron and result in loss of aileron control and consequent reduced controllability of the airplane, accomplish the following:

Measurement of Clearance and Corrective Actions

(a) For airplanes having serial numbers 120–0291, 120–0294, and 120–0296 through 120–0333 inclusive: Within 150 flight hours after the effective date of this AD, measure the clearance between the aileron mass-balance weights and attach fittings on the left and right sides of the airplane, in accordance with PART I of the Accomplishment Instructions of EMBRAER Service Bulletin 120–27–0077, Change No. 01, dated October 24, 1997.

(1) If the clearance is within the acceptable limits described in the service bulletin, thereafter, repeat the measurement at intervals not to exceed 1,000 flight hours until the actions required by paragraph (b) of this AD have been accomplished.

(2) If the clearance is outside the acceptable limits described in the service bulletin, prior to further flight, replace the affected mass-balance weight with a new, improved mass-balance weight, in accordance with PART III of the Accomplishment Instructions of the service bulletin. Such replacement terminates the requirement to accomplish paragraph (b) of this AD.

Detailed Visual Inspection and Follow-On Actions

(b) *For all airplanes:* Within 2,000 flight hours after the effective date of this AD, perform a one-time detailed visual inspection of the aileron mass-balance weights to detect any cavity, hole, or delamination, in accordance with PART II of the Accomplishment Instructions of EMBRAER Service Bulletin 120–27–0077, Change No. 01, dated October 24, 1997. Such inspection constitutes terminating action for the repetitive inspections required by paragraph (a)(1) of this AD for airplanes subject to paragraph (a) of this AD.

(1) If no cavity, hole, or delamination is detected: Prior to further flight, perform a one-time detailed visual inspection to detect white powder on the surface of the mass-balance weights, in accordance with PART II of the Accomplishment Instructions of the service bulletin. If any white powder is found, remove the white powder in accordance with the service bulletin.

(2) If any cavity, hole, or delamination is found, prior to further flight, replace the affected mass-balance weight with a new, improved mass-balance weight, in accordance with PART III of the Accomplishment Instructions of the service bulletin.

Alternative Methods of Compliance

(c) An alternative method of compliance or adjustment of the compliance time that provides an acceptable level of safety may be used if approved by the Manager, Atlanta Aircraft Certification Office (ACO), FAA, Small Airplane Directorate. Operators shall submit their requests through an appropriate FAA Principal Maintenance Inspector, who may add comments and then send it to the Manager, Atlanta ACO.

Note 2: Information concerning the existence of approved alternative methods of compliance with this AD, if any, may be obtained from the Atlanta ACO.

Special Flight Permits

(d) Special flight permits may be issued in accordance with sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate the airplane to a location where the requirements of this AD can be accomplished.

Note 3: The subject of this AD is addressed in Brazilian airworthiness directive 98–01–02, dated January 15, 1998.

Issued in Renton, Washington, on July 11, 2000.

Donald L. Riggin,

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. 00–18042 Filed 7–14–00; 8:45 am]

BILLING CODE 4910–13–U

DEPARTMENT OF THE INTERIOR

Office of Surface Mining Reclamation and Enforcement

30 CFR Part 934

[SPATS No. ND–041–FOR; North Dakota State Program Amendment No. XXX]

North Dakota Regulatory Program

AGENCY: Office of Surface Mining Reclamation and Enforcement, Interior.

ACTION: Proposed rule; public comment period and opportunity for public hearing on proposed amendment.

SUMMARY: The Office of Surface Mining Reclamation and Enforcement (OSM) is announcing receipt of a proposed amendment to the North Dakota regulatory program (hereinafter, the ''North Dakota program'') under the Surface Mining Control and Reclamation Act of 1977 (SMCRA). North Dakota proposes revisions of rules about: Rulemaking notices; prime farmland reclamation plans; permit approval and denial criteria; performance bond liability period; bond release applications; surface water monitoring; revegetation success standards; prime farmland reclamation standards; and small operator assistance.

North Dakota intends to revise its program to be consistent with the corresponding Federal regulations, clarify ambiguities, and improve operational efficiency.

DATES: We will accept written comments on this amendment until 4:00 p.m., m.d.t. August 16, 2000. If requested, we will hold a public hearing on the amendment on August 11, 2000. We will accept requests to speak until 4:00 p.m., m.d.t. on August 1, 2000.

ADDRESSES: You should mail or hand deliver written comments and requests to speak at the hearing to Guy Padgett at the address listed below.

You may review copies of the North Dakota program, this amendment, a listing of any scheduled public hearings, and all written comments received in response to this document at the addresses listed below during normal business hours, Monday through Friday, excluding holidays. You may receive one free copy of the amendment by contacting OSM's Casper Field Office.

Guy Padgett, Chief, Casper Field Office, Office of Surface Mining Reclamation and Enforcement, 100 East ''B'' Street, Federal Building, Room 2128, Casper, Wyoming 82601–1918

James R. Deutsch, Director, Reclamation Division, North Dakota Public Service Commission, Capitol Building, Bismarck, North Dakota 58505, Telephone: 701–328–2251.

FOR FURTHER INFORMATION CONTACT: Guy Padgett, Telephone: 307–261–6550. Internet: GPadgett@OSMRE.GOV.

SUPPLEMENTARY INFORMATION:

I. Background on the North Dakota Program.
II. Description of the Proposed Amendment.
III. Public Comment Procedures.
IV. Procedural Determinations.

I. Background on the North Dakota Program

On December 15, 1980, the Secretary of the Interior conditionally approved the North Dakota program. You can find background information on the North Dakota program, including the Secretary's findings, the disposition of comments, and conditions of approval of the North Dakota program in the December 15, 1980 **Federal Register** (45 FR 82214). You can also find later actions concerning North Dakota's program and program amendments at 30 CFR 934.15 and 934.16.

II. Description of the Proposed Amendment

By letter dated June 20, 2000, North Dakota sent us a proposed amendment to its program (Amendment number XXX, administrative record No. ND–EE–01) under SMCRA (30 U.S.C. 1201 *et*

seq.). North Dakota sent the amendment in response to a July 17, 1997 letter (administrative record No. ND–EE–02) that we sent to it in accordance with 30 CFR 732.17(c) and, in addition, to include changes made at its own initiative. The full text of the program amendment is available for you to read at the locations listed above under **ADDRESSES.**

The provisions of the North Dakota Administrative Code that North Dakota proposes to revise are: (1) NDAC 69–05.2–01–03, Rulemaking notices; (2) NDAC 69–05.2–09–15, Prime farmland reclamation plans; (3) NDAC 69–05.2–10–03(6)(c), Permit approval or denial criteria; (4) NDAC 69–05.2–12–09, Period of performance bond liability; (5) NDAC 69–05.2–12(2), Bond release applications; (6) NDAC 69–05.2–16–05, Surface water monitoring; (7) NDAC 69–05.2–22–07, Revegetation success standards; (8) NDAC 69–05.2–26–05, Prime farmland revegetation requirements; and (9) NDAC 69–05.2–29–03, Small operator assistance.

III. Public Comment Procedures

Under the provisions of 30 CFR 732.17(h), we request your comments on whether the amendment satisfies the applicable program approval criteria of 30 CFR 732.15. If we approve the amendment, it will become part of the North Dakota program.

Written Comments

Send your written comments to us at the address given above. Your written comments should be specific, pertain only to the issues proposed in this rulemaking, and include explanations in support of your recommendations. In the final rulemaking, we will not necessarily consider or include in the administrative record any comments received after the time indicated under **DATES** or at locations other than the Casper Field Office.

Electronic Comments

Please submit Internet comments as an ASCII file avoiding the use of special characters and any form of encryption. Please also include ''Attn: SPATS No. ND–041–FOR'' and your name and return address in your Internet message. If you do not receive a confirmation that we have received your Internet message, contact the Casper Field Office at 307/261–6550.

Availability of Comments

We will make comments, including names and addresses of respondents, available for public review during normal business hours. We will not consider anonymous comments. If individual respondents request confidentiality, we will honor their request to the extent allowable by law. Individual respondents who wish to withhold their name or address from public review, except for the city or town, must state this prominently at the beginning of their comments. We will make all submissions from organizations or businesses, and from individuals identifying themselves as representatives or officials of organizations or businesses, available for public review in their entirety.

Public Hearing

If you wish to speak at the public hearing, contact the person listed under **FOR FURTHER INFORMATION CONTACT** by 4:00 p.m., m.d.t. on August 1, 2000. If you are disabled and need special accommdations to attend a public hearing, contact the person listed under **FOR FURTHER INFORMATION CONTACT.** We will arrange the location and time of the hearing with those persons requesting the hearing. If no one requests an opportunity to speak, we will not hold the hearing.

To assist the transcriber and ensure an accurate record, we request, if possible, that each person who speaks at a public hearing provide us with a written copy of his or her comments. The public hearing will continue on the specified date until everyone scheduled to speak has been heard. If you are in the audience and have not been scheduled to speak and wish to do so, you will be allowed to speak after those who have been scheduled. We will end the hearing after everyone scheduled to speak and others present in the audience who wish to speak, have been heard.

Public Meeting

If only one person requests an opportunity to speak, we may hold a public meeting rather than a public hearing. If you wish to meet with us to discuss the amendment, please request a meeting by contacting the person listed under **FOR FURTHER INFORMATION CONTACT.** All such meetings are open to the public and, if possible, we will post notices of meetings at the locations listed under **ADDRESSES.** We will make a written summary of each meeting a part of the administrative record.

IV. Procedural Determinations

Executive Order 12630—Takings

This rule does not have takings implications. This determination is based on the analysis performed for the counterpart Federal regulations.

Executive Order 12866—Regulatory Planning and Review

This rule is exempted from review by the Office of Management and Budget (OMB) under Executive Order 12866.

Executive Order 12988—Civil Justice Reform

The Department of the Interior has conducted the reviews required by section 3 of Executive Order 12988 and has determined that, to the extent allowable by law, this rule meets the applicable standards of subsections (a) and (b) of that section. However, these standards are not applicable to the actual language of State regulatory programs and program amendments since each such program is drafted and promulgated by a specific State, not by OSM. Under sections 503 and 505 of SMCRA (30 U.S.C. 1253 and 1255) and the Federal regulations at 30 CFR 730.11, 732.15, and 732.17(h)(10), decisions on proposed State regulatory programs and program amendments submitted by the States must be based solely on a determination of whether the submittal is consistent with SMCRA and its implementing Federal regulations and whether the other requirements of 30 CFR Parts 730, 731, and 732 have been met.

Executive Order 13132—Federalism

This rule does not have Federalism implications. SMCRA delineates the roles of the Federal and State governments with regard to the regulation of surface coal mining and reclamation operations. One of the purposes of SMCRA is to ''establish a nationwide program to protect society and the environment from the adverse effects of surface coal mining operations.'' Section 503(a)(1) of SMCRA requires that State laws regulating surface coal mining and reclamation operations be ''in accordance with'' the requirements of SMCRA. Section 503(a)(7) requires that State programs contain rules and regulations ''consistent with'' regulations issued by the Secretary pursuant to SMCRA.

National Environmental Policy Act

Section 702(d) of SMCRA (30 U.S.C. 1292(d)) provides that a decision on a proposed State regulatory program provision does not constitute a major Federal action within the meaning of section 102(2)(C) of the National Environmental Policy Act (42 U.S.C. 4332(2)(C)). A determination has been made that such decisions are categorically excluded from the NEPA process (516 DM 8.4.A).

Paperwork Reduction Act

This rule does not contain information collection requirements that require approval by OMB under the Paperwork Reduction Act (44 U.S.C. 3507 *et seq.*).

Regulatory Flexibility Act

The Department of the Interior has determined that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). The State submittal that is the subject of this rule is based upon counterpart Federal regulations for which an economic analysis was prepared and certification made that such regulations would not have a significant economic effect upon a substantial number of small entities. Accordingly, this rule will ensure that existing requirements previously promulgated by OSM will be implemented by the State. In making the determination as to whether this rule would have a significant economic impact, the Department relief upon the data and assumptions for the counterpart Federal regulations.

Small Business Regulatory Enforcement Fairness Act

This rule is not a major rule under 5 U.S.C. 804(2), the Small Business Regulatory Enforcement Fairness Act. This rule: (a) Does not have an annual effect on the economy of $100 million; (b) Will not cause a major increase in costs or prices for consumers, individual industries, geographic regions, or Federal, State or local governmental agencies; and (c) Does not have significant adverse effects on competition, employment, investment, productivity, innovation, or the ability of U.S. based enterprises to compete with foreign-based enterprises. This determination is based upon the fact that the State submittal which is the subject of this rule is based upon counterpart Federal regulations for which an analysis was prepared and a determination made that the Federal regulation was not considered a major rule.

Unfunded Mandates

This rule will not impose a cost of $100 million or more in any given year on any governmental entity or the private sector.

List of Subjects in 30 CFR Part 934

Intergovernmental relations, Surface mining, Underground mining.

Dated: July 7, 2000.

Brent Wahlquist,

Regional Director, Western Regional Coordinating Center.

[FR Doc. 00–18009 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–05–M

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA–1539, MM Docket No. 00–124, RM–9893]

Digital Television Broadcast Service; Bryan, TX

AGENCY: Federal Communications Commission.

ACTION: Proposed rule.

SUMMARY: The Commission requests comments on a petition filed by KWTX/KBTX Licensee Corporation, licensee of station KBTX, NTSC Channel 3, Bryan, Texas, requesting the substitution of DTV Channel 33 for its assigned DTV Channel 59. DTV Channel 33 can be allotted to Bryan, Texas, in compliance with the principle community coverage requirements of Section 73.625(a) at reference coordinates (30–33–16 N. and 96–01–51 W.). As requested, we propose to allot DTV Channel 33 to Bryan with a power of 1000 and a height above average terrain (HAAT) of 477 meters.

DATES: Comments must be filed on or before September 5, 2000, and reply comments on or before September 20, 2000.

ADDRESSES: Federal Communications Commission, 445 12th Street, SW., Room TW–A325, Washington, DC 20554. In addition to filing comments with the FCC, interested parties should serve the petitioner, or its counsel or consultant, as follows: Howard J. Barr, Pepper & Corazzini, LLP, 1776 K Street, NW, Suite 200, Washington, DC 20006–2334 (Counsel for KWTX/KBTX Licensee Corporation).

FOR FURTHER INFORMATION CONTACT: Pam Blumenthal, Mass Media Bureau, (202) 418–1600.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's Notice of Proposed Rule Making, MM Docket No. 00-125, adopted July 12, 2000, and released July 13, 2000. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC Reference Center, 445 12th Street, SW., Washington, DC. The complete text of this decision may also be purchased from the Commission's copy contractor, International Transcription Services, Inc., (202) 857–3800, 1231 20th Street, NW., Washington, DC 20036.

Provisions of the Regulatory Flexibility Act of 1980 do not apply to this proceeding.

Members of the public should note that from the time a Notice of Proposed Rule Making is issued until the matter is no longer subject to Commission consideration or court review, all *ex parte* contacts are prohibited in Commission proceedings, such as this one, which involve channel allotments. See 47 CFR 1.1204(b) for rules governing permissible *ex parte* contacts.

For information regarding proper filing procedures for comments, see 47 CFR 1.415 and 1.420.

Federal Communications Commission.

Barbara A. Kreisman,

Chief, Video Services Division, Mass Media Bureau.

[FR Doc. 00–18053 Filed 7–14–00; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA–1538, MM Docket No. 00–125, RM–9908]

Digital Television Broadcast Service; Miami, FL

AGENCY: Federal Communications Commission.

ACTION: Proposed rule.

SUMMARY: The Commission requests comments on a petition filed by NBC Stations Management, Inc., licensee of station WTVJ(TV), NTSC Channel 6, Miami, Florida, requesting the substitution of DTV Channel 31 for its assigned DTV Channel 30. DTV Channel 31 can be allotted to Miami, Florida, in compliance with the principle community coverage requirements of Section 73.625(a) at reference coordinates (25–58–07 N. and 80–13–20 W). As requested, we propose to allot DTV Channel 31 to Miami with a power of 1000 and a height above average terrain (HAAT) of 318 meters.

DATES: Comments must be filed on or before September 5, 2000, and reply comments on or before September 20, 2000.

ADDRESSES: Federal Communications Commission, 445 12th Street, SW., Room TW–A325, Washington, DC 20554. In addition to filing comments with the FCC, interested parties should serve the petitioner, or its counsel or consultant, as follows: Diane Zipursky, National Broadcasting Company, Inc.,

1229 Pennsylvania Avenue, NW., 11th Floor, Washington, DC 20004 (Counsel for NBC Stations Management, Inc.).

FOR FURTHER INFORMATION CONTACT: Pam Blumenthal, Mass Media Bureau, (202) 418–1600.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's Notice of Proposed Rule Making, MM Docket No. 00–125, adopted July 12, 2000, and released July 13, 2000. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC Reference Center 445 12th Street, SW., Washington, DC. The complete text of this decision may also be purchased from the Commission's copy contractor, International Transcription Services, Inc., (202) 857–3800, 1231 20th Street, NW., Washington, DC 20036.

Provisions of the Regulatory Flexibility Act of 1980 do not apply to this proceeding.

Members of the public should note that from the time a Notice of Proposed Rule Making is issued until the matter is no longer subject to Commission consideration or court review, all *ex parte* contacts are prohibited in Commission proceedings, such as this one, which involve channel allotments. See 47 CFR 1.1204(b) for rules governing permissible *ex parte* contacts.

For information regarding proper filing procedures for comments, see 47 CFR 1.415 and 1.420.

Federal Communications Commission.

Barbara A. Kreisman,

Chief, Video Services Division, Mass Media Bureau.

[FR Doc. 00–18052 Filed 7–14–00; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA 00–1446; MM Docket No. 99–232; RM–9321]

Radio Broadcasting Services; Fort Bridger, WY and Hyrum, UT

AGENCY: Federal Communications Commission.

ACTION: Proposed rule; dismissal.

SUMMARY: M. Kent Frandsen requested the downgrade of Channel 256C1 to Channel 256C3 at Fort Bridger, Wyoming, the reallotment of Channel 256C3 from Fort Bridger to Hyrum, Utah, and the modification of Station KNYN(FM)'s construction permit accordingly. *See* 64 FR 36323, July 6, 1999. On June 16, 2000, petitioner filed a request for dismissal. A showing of continuing interest is required before a channel will be allotted. It is the Commission's policy to refrain from making an allotment to a community absent an expression of interest. Therefore, we will dismiss the instant petition.

FOR FURTHER INFORMATION CONTACT: Sharon P. McDonald, Mass Media Bureau, (202) 418–2180.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's Report and Order, MM Docket No. 99–232, adopted June 21, 2000, and released June 30, 2000. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC Reference Information Center (Room CY–A257), 445 12th Street, SW., Washington, DC. The complete text of this decision may also be purchased from the Commission's copy contractors, International Transcription Service, Inc., (202) 857–3800, 1231 20th Street, NW., Washington, DC 20036.

Federal Communications Commission.

John A. Karousos,

Chief, Allocations Branch, Policy and Rules Division, Mass Media Bureau.

[FR Doc. 00–18056 Filed 7–14–00; 8:45 am]

BILLING CODE 6712–01–P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 679

[Docket No. 000629198–0198–01; I.D. 051500D]

RIN 0648–AM72

Fisheries of the Exclusive Economic Zone Off Alaska; Western Alaska Community Development Quota Program

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Proposed rule; request for comments.

SUMMARY: NMFS proposes regulations to implement Amendment 66 to the Fishery Management Plan for the Groundfish Fishery of the Bering Sea and Aleutian Islands Area (FMP) to remove the allocation of squid to the Western Alaska Community Development Quota (CDQ) Program. This proposed rule also would implement regulatory amendments under the American Fisheries Act (AFA) requiring that only pollock caught while directed fishing for pollock CDQ accrue against the pollock CDQ allocation, and revising the definition of ''directed fishing for pollock CDQ.'' Pollock caught incidentally in other groundfish CDQ fisheries would accrue against the pollock incidental catch allowance (ICA) established under the AFA. This action is necessary to implement Amendment 66 and the CDQ Program-related provisions of the AFA. It is intended to further the goals and objectives of the FMP.

DATES: Comments must be received by August 31, 2000.

ADDRESSES: Written comments should be sent to Sue Salveson, Assistant Regional Administrator, Sustainable Fisheries Division, Alaska Region, NMFS, P.O. Box 21668, Juneau, AK 99802, Attn: Lori Gravel. Comments also may be hand delivered or couriered to the Federal Building, 709 West 9th Street, Juneau, AK. Comments also may be sent via facsimile (fax) to 907–586–7465. Comments will not be accepted if submitted via e-mail or the Internet. Copies of Amendment 66 to the FMP and the two Environmental Assessment/Regulatory Impact Review/Initial Regulatory Flexibility Analyses (EA/RIR/IRFA) prepared for these actions are available from NMFS at the above address, or by calling the Alaska Region, NMFS, at 907–586–7228.

FOR FURTHER INFORMATION CONTACT: Sally Bibb, 907–586–7389, sally.bibb@noaa.gov.

SUPPLEMENTARY INFORMATION:

Management Background and Need for Action

NMFS manages fishing for groundfish by U.S. vessels in the exclusive economic zone of the Bering Sea and Aleutian Islands management area (BSAI) according to the FMP. The North Pacific Fishery Management Council (Council) prepared the FMP under authority of the Magnuson-Stevens Fishery Conservation and Management Act (Magnuson-Stevens Act). Regulations governing fishing by U.S. vessels appear at 50 CFR parts 600 and 679.

The Council has submitted Amendment 66 for Secretarial review. NMFS published a Notice of Availability of the FMP amendment at 65 FR 34434, May 30, 2000, and invited comments on the FMP amendment through July 31, 2000. All written comments received by July 31, 2000, whether specifically directed to the FMP amendment, the proposed rule, or both, will be considered in the

approval/disapproval decision on the FMP amendment.

Two issues are addressed in this proposed rulemaking. First, the proposed rule would add a definition to 50 CFR part 679 for ''directed fishing for pollock CDQ'' to permanently implement the intent of the AFA with respect to pollock CDQ accounting. The proposed definition would determine whether pollock caught while CDQ fishing accrues against the pollock CDQ allocation or the pollock ICA. Second, the proposed rule would remove the allocation of squid to the CDQ Program to prevent the catch of squid CDQ from limiting the catch of pollock CDQ.

Defining Directed Fishing for Pollock CDQ

Section 206(a) of the AFA specifies that ''10 percent of the total allowable catch of pollock in the Bering Sea and Aleutian Islands Management Area shall be allocated as a directed fishing allowance to the Western Alaska Community Development Quota Program established under section 305(i) of the Magnuson-Stevens Act.'' Under section 206(b) of the AFA the incidental catch of pollock in non-pollock CDQ fisheries does not accrue against the pollock CDQ allocation created in section 206(a). Rather, the incidental catch of pollock in the CDQ fisheries accrues against the pollock ICA established in the groundfish specifications for pollock incidental catch from the CDQ and non-CDQ fisheries.

NMFS regulations at the time the AFA became effective required that all pollock caught in all groundfish CDQ fisheries accrue against the CDQ group's pollock CDQ allocation. NMFS issued an emergency interim rule (EIR) on January 26, 1999 (64 FR 3877, which was extended through December 31, 1999, at 64 FR 34743 on June 29, 1999), to revise CDQ catch accounting regulations for 1999 to be consistent with the AFA. Permanent rulemaking is necessary to revise CDQ catch accounting regulations to implement the AFA.

NMFS and the Council have considered four alternatives for defining directed fishing for pollock CDQ. Alternative 1 is the status quo, which would not distinguish between pollock caught while directed fishing for pollock CDQ from pollock caught incidentally to other groundfish CDQ fisheries. This alternative is not consistent with the AFA.

Alternative 2 would define directed fishing for pollock CDQ in the same manner as was implemented under the EIR in 1999. Pollock caught in hauls by a catcher/processor or deliveries by a catcher vessel in which pollock represents 40 percent or more of the total groundfish catch by weight would accrue against the pollock CDQ (the ''40–percent threshold''). Pollock caught in hauls or deliveries in which pollock represents less than 40 percent of the total groundfish catch would accrue against the pollock ICA.

Alternative 3 is the same as Alternative 2 except that the threshold for defining directed fishing for pollock CDQ would be increased from 40 percent to 60 percent.

Alternative 4 would use maximum retainable amounts to define directed fishing for pollock CDQ, which is the method used to define directed fishing in all non-CDQ groundfish fisheries. A vessel operator would be directed fishing for pollock CDQ if the weight of pollock CDQ retained onboard the vessel was 20 percent or more of the weight of all retained CDQ species onboard the vessel. Under Alternative 4, vessel operators could control whether they were directed fishing for pollock CDQ by discarding the amount of pollock that exceeded the maximum retainable amount. Under Alternatives 2 and 3, vessel operators cannot discard pollock to control whether they are directed fishing for pollock CDQ because the determination of their directed fishery is made on the basis of the percent of pollock in each haul rather than on retained catch composition.

At its June 1999 meeting, the Council considered the alternatives presented in a draft analysis, catch data from the 1998 pollock CDQ fisheries, NMFS' projections about catch in the 1999 CDQ fisheries, public testimony at the Council meeting, and the recommendation of the Council's Advisory Panel (AP). The Council agreed with the AP's recommendations to increase the percentage threshold from 40 percent (Alternative 2) to 60 percent (Alternative 3) for the following reasons. The Council recognized that the AFA allows the CDQ groups to harvest incidental catches of pollock without that pollock catch accruing against the CDQ group's pollock CDQ allocation. The Council believed that NMFS' estimates of the maximum potential incidental catch of pollock under all of the alternatives were high and unlikely to be realized in the actual CDQ fisheries. The Council also believed that the CDQ groups would discourage non-pollock CDQ partners from maximizing the amount of pollock that they can legally catch under the preferred alternative because the CDQ groups are aware that if NMFS' maximum estimates of pollock incidental catch prove true, the Council may be requested to re-evaluate this issue and consider more restrictive measures for the CDQ fisheries.

The Council also recognized that vessels not intending to target on pollock periodically would catch hauls with a high proportion of pollock. The objective in selecting the appropriate percentage threshold is to minimize situations in which (1) a haul or delivery by a vessel intending to target pollock did not meet the definition of directed fishing for pollock CDQ, and (2) a haul or delivery by a vessel not intending to target pollock CDQ did meet the definition of directed fishing for pollock CDQ. However, regardless of the percentage threshold selected, some pollock caught by vessels intending to target pollock would be caught in hauls or deliveries that do not meet the definition of directed fishing for pollock CDQ and that pollock would accrue against the pollock ICA. The opposite situation also may occur. Some vessels not intending to target pollock CDQ may catch pollock in hauls or make deliveries that exceed the 60–percent threshold, in which case, this pollock would accrue against the CDQ group's pollock CDQ allocation.

Three categories of vessels catch pollock in the CDQ fisheries: (1) Trawl vessels that the CDQ group identifies as intending to catch pollock CDQ; (2) trawl vessels intending to target other groundfish CDQ species, such as flatfish, Atka mackerel, rockfish, or Pacific cod; and (3) vessels using nontrawl gear. The proposed definition of directed fishing for pollock CDQ would apply only to vessels using trawl gear. Therefore, all catch of pollock by vessels using longline, pot, jig, or any other nontrawl gear would accrue against the pollock ICA.

In 1999, approximately 100,000 mt of pollock were caught by vessels participating in some CDQ fishery. Of this, 98,800 mt of pollock was caught in trawl hauls in which pollock was equal to or greater than 60 percent of the total catch. The remaining 1,200 mt accrued against the pollock ICA because it was caught by CDQ vessels using nontrawl gear (500 mt pollock) or in trawl hauls in which pollock represented less than 60 percent of the total catch (700 mt).

Removing Squid as a CDQ Species

Currently, all groundfish species or species groups allocated to the CDQ Program are considered CDQ species and each CDQ group is prohibited from exceeding its allocation of any CDQ species. The CDQ groups are expected to reach quotas for some CDQ species

before they fully harvest all of their CDQ allocations.

Squid incidental catch is caught primarily by vessels using pelagic trawl gear to fish for pollock. Very little squid is caught in any other BSAI fisheries. Since implementation of the MS CDQ Program in 1998, the CDQ groups have been particularly concerned that they will reach their squid CDQ allocations before they harvest all of their pollock CDQ allocations. The increase of the pollock CDQ allocation to 10 percent of the pollock TAC under the AFA without an increase in the squid CDQ allocation heightened these concerns.

The proposal to remove squid as a CDQ species arose in mid-1998. In the 1998 pollock CDQ fisheries, approximately 342 mt of squid were caught. The squid CDQ allocation was not effective for the 1998 pollock CDQ fisheries. However, the squid catch of 342 mt significantly exceeded 7.5 percent of the squid TAC (148 mt). Catch in the 1998 pollock CDQ fisheries indicated that 148 mt of squid were harvested by August 22, 1998, when the pollock CDQ catch was 57,153 mt. If the squid CDQ allocation had been effective in 1998, this would have resulted in the CDQ groups being unable to harvest 27,669 mt of pollock (84,822 mt—57,153 mt). Based on an average royalty value of $200 per mt for pollock harvested during the B-season, this amount of pollock would have been valued at $5.5 million. Under the 10–percent pollock CDQ allocation, and assuming the same pollock and squid catch rates as achieved in 1998, the amount and value of the pollock catch CDQ that could be foregone would be approximately 42,200 mt (99,200 mt—57,000 mt) and $8.4 million. No specific provision exists in current regulation to allocate back to the non-CDQ fisheries any unharvested pollock CDQ or any other CDQ species.

The 1998 experience with squid incidental catch in the BSAI groundfish fisheries did not occur in 1999. Total squid incidental catch decreased from 915 mt in 1998 to 441 mt in 1999 and squid incidental catch in the CDQ fisheries decreased from 342 mt in 1998 to 41 mt in 1999. The reason for this change in squid incidental catch is not known. However, catch statistics presented in the analysis indicate that squid incidental catch has varied between several hundred mt to over 1,000 mt in the last 10 years.

NMFS and the Council considered two alternatives for the status of squid as a CDQ species: (1) The status quo, which would continue to allocate 7.5 percent of the squid TAC to the CDQ Program; and (2) discontinuing the squid CDQ allocation. An increase of the squid CDQ allocation corresponding to the AFA's increased pollock CDQ allocation is not an available management measure. Section 305(i)(1)(C)(ii)(II) of the Magnuson-Stevens Act requires that, until October 1, 2001, the percentage of a groundfish TAC allocated to the CDQ Program cannot exceed the amount approved by the Council prior to October 1, 1995.

If the allocation of 7.5 percent of the squid TAC to the CDQ Program were removed, squid would no longer be a CDQ species, and the individual CDQ groups would no longer receive allocations of squid CDQ each year. The catch of squid in the CDQ fisheries would accrue to a single squid TAC together with the squid catch from the non-CDQ fisheries. The catch of squid by a CDQ group would not prevent the harvest of their other CDQ species, such as pollock CDQ, because the CDQ groups are only prohibited from exceeding allocations of those species allocated to the CDQ Program.

If squid is removed from the CDQ allocations, NMFS would manage the overall squid TAC to ensure that catch in CDQ and non-CDQ fisheries combined remains within the TAC and does not exceed the overfishing limit. If the catch of squid reaches the overfishing level of 2,620 mt, NMFS would be required to take action to limit all fisheries in which squid catch occurs to ensure that the squid OFL is not exceeded.

In the EA/RIR/IRFA, NMFS presents information about the squid overfishing, acceptable biological catch, TAC limits, and estimated total catch, for the years 1994 through 1999. This information shows that the squid catch by the CDQ and non-CDQ fisheries combined has not exceeded the TAC since 1996 (revisions to ABC and overfishing level definitions were implemented under Amendment 44 to the BSAI FMP in 1997). Based on these data, the overall catch of squid should not exceed amounts harvested in previous years, unless factors related to the amount or location of squid change (factors not related to the pollock catch).

At its June 1999 meeting, the Council recommended removal of squid as a CDQ species. Discontinuing the allocation of squid to the CDQ Program would eliminate the possibility that the incidental catch of squid would constrain a CDQ group's ability to harvest its pollock CDQ allocations. In making this recommendation, the Council believed that allowing the CDQ fisheries to harvest more than 7.5 percent of the squid TAC would not negatively affect overall management of squid and would remove a significant barrier to the CDQ group's realizing the full value of its pollock CDQ allocations.

Removal of squid as a CDQ species would require an amendment to the FMP because Section 13.4.7.3.5 of the FMP currently states that ''CDQs will be issued for 7.5 percent of the TAC for all BSAI groundfish species not already covered by another CDQ program.'' Squid is one of the groundfish TAC species. The FMP language would have to be amended to issue CDQs for all BSAI groundfish species except squid.

Description of the Proposed Regulations

NMFS proposes the following regulatory amendments to 50 CFR part 679:

1. Define directed fishing for pollock CDQ at § 679.2 as a haul by a catcher/processor or a delivery by a catcher vessel in which pollock represents 60 percent or more of the groundfish catch by weight in the haul or delivery. Clarify that the groundfish species used to calculate total catch includes all species categories defined in Table 1 of the annual BSAI specifications, including squid.

2. In § 679.20, revise paragraph (b)(1)(iii)(A) to remove the allocation of 7.5 percent of the squid TAC to the CDQ Program.

3. In § 679.31(f), remove the reference to the squid CDQ from the paragraph describing the non-specific CDQ reserve. Under this proposed rule, squid would no longer be allocated to the CDQ Program, so NMFS could not allocate a portion of the squid CDQ to each CDQ groups' non-specific CDQ reserve.

4. In § 679.32, permanently implement paragraphs (a)(2) and (e), which were in effect in 1999 under the EIR. Paragraph (a)(2) is a reference to the location of the pollock CDQ catch accounting regulations at paragraph (e). Paragraph (e) contains the requirements that pollock catch meeting the definition of directed fishing for pollock CDQ would accrue against the pollock CDQ allocation, and all other catch of pollock in the CDQ fisheries would accrue against the pollock ICA. Paragraph (e) also reiterates that 100 percent of all pollock caught in the groundfish CDQ fisheries, regardless of the percent of pollock in the haul or delivery, would be retained under the Improved Retention/Improved Utilization regulations at § 679.27.

Classification

At this time, NMFS has not determined that the FMP amendment this proposed rule would implement is consistent with the national standards of the Magnuson-Stevens Act and other

applicable law. NMFS, in making that determination, will take into account the data, views, and comments received during the comment period.

This action has been determined to be not significant for purposes of E.O. 12866.

NMFS has prepared an IRFA that describes the impact this proposed rule, if adopted, would have on small entities. A copy of this analysis is available (see **ADDRESSES**). The IRFA consists of the IRFA for Amendment 66, the IRFA for defining directed fishing for pollock CDQ, and the preamble to this proposed rule. The following is a summary of the IRFA that (1) identifies all of the entities that NMFS believes would be impacted by these proposed regulatory amendments, (2) identifies which of these impacted entities are considered small entities under the Regulatory Flexibility Analysis (RFA), (3) describes how the small entities could be affected by the proposed regulatory amendments and the alternatives considered, (4) discusses significant alternatives that would minimize the economic impacts on these small entities, and (5) describes the projected cumulative effects on small entities of the proposed regulatory amendments to define directed fishing for pollock CDQ and to remove squid as a CDQ species.

The following table summarizes the total number of entities that could be affected by the proposed regulations and the number that are small entities under the RFA. The table shows that the proposed regulatory amendments would affect (1) the six CDQ groups representing the 65 western Alaska communities that are eligible for the CDQ Program; (2) the owners of 10 trawl catcher/processors, 1 mothership, 22 trawl catcher vessels, 3 shoreside processors that harvest and process pollock CDQ; (3) the owners of 7 trawl catcher/processors fishing for other groundfish CDQ; and (4) up to 20 catcher/processors, 3 motherships, 8 shoreside processors, and 120 catcher vessels that participate in the AFA pollock fisheries. The CDQ groups and the communities they represent are small entities under the RFA, as are 40 of the 120 catcher vessels that participate in the AFA pollock fisheries. However, none of the catcher/processors, motherships, shoreside processors, the 22 trawl catcher vessels participating in the CDQ fisheries, or 80 of the 120 trawl catcher vessels participating in the AFA pollock fisheries are small entities.

Category	Total Number That Could Be Affected	Number That are Small Entities
CDQ groups	6 groups representing 65 communities	6 groups representing 65 communities
Vessels and Processors in the BSAI Pollock Fisheries	20 trawl catcher/processors(c/p) 3 motherships 8 shoreplants 120 trawl catcher vessels (cv)	40 trawl cv
Number that also Participate in Pollock CDQ Fisheries	10 c/p 1 mothership 3 shoreplants 22 trawl cv	0
Trawl Vessels that Participate in non-Pollock CDQ Fisheries	7 trawl c/p	0

The IRFA, and the remainder of this summary, describes the impacts of the proposed regulatory amendment and alternatives on the affected small entities: the CDQ groups and the communities they represent, and the 40 trawl catcher vessels that participate in the AFA pollock fisheries but do not participate in the CDQ fisheries.

This proposed rule involves two distinct changes that could affect small entities individually or cumulatively: by creating a definition of directed fishing for pollock CDQ, and by removing squid from the CDQ allocations. The proposed definition of directed fishing for pollock CDQ would affect CDQ groups because it would determine how much of the pollock caught by vessels fishing for the CDQ groups would accrue against the pollock CDQ allocation and how much would accrue against the pollock ICA. The total catch of pollock in the CDQ fisheries is the sum of pollock that accrues against the pollock CDQ allocation and pollock that accrues against the pollock ICA. In general, the more pollock from the CDQ fisheries that accrues against the pollock ICA, the higher the royalties to the CDQ groups. In comparison with the status quo, the proposed rule would benefit the CDQ groups because it would allow some pollock catch in the CDQ fisheries to accrue against the pollock ICA rather than requiring all pollock catch in the CDQ fisheries to accrue against the pollock CDQ allocation.

The 40 catcher vessels in the BSAI pollock fisheries that are small entities do not participate in the CDQ fisheries. However, the proposed definition could affect them because any pollock from the CDQ fisheries that accrues against the pollock ICA reduces the pollock directed fishing allowances available to the sector under the AFA. Therefore, the more pollock from the CDQ fisheries that accrues against the pollock ICA, the less pollock that is available to these 40 catcher vessels in directed pollock fisheries. In comparison to the status quo, the proposed rule would not benefit the 40 catcher vessels because it could slightly reduce the amount of pollock available to these 40 catcher vessels in their directed pollock fisheries.

If this proposed definition had been in place in 1999, approximately 98,800 mt of pollock would have accrued to the pollock CDQ allocation and approximately 1,200 mt to the pollock ICA. If this 1,200 mt had been required to accrue against the pollock CDQ allocation (under the status quo), this 1,200 mt would have been available for the directed AFA fisheries. The 40 catcher vessels from the AFA that are small entities could have participated in a 600 mt increase in the pollock AFA allocation to the inshore sector (because

the inshore sector is allocated 50 percent of the pollock available to the directed AFA fisheries; 1,200 mt * 50 percent = 600 mt). However, 600 mt of pollock is about 1/10 percent of the total pollock allocation to the inshore sector (423,187 mt pollock). Therefore, NMFS believes that the increase in pollock that would accrue to the pollock ICA under this proposed rule would have a minimal negative impact on the small entities participating in the pollock AFA fisheries (the 40 trawl catcher vessels).

The proposal to remove squid as a CDQ species would likely affect only the 6 CDQ groups. The proposed rule should allow the CDQ groups to fully harvest their pollock CDQ allocations. Without this proposed action, some risk exists that the squid CDQ allocation would be reached before all of the pollock CDQ was harvested. If this occurs, the CDQ groups would lose the opportunity to harvest all of their pollock CDQ and the royalties associated with this pollock catch. Based on the 1998 squid incidental catch rates, this potential loss to the CDQ groups could range from $0 to $8.4 million annually. In addition to the loss of royalty revenue, the CDQ groups also would lose profit sharing and employment opportunities that would have been associated with full harvest of the pollock CDQ. Therefore, NMFS expects this proposed action to benefit the CDQ groups.

The proposal to remove squid as a CDQ species is not expected to negatively affect any other entity participating in the BSAI groundfish fisheries. The catch of squid in the CDQ fisheries would accrue against the overall squid TAC together with squid catch from the non-CDQ fisheries. The CDQ and non-CDQ trawl fisheries could be restricted if the total catch of squid exceeded the squid TAC or overfishing limit. However, the squid TAC has not been exceeded since 1996. NMFS does not expect that the TACs for squid or pollock would be exceeded in future years as a result of the proposed action.

The cumulative impacts of the proposed action to define directed fishing for pollock CDQ and to remove squid as a CDQ species on small entities are (1) benefits to the CDQ groups and the 65 communities they represent in the form of increased total catch of pollock in the CDQ fisheries and decreased potential that they would catch less than their full pollock CDQ allocation due to the incidental catch of squid; and (2) potential costs to 40 trawl catcher vessels in the BSAI pollock AFA fisheries in the form of slightly reduced pollock directed fishing allowances to allow for the incidental catch of pollock in the CDQ fisheries as required by the AFA.

NMFS considered several alternatives that could have minimized the negative economic impacts on some of the small entities. The Council could have recommended a definition of directed fishing for pollock CDQ that further increased the amount of pollock catch in the CDQ fisheries that would accrue against the pollock ICA, thereby increasing the benefits to certain small entities. Using maximum retainable amounts to define directed fishing for pollock CDQ would have allowed the CDQ groups to catch as much pollock as they wished while CDQ fishing and to discard amounts of pollock above the maximum retainable amounts. This alternative would require regulatory discards of pollock catch that exceeds the maximum retainable amounts. In addition, this alternative would increase the potential negative impacts to another group of small entities affected by the proposed action—the 40 catcher vessels in the AFA pollock fisheries—because increases in the amount of pollock from the CDQ fisheries accruing against the pollock ICA would decrease the directed pollock allowance to the AFA fisheries.

The Council also considered an alternative that could have further minimized negative economic impacts on the 40 catcher vessels in the AFA pollock fisheries: establishing a 40–percent threshold rather than 60 percent. Under this alternative, less pollock from the CDQ fisheries would accrue against the pollock ICA than would accrue under the preferred alternative. However, the Council considered the trade-off in impacts to the participants in the AFA pollock fisheries and the CDQ fisheries and determined that the amount of pollock that would accrue against the pollock ICA under the preferred alternative was not likely to significantly affect the 40 trawl catcher vessels or other participants in the AFA fisheries.

The President has directed Federal agencies to use plain language in their communications with the public, including regulations. To comply with that directive, we seek public comment on any ambiguity or unnecessary complexity arising from the language used in this proposed rule.

List of Subjects in 50 CFR Part 679

Alaska, Fisheries, Recordkeeping and reporting requirements.

Dated: July 9, 2000 .

Penelope D. Dalton,

Assistant Administrator for Fisheries, National Marine Fisheries Service.

For the reasons set out in the preamble, 50 CFR part 679 is proposed to be amended as follows:

PART 679—FISHERIES OF THE EXCLUSIVE ECONOMIC ZONE OFF ALASKA

1. The authority citation for part 679 continues to read as follows:

Authority: 16 U.S.C. 773 *et seq.*, 1801 *et seq.* and 3631 *et seq.*

2. In § 679.2, the definition for ''Directed fishing for pollock CDQ'' is added to read as follows:

§ 679.2 Definitions.

* * * * *

Directed fishing for pollock CDQ means, for purposes of determining whether pollock caught while CDQ fishing accrues against the pollock CDQ allocation or the pollock incidental catch allowance, a vessel operator using trawl gear is directed fishing for pollock CDQ if pollock represents 60 percent or more of the total catch of groundfish species by weight in a haul by a catcher/processor or a delivery by a catcher vessel. The groundfish species used to calculate total catch includes all species categories defined in Table 1 of the annual BSAI specifications.

* * * * *

3. In § 679.20, paragraph (b)(1)(iii)(A) is revised to read as follows:

§ 679.20 General limitations.

* * * * *

(b) * * *

(1) * * *

(iii) * * *

(A) *Groundfish CDQ Reserve.* Except as limited by § 679.31(a), one half of the nonspecified reserve established by paragraph (b)(1)(i) of this section for all species except squid is apportioned to the groundfish CDQ reserve.

* * * * *

4. In § 679.31, paragraph (f) is revised to read as follows:

§ 679.31 CDQ reserves.

* * * * *

(f) *Non-specific CDQ reserve.* Annually, NMFS will apportion 15 percent of each arrowtooth flounder and ''other species'' CDQ for each CDQ group to a non-specific CDQ reserve. A CDQ group's non-specific CDQ reserve must be for the exclusive use of that CDQ group. A release from the non-specific CDQ reserve to the CDQ group's arrowtooth flounder or ''other species'' CDQ is a technical amendment to a

community development plan as described in § 679.30(g)(5). The technical amendment must be approved before harvests relying on CDQ transferred from the non-specific CDQ reserve may be conducted.

* * * * *

5. In § 679.32, paragraph (a)(2) is revised and paragraph (e) is added to read as follows:

§ 679.32 Groundfish and halibut CDQ catch monitoring.

(a) * * *

(2) *Pollock CDQ*. Requirements for the accounting of pollock while CDQ fishing are at paragraph (e) of this section.

* * * * *

(e) *Pollock CDQ*. (1) *Directed fishing for pollock CDQ*. Owners and operators of vessels directed fishing for pollock CDQ as defined at § 679.2 and processors taking deliveries from vessels directed fishing for pollock CDQ must comply with all applicable requirements of paragraphs (a) through (d) of this section. Pollock catch by vessels directed fishing for pollock CDQ will accrue against the pollock CDQ for the CDQ group.

(2) *Catch of pollock by vessels not directed fishing for pollock CDQ*. Pollock catch by vessels groundfish CDQ fishing, but not directed fishing for pollock CDQ as defined at § 679.2, will not accrue against the pollock CDQ for the CDQ group.

(3) Operators of all vessels participating in any CDQ fishery must retain all pollock caught while CDQ fishing as required at § 679.27 (IR/IU).

* * * * *

[FR Doc. 00–18019 Filed 7–14–00; 8:45 am]

BILLING CODE 3510–22–F

Notices

Federal Register
Vol. 65, No. 137
Monday, July 17, 2000

This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

DEPARTMENT OF AGRICULTURE

Agricultural Marketing Service

[Docket No. DA–98–03]

United States Standards for Dry Whey; Correction

AGENCY: Agricultural Marketing Service, USDA.

ACTION: Notice; correction.

SUMMARY: The Agricultural Marketing Service published in the **Federal Register** of June 20, 2000 (65 FR 38235) a document (DA–98–03) soliciting comments on a proposal to change the United States Standards for Dry Whey. Text was inadvertently omitted in four paragraphs in the Notice, in one place a word was misspelled, and in another place an incorrect title for an industry organization appeared. This document corrects those errors.

DATES: July 17, 2000.

FOR FURTHER INFORMATION CONTACT: Duane R. Spomer, Chief, Dairy Standardization Branch, AMS/USDA/Dairy Programs, Room 2764-South, P.O. Box 96956, Washington, DC 20090–6456; telephone (202) 720–7473; fax (202) 720–2643; e-mail Duane.Spomer@usda.gov.

SUPPLEMENTARY INFORMATION:

Background

The Department of Agriculture (Department) published a Notice (DA–98–03) in the **Federal Register** of June 20, 2000 (65 FR 38235). The Notice (issued on June 13, 2000) solicited comments on a proposal to change the United States Standards for Dry Whey. AMS is proposing changes that would lower the bacterial estimate of not more than 50,000 per gram to not more than 30,000 per gram, incorporate maximum scorched particle content as a requirement for U.S. grade, and expand the Test Methods section to allow product evaluation using the latest methods included in Standard Methods for Examination of Dairy Products, in the Official Methods of Analysis of the Association of Official Analytical Chemists, and in standards developed by the International Dairy Federation. These changes are being proposed to strengthen the quality requirements of this Standard to reflect improvements that have occurred in dry whey quality since the Standards were last reviewed. AMS is also proposing editorial changes to provide consistency with other dry milk standards. This Notice Correction is necessary in order to provide complete data on which to solicit comments. The due date for comments on the proposed changes (August 21, 2000) is unchanged.

Correction

This **Federal Register** Notice makes correction to the Notice published on June 20, 2000 (65 FR 38235). The Department makes the following corrections:

(1) In the third column, under ''Proposed by Dairy Programs, Agricultural Marketing Service'' (FR page 38235), the paragraph which begins ''Concerning the suggestion by the * * *'', change ''American Dairy Products Association'' to read ''American Dairy Products Institute.''

(2) In the first paragraph of the first column ''current standard,'' second sentence (FR page 38236), correct the spelling of ''Mositure'' to read ''Moisture''.

(3) In paragraph (a)(1) of the first column, ''Requirements for U.S. grade,'' (FR page 38236), add the following omitted words in the Current standard section immediately following the last published line in the paragraph (which reads ''possess the following flavors to a.''):

'' * * * slight degree: Bitter, fermented, storage, and utensil; and the following to a definite degree: feed and weedy.''

The paragraph should read as follows:

(1) Flavor. (Applies to the reliquefied form). Shall have a normal whey flavor free from undesirable flavors, but may possess the following flavors to a slight degree: Bitter, fermented, storage, and utensil; and the following to a definite degree: feed and weedy.

(4) In paragraph (1) of that same section (Requirements for U.S. grade) (FR page 38236) add the following omitted words in the second column, Proposed section immediately following the last published line in the paragraph (which reads ''and the following to a definite degree: feed and''):

'' * * * weedy. See Table 1 of this section.''

The paragraph should read as follows:

(1) Flavor. Reconstituted whey shall have a normal whey flavor free from undesirable flavors, but may possess the following flavors to a slight degree: Bitter, fermented, storage, and utensil; and the following to a definite degree: feed and weedy. See Table 1 of this section.

(5) In the paragraph of that same section (FR page 38236) add the following omitted words in the third column (Discussion section), immediately following the words in the last published line in that paragraph (which reads ''and their''):

''intensities. This would allow the reader to quickly identify flavor characteristics and intensities included in this standard.''

The paragraph should read as follows:

We propose to change ''reliquefied'' to ''reconstituted'' to more accurately describe the process of converting dry whey to a liquid product. We propose to provide a Table 1 that includes the allowed flavors and their intensities. This would allow the reader to quickly identify flavor characteristics and intensities included in this standard.

(6) Proposed paragraph (b) in the second column under ''Test Methods'' (FR page 38238), add the following omitted words in the Proposed column immediately following the last published line in the paragraph (which reads ''Methods for the Examination of Dairy.''):

''Products,'' available from the American Public Health Association, 1015 Fifteenth Street NW, Washington, DC 20005, or by methods published by the International Dairy Federation, available from the International Dairy Federation, 41 Square Vergate, B–1030 Brussels, Belgium.''

The paragraph should read as follows:

(b) All other tests shall be performed by the methods contained in the latest edition of the ''Official Methods of Analysis of the Association of Official Analytical Chemists,'' published by the Association of Official Analytical Chemists International, 481 North

Frederick Avenue, Suite 500, Gaithersburg, MD 20877–2504; by the methods provided in the latest edition of the ''Standard Methods for the Examination of Dairy Products,'' available from the American Public Health Association, 1015 Fifteenth Street NW, Washington, DC 20005, or by methods published by the International Dairy Federation, available from the International Dairy Federation, 41 Square Vergate, B–1030 Brussels, Belgium.

Authority: (7 U.S.C. 1621–1627).

Dated: July 11, 2000.

Kathleen A. Merrigan,

Administrator, Agricultural Marketing Service.

[FR Doc. 00–17957 Filed 7–14–00; 8:45 am]

BILLING CODE 3410–02–P

DEPARTMENT OF AGRICULTURE

Office of the Under Secretary, Research, Education, and Economics

Notice of the Advisory Committee on Agricultural Biotechnology Meeting

AGENCY: Agricultural Research Service, USDA.

ACTION: Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, 5 U.S.C. App., the United States Department of Agriculture announces a meeting of the Advisory Committee on Agricultural Biotechnology (ACAB).

SUPPLEMENTARY INFORMATION: The ACAB has scheduled its second meeting on July 26–27, 2000. The topics to be discussed will include: (1) finalization of ACAB Bylaws and Operating Procedures; (2) update on recent relevant issues, projects, and activities; (3) potential impacts of the licensing of USDA Control of Gene Expression (CGE) patents; (4) agricultural biotechnology statistics collection and analyses; (5) topics for potential consideration by the National Academy of Sciences' Standing Committee on Biotechnology, Food and Fiber Production, and the Environment; (6) FY 2002 biotechnology budget priorities; and (7) framing of additional issues for future ACAB deliberations.

Background information regarding the work of the ACAB is available on the USDA web site at *http://www.usda.gov/agencies/biotech/acab.html.* Members of the public who wish to make oral statements should also inform Dr. Schechtman in writing or via E-mail at the indicated addresses at least three business days before the meeting. On July 26, 2000, if time permits, reasonable provision will be made for oral presentations of no more than five minutes each in duration. Interested individuals may file written comments with the committee before or after the meeting by sending them to Dr. Schecntman at the address below. Written comments may be submitted by regular mail, fax, or e-mail.

DATES: The meeting will be held in the Empire Room in the Omni Shoreham Hotel, 2500 Calvert Street, NW, Washington, DC 20008, on July 26–27, 2000. The meeting is scheduled to run from 8:30 am until 7 pm on July 26 and 8:30 am until 5 pm on July 27. The meeting will be open to the public, but space is limited. If you would like to attend the meetings, you must register by contacting Ms. Cindi White at (202) 690–8647, by fax at (202) 720–3191 or by E-mail at *cwhite@ars.usda.gov* at least 7 days prior to the meeting. Please provide your name, title, business affiliation, address, telephone, and fax number when you register. If you require a sign language interpreter or other special accommodation due to disability, please indicate those needs at the time of registration.

FOR FURTHER INFORMATION CONTACT: Michael Schechtman, Designated Federal Official, Office of the Deputy Secretary, USDA, 202B Jamie L. Whitten Federal Building, 12th and Independence Avenue, SW, Washington, DC 20250; Telephone (202) 720–3817; Fax (202) 690–4265; E-mail *mschechtman@ars.usda.gov.*

Floyd P. Horn,

Administrator.

[FR Doc. 00–17939 Filed 7–14–00; 8:45 am]

BILLING CODE 3410–03–P

DEPARTMENT OF AGRICULTURE

Forest Service

West Gold Project, Idaho Panhandle National Forests, Bonner County, Idaho

AGENCY: Forest Service, USDA.

ACTION: Notice of Intent to Prepare an Environmental Impact Statement.

SUMMARY: The USDA Forest Service will prepare an environmental impact statement (EIS) to document and disclose the potential environmental effects of proposed activities within the West Gold watershed in the Sandpoint Ranger District, Idaho Panhandle National Forests. The watershed is located about 25 miles south of Sandpoint, Idaho, near the town of Lakeview.

The proposal was designed using science from broad scale assessments including the Interior Columbia Basin Ecosystem Management Project. The proposal is intended to improve the health and productivity of terrestrial and aquatic habitats by: (1) Restoring desired forest structures, habitats, and species composition where they are decreasing and where root disease occurs, (2) restoring fire as an ecological process, (3) reducing the level of forest fuels and the risk of catastrophic wildfire; (4) reducing existing and potential sediment risks and improving aquatic habitat, and (5) providing public access and managing motorized recreation to protect resource values such as wildlife and water.

Activities would include thinning overcrowded stands of trees, cutting stands dead or dying from insects and root disease and replanting them with longer lived seral species; burning to reduce fuels, improve growing conditions, and improve forage for wildlife; placing woody debris in stream segments where needed, improving drainage structures and the design of existing roads; decommissioning or recontouring unneeded road segments; and redesigning gates to allow limited, dry season, off-road vehicle use on some existing roads.

The Sandpoint Ranger District of the Idaho Panhandle National Forests in Bonner County, Idaho will administer these activities. The EIS will tier to the Idaho Panhandle National Forests Forest Plan (September 1987).

DATES: Comments should be postmarked on or before August 16, 2000. Please include your name and address and the name of the project you are commenting on.

ADDRESSES: Submit written comments and suggestions on the proposed management activities or request to be placed on the project mailing list by writing to: West Gold Project, Attn: Judy York Sandpoint Ranger District, 1500 Hwy 2, Suite 110, Sandpoint, ID 83864.

FOR FURTHER INFORMATION CONTACT: Judy York, Project Team Leader, Sandpoint Ranger District, 208–265–6665.

Comments received in response to this solicitation, including names and addresses of those who comment, will be considered part of the public record on this proposed action and will be available for public inspection. Comments submitted anonymously will be accepted and considered; however, those who submit anonymous comments will not have standing to appeal the subsequent decision under 36 CFR Parts 215 or 217, Additionally, pursuant to 7 CFR 1.27(D), any person may request the agency to withhold a submission from the public record by

showing how the Freedom of Information Act (FOIA) permits such confidentiality. For persons requesting such confidentiality, it may be granted in only very limited circumstances, such as to protect trade secrets. The Forest Service will inform the requester of the agency's decision regarding the request for confidentiality, and where the request is denied, the agency will return the submission and notify the requester that the comments may be resubmitted with or without name and address within 10 days.

SUPPLEMENTARY INFORMATION: The legal description for the project area includes all or portions of sections 13, 14, 23, 24, 25, 26, 35, and 36 in Township 53 North; Range 2 West and sections 8, 9, 10, 16, 17, 20, 21, and 29 in Township 53 North, Ranger 1 West. This project was initially presented in a letter to the public in June of 1997, soliciting comments on a proposal to be analyzed in an environmental analysis. An update letter was sent in October of 1998 describing public and Forest Service issues identified and alternatives developed by the interdisciplinary team at that time. Key issues identified were the effects of logging and road construction on the watershed, aquatic habitat, fisheries, wildlife, and noxious weed spread, and how much motorized access should occur on existing roads.

A new proposal has been developed and the Forest Service is now preparing an environmental impact statement. In the new proposal, treatment of vegetation would occur on about 1,300 acres of a 4,500-acre project area. Cutting techniques would include thinning to reduce competition and increase tree growth within stands. Irregular shelterwood, seed tree with reserves, final removal with reserves, and rehabilitation would be used to improve forest health and promote longer-lived seral species in areas of root disease and insect infestations. Prescribed fire would be used to reduce fuels and prepare some sites for planting. There would be approximately 3 miles of road construction for short-term treatment access, and 15 miles of existing road reconstruction (most of which includes road reconditioning) to reduce potential sediment risk to the watershed. Of the 3 miles of road construction, all except ⅓ of a mile would be fully recontoured upon completion of project activities. An additional 2 miles of existing road would be fully recontoured. Logs and other woody debris would be placed in headwater areas where needed, and in other areas where lacking.

Two periods are specifically designated for comments on this analysis: (1) During the scoping period which is 30 days from the date of this notice in the **Federal Register** and (2) during the draft EIS comment period. The mailing list for this project will include those individuals who have previously expressed interest in this project as well as adjacent landowners and those responding to this NOI or to the Idaho Panhandle National Forests Quarterly Schedule of proposed Actions. In addition, the public is encouraged to visit with Forest Service officials during the analysis and prior to the decision. The forest Service will continue to seek information, comments, and assistance from Federal, Tribal, State, and local agencies and other individuals or organizations that may be interested in or affected by the proposed actions. The United States Fish and Wildlife Service will be consulted concerning any effects to threatened and endangered species. The agency invites written comments and suggestions on this action, particularly in terms of identification of issues and alternative development.

Comments from the public and other agencies will be used in preparation of the Draft EIS to identify potential issues and concerns, potential alternatives to the proposed action and to promote communications with members of the public or other agencies.

The draft environmental impact statement (DEIS) is expected to be filed with the Environmental Protection Agency (EPA) and made available for public review in September of 2000. The final environmental impact statement is expected to be completed in November or December of 2000.

The comment period on the draft environmental impact statement will be 45 days from the date the Environmental Protection Agency publishes the notice of availability in the **Federal Register**.

The Forest Service believes, at this early stage, it is important to give reviewers notice of several court rulings related to public participation in the environmental review process. First, reviewers of draft environmental impact statements must structure their participation in the environmental review of the proposal so that it is meaningful and alerts and agency to the reviewer's position and contentions. *Vermont Yankee Nuclear Power Corp.* v. *NRDC,* 435 U.S. 519, 533 (1978). Also, environmental objections that could be raised at the draft environmental statement stage but that are not raised until after completion of the final environmental statement may be waived or dismissed by the courts. *City of Angoon* v. *Hodel,* 803 F 2d 1016, 1022 (9th Cir. 1986) and *Wisconsin Heritages, Inc.* v. *Harris,* 490 F. Supp. 1334, 1338 (E.D. Wis. 1980). Because of these court rulings, it is very important that those interested in this proposed action participate by the close of the 45-day comment period so that substantive comments and objections are made available to the Forest Service at a time when it can meaningfully consider them and respond to them in the final environmental impact statement.

To assist the Forest Service in identifying and considering issues related to the proposed action, comments on the draft environmental impact statement should be as specific as possible. It is also helpful if comments refer to specific pages or chapters of the draft statement. Comments may also address the adequacy of the draft environmental impact statement or the merits of the alternatives formulated and discussed in the statement. Reviewers may wish to refer to the Council on Environmental Quality Regulations for implementing the procedural provisions of the National Environmental Policy Act at 40 CFR 1503.3 in addressing these points.

The United States Department of Agriculture (USDA) prohibits discrimination in its programs on the basis of race, color, national origin, sex, religion, age, disability, political beliefs, and marital or familial status. (Not all prohibited bases apply to all programs.) Persons with disabilities who require alternative means of communication of program information (braille, large print, audiotape, etc.) should contact USDA's TARGET Center at (202) 720–2600 (voice and TDD). To file a complaint, write the Secretary of Agriculture, U.S. Department of Agriculture, Washington, DC 20250, or call 1–800–245–6340 (voice) or (202) 720–1127 (TDD). USDA is an equal employment opportunity employer.

The Idaho Panhandle National Forests Supervisor is the responsible official who will make the decision on this project. The decision will be made after considering comments and responses, environmental consequences discussed in the Final EIS, and applicable laws, regulations and policies. The decision and supporting reasons will be documented in a Record of Decision upon release of the Final EIS.

Dated: June 30, 2000.

David J. Wright,

Forest Supervisor, Idaho Panhandle National Forests.

[FR Doc. 00–17946 Filed 7–14–00; 8:45 am]

BILLING CODE 3410–11–M

DEPARTMENT OF AGRICULTURE

Forest Service

Santa Fe Municipal Watershed Wildland-Urban Interface Fuels Reduction Project, Santa Fe National Forest, Santa Fe County, NM

AGENCY: Forest Service, USDA.

ACTION: Notice of intent to prepare an environment impact statement.

SUMMARY: The Forest Service and City of Santa Fe (City) are proposing a project to reduce the potential for a large scale, high intensity wildfire to destroy the municipal watershed and impact the City's potable water supply. Current conditions indicate that the watershed is at high risk of catastrophic wildfire and subsequent severe flooding.

The Forest Service will prepare an environmental impact statement (EIS) to disclose the potential environmental effects of treating vegetation in portions of the municipal watershed to reduce the severity of a high intensity wildfire. The EIS will be prepared pursuant to the National Environmental Policy Act (NEPA) of 1969, as amended (42 U.S.C. 4321, *et seq.*), the Council on Environmental Quality (CEQ) Regulations for Implementing the Procedural Provisions of NEPA (40 CFR parts 1500 to 1508), and USDA NEPA Policies and Procedures (7 CFR part 1b; Forest Service Manual 1950).

The City of Sante Fe, Sangre de Cristo Water Division, is a cooperating agency in the proposed project.

The proposed project would be accomplished in multiple stages, treating several hundred acres each year, over a five-to-ten year period. Treatment effectiveness and results would be evaluated and adjustments made as needed, prior to implementing the following years treatments. The proposal involves thinning the smaller trees in the forest over approximately 2,500 acres. After removing thinned trees that are accessible along the existing road and chipping and hauling out the limbs and tops from along the road, any remaining thinned materials would be piled and burned. In addition, approximately 4,500 acres would be broadcast prescribed burned to reduce fuels on the steep, remote upper slopes. The proposed project does NOT involve road construction, commercial timber sales, or removal of mature trees. The proposed project would treat patches of forested land on both National Forest System and City lands within the Santa Fe municipal watershed.

DATES: Written comments and suggestions should be received on or before July 31, 2000. The draft environmental impact statement is expected to be filed with the Environmental Protection Agency (EPA) and available for public review in October 2000. A Final Environmental Impact Statement is expected to be published in January 2001.

ADDRESSES: Submit written comments and suggestions on the proposal, or requests to be placed on the project mailing list, to Land Management Planning, Santa Fe National Forest, 1474 Rodeo Road, P.O. Box 1689, Santa Fe, NM 87505–1689.

FOR FURTHER INFORMATION CONTACT: David W. Tippets, Project Public Affairs Leader, (505) 438–7685 or *dtippets@fs.fed.us.*

SUPPLEMENTARY INFORMATION: The Santa Fe River watershed within the national forest was designated a municipal watershed and closed to public entry in 1932. Within the national forest boundary, the City has two reservoirs, potable water delivery system facilities, stream flow gauging stations, and a primitive service road. Most of the canyon is roadless and very rugged. The watershed is the source of approximately 40 percent of Santa Fe's drinking water.

The proposed treatments are within pinon-juniper, ponderosa pine, and drier mixed conifer forest. Treatments are designed primarily to break up fuel continuity, increase soil-stabilizing grasses and shrubs, and reduce the amount of small trees, which act as fuel ladders and carry fire into the tree crowns. Treatments would also enhance the diversity of vegetation and wildlife habitats over the landscape. The treatments proposed are consistent with the Santa Fe National Forest Land and Resource Management Plan.

Preliminary issues include potential effects to human health and safety; soil and water; air quality; aquatic, riparian and upland habitats; threatened, endangered, and sensitive wildlife, fish, and plants; social and economic; and the effectiveness of treatments on fuel loading and fire behavior. To address these issues, the Forest Service and City will develop a range of alternatives, including a No Action alternative and other action alternatives.

Public participation has been an integral component of this proposed project and will continue to be important throughout the course of the NEPA process. During the last year, the Forest Service has been actively seeking information, comments, and assistance from individuals and organizations, State, local agencies, Indian tribes, and other Federal agencies that may be interested in, or affected by, the proposed project. Local environmental groups, other non-profit organizations, and scientists from universities and research stations have been active participants and partners throughout the early stages of the planning for this proposed project. Involvement efforts have included numerous public field trips, a January 2000 scoping letter, meetings with interest groups, and a scientific forum with the community.

The public involvement scoping process includes: (1) Identification of potential issues; (2) identification of issues to be analyzed in depth; and (3) elimination of insignificant issues or those which have been covered by a previous environmental review. For the Forest Service to best use the scoping input, comments should be received no later than 30 days from the date of this publication.

The draft environmental impact statement (DEIS) is expected to be filed with the Environmental Protection Agency and available for public review in October 2000. At that time, the EPA will publish a Notice of Availability of the DEIS in the **Federal Register**. The comment period on the draft environmental impact statement will be 45 days from the date the EPA publishes the Notice of Availability in the **Federal Register**. A final environmental impact statement (FEIS) will be published after all comments are reviewed and responded prepared. A Record of Decision (ROD) will be published at the time the FEIS is released. The final decision will be subject to administrative review under CFR 215.17.

The Forest Service believes, at this early stage, it is important to give reviewers notice of several court rulings related to public participation in the environmental review process. First, reviewers of DEIS must structure their participation in the environmental review of the proposal so that it is meaningful and alerts an agency to the reviewer's position and contentions (*Vermont Yankee Nuclear Power Corp.* v. *NRDC*, 435 U.S. 519, 553 (1978)). Also, environmental objections that could be raised at the DEIS stage but that are not raised until after completion of the FEIS may be waived or dismissed by the courts (*City of Angoon* v. *Hodel*, 803 F. 2d 1016, 1022 (9th Cir. 1986) and *Wisconsin Heritages, Inc.* v. *Harris*, 490 F. Supp. 1334, 1338 (E.D. Wis. 1980). Because of these court rulings, it is very important that those interested in this proposed action participate by the close of the 45-day comment period so that substantive comments and objections are made available to the Forest Service

at a time when it can meaningfully consider them and respond to them in the final environmental impact statement.

To assist the Forest Service in identifying and considering issues and concerns regarding the proposed action, comments should be as specific as possible. Reviewers may wish to refer to the Council on Environmental Quality Regulations for implementing the procedural provisions of the National Environmental Policy Act at 40 CFR 1503.3 in addressing these points.

Comments received in response to this solicitation, including names and addresses of those who comment, will be considered part of the public record and available for public inspection. Comments submitted anonymously will be accepted and considered; however, those who submit anonymous comments may not have standing to appeal the subsequent decision under 36 CFR part 215.

Additionally, pursuant to 7 CFR 1.27(d), any person may request the agency to withhold a submission from the public record by showing how the Freedom of Information Act (FOIA) permits such confidentiality. Persons requesting such confidentiality should be aware that, under the FOIA, confidentiality may be granted in only very limited circumstances, such as to protect trade secrets. The Forest Service will inform the requester of the agency's decision regarding the request for confidentiality, and where the request is denied, the agency will return the submission and notify the requester that the comments may be resubmitted with or without name and address within a specified number of days.

The Forest Service is the lead agency for the preparation of the Environmental Impact Statement. The Responsible Official for this environmental analysis is Leonard Atencio, Forest Supervisor, Santa Fe National Forest.

Dated: July 5, 2000.

Leonard Atencio,

Forest Supervisor, Santa Fe National Forest.

[FR Doc. 00–17945 Filed 7–14–00; 8:45 am]

BILLING CODE 3410–11–M

DEPARTMENT OF COMMERCE

Submission for OMB Review; Comment Request

DOC has submitted to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. chapter 35).

Agency: U.S. Census Bureau.

Title: Current Industrial Reports Program—Wave I (Voluntary).

Form Number(s): M336L, MQ325B, MQ327D, MQ332E.

Agency Approval Number: 0607–0393.

Type of Request: Extension of a currently approved collection.

Burden: 2,092 hours.

Number of Respondents: 1,006.

Avg Hours Per Response: 2.08 hours over all forms in this request.

Needs and Uses: The Current Industrial Reports (CIR) program is a series of monthly, quarterly, and annual surveys which provide key measures of production, shipments, and/or inventories on a national basis for selected manufactured products. Government agencies, business firms, trade associations, and private research and consulting organizations use these data to make trade policy, production, and investment decisions.

For clearance purposes, the surveys are divided into ''waves.'' Each wave has an associated voluntary and mandatory clearance package, making 6 separate clearances. Each year, one wave (2 clearance packages) is submitted for review. Some voluntary CIR surveys have annual ''counterparts'' which collect data on a mandatory basis from firms that do not participate in the more frequent voluntary collection. This clearance contains counterpart collections.

In this request, we are seeking a 3-year extension of the current clearance.

Affected Public: Businesses or other for-profit organizations.

Frequency: This request contains monthly, quarterly, and annual collections.

Respondent's Obligation: Monthly and quarterly forms are Voluntary; Annual counterpart collections are mandatory.

Legal Authority: Title 13 USC, Sections 182, 224, and 225.

OMB Desk Officer: Susan Schechter, (202) 395–5103.

Copies of the above information collection proposal can be obtained by calling or writing Linda Engelmeier, DOC Forms Clearance Officer, (202) 482–3272, Department of Commerce, Room 6068, 14th and Constitution Avenue, NW, Washington, DC 20230 (or via the Internet at LEngelme@doc.gov).

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to Susan Schechter, OMB Desk Officer, room 10201, New Executive Office Building, Washington, DC 20503.

Dated: July 11, 2000.

Madeleine Clayton,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. 00–17940 Filed 7–14–00; 8:45 am]

BILLING CODE 3510–07–P

DEPARTMENT OF COMMERCE

Submission for OMB Review; Comment Request

DOC has submitted to the Office of Management and Budget (OMB) for clearance the following proposal for collection of information under the provisions of the Paperwork Reduction Act (44 U.S.C. chapter 35).

Agency: U.S. Census Bureau.

Title: Current Industrial Reports Program—Wave I (Mandatory).

Form Number(s): M311H, M311M, M311N, MA325F, MA327C, MA331A, MA331B, MA331E, MA332Q, MA333A, MA333M, MA334B, MA334R, MA335A, MA335F, MA335H, MA335K.

Agency Approval Number: 0607–0392.

Type of Request: Revision of a currently approved collection.

Burden: 12,825 hours.

Number of Respondents: 10,275.

Avg Hours Per Response: 1.25 hours over all forms in this request.

Needs and Uses: The Current Industrial Reports (CIR) program is a series of monthly, quarterly, and annual surveys which provide key measures of production, shipments, and/or inventories on a national basis for selected manufactured products. Government agencies, business firms, trade associations, and private research and consulting organizations use these data to make trade policy, production, and investment decisions.

For clearance purposes, the surveys are divided into ''waves.'' Each wave has an associated voluntary and mandatory clearance package, making 6 separate clearances. Each year, one wave (2 clearance packages) is submitted for OMB review.

In this request, we are seeking a 3-year extension of the clearance and we are discontinuing MA332K, ''Steel Shipping Drums and Pails,'' due to budgetary reductions.

Affected Public: Businesses or other for-profit organizations.

Frequency: This request contains both monthly and annual collections.

Respondent's Obligation: Mandatory.

Legal Authority: Title 13 U.S.C., Sections 61, 182, 224, and 225.

OMB Desk Officer: Susan Schechter, (202) 395–5103.

Copies of the above information collection proposal can be obtained by

calling or writing Linda Engelmeier, DOC Forms Clearance Officer, (202) 482–3272, Department of Commerce, Room 6086, 14th and Constitution Avenue, NW, Washington, DC 20230 (or via the Internet at LEngelme@doc.gov).

Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to Susan Schechter, OMB Desk Officer, room 10201, New Executive Office Building, Washington, DC 20503.

Dated: July 11, 2000.

Madeleine Clayton,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. 00–17941 Filed 7–14–00; 8:45 am]

BILLING CODE 3510–07–P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 071100A]

Caribbean Fishery Management Council; Public Meetings

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of public meetings.

SUMMARY: The Caribbean Fishery Management Council (Council) and its Administrative Committee will hold meetings.

DATES: The meetings will be held on August 15–17, 2000. The Council will convene on Wednesday, August 16, 2000, from 9:00 a.m. to 5:00 p.m., through Thursday, August 17, 2000, from 9:00 a.m. until noon, approximately.

The Administrative Committee will meet on Tuesday, August 15, 2000, from 2:00 p.m. to 5:00 p.m., to discuss administrative matters regarding Council operation.

ADDRESSES: All meetings will be held at the Windward Passage Holiday Inn Hotel, located at Veterans Drive, Charlotte Amalie, St. Thomas, U.S.V.I.

FOR FURTHER INFORMATION CONTACT: Caribbean Fishery Management Council, 268 Munoz Rivera Avenue, Suite 1108, San Juan, Puerto Rico 00918–2577; telephone: (787) 766–5926.

SUPPLEMENTARY INFORMATION: The Council will hold its 101st regular public meeting to discuss the items contained in the following agenda:

Call to Order

Adoption of Agenda

Consideration of 100th Council Meeting Summary Minutes

Executive Director's Report

Outreach Program Sea Grant

Coral Fishery Management Plan (FMP)

—Marine Conservation District Research Progress Report
—Coral Reef Task Force

Dolphin/Wahoo FMP

—Public Hearings Report
—Final Action in the Ten Measures for the Gulf, South Atlantic and Caribbean
—Councils' Areas

Reef Fish FMP

—Discussion on Next Amendment to the Reeffish FMP

Queen Conch FMP

—Amendment Number 1 Public Hearings Report
—Regulatory Impact Review

Enforcement

—Federal Government
—Puerto Rico
—U.S. Virgin Islands

Administrative Committee Recommendations

Meetings Attended by Council Members and Staff

Other Business

Next Council Meeting

The meetings are open to the public, and will be conducted in English. Fishers and other interested persons are invited to attend and participate with oral or written statements regarding agenda issues.

Although non-emergency issues not contained in this agenda may come before this Council for discussion, those issues may not be the subject of formal action during this meeting. Action will be restricted to those issues specifically identified in this notice and any issues arising after publication of this notice that require emergency action under Section 305(c) of the Magnuson-Stevens Fishery Conservation and Management Act, provided the public has been notified of the Council's intent to take action to address the emergency.

Special Accommodations

These meetings are physically accessible to people with disabilities. For more information or request for sign language interpretation and/other auxiliary aids, please contact Mr. Miguel A. Rolon, Executive Director, Caribbean Fishery Management Council, 268 Munoz Rivera Avenue, Suite 1108, San Juan, Puerto Rico, 00918–2577, telephone (787) 766–5926, at least 5 days prior to the meeting date.

Dated: July 11, 2000.

Richard W. Surdi,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 00–18016 Filed 7–14–00; 8:45 am]

BILLING CODE 3510–22–P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 071100B]

Pacific Fishery Management Council; Public Meeting

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of public meeting.

SUMMARY: The Pacific Fishery Management Council's (Council) Ad-Hoc Allocation Committee will hold a meeting which is open to the public.

DATES: The meeting will begin on Wednesday, August 9 at 8 a.m. and will continue through Thursday, August 10, as necessary.

ADDRESSES: The meeting will be held at the Pacific Fishery Management Council Office, 2130 SW Fifth Avenue, Suite 224, Portland, OR.

Council address: Pacific Fishery Management Council, 2130 SW Fifth Avenue, Suite 224, Portland, OR 97201.

FOR FURTHER INFORMATION CONTACT: Jim Glock, Fishery Management Coordinator, telephone: (503) 326–6352.

SUPPLEMENTARY INFORMATION: The purpose of the meeting is to develop preliminary options for allocations and other management measures involved in rebuilding plans for canary rockfish and cowcod rockfish. In addition, the Committee will evaluate current Council and catch levels of lingcod and bocaccio, and may propose inseason adjustments. The Committee will discuss the types of provisions that may be necessary to prevent further overfishing, to reduce bycatch of overfished species in the various groundfish fisheries, and to reduce bycatch in non-groundfish fisheries. The Committee will prepare recommendations and contribute to draft rebuilding plans for cowcod and canary rockfish that will be presented to the Council at its September meeting. If available, the Committee may also

review new assessments for Pacific ocean perch and coastwide lingcod stocks and may propose revisions to the current rebuilding plans and management measures.

Although non-emergency issues not contained in this agenda may come before this Committee for discussion, those issues may not be the subject of formal action during this meeting. Action will be restricted to those issues specifically listed in this notice and any issues arising after publication of this notice that require emergency action under Section 305(c) of the Magnuson-Stevens Fishery Conservation and Management Act, provided the public has been notified of the Council's intent to take final action to address the emergency.

Special Accommodations

The meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Ms. Carolyn Porter at (503) 326–6352 at least 5 days prior to the meeting date.

Dated: July 11, 2000.

Richard W. Surdi,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 00–18017 Filed 7–14–00; 8:45 am]

BILLING CODE 3510–22–F

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 062600C]

Marine Mammals

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Issuance of permit amendment.

SUMMARY: Notice is hereby given that Rachel Cartwright, P.O. Box 1317, Lahaina, Hawaii 96767, has been issued an amendment to scientific research Permit No. 895–1450.

ADDRESSES: The amendment and related documents are available for review upon written request or by appointment in the following offices:

Permits Division, Office of Protected Resources, NMFS,

1315 East-West Highway, Room 13130, Silver Spring, MD 20910 (301/713–2289);

Regional Administrator, Southwest Region, NMFS, 501 West Ocean Boulevard, Suite 4200, Long Beach, CA 90802–4213 (310/980–4001); and

Protected Species Program Manager, Pacific Islands Area Office, Southwest Region, NMFS, 1601 Kapiolani Boulevard, Suite 1110, Honolulu, HI (808/973–2937);

Alaska Regional Office, Federal Building Room 461, 709 West 9th Street, Juneau, Alaska (907/586–7235).

SUPPLEMENTARY INFORMATION: On March 30, 2000, notice was published in the **Federal Register** (65 FR 16894) that an amendment of Permit No. 895–1450, issued December 23, 1998 (64 FR 862), had been requested by the above-named person. The requested amendment has been issued under the authority of the Marine Mammal Protection Act of 1972, as amended (16 U.S.C. 1361 *et seq.*), the Regulations Governing the Taking and Importing of Marine Mammals (50 CFR Part 216), the Endangered Species Act (ESA) of 1973, as amended (16 U.S.C. 1531 *et seq.*), and the Regulations Governing the Taking, Importing, and Exporting of Endangered Fish and Wildlife (50 CFR part 222). The amendment authorizes the extension of the study to specified Alaskan waters with no increase in takes.

Issuance of this amendment, as required by the ESA, was based on a finding that such permit: (1) was applied for in good faith; (2) will not operate to the disadvantage of the endangered species which is the subject of this permit; and (3) is consistent with the purposes and policies set forth in section 2 of the ESA.

Dated: July 11, 2000.

Jeannie Drevenak,

Acting Chief, Permits and Documentation Division, Office of Protected Resources, National Marine Fisheries Service.

[FR Doc. 00–18018 Filed 7–14–00; 8:45 am]

BILLING CODE 3510–22–F

DEPARTMENT OF EDUCATION

Notice of Proposed Information Collection Requests

AGENCY: Department of Education.

SUMMARY: The Leader, Regulatory Information Management, Office of the Chief Information Officer, invites comments on the proposed information collection requests as required by the Paperwork Reduction Act of 1995.

DATES: Interested persons are invited to submit comments on or before September 15, 2000.

SUPPLEMENTARY INFORMATION: Section 3506 of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) requires that the Office of Management and Budget (OMB) provide interested Federal agencies and the public an early opportunity to comment on information collection requests. OMB may amend or waive the requirement for public consultation to the extent that public participation in the approval process would defeat the purpose of the information collection, violate State or Federal law, or substantially interfere with any agency's ability to perform its statutory obligations. The Leader, Regulatory Information Management, Office of the Chief Information Officer, publishes that notice containing proposed information collection requests prior to submission of these requests to OMB. Each proposed information collection, grouped by office, contains the following: (1) Type of review requested, *e.g.* new, revision, extension, existing or reinstatement; (2) Title; (3) Summary of the collection; (4) Description of the need for, and proposed use of, the information; (5) Respondents and frequency of collection; and (6) Reporting and/or Recordkeeping burden. OMB invites public comment. The Department of Education is especially interested in public comment addressing the following issues: (1) Is this collection necessary to the proper functions of the Department; (2) will this information be processed and used in a timely manner; (3) is the estimate of burden accurate; (4) how might the Department enhance the quality, utility, and clarity of the information to be collected; and (5) how might the Department minimize the burden of this collection on the respondents, including through the use of information technology.

Dated: July 11, 2000.

John Tressler,

Leader, Regulatory Information Management, Office of the Chief Information Officer.

Office of Vocational and Adult Education

Type of Review: New.

Title: Indian Vocational Education Program Technology Survey.

Frequency: Annually.

Affected Public: State, Local, or Tribal Gov't, SEAs or LEAs.

Reporting and Recordkeeping Hour Burden: Responses: 38; Burden Hours: 95.

Abstract: This collection will assess the technology and technical assistance needs of current Indian Vocational Education Program grantees. Program staff will use the results of this collection to promote greater and more effective use of technology by vocational and technical education programs that serve Native Americans.

Requests for copies of the proposed information collection request may be

accessed from *http://edicsweb.ed.gov,* or should be addressed to Vivian Reese, Department of Education, 400 Maryland Avenue, SW., Room 4050, Regional Office Building 3, Washington, DC 20202–4651. Requests may also be electronically mailed to the internet address OCIO_IMG_Issues@ed.gov or faxed to 202–708–9346. Please specify the complete title of the information collection when making your request. Comments regarding burden and/or the collection activity requirements should be directed to Sheila Carey at (202) 708–6287 or via her internet address Sheila Carey@ed.gov. Individuals who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1–800–877–8339.

[FR Doc. 00–17977 Filed 7–14–00; 8:45 am]

BILLING CODE 4000–01–P

DEPARTMENT OF EDUCATION

Submission for OMB Review; Comment Request

AGENCY: Department of Education.

SUMMARY: The Leader, Regulatory Information Management, Office of the Chief Information Officer invites comments on the submission for OMB review as required by the Paperwork Reduction Act of 1995.

DATES: Interested persons are invited to submit comments on or before August 16, 2000.

ADDRESSES: Written comments should be addressed to the Office of Information and Regulatory Affairs, Attention: Wai-Sinn Chan, Acting Desk Officer, Department of Education, Office of Management and Budget, 725 17th Street, NW., Room 10235, New Executive Office Building, Washington, DC 20503 or should be electronically mailed to the internet address Wai-Sinn_L._Chan@omb.eop.gov.

SUPPLEMENTARY INFORMATION: Section 3506 of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) requires that the Office of Management and Budget (OMB) provide interested Federal agencies and the public an early opportunity to comment on information collection requests. OMB may amend or waive the requirement for public consultation to the extent that public participation in the approval process would defeat the purpose of the information collection, violate State or Federal law, or substantially interfere with any agency's ability to perform its statutory obligations. The Leader, Regulatory Information Management, Office of the Chief Information Officer, publishes that notice containing proposed information collection requests prior to submission of these requests to OMB. Each proposed information collection, grouped by office, contains the following: (1) Type of review requested, *e.g.* new, revision, extension, existing or reinstatement; (2) Title; (3) Summary of the collection; (4) Description of the need for, and proposed use of, the information; (5) Respondents and frequency of collection; and (6) Reporting and/or Recordkeeping burden. OMB invites public comment.

Dated: July 11, 2000.

John Tressler,

Leader, Regulatory Information Management, Office of the Chief Information Officer.

Office of Elementary and Secondary Education

Type of Review: Reinstatement.

Title: Gun-Free Schools Act Report.

Frequency: Annually.

Affected Public: State, Local, or Tribal Gov't, SEAs or LEAs.

Reporting and Recordkeeping Hour Burden: Responses: 12,672; Burden Hours: 27,042.

Abstract: The Gun-Free Schools Act (GFSA) requires each State to provide annual reports to the Secretary concerning implementation of the Act's requirements regarding expulsions from schools resulting from weapons violations. The GFSA requires the Secretary to report to Congress if any State is not in compliance with the GFSA, and requires the Secretary to collect data on the incidence of children with disabilities engaging in threatening behavior or bringing weapons to school.

Requests for copies of the proposed information collection request may be accessed from *http://edicsweb.ed.gov,* or should be addressed to Vivian Reese, Department of Education, 400 Maryland Avenue, SW., Room 4050, Regional Office Building 3, Washington, DC 20202–4651. Requests may also be electronically mailed to the internet address OCIO_IMG_Issues@ed.gov or faxed to 202–708–9346. Please specify the complete title of the information collection when making your request. Comments regarding burden and/or the collection activity requirements should be directed to Kathy Axt at her internet address Kathy_Axt@ed.gov. Individuals who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1–800–877–8339.

[FR Doc. 00–17978 Filed 7–14–00; 8:45 am]

BILLING CODE 4000–01–P

DEPARTMENT OF ENERGY

Environmental Management Site-Specific Advisory Board, Semi-Annual Chairs Meeting

AGENCY: Department of Energy.

ACTION: Notice of Open Meeting.

SUMMARY: This notice announces a meeting of the Environmental Management Site-Specific Advisory Board (EM SSAB), Semi-Annual Chairs Meeting. Federal Advisory Committee Act (Pub. L. 92–463, 86 Stat. 770) requires that public notice of these meetings be announced in the **Federal Register**.

DATE: Thursday, August 3, 2000—7:30 a.m.–4:30 p.m.; Friday, August 4, 2000—7:30 a.m.–4:30 p.m.; Saturday, August 5, 2000—7:30 a.m.–11:30 a.m.

ADDRESS: The Ambassador Hotel, 3100 I–40 West, Amarillo, TX 79102, 806–358–6161.

FOR FURTHER INFORMATION CONTACT: Martha Crosland, Designated Federal Officer, U.S. Department of Energy, 1000 Independence Avenue, SW, Washington DC, 20585, (202) 586–5793.

SUPPLEMENTARY INFORMATION:

Purpose of the Board: The purpose of the Board is to make recommendations to DOE and its regulators in the areas of future use, cleanup levels, waste disposition and cleanup priorities.

Tentative Agenda

Thursday August 3, 2000: EM SSAB Chairs Meeting (Day 1)

07:30–8:15 a.m. Registration.

08:15–08:45 Opening Remarks/Welcome (Martha Crosland, Director, EM–11 Hqtrs and John Bernier, Deputy Manager, DOE, Amarillo Area Office).

08:45–09:00 Welcoming/Ground Rules (Facilitator).

09:00–11:30 Round robin (limit to 20 min or less/each site). A representative(s) from each SSAB will discuss:

—Site issues of concern.

—Site Ground Water Issues/Technologies.

—Board Outreach to the Community (as requested by Oak Ridge SSAB).

10:00–10:15 Break.

11:30–12:30 Status Update by (David Huizenga, Deputy Assistant Secretary, Deputy Assistant Secretary, Office of Integration and Disposition, DOE Headquarters.

- Integration.
- Transportation.
- Implementation of the Records of Decision for Mixed and Low Level Waste.
- WIPP.

12:30–01:10 Depart Hotel on Bus to Pantex Site for:

01:10–01:35 Introductions.

—Security Briefings.

—Stage Right Videos.

(For this tour you must be a U.S. Citizen, wear shoes with closed toes and show a driver's license or picture ID)

01:35–02:10 Lunch in Building 16–12 (Prepared by Pantex —Cost will be $6.00 per person (includes drinks and dessert)).
02:15–04:00 Board Bus for DOE Pantex Site ''Windshield Tour''.
04:15 Return to the Ambassador Hotel to rest and freshen up for the evening show of ''Texas''.
06:00 Meet bus at the Hotel for trip to the Palo Duro Canyon for dinner and the show. Prior to this spectacular show, (6–8 pm, a barbeque dinner will be served. Additional cost is $6.50 adults, $5.50 for children and should be paid at that time).
—6:45 Dinner.
—7:45 Seating for show.
—8:00 Showtime ends at 11:00 pm.

Friday August 4, 2000: EM SSAB Chairs Meeting (Day 2)

07:30–08:20 Coffee in meeting room.
08:30–08:45 Opening Remarks—Martha Crosland & Dr. James Hallmark, Facilitator.
08:50–10:00 Ground water Contamination Presentation, Paul Beam, Office of Integration and Disposition, EM–20, DOE, Headquarters).
- Overview presentation on ground water contamination around the complex and remediation of such contamination.
- Discussion of the integration of these issues (problems and solutions) around the complex.
- Discussion of the technologies for characterizing and remediating ground water contamination around the complex.

10:00–10:15 a.m. Break.
10:15–11:30 a.m. Conflict of Interest Discussion (Gregg Burgess, General Counsel, DOE Headquarters) (will include question & answer period).
11:30–12:30 DOE–EM Informational and Status Updates (Martha Crosland).
- SSAB Guidance Document.
- Stewardship Activities.
- NEPA (EIS/EA) Status Updates.
- National Nuclear Security Administration.
- Environmental Management Advisory Board.

12:30–02:00 p.m. Lunch.
02:00–02:30 Pantex case study—what is being done to solve the problem (likely to be given by State of Texas regulators and by site representative).
02:30–02:45 Break.
03:00–03:45 SSAB Common Values (Martha Crosland, Director, EM–11).
- Discussion and finalization of SSAB Common Values.

04:00–04:30 Wrap up Day 2 session—(Dr. Hallmark).

Saturday, August 5, 2000, EM SSAB Chairs Meeting (Day 3)

07:30–08:20 Coffee (meeting room).
08:30–08:45 Opening Remarks (Martha Crosland & Dr. Hallmark).
08:45–09:30 Planning for Rocky Flats SSAB Stewardship Workshop Ken Korkia, Rocky Flats Advisory Board.
09:30–09:45 Break.
10:00–10:30 General discussion items: Martha Crosland.
—Location and subject of the next SSAB Chairs' Meeting.
—Future EM SSAB Seminars/Workshops.
—New business.
10:30–11:00 Public comment period.
11:00–11:30 Closing remarks/wrap-up session (Dr. Hallmark).
11:35 Meeting adjournment (Martha Crosland).

(Agenda topics may change up to the day of the meeting; please call the **FOR FURTHER INFORMATION CONTACT** in this notice for the current agenda)

Public Participation: This meeting is open to the public. Written statements may be filed with the Board facilitator before or after the meeting. Individuals who wish to make oral presentations pertaining to agenda items should contact the Board Chair at their specific site, or Fred Butterfield at the address listed above. Requests must be received 5 days prior to the meeting and reasonable provision will be made to include the presentation in the agenda. The Designated Federal Officer, Martha Crosland, U.S. Department of Energy, is empowered to conduct the meeting in a fashion that will facilitate the orderly conduct of business.

Minutes: A written summary of this meeting will be available for public review and copying at the Freedom of Information Public Reading Room, 1E–190, Forrestal Building, 1000 Independence Avenue, SW, Washington, DC 20585 between 9:00 a.m. and 4:00 p.m., Monday–Friday, except Federal holidays. The meeting summary will also be available by writing the EM–SSAB Chair or Designated Deputy Federal Officer of every EM–SSAB that participated in the meeting.

Issued at Washington, DC on July 11, 2000.

Rachel Samuel,

Deputy Advisory Committee Management Officer.

[FR Doc. 00–18005 Filed 7–14–00; 8:45 am]

BILLING CODE 6450–01–P

DEPARTMENT OF ENERGY

Office of Energy Efficiency and Renewable Energy

AGENCY: Department of Energy.

ACTION: Notice of Open Meeting.

SUMMARY: This notice announces a meeting of the State Energy Advisory Board. Federal Advisory Committee Act (Public Law 92–463; 86 Stat. 770) requires that public notice be announced in the **Federal Register**.

DATES: August 3, 2000 from 8 AM to 5 PM, and August 4, 2000 from 8 AM to 1 PM. Phone: 800/689–6765 or 910/256–8696.

PLACE: The Ocean View Inn and Resort, Gloucester, MA.

FOR FURTHER INFORMATION CONTACT: William J. Raup, Office of Building Technology, State, and Community Programs, Energy Efficiency and Renewable Energy, U.S. Department of Energy (DOE), Washington, DC 20585, Telephone 202/586–2214.

SUPPLEMENTARY INFORMATION:

Purpose of the Board: To make recommendations to the Assistant Secretary for Energy Efficiency and Renewable Energy regarding goals and objectives and programmatic and administrative policies, and to otherwise carry out the Board's responsibilities as designated in the State Energy Efficiency Programs Improvement Act of 1990 (P.L. 101–440).

Tentative Agenda:

- Introduction of new members and discussion of new member nominees.
- Discussion of current energy end use and supply issues.
- National Lab Presentation
- Review of STEAB contract support
- STEAB Committee updates

Public Participation: The meeting is open to the public. Written statements may be filed with the Board either before or after the meeting. Members of the public who wish to make oral statements pertaining to agenda items should contact William J. Raup at the address or telephone number listed above. Requests to make oral presentations must be received five days prior to the meeting; reasonable provision will be made to include the statements in the agenda. The Chair of the Board is empowered to conduct the meeting in a fashion that will facilitate the orderly conduct of business.

Minutes: The minutes of the meeting will be available for public review and copying within 30 days at the Freedom of Information Public Reading Room, 1E–190, Forrestal Building, 1000 Independence Avenue, SW., Washington, DC, between 9 a.m. and 4 p.m., Monday through Friday, except Federal holidays.

Issued at Washington, DC, on July 11, 2000.

Rachel Samuel,

Deputy Advisory Committee Management Officer.

[FR Doc. 00–18004 Filed 7–14–00; 8:45 am]

BILLING CODE 6450–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER00–3091–000]

MidAmerican Energy Company; Notice of Filing

July 11, 2000.

Take notice that on June 14, 2000, MidAmerican Energy Company (MidAmerican), tendered for filing in compliance with the Commission's May 26, 2000 Commission Order in Docket No. ER00–2317–000, notice that the open access tariff of MidAmerican Energy Company is modified, effective May 1, 2000, to incorporate the Mid-Continent Area Power Pool's Line Loading Relief Procedures.

Any person desiring to be heard or to protest filing should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). All such motions and protests should be filed on or before July 21, 2000. Protests will be considered by the Commission to determine the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection. This filing may also be viewed on the Internet at http://www.ferc.fed.us/online/rims.htm (call 202–208–2222 for assistance).

Linwood A. Watson, Jr.,

Acting Secretary.

[FR Doc. 00–17962 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP00–381–000]

National Fuel Gas Supply Corporation; Notice of Tariff Filing

July 11, 2000.

Take notice that on June 30, 2000, National Fuel Gas Supply Corporation (National) tendered for filing as part of its FERC Gas Tariff Fourth Revised Volume No. 1, the following tariff sheet to become effective July 1, 2000.

Twenty Fourth Revised Sheet No. 9

National asserts that the purpose of this filing is to comply with the Commission's order issued February 16, 1996, in Docket Nos. RP94–367–000, et al. Under Article I, Section 4, of the settlement approved in that order, National must redetermine quarterly the Amortization Surcharge to reflect revisions in the Plant to be Amortized, interest and associated taxes, and a change in the determinants. The recalculation produced an Amortization Surcharge of 7.81 cents per dth.

Further, National states that under Article II, Section 1, of the settlement, it is required to recalculate the maximum Interruptible Gathering (''IG'') rate semi-annually and to charge that rate to be effective July 1 and on January 1. The recalculation produced an IG rate of 13 cents per dth, which is the same as National's current IG rate. National also states that Article II, Section 2 is not applicable as the monthly recalculation did not result in a rate more than 2 cents above or below the semi-annual calculation. As there is no change in National's IG rate, Appendix E is filed for informational purposes only.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, in accordance with Sections 385.214 or 385.211 of the Commission's Rules and Regulations. All such motions or protests must be filed in accordance with Section 154.210 of the Commission's Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing may be viewed on the web at http://www.ferc.fed.us/online/rims.htm (call 202–208–2222 for assistance).

David P. Boergers,

Secretary.

[FR Doc. 00–17965 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 1927–008]

Pacificorp; Notice

July 11, 2000.

Vince Yearick, of the Commission's Office of Energy Projects, (202) 219–3073, has been assigned to participate in any settlement discussions that may transpire in the above-captioned proceeding. He has been separated from, and will not participate as, advisory staff in this proceeding.

David P. Boergers,

Secretary.

[FR Doc. 00–17966 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER00–3090–000]

PJM Interconnection, L.L.C.; Notice of Filing

July 11, 2000.

Take notice that on July 7, 200, PJM Interconnection, L.L.C. (PJM), tendered for filing supplements to the Appendix of Attachment K of the PJM Open Access Transmission Tariff (PJM Tariff) and a supplement to Schedule 1 of the Amended and Restated Operating Agreement of PJM Interconnection, L.L.C., to set forth a Customer Load Reduction Pilot Program to be implemented on a temporary basis to ensure the continued reliability of the electric power system during the summer. For informational purposes, PJM also included its streamlined procedures pursuant to section 36.12 of the PJM Tariff for the interconnection of generation of less than 10 megawatts. In the alternative, to the extent these procedures are considered amendments to the PJM Tariff, PJM proposed these procedures also be accepted for filing.

PJM requests a waiver of the Commission's 60-day notice requirement to permit an effective date of July 8, 2000 for the amendments. PJM also requested that responses to the filing be due on July 17, 2000 and that the Commission issue a final order by July 26, 200.

Copies of this filling were served upon all members of PJM and each state electric utility regulatory commission in the PJM control area.

Any person desiring to be heard or to protest such filing should file a motion

to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). All such motions and protests should be filed on or before July 18, 2000. Protests will be considered by the Commission to determine the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. Copies of this filing are on file with the Commission and are available for public inspection. This filing may also be viewed on the Internet at http://www.ferc.fed.us/online/rims.htm (call 202–208–2222 for assistance).

Linwood A. Watson, Jr.,

Acting Secretary.

[FR Doc. 00–17961 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP00–397–000]

PNM Electric and Gas Services, Inc. and PNM Gas Services, a Division of Public Service Company of New Mexico; Notice of Filing

July 11, 2000.

Take notice that on June 29, 2000, PNM Electric and Gas Services, Inc. (UtilityCo), 414 Silver Avenue S.W., Albuquerque, New Mexico, 87158, and PNM Gas Services, a Division of Public Service Company of New Mexco (PNM), Alvarado Square, MN 0920, Albuquerque, New Mexico, 87158, filed in Docket No. CP00–397–000 an application for Natural Gas Act Section 3 authorization and a Presidential Permit for the exportation of natural gas at the international border with Mexico, and for authorization to relinquish the permit that presently grants such authority, all as more fully set forth in the filing which is on file with the Commission and open to public inspection. This filing may be viewed on the web at http://www.ferc.fed.us/online/rims.htm (call 202–208–2222 for assistance).

UtilityCo states that this filing is being made in connection with a corporate reorganization of Public Service Company of New Mexico mandated by the Electric Utility Industry Restructuring Act of 1999 (Restructuring Act). As stated in the application, UtilityCo's requested Section 3 authorization and Presidential Permit are for the facilities and operations for which the Commission issued Section 3 authorization and a Presidential Permit to PNM in Docket No. CP93–98–000. It is also stated that PNM proposes to relinquish its Presidential Permit issued in Docket No. CP93–98–000 effective on the date on which the Presidential Permit and Section 3 authorization are issued to UtilityCo. It is stated that the purpose and substantive effect will be to permit the PNM corporate family to continue to conduct the same business activity previously authorized by the Commission but using new corporate entities required by the Restructuring Act. UtilityCo states that it is not seeking any authorizations that are different from those held by PNM. It is also stated that upon the receipt of the necessary regulatory approvals, including the Commission's disposition of this application, the existing gas transmission and distribution facilities and operations of PNM will be acquired by and operated by UtilityCo. It is further stated that UtilityCo, as the successor to PNM, will be a natural gas distribution company with facilities located entirely within the State of New Mexico, and that all of the gas purchased by UtilityCo will be subject to regulation by the New Mexico Public Regulation Commission with respect to its natural gas rates, services and facilities. The contact person for this filing is Thomas J. Wander, Director, Gas Regulatory Policy, Public Service Company of New Mexico, Alvarado Square, MS 0920, Albuquerque, New Mexico 87158, (505) 241–2479.

Any person desiring to be heard or to make any protest with reference to said filing should, on or before August 1, 2000, file with the Federal Energy Regulatory Commission, Washington, D.C., 20426, a protest or motion to intervene in accordance with the requirements of Rule 211 or 214 of the Commission's rules of Practice and Procedure (18 CFR 385.211 or 385.214). All protests filed with the Commission will be considered in determining the appropriate action to be taken, but will not serve to make the Protestants parties to the proceeding. Any person wishing to become a party to a proceeding or to participate as a party in any hearing therein must file a motion to intervene in accordance with the Commission's Rules.

David P. Boergers,

Secretary.

[FR Doc. 00–17959 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP00–282–001]

Questar Pipeline Company; Notice of Compliance Filing

July 12, 2000.

Take notice that on June 23, 2000, in response to the Commission's June 9, 2000, order in the captioned docket, Questar Pipeline Company (Questar) submitted clarifications of its May 12, 2000, tariff filing.

On May 12, 2000, Questar filed proposed tariff language to allow its Rate Schedule PKS peaking storage reservoir customers to leave working gas in place in Questar's Leroy and Coalville storage reservoirs during the summer months. By the Commission's June 9 order, Questar was directed to provide additional information and clarification of its tariff language. Questar's June 23 filing is submitted in response to the June 23 order, and is on file with the Commission.

Any person desiring to comment or protest this filing should file a comment or protest with the Federal Energy Regulatory Commission 888 First Street, NE, Washington, D.C. 20426. all such comments or protests should be filed on or before July 19, 2000. Protest must be filed in accordance with Section 385.211 of the Commission's Rules and Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection. This filing may also be viewed on the Internet at *http://www.ferc.fed.us/online/rims.htm* (call 202–208–2222 for assistance).

Linwood A. Watson, Jr.,

Acting Secretary.

[FR Doc. 00–18000 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulation Commission

[Docket No. RP00–289–001]

Tennessee Gas Pipeline Company; Notice of Compliance Filing

July 11, 2000.

Take notice that on June 30, 2000, Tennessee Gas Pipeline Company (Tennessee) tendered for filing as part of

its FERC Gas Tariff, Fifth Revised Volume No. 1, the following tariff sheets with an effective date of August 1, 2000:

Sixteenth Revised Sheet No. 26
Eight Revised Sheet No. 413

Tennessee states that it is also including with this filing the information concerning Ocean State Power I and Ocean State Power II (Ocean State) requested by the Commission.

Tennessee states that the filing is being made in compliance with the Commission's order issued June 15, 2000 in Docket No. RP00–289 (91 FERC ¶ 61,266 (2000). In the October 15th order, the Commission directed Tennessee, within 15 days of issuance of the order, to (1) respond the issues raised by Ocean State, (2) list the tariff as containing material deviations the contracts with Ocean State and Orchard Gas Corporation (MassPower) and (3) delete footnote 4 transmittal letter comply with the requirements of the order.

Any person desiring to protest this filing should file a protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, in accordance with Section 385.211 of the Commission's Rules and Regulations. All such protests must be filed as provided in Section 154.210 of the Commission's Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing may be viewed on the web at http://www.ferc.fed.us/online/rims.htm (call 202–208–2222 for assistance).

David P. Boergers,

Secretary.

[FR Doc. 00–17964 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP00–7–004]

Texas Eastern Transmission Corporation; Notice of Refund Report

July 12, 2000.

Take notice that on June 29, 2000, Texas Eastern Transmission Cororation (Texas Eastern) tendered for filing a refund report of Storage Cost Credit amounts totaling $145,767.07 credited to customers on their June 10, 2000, invoices. Texas Eastern states that the refund was made pursuant to the Commission's Order On Rehearing and Compliance issued on April 14, 2000, in Docket Nos. RP00–7–001 and RP00–7–002.

Any person desiring to protest said filing should file a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Section 385.211 of the Commission's Rules and Regulations. All such protests must be filed on or before July 18, 2000. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing may be viewed on the web at http://www.ferc.fed.us/online/rims.htm (call 202–208–2222 for assistance).

Linwood A. Watson, Jr.,

Acting Secretary.

[FR Doc. 00–17999 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP00–17–002]

Transcontinental Gas Pipe Line Corporation; Notice of Tariff Filing

July 11, 2000.

Take notice that on June 30, 2000, Transcontinental Gas Pipe Line Corporation (Transco) tendered for filing as part of its FERC Gas Tariff, Third Revised Volume No. 1, certain revised tariff sheets listed on Appendix A attached to the filing. Such tariff sheets are proposed to be effective September 1, 2000.

Transco states that the purpose of the instant filing is to implement Transco's proposal in the referenced docket to limit capacity usage to the extent that combined nominations of releasing and replacement shippers in a segment exceed the releasing shipper's original firm capacity entitlement, consistent with the Commission's November 12, 1999 ''Order on Pro Forma Tariff Sheets Establishing Technical Conference'' in the referenced docket (''November 12 Order''). In order to implement its proposal, Transco also is filing to remove the Rate Schedules FT–R and FTN–R Commodity Form of Service Agreement from its Tariff and make changes to its Rate Schedules FT–R and FTN–R Demand Form of Service Agreement to reflect that removal.

Transco states that it is serving copies of the instant filing to the affected customers, State Commissions and other interested parties.

Any person desiring to protest this filing should file a protest with the Federal Energy Regulatory Commission, 888 First Street, NE, Washington, DC 20426, in accordance with Section 385.211 of the Commission's Rules and Regulations. All such protests must be filed as provided in Section 154.210 of the Commission's Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing may be viewed on the web at http://www.ferc.fed.us/online/rims.htm (call 202–208–2222 for assistance).

David P. Boergers,

Secretary.

[FR Doc. 00–17963 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EC00–104–000, et al.]

El Paso Electric Company, et al.; Electric Rate and Corporate Regulation Filings

July 7, 2000.

Take notice that the following filings have been made with the Commission:

1. El Paso Electric Company, El Paso Electric Generating Company, El Paso Electric Transmission and Distribution Company

[Docket Nos. EC00–104–000, ER00–2870–000 and ES00–46–000]

Take notice that on June 16, 2000, El Paso Electric Company (EPE), El Paso Electric Generating Company (EPE Genco), and El Paso Electric Transmission and Distribution Company (T&D Utility) (collectively, Applicants) tendered for filing an application under section 203 of the Federal Power Act for approval to transfer certain jurisdictional facilities and under section 204 of the Federal Power Act for approval of certain securities transactions necessary to implement a corporate restructuring. The Applicants also tendered for filing under section 205 of the Federal Power

Act certain related wholesale power sale contracts.

Comment date: July 24, 2000, in accordance with Standard Paragraph E at the end of this notice.

2. CD Stillwater-A, Inc.

[Docket No. EG00–195–000]

Take notice that on June 29, 2000, CD Stillwater-A, Inc. (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

3. CD Stillwater-B, Inc.

[Docket No. EG00–196–000]

Take notice that on June 29, 2000, CD Stillwater-B, Inc. (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

4. CD Stillwater-C, Inc.

[Docket No. EG00–197–000]

Take notice that on June 29, 2000, CD Stillwater-C, Inc. (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

5. CE Puna Limited Partnership

[Docket No. EG00–198–000]

Take notice that on June 29, 2000, CE Puna Limited Partnership (Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

6. Aques Investments Corporation II

[Docket No. EG00–199–000]

Take notice that on June 29, 2000, Aques Investments Corporation II (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

7. CD Soda III, Inc.

[Docket No. EG00–200–000]

Take notice that on June 29, 2000, CD Soda III, Inc. (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

8. CD ACE I, Inc.

[Docket No. EG00–201–000]

Take notice that on June 30, 2000, CD ACE I, Inc. (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

9. CD ACE II, Inc.

[Docket No. EG00–202–000]

Take notice that on June 30, 2000, CD ACE II, Inc. (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

10. CD ACE III, Inc.

[Docket No. EG00–203–000]

Take notice that on June 30, 2000, CD ACE III, Inc. (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

11. CD ACE IV, Inc.

[Docket No. EG00–204–000]

Take notice that on June 30, 2000, CD ACE IV, Inc. (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

12. CE Wayne I, Inc.

[Docket No. EG00–205–000]

Take notice that on June 30, 2000, CE Wayne I, Inc. (the Applicant), with its principal place of business at 111 Market Place, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission (Commission)

an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

13. COSI Sunnyside, Inc.

[Docket No. EG00–206–000]

Take notice that on June 30, 2000, COSI Sunnyside, Inc. (Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

14. Sunnyside II, L.P.

[Docket No. EG00–207–000]

Take notice that on June 30, 2000, Sunnyside II, L.P. (Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

15. COSI Central Wayne, Inc.

[Docket No. EG00–208–000]

Take notice that on June 30, 2000, COSI Central Wayne, Inc. (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission (''Commission'') an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

16. Oleander Power Project, Limited Partnership

[Docket No. EG00–209–000]

Take notice that on June 30, 2000, Oleander Power Project, Limited Partnership (Oleander), a Florida limited partnership with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202 filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Oleander proposes to construct, own and/or operate, a nominally rated approximately 875 MW natural gas and oil fired, simple cycle power plant (the ''Eligible Facility'') in Brevard County, Florida and to sell electricity exclusively at wholesale. The proposed Eligible Facility is expected to commence commercial operation in the second quarter of 2002. All capacity, energy, and ancillary services from the Eligible Facility will be sold by Oleander exclusively at wholesale.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

17. Wolf Hills Energy, LLC

[Docket No. EG00–210–000]

Take notice that on June 30, 2000, Wolf Hills Energy, LLC (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

18. Holland Energy, LLC

[Docket No. EG00–211–000]

Take notice that on June 30, 2000, Holland Energy, LLC (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

19. University Park Energy, LLC

[Docket No. EG00–212–000]

Take notice that on June 30, 2000, University Park Energy, LLC (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

20. CD Panther Partners, L.P.

[Docket No. EG00–213–000]

Take notice that on June 30, 2000, CD Panther Partners, L.P. (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

21. Constellation Operating Services

[Docket No. EG00–214–000]

Take notice that on June 30, 2000, Constellation Operating Services (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission (Commission) an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

22. Rio Nogales Power Project, L.P.

[Docket No. EG00–215–000]

Take notice that on June 30, 2000, Rio Nogales Power Project, L.P. (Rio Nogales), a Delaware limited partnership with its principal place of

business at 111 Market Place, Suite 200, Baltimore, MD 21202 filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Rio Nogales proposes to construct, own and/or operate, a nominally rated approximately 800 MW natural gas-fired, combined cycle power plant (the Eligible Facility) to be located in Seguin, Texas and to sell electricity exclusively at wholesale. The proposed Eligible Facility is expected to commence commercial operation in the second quarter of 2002. All capacity, energy and ancillary services from the Eligible Facility will be sold by Rio Nogales exclusively at wholesale.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

23. CE Colver Limited Partnership

[Docket No. EG00–216–000]

Take notice that on June 30, 2000, CE Colver Limited Partnership (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

24. CE Colver I, Inc.

[Docket No. EG00–217–000]

Take notice that on June 30, 2000, CE Colver I, Inc. (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

25. CE Central Wayne Energy Recovery, Limited Partnership

[Docket No. EG00–218–000]

Take notice that on June 30, 2000, CE Central Wayne Energy Recovery, Limited Partnership (the Applicant), with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission (Commission) an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

26. COSI A/C Power, Inc.

[Docket No. EG00–219–000]

Take notice that on June 30, 2000, COSI A/C Power, Inc., with its principal place of business at 111 Market Place, Suite 200, Baltimore, Maryland 21202, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

27. ANP Operations Company

[Docket No. EG00–220–000]

Take notice that on July 3, 2000, ANP Operations Company (Applicant), a Delaware corporation, whose address is 10000 Memorial Drive, Suite 500, Houston, Texas 77024, filed with the Federal Energy Regulatory Commission an application for determination of exempt wholesale generator status pursuant to part 365 of the Commission's regulations.

Applicant intends to operate the following eligible facilities: (i) An approximate 1,650 MW natural gas-fired combined-cycle independent power production facility, including ancillary and appurtenant structures, located near Midlothian, Texas; (ii) an approximate 550 MW natural gas-fired combined-cycle independent power production facility, including ancillary and appurtenant structures, located in Bellingham, Massachusetts; (iii) an approximate 550 MW natural gas-fired combined-cycle independent power production facility, including ancillary and appurtenant structures, located in Blackstone, Massachusetts; and (iv) an approximate 1,100 MW natural gas-fired combined-cycle independent power production facility, including ancillary and appurtenant structures, located in Hays County, Texas (collectively, the Facilities). The Facilities are or, to the extent currently under development, will be operated by Applicant.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

28. ISO New England Inc.

[Docket Nos. EL00–59–001, EL00–62–003, ER00–2005–001, ER00–2016–001 and ER00–2052–004]

Take notice that on June 30, 2000, the New England Power Pool (NEPOOL) submitted the Fifty-Seventh Agreement Amending New England Power Pool Agreement (Fifty-Seventh Agreement) which extends the termination date for the conceptual agreement for a replacement Congestion Cost allocation methodology until the implementation effective date of a Commission order regarding a new Congestion Cost allocation methodology. A June 1, 2000 effective date has been requested.

NEPOOL states that copies of these materials were sent to the New England state governors and regulatory commissions and the NEPOOL Participants.

Comment date: July 31, 2000, in accordance with Standard Paragraph E at the end of this notice.

29. Entergy Services, Inc.

[Docket No. ER00–2854–000]

Take notice that on June 27, 2000, Entergy Services, Inc. (ESI), on behalf of the Entergy Operating Companies' (collectively, Entergy) filed amendments to the System Agreement consisting of work papers associated with the testimony contained in the June 15, 2000 filing in the above-referenced docket.

Comment date: July 18, 2000, in accordance with Standard Paragraph E at the end of this notice.

Standard Paragraphs

E. Any person desiring to be heard or to protest such filing should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). All such motions or protests should be filed on or before the comment date. Protests will be considered by the Commission in

determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. Copies of these filings are on file with the Commission and are available for public inspection. This filing may also be viewed on the Internet at http://www.ferc.fed.us/ online/rims.htm (call 202–208–2222 for assistance).

David P. Boergers,

Secretary.

[FR Doc. 00–17958 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EG00–148–000, et al.]

Electric Energy, Inc., et al.; Electric Rate and Corporate Regulation Filings

July 10, 2000.

Take notice that the following filings have been made with the Commission:

1. Electric Energy, Inc.

[Docket No. EG00–148–000]

Take notice that on July 7, 2000, Electric Energy, Inc. (EEInc), 2100 Portland Road, P.O. Box 165, Joppa, IL 62953, filed with the Federal Energy Regulatory Commission an amendment to its application for determination of exempt wholesale generator status pursuant to Part 365 of the Commission's Regulations.

Comment date: July 24, 2000, in accordance with Standard Paragraph E at the end of this notice. The Commission will limit its consideration of comments to those that concern the adequacy or accuracy of the application.

2. Allegheny Energy Service Corporation, on behalf of Allegheny Energy Supply Company, LLC

[Docket No. ER00–3066–000]

Take notice that on July 3, 2000, Allegheny Energy Service Corporation on behalf of Allegheny Energy Supply Company, LLC (Allegheny Energy Supply), tendered for filing the First Revised Service Agreement No. 20 under the Market Rate Tariff to incorporate a Netting Agreement with Cinergy Services, Inc. into the tariff provisions.

Allegheny Energy Supply requests a waiver of notice requirements to make the Netting Agreement effective as of June 5, 2000 or such other date as ordered by the Commission.

Copies of the filing have been provided to the Public Utilities Commission of Ohio, the Pennsylvania Public Utility Commission, the Maryland Public Service Commission, the Virginia State Corporation Commission, the West Virginia Public Service Commission, and all parties of record.

Comment date: July 24, 2000, in accordance with Standard Paragraph E at the end of this notice.

3. Allegheny Energy Service Corporation, on behalf of Monongahela Power Company Potomac Edison Company, and West Penn Power Company (Allegheny Power)

[Docket No. ER00–3067–000]

Take notice that on July 3, 2000, Allegheny Energy Service Corporation on behalf of Monongahela Power Company, Potomac Edison Company and West Penn Power Company (Allegheny Power), tendered for filing Service Agreement No. 314 to add Cinergy Services, Inc., to Allegheny Power Open Access Transmission Service Tariff which has been accepted for filing by the Federal Energy Regulatory Commission in Docket No. ER96–58–000.

The proposed effective date under the Service Agreement is June 30, 2000 or a date ordered by the Commission.

Copies of the filing have been provided to the Public Utilities Commission of Ohio, the Pennsylvania Public Utility Commission, the Maryland Public Service Commission, the Virginia State Corporation Commission, and the West Virginia Public Service Commission.

Comment date: July 24, 2000, in accordance with Standard Paragraph E at the end of this notice.

4. California Independent System Operator Corporation

[Docket No. ER00–3070–000]

Take notice that on July 5, 2000, the California Independent System Operator Corporation, tendered for filing a Scheduling Coordinator Agreement between the ISO and the City of Glendale for acceptance by the Commission.

The ISO states that this filing has been served on the City of Glendale and the California Public Utilities Commission.

The ISO is requesting waiver of the 60-day notice requirement to allow the Scheduling Coordinator Agreement to be made effective as of June 21, 2000.

Comment date: July 26, 2000, in accordance with Standard Paragraph E at the end of this notice.

5. California Independent System Operator Corporation

[Docket No. ER00–3071–000]

Take notice that on July 5, 2000, the California Independent System Operator Corporation, tendered for filing a Meter Service Agreement for ISO Metered Entities between the ISO and Gas Recovery Systems, Inc., for acceptance by the Commission.

The ISO states that this filing has been served on Gas Recovery Systems, Inc., and the California Public Utilities Commission.

The ISO is requesting waiver of the 60-day notice requirement to allow the Meter Service Agreement for ISO Metered Entities to be made effective June 12, 2000.

Comment date: July 26, 2000, in accordance with Standard Paragraph E at the end of this notice.

6. Otter Tail Power Company

[Docket No. ER00–3072–000]

Take notice that on July 5, 2000, Otter Tail Power Company (OTP), tendered for filing a Service Agreement between OTP and the Energy Authority, Inc. (Energy Authority). The Service Agreement allows Energy Authority to purchase capacity and/or energy under OTP's Coordination Sales Tariff.

Comment date: July 26, 2000, in accordance with Standard Paragraph E at the end of this notice.

7. Entergy Services, Inc.

[Docket No. ER00–3073–000]

Take notice that on July 5, 2000, Entergy Services, Inc., on behalf of Entergy Gulf States, Inc., tendered for filing an Interconnection and Operating Agreement with Formosa Plastics Corporation (Formosa), and a Generator Imbalance Agreement with Formosa.

Comment date: July 26, 2000, in accordance with Standard Paragraph E at the end of this notice.

8. Entergy Services, Inc.

[Docket No. ER00–3075–000]

Take notice that on July 5, 2000, Entergy Services, Inc., on behalf of Entergy Gulf States, Inc., tendered for filing an Interconnection and Operating Agreement with CITGO Petroleum Corporation (CITGO), and a Generator Imbalance Agreement with CITGO.

Comment date: July 26, 2000, in accordance with Standard Paragraph E at the end of this notice.

9. Tucson Electric Power Company

[Docket No. ER00–771–004]

Take notice that on July 3, 2000, Tucson Electric Power Company (Tucson), tendered for filing a

compliance filing with respect to the Commission's May 19, 2000, Commission Order concerning the above listed dockets.

Comment date: July 26, 2000, in accordance with Standard Paragraph E at the end of this notice.

10. Madison Gas and Electric Company

[Docket No. ER00–3069–000]

Take notice that on July 3, 2000, Madison Gas and Electric Company (MGE), tendered for filing service agreements under MGE's Market-Based Power Sales Tariff with:

- Rainbow Energy Marketing Corporation
- Reliant Energy Services, Inc.

MGE requests the agreements be effective the date of filing.

Comment date: July 24, 2000, in accordance with Standard Paragraph E at the end of this notice.

11. PJM Interconnection, L.L.C.

[Docket No. ER99–3393–003]

Take notice that on July 5, 2000, Jersey Central Power & Light Company (doing business as GPU Energy), tendered for filing an amendment to the Refund Report originally submitted on May 30, 2000 in this docket.

Comment date: July 26, 2000, in accordance with Standard Paragraph E at the end of this notice.

12. TransEnergie U.S. Ltd

[Docket No. ER00–1–002]

Take notice that on July 3, 2000, TransEnergie US Ltd., tendered for filing, in compliance with the Commission's Order of June 1, 2000, 91 FERC ¶ 61,230 (2000), a report specifying the procedures for customers to reassign their firm transmission rights over the Cross Sound Cable Interconnector and a description of the procedures for implementing the Standards of Conduct required under Order No. 889.

Copies of the filing have been served on the parties to this proceeding.

Comment date: July 24, 2000, in accordance with Standard Paragraph E at the end of this notice.

13. Central Power and Light Company Public Service Company of Oklahoma Southwestern Electric Power Company West Texas Utilities Company

[Docket No. ER00–2100–001]

Take notice that on July 5, 2000, Central Power and Light Company, Public Service Company of Oklahoma, Southwestern Electric Power Company and West Texas Utilities Company in compliance with Commission staff request tendered for filing additional information in the above-captioned proceeding.

Comment date: July 26, 2000, in accordance with Standard Paragraph E at the end of this notice.

14. Virginia Electric and Power Company

[Docket No. ER00–2739–001]

Take notice that on July 5, 2000, Virginia Electric and Power Company (Virginia Power), tendered for filing a tariff sheet numbered ''Original Sheet No. 1'' that is blank and marked ''Reserved'' under Virginia Electric and Power Company, FERC Electric Tariff, Second Revised Volume No. 5 in compliance with Designation of Electric Rate Schedule Sheets, 90 FERC ¶ 61,352 (2000).

Virginia Power respectfully requested that the tariff sheet be accepted for filing as of June 7, 2000.

Copies of the filing were served upon the public utility's jurisdictional customers, Virginia State Corporation Commission and North Carolina Utilities Commission.

Comment date: July 26, 2000, in accordance with Standard Paragraph E at the end of this notice.

15. Carolina Power & Light Company

[Docket No. ER00–2741–001]

Take notice that on July 5, 2000, Carolina Power & Light Company (CP&L), tendered for filing a title page with no pagination and a tariff sheet numbered ''Original Sheet No. 1'' that is blank and marked ''Reserved'' under Carolina Power & Light Company, FERC Electric Tariff, Second Revised Volume No. 3 in compliance with Designation of Electric Rate Schedule Sheets, 90 FERC ¶ 61,352 (2000).

CP&L respectfully requested that the sheets be accepted for filing as of June 7, 2000.

Copies of the filing were served upon the public utility's jurisdictional customers, North Carolina Utilities Commission and South Carolina Public Service Commission.

Comment date: July 26, 2000, in accordance with Standard Paragraph E at the end of this notice.

16. Wisconsin Energy Corporation Operating Companies

[Docket No. ER00–2763–001]

Take notice that on July 5, 2000, Wisconsin Energy Corporation Operating Companies (Wisconsin Energy), tendered for filing a title page with the correct designation and a tariff sheet numbered ''Original Sheet No. 1'' that is blank and marked ''Reserved'' under Wisconsin Energy Corporation Operating Companies, FERC Electric Tariff, First Revised Volume No. 1 in compliance with Designation of Electric Rate Schedule Sheets, 90 FERC ¶ 61,352 (2000).

Wisconsin Energy requested that the sheets be accepted for filing as of June 7, 2000.

Copies of the filing were served upon the public utility's jurisdictional customers, Public Service Commission of Wisconsin and Michigan Public Service Commission.

Comment date: July 26, 2000, in accordance with Standard Paragraph E at the end of this notice.

17. Wisconsin Electric Power Company

[Docket No. ER00–2838–001]

Take notice that on July 5, 2000, Wisconsin Electric Power Company tendered for filing an amendment to its FERC Electric Tariff No. 1, Wholesale Power Service '' Schedule W. The amendment provides for the addition of Sheet No. 1, marked ''Reserved.''

Copies of the filing were served upon the public utility's jurisdictional customers, Public Service Commission of Wisconsin and Michigan Public Service Commission.

Comment date: July 26, 2000, in accordance with Standard Paragraph E at the end of this notice.

18. FirstEnergy System

[Docket No. ER00–3064–000]

Take notice that on July 3, 2000, FirstEnergy System tendered for filing Service Agreements to provide Firm Point-to-Point Transmission Service for The Legacy Energy Group, LLC , the Transmission Customer. Services are being provided under the FirstEnergy System Open Access Transmission Tariff submitted for filing by the Federal Energy Regulatory Commission in Docket No. ER97–412–000.

The proposed effective date under this Service Agreement is June 30, 2000 for the above mentioned Service Agreement in this filing.

Comment date: July 24, 2000, in accordance with Standard Paragraph E at the end of this notice.

19. FirstEnergy System

[Docket No. ER00–3065–000]

Take notice that on July 3, 2000, FirstEnergy System tendered for filing a Service Agreement to provide Non-Firm Point-to-Point Transmission Service for The Legacy Energy Group, LLC, the Transmission Customer. Services are being provided under the FirstEnergy System Open Access Transmission Tariff submitted for filing by the Federal Energy Regulatory Commission in Docket No. ER97–412–000.

The proposed effective date under this Service Agreement is June 30, 2000, for the above mentioned Service Agreement in this filing.

Comment date: July 24, 2000, in accordance with Standard Paragraph E at the end of this notice.

Standard Paragraphs

E. Any person desiring to be heard or to protest such filing should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). All such motions or protests should be filed on or before the comment date. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. Copies of these filings are on file with the Commission and are available for public inspection. This filing may also be viewed on the Internet at http://www.ferc.fed.us/ online/rims.htm (call 202–208–2222 for assistance).

David P. Boergers,

Secretary.

[FR Doc. 00–17997 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–U

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EF00–2012–000, et al.]

Department of Energy, et al.; Electric Rate and Corporate Regulation Filings

July 11, 2000.

Take notice that the following filings have been made with the Commission:

1. U.S. Department of Energy, Bonneville Power Administration

[Docket Nos. EF00–2012–000 and EF00–2013–000]

Take notice that the Bonneville Power Administration (BPA) on July 6, 2000, tendered for filing proposed rate adjustments for its wholesale power rates pursuant to pursuant to section 7(a)(2) of the Pacific Northwest Electric Power Planning and Conservation Act, 16 U.S.C. § 839e(a)(2). BPA seeks interim approval of its proposed rates effective September 15, 2000, pursuant to Commission regulation 300.20, 18 CFR 300.20. Pursuant to Commission regulation 300.21, 18 CFR 300.21, BPA seeks interim approval and final confirmation of the proposed rates for the periods set forth in this notice.

BPA requests approval effective October 1, 2001, through September 30, 2006, for the following proposed wholesale power rates: PF–02 Priority Firm Power Rate, RL–02 Residential Load Firm Power Rate, NR–02 New Resource Firm Power Rate, IP–02 Industrial Firm Power Rate, including the IPTAC, and NF–02 Nonfirm Energy Rate. In addition, BPA requests approval of the General Rate Schedule Provisions (GRSPs) for the period of October 1, 2001, through September 30, 2006. The GRSPs will apply to the 2002 wholesale power rates. BPA requests approval of the methodology used to calculate the rate for the Slice product sold under the PF rate schedule for the period October 1, 2001, to September 30, 2011. BPA requests final approval be granted by January 19, 2001, for the rate adjustments discussed above.

BPA requests interim approval by September 15, 2000, and final approval by December 8, 2000, of an adjustment to the 1996 GRSPs to enable BPA to recover costs of serving load unanticipated and not forecast in the 1996 rate case. This charge, known as Targeted Adjustment Charge for Uncommitted Loads (TACUL), will impose on certain PF–96 and NR–96 customers, only for the period December 8, 2000, to September 30, 2001, the costs of acquiring power to serve these loads which were not served by BPA during the 1996 rate period, but which are returning to BPA service before the 1996 rate period ends as these customers' other supply contracts expire.

Comment date: August 1, 2000, in accordance with Standard Paragraph E at the end of this notice.

2. Southern California Edison Company

[Docket No. EL00–89–000]

Take notice that on June 30, 2000, Southern California Edison Company (SCE) filed a Petition for Declaratory order pursuant to Rule 207(a)(2) of the Commission's Rules of Practice and Procedure (18 CFR 385.207(a)(2)). Southern California Edison asks the Commission to declare that the decision of the U.S. Court of Appeals for the District of Columbia Circuit in Southern California Edison Co. v. FERC, 195 F.3d 17 (1999) invalidating the ''essential fixed assets'' standard announced in Luz Solar Partners, Ltd., 30 FERC ¶ 61,122 at p. 61, 226 (1985), under which the Commission permitted uses of fossil fuel not authorized by PURPA by qualifying small power production facilities, is retroactively applicable to all qualifying small power production facilities; and that qualifying small power production facilities may not continue to use fossil fuel under the ''essential fixed assets'' standard and may be required to make refunds. SCE has attached to its petition a list of qualifying small power production facilities from which it purchases power and which it has served with a copy of the petition. SCE has asked the Commission to set this matter for alternative dispute resolution (ADR).

Comment date: August 11, 2000, in accordance with Standard Paragraph E at the end of this notice.

3. Western Resources, Inc.

[Docket No. ER00–3074–000]

Take notice that on July 6, 2000, Western Resources, Inc., tendered for filing a Service Agreement between Western Resources, Inc. and City of Columbia, Missouri, Water and Light Department (City). Western Resources states that the purpose of this agreement is to permit the City to take service under Western Resources' Market Based Power Sales Tariff on file with the Commission.

This agreement is proposed to be effective July 6, 2000.

Copies of the filing were served upon the City and the Kansas Corporation Commission.

Comment date: July 27, 2000, in accordance with Standard Paragraph E at the end of this notice.

4. California Independent System Operator Corporation

[Docket No. ER00–3076–000]

Take notice that on July 6, 2000, the California Independent System Operator Corporation, tendered for filing a Meter Service Agreement for ISO Metered Entities between the ISO and Lassen Municipal Utility District for acceptance by the Commission.

The ISO states that this filing has been served on Lassen Municipal Utility District and the California Public Utilities Commission.

The ISO is requesting waiver of the 60-day notice requirement to allow the Meter Service Agreement for ISO Metered Entities to be made effective June 28, 2000.

Comment date: July 27, 2000, in accordance with Standard Paragraph E at the end of this notice.

5. Public Service Company of New Mexico

[Docket No. ER00–3077–000]

Take notice that on July 6, 2000, Public Service Company of New Mexico (PNM), tendered for filing two executed service agreements with Cinergy

Services, Inc., dated June 27, 2000, under PNM's Open Access Transmission Service Tariff. One agreement is for non-firm point-to-point transmission service and one agreement is for firm point-to-point transmission service. PNM's filing is available for public inspection at its offices in Albuquerque, New Mexico.

Copies of the filing have been sent to Cinergy Services, Inc., and to the New Mexico Public Regulation Commission.

Comment date: July 27, 2000, in accordance with Standard Paragraph E at the end of this notice.

6. PacifiCorp

[Docket No. ER00–3079–000]

Take notice that on July 6, 2000, PacifiCorp, tendered for filing in accordance with 18 CFR 35 of the Commission's Rules and Regulations, Revisions to Exhibits to the General Transfer Agreement between PacifiCorp and the Bonneville Power Administration (Bonneville).

Copies of this filing were supplied to Bonneville, the Washington Utilities and Transportation Commission and the Public Utility Commission of Oregon.

Comment date: July 27, 2000, in accordance with Standard Paragraph E at the end of this notice.

7. Otter Tail Power Company

[Docket No. ER00–3080–000]

Take notice that on July 6, 2000, Otter Tail Power Company (Otter Tail), tendered for filing with the Federal Energy Regulatory Commission a Wholesale Market-Based Rate Tariff and a *pro forma* Service Agreement, and proposed modifications to Otter Tail's Wholesale Coordination Sales Tariff No. 2. Otter Tail has mailed a copy of this filing to all of its customers under its Wholesale Coordination Sales Tariff No. 2.

Otter Tail states that its Wholesale Market-Based Rate Tariff and pro forma Service Agreement are being filed in order to conform to a pro forma tariff prepared by a group of representatives from various segments of the electric industry. Otter Tail will continue to utilize its existing Wholesale Coordination Sales Tariff No. 2 for existing service agreements, until such agreements expire.

Comment date: July 27, 2000, in accordance with Standard Paragraph E at the end of this notice.

8. Southwest Power Pool, Inc.

[Docket No. ER00–3081–000]

Take notice that on July 6, 2000, Southwest Power Pool, Inc. (SPP), tendered for filing executed service agreements for Firm Point-to-Point Transmission Service, Non-Firm Point-to-Point Transmission Service and Loss Compensation Service with DTE Energy Trading, Inc (DTE).

SPP seeks an effective date of June 26, 2000 for each of the service agreements.

Copies of this filing were served on DTE.

Comment date: July 27, 2000, in accordance with Standard Paragraph E at the end of this notice.

9. Florida Power & Light Company

[Docket No. ER00–3082–000]

Take notice that on July 7, 2000, Florida Power & Light Company (FPL), tendered for filing proposed service agreements with Allegheny Energy Supply Company, L.L.C. for Non-Firm transmission service and Firm transmission service under FPL's Open Access Transmission Tariff.

FPL requests that the proposed service agreements are permitted to become effective on July 7, 2000.

FPL states that this filing is in accordance with Part 35 of the Commission's Regulations.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice.

10. South Carolina Electric & Gas Company

[Docket No. ER00–3083–000]

Take notice that on July 6, 2000, South Carolina Electric & Gas Company (SCE&G), tendered for filing a service agreement establishing DTE Energy Trading, Inc., as a non-firm point-to-point customer under the terms of SCE&G's Open Access Transmission Tariff.

SCE&G requests an effective date of one day subsequent to the filing of the service agreement. Accordingly, SCE&G requests waiver of the Commission's notice requirements.

Copies of this filing were served upon DTE Energy Trading, Inc. and the South Carolina Public Service Commission.

Comment date: July 27, 2000, in accordance with Standard Paragraph E at the end of this notice.

11. MidAmerican Energy Company

[Docket No. ER00–3084–000]

Take notice that on July 7, 2000, MidAmerican Energy Company (MidAmerican), 666 Grand Avenue, Des Moines, Iowa 50309, tendered for filing with the Commission a Firm Transmission Service Agreement with Corn Belt Power Cooperative (Corn Belt Power), dated June 12, 2000, entered into pursuant to MidAmerican's Open Access Transmission Tariff.

MidAmerican requests an effective date of June 15, 2000 for the Agreements with Corn Belt Power, and accordingly seeks a waiver of the Commission's notice requirement.

MidAmerican has served a copy of the filing on Corn Belt Power, the Iowa Utilities Board, the Illinois Commerce Commission and the South Dakota Public Utilities Commission.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice.

12. Ameren Services Company

[Docket No. ER00–3085–000]

Take notice that on July 28, 2000, Ameren Services Company (ASC), tendered for filing a Service Agreement for Non-Firm Point-to-Point Transmission Service between ASC and Entergy Power Marketing Corp. (Entergy). ASC asserts that the purpose of the Agreement is to permit ASC to provide transmission service to Entergy pursuant to Ameren's Open Access Transmission Tariff filed in Docket No. ER96–677–004.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice.

13. MidAmerican Energy Company

[Docket No. ER00–3086–000]

Take notice that on July 7, 2000, MidAmerican Energy Company (MidAmerican), 666 Grand Avenue, Des Moines, Iowa 50309, tendered for filing with the Commission a Firm Transmission Service Agreement with Cedar Falls Utilities (Cedar Falls), dated June 15, 2000, and a Non-Firm Transmission Service Agreement with Cedar Falls, dated June 15, 2000, entered into pursuant to MidAmerican's Open Access Transmission Tariff.

MidAmerican requests an effective date of June 15, 2000 for the Agreements with Cedar Falls, and accordingly seeks a waiver of the Commission's notice requirement.

MidAmerican has served a copy of the filing on Cedar Falls Utilities, the Iowa Utilities Board, the Illinois Commerce Commission and the South Dakota Public Utilities Commission.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice.

14. Cleco Utility Group Inc.

[Docket No. ER00–3087–000]

Take notice that on July 7, 2000, Cleco Utility Group, Inc. (CLECO), tendered for filing Non-Firm and Short term firm point-to-point transmission service agreements under its Open Access Transmission Tariff with The Energy Authority, Inc.

CLECO requests that the Commission accept the Service Agreement with an effective date of July 7, 2000.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice.

15. Commonwealth Edison Company

[Docket No. ER00–3088–000]

Take notice that on July 7, 2000, Commonwealth Edison Company (ComEd), tendered for filing a Short-Term Firm Transmission Service Agreements with Edison Mission Marketing & Trading, Inc. (EMMT) under the terms of ComEd's Open Access Transmission Tariff (OATT).

ComEd requests an effective date of ComEd of June 10, 2000, for the agreement with EMMT, and accordingly, seeks waiver of the Commission's notice requirements.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice.

16. Northern Indiana Public Service Company

[Docket No. ER00–3089–000]

Take notice that on July 7, 2000, Northern Indiana Public Service Company tendered for filing an executed Standard Transmission Service Agreement for Non-Firm Point-to-Point Transmission Service between Northern Indiana Public Service Company and Detroit Edison Merchant Operations (Transmission Customer).

Under the Transmission Service Agreement, Northern Indiana Public Service Company will provide Point-to-Point Transmission Service to Transmission Customer pursuant to the Transmission Service Tariff filed by Northern Indiana Public Service Company in Docket No. OA96–47–000 and allowed to become effective by the Commission.

Northern Indiana Public Service Company has requested waivers to permit the Service Agreement to become effective as of June 1, 2000.

Copies of this filing have been sent to Detroit Edison Merchant Operations, the Indiana Utility Regulatory Commission, and the Indiana Office of Utility Consumer Counselor.

Comment date: July 28, 2000, in accordance with Standard Paragraph E at the end of this notice.

Standard Paragraphs

E. Any person desiring to be heard or to protest such filing should file a motion to intervene or protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). All such motions or protests should be filed on or before the comment date. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. Copies of these filings are on file with the Commission and are available for public inspection. This filing may also be viewed on the Internet at http://www.ferc.fed.us/ online/rims.htm (call 202–208–2222 for assistance).

David P. Boergers,

Secretary.

[FR Doc. 00–17996 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–U

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. GT00–32–000]

Tennessee Gas Pipeline Company; Notice of Termination of Service

July 11, 2000.

Take notice that on June 19, 2000, Tennessee Gas Pipeline Company (Tennessee), tendered for filing a notice of its intent to terminate service to certain shippers pursuant to Article XXVIII of its General Terms and Conditions. Tennessee proposes that the termination be made effective on July 19, 2000.

Tennessee states that these shippers are part of the Service Package 8822 group of shippers that entered into a single transportation agreement on February 1, 1995, with Tennessee to receive and deliver gas to Columbia Gas Transmission Corporation under Rate Schedule FT–A. Tennessee states that after several and various attempts they have not been able to verify the creditworthiness of certain shippers and, therefore, proposes to remove them from the list of eligible shippers.

Any person desiring to protest said filing should file a protest with the Federal Energy Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, in accordance with Section 385.211 of the Commission's Rules and Regulations. All such protests must be filed on or before July 18, 2000. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Copies of this filing are on file with the Commission and are available for public inspection in the Public Reference Room. This filing may be viewed on the web at http://www.ferc.fed.us/online/rims.htm (call 202–208–2222 for assistance).

David P. Boergers,

Secretary.

[FR Doc. 00–17960 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 11150–000–Michigan]

Cameron Gas and Electric Company; Notice of Availability of Draft Environmental Assessment

July 12, 2000.

In accordance with the National Environmental Policy Act of 1969 and the Federal Energy Regulatory Commission's (Commission's) regulations, 18 CFR Part 380 (Order No. 486, 52 FR 47897), the Office of Energy Projects has reviewed the application for an original license for the unlicensed Smithville and Mix Hydroelectric Project located on the Grand River, in the city of Eaton Rapids, Eaton County, Michigan, and has prepared a draft Environmental Assessment (EA) for the project. In the draft EA, the Commission's staff has analyzed the potential environmental effects of the project and has concluded that approval of the project, with appropriate environmental measures, would not constitute a major federal action significantly affecting the quality of the human environment.

Copies of the draft EA are available for review in the Public Reference Branch, Room 2–A, of the Commission's offices at 888 First Street, N.E., Washington, D.C. 20426. The draft EA may also be viewed on the web at *http://www.ferc.fed.us/online/rims.htm.* Please call (202) 208–222 for assistance.

Any comments should be filed within 45 days from the date of this notice and should be addressed to David P. Boergers, Secretary, Federal Energy Regulatory Commission, 888 First Street, N.E., Room 1–A, Washington, D.C. 20426. Please affix ''Smithville and Mix Hydroelectric Project No. 11150'' to all comments. For further information, contact William Guey-Lee at (202) 219–2808.

Linwood A. Watson, Jr.,

Acting Secretary.

[FR Doc. 00–17998 Filed 7–14–00; 8:45 am]

BILLING CODE 6717–01–M

DEPARTMENT OF ENERGY

Western Area Power Administration

Loveland Area Projects—Notice of Order Confirming and Approving an Extension of the Firm Electric Service Rate for Rate Order No. WAPA–89

AGENCY: Western Area Power Administration, DOE.

ACTION: Notice of rate order.

SUMMARY: This action is to extend the existing Loveland Area Projects' (LAP) firm electric service rate, Rate Order No. WAPA–51, through September 30, 2003. The existing firm electric service rate will expire January 31, 2001. This notice of an extension of the rate is issued pursuant to 10 CFR 903.23. Rate Order No. WAPA–51, previously extended under Rate Order No. WAPA–82, is further extended under Rate Order WAPA–89.

FOR FURTHER INFORMATION CONTACT: Mr. Daniel T. Payton, Rates Manager, Rocky Mountain Customer Service Region, Western Area Power Administration, P.O. Box 3700, Loveland, CO 80539–3003, (970) 461–7442, or e-mail dpayton@wapa.gov.

SUPPLEMENTARY INFORMATION: By Amendment No. 3 to Delegation Order No. 0204–108, published November 10, 1993 (58 FR 59716), the Secretary of Energy delegated (1) the authority to develop long-term power and transmission rates on a nonexclusive basis to the Administrator of the Western Area Power Administration (Western); and (2) the authority to confirm, approve, and place into effect on a final basis, to remand, or to disapprove such rates to the Federal Energy Regulatory Commission (FERC). In Delegation Order No. 0204–172, effective November 24, 1999, the Secretary of Energy delegated the authority to confirm, approve, and place such rates into effect on an interim basis to the Deputy Secretary.

Pursuant to Delegation Order No. 0204–108 and existing Department of Energy procedures for public participation in firm electric service rate adjustments at 10 CFR part 903, Western's LAP firm electric service rate was submitted to FERC for confirmation and approval on January 10, 1994. On July 14, 1994, in Docket No. EF94–5181–000 at 68 FERC ¶ 62,040, FERC issued an order confirming, approving, and placing into effect on a final basis the firm electric service rate for LAP. LAP consists of the Fryingpan-Arkansas Project and the Pick-Sloan Missouri Basin Program, Western Division. The rate set forth in Rate Order No. WAPA–51 was approved for a 5-year period beginning February 1, 1994, and ending January 31, 1999. On October 16, 1998, upon signing Rate Order No. WAPA–82, the Deputy Secretary extended the existing rate for a 2-year period beginning February 1, 1999, through January 31, 2001. On January 31, 2001, the LAP firm electric rate will expire.

Western proposed to extend the existing rate of $2.85/kilowattmonth for capacity and 10.85 mills/kilowatthour for energy which is sufficient to recover the LAP annual revenue requirement of $44.3 million. This requirement includes project expenses, interest, and capital requirements through September 30, 2003. Increased revenue from good hydrologic conditions and lower operation and maintenance expenses over the cost evaluation period have made this possible. Western, therefore, has decided to extend the existing rate pursuant to 10 CFR 903.23.

In accordance with 10 CFR 903.23(a)(2), Western did not have a consultation and comment period. The notice of proposed extension of the firm electric service rate was published in the **Federal Register** on March 29, 2000.

Following review of Western's proposal within the Department of Energy, I approved Rate Order No. WAPA–89, which extends the existing Loveland Area Projects' firm electric service Rate Schedule L–F4 on an interim basis through September 30, 2003.

Dated: July 10, 2000.

T.J. Glauthier,

Deputy Secretary.

Department of Energy Deputy Secretary

In the Matter of: Western Area Power Administration Rate Extension for Loveland Area Projects Firm Electric Service Rate.

Rate Order No. WAPA–89

Order Confirming and Approving an Extension of the Loveland Area Projects' Firm Electric Service Rate

(_____, 2000)

This rate was established pursuant to section 302(a) of the Department of Energy Organization Act (42 U.S.C. 7152(a)), through which the power marketing functions of the Secretary of the Department of the Interior and the Bureau of Reclamation under the Reclamation Act of 1902 (ch. 1093, 32 stat. 388), as amended and supplemented by subsequent enactments, particularly section 9(c) of the Reclamation Project Act of 1939 (43 U.S.C. 485h(c)), were transferred to and vested in the Secretary of Energy (Secretary).

By Amendment No. 3 to Delegation Order No. 0204–108, published November 10, 1993 (58 FR 59716), the Secretary delegated (1) the authority to develop long-term power and transmission rates on a nonexclusive basis to the Administrator of the Western Area Power Administration (Western); and (2) the authority to confirm, approve, and place into effect on a final basis, to remand, or to disapprove such rates to the Federal Energy Regulatory Commission (FERC). In Delegation Order No. 0204–172, effective November 24, 1999, the Secretary delegated the authority to confirm, approve, and place such rates into effect on an interim basis to the Deputy Secretary.

Background

In the order issued July 14, 1994, in Docket No. ER94–5181–000 at 68 FERC ¶ 62,040, FERC confirmed, approved, and placed into effect on a final basis Rate Order No. WAPA–51 for the firm electric service rate for the Loveland Area Projects (LAP). The rate was approved for the period from February 1, 1994, through January 31, 1999. On October 16, 1998, upon signing Rate Order No. WAPA–82, the Deputy Secretary extended the existing rate for a 2-year period beginning February 1, 1999, through January 31, 2001. On January 31, 2001, the LAP firm electric rate will expire. This makes it necessary to extend the current rate pursuant to 10 CFR part 903. With this approval, Rate Order No. WAPA–51, previously extended under Rate Order No. WAPA–82, will be extended under Rate Order No. WAPA–89.

Discussion

The LAP consists of the Pick-Sloan Missouri Basin Program, Western Division, and the Fryingpan-Arkansas Project. The existing LAP rate of $2.85/kilowattmonth for capacity and 10.85 mills/kilowatthour for energy is sufficient to recover the LAP annual revenue requirement of $44.3 million. This requirement includes project expenses, interest, and capital requirements through September 30, 2003. Increased revenue from good hydrologic conditions and lower operation and maintenance expenses over the cost evaluation period have made this possible.

In accordance with 10 CFR 903.23(a)(2), Western did not have a consultation and comment period. The notice of proposed extension of the firm electric service rate was published in the **Federal Register** on March 29, 2000.

Order

In view of the foregoing and pursuant to the authority delegated to me by the Secretary, I hereby extend for the period effective February 1, 2001, through September 30, 2003, the existing Rate Schedule L-F4 on an interim basis for firm electric service for the Loveland Area Projects.

Dated: July 10, 2000.

T.J. Glauthier,

Deputy Secretary.

[FR Doc. 00–18002 Filed 7–14–00; 8:45 am]

BILLING CODE 6450–01–P

DEPARTMENT OF ENERGY

Western Area Power Administration

Pick-Sloan Missouri Basin Program-Eastern Division—Notice of Order Confirming and Approving an Extension of the Firm Power Service and Firm Peaking Power Service Rates for Rate Order No. WAPA–90

AGENCY: Western Area Power Administration, DOE.

ACTION: Notice of rate order.

SUMMARY: This action is to extend the existing Pick-Sloan Missouri Basin Program-Eastern Division (P–SMBP–ED) firm power service and firm peaking power service rates, Rate Order No. WAPA–60, through September 30, 2003. The existing firm power service and firm peaking power service rates will expire January 31, 2001. This notice of an extension of rates is issued pursuant to 10 CFR 903.23. Rate Order No. WAPA–60, previously extended under Rate Order No. WAPA–83, is further extended under Rate Order No. WAPA–90.

FOR FURTHER INFORMATION CONTACT: Mr. Robert F. Riehl, Rates Manager, Upper Great Plains Customer Service Region, Western Area Power Administration, P.O. Box 35800, Billings, MT 59107–5800, telephone (406) 247–7388, or e-mail riehl@wapa.gov.

SUPPLEMENTARY INFORMATION: By Amendment No. 3 to Delegation Order No. 0204–108, published November 10, 1993 (58 FR 59716), the Secretary of Energy delegated (1) the authority to develop long-term power and transmission rates on a nonexclusive basis to the Administrator of the Western Area Power Administration (Western); and (2) the authority to confirm, approve, and place into effect on a final basis, to remand, or to disapprove such rates to the Federal Energy Regulatory Commission (FERC). In Delegation Order No. 0204–172, effective November 24, 1999, the Secretary of Energy delegated the authority to confirm, approve, and place such rates into effect on an interim basis to the Deputy Secretary of Energy.

Pursuant to Delegation Order No. 0204–108 and existing Department of Energy procedures for public participation in power rate adjustments at 10 CFR part 903, Western's P–SMBP–ED firm power service and firm peaking power service rates were submitted to FERC for confirmation and approval on January 10, 1994. On July 14, 1994, in Docket No. EF94–5031–000 at 68 FERC ¶ 62,040, FERC issued an order confirming, approving, and placing into effect on a final basis the firm power service and firm peaking power service rates for the P–SMBP–ED. The rates set forth, Rate Order No. WAPA–60, were approved for the 5-year period beginning February 1, 1994, and ending January 31, 1999. On October 16, 1998, upon signing Rate Order No. WAPA 83, the Deputy Secretary extended the existing rates for a 2-year period beginning February 1, 1999, and ending January 31, 2001.

On January 31, 2001, the P-SMBP-ED firm power service and firm peaking power service rates will expire.

Western proposed to extend the existing rate of $3.20/kilowattmonth for capacity and the rate of 8.32 mills/kilowatthour for energy which are sufficient to recover project expenses, including interest, and capital requirements through September 30, 2003. Increased revenue from good hydrologic conditions and effective cost containment efforts have resulted in lower operation and maintenance expenses over the cost-evaluation period to make this possible. For the Pick-Sloan Missouri Basin Program, the rate setting study projected the deficit associated with the drought starting in 1989 to peak at $178 million in fiscal year (FY) 1994 and to be repaid in FY 2002. The deficit actually peaked at $171 million in FY 1993 and was totally repaid, with interest, in FY 1997. The total revenue requirement of $135.2 million is sufficient to cover the expenses and capital requirements through September 30, 2003. Western, therefore, has decided to extend the existing rates pursuant to 10 CFR 903.23.

In accordance with 10 CFR 903.23(a)(2), Western did not have a consultation and comment period. The notice of an extension of the firm power service and firm peaking power service rates was published in the **Federal Register** on March 29, 2000.

Following review of Western's proposal within the Department of Energy, I approved Rate Order No. WAPA–90, which extends the existing P–SMBP–ED firm power service and firm peaking power service rate schedules P–SED–F6 and P–SED–FP6 on an interim basis through September 30, 2003.

Dated: July 10, 2000.

T.J. Glauthier,

Deputy Secretary.

Department of Energy Deputy Secretary

Rate Order No. WAPA–90

In the Matter of: Western Area Power Administration Extension of the Firm Power Service and Firm Peaking Power Service Rates for the Pick-Sloan Missouri Basin Program-Eastern Division

Order Confirming and Approving an Extension of the Pick-Sloan Missouri Basin Program-Eastern Division Firm Power Service and Firm Peaking Power Service Rates

This rate extension was established pursuant to section 302(a) of the Department of Energy Organization Act, 42 U.S.C. 7152(a), through which the power marketing functions of the Secretary of the Department of the Interior and the Bureau of Reclamation under the Reclamation Act of 1902 (ch. 1093, 32 stat. 388), as amended and supplemented by subsequent enactments, particularly section 9(c) of the Reclamation Project Act of 1939, 43 U.S.C. 485h(c), were transferred to and vested in the Secretary of Energy (Secretary).

By Amendment No. 3 to Delegation Order No. 0204–108, published November 10, 1993 (58 FR 59716), the Secretary delegated (1) the authority to develop long-term power and transmission rates on a nonexclusive basis to the Administrator of the Western Area Power Administration (Western); and (2) the authority to confirm, approve, and place into effect on a final basis, to remand, or to disapprove such rates to the Federal Energy Regulatory Commission (FERC). In Delegation Order No. 0204–172, effective November 24, 1999, the Secretary delegated the authority to confirm, approve, and place such rates into effect on an interim basis to the Deputy Secretary. This rate extension is issued pursuant to the Delegation Order and the Department of Energy rate extension procedures at 10 CFR part 903.

Background

In the order issued July 14, 1994, in Docket No. EF94–5031–000 at 68 FERC ¶ 62,040, FERC confirmed, approved, and placed in effect on a final basis Rate Order No. WAPA–60, for the firm power service and firm peaking power service rates for the Pick-Sloan Missouri Basin Program-Eastern Division (P–SMBP–ED), The rates were approved for the period from February 1, 1994, through January 31, 1999. On October 16, 1998, upon signing Rate Order No. WAPA–83 the Secretary extended the existing rates for a 2-year period beginning February 1, 1999, through January 31, 2001. On January 21, 2001, the P–SMBP–ED firm power service and firm peaking power service rates will expire. This makes it necessary to extend the current rates pursuant to 10 CFR part 903. With this

approval, Rate Order No. WAPA–60, previously extended under Rate Order No. WAPA–83, will be extended under Rate Order WAPA–90. A notice of an extension of the firm power and firm peaking power service rates was published in the **Federal Register** on March 29, 2000. Therefore, Western is extending P–SMBP–ED firm power and firm peaking power service rates under Rate Order No. WAPA–90.

Discussion

The existing P–SMBP–ED rate is $3.20/kilowattmonth for capacity and 8.32 mills/kilowatthour for energy. The existing rates are sufficient to recover project expenses, including interest and capital requirements through September 30, 2003. Increased revenue from good hydrologic conditions and effective cost containment efforts have resulted in lower operation and maintenance expenses over the cost-evaluation period. For the Pick-Sloan Missouri Basin Program, the rate setting study projected the deficit associated with the drought starting in 1989 to peak at $178 million in fiscal year (FY) 1994 and to be repaid in FY 2002. The deficit actually peaked at $171 million in FY 1993 and was totally repaid, with interest, in FY 1997. The total revenue requirement of $135.2 million is sufficient to cover the expenses and capital requirements through September 30, 2003.

In accordance with 10 CFR part 903.23(a)(2), Western did not have a consultation and comment period. The notice of proposed extension of the firm power service and firm peaking power service rates was published in the **Federal Register** on March 29, 2000.

Order

In view of the foregoing and pursuant to the authority delegated to me by the Secretary, I hereby extend for a period effective February 1, 2001, and ending September 30, 2003, the existing Rate Schedules P–SED–F6 for firm power service and P–SED–FP6 on an interim basis for firm peaking power service for the P–SMBP–ED.

Dated: July 10, 2000.

T.J. Glauthier,

Deputy Secretary.

[FR Doc. 00–18003 Filed 7–14–00; 8:45 am]

BILLING CODE 6450–01–P

ENVIRONMENTAL PROTECTION AGENCY

[FRL–6837–2]

Agency Information Collection Activities: Submission for OMB Review; Comment Request; Land Disposal Restrictions No-Migration Variances

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (44 U.S.C. 3501 *et seq.*), this document announces that the following Information Collection Request (ICR) has been forwarded to the Office of Management and Budget (OMB) for review and approval: Land Disposal Restrictions No-Migration Variances, OMB Control Number 2050–0062, EPA ICR No. 1353.06 expiring on August 31, 2000. The ICR describes the nature of the information collection and its expected burden and cost; where appropriate, it includes the actual data collection instrument.

DATES: Comments must be submitted on or before August 16, 2000.

FOR FURTHER INFORMATION CONTACT: For a copy of the ICR, contact Sandy Farmer at EPA by phone at (202) 260–2740, by email at farmer.sandy@epamail.epa.gov, or download a copy of the ICR off the Internet at http://www.epa.gov/icr and refer to EPA ICR No. 1353.06. For technical questions about the ICR contact David A. Eberly on 703–308–8645.

SUPPLEMENTARY INFORMATION:

Title: Land Disposal Restrictions No-Migration Variances, OMB Control Number 2050–0062, EPA ICR No. 1353.06, expiring August 31, 2000. This is a request for extension of a currently approved collection.

Abstract: To receive a variance from the hazardous waste land disposal prohibitions, owner/operators of hazardous waste storage or disposal facilities may petition the Environmental Protection Agency to allow land disposal of a specific restricted waste at a specific site. The EPA Regional Offices will review the petitions and determine if they successfully demonstrate ''no migration.'' The applicant must demonstrate that hazardous wastes can be managed safely in a particular land disposal unit, so that ''no migration'' of any hazardous constituents occurs from the unit for as long as the waste remains hazardous. If EPA grants the variance, the waste is no longer prohibited from land disposal in that particular unit. If the owner/operator fails to make this demonstration, or chooses not to petition for the variance, best demonstrated available technology (BDAT) requirements of 40 CFR 268.40 must be met before the hazardous wastes are placed in a land disposal unit.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations are listed in 40 CFR part 9 and 48 CFR Chapter 15. The **Federal Register** document required under 5 CFR 1320.8(d), soliciting comments on this collection of information was published on February 22, 2000 (65 FR 8699); no comments were received.

Burden Statement: The annual public reporting and recordkeeping burden for this collection of information is estimated to average 3,137 hours per response. Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information.

Respondents/Affected Entities: 1.

Estimated Number of Respondents: 1.

Frequency of Response: once every three years.

Estimated Total Annual Hour Burden: 3,137 hours.

Estimated Total Annualized Capital, O&M Cost Burden: $72.

Send comments on the Agency's need for this information, the accuracy of the provided burden estimates, and any suggested methods for minimizing respondent burden, including through the use of automated collection techniques to the following addresses. Please refer to EPA ICR No. 1353.06 and OMB Control No. 2050–0062 in any correspondence.

Ms. Sandy Farmer, U.S. Environmental Protection Agency, Office of Environmental Information, Collection Strategies Division (2822),

1200 Pennsylvania Ave., NW, Washington, DC 20460;
and
Office of Information and Regulatory Affairs, Office of Management and Budget, Attention: Desk Officer for EPA, 725 17th Street, NW, Washington, DC 20503.

Dated: July 1, 2000.

Oscar Morales,

Director, Collection Strategies Division.

[FR Doc. 00–18026 Filed 7–14–00; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

[FRL–6736–3]

Retrofit/Rebuild Requirements for 1993 and Earlier Model Year Urban Buses; Certification of Equipment

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of EPA certification of equipment provided by Turbodyne Systems, Inc.

SUMMARY: Today's **Federal Register** document announces EPA's decision to certify equipment to the 0.10 g/bhp-hr standard for the Urban Bus Retrofit/Rebuild Program. The equipment is provided by Turbodyne Systems, Inc. (Turbodyne).

Turbodyne submitted to EPA a notification of intent to certify equipment, signed November 14, 1997, pursuant to the program regulations at 40 CFR part 85, subpart O. On April 19, 1999, EPA published a document in the **Federal Register** that the Turbodyne notification had been received and made the notification available for public review and comment for a period of 45 days (64 FR 19151). EPA has completed its review and the Director of the Certification & Compliance Division has determined that it meets all requirements for certification. Accordingly, EPA approves the certification of this equipment effective July 17, 2000.

The equipment consists of the base engine components used on the 25% reduction retrofit/rebuild kit certified by the Detroit Diesel Corporation (DDC), components from the 25% retrofit catalyst kit certified by Engine Control Systems, Ltd. (ECS) and a TurboPac supercharger system supplied by Turbodyne that supplies additional air for combustion during engine acceleration. This Turbodyne kit is identical to the kit that was certified by the Detroit Diesel Corporation on May 14, 1998 (63 FR 26798) and is applicable to the same models, and model year engines as the DDC kit.

The kit is applicable to 6V92TA urban bus engine models made by Detroit Diesel Corporation (DDC) from model years 1979 to 1989 and equipped with mechanical unit injectors (MUI), and may be used immediately by transit operators in compliance with program requirements. The kit is available in three horsepower levels (253, 277, and 294).

EPA has determined that this Turbodyne kit complies with the 0.10 gram per brake horsepower-hour (g/bhp-hr) particulate matter (PM) standard for the applicable engines. EPA has not determined that Turbodyne's notification complies with the life cycle cost requirements of the program regulations because no life cycle costs were supplied with the application.

Today's **Federal Register** document does not trigger any additional program requirements for transit operators. The 0.10 g/bhp-hr PM level has already been triggered for all engines covered by this notification.

The notification of intent to certify, as well as other materials specifically relevant to it, are contained in Category XXIII–A of Public Docket A–93–42, entitled ''Certification of Urban Bus Retrofit/Rebuild Equipment.'' This docket is located at the address listed below.

Additional details concerning this certification, the Turbodyne kit, and responsibilities of transit operators, are provided below.

DATES: Today's **Federal Register** document dated July 17, 2000, is the certification date for this equipment. The 0.10 g/bhp-hr standard was triggered on March 14, 1997 (62 FR 12166) for all engines covered by this certification.

ADDRESSES: The Turbodyne notification of intent to certify, as well as other material specifically relevant to it, are contained at the U.S. Environmental Protection Agency's Public Air Docket A–93–42 (Category XXIII–A), Room M–1500, 401 ''M'' Street SW, Washington, DC 20460.

Docket items may be inspected from 8:00 a.m. until 5:30 p.m., Monday through Friday. As provided in 40 CFR part 2, a reasonable fee may be charged by EPA for copying docket materials.

FOR FURTHER INFORMATION CONTACT: Anthony Erb, Certification & Compliance Division (6403J), U.S. Environmental Protection Agency, Ariel Rios Building, 1200 Pennsylvania Avenue, N.W. Washington, D.C. 20460. Telephone: (202) 564–9259. Email Address: ERB.ANTHONY@EPA.GOV.

SUPPLEMENTARY INFORMATION:

I. Description of the Certified Kit

The certified kit described in today's **Federal Register** document, is provided by Turbodyne. It is certified to the 0.10 g/bhp-hr standard. It is not required to comply with the applicable life cycle cost requirements of the program. No cost data were provided in the notification.

The certification described in today's document applies to 1979 though 1989 model year DDC 6V92TA engines that are equipped with mechanical unit injectors (MUI) and certified to federal emissions standards. It does not apply to engines certified to California emissions standards. The impact of this decision on transit operators is discussed in more detail in the ''Transit Operator Requirements'' section below.

The kit, described further below, consists of base engine components used on the 25% reduction kit certified by DDC earlier, a catalytic exhaust muffler supplied by Engine Control Systems, Ltd. (ECS), and a TurboPac supercharger system supplied by Turbodyne Systems, Inc. that supplies additional combustion air during acceleration. The kit is available in three horsepower (hp) ratings (253, 277, and 294 hp). The kit being certified by Turbodyne is identical to the kit certified by DDC earlier (63 FR 26798).

For retrofit with the Turbodyne kit, an engine is rebuilt in accordance with standard DDC rebuild procedures, using specified engine components. This component set essentially includes the equipment certified by EPA to provide a 25% particulate reduction on October 2, 1995, at 60 FR 51472. These components are provided in two separate sets of parts. The first set of components is comprised of newly manufactured parts, including a gasket kit, air inlet hose, cylinder kits (piston assemblies and cylinder liners) a by-pass valve and a truck type throttle delay. The second set of components includes Reliabilt™ remanufactured parts, including the fuel injectors, camshafts, blower assembly, turbocharger, and head assemblies. Kit usage is based on engine rotation (righthand (RH) or lefthand (LH)), engine orientation, right bank cam gear mounting (bolt or nut), and engine power output based on injector size. The only difference from the previously certified equipment is the inclusion of a truck-style throttle delay, adjustment of the throttle delay and injector timing settings to improve driveability. Additionally, the cylinder kit components have been modified to improve durability.

The converter is the same as the catalytic converter muffler certified by DDC for the Urban Bus Program as described in the **Federal Register** on May 14, 1998 (63 FR 26798), is a direct replacement for the original equipment muffler, and is designed to fit the specific bus/engine combination. The use of diesel fuel that has been mixed with crankcase oil is prohibited.

The third constituent of the kit consists of an electrically powered supercharger system which is supplied by Turbodyne Systems, Inc. This component set, referred to as the TurboPac™ supplies additional intake air during engine acceleration from low engine speeds. Turbodyne states that in addition to decreasing PM emissions and visible smoke during engine acceleration, the supercharger also improves engine response and vehicle driveability by reducing the fuel modulation during acceleration. The basic system consists of a supercharger blower, a diverter valve, a boost pressure sensor, an electrical control box and power cables, and a throttle switch for detecting the start of the engine acceleration mode. It will be supplied in two kits. One kit includes those components common to all installations. The second kit accommodates the installation requirements of the various engine and vehicle configurations.

To complete an engine rebuild two (2) base engine component kits, one (1) converter muffler kit, and two(2) supercharger kits are required. The specific kits used will depend on the engine/vehicle combination.

There are no differences in the service intervals or maintenance practices for the base engine associated with the installation of the upgrade kit. The converter/muffler requires no regularly scheduled maintenance, only an occasional cleaning if the maximum back pressure of the exhaust system is exceeded. The supercharger does not require scheduled maintenance: however, a visual inspection for air leaks is recommended whenever the engine is serviced.

Standard procedures as described in the service manual for 92 Series engines are to be used when rebuilding the base engines using the candidate equipment. No unique rebuild procedures are required.

Use of the candidate kit is restricted to 6V92TA Detroit Diesel Corporation engines manufactured from January 1979 through December 1989, equipped with mechanical unit fuel injectors (MUI), and originally certified to meet Federal emission standards. The required fuel is low sulfur (0.05% max by weight) diesel fuel, either number 1 or number 2.

All of the testing presented for this certification was conducted using original equipment ''OE'' parts, except for the converter muffler and the TurboPac components. EPA has no assurance that engines rebuilt using parts that are not ''OE'' would comply with the 0.10 g/bhp-hr standard. Therefore, use of engine parts that are not the specified OE parts are not covered by the certification described in today's **Federal Register** document.

Pursuant to 40 CFR 85.1409, Turbodyne will provide a 100,000-mile defect warranty and a 150,000-mile emissions performance warranty for the kit, and all of its components.

EPA's certification of the Engelhard Corporation's ETX™ kit (62 FR 12166; March 14, 1997) triggered the 0.10 g/bhp-hr standard for 1979–1989 6V92TA MUI engines. That kit provided the three power ratings: 253, 277, and 294 hp that are included in this certification. Consequently, the certification of the kit described in today's **Federal Register** document, does not trigger the 0.10 g/bhp-hr standard for engines included in the certification.

II. Background and Basis for Certification

In a notification of intent to certify equipment, composed of an initial document signed November 14, 1997 and subsequent documents, Turbodyne applied for certification of the kit under the Environmental Protection Agency's (EPA) Urban Bus Retrofit/Rebuild Program. Engines applicable to the certified kit are 6V92TA urban bus engine models made by Detroit Diesel Corporation (DDC) from model years 1979 to 1989 that are equipped with mechanical unit injectors (MUI) and certified to, or rebuilt to, comply with federal emissions standards. The certifier's principal place of business is: Turbodyne Systems, Inc., 6155 Carpinteria Avenue, Carpinteria, CA 93013.

Using engine dynamometer (transient) testing in accordance with the Federal Test Procedure for heavy-duty diesel engines, Turbodyne demonstrated compliance with the 0.10 g/bhp-hr particulate matter (PM) emissions standard. This is the same test data that was presented for the DDC certification dated May 14, 1998 as referenced earlier. Engine dynamometer data, shown below in Table A, is the basis for the certification approval of the kit when used on applicable engines. The emissions test data is part of Turbodyne's notification of intent to certify, which is available in the public docket located at the above-mentioned address. All testing was conducted using #2 low-sulfur diesel fuel.

TABLE A.—EXHAUST EMISSIONS SUMMARY

Gaseous and Particulate Test:	g/bhp-hr	
	1989 HDDE Standards	6V92TA MUI with Turbodyne kit
HC	1.3	0.1
CO	15.5	0.4
NOx	10.7	9.8
PM	0.60	0.091
BSFC [1]	.....	0.464
Smoke Test:	Standards	
ACCEL	20%	3.3%
LUG	15	2.5
PEAK	50	4.2

[1] Brake Specific Fuel Consumption (BSFC) is measured in units of lb/bhp-hr.

The exhaust emissions data presented by Turbodyne is from testing a Detroit Diesel Corporation (DDC) engine model 6V92TA, in accordance with procedures set forth at 40 CFR part 86, subparts N and I. The engine model was tested after being equipped with the Turbodyne kit. The 6V92 engine was tested in one horsepower (hp) rating: 277hp.

The data of Table A demonstrates that for the test engine, when rebuilt with the kit, PM emissions are less than 0.10 g/bhp-hr, and emissions of hydrocarbon (HC), carbon monoxide (CO), NOx and smoke opacity are within applicable federal standards.

This action applies a PM emissions level of 0.10 g/bhp-hr to all 1979 through 1989 DDC 6V92TA MUI urban bus engines, when properly equipped with the Turbodyne kit and when using either diesel fuel #1 or #2. Table B lists the applicable engine models and certification levels associated with the certification announced in today's **Federal Register**.

TABLE B.—CERTIFICATION LEVEL OF TURBODYNE KIT

Engine models	Engine codes	Certification PM level
1979–1989, DDC 6V92TA MUI	All certified to meet federal emissions standards.	0.10 g/bhp-hr.

All engines for which the Turbodyne kit is intended to apply are expected to meet the 0.10 g/bhp-hr PM standard because the kit instructs the rebuilder to replace all emissions-related parts during the rebuild with Turbodyne specified parts included in the kit, install the converter muffler and install the TurboPac system. The engine-out emissions level (upstream of the catalyst) is expected to be predictable because all emission-related parts are replaced using the Turbodyne specified emissions-related parts and settings of the kit. As demonstrated by the test engine, the combination of the specified parts, the specified settings of the kit, the converter muffler and the TurboPac system, result in a PM level less than 0.10 g/bhp-hr.

A life cycle cost analysis is necessary only for certification of equipment that is meant to trigger a program emissions standard. Certification of Engelhard Corporation's ETX™ kit triggered the 0.10 g/bhp-hr standard for 6V92TA MUI engines, and made available kits rated at 253, 277, and 294 hp. The Turbodyne certification does not include a cost analysis and one is not necessary for this certification. Turbodyne states that engines equipped with the kit will have no additional maintenance or service requirements.

III. Summary and Analysis of Comments and Concerns

No comments were received in response to the **Federal Register** document of April 19, 1999 (64 FR 19151). However, comments were received from five commenters on the identical equipment which was certified by DDC earlier. Comments or issues on the earlier DDC certification fell into the following general categories: (A) applicability of the kit; (B) description of the kit; (C) testing demonstration and documentation; (D) life cycle cost analysis; (E) warranty; (F) durability, and (G) in-use experience. All correspondence, comments, and other documentation are located in the public docket at the address above. Interested parties may wish to review these comments which are located in the Public Air Docket A–93–42 (Category XX–A) at the address listed earlier in this document as they would also be relevant to the Turbodyne certification discussed herein due to the fact that the equipment being certified is identical. The comments were summarized in the **Federal Register** Document that was published on May 14, 1998 announcing DDC's certification of identical equipment.

IV. Certification

The Agency has reviewed the notification of intent to certify and other information provided by Turbodyne, and finds that the Turbodyne kit described herein:

(1) complies with the particulate matter exhaust emissions standard of 0.10 g/bhp-hr, without causing the applicable engine families to exceed other exhaust emissions standards;

(2) will not cause an unreasonable risk to the public health, welfare, or safety;

(3) will not result in any additional range of parameter adjustability; and, (4) meets other requirements necessary for certification under the Retrofit/Rebuild Requirements for 1993 and Earlier Model Year Urban Buses (40 CFR 85.1401 through 85.1415).

Therefore, today's **Federal Register** document announces certification of the above-described Turbodyne kit for use in the urban bus retrofit/rebuild program as discussed below in section V.

V. Transit Operator Responsibilities

Today's **Federal Register** document announces certification of the above-described Turbodyne kit, when properly applied, as meeting the 0.10 g/bhp-hr particulate matter standard of the Urban Bus Retrofit/Rebuild Program.

In a **Federal Register** document dated March 14, 1997 (62 FR 12166), EPA announced certification of a retrofit/rebuild kit produced by the Engelhard Corporation (the ETX™ kit). That certification means that urban bus operators using compliance program 1 must use equipment certified to the 0.10 g/bhp-hr standard when rebuilding or replacing applicable 1979 through 1989 model year DDC 6V92TA MUI model engines after September 14, 1997. The certified Turbodyne equipment described in today's document may be used by operators in compliance with the 0.10 g/bhp-hr standard. Operators using compliance program 2 having applicable engines may use the certified Turbodyne kit and claim the certification PM level from Table B above, when calculating their Fleet Level Attained (FLA). Under program 2, an operator must use sufficient certified equipment so that its actual fleet emission level complies with the target level for its fleet.

As mentioned above, certification of the Engelhard ETX™ kit triggered the 0.10 g/bhp-hr standard for applicable 1979—1989 6V92TA MUI engines. That kit provides three power ratings: 253, 277, and 294 horsepower. Turbodyne will offer this kit in these three power ratings as well: 253, 277, and 294hp.

The kit discussed in today's **Federal Register** document is not applicable to urban bus engines certified to meet California emission standards. Additionally, the 0.10 g/bhp-hr PM standard is not triggered for engines certified to meet California emission standards. Operators of such urban buses, who choose to comply with program 1, are not required to use equipment certified to the 0.10 g/bhp-hr PM standard until the standard has been triggered for such engines. Operators of urban buses having engines certified to meet California emission standards, and who choose to comply with program 2, may not use the kit described in today's document to meet program requirements.

As stated in the program regulations (40 CFR 85.1401 through 85.1415), operators must, beginning January 1, 1995, maintain records for each engine in their fleet to demonstrate that they are in compliance with the requirements of the Urban Bus Retrofit/Rebuild Program. These records include purchase records, receipts, and part numbers for the parts and components used in the rebuilding of urban bus engines.

Robert D. Brenner,

Acting Assistant Administrator for Air and Radiation.

[FR Doc. 00–18023 Filed 7–14–00; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

[FRL–6837–1]

Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) or Superfund, Section 311(b)(9)(A), CERCLA Section 311(b)(3) ''Announcement of Competition for EPA's Brownfields Job Training and Development Demonstration Pilots''

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: The Environmental Protection Agency will begin accepting applications for Brownfields Job Training and Development Demonstration Pilots through October 16, 2000. The application period will close October 16, 2000 and the Agency intends to competitively select ten Pilots by December 2000. All funding will be contingent upon availability of appropriated funds.

DATES: This action is effective July 17, 2000. All proposals must be received by October 16, 2000.

ADDRESSES: Interested applicants must submit a response to the Brownfields Job Training and Development Demonstration Pilot Guidelines. Job training guidelines can be obtained via the Internet: http://www.epa.gov/brownfields/, or by calling the Superfund Hotline at 1–800–424–9346 (TDD for the hearing impaired at 1–800–553–7672).

FOR FURTHER INFORMATION CONTACT: EPA's Office of Solid Waste and Emergency Response, Myra Blakely, Outreach and Special Projects Staff, (202) 260–4527 or Doris Thompson at (202) 260–4483.

SUPPLEMENTARY INFORMATION: The Brownfields Job Training and Development Demonstration Pilots will each be funded up to $200,000 over two-years. These funds are to be used to bring together community groups, job training organizations, employers, investors, lenders, developers, and other affected parties to address the issue of providing training for residents in communities impacted by brownfields. The goals of the pilots are to facilitate cleanup of brownfields sites contaminated with hazardous substances and prepare the trainees for future employment in the environmental field. The pilot projects must prepare trainees in activities that can be usefully applied to a cleanup employing an alternative or innovative technology.

EPA expects to select approximately 10 Brownfields Environmental Job Training and Development pilots by the end of December 2000. Pilot applicants must be located within or near one of the 362 pre-2001 brownfields assessment pilot communities. Colleges, universities, non-profit training centers, community-based job training organizations, states, cities, towns, counties, U.S. Territories, and Federally recognized Indian Tribes are eligible to apply for funds. EPA welcomes and encourages applications from coalitions of such entities, but a single eligible entity must be identified as the legal recipient. Entities with experience in providing environmental job training and placement programs are invited to apply. The deadline for applications is October 16, 2000.

EPA's Brownfields Initiative is an organized commitment to help communities revitalize abandoned contaminated properties, and to thereby eliminate potential health risks and restore economic vitality to areas where these properties exist. EPA defines brownfields as abandoned, idled or under-used industrial and commercial facilities where expansion or redevelopment is complicated by real or perceived environmental contamination.

Submission to Congress and the General Accounting Office

The Congressional Review Act, 5 U.S.C. 801 *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing this action and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the **Federal Register**. This action is not a ''major rule'' as defined by 5 U.S.C. 804(2).

Dated: July 10, 2000.

Barbara Bassuener,

Acting Director, Outreach and Special Projects Staff, Office of Solid Waste and Emergency Response.

[FR Doc. 00–18025 Filed 7–14–00; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

[FRL–6837–3]

Focus Group Meeting on Draft Reference Guide for Public Participation in Permitting Programs

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of meeting.

SUMMARY: The Environmental Protection Agency is drafting a Reference Guide (Guide) of the requirements and recommended best practices in public participation for use by states authorized to implement the air, water, and waste permitting programs. The purpose of this focus group meeting is to exchange information on the development and content of the Guide and to seek feedback with the expected outcomes of refining the Guide and the methods for distributing it. Comments and questions from the general public will also be discussed at this meeting. The authority to issue this notice is in the EPA Policy on Public Participation, published on January 19, 1981 at 46 FR 5736.

DATES: The meeting date is Tuesday, August 1, 2000 at the Houston Laboratory. To accommodate the wide range of schedules from all interested parties, two sessions will be held. The first session will be from 2:00 p.m. to 5:00 p.m., and then 7:00 p.m. to 10:00 p.m (CST).

ADDRESSES: Environmental Protection Agency Laboratory, 10625 Fallstone Rd., Houston, Texas 77099, phone, 281–983–2100.

FOR FURTHER INFORMATION CONTACT: David S. Nicholas, U.S. EPA, 1200 Pennsylvania Avenue NW (5103) Washington DC 20460, phone: (202) 260–4512, facsimile: (202) 401–1496 or email: *nicholas.david@epa.gov*

SUPPLEMENTARY INFORMATION: The Guide describes the current public participation requirements within the EPA programs and discusses how all permitting programs can effectively inform and involve the public during the permitting process. This document has undergone significant review by EPA's media program offices as well as the Environmental Council of States (ECOS) and the National Environmental Justice Advisory Council (NEJAC). In addition, a focus group meeting was held in Washington DC on June 26, and was attended by a number of associations with permitting expertise, environmental groups, and industry. The purpose of these focus group meetings is to obtain comments on what

information needs to be in the Guide in order for it to be a valuable resource. While the Guide will be available to the public and to regulated entities, the primary audience for the Guide is the regulating community, specifically the states and tribes that are authorized to implement these programs. To prepare for the upcoming meeting participants should focus their review and comments around these questions:

(1) Are the events, processes, and/or milestones that occur in the permitting process that currently provide meaningful public involvement accurately described in the Guide?

(2) Are there any lessons you have learned in the permitting process that lend themselves to developing a comprehensive effective strategy for community involvement (milestones, steps, key principles/actions)?

(3) Are there any potential regulatory gaps in existing public participation activities?

As a point of clarification, this public participation Guide does not address Title VI issues. It is important to note that while EPA's Office of Civil Rights plans to hold a public listening session to receive comments on the new Title VI Guidance document in Dallas, Texas, these are separate EPA initiatives. Again, the Guide that will be discussed at the August 1 meeting will only address public participation activities within the context of EPA's existing permitting regulations.

Individuals requiring special accommodation at this meeting, including wheelchair access to the conference room, should contact EPA at least five business days prior to the meeting so that appropriate arrangements can be made.

Dated: July 7, 2000.

Timothy Fields, Jr.,

Assistant Administrator, Office of Solid Waste and Emergency Response.

[FR Doc. 00–18027 Filed 7–14–00; 8:45 am]

BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

[FRL—6837–7]

Science Advisory Board; Notification of Public Advisory Committee Meetings

Pursuant to the Federal Advisory Committee Act, Public Law 92–463, notice is hereby given of two meetings of Committees of the US EPA Science Advisory Board on the dates and times noted below. All times noted are Eastern Daylight Time. All meetings are open to the public, however, seating is limited and available on a first come basis. *Important Notice:* Documents that are the subject of SAB reviews are normally available from the originating EPA office and are not available from the SAB Office—information concerning availability of documents from the relevant Program Office is included below.

1. Radiation Advisory Committee (RAC) Teleconference—August 1, 2000

The Science Advisory Board's (SAB) Radiation Advisory Committee (RAC) will conduct a public teleconference meeting on Tuesday, August 1, 2000, between the hours of 11:00 a.m.–2:00 p.m (Eastern Daylight Time). The meeting will be coordinated through a conference call connection in Room 6013 in the Ariel Rios Building North, 1200 Pennsylvania Avenue, NW, Washington, DC 20004 (adjacent to the escalator to the Federal Triangle Metro Station on 12th Street NW). The public is welcome to attend the meeting in person or through a telephonic link, to the extent that lines are available (phone lines will be very limited). Additional instructions about how to participate in the conference call can be obtained by calling Ms. Diana Pozun at (202) 564–4544, or via e-mail at: *pozun.diana@epa.gov* by Thursday, July 27, 2000.

Purpose of the Meeting—At this meeting the RAC plans to review and recap the EPA's response to the Committee's Low Activity Mixed Waste Advisory (EPA–SAB–RAC–ADV–99–006), receive a brief overview presentation on a Multi-Agency Radiation Laboratory Analytical Protocols (MARLAP) Manual by the Office of Radiation and Indoor Air (SAB Project 00–22), and tentatively have a discussion on RAC FY2001 self-initiated projects and other Agency proposed FY2001 projects.

Availability of Review Materials: Single copies of the EPA response to the RAC's Low Activity Mixed Waste Advisory (EPA–SAB–RAC–ADV–99–006) USEPA are available from Ms. Diana Pozun, Radiation Advisory Committee, Science Advisory Board (1400A), U.S. EPA, 1200 Pennsylvania Avenue, NW, Washington, DC 20460. Ms. Pozun can also be reached by telephone at (202) 564–4544, fax at (202) 501–0582, or e-mail: *pozun.diana@epa.gov.* The Committee's report (EPA–SAB–RAC–ADV–99–006) is available on the SAB Website (*www.epa.gov/sab*) under the *Reports* heading. An electronic copy of the overview of MARLAP is available at the website address: *http://www.epa.gov/radiation/marlap/* by clicking on the underlined hotlink titled *''Introduction to MARLAP''.*

For Further Information: Members of the public desiring additional information about the meeting should contact Ms. Melanie Medina-Metzger, Designated Federal Officer, Radiation Advisory Committee, Science Advisory Board (1400A), Suite 6450, U.S. EPA, 1200 Pennsylvania Avenue, NW, Washington, DC 20460; telephone/voice mail at (202) 564–5987; fax at (202) 501–0582; or via e-mail at *medina-metzger.melanie@epa.gov.* A copy of the draft agenda is available from Ms. Diana Pozun at (202) 564–4544 or by FAX at (202) 501–0582 or via e-mail at *pozun.diana@epa.gov.* Members of the public who wish to make a brief oral presentation to the Committee (in Room 6013 only) must contact Ms. Medina-Metzger in writing (by letter or by fax—see previously stated information) no later than 12 noon Eastern Standard Time, Friday, July 28, 2000 in order to be included on the Agenda. Public comments will be limited to five minutes per speaker or organization; 15 minutes total. The request should identify the name of the individual making the presentation, and the organization (if any) that they will represent. *Please note:* If we receive more requests than we can accommodate, time of receipt of the materials at the office will determine priority, with the first three requests granted time (additional requests may be granted to the extent that time is available, as determined by the RAC Chair at the time of the meeting). All others will have to provide written comments. Written comments of any length may be submitted to Ms. Medina-Metzger at any time until the date of the meeting.

2. Drinking Water Committee (DWC) Meeting—August 8–9, 2000

The Drinking Water Committee of the US EPA Science Advisory Board (SAB), will meet on August 8 and 9, 2000 in Room 120/126 of the Andrew W. Breidenbach Environmental Research Center, 26 West Martin Luther King Drive, Cincinnati, OH 45268; telephone (513) 569–7772. The meeting will begin at 9:00 a.m. on August 8 and adjourn no later than 3:00 p.m. on August 9, 2000.

Purpose of the Meeting—The Drinking Water Committee will conduct a review of EPA's draft research plan in support of the Safe Drinking Water Act's Candidate Contaminant Listing (CCL) program. The Committee will also complete its deliberations on the EPA proposed arsenic drinking water

regulation and discuss possible interactions it might have with the Agency on the pending Microbial/Disinfection Byproduct Stage 2 rule-making proposal.

Background—(a) Research Plan for Candidate Contaminant Listing (CCL)—The Safe Drinking Water Act (SDWA), as amended in 1996, requires the EPA to establish a list of unregulated microbiological and chemical contaminants to aid in priority setting for the Agency's drinking water program. A new list must be published every five years. The first Contaminant Candidate List (CCL1) was first proposed by EPA in 1997 and was then finalized in 1998, following extensive consultation with stakeholders.

The Agency must select five or more contaminants from the CCL1 and determine, by August 2001, whether they should be regulated. To support these decisions, the Agency will have to evaluate when and where these contaminants occur, the extent of exposure and risk to public health, and determine if cost effective control methods are available.

EPA has sorted CCL1 contaminants into categories depending upon whether they need additional research (Research or Occurrence Priorities categories) or have sufficient data for the evaluation of exposure and risk to public health, and therefore enough data to support a drinking water standard (Regulatory Determination Priorities category). The contaminants considered for selection and regulatory determination by August 2001 will be drawn from the Regulatory Determination category and are not duplicated under the Research or Occurrence Priorities categories.

A Research Plan has been prepared to describe the nature, timing and priority of research needed in order to meet the CCL research information needs of the Agency. The plan focuses on contaminants that are on CCL1. Nevertheless, it is important for some research to be conducted on emerging pathogens and chemicals to ensure that any future CCL includes contaminants that are of potential public health concern. The SAB has been asked to review this plan.

(b) Proposed Arsenic Drinking Water Standard—The DWC met from June 5–7, 2000 to discuss various elements of the proposed EPA proposal for an arsenic drinking water standard (for further information, see 65 FR 30589–30590). The charge questions were discussed by panelists and a number of conclusions reached on responses. The report to EPA is now being drafted to convey the SAB's advice on the arsenic proposal. The discussion at the August 8–9, 2000 DWC meeting will focus on, and reach closure on, any remaining issues that are identified as the Committee reviews and comments on its draft report to the Administrator.

Charge to the Committee—(a) CCL—EPA asks whether: (i) It considered the appropriate existing information about CCL contaminants in formulating the Plan; (ii) it identified the key science questions; (iii) they identified appropriate research by subject and scope to address the identified science questions; (iv) the relative priorities and timetable proposed for the planned research are appropriate; and (v) the process used to identify data gaps and prioritize research needs is sound.

(b) Arsenic—Questions asked of the DWC for the June arsenic review included: (i) Concentration on inorganic arsenic as principal form causing health effects—Does the SAB have perspectives on this issue that it believes EPA should consider in developing its risk assessment?

(ii) Implications of natural arsenic exposure through food—Does SAB agree with the implied NRC perspective that relative source contribution of food should be taken into consideration in the setting of the drinking water standard and how might we consider this and communicate it to the public?

(iii) Accounting for Cardiovascular Health End Point—Is precautionary advice on use of low-arsenic water in preparation of infant formula appropriate given the available information?

(iv) Decision tree for waste disposal options for arsenic treatment brines and spent media—Based upon a review of the submitted materials, does the SAB believe that the EPA produced an accurate projection of the likely disposal options for arsenic residuals and the distribution of these options by treatment type? What are the SAB's views on the advantages and the limitations of the various waste disposal options? What effect, if any, would the SAB's analysis of these advantages and limitations have on the probabilities assigned? What are the SAB's views on which options will be more likely used by small systems (less than 10,000 people), and which will be more likely used by larger ones?

(v) Decision tree for ground water treatment technologies—Does the SAB agree with the principal ''branches'' of EPA's decision tree described in the submitted documents and the likelihood that these options will be used for systems of various sizes with various source water characteristics? What views does the SAB have on EPA's description of the advantages and limitations of these treatment technologies? Would the SAB's views on these advantages and limitations affect the probabilities assigned?

Availability of Review Materials—Additional information on the materials provided to the Committee for its arsenic review can be obtained by contacting Ms. Irene Dooley, US EPA Office of Water by telephone at (202) 260–9531 or by e-mail at *dooley.irene@epa.gov.* Additional information on the materials provided to the Committee for its CCL Research Plan review can be obtained by contacting Dr. Robert Clark, US EPA, National Risk Management Research Laboratory, Cincinnati, OH by telephone at (513) 569–7201 or by e-mail at *clark.robertm@epa.gov.*

For Further Information—Any member of the public wishing further information concerning this meeting or wishing to submit brief oral comments (10 minutes or less) must contact Thomas O. Miller, Designated Federal Officer, Science Advisory Board (1400A), U.S. Environmental Protection Agency, 1200 Pennsylvania Avenue, NW, Washington, DC 20460; telephone (202) 564–4558; FAX (202) 501–0582; or via e-mail at *miller.tom@epa.gov.* Requests for oral comments must be *in writing* (e-mail, fax or mail) and received by Mr. Miller no later than noon Eastern Time on August 2, 2000.

Providing Oral or Written Comments at SAB Meetings

It is the policy of the Science Advisory Board to accept written public comments of any length, and to accommodate oral public comments whenever possible. The Science Advisory Board expects that public statements presented at its meetings will not be repetitive of previously submitted oral or written statements. *Oral Comments:* In general, each individual or group requesting an oral presentation at a face-to-face meeting will be limited to a total time of ten minutes. For teleconference meetings, opportunities for oral comment will usually be limited to no more than three minutes per speaker and no more than fifteen minutes total. Deadlines for getting on the public speaker list for a meeting are given above. Speakers should bring at least 35 copies of their comments and presentation slides for distribution to the reviewers and public at the meeting. *Written Comments:* Although the SAB accepts written comments until the date of the meeting (unless otherwise stated), written comments should be received in the SAB Staff Office at least one week prior to the meeting date so that the

comments may be made available to the committee for their consideration. Comments should be supplied to the appropriate DFO at the address/contact information noted above in the following formats: One hard copy with original signature, and one electronic copy via e-mail (acceptable file format: WordPerfect, Word, or Rich Text files (in IBM–PC/Windows 95/98 format). Those providing written comments and who attend the meeting are also asked to bring 25 copies of their comments for public distribution.

General Information—Additional information concerning the Science Advisory Board, its structure, function, and composition, may be found on the SAB Website (*http://www.epa.gov/sab*) and in The FY1999 Annual Report of the Staff Director which is available from the SAB Publications Staff at (202) 564–4533 or via fax at (202) 501–0256. Committee rosters, draft Agendas and meeting calendars are also located on our website.

Meeting Access—Individuals requiring special accommodation at this meeting, including wheelchair access to the conference room, should contact the appropriate DFO at least five business days prior to the meeting so that appropriate arrangements can be made.

Dated: July 10, 2000.

John R. Fowle, III,

Acting Staff Director, Science Advisory Board.

[FR Doc. 00–18028 Filed 7–14–00; 8:45 am]

BILLING CODE 6560–50–P

EQUAL EMPLOYMENT OPPORTUNITY COMMISSION

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Equal Employment Opportunity Commission.

DATE AND TIME: Thursday, July 27, 2000 at 2 p.m. (Eastern Time).

PLACE: Conference Room on the Ninth Floor of the EEOC Office Building, 1801 ''L'' Street, NW, Washington, DC 20507.

STATUS: The meeting will be open to the public.

MATTERS TO BE CONSIDERED: Open Session

The 10th Anniversary of the Americans with Disabilities Act: EEOC's Past Accomplishments and Future Trends.

Note: Any matter not discussed or concluded may be carried over to a later meeting. (In addition to publishing notices on EEOC Commission meetings in the **Federal Register**, the Commission also provides a recorded announcement a full week in advance on future Commission sessions.) Please telephone (202) 663–7100 (voice) and (202) 663–4074 (TTD) at any time for information on these meetings.

CONTACT PERSON FOR MORE INFORMATION: Frances M. Hart, Executive Officer on (202) 663–4070.

This Notice Issued: July 13, 2000.

Frances M. Hart,

Executive Officer, Executive Secretariat.

[FR Doc. 00–18084 Filed 7–13–00; 11:19 am]

BILLING CODE 6750–06–M

FEDERAL COMMUNICATIONS COMMISSION

FEDERAL TRADE COMMISSION

[FTC File No. P974405]

Joint FCC/FTC Policy Statement for the Advertising of Dial-Around and Other Long-Distance Services to Consumers

AGENCIES: Federal Communications Commission and Federal Trade Commission.

ACTION: Notice of issuance of joint policy statement.

SUMMARY: This document was issued by the Federal Communications Commission and the Federal Trade Commission to jointly address questions raised by the proliferation of advertisements for dial-around numbers, long-distance calling plans, and other new telecommunications services, as well as to address an increase in the number of complaints regarding how these services are promoted and how the principles of truthful advertising apply in this dynamic marketplace. Commissioner Furchtgott-Roth of the FCC dissented and issued a separate statement available from the FCC.

DATES: Adopted by the FCC on February 29, 2000. Adopted by the FTC on February 23, 2000. Jointly released on March 1, 2000.

FOR FURTHER INFORMATION CONTACT: Emmitt Carlton, Assistant Chief, Telecommunications Consumers Division, Enforcement Bureau, Federal Communications Commission, (202) 418–7320, or Lesley Fair, Attorney, Division of Advertising Practices, Bureau of Consumer Protection, Federal Trade Commission, (202) 326–3081. This document is available from the FTC's web site at *http://www.ftc.gov/bcp/menu-call.htm* or you may call the FTC's Consumer Response Center at (877) FTC–HELP. This document is available from the FCC's website at *http://www.fcc.gov/Bureaus/Enforcement/Orders/2000/fcc00072.doc* or you may visit the Reference Information Center at the FCC's headquarters located at 445 12th Street, SW., Room CY–A257, Washington, DC 20554. The FCC reference center is open to the public Monday from 9:45 a.m. until 4:30 p.m. and Tuesday through Friday from 9:00 a.m. until 4:30 p.m. You may also reach the reference center at (202) 418–0270. As an alternative, information that is routinely available to the public can be obtained from International Transcription Services (ITS), a private government contractor. ITS has an office at the FCC's Washington, DC location and can be reached directly at (202) 857–3800.

SUPPLEMENTARY INFORMATION:

Policy Statement

I. Introduction

1. In recent years there has been an explosion in competition and innovation in the telecommunications industry. Long-distance customers have reaped substantial benefits in the form of greater choice in deciding which carrier to use and a greater diversity in the prices charged for those calls. For example, dial-around (or ''10–10'') numbers allow consumers to bypass or ''dial-around'' their chosen long-distance carrier to get a better rate in certain circumstances. Consumers also can opt for calling plans that offer a fixed per-minute rate during certain hours or on particular days.

2. Numerous carriers, both large and small, promote their services through national television, print, and direct mail advertising campaigns. Because no one plan is right for everyone, advertising plays a critical role in informing consumers about the myriad choices in long-distance calling and, in the case of dial-around services, advertising is generally the only source of information consumers typically have before incurring charges. With accurate information, consumers benefit from being able to choose the particular carrier that meets their long-distance calling needs at the most economical price. However, if consumers are deceived by the advertising claims, they cannot make informed purchasing decisions and ultimately the growth of competition in the long-distance market will be stifled.

3. The proliferation of advertisements for dial-around numbers, long-distance calling plans, and other new telecommunications services, as well as an increase in the number of complaints regarding how these services are promoted, have raised questions about how the principles of truthful advertising apply in this dynamic marketplace. To address these questions

the Federal Trade Commission and the Federal Communications Commission issue this Joint Policy Statement.

4. Section 201(b) of the Communications Act of 1934, as amended, requires that common carriers' ''practices * * * for and in connection with * * * communications service, shall be just and reasonable, and any such * * * practice * * * that is unjust or unreasonable is hereby declared to be unlawful * * *.''[1] The FCC has found that unfair and deceptive marketing practices by common carriers constitute unjust and unreasonable practices under section 201(b).[2] Principles of truth-in-advertising law developed by the FTC under section 5 of the FTC Act[3] provide helpful guidance to carriers regarding how to comply with section 201(b) of the Communications Act in this context.

5. The FTC's truth-in-advertising law can be boiled down to two common-sense propositions: (1) Advertising must be truthful and not misleading; and (2) before disseminating an ad, advertisers must have adequate substantiation for all objective product claims.[4] A deceptive ad is one that contains a misrepresentation or omission that is likely to mislead consumers acting reasonably under the circumstances about a material fact.[5] Material facts are those that are important to a consumer's decision to buy or use a product. Information pertaining to the central characteristics of the product or service is presumed material. The cost of a product or service is an example of an attribute presumed material.[6]

6. Advertisers are responsible for substantiating all objective express and implied claims that an ad conveys to reasonable consumers, regardless of whether the advertiser intended to convey those claims. In determining the claims that an ad conveys, the FTC looks to the ''net impression'' conveyed to consumers—often described as ''the entire mosaic, rather than each tile separately.''[7] Even if the wording of an ad may be literally truthful, the net impression conveyed to consumers may still be misleading. The entire advertisement, transaction or course of dealing will be considered. The issue is whether the act or practice is likely to mislead, rather than whether it causes actual deception.

7. An ad may be deceptive by omission. For example, an ad may be deceptive if it fails to disclose qualifying information that, in light of the representations made, would be necessary to prevent consumers from being misled. The failure to disclose is examined in light of expectations and understandings of the typical buyer regarding the claims made.[8]

8. In many circumstances, reasonable consumers do not read the entirety of an ad or are directed away from the importance of the qualifying phrase by the acts or statements of the seller. Depending on the circumstances, accurate information in the text may not remedy a misleading impression created by a headline because reasonable consumers may glance only at the headline. Written disclosures in fine print may be insufficient to correct a misleading impression. Legalistic disclaimers too complex for consumers to understand may not cure otherwise deceptive messages or practices. Qualifying disclosures must be legible and understandable. The totality of the ad or the practice must be evaluated with questions such as: How clear is the representation? How conspicuous is any qualifying information? How important is the omitted information? Do other sources for the omitted information exist? How familiar is the public with the product or service?

9. At the outset, it is important to note that these fundamental principles apply across the board. For example, a misrepresentation or omission of material information in an advertisement for a dial-around service would likely be deceptive if the same misrepresentation or omission occurred in an ad for a long-distance calling plan. Furthermore, the same standards of truthfulness apply regardless of the medium advertisers choose to communicate their message to consumers. Although the most effective method for disclosing information to consumers may vary depending on the medium, the principles of truth and accuracy apply to advertisements conveyed via television, radio, magazines, newspapers, direct mail, telemarketing, the Internet, or oral representations made by customer service operators.[9]

10. In issuing this Policy Statement, the FCC and the FTC hope to provide guidance for carriers who market long-distance service. As a matter of clarification, we note that this Policy Statement does not preempt existing state law.

II. Discussion

A. Misrepresentations in Advertisements for Long-Distance Calling Services

11. As a general matter, advertisers are free to highlight whatever attribute of their products or services they choose—quality, convenience, customer service, availability, price, or other benefit. However, once an advertisement makes an implied or express objective claim that conveys a material representation to reasonable consumers, the advertiser is responsible for the truthfulness of the representation and for substantiating the representation, regardless of whether the advertiser intended to convey those messages to consumers. If a claim is false, a disclosure that provides contradictory information is unlikely to cure the deception.

Example #1: The headline of a direct mail ad for a dial-around service reads, ''All day. All night. All calls. 10¢ a minute.'' In fact,

[1] 47 U.S.C. 201(b).

[2] Business Discount Plan, Inc., 14 FCC Rcd 340, 355–358 (1998); AT&T Corp., 71 RR2d 775 (1992).

[3] 15 U.S.C. 45. Section 5 declares unlawful ''unfair or deceptive acts or practices in or affecting commerce.

[4] These principles are articulated in the FTC's Deception Policy Statement and Advertising Substantiation Policy Statement. See generally Federal Trade Commission Policy Statement on Deception, appended to Cliffdale Associates, Inc., 103 F.T.C. 110, 174 *et seq.* (1984) (''Deception Statement''); Advertising Substantiation Policy Statement, appended to Thompson Medical Co., 104 F.T.C. 648, 839 (1984), aff'd, 791 F.2d 189 (D.C. Cir. 1986), cert. denied, 479 U.S.1086 (1987). The FTC also has authority to challenge unfair trade practices. An unfair practice is one that causes or is likely to cause substantial injury to consumers which is not reasonably avoidable by consumers themselves and not outweighed by countervailing benefits to consumers or competition. 15 U.S.C. 45(n). The majority of FTC advertising cases are brought pursuant to the FTC's deception authority.

[5] The FCC has taken a similar approach under section 201(b) of the Communications Act: ''BDP knew, or should have known, that customers acting reasonably under the circumstances would be misled and confused by misrepresentations regarding the material issue of BDP's identity, and that customers would rely on such misrepresentations to their detriment.'' Business Discount Plan, 14 FCC Rcd at 356.

[6] Deception Statement, 103 F.T.C. at 182.

[7] *Id.* at 179, quoting FTC v. Sterling Drug, Inc., 317 F.2d 669, 674 (2d Cir. 1963).

[8] The law does not require that every item of information that might be useful or interesting to consumers be disclosed in advertising. Only information necessary to prevent consumer deception on a matter of importance to them must be disclosed. See International Harvester Co., 104 F.T.C. 949, 1059–60 (1984).

[9] The FTC's Telemarketing Sales Rule, (''TSR''), 16 CFR part 310, provides specific provisions on what constitute material misrepresentations in the context of telemarketing, and what material information must be disclosed in order to avoid deceiving consumers through telemarketing. The TSR covers all ''telemarketing''—defined as any plan, program, or campaign to sell goods or services through interstate telephone calls. It applies to all telemarketers, regardless of on whose behalf they are calling or what product or service they are selling, even telemarketing companies that call on behalf of organizations whose activities are exempt from FTC jurisdiction. Coverage of the Rule extends both to calls placed to and received from consumers, so long as the calls are part of a plan, program, or campaign to sell goods or services through interstate telephone calls.

the rate is applicable only for state-to-state calls after 7 p.m. and on weekends. Even an otherwise prominent disclosure to that effect will likely not be sufficient considering that the disclosure directly contradicts the express, and false, representations in the headline.

B. Material Information That Should Be Disclosed in Advertisements for Long-Distance Calling Services

12. In situations where an advertisement makes claims that are not directly false but might be misleading in the absence of qualifying or limiting information, advertisers are responsible both for making any necessary disclosures and for ensuring that they are clear and conspicuous. The following are some of the types of disclosures that may be necessary to prevent price claims in long-distance telephone advertising from deceiving customers.

1. Minimum Per-Call Charges, Monthly Fees, and Other Cost-Related Information

13. The central characteristic touted in most long-distance advertising is price. As noted above, price representations are presumptively material to consumers. What matters to consumers is not just the per-minute rate, but rather how that rate, along with all additional fees and charges, will ultimately be reflected in the charges they see on their monthly phone bills.[10] Therefore, advertisers should exercise the greatest care in ensuring the accuracy of their claims related to price, including the clear and conspicuous disclosure [11] of information such as minimum per-call charges, monthly fees, fees for additional minutes beyond the initial calling period, and other information that significantly affects the total charge of a particular call or calling plan or service.

Example #2—Minimum Charges: An advertisement conveys the message that long-distance calls cost 10¢ a minute. In fact, all calls are subject to a 50¢ minimum charge. Given that reasonable consumers would likely conclude from the ''10¢ a minute'' representation that a one-minute call would cost 10¢, and would not expect there to be a substantial additional charge, the advertiser's failure to clearly and conspicuously disclose the minimum fee in the ad would likely be deceptive.

Example #3—Monthly Fees: An advertisement says that long-distance calls cost 10¢ a minute. In fact, that rate is only available if customers pay a $5.95 monthly fee. Because the imposition of the monthly fee would significantly increase the consumer's per-minute charge, the advertiser's failure to clearly and conspicuously disclose the monthly fee in the ad would likely be deceptive.

Example #4—Cost After Initial Promoted Calling Period: A company advertises ''all calls up to 20 minutes for only $1.00,'' but charges 10¢ for each additional minute. Consumers are likely to be misled by the affirmative claim in the absence of a disclosure about the significantly higher rate after 20 minutes. Because many consumers will make calls that last longer than 20 minutes, the cost of each minute beyond the first 20 minutes' duration of a call is information that likely would be material to consumers considering whether to use the service. Thus, the advertiser's failure to clearly and conspicuously disclose in the ad the per-minute rate for calls longer than the initial calling period would likely be deceptive.

2. Time Restrictions or Limitations on the Availability of the Advertised Rate

14. Given the importance of price information, any significant conditions or limitations on the availability of the advertised rates should also be clearly and conspicuously disclosed. Examples of such restrictions would include limitations on the time of day or day of the week that the rate applies or the fact that the rate is good only during a limited promotional or sale period.

Example #5—Time Restrictions: A company's advertisements prominently feature the phrase ''10¢ a minute.'' In fact, the 10¢ a minute rate is good only between 7 p.m. and 7 a.m. Consumers are likely to view this time limitation as a significant restriction on the availability of the advertised 10¢ a minute rate. The advertiser's failure to clearly and conspicuously disclose the limited hours in the ad would likely be deceptive.

Example #6—Promotional Rates: A company's advertisements prominently feature the phrase ''5¢ a minute.'' Peel-off stickers, intended to be placed on the phone, featuring the ''5¢ a minute'' offer accompany the advertisement. In fact, the 5¢ a minute rate is a special promotional offer good only for 60 days. Consumers are likely to view the limited duration of the 5¢ a minute rate as a significant qualification. The advertiser's failure to clearly and conspicuously disclose this limitation in the ad would likely be deceptive. Furthermore, in this instance, the use of peel-off stickers advertising the 5¢ a minute rate without adequate disclosure of the limited duration of the offer would likely be deceptive because the stickers would remain on consumers' telephones long after the promotional rate had expired.

3. Geographic Restrictions

15. Another important qualification that would likely be material to consumers and necessary to disclose to avoid deception is a significant geographic restriction on the applicability of an advertised rate. For example, many long-distance services and plans are limited to state-to-state calls. The disclosure of this information is particularly important because in-state long-distance rates are often substantially more expensive than state-to-state rates, a fact that may be surprising and significant to reasonable consumers. Where reasonable consumers may be deceived about such significant differences in price between in-state and state-to-state calls, the advertiser should clearly and conspicuously disclose whether the advertised service includes in-state calls, and the fact that such calls are charged at a higher rate, if such is the case.

Example #7—Geographic Restrictions: A company advertises a ''10¢ a minute'' rate. In fact, that rate is good only for state-to-state calls, and in-state calls may be charged at a significantly higher rate. The failure to clearly and conspicuously disclose in the ad, for example, that ''in state rates may be higher,'' would likely be deceptive.

4. The Use of the Phrase ''Basic Rates''

16. Advertisers should also exercise care to adequately explain phrases such as ''basic rates'' in their ads. The meaning of an ad is evaluated from the point of view of the ''reasonable consumer''—the typical person looking at the ad. A telecommunications professional may understand the term ''basic rate'' to refer to a specific class of tariffed service, which may be billed at the most expensive rates. However, the typical consumer would likely interpret the phrase differently, concluding that it refers to the discounted rates he or she is normally charged by his or her selected carrier. Therefore, when making claims using such terms as ''basic rates'' or ''regular rates,'' advertisers should be mindful that those terms will be evaluated from the point of view of the reasonable consumer, and may be deceptive.

Example #8—''Basic Rates'': A company offers consumers a directory assistance service for 99¢. According to the television ad, callers who use this service can be connected to the requested number at no additional charge. In fact, consumers who opt to be connected to the requested number are connected via the advertiser's network and are billed at the advertiser's expensive per-minute rates. This information is disclosed only by a superscript reading ''basic rates apply.'' Reasonable consumers would expect to pay the promoted 99¢ charge, but would not likely expect to pay a charge greater than the amount their selected long-distance carrier would charge for a call to the

[10] For example, if a consumer paying 10¢ a minute and a $5.95 monthly fee places 100 minutes of calls per month, his or her total would be $15.95 a month or almost 16¢ per minute. This figure would contrast sharply with the ''10¢ a minute'' rates prominently touted in typical ads for long-distance calling plans.

[11] See Section III for a discussion of the factors to consider in assessing whether a disclosure is ''clear and conspicuous.''

requested number. Because the consumer will be charged a rate higher than the consumer's presubscribed rate, use of the term ''basic rates apply,'' even if clearly and conspicuously disclosed, would not likely be sufficient to avoid deception. The advertiser's failure to disclose that the consumer will be charged a rate higher than the consumer's presubscribed rate would likely be deceptive.

5. Comparative Price Claims

17. A technique commonly employed in long-distance advertising is the comparison of an advertiser's price to the prices of its competitors. By representing a competitor's rates, an advertiser is making an implied claim that these rates are reasonably current. As in the case of any other objective claim, the advertiser must have a reasonable basis for this representation. The time elapsing between the creation of an ad and the distribution of the ad to the public may vary, depending upon the medium in which the ad appears. This is a consideration in determining whether an advertiser possesses a reasonable basis for a claim that compared rates are reasonably current.

Example #9—Comparative Price Claims: In an advertisement in a daily newspaper, an advertiser conveys the message that its rates are the lowest, using a chart that compares its per-minute rate to the rates offered by two competitors. The stated rates of one of the competitors are three months old, and the stated rate of the other is eight months old. By representing the competitors' rates, the advertiser is implying that those rates are reasonably current. If the information upon which the ad is based is outdated and the rates have changed materially, the ad would likely be deceptive.

Example #10—Comparative Price Claims: An advertisement in a monthly magazine states that the advertiser's rates are better than those of another competitor. In January the advertiser verified that the competitor was offering the rate as stated in the ad. When the ad is published in February, it clearly and conspicuously discloses that the competitor's rate is as of January of this year. This disclosure is likely to be sufficient to avoid deception.

6. The Effect of the Use of Toll-Free Numbers and Other Alternate Sources of Information

18. The fact that information about significant limitations or restrictions on advertised prices may be available by calling a toll-free number or a clicking on a Web site is generally insufficient to cure an otherwise deceptive price claim in advertising. Advertisers are encouraged to use customer service numbers and Internet sites to offer consumers more information, but these sources cannot cure misleading information in the ad itself.[12]

19. Dial-around services are unique in that consumers typically incur charges for using them before receiving any information other than what is conveyed in the dial-around service's advertising. This underscores the importance that significant restrictions and limitations on price claims be disclosed in the ad itself; users of those services must rely on the information contained in the ad as the basis for determining whether to choose a particular service. However, even if the use of an advertised service requires a consumer to interact further with the advertiser—for example, if a consumer must call a toll-free customer service number to switch to a different calling plan—it would still be deceptive if the advertisement failed to disclose significant restrictions necessary to qualify representations made in the ad.

Example #11—Use of Toll-Free Numbers: A television advertisement for a long-distance calling plan prominently features the phrase ''10¢ a minute'' as a graphic and in the narration read by the spokesperson. The ad gives a toll-free number and tells consumers ''call now to switch.'' In fact, the 10¢ a minute rate is good only between 7 p.m. and 7 a.m. The inclusion of a superscript that reads ''call for restrictions'' would not likely be effective to qualify the claim.

C. Principles Related to the Clear and Conspicuous Disclosure of Material Information in Advertisements for Long-Distance Calling Services

20. When the disclosure of qualifying information is necessary to prevent an ad from being deceptive, that information should be presented clearly and prominently so that it is actually noticed and understood by consumers. Disclosures should be effectively communicated to consumers. A fine-print disclosure at the bottom of a print ad, a disclaimer buried in a body of text unrelated to the claim being qualified, a brief video superscript in a television ad, or a disclaimer that is easily missed on an Internet Web site is not likely to be effective. To ensure that disclosures are effective, advertisers should use clear and unambiguous language, avoid small type, place any qualifying information close to the claim being qualified, and avoid making inconsistent statements or using distracting elements that could undercut or contradict the disclosure.

21. In some cases, the FTC has specified the precise fashion in which qualifying disclosures must be conveyed.[13] However, more frequently, the FTC has used the term ''clear and conspicuous'' to describe a general performance standard flexible enough to take into account both the consumer's right to accurate information necessary to make an informed purchase decision and the many ways that creative advertisers can effectively convey that information.[14] Because the FTC considers the disclosure in the context of all of the elements of the ad, the focus is not on the wording of the specific disclosure in isolation, but rather on the overall or ''net'' impression that the entire advertisement—including the disclosure—conveys to reasonable consumers.[15]

22. Ordinarily, a disclosure is ''clear and conspicuous,'' and therefore is effectively communicated, when it is displayed in a manner that is readily noticeable, readable and/or audible, and understandable to the audience to whom it is disseminated. Factors that the FTC considers in evaluating the effectiveness of disclosures include:

- The prominence of the qualifying information, especially in comparison to the advertising representation itself;
- The proximity and placement of the qualifying information, vis-a-vis the representation that it modifies;
- The absence of distracting elements, such as text, graphics, or sound that may distract a consumer's attention away from the disclosure; and
- The clarity and understandability of the text of the disclosure.[16]

[12] See generally General Motors Corp., 123 F.T.C. 241 (1997); American Honda Motor Co., 123 F.T.C. 262 (1997); American Isuzu Motor Co., 123 F.T.C. 275 (1997); Mitsubishi Motor Sales of America, Inc., 123 F.T.C. 288 (1997); Mazda Motor of America, Inc., 123 F.T.C. 312 (1997) (consent orders) (complaint alleging that ads touting ''zero down'' are deceptive even though fine print disclosures and/or point of sale or other sources make clear that significant costs apply at lease inception; order defining clear and conspicuous disclosure of terms in ads for car leases as ''readable [or audible] and understandable to a reasonable consumer'').

[13] See, *e.g.,* Regulations Under the Comprehensive Smokeless Tobacco Health Education Act of 1986, 16 CFR 307.

[14] The FTC has also used phrases such as ''clear and prominent'' and ''of sufficient clarity and conspicuousness'' to articulate the same concept. 63 FR 25002, FTC's Notice Seeking Comment on the Interpretation of FTC Rules and Guides for Electronic Media (May 6, 1998).

[15] Deception Statement, 103 F.T.C. at 175–76. See also American Home Products, 98 F.T.C. 136, 374 (1981), aff'd, 695 F.2d 681 (3d Cir. 1982).

[16] See generally General Motors Corp., 123 F.T.C. 241 (1997); American Honda Motor Co., 123 F.T.C. 262 (1997); American Isuzu Motor Co., 123 F.T.C. 275 (1997); Mitsubishi Motor Sales of America, Inc., 123 F.T.C. 288 (1997); Mazda Motor of America, Inc., 123 F.T.C. 312 (1997) (consent orders) (complaint alleging that ads touting ''zero down'' are deceptive even though fine print disclosures and/or point of sale or other sources make clear that significant costs apply at lease inception; order defining clear and conspicuous disclosure of terms in ads for car leases as ''readable [or audible] and

23. Reference to an existing regulatory scheme provides considerable guidance. In 1992 Congress passed the Telephone Disclosure and Dispute Resolution Act (''TDDRA''), directing the FCC and the FTC to issue regulations governing, among other things, the advertising and marketing of pay-per-call services. TDDRA was enacted in response to a history of fraudulent or abusive practices. In adopting its Pay-Per-Call Rule (previously called the 900-Number Rule),[17] the FTC provided very specific provisions on how to make effective disclosures of material cost information in the context of advertising telephone-based entertainment or information programs that are billed to consumers' telephone bills. The basic principles embodied in the advertising provisions of the Rule show how the FTC determines whether a particular disclosure of cost information is clear and conspicuous in the context of advertising for pay-per-call services. According to the Rule's provisions governing the advertising of those services, the provider must ''clearly and conspicuously'' disclose in the advertisement the total cost of the call. If there is a flat fee for the call, the ad must state the total cost. If the call is billed on a time-sensitive basis, the ad must state ''the cost per minute and any minimum charges.'' If the call is billed on a variable rate basis, the ad must state the cost of the initial portion of the call, any minimum charges, and the range of rates that may be charged for the service including any other fees that will be charged for the service. Regardless of how the service is billed, the Rule requires that ''the advertisement shall disclose any other fees that will be charged for the service.''

24. To ensure that consumers understand the central factor in the transaction—the cost of the call—the Rule specifies that all necessary disclosures must be made clearly and conspicuously. Initially, the Rule specifies that these disclosures must be made in the same language as the advertisement; for print disclosures, ''in a color or shade that readily contrasts with the background of the ad''; and for oral disclosures, ''in a slow and deliberate manner and in a reasonably understandable volume.'' However, the Rule outlines with more specificity the required type size of these disclosures, their proximity to the triggering information, and the necessity of both oral and visual disclosures for television ads.

25. In print advertisements, the FTC Rule requires:

(1) That the cost of the call shall be placed adjacent to each presentation of the pay-per-call number; and

(2) That each letter or numeral of any necessary price disclosures shall be, ''at a minimum, one-half the size of each letter or numeral of the pay-per-call number to which the disclosure is adjacent.''

26. For television advertisements, the FTC Rule requires:

(1) That a visual disclosure shall appear adjacent to each visual presentation of the pay-per-call number;

(2) That each letter or numeral of any necessary price disclosures shall be, ''at a minimum, one-half the size of each letter or numeral of the pay-per-call number to which the disclosure is adjacent'';

(3) That a visual disclosure shall appear on the screen for the duration of the presentation of the pay-per-call number; and

(4) That an oral disclosure shall be made at least once, simultaneously with a visual presentation of the disclosure.

27. The measures that the FTC thought were necessary to ensure that cost disclosures were clear and conspicuous in the context of pay-per-call services—the prominent disclosure of important cost information adjacent to the central feature of the ad—are certainly relevant to price advertising by dial-around services and long-distance calling plans. While not every single aspect of the Rule may be appropriate or required to ensure truthful, nondeceptive advertising by the long-distance telephone industry, the Rule nonetheless offers guidance and a set of ''best practices'' to advertisers of dial-around and other long-distance telephone services.

1. Prominence

28. Disclosures that are large in size, are emphasized through a sharply contrasting color, and, in the case of television advertisements, remain visible and/or audible for a sufficiently long duration are likely to be more effective than those lacking such prominence. The FTC's experience consistently demonstrates that fine-print footnotes and brief video superscripts are often overlooked. For example, in concluding that a television superscript was insufficiently clear and conspicuous to qualify a nutritional claim in a food ad, the FTC stated, ''[g]enerally recognized marketing principles suggest that, given the distracting visual and audio elements and the brief appearance of the complex superscript in the middle of the commercial, it is unlikely that the visual disclosure is effective as a corrective measure.''[18]

29. The FTC's analysis focuses not just on whether the type size of the disclosure is large enough to be *readable* when read in isolation, but rather whether the disclosure itself is prominent enough so that typical consumers will actually read and understand it in the context of an actual ad. Although the FTC has not, as a general rule, required disclosures to be identical in size and repeated the same number of times as the triggering representation, substantial disparities between the two reduce the likelihood that a disclosure will be clear and conspicuous.

Example #12: In a full-page newspaper ad for a long-distance calling plan, the phrase ''10¢ a minute'' appears in 70-point type at the top of the page. In fact, the advertised 10¢ a minute rate applies only with a $3.95 monthly fee. The fee is disclosed in the body of the ad in 12-point type. Given the disparity in type size between the ''10¢ a minute'' claim and the $3.95 monthly fee, it is unlikely that the disclosure of the monthly fee is sufficiently clear and conspicuous to avoid deception.

Example #13: In a 30-second television ad for a dial-around service, the phrase ''10¢ a minute'' is used four times by the narrator and appears as a graphic twice. A superscript appearing on the bottom of the screen for three seconds reads ''Rate available from 7 p.m. until 7 a.m., Monday through Friday and all day weekends.'' In fact, calls before 7 p.m. cost 25¢ per minute. Given the prominence of the ''10¢ a minute'' claim and the complexity and small print of the superscript, it is unlikely that the disclosure of the time restrictions is sufficiently clear and conspicuous to avoid deception

Example #14: In a full-page newspaper ad for a long-distance calling plan, the phrase ''10¢ a minute'' appears in 70-point type at the top of the page. Immediately under it, the phrase ''plus $3.95 monthly fee'' appears in 35-point type. Given the proportional similarity in type size between the ''10¢ a minute'' claim and the $3.95 monthly fee and their proximity, the disclosure of the monthly fee is likely to be sufficient to avoid deception.

2. Proximity and Placement

30. In addition to their size and duration, the proximity and placement of disclosures are important factors in determining whether they are clear and

understandable to a reasonable consumer''). See also *United States v. Mazda Motor of America, Inc.,* (C.D. Cal. Sept. 30, 1999) (consent decree) ($5.25 million total civil penalty for violations of FTC and state orders related to disclosures in car leasing advertising).

[17] 16 CFR part 308.

[18] *Kraft, Inc.* 114 F.T.C. 40, 124 (1991), *aff'd,* 970 F.2d 311 (7th Cir. 1992), *cert. denied,* 479 U.S. 1086 (1987). See Thompson Medical Co., 104 F.T.C. 648, 797–98 & n. 22 (1984), *aff'd,* 791 F.2d 189 (D.C. Cir. 1986), *cert. denied,* 479 U.S. 1086 (1987); Deception Statement, 103 F.T.C. at 180.

conspicuous. The effectiveness of disclosures is ordinarily enhanced by their proximity to the representation they qualify, because reasonable consumers do not necessarily read an ad in its entirety.[19] The placement of qualifying information away from the triggering representation—for example, in footnotes, in margins, or on a separate page of a multi-page promotion—reduces the effectiveness of the disclosure.[20] Furthermore, when significant qualifying information about the cost of a long-distance plan or service is necessary to prevent the ad from misleading consumers, the use of an asterisk will generally be considered insufficient to draw a consumer's attention to a disclosure placed elsewhere in an ad.[21]

Example #15: A full-page newspaper advertisement for a company's long-distance calling plan features in 70-point type the statement, ''7¢ a minute all the time'' followed by an asterisk. A 12-point disclosure at the bottom of the page states, ''*$5.95 monthly fee applies.'' Given the disparity in prominence and location between the two lines of text, it is unlikely that the disclosure of the monthly fee is sufficiently clear and conspicuous.

Example #16: A dial-around company promotes its services via a three-page direct mail letter sent to consumers. The envelope includes a depiction of a nickel surrounded by the phrase ''long-distance calls for just 5¢ a minute,'' a depiction repeated on the first page of the letter. In fact, the 5¢ a minute rate is good only for state-to-state calls 20 minutes or longer. That information is prominently disclosed only on the last page of the letter. The disclosure of these material conditions on the third page of the letter would likely be ineffective.

Example #17: In a 60-second television ad, a company wants to promote both its domestic and international dial-around service. In the first 50 seconds of the ad, the spokesperson refers to the company's rate as ''7¢ a minute'' three times with an accompanying graphic. In the last 10 seconds of the ad, the spokesperson says, ''And call 878–555–0000 to find out about our low international rates.'' During the 10-second segment in which the spokesperson discusses the company's international rates, the superscript appears ''7¢ a minute rate applies after 7:00 p.m. Monday-Friday and all day weekends.'' Given the lack of proximity between the ''7¢ a minute'' claim and the disclosure of the material time restriction, the superscript would likely not be considered clear and conspicuous.

Example #18: A company wants to promote its international long-distance service by reducing its regular prices during a special promotional period. The print ad features the prominent headline, ''Big holiday sale! Call between November 1, 2000, and December 31, 2000, and save on all international calls.'' The ad also features a box listing ten foreign cities. The list, prominently headed ''sale prices good through December 31, 2000'' gives the cost per minute to each of the advertised cities. Considering the close proximity between the promotional per-minute rates and the prominently displayed information that the advertised rates are good only until December 31, 2000, the disclosure would likely be effective.

3. Absence of Distracting Elements

31. Even if a disclosure is large in size and long in duration, other elements of an advertisement may distract consumers so that they may fail to notice the disclosure. As the FTC has held, consumers may be ''directed away from the importance of the qualifying phrase by the acts or statements of the seller.''[22] Advertisers should take care not to undercut the effectiveness of disclosures by placing them in competition with other arresting elements of the ad.

Example #19: A 30-second television advertisement for a dial-around service features a famous movie star as a spokesperson. On three occasions, the celebrity states that calls completed through this service cost 10¢ a minute. The ad closes with a quick-cut montage of the celebrity talking on the telephone in front of the Grand Canyon, Niagara Falls, Golden Gate Bridge, and other visually arresting national landmarks. In fact, calls are subject to a 50¢ minimum. This information is disclosed only through a visual superscript appearing at the bottom of the screen during the montage. Given the likelihood that consumers will focus on the quick-cut montage rather than on the superscript, it is unlikely that the disclosure would be considered clear and conspicuous.

4. Factors Relating Specifically to Television Ads

32. In television ads, the same factors of prominence, proximity, and absence of distractions determine whether material information is disclosed in a manner that consumers notice and understand. Other considerations specific to television ads include volume, cadence, and placement of any audio disclosures.[23] Disclosures generally are more effective when they are made in the same mode (visual or oral) in which the claim necessitating the disclosure is presented. Furthermore, research suggests that disclosures that are made simultaneously in both visual and audio modes generally are more effectively communicated than disclosures made in either mode alone.[24] For example, the FTC's Pay-Per-Call Rule requires that the price of a call to a 900-number service be disclosed in both the video and audio in a television ad. Thus, for television ads for long-distance services, a disclosure that includes both a sufficiently large superscript and a voice-over statement is likely to be more effective than a superscript alone.

Example #20: A 30-second television advertisement for a long-distance calling plan features a spokesperson who on three occasions states that calls on the plan are ''10¢ a minute anytime.'' In addition, a graphic reading ''10¢ a minute anytime'' is depicted twice during the ad. In fact, the 10¢ a minute rate requires the payment of a $5.95 monthly fee. The only disclosure of the monthly fee is through a visual superscript at the end of the ad. Especially because the triggering representation—that calls on the plan are ''10¢ a minute anytime''was made both orally and visually, the visual superscript would likely be less effective in disclosing the monthly fee than had the same information been conveyed both orally and visually.

III. Ordering Clause

33. Accordingly, *it is ordered that* this Policy Statement *is adopted.*

[19] Deception Statement, 103 F.T.C. at 180–81.

[20] See, *e.g.,* Dell Computer Corp., C–3888 (Aug. 6, 1999) (consent order); Micron Electronics, Inc., C–3887 (Aug. 6, 1999) (consent order); Haagen-Dazs Co., 119 F.T.C. 762 (1995) (consent order); Stouffer Foods Corp., 118 F.T.C. 746, 802 n.10 (1994).

[21] See, *e.g.,* Frank Bommartino Oldsmobile, Inc., C–3774 (Jan. 5, 1998) (consent order); Archer Daniels Midland Co., 117 F.T.C. 403 (1994) (consent order).

[22] Deception Statement, 103 F.T.C. at 180–81.

[23] *See* generally General Motors Corp., 123 F.T.C. 241 (1997); American Honda Motor Co., 123 F.T.C. 262 (1997); American Isuzu Motor Co., 123 F.T.C. 275 (1997); Mitsubishi Motor Sales of America, Inc., 123 F.T.C. 288 (1997); Mazda Motor of America, Inc., 123 F.T.C. 312 (1997) (consent orders) (complaint alleging that ads touting ''zero down'' are deceptive even though fine print disclosures and/or point of sale or other sources make clear that significant costs apply at lease inception; order defining clear and conspicuous disclosure of terms in television and other ads for car leases as ''readable [or audible] and understandable to a reasonable consumer''). See also *United States* v. *Mazda Motor of America, Inc.,* (C.D. Cal. Sept. 30, 1999) (consent decree) ($5.25 million total civil penalty for violations of FTC and state orders related to disclosures in car leasing advertising); Kraft, Inc., 114 F.T.C. 40, 124 (1991), aff'd, 970 F.2d 311 (7th Cir. 1992), cert. denied, 507 U.S. 909 (1993); Thompson Medical Co., 104 F.T.C. 648, 797–98 (1984), aff'd, 791 F.2d 189 (D.C. Cir. 1986), cert. denied, 479 U.S. 1086 (1987).

[24] Maria Grubbs Hoy & Michael J. Stankey, Structural Characteristics of Televised Advertising Disclosures: A Comparison with the FTC Clear and Conspicuous Standard, J. Advertising, June 1993, at 47, 50; Todd Barlow & Michael S. Wogalter, Alcoholic Beverage Warnings in Magazine and Television Advertisements, 20 J. Consumer Res. 147, 151, 153 (1993); Noel M. Murray, *et al.,* Public Policy Relating to Consumer Comprehension of Television Commercials: A Review and Some Empirical Results, 16 J. Consumer Pol'y 145, 164 (1993).

Federal Communications Commission.

Magalie Roman Salas,

Secretary.

Federal Trade Commission.

Donald S. Clark,

Secretary.

[FR Doc. 00–17995 Filed 7–14–00; 8:45 am]

BILLING CODE 6750–01–P

GENERAL SERVICES ADMINISTRATION

[OMB Control No. 3090–0021]

Submission for OMB Review; Comment Request Entitled Profit and Loss Statement—Operating Statement

AGENCY: Regional Support Division (PMR), GSA.

ACTION: Notice of request for public comments regarding an extension to an existing OMB clearance (3090–0021).

SUMMARY: Under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. chapter 35), the Office of Acquisition Policy will be submitting to the Office of Management and Budget (OMB) a request to review and approve an extension of a currently approved information collection requirement concerning Profit and Loss Statement—Operating Statement. This information collection was published in the **Federal Register** on May 3, 2000 at 65 FR 25730 allowing for the standard 60-day public comment period. No comments were received.

DATES: *Comment Due Date:* August 16, 2000.

ADDRESSES: Comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, should be submitted to: Edward Springer, GSA Desk Officer, Room 3235, NEOB, Washington, DC 20503 and also may be submitted to Marjorie Ashby, General Services Administration (MVP), Room 4011, 1800 F Street NW., Washington, DC 20405.

FOR FURTHER INFORMATION CONTACT: Deborah Purdie, (202) 501–4226.

SUPPLEMENTARY INFORMATION:

A. Purpose

The Profit and Loss Statement—Operating Statement is the financial planning document in an offeror's proposal to perform a GSA cafeteria service contract and its contents are one factor considered by the contracting officer in deciding to award a contract. The GSA Form 2817 is also the non-ADP financial reporting vehicle used by cafeteria contractors.

B. Annual Reporting Burden

Respondents: 250; *annual responses:* 250; *average hours per response:* 1; *burden hours:* 250.

Copy of Proposal: A copy of this proposal may be obtained from the GSA Acquisition Policy Division (MVP), Room 4011, GSA Building, 1800 F Street NW., Washington, DC 20405, or by telephoning (202) 501–3822.

Dated: July 7, 2000.

David A. Drabkin,

Deputy Associate Administrator for Acquisition Policy.

[FR Doc. 00–18035 Filed 7–14–00; 8:45 am]

BILLING CODE 6820–61–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration on Aging

Announcement on Tribal Consultation With American Indian/Alaskan Native Tribal Representatives

The Department of Health and Human Services policy on consultation with American Indian/Alaska Native (AI/AN) Governments and Organizations calls for each OPDIV to convene a meeting with AI/AN Tribal Representatives.

In accordance with Departmental policy on Tribal Consultation with AI/AN Governments and Organizations, the Administration on Aging will be hosting a one day session to give AI/AN Tribal Representatives and their Title VI Director an opportunity to discuss Indian elder issues related to (1) Policy Directions; (2) Capacity Building; (3) Long-Term Care; and (4) Health Care and to develop recommendations to be presented to the Assistant Secretary for Aging.

This Tribal Listening Session will be held from 9 am to 4 pm on August 8, 2000 at: Hubert Humphrey Building; 200 Independence Avenue, SW, Washington, DC 20201.

A final agenda will be distributed at the meeting when you sign in.

To register and for additional information please contact: M. Yvonne Jackson, Ph.D., Director, Office for American Indian, Alaskan Native and Native Hawaiian Programs, Administration on Aging, 330 Independence Ave., SW, Washington, DC 20201, (202) 619–2713, Email: Yvonne.Jackson@aoa.gov.

Purpose: In accordance with Departmental policy on consultation with (AI/AN) Governments and Organizations, AoA will host this meeting to give AI/AN Tribal Representatives an opportunity to discuss the four above mentioned areas and develop recommendations to present to the Assistant Secretary on Aging.

Date and Time: August 8, 2000, 9 am–4 pm EST.

Matters to be Discussed: The agenda will include opening remarks/break-out sessions to discuss the four above mentioned areas, a general session, open comment time and closing remarks.

If you are unable to attend but wish to provide comments or Tribal Resolutions these may be faxed to M. Yvonne Jacksons attention at (202) 260–1012.

Dated: July 11, 2000.

Jeanette C. Takamura,

Assistant Secretary for Aging.

[FR Doc. 00–17920 Filed 7–14–00; 8:45 am]

BILLING CODE 4150–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day–00–43]

Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call the CDC Reports Clearance Officer on (404) 639–7090.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques for other forms of information technology. Send comments to Seleda Perryman, CDC Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24, Atlanta, GA 30333. Written comments should be received within 60 days of this notice.

Proposed Project

Nursing Homes' Access to Influenza Vaccine and Use of Rapid Influenza Tests and Antivirals—New—National Center for Infectious Diseases (NCID)—Uncontrolled nursing home influenza outbreaks can result in illness in ≥ 60 percent and death in ≥ 10 percent of residents. Vaccine is the primary means to prevent influenza and its complications. However, outbreaks can occur despite high vaccination levels. The use of rapid diagnostic tests and the timely administration of antiviral medications can lessen the impact of influenza outbreaks. In 1998, a study was conducted among nursing homes in 9 states to determine the use of vaccine, rapid influenza tests, and antivirals, amantadine and rimantadine. Since that time, new rapid diagnostic tests and neuraminidase inhibitor antiviral medications have been approved. In addition, a substantial delay in the distribution of influenza vaccine and a possible vaccine shortage are anticipated for the 2000–01 influenza season.

The purpose of this study is to assess nursing homes' access to vaccine in 2000–01, the use of rapid influenza diagnostic tests, and the influenza inhibitor antivirals. A survey will be mailed to a sample of randomly selected nursing homes in the same 9 states surveyed in 1998. The results will be used to evaluate resident and staff vaccination levels and the use of rapid influenza tests and antiviral medications. We will also assess the relationship between access to vaccine and the occurrence of outbreaks. There is no cost to the respondents.

Respondents	Number of respondents	Number of responses per respondent	Avg. burden/ respondents (in hrs)	Total burden
Nursing Home staff	1017	1	10/60	170

Dated: July 11, 2000.

Nancy Cheal,

Acting Associate Director for Policy, Planning and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 00–17982 Filed 7–14–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: LIHEAP Household Report

OMB No.: 0970–0060

Description: The report is an annual activity which is required by law of Low Income Home Energy Assistance Program (LIHEAP) grantees for receipt of federal LIHEAP block grant funds. States, the District of Columbia, and the Commonwealth of Puerto are required to report statistics for the previous federal fiscal year on the number and income levels of LIHEAP applicant and assisted households, and the number of LIHEAP assisted households with at least one member who is elderly, disabled or a young child. Insular areas receiving less than $200,000 annually in LIHEAP funds and Indian Tribal Grantees are required to submit data only on the number of households receiving heating, cooling, energy crisis, or weatherization benefits. The information is being collected for the Department's annual LIHEAP report to Congress. The data also provide information about the need for LIHEAP funds. Finally, the data are being used in the calculation of LIHEAP performance measures under the Government Performance Results Act of 1993.

Respondents: State Governments, Tribal Governments and Territories

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Recommended LF LIHEAP assist. household	52	1	25	1,300
Recommended SF LIHEAP assist. household	132	1	1	132
Recommended format for LIHEAP applicant households	52	1	13	676
Estimated Total Annual Burden Hours				2,108

Additional Information

Copies of the proposed collection may be obtained by writing to The Administration for Children and Families, Office of Information Services, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer.

OMB Comment

OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Desk Officer for ACF.

Dated: July 11, 2000.

Bob Sargis,

Reports Clearance Officer.

[FR Doc. 00–17938 Filed 7–14–00; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 00N–1373]

Agency Information Collection Activities: Proposed Collection; Comment Request; Reporting and Recordkeeping Requirements for Mammography Facilities

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing information collection, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection requirements for mammography facilities, standards, and lay summaries for patients.

DATES: Submit written comments on the collection of information by September 15, 2000.

ADDRESSES: Submit written comments on the collection of information to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Peggy Schlosburg, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Reporting and Recordkeeping Requirements for Mammography Facilities—21 CFR Part 900 (OMB Control Number 0910–0309)—Extension

Public Law 102–539, the Mammography Quality Standards Act of 1992 (MQSA) (42 U.S.C. 263b) as amended by the Mammography Quality Standards Reauthorization Act (MQSRA) of 1998 (Public Law 105–248) establishes the authority for a Federal certification and inspection program for mammography facilities; regulations and standards for accreditation bodies for mammography facilities; and standards for mammography equipment, personnel, and practices, including quality assurance. MQSRA extended the life of the MQSA program for 4 years from its original expiration date of 1998 until 2002, and also modified some of the provisions. The most significant modification from a report and recordkeeping viewpoint under 21 CFR 900.12(c)(2) was that mammography facilities were required to send a lay summary of each examination to the patient.

FDA, under this regulation, collects information from accreditation bodies and mammography facilities by requiring each accreditation body to submit an application for approval and to establish a quality assurance program. On the basis of accreditation, facilities are certified by FDA and must prominently display their certificate. FDA uses the information to ensure that private, nonprofit organizations or State agencies meet the standards established by FDA for accreditation bodies to accredit facilities that provide mammography services. Information collected from mammography facilities has also been used to ensure that the personnel, equipment, and quality systems has and continues to meet the regulations under MQSA and will be used by patients to manage their health care properly. The intent of these regulations is to assure safe, reliable, and accurate mammography on a nationwide level. The most likely respondents to this information collection will be accreditation bodies and mammography facilities seeking certification.

FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN

21 CFR Section	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours	Total Capital Costs	Total Operating & Maintenance Costs
900.3	6	1	6	60	360		
900.3(b)(3)	10	1	10	60	600	$50	
900.3(c)	4	0.14	0.56	15	8.4		
900.3(e)	1	0.2	0.2	1	0.2		
900.3(f)(2)	1	0.2	0.2	200	40		
900.4(c)	834	1	834	1	834		
900.4(e)	10,000	1	10,000	8	80,000		
900.4(f)	1,000	1	1,000	14.5	14,500		
900.4(h)	6	1	750	6	4,500		
900.4(i)(2)	1	1	1	1	1		
900.6(c)(1)	1	1	1	1	1		
900.11(b)(2)	25	1	25	2	50		
900.11(b)(3)	5	1	5	0.5	2.5		

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN—Continued

21 CFR Section	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours	Total Capital Costs	Total Operating & Maintenance Costs
900.11(c)	10,000	0.0050	50	20	1,000		$1,000
900.12(c)(2)	9,800	4,080	39,984,000	5 Minutes	3,332,000		
900.12(j)(1)	10	1	10	1	10		
900.12(j)(2)	1	1	1	50	50		
900.15(d)(3)(ii)	10,000	0.0020	20	2	40		$100
900.18(c)	10,000	0.0005	6	2	12		$60
900.18(e)	10	0.1000	1	1	1		$10
TOTAL					3,434,010	$50	$1,170

TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN [1]

21 CFR Section	No. of Recordkeepers	Annual Frequency per Recordkeeping	Total Annual Records	Hours per Recordkeeper	Total Hours	Total Operating & Maintenance Costs
900.3(f)(1)	10	130	1,300	200	2,000	
900.4(g)	10,000	1	10,000	1	10,000	
900.11(b)(1)	1,000	1	1,000	1	1,000	
900.12(c)(4)	10,000	1	10,000	1	10,000	
900.12(e)(13)	6,000	52	312,000	0.125	39,000	
900.12(f)	10,000	1	10,000	1	10,000	
900.12(h)	10,000	2	20,000	0.5	10,000	$20,000
TOTAL					82,000	$20,000

[1] There are no capital costs associated with this collection of information.

All costs of implementing requirements for certification of mammography facilities will be borne by accreditation bodies; the incremental costs that accreditation bodies will face are not expected to be significant. The collection's burden is based upon the estimated number of summaries received by FDA, which in turn is based on the estimated number of examinations expected to be performed in a given year. If mammography examinations increase in number in subsequent years, which is expected for at least the foreseeable future, the annual burden and costs to meet this requirement will increase.

Included in the burden estimate is the FDA estimate for mammography lay summaries, which is the practice of notifying the patient in layman's terms of the results of the patient's mammography examination. FDA estimates that there are 9,800 facilities performing mammography in the United States. FDA also estimates that those facilities perform a total of 40 million mammography examinations in a year. In 90 percent of these cases, the notification to the patient can be established by a brief standardized letter to the patient. FDA estimates that preparing and sending this letter will take approximately 5 minutes. In the 10 percent of the cases in which there is a finding of ''Suspicious'' or ''Highly suggestive of malignancy,'' the facility is required to make reasonable attempts to ensure that the results are communicated to the patients as soon as possible. FDA believes that this requirement can be met by a 5 minute call from the health professional to the patient.

Dated: July 10, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 00–17944 Filed 7–14–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 00N–0356]

Agency Information Collection Activities; Announcement of OMB Approval; Survey of Incidence of Gastroenterological Parasitic Infections in the United States as a Result of Consumption of Raw Fish

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Survey of Incidence of Gastroenterological Parasitic Infections in the United States as a Result of Consumption of Raw Fish'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Peggy Schlosburg, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of May 23, 2000 (65 FR 33329), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0443. The approval expires on June 30, 2003. A copy of the supporting statement for this information collection is available on the Internet at http://www.fda.gov/ohrms/dockets.

Dated: July 10, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 00–17943 Filed 7–14–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provision set forth in sections 552(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Cooperative Family Registry for Breast Cancer Study.

Date: August 2, 2000.

Time: 8:30 a.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Gerald G. Lovinger, Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute National Institutes of Health, 6116 Executive Boulevard, Room 8070, Rockville, MD 20892–7405, 301/496–7987.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: July 7, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–17931 Filed 7–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Initial Review Group, Subcommittee D—Clinical Studies.

Date: July 23–24, 2000.

Time: 7:30 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn, 8777 Georgia Avenue, Silver Spring, MD 20910.

Contact Person: Martin H. Goldrosen, Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8050, Rockville, MD 20852–7408, (301) 496–7930.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: July 7, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–17932 Filed 7–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Cancer Institute Director's Consumer Liaison Group.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: National Cancer Institute Director's Consumer Liaison Group.

Date: July 21, 2000.

Time: 2:30 p.m. to 4:30 p.m.

Agenda: To discuss the DCLG Team Leaders Reports on: Clinical Trials Participation, Advocacy Involvement, Communications Extraordinary Opportunity, NCI Brand, DCLG Operations, NCI Website, Quality Cancer Care Committee/Health Disparities, NCI Priorities and to discuss agenda topics for the upcoming September 2000 Advocates Summit Conference.

Place: Federal Building, Room 6C10, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Elaine Lee, Acting Executive Secretary, Office of Liaison Activities, National Cancer Institute, National Institutes of Health, Federal Building, Room 6C10, Bethesda, MD 20892–2580, (301) 594–3194.

This notice is being published less than 15 days prior to the meeting due to scheduling conflicts.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: July 7, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–17933 Filed 7–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Human Genome Research Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which

would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Human Genome Research Institute Special Emphasis Panel

Date: August 8, 2000,

Time: 3:30 pm to 4:30 pm.

Agenda: To review and evaluate grant applications.

Place: Conference Room B2B32/Bldg 31, 31 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Rudy O. Pozzatti, PhD, Scientific Review Administrator, Office of Scientific Review, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, 301 402–0838.

(Catalog of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: July 7, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–17934 Filed 7–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel.

Date: August 3–4, 2000.

Time: 8:00 a.m. to 5:00 p.m.

Place: Holiday Inn—Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.

Contact Person: John R. Ranhand, PhD, Scientist Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5E03, Bethesda, MD 20892, (301) 435–6884.

(Catalogue of Federal Domestic Assistance Program Nos. 93.209, Contraception and Infertility Loan Repayment Program; 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for medical Rehabilitation Research, National Institutes of Health, HHS)

Dated: July 7, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–17935 Filed 7–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Minority Programs Review Committee, MARC Review Subcommittee A.

Date: July 26, 2000.

Time: 1 pm to 2 pm.

Agenda: To review and evaluate grant applications.

Place: Natcher Building, Room 1AS19, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Richard I. Martinez, PhD, Scientific Review Administrator, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 1AS–19G, Bethesda, MD 20892–6200, (301) 594–2849.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: July 7, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–17936 Filed 7–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 14, 2000.

Time: 8:30 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Ramada Inn Rockville, 1775 Rockville Pike, Rockvile, MD 20852.

Contact Person: Luigi Giacometti, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5208, MSC 7850, Bethesda, MD 20892, (301) 435–1246.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 18, 2000.

Time: 8 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Place: The Hyatt Regency Hotel, One Bethesda Metro Center, Bethesda, MD 20814

Contact Person: Mary Clare Walker, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5104, MSC 7852, Bethesda, MD 20892, (301) 435–1165.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 18, 2000.

Time: 8:30 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Ramada Inn Rockville, 1775 Rockville Pike, Rockville, MD 20852.

Contact Person: Joe Marwah, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701

Rockledge Drive, Room 5188, MSC 7846,Bethesda, MD 20892, (301) 435–1253.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 18, 2000.

Time: 1 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: John Bishop, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5180, MSC 7844, Bethesda, MD 20892, (301) 435–1250.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 18, 2000.

Time: 1 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Julian L. Azorlosa, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3190, MSC 7848, (301) 435–1507.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 18, 2000.

Time: 2 p.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Sami A. Mayyasi, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5112, MSC 7852, Bethesda, MD 20892, (301) 435–1169.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 19, 2000.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: The Hyatt Regency Hotel, One Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Mary Clare Walker, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5104, MSC 7852, Bethesda, MD 20892, (301) 435–1165.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 19, 2000.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Ramanda Inn Rockville, 1775 Rockville Pike, Rockville, MD 20852.

Contact Person: Jay Cinque, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5186, MSC 7846, Bethesda, MD 20892, (301) 435–1252.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 19, 2000.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Gamil C. Debbas, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5170, MSC 7844, Bethesda, MD 20892, (301) 435–1018.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 19–21, 2000.

Time: 8:30 p.m. to 11 a.m.

Agenda: To review and evaluate grant applications.

Place: Eldorado Hotel, 309 W. San Francisco St., Santa Fe, NM 87501.

Contact Person: Mike Radtke, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4176, MSC 7806, Bethesda, MD 20892, (301) 435–1728.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Cell Development and Function Integrated Review Group, International and Cooperative Projects Study Section.

Date: July 20–21, 2000.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Georgetown Suites Hotel-Harbor Building, 1000 29th Street NW, Washington, DC 20007.

Contact Person: Sandy Warren, DMD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5134, MDC 7840, Bethesda, MD 20892, (301) 435–1019.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 20, 2000.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD 20852.

Contact Person: Ann A. Jerkins, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6154, MSC 7892, Bethesda, MD 20892, (301) 435–4514.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 20, 2000.

Time: 11 a.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Betty Hayden, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4206, MSC 7812, Bethesda, MD 20892, 301–435–1223, haydenb@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 20, 2000.

Time: 1 p.m. to 2 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Jerry L. Klein, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4138, MSC 7804, Bethesda, MD 20892, (301) 435–1213.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 20, 2000.

Time: 1 p.m. to 2 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Ranga V. Srinivas, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5108, MSC 7852, Bethesda, MD 20892, (301) 435–1167, srinivar@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 21, 2000.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Georgetown Holiday Inn, 2101 Wisconsin Avenue, NW, Washington, DC 20007.

Contact Person: Gordon L. Johnson, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4122, MSC 7802, Bethesda, MD 20892, (301) 435–1212, johnsong@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 21, 2000.

Time: 11 a.m. to 1 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Rita Anand, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4188, MSC 7808, Bethesda, MD 20892, (301) 435–1151.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 21, 2000.

Time: 4 p.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Mariana Dimitrov, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3180, MSC 7848, Bethesda, MD 20892, (301) 435–1261.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: July 21, 2000.

Time: 12 p.m. to 1:30 p.m.

Agenda: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Michael A. Lang, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5210, MSC 7850, Bethesda, MD 20892, (301) 435–1265.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 7, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–17930 Filed 7–14–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4565–N–17]

Notice of Proposed Information Collection: Comment Request; Monthly Reports for Establishing Net Income

AGENCY: Office of the Assistant Secretary for Housing, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: *Comments Due Date:* September 15, 2000.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Wayne Eddins, Reports Management Officer, Department of Housing and Urban Development, 451 7th Street, SW, Washington, DC 20410, telephone (202) 708–5221 (this is not a toll-free number) for copies of the proposed forms and other available information.

FOR FURTHER INFORMATION CONTACT: Willie Spearmon, Department of Housing and Urban Development, 451 7th Street, SW, Washington, DC 20410, telephone (202) 708–3000, (this is not a toll-free number) for copies of the proposed forms and other available.

SUPPLEMENTARY INFORMATION: The Department is submitting the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended).

This Notice is soliciting comments from members of the public and affected agencies concerning the proposed collection of information to: (1) Evaluate whether the proposed collection is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond; including the use of appropriate automated collection techniques or other forms of information technology, *e.g.,* permitting electronic submission of responses.

This Notice also lists the following information;

Title of Proposal: Monthly Reports for Establishing Net Income.

OMB Control Number, if applicable: 2502–0108.

Description of the need for the information and proposed use: Field Office staff use Monthly Accounting Reports to assess the need for remedial actions to correct project deficiencies or to prevent a potential default of the project of the project mortgage. HUD Forms 93480 and 93481 are related to the project owners costs. When a project is experiencing rent collection problems, expenses directly effect this income. Loan Servicers are responsible for reviewing trends in a project's expenses and income.

Agency form numbers, if applicable: HUD–93479, 93480, 93481.

Estimation of the total numbers of hours needed to prepare the information collection including number of respondents, frequency of response, and hours of response: The number of respondents for each form (HUD–93479, 93480, and 93481) is 4,000, the frequency of responses per form is one per month (12 yearly). The number of responses for the 3 forms is 48,000, for a total of 144,000 responses per year. The hours per response is 1.50 hours for HUD–93479, 1 hour for forms HUD–93480 and HUD–93481, estimating the annual burden hours requested to be 168,000.

Status of the proposed information collection: Reinstatement, without change, of previously approved collection for which approved has expired.

Authority: The Paperwork Reduction Act of 1995, 44 U.S.C. Chapter 35, as amended.

Dated: July 6, 2000.

William C. Apgar,

Assistant Secretary for Housing-FHC.

[FR Doc. 00–17969 Filed 7–14–00; 8:45 am]

BILLING CODE 4210–27–M

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Availability of an Environmental Assessment/Habitat Conservation Plan and Receipt of an Application for a Permit for the Incidental Take of the Houston Toad (Bufo houstonensis) During Construction of One Single Family Residence on the approximately 0.25-Acre Lot 1217, Unit 1, Block 9 in the Tahitian Village Subdivision, Bastrop County, Texas (Broussard)

SUMMARY: Gordon and Mary Broussard (Applicants) have applied to the U.S. Fish and Wildlife Service (Service) for an incidental take permit pursuant to Section 10(a) of the Endangered Species Act (Act). The Applicants have been assigned permit number TE–029946–0. The requested permit, which is for a period of 5 years, would authorize the incidental take of the endangered Houston toad (Bufo houstonensis). The proposed take would occur as a result of the construction and occupation of one single family residence on up to 0.25 acres of the approximately 0.25-acre Lot 1217, Unit 1, Block 9 in the Tahitian Village Subdivision, Bastrop County, Texas.

The Service has prepared the Environmental Assessment/Habitat Conservation Plan (EA/HCP) for the incidental take application. A determination of jeopardy to the species or a Finding of No Significant Impact (FONSI) will not be made until at least 30 days from the date of publication of this notice. This notice is provided pursuant to Section 10(c) of the Act and National Environmental Policy Act regulations (40 CFR 1506.6).

DATES: Written comments on the application should be received on or before August 16, 2000.

ADDRESSES: Persons wishing to review the application may obtain a copy by writing to the Regional Director, U.S. Fish and Wildlife Service, P.O. Box 1306, Albuquerque, New Mexico 87103. Persons wishing to review the EA/HCP may obtain a copy by contacting Tannika Engelhard, U.S. Fish and Wildlife Service, 10711 Burnet Road, Suite 200, Austin, Texas 78758 (512/490–0057). Documents will be available for public inspection by written request, by appointment only, during normal business hours (8:00 to 4:30) at the U.S. Fish and Wildlife Service, Austin, Texas. Written data or comments concerning the application and EA/HCP should be submitted to the Supervisor, U.S. Fish and Wildlife Service, Austin, Texas, at the above address. Please refer to permit number TE–029946–0 (Broussard) when submitting comments.

FOR FURTHER INFORMATION CONTACT: Tannika Engelhard at the above U.S. Fish and Wildlife Service, Austin Office.

SUPPLEMENTARY INFORMATION: Section 9 of the Act prohibits the ''taking'' of endangered species such as the Houston toad. However, the Service, under limited circumstances, may issue permits to take endangered wildlife species incidental to, and not the purpose of, otherwise lawful activities. Regulations governing permits for endangered species are at 50 CFR 17.22.

Applicant

Gordon and Mary Broussard plan to construct a single family residence on up to 0.25 acres of the 0.25-acre Lot 1217, Unit 1, Block 9, of the Tahitian Village Subdivision, Bastrop County, Texas. This action will eliminate 0.25 acres or less of Houston toad habitat and result in indirect impacts within the lot. The Applicants propose to compensate for this incidental take of the Houston toad by providing $1,000.00 to the National Fish and Wildlife Foundation for the specific purpose of land acquisition and management within Houston toad habitat, as identified by the Service.

Renne Lohoefener,

Acting Regional Director, Region 2, Albuquerque, New Mexico.

[FR Doc. 00–17983 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–55–U

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Availability of an Environmental Assessment/Habitat Conservation Plan and Receipt of an Application for a Permit for the Incidental Take of the Houston Toad (Bufo houstonensis) During Construction of One Single Family Residence on 0.5 Acres of the 2.57-Acre Lots 18 (1.38 Acres) and 19 (1.19 Acres), Section 5, in the Circle D Country Acres Subdivision, Bastrop County, Texas (Miles)

SUMMARY: William and Phyllis Miles (Applicants) have applied to the U.S. Fish and Wildlife Service (Service) for an incidental take permit pursuant to Section 10(a) of the Endangered Species Act (Act). The Applicants have been assigned permit number TE–029947–0. The requested permit, which is for a period of 5 years, would authorize the incidental take of the endangered Houston toad (*Bufo houstonensis*). The proposed take would occur as a result of the construction and occupation of one single family residence on 0.5 acres of the 2.57-acre Lots 18 (1.38 acres) and 19 (1.19 acres), Section 5, in the Circle D Country Acres Subdivision, Bastrop County, Texas.

The Service has prepared the Environmental Assessment/Habitat Conservation Plan (EA/HCP) for the incidental take application. A determination of jeopardy to the species or a Finding of No Significant Impact (FONSI) will not be made until at least 30 days from the date of publication of this notice. This notice is provided pursuant to Section 10(c) of the Act and National Environmental Policy Act regulations (40 CFR 1506.6).

DATES: Written comments on the application should be received on or before August 16, 2000.

ADDRESSES: Persons wishing to review the application may obtain a copy by writing to the Regional Director, U.S. Fish and Wildlife Service, P.O. Box 1306, Albuquerque, New Mexico 87103. Persons wishing to review the EA/HCP may obtain a copy by contacting Tannika Engelhard, U.S. Fish and Wildlife Service, 10711 Burnet Road, Suite 200, Austin, Texas 78758 (512/490–0057). Documents will be available for public inspection by written request, by appointment only, during normal business hours (8:00 to 4:30) at the U.S. Fish and Wildlife Service, Austin, Texas. Written data or comments concerning the application and EA/HCP should be submitted to the Supervisor, U.S. Fish and Wildlife Service, Austin, Texas, at the above address. Please refer to permit number TE–029947–0 (Miles) when submitting comments.

FOR FURTHER INFORMATION CONTACT: Tannika Engelhard at the above U.S. Fish and Wildlife Service, Austin Office.

SUPPLEMENTARY INFORMATION: Section 9 of the Act prohibits the ''taking'' of endangered species such as the Houston toad. However, the Service, under limited circumstances, may issue permits to take endangered wildlife species incidental to, and not the purpose of, otherwise lawful activities. Regulations governing permits for endangered species are at 50 CFR 17.22.

Applicant

William and Phyllis Miles plan to construct a single family residence on 0.5 acres of the 2.57-acre Lots 18 (1.38 acres) and 19 (1.19 acres), Section 5, in the Circle D Country Acres Subdivision, Bastrop County, Texas. This action will eliminate 0.5 acres or less of Houston

toad habitat and result in indirect impacts within the lot. The applicants propose to compensate for this incidental take of the Houston toad by providing $1,500.00 to the National Fish and Wildlife Foundation for the specific purpose of land acquisition and management within Houston toad habitat, as identified by the Service.

Renne Lohefener,

Acting Regional Director, Region 2, Albuquerque, New Mexico.

[FR Doc. 00–17984 Filed 7–14–00; 8:45 am]

BILLING CODE 4510–55–U

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Availability of an Environmental Assessment/Habitat Conservation Plan and Receipt of an Application for a Permit for the Incidental Take of the Houston Toad (Bufo houstonensis) During Construction of Two Single Family Residences on up to 0.5 acres Each of the 0.567-acre Lot 48, Section 8, and of the 0.493-acre Lot 70, Section 8, in the Circle D Country Acres Subdivision, Bastrop County, Texas (Rush)

SUMMARY: Jim Rush, Green Builder Inc. (Applicant) has applied to the U.S. Fish and Wildlife Service (Service) for an incidental take permit pursuant to Section 10(a) of the Endangered Species Act (Act). The Applicant has been assigned permit number TE–029949–0. The requested permit, which is for a period of 5 years, would authorize the incidental take of the endangered Houston toad *(Bufo houstonensis).* The proposed take would occur as a result of the construction and occupation of two single family residences on up to 0.5 acres each of the following two lots in the Circle D Country Acres Subdivision, Bastrop County, Texas: (1) the 0.567-acre Lot 48, Section 8, and, (2) the 0.493-acre Lot 70, Section 8.

The Service has prepared the Environmental Assessment/Habitat Conservation Plan (EA/HCP) for the incidental take application. A determination of jeopardy to the species or a Finding of No Significant Impact (FONSI) will not be made until at least 30 days from the date of publication of this notice. This notice is provided pursuant to Section 10(c) of the Act and National Environmental Policy Act regulations (40 CFR 1506.6).

DATES: Written comments on the application should be received on or before August 16, 2000.

ADDRESSES: Persons wishing to review the application may obtain a copy by writing to the Regional Director, U.S. Fish and Wildlife Service, P.O. Box 1306, Albuquerque, New Mexico 87103. Persons wishing to review the EA/HCP may obtain a copy by contacting Tannika Engelhard, U.S. Fish and Wildlife Service, 10711 Burnet Road, Suite 200, Austin, Texas 78758 (512/490–0057). Documents will be available for public inspection by written request, by appointment only, during normal business hours (8:00 to 4:30) at the U.S. Fish and Wildlife Service, Austin, Texas. Written data or comments concerning the application and EA/HCP should be submitted to the Supervisor, U.S. Fish and Wildlife Service, Austin, Texas, at the above address. Please refer to permit number TE–029949–0 (Rush) when submitting comments.

FOR FURTHER INFORMATION CONTACT: Tannika Engelhard at the above U.S. Fish and Wildlife Service, Austin Office.

SUPPLEMENTARY INFORMATION: Section 9 of the Act prohibits the ''taking'' of endangered species such as the Houston toad. However, the Service, under limited circumstances, may issue permits to take endangered wildlife species incidental to, and not the purpose of, otherwise lawful activities. Regulations governing permits for endangered species are at 50 CFR 17.22.

Applicant

Jim Rush, Green Builder, Inc. plans to construct a single family residence on up to 0.5 acres of the 0.567-acre Lot 48, Section 8 and of the 0.493-acre Lot 70, Section 8 in the Circle D Country Acres Subdivision, Bastrop County, Texas. This action will eliminate less than 1.0 acre (0.5 acres or less per homesite) of Houston toad habitat and result in indirect impacts within the lot. The Applicant proposes to compensate for this incidental take of the Houston toad by providing $3,000.00 ($1,500.00 per homesite) to the National Fish and Wildlife Foundation for the specific purpose of land acquisition and management within Houston toad habitat, as identified by the Service.

Renne Lohoefener,

Regional Director, Region 2, Albuquerque, New Mexico.

[FR Doc. 00–17985 Filed 7–14–00; 8:45 am]

BILLING CODE 4510–55–U

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WY–920–1310–01; WYW147899]

Notice of Proposed Reinstatement of Terminated Oil and Gas Lease

Pursuant to the provisions of 30 U.S.C. 188(d) and (e), and 43 CFR 3108.2–3(a) and (b)(1), a petition for the reinstatement of oil and gas lease WYW147899 for lands in Sweetwater County, Wyoming, was timely filed and was accompanied by all the required rentals accruing from the date of termination. The lessee has agreed to the amended lease terms for rentals and royalties at rates of $10.00 per acre, or fraction thereof, per year and 16⅔ percent, respectively.

The lessee has paid the required $500 administrative fee and $125 to reimburse the Department for the cost of this **Federal Register** notice. The lessee has met all the requirements for reinstatement of the lease as set out in Sections 31 (d) and (e) of the Mineral Lands Leasing Act of 1920 (30 U.S.C. 188), and the Bureau of Land Management is proposing to reinstate lease WYW147899 effective March 1, 2000, subject to the original terms and conditions of the lease and the increased rental and royalty rates cited above.

Pamela J. Lewis,

Chief, Leasable Minerals Section.

[FR Doc. 00–17950 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–22–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WY–920–1310–01; WYW147898]

Notice of Proposed Reinstatement of Terminated Oil and Gas Lease

Pursuant to the provisions of 30 U.S.C. 188(d) and (e), and 43 CFR 3108.2–3(a) and (b)(1), a petition for reinstatement of oil and gas lease WYW147898 for lands in Sweetwater County, Wyoming, was timely filed and was accompanied by all the required rentals accruing from the date of termination.

The lessee has agreed to the amended lease terms for rentals and royalties at rates of $10.00 per acre, or fraction thereof, per year and 16⅔ percent, respectively.

The lessee has paid the required $500 administrative fee and $125 to reimburse the Department for the cost of this **Federal Register** notice. The lessee

has met all the requirements for reinstatement of the lease as set out in Section 31(d) and (e) of the Mineral Lands Leasing Act of 1920 (30 U.S.C. 188), and the Bureau of Land Management is proposing to reinstate lease WYW147898 effective March 1, 2000, subject to the original terms and conditions of the lease and the increased rental and royalty rates cited above.

Pamela J. Lewis,

Chief, Leasable Minerals Section.

[FR Doc. 00–17951 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–22–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WY–920–1310–01; WYW147897]

Notice of Proposed Reinstatement of Terminated Oil and Gas Lease

Pursuant to the provisions of 30 U.S.C. 188(d) and (e), and 43 CFR 3108.2–3(a) and (b)(1), a petition for reinstatement of oil and gas lease WYW147897 for lands in Sweetwater Counter, Wyoming, was timely filed and was accompanied by all the required rentals accruing from the date of termination. The lessee has agreed to the amended lease terms for rentals and royalties at rates of $10.00 per acre, or fraction thereof, per year and 16⅔ percent, respectively.

The lessee has paid the required $500 administrative fee and $125 to reimburse the Department for the cost of this **Federal Register** notice. The lessee has met all the requirements for reinstatement of the lease as set out in Section 31(d) and (e) of the Mineral Lands Leasing Act of 1920 (30 U.S.C. 188), and the Bureau of Land Management is proposing to reinstate lease WYW147897 effective March 1, 2000, subject to the original terms and conditions of the lease and the increased rental and royalty rates cited above.

Pamela J. Lewis,

Chief, Leasable Minerals Section.

[FR Doc. 00–17952 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–22–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WY–920–1310–01; WYW 134972]

Notice of Proposed Reinstatement of Terminated Oil and Gas Lease

June 29, 2000.

Pursuant to the provisions of 30 U.S.C. 188(d) and (e), and 43 CFR 3108.2–3(a) and (b)(1), a petition for reinstatement of oil and gas lease WYW134972 for lands in Fremont County, Wyoming, was timely filed and was accompanied by all the required rentals accruing from the date of termination.

The lessee has agreed to the amended lease terms for rentals and royalties at rates of $10.00 per acre, or fraction thereof, per year and 16⅔ percent, respectively.

The lessee has paid the required $500 administrative fee and $125 to reimburse the Department for the cost of this **Federal Register** notice. The lessee has met all the requirements for reinstatement of the lease as set out in Section 31(d) and (e) of the Mineral Lands Leasing Act of 1920 (30 U.S.C. 188), and the Bureau of Land Management is proposing to reinstate lease WYW134972 effective February 1, 2000, subject to the original terms and conditions of the lease and the increased rental and royalty rates cited above.

Pamela J. Lewis,

Chief, Leasable Minerals Section.

[FR Doc. 00–17953 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–22–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[AZ–050–00–1430–EU; AZA 29964, AZA 29970, AZA 29972–AZA 29975, AZA 29977, AZA 29979–AZA 29983, AZA 29985–AZA 29989]

Arizona: Notice of Realty Action; Competitive Sale of Public Land in Quartzsite, La Paz County, Arizona

AGENCY: Bureau of Land Management, Interior.

ACTION: Extension of notice.

SUMMARY: The following land in La Paz County, Arizona has been found suitable for disposal under sections 203 and 209 of the Federal Land Policy and Management Act of 1976 (90 Stat. 2750, 43 U.S.C. 1713; 90 Stat. 2757, 43 U.S.C. 1719). The extension will allow additional time to complete the sale.

Gila and Salt River Meridian, Arizona

T. 4 N., R. 19 W.,
Sec. 22, NE¼NE¼SE¼;
Sec. 23, NE¼SW¼,S½NE¼SW¼SW¼, NW¼SW¼SW¼, N½SE¼SW¼, SW¼SE¼SW¼;
Sec. 29, W½NE¼NE¼NE¼, W½NW¼NE¼NE¼, NW¼NE¼, W½NE¼NW¼, SE¼NE¼NW¼, NW¼NW¼.

Aggregating 215.00 acres, more or less.

SUPPLEMENTARY INFORMATION: On December 20, 1996, the Yuma Field Office published a notice for this public land sale in the **Federal Register** (61 FR 67342). This notice segregated the subject public land from appropriation under the public land laws, including the mining laws, pending disposition of the action or 270 days from the date of publication of the notice in the **Federal Register**. Four extensions of the Notice have been published in the **Federal Register:** October 15, 1999 (64 FR 55956); September 23, 1997 (62 FR 49701); June 1, 1998 (63 FR 29746); and January 22, 1999 (64 FR 3543–3544). Upon publication of this Notice in the **Federal Register**, the segregation will be extended pending disposition of the action or for another 270-day period, whichever occurs first.

FOR FURTHER INFORMATION CONTACT: Debbie DeBock, Realty Specialist, Bureau of Land Management, Yuma Field Office, 2555 East Gila Ridge Road, Yuma, AZ 85365, (520) 317–3208.

Dated: July 11, 2000.

Maureen A. Merrell,

Assistant Field Manager/Acting Field Manager.

[FR Doc. 00–17988 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–32–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

Notice of Realty Action; Competitive Sale of Public Lands in Clark County, Nevada

The following lands have been designated for disposal under Public Law 105–263, the Southern Nevada Public Land Management Act of 1998 (112 Stat. 2343); they will be sold competitively in accordance with Section 203 and Section 209 of the Federal Land Policy and Management Act of 1976 (90 Stat. 2750, 43 U.S.C. 1713,1719, and 1740) at not less than the appraised fair market value (FMV).

MOUNT DIABLO MERIDIAN, NEVADA

Serial No.	Legal description	Gross acreage
N–66693–00–90	T. 21 S., R. 60 E., sec. 17: SW¼NW¼SE¼	10.00
N–66694–00–91	T. 21 S., R. 60 E., sec. 18: E½NW¼SE¼SW¼	5.00
N–66695–00–92	T. 21 S., R. 60 E., sec. 31: lot 13	5.00
N–66696–00–93	T. 21 S., R. 60 E., sec. 31: E½SW¼SW¼NE¼	5.00
N–66697–00–94	T. 22 S., R. 60 E., sec. 11: NE¼NW¼NW¼	10.00
N–66698–00–95	T. 22 S., R. 60 E., sec. 12: SE¼NE¼SE¼NW¼, E½SE¼SE¼NW¼	7.50
N–66699–00–96	T. 22 S., R. 60 E., sec. 12: NE¼SE¼NE¼NE¼	2.50
N–66700–00–97	T. 22 S., R. 60 E., sec. 12: S½SW¼NW¼NE¼	5.00
N–66701–00–98	T. 22 S., R. 60 E., sec. 12: SE¼SE¼NW¼NE¼	2.50
N–66702–00–99	T. 22 S., R. 60 E., sec. 12: E½SW¼SE¼NE¼, SW¼SE¼SE¼NE¼	7.50
N–66703–00–100	T. 22 S., R. 60 E., sec. 12: SW¼SE¼NE¼NE¼, N½NE¼SE¼NE¼, NE¼NW¼SE¼NE¼, W½NW¼SE¼NE¼.	15.00
N–66704–00–101	T. 22 S., R. 60 E., sec. 12: E½SE¼SW¼NE¼	5.00
N–66705–00–102	T. 22 S., R. 61 E., sec. 7: SE¼SE¼NW¼	10.00
N–66706–00–103	T. 22 S., R. 61 E., sec. 19: lot 5	1.25
N–66707–00–104	T. 22 S., R. 61 E., sec. 19: lot 9	1.25
N–66708–00–105	T. 22 S., R. 61 E., sec. 19: lot 10	1.25
N–66709–00–106	T. 22 S., R. 61 E., sec. 19: lot 11	1.25
N–66710–00–107	T. 22 S., R. 61 E., sec. 19: lot 12	1.25
N–66711–00–108	T. 22 S., R. 61 E., sec. 19: lot 14	1.33
N–66712–00–109	T. 22 S., R. 61 E., sec. 20: lot 60	5.00
N–66713–00–110	T. 22 S., R. 61 E., sec. 20: lot 79	5.00
N–66714–00–111	T. 22 S., R. 61 E., sec. 20: lot 80	5.00
N–66715–00–112	T. 22 S., R. 61 E., sec. 20: lot 72	5.00
N–66716–00–113	T. 22 S., R. 61 E., sec. 20: lot 84	5.00
N–66717–00–114	T. 22 S., R. 61 E., sec. 20: lot 87	5.00
N–66729–00–115	T. 22 S., R. 61 E., sec. 19: lot 15	1.25

Upon publication of this notice and until the completion of the sale, the BLM is no longer accepting land use applications affecting any parcel being offered for sale. Any applications filed after this notice for rights-of-way, permits, leases, and other uses will be returned to the applicants with no action taken. If the land is sold, conveyance of the locatable mineral interests will occur simultaneously with the sale of the land. The locatable mineral interests being offered have no known mineral value. Acceptance of a sale offer will constitute an application for conveyance of those mineral interests. The applicant will be required to pay a $50.00 nonrefundable filing fee in conjunction with the final payment for processing of the conveyance of the locatable mineral interests.

The terms and conditions applicable to the sale are as follows:

All Parcels Subject to the Following

1. All leaseable and saleable mineral deposits are reserved on land sold; permittees, licensees, and lessees, retain the right to prospect for, mine, and remove the minerals owned by the United States under applicable law and any regulations that the Secretary of the Interior may prescribe, including all necessary access and exit rights.

2. A right-of-way is reserved for ditches and canals constructed by authority of the United States under the Act of August 30, 1890 (43 U.S.C. 945).

3. All land parcels are subject to all valid and existing rights. Encumbrances of record are available for review during business hours, 7:30 a.m. to 4:15 p.m., Monday through Friday, at the Bureau of Land Management, Las Vegas Field Office, 4765 Vegas Drive, Las Vegas, Nevada.

4. All land parcels are subject to reservations for roads, public utilities and flood control purposes, both existing and proposed, in accordance with the local governing entities' Transportation Plans.

5. All purchaser's/patentees, by accepting a patent, agree to indemnify, defend, and hold the United States harmless from any costs, damages, claims, causes of action, penalties, fines, liabilities, and judgements of any kind or nature arising from the past, present, and future acts or omissions of the patentee or their employees, agents, contractors, or lessees, or any third-party, arising out of, or in connection with, the patentee's use, occupancy, or operations on the patented real property. This indemnification and hold harmless agreement includes, but is not limited to, acts and omissions of the patentee and their employees, agents, contractors, or lessees, or any third party, arising out of or in connection with the use and/or occupancy of the patented real property which has already resulted or does hereafter result in: (1) Violations of federal, state, and local laws and regulations that are now, or may in the future become, applicable to the real property; (2) Judgements, claims or demands of any kind assessed against the United States; (3) Costs, expenses, or damages of any kind incurred by the United States; (4) Other releases or threatened releases of solid or hazardous waste(s) and/or hazardous substances(s), as defined by federal or state environmental laws; off, on, into or under land, property and other interests of the United States; (5) Other activities by which solids or hazardous substances or wastes, as defined by federal and state environmental laws are generated, released, stored, used or otherwise disposed of on the patented real property, and any cleanup response, remedial action, or other actions related in any manner to said solid or hazardous substances or wastes; or (6) Natural resource damages as defined by federal and state law. This covenant shall be construed as running with the patented real property and may be enforced by the United States in a court of competent jurisdiction.

The appraisal reports for each parcel will be available for public review at the BLM's Las Vegas Field Office on or before September 1, 2000.

Each parcel will be offered via the Internet, by sealed bid, and at oral auction. Pre-auction bidding via the

Internet will be conducted from September 25, 2000, through October 24, 2000. Internet bidding procedures will be available on or before September 25, 2000 at www.auctionrp.com. All sealed bids must be received in the BLM's Las Vegas Field Office(LVFO), 4765 Vegas Drive, Las Vegas, NV 89108, by no later than 4:15 p.m. PST, October 30, 2000. Sealed bid envelopes must be marked on the lower front left corner with the parcel number and sale date. Bids must be for not less than the appraised fair market value (FMV), with a separate bid submitted for each parcel.

Each sealed bid and the highest written Internet bid shall be accompanied by a certified check, money order, bank draft, or cashier's check made payable to the Bureau of Land Management, for not less than 10 percent of the amount bid.

The bid deposit for the highest qualified written Internet bid must be received at the Bureau of Land Management, Las Vegas Field Office, 4765 Vegas Drive, Las Vegas, NV 89108 by 4:15 PST on October 27, 2000. The highest qualified written Internet bid or sealed bid on each parcel will determine the starting monetary point for oral bidding. If no written Internet bids or sealed bids are received, oral bidding will begin at the appraised FMV. The parcels will be offered for competitive sale by oral auction beginning at 9 a.m. PDT, November 2, 2000, at the Clark County Commission Chambers, Clark County Government Center, 500 S. Grand Central Parkway, Las Vegas, Nevada. Registration for oral bidding will begin at 8 a.m. the day of sale and will continue throughout the auction. All bidders oral are required to register.

The highest qualifying bid for any parcel, whether written Internet, sealed, or oral, will be declared the highest bid. The apparent high bidder, if an oral bidder, must submit the required bid deposit immediately following the close of the sale in the form of cash, personal check, bank draft, cashiers check, money order, or any combination thereof, made payable to the Bureau of Land Management, for not less than 20 percent of the amount bid.

The remainder of the full bid price, whether written Internet, sealed or oral, must be paid within 180 calendar days of the date of the sale. Failure to pay the full price within the 180 days will disqualify the apparent high bidder and cause the bid deposit to be forfeited to the BLM. Unsold parcels may be offered on the Internet beginning November 13, 2000. Internet auction procedures will be available at www.auctionrp.com on or before November 13, 2000. If unsold on the Internet, parcels may be offered at future auctions without additional legal notice.

Federal law requires that bidders must be U.S. citizens 18 years of age or older; a corporation subject to the laws of any State or of the United States; a State, State instrumentality, or political subdivision authorized to hold property; or an entity, including but not limited to associations or partnerships, capable of holding property or interests therein under the law of the State of Nevada. Certification of qualification, including citizenship or corporation or partnership, must accompany the bid deposit.

In order to determine the fair market value of the subject public lands through appraisal, certain assumptions have been made on the attributes and limitations of the lands and potential effects of local regulations and policies on potential future land uses. Through publication of this notice, the Bureau of Land Management gives notice that these assumptions may not be endorsed or approved by units of local government. Furthermore, no warranty of any kind shall be given or implied by the United States as to the potential uses of the lands offered for sale; conveyance of the subject lands will not be on a contingency basis. It is the buyers' responsibility to be aware of all applicable local government policies and regulations that would affect the subject lands. It is also the buyers responsibility to be aware of existing or projected use of nearby properties. When conveyed out of federal ownership, the lands will be subject to any applicable reviews and approvals by the respective unit of local government for proposed future uses, and any such reviews and approvals would be the responsibility of the buyer. Any land lacking access from a public road or highway will be conveyed as such, and future access acquisition will be the responsibility of the buyer.

Detailed information concerning the sale, including the reservations, sale procedures and conditions, planning and environmental documents, is available at the Bureau of Land Management, Las Vegas Field Office, 4765 Vegas Drive, Las Vegas, NV 89108, or by calling (702) 647–5114. Some but not all of this information will also available on the Internet at http://www.nv.blm.gov. Click on Southern Nevada Public Land Management Act, then click on Land Sale Information.

For a period of 45 days from the date of publication of this notice in the **Federal Register**, the general public and interested parties may submit comments to the Field Manager, Las Vegas Field Office, 4765 Vegas Drive, Las Vegas, Nevada 89108. Any adverse comments will be reviewed by the State Director, who may sustain, vacate, or modify this realty action. In the absence of any adverse comments, this realty action will become the final determination of the Department of the Interior. The Bureau of Land Management may accept or reject any or all offers, or withdraw any land or interest in the land from sale, if, in the opinion of the authorized officer, consummation of the sale would not be fully consistent with FLPMA or other applicable laws or is determined not in the publics interest. Any comments received during this process, as well as the commentors name and address, will be available to the public in the administrative record and/or pursuant to a Freedom of Information Act request. You may indicate for the record that you do not wish your name and/or address made available to the public. Any determination by the Bureau of Land Management to release or withhold the names and/or addresses of those who comment will be made on a case-by-case basis. A commentor's request to have their name and/or address withheld from public release will be honored to the extent permissible by law.

Lands will not be offered for sale until at least 60 days after the date of publication of this notice in the **Federal Register**.

Dated: June 30, 2000.

Mark T. Morse,

Field Manager.

[FR Doc. 00–17854 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–HC–U

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[AZ–050–00–1230–00; 8371]

Arizona: Long-Term Visitor Area Program for 2000–2001 and Subsequent Use Seasons; Revision to Existing Supplementary Rules, Yuma Field Office, Arizona, and California Desert District, California

AGENCY: Bureau of Land Management, Interior.

ACTION: Publication of supplementary rules for Long-Term Visitor Areas within the California Desert District, El Centro Resource Area.

SUMMARY: The Bureau of Land Management (BLM) Yuma Field Office and California Desert District announce revisions to the Long-Term Visitor Area (LTVA) Program. The program, which was instituted in 1983, established

designated LTVAs and identified an annual long-term use season from September 15 to April 15. During the long-term season, visitors who wish to camp to public lands in one location for extended periods must stay in the designated LTVAs and purchase an LTVA permit.

EFFECTIVE DATE: September 15, 2000.

FOR FURTHER INFORMATION CONTACT: Mark Lowans, Outdoor Recreation Planner, Yuma Field Office, 2555 East Gila Ridge Road, Yuma, Arizona 85365, telephone (520) 317–3210; and Anna Atkinson, Outdoor Recreation Planner, Palm Springs-South Coast Research Area, 690 West Garnet Avenue, North Palm Springs, California 92258, telephone (760) 251–4800; or Bob Haggerty, Outdoor Recreation Planner, El Centro Resource Area, 1661 South Fourth Street, El Centro, California 92243, telephone (760) 337–4400.

SUPPLEMENTARY INFORMATION: The purpose of the LTVA program is to provide areas for long-term winter camping use. The sites designated as LTVAs are, in most cases, the traditional use areas of long-term visitors. Designated sites were selected using criteria developed during the land management planning process, and environmental assessments were completed for each site location.

The program was established to safely and properly accommodate the increasing demand for long-term winter visitation and to provide natural resource protection through improved management of this use. The designation of LTVAs assures that specific locations are available for long-term use year after year, and that inappropriate areas are not used for extended periods.

Visitors may camp without an LTVA permit outside of LTVAS, on public lands not otherwise posted or closed to camping, for up to 14 days in any 28-day period.

Authority for the designation of LTVAs is contained in Title 43, Code of Federal Regulations, Subpart 8372, Sections 0–3 and 0–5(g). Authority for the establishment of an LTVA program is contained in Title 43, Code of Federal Regulations, Subpart 8372, Section 1, and for the payment of fees in Title 36, Code of Federal Regulations, Subpart 71. The authority for establishing supplementary rules is contained in Title 43, Subpart 8365, Section 1–6. The LTVA supplementary rules have been developed to meet the goals of individual resource management plans. These rules will be available in each local office having jurisdiction over the lands, sites, or facilities affected, and will be posted near and/or within the lands, sites, or facilities affected. Violations of supplementary rules are punishable by a fine not to exceed $100,000 and/or imprisonment not to exceed 12 months.

The following are the supplemental rules for the designated LTVAs and are in addition to rules of conduct set forth in Title 43, Code of Federal Regulations, Subpart 8365, Section 0.1 through 1–7.

The following supplemental rules apply year-long to all public land users who enter the LTVAS.

1. The Permit. A permit is required to camp in a designated LTVA between September 15 and April 15. The permit authorizes the permittee to camp within any designated LTVA using those camping or dwelling unit(s) indicated on the permit between the period from September 15 to April 15. There are two types of permits: Long-term and short-visit. The long-term permit fee is $100.00, U.S. funds only, for the entire season and any part of the season. The short-term permit is $20.00 for seven (7) consecutive days. The short-visit permit may be renewal an unlimited number of times for the cost of $20.00 for seven consecutive days. *No refunds are made on permit fees.*

2. The Permit. The be valid, the short-visit permit decal or long-term permit decal must be affixed at the time of purchase, with the adhesive backing, to the bottom right-hand corner of the windshield of all transportation vehicles and in a clearly visible location on all camping units. A maximum of two (2) secondary vehicles is permitted.

3. Permit Transfers. The permit may not be reassigned or transferred by the permittee.

4. Permit Revocation. An authorized BLM officer may revoke, without reimbursement, any LTVA permit issued to any person when the permittee violates any BLM rule or regulation, or when the permittee, permittee's family, or guest's conduct is inconsistent with the goal of BLM's LTVA Program. Failure to return any LTVA permit to an authorized BLM officer upon demand is a violation of this supplemental rule. Any permittee whose permit is revoked must remove all property and leave the LTVA system within 12 hours of notice. The revoked permittee will not be allowed into any other LTVA in Arizona or California for the remainder of the LTVA season.

5. Unoccupied Camping Units. Camping units or campsites must not be left unoccupied within any LTVA for periods of greater than 5 days unless approved in advance by an authorized BLM officer.

6. Parking. For your safety and privacy, you must maintain a minimum of 15 feet of space between dwelling units.

7. Removal of Wheels and Campers. Campers, trailers, and other dwelling units must remain mobile. Wheels must remain on all wheeled vehicles. Pickup campers may be set on jacks manufactured for that purpose.

8. Quiet Hours. Quiet hours are from 10 p.m. to 6 a.m. in accordance with applicable State time zone standards, or as otherwise posted.

9. Noise. Operation of audio devices or motorized equipment, including generators, in a manner that makes unreasonable noise as determined by the authorized BLM officer is prohibited. Amplified music is allowed only within La Posa and Imperial Dam LTVAs and only in locations designated by BLM or when approved in advance by an authorized BLM officer.

10. Access. Do not block roads or trails commonly in public use with your parked vehicles, stones, wooden barricades, or by any other means.

11. Structures and Landscaping. Fixed structures of any type are prohibited and temporary structures must conform to posted policies. This includes, but is not limited to fences, dog runs, storage units, and windbreaks. Alterations to the natural landscape are not allowed. Painting rocks or defacing or damaging any natural or archaeological feature is prohibited.

12. Livestock. Boarding of livestock (horses, cattle, sheep, goats, *etc.*) within LTVA boundaries is permitted only when approved in advance by an authorized BLM officer.

13. Pets. Pets must be kept on a leash at all times. Keep an eye on your pets. Unattended and unwatched pets may fall prey to coyotes or other desert predators. Pet owners are responsible for clean-up and sanitary disposal of pet waste.

14. Cultural Resources. Do not disturb any archaeological or historical values including, but not limited to, petroglyphs, ruins, historic buildings, and artifacts that may occur on public lands.

15. Trash. Place all trash in designated receptacles. Public trash facilities are shown in the LTVA brochure. Depositing trash or holding-tank sewage in vault toilets is prohibited. An LTVA permit is require for trash disposal within all LTVA campgrounds except for the Mule Mountain LTVA. The changing of motor oil, vehicular fluids, or disposal and possession of these used substances within an LTVA is strictly prohibited.

16. Dumping. Absolutely no dumping of sewage, gray water, or garbage on the ground. This includes motor oil and any other waste products: Federal, state and county sanitation laws and county ordinances specifically prohibit these practices. Sanitary dump station locations are shown in the LTVA brochure. LTVA permits are required for dumping within all LTVA campgrounds except for the Midland LTVA.

17. Self-Contained Vehicles. In Pilot Knob, Midland, Tamarisk, and Hot Springs LTVAs, camping is restricted to self-contained camping units only. Self-contained units must have a permanent affixed waste water holding tank of 10-gallon minimum capacity. Port-a-potty systems, or systems which utilize portable holding tanks, or permanent holding tanks of less than 10-gallon capacity are not considered to be self-contained. The La Posa, Imperial Dam, and Mule Mountain LTVAs are restricted to self-contained camping units, except within 500 feet of a vault or rest room.

18. Campfires. Campfires are permitted in LTVAs subject to all local, state, and Federal regulations. Comply with posted rules.

19. Wood Collection. No wood collection is permitted within the LTVAs. Possession of native firewood is prohibited. Please contact the nearest BLM office for current regulations concerning wood collection.

20. Speed Limit. The speed limit in LTVAs is 15 mph or as otherwise posted.

21. Off-Highway Vehicle Use. Motorized vehicles must remain on existing roads, trails, and washes.

22. Vehicle Use. It is prohibited to operate any vehicle in violation of State or local laws and regulations relating to use, standards, registration, operation, and inspection.

23. Firearms. The discharge or use of firearms or weapons if prohibited inside or within ½ mile of the LTVAS.

24. Vending Permits. Any commercial activity requires a vending permit. Please contact the nearest BLM office for information on vending or concession permits.

25. Aircraft Use. Landing or taking off of aircraft, including ultralights and hot air balloons, is prohibited in LTVAs.

26. Perimeter Camping. No camping is allowed within 1 mile of Hot Spring, Tamarisk, Pilot Knob LTVAs and within 2 miles of Midland LTVA.

27. Hot Spring Spa and Day Use Area: Food, beverages, glass containers, soap, and pets are prohibited within the fenced-in area at the Hot Springs Spa. Day use hours are 5 a.m. to midnight.

28. Mule Mountain LTVA. All camping within Wiley's Well and Coon Hollow campgrounds is restricted to designated sites only and is limited to one (1) camping or dwelling unit per site.

29. Imperial Dam and La Posa LTVAs. Overnight occupancy is prohibited in desert washes in Imperial Dam and La Posa LTVAs.

30. La Posa LTVA. Access to La Posa LTVA is restricted to legal access roads along U.S. Highway 95. Construction and use of other access points are prohibited. This includes removal or modification of barricades, such as fences, ditches, and berms.

31. Posted Rules. Observe all posted rules. Individual LTVAs may have additional specific rules. If posted rules differ from these supplemental rules, the posted rules take precedence.

32. Other Laws. LTVA permit holders are required to observe all Federal, State, and local laws and regulations applicable to the LTVA and shall keep the LTVA and, specifically, their campsite, in a neat, orderly, and sanitary condition.

33. Length of Stay. Length of stay in an LTVA between April 16 and September 14 is limited to 14 days in a 28–day period. After the 14th day of occupation campers must move outside of a 25–mile radius of the previous location.

Violation of these supplementary rules may result in revocation of the LTVA permit, issuance of a citation, and/or arrest which may require appearance before a U.S. Magistrate or penalties upt o $100,000 and/or one-year imprisonment.

This notice is published under the authority of Title 43, Code of Federal Regulations, Subpart 8365, Section 1–6.

Dated: June 30, 2000.

Gail Acheson,

Field Manager, Yuma Field Office.

James G. Kenna,

Field Manager, Palm Spring-South Coast Field Office.

Elayn Briggs,

Acting Field Manager, El Centro Field Office.

[FR Doc. 00–17858 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–32–M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[OR–130–2810–HT; GPO–0284]

Notice of Regulated Fire Closure for Bureau of Land Management Public Lands in the State of Washington

AGENCY: Bureau of Land Management, Spokane District.

SUMMARY: Pursuant to 43 CFR 9212.2, the following acts are prohibited on public lands within the Spokane District, Bureau of Land Management (BLM) including Juniper Forest/Juniper Dunes Recreation Area, and areas surrounding Hog Canyon, Miller Ranch/Fishtrap, Pacific Lake, Twin Lakes, Coffeepot, Yakima River Canyon, Douglas Creek, Chopaka/Palmer Mountain, Split Rock, Liberty, Saddle Mountains, Lakeview Ranch/Lake Creek, Boundary Dam, and Escure Ranch/Rock Creek recreation sites, beginning at noon July 15, 2000 until further notice.

1. Building, maintaining, attending or using a fire, campfire or stove fire, including charcoal briquette fire (43 CFR 9212.2).

Note: Liquified and bottled gas stoves and heaters are permitted provided that they are within an area at least 10 feet in diameter that is barren or clear of all flammable material.

2. Smoking while traveling in timber, brush or grass areas, except in vehicles on roads, on barren or cleared areas at least 3 feet in diameter or boats on rivers and lakes.

3. Operating any type of motorized vehicle off developed roadways. Parking of vehicles off roadways must be done in an area barren of flammable materials (43 CFR 9212.2(b)(1)).

Note: Developed roadways are those which are clear of flammable debris, berm to berm. Juniper Dunes Recreation Area is Exempt.

Pursuant to 43 CFR 9212.3(a) the following persons are exempt from this order:

1. Persons with a permit that specifically authorized the otherwise prohibited act or omission.

2. Any Federal, State or local officer or a member of an organized rescue or firefighting force in the performance of an official duty.

Violation of these prohibitions is punishable by a fine of not more than $1,000.00 or to imprisonment of not more than 12 months, or both.

FOR FURTHER INFORMATION CONTACT: Scott Boyd, Fire Management Officer, Bureau of Land Management, Spokane District Officer, 1103 N. Fancher Road, Spokane Washington, 99212; or call (509) 536–1200.

Dated July 11, 2000.

Joseph K. Buesing,

District Manager.

[FR Doc. 00–17987 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–33–U

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[ID–957–1430–BJ]

Idaho: Filing of Plats of Survey

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice.

SUMMARY: The plats of the following described lands were officially filed in the Idaho State Office, Bureau of Land Management, Boise, Idaho, effective 9 a.m., on the dates specified:

The plat representing the dependent resurvey of a portion of the subdivisional lines, and the subdivision of sections 16 and 17, T. 5 S., R. 36 E., Boise Meridian, Idaho, Group Number 945 (Part 1 of 2), was accepted April 12, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Indian Affairs, Fort Hall Agency.

The plat representing the corrective dependent resurvey of portions of the west and north boundaries, and the dependent resurvey of portions of the north boundary, subdivisional lines, and the subdivision of sections 4, 5, 6, 7, and 9, T. 5 S., R. 36 E., Boise Meridian, Idaho, Group Number 945 (Part 2 of 2), was accepted April 12, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Indian Affairs, Fort Hall Agency.

The plat representing the dependent resurvey of portions of the subdivisional lines and of the subdivision of sections 21 and 22, and the further subdivision of section 21, and the subdivision of section 27, T. 2 N., R. 5 W., Boise Meridian, Idaho, Group Number 1049, was accepted April 17, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Land Management.

The plat representing the dependent resurvey of portions of the south boundary, subdivisional lines, and adjusted 1892 meanders of the left bank of the Clearwater River, and the subdivision of section 33, the survey of 1997 meanders of the left bank of the Clearwater River, and the metes-and-bounds survey of certain partition lines in section 33, T. 37 N., R. 2 W., Boise Meridian, Idaho, Group Number 1006, was accepted April 20, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Indian Affairs, Northern Idaho Agency.

The plat representing the dependent resurvey of portions of the south boundary, the east boundary, the subdivisional lines, and of the subdivision of sections 23, 25, 26, 27, 34, 35, and 36, and the additional subdivision of sections 23, 25, 26, 27, 34, 35, and 36, and the metes-and-bounds survey of a portion of the centerline of Webb Road in section 23, T. 35 N., R. 4 W., Boise Meridian, Idaho, Group Number 1018, was accepted April 20, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Indian Affairs, Northern Idaho Agency.

A supplemental plat was prepared to correct certain erroneously depicted distances and lines in sections 6, 7, and 8, T. 47 N., R. 5 E., and to correct a portion of the plat accepted July 1, 1997, and was accepted May 8, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Land Management, Idaho.

The plat representing the dependent resurvey of a portion of the north boundary, and a portion of the subdivisional lines, and the subdivision of section 2, and a metes-and-bounds survey in section 2, T. 5 S., R. 3 E., Boise Meridian, Idaho, Group Number 1063, was accepted May 8, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Land Management.

The plat constituting the entire survey record of the dependent resurvey of a portion of the subdivisional lines, and a metes-and-bounds survey in former lot 18 in section 7, T. 5 S., R. 36 E., Boise Meridian, Idaho, Group Number 1069, was accepted May 12, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Indian Affairs, Fort Hall Agency.

The plat representing the dependent resurvey of a portion of the subdivisional lines, and the subdivision of section 14, T. 10 N., R. 4 E., Boise Meridian, Idaho, Group Number 990, was accepted May 26, 2000.

The plat was prepared to meet certain administrative needs of the USDA, Forest Service, Boise National Forest.

The plat representing the dependent resurvey of portions of the east boundary, the subdivisional lines, and the subdivision of sections 1 and 11, and the subdivision of section 12, T. 8 S., R. 12 E., Boise Meridian, Idaho, Group Number 1024, was accepted June 1, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Land Management.

The plat representing the dependent resurvey of portions of the south boundary and subdivisional lines, and the subdivision of sections 27, 28, 29, 32, and 34, T. 9 S., R. 12 E., Boise Meridian, Idaho, Group Number 1057, was accepted June 15, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Land Management.

The plat representing the dependent resurvey of a portion of the subdivisional lines, and the subdivision of section 3, T. 10 S., R. 12 E., Boise Meridian, Idaho, Group Number 1058, was accepted June 16, 2000.

The plat was prepared to meet certain administrative needs of the Bureau of Land Management.

The plat representing the dependent resurvey of a portion of the subdivisional lines, T. 2 S., R. 9 E., Boise Meridian, Idaho, Group Number 1051, was accepted June 21, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Land Management.

The plat constituting the entire survey record of the dependent resurvey of a portion of the subdivisional lines, and the subdivision of section 14, and the execution of a metes-and-bounds survey of the centerline of an existing road in section 14, T. 13 S., R. 4 E., Boise Meridian, Idaho, Group Number 1073, was accepted June 21, 2000. The plat was prepared to meet certain administrative needs of the U.S.A.F., Mountain Home Air Force Base.

The plat representing the dependent resurvey of portions of the west boundary and of the subdivisional lines, and the subdivision of section 30, T. 1 N., R. 4 W., Boise Meridian, Idaho, Group Number 1047, was accepted June 22, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Land Management.

The plat representing the dependent resurvey of a portion of the subdivisional lines, the corrective dependent resurvey of a portion of the subdivisional lines, and the corrective resurvey of the subdivision of sections 14 and 15, and the further subdivision of section 14, T. 12 S., R. 20 E., Boise Meridian, Idaho, Group Number 1053, was accepted June 30, 2000. The plat was prepared to meet certain administrative needs of the Bureau of Land Management.

FOR FURTHER INFORMATION CONTACT: Duane Olsen, Chief, Cadastral Survey, Idaho State Office, Bureau of Land Management, 1387 South Vinnell Way, Boise, Idaho, 83709–1657, 208–373–3980.

Dated: July 6, 2000.

Duane E. Olsen,

Chief, Cadastral Surveyor for Idaho.

[FR Doc. 00–17949 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–GG–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[NM–952–00–1420–BJ]

Notice of Filing of Plats of Survey; New Mexico

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice.

SUMMARY: The plats of survey described below are scheduled to be officially filed in the New Mexico State Office, Bureau of Land Management, Santa Fe, New Mexico, (30) thirty calendar days from the date of this publication.

New Mexico Principal Meridian, New Mexico

T. 29 N., R. 11 W., approved June 8, 2000, for Group 944 NM.

Tigua Indian Reservation, approved June 8, 2000, Supplemental Plat.

If a protest against a survey, as shown on any of the above plats is received prior to the date of official filing, the filing will be stayed pending consideration of the protest. A plat will not be officially filed until the day after all protests have been dismissed and become final or appeals from the dismissal affirmed.

A person or party who wishes to protest against any of these surveys must file a written protest with the NM State Director, Bureau of Land Management, stating that they wish to protest.

A statement of reasons for a protest may be filed with the notice of protest to the State Director, or the statement of reasons must be filed with the State Director within thirty (30) days after the protest is filed. The above-listed plats represent dependent resurveys, surveys, and subdivisions.

These plats will be available for inspection in the New Mexico State Office, Bureau of Land Management, P.O. Box 27115, Santa Fe, New Mexico, 87502–0115. Copies may be obtained from this office upon payment of $1.10 per sheet.

Dated: July 6, 2000.

John P. Bennett,

Chief Cadastral Surveyor for New Mexico.

[FR Doc. 00–17948 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–FB–M

DEPARTMENT OF THE INTERIOR

National Park Service

Availability of the Great Egg Harbor National Scenic and Recreational River Final Comprehensive Management Plan and Environmental Impact Statement

AGENCY: National Park Service, Interior.

ACTION: Notice of Availability of the Great Egg Harbor National Scenic and Recreational River Final Comprehensive Management Plan and Environmental Impact Statement.

SUMMARY: The National Park Service has finalized the Comprehensive Management Plan and Environmental Impact Statement for the management, protection, and use of the Great Egg Harbor National Scenic and Recreational River in New Jersey. Comments will be accepted for 30 days from the date of this notice. Please be advised that, if requested, the National Park Service is required to supply the names and addresses of individuals providing comments. For more information about this document, contact Mary Vavra, National Park Service Manager by letter or telephone.

FOR FURTHER INFORMATION CONTACT: Mary Vavra, Program Manager, National Park Service, Philadelphia Support Office, 200 Chestnut Street, 3rd Floor, Philadelphia, PA 19106, (215) 597–9175.

Dated: July 6, 2000.

Marie Rust,

Regional Director, Northeast Region, National Park Service.

[FR Doc. 00–18033 Filed 7–14–00; 8:45 am]

BILLING CODE 4310–70–M

UNITED STATES INTERNATIONAL TRADE COMMISSION

[Investigation No. 731–TA–884 (Preliminary)]

Anhydrous Sodium Sulfate From Canada

AGENCY: United States International Trade Commission.

ACTION: Institution of antidumping investigation and scheduling of a preliminary phase investigation.

SUMMARY: The Commission hereby gives notice of the institution of an investigation and commencement of preliminary phase antidumping investigation No. 731–TA–884 (Preliminary) under section 733(a) of the Tariff Act of 1930 (19 U.S.C. 1673b(a)) (the Act) to determine whether there is a reasonable indication that an industry in the United States is materially injured or threatened with material injury, or the establishment of an industry in the United States is materially retarded, by reason of imports from Canada of anhydrous sodium sulfate, provided for in subheadings 2833.11.10 and 2833.11.50 of the Harmonized Tariff Schedule of the United States, that are alleged to be sold in the United States at less than fair value. Unless the Department of Commerce extends the time for initiation pursuant to section 732(c)(1)(B) of the Act (19 U.S.C. 1673a(c)(1)(B)), the Commission must reach a preliminary determination in antidumping investigations in 45 days, or in this case by August 24, 2000. The Commission's views are due at the Department of Commerce within five business days thereafter, or by August 31, 2000.

For further information concerning the conduct of this investigation and rules of general application, consult the Commission's rules of practice and procedure, part 201, subparts A through E (19 CFR part 201), and part 207, subparts A and B (19 CFR part 207).

EFFECTIVE DATE: July 10, 2000.

FOR FURTHER INFORMATION CONTACT: Fred Fischer (202–205–3179 or ffischer@usitc.gov), Office of Investigations, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436. Hearing-impaired persons can obtain information on this matter by contacting the Commission's TDD terminal on 202–205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (*http://www.usitc.gov*).

SUPPLEMENTARY INFORMATION:

Background.—This investigation is being instituted in response to a petition filed on July 10, 2000, by Cooper Natural Resources, Tulsa, OK, and IMC Chemicals Inc., New York, NY.

Participation in the investigation and public service list.—Persons (other than petitioners) wishing to participate in the investigation as parties must file an entry of appearance with the Secretary to the Commission, as provided in §§ 201.11 and 207.10 of the Commission's rules, not later than seven days after publication of this notice in the **Federal Register**. Industrial users and (if the merchandise under investigation is sold at the retail level)

representative consumer organizations have the right to appear as parties in Commission antidumping investigations. The Secretary will prepare a public service list containing the names and addresses of all persons, or their representatives, who are parties to this investigation upon the expiration of the period for filing entries of appearance.

Limited disclosure of business proprietary information (BPI) under an administrative protective order (APO) and BPI service list.—Pursuant to § 207.7(a) of the Commission's rules, the Secretary will make BPI gathered in this investigation available to authorized applicants representing interested parties (as defined in 19 U.S.C. 1677(9)) who are parties to the investigation under the APO issued in the investigation, provided that the application is made not later than seven days after the publication of this notice in the **Federal Register**. A separate service list will be maintained by the Secretary for those parties authorized to receive BPI under the APO.

Conference.—The Commission's Director of Operations has scheduled a conference in connection with this investigation for 9:30 a.m. on July 31, 2000, at the U.S. International Trade Commission Building, 500 E Street SW., Washington, DC. Parties wishing to participate in the conference should contact Fred Fischer (202–205–3179 or ffischer@usitc.gov) not later than July 24, 2000, to arrange for their appearance. Parties in support of the imposition of antidumping duties in this investigation and parties in opposition to the imposition of such duties will each be collectively allocated one hour within which to make an oral presentation at the conference. A nonparty who has testimony that may aid the Commission's deliberations may request permission to present a short statement at the conference.

Written submissions.—As provided in §§ 201.8 and 207.15 of the Commission's rules, any person may submit to the Commission on or before August 3, 2000, a written brief containing information and arguments pertinent to the subject matter of the investigation. Parties may file written testimony in connection with their presentation at the conference no later than three days before the conference. If briefs or written testimony contain BPI, they must conform with the requirements of §§ 201.6, 207.3, and 207.7 of the Commission's rules. The Commission's rules do not authorize filing of submissions with the Secretary by facsimile or electronic means.

In accordance with § 201.16(c) and 207.3 of the rules, each document filed by a party to the investigation must be served on all other parties to the investigation (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

Authority: This investigation is being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.12 of the Commission's rules.

By order of the Commission.
Issued: July 11, 2000.

Donna R. Koehnke,
Secretary.

[FR Doc. 00–17992 Filed 7–14–00; 8:45 am]

BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigations Nos. 731–TA–831–832, 835, 837 (Final)]

Certain Cold-Rolled Steel Products From China, Indonesia, Slovakia, and Taiwan

Determination

On the basis of the record[1] developed in the subject investigations, the United States International Trade Commission determines,[2] pursuant to section 735(b) of the Tariff Act of 1930 (19 U.S.C. 1673d(b)) (the Act), that an industry in the United States is not materially injured or threatened with material injury, and the establishment of an industry in the United States is not materially retarded, by reason of imports from China, Indonesia, Slovakia, and Taiwan of certain cold-rolled steel products that have been found by the Department of Commerce to be sold in the United States at less than fair value (LTFV).

Background

The Commission instituted these investigations effective June 2, 1999, following receipt of petitions filed with the Commission and the Department of Commerce by Bethlehem Steel Corporation (Bethlehem, PA); U.S. Steel Group (Pittsburgh, PA); Ispat Inland, Inc. (East Chicago, IL); LTV Steel Co., Inc. (Cleveland, OH); National Steel Corporation (Mishawaka, IN); Gulf States Steel, Inc. (Gadsden, AL); Steel Dynamics, Inc. (Butler, IN); Weirton Steel Corporation (Weirton, WV); and the United States Steelworkers of America, Pittsburgh, PA. The final phase of the investigations was scheduled by the Commission following notification of preliminary determinations by the Department of Commerce that imports of certain cold-rolled steel products from China, Indonesia, Slovakia, and Taiwan were being sold at LTFV within the meaning of section 733(b) of the Act (19 U.S.C. 1673b(b)). Notice of the scheduling of the Commission's investigations and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the **Federal Register** of December 1, 1999 (64 FR 67307). The hearing was held in Washington, DC, on January 20, 2000, and all persons who requested the opportunity were permitted to appear in person or by counsel.

The Commission transmitted its determinations in these investigations to the Secretary of Commerce on July 10, 2000. The views of the Commission are contained in USITC Publication 3320 (July 2000), entitled *Certain Cold-Rolled Steel Products from China, Indonesia, Slovakia, and Taiwan: Investigations Nos. 731–TA–831–832, 835, 837 (Final).*

Issued: July 11, 2000.
By order of the Commission.

Donna R. Koehnke,
Secretary.

[FR Doc. 00–17991 Filed 7–14–00; 8:45 am]

BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 731–TA–697 (Review)]

Pure Magnesium From Russia

AGENCY: United States International Trade Commission.

ACTION: Termination of five-year review.

SUMMARY: The subject five-year review was initiated in April 2000 to determine whether revocation of the existing antidumping duty order on pure magnesium from Russia would be likely to lead to continuation or recurrence of dumping and of material injury to a domestic industry. On July 7, 2000, the Department of Commerce published notice that it was revoking the order ''[b]ecause no domestic party responded to the sunset review notice of initiation by the applicable deadline'' (65 FR 41944). Accordingly, pursuant to section 751(c) of the Tariff Act of 1930

[1] The record is defined in sec. 207.2(f) of the Commission's Rules of Practice and Procedure (19 CFR 207.2(f)).

[2] Commissioner Lynn M. Bragg dissenting.

(19 U.S.C. 1675(c)), the subject review is terminated.

EFFECTIVE DATE: July 7, 2000.

FOR FURTHER INFORMATION CONTACT: Vera Libeau (202–205–3176), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearing-impaired individuals are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on 202–205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (http://www.usitc.gov).

Authority: This review is being terminated under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to § 207.69 of the Commission's rules (19 CFR 207.69).

Issued: July 10, 2000.

By order of the Commission.

Donna R. Koehnke,

Secretary.

[FR Doc. 00–17990 Filed 7–14–00; 8:45 am]

BILLING CODE 7020–02–P

MERIT SYSTEMS PROTECTION BOARD

Notice; Relocation of Headquarters

AGENCY: Merit Systems Protection Board.

ACTION: Notice of relocation of the Board's headquarters offices.

SUMMARY: The Merit Systems Protection Board (MSPB) publishes this notice to announces to the public the relocation of its headquarters offices. The Board will continue to receive filings through the move, which will take place over the weekend beginning on Friday night, July 21, 2000. Filings due to the Board after July 21, 2000 are to be addressed to U.S. Merit Systems Protection Board, 1615 M Street, NW., Washington, DC 20419. Headquarters telephone numbers, fax numbers and e-mail addresses will not change. The telephone, fax and e-mail systems will be out of operation from 12 noon on July 21, 2000 until 8:30 am Monday, July 24, 2000. The headquarters office will be open for business beginning on July 24, 2000.

EFFECTIVE DATE: July 17, 2000.

ADDRESSES: Office of the Clerk of the Board, U.S. Merit Systems Protection Board, 1120 Vermont Avenue, NW., Washington, DC 20419.

FOR FURTHER INFORMATION CONTACT: Matthew Shannon, or Shannon McCarthy(202) 653–7200.

Dated: July 11, 2000.

Robert E. Taylor,

Clerk of the Board.

[FR Doc. 00–17976 Filed 7–14–00; 8:45 am]

BILLING CODE 7400–01–M

NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES

National Endowment for the Arts; Combined Arts Advisory Panel

Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), as amended, notice is hereby given that two meetings of the Combined Arts Advisory Panel to the National Council on the Arts will be held at the Nancy Hanks Center, 1100 Pennsylvania Avenue, NW, Washington, D.C., 20506 as follows:

Theater/Musical Theater section B (Creativity and Organizational Capacity categories)—July 31—August 4, 2000, Room 714. A portion of this meeting, from 3:30 p.m. to 5:30 p.m. on August 3rd, will be open to the public for policy discussion. The remaining portions of this meeting, from 9:30 a.m. to 7 p.m. on July 31st—August 2nd, from 9:30 a.m. to 3:30 p.m. on August 3rd, and from 9:30 a.m. to 5 p.m. on August 4th, will be closed.

Local Arts Agencies section (Creativity and Organizational Capacity categories)—August 8–9, 2000, Room 730. A portion of this meeting, from 10:30 a.m. to 12 p.m. on August 9th, will be open to the public for policy discussion. The remaining portions of this meeting, from 9:00 a.m. to 5 p.m. on August 8th and from 9 a.m. to 10:30 a.m. and 12 p.m. to 3 p.m. on August 9th, will be closed.

The closed portions of these meetings are for the purpose of Panel review, discussion, evaluation, and recommendation on applications for financial assistance under the National Foundation on the Arts and the Humanities Act of 1965, as amended, including information given in confidence to the agency by grant applications. In accordance with the determination of the Chairman of May 12, 2000, these sessions will be closed to the public pursuant to (c)(4)(6) and (9)(B) of section 552b of Title 5, United States Code.

Any person may observe meetings, or portions thereof, of advisory panels that are open to the public, and, if time allows, may be permitted to participate in the panel's discussions at the discretion of the panel chairman and with the approval of the full-time Federal employee in attendance.

If you need special accommodations due to a disability, please contact the Office of AccessAbility, National Endowment for the Arts, 1100 Pennsylvania Avenue, NW, Washington, D.C. 20506, 202/682–5532, TDY–TDD 202/682–5496, at least seven (7) days prior to the meeting.

Further information with reference to this meeting can be obtained from Ms. Kathy Plowitz-Worden, Office of Guidelines & Panel Operations, National Endowment for the Arts, Washington, D.C. 20506, or call 202/682–5691.

Dated: July 7, 2000.

Kathy Plowitz-Worden,

Panel Coordination, Panel Operations, National Endowment for the Arts.

[FR Doc. 00–18048 Filed 7–14–00; 8:45 am]

BILLING CODE 7537–01–M

NATIONAL SCIENCE FOUNDATION

Advisory Committee for Geosciences; Committee of Visitors; Notice of Meeting

In accordance with the Federal Advisory Committee Act (Pub. L. 92–463, as amended), the National Science Foundation announces the following meeting.

Name: Advisory Committee for Geosciences (1755).

Date and Time: August 1–3, 2000; 8 a.m. to 5 p.m. each day.

Place: Room 770; National Science Foundation, 4201 Wilson Blvd., Arlington, VA 22230.

Type of Meeting: Part-Open (See Agenda, below).

Contact Person: Dr. Clifford Jacobs, Section Head, UCAR and Lower Atmospheric Facilities Oversight Section, Room 775, Division of Atmospheric Sciences, National Science Foundation, 4201 Wilson Blvd., Arlington, VA 22230, Telephone: (703) 306–1521.

Purpose of Meeting: To carry out Committee of Visitors (COV) review, including program evaluation, GPRA assessments, and access to privileged materials.

Agenda

Closed: August 1 from 1 p.m.–5 p.m. and August 2 from 8 a.m.–12 p.m. To review the merit review processes covering funding decisions made during the immediately preceding three fiscal years of the UCAR and Lower Atmospheric Facilities Oversight Section.

Open: August 1 from 8 a.m.–12 p.m.; August 2 from 1 p.m.–5 p.m.; and August 3 from 8 a.m.–5 p.m.—To assess the results of

NSF program investments in the UCAR and Lower Atmospheric Facilities Oversight Section. This shall involve a discussion and review of results focused on NSF and grantee outputs and related outcomes achieved or realized during the preceding three fiscal years. These results may be based on NSF grants or other investments made in earlier years.

Reason for Closing: During the closed session, the Committee will be reviewing proposal actions that will include privileged intellectual property and personal information that could harm individuals if they are disclosed. If discussions were open to the public, these matters that are exempt under 5 U.S.C.. 552b(c), (4) and (6) of the Government in the Sunshine Act would be improperly disclosed.

Dated: July 11, 2000.

Karen J. York,

Committee Management Officer.

[FR Doc. 00–17974 Filed 7–14–00; 8:45 am]

BILLING CODE 7555–01–M

NATIONAL SCIENCE FOUNDATION

Special Emphasis Panel in Graduate Education; Notice of Meeting

In accordance with the Federal Advisory Committee Act (Pub. L. 92–463, as amended), the National Science Foundation announces the following meeting:

Name: Special Emphasis Panel in Graduate Education (57).

Date/Time: September 25th and 26th 2000, 8 a.m. to 5 p.m.

Place: National Science Foundation, 4201 Wilson Blvd., Room 375, Arlington, VA.

Type of Meeting: Closed.

Contact Persons: Dr. Paul W. Jennings, Program Director and co-chairperson, IGERT and Ms. Deborah A. Daniels, Senior Program Assistant, Division of Graduate Education, National Science Foundation, 4201 Wilson Blvd., Room 907N, Arlington, VA 22230. (703) 306–1697.

Purpose of Meeting: To provide advice and recommendations concerning preproposals submitted to NSF for financial support.

Agenda: To review and evaluate applications submitted to the NSF-Integrative Graduate Education and Research Traineeship (IGERT) Program as part of the selection process for awards.

Reason for Closing: The preproposals being reviewed include information of a proprietary or confidential nature, including technical information, financial data, such as salaries, and personal information concerning individuals associated with the proposals. These matters are exempt under 5 U.S.C. 552b(c), (4) and (6) of the Government in the Sunshine Act.

Dated: July 11, 2000.

Karen J. York,

Committee Management Officer.

[FR Doc. 00–17975 Filed 7–14–00; 8:45 am]

BILLING CODE 7555–01–M

NUCLEAR REGULATORY COMMISSION

[Docket No. 40–8681]

International Uranium (USA) Corporation

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of Receipt of Request from International Uranium (IUSA) Corporation to Amend Source Material License SUA–1358 to Receive and Process Alternate Feed Materials Notice of Opportunity for Hearing.

SUMMARY: Notice is hereby given that the U.S. Nuclear Regulatory Commission has received, by letter dated July 5, 2000, a request from International Uranium (IUSA) Corporation to amend its NRC Source Material License SUA–1358, to allow its White Mesa Uranium Mill near Blanding, Utah, to receive and process up to 2000 cubic yards of alternate feed material from the Heritage Minerals Site located in Lakehurst, New Jersey. The Heritage site is in decommissioning under NRC Source Materials License No. SMB–1541. The Final Status Survey Plan (''Decommissioning Plan'') includes the removal of a monazite sand pile for shipment off-site. IUSA proposes to process the material for it's uranium content and dispose of the tailings in their tailings cells.

FOR FURTHER INFORMATION CONTACT: Mr. William von Till, Fuel Cycle Licensing Branch, Division of Fuel Cycle Safety and Safeguards, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Mail Stop T7–J8, Washington, DC 20555. Telephone (301) 415–6251. 2

SUPPLEMENTARY INFORMATION: By its submittal dated July 5, 2000, IUSA requested that the NRC amend Materials License SUA–1358 to allow the receipt and processing of material other than natural uranium ore (*i.e.,* alternate feed material) at its White Mesa uranium mill located near Blanding, Utah. These materials would be used as an ''alternate feed material'' (*i.e.,* matter that is processed in the mill to remove the uranium but which is different from natural uranium ores, the normal feed material).

IUSA proposes to receive and process, for it's uranium content, monazite sands that are being stored at the Heritage Minerals, Inc. (HMI) site in Lakehurst, New Jersey. This site is regulated by the NRC under Source Material License SMB–1541 and is in decommissioning. This material consists of monazite sands which were processed for heavy minerals (primarily titanium mineral ilmenite) by mechanical methods with no chemical leaching or extraction. IUSA estimates the amount of material for this amendment request to be up to 2000 yds^3. HMI has estimated that the material has a uranium content of approximately 0.05 weight percent, or greater. IUSA has determined that the material does not contain listed hazardous waste as defined in the Resource Recovery and Conservation Act, as amended, 42 U.S.C. Section 6901–6991. IUSA proposes to process the material in a similar manner to normal processing of conventional ore, either alone or in combination with other approved alternate feed materials.

IUSA has proposed that It will be a condition of the license that the mill shall not accept any of the Heritage material at the site unless and until the mill's Safety and Environmental Review Panel (SERP) has determined that the mill has sufficient licensed tailings capacity. The tailings capacity must be sufficient to permanently store:

(1) All 11e.(2) byproduct material, as defined under the Atomic Energy act, that would result from the processing of all of the material;

(2) All other ores and alternate feed materials on site; and

(3) All other materials required to be disposed of in the mill's tailings impoundments pursuant to the mill's reclamation plan.

The material will be shipped by rail and truck in intermodal containers. The covered containers will be loaded onto railcars and transported cross-country to a transfer point where the intermodal containers will then be loaded onto trucks for the final leg of the trip to the mill. The transfer point is expected to be either near Grand Junction, Colorado; Cisco, Utah; Green River, Utah; or East Carbon, Utah. The material will be shipped in exclusive containers as ''low specific activity'' (LSA) Hazard Class 7 Hazardous Material as defined by Department of Transportation regulations.

This application will be reviewed using NRC formal guidance, ''Final Position and Guidance on the Use of Uranium Mill Feed Material Other Than Natural Ores' and the guidance contained in the Nuclear Regulatory Commission's Memorandum and Order, *International Uranium (IUSA) Corp.,* CLI–00–01, (February 10, 2000). The NRC has approved similar amendment requests in the past for separate alternate feed material under this license.

The amendment application is available for public inspection and copying at the NRC Public Document

Room, in the Gelman Building, 2120 L Street NW., Washington DC 20555.

Notice of Opportunity for Hearing

The NRC hereby provides notice of an opportunity for a hearing on the license amendment under the provisions of 10 CFR Part 2, Subpart L, ''Informal Hearing Procedures for Adjudications in Materials and Operator Licensing Proceedings.'' Pursuant to § 2.1205(a), any person whose interest may be affected by this proceeding may file a request for a hearing. In accordance with § 2.1205(d), a request for hearing must be filed within 30 days of the publication of this notice in the **Federal Register**. The request for a hearing must be filed with the Office of the Secretary, either:

(1) By delivery to the Docketing and Service Branch of the Office of the Secretary at One White Flint North, 11555 Rockville Pike, Rockville, MD 20852; or

(2) By mail or telegram addressed to the Secretary, U.S. Nuclear Regulatory Commission, Washington, DC 20555, Attention: Docketing and Service Branch.

In accordance with 10 CFR 2.1205(f), each request for a hearing must also be served, by delivering it personally or by mail, to:

(1) The applicant, International Uranium (USA) Corporation, Independence Plaza, Suite 950, 1050 Seventeenth Street, Denver, Colorado 80265; Attention: Michelle Rehmann; and

(2) The NRC staff, by delivery to the Executive Director for Operations, One White Flint North, 11555 Rockville Pike, Rockville, MD 20852, or by mail addressed to the Executive Director for Operations, U.S. Nuclear Regulatory Commission, Washington, DC 20555.

In addition to meeting other applicable requirements of 10 CFR Part 2 of the NRC's regulations, a request for a hearing filed by a person other than an applicant must describe in detail:

(1) The interest of the requestor in the proceeding;

(2) How that interest may be affected by the results of the proceeding, including the reasons why the requestor should be permitted a hearing, with particular reference to the factors set out in § 2.1205(h);

(3) The requestor's areas of concern about the licensing activity that is the subject matter of the proceeding; and

(4) The circumstances establishing that the request for a hearing is timely in accordance with § 2.1205(d).

The request must also set forth the specific aspect or aspects of the subject matter of the proceeding as to which petitioner wishes a hearing.

In addition, members of the public may provide comments on the subject application within 30 days of the publication of this notice in the **Federal Register**. The comments may be provided to David L. Meyer, Chief, Rules Review and Directives Branch, Division of Administration Services, Office of Administration, U.S. Nuclear Regulatory Commission, Washington DC 20555.

Dated at Rockville, Maryland, this 11 day of July 2000.

For the U.S. Nuclear Regulatory Commission.

Philip Ting,

Chief, Fuel Cycle Licensing Branch, Division of Fuel Cycle Safety and Safeguards, Office of Nuclear Material Safety and Safeguards.

[FR Doc. 00–18031 Filed 7–14–00; 8:45 am]

BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

[Docket No. 50–423]

Northeast Nuclear Energy Company, et al.; Notice of Withdrawal of Application for Amendment to Facility Operating License

The U.S. Nuclear Regulatory Commission (the Commission) has granted the request of Northeast Nuclear Energy Company (the licensee) to withdraw its March 2, 1999, application for proposed amendment to Facility Operating License No. NPF–49 for the Millstone Nuclear Power Station, Unit No. 3, located in New London County, Connecticut.

The proposed amendment would have revised the operability requirements for the service water pumps and their associated strainers.

The Commission had previously issued a Notice of Consideration of Issuance of Amendment published in the **Federal Register** on May 5, 1999, (64 FR 24198). However, by letter dated June 12, 2000, the licensee withdrew the proposed change.

For further details with respect to this action, see the application for amendment dated March 2, 1999, and the licensee's letter dated June 12, 2000, which withdrew the application for license amendment. The above documents are available for public inspection at the Commission's Public Document Room, the Gelman Building, 2120 L Street, NW., Washington, DC, and accessible electronically through the ADAMS Public Electronic Reading Room link at the NRC Web site (*http://www.nrc.gov*).

Dated at Rockville, Maryland, this 29th day of June 2000.

For the Nuclear Regulatory Commission.

Victor Nerses,

Sr. Project Manager, Section 2, Project Directorate I, Division of Licensing Project Management, Office of Nuclear Reactor Regulation.

[FR Doc. 00–18032 Filed 7–14–00; 8:45 am]

BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

Advisory Committee on Reactor Safeguards; Meeting of the ACRS Subcommittee on Reliability and Probabilistic Risk Assessment; Notice of Meeting

The ACRS Subcommittee on Reliability and Probabilistic Risk Assessment will hold a meeting on July 11, 2000, Room T–2B3, 11545 Rockville Pike, Rockville, Maryland.

The entire meeting will be open to public attendance.

The agenda for the subject meeting shall be as follows: *Tuesday, July 11, 2000—1:00 p.m. until the conclusion of business.*

The Subcommittee will review the NRC framework for risk information 10 CFR Part 50 described in SECY–00–0086, and related matters. The purpose of this meeting is to gather information, analyze relevant issues and facts, and to formulate proposed positions and actions, as appropriate, for deliberation by the full Committee.

Oral statements may be presented by members of the public with the concurrence of the Subcommittee Chairman; written statements will be accepted and made available to the Committee. Electronic recordings will be permitted only during those portions of the meeting that are open to the public, and questions may be asked only by members of the Subcommittee, its consultants, and staff. Persons desiring to make oral statements should notify the cognizant ACRS staff engineer named below five days prior to the meeting, if possible, so that appropriate arrangements can be made.

The transcript record will be held open for ten additional days subsequent to the availability of the transcript to the public to enable persons who desire to have written comments or oral statements entered into the official record to do so.

During the initial portion of the meeting, the Subcommittee, along with any of its consultants who may be present, may exchange preliminary views regarding matters to be

considered during the balance of the meeting.

The Subcommittee will then hear presentations by and hold discussions with representatives of the NRC staff, and other interested persons regarding this review.

Further information regarding topics to be discussed, whether the meeting has been canceled or rescheduled, and the Chairman's ruling on requests for the opportunity to present oral statements and the time allotted therefor can be obtained by contacting the cognizant ACRS staff engineer, Mr. Michael T. Markley (telephone 301/415–6885) between 7:30 a.m. and 4:15 p.m. (EDT). Persons planning to attend this meeting are urged to contact the above named individual one or two working days prior to the meeting to be advised of any potential changes to the agenda, etc., that may have occurred.

Dated: July 11, 2000.

Howard J. Larson,

Acting Associate Director for Technical Support, ACRS/ACNW.

[FR Doc. 00–18015 Filed 7–14–00; 8:45 am]

BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

Regulatory Guide; Issuance, Availability

The Nuclear Regulatory Commission has issued a revision to a guide in its Regulatory Guide Series. This series has been developed to describe and make available to the public such information as methods acceptable to the NRC staff for implementing specific parts of the Commission's regulations, techniques used by the staff in evaluating specific problems or postulated accidents, and data needed by the staff in its review of applications for permits and licenses.

Revision 1 of Regulatory Guide 1.54, ''Service Level I, II, and III Protective Coatings Applied to Nuclear Power Plants,'' provides guidance on practices and programs that are acceptable to the NRC staff for the selection, application, qualification, inspection, and maintenance of protective coatings applied in nuclear power plants. This guide endorses multiple standards of the American Society for Testing and Materials to provide this guidance.

Comments and suggestions in connection with items for inclusion in guides currently being developed or improvements in all published guides are encouraged at any time. Written comments may be submitted to the Rules and Directives Branch, Division of Administrative Services, Office of Administration, U.S. Nuclear Regulatory Commission, Washington, DC 20555. For further information on the guide, contact A.W. Serkiz at (301) 415–6563 or by email at <AWS@NRC.GOV>.

Regulatory guides are available for inspection at the Commission's Public Document Room, 2120 L Street NW., Washington, DC. Recent regulatory guides, both draft and active, may be read or downloaded from the NRC website at http://www.nrc.gov. Single copies of regulatory guides may be obtained free of charge by writing the Reproduction and Distribution Services Section, OCIO, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001, or by fax to (301) 415–2289, or by email to <DISTRIBUTION@NRC.GOV>. Issued guides may also be purchased from the National Technical Information Service on a standing order basis. Details on this service may be obtained by writing NTIS, 5285 Port Royal Road, Springfield, VA 22161. Regulatory guides are not copyrighted, and Commission approval is not required to reproduce them.

(5 U.S.C. 552(a))

Dated at Rockville, Maryland, this 6th day of July 2000.

For the Nuclear Regulatory Commission.

Margaret V. Federline,

Deputy Director, Office of Nuclear Regulatory Research.

[FR Doc. 00–18030 Filed 7–14–00; 8:45 am]

BILLING CODE 7590–01–P

NUCLEAR REGULATORY COMMISSION

Draft Supplementary Changes to Revision 8 of NUREG–1021, ''Operator Licensing Examination Standards for Power Reactors;'' Notice of Availability

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of availability and extension of comment period.

SUMMARY: On March 20, 2000 (65 FR 15020), the Nuclear Regulatory Commission (NRC) issued for public comment and voluntary use, on a trial basis, a draft supplementary change to Revision 8 of NUREG–1021, ''Operator Licensing Examination Standards for Power Reactors.'' The Commission uses NUREG–1021 to provide policy and guidance for the development, administration, and grading of written examinations and operating tests used to determine the qualifications of individuals who apply for operator and senior operator licenses at nuclear power plants pursuant to the Commission's regulations. NUREG–1021 provides similar guidance for verifying the continued qualifications of licensed operators when the staff determines that NRC requalification examinations are necessary.

Based upon the small number of examinations that have thus far been prepared using the revised examination guidance, the NRC has decided to extend the trial use and public comment period for the draft supplementary change in order to allow additional opportunities for feedback that will support the issuance of the final supplement. This delay in preparing the final supplement has also created an opportunity to solicit comments on some additional changes that will bring NUREG–1021 into conformance with Revision 3 of Regulatory Guide (RG) 1.8, ''Qualification and Training of Personnel for Nuclear Power Plants,'' which has been published since the original draft supplement was issued on March 20, 2000. Revision 3 of RG 1.8 has revised a long-standing regulatory position regarding operator license eligibility by endorsing, with additions, exceptions, and clarifications, the 1993 version of ANSI/ANS 3.1, ''Selection, Qualification, and Training of Personnel for Nuclear Power Plants.''

The draft supplement and the newly issued addendum are available for review via the NRC Public Electronic Reading Room (http://www.nrc.gov/NRC/ADAMS/index.html), on the NRC's Operator Licensing web site (http://www.nrc.gov/NRC/REACTOR/OL/OLguidance.html), and at the NRC Public Document Room, 2120 L Street NW, Washington, DC. If you do not have electronic access to NRC documents, you may request a single copy of the draft supplement by writing to the Office of the Chief Information Officer, Reproduction and Distribution Services Section, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001 (Facsimile: 301–512–2289). Telephone requests cannot be accommodated. NUREG documents are not copyrighted, and Commission approval is not required to reproduce them.

The draft supplement is being implemented on a voluntary, trial basis. The NRC will evaluate any comments and recommendations that are received and any lessons that are learned during the trial period, incorporate any additional changes, as appropriate, and, thereafter, publish final Supplement 1 for general use.

DATE: The comment period ends October 31, 2000. Comments received after this date will be considered if it is practical to do so, but the staff is able

to assure consideration only for comments received on or before this date.

ADDRESSES: Written comments may be submitted to the Rules and Directives Branch, Division of Administrative Services, Office of Administration, U.S. Nuclear Regulatory Commission, Washington, DC 20555–0001. You may also provide comments via the NRC's Operator Licensing web site (http://www.nrc.gov/NRC/REACTOR/OL/OLguidance.html). Copies of comments received may be examined on the NRC Public Electronic Reading Room (http://www.nrc.gov/NRC/ADAMS/index.html) and at the NRC Public Document Room, 2120 L Street NW, Washington, DC.

FOR FURTHER INFORMATION CONTACT: Mr. S. Guenther by telephone at (301) 415–1056, or by e-mail sxg@nrc.gov.

Dated at Rockville, Maryland, this 6th day of July 2000.

For the Nuclear Regulatory Commission.

Glenn M. Tracy,

Chief, Operator Licensing, Human Performance and Plant Support Branch, Division of Inspection Program Management, Office of Nuclear Reactor Regulation.

[FR Doc. 00–18022 Filed 7–14–00; 8:45 am]

BILLING CODE 7590–01–P

SECURITIES AND EXCHANGE COMMISSION

Submission for OMB Review; Comment Request

Upon Written Request, Copies Available From: Securities and Exchange Commission, Office of Filings and Information Services, Washington, DC 20549.

Extension: Rule 17g–1; SEC File No. 270–208; OMB Control No. 3235–0213.

Notice is hereby given that, pursuant to the Paperwork Reduction Act of 1995 [44 U.S.C. 3501–3520], the Securities and Exchange Commission (the ''Commission'') has submitted to the Office of Management and Budget (''OMB'') a request for extension of approval of rule 17g–1 [17 CFR 270.17g–1] under the Investment Company Act of 1940 (the ''Act'').

Rule 17g–1 governs the fidelity bonding of officers and employees of registered management investment companies (''funds'') and their advisers. Rule 17g–1 requires, in part, the following:

• *Independent Directors' Approval Requirements.* At least annually, the independent directors of a fund must approve the form and amount of the fund's fidelity bond. Rule 17g–1 provides a schedule of minimum amounts for fidelity bonds based on a fund's size. The independent directors also must approve the amount of any premium paid for any ''joint bond'' covering multiple funds or certain other affiliates of the fund.

• *Fidelity Bond Content Requirements.* The fidelity bond must provide that it shall not be cancelled, terminated or modified except upon 60-days written notice to the affected party and to the Commission. In addition, a joint bond must provide that the fidelity insurance company will provide all funds covered by the bond with (i) a copy of the bond and any amendments to the bond; (ii) a copy of any formal filing of a claim on the bond; and (iii) notification of the terms of the settlement on any claim prior to execution of that settlement.

• *Joint Bond Agreement Requirement.* A fund that is insured by a joint bond must enter into an agreement with all other parties insured by the joint bond regarding recovery under the joint bond.

• *Required Filings with the Commission.* Upon execution of a fidelity bond or any amendment thereto, a fund must file with the Commission a copy of: (i) the executed fidelity bond; (ii) the resolution of the fund's independent directors approving the fidelity bond; and (iii) a statement as to the period for which the fidelity bond premiums have been paid. In the case of a joint bond, a fund also must file a copy of: (i) a statement showing the amount of a single insured bond the fund would have maintained under the rule had it not been named under a joint bond; and (ii) each agreement between the fund and all other insured parties. A fund also must notify the Commission in writing within 5 days of any claim and settlement on a claim made under a fidelity bond.

• *Required Notices to Directors.* A fund must notify by registered mail each member of its board of directors of (i) any cancellation, termination or modification of the fidelity bond at least 45 days prior to the effective date; and (ii) the filing or settlement of any claim under the fidelity bond when the notification is filed with the Commission.

Rule 17g–1's independent directors' annual review requirements, fidelity bond content requirements, joint bond agreement requirement and required notices to directors are designed to ensure the safety of fund assets against losses due to the conduct of persons who may obtain access to those assets. These requirements also facilitate oversight of a fund's fidelity bond. The rule's required filing with the Commission are designed to assist the Commission in monitoring funds' compliance with the fidelity bond requirements.

The Commission staff estimates that approximately 3500 funds are subject to the requirements of rule 17g–1, and that on average a fund spends approximately one hour per year complying with the rule's paperwork requirements. The Commission staff therefore estimates the total annual burden of the rule's paperwork requirements to be 3500 hours.

These estimates of average burden hours are made solely for the purposes of the Paperwork Reduction Act. These estimates are not derived from a comprehensive or even a respresentative survey or study of Commission rules. The collection of information required by rule 17g–1 is mandatory and will not be kept confidential. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid control number.

Please direct general comments regarding the information above to: (i) Desk Officer for the Securities and Exchange Commission, Office of Information and Regulatory Affairs, Office of Management and Budget, New Executive Office Building, Washington, DC 20503; and (ii) Michael Bartell, Associate Executive Director, Office of Information Technology, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549. Comments must be submitted to OMB within 30 days of this notice.

Dated: July 11, 2000.

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 00–17967 Filed 7–14–00; 8:45 am]

BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE COMMISSION

Submission for OMB Review; Comment Request

Upon Written Request, Copies Available From: Securities and Exchange Commission, Office of Filings and Information Services, Washington, DC 20549.

Extension:

Rule 17Ad–4(b) & (c), SEC File No. 270–264, OMB Control No. 3235–0341.

Rule 15, SEC File No. 270–360, OMB Control No. 3235–0409.

Notice is hereby given that pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*), the Securities and Exchange Commission (''Commission'') has submitted to the Office of Management and Budget requests for extension on the previously

approved collections of information discussed below.

Rule 17Ad–4(b) & (c) Notices Regarding Exempt Transfer Agent Status

Rule 17Ad–4(b) & (c) is used to document when transfer agents are exempt, or no longer exempt, from the minimum performance standards and certain recordkeeping provisions of the Commission's transfer agent rules. Rule 17Ad–4(c) sets forth the conditions under which a registered transfer agent loses it exempt status. Once the conditions for exemption no longer exist, the transfer agent, to keep the appropriate regulatory authority (''ARA'' apprised of its current status, must prepare, and file if the ARA for the transfer agent is the Board of Governors of the Federal Reserve System (''BGFRS'') or the Federal Deposit Insurance Corporation (''FDIC''), a notice of loss of exempt status under paragraph (c). The transfer agent then cannot claim exempt status under Rule 17Ad–4(b) again until it remains subject to the minimum performance standards for non-exempt transfer agents for six consecutive months. The ARAs use the information contained in the notice to determine whether a registered transfer agent qualifies for the exemption, to determine when a registered transfer agent no longer qualifies for the exemption, and to determine the extent to which the transfer agent is subject to regulation.

The BGFRS receives approximately twelve notices of exempt status and six notices of loss of exempt status annually. The FDIC receives approximately eighteen notices of exempt status and three notices of loss of exempt status annually. The Commission and the Office of the Comptroller of the Currency (''OCC'') do not require transfer agents to file notice of exempt status or loss of exempt status. Instead, transfer agents whose ARA is the Commission or OCC need only to prepare and maintain these notices. The Commission estimates that approximately sixteen notices of exempt status and loss of exempt status are prepared annually by transfer agents whose ARA is the Commission. Similarly, the OCC estimates that the transfer agents for which it is the ARA, prepare and maintain approximately fifteen notices of exempt status and loss of exempt status annually. Thus, a total of approximately seventy notices of exempt status and loss of exempt status are prepared and maintained by transfer agents annually. Of these seventy notices, approximately forty are filed with an ARA. Any additional costs associated with filing such notices would be limited primarily to postage, which would be minimal. Since the Commission estimates that no more than one-half hour is required to prepare each notice, the total annual burden to transfer agents is approximately thirty-five hours. The average cost per hour is approximately $30. Therefore, the total cost of compliance to the transfer agent community is $1,050.

Rule 17Ad–15 Signature Guarantees

Rule 17Ad–15 requires approximately 1,093 transfer agents to establish written standards for accepting and rejecting guarantees of securities transfers from eligible guarantor institutions. Transfer agents are also required to establish procedures to ensure that those standards are used by the transfer agent to determine whether to accept or reject guarantees from eligible guarantor institutions. Transfer agents must maintain, for a period of three years following the date of a rejection of transfer, a record of all transfers rejected, along with the reason for the rejection, identification of the guarantor, and whether the guarantor filed to meet the transfer agent's guaranteed standard. These recordkeeping requirements assist the Commission and other regulatory agencies with monitoring transfer agents and ensuring compliance with the rule.

There are approximately 1,093 registered transfer agents. Of the 1,093 registered transfer agents, approximately 120 will receive fewer than 100 items for transfer. The staff expects that more small transfer agents will have few, if any, rejections. The average number of hours necessary for every transfer agents agent to comply with the Rule 17Ad–15 is about forty hours annually. The total burden is 43,720 hours for all transfer agents. The average cost per hour is approximately $30. Therefore, the total cost of compliance for all transfer agents is about $1,311,600.

The retention period for the recordkeeping requirement under Rule 17Ad–15 is three years following the date of a rejection of transfer. The recordkeeping requirement under the rule is mandatory to assist the Commission and other regulatory agencies with monitoring transfer agents and ensuring compliance with the rule. This rule does not involve the collection of confidential information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid control number.

General comments regarding the estimated burden hours should be directed to the following persons: (i) Desk Officer for the Securities and Exchange Commission, Office of Information and Regulatory Affairs, Office of Management and Budget, Room 3208, New Executive Office Building, Washington, D.C. 20503. and (ii) Micheal E. Bartell, Associate Executive Director, Office of Information Technology, Securities and Exchange Commission, 450 Fifth Street, Washington, D.C. 20549. Comments must be submitted to OMB within 30 days of this notice.

Dated: July 10, 2000.

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 00–18006 Filed 7–14–00; 8:45 am]

BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–43021; File No. SR–NASD–99–41]

Self-Regulatory Organizations; National Association of Securities Dealers, Inc.; Order Approving Proposed Rule Change and Amendment No. 1 and Notice of Filing and Order Granting Accelerated Approval of Amendment No. 2 Relating to the Opening of Day-Trading Accounts

July 10, 2000.

I. Introduction

On August 20, 1999, the National Association of Securities Dealers, Inc. (''NASD'' or ''Association''), through its wholly owned subsidiary, NASD Regulation, Inc. (''NASD Regulation''), filed with the Securities and Exchange Commission (''SEC'' or ''Commission''), pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act'') [1] and Rule 19b–4 thereunder,[2] a proposed rule change relating to the opening of day-trading accounts.

The proposed rule change was published for comment in the **Federal Register** on September 21, 1999.[3] The Commission received three comment letters on the proposed rule change.[4] On

[1] 15 U.S.C. 78s(b)(1).

[2] 17 CFR 240.19b–4.

[3] Securities Exchange Act Release No. 41432 (September 14, 1999), 64 FR 51165.

[4] *See* Letters from James H. Lee, President, Electronic Traders Association (''ETA''), to Jonathan G. Katz, Secretary, SEC, dated October 11, 1999; Bradley W. Skolnik, President, Indiana Securities Commissioner, North American Securities Administrators Association (''NASAA''), to Jonathan G. Katz, Secretary, SEC, dated October 12, 1999; and Lee B. Spencer, Jr., Chairman, Federal Regulation Committee, Everett Lang, Co-Chairman, Discount Brokerage Committee, Michael L. Michael, Chairman, Ad-Hoc Committee on Technology and

February 18, 2000, NASD Regulation submitted Amendment No. 1 to the proposed rule change.[5] Amendment No. 1 was published for comment in the **Federal Register** on March 2, 2000.[6] The Commission received four comment letters on the proposed rule change in Amemdment No. 1.[7] On June 21, 2000, NASD Regulation submitted Amendment No. 2 to the proposed rule change.[8] In this notice and order, the Commission is seeking comment from interested persons on Amendment No. 2 and approving the proposed rule change and Amendment No. 1, and is approving Amendment No. 2 on an accelerated basis.

II. Description of the Proposal

The NASD, through NASD Regulation, proposes to add two new rules to its Rule 2300 series.[9] New Rules 2360, approval Procedures for Day-Trading Accounts, and 2361, Day-Trading Risk Disclosure Statement, only apply to firms that are ''promoting a day-trading strategy.''

The proposal focuses on disclosing the basis risks of engaging in a day-trading strategy and assessing the appropriateness of day-trading strategies for individuals. In particular, the proposal would require a firm that is ''promoting a day-trading strategy,'' directly or indirectly, to deliver a specified risk disclosure statement to a non-institutional customer prior to opening an account for the customer. In addition to delivering the risk disclosure statement, the proposal would require a firm to either: (1) Approve the customer's account for day trading; or (2) obtain a written agreement from the customer stating that the customer does not intend to use the account for day-trading activities. A firm would not be permitted to rely on the written agreement from the customer if the firm knows that the customer intends to use the account for day trading. In addition, if a firm knows that a customer who provided such an agreement is engaging in a day-trading strategy, the firm would be required to approve the account for day trading.

As part of approving an account for day trading, a firm would be required to have reasonable grounds for believing that the day-trading strategy is appropriate for the customer. In making this determination, the firm would be required to exercise reasonable diligence to ascertain the essential facts about the customer, including his or her financial situation, tax status, prior investment and trading experience, and investment objectives. The firm also would be required to prepare a record setting forth the basis on which the firm has approved the customer's account for day trading. Any record or written statement prepared or obtained by the firm pursuant to the proposed rule change would have to be preserved in accordance with NASD Rule 3110(a).

A. Scope of Proposal

1. Firms ''Promoting a Day-Trading Strategy''

As discussed below, the proposed new rules only apply to firms that are ''promoting a day-trading strategy'' and to new accounts opened by all non-institutional customers at those firms.[10] While the proposal does not expressly define ''promoting a day-trading strategy,'' it does state that none of the following actions alone would trigger the proposed rule's requirements: (1) The promotion by a member of efficient execution services or lower execution costs based on multiple trades; (2) providing general investment research or advertising the high quality or prompt availability of such general research; and (3) having a web site that provides general financial information or news or that allows the multiple entry of intra-day purchases and sales of the same securities.[11]

The proposal would apply to a member that affirmatively promotes day-trading activities or strategies through advertising, training seminars, or direct outreach programs. The proposal would only be triggered by the firm's general promotional efforts or by firm-sponsored promotional efforts.[12] For instance, a firm generally would be subject to the proposed rule if its advertisements address the benefits of day trading, rapid-fire trading, or momentum trading, or encourage persons to trade or profit like a professional trader. A firm also would be subject to the proposed rule if it promotes its day-trading services through a third party. Moreover, the fact that many of a firm's customers are engaging in a day-trading strategy would be relevant in determining whether a firm has promoted itself in this way. Firms may not, however, promote day trading through individuals in an effort to circumvent the proposed rule. In addition, if a principal or officer of the firm is aware that brokers in the firm are soliciting customers for day trading, then firm will be deemed to be promoting day trading.[13]

While the proposal does not define the term ''promoting a day-trading strategy,'' NASD Regulation represents that firms could submit their advertisements to NASD Regulation's Advertising/Investment Companies Regulation Department for review and guidance on whether the content of the

---

Regulation, and Michael Anderson, Co-Chairman, Discount Brokerage Committee, Securities Industry Association (''SiA''), to Margaret H. McFarland, Deputy Secretary, SEC, dated October 22, 1999.

[5] In Amendment No. 1, NASD Regulation responded to issues raised in the initial three comment letters by revising the proposed rule change and the proposed rule text with respect to: modifying the disclosure statement; revising the method for delivering the disclosure statement; describing certain activities that will not trigger application of the proposed day-trading rules; and clarifying information-gathering requirements. *See* Letter from Alden S. Adkins, Sr. Vice President and General Counsel, NASD Regulation, to Katherine A. England, Assistant Director, Division of Market Regulation (''Division''), SEC, dated February 10, 1999 (''Amendment No. 1'').

[6] Securities Exchange Act Release No. 42452 (February 23. 2000), 65 FR 11353.

[7] *See* Letters from The Honorable Susan M. Collins, Chairman, Permanent Subcommittee on Investigations, The Honorable Carl Levin, Ranking Minority Member, Permanent Subcommittee on Investigations, and The Honorable Richard J. Durbin, Committee on Governmental Affairs, U.S. Senate, to Jonathan G. Katz, Secretary, SEC, dated March 17, 2000 (''Senators''); Linda Lerner, General Counsel, All-Tech Direct, Inc., to Jonathan G. Katz, Secretary, SEC, dated March 20, 2000 (''All-Tech''); Bradley W. Skolnik, President, Indiana Securities Commissioner, NASAA, to Jonathan G. Katz, Secretary, SEC, dated March 23, 2000; and Robert P. Mazzarella, Chairman, Discount Brokerage Committee, and Michael L. Michael, Chairman, Ad Hoc Committee on Technology and Regulation, SIA, to Jonathan G. Katz, Secretary, SEC, dated March 23, 2000.

[8] In Amendment No. 2, NASD Regulation responded to the comment letters submitted on Amendment No. 1 and incorporated several recommendations from the letters into the proposed disclosure statement. *See* Letter from Joan Conley, Senior Vice President and Corporate Secretary, NASD Regulations, to Nancy Sanow, Assistant Director, Division, SEC, dated June 21, 2000 (''Amendment No. 2'').

[9] NASD's 2300 series of rules covers *Transactions With Customers.*

[10] As proposed, ''day-trading strategy'' is defined as ''an overall trading strategy characterized by the regular transmission by a customer of intra-day orders to effect both purchase and sale transactions in the same security or securities.'' The proposed definition would include those instances where an individual regularly transmits one or more purchase and sale (*i.e.,* ''round-trip'') transactions in a single day. The proposed definition of ''day-trading strategy'' also includes orders transmitted by non-electronic means, such as by telephone.

[11] In the original filing, activities that would not alone trigger application of the rule were described in the proposed rule change but were not part of the proposed rule text. In Amendment No. 1, NASD Regulation added these provisions to the proposed rule text. *See* Amendment No., *supra* note 5.

[12] *See* amendment Nos. 1 and 2, *supra* notes 5 and 8.

[13] *Id.* In Amendment No. 2, NASD Regulation noted that NASD Rule 3010(a) requires that firms maintain a system to supervise the activities of each registered representative that is reasonably designed to achieve compliance with applicable securities laws and regulations, and with NASD rules.

advertisement constitutes such activity for purposes of the proposal.[14]

2. Accounts Covered by the Proposed Rule

The term ''non-institutional customer'' would mean a customer that does not qualify as an ''institutional account'' to mean the account of: (1) A bank, savings and loan association, insurance company, or registered investment company; (2) an investment adviser registered either with the SEC under Section 203 of the Investment Advisers Act of 1940 or with a state securities commission (or agency or office performing similar functions); or (3) any other entity (whether a natural person, corporation, partnership, trust, or otherwise) with total assets of at least $50 million.[15] The proposal would not apply to an existing customer unless the customer opens a new account at a firm that is promoting a day-trading strategy.

B. Requirements for New Customer Accounts of Firms Promoting a Day-Trading Strategy

Before opening a new account for a customer, a firm that is promoting a day-trading strategy must deliver a risk disclosure document and either approve the account for day trading or obtain a written agreement from the customer stating that the customer does not intend to use the account for day-trading activities. Each of these requirements is described below.

1. Requirement to Provide a Day-Trading Risk Disclosure Statement

As discussed above, the proposal would require a firm that is promoting a day-trading strategy to deliver a risk disclosure statement, discussing the unique risks posed by day trading, to all non-institutional customers prior to opening an account for such customers.[16] The disclosure statement would include several factors that a customer should consider before engaging in day trading, including that: The customer should be prepared to lose all of the funds that he or she uses for day trading; day trading generally requires significant resource;[17] and day trading on margin or short selling may result in losses beyond the initial investment.

The disclosure statement also would include a provision stating that day trading generally is not appropriate for persons of limited resources and limited investment or trading experience and low risk tolerance. Another provision would explain that a day trader should know its firm's business practices[18] because under certain market conditions, a day trader may find it difficult or impossible to liquidate a position quickly at a reasonable price, such as when the market for a stock suddenly drops, or if trading is halted due to recent news events or unusual trading activity. The provision would further state that the more volatile a stock is, the greater the likelihood that problems may be encountered in executing a transaction.[19]

The disclosure statement would further explain that, because a day-trading strategy requires frequent trades, payment of commissions will add to losses or significantly decrease earnings. The disclosure document also would provide an example of how much annual profit a day trader would need to generate just to cover commission costs.[20] The disclosure statement would conclude with a provision that informs investors of the potential need to register as an investment adviser or as a broker or dealer under federal and state registration requirements.[21]

The firm would be permitted to develop an alternative risk disclosure statement, provided that the alternative statement was substantially similar to the mandated statement and was filed with, and approved, by NASD Regulation's Advertising/Investment Companies Regulation Department. In addition, NASD Regulation encourages all firms, particularly firms that provide on-line trading capability, to provide the mandated risk disclosure statement or a substantially similar disclosure statement to their customers. The proposed risk disclosure statement, as amended, follows. Proposed additions from Amendment No. 2 are in italics and proposed deletions are in brackets.[22]

Rule 2361. Day-Trading Risk Disclosure Statement

(a) Except as provided in paragraph (b), no member that is promoting a day-trading strategy, directly or indirectly, shall open an account for or on behalf of a non-institutional customer unless, prior to opening the account, the member has furnished to each customer, individually, in writing or electronically, the following disclosure statement:

You should consider the following points before engaging in a day-trading strategy. For purposes of this notice, a ''day-trading strategy'' means an overall trading strategy characterized by the regular transmission by a customer of intra-day orders to effect both purchase and sale transactions in the same security or securities.

Day trading can be extremely risky. Day trading generally is not appropriate for someone of limited resources and limited investment or trading experience and low risk tolerance. You should be prepared to lose all of the funds that you use for day trading. In particular, you should not fund day-trading activities with retirement savings, student loans, second mortgages, emergency funds, funds set aside for purposes such as education or home ownership, or funds required to meet your living expenses. *Further, certain evidence indicates that an investment of less than $50,000 will significantly impair the ability of a day trader to make a profit. Of course, an investment of $50,000 or more will in no way guarantee success.*

Be cautious of claims of large profits from day trading. You should be wary of advertisements or other statements that emphasize the potential for large profits in day trading. Day trading can also lead to large and immediate financial losses.

Day trading requires knowledge of securities markets. Day trading requires in-depth knowledge of the securities markets and trading techniques and strategies. In attempting to profit through day trading, you must compete with professional, licensed traders employed by securities firms. You should have appropriate experience before engaging in day trading.

Day trading requires knowledge of a firm's operations. *You should be familiar with a securities firm's business practices, including the operation of the firm's order execution systems and procedures.* Under certain market conditions, you may find it difficult or impossible to liquidate a position quickly at a reasonable price. This can occur, for example, when the market for a stock suddenly drops, or if trading is halted due to recent news events or unusual trading activity. The more volatile a stock is, the greater the likelihood that problems may be

[14] As a result, NASD Regulation believes that the proposal should both limit concerns about any effect of the proposal on the NASD's general suitability rule and allow firms to better determine whether a particular advertisement would trigger the rule prior to publication or distribution of the advertisement.

[15] NASD Regulation believes that applying the proposed rule change to non-institutional customers would ensure that most individuals would be covered by the proposal, regardless of whether they engage in day-trading activities in their own name or in the name of a corporation or partnership.

[16] NASD Regulation did not recommend that all firms, whether or not they promote day trading, be required to disseminate the disclosure statement to all new customers because the benefits of such a requirement are unclear. However, NASD Regulation advised that it will continue to monitor the growth of day-trading activities to determine whether, in the future, such a requirement might be justified. *See* Amendment No. 1, *supra* note 5.

[17] In Amendment No. 2, NASD Regulation adopted the Senators' suggestion to include in the risk disclosure statement a warning that investors with less than $50,000 in risk capital are not likely to succeed as day traders. *See* Amendment No. 2, *supra* note 8.

[18] *See* Amendment No. 2, *supra* note 8.

[19] *See* Amendment No. 1, *supra* note 5.

[20] *See* Amendment No. 2, *supra* note 8.

[21] *Id.*

[22] Proposed NASD Rule 2360, pertaining to approval procedures for day trading accounts, remains unchanged from Amendment No. 1 and therefore its text is not set forth in this release.

encountered in executing a transaction. In addition to normal market risks, you may experience losses due to system failures.

Day trading will generate substantial commissions, even if the per trade cost is low. [Day trading may result in your paying large commissions.] Day trading *involves* [may require you to trade your account] aggressive[ly] *trading,* and *generally* you *will* [may] pay commissions on each trade. The total daily commissions that you pay on your trades *will* [may] add to your losses or significantly reduce your earnings. *For instance, assuming that a trade cost $16 and an average of 29 transactions are conducted per day, an investor would need to generate an annual profit of $111,360 just to cover commission expenses.*

Day trading on margin or short selling may result in losses beyond your initial investment. When you day trade with funds borrowed from a firm or someone else, you can lose more than the funds you originally placed at risk. A decline in the value of the securities that are purchased may require you to provide additional funds to the firm to avoid the forced sale of those securities or other securities in your account. Short selling as part of your day-trading strategy also may lead to extraordinary losses, because you may have to purchase a stock at a very high price in order to cover a short position.

Potential Registration Requirements. *Persons providing investment advice for others or managing the securities accounts for others may need to register as either an ''Investment Advisor'' under the Investment Advisors Act of 1940 or as a ''Broker'' or ''Dealer'' under the Securities Exchange Act of 1934. Such activities may also trigger state registration requirements.*

(b) In lieu of providing the disclosure statement specified in paragraph (a), a member that is promoting a day-trading strategy may provide to the customer, individually, in writing or electronically, prior to opening the account, an alternative disclosure statement, provided that:

(1) The alternative disclosure statement shall be substantially similar to the disclosure statement specified in paragraph (a); and

(2) The alternative disclosure statement shall be filed with the Association's Advertising Department (Department) for review at least 10 days prior to use (or such shorter period as the Department may allow in particular circumstances) for approval and, if changes are recommended by the Association, shall be withheld from use until any changes specified by the Association have been made or, if expressly disapproved, until the alternative disclosure statement has been refiled for, and has received, Association approval. The member must provide with each filing the anticipated date of first use.

(c) For purposes of this rule, the term ''day-trading strategy'' shall have the meaning provided in Rule 2360(e).

(d) For purposes of this *R*[r]ule, the term ''non-institutional customer'' means a customer that does not qualify as an ''institutional account'' under Rule 3110(c)(4).

* * * * *

2. Customer Acknowledgment

The proposal would require firms to deliver the disclosure statement to each customer individually, by mail or electronic means, prior to opening the account. A firm would not satisfy the proposal's requirements by posting the disclosure statement in a remote location on its web site, and claiming that it was delivered to all customers in such manner. The proposal would not require customers to sign the disclosure statements.[23]

3. Approving Customer Accounts for Day Trading

In addition to delivering a risk disclosure document. A firm must approve a customer's account for a day-trading strategy in accordance with certain procedures. Specifically, to approve a customer's account for a day-trading strategy, a firm must have reasonable grounds for believing that the strategy is appropriate for the customer and to exercise reasonable diligence to ascertain the essential facts relative to the customer. The proposal would expressly require a firm to review a customer's investment objectives, investment and trading experience and knowledge, financial situation (including estimated annual income from all sources, estimated net worth exclusive of family residence, and estimated liquid net worth), tax status, employment status (name of employer, self-employed or retired, marital status, number of dependents, and age.[24] The proposal would not required firms to determine the source of funds, primarily because of concerns with defining the scope of any such obligation and the risks of imposing disproportionate burdens on firms.[25]

4. Accounts Used for Purposes Other Than Day-Trading Activities

As an alternative to approving an account for a day-trading strategy, the proposal would permit a firm that is promoting a day-trading strategy to obtain from the customer a written agreement that the customer does not intend to use the account for the purposes of day trading (''other-use agreement'').[26] A firm would not be permitted to rely on an other-use agreement if it knows that the customer intends to use the account for day trading. Moreover, if a firm opens an account for a customer in reliance on an other-use agreement, but later knows that the customer is using the account for day-trading activities, then the firm would be required to approve the customer's account for day trading in accordance with the rule as soon as practicable, but in no event later than ten days from the date of discovery. The standard of knowledge is one of actual knowledge.[27]

III. Summary of Comments

After the original publication of the proposed rule change in the **Federal Register,**[28] the Commission received comment letters form the ETA, NASAA, and the SIA,[29] generally supporting aspects of the proposed rule change but recommending numerous significant changes to the proposal itself. NASD Regulation responded to these letters in Amendment No. 1.[30] The Commission then published Amendment No. 1 for comment,[31] and, in response, the commission received comments letters form All-Tech, the SIA, NASAA, and the Senators, again generally supporting features of the proposal but recommending various modifications.[32]

A. Issues Raised in Comment Letters to Amendment No. 1

1. Application of the Rule

In its comment letter to Amendment No. 1, the SIA restated its concern that individual solicitations by a broker or brokers of a day-trading strategy could cause an entire firm to be deemed to be promoting a day-trading strategy. In Amendment No. 1, NASD Regulation stated that if a broker targeted, for example, five customers for day trading without the firm's knowledge, the firm would not be deemed to be promoting day trading. However, if a principal or officer of the firm knew that the firm's brokers were promoting a day-trading strategy, the firm would be deemed to

[23] NASD Regulation added the ''individual'' delivery requirement in Amendment No. 1. NASD Regulation believes that any abuses of the delivery requirement could be detected during routine examinations. *See* Amendment No. 1, *supra* note 5.

[24] The proposed rule change originally included only an evaluation of the investment objectives, investment and trading experience and knowledge, financial situation and tax status. The additional factors were added in Amendment No. 1. *See* Amendment No. 1, *supra* note 5.

[25] *See* Amendment No. 2, *supra* note 8.

[26] The firm would be required to provide a risk disclosure statement to the customer even if the firm obtains an other-use agreement

[27] *See* Amendment No. 1, *supra* note 5. NASD Regulation believes that it is proper to hold a firm accountable for facts known to the firm. *See* Amendment No. 2, *supra* note 8.

[28] *See supra* note 3.

[29] *See supra* note 4.

[30] *See* Amendment No. 1 *supra* note 5. A summary of comments received on the original filing is included in Securities Exchange Act Release No. 42452 (February 23, 2000), 65 FR 11353 (March 2, 2000).

[31] *See supra* note 6.

[32] *See supra* note 7.

be promoting day trading. The SIA argued that knowing the strategies employed by its brokers is a good supervisory practice and should not trigger application of the day-trading rules to the entire firm. Alternatively, the SIA argued that the commentary accompanying the proposal should state that a number of the firm's brokers would need to be individually soliciting customers to day trade for these solicitations to cause the firm itself to be considered to be promoting a day-trading strategy. In response, NASD Regulation stated that, while solicitations by individual brokers would not alone cause a firm to be considered to be promoting a day-trading strategy, when an officer or a principal has knowledge of brokers soliciting accounts for day trading, the firm would be deemed to be promoting day trading and thus subject to the day-trading rules.[33]

The SIA also suggested that the proposal unfairly assigns the firm the responsibility for customers changing their minds with respect to the ''other use'' agreement. The SIA stated that because firms maintain records of customers' trades, it can be argued that firms always have actual knowledge. The NASD responded that, on balance, it believes the provision is appropriate and not overly burdensome, and that it is proper to hold a firm accountable for facts known to the firm.[34]

On the other hand, NASAA expressed concern that the proposal could be read narrowly so as to not cover certain firms promoting day-trading activities. Accordingly, NASAA recommended that the NASD clarify that although the enumerated activities would not by themselves be deemed to be promoting a day-trading strategy, they could nevertheless still be considered part of a plan to promote day trading when combined with other acts. NASD Regulation stated that it believes that the proposed rule, as amended, addresses NASAA's concerns and pointed out that the proposed rule language specifies that firms would not be deemed to be promoting day trading activities *solely* by engaging in one of the listed activities, and that therefore such activities may be considered part of a plan to promote day-trading activities when combined with other acts.[35]

Finally, All-Tech argued that the risk disclosure requirements were ''hypocritical'' because they would impose additional regulatory requirements on day-trading firms and not on other firms that facilitate online trading. Citing findings by the Permanent Subcommittee on Investigations of the Senate Committee on Governmental Affairs, the NASD responded that it believes day-trading strategies present unique investor protection concerns that do not necessarily translate to other forms of trading. Thus, the NASD determined that there is no reason to change its position on this issue.[36]

Risk Disclosure Statement

The Senators recommended that the risk disclosure statement warn customers that investors with less than $50,000 in risk capital are not likely to succeed as day traders. NASD Regulation adopted this recommendation in Amendment No. 2, and qualified the warning by stating that risking capital of $50,000 or more does not, however, guarantee successful day trading. The Senators also recommended a provision explaining that there is substantial evidence that most day traders would need to generate at least $100,000 per year just to cover commission costs and trading fees. NASD Regulation incorporated this suggestion into the risk disclosure statement by supplementing the statement with a mathematical example highlighting the need to generate substantial earnings to cover day-trading costs.

In addition, NASAA recommended changing the provision, captioned ''Day trading requires knowledge of a firm's operations,'' to include the language removed by NASD Regulation in Amendment No. 1. NASD Regulation, in Amendment No. 1, replaced language in the original proposal with language suggested in a comment letter. NASAA stated that it believes that the deleted language better explained the need for customers to understand their own firm's execution systems and evaluate potential problems for themselves. Agreeing with the suggestion, NASD Regulation reinserted the removed text into the risk disclosure document.[37]

Appropriateness Determination

As mentioned above, the Senators suggested establishing a ''rebuttable presumption'' that if an investor has less than $50,000 of risk capital, day trading is not appropriate for the customer. This presumption could be rebutted by other factors that the firm concludes outweigh the inadequate risk capital. The Senators further suggested that where a firm determines that day trading is an appropriate strategy for customers who do not possess $50,000 for investment purposes, the firm would be required to prepare and maintain a record setting forth the reasons that it deemed day trading to be appropriate for the customers. NASD Regulation chose not to incorporate this presumption into Amendment No. 2 for several reasons. First, NASD Regulation stated its belief that the $50,000 threshold may make sense for many investors, but it arguably is too low for very active day traders and too high for less active day traders. Second, imposing such a presumption could encourage individuals to misrepresent the value of their assets. Finally, NASD Regulation noted that the current proposal already requires a firm to document the basis on which it approves an account for a day-trading strategy.[38]

NASAA again recommended that the proposal incorporate some additional recordkeeping requirements included in the NASD options rules. Noting that it had considered this issue in preparing Amendment No. 1, NASD Regulation disagreed with this suggestion because it believes that many of these requirements are duplicative of obligations currently imposed on firms.[39]

4. Sources of Customer funds

The Senators suggested modifying the proposal to require broker-dealers that are promoting day-trading strategies to inquire whether parties opening accounts plan to trade for others, and if so, to require firms to determine if parties need to be registered as investment advisors. In Amendment No. 2, NASD Regulation responded to this comment by stating that it believes that it would ''be difficult, if not impossible'' for firms to make this determination. However, NASD Regulation stated that customers should be informed of potential registration requirements and therefore amended the risk disclosure statement to include such a warning.

[33] *See* Amendment Nos. 1 and 2, *supra* notes 5 and 8.

[34] *See* Amendment No. 1, *supra* note 5.

[36] *Id.*

[36] *Id.*

[37] *Id.*

[38] *Id.*

[39] *See* Amendment Nos. 1 and 2, *supra* notes 5 and 8.

NASAA recommended that the proposal require firms to obtain information on the sources of customer funds invested because of the prevalence of day traders using borrowed money to fund their accounts. NASD Regulation represented in Amendment No. 2 that is it considering a separate response to address this concern.[40]

B. Issues Raised in Comment Letters to Amendment No. 2

Although Amendment No. 2 was not yet published, the Commission received one comment letter regarding the amendment.[41] The SIA reiterated its concern that the proposed rule language may undermine what the SIA refers to as the safe harbor provision of the proposed rule. The SIA is concerned that, under the proposed rule, a firm could engage in the activities listed in proposed Rule 2360(g) and have the fact that they engage in those activities—activities that are specifically enumerated in the Rule as not deemed to be promoting a day-trading strategy—used in the determination that the firm is promoting a day-trading strategy.

IV. Discussion

The Commission finds that the proposed rule change is consistent with the requirements of the Act[42] and the rules and regulations thereunder applicable to a national securities association. In particular, the Commission finds the proposal is consistent with the requirements of Section15A(b)(6) of the Act,[43] because the proposed rule change is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, and, in general, to protect investors and the public interest.

During the past few years, the problems and risks associated with day trading have received widespread attention by regulators, legislators, the media, and the public. For example, on February 25 of this year, the Commission's staff issued a report providing the results of its examination of 47 registered broker-dealers providing day-trading facilities to the general public.[44] In addition, earlier this year, the Permanent Subcommittee on Investigations of the Senate Committee on Governmental Affairs held a series of hearings detailing day trading practices.[45] The NASD Regulation proposal, as amended, is intended to provide a measured regulatory response to assure that firms promoting a day-trading strategy check to make certain that day trading is an appropriate investment strategy for a customer opening a day-trading account and that the customer is aware of its risks.

Certain brokerage firms focus primarily, or even exclusively, on promoting day-trading strategies to individuals. These firms generally advertise on the Internet and elsewhere as ''day-trading'' firms or otherwise highlight their execution and other services as desirable for ''serious'' or ''professional'' traders. In addition, many of these firms offer training on day-trading techniques, as well as provide computer facilities and software packages specifically designed to support and accommodate day trading.

Day trading, however, raises unique investor protection concerns. In general, day traders seek to profit from very small movements in the price of a security. Such a strategy often requires aggressive trading of a brokerage account and the use of strategies including margin trading and short selling. As a result, day trading generally requires a significant amount of capital, a sophisticated understanding of securities markets and trading techniques, and a high tolerance for risk. Even experienced day traders with in-depth knowledge of the securities markets may suffer severe and unexpected financial losses.

The Commission finds that requiring a member firm to disclose the risks of day trading to non-institutional customers when the firm promotes a day-trading strategy should help alert individuals who are new to day trading to the risks associated with that strategy. In addition, requiring a member firm to determine whether a day-trading strategy is appropriate for a customer should help to assure that individuals who are unable to bear the risks of day trading, or who have investment objectives incompatible with day trading, are not approved for day trading. In summary, the Commission finds that the risk disclosure statement and appropriateness review mandated by the proposed NASD rules are thoughtfully designed and tailored to address investor protection concerns raised by the increasingly popular trading strategy referred to as day trading.

The Commission notes that the proposed rule change focuses on the promotion of trading strategies that can present high risks to individuals that do not have the investing experience or financial means to sustain those risks and, as revised, the proposed NASD rules should not be unduly burdensome for firms to apply. Firms that are actively promoting a day-trading strategy should be responsible for assessing whether the strategy is appropriate for an individual who opens a day-trading account at that firm. These firms also should be required to disclose the risks of engaging in a day-trading strategy to an individual prior to opening an account for that individual.

While the commenters generally favored the concept of providing greater disclosure of day-trading risks, they also suggested various modifications to the proposal. The Commission believes that NASD Regulation has responded adequately to commenters' concerns and suggestions by incorporating some recommendations into the proposal and explaining why it was not incorporating others. In particular, in response to comments submitted on the original proposed rule change, NASD Regulation: (1) Refined the definition of ''day-trading strategy,'' (2) added more detail regarding the information that a firm must obtain at a minimum from a customer before approving the account for a day-trading strategy; (3) incorporated into the rule those activities that would not be deemed to be ''promoting a day-trading strategy,'' and (4) revised the disclosure statement to discuss the risks associated with trade executions during volatile market conditions and systems failures, among other revisions.

Amendment No. 2 further refines the risk disclosure document to take into account various comments and suggestions submitted regarding Amendment No.1. Amendment No.2 amends the risk disclosure document to: (1) Indicate that an investment of less than $50,000 will impair the ability of a day trader to profit, while an investment of $50,000 or more does not guarantee success; (2) provide an example of the annual profits needed to cover commission costs; (3) encourage investors to become familiar with the firm's business practices, including its order execution systems and procedures; and (4) inform investors

[40] *See* Amendment No. 2, *supra* note 8.

[41] *See* Letter from Michael L. Michael, Chairman, Technology and Regulation Committee, and Michael Hogan, Chairman, Ad-hoc Online Brokerage Legal Committee, SIA, to Nancy Sanow, Assistant Director, SEC, dated June 30, 2000 (''June 30 SIA Letter'').

[42] In approving the proposed rule change, the Commission has considered the proposed rule's impact on efficiency, competition, and capital formation. 15 U.S.C. 78c(f).

[43] 15 U.S.C. 78*o*–3(b)(6).

[44] This study, *Report of Examinations of Day-Trading Broker-Dealers,* is available on the internet at http://www.sec.gov/news/studies/daytrep.htm.

[45] Staff of the Permanent Subcommittee on Investigations, Senate Comm. On Governmental Affairs. 106th Cong., 2d Sess., Memorandum on Day Trading (February 24, 2000).

about the potential need to register as an investment advisor or broker-dealer under certain conditions.

As noted above, the SIA expressed concern about a statement in Amendment No. 2 advising firms that the activities specified in Rule 2360(g) may be considered part of a plan to promote day trading when combined with other acts.[46] Rule 2360(g) provides that firms will not be deemed to be promoting a day-trading strategy *solely* by engaging in one of the listed activities. The Commission believes that NASD Regulation addressed this concern in its Amendment No. 2 by correctly noting that Rule 2360(g) would not subject a firm to the new rules *solely* by engaging in the activities listed in that rule. The Commission finds that, in making the determination of whether a firm is promoting a day-trading strategy, it is reasonable for NASD Regulation to consider all of the firm's activities, including those listed in Rule 2360(g).

Finally, the Commission notes that the NASD will announce the operational date of the proposed rule change in a Notice of Members to be published no later than 60 days following the date of approval by the Commission. The operational date will be 30 days following the date of publication of the Notice to Members announcing Commission approval.

The Commission finds good cause for approving Amendment No. 2 prior to the thirtieth day after the date of publication of notice in the **Federal Register**. The Commission finds that the additional disclosures noted in Amendment No. 2 will provide greater information to investors about the risk of day trading and thus should strengthen the proposal. Moreover, the amendment raises no significant regulatory issues. Accordingly, the Commission finds good cause, consistent with Sections 15A(b)(6)[47] and 19(b)(2)[48] of the Act, to approve Amendment No. 2 to the proposed rule change on an accelerated basis.

V. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning Amendment No. 2, including whether Amendment No. 2 is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the NASD. All submissions should refeer to File No. SR–NASD–99–41 and should be submitted by August 7, 2001.

VI. Conclusion

It Is Therefore Ordered, pursuant to Section 19(b)(2) of the Act[49] that the proposed rule change (SR–NASD–99–4), as amended, is approved and Amendment No. 2 to the proposed rule change is approved on an accelerated basis.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.[50]

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 00–17968 Filed 7–14–00; 8:45 am]

BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–43023; File No. SR–0CC–99–14]

Self-Regulatory Organizations; The Options Clearing Corporation; Notice of Filing of Proposed Rule Change Relating to Price Used in Calculating Premium Margin

July 11, 2000.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act''),[1] notice is hereby given that on October 26, 1999, The Options Clearing Corporation (''OCC'') filed with the Securities and Exchange Commission (''Commission'') the proposed rule change as described in Items I, II, and III below, which items have been prepared primarily by OCC. The Commission is publishing this notice to solicit comments on the proposed rule change from interested parties.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The proposed rule change would set an option's marking price at the last sale price for purposes of calculating premium margin.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, OCC included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. OCC has prepared summaries, set forth in sections (A), (B), and (C) below, of the most significant aspects of these statements.[2]

(A) Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

OCC proposes to amend Rule 601 (relating to margining of equity options) and Rule 602 (relating to margining of non-equity options) to set marking prices at the last sale price, adjusted to the highest bid if the last sale price is below the highest bid or adjusted to the lowest offer if the last sale price is above the lowest offer. The purpose of the proposed rule change is twofold. First, OCC believes that the proposed change results in a more accurate assessment of risk and therefore a more appropriate margin requirement. Second, OCC believes that the proposed rule change will provide consistency with the marking practices of clearing members, the majority of whom are believed to use the method currently proposed.

OCC believes that the proposed rule change is consistent with the requirements of Section 17A(b)(3)(A) of the Act[3] and the rules and regulations thereunder applicable to OCC because the proposed rule change will enable OCC to better facilitate the prompt and accurate clearance and settlement of securities transactions.

(B) Self-Regulatory Organization's Statement on Burden on Competition

OCC does not believe that the proposed rule change will have any impact or impose any burden on competition.

---

[46] *See* June 30 SIA Letter, *supra* note 29.

[47] 15 U.S.C. 78*o*–3(b)(6).

[48] 15 U.S.C. 78s(b)(2).

[49] 15 U.S.C. 78s(b)(2).

[50] 17 CFR 200.30–3(a)(12).

[1] 15 U.S.C. 78s(b)(1).

[2] The Commission has notified the text of the summaries prepared by OCC.

[3] 15 U.S.C. 78q–1(b)(3)(A).

(C) Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

Written comments relating to the proposed rule change have not yet been solicited or received. OCC will notify the Commission of any written comments received by OCC.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within thirty-five days of the date of publication of this notice in the **Federal Register** or within such longer period (i) as the Commission may designate up to ninety days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the self-regulatory organization consents, the Commission will:

(A) By order approve such proposed rule change or

(B) Institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 450 Fifth Street, NW., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal office of OCC. All submissions should refer to File No. SR–OCC–99–14 and should be submitted by August 7, 2000.

For the Commission by the Division of Market Regulation, pursuant to delegated authority.[4]

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 00–18007 Filed 7–14–00; 8:45 am]

BILLING CODE 8010–01–M

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–43022; File No. SR–OCC–99–12]

Self-Regulatory Organizations; The Options Clearing Corporation; Notice of Filing of a Proposed Rule Change Relating to Adjustments to Index Options

July 11, 2000.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (''Act''),[1] notice is hereby given that on November 2, 1999, The Options Clearing Corporation (''OCC'') filed with the Securities and Exchange Commission (''Commission'') the proposed rule change as described in Items I, II, and III below, which items have been prepared primarily by OCC. The Commission is publishing this notice to solicit comments on the proposed rule change from interested parties.

I. Self-Regulatory Organizations Statement of the Terms of Substance of the Proposed Rule Change

The proposed rule change would amend OCC's By-Laws governing index option adjustment to permit the substitution of a successor index for an underlying index.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, OCC included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. OCC has prepared summaries, set forth in sections (A), (B), and (C) below, of the most significant aspects of these statements.[2]

(A) Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

The primary reason for the proposed rule change is to provide for the substitution of a successor index for an underlying index. Because substitution of a successor index for an underlying index may require changes to the terms of outstanding options, OCC also seeks the authority to make adjustments to such terms as necessary to reflect the substitution. While OCC believes such substitution and adjustment are already implicitly provided for under the provisions of OCC's By-Laws at Article XVII, Section 4 (''Unavailability or Inaccuracy of Current Index Value''), OCC seeks to clarify its authority through the proposed rule change.

New paragraph (d) of Article XVII, Section 3 will provide that a successor index may be substituted for an underlying index in the event that the underlying index's publication is discontinued, when the underlying index is replaced with another index, or when an index's composition or method of calculation has so materially changed that it is deemed to be a different index. As in the case of other adjustments, the determination to substitute a successor index and the selection of the index will be made by an adjustment panel. The successor index is to be an index which is deemed to be reasonably comparable to the index for which it substitutes.

Article XVII, Section 3, paragraph (c), which is applicable to adjustments to index options generally, will be amended to provide for adjustments as necessary to accommodate a successor index. In addition, paragraph (c) will be amended to expand the rule in other respects to cover a broader range of potential changes in the calculation of index values and to give added flexibility to OCC in making appropriate adjustments to reflect such changes.

These amendments will grant OCC the authority to adjust outstanding options in the event that an exchange increases or decreases the index multiplier for any index option contract or in the event that any change in the method of calculation of an underlying index creates a discontinuity or change in the level of the index that does not reflect a change in the prices or values of the index's constituent securities. Such a change would occur, for example, if the value of an index were reset from 10,000 to 1,000, which would create a discontinuity that would affect all outstanding options. The changes proposed to Article 1, Section 1 and to Article XVII, Section 1 are designed to

[4] 17 CFR 200.30–3(a)(12).

[1] 15 U.S.C. 78s(b)(1).

[2] The Commission has modified the text of the summaries prepared by OCC.

clarify and conform the terminology to usage as it has developed since the index options provisions were originally drafted.

OCC believes that the proposed rule change is consistent with the requirements of Section 17A of the Act because it refines and amplifies existing OCC rules that have proven effective in promoting the prompt and accurate clearance and settlement of securities transactions and in safeguarding securities and funds.

(B) Self-Regulatory Organization's Statement on Burden on Competition

OCC does not believe that the proposed rule change would impose any burden on competition.

(C) Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

Written comments were not and are not intended to be solicited with respect to the proposed rule change, and none have been received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within thirty-five days of the date of publication of this notice in the **Federal Register** or within such larger period (i) as the Commission may designate up to ninety days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which OCC consents, the Commission will:

(A) By order approve such proposed rule change or

(B) Institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 450 Fifth Street, N.W., Washington, D.C. 20549. Copies of such filing also will be available for inspection and copying at the principal office of OCC. All submissions should refer to File No. SR–OCC–99–12 and should be submitted by August 7, 2000.

For the Commission by the Division of Market Regulation, pursuant to delegated authority.[3]

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 00–18008 Filed 7–14–00; 8:45 am]

BILLING CODE 8010–01–M

[3] 17 CFR 200.30–3(a)(12).

TENNESSEE VALLEY AUTHORITY

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Tennessee Valley Authority (Meeting No. 1521).

TIME AND DATE: 9 a.m. (EDT), July 19, 2000.

PLACE: TVA Knoxville West Tower Auditorium, 400 West Summit Hill Drive, Knoxville, Tennessee.

STATUS: Open.

Agenda

Approval of minutes of meeting held on June 21, 2000.

New Business

C—Energy

C1. Award of contracts to General Electric Company and TurboCare for the engineering, manufacturing, and supply of steam turbine blades to support TVA's fleet of steam turbine rotors.

E—Real Property Transactions

E1. Sale of a noncommercial, nonexclusive permanent easement to Emerson Fizer affecting approximately 0.017 acre of land on Tellico Reservoir in Loudon County, Tennessee, for the construction, operation, and maintenance of private water-use facilities (Tract No. XTELR–215RE).

E2. Grant of a permanent easement to the City of New Johnsonville, Tennessee, affecting approximately 14 acres of land on Kentucky Reservoir in Humphreys County, Tennessee, for a road (Tract No. XTGIR–937H).

E3. Grant of a permanent easement to the State of Tennessee for highway improvement purposes affecting approximately 0.16 acre of TVA land on Chickamauga Reservoir in Hamilton County, Tennessee (Tract No. XTCR–196H).

E4. Grant of a permanent easement to the Sevier Water Board, Inc., for the expansion of a water system intake site affecting approximately 1 acre of TVA land on Douglas Reservoir in Sevier County, Tennessee (Tract No. XTDR–34E).

F—Unclassified

1. Approval of file a condemnation case to acquire permanent easements and rights-of-way for transmission lines and a temporary right to enter upon land to survey and appraise for an electric transmission line at Madison West-South Jackson in Madison County, Tennessee, and the Rock Springs-Center Point transmission line in Whitfield County, Georgia.

Information Items

1. Amendments to the section 16, Variable Annuity Plan, and section 1(1) Definitions, of the Rules and Regulations of the TVA Retirement System.

2. Delegation of authority to the Vice President, Fuel Supply and Engineering Services, or such officer's designee, to modify Contract No. P97P01–196487 with Bowie Resources, Limited, resulting from renegotiation under a reopener provision.

3. Approval to implement results of negotiations with the Tennessee Valley Trades and Labor Council over Revised Project Agreements and Wage Rates for Trades and Labor Work Performed by TVA Contractors.

4. Public auction sale of approximately 6.17 acres of TVA's Nashville, Tennessee, Power Service Center site located in Davidson County, Tennessee (Tract No. XNTPSC–3).

5. Approval to file condemnation cases to acquire permanent easements and rights-of-way for the Weaver-Young Cane Transmission Line in Union County, Georgia.

6. Concurrence by the individual Board members of the Board of Directors for the issuance of TVA Power Bonds.

For more information: Please call TVA Public Relations at (423) 632–6000, Knoxville, Tennessee. Information is also available at TVA's Washington Office (202) 898–2999. People who plan to attend the meeting and have special needs should call (865) 632–6000.

Dated: July 12, 2000.

Edward S. Christenbury,

General Counsel and Secretary.

[FR Doc. 00–18129 Filed 7–13–00; 2:08 am]

BILLING CODE 8120–08–M

DEPARTMENT OF TRANSPORTATION

Office of the Secretary; Applications of Servicios Aereos Profesionales, Inc. for Issuance of New Certificate Authority

AGENCY: Office of the Secretary, DOT.

ACTION: Notice of Order to Show Cause (Order 2000–7–15). Dockets OST–00–6978 and 00–6979.

SUMMARY: The Department of Transportation is directing all interested persons to show cause why it should not issue orders (1) Finding Servicios Aereos Profesionales, Inc., fails to meet the U.S. citizenship requirements of 49 U.S.C. 41102(a)(15), (2) denying it certificates to engage in interstate and foreign scheduled air transportation of persons, property, and mail, and (3) canceling its existing air taxi authority.

DATES: Persons wishing to file objections should do so no later than July 28, 2000.

ADDRESSES: Objections and answers to objections should be filed in Dockets OST–00–6978 and OST–00–6979 and addressed to Department of Transportation Dockets (SVC–124, Room PL–401), 400 Seventh Street, SW., Washington, DC 20590 and should be served upon the parties listed in Attachment A to the order.

FOR FURTHER INFORMATION CONTACT: Ms. Janet A. Davis, Air Carrier Fitness Division (X–56, Room 6401), U.S. Department of Transportation, 400 Seventh Street, SW., Washington, DC 20590, (202) 366–9721.

Dated: July 12, 2000.

A. Bradley Mims,

Acting Assistant Secretary for Aviation and International Affairs.

[FR Doc. 00–18014 Filed 7–14–00; 8:45 am]

BILLING CODE 4910–62–P

DEPARTMENT OF TRANSPORTATION

Federal Highway Administration

Environmental Impact Statement; Crow Wing and Mille Lacs Counties, Minnesota

AGENCY: Federal Highway Administration (FHWA), DOT.

ACTION: Notice of intent.

SUMMARY: The FHWA is issuing this notice to advise the public that an environmental impact statement (EIS) will be prepared for proposed highway improvements to Trunk Highway (TH) 169 in Crow Wing and Mille Lacs Counties, Minnesota.

FOR FURTHER INFORMATION CONTACT: Cheryl Martin, Federal Highway Administration, Galtier Plaza, Box 75, 175 East Fifth Street, Suite 500, St. Paul, Minnesota 55101–2904, Telephone (651) 291–6120; or Jim Hallgren, Project Manager, Minnesota Department of Transportation—District 3, 1991 Industrial Park, Baxter, Minnesota 56425, Telephone (218) 828–2773; (651) 296–9930 TTY.

SUPPLEMENTARY INFORMATION: The FHWA, in cooperation with the Minnesota Department of Transportation, will prepare an EIS on a proposal to improve TH 169 from the north junction of TH 27 near Onamia to the junction of TH 18 in Garrison in Crow Wing and Mille Lacs Counties, Minnesota, a distance of approximately 28.2 kilometers.

The proposed action is being considered to address transportation demand, safety problems, access management, interregional corridor status, design deficiencies and pavement condition. Alternatives under consideration include (1) No build; and (2) variations of ''Build'' alternatives involving reconstruction and/or realignment and new construction of TH 169, including the expansion of the two lane roadway to a four-lane facility.

The ''Trunk Highway 169 Scoping Document/Draft Scoping Decision Document'' will be published in the late summer 2000. A press release will be published to inform the public of the document's availability. Copies of the scoping document will be distributed to agencies, interested persons and libraries for review to aid in identifying issues and analyses to be contained in the EIS. A 30-day comment period for review of the document will be provided to afford an opportunity for all interested persons, agencies and groups to comment on the proposed action. A public scoping meeting will also be held during the comment period. Public notice will be given for the time and place of the meeting.

Coordination has been initiated and will continue with appropriate Federal, State and local agencies and private organizations and citizens who have previously expressed or are known to have an interest in the proposed action. To ensure that the full range of issues related to this proposed action are addressed and all significant issues identified, comments and suggestions are invited from all interested parties. Comments or questions concerning this proposed action and the EIS should be directed to the FHWA at the address provided above.

(Catalog of Federal Domestic Assistance Program Number 20.205, Highway Planning and Construction. The regulations implementing Executive Order 12372 regarding intergovernmental consultation on Federal programs and activities apply to this program)

Issued on: July 6, 2000.

Alan R. Steger,

Division Administrator, Federal Highway Administration, St. Paul, Minnesota.

[FR Doc. 00–17955 Filed 7–14–00; 8:45 am]

BILLING CODE 4910–22–M

DEPARTMENT OF TRANSPORTATION

Federal Highway Administration

Environmental Impact Statement; Martin County, FL

AGENCY: Federal Highway Administration (FHWA), DOT.

ACTION: Notice of intent.

SUMMARY: The FHWA is issuing this notice to advise the public that an Environmental Impact Statement (EIS) will be prepared for a proposed highway project in Martin County, Florida.

FOR FURTHER INFORMATION CONTACT: Patrick A. Bauer, Program Operation Engineer, Federal Highway Administration, 227 North Bronough Street, Tallahassee, Florida 32301, Telephone: (850) 942–9650, Extension 3035.

SUPPLEMENTARY INFORMATION: The FHWA, in cooperation with the Florida Department of Transportation will prepare an EIS for a proposal to provide an additional crossing of the St. Lucie River in Martin County, Florida. The proposed improvements will involve utilizing existing roadways as footprints for a new corridor. Improvements to the corridor are considered necessary to provide for existing and projected traffic demand.

Alternatives under consideration include (1) taking no action; (2) widening the existing State Road 714 corridor to a six- or eight-lane roadway; (3) an additional four-lane corridor; or (4) two additional two-lane corridors.

Letters describing the proposed action and soliciting comments will be sent to appropriate Federal, State, and local agencies, and to private organizations and citizens who have expressed interest in the proposal. A series of public meetings will be held in Martin County between October 2000 and January 2001. In addition, a public hearing will be held. Public notice will be given of the time and place of the meetings and hearings. The Draft EIS will be made available for public and agency review and comment. A formal

scoping meeting is planned in the project vicinity site during the latter part of 2000.

To ensure that the full range of issues related to the proposed action are addressed and all significant issues identified, comments and suggestions are invited from all interested parties. Comments or questions concerning this proposed action and the EIS should be directed to the FHWA at the address provided above.

(Catalog of Federal Domestic Assistance Program Number 20.205, Highway Research, Planning and Construction. The regulations implementing Executive Order 12372 regarding inter-governmental consultation on Federal programs and activities apply to this program.)

Issued on: July 6, 2000.

Patrick A. Bauer P.E.,

Program Operations Engineer, Tallahassee, Florida.

[FR Doc. 00–17954 Filed 7–14–00; 8:45 am]

BILLING CODE 4910–22–M

DEPARTMENT OF TRANSPORTATION

National Highway Traffic Safety Administration

[Docket No. NHTSA–99–6324; Notice 1]

EMB Incorporated; Application for Temporary Exemption From Federal Motor Vehicle Safety Standards Nos. 108 and 120

We are asking for comments on the application by EMB Incorporated (''EMB'') of Sebastopol, California, for a 2-year exemption from portions of Federal Motor Vehicle Safety Standard Nos. 108 *Lamps, Reflective Devices and Associated Equipment,* and 120 *Tire Selection and Rims for Motor Vehicles Other Than Passenger Cars.* The company does business as Electric Motorbike, Inc., and has petitioned on behalf of its Lectra VR24 motorcycle. In the opinion of the company, a temporary exemption ''would make the development or field evaluation of a low-emission motor vehicle easier and would not unreasonably lower the safety level of that vehicle'' (49 U.S.C. 30113(b)(3)(B)(iii)).

We are publishing this notice of receipt of the application in accordance with our regulations on temporary exemptions. This action does not mean that we have made any judgment about the merits of the application. The discussion that follows is based on information contained in EMB's application.

Why EMB Needs a Temporary Exemption

The company is developing zero-emission (electric battery-powered) vehicles. Due to a lack of readily-available components for these vehicles needed to comply with Federal Motor Vehicle Safety Standards Nos. 108 and 120, as explained below, EMB must petition for an exemption from portions of them, until July 1, 2001, as explained below.

Why an Exemption Would Make Easier the Development and Field Evaluation of a Low-Emission Motor Vehicle and Would Not Unreasonably Degrade the Safety of That Vehicle

In order to make the company's products available for wider use, EMB believes that a test and development period is required to optimize product features and functions. During the development stage, it is likely that several design changes will be made ''to optimize the product for acceptance by the wider public.''

It is important to place a limited number of product in service in order to gain insights into the features, functions and operating characteristics of the product.

In order to do so, the following temporary exemptions are requested:

1. Standard No. 108

EMB utilizes a 24-volt lighting system which presently creates an incompatibility with available lighting equipment, requiring a temporary exemption from three requirements of Standard No. 108.

Table IV of Standard No. 108 requires motorcycle turn signal lamps to meet the applicable requirements of SAE Standard J588NOV84 *Turn Signal Lamps.* However, S5.1.1.7 of Standard No. 108 provides that ''a motorcycle turn signal lamp need meet only one-half of the minimum photometric values specified in Table 1 and Table 3'' of SAE J588NOV84. EMB states that ''turn signals which operate at this voltage are difficult to locate.'' However, it has found a supplier in Spain ''which offers European-compliant turn signals for 24-volt operation.'' The turn signal unit that the company has found ''meets European requirements 50R E9.'' EMB believes that the European standard is equivalent to that of S5.1.1.7, e.g., that an exemption would not unduly degrade the safety of the vehicle.

Table III of Standard No. 108 requires motorcycles to be equipped with turn signal lamps and a turn signal operating unit. S5.5.6 requires all vehicles equipped with a turn signal operating unit to also have an illuminated pilot indicator, which will inform the operator when one or more turn signal lamps fails to operate. However, no indication is required if a variable-load turn signal flasher has been installed on a motor vehicle type specified in S5.5.6. A motorcycle is not one of the vehicle types specified, and the Lectra VR24 incorporates a variable load flasher. As noted above, the company uses a 24-volt DC power source for turn signal lamps. Outage indication is not presently available in 24 volt DC flasher units, therefore, the turn signal indicator on the dash board will not indicate a failed lamp.

EMB argues that the open nature of the motorcycle makes it ''easy for an operator to check for proper operation of all lights and signals. * * *''

EMB also seeks exemption from certain portions of S7.9 which specifies headlighting requirements for motorcycles. In pertinent part, EMB has chosen to meet the photometric specifications of Figure 32. At the present time, motorcycle headlamps are not available in 24-volt versions, and the company has chosen ''a military vehicle headlamp'' manufactured by ''Wagner Corporation.'' This headlamp ''does meet requirements for passenger car headlighting systems.'' The upper beam of the headlamp meets all requirements for motorcycle headlamp upper beams, and complies with all lower beam test points as well, with the exception of Test Point 2D–3L, where there is a shortfall of 7 percent.

EMB argues that the shortfall does not unreasonably degrade safety because the Lectra VR24 is designed for a cruising speed of 30 mph and the headlamp does meet requirements for this equipment on motor driven cycles.

Finally, the lens of the headlamp will not be marked ''motorcycle'' as required by S7.9.5 for a headlamp of the type intended to be used.

During the exemption period, EMB plans to develop a lighting system that fully complies with Standard No. 108.

2. Standard No. 120

S5.2 *Rim marking* of Standard No. 120 requires, in pertinent part, that each rim be embossed or debossed with certain specified information. The wheel that EMB has selected was not embossed with the information at time of manufacture but has been subsequently stamped with indelible ink. All the information is present and in the required location. These wheels meet ISO 8644, ISO 8645, and TUV specifications. EMB will work with suppliers to ensure that future rims are properly marked.

Why Exempting EMB Would Be Consistent With the Public Interest and Objectives of Motor Vehicle Safety

EMB ''is developing zero-emission vehicles which are consistent with the goals and desires of society for a cleaner and quieter environment, and reduced reliance on fossil fuels.''

Even with the exemptions requested, EMB believes that the Lectra VR24 exhibits an overall level of safety equivalent to that prescribed by the Federal motor vehicle safety standards.

How To Comment on EMB's Application

If you would like to comment on EMB's application, send two copies of your comments, in writing, to: Docket Management, National Highway Traffic Safety Administration, Room PL–401, 400 Seventh Street, SW, Washington, DC 20590, in care of the docket and notice number shown at the top of this document.

We shall consider all comments received before the close of business on the comment closing date stated below. To the extent possible, we shall also consider comments filed after the closing date. You may examine the docket in Room PL–401, both before and after that date, between 10 a.m. and 5 p.m.

When we have reached a decision, we shall publish it in the **Federal Register**.

Comment closing date: August 16, 2000.

Authority: 49 U.S.C. 30113; delegations of authority at 49 CFR 1.50 and 501.4.

Issued on: July 11, 2000.

Stephen R. Kratzke,

Associate Administrator for Safety Performance Standards.

[FR Doc. 00–18010 Filed 7–14–00; 8:45 am]

BILLING CODE 4910–59–P

DEPARTMENT OF TRANSPORTATION

National Highway Traffic Safety Administration

[Docket No. NHTSA 2000–7616; Notice 1]

Piaggio & c., S.p.A.; Receipt of Application for Temporary Exemption From Federal Motor Vehicle Safety Standard No. 123

Piaggo & c., S.p.A. (''Piaggio''), an Italian corporation, of Pontedera, Italy, has applied for a temporary exemption of two years from a requirement of S5.2.1 (Table 1) of Federal Motor Vehicle Safety Standard No. 123 *Motorcycle Controls and Displays.* The basis of the request is that ''compliance with the standard would prevent the manufacturer from selling a motor vehicle with an overall safety level at least equal to the overall safety level of nonexempt vehicles,'' 49 U.S.C. 30113(b)(3)(B)(iv).

We are publishing this notice of receipt of an application in accordance with the requirements of 49 U.S.C. 30113(b)(2). This action does not represent any judgment of the agency on the merits of the application.

Piaggio has applied on behalf of its Vespa ET4 (125 and 150 cc) motor scooters. The scooters are defined as ''motorcycles'' for purposes of compliance with the Federal motor vehicle safety standards. If a motorcycle is produced with rear wheel brakes, S5.2.1 of Standard No. 123 requires that the brakes be operable through the right foot control (the left handlebar is permissible only for a motor driven cycle (Item 11, Table 1), *i.e.,* a motorcycle with a motor that produces 5 brake horsepower or less).

Piaggio petitions that it be allowed to use the left handlebar as the control for the rear brakes of its Vespa ET4, which is a motorcycle and not a motor driven cycle. The model features an automatic clutch that eliminates the left-hand clutch lever as well as any left-foot gearshift lever. According to Piaggio, ''the motor scooter is therefore very similar to a bicycle, both in ergonomic stance and operation.'' The model will feature a hand-actuated lever on the left handlebar that will actuate the rear brake, and a hand-actuated lever on the right handlebar that will control the front brake.

Piaggio argues that the overall level of safety of the scooters equals or exceeds that of a motorcycle that complies with the brake control location requirement of Standard No. 123. The Vespa ET4 is equipped with disc brakes on the front wheels, and ''easily meets and exceeds all the performance requirements of FMVSS 122'' for motorcycle brake systems. The vehicle meets the braking performance requirements of ECE 93/14 as well.

Piaggio avers that no other country in Europe, Japan, or elsewhere in Asia requires scooters to be equipped with a right foot-operated brake control. Absent an exemption, then, Piaggio will be unable to sell the Vespa ET4 in the United States. Piaggio ''is in the process of introducing a complete modification of the Vespa braking system to conform with FMVSS 123,'' and intends to complete its development work during the two-year period that its exemption would be in effect.

Piaggio will not sell more than 2,500 scooters a year while an exemption is in effect. The exemption would cover Model Year 2000 and 2001 vehicles. The company believes that an exemption would be consistent with the objectives of traffic safety because the scooter provide ''for much more natural braking response by the rider than non-exempt vehicles.'' Extended use in Europe and the rest of the world has not resulted in either consumer groups or governmental authorities raising any safety concerns. The exemption would also be in the public interest because it is ''environmentally clean and fuel efficient * * * convenient urban transportation.''

You may submit comments on the application described above. Comments should refer to the docket number and the notice number, and be submitted to: Docket Management, Room PL–401, 400 Seventh Street, SW, Washington, DC 20590. You should send at least two copies.

We shall consider all comments received before the close of business on the comment closing date indicated below. Comments will be available for examination in the docket at the above address both before and after that date. The Docket Room is open from 10:00 a.m. until 5:00 p.m. To the extent possible, comments filed after the closing date will also be considered.

We shall publish a notice of final action on the application pursuant to the authority indicated below.

Comment closing date: August 16, 2000.

(49 U.S.C. 30113; delegations of authority at 49 CFR 1.50. and 501.8)

Issued on July 11, 20000.

Stephen R. Kratzke,

Associate Administrator for Safety Performance Standards.

[FR Doc. 00–18011 Filed 7–14–00; 8:45 am]

BILLING CODE 4910–59–P

DEPARTMENT OF TRANSPORTATION

Bureau of Transportation Statistics

Reports, Forms and Recordkeeping Requirements; Agency Information Collection Activity Under OMB Review

AGENCY: Bureau of Transportation Statistics, DOT.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*), this notice announces that the Information Collection Request (ICR) abstracted below has been forwarded to the Office of Management and Budget (OMB) for extension of currently approved collections. The ICR describes the

nature of the information collection and its expected burden. The Federal Register Notice with a 60-day comment period soliciting comments on the following collection of information was published on April 13, 2000 [65 FR 19961–19962].

DATES: Comments must be submitted on or before August 16, 2000.

FOR FURTHER INFORMATION CONTACT: Bernie Stankus, (202) 366–4387, DOT, Office of Airline Information, Room 4125, K–25, 400 Seventh Street, NW., Washington, DC 20590–0001.

SUPPLEMENTARY INFORMATION:

Bureau of Transportation Statistics (BTS)

Title: Passenger Origin Destination Survey Report.

Type of Request: Extension of a currently approved Collection.

OMB Control Number: 2139–0001.

Affected Public: Large certificated scheduled passenger air carriers.

Abstract: DOT uses the Passenger Origin-Destination Survey Report in administering its international aviation program, in evaluating carrier fitness, monitoring passenger fares, assessing airline competition and assessing airport needs.

Estimated Annual Burden Hours: 38,080.

ADDRESSES: Send comments to the Office of Information and Regulatory Affairs, Office of Management and Budget, 725–17th Street, NW., Washington, DC 20503, Attention BTS Desk Officer.

Comments are Invited on: whether the proposed collection of information is necessary for the proper performance of the functions of the Department, including whether the information will have practical utility; the accuracy of the Department's estimate of the burden of the proposed information collection; ways to enhance the quality, utility and clarity of the information to be collected; and ways to minimize the burden of the collection of information on respondents, including the use of automated collection techniques or other forms of information technology. A comment to OMB is most effective if OMB receives it within 30 days of publication.

Issued in Washington, DC on July 10, 2000.

Donald W. Bright,

Acting Director, Office of Airline Information, Bureau of Transportation Statistics.

[FR Doc. 00–18013 Filed 7–14–00; 8:45 am]

BILLING CODE 4910–FE–P

DEPARTMENT OF THE TREASURY

Internal Revenue Service

Open Meeting of Citizen Advocacy Panel, Brooklyn District

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Notice of cancellation of open meeting of Citizen Advocacy Panel, Brooklyn District.

SUMMARY: The meeting scheduled for July 20, 2000 has been cancelled due to scheduling conflicts.

DATES: The meeting will be rescheduled and published at a later date.

FOR FURTHER INFORMATION CONTACT: Eileen Cain at 1–888–912–1227 or 718–488–3555.

SUPPLEMENTARY INFORMATION: Notice is hereby given pursuant to Section 10(a)(2) of the Federal Advisory Committee Act, 5 U.S.C. App. (1988) that an operational meeting of the Citizen Advocacy Panel originally scheduled for Thursday July 20, 2000, 6:00 p.m. to 9:00 p.m. at the Internal Revenue Service Brooklyn Building located at 625 Fulton Street, Brooklyn, NY 11201 has been cancelled due to scheduling conflicts. The meeting will be rescheduled and published at a later date.

Dated: June 29, 2000.

M. Cathy Vanhorn,

Director, CAP, Communications & Liaison.

[FR Doc. 00–18001 Filed 7–14–00; 8:45 am]

BILLING CODE 4830–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0569]

Proposed Information Collection Activity: Proposed Collection; Comment Request

AGENCY: Veterans Benefits Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: The Veterans Benefits Administration (VBA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act (PRA) of 1995, Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed revision of a currently approved collection, and allow 60 days for public comment in response to the notice. This notice solicits comments on requirements relating to customer satisfaction surveys.

DATES: Written comments and recommendations on the proposed collection of information should be received on or before September 15, 2000.

ADDRESSES: Submit written comments on the collection of information to Lynne R. Heltman, Veterans Benefits Administration (245), Department of Veterans Affairs, 810 Vermont Avenue, NW, Washington, DC 20420. Please refer to ''OMB Control No. 2900–0569'' in any correspondence.

FOR FURTHER INFORMATION CONTACT: Lynne R. Heltman at (202) 273–5440.

SUPPLEMENTARY INFORMATION: Under the PRA of 1995 (Public Law 104–13; 44 U.S.C., 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. This request for comment is being made pursuant to Section 3506(c)(2)(A) of the PRA.

With respect to the following collection of information, VBA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of VBA's functions, including whether the information will have practical utility; (2) the accuracy of VBA's estimate of the burden of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or the use of other forms of information technology.

Title: Generic Clearance for the Veterans Benefits Administration Customer Satisfaction Surveys.

OMB Control Number: 2900–0569.

Type of Review: Extension of a currently approved collection.

Abstract: VBA administers integrated programs of benefits and services, established by law for veterans and their survivors, and service personnel. Executive Order 12862, Setting Customer Service Standards, requires Federal agencies and departments to identify and survey its customers to determine the kind and quality of services they want and their level of satisfaction with existing service. VBA uses customer satisfaction surveys to gauge customer perceptions of VA services as well as customer expectations and desires. The results of these information collections lead to improvements in the quality of VBA

service delivery by helping to shape the direction and focus of specific programs and services.

Affected Public: Individuals or households, non-profit organizations, educational institutions, veterans' service organizations, and businesses or other for-profits.

NATIONAL SURVEY ACTIVITIES

Year	Number of respondents	Estimated annual burden (hours)	Frequency of response
Survey of Veterans' Satisfaction With the VA Compensation and Pension Claims Process			
2001	22,800	5,700	One-time.
2002	22,800	5,700	Do.
2003	22,800	5,700	Do.
Survey of Veterans' Satisfaction With the VA Education Claims Process			
2001	3,200	800	One-time.
2002	3,200	800	Do.
2003	3,200	800	Do.
Survey of Educational Institution Certifying Officials			
2002	1,000	330	One-time.
2003	1,000	330	Do.
Loan Guaranty Customer Satisfaction Survey—Veteran			
2001	7,200	1,202	One-time.
2002	7,200	1,202	Do.
2003	7,200	1,202	Do.
Loan Guaranty Customer Satisfaction Survey—Lender			
2001	1,000	330	One-time.
2002	1,000	330	Do.
2003	1,000	330	Do.
Vocational Rehabilitation & Employment Program Survey			
2001	10,800	2,700	One-time.
2002	10,800	2,700	Do.
2003	10,800	2,700	Do.
Insurance Customer Surveys			
2001	2,800	280	One-time.
2002	2,800	280	Do.
2003	2,800	280	Do.
Undetermined Focus Groups			
2001	500	1,000	One-time.
2002	500	1,000	Do.
2003	500	1,000	Do.
National Telephone Survey			
2001	7,200	1,224	One-time.
2002	7,200	1,224	Do.
2003	7,200	1,224	Do.
VA Regional Office-Based Survey Activities—VA Regional Office-Based Customer Satisfaction Focus Groups			
2001	600	1,800	One-time.
2002	600	1,800	Do.

NATIONAL SURVEY ACTIVITIES—Continued

Year	Number of respondents	Estimated annual burden (hours)	Frequency of response
2003	600	1,800	Do.
VA Regional Office-Specific Service Improvement Initiatives (Comment Card)			
2001	139,200	11,554	One-time.
2002	139,200	11,554	Do.
2003	139,200	11,554	Do.

Most customer satisfaction surveys will be recurring so that VBA can create ongoing measures of performance and to determine how well the agency meets customer service standards. Each collection of information will consist of the minimum amount of information necessary to determine customer needs and to evaluate VBA's performance. VBA expects to conduct an estimated 100 focus groups and receive up to 139,200 comment cards involving a total of 14,354 hours each year for 2001, 2002, and 2003. In addition, VBA expects to distribute written surveys with a total annual burden of approximately 12,236 hours in 2001, 12,566 hours in 2002, and 12,566 hours in 1999. The grand totals for both focus groups, comment cards, and written surveys are: 26,590 hours in 2001, 26,920 hours in 2002, and 26,920 hours in 2003.

Anyone may view the results of previously administered surveys on the internet by going to the following VBA surveys website: http://www.vba.va.gov/surveys/.

The areas of concern to VBA and its customers may change over time, and it is important to have the ability to evaluate customer concerns quickly. OMB will be requested to grant generic clearance approval for a 3-year period to conduct customer satisfaction surveys, focus groups and to send out comment cards. Participation in the surveys, focus groups, and comment cards will be voluntary and the generic clearance will not be used to collect information required to obtain or maintain eligibility for a VA program or benefit. In order to maximize the voluntary response rates, the information collection will be designed to make participation convenient, simple, and free of unnecessary barriers. Baseline data obtained through these information collections will be used to improve customer service standards. VBA will consult with OMB regarding each specific information collection during this approval period.

Dated: June 16, 2000.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 00–17971 Filed 7–14–00; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

[OMB Control No. 2900–0570]

Proposed Information Collection Activity: Proposed Collection; Comment Request

AGENCY: Veterans Health Administration, Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: The Veterans Health Administration (VHA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act (PRA) of 1995, Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of a currently approved collection, and allow 60 days for public comment in response to the notice. This notice solicits comments on the burden estimates relating to customer satisfaction surveys.

DATES: Written comments and recommendations on the proposed collection of information should be received on or before September 15, 2000.

ADDRESSES: Submit written comments on the collection of information to Ann Bickoff, Veterans Health Administration (193B1), Department of Veterans Affairs, 810 Vermont Avenue, NW, Washington, DC 20420. Please refer to ''OMB Control No. 2900–0570'' in any correspondence.

FOR FURTHER INFORMATION CONTACT: Ann Bickoff at (202) 273–8310.

SUPPLEMENTARY INFORMATION: Under the PRA of 1995 (Public Law 104–13; 44 U.S.C., 3501—3520), Federal agencies must obtain approval from OMB for each collection of information they conduct or sponsor. This request for comment is being made pursuant to Section 3506(c)(2)(A) of the PRA.

With respect to the following collection of information, VHA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of VHA's functions, including whether the information will have practical utility; (2) the accuracy of VHA's estimate of the burden of the proposed collection of information; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or the use of other forms of information technology.

Title: Generic Clearance for the Veterans Health Administration Customer Satisfaction Surveys.

OMB Control Number: 2900–0570.

Type of Review: Extension of a currently approved collection.

Abstract: Executive Order 12862, Setting Customer Service Standards, requires Federal agencies and departments to identify and survey its customers to determine the kind and quality of services they want and their level of satisfaction with existing services. VHA uses customer satisfaction surveys to gauge customer perceptions of VA services as well as customer expectations and desires. The results of these information collections lead to improvements in the quality of VHA service delivery by helping to shape the direction and focus of specific programs and services.

Affected Public: Individuals or households.

Listing of Survey Activities

I. Special Emphasis Programs

The following list of activities is a compendium of customer satisfaction survey plans by VHA. Different special emphasis programs will be surveyed annually; however, program selections have not been made for FYs 2001–2003. Burden hours for the out-years are based on FY 2000 estimates.)

Year	Number of respondents	Estimated annual burden (hours)	Frequency
2001	46,800	11,700	Annually.
2002	46,800	11,700	Do.
2003	46,800	11,700	Do.

II. Local Facilities Surveys

Year	Number of respondents	Estimated annual burden (hours)	Frequency
1998	12,000	2,000	One-time.
1999	12,000	2,000	Do.
2000	12,000	2,000	Do.

Most customer satisfaction surveys will be recurring so that VHA can create ongoing measures of performance and to determine how well the Agency meets customer service standards. Each collection of information will consist of the minimum amount of information necessary to determine customer needs and to evaluate VHA's performance. VHA expects to distribute written surveys with a total annual burden of approximately 13,700 hours in FYs 2001, 2002, and 2003.

Dated: June 8, 2000.

By direction of the Secretary.

Donald L. Neilson,

Director, Information Management Service.

[FR Doc. 00–17972 Filed 7–14–00; 8:45 am]

BILLING CODE 8320–01–P

DEPARTMENT OF VETERANS AFFAIRS

Privacy Act of 1974; Amendment of System of Records

AGENCY: Department of Veterans Affairs.

ACTION: Notice.

Notice is hereby given that the Department of Veterans Affairs (VA) is revising an existing routine use to the system of records entitled ''Personnel and Accounting Pay System-VA'' (27VA047) as set forth in the **Federal Register** 40 FR 38095 (8/26/75) and amended in 48 FR 16372 (4/15/83), 50 FR 23009 (5/30/85), 51 FR 6858 (2/26/86), 51 FR 25968 (7/17/86), 55 FR 42534 (10/19/90), 56 FR 23952 (5/24/91), 58 FR 39088 (7/21/93), 58 FR 40852 (7/30/93), 60 FR 35448 (7/7/95), 62 FR 41483 (8/1/97), 62 FR 68362 (12/31/97), and 65 FR 20850 (4/18/00). This system of records contains information on current and former salaried VA employees.

The Federal Labor Relations Authority (FLRA) was established in accordance with 5 U.S.C. 7104. The FLRA's powers and duties are outlined in 5 U.S.C. 7105. These include the investigation and resolution of allegations of unfair labor practices, exceptions to arbitrator awards when a question of material fact is raised, and matters before the Federal Service Impasses Panel. The FLRA also investigates representation petitions and conducts or supervises representation elections. The FLRA's purpose, scope, powers, and duties are also set forth in Subchapter C of Title 5 of the Code of Federal Regulations (CFR). As part of its powers and duties, the FLRA may make any appropriate inquiry to carry out its duties. The FLRA has the authority to request certain information, including employee names and home addresses, in connection with its investigations and other activities. Employee's home addresses are necessary information for FLRA investigation of elections where the elections are by mail ballot, rather than by on-site election.

The Privacy Act (5 U.S.C. 552a) requires any records under the control of a federal agency from which information is retrieved by the name of an individual, or by some identifying number, symbol, or other identifying particular assigned to an individual, to be grouped in a system of records. Information cannot be released from a Privacy Act system of records without the individual's consent, unless an exception applies or a routine use for the release of the information is developed for the system of records.

The VA Office of General Counsel has determined that release of information to FLRA from Privacy Act system of records ''Personnel and Accounting Pay System-VA'' (27VA047), including the names and home addresses of employees, is necessary to comply with the statutory mandate under which FLRA operates. It has also been determined that the release of information for this purpose is a necessary and proper use of the information in this system of records and the addition of the new routine use number 33 for transfer of this information is appropriate.

An altered system of records report and a copy of the revised system notice have been sent to the House of Representatives Committee on Government Reform, the Senate Committee on Governmental Affairs, and the Office of Management and Budget (OMB) as required by 5 U.S.C. 552a(r) and guidelines issued by OMB (59 FR 37906, 37916–18 (7/25/94)).

Interested persons are invited to submit written comments, suggestions, or objections regarding the proposed routine use of the system of records to the Director, Office of Regulations Management (02D), Department of Veterans Affairs, 810 Vermont Avenue, NW, Room 1154, Washington, DC 20420. All relevant material received before August 16, 2000, will be considered. All written comments

received will be available for public inspection at the above address in the Office of Regulations Management, Room 1158, between the hours of 8 a.m. and 4:30 p.m., Monday through Friday, except holidays.

If no public comment is received during the 30-day review period allowed for public comment, or unless otherwise published in the **Federal Register** by VA, the new routine use statement is effective August 16, 2000.

Approved: June 29, 2000.

Togo D. West, Jr.,

Secretary of Veterans Affairs.

Notice of Amendment to System of Records

In the system of records identified as 27VA047, ''Personnel and Accounting Pay System-VA,'' as set forth in the **Federal Register** 40 FR 38095 (8/26/75) and amended in 48 FR 16372 (4/15/83), 50 FR 23009 (5/30/85), 51 FR 6858 (2/26/86), 51 FR 25968 (7/17/86), 55 FR 42534 (10/19/90), 56 FR 23952 (5/24/91), 58 FR 39088 (7/21/93), 58 FR 40852 (7/30/93), 60 FR 35448 (7/7/95), 62 FR 41483 (8/1/97), 62 FR 68362 (12/31/97), and 65 FR 20850 (4/18/00) the system is amended as follows:

* * * * *

ROUTINE USES OF RECORDS MAINTAINED IN THE SYSTEM, INCLUDING CATEGORIES OF USERS AND THE PURPOSE OF SUCH USES:

* * * * *

33. To disclose information to the Federal Labor Relations Authority (including its General Counsel) when requested in connection with the investigation and resolution of allegations of unfair labor practices, in connection with the resolution of exceptions to arbitrator awards when a question of material fact is raised, in connection with matters before the Federal Service Impasses Panel, and to investigate representation petitions and conduct or supervise representation elections.

* * * * *

[FR Doc. 00–17973 Filed 7–14–00; 8:45 am]

BILLING CODE 8320–01–M

Federal Register

Monday,
July 17, 2000

Part II

Office of Personnel Management

5 CFR Part 591

Cost-of-Living Allowances (Nonforeign Areas); Guam and the Commonwealth of the Northern Mariana Islands and Honolulu, HI; Interim and Final Rules

Report on 1998 Surveys Used To Determine Cost-of-Living Allowances in Nonforeign Areas; Notice

OFFICE OF PERSONNEL MANAGEMENT

5 CFR Part 591

RIN 3206–AJ15

Cost-of-Living Allowances (Nonforeign Areas); Guam and the Commonwealth of the Northern Mariana Islands

AGENCY: Office of Personnel Management.

ACTION: Interim rule with request for comments.

SUMMARY: The Office of Personnel Management (OPM) is publishing an interim regulation to increase the cost-of-living allowance (COLA) rate paid to certain Federal employees in Guam and the Commonwealth of the Northern Mariana Islands (CNMI). This regulation increases the local retail COLA rate for the Guam/CNMI allowance area from 22.5 percent to 25 percent. This increase is a result of cost-of-living surveys conducted in October and November 1998 using our current methodology for calculating COLA rates. A settlement agreement that is currently awaiting court approval calls for OPM to use a new methodology in conducting future surveys and in calculating future COLA rates. Therefore, the survey results reflected in this rule are not an indication of what survey results or COLA rates would be under the new methodology.

DATES: *Effective date:* July 17, 2000. *Implementation date:* First day of the first pay period beginning on or after July 17, 2000. *Comment date:* Submit comments on or before October 16, 2000.

ADDRESSES: Send or deliver comments to Donald J. Winstead, Assistant Director for Compensation Administration, Workforce Compensation and Performance Service, Office of Personnel Management, Room 7H31, 1900 E Street NW., Washington, DC 20415–8200; fax: (202) 606–4264; or email: COLA@opm.gov.

FOR FURTHER INFORMATION CONTACT: Donald L. Paquin, (202) 606–2838; fax: (202) 606–4264; or email: COLA@opm.gov.

SUPPLEMENTARY INFORMATION: The Federal Government pays cost-of-living allowances (COLAs) to General Schedule, U.S. Postal Service, and certain other Federal employees in Alaska, Hawaii, Guam and the Commonwealth of the Northern Mariana Islands, Puerto Rico, and the U.S. Virgin Islands. The Office of Personnel Management (OPM) conducts cost-of-living surveys in each allowance area to determine whether, and to what degree, local living costs are higher than those in the Washington, DC, area. OPM sets the COLA rate for each area based on the results of these surveys.

In October and November 1998, we conducted cost-of-living surveys in Alaska, Hawaii, Guam, Puerto Rico, the U.S. Virgin Islands, and the Washington, DC, area. We compared the results of the Washington, DC, area survey with the results of the other surveys to derive an index for each of the areas. We provide the details of this process in a separate report in this issue of the **Federal Register**.

The 1998 surveys indicate that the local retail COLA rate for the Guam/CNMI allowance area should be increased to 25 percent, as shown in the following table. Under the Treasury, Postal Service, and General Government Appropriations Act, 1992 (Pub. L. 102–141), as amended, no COLA rates may decrease until after December 31, 2000.

INCREASE IN COLA RATE

Allowance area/category	Current rate	New rate
Guam/CNMI, Local Retail ...	22.5	25

Appendix text changes

We inadvertently omitted the introductory text to appendix A of subpart B in the interim rule published with our 1997 survey report. (See 63 FR 56430, October 21, 1998.) We are reinstating the text with this rule. We have also rewritten a portion of the introductory text and other text in appendix A to improve clarity. These changes are not substantive.

Rulemaking waivers

Under 5 U.S.C. 553 (b)(3)(B) and (d)(3), OPM finds that good cause exists to waive the publication of proposed rulemaking and the 30-day delay in the effective date of this regulation. Because of unexpected delays in completing these surveys and calculating the living-cost indexes, we believe it is in the public interest to implement the COLA rate increase immediately. In the future, as we have done in the past, we plan to announce COLA rate adjustments in a proposed rule for public notice and comment.

Regulatory Flexibility Act

I certify that this regulation will not have a significant economic impact on a substantial number of small entities because the regulation will affect only Federal agencies and employees.

List of Subjects in 5 CFR Part 591

Government employees, Travel and transportation expenses, Wages.

Office of Personnel Management.

Janice R. Lachance,

Director.

Accordingly, OPM is amending 5 CFR part 591 as follows:

PART 591—ALLOWANCES AND DIFFERENTIALS

Subpart B—Cost-of-Living Allowance and Post Differential—Nonforeign Areas

1. The authority citation for subpart B of part 591 continues to read as follows:

Authority: 5 U.S.C. 5941; E.O. 10000, 3 CFR, 1943–1948 Comp., p. 792; E.O. 12510, 3 CFR, 1985 Comp., p. 338.

2. Appendix A of subpart B is revised to read as follows:

Appendix A of Subpart B—Places and Rates at Which Allowances Shall Be Paid

This appendix lists the places approved for a cost-of-living allowance and shows the allowance rate and any special eligibility requirements for the allowance payment. The allowance percentage rate shown is paid as a percentage of an employee's rate of basic pay.

Geographic coverage/allowance category	Authorized allowance rate (percent)
State of Alaska	
City of Anchorage and 80-kilometer (50-mile) radius by road:	
All Employees	25.0
City of Fairbanks and 80-kilometer (50-mile) radius by road:	
All Employees	25.0
City of Juneau and 80-kilometer (50-mile) radius by road:	
All Employees	25.0

Geographic coverage/allowance category	Authorized allowance rate (percent)
Rest of the State:	
All Employees	25.0
State of Hawaii	
City and County of Honolulu:	
All Employees	25.0
County of Hawaii:	
All Employees	15.0
County of Kauai:	
All Employees	22.5
County of Maui and County of Kalawao:	
All Employees	22.5
Territory of Guam and Commonwealth of the Northern Mariana Islands	
Local Retail	25.0
Commissary/Exchange	20.0
Commonwealth of Puerto Rico	
All Employees	10.0
U.S. Virgin Islands	
All Employees	20.0

Definitions of Allowance Categories

The following are definitions of the allowance categories used in the tables in this appendix.

All Employees: This category covers all Federal employees eligible for an allowance under 5 U.S.C. 5941.

Local Retail: This category covers all Federal employees eligible for an allowance who do *not* have unlimited access to commissary and exchange facilities by virtue of their Federal civilian employment.

Commissary/Exchange: This category covers all Federal employees eligible for an allowance who have unlimited access to commissary and exchange facilities by virtue of their Federal civilian employment.

Note: The appropriate military department determines eligibility for access to military commissary and exchange facilities. If an employee is furnished with these privileges for reasons associated with his or her Federal civilian employment, he or she will receive an identification card that authorizes access to such facilities. Possession of such an identification card is sufficient evidence that the employee uses the facilities.

[FR Doc. 00–17568 Filed 7–14–00; 8:45 am]

BILLING CODE 6325–01–P

OFFICE OF PERSONNEL MANAGEMENT

5 CFR Part 591

RIN 3206–AI38

Cost-of-Living Allowances (Nonforeign Areas); Honolulu, HI

AGENCY: Office of Personnel Management.

ACTION: Final rule.

SUMMARY: The Office of Personnel Management is adopting as final an interim increase in the cost-of-living allowance (COLA) rate for Honolulu. The increase was the result of our 1997 cost-of-living surveys in certain nonforeign areas. We are also making a change in the Miscellaneous Expense category we use in the COLA methodology that will identify education as an expense. This increase is a result of cost-of-living surveys conducted in the summer of 1997 using our current methodology for calculating COLA rates. A settlement agreement that is currently awaiting court approval calls for OPM to use a new methodology in conducting future surveys and in calculating future COLA rates. Therefore, the survey results reflected in this rule are not an indication of what survey results or COLA rates would be under the new methodology.

DATES: *Effective date:* August 16, 2000.

FOR FURTHER INFORMATION CONTACT: Donald L. Paquin, (202) 606–2838; fax: (202) 606–4264; or email: COLA@opm.gov.

SUPPLEMENTARY INFORMATION: The Federal Government pays cost-of-living allowances (COLAs) to General Schedule, U.S. Postal Service, and certain other Federal employees in Alaska, Hawaii, Guam and the Commonwealth of the Northern Mariana Islands, Puerto Rico, and the U.S. Virgin Islands. The Office of Personnel Management (OPM) conducts cost-of-living surveys in each allowance area to determine whether, and to what degree, local living costs are higher than those in Washington, DC. OPM sets the COLA rate for each area based on the results of these surveys.

On October 21, 1998, we published an interim rule for comment in the **Federal Register** (63 FR 56430) that—

—Increased the COLA rate for the Honolulu allowance area from 22.5 percent to 25 percent based on the 1997 survey results, and

—Broadened the composition of the Miscellaneous Expense category used in the COLA methodology.

We received one comment on the interim regulations. The commenter felt that the change in the Miscellaneous Expense category should identify education as an expense. Alternatively, the commenter thought we should emphasize that other expenses are possible or describe the kinds of expenses that may be included in the category. We agree that adding education to the listing would be helpful, and we have changed the wording as suggested.

Regulatory Flexibility Act

I certify that this regulation will not have a significant economic impact on a substantial number of small entities because the regulation will affect only Federal agencies and employees.

List of Subjects in 5 CFR Part 591

Government employees, Travel and transportation expenses, Wages.

Office of Personnel Management.

Janice R. Lachance,

Director.

Accordingly, OPM is adopting the interim regulations for 5 CFR part 591 published on October 21, 1998, at 63 FR 56430 as final with one change, as set forth below:

PART 591—ALLOWANCES AND DIFFERENTIALS

Subpart B—Cost-of-Living Allowance and Post Differential—Nonforeign Areas

1. The authority citation for subpart B of part 591 continues to read as follows:

Authority: 5 U.S.C. 5941; E.O. 10000, 3 CFR, 1943–1948 Comp., p. 792; E.O. 12510, 3 CFR, 1985 Comp., p. 338.

2. In § 591.205, paragraph (b)(4) is revised to read as follows:

§ 591.205 Comparative cost index.

* * * * *

(b) * * *

(4) *Miscellaneous expenses.* Miscellaneous expenses, including expenses for health care, gifts, contributions, savings and investments, retirement, life insurance, and education, are estimated from consumer expenditure surveys and other data appropriate for Federal employees for each income level.

* * * * *

[FR Doc. 00–17569 Filed 7–14–00; 8:45 am]

BILLING CODE 6325–01–P

OFFICE OF PERSONNEL MANAGEMENT

Report On 1998 Surveys Used to Determine

Cost-of-Living Allowances in Nonforeign Areas

AGENCY: Office of Personnel Management.

ACTION: Notice.

SUMMARY: This notice publishes the ''Report on 1998 Surveys Used to Determine Cost-of-Living Allowances in Nonforeign Areas.'' The Federal Government uses the results of these surveys to set cost-of-living allowance (COLA) rates for General Schedule, U.S. Postal Service, and certain other Federal employees in Alaska, Hawaii, Guam and the Commonwealth of the Northern Mariana Islands, Puerto Rico, and the U.S. Virgin Islands. Based on the survey findings, the Office of Personnel Management is increasing the local retail COLA rate for the Guam and Commonwealth of the Northern Mariana Islands allowance area in an interim regulation published with this notice. This increase is a result of cost-of-living surveys conducted in October and November 1998 using our current methodology for calculating COLA rates. A settlement agreement that is currently awaiting court approval calls for OPM to use a new methodology in conducting future surveys and in calculating future COLA rates. Therefore, the survey results reflected in this rule are not an indication of what survey results or COLA rates would be under the new methodology.

DATES: We must receive comments on or before November 14, 2000.

ADDRESSES: Send or deliver comments to Donald J. Winstead, Assistant Director for Compensation Administration, Workforce Compensation and Performance Service, Office of Personnel Management, Room 7H31, 1900 E Street NW., Washington, DC 20415–8200; fax: (202) 606–4264; or email: COLA@opm.gov.

FOR FURTHER INFORMATION CONTACT: Donald L. Paquin, (202) 606–2838; fax: (202) 606–4264; or email: COLA@opm.gov.

SUPPLEMENTARY INFORMATION: Section 591.206(c) of title 5, Code of Federal Regulations, requires the Office of Personnel Management (OPM) to publish nonforeign area cost-of-living allowance (COLA) survey summaries and calculations in the **Federal Register**. We are publishing the complete ''Report on 1998 Surveys Used to Determine Cost-of-Living Allowances in Nonforeign Areas'' with this notice. In the report, we explain the methodologies, calculations, and findings of the 1998 COLA surveys.

Results of Surveys

Using an index scale with the living costs in the Washington, DC, area equal to 100, we computed index values of relative living costs in each of the allowance areas. (See the final cost comparison indexes in the Executive Summary of the report.) The results of the surveys show that the local retail COLA rate for the Guam and Commonwealth of the Northern Mariana Islands allowance area should increase from 22.5 percent to 25 percent, the COLA rates for two other areas are currently at the appropriate level, and the COLA rates in eight areas are above the levels indicated by the living-cost indexes. However, the Treasury, Postal Service, and General Government Appropriations Act, 1992 (Pub. L. 102–141), as amended, prohibits reductions in COLA rates through December 31, 2000. Therefore, the interim regulation contains no COLA rate reductions.

Corrections to the 1997 Report

In preparing our report on the 1998 surveys, we discovered three errors in the 1997 survey report. We discuss these errors below, and we have corrected them in the 1998 analyses and report. We note that these corrections did not affect the COLA rates for any allowance area.

Median values for housing. We further analyzed our data on 1997 median housing values and discovered an error that resulted in our publishing incorrect values for Anchorage and Fairbanks in appendix 9. We made these corrections. Although these changes had no effect on the Anchorage index, the Fairbanks index decreased from 107.57 to 107.53. The original and corrected home sales values are as follows:

	Original	Corrected
Anchorage:		
Lower	$86,859	$86,733
Middle	119,561	119,236
Upper	149,073	149,124
Fairbanks:		
Lower	78,804	76,086
Middle	97,110	No change
Upper	122,196	112,128

Guam indexes. We had inadvertently omitted cellular phone service when calculating telephone expenses for the homeowner and renter indexes in Guam. We had also used an incorrect value for the Guam personal insurance and pensions index. While correcting these increased the Guam local retail total comparative cost index to 122.63 and the Guam commissary and exchange index to 119.09, these increases did not increase the actual COLA rates for Guam.

Renter characteristics and survey communities. In Table 4–2, Housing Profiles, we should have shown one bath instead of two for middle income renters. For upper income renters, we should have shown the rooms as 2–3 bedrooms and 4–5 rooms total. Also, in appendix 11, we should have noted in the footnotes that we relaxed the community specifications for the broker data. We have made these corrections in the 1998 survey report. None of these changes affected the indexes.

Comments on 1997 Survey Report

OPM published the report on the 1997 surveys for comment in the **Federal Register** on October 21, 1998 (63 FR 56432). We received five written comments and additional oral comments.

Generally, the commenters believed the surveys did not fully consider all expenses incurred in the allowance areas. Some commenters felt the surveys did not account for dissimilarities between the allowance areas and the Washington, DC, area, and that this affected the accuracy of the survey results.

OPM recently participated in a major initiative under a memorandum of understanding with plaintiffs in certain COLA litigation. That initiative studied many of these issues. We also engaged in a 2-year partnership pilot project that looked into many of the same issues. We describe these two efforts below, then discuss the substantive comments we received in response to the 1997 survey report.

Memorandum of Understanding and Report to Congress

In 1996, OPM entered into a memorandum of understanding (MOU) with litigants in the cases of *Alaniz* v. *Office of Personnel Management* and *Karamatsu* v. *United States.* The MOU committed OPM and the litigants to a ''Safe Harbor'' process for conducting studies relating to the COLA program and the compensation of Federal employees in the allowance areas. The purpose of the Safe Harbor process was to resolve long-contested COLA issues and to assist OPM in preparing a report to Congress on the COLA program. This report, required by the Treasury, Postal Service, and General Government Appropriations Act, 1992 (Pub. L. 102–141), as amended, was due by March 1, 2000. However, the Government and

plaintiffs are currently negotiating to settle the contested issues. If the parties achieve settlement, OPM will make many substantive changes in the COLA methodology. Therefore, we have notified Congress that we will report after we conclude the settlement process.

During the Safe Harbor process, we avoided making substantive policy changes in the COLA program. We made administrative changes as necessary and implemented other improvements in response to the comments we received. We list these changes in the survey report.

COLA Partnership

In November 1996, we established a 2-year pilot project to involve agency and employee representatives in a partnership with OPM to help us administer the nonforeign area COLA program. Our goal was to introduce a cooperative effort to help us plan and conduct COLA surveys, explore ways to improve the COLA program, and help everyone, including OPM, better understand issues related to the compensation of Federal employees in the COLA areas.

OPM worked with committees established under the pilot project to plan and conduct both the 1997 and 1998 living-cost surveys in the COLA areas. Although the pilot project expired in November 1998, OPM continued to work informally with interested committee members in the analysis of the 1998 survey results.

Goods and Services

One commenter suggested that we survey costs for building materials such as plywood, framing lumber, cabinets, carpet, and roofing materials. The commenter noted that delivery of these materials to Juneau takes a minimum of 2 weeks, resulting in project delays and higher costs. We currently survey various building material items, including paint, electrical outlets, area rugs, and caulking. We also survey the cost for interior painting and an electrical project, which should reflect higher costs due to material supply delays. Based on this suggestion, we collected prices for plywood on a test basis during the 1998 surveys. We obtained usable data and included these prices in our analysis.

The same commenter suggested that OPM consider surveying the cost of an oil change, appliance repair, and dry cleaning. In this and previous surveys, we surveyed both the cost of oil changes and dry cleaning. This year, we added appliance repair as a test item and found that we were able to collect comparable data across areas. Therefore, we used the results of this test item.

The commenter also suggested that OPM survey landfill charges for trash and recyclable material disposal. Consumer trash removal is often a tax-supported service or is included in the water-sewer bill. We believe the extent to which consumers pay landfill fees in lieu of higher taxes or utility fees probably differs significantly by area, and we have no information that would allow us to take these differences into consideration. Therefore, we are not adopting this suggestion.

One commenter suggested that OPM consider pricing both basic cable TV service and the next higher level of service, at least on a test basis. We adopted the change as a test item for the 1998 survey, but found we could not obtain comparable data across areas. Therefore, we did not use prices for level 1 cable TV service in any area.

The same commenter noted that some hospitals in Hawaii have only private rooms, not semi-private rooms as OPM surveyed in 1997. The commenter suggested pricing both private and semi-private hospital rooms. We adopted this change for the 1998 survey.

A commenter suggested surveying the price of specially formulated paints that inhibit mildew or pricing mildew additive. For the 1998 survey, we priced mildew additive in each area and added it to the price of a gallon of paint.

A commenter suggested OPM add personal computers to the survey. We researched this, but found that it was not feasible to survey comparable brands and models across areas. However, we plan to reconsider surveying this item, perhaps on a test basis, in future surveys.

One commenter noted that sales taxes were increasing in Juneau to cover various new facilities and services. We include the local sales tax in the price of items we survey; therefore, the data we use in our price comparisons reflect sales tax increases.

The same commenter remarked that the closing of a department store and a pharmacy in Juneau reduced the availability of certain items. The extent to which fewer goods or services leads to higher costs is reflected in the item prices we collect. The availability of goods and services in the allowance areas was one of the research topics under the MOU.

One commenter remarked on the frequency of sales in the Washington, DC, area compared to Juneau. In the 1998 and previous surveys, we compared only non-sale prices of identical items from similar outlets. In future surveys, however, we plan to survey the price of the item at the time of the survey. If we adopt this change, we will collect both sale prices and regular prices, depending on whether the item is on sale at the time we visit the outlet.

Housing

One commenter felt that the median price used by OPM for upper income house sales in Anchorage was too low to be an accurate reflection of prices for upper income homes. The commenter believed that the lower priced homes could not have been in liveable condition or in a safe neighborhood. We used data provided by an Anchorage real estate broker on homes that were sold during the period August 1, 1996, through July 31, 1997. We looked at over 750 upper income home sale prices in south Anchorage, and we believe these produced a representational median.

The same commenter recommended that we examine earthquake and flood insurance needs by individual allowance area. In 1992, OPM's contractor for the cost-of-living surveys, Runzheimer International, investigated homeowner/renter insurance coverage for floods and earthquakes in each individual allowance area. Runzheimer found that less than 10 percent of the population in each of the allowance areas purchased these coverages. Because most homeowners and renters do not purchase an earthquake rider, we do not include it in our surveys. Furthermore, whether lenders require homeowners to buy flood insurance depends on where the property is located, and this can be an insurance requirement in any area, including for properties along the rivers and streams in the Washington, DC, area. We are not aware of any data source that would allow us to determine for each survey area the percent of properties in a flood zone.Therefore, we do not survey the cost of this type of coverage. However, we do survey the cost of hurricane and typhoon insurance in tropical COLA areas, where lenders typically require this coverage.

Another commenter noted that housing costs are high in Juneau. Our survey of home sales data and other housing expenses in Juneau should capture these costs.

A commenter from the Virgin Islands noted that many employees live on the island of St. John. Recognizing that it was not feasible to price all survey items on St. John, the commenter suggested that OPM survey home sales and rental prices and combine these data with the St. Thomas data. We adopted this change for the 1998 survey.

Transportation Component

Two commenters suggested that OPM reconsider the models of automobiles it prices in the COLA surveys. One commenter suggested that OPM survey more sports utility vehicles. The other suggested that OPM survey a luxury brand, such as BMW. We did not adopt either of these suggestions. We survey three models—Honda Civic, Ford Taurus, and Chevrolet Blazer. These are popular brands and models, although their popularity differs from one area to the next. It was not feasible for us to vary the brands and models by area with the 1998 survey. However, it may be possible to do this in future surveys. As with all survey items, we will consider changing models and brands in future surveys in response to changes in consumer preferences.

One commenter believed we should include the cost of windshield repairs in our survey of vehicle repair costs for Alaskans. In the 1997 survey, we surveyed the frequency and cost of windshield replacement in all of the COLA areas and in the DC area. We found that frequency of windshield replacement was greater in Alaska than in the DC area, but that the frequency of windshield replacement in the other COLA areas was about the same as in the DC area. We also found that the cost of windshield replacement in Alaska was greater than the automobile insurance deductible priced in the COLA surveys. Since consumers pay only the deductible for these repairs, we do not need to survey this item. Instead, we add the cost of the deductible to the annual private transportation costs for the Alaska areas. This was done for both the 1997 and 1998 surveys.

One commenter suggested that we use the NADA or Kelly Blue Book for the Pacific region to determine the used car values we use in the COLA model. We use the residual value of a car after 4 years to calculate the annual depreciation expense associated with owning an automobile. We currently use books covering the Eastern region. We researched this issue and found that prices in the Pacific region books tend to be slightly higher than in the Eastern region books. However, for administrative simplicity, we did not adopt the proposal because using different residual values for some areas and not others would have significantly complicated the COLA model. The effect of retaining the current practice may slightly overstate living costs in the COLA areas.

One commenter noted that airline competition decreased in Juneau. Our survey of airfare costs should capture any higher ticket prices that result from reduced competition.

Another commenter suggested that OPM price the cost of an airline ticket purchased 2 weeks in advance. As used in the COLA model, airfares reflect the cost of vacation travel. We researched the availability and prices of airline tickets and found that generally the best deals were available if the ticket was purchased at least 3 weeks in advance and the traveler flew mid-week (*i.e.,* Tuesday through Thursday). Therefore, for the 1998 surveys in both the COLA areas and the Washington, DC, area, we priced the lowest airfares available 3 weeks in advance, departing on a Tuesday and returning on a Thursday, because this best reflects likely vacation travel.

Miscellaneous Component

Medical care. One commenter felt that medical care in Juneau was limited, resulting in higher health care costs and inferior health care. The commenter said there was a need for costly travel outside the area to obtain some medical services. We currently price a range of medical services within each area, and the COLA model captures any higher local prices.

Travel outside the area for medical service is another issue. Some travel may result from an employee's perceptions about the quality of local medical services. We know of no source that allows us to compare objectively the quality of medical services across areas. Therefore, we do not take into account the cost of unreimbursed travel for medical services or any differences in the quality of health care.

A commenter from Puerto Rico believed that a major health benefits plan in that area provided a lower level of coverage than most plans in the DC area. The commenter also said the service covered was inconvenient because it required the employee to use preferred providers who often did not accept appointments. Employees had to show up and wait to be seen. The commenter suggested that OPM review and compare the various Federal health benefits plans. We were unable to do this because it would require us to make subjective decisions about what employees do. For example, if an employee chooses a plan that is less convenient or provides a lower level of coverage, the employee accepts inconvenience and lower coverage as a trade-off for the lower insurance premium, presumably with the expectation that the service/coverage may not be necessary. It is a highly subjective decision that each employee makes. We know of no objective way to quantify this.

Another commenter suggested that OPM price psychiatric counseling. We believe it might be feasible to collect prices for this service in each area, but under the current methodology, the weight we would assign it would be very small. (We discuss how we derive and assign weights in section 2.3 of the report.) Therefore, we did not add this item to the survey because it would have increased the administrative and public burden of the survey with little chance of affecting the results.

Other Comments

Locality pay. One commenter noted that Federal employees in Juneau do not receive the locality pay increases received by employees in the Washington, DC, area. The locality pay law (5 U.S.C. 5304) prohibits the Government from providing locality pay to employees outside the 48 States and the District of Columbia.

Retirement. The same commenter was concerned that COLAs do not count for retirement purposes for employees in the allowance areas. Federal law excludes allowances (including COLAs) from basic pay in the computation of retirement annuities. (See 5 U.S.C. 8331(3) and 8401(4).)

Office of Personnel Management.

Janice R. Lachance,

Director.

Report on 1998 Surveys Used to Determine Cost-of-Living Allowances in Nonforeign Areas

Table of Contents

Executive Summary
1. Introduction
1.1 Report Objectives
1.2 The COLA Partnership Pilot Project
1.3 The Safe Harbor Process
1.4 Changes in the 1998 Survey
1.5 Pricing Period
2. The COLA Model
2.1 Measurement of Living-Cost Differences
2.2 Step 1: Identifying the Target Population
2.2.1 Federal Salaries
2.2.2 Federal Employment Weights
2.3 Step 2: Estimating How People Spend Their Money
2.3.1 Consumer Expenditure Survey
2.3.2 Expenditure Categories and Components
2.4 Step 3: Selecting Items and Outlets
2.4.1 Item Selections—The Market Basket
2.4.2 Geographic Coverage and Outlet Selection
2.4.2.1 Geographic Areas
2.4.2.2 Similarity of Outlets
2.4.2.3 Catalog Pricing
2.5 Step 4: Surveying Prices
2.5.1 Data Collection

2.5.2 Inclusion of Sales and Excise Taxes
2.5.3 Surveying the Washington, DC, Area
2.6 Step 5: Analyzing Data and Computing Indexes
2.6.1 Indexes
2.6.2 Item Weights
2.6.3 Category and Component Weights
2.6.4 Computing the Overall Index
3. Consumption Goods and Services
3.1 Categories and Category Weights
3.2 Goods and Services Survey Results
3.2.1 Exchange and Commissary Expenditure Research
4. Housing
4.1 Component Overview
4.2 Housing Model
4.2.1 Expenditure Research
4.2.2 Housing Profiles
4.2.3 Living Community Selection
4.2.4 Housing-Related Expenses
4.2.4.1 Utilities
4.2.4.2 Real Estate Taxes
4.2.4.3 Owners/Renters Insurance
4.2.4.4 Home Maintenance
4.3 Housing Data Collection Procedures
4.3.1 Homeowner Data Collection
4.3.2 Renter Data Collection
4.4 Housing Analysis
4.4.1 Homeowner Data Analysis
4.4.2 Rental Data Analysis
4.5 Housing Survey Results
5. Transportation
5.1 Component Overview
5.2 Private Transportation Methodology
5.2.1 Vehicle Selection and Pricing
5.2.2 Vehicle Trade Cycle
5.2.3 Fuel Performance and Type
5.2.3.1 Impact of Temperature upon Fuel Performance
5.2.3.2 Impact of Road Surface upon Fuel Performance
5.2.3.3 Impact of Gradient Upon Fuel Performance
5.2.3.4 Overall Impact upon Fuel Performance
5.2.4 Vehicle Maintenance
5.2.5 Tires
5.2.6 License and Registration Fees and Miscellaneous Taxes
5.2.7 Depreciation
5.2.8 Finance Expense
5.2.9 Vehicle Insurance
5.2.10 Overall Annual Costs
5.3 Other Transportation Costs—Air Fares
5.4 Transportation Component Analyses
6. Miscellaneous Expenses
6.1 Component Overview
6.2 Component Weights
6.3 Component Categories
6.3.1 Medical Expense Category
6.3.2 Private Education (K–12) Category
6.3.3 Contributions Category
6.3.4 Personal Insurance and Retirement Category
6.4 Miscellaneous Expense Analyses
7. Final Results
7.1 Total Comparative Cost Indexes

List of Appendices

Appendix 1: Publication in the **Federal Register** of Prior Survey Results: 1990–1998
Appendix 2: Federal Employment Weights
Appendix 3: Consumer Expenditure Surveys
Appendix 4: CES Category and Component Expenditures
Appendix 5: Item Descriptions
Appendix 6: Principal Pricing Changes
Appendix 7: Consumption Goods and Services Analysis
Appendix 8: OPM Living Community List
Appendix 9: Historical Home Market Values and Interest Rates
Appendix 10: Historical Housing Data
Appendix 11: Summary of Rental Data Analyses
Appendix 12: Housing Cost Analysis
Appendix 13: Housing Analysis
Appendix 14: Private Transportation Cost Analysis
Appendix 15: Auto Insurance Calculation Worksheet Special Limits Adjustments
Appendix 16: Air Fares Cost Analysis
Appendix 17: Transportation Analysis
Appendix 18: Transportation Summary
Appendix 19: Miscellaneous Expense Analysis—Total Index Development
Appendix 20: Miscellaneous Expense Summary
Appendix 21: Component Expenditure Accounts
Appendix 22: Total Comparative Cost Indexes

Executive Summary

The Government pays cost-of-living allowances (COLAs) to Federal employees in nonforeign areas in consideration of living costs higher than in the Washington, DC, area. The Office of Personnel Management (OPM) conducts living-cost surveys in order to set the COLA rates. This report provides the results of the 1998 living-cost surveys and compares living costs in the nonforeign COLA areas to those in the Washington, DC, area.

We conducted surveys in Alaska, Hawaii, Guam, Puerto Rico, the U.S. Virgin Islands, and the Washington, DC, area. We then analyzed the survey data and produced this report. For the surveys, we contacted about 4,000 outlets and collected approximately 26,000 prices on about 252 items representing typical consumer purchases. We then combined the data using consumer expenditure information developed by the Bureau of Labor Statistics. The final result is a series of living-cost indexes, shown in Table E–1, that compare living costs in the allowance areas to those in the Washington, DC, area. The index for the DC area (not shown) is 100.00 because it is, by definition, the reference area.

TABLE E–1.—FINAL COST COMPARISON INDEXES

Allowance area	Index
Anchorage, Alaska	105.65
Fairbanks, Alaska	109.19
Juneau, Alaska	110.46
The rest of the State of Alaska	131.58
City and County of Honolulu, Hawaii	124.51
Hawaii County, Hawaii	110.89
Kauai County, Hawaii	117.19
Maui County, Hawaii	120.32
Guam/CNMI*, Local Retail	125.23
Guam/CNMI, Commissary/Exchange	121.12
Puerto Rico	105.93
U.S. Virgin Islands	116.33

*CNMI=Commonwealth of the Northern Mariana Islands

1. Introduction

1.1 Report Objectives

This report provides the results of the 1998 surveys. Appendix 1 lists previous survey reports and their publication dates. The analyses show the comparative living-cost differences between the Washington, DC, area and the allowance areas listed below. By law, Washington, DC, is the base or ''reference'' area for the nonforeign area cost-of-living allowance program.

1. Anchorage, Alaska
2. Fairbanks, Alaska
3. Juneau, Alaska
4. The rest of the State of Alaska
5. City and County of Honolulu, Hawaii
6. Hawaii County, Hawaii
7. Kauai County, Hawaii
8. Maui County, Hawaii
9. Guam and the Commonwealth of the Northern Mariana Islands (CNMI)
10. Puerto Rico
11. U.S. Virgin Islands

1.2 The COLA Partnership Pilot Project

In November 1996, OPM established the COLA Partnership Pilot Project, a 2-year pilot project designed to assist us in administering the COLA program. (See 61 FR 59173.) The pilot project established COLA Partnership Committees and Subcommittees in Alaska, Hawaii, Guam, Puerto Rico, and the U.S. Virgin Islands. Members of the committees and subcommittees included representatives from local area unions and agencies, as well as representatives from OPM.

The Committees and Subcommittees worked with OPM in varying degrees to plan the COLA surveys, observe the data collection, and advise OPM on the COLA program and on compensation issues relating to the COLA areas. We have adopted a number of the changes recommended by the Committees and Subcommittees since the start of the project. However, OPM did not renew the COLA Partnership Pilot Project

when it expired because we were involved in discussing the nature of future employee involvement in the COLA program as part of the MOU process. The pilot project ended on November 23, 1998.

1.3 The Safe Harbor Process

In 1996, we entered into a memorandum of understanding (MOU) with litigants in the cases of *Alaniz* v. *Office of Personnel Management* and *Karamatsu* v. *United States.* Under the MOU, we committed to a ''Safe Harbor'' process with the litigants to conduct studies relating to the COLA program and the compensation of Federal employees in the allowance areas. The Safe Harbor process had two primary goals: (1) To resolve long-contested issues in the COLA program and (2) to assist OPM in preparing a report to Congress on the COLA program.

This report, required by the Treasury, Postal Service, and General Government Appropriations Act, 1992 (Pub. L. 102–141), as amended, was due by March 1, 2000. However, since the Government is currently negotiating to settle several pending court cases in the COLA areas, we will not report to Congress until after the Government concludes these negotiations.

1.4 Changes in the 1998 Survey

During the course of the COLA Partnership Pilot Project and the Safe Harbor process, we generally avoided making substantive changes in the COLA program. As with previous surveys, we did make a few non-substantive changes in the 1998 surveys. The majority of these changes related to items or outlets surveyed. (See Appendix 6.)

One of the changes was in the Goods and Services Component that involved obtaining more price quotes for each item. In previous surveys, we attempted to get three price quotes (one for each item at three different suitable outlets) for most items in each survey area. In the 1998 survey, we attempted to obtain up to nine price quotes for many items. This significantly increased the number of price observations we used in this survey.

1.5 Pricing Period

We traveled to the COLA areas in October and November 1998 to collect the living-cost data. During the same time frame, we collected data in the Washington, DC, area. We collected the prices of some items—those dependent upon the pricing of other items—later. Because we conducted the surveys in October and November, we were not able to collect prices for some winter items, such as downhill skiing.

As in previous surveys, we priced some catalog items. We used only catalogs that sell merchandise in both the allowance areas and the Washington, DC, area. To ensure consistent catalog pricing, we used only current catalogs for all catalog items surveyed.

2. The Cola Model

2.1 Measurement of Living-Cost Differences

The COLA model measures living-cost differences between the allowance areas and the Washington, DC, area by—

—Selecting typical items that people purchase in these locations,
—Calculating their respective cost differences, and
—Combining costs according to their relative importance to each other (as measured by relative percentage of expenditures).

This involves the following major steps:

Step 1: Identify the segment of the population for the target analysis (*i.e.,* typical Federal white-collar employees).

Step 2: Estimate how these people spend their money.

Step 3: Select items to represent the types of expenditures people usually make and outlets at which people typically make purchases for each selected item.

Step 4: Conduct pricing surveys of the selected items in each area.

Step 5: Compute price ratios for the surveyed items and aggregate them according to the relative importance of each item.

2.2 Step 1: Identifying the Target Population

The study estimates living-cost differences for typical white-collar Federal employees who have annual base salaries between approximately $13,000 and $94,300, the range of the 1998 General Schedule. Because living costs may vary depending on an employee's income level, we analyze living costs at three income levels.

2.2.1 Federal Salaries

To determine the appropriate income levels, we—

1. Analyzed the 1998 distribution of salaries for General Schedule employees in all of the allowance areas combined;
2. Divided this distribution into three income groups of equal size and identified the minimum, maximum, and median salary in each group;
3. Rounded the median values to the nearest $100 to produce the three representative income levels of $23,300, $35,300, and $52,700;
4. Compared living costs at each of these three income levels to produce three sets of estimated expenditures for each allowance area and for the Washington, DC, area; and
5. Combined these estimated expenditures into a single overall index for each allowance area using the employment weights described below.

2.2.2 Federal Employment Weights

We used the minimum and maximum values of each income group and the 1998 distribution of General Schedule employees by salary in each allowance area to derive employment weights. We combined these with similar data from 1995 and 1996 to produce a moving average. (We use moving averages to lessen index changes caused by the introduction of new weights over time.) From these averages, we calculated the percentage of the General Schedule workforce in each income group in each area. These percentages became the weights we used to combine estimated expenditures to compute the final index. Appendix 2 shows the General Schedule employment distributions and how we derived the percentage weights. Appendix 21 shows how we used the weights in the final calculations.

2.3 Step 2: Estimating How People Spend Their Money

2.3.1 Consumer Expenditure Survey

We base expenditure patterns used in the calculations on national data from the Consumer Expenditure Survey (CES). We obtained from the Bureau of Labor Statistics (BLS) ''prepublished'' CES results for 1994, 1995, and 1997. BLS has advised us that ''prepublished'' CES data may not be statistically significant. To our knowledge, however, it is the only source of comprehensive consumer expenditure information by income level. Therefore, we use it in the model.

We use CES data in two ways: (1) To identify appropriate items for the survey and (2) to derive item, category, and component weights. The item weights are not income-sensitive. We analyze aggregated CES data by income level to derive category and component weights. These weights are income-sensitive. Appendices 3 and 4 show the CES data we used in this study. As with the Federal employment weights, we combined the 3 years of CES data to produce a moving average.

2.3.2 Expenditure Categories and Components

BLS groups CES items into small, logical families. For example, BLS

groups CES pre-published data for beef into four subcategories: Ground beef, roast, steak, and other. BLS further separates the steak and roast groupings into smaller clusters of items (*e.g.,* sirloin and round steak, chuck and round roast). We separated the CES items into the four main cost components specified in our regulations: Consumption Goods and Services, Transportation, Housing, and Miscellaneous Expenses. To develop weighting patterns for the three income levels, we performed linear regression analyses on the CES data shown in Appendix 3.[1] These analyses produced estimated expenditures at the three income levels identified in section 2.2.1, above. We converted these expenditures to percentages of total expenditures for the four components to produce the values shown in table 2–1. These were the weights we used to combine the expenditures for each of the components into an overall value for each income level in each allowance area and the Washington, DC, area.

TABLE 2–1.—COMPONENT EXPENSES EXPRESSED AS A PERCENTAGE OF TOTAL EXPENSES

1998 income level	1995 adjusted income level*	Goods and services (percent)	Housing (percent)	Transportation (pecent)	Misc. (percent)	Total (percent)
$23,300	$21,826	38.07	26.42	19.24	16.27	100.00
35,300	33,071	37.48	25.00	19.12	18.40	100.00
52,700	49,326	36.96	23.72	19.01	20.68	100.00

NOTE: Values may not total 100 because of rounding.
*Income levels are adjusted as described in footnote 1.

We further separated Goods and Services Component items into 10 categories and used linear regression techniques to estimate expenditures on these 10 categories by income level. Section 3.1 shows the weights for these categories. We also used the same technique to compute category weights for the Transportation and Miscellaneous Expense Components and to produce ratios of renters to homeowners at each income level.

2.4 Step 3: Selecting Items and Outlets

2.4.1 Item Selections—The Market Basket

As noted above, we grouped CES items into ''clusters'' of expenses to determine which items to survey. We chose these clusters so that no market basket item would have an overwhelmingly large or an insignificantly small item weight.

For each of these clusters, we identified a set of items to price. Collectively, we call these items a ''market basket.'' Because it would have been impractical to survey each of the thousands of items consumers might buy, the market basket contains representative items. For example, cheddar cheese represents itself and the many other cheeses and related products that consumers purchase. The market basket that we used had approximately 250 items ranging from table salt to new cars to home purchases.

Whenever practical, we included in the item description the exact brand, model, type, and size, so that we could price exactly the same items in all areas if possible. For example, we selected a 10.5-ounce can of Campbell's vegetable soup for the survey because it is typical of canned soups, consumers commonly purchase it, and we find it in all areas. Appendix 5 lists the items we survey and their descriptions.

Changes in the item list and descriptions are an important aspect of the COLA survey. These changes are necessary to improve the survey and keep the item descriptions current. For this survey, we changed several of the items and descriptions. Appendix 6 lists the major changes and the reason for each.

2.4.2 Geographic Coverage and Outlet Selection

Just as it is important to select commonly-purchased items and survey the same items in all areas, it is important to select outlets frequented by consumers and find equivalent outlets in all areas. This involves deciding which geographic areas to survey and which outlets to survey within these geographic areas.

2.4.2.1 Geographic Areas

For some areas, the choice of which area(s) to survey was obvious. On St. Thomas, for example, we survey essentially the whole island because the island is not that large, and Federal employees live throughout the island. For other areas, we had to identify specific communities. To do this, we relied mainly on the results of the 1992 Federal Employee Housing and Living Patterns Survey. Among other things, that survey obtained information on where Federal employees lived. We used this information, in consultation with the COLA Partnership Committees and Subcommittees, to select the living communities for pricing housing costs. Again in consultation with the Committees and Subcommittees, we identified outlets within a normal shopping radius of these housing communities. We generally considered outlets within a living community or within an adjoining living community to be within a normal shopping radius.

2.4.2.2 Similarity of Outlets

Whenever possible, we (and the Committees/Subcommittees) selected outlets that were popular with consumers and that were comparable to outlets in other areas. For example, we surveyed grocery items at supermarkets in all areas because most people purchase their groceries at such stores and because supermarkets exist in nearly all areas.[2] The selection of comparable outlets is particularly important because of the significant price variations that may occur between dissimilar outlets (*e.g.,* comparing supermarket prices with convenience store prices).

Although major supermarkets, department stores, and discount stores represented a sizable portion of the survey, we also selected outlets to represent the diversity of consumer shopping options. For example, we could have used department stores for

[1] The midpoint of the moving average of CES data was 1995. Therefore, for the purpose of these regressions, we adjusted Federal salaries to reflect 1995 pay rates. We used the pay increases for 1996 (2.0%), 1997 (2.3%), and 1998 (2.3%) to deflate the 1998 salaries. This produced adjusted Federal salaries of $21,826, $33,071, and $49,326 for use in the regression equations.

[2] We surveyed groceries at two kinds of supermarkets (*i.e.,* full-service supermarkets and ''warehouse-type'' supermarkets) in areas where both types of supermarkets were common and within a normal shopping radius of the living communities surveyed. We note, however, that some areas do not have warehouse-type supermarkets. We did not survey mebership stores, such as Costco, in any area.

pricing all clothing items. However, this would not have reflected the range of consumer choices. Therefore, we priced some clothing items in department stores, others in shoe stores, others in discount stores, and still others via mail order. For each item, we selected the same type of outlet (*e.g.*, clothing store, discount store, department store) in each area whenever possible.

2.4.2.3 Catalog Pricing

We collected 13 item prices by catalog in the survey to reflect this common purchasing option. Catalog pricing also allowed the comparison of items that we would have had difficulty pricing otherwise. We included in the catalog prices any charges for shipping and handling and all applicable taxes.

2.5 Step 4: Surveying Prices

As noted earlier, we obtained approximately 26,000 prices on about 250 items from about 4,000 outlets. The 26,000 price observations represents a significant increase over the 1997 survey. In prior surveys, we attempted to get three price quotes (one for each item at three different suitable outlets) for most items in each survey area. In the 1998 survey, we attempted to obtain up to nine price quotes for many items, although we frequently were not able to achieve this goal. Also, there were certain exceptions. For example, we obtained essentially all of the available home sales and rental data meeting the survey specifications. For other items, such as utilities and real estate tax rates, we obtained only one quote in each area because these items have uniform rates within an area. Because the Washington, DC, area has six survey areas, we attempted to get up to nine price quotes for many items in each survey area.

2.5.1 Data Collection

To avoid possible conflicts of interest, OPM central office staff collected the price data in each area. In many of the COLA areas, data collection observers, usually designated by the local COLA Partnership Committee or Subcommittee, accompanied our staff. The observers advised and assisted us in contacting outlets, matching items, and selecting substitutes. The observers also advised us on living costs and related compensation issues in their areas. We found this to be a very informative process.

We collected most data onsite in stores, repair shops, etc. However, we priced many items, such as insurance, home maintenance services, and private education expenses, by telephone. We collected some items, such as property tax rates, from websites on the Internet. We also purchased home sales and some rental data from various sources.

2.5.2 Inclusion of Sales and Excise Taxes

For all items subject to sales and/or excise taxes, we added the appropriate amount of tax prior to analysis. We gathered applicable information on taxes by contacting appropriate sources of information in the allowance areas and the Washington, DC, area.

2.5.3 Surveying the Washington, DC, Area

As noted above, we attempted to get more price quotes in the DC area than in the allowance areas because of the size and diversity of the DC metropolitan area and because DC is the basis for all comparisons. For the purposes of the COLA surveys, we divided the DC area into six survey areas: two in the District of Columbia, two in Maryland, and two in Virginia. We surveyed outlets within a normal shopping radius of the housing communities identified in Appendix 8. We combined survey data from each of the six DC survey areas using equal weights.

As in the COLA areas, OPM central office staff collected data onsite and by phone in the DC area. Due to funding limitations, allowance area data collection observers did not travel to the DC area to observe and assist in data collection.

2.6 Step 5: Analyzing Data and Computing Indexes

2.6.1 Indexes

We derive nonforeign area COLAs from living-cost indexes. These indexes are mathematical comparisons of living costs in the allowance areas to living costs in the Washington, DC, area. An index is a way to state the difference between two prices (or sets of prices). For example, if a can of green beans costs $1.00 in the allowance area and 80 cents in the DC area, canned green beans are 25 percent more expensive in the allowance area than in DC. We can state that difference as a price index of 125.

2.6.2 Item Weights

We computed indexes for hundreds of items. As briefly described in section 2.3, we used weights derived from the CES to combine these indexes. These weights reflected the relative amount consumers normally spend on different items. For example, the price of a can of green beans has a lower weight than the price of a pound of apples because, according to the CES, people generally spend less on canned green beans than on apples. (People typically buy more apples than green beans.)

The COLA model uses a fixed-weight indexing methodology. The model bases the weights used on the expenditure patterns of consumers nationwide as reported by the CES. This is the only source we are aware of that provides expenditure information by income level.

2.6.3 Category and Component Weights

As described in section 2.3.2, we also computed income sensitive category and component weights. This allowed us to combine comparative price data in a manner that reflected the spending patterns of people at each income level. The way we combined data varied among the components.

For the Goods and Services and Miscellaneous Expense Components, we combined indexes within each category using the CES weights to derive an overall index for the category. We then combined the category indexes into an overall component index using the income-sensitive category weights described above. For the Transportation and Housing Components, we used the same approach in combination with a cost-build-up approach. For example, we computed the annual cost of owning and operating an automobile by taking individual prices (*e.g.*, automobile financing, insurance, gas and oil, and maintenance) and computing an overall dollar cost for each area. We compared these costs with those in the DC area to compute the Private Transportation Category index. We then combined this index with the Other Transportation Category index using income sensitive category weights to compute an overall Transportation Component index for each area.

2.6.4 Computing the Overall Index

We combined the item, category, and component indexes using the process prescribed in section 591.205(c) of title 5, Code of Federal Regulations. This is a five-step process that involves converting the indexes to dollar values, which we then weight, combine, and compare to compute a final weighted-average index. We describe the process in detail below.

First, we used the CES data and the income ranges described in section 2.2.1 to determine how much money consumers typically spend on each component at each income level. These amounts appear in the table below and in Appendix 21. We derived the amounts by taking the component weights shown in Table 2–1 and multiplying them times the

representative income levels described in section 2.2.1.

TABLE 2–2.—TYPICAL CONSUMER EXPENDITURES BY INCOME LEVEL AND COMPONENT

Income level	Goods and services	Own/rent	Transpor-tation	Misc.	Total
Lower	$8,870	$6,156	$4,483	$3,791	$23,300
Middle	13,230	8,825	6,749	6,495	35,300
Upper	19,478	12,500	10,018	10,709	52,700

NOTE: Values may not total because of rounding here and in Table 2–1.

Second, for each allowance area, we multiplied the dollar values above by the component indexes for the allowance area. Because the housing component consisted of two indexes (one for owners and another for renters), we produced total relative costs separately for owners and renters.

Third, for each allowance area and income level, we combined the total relative costs for owners and renters using as weights the proportion of owners and renters as identified in the CES. (See section 4.2.1.) This produced an overall expenditure dollar amount for each income level in each allowance area.

Fourth, we computed a single overall average expenditure for each allowance area by combining the income level expenditures using the allowance area General Schedule employment distribution as weights. This produced a single overall dollar expenditure value for the allowance area. Using the same General Schedule employment weights, we also computed a single overall dollar expenditure value for the DC area.

The final step was to divide the overall dollar expenditure for the allowance area by the overall dollar expenditure for the DC area to compute a final index. The last section of this report and Appendix 22 show these indexes.

3. Consumption Goods and Services

3.1 Categories and Category Weights

Based on the CES data, we identified 10 categories of expenses within the Goods and Services Component. Using linear regression analyses and the CES data, we identified the portion of total Goods and Services expenditures that the typical consumer spends in each category at various income levels. Table 3–1 shows the categories and the relative expenditures.

TABLE 3–1.—CATEGORY WEIGHTS EXPRESSED AS A PERCENTAGE OF GOODS AND SERVICES EXPENDITURES BY INCOME LEVEL

Category	Income levels		
	Lower	Middle	Upper
Food at home	27.03	24.05	21.30
Food away from home	13.43	14.18	14.87
Tobacco	2.82	2.34	1.90
Alcohol	2.33	2.40	2.47
Furnishings & household operations	15.36	16.64	17.82
Clothing	13.02	13.50	13.94
Domestic service	1.73	1.95	2.15
Professional services	7.09	6.82	6.57
Personal care	3.91	3.77	3.64
Recreation	13.27	14.35	15.34 &radic
Totals	100.00	100.00	100.00

NOTE: Values may not total 100 because of rounding.

3.2 Goods and Services Survey Results

Section 2.6 of this report provides a detailed explanation of the economic model used to analyze the price data. As it applies to Goods and Services, the approach involved comparing the average prices of market basket items in each allowance area with those in the Washington, DC, area. We aggregated the resulting price ratios into subcategory and then category indexes using the moving-average expenditure weights derived from the CES data.

Appendix 7 shows for each allowance area 10 category indexes, the weights used at each of the 3 income levels, and the overall Goods and Services Component indexes. The appendix does not include the Washington, DC, area because it is, by definition, the reference area. Therefore, the DC indexes are 100.

3.2.1 Exchange and Commissary Expenditure Research

Executive Order 10000, as amended, requires OPM to adjust COLA rates when employees have special purchasing privileges, such as unlimited access to commissaries and exchanges. In Guam, some employees have such access, so we priced the same market basket of Goods and Services items at the commissaries and exchanges in Guam as we used for the local retail pricing. We obtained one price quote for each market basket item found in these facilities.

Employees who have access to military facilities make some of their purchases in these facilities and make other purchases elsewhere. Therefore, we used the results of a survey of Federal employees to determine the percentage of purchases that families typically make in military facilities versus local outlets. For example, as Table 3–2 shows, we estimated that employees with commissary/exchange

access in Guam purchase approximately 70 percent of their Food at Home items at a commissary and purchase the remaining 30 percent in local retail outlets.

TABLE 3–2.—PERCENTAGES OF PURCHASES MADE AT THE COMMISSARIES AND EXCHANGES IN GUAM

Category	Percentage
Food at home	70.0
Food away	0.0
Tobacco	64.0
Alcohol	76.0
Furnishings & hsld. oper	64.5
Clothing	43.7
Domestic service	0.0
Professional services	0.0
Personal care	49.3
Recreation	49.7

We used these percentages to aggregate the local retail and commissary/exchange prices into one set of appropriate, blended prices, which we refer to as the Commissary/PX prices. We compared the blended prices to the local retail prices in the Washington, DC, area to compute Commissary/PX Goods and Services Category indexes. We then combined these indexes using CES weights to derive an overall Commissary/PX Goods and Services Component index. Just as with the Guam Local Retail Goods and Services Component index, we combined the Guam Commissary/PX Goods and Services Component index with the indexes for the Housing, Transportation, and Miscellaneous Expense Components to derive a single, overall Commissary/PX index for the Guam allowance area.

4. Housing

4.1 Component Overview

The Housing Component consists of the following expenses related to owning or renting a dwelling:

- Mortgage or rent payments,
- Utilities,
- Real estate taxes,
- Homeowner's or renter's insurance,
- Home maintenance, and
- Telephone expenses.

At each of the three income levels, we measured the annual housing costs for homeowners and renters separately. We then combined the results using as weights the percentages of owners and renters reported by the CES.

4.2 Housing Model

4.2.1 Expenditure Research

We used the CES to determine the national average ratio of families who own, as opposed to rent, their residences at each income level. Using the tenure data by income range as input into a linear regression analysis, we calculated the owner and rental weights shown in Table 4–1 and in Appendix 22. We excluded data for homeowning families without a mortgage because they were not typical of Federal homeowners in the base area or in the allowance areas.

TABLE 4–1.—OWNER/RENTER WEIGHTS

Category	Income levels		
	Lower (percent)	Middle (percent)	Upper (percent)
Homeowner with mortgage	37.96	47.26	60.70
Renter	62.04	52.74	39.30
Totals	100.00	100.00	100.00

We also used the CES data to identify which home-maintenance items to price and to establish the relative importance of those items.

4.2.2 Housing Profiles

To compare housing costs in all locations, we used six typical housing profiles—three for homeowners and three for renters. Table 4–2 shows these profiles. We assigned one owner and one renter profile to each income level. We attempted to collect information on the living area, numbers and types of rooms, and other information that might influence home sale or rental prices. This information was rarely available for rental units, so we relied on bedroom count and living community to segregate rental prices by income level. We used the additional information shown in Table 4–2, however, during the interview of rental brokers to collect broker data.

Information about characteristics of houses sold was also difficult to collect on a consistent basis across all areas. Although detailed information about the houses sold was available for many areas, it was not available for other areas, including the District of Columbia and the Maryland suburbs of the Washington, DC, area. The only housing characteristics that were consistently available across all areas were house type and size. We surveyed only the prices of single family detached houses in each area and relied mainly on house size and living community to segregate home sales by income level. As shown in Table 4–2, these size ranges overlap. Therefore, when we priced housing in the same living community at two or more income levels, we used the additional information to separate home sales observations into the appropriate income level so that no single home sale observation appeared at more than one income level.

TABLE 4–2.—HOUSING PROFILES

Income level	Renters		Owners	
	Key characteristic	Additional information	Key characteristic	Additional information
Lower	1 bedroom apartment	3 rooms total, 1 bath; reference size: 600 sq. ft.	Detached house, 600 to 1,200 sq. ft.	4 rooms total, 2 bedrooms, 1 bath; reference size: 900 sq. ft.
Middle	2 bedroom apartment	4 rooms total, 1 bath; reference size: 900 sq. ft.	Detached house, 1,000 to 1,600 sq. ft.	5 rooms total, 3 bedrooms, 1 bath; reference size: 1,300 sq. ft.

TABLE 4–2.—HOUSING PROFILES—Continued

Income level	Renters		Owners	
	Key characteristic	Additional information	Key characteristic	Additional information
Upper	2 bedroom townhouse or detached house.	4 rooms total, 2 baths; reference size: 1,100 sq. ft.	Detached house, 1,400 to 2,300 sq. ft.	7 rooms total, 3 bedrooms, 2 baths; reference size: 1,700 sq. ft.

We use the reference sizes in Table 4–2 for the calculation of utility costs in the model. (See section 4.2.4.1.) As noted above, they are not the only sizes surveyed for each profile.

4.2.3 Living Community Selection

As discussed briefly in section 2.4.2.1, we identified the living communities for the survey based on the results of the 1992 Federal Employee Housing and Living Patterns Survey and in consultation with the COLA Partnership Committees and Subcommittees. Appendix 8 identifies the survey communities. As with previous surveys, we identified nine homeowner and nine renter communities for the Washington, DC, area—one for each income level in each of the three areas (DC, Maryland, and Virginia). In the allowance areas, we identified up to three homeowner and three renter communities—one for each income level.

We could not achieve the three-community owner/renter goal in many of the allowance areas because of the relatively few home sales and rental opportunities or data availability in these areas. In such areas, we collected prices for the entire survey area or allowance area rather than in specific communities. We did this in Fairbanks, Juneau, Nome, Hilo, Kailua Kona, Kauai, Maui, Guam, St. Croix, and St. Thomas/St. John. In these areas, we included all home sales and/or rental rates meeting the housing characteristics for the particular income group in the analysis.[3]

For most areas in which we identified discrete living communities, we used zip code boundaries. The exceptions were Anchorage and San Juan. In Anchorage, we used the multiple listing service location codes that realtors commonly use in that area. In San Juan, we used the name of the municipio or community.

4.2.4 Housing-Related Expenses

Based on the CES data, we categorized housing-related expense items into one of five groups in the COLA model. These groups were—

—Utilities,
—Real estate taxes,
—Owners/renters insurance,
—Maintenance, and
—Telephone expenses.

4.2.4.1 Utilities

Electricity, oil, gas, and water. Many utility companies were able to provide current charges per unit of consumption and average consumption patterns for all households. The companies were not, however, able to provide separate consumption patterns by the size or type of housing.

Because many utility costs vary by size of house, we needed a factor to derive the utility rates at each of the home profiles. Table 4–3 shows the standard square foot sizes and utility factors used for each home profile. We calculated the factors by assuming that utility use increases or decreases at half the rate that square footage increases or decreases.

TABLE 4–3.—UTILITY FACTORS

Income level	Renter profile		Owner profile	
	Sq. ft.	Factor	Sq. ft.	Factor
Lower	600	.73	900	.85
Middle	900	.85	1,300	1.00
Upper	1,100	.92	1,700	1.15

In each area, we obtained the price of each of the types of utilities noted above. Where available, we also gathered from local utility companies information on average annual consumption data per household. We used the local rates and consumption information to compute average annual utility costs. We then used the above factors to adjust the total annual utility costs for each of the various housing profiles.

In the DC area, we were unable to obtain estimates for electricity usage for houses heated by gas or oil. However, we were able to obtain kilowatt usage for all-electric houses. In order to avoid potential double counting of utility costs, we used the all-electric data for the DC area. Double counting utility costs was not a problem in the warm-area COLA areas, where there is little heat expense. It also was not a problem in Alaska, where most consumers use gas or oil heat, not electric heat. In the Alaska surveys, we price gas or oil in addition to electricity.

Telephone. Telephone expenses consisted of local service charges, additional charges for local calls (if applicable), charges for long distance calls, and basic cellular phone service. To measure estimated expenses for local service and local calls, we surveyed the cost of touch-tone service with unlimited calling in each area. To estimate long distance charges in all areas, we priced from a major long distance provider the cost of three 10-minute direct dial calls per month to large U.S. mainland cities (Los Angeles, Chicago, and New York). As in previous surveys, we priced a call placed in the survey area at the time of day necessary to be received in the respective city at 8:00 p.m. local time. In many areas, this resulted in pricing a combination of daytime and evening-rate calls.

We also priced the basic monthly plan for cellular phone service in each area. We derived weights from CES data to

[3] In Puerto Rico we were able to obtain relatively few broker rental quotes for the communities identified in the survey specifications. Therefore, we relaxed the community specifications and used broker rental data for all communities in the greater San Juan metropolitan area.

account for the portion consumers spend on regular phone service and cellular phone service. We then used these weights to combine the prices of these two types of phone service.

4.2.4.2 Real Estate Taxes

For this study, we contacted the local tax assessors or municipal websites on the Internet to obtain real estate tax information on the living communities surveyed. We applied these real estate tax formulas to the median home values for each income level to estimate annual real estate taxes.

4.2.4.3 Owners/Renters Insurance

We gathered homeowners' insurance rates for each of the survey areas for both renter and owner profiles. For renters, we used the following estimated content values: $25,000 at the lower income level, $30,000 at the middle income level, and $35,000 at the upper income level. We raised the values for the middle and upper income levels this year after examining test data collected during the 1997 surveys at the request of the Guam COLA Partnership Committee.

For homeowners, the cost of insurance was dependent on the median home values calculated as part of this survey. In most areas, we assumed that the structure was equal to 80 percent of the total home value. In Hawaii, where the land represents a greater proportion of property value, we used 50 percent.

We priced hurricane insurance in all of the Hawaii allowance areas, Guam, Puerto Rico, and the U.S. Virgin Islands. In research previously conducted for OPM, the contractor found that homeowners and renters rarely purchased insurance coverage for other disasters, such as floods and earthquakes, in any of the allowance areas. (See section 4.2.4.3 of the Report to OPM on Living Costs in Selected Nonforeign Areas and in the Washington, DC, Area, December 10, 1992, at 57 FR 58556.) Insurers we contacted in the 1998 survey indicated that this is still the case. Therefore, we did not survey additional riders for flood or earthquake insurance.

4.2.4.4 Home Maintenance

We computed estimated home maintenance expenses for each of the homeowner and renter profiles. We derived separate home maintenance expenditure amounts for both owners and renters from the CES. Not surprisingly, the CES indicates that renters spend relatively little on home maintenance compared with homeowners.

As done in previous surveys, we priced both home maintenance services as well as home maintenance commodities using the CES information to identify items to price and the weights associated with these items. The maintenance service items priced were interior painting, plumbing repair, electrical repair, and pest control. In the Nome area, however, we did not price pest control because local sources indicated it is not necessary. The maintenance commodities priced were bathroom caulking, a kitchen faucet set, an electrical outlet, latex interior paint, and a fire extinguisher.

To compute home maintenance cost differences between each allowance area and the Washington, DC, area for the homeowner and renter profiles, we computed an index for each maintenance item by comparing the allowance area price to the DC area price. As with the Goods and Services Component items, we used the CES data to weight these maintenance indexes into an overall home maintenance index for each area.

To combine the maintenance indexes with the other homeowner and renter costs, which were expressed in dollar amounts, we converted the indexes to dollars. We did this by multiplying the index for each area by the average maintenance expense reported in the CES for owners and renters. We assigned this cost to the middle-income homeowner and renter profile. Logically, maintenance costs for larger homes would generally be greater than costs for middle-sized homes, while costs for smaller homes would generally be less. Therefore, we applied the same owner and renter multipliers used in the utilities model to recognize differences in maintenance costs due to house size at the various income levels.

4.3 Housing Data Collection Procedures

We collected home sales information from multiple listing type services and rental information mainly from rental brokers and advertisements.

4.3.1 Homeowner Data Collection

We obtained the selling prices of homes that matched the housing profiles in each living community for home sales that occurred roughly during the 12-month period preceding and including the survey month. The amount of data obtained depended on the number of home sales in the community and the availability of square footage and other information on housing characteristics. This in turn depended on the size of the community, economic conditions, the quality and quantity of realty data available, and the willingness and ability of local realty professionals to provide data.

We obtained relatively large quantities of home sales data in all areas except Nome. In Nome, home sales were extremely limited because Nome is not very large. In previous surveys, we also obtained relatively little data in St. Thomas. This year, we obtained and used housing data for both St. Thomas and St. John. Also, with the assistance of the Virgin Islands Assessor's Office, we obtained significantly more data than we have been able to get in previous years. These data identified houses that had been significantly damaged by hurricanes or other factors, and we excluded these from our calculations.

Identifying houses that were uninhabitable, severely damaged, or otherwise in need of significant repairs was impossible for most areas, given the limited amount of information available from the listing services. As discussed in section 4.4.1 below, we use the median rather than the average home value to compute housing costs. (The median is the middle value in a rank-ordered set of observations and tends to be less sensitive than the average to unusually low or high values at the ends of a range of data.) Nevertheless, in some of the databases we purchased, the quantity of exceptionally low priced homes had a significant effect on the median. Therefore, in all areas, we trimmed home sale prices that were less than $30,000, recognizing that $30,000 was probably a conservative price threshold for most areas. We trimmed homes of $1,000,000 or more at the upper level. We also trimmed properties of 1 acre or larger.

4.3.2 Renter Data Collection

We also obtained rental data from a variety of sources, *e.g.,* brokers, rental management firms, property managers, newspaper advertisements, and other listings. Analyses of these data revealed what appeared to be two separate rental markets: A broker market and a non-broker market. Rental rates and estimates provided by brokers generally exceeded those obtained from other sources. We discuss the methodology used to analyze these two data sets in section 4.4.2.

4.4 Housing Analysis

4.4.1 Homeowner Data Analysis

One of the most important factors relating to the price of a home is the number of square feet of living space. For each income profile in each allowance area and the Washington, DC,

area, we computed price per square foot for each of the comparables and determined the median price per square foot. We use the median to reduce the volatility of the housing data from one survey to the next because a relatively few extremely high or low home prices could significantly influence average housing prices. We then multiplied the median price per square foot by the reference square footage for the income level to determine the home purchase price.

As was done in the last survey, we also used historical housing data in addition to data collected in this survey. Appendix 9 shows these data. For all areas except Oahu, the historical data are from previous living-cost surveys that were published in the **Federal Register** beginning with the 1990 report. (See Appendix 1 for a listing of these publications). The data for the period prior to 1990 were published with the results of the 1991–1992 living-cost surveys at 57 FR 58617 (December 10, 1992) . All housing values are based on the community selections and analytical methodologies used at the time of each respective survey.

For Oahu, we surveyed housing prices in new living communities beginning with the 1997 surveys. Because our historical data did not cover these communities, we obtained additional historical price data for use in our 1997 and subsequent survey analyses.

The historical housing data used were estimated annual principal plus interest payments by income level in each area. To combine these data, we used weights that we derived from the 1992 Federal Employee Housing and Living Patterns Survey. These weights reflect the proportion of Federal employee homeowners by year of purchase in all allowance areas and in the Washington, DC, area. Appendix 10 shows the historical housing weights and analyses.

4.4.2 Rental Data Analysis

We assigned each rental quote to a single income level based on the criteria shown in Table 4–2. As discussed earlier, we received rental data from both broker and non-broker sources. In each area, the quantity of data obtained from either source varied significantly. Therefore, we found that analyzing all of the rental data (both broker and non-broker) together for an area and income level was undesirable. Instead, we analyzed broker and non-broker data separately by income level.

As with the housing data analyses, we used the median rental values. For each income level, we separately ranked rental rates from low to high for broker and non-broker data. We determined the median values for broker and non-broker data for each group and then averaged them to compute a single rental value for each income level. Because we have no information on how the Federal employees who rent generally secure their lodgings, we applied equal weights to the broker and non-broker data to compute an overall average rental rate for the area and income level.

Because there was insufficient non-broker data in the unfurnished rental units category, we used partly furnished and unfurnished units in the Hawaii areas. Similarly, we used apartment and furnished units in St. Croix at the middle and upper income levels because no other data were available.

Appendix 11 shows the broker and non-broker medians and final results. As noted in the appendix, we found inexplicable rental price trends in some of the data, particularly in the broker data. Therefore, as we explain in the footnotes of the appendix, we adjusted the rental data to address these anomalies.

4.5 Housing Survey Results

In the above sections, we described the processes used for determining the costs for maintenance, insurance, utilities, real estate taxes, rents, and homeowner mortgages. Appendix 12 shows the cost of each of these items for renters and homeowners in each allowance area and in the Washington, DC, area. Appendix 13 compares the total cost of these items by income level in each allowance area with the total cost of the same items by income level in the DC area. Again, there are separate comparisons for renters and homeowners. The final housing-cost comparisons take the form of indexes that are used in Appendix 21 to derive the total, overall indexes for owners and renters.

5. Transportation

5.1 Component Overview

The transportation component consists of two categories: Automobile Expense and Other Transportation Costs. The Automobile Expense Category reflects costs relating to owning and operating a car in each area. The Other Transportation Costs Category is represented by the cost of air travel from each location to common points within the contiguous 48 States.

5.2 Private Transportation Methodology

As in previous surveys, we analyzed automobile transportation costs for three commonly purchased vehicles: A domestic auto, an import auto, and a utility vehicle. We used new car costs for these analyses because we believe pricing used vehicles of equivalent quality in each area would require value judgments that could introduce inconsistencies.

5.2.1 Vehicle Selection and Pricing

We surveyed the same three models of automobiles in all areas—

—Domestic: Ford Taurus SE 4-door sedan 3.0L 6 cyl.
—Import: Honda Civic DX 4-door sedan 1.5L 4 cyl.
—Utility: Chevrolet S10 Blazer 4X4 2 door 4.3L 6 cyl.

For each model car, we collected new vehicle prices at dealerships in each area. All vehicles had standard options, such as automatic transmission, AM/FM stereo radio, and air conditioning. In Alaska locations, we included special additional equipment (*i.e.*, engine-block heaters and heavy-duty batteries) in new-vehicle prices. We also priced snow tires in Alaska. (See section 5.2.5.) In addition to the manufacturer's suggested retail price, the price included additional charges such as shipping, dealer preparation, additional dealer markup, excise tax, sales tax, documentation fees, and any other one-time taxes or charges.

We encountered problems in obtaining comparable car sales data in each area because of survey timing. As stated in section 1.5, we conducted the survey in October and November 1998, when the dealers were just beginning to receive shipments of the new 1999 models. However, not all dealers had the models we were surveying. Therefore, we obtained the prices of both the 1998 and 1999 models (to the extent the 1999 prices were available). Not surprisingly, we discovered that many dealers were charging significant markups for the 1999 models and significantly reducing or eliminating markups on the 1998 models. We found this in many areas, including the Washington, DC, area. Because we had only 1998 model prices across all areas, we used the 1998 model prices instead of the 1999 model prices. To overcome the problem caused by the usual dealer markups, we used the dealer markup for the same brands surveyed in the 1997 survey on the premise that these markups, which were obtained in the summer of 1997, were more typical.

5.2.2 Vehicle Trade Cycle

Calculating the cost of owning and operating a vehicle requires knowing the mileage and period of ownership. The automobile industry uses the term

''trade cycle'' to describe these two factors. The trade cycle is the length of time (in months or years) and the total number of miles driven in that time period. The OPM model uses this information to compute annual costs related to fuel, oil, tires, maintenance, and depreciation. As with the previous living-cost analyses, we used a 4-year, 60,000-mile trade cycle in all areas.

5.2.3 Fuel Performance and Type

All vehicles in the 1998 study used regular unleaded fuel. We collected self-service cash prices of unleaded regular gasoline at name-brand gas stations in the Washington, DC, area and in all allowance areas. In Alaska, we surveyed both self-serve and full-serve gas prices.

To establish average fuel-performance ratings, the COLA model uses the ''city driving'' figures published by the U.S. Environmental Protection Agency (EPA). The model uses the ''city'' figures instead of ''highway'' figures because all locations contained considerable stop-and-go driving conditions or required cautious driving because of poor road conditions. As in previous COLA surveys, we included in our analysis the following fuel-performance factors: temperature, road surface, and gradient.

OPM conducted previous research to determine these factors. We discuss this research and the factors below.

5.2.3.1 Impact of Temperature Upon Fuel Performance

Temperature affects gas mileage. The lower the temperature, the fewer miles-per-gallon achieved, and vice versa. According to EPA's *Passenger Car Fuel Economy: EPA and Road*, the temperature at which no adjustments to fuel performance occur is 77°F. Below that temperature, miles-per-gallon achieved drops. Above 77°F miles-per-gallon achieved improves. The model uses the average monthly temperatures for each allowance area and the DC area as reported in *The Weather Almanac*, published by Ruffner and Blair. For each location and month, the model uses the appropriate factor from the EPA study based on the average monthly temperature for the area. We then average these factors to derive a single overall factor for each location. Table 5–1 shows the results of these calculations.

5.2.3.2 Impact of Road Surface Upon Fuel Performance

The model assumes that Federally controlled roadways are typically composed of concrete and/or high-load asphalt and that locally controlled roadways are typically composed of low-load asphalt. EPA's research indicates that cars are generally more fuel-efficient on the firmer, high-load surfaces than on the softer, low-load surfaces. Although traffic patterns and road usage vary among areas, previous research conducted for OPM produced no relevant findings regarding this issue. Therefore, the model uses the assumption that Federally-controlled roadways generally support twice the traffic of, or are used at least twice as much as, locally controlled roadways.

In each allowance area, we collected the total mileage falling into either the Federal or local categories. For example, Alaska contains 5,512 miles of Federally controlled roads and 7,120 miles of locally controlled roads. The usage assumption increased Federal road mileage by a factor of two for the Alaska allowance areas.

We applied the average low-load asphalt factor (which reflects dry, wet, and snowy conditions) to the local mileage percentage and the average concrete and/or high-load asphalt factor to the Federal mileage percentage. This produced two weighted average factors—one for the Alaska allowance areas and another for the other allowance areas. Table 5–1 shows these factors. We assigned the Washington, DC, area a factor of 1.00 on the premise that the vast majority of traffic in that area travels on dry, high-load surfaces. Section 5.2.3.4 describes the application of these factors.

5.2.3.3 Impact of Gradient Upon Fuel Performance

We also estimated the effect of gradient on gas mileage from EPA's *Passenger Car Fuel Economy: EPA and Road.* Local topography (*i.e.*, gradient) affects fuel efficiency. EPA provides mileage factors based upon various gradients ranging from less than 0.5 percent (essentially flat) to greater than 6 percent (steep).

In research previously conducted for OPM, the contractor reviewed the topographic features of each area and found a wide range of road conditions. However, the contractor was unable to find relevant information on the types of terrain drivers typically encounter in each area or the number of miles drivers travel in each type of terrain. Lacking such information, the contractor assumed that drivers in the allowance areas generally traveled roads having approximately the same gradients that are found on average in the United States.

Applying the information from EPA's research, we computed a fuel-performance factor of 0.98 for this type of driving.

We assigned this factor to each allowance area. For the DC area, we used a factor of 1.00 on the premise that the vast majority of traffic in that area travels on major freeways and highways that are relatively flat. The next section describes the application of these factors.

5.2.3.4 Overall Impact Upon Fuel Performance

We applied the factors described above to make adjustments in the average gas mileage ratings for each type of automobile surveyed for each allowance area and for the Washington, DC, area. The adjustment factors compound; that is, the total adjustment is the result of multiplying the three individual factors together for each area.

In Table 5–1, the factor 1.00 means that no adjustment in EPA fuel performance is appropriate. A factor of less than 1.00 means that the estimated gasoline mileage in the area is less than the EPA average. For example, the total adjustment factor for Juneau is 0.84. This means that the estimated gasoline mileage in Juneau is 84 percent of the EPA estimated average. Note that the adjustment factor for the DC area (0.94) indicates that average gasoline mileage in that area is also below the EPA estimate.

TABLE 5–1.—SUMMARY OF FUEL-PERFORMANCE ADJUSTMENTS

Location	Temperature	Road surface	Gradient	Total
Anchorage	0.88	0.96	0.98	0.83
Fairbanks	0.85	0.96	0.98	0.80
Juneau	0.89	0.96	0.98	0.84
Nome	0.85	0.96	0.98	0.80
Hawaii	0.99	0.98	0.98	0.95
Virgin Islands	1.01	0.98	0.98	0.97

TABLE 5–1.—SUMMARY OF FUEL-PERFORMANCE ADJUSTMENTS—Continued

Location	Temperature	Road surface	Gradient	Total
Puerto Rico	1.01	0.98	0.98	0.97
Guam	0.99	0.98	0.98	0.95
Washington, DC	0.94	1.00	1.00	0.94

5.2.4 Vehicle Maintenance

We surveyed the cost of common maintenance services and repairs performed on the vehicles surveyed. The services and repairs were:

- Tuneup
- Oil change
- Automatic transmission fluid change
- Flush/fill coolant
- Muffler/exhaust pipe replacement
- Constant velocity joint (CVJ) boot replacement
- Windshield replacement

We used the automobile manufacturers' recommended maintenance schedules to determine the frequency of performing each of the first five maintenance jobs. Maintenance schedules vary, depending on the driving conditions typically encountered.

Consistent with the assumptions used for fuel economy and tire mileage, we assumed that driving conditions in the allowance areas are generally severe, and the maintenance schedules used reflected that kind of driving. For the DC area, we assumed that driving conditions are normal, and the maintenance schedules used for that area reflected that kind of driving.

We combined the recommended frequency of performing each of these jobs with the prices charged by local dealers and service stations to compute an estimated annual maintenance expense. We collected the cost of the complete maintenance service or repair job for each vehicle. For example, we collected the cost of a complete oil change for each vehicle, including the total charge for parts and the total charge for labor.

Previous research conducted for OPM revealed varying replacement cycles for constant velocity joint (CVJ) boots among the Alaska allowance areas and between the Alaska areas and the DC area. These were: Anchorage and Juneau—every 45,000 miles (3 years), Nome—every 30,000 miles (2 years), Fairbanks—every 15,000 miles (1 year), and the Washington, DC, area—every 60,000 miles (4 years). We used the Washington, DC, area frequency of repair for the other (*i.e.*, non-Alaska) COLA areas. In each area, we factored the cost of replacement for all three vehicle types into the indexes based upon the frequency of the replacement. In Fairbanks, for example, we included 100 percent of the cost because previous research indicated annual replacement was the norm.

To determine the frequency of replacement of windshields, we contacted local dealers and automobile repair shops. Based on the information obtained, we determined that windshield replacement was much more frequent in Alaska than in the other allowance areas or the Washington, DC, area. Therefore, we assumed that windshields had to be replaced every 2 years in the Alaska areas but rarely (*i.e.*, never) in the other areas or in the DC area during the 4-year trade cycle used in the COLA model. The owner's automotive insurance normally covers windshield replacement. Therefore, we used the deductible rather than the surveyed price of windshield replacement, since the deductible was always less than the replacement prices.

5.2.5 Tires

Research previously conducted for OPM revealed that various factors (*e.g.,* road quality/state of repair, road composition) appeared to reduce tread life (*i.e.,* the average number of miles a tire is expected to last) in the allowance areas compared with the Washington, DC, area. Based on this research, the model uses tire expense based on a 40,000-mile tread life in allowance areas and a 55,000-mile tread life in the DC area.

We priced the cost of a new set of tires, including mounting and balancing and all applicable taxes, in each area. We converted this cost into an annual cost by dividing the estimated number of annual miles driven by the expected tread life and multiplying this by the new tire price. Previous research indicated that four extra studded snow tires would be required for all three vehicles in the Alaska allowance areas (but not in the DC area). Therefore, we surveyed the prices of studded snow tires for all vehicles in Anchorage, Fairbanks, Juneau, and Nome. We also priced the cost of rims and switching snow and street tires semi-annually in these Alaska areas.

5.2.6 License and Registration Fees and Miscellaneous Taxes

We obtained information regarding license and registration fees, miscellaneous taxes, and personal property taxes (where applicable). We included license and registration fees as part of the annual cost of owning an automobile. We computed miscellaneous and personal-property taxes for each year of the vehicle's 4-year trade cycle using the vehicle's estimated used-car value for each year. We then averaged the resulting four personal property tax values and included that average as part of the annual cost of owning an automobile.

As stated in section 5.2.1, we included sales and excise taxes in the purchase price of the vehicle and accounted for them under the annual vehicle purchase and finance costs. We also include vehicle inspection fees in any area that requires periodic vehicle inspections.

5.2.7 Depreciation

The single largest annual expense related to owning and operating a new car is depreciation—the lost value of the vehicle as it ages and is driven. The COLA model calculates total depreciation by subtracting from the purchase price the estimated residual value (used car value) 4 years later. The model then divides this value by four to produce an annual depreciation amount.

As described earlier, the new car price was the manufacturer's suggested retail price plus any additional charges, such as shipping, dealer prep, additional dealer markup, documentation fees, excise tax, and sales tax. We based the used car value on information from sources such as the *Kelly Blue Book.* Although such sources track prices of vehicles sold only in the contiguous 48 States, previous research performed by a contractor for OPM did not indicate that used cars in allowance areas were (on average) worth more or less than used cars in the DC area, except for Fairbanks and Nome. For Fairbanks and Nome, we used 90 percent of the projected residual values to reflect more severe conditions.

We note that identical residual values did not result in identical depreciation

amounts. Depreciation amounts were generally higher in the allowance areas than in the Washington, DC, area because new car prices were generally higher in the allowance areas.

5.2.8 Finance Expense

The COLA model assumes that employees finance new car purchases. Therefore, we surveyed banks in all areas to obtain their auto-loan interest rates for a 48-month loan with 80 percent financing. We computed the finance cost for each vehicle in each area and included it in the annual cost of owning and operating an automobile.

5.2.9 Vehicle Insurance

We surveyed the cost of car insurance in each location using the following common coverages, limits, and deductibles:

Bodily Injury	$100,000/$300,000.
Property Damage	$25,000.
Medical	$15,000.
Uninsured Motorist	$100,000/$300,000.
Comprehensive	$100 Deductible.
Collision	$250 Deductible.

For the 1998 surveys, we adjusted the limits for Property Damage and Medical based on recommendations from insurance carriers during the 1997 surveys.

In each survey area, we identified the common automobile insurance companies and attempted to obtain three insurance price quotes for each type of car surveyed. We averaged these quotes by type of car to produce estimated insurance costs for each area.

As in previous surveys, we found that some insurance companies in Guam, Puerto Rico, and the Virgin Islands did not offer the coverages, limits, and deductibles shown above. To allow the comparison of the cost of these different policies with Washington, DC, area costs, we surveyed the cost of insurance in the DC area with comparable offerings in the three allowance areas. We then compared the costs of these equivalent policies to derive adjustment factors that could be applied to the cost of the standard coverage shown above. By applying these factors to the DC area average price, we estimated the cost of equivalent coverage for these particular allowance areas. Appendix 15 shows the factors and their derivation.

5.2.10 Overall Annual Costs

As described above, we surveyed the annual costs for fuel, maintenance and oil, tires, licensing, taxes, depreciation, finance, and insurance for three types of automobiles in each allowance area and in the Washington, DC, area. We then summed these costs to determine the overall annual costs by area for owning and operating each type of automobile. Appendix 14 shows these costs for each area by type of vehicle.

5.3 Other Transportation Costs—Air Fares

Air fare is the only item we price for the Other Transportation Costs Category. For this item, we surveyed the lowest priced round-trip air fare on a major carrier with a 3-week advance purchase, a 1-week stay over, and travel on Tuesdays and Thursdays. In the previous survey, we used Monday as the travel day. In this survey we used Tuesday (departure date) and Thursday (return date) to avoid peak business travel days and reflect choices consumers might make for recreational travel. While the selection of Tuesday and Thursday as travel days tended to reduce airfares for all areas, it greatly reduced airfares from the Washington, DC, area. This substantially raised the airfare index for each of the COLA areas.

We priced trips from each allowance area and the Washington, DC, area to Chicago, Los Angeles, Miami, New York, Seattle, St. Louis, and Omaha. We selected these cities to represent a range of travel destinations coast-to-coast for COLA-area and DC-area Federal employees. To compute the category indexes, we averaged the costs of the trips from each allowance area and then compared these average costs with the average cost of the trips from the DC area. Appendix 16 shows the fares.

5.4 Transportation Component Analyses

We compared the total cost of private auto transportation for each vehicle in each allowance area with the total cost for the same vehicle in the Washington, DC, area. We express these comparisons as indexes and show them in Appendix 17. Likewise, we compared the cost of air fares for each area with those for the DC area and computed a cost index. Appendixes 16 and 18 show these indexes. We used national average expenditure data to derive weights that reflected how much consumers typically spend to own and operate an automobile versus other transportation expenses. We used these weights, which vary by income level, to combine the Automobile Expense Category index with the Other Transportation Costs index by area to derive the overall Transportation Component index for the area. Appendix 18 shows the weights, computations, and final Transportation Component indexes.

6. Miscellaneous Expenses

6.1 Component Overview

The Miscellaneous Expense Component consists of four categories of expenses:

- Medical care.
- Private education (K–12).
- Contributions (including gifts to non-family members).
- Personal insurance and retirement contributions/investments.

6.2 Component Weights

We used CES data to determine the appropriate weights for each of the items and categories in the Miscellaneous Expense Component. We show the category weights in Table 6–1 and in Appendix 20. Appendix 19 shows item weights.

TABLE 6–1.—MISCELLANEOUS EXPENSE CATEGORIES AND WEIGHTS

Categories	Income level		
	Lower (percent)	Middle (percent)	Upper (percent)
Medical care	40.96	31.24	24.27
Private education (K–12)	0.98	1.26	1.45
Contributions	16.63	16.27	16.01
Personal insurance and retirement contributions	41.44	51.24	58.27
Totals	100.00	100.00	100.00

Note: Values may not total 100 because of rounding.

6.3 Component Categories

6.3.1 Medical Expense Category

We surveyed the price of medical care items using essentially the same approach we used for the Goods and Services Component items. We priced the following medical care items in each allowance area and in the Washington, DC, area:

- Nonprescription pain reliever
- Prescription drugs
- Contact lenses
- Dental service
- Doctor visit
- Hospital room
- Federal health insurance

In addition, we surveyed the price of hospital attendant services in Puerto Rico and air ambulance insurance in the U.S. Virgin Islands. We researched these services during the 1997 surveys, and we found that hospital attendant services were available only in Puerto Rico, where hospital services are significantly different from those in the Washington, DC, area. Therefore, we added the price of hospital attendant service to the price of a hospital room in Puerto Rico. We also found air ambulance insurance to be available only in the Virgin Islands, where on-island hospital services are limited. Therefore, we added the price of air ambulance insurance to the cost of health insurance in the Virgin Islands.

We used Federal employee health benefit enrollment information from OPM's Central Personnel Data File along with Federal health benefit premiums to compute average health benefit expense by areas. These expenses varied by area, and we used these averages rather than assuming that costs were constant among areas.

We surveyed the cost of the health care items in both the allowance areas and in the DC area. We compared the prices to produce an index for each item in each area, then combined these indexes using CES weights to produce a single Medical Care Category index for each area.

6.3.2 Private Education (K–12) Category

Since not everyone sends their children to private school, we derived use factors from the results of the 1992/93 Federal Employee Housing and Living Patterns Survey. Table 6–2 shows these factors and the resulting adjustment of price indexes by area. The factors reflect the relative extent to which Federal employees make use of private education in the COLA areas compared with the Washington, DC, area. For example, the table indicates a use factor of 4.1066 for Puerto Rico because about 54 percent of Federal employees with school age children there send at least one child to private school, compared with about 13 percent for the DC area.

TABLE 6–2.—SUMMARY OF PRIVATE EDUCATION USE FACTORS AND INDEXES

Location	Employees w/children in private schools		Use factor	Price index	Price index w/use factor
	Local area	DC area			
Anchorage	10.34	13.23	0.7816	55.53	43.40
Fairbanks	8.56	13.23	0.6470	41.59	26.91
Juneau	12.43	13.23	0.9395	57.30	53.84
Nome	8.08	13.23	0.6107	38.42	23.46
Honolulu	26.86	13.23	2.0302	113.03	229.48
Hilo*	18.94	13.23	1.4316	44.23	63.32
Kona*	18.94	13.23	1.4316	87.03	124.59
Kauai	22.46	13.23	1.6977	95.72	162.50
Maui	20.39	13.23	1.5412	89.05	137.24
Guam	42.26	13.23	3.1943	90.95	290.52
Puerto Rico	54.33	13.23	4.1066	66.85	274.52
St. Croix	57.27	13.23	4.3288	90.26	390.72
St. Thomas	51.90	13.23	3.9229	95.78	375.74

*Use data available only for Hawaii County.

6.3.3 Contributions Category

The index for the Contributions Category is the same as the Goods and Services Component index for the area. We use the Goods and Services index based on our assumption that the relative level of contributions is roughly equivalent to that reflected by the Goods and Services index.

6.3.4—Personal Insurance and Retirement Category

We assume the index for personal insurance and retirement contributions and investments to be constant among areas. The cost of Federal Employees Group Life Insurance is a matter of personal preference and is constant in all areas for the same age, salary, and benefit option combinations. Likewise, retirement contributions are a matter of personal preference, and the minimum contribution requirements are constant among areas for equivalent salary levels.

6.4 Miscellaneous Expense Analyses

As with the Goods and Services Component, we combined the indexes for each of the Miscellaneous Component categories using CES weights to produce component indexes by income level for each area. Appendix 20 shows these indexes. Section 2.6 describes how we combine miscellaneous expense component indexes with the other component indexes to derive the final index for each area.

7. Final Results

7.1 Total Comparative Cost Indexes

The total comparative cost indexes appear in Table 7–1. Appendix 22 shows how we derived each index from the component indexes.

TABLE 7–1.—FINAL COST COMPARISON INDEXES

Allowance area	Index
Anchorage, Alaska	105.65
Fairbanks, Alaska	109.19
Juneau, Alaska	110.46
The rest of the State of Alaska	131.58
City and County of Honolulu, Hawaii	124.51
Hawaii County, Hawaii	110.89
Kauai County, Hawaii	117.19
Maui County, Hawaii	120.32
Guam/CNMI, Local Retail	125.23
Guam/CNMI, Commissary/Exchange	121.12

TABLE 7–1.—FINAL COST COMPARISON INDEXES—Continued

Allowance area	Index
Puerto Rico	105.93

TABLE 7–1.—FINAL COST COMPARISON INDEXES—Continued

Allowance area	Index
U.S. Virgin Islands	116.33

Appendix 1—Publication in the Federal Register of Prior Survey Results: 1990–1998

Citation	Title	Contents
56 FR 7902	Cost-of-Living Allowances and Post Differentials (Nonforeign Areas).	Results of summer 1990 living-cost surveys conducted in Alaska, Hawaii, Guam, Puerto Rico, and the U.S. Virgin Islands.
57 FR 58556	Report on 1991/1992 Surveys Used to Determine Cost-of-Living Allowances in Nonforeign Areas.	Results of summer 1991 and winter 1992 living-cost surveys conducted in Alaska, Hawaii, Guam, Puerto Rico, and the U.S. Virgin Islands.
58 FR 45558	Report on 1992/1993 Surveys Used to Determine Cost-of-Living Allowances in Nonforeign Areas.	Results of summer 1992 and winter 1993 living-cost surveys conducted in Alaska, Hawaii, Guam, Puerto Rico, and the U.S. Virgin Islands.
58 FR 27316	Report on Summer 1993 Surveys Used to Determine Cost-of-Living Allowances in Nonforegin areas.	Results of summer 1993 living-cost surveys conducted in Hawaii, Guam, Puerto Rico, and the U.S. Virgin Islands.
59 FR 45066	Report on Winter 1994 Surveys Used to Determine Cost-of-Living allowances in Alaska..	Results of winter 1994 living-cost surveys conducted in Alaska.
60 FR 61332	Report on Summer 1994 Surveys Used to Determine Cost-of-Living Allowances in Selected Nonforeign Areas.	Results of summer 1994 living-cost surveys conducted in Hawaii, Guam, Puerto Rico, and the U.S. Virgin Islands.
61 FR 4070	Report on Winter 1995 Surveys Used to Determine Cost-of-Living Allowances in Alaska.	Results of winter 1995 living-cost surveys conducted in Alaska.
61 FR 14190	Report on 1996 Surveys Used to Determine Cost-of-Living Allowances in Nonforeign Areas.	Results of 1996 living-cost surveys conducted in Alaska, Hawaii, Guam, Puerto Rico, and the U.S. Virgin Islands.
63 FR 56432	Report on 1997 Surveys Used to Determine Cost-of-Living Allowances in Nonforeign Areas.	Results of 1997 living-cost surveys conducted in Hawaii, Guam, Puerto Rico, and the U.S. Virgin Islands.

Appendix 2.—Federal Employment Weights

MULTIPLE INCOME LEVELS: 1998 SURVEY

[Data from multiple income levels within a single allowance area]

Location and income level	1995	1996	1998	Average	Weights
Anchorage:					
Lower	1,540	1,445	1,401	1,462	27.02
Middle	1,754	1,719	1,500	1,658	30.64
Upper	2,522	2,448	1,903	2,291	42.34
Totals				5,411	100.00
Fairbanks:					
Lower	388	449	466	434	35.20
Middle	446	456	386	429	34.79
Upper	405	397	308	370	30.01
Totals				1,233	100.00
Juneau:					
Lower	139	126	100	122	18.91
Middle	203	199	174	192	29.77
Upper	341	346	306	331	51.32
Totals				645	100.00
Rest of Alaska:					
Lower	349	363	306	339	23.96
Middle	703	687	543	644	45.51
Upper	481	462	352	432	30.53
Totals				1,415	100.00
Honolulu:					
Lower	4,140	4,453	3,919	4,171	33.01
Middle	3,952	4,009	3,858	3,940	31.19
Upper	4,514	4,476	4,580	4,523	35.80
Totals				12,634	100.00
Hawaii:					
Lower	139	152	138	143	35.40
Middle	164	163	160	162	40.10
Upper	98	101	99	99	24.50
Totals				404	100.00
Kauai:					

MULTIPLE INCOME LEVELS: 1998 SURVEY—Continued

[Data from multiple income levels within a single allowance area]

Location and income level	1995	1996	1998	Average	Weights
Lower	73	59	51	61	27.23
Middle	76	80	64	73	32.59
Upper	97	92	80	90	40.18
Totals	.....	.....	.....	224	100.00
Maui:					
Lower	35	35	23	31	22.79
Middle	59	62	60	60	44.12
Upper	51	51	33	45	33.09
Totals	.....	.....	.....	136	100.00
Guam/CNMI:					
Lower	947	873	763	861	45.15
Middle	669	640	561	623	32.67
Upper	464	430	375	423	22.18
Totals	.....	.....	.....	1,907	100.00
Puerto Rico:					
Lower	2,370	2,281	2,205	2,285	39.89
Middle	2,166	2,177	2,073	2,139	37.34
Upper	1,303	1,286	1,322	1,304	22.77
Totals	.....	.....	.....	5,728	100.00
Virgin Islands:					
Lower	98	123	88	103	32.49
Middle	133	137	130	133	41.96
Upper	83	76	84	81	25.55
Totals	.....	.....	.....	317	100.00

MULTIPLE SURVEY AREAS: 1998 SURVEY

[Data from multiple survey areas within a single allowance area]

Location	1995	1996	1998	Average	Weights
Hawaii County:					
Hilo	304	308	300	304	75.81
Kona	97	96	97	97	24.19
Totals	.....	.....	.....	401	100.00
Virgin Islands:					
St. Croix	154	166	140	153	48.26
St. Thomas/St. John	160	170	162	164	51.74
Totals	.....	.....	.....	31	100.00

Appendix 3—Consumer Expenditure Surveys

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*

	Total complete reporting			
	1994	1995	1997	Average
Average before tax income	36,838.00	36,948.00	39,926.00	37,904.00
Average annual expenditures	32,762.99	33,610.38	36,145.95	34,173.11
Food	4,526.94	4,690.51	4,902.06	4,706.50
Food at home	2,764.21	2,885.98	2,970.28	2,873.49
Cereals and bakery products	439.36	454.64	464.66	452.89
Cereals and cereal products	166.94	169.16	165.56	167.22
Flour	7.93	8.93	8.94	8.60
Prepared flour mixes	13.20	13.29	16.51	14.33
Ready-to-eat and cooked cereals	102.02	99.83	92.76	98.20
Rice	15.47	19.43	18.21	17.70
Pasta, cornmeal and other cereal products	28.32	27.68	29.13	28.38
Bakery products	272.42	285.49	299.10	285.67
Bread	77.20	78.18	86.16	80.51
White bread	38.02	38.37	42.35	39.58
Bread, other than white	39.17	39.81	43.81	40.93

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	Total complete reporting			
	1994	1995	1997	Average
Crackers and cookies	64.36	70.09	70.06	68.17
Cookies	43.78	46.76	45.86	45.47
Crackers	20.58	23.33	24.19	22.70
Frozen and refrigerated bakery products	22.16	22.42	23.43	22.67
Other bakery products	108.70	114.79	119.45	114.31
Biscuits and rolls	37.26	39.48	42.66	39.80
Cakes and cupcakes	31.12	36.15	34.41	33.89
Bread and cracker products	4.68	4.45	4.68	4.60
Sweetrolls, coffee cakes, doughnuts	23.08	21.57	23.58	22.74
Pies, tarts, turnovers	12.55	13.14	14.11	13.27
Meats, poultry, fish, and eggs	728.89	758.30	756.18	747.79
Beef	226.73	232.15	226.37	228.42
Ground beef	89.79	87.81	84.79	87.46
Roast	37.79	40.70	40.06	39.52
Chuck roast	12.10	12.54	13.59	12.74
Round roast	14.18	13.55	12.01	13.25
Other roast	11.51	14.62	14.46	13.53
Steak	85.81	87.57	89.04	87.47
Round steak	16.44	18.92	17.82	17.73
Sirloin steak	24.09	22.70	23.86	23.55
Other steak	45.28	45.95	47.36	46.20
Other beef	13.34	16.06	12.48	13.96
Pork	154.66	157.51	161.13	157.77
Bacon	23.01	20.26	26.23	23.17
Pork chops	37.47	39.03	39.60	38.70
Ham	36.74	38.51	38.45	37.90
Ham, not canned	33.91	36.23	36.03	35.39
Canned ham	2.84	2.28	2.43	2.52
Sausage	22.63	21.35	25.09	23.02
Other pork	34.80	38.36	31.75	34.97
Other meats	94.34	105.31	98.81	99.49
Frankfurters	19.13	22.78	23.52	21.81
Lunch meats (cold cuts)	65.67	71.55	67.48	68.23
Bologna, liverwurst, salami	23.25	25.15	23.88	24.09
Other lunch meats	42.41	46.40	43.60	44.14
Lamb, organ meats and others	9.54	10.98	7.80	9.44
Lamb and organ meats	9.31	8.92	7.10	8.44
Mutton, goat and game	0.24	2.06	0.70	1.00
Poultry	135.32	136.43	145.61	139.12
Fresh and frozen chickens	107.49	105.79	114.50	109.26
Fresh whole chicken	NA	NA	NA	NA
Fresh and frozen whole chicken	29.05	28.37	29.94	19.44
Fresh and frozen chicken parts	78.44	77.43	84.56	80.14
Other poultry, incl. whole frozen chickens	NA	NA	NA	NA
Other poultry	27.83	30.64	31.11	20.58
Fish and seafood	87.13	95.34	90.67	91.05
Canned fish and seafood	15.60	17.95	14.42	15.99
Fresh and frozen shellfish	NA	NA	NA	NA
Fresh and frozen finfish	NA	NA	NA	NA
Fresh fish and shellfish	48.29	50.11	51.69	50.90
Frozen fish and shellfish	23.23	27.28	24.55	25.92
Eggs	30.72	31.55	33.59	31.95
Dairy products	297.87	311.48	328.97	312.77
Fresh milk and cream	131.98	129.41	134.35	131.91
Whole milk	NA	NA	NA	NA
Other milk and cream	NA	NA	NA	NA
Fresh milk, all types	123.44	119.84	124.37	122.10
Cream	8.55	9.56	9.97	9.76
Other dairy products	165.88	182.07	194.62	180.86
Butter	11.78	13.03	15.08	13.30
Cheese	84.78	93.13	99.99	92.63
Ice cream and related products	48.15	53.06	54.45	51.89
Miscellaneous dairy products	21.17	22.85	25.11	23.04
Fruits and vegetables	446.10	467.45	485.34	466.30
Fresh fruits	135.12	148.22	154.00	145.78
Apples	25.34	29.98	28.67	28.00
Bananas	30.25	31.09	32.54	31.29
Oranges	16.05	16.21	18.05	16.77
Other fresh fruits	63.49	70.94	74.73	69.72
Fresh vegetables	138.99	140.83	145.02	141.61

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	Total complete reporting			
	1994	1995	1997	Average
Potatoes	28.24	28.75	26.24	27.74
Lettuce	17.65	18.31	19.04	18.33
Tomatoes	21.59	21.89	24.47	22.65
Other fresh vegetables	71.52	71.89	75.27	72.89
Processed fruits	95.31	96.98	104.68	98.99
Frozen fruits and fruit juices	16.38	17.35	15.49	16.41
Frozen orange juice	9.57	9.19	8.56	9.11
Other frozen fruits and juices	6.81	8.15	6.93	7.30
Canned and dried fruits	21.11	20.11	20.50	20.57
Fresh, canned or bottled fruit juices	57.83	59.52	68.69	62.01
Processed vegetables	76.68	81.42	81.65	79.92
Frozen vegetables	24.78	29.55	27.14	27.16
Canned and dried vegetables and juices	51.90	51.88	54.51	52.76
Canned beans	10.61	11.26	11.95	11.27
Canned corn	6.99	6.80	7.38	7.06
Other canned and dried veg. and juices	34.30	33.80	35.17	34.42
Other food at home	851.99	894.10	935.13	893.74
Sugar and other sweets	110.67	119.49	118.31	116.16
Candy and chewing gum	66.52	73.02	71.95	70.50
Sugar	18.30	17.88	19.59	18.59
Artificial sweeteners	3.57	4.56	3.45	3.86
Jams, preserves, other sweets	22.28	24.02	23.32	23.21
Fats and oils	80.76	83.63	83.38	82.59
Margarine	14.68	13.13	12.25	13.35
Other fats, oils, and salad dressing	47.48	51.88	51.07	50.14
Nondairy cream and imitation milk	6.71	6.96	8.56	7.41
Peanut butter	11.89	11.66	11.50	11.68
Miscellaneous foods	369.77	394.39	424.58	396.25
Frozen prepared foods	65.79	69.94	82.25	72.66
Frozen meals	20.54	21.71	21.74	21.33
Other frozen prepared foods	45.25	48.22	60.51	51.33
Canned and packaged soups	30.21	31.92	33.24	31.79
Potato chips, nuts, and other snacks	75.91	84.32	88.63	82.95
Potato chips and other snacks	59.81	65.63	70.36	65.27
Nuts	16.10	18.69	18.27	17.69
Condiments and seasonings	82.47	89.18	91.74	87.80
Salt, spices, other seasonings	19.68	20.55	20.23	20.15
Olives, pickles, relishes	10.76	10.13	11.26	10.72
Sauces and gravies	38.05	41.78	43.18	41.00
Baking needs and misc. products	13.98	16.71	17.07	15.92
Other canned and packaged prepared foods	115.39	119.03	128.73	121.05
Salads and desserts	19.30	23.19	25.84	22.78
Baby food	27.68	25.42	28.65	27.25
Miscellaneous prepared foods	68.41	70.42	74.24	71.02
Nonalcoholic beverages	241.81	250.31	254.04	248.72
Cola	93.27	94.76	94.27	94.10
Other carbonated drinks	40.20	43.28	45.17	42.88
Coffee	43.29	47.76	49.87	46.97
Roasted coffee	29.20	32.11	33.41	31.57
Instant and freeze dried coffee	14.09	15.65	16.47	15.40
Noncarbonated fruit flavored drinks	NA	NA	NA	NA
Noncarb. fruit flavored drinks, inc. non-frozen lemonade	23.02	25.18	19.81	15.00
Tea	16.75	16.01	15.22	15.99
Nonalcoholic beer	0.76	1.17	0.33	0.75
Other nonalcoholic beverages	24.52	22.13	29.37	25.34
Food prepared by consumer unit on out-of-town trips	48.98	46.29	54.82	50.03
Food away from home	1,762.72	1,804.53	1,931.78	1,833.01
Meals at restaurants, carry-outs and other	1,363.26	1,426.22	1,516.51	1,435.33
Lunch	475.88	499.50	517.92	497.77
Dinner	668.88	691.44	753.30	704.54
Snacks and nonalcoholic beverages	110.46	126.30	128.93	121.90
Breakfast and brunch	108.05	108.98	116.35	111.13
Board (including at school)	50.40	58.40	49.67	52.82
Catered affairs	55.38	37.05	40.15	44.19
Food on out-of-town trips	213.45	204.85	235.69	218.00
School lunches	54.93	49.47	55.88	53.43
Meals as pay	25.30	28.53	33.87	29.23
Alcoholic beverages	296.57	301.83	330.23	309.54
At home	175.40	179.33	190.83	181.85
Beer and ale	108.74	94.20	98.68	100.54

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	Total complete reporting			
	1994	1995	1997	Average
Whiskey	14.25	12.83	14.43	13.84
Wine	36.06	54.77	54.55	48.46
Other alcoholic beverages	16.36	17.53	23.17	19.02
Away from home	121.17	122.51	139.40	127.69
Beer and ale	42.50	36.61	43.35	40.82
Wine	16.74	22.55	26.02	21.77
Other alcoholic beverages	30.22	33.33	35.10	32.88
Alcoholic beverages purchased on trips	31.71	30.02	34.93	32.22
Housing	10,189.41	10,576.98	11,348.00	10,704.80
Shelter	5695.83	5912.61	6339.07	5982.50
Owned dwellings	3464.04	3750.08	3933.15	3715.76
Mortgage interest and charges	1925.26	2120.77	2235.07	2093.70
Mortgage interest	1825.30	1997.99	2114.98	1979.42
Interest paid, home equity loan	44.67	56.26	60.52	53.82
Interest paid, home equity line of credit	54.73	66.06	59.38	60.06
Prepayment penalty charges	0.56	0.46	0.19	0.40
Property taxes	879.41	909.28	946.59	911.76
Maintenance, repairs, insurance, other expenses	659.37	720.02	751.49	710.29
Homeowners and related insurance	209.07	224.86	233.28	222.40
Fire and extended coverage	6.34	7.31	8.19	7.28
Homeowners insurance	202.73	217.55	225.09	215.12
Ground rent	40.26	33.61	37.61	37.16
Maintenance and repair services	312.65	366.16	369.97	349.59
Painting and papering	43.27	38.26	38.94	40.16
Plumbing and water heating	36.45	32.01	35.81	34.76
Heat, a/c, electrical work	55.08	75.83	62.71	64.54
Roofing and gutters	48.91	66.13	81.75	65.60
Other repair and maintenance services (old)	NA	NA	NA	NA
Other repair and maintenance services	112.39	136.51	128.52	88.34
Repair and replacement of hard surface flooring	14.76	15.56	20.35	16.89
Repair of built in appliances	1.78	1.86	1.89	1.84
Maintenance and repair commodities	75.59	70.72	88.29	78.20
Paints, wallpaper and supplies	18.95	19.73	19.34	19.34
Tools and equipment for painting and wallpapering	2.04	2.12	2.08	2.08
Plumbing supplies and equipment	8.57	7.42	6.15	7.38
Electrical supplies, heating and cooling equipment	5.86	4.97	4.16	5.00
Materials for hard surface flooring, repair/replace	5.08	3.33	7.78	5.40
Materials and equipment for roof and gutters	5.94	4.96	8.88	6.59
Materials for plaster, paneling, siding, doors, etc.	12.78	10.72	16.64	13.38
Materials for patio, walk, fence, driveway, etc.	0.52	0.59	0.72	0.61
Materials for landscaping maintenance	1.48	1.66	4.99	2.71
Miscellaneous supplies and equipment	14.37	15.22	17.55	15.71
Material for insulation, other maint., and repair	10.19	11.05	10.06	10.43
Materials to finish basements, remodeling, etc.	4.18	4.17	7.49	5.28
Property management and security	21.59	24.67	20.87	22.38
Property management	12.78	18.44	17.75	16.32
Management and upkeep services for security	8.81	6.22	3.12	6.05
Parking	0.21	0.00	1.47	0.74
Rented dwellings	1,828.52	1,786.70	1,979.74	1,864.99
Rent	1,755.05	1,716.57	1,867.90	1,779.84
Rent as pay	42.31	48.19	75.65	55.38
Maintenance, insurance and other expenses	31.16	21.94	36.18	29.76
Tenant's insurance	9.65	7.50	10.07	9.07
Maintenance and repair services	11.56	5.29	18.06	11.64
Repair or maintenance services (old)	NA	NA	NA	NA
Repair or maintenance services	10.37	4.97	16.63	7.20
Repair and replacement of hard surface flooring	1.05	0.25	1.40	0.90
Repair of built-in appliances	0.13	0.07	0.04	0.08
Maintenance and repair commodities	9.95	9.15	8.05	9.05
Paint, wallpaper, and supplies	2.09	1.62	1.57	1.76
Tools and equipment for painting and wallpapering	0.22	0.17	0.17	0.19
Materials for plastering, panels, roofing, gutters, etc.	1.23	0.87	1.10	1.07
Materials for patio, walk, fence, driveway, etc.	0.09	0.04	0.00	0.04
Plumbing supplies and equipment	0.70	1.35	0.40	0.82
Electrical supplies, heating and cooling equipment	1.36	0.37	0.09	0.61
Miscellaneous supplies and equipment	3.41	4.00	3.30	3.57
Material for insulation, other maint. and repair	1.13	1.51	1.10	1.25
Termite and pest control (capital improvement)	NA	NA	NA	NA
Materials for additions, finishing basements, etc.	1.67	2.44	1.88	2.00

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	Total complete reporting			
	1994	1995	1997	Average
Construction materials for jobs not started	0.61	0.04	0.31	0.32
Material for hard surface flooring	0.54	0.27	0.92	0.58
Material for landscape maintenance	0.31	0.47	0.49	0.42
Other lodging.				
Owned vacation homes	122.14	110.00	135.60	122.58
Mortgage interest and charges	43.30	38.31	59.25	46.95
Mortgage interest	39.56	36.36	57.41	44.44
Interest paid, home equity loan	0.43	0.15	0.72	0.43
Interest paid, home equity line of credit	3.31	1.80	1.11	2.07
Prepayment penalty charge	NA	NA	NA	NA
Property taxes	51.02	48.11	54.07	51.07
Maintenance, insurance, and other expenses	27.82	23.58	22.28	24.56
Homeowners and related insurance	7.66	5.66	4.66	5.99
Homeowners insurance	7.35	5.53	4.25	5.71
Fire and extended coverage	0.31	0.14	0.41	0.29
Ground rent	3.62	2.15	1.10	2.29
Maintenance and repair services	11.87	11.13	11.54	11.51
Repair and remodeling services (old)	NA	NA	NA	NA
Repair and remodeling services	11.40	11.07	11.35	7.47
Repair and replacement of surface flooring	0.47	0.06	0.19	0.24
Maintenance and repair commodities	1.35	2.35	0.98	1.56
Paints, wallpaper, supplies	0.16	0.58	0.37	0.37
Tools and equip. for painting and wallpapering	0.02	0.06	0.04	0.04
Materials for plaster., panel., roof., gutters, etc.	0.10	0.51	0.35	0.32
Material for patio, walk, fence, drive, masonry, etc	NA	NA	NA	NA
Plumbing supplies and equipment	0.05	0.07	0.08	0.07
Electrical supplies, heating and cooling equipment	NA	NA	NA	NA
Miscellaneous supplies and equipment	0.99	0.29	0.14	0.47
Material for insulation, other maint. and repair	0.99	0.29	0.13	0.47
Material for finishing basements & remodeling rooms	NA	NA	0.00	0.00
Materials for hard surface flooring	0.03	0.84	0.00	0.42
Materials for landscaping maintenance	NA	NA	NA	NA
Property management and security	3.27	2.28	3.67	3.07
Property management	2.36	1.51	3.24	2.37
Management and upkeep services for security	0.91	0.77	0.43	0.70
Parking	0.06	0.00	0.33	0.13
Housing while attending school	59.54	56.69	57.09	57.77
Lodging on out-of-town trips	221.60	209.14	233.48	221.41
Utilities, fuels, and public services	2,170.32	2,180.19	2,407.84	2,252.78
Natural gas	280.09	268.59	298.08	282.25
Utility—natural gas (renter)	60.54	60.43	60.79	60.59
Utility—natural gas (owned home)	216.97	206.77	235.78	219.84
Utility—natural gas (owned vacation)	2.53	1.25	1.35	1.71
Utility—natural gas (rented vacation)	0.05	0.14	0.17	0.12
Electricity	846.21	854.21	899.68	866.70
Electricity (renter)	207.80	201.80	211.65	207.08
Electricity (owned home)	630.39	643.72	679.66	651.26
Electricity (owned vacation)	7.36	7.78	7.45	7.53
Electricity (rented vacation).	0.65	0.92	0.92	0.83
Fuel oil and other fuels	98.11	85.56	109.11	97.59
Fuel oil	59.27	48.19	54.87	54.11
Fuel oil (renter)	6.49	3.92	5.14	5.18
Fuel oil (owned home)	52.38	43.76	49.16	48.43
Fuel oil (owned vacation)	0.40	0.47	0.54	0.47
Fuel oil (rented vacation)	NA	0.04	0.04	0.03
Coal	1.66	2.47	0.94	1.69
Coal (renter)	0.55	0.10	0.02	0.22
Coal (owned home)	1.12	2.37	0.92	1.47
Coal (owned vacation)	NA	NA	NA	NA
Coal (rented vacation)	NA	NA	NA	NA
Bottled gas	30.68	28.71	45.55	34.98
Gas, btld/tank (renter)	4.19	4.12	5.18	4.50
Gas, btld/tank (owned home).	23.43	21.80	37.31	27.51
Gas, btld/tank (owned vacation)	3.03	2.78	3.04	2.95
Gas, btld/tank (rented vacation)	0.04	0.02	0.02	0.02
Wood and other fuels	6.49	6.19	7.75	6.81
Wood/other fuels (renter)	0.61	0.80	1.66	1.02
Wood/other fuels (owned home)	5.81	5.36	5.99	5.72
Wood/other fuels (owned vacation)	0.06	0.04	0.09	0.06
Wood/other fuels (rented vacation)	NA	NA	0.01	0.00

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	Total complete reporting			
	1994	1995	1997	Average
Telephone services	688.52	709.69	809.32	735.84
Telephone (old)	NA	NA	NA	NA
Telephone services in home city, excluding car phones	674.31	683.24	755.32	704.29
Telephone services for mobile car phone	14.21	26.45	54.00	40.22
Water and other public services	257.41	262.14	291.65	270.40
Water and sewerage maintenance	182.67	188.59	210.76	194.01
Water/sewer maint. (renter)	26.75	26.25	28.93	27.31
Water/sewer maint. (owned home)	154.37	160.72	179.88	164.99
Water/sewer maint. (owned vacation)	1.50	1.47	1.79	1.59
Water/sewer maint. (rented vacation)	0.04	0.16	0.16	0.12
Trash and garbage collection	73.48	71.56	78.22	74.42
Trash/garb. coll. (renter)	9.37	8.40	9.16	8.98
Trash/garb. coll. (owned home)	62.61	62.16	67.47	64.08
Trash/garb. coll. (owned vacation)	1.45	0.96	1.52	1.31
Trash/garb. coll. (rented vacation)	0.04	0.05	0.08	0.06
Septic tank cleaning	1.26	1.99	2.68	1.98
Septic tank clean. (renter)	0.01	0.02	0.17	0.07
Septic tank clean. (owned home)	1.23	1.88	2.49	1.87
Septic tank clean. (owned vacation)	NA	0.08	0.01	0.03
Septic tank clean. (rented vacation)	0.01	0.00	0.00	0.00
Household operations	499.86	517.87	561.77	526.50
Personal services	240.70	263.71	272.92	259.11
Babysitting	81.17	78.64	76.94	78.92
Care for elderly, invalids, handicapped, etc	19.24	32.74	24.69	25.56
Day-care centers, nursery, and preschools	140.29	152.33	171.29	154.64
Other household expenses	259.16	254.16	288.84	267.39
Housekeeping services	82.83	86.51	76.51	81.95
Gardening, lawn care service	69.73	63.82	73.37	68.97
Water softening service	2.65	3.12	5.11	3.63
Household laundry, dry cleaning, sent out (nonclothing)	1.79	1.78	10.34	4.64
Coin-operated laundry and dry cleaning (nonclothing)	5.40	4.72	4.74	4.95
Services for termite/pest control maintenance	7.46	12.01	11.71	11.86
Other home services	20.11	16.38	16.58	17.69
Termite/pest control products	0.29	0.13	0.15	0.19
Moving, storage, freight express	27.54	27.59	32.44	29.19
Appliance repair, including service center	15.24	15.45	13.77	14.82
Reupholstering, furniture repair	11.03	11.54	11.78	11.45
Repair/rental of lawn/garden equipment, tools, etc.	9.20	5.85	5.47	6.84
Appliance rental	1.55	1.76	1.10	1.47
Rental of office equipment for nonbusiness use	0.31	0.35	0.46	0.37
Repair of misc. household equipment and furnishings	2.46	1.98	1.25	1.90
Repair of computer systems for nonbusiness use	1.57	1.18	2.70	1.82
Computer information services	NA	NA	21.35	7.12
Housekeeping supplies	424.30	465.39	484.90	458.20
Laundry and cleaning supplies	117.94	117.93	124.91	120.26
Soaps and detergents	66.49	66.92	69.41	67.61
Other laundry cleaning products	51.45	51.00	55.50	52.65
Other household products	187.75	207.85	222.40	206.00
Cleansing and toilet tissue, paper towels and napkins	60.17	65.62	69.32	65.04
Miscellaneous household products	80.66	74.41	94.06	83.04
Lawn and garden supplies	46.92	67.82	59.02	57.92
Postage and stationery	118.61	139.62	137.60	131.94
Stationery, stationery supplies, giftwraps	62.86	68.49	67.06	66.14
Postage	55.74	71.12	70.54	65.80
Household furnishings and equipment	1399.10	1500.92	1554.42	1484.81
Household textiles	106.15	107.85	81.91	98.64
Bathroom linens	13.89	17.82	12.07	14.59
Bedroom linens	52.67	47.70	35.52	45.30
Kitchen and dining room linens	7.27	9.73	2.39	6.46
Curtains and draperies	19.08	18.51	16.52	18.04
Slipcovers, decorative pillows	2.08	1.38	2.40	1.95
Sewing material for slipcovers, curtains, etc.	10.11	11.54	11.73	11.13
Other linens	1.04	1.18	1.28	1.17
Furniture	323.70	320.03	380.46	341.40
Mattress and springs	44.00	41.99	45.54	43.84
Other bedroom furniture	53.64	52.39	60.38	55.47
Sofas	76.89	69.70	89.42	78.67
Living room chairs	34.47	35.69	51.17	40.44
Living room tables	14.27	17.12	21.35	17.58
Kitchen, dining room furniture	49.61	48.99	46.41	48.34

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	Total complete reporting			
	1994	1995	1997	Average
Infants' furniture	6.04	6.46	11.19	7.90
Outdoor furniture	12.29	10.46	12.33	11.69
Occasional furniture	32.50	37.23	42.67	37.47
Floor coverings	131.65	211.89	82.77	142.10
Wall-to-wall carpeting (renter)	2.50	4.40	1.92	2.94
Wall-to-wall carpet, installed (renter)	2.12	3.79	1.49	2.47
Wall-to-wall carpet, not installed carpet squares (renter)	0.38	0.61	0.43	0.47
Wall-to-wall carpet (replacement) (owned home)	34.44	33.43	35.44	34.44
Wall-to-wall carpet, not installed, carpet squares (owner)	1.81	2.20	2.72	2.24
Wall-to-wall carpet, installed (replacement) (owner)	32.63	31.24	32.72	32.20
Room size rugs and other floor covering, nonpermanent	94.72	174.05	45.41	104.73
Major appliances	152.32	155.56	174.03	160.64
Dishwashers (built-in), garbage disposals, etc. (renter)	0.75	1.00	0.89	0.88
Dishwashers (built-in), garbage disposals, etc. (owner)	10.97	9.72	11.18	10.62
Refrigerators, freezers (renter)	6.90	6.34	10.51	7.92
Refrigerators, freezers (owned home)	38.91	41.01	49.16	43.03
Washing machines (renter)	6.05	4.51	5.51	5.36
Washing machines (owned home).	14.39	15.37	17.52	15.76
Clothes dryers (renter)	4.04	2.99	4.64	3.89
Clothes dryers (owned home)	9.31	11.07	12.07	10.82
Cooking stoves, ovens (renter)	2.42	2.79	2.87	2.69
Cooking stoves, ovens (owned home)	22.97	18.73	18.99	20.23
Microwave ovens (renter)	3.35	3.29	3.15	3.26
Microwave ovens (owned home)	6.48	5.74	6.97	6.40
Portable dishwasher (renter)	0.08	0.21	0.51	0.27
Portable dishwasher (owned home)	0.49	0.64	0.23	0.45
Window air conditioners (renter)	2.83	3.08	2.04	2.65
Window air conditioners (owned home)	3.93	9.56	3.78	5.76
Electric floor cleaning equipment	13.92	13.86	16.13	14.64
Sewing machines	2.92	4.88	3.49	3.76
Miscellaneous household appliances	1.61	0.75	4.38	2.25
Small appliances, miscellaneous housewares	85.73	90.94	100.26	92.31
Housewares	60.60	67.05	72.38	66.68
Plastic dinnerware	1.60	1.69	1.89	1.73
China and other dinnerware	11.63	12.23	9.65	11.17
Flatware	5.16	4.46	4.42	4.68
Glassware	8.14	7.26	8.60	8.00
Silver serving pieces	1.31	2.20	2.69	2.07
Other serving pieces	1.63	1.26	1.92	1.60
Nonelectric cookware	15.22	16.70	16.34	16.09
Tableware, nonelectric kitchenware	15.92	21.25	26.86	21.34
Small appliances	25.13	23.90	27.88	25.64
Small electric kitchen appliances	18.19	16.55	17.50	17.41
Portable heating and cooling equipment	6.94	7.34	10.38	8.22
Miscellaneous household equipment	599.55	614.64	734.99	649.73
Window coverings	14.48	11.21	11.69	12.46
Infants' equipment	7.46	8.08	8.25	7.93
Laundry and cleaning equip.	11.25	12.49	14.51	12.75
Outdoor equipment	5.48	4.61	15.99	8.69
Clocks	5.32	3.28	5.03	4.54
Lamps and lighting fixtures	36.98	33.94	13.73	28.22
Other household decorative items	119.06	158.39	134.65	137.37
Telephones and accessories	38.10	16.02	103.30	52.47
Lawn and garden equipment	53.17	44.68	40.53	46.13
Power tools	13.51	16.39	17.48	15.79
Small miscellaneous furnishings	1.88	2.64	0.00	1.51
Office furniture for home use	0.00	0.00	12.79	4.26
Hand tools	9.88	11.98	9.99	10.62
Indoor plants, fresh flowers	52.70	49.20	53.57	51.82
Closet and storage items	8.33	8.09	9.57	8.66
Rental of furniture	4.53	3.62	3.50	3.88
Luggage	8.00	10.25	10.01	9.42
Computers and computer hardware nonbusiness use	115.01	145.69	169.01	143.24
Computer software/accessories for nonbusiness use	20.05	19.51	26.83	22.13
Telephone answering devices	3.95	3.74	3.52	3.74
Calculators	2.35	2.10	2.10	2.18
Business equipment for home use	4.75	4.63	2.54	3.97
Other hardware	25.27	16.69	26.24	22.73
Smoke alarms (owned home)	0.86	1.32	0.94	1.04
Smoke alarms (renter)	0.15	0.18	0.18	0.17

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	Total complete reporting			
	1994	1995	1997	Average
Smoke alarms (owned vacation)	NA	NA	NA	NA
Other household appliances (owned home)	6.69	4.94	8.05	6.56
Other household appliances (renter)	1.36	1.10	1.61	1.36
Miscellaneous household equipment and parts	28.95	19.90	29.39	26.08
Apparel and services	1688.22	1770.53	1786.46	1748.40
Men and boys	418.74	437.23	422.86	426.28
Men, 16 and over	320.76	339.22	337.81	332.60
Men's suits	32.42	33.44	34.72	33.53
Men's sportcoats, tailored jackets	13.87	13.43	14.51	13.94
Men's coats and jackets	29.56	31.87	32.90	31.44
Men's underwear	12.90	19.04	13.47	15.14
Men's hosiery	10.30	14.66	10.13	11.70
Men's nightwear	2.73	3.93	2.74	3.13
Men's accessories	29.43	32.09	32.41	31.31
Men's sweaters and vests	14.23	12.51	15.51	14.08
Men's active sportswear	11.96	10.37	11.60	11.31
Men's shirts	79.19	78.33	81.15	79.56
Men's pants	62.55	65.60	68.67	65.61
Men's shorts, shorts sets	15.91	18.79	15.16	16.62
Men's uniforms	3.35	4.01	2.13	3.16
Men's costumes	2.34	1.14	2.70	2.06
Boys, 2 to 15	97.98	98.01	85.05	93.68
Boys' coats and jackets	6.61	11.14	8.48	8.74
Boys' sweaters	2.76	1.94	2.87	2.52
Boys' shirts	21.53	21.66	17.77	20.32
Boys' underwear	4.57	5.52	3.22	4.44
Boys' nightwear	2.13	0.81	2.05	1.66
Boys' hosiery	3.75	4.69	2.99	3.81
Boys' accessories	7.57	5.72	4.53	5.94
Boys' suits, sportcoats, vests	6.10	3.30	3.04	4.15
Boys' pants	21.77	23.82	22.80	22.80
Boys' shorts, shorts sets	12.15	12.16	8.92	11.08
Boys' uniforms, active sportswear	7.76	6.45	7.16	7.12
Boys' costumes	1.30	0.81	1.22	1.11
Women and girls	653.73	694.23	699.25	682.40
Women, 16 and over	552.35	591.01	591.18	578.18
Women's coats and jackets	49.54	45.93	44.40	46.62
Women's dresses	81.37	93.51	86.35	87.08
Women's sportcoats, tailored jackets	4.15	4.49	3.39	4.01
Women's vests and sweaters	32.73	31.47	40.33	34.84
Women's shirts, tops, blouses	96.49	106.16	99.89	100.85
Women's skirts	19.13	22.83	20.99	20.98
Women's pants	58.46	72.07	74.88	68.47
Women's shorts, shorts sets	23.01	25.21	22.75	23.66
Women's active sportswear	24.30	29.46	29.78	27.85
Women's sleepwear	24.72	22.66	24.69	24.02
Women's undergarments	24.46	31.17	31.74	29.12
Women's hosiery	25.02	21.93	24.03	23.66
Women's suits	37.27	33.78	36.91	35.99
Women's accessories	49.54	46.86	46.34	47.58
Women's uniforms	0.42	2.00	2.40	1.61
Women's costumes	1.73	1.48	2.30	1.84
Girls, 2 to 15	101.38	103.22	108.07	104.22
Girls' coats and jackets	7.23	6.84	6.87	6.98
Girls' dresses, suits	13.99	13.73	13.78	13.83
Girls' shirts, blouses, sweaters	25.48	20.64	25.29	23.80
Girls' skirts and pants	16.06	17.94	20.22	18.07
Girls' shorts, shorts sets	9.07	9.98	9.57	9.54
Girls' active sportswear	6.56	12.65	7.61	8.94
Girls' underwear and sleepwear	7.49	7.67	6.85	7.34
Girls' hosiery	5.82	4.87	5.30	5.33
Girls' accessories	4.55	4.61	5.78	4.98
Girls' uniforms	2.15	1.94	3.49	2.53
Girls' costumes	2.98	2.35	3.31	2.88
Children under 2	83.32	83.72	83.64	83.56
Infant coat, jacket, snowsuit	2.69	3.30	3.19	3.06
Infant dresses, outerwear	22.30	23.32	15.99	20.54
Infant underwear	49.15	48.46	48.36	48.66
Infant nightwear, loungewear	3.94	3.78	4.65	4.12
Infant accessories	5.23	4.86	11.46	7.18

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	Total complete reporting			
	1994	1995	1997	Average
Infant hosiery	NA	NA	NA	NA
Footwear	258.43	287.27	325.60	290.43
Men's footwear	84.05	103.76	102.71	96.84
Boys' footwear	34.18	28.94	30.90	31.34
Women's footwear	113.26	121.72	160.65	131.88
Girls' footwear	26.94	32.85	31.34	30.38
Other apparel products and services	274.00	268.09	255.13	265.74
Material for making clothes	7.24	5.46	4.55	5.75
Sewing patterns and notions	2.57	2.13	5.49	3.40
Watches	24.45	20.37	30.26	25.03
Jewelry	108.96	109.19	144.54	120.90
Shoe repair and other shoe service	3.16	2.88	2.47	2.84
Coin-operated apparel laundry and dry cleaning	37.33	40.94	20.94	33.07
Apparel alteration and repair	6.90	5.90	6.41	6.40
Clothing rental	3.75	3.46	4.00	3.74
Watch and jewelry repair	5.99	5.41	5.54	5.65
Apparel laundry and dry cleaning not coin operated	73.18	71.82	30.57	58.52
Clothing storage	0.47	0.52	0.35	0.45
Transportation	6075.53	6123.07	6669.29	6289.30
Vehicle purchases (net outlay)	2703.01	2677.81	2856.48	2745.77
Cars and trucks, new	1333.33	1188.62	1310.11	1277.35
New cars	727.70	688.75	748.92	721.79
New trucks	605.63	499.87	561.19	555.56
Cars and trucks, used	1320.82	1456.39	1499.72	1425.64
Used cars	866.68	963.07	935.75	921.83
Used trucks	454.14	493.32	563.97	503.81
Other vehicles	48.85	32.80	46.64	42.76
New motorcycles	25.77	17.64	26.57	23.33
New aircraft	NA	NA	NA	NA
Used motorcycles	23.09	15.16	18.52	18.92
Used aircraft	NA	NA	1.55	0.52
Gasoline and motor oil	989.97	1014.48	1110.22	1038.22
Gasoline	877.48	904.95	990.79	924.41
Diesel fuel	9.16	10.91	10.97	10.35
Gasoline on out-of-town trips	90.64	86.11	94.78	90.51
Gasohol	0.18	0.00	0.00	0.06
Motor oil	11.60	11.64	12.73	11.99
Motor oil on out-of-town trips	0.92	0.87	0.96	0.92
Other vehicle expenses	1989.07	2064.09	2312.48	2121.88
Vehicle finance charges	238.49	267.24	304.80	270.18
Automobile finance charges	139.82	154.84	166.22	153.63
Truck finance charges	86.72	99.05	122.32	102.70
Motorcycle and plane finance charges	1.05	1.36	1.64	1.35
Other vehicle finance charges	10.90	11.98	14.63	12.50
Maintenance and repairs	700.79	675.26	719.82	698.62
Coolant, additives, brake, transmission fluids	6.32	5.79	6.21	6.11
Tires—purchased, replaced, installed	89.79	90.02	91.83	90.55
Parts, equipment, and accessories	111.43	64.20	55.56	77.06
Vehicle audio equipment, excluding labor	5.45	10.74	2.59	6.66
Vehicle products	5.28	3.89	8.44	6.16
Misc. auto repair, servicing	33.34	36.88	62.12	44.11
Body work and painting	36.88	32.55	34.22	34.55
Clutch, transmission repair	46.56	45.07	44.96	45.53
Drive shaft and rear-end repair	5.94	6.61	4.90	5.82
Brake work	43.70	48.70	59.86	50.75
Repair to steering or front-end	18.42	20.05	17.55	18.67
Repair to engine cooling system	22.60	24.32	20.86	22.59
Motor tune-up	42.86	43.84	47.84	44.85
Lube, oil change, and oil filters	39.86	44.30	56.59	46.92
Front-end alignment, wheel balance	NA	NA	NA	NA
Front-end alignment, wheel balance and rotation	9.78	11.19	12.81	8.00
Shock absorber replacement	7.04	6.98	5.46	6.49
Brake adjustment	3.89	3.18	0.00	2.36
Gas tank repair, replacement	2.52	1.73	1.50	1.92
Repair tires and other repair work	27.94	34.28	30.50	30.91
Vehicle air conditioning repair	14.87	15.01	19.49	17.25
Exhaust system repair	20.56	20.98	19.73	20.42
Electrical system repair	31.39	30.57	30.71	30.89
Motor repair, replacement	69.19	68.10	78.68	71.99
Auto repair service policy	5.17	6.27	7.41	6.28

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	Total complete reporting			
	1994	1995	1997	Average
Vehicle insurance	698.00	726.03	779.47	734.50
Vehicle rental, leases, licenses, other charges	351.79	395.56	508.38	418.58
Leased and rented vehicles	196.83	230.89	325.60	251.11
Rented vehicles	39.82	38.99	41.38	40.06
Auto rental	6.03	7.41	7.28	6.91
Auto rental, out-of-town trips	26.09	26.90	27.04	26.68
Truck rental	1.68	1.13	2.20	1.67
Truck rental, out-of-town trips	4.61	3.35	4.43	4.13
Motorcycle rental	NA	NA	NA	NA
Aircraft rental	0.16	0.00	0.12	0.08
Motorcycle rental, out-of-town trips	0.09	0.12	0.07	0.09
Aircraft rental, out-of-town trips	1.16	0.09	0.24	0.50
Leased vehicles	157.01	191.89	284.22	211.04
Car lease payments	104.24	125.21	157.26	128.90
Cash downpayment (car lease)	9.84	12.91	12.37	11.71
Termination fee (car lease)	0.44	0.28	1.88	0.87
Truck lease payments	38.15	51.07	99.28	62.83
Cash downpayment (truck lease)	4.30	2.13	12.66	6.36
Termination fee (truck lease)	0.03	0.29	0.78	0.37
State and local registration	82.74	89.55	102.43	91.57
Driver's license	7.34	7.34	7.75	7.48
Vehicle inspection	8.78	9.52	9.42	9.24
Parking fees	27.47	27.86	30.22	28.52
Parking fees (old)	NA	NA	NA	NA
Parking fees in home city, excluding residence	24.17	24.09	26.27	24.84
Parking fees, out-of-town trips	3.30	3.77	3.95	3.67
Tolls	10.47	12.04	14.49	12.33
Tolls on out-of-town trips	4.69	4.76	4.53	4.66
Towing charges	5.37	5.11	5.24	5.24
Automobile service clubs	8.10	8.49	8.68	8.42
Public transportation	393.48	366.69	390.11	383.43
Airline fares	253.06	234.86	253.59	247.17
Intercity bus fares	11.57	14.61	11.46	12.55
Intracity mass transit fares	49.28	49.60	54.55	51.14
Local trans. on out-of-town trips	10.19	9.25	12.23	10.56
Taxi fares on trips	5.99	5.43	7.18	6.20
Taxi fares	8.23	7.61	9.81	8.55
Intercity train fares	17.13	19.01	21.26	19.13
Ship fares	36.91	25.86	18.98	27.25
School bus	1.12	0.47	1.05	0.88
Health care	1768.03	1746.75	1897.69	1804.16
Health insurance	818.43	864.44	899.75	860.87
Commercial health insurance	251.06	234.49	202.04	229.20
Blue Cross, Blue Shield	159.34	170.15	196.27	175.25
Health maintenance plans (HMO's)	127.97	150.70	232.26	170.31
Medicare payments	157.72	175.97	166.85	166.85
Commercial medicare supplements	122.35	133.13	102.33	119.27
Medical services	567.28	501.51	543.63	537.47
Physician's services	159.89	140.03	137.85	145.92
Dental services	194.50	192.07	209.60	198.72
Eyecare services	29.81	29.82	27.68	29.10
Service by professionals other than physician	32.95	38.29	40.94	37.39
Lab tests, x-rays	25.73	22.15	24.56	24.15
Hospital room	44.70	32.45	33.78	36.98
Hospital service other than room	54.60	28.76	50.70	44.69
Medical care in retirement community	NA	NA	NA	NA
Care in convalescent or nursing home	13.21	8.79	12.24	11.41
Repair of medical equipment	NA	NA	0.31	0.10
Other medical care services	11.88	9.16	5.98	9.01
Drugs	294.24	293.39	341.61	309.75
Nonprescription drugs	84.17	86.92	117.91	96.33
Prescription drugs	210.08	206.47	223.69	213.41
Medical supplies	88.07	87.41	112.71	96.06
Eyeglasses and contact lenses	54.20	55.05	61.25	56.83
Hearing aids	0.94	0.00	12.21	0.47
Topicals and dressings	24.55	23.49	31.34	26.46
Medical equipment for general use	2.41	2.90	2.67	2.66
Supportive and convalescent medical equipment	3.82	4.61	2.87	3.77
Rental of medical equipment	0.72	0.34	0.44	0.50
Rental of supportive, convalescent medical equipment	1.43	1.02	1.92	1.46

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	Total complete reporting			
	1994	1995	1997	Average
Entertainment	1619.28	1687.41	1867.58	1724.76
Fees and admissions	451.13	447.26	490.22	462.87
Recreation expenses, out-of-town trips	22.00	22.61	26.13	23.58
Social, recreation, civic club membership	87.17	80.62	78.75	82.18
Fees for participant sports	73.87	69.49	76.71	73.36
Participant sports, out-of-town trips	27.40	27.94	30.43	28.59
Movie, theater, opera, ballet	78.89	75.36	89.89	81.38
Movie, other admissions, out-of-town trips	37.79	42.78	44.47	41.68
Admission to sporting events	32.52	31.57	35.80	33.30
Admission to sports events, out-of-town trips	12.59	14.26	14.82	13.89
Fees for recreational lessons	56.90	60.02	67.09	61.34
Other entertainment services, out-of-town trips	22.00	22.61	26.13	23.58
Television, radios, sound equipment	545.23	560.84	596.05	567.37
Televisions	376.08	376.88	411.26	388.07
Community antenna or cable tv	209.78	220.04	265.14	231.65
Black and white tv	2.23	2.51	0.75	1.83
Color tv—console	25.51	27.65	24.22	25.79
Color tv—portable, table model	54.63	47.71	41.13	47.82
VCR's and video disc players	32.98	29.11	28.25	30.11
Video cassettes, tapes, and discs	22.55	25.44	23.81	23.93
Video game hardware and software	19.24	15.27	20.40	18.30
Repair of tv, radio, and sound equipment	8.79	7.99	7.31	8.03
Rental of televisions	0.36	1.16	0.26	0.59
Radios, sound equipment	169.15	183.96	184.79	179.30
Radios	9.05	12.59	13.28	11.64
Phonographs	NA	NA	NA	NA
Tape recorders and players	5.86	12.77	7.72	8.78
Sound components and component systems	31.51	33.69	31.48	32.23
Miscellaneous sound equipment	1.51	0.64	0.77	0.97
Sound equipment accessories	4.83	4.82	5.84	5.16
Satellite dishes	NA	NA	2.98	0.99
Compact disc, tape, record and video mail order clubs	13.11	13.35	11.02	12.49
Records, CDs, audio tapes, needles	37.80	40.00	41.96	39.92
Rental of VCR, radio, and sound equipment	0.35	0.28	0.46	0.36
Musical instruments and accessories	17.62	20.47	24.88	20.99
Rental and repair of musical instruments	2.06	1.86	1.78	1.90
Rental of video cassettes, tapes, films, and discs	45.45	43.48	42.63	43.85
Pets, toys, and playground equipment	305.98	348.78	339.01	331.26
Pets	177.55	223.00	207.71	202.75
Pet food	82.75	86.92	94.36	88.01
Pet purchase, supplies, medicine	29.36	57.03	40.02	42.14
Pet services	16.52	20.41	17.95	18.29
Vet services	48.92	58.65	55.38	54.32
Toys, games, hobbies, and tricycles	125.48	123.52	130.24	126.41
Playground equipment	2.95	2.26	1.06	2.09
Other entertainment supplies, equipment, and services	316.93	330.53	442.30	363.25
Unmotored recreational vehicles	29.18	30.46	44.74	34.79
Boat without motor and boat trailers	5.16	3.63	9.03	5.94
Trailer and other attachable campers	24.02	26.84	35.71	28.86
Motorized recreational vehicles	81.72	77.55	133.84	97.70
Motorized camper coaches and other vehicles	43.13	36.43	34.01	37.86
Purchase of boat with motor	38.58	41.12	99.84	59.85
Rental of recreational vehicles	2.42	3.01	3.86	3.10
Rental noncamper trailer	0.13	0.14	0.03	0.10
Boat and trailer rental, out-of-town trips	0.74	1.24	2.77	1.58
Rental of campers, etc. on out-of-town trips (old)	NA	NA	NA	NA
Rental of campers on out-of-town trips	0.39	0.36	0.33	0.36
Rental of other vehicles on out-of-town trips	0.66	1.03	0.54	0.74
Rental of boat	0.10	0.01	0.03	0.05
Rental of campers, other r.v.'s	0.40	0.24	0.15	0.26
Outboard motors	2.05	0.44	2.84	1.78
Docking and landing fees	5.05	4.76	8.96	6.26
Sports, recreation and exercise equipment	115.10	115.57	133.36	121.34
Athletic gear, game tables, and exercise equipment	54.37	51.11	61.04	55.51
Bicycles	14.10	13.23	16.25	14.53
Camping equipment	3.61	7.30	8.56	6.49
Hunting and fishing equipment	20.58	17.87	18.35	18.93
Winter sports equipment	4.99	3.73	5.48	4.73
Water and miscellaneous sport equipment	15.51	20.52	21.51	19.18
Rental and repair of misc. sports equipment	1.95	1.83	2.18	1.99

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	Total complete reporting			
	1994	1995	1997	Average
Photographic equipment and supplies	74.17	87.03	94.84	85.35
Film	20.48	20.91	21.93	21.11
Other photographic supplies	0.31	0.40	1.29	0.67
Film processing	28.34	29.72	30.86	29.64
Repair and rental of photographic equipment	0.33	0.30	0.56	0.40
Photographic equipment	12.63	12.58	14.83	13.35
Photographer fees	12.09	23.10	25.37	20.19
Fireworks	0.76	2.69	2.93	2.13
Souvenirs	0.49	0.18	0.91	0.53
Visual goods	1.49	1.76	3.55	2.27
Pinball, electronic video games	4.50	7.07	12.48	8.02
Personal care products and services	414.76	429.80	551.28	465.28
Personal care products	235.24	229.70	262.83	242.59
Hair care products	49.23	42.18	55.39	48.93
Nonelectric articles for the hair	7.26	4.70	7.59	6.52
Wigs and hairpieces	0.89	0.89	1.35	1.04
Oral hygiene products, articles	25.52	23.92	29.26	26.23
Shaving needs	12.64	13.06	11.85	12.52
Cosmetics, perfume, bath preparation	106.82	112.96	120.23	113.34
Deodorants, feminine hygiene, misc. personal care	28.40	28.04	32.35	29.60
Electric personal care appliances	4.46	3.94	4.80	4.40
Personal care services	179.53	200.11	288.45	222.70
Personal care service for females	89.46	107.59	190.41	129.15
Personal care service for males	89.94	92.24	97.86	93.35
Repair of personal care appliances	0.12	0.28	0.18	0.19
Reading	171.39	170.42	171.24	171.02
Newspapers	70.94	71.14	69.98	70.69
Magazines	39.53	38.06	36.36	37.98
Newsletters	0.15	0.27	0.00	0.14
Books thru book clubs	11.44	10.29	11.18	10.97
Books not thru book clubs	47.99	48.98	52.79	49.92
Encyclopedia and other sets of reference books	1.33	1.67	0.94	1.31
Education	469.39	477.94	547.80	498.38
College tuition	275.33	271.57	303.14	283.35
Elementary and high school tuition	65.45	76.52	87.97	76.65
Other schools tuition	15.34	14.55	16.61	15.50
Other school expenses including rentals	19.50	17.94	28.77	22.07
School books, supplies, equipment for college	39.14	36.93	47.48	41.18
School books, supplies, etc. for elementary and high school	9.71	8.71	12.88	10.43
School books, supplies, etc. for day care, nursery, other	3.49	1.99	2.95	2.81
School supplies, etc.—unspecified	41.43	49.73	48.00	46.39
Tobacco products and smoking supplies	261.81	271.59	271.17	268.19
Cigarettes	238.23	244.94	237.35	240.17
Other tobacco products	21.96	25.50	31.47	26.31
Smoking accessories	1.62	1.15	2.35	1.71
Miscellaneous	810.79	808.33	888.10	835.74
Miscellaneous fees, pari-mutuel losses	50.63	53.69	54.63	52.98
Legal fees	119.22	99.93	124.33	114.49
Funeral expenses	91.97	86.77	69.79	82.84
Safe deposit box rental	5.79	5.47	6.65	5.97
Checking accounts, other bank service charges	27.69	27.35	25.65	26.90
Cemetery lots, vaults, maintenance fees	19.45	14.55	20.06	18.02
Accounting fees	44.90	41.35	50.62	45.62
Miscellaneous personal services	27.76	23.44	41.30	30.83
Finance charges excluding mortgage and vehicle	228.84	244.92	272.33	248.70
Occupational expenses	94.19	115.56	115.16	108.30
Expenses for other properties	94.77	90.93	102.70	96.13
Interest paid, home equity line of credit (other property)	0.50	0.15	0.57	0.41
Credit card memberships	5.08	4.23	4.32	4.54
Cash contributions	1066.81	1034.59	1084.76	1062.05
Cash contributions to non-CU memb., incl. child sup., etc.	292.68	256.97	265.70	271.78
Gifts of cash, stocks and bonds to non-CU members	228.78	198.88	246.98	224.88
Contributions to charity	102.81	97.57	112.21	104.20
Contributions to church	404.30	428.54	426.74	419.86
Contributions to educational organizations	22.66	40.51	18.37	27.18
Contributions to political organizations	8.33	3.69	7.27	6.43
Other contributions	7.25	8.44	7.48	7.72
Personal insurance and pensions	3404.08	3520.62	3830.30	3585.00
Life and other personal insurance	413.43	382.39	386.53	394.12
Life, endowment, annuity, other personal insurance	395.89	369.76	376.74	380.80

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	Total complete reporting			
	1994	1995	1997	Average
Other nonhealth insurance	17.54	12.63	9.79	13.32
Pensions and Social Security	2990.65	3138.23	3443.76	3190.88
Deductions for government retirement	84.07	81.20	99.84	88.37
Deductions for railroad retirement	5.38	6.53	2.81	4.91
Deductions for private pensions	324.08	399.84	416.13	380.02
Non-payroll deposit to retirement plans	331.09	352.23	426.72	370.01
Deductions for Social Security	2246.03	2298.44	2498.27	2347.58

*Data might not be statistically significant.
Source: Bureau of Labor Statistics.

Appendix 4—CES Category and Component Expenditures

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*

	$10,000 to $14,999	$15,000 to $19,999	$20,000 to $29,999	$30,000 to $39,999	$40,000 to $49,999	$50,000 and over
Average income before taxes:						
1994	$12,340.00	$17,229.00	$24,721.00	$34,402.00	$44,388.00	$84,162.24
1995	12,420.00	17,341.00	24,603.00	34,606.00	44,408.00	81,698.83
1997	12,411.00	17,393.00	24,599.00	34,583.00	44,396.00	83,479.01
Average	12,390.33	17,321.00	24,641.00	34,530.33	44,397.33	83,113.36
Goods and services:						
1994	6,989.07	8,346.77	10,014.51	12,274.85	14,404.18	21,193.80
1995	7,340.81	8,788.33	10,287.78	12,679.10	14,447.22	21,289.89
1997	7,126.13	9,182.97	10,341.33	12,694.83	14,648.83	21,839.22
Average	7,152.00	8,772.69	10,214.54	12,549.59	14,500.08	21,440.97
Food at home:						
1994	2,219.92	2,437.04	2,597.85	2,833.99	3,175.54	3,797.84
1995	2,205.73	2,732.23	2,611.14	2,906.99	3,358.72	3,871.65
1997	2,155.29	2,634.17	2,700.57	3,061.75	3,221.35	3,947.54
Average	2,193.65	2,601.15	2,636.52	2,934.24	3,251.87	3,872.34
Food away from home:						
1994	822.30	1,089.35	1,334.07	1,820.82	2,211.78	3,383.08
1995	866.36	1,148.01	1,454.82	1,803.04	2,139.09	3,265.04
1997	850.96	1,129.49	1,408.37	1,826.26	2,208.13	3,334.44
Average	846.54	1,122.28	1,399.09	1,816.71	2,186.33	3,327.52
Alcohol:						
1994	135.15	215.61	287.46	347.42	327.07	495.08
1995	194.58	179.17	218.69	242.44	378.37	568.80
1997	127.94	189.83	255.66	319.14	362.58	562.22
Average	152.56	194.87	253.94	303.00	356.01	542.03
Domestic Service:						
1994	85.17	111.05	203.94	235.13	310.43	489.65
1995	111.01	126.23	166.25	343.84	349.86	473.43
1997	135.46	140.64	173.64	179.50	271.20	557.40
Average	110.55	125.97	181.28	252.82	310.50	506.83
Furnishings & household operations:						
1994	1,128.53	1,178.62	1,521.80	1,938.32	2,574.21	4,075.65
1995	1,109.71	1,246.51	1,649.53	1,999.62	2,229.32	4,360.44
1997	1,142.56	1,394.61	1,559.08	2,066.86	2,519.05	4,160.24
Average	1,126.93	1,273.25	1,576.80	2,001.60	2,440.86	4,198.78
Clothing:						
1994	790.15	1,079.54	1,464.58	1,672.99	1,890.64	3,188.54
1995	923.98	1,186.11	1,469.03	1,658.21	2,075.29	3,128.63
1997	771.06	1,183.65	1,363.48	1,772.40	1,778.08	3,041.32
Average	828.4	1,149.77	1,432.36	1,701.20	1,914.67	3,119.50
Recreation:						
1994	828.97	1,060.46	1,342.40	1,741.22	2,128.85	3,451.76
1995	988.13	1,015.06	1,357.80	1,942.08	2,113.61	3,445.93
1997	924.79	1,174.72	1,414.87	1,672.88	2,223.76	3,794.38
Average	913.96	1,083.41	1,371.69	1,785.39	2,155.41	3,564.02
Personal Care:						
1994	256.43	286.31	348.68	454.00	491.54	693.28
1995	272.68	299.08	362.99	450.49	541.39	685.06
1997	329.05	402.15	497.08	593.70	571.42	836.32
Average	286.05	329.18	402.92	499.40	534.78	738.22
Tobacco:						
1994	222.20	250.93	280.57	340.50	295.12	278.18
1995	198.73	275.38	309.00	324.43	274.74	297.88

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	$10,000 to $14,999	$15,000 to $19,999	$20,000 to $29,999	$30,000 to $39,999	$40,000 to $49,999	$50,000 and over
1997	248.16	271.68	263.44	320.89	286.42	287.99
Average	223.03	266.00	284.34	328.61	285.43	288.02
Professional Services:						
1994	500.25	637.86	633.16	890.46	999.00	1,340.74
1995	469.90	580.55	688.53	1,007.96	986.83	1,193.04
1997	440.86	662.03	705.14	881.45	1,206.84	1,317.38
Average	470.34	626.81	675.61	926.62	1,064.22	1,283.72
Housing:						
1994	5,231.62	5,948.47	6,764.14	7,878.29	9,000.79	12,785.95
1995	5,523.22	6,036.42	6,602.85	8,126.79	9,423.94	13,031.92
1997	5,600.14	6,512.21	7,049.74	8,407.00	10,626.32	13,497.32
Average	5,451.66	6,165.70	6,805.58	8,137.36	9,683.68	13,105.07
Transportation:						
1994	2,757.80	4,313.27	5,598.36	6,010.98	8,886.15	10,415.29
1995	3,326.35	4,016.68	5,281.03	6,411.15	7,505.49	10,725.91
1997	3,145.83	4,234.05	5,248.86	7,139.14	8,443.90	10,957.66
Average	3,076.66	4,188.00	5,376.08	6,520.42	8,278.51	10,699.62
Private transportation:						
1994	2,560.05	4,021.24	5,343.02	5,696.30	8,493.93	9,583.58
1995	3,141.90	3,812.35	5,051.61	6,087.00	7,181.50	9,948.58
1997	2,996.28	4,017.36	4,992.24	6,851.42	8,086.29	10,183.37
Average	2,899.41	3,950.32	5,128.96	6,211.57	7,920.57	9,905.18
Air fares & other transportation expenses:						
1994	197.75	292.03	255.34	314.68	392.22	831.71
1995	184.45	204.33	229.42	324.15	323.99	777.33
1997	149.55	216.69	256.62	287.72	357.61	774.29
Average	177.25	237.68	247.13	308.85	357.94	794.44
Miscellaneous:						
1994	2,574.86	3,285.99	4,378.03	6,077.48	7,606.33	13,486.24
1995	2,572.70	3,626.25	4,410.77	5,771.32	7,520.24	13,325.24
1997	2,586.22	3,756.39	4,956.00	5,797.64	7,733.97	13,397.80
Average	2,577.93	3,556.21	4,581.60	5,882.15	7,620.18	13,403.09
Education, K–12, Private:						
1994	7.13	47.92	41.54	58.93	79.83	216.02
1995	38.05	9.99	45.96	39.93	75.34	252.12
1997	13.92	32.62	113.72	60.22	115.60	222.99
Average	19.70	30.18	67.07	53.03	90.26	230.38
Health care:						
1994	1,484.32	1,666.38	1,578.60	1,761.97	2,007.63	2,447.22
1995	1,485.92	1,612.11	1,724.73	1,666.17	1,959.98	2,329.26
1997	1,562.88	1,830.30	1,917.78	1,819.54	2,052.42	2,434.81
Average	1,511.04	1,702.93	1,740.37	1,749.23	2,006.68	2,403.77
Cash contributions:						
1994	396.39	455.67	771.77	1,049.71	1,005.01	2,428.04
1995	452.91	804.69	730.13	816.26	1,046.00	2,171.79
1997	380.68	827.79	998.84	841.16	1,176.10	1,934.48
Average	409.99	696.05	833.58	902.38	1,075.70	2,178.10
Personal insurance:						
1994	687.02	1,116.02	1,986.12	3,206.87	4,513.86	8,394.96
1995	595.82	1,199.46	1,909.95	3,248.96	4,438.92	8,572.07
1997	628.74	1,065.68	1,925.66	3,076.72	4,389.85	8,805.52
Average	637.19	1,127.05	1,940.58	3,177.52	4,447.54	8,590.85
Consumer units:						
1994	9,780	7,851	13,975	10,922	8,280	20,609
1995	8,725	7,724	12,643	10,648	8,191	20,952
1997	9,096	7,424	12,415	10,392	7,949	24,635
Percentage of Owners with Mortgage:						
1994	14%	17%	31%	44%	53%	68%
1995	14%	24%	31%	42%	52%	70%
1997	14%	20%	26%	40%	51%	68%
Percentage of Renters:						
1994	49%	47%	42%	34%	25%	15%
1995	49%	43%	39%	35%	26%	13%
1997	47%	43%	42%	38%	28%	15%
Owners with Mortgages as Percentage of Renters Plus Owners with Mortgages:						
1994	22.22%	26.56%	42.47%	56.41%	67.95%	81.93%
1995	22.22%	35.82%	44.29%	54.55%	66.67%	83.78%
1997	22.95%	31.75%	38.24%	51.28%	64.56%	81.57%
Average	22.46%	31.38%	41.67%	54.08%	66.39%	82.43%
Renters as Percentage of Renters Plus Owners with Mortgages:						

PRE-PUBLISHED DATA FOR ALL CONSUMER UNITS NATIONWIDE*—Continued

	$10,000 to $14,999	$15,000 to $19,999	$20,000 to $29,999	$30,000 to $39,999	$40,000 to $49,999	$50,000 and over
1994	77.78%	73.44%	57.53%	43.59%	32.05%	18.07%
1995	77.78%	64.18%	55.71%	45.45%	33.33%	16.22%
1997	77.05%	68.25%	61.76%	48.72%	35.44%	18.43%
Average	77.54%	68.62%	58.33%	45.92%	33.61%	17.57%

*Data may not be statistically significant.

Appendix 5—Item Descriptions

Accounting services—Hourly rate for individual tax work (not business). Obtain rate for preparing Federal 1040 and Schedule A tax forms with typical itemized deductions. Price separately and note in comments the charge for preparing equivalent State or local tax forms.

Apples, fresh—Price per lb of apples, loose (not in bag). If only bagged apples are available, report the weight of the bag. Use: Red delicious, Golden delicious.

Area rug—Catalog Item. 8 × 11 braided rug, 100% wool or wool blend. Include shipping and handling. Use: JC Penney.

ATV—All terrain sports vehicle with 4-wheel drive and a 250 to 300 CC (approximate size) engine. Do not price industrial ATVs (similar to sports model but heavier duty) or Arctic Cat models. Use: Honda TRX399FW, Suzuki 250LT4WDT, Polaris W968040.

Automobile finance—Interest rate for a 4-year loan based on a down payment of 20 percent. Assume the loan applicant is a current bank customer who will make payments by cash/check and not by automatic deduction from the account.

Baby food—4 oz jar strained vegetables or fruit. Use: Gerber Second Foods, Heinz.

Babysitter—Use minimum hourly wage appropriate to area.

Bacon, sliced—16 oz (1 lb) package USDA grade, regular sliced bacon. Do not price Canadian bacon, extra thick sliced, or extra lean. Use: Oscar Mayer, Hormel, Armour.

Baking dish—8″ square glass baking dish (any color), no cover or lid. Use: Pyrex, Anchor Hocking.

Bananas, fresh—1 lb of bananas. If sold by bunch, report price and weight of bunch. Use: Available Variety.

Basic cable service—Rate for one month of lowest level of service for cable TV. Report the number of channels offered. If service provides 12 or fewer channels, price the next level of service. Do not include hookup charges or premium (*e.g.,* movie) channels. Convert monthly cost to price per channel, per month.

Bath towel—Catalog Item. 27 × 50″ bath towel made of 100% cotton. Include shipping and handling. Use: JC Penney Fieldcrest Royal Velvet.

Bathroom caulking—5.5 oz plastic tube (not caulking gun type) of latex white bathroom caulking. Use: DAP Kwik Seal, Red Devil.

Bed sheet set—Catalog Item. One flat queen-size no iron cotton/polyester percale sheet (200 thread count). Include shipping and handling. Use: JC Penney Home Collection.

Bedroom set—Catalog Item. Five-piece oak bedroom set; vertical mirror, triple dresser, five-drawer chest, nightstand, full/queen headboard. Include shipping and handling. Use: JC Penney.

Beer at home—Six-pack of 12 oz cans (Puerto Rico—10 oz cans). Do not price refrigerated beer unless that is the only type available. Use: Budweiser.

Beer away—One glass of Budweiser/Miller Lite beer. Use: Same restaurant where dinner price is obtained.

Board game—Do not price deluxe edition. Use: Monopoly, Sorry, Scrabble.

Book—Store price (not publisher's price unless that is the store price) for top selling paperback. Use: Special Delivery, Cold Mountain, Devine.

Bottled water—One gallon (128 fl oz) bottled spring water. Do not price sparkling or distilled water. Use: Store brand.

Bowling—One game of open (or non-league) 10-pin bowling on Saturday night. Exclude shoe rental. If priced by the hour, report the estimated number of games per hour. Do not price duck-pin bowling.

Boy's jeans—Regular fit (size 9–14), inexpensive jeans. Do not price bleached, stone-washed, or designer jeans. Use: Wrangler, Rustlers.

Boy's polo shirt—Knit polo shirt with collar, solid color, preferably without embroidered emblem. Size 7–14. Price department store brand not Izod, Polo or equivalents. Use: JC Penney, Sears.

Boy's t-shirt—Screen-printed t-shirt commonly worn by boys ages 8 thru 10 (size 7–14). Pullover with crew neck, short sleeves and polyester/cotton blend. Use: Ocean Pacific, Team Shirts (NFL), Miller.

Bread, white—16 oz loaf of sliced white bread. Do not price store brand. Use: Wonder, Sunbeam.

Breakfast—One breakfast consisting of 2 strips of bacon or 2 sausages, 2 eggs, toast, and coffee or juice. Report percentages added for tax. Use: Denny's, Holiday Inn type, IHOP type.

Broker rental low—Monthly rent for three room, one bedroom, one bath apartments (average size roughly 600 sq ft.). Obtain three price estimates of the prevailing range of rental rates in area (low, median & high). To the extent practical, obtain square footage, age of the unit, total room count, whether utilities are included, and special amenities.

Broker rental mid—Monthly rent for four room, two bedroom, one bath apartments (average size roughly 900 sq ft.). Obtain three price estimates of the prevailing range of rental rates in area (low, median & high). To the extent practical, obtain square footage, age of the unit, total room count, whether utilities are included, and special amenities.

Broker rental upr—Monthly rent for four room, two bedroom, two bath townhouse or detached house (average size roughly 1100 sq ft.). Obtain three price estimates of the prevailing range of rental rates in area (low, median & high). To the extent practical, obtain square footage, age of the unit, total room count, whether utilities are included, and special amenities.

Camera film—35 millimeter, 24 exposure, 100 ASA Kodak camera film in single pack. Use: Kodak, Fuji.

Candy bar—One regular size candy bar. Weight could range from 1.55 oz to 2.13 oz. Do not price king-size or multi-pack candy bars. Use: Snickers, Hersheys, Mars.

Canned soup—One can Campbell's soup, regular size (approximately 10 oz). Do not price hearty, reduced fat or salt free varieties. Use: Campbell's Vegetable, Campbell's Chicken Noodle.

Celery, fresh—Price per pound for celery. Do not price celery hearts or Pascal type celery. If celery is sold only by the bunch, report the price and the weight of an average bunch. Find equivalent size bunches at each store. Use: Available Brand.

Cereal—20 oz box of cereal. Do not price significantly larger or smaller size. Use: Post Raisin Bran, Kellogg's Raisin Bran.

Charge card annl fee—Annual fee on major charge card through local bank. Note: Finance charges are reported as Charge Card Finance (see item description immediately below). Both charges must be obtained for the same card. Use: Mastercard, Visa.

Charge card finance—Finance charges on a major charge card through a local bank. Record Annual Percentage Rate. Report the financial charge on the first month's balance of $1500. Do not include principal payments. Note: Annual fees are reported as a Charge Card Annual Fee (see item description immediately above). Both charges must be for the same card. Do not price special introductory rates. Use: Mastercard, Visa.

Cheddar cheese—10 oz package cheese. Price mild cheddar if available. Use: Kraft, Cracker Barrel, Tillamook.

Chevy AFT change—Automatic transmission fluid change for a 1-year-old Chevrolet Blazer, similar to current year model. Include parts and labor for the following: Drain and replace transmission fluid and test vehicle. Include filter and pan gasket replacement.

Chevy blazer—Chevrolet Blazer, current year model, T-Series, 2-door, 4-wheel drive, 4.3 liter, 6 cylinder. Use: Chevrolet Blazer T10.

Chevy coolant serv—Flush and fill engine coolant in a 1-year-old Chevrolet Blazer, similar to current year model. Include parts and labor for the following: Remove old

coolant, flush contaminants, and replace with new coolant.

Chevy CVJ boots—Replacement cost of the inner and outer CVJ (constant velocity joint) boots on both front wheels for a 3-year old Chevrolet Blazer, T-Series, 2-Door, 4-wheel drive, 4.3 liter, 6 cylinder.

Chevy license/reg—Title fee, lien fee, passenger vehicle registration fees, plate fees, administration/clerical/other fees, and any local added fees for a current year Chevrolet Blazer, T-Series, 2-door, 4-wheel drive, 4.3 liter, 6 cylinder.

Chevy min insurance—DC AND VI ONLY. Assume that vehicles are used in commuting 15 miles one-way per day, 15,000 miles per year, and that the driver is a 35-year-old married male with no accidents or violations in the last 5 years. Include related fees and taxes. Include applicable safety feature discounts. COVERAGES (BI minimum avail., PD minimum, Med minimum or PIP minimum, and UM minimum. Com 250 deductible. Col 500 ded. If these deductibles are not avail., price the policy with the closest coverage.

Chevy misc taxes—Annual miscellaneous tax (*e.g.,* personal property tax, use tax, etc) for a current year model Chevrolet Blazer, T-Series, 2-door, 4-wheel drive, 4.3 liter, 6 cylinder. Report how rate is determined and formula for new vehicle purchase and for subsequent years (2 to 5). Explain billing.

Chevy muffler—Complete muffler system for a 4-year-old Chevrolet Blazer, T-Series, 2-door, 4-wheel drive, 4.3 liter, 6 cylinder. Include parts and labor for the following: Install all parts after the catalytic converter. These parts include mid pipes, clamps, muffler, and tail pipes.

Chevy oil change—Oil change for a 1-year-old Chevrolet Blazer, T-Series, 2-door, 4-wheel drive, 4.3 liter, 6 cylinder. Include parts and labor for the following: Drain old oil, replace oil filter and refill with appropriate number of qts of 10W30 SG grade oil. If SG grade not available, price SF grade oil.

Chevy reg insurance—Assume that vehicles are used in commuting 15 miles one-way per day, 15,000 miles per year and that the driver is a 35-year-old married male with no accidents or violations in the last 5 years. Include related expense fees and taxes. Include applicable safety feature discounts. COVERAGES (BI 100/300,000 PD 25,000 Med 15,000 or PIP 50,000 UM 100/300,000. Com 100 deductible. Col 250 deductible.). If these deductibles are not available, price the policy with the closest coverage.

Chevy regular tires—Black side wall tires size P205/75R15 for Chevrolet Blazer. Use: Goodyear Wrangler AT, Michelin XCHF, BF Goodrich Radial TA.

Chevy snow tire—Studded snow tire size P205/75R15 for the Chevy Blazer. Use: Goodyear Ultra Grip, Michelin XM+S ALPIN, BF Goodrich Trailmaker Plus.

Chevy tire change—Remove street tire and mount snow tire. Model adjusts for 4 tires.

Chevy tune-up—Basic tune-up for a 1-year-old Chevrolet Blazer. Include replacing spark plugs (do not price platinum), check distributor cap, and rotor. Check and adjust ignition timing, adjust idle, inspect air cleaner. Do not include cost to replace PVC valve, fuel filter or air filter. Sales tax should not be included in price.

Chevy 4-yr value—Retail value of a 4-year-old Chevrolet Blazer.

Chevy windshield rpl—Windshield replacement on 1-year-old Chevy Blazer. Ask outlet about the frequency of windshield replacement and record in comments. Price at specialty shop or, if not available, at car dealer.

Chicken, whole—Price per pound of USDA grade fresh whole fryer chicken. Price store brand if available, otherwise record brand. Do not price family-pack, value-pack, super-saver pack or equivalent; frozen chicken or roasters. Use: Whole fryer.

China—Corelle Abundance pattern tableware set consisting of 20 pieces: 4 dinner plates, 4 luncheon plates, 4 bowls, 4 cups, and 4 saucers. The pattern is beige with a fruit and flower motif. Use: Corelle Impressions, New Corelle.

Cigarettes king size—One soft pack of filter kings. Do not price generic brand. Use: Winston, Marlboro, Salem.

Coffee, ground—13 oz can ground coffee. Do not price decaffeinated or special roasts. Use: Folger's, Maxwell House, Hills Bros.

Coin laundry—One regular-size load of laundry using top loading commercial washing machine. Do not include cost of drying.

Color television—20″ table model color TV with a remote, auto channel search, closed captions, sleep timer, on-screen channel/time and menus, channel flashback, and 181 channel tuning. Use: Sony KV20S40, JVC AV20820, Panasonic CT20G23, or brand equivalents.

Compact disc—Current best-selling CD. Do not price double CDs. Use: Armageddon Soundtrack, Backstreet Boys, Come On Over.

Compact disc player—5-disc CD player with rotary changer system, 10 key access, 32 track programming, 8 times over sampling, and a remote. Use: Sony CDP-CE315, JVC XLF254BK, Technics SL–PD888.

Contact lenses—1-year supply of soft 2-week replacement contact lenses. Use: Medalists, Sequence, AcuVue.

Cookies—18 or 20 oz package. Use: Nabisco Oreo Cookies, Keebler Chips Deluxe, Nabisco Chips Ahoy.

Cooking oil—48 fl oz bottle. Use: Crisco, Wesson.

Day-care—One month of day-care for a 3-year-old child (5 days a week, about 10 hours per day). If monthly rate is not available: (1) Obtain weekly rate and record in the comment section (2) multiply weekly rate by 4.33 to obtain monthly rate. Price at day care center in a Federal building (but not on a military base) if available.

Dentist clean/check—Rate for x-rays, exam and prophylaxis (light scaling and polishing) or cleaning of teeth without special treatment of gums or teeth. Do not price initial visit. Do not price specialist or oral surgeon.

Dining table—Catalog Item. Pedestal oak veneer tabletop with 4 standard spindled hardwood chairs. Include shipping and handling. Use: JC Penney.

Dinner—One dinner consisting of a New York strip steak, small side dish (*e.g.,* rice or potato), side salad or salad bar, and coffee. Meal should not include dessert. Use: Denny's type, TGIF type, Chart House type.

Disposable diaper—34 count package of Stage 2 disposable diapers (child 12–18 lbs). Do not price jumbo, overnight, or larger size diapers. Use: Pampers, Huggies.

Doctor office visit—Typical fee for an office visit with patient's regular physician when medical advice or simple treatment is needed. Do not include the charge for a regular physical examination, injections, medication or lab tests (routine brief visit). Price general practitioner, not specialist.

Drill, cord-type—3/8″ reversible, variable speed, 3 amp (1200 rpm. max) electric drill with 6' cord. Price a typical homeowner's drill. Do not price Dewalt, Milwaukee, or similar brands used by professionals. Use: Black & Decker 7152, Makita 6406, Skil 6340.

Drill, cordless—3/8″ reversible, variable speed, 7 to 9 volt, cordless electric drill with 3-hour recharge. Price a typical homeowner's drill. Do not price Makita, Dewalt, Milwaukee, or similar brands used by professionals. Use: Skil 2380 and 2375.

Dry clean man's suit—2-piece man's suit of typical fabric. Do not price for silk, suede or other unusual materials.

Education, K–12 priv—Tuition rate, books and uniforms (if required) for K–12 education at a private school.

Eggs, large—One dozen. Do not price brown eggs. Use: Local brand, Regional brand, non-local brand.

Electric bill—Average monthly cost including any additional charges. Record the average monthly consumption in KWH, cost for first xxx KWH, and cost over xxx KWH. If monthly amounts vary based on time of year, obtain data on annual basis. In Alaska (except Juneau) assume oil or gas for heating. In all other areas, assume all electric homes.

Electrical outlet—2-plug 15-amp (duplex) grounded electrical outlet. Note: This is a standard wall outlet or plug commonly found in homes. Price single blister pack or cardboard mounted package, and a loose electric outlet or 20 amp outlet. Use: GE, Levitron, Eagle.

Electrical work—Labor cost per hour to add circuit breaker for dishwasher. Description: Cut 3/4″ hole in wooden floor for cable and connect dishwasher directly to power box (power box is easy to reach). Obtain estimated time for job and travel. Exclude cost of materials. Ask whether outlet is a licensed contractor.

Fast food—Hamburger meal consisting of Big Mac, medium french fries, and medium soft drink. Pizza meal consisting of personal size cheese pizza (or one slice of cheese pizza) and small soft drink. Do not include salad. Report percentages added for tax. Use: McDonald's type and Pizza Hut type.

Film developing—Cost to process and print 35 millimeter, 24 exposure, 100 ASA color. Regular size (3 x 5) single prints only. Price at local lab with 2–3 day service. Do not price Kodak or mail order service.

Fire extinguisher—Fire extinguisher with a UL rating of 10 BC, 2.5 pound size. Do not price an ABC type extinguisher. Use: Kidde, First Alert.

Fish filet, frozen—Price per pound of frozen ocean whitefish filet. Do not price breaded filets. Do not price family-pack, value-pack, super-saver pack or equivalent. Use: Cod, Haddock, Snapper.

Fish, fresh—Price per pound of salmon steak. Do not price previously frozen (PF) or specially prepared skinless or boneless varieties. Do not price family-pack, value-pack, super-save pack, or equivalent. Use: Salmon steak.

Ford ATF change—Automatic transmission fluid change in a 1-year-old Ford. Include parts and labor for the following: Drain and replace transmission fluid and test vehicle. Include filter and pan gasket replacement.

Ford coolant serv—Flush and fill engine coolant in a 1-year-old Ford Taurus similar to current year model. Include parts and labor for the following: Remove old coolant, flush contaminants, and replace with new coolant.

Ford CVJ boots—Replacement cost of the inner and outer CVJ Boots (constant velocity joint) on both front wheels for a 3-year-old Ford Taurus GL 4-door sedan, 3.0 liter, 6 cylinder.

Ford license/reg—Title fee, lien fee, passenger vehicle registration fees, plate fees, administration/clerical/other fees and any local added fees for a current year Ford Taurus GL 4-door sedan, 3.0 liter, 6 cylinder.

Ford min insurance—DC AND VI ONLY. Assume that vehicles are used in commuting 15 miles one-way per day, 15,000 miles per year and that the driver is a 35-year-old married male with no accidents or violations in the last 5 years. Include related fees and taxes. Include applicable safety feature discounts. COVERAGES (BI minimum avail., PD minimum, Med minimum or PIP minimum, and UM minimum. Com 250 deductible. Col 500 deductible.) If these deductibles are not available, price the policy with the closest coverage.

Ford misc taxes—Annual miscellaneous tax (*e.g.,* personal property tax, use tax, etc) for a current year model Ford Taurus. Report how rate is determined, give formula for new vehicle purchase and for subsequent years (2 to 5). Explain billing.

Ford muffler—Complete muffler system for a 4-year-old Ford Taurus. Include parts and labor for the following: Install all parts after the catalytic converter. These parts include mid pipes, clamps, muffler, and tail pipes.

Ford oil change—Oil change for a 1-year-old Ford Taurus. Include parts and labor for the following: Drain old oil, replace oil filter and refill with appropriate number of quarts of 10W30 SG grade oil. If SG grade not available, price SF grade oil.

Ford reg insurance—Assume that vehicles are used in commuting 15 miles one-way per day, 15,000 miles per year and that the driver is a 35-year-old married male with no accidents or violations in the last 5 years. Include related fees and taxes. Include applicable safety feature discounts COVERAGES (BI 100/300,000 PD 25,000 Med 15,000 or PIP 50,000 UM 100/300,000. Com 100 deductible. Col 250 ded.). If these deductibles are not available, price the policy with the closest coverage available.

Ford regular tires—Black side wall tire size P205/65R15 for the Ford Taurus GL. Use: Goodyear Invicta GL, Michelin XW4, BF Goodrich Touring TA.

Ford snow tire—Studded snow tire size P205/65R15 for the Ford Taurus GL. Use: Goodyear Ultra Grip, Michelin XM+S ALPIN, BF Goodrich Trailmaker Plus.

Ford Taurus—Ford Taurus, current year model, GL 4-door sedan, 3.0 liter, 6 cylinder.

Ford Taurus—Ford Taurus, current year model, GL 4-door sedan, 3.0 liter, 6 cylinder.

Ford tire change—Remove street tire and mount snow tire. Model adjusts for 4 tires.

Ford tune-up—Basic tune-up for a 1-year-old Ford Taurus GL. Include replacing spark plugs (do not price platinum), check distributor cap, and rotor. Check and adjust ignition timing. Adjust idle speed. Inspect air cleaner. Do not include cost to replace PVC valve, fuel filter or air filter. Sales tax should not be included in price.

Ford 4-yr value—Retail value of a 4-year-old Ford Taurus.

Ford windshield rpl—Windshield replacement on 1-year-old Ford Taurus GL. Ask outlet about the frequency of windshield replacement and record in comments. Price at specialty shop or, if not available, at car dealer.

Frankfurter—16 oz (1 lb) package, all beef, USDA graded. Do not price chicken, turkey, extra lean, or fat free frankfurters. Use: Oscar Mayer, Hormel, Ball Park.

Frozen dinner—One 1.5 oz frozen turkey dinner including whipped potatoes, peas, and fruit compote. Do not price Hungry Man or equivalent extra-portion sizes. Use: Swanson.

Frozen orange juice—12 fl oz orange juice concentrate (makes 48 fl oz). Do not price calcium fortified, pulp free, country style etc. Use: Minute Maid, Sunkist.

Frozen waffles—8 to 10 waffles approximately 11 oz package. Use: Kellogg's Eggo, Aunt Jemina, Hungry Jack.

Fruit drink—64 fl oz glass or plastic bottle. Do not price powdered mixes or individual serving sized drinks. Use: Hawaiian Punch, HI-C regular.

Fruit juice—48 oz glass or plastic bottle of cranberry juice. Do not price frozen or boxed drink or drink in significantly different size bottle. Use: Ocean Spray Cranberry Cocktail, Ocean Spray Cranapple Cocktail.

Funeral services—Cost of direct cremation. Includes removal of remains, local transportation to crematory, necessary body care and minimal services of the staff. Do not include the fee for the crematory, container, or use of facilities and staff.

Gas/oil bill—ALASKA ONLY (except Juneau). Average monthly cost including all charges. Record in comments average monthly consumption in cu. ft./gallons, customer service charge, cost for first cu. ft./gallons, and cost for over first xxx cu. ft/gallons.

Gasoline full serv—Price per gallon for full-service unleaded regular gasoline. Record in comments prevalence of self-serve vs. full-serve pumps.

Gasoline self serv—Price per gallon for self-service unleaded regular gasoline.

Girl's dress—Cotton blend short or long-sleeve dress appropriate for school for ages 8 to 10 (size 7–14). Minimal ornamentation. Use: Amy Too, Disorderly Kids, Swat.

Girl's jeans—Basic plain jeans for girls ages 8 to 10 (size 7–14). Use: Lee.

Girl's knit top—Knit short or long sleeve pullover of cotton/poly blend for girls ages 8 to 10 (size 7–14). Use: Basic Edition, Route 66, One Story Up.

Golf—18 holes of golf on a weekend. Do not price par 3 courses. Do not include golf-cart rental, early-bird specials, or off-hours pricing. If only 9-hole rate is available, note and report twice. If only daily rate is available (unlimited number of holes), report the Saturday or Sunday rate. Ask if course is publicly or privately-owned and note in the comment section.

Green beans, canned—14.5 oz can of plain cut green beans. Do not price French style, Italian style, canned vegetable mixtures or similar variations. Use: Del Monte, Green Giant.

Ground beef—Price per pound of fresh USDA graded (select not choice) with no more than 30% fat content. Do not price lean, ground round, frozen beef, etc. Do not price family-pack, value-pack, super-saver pack, or equivalent. Use: Regular ground beef.

Ham, canned—3 lb tin of canned ham. Do not price Hormel's supreme cut ham or equivalent. Use: Hormel, Dubuque, Bar–S.

Hamburger buns—8-count package of sliced enriched white hamburger buns. Do not price store brand, whole wheat or sesame seed buns. Use: Wonder, Sunbeam, Regional brand.

Hammer—Curved claw hammer with a 16 oz head, wood handle, high carbon steel head, black finish. Overall length 13 1/4''. This is a typical homeowner's hammer. Do not price hammers with non-wooden handles or those typically used by carpenters or cabinet makers. Use: Stanley 51616, Sears Craftsman 38312.

Health club—Regular individual membership for 1 year for existing member. Do not include any initial fees assessed only to new members or any special offers provided only to new members. If yearly rate is not available, price per month and note as such. Minimum services must include free weights, cardiovascular equipment, and aerobic classes. Note if pool, tennis, racquet ball, or other significant services are also offered.

Home sale low—Obtain comparable sales between 600 and 1200 square feet. Collect selling price, sale date, and square footage for each comparable. Collect age and room count when available. Obtain data for the most recently available 12 month time frame. 4 rooms, 2 BR, 1 bath; condo or detached house.

Home sale mid—Obtain comparable sales between 1000 and 1600 square feet. Collect selling price, sale date, and square footage for each comparable. Collect age and room count when available. Obtain data for the most recently available 12 month time frame. 5 rooms, 3 BR, 1 bath; detached house.

Home sale upr—Obtain comparable sales between 1400 and 2300 square feet. Collect selling price, sale date, and square footage for each comparable. Collect age and room count when available. Obtain data for the most recently available 12 month time frame. 7 rooms, 3 BR, 2 baths; detached house.

Homeowner insur low—Annual renewal premium for HO–2 type coverage. If the company does not refer to the coverage as HO–2, obtain the cost for a comprehensive coverage that covers all risk for dwelling and named peril as required by mortgage companies in the area for contents with

contents at replacement value. as required by mortgage companies in the area.

Homeowner insur mid—Annual renewal premium for HO–2 type coverage. If the company does not refer to the coverage as HO–2, obtain the cost for a comprehensive coverage that covers all risk for dwelling and named peril as required by mortgage companies in the area for contents with contents at replacement value.

Homeowner insur upr—Annual renewal premium for HO–2 type coverage. If the company does not refer to the coverage as HO–2, obtain the cost for a comprehensive coverage that covers all risk for dwelling and named peril as required by mortgage companies in the area for contents with contents at replacement value.

Honda ATF change—Automatic transmission fluid change in a 1-year-old Honda Civic DX. Include parts and labor for the following: Drain and replace transmission fluid and test vehicle.

Honda civic—Honda Civic current year model, DX 4-door sedan, 1.5 liter, 4 cylinder.

Honda coolant serv—Flush and fill engine coolant in a 1-year-old Honda Civic DX. Include parts and labor for the following: remove old coolant, flush contaminants, and replace with new coolant.

Honda CVJ boots—Replacement cost of the inner and outer CVJ (constant velocity joint) boots on both front wheels for a 3-year-old Honda Civic DX 4-door sedan, 1.5 liter, 4 cylinder.

Honda license/reg—Title fee, lien fee, passenger vehicle registration fees, plate fees, administration/clerical/other fees and local added fees for a current year Honda Civic DX 4-door sedan, 1.5 liter, 4 cylinder.

Honda min insurance—DC AND VI ONLY. Assume that vehicles are used in commuting 15 miles one-way per day, 15,000 miles per year and that the driver is a 35-year-old married male with no accidents or violations in the last 5 years. Include related fees and taxes. Include applicable safety feature discounts. COVERAGES (BI minimum avail., PD minimum, Med minimum or PIP minimum, and UM minimum. Com 250 deductible Col 500 deductible.) If these deductibles are not available, price the policy with the closest coverage.

Honda misc taxes—Annual miscellaneous tax (*e.g.*, personal property tax, use tax, etc.) for a current year model Honda Civic DX 4-door sedan, 1.5 liter, 4 cylinder. Report how rate is determined and give formula for new vehicle purchase and for subsequent years (2 to 5). Explain billing.

Honda muffler—Complete muffler system for a 4-year-old Honda Civic DX . Include parts and labor for the following: install all parts after the catalytic converter. These parts include mid pipes, clamps, muffler, and tail pipes.

Honda oil change—Oil change for a 1-year-old Honda Civic DX. Include parts and labor for the following: drain old oil, replace oil filter and refill with appropriate number of quarts of 10W30 SG grade oil. If SG grade not available, price SF grade oil.

Honda reg insurance—Assume that vehicles are used in commuting 15 miles one-way per day, 15,000 miles per year and that the driver is a 35-year-old married male with no accidents or violations in the last 5 years. Include related fees and taxes. Include applicable safety feature discounts. COVERAGES (BI 100/300,000 PD 25,000 Med 15,000 or PIP 50,000 UM 100/300,000. Com 100 deductible. Col 250 deductible.) If these deductibles are not available, price the policy with the closest coverage.

Honda regular tires—Black side wall tire size P175/70R13 for the Honda Civic. Use: Goodyear Invicta GL, Michelin LX1, BF Goodrich Touring TA.

Honda snow tire—Studded snow tire size P175/70R13 for Honda Civic DX. Use: Goodyear Ultra Grip, Michelin XM+S ALPIN, BF Goodrich Trailmaker Plus.

Honda tire change—Remove street tire and mount snow tire. Model adjusts for 4 tires.

Honda tune-up—Basic tune-up for a 1-year-old Honda Civic DX. Include replacing spark plugs (do not price platinum), check distributor cap, and rotor. Check and adjust ignition timing. Adjust idle speed. Inspect air cleaner. Do not include cost to replace PVC valve, fuel filter or air filter. Sales tax should not be included in price.

Honda 4-yr value—Retail value of a 4-year old Honda Civic DX.

Honda windshield rpl—Windshield replacement on 1-year-old Honda Civic DX. Ask outlet about the frequency of windshield replacement and record in comments. Price at specialty shop or, if not available, at car dealer.

Hospital attendant—Nightly charge for an attendant (*e.g.* LPN). Price only if typical hospital service is not equivalent to that found in DC area.

Hospital room—Nightly charge for a semi-private room. Include food and routine care. Does not include cost of operating room, surgery, medicine, lab fees, etc. Do not price speciality rooms, *e.g.*, those in cardiac care units.

Housekeeping service—Job rate for twice per month cleaning. HOUSE: approximately 2,000 sq. ft., family of four (2 adults, 2 children), no pets. Includes 1.5 bathrooms—clean floor, counter, bathtub, toilet. Kitchen—clean floor, counter, cabinets, sink. Living and dining room—dust furniture and vacuum. Two bedroom—dust furniture and vacuum. Note any other routine services and estimated number of hours to complete service. Exclude initial house cleaning service. Ask if price varies if ranch-style or two-story type house (latter would include vacuuming stairs).

Ice cream—½ gallon (2 qts) of vanilla ice cream. Do not price ice milk or frozen yogurt. Use: Store brand.

Ice cream cone—Regular (one scoop) vanilla ice cream on cone. Do not price frozen yogurt or soft-serve ice cream. Use: Baskin-Robbins type, Lapperts type.

Infant's sleeper—One-piece sleeping garment with legs, covering the body including the feet. Use: Gerber, Playskool, Sesame Street.

Insurance, air ambul—Annual premium for air ambulance insurance for family of four.

Interior painting—Job rate to repaint living room (one coat over same color)—12′ x 14′ with 8′ ceiling, 2 standard-sized sash windows, 1 standard-size door. Walls are drywall in good repair with simple wood baseboards and moulding (no crown moulding). Existing paint is flat-white latex, smooth finish, about 3 years old. Trim paint is gloss-white latex enamel, also 3 years old. No surface prep required. Include time estimate for job and travel costs. If only hourly rate available, obtain time estimate. Do not include materials.

Jello gelatin—3 oz box gelatin dessert. Use: Jello, Royal.

Jewelry—One pair 6mm 14K gold ball earrings for pierced ears.

Ketchup—28 oz plastic squeeze bottle. Use: Heinz.

Kitchen faucet—Single control chrome-plated faucet with spray. Solid brass and stainless steel with copper waterways, triple chrome plating, and washerless design. Sprayer sits in a separate hole in the sink. Do not price decorator models. Guaranteed for 2 years or longer. Use: Peerless 8500–ECP, Delta 400, Moen 87511.

Kitchen range—30″ wide electric range. Features: Upswept cook-top, removable coil elements, electronic clock with timer, oven light, delay-start cook control, storage drawer, glass front with see-thru window, self-cleaning oven with two oven racks and a porcelain enamel broiler pan. Use: Maytag MER5530, General Electric JBP26BYWH.

Latex interior paint—One gallon flat-white interior latex paint. Price a national brand with one coat coverage. Use: Dutch Boy, Glidden, Benjamin Moore, Pittsburgh.

Laundry soap—100 fl oz of liquid household laundry detergent. Do not price detergent with bleach or whiteners. Use: Tide, Cheer, Wisk.

Lawn care service—Cut and trim a ¼ acre lot on a weekly basis. Do not include any other yard services (*e.g.* fertilizing, raking, or watering).

Lawn trimmer—Gas powered 31 CC two-cycle engine, dual feed line, 16 to 17'' wide cut. Bump or semi-automatic line feed.

LD call Chicago—Cost of a 10 minute call using AT&T, received in Chicago (use Chicago time) on a weekday at 8:00 p.m.; direct dial from the location being surveyed. Include any Federal, State, local, or excise tax that is applicable. Use: AT&T Regional Service.

Ld call LA—Cost of a 10 minute call using AT&T, received in Los Angeles (use LA time) on a weekday in LA at 8:00 p.m.; direct dial from the location being surveyed. Include any Federal, State, local, or excise tax that is applicable. Use: AT&T Regional Service.

Ld call NYC—Cost of a 10 minute call using AT&T, received in New York (use NY time) on a weekday at 8:00 p.m.; direct dial from the location being surveyed. Include any Federal, State, local, or excise tax that is applicable. Use: AT&T Regional Service.

Legal services—Hourly rate for preparing a simple will or trust. Obtain lawyer fee, not paralegal.

Lettuce, fresh—Price per pound of iceberg lettuce. If sold by the head, report the price and weight of an average head. Find equivalent-size heads at each store. Use: Available Brand.

Lipstick—One tube of lipstick. Use: Revlon Super Lustrous, Revlon Moondrops.

Living room chair—Catalog Item. Flexsteel rocker/recliner. Include shipping and handling. Use: JC Penney.

Lunch—One lunch consisting of a cheeseburger platter with fries and small soft drink. Use: Denny's type, TGIF type, Chart House type.

Lunch meat—8 oz pkg. Do not price all beef variety. Use: Oscar Mayer Bologna, Oscar Mayer Cotto Salami.

Magazine—Store price (not publisher's price unless that is the store price) for a single copy. Use: Time, Newsweek, US News & World Report.

Man's boots—ALASKA AND DC ONLY. 8″ shaft, waterproof leather upper, padded collar (top of shaft), Cambrelle lining, insulated, rubber lug-type sole. Do not price steel toe. Use: Timberland, Sorel, Wolverine.

Man's dress shirt—White or solid color, long sleeve, button cuff, plain collar dress shirt, approximately 35% cotton, 65% polyester. Use: Arrow, Van Heusen, Moose Creek.

Man's haircut—Typical haircut. Do not include wash.

Man's jacket—Catalog Item. TROPICAL AND DC ONLY. Summer weight denim jacket. Relaxed fit and machine washable. Include shipping and handling. Use: JC Penney, Lands' End, L.L. Bean.

Man's jeans—Regular loose fit, non-designer jeans. Do not price bleached, stone-washed or designer jeans. Use: Wrangler, Rustlers.

Man's Parka—Catalog Item. ALASKA AND DC ONLY. Water resistant nylon-outer shell, insulated, nylon lining, removable hood, multiple pockets, drawstring waist. Machine washable. Include shipping and handling. Use: JC Penney, Lands' End, L.L. Bean.

Man's shoes—100% leather wing tips or plain toe. Remaining parts are man-made materials. Lightweight with rubber/EVA sole. Use: Rockport, Bostonian.

Man's suit—Catalog Item. Double-breasted worsted wool, ventless back. Include shipping and handling. Use: JC Penney, Bachrach.

Man's undershirt—White 100% cotton undershirts with short sleeves, set of three. If not in set of three, report the number per package. Use: Fruit of the Loom, Hanes, Northwest Territory.

Margarine—1 lb (4 sticks) regular margarine. Do not price reduced fat variety. Use: Parkay, Fleishmans.

Milk, 2%—One Gallon (128 fl oz). Use: Store brand.

Mortgage interest—Current interest rate for a 30-year loan on the average house assuming 80 percent financing.

Motor scooter—Price for a 50 CC scooter. One seater with electric start, oil injection 2-stroke engine. Use: Yamaha JOG CY 50, Honda Elite SA 50.

Movie theater—Typical adult price for regular length, current-release (currently advertised on television) evening film. Report weekend evening price if different from weekday.

Moving—Hourly rate for a within-city move, two men, enclosed van. Include any van rental fees. Do not include any extra insurance options or specialty packaging options. If more than two men, note number of workers.

Non-aspirin pain rel—60 tablets of extra-strength Tylenol. Do not price caplets or gelcaps.

Non-broker rntl low—Monthly rent for 3 room, 1 BR, 1 bath apartments (average size roughly 600 sq ft.). If possible, obtain square footage, age, room count whether utilities are included and special amenities.

Non-broker rntl mid—Monthly rent for 4 room, 2 BR , 1 bath apartments (average size roughly 900 sq ft.). If possible, obtain square footage, age, room count whether utilities are included and special amenities.

Non-broker rntl upr—Obtain monthly rent for 4 room, 2 BR, 2 bath townhouse or detached house (average size roughly 1100 sq ft.). If possible, obtain square footage, age, room count whether utilities are included and special amenities.

Oranges, fresh—Price per pound of loose Valencia oranges. If only bagged oranges are available, also report the weight of the bag. Use: California Valencia, Florida Valencia.

Parcel post—Cost of mailing a 5 pound package to each of the following cities: Chicago, Los Angeles, New York Use: United States Postal.

Peaches, canned—16 oz can sliced yellow cling peaches. Do not price lite. Use: Libby, Del Monte.

Peas, frozen—16 oz package. Do not price peas with sauce or Green Giant Select. Use: Green Giant, Birdseye, Hanover.

Pen—10-count package round stick medium pen. Use: Bic Round Stic, Paper Mate.

Pest control—Basic pest control maintenance (one visit to control crawling insects, not wood eating), based on the inside of a 1,200 sq. ft. single story home. Price follow-up maintenance only, not the initial application.

Pet food—5.5 oz can of cat food. Use: Purina, 9 Lives, Whiskas.

Piano lessons—Private lesson for a beginner one-half hour in length. Price through a music studio if possible.

Plant food—24 oz container of granulated indoor plant food. Use: Miracle Grow.

Pork chops, bone in—Price per pound of an average size USDA graded (select not choice) package. Do not price family-pack, value-pack, super-saver pack or equivalent. Do not price frozen chops. Use: Center cut rib chop, Loin chop with bone.

Postage stamp—First Class postage.

Potatoes—1 lb of potatoes. Use: Russet baking and No 2. White.

Real estate tax low—Current real property tax rate, any special charges that are added to the tax bill and any homestead credits that might be deducted from the bill. Report when properties were last assessed and to what base year the tax rate should be applied. Report when rates are certified and when bills are mailed.

Real estate tax mid—Current real property tax rate, any special charges that are added to the tax bill and any homestead credits that might be deducted from the bill. Report when properties were last assessed and to what base year the tax rate should be applied. Report when rates are certified and when bills are mailed.

Real estate tax upr—Current real property tax rate, any special charges that are added to the tax bill and any homestead credits that might be deducted from the bill. Report when properties were last assessed and to what base year the tax rate should be applied. Report when rates are certified and when bills are mailed.

Red roses, fresh cut—One dozen long stemmed, fresh cut red roses. Do not price boxed or arranged.

Refrigerator—No-frost top-mount 20.5 to 21.5 cubic ft. refrigerator with reversible doors, glass shelves, moisture controlled crisper drawers, and meat drawer. Door contains one or more covered compartments and adjustable bins. Freezer has adjustable wire shelves, door bins and ice trays. Do not price models with ice makers, chilled water dispensers, or other extra features. Use: Maytag MTB2154A, General Electric TBX2lIABAA.

Regional newspaper—1 year of home delivery of the largest selling daily regional paper (including Sunday edition) distributed in the area. Do not include tip. In Alaska, price the major Anchorage newspaper. In Hawaii, price the major Honolulu newspaper.

Renter insur low—HO–4 type coverage; assume value of contents at $25,000.

Renter insur mid—HO–4 type coverage; assume value of contents at $30,000.

Renter insur upr—HO–4 type coverage; assume value of contents at $35,000.

Round roast boneless—Price per pound of an average size USDA graded (select not choice) package. Do not price family-pack, value-pack, super-saver pack or equivalent. Do not price frozen roast. Use: Boneless rump, Sirloin tip rolled, Boneless top round.

Round steak boneless—Price per pound of an average size USDA graded (select not choice) package. Do not price family-pack, value-pack, super-saver pack or equivalent. Do not price frozen steak. Use: Boneless beef round, Boneless top round, Boneless bottom rnd.

Round trip Chicago—Lowest round trip ticket to Chicago, IL, with 3-week advance reservation departing and returning midweek. Disregard restrictions, super-saver fares and special promotions. (In reference area, price all flights from National Airport.)

Round trip LA—Lowest round trip ticket to Los Angeles, CA, with 3-week advance reservation, departing and returning midweek. Disregard restrictions, super-saver fares and special promotions. (In reference area, price all flights from National Airport.)

Round trip Miami—Lowest round trip ticket to Miami, FL, with 3-week advance reservation departing and returning midweek. Disregard restrictions, super-saver fares and special promotions. (In reference area, price all flights from National Airport.)

Round trip NYC—Lowest round trip ticket to New York, NY, with 3-week advance reservation departing and returning midweek. Disregard restrictions, super-saver fares and special promotions. (In reference area, price all fares from National Airport.)

Round trip Omaha—Lowest round trip ticket to Omaha, NE, with 3-week advance reservation departing and returning midweek. Disregard restrictions, super-saver fares and special promotions. (In reference area, price all flights from National Airport.)

Round trip Seattle—Lowest round trip ticket to Seattle, WA, with 3-week advance

reservation departing and returning midweek. Disregard restrictions, super-saver fares and special promotions. (In reference area, price all flights from National Airport.)

Round trip St. Louis—Lowest round trip ticket to St. Louis, MO, with 3-week advance reservation departing and returning midweek. Disregard restrictions, super-saver fares and special promotions. (In reference area, price all flights from National Airport.)

Salt—26 oz box of iodized salt. Do not price sea-salt, kosher-style salt etc. Use: Morton, Ivory, Regional Brand.

Shampoo—15 ounce bottle of shampoo for normal hair. Use: Suave, VO5, White Rain.

Snack cake—Package of two cellophane wrapped, cream-filled sponge cake deserts. Do not price fresh baked desserts, boxed, or family packs. Use: Hostess Twinkees, Krispy Kreme, Hostess Cupcakes.

Snack food—6 oz bag or box of regular potato chips. Use: Ruffles, Lays.

Soft drink—2 liter, plastic bottle. Use: Coca-Cola, Pepsi.

Spaghetti, dry—16 oz box or bag. Do not price store brand. Use: Creamette, American Beauty Mission.

Sugar, granulated—5 lb bag of granulated cane or beet sugar. Do not price superfine or generic. Use: Non-store brand, Store brand.

Telephone service—Monthly cost for unmeasured touchtone service. Include tax. Do not include options such as call waiting, call forwarding or fees for equipment rental.

Telephone, cellular—Cost of basic monthly cellular phone service plus 10 prime-time 2-minute calls per month. Do not price special offers.

Tennis balls—One can, 3 heavy-duty felt, yellow, tennis balls. Do not price special gas-filled or premium tennis balls. Use: Wilson, Penn.

Tetracycline—Price of 40 capsules of tetracycline, 250 milligram strength. Record whether generic or non-generic. If price differs record both prices in comment area.

Toilet tissue—Regular 4-roll pack. Do not price family-pack, double roll, value-pack, super-saver size package, or equivalent. Use: Cottonelle, Northern, Charmin.

Tomatoes, fresh—Price per pound of medium-size tomatoes. Do not price organic, hydro, plum, or extra fancy tomatoes. Note quality in comments. Use: Available Variety.

Tuna, canned—Chunk light, packed in water (6.0 oz to 6.13 oz). Do not price fancy style. Use: Star Kist, Chicken of the Sea, Bumble Bee.

Two-slice toaster—Two-slice toaster, chrome body, wide slot with pastry defrost setting. Use: Proctor-Silex 22425, Proctor Silex 22430.

Unclog drain—Hourly rate to unclog kitchen sink drain by mechanical means (small snake or auger, etc.). Assume clog is in the plumbing inside the house, not in the yard. Exclude extra charges such as excess travel, overtime, weekend rates or emergencies. If JOB RATE get low-end quote because this is a simple clog.

Vacuum—Upright vacuum cleaner with approximately 12 amps, 120 volts, minimum 5 above-the-floor attachments, height adjustment, regular bag and 20 to 25 foot cord. Use: Eureka 4470 and 4471, Dirt Devil Swivel Glide 86400 and 86410.

Veterinary services—Routine annual exam for a small dog (approx. 25 to 30 lbs.). No booster shots, medication, or other extras such as nail clipping, ear cleaning, etc.

Video recorder—4-head Hi-Fi Stereo. FEATURES: VCR Plus programming, on-screen menu system, multi-lingual, universal remote. Use: Sony SLV678 and SLV778.

Video rental—One video tape, 1-day or minimum rental rate for Saturday night. Non-member fee. Do not price new releases, oldies or classics where price is different from a regular rental.

Washing machine—FEATURES: Super capacity, 3 water temperatures, 8 wash cycles, 3 water levels, white porcelain tub (no stainless steel), self-clean lint filter, fabric softener & bleach dispenser, 2 speed combinations. Use: Maytag LAT9306, General Electric WJX(S)R2080XXX, Whirlpool LSR8233EQ.

Water bill—Average monthly consumption in gallons and dollars (cost for first xxx gallons; cost for over xxx gallons), sewage and related charges, and customer service charge.

Window shade—Catalog Item. Light-filtering unfringed 37.5″ width. Include shipping and handling. Use: JC Penney.

Wine at home—1.5 liter of Chablis blanc. Use: Gallo, Inglenook.

Wine away—One glass of house white wine. Use: Same restaurant where dinner price is obtained.

Woman's accessory—Clutch/checkbook style wallet. Split-grain, cowhide leather. Do not price eel skin, snake skin or other varieties. Use: Princess Gardner, Mundi, Buxton.

Woman's blouse—100 % polyester, white, long sleeve, button front blouse with minimum trim. Use: Laura Scott, Christy Jill, Impressions.

Woman's boots—ALASKA AND DC ONLY. Calf height boot, pile or fleece lining, urethane upper, broad-based 1″ heel, non-skid traction sole, prefer zipper closure if available. Use: Sorel, Naturalizer.

Woman's coat—Catalog Item. ALASKA AND DC ONLY. 100 % wool, double-breasted coat. Include shipping and handling. Use: JC Penney, Chadwicks.

Woman's cut & style—Wash, cut, and styled blow dry. Exclude curling iron if extra. Price hair salons in major department stores and malls.

Woman's dress—Catalog Item. Sheath style dress appropriate for office attire. Dress is fully lined and 100% polyester. Include shipping and handing. Use: JC Penney.

Woman's shoes—TROPICAL AND DC ONLY. Plain pump (not open toed or open back style), tapered 2″ heel matches shoe (not stacked/wooden type or extra thick), leather uppers, the remaining parts are man-made materials. Use: JC Penney, Worthington, Sears Apostrophe and Luv Comfort, Life Stride.

Woman's slacks—Unlined, cotton/polyester blend with or without a belt appropriate for office attire. Do not price elastic waist. Use: Donnkenny, Alfred Dunner, Fundamental Things.

Woman's sweater—Catalog Item. Cotton knit crewneck pullover sweater. Machine washable. Include shipping and handling. Use: JC Penney, Lands' End.

Appendix 6—Principal Pricing Changes

FOR HOME SALE AND RENTAL COMMUNITIES, SEE APPENDIX 8

Current	Previous	Reason
Babysitter, area minimum wage	Hourly rate	Change improves price comparison.
Bath Towel, catalog	Department store	Change improves price comparison.
Bed Sheet, catalog	Department store	Change improves price comparison.
Cigarettes, single pack (convenience store)	Carton, grocery store	Change improves price comparison.
Dryer repair (test)	Not surveyed	Improves appliance repair comparison.
Hospital attendant, nightly charge	Daily charge	Change reflects more common use.
Housekeeping, job rate	Hourly rate	Specification improves price comparison.
Man's insulated undershirt, discount store	Department store	More widely used outlet type.
Man's undershirt, discount store	Department store	More widely used outlet type.
Plywood	Not surveyed	Improves building material selection.
Snack cake, 8–10 cnt, grocery store	2 pack, convenience store	Change improves price comparison.
Woman's dress, catalog	Department store	Change improves price comparison.
Waffles: 11 oz package or package of 8	Package of 8	Change improves price comparison.
Dropped	Frozen fish, lawn trimmer, skiing	Insufficient data.
Not surveyed	Car rental	Test.

Appendix 7—Consumption Goods and Services Analysis

Categories	Category indexes	Lower income		Middle income		Upper income	
		Weights*	Subtotal	Weights*	Subtotal	Weights*	Subtotal
Anchorage, AK:							
1. Food At Home	119.33	27.03	32.25	24.05	28.70	21.30	25.42
2. Food Away From Home	102.93	13.43	13.82	14.18	14.60	14.87	15.31
3. Tobacco	130.23	2.82	3.67	2.34	3.05	1.90	2.47
4. Alcohol	97.03	2.33	2.26	2.40	2.33	2.47	2.40
5. Furnishings and Household Operations	109.49	15.36	16.82	16.64	18.22	17.82	19.51
6. Clothing	108.71	13.02	14.15	13.50	14.68	13.94	15.15
7. Domestic Services	106.58	1.73	1.84	1.95	2.08	2.15	2.29
8. Professional Services	106.88	7.09	7.58	6.82	7.29	6.57	7.02
9. Personal Care	103.12	3.91	4.03	3.77	3.89	3.64	3.75
10. Recreation	121.90	13.27	16.18	14.35	17.49	15.34	18.70
Total Weights		100.00		100.00		100	
Total Indexes:							
Lower			112.60				
Middle					112.33		
Upper							112.02
Fairbanks, AK:							
1. Food At Home	119.70	27.03	32.35	24.05	28.79	21.30	25.50
2. Food Away From Home	106.53	13.43	14.31	14.18	15.11	14.87	15.84
3. Tobacco	125.45	2.82	3.54	2.34	2.94	1.90	2.38
4. Alcohol	106.36	2.33	2.48	2.40	2.55	2.47	2.63
5. Furnishings and Household Operations	114.81	15.36	17.63	16.64	19.10	17.82	20.46
6. Clothing	105.24	13.02	13.70	13.50	14.21	13.94	14.67
7. Domestic Services	98.31	1.73	1.70	1.95	1.92	2.15	2.11
8. Professional Services	109.56	7.09	7.77	6.82	7.47	6.57	7.20
9. Personal Care	107.48	3.91	4.20	3.77	4.05	3.64	3.91
10. Recreation	130.29	13.27	17.29	14.35	18.70	15.34	19.99
Total Weights		100.00		100.00		100.00	
Total Indexes:							
Lower			114.97				
Middle					114.84		
Upper							114.69
Juneau, AK:							
1. Food At Home	126.62	27.03	34.23	24.05	30.45	21.30	26.97
2. Food Away From Home	109.41	13.43	14.69	14.18	15.51	14.87	16.27
3. Tobacco	127.39	2.82	3.59	2.34	2.98	1.90	2.42
4. Alcohol	110.14	2.33	2.57	2.40	2.64	2.47	2.72
5. Furnishings and Household Operations	119.83	15.36	18.41	16.64	19.94	17.82	21.35
6. Clothing	100.45	13.02	13.08	13.50	13.56	13.94	14.00
7. Domestic Services	105.65	1.73	1.83	1.95	2.06	2.15	2.27
8. Professional Services	107.46	7.09	7.62	6.82	7.33	6.57	7.06
9. Personal Care	109.96	3.91	4.30	3.77	4.15	3.64	4.00
10. Recreation	138.92	13.27	18.43	14.35	19.94	15.34	21.31
Total Weights		100.00		100.00		100.00	
Total Indexes:							
Lower			118.75				
Middle					18.56		
Upper							118.37
Nome, AK:							
1. Food At Home	167.79	27.03	45.35	24.05	40.35	21.30	35.74
2. Food Away From Home	162.90	13.43	21.88	14.18	23.10	14.87	24.22
3. Tobacco	136.45	2.82	3.85	2.34	3.19	1.90	2.59
4. Alcohol	113.45	2.33	2.64	2.40	2.72	2.47	2.80
5. Furnishings and Household Operations	129.08	15.36	19.83	16.64	21.48	17.82	23.00
6. Clothing	115.22	13.02	15.00	13.50	15.55	13.94	16.06
7. Domestic Services	110.89	1.73	1.92	1.95	2.16	2.15	2.38
8. Professional Services	105.83	7.09	7.50	6.82	7.22	6.57	6.95
9. Personal Care	111.36	3.91	4.35	3.77	4.20	3.64	4.05
10. Recreation	161.55	13.27	21.44	14.35	23.18	15.34	24.78

Categories	Category indexes	Lower income		Middle income		Upper income	
		Weights*	Subtotal	Weights*	Subtotal	Weights*	Subtotal
Total Weights	.....	100.00	.....	100.00	.....	100.00	.....
Total Indexes:							
Lower	.....	.....	143.76	.....	.....	.....	.....
Middle	.....	.....	.....	.....	143.15	.....	.....
Upper	.....	.....	.....	.....	.....	.....	142.57
Honolulu, HI:							
1. Food At Home	138.34	27.03	37.39	24.05	33.27	21.30	29.47
2. Food Away From Home	122.35	13.43	16.43	14.18	17.35	14.87	18.19
3. Tobacco	118.94	2.82	3.35	2.34	2.78	1.90	2.26
4. Alcohol	105.07	2.33	2.45	2.40	2.52	2.47	2.60
5. Furnishings and Household Operations	116.34	15.36	17.87	16.64	19.36	17.82	20.73
6. Clothing	104.69	13.02	13.63	13.50	14.13	13.94	14.59
7. Domestic Services	97.91	1.73	1.69	1.95	1.91	2.15	2.11
8. Professional Services	94.12	7.09	6.67	6.82	6.42	6.57	6.18
9. Personal Care	99.83	3.91	3.90	3.77	3.76	3.64	3.63
10. Recreation	113.05	13.27	15.00	14.35	16.22	15.34	17.34
Total Weights	.....	100.00	.....	100.00	.....	100.00	.....
Total Indexes:							
Lower	.....	.....	118.38	.....	.....	.....	.....
Middle	.....	.....	.....	.....	117.72	.....	.....
Upper	.....	.....	.....	.....	.....	.....	117.10
Hilo, HI:							
1. Food At Home	137.49	27.03	37.16	24.05	33.07	21.30	29.29
2. Food Away From Home	104.45	13.43	14.03	14.18	14.81	14.87	15.53
3. Tobacco	135.87	2.82	3.83	2.34	3.18	1.90	2.58
4. Alcohol	103.93	2.33	2.42	2.40	2.49	2.47	2.57
5. Furnishings and Household Operations	111.57	15.36	17.14	16.64	18.57	17.82	19.88
6. Clothing	99.56	13.02	12.96	13.50	13.44	13.94	13.88
7. Domestic Services	83.88	1.73	1.45	1.95	1.64	2.15	1.80
8. Professional Services	99.85	7.09	7.08	6.82	6.81	6.57	6.56
9. Personal Care	98.19	3.91	3.84	3.77	3.70	3.64	3.57
10. Recreation	107.12	13.27	14.21	14.35	15.37	15.34	16.43
Total Weights	.....	100.00	.....	100.00	.....	100.00	.....
Total Indexes:							
Lower	.....	.....	114.12	.....	.....	.....	.....
Middle	.....	.....	.....	.....	113.08	.....	.....
Upper	.....	.....	.....	.....	.....	.....	112.09
Kailua Kona, HI:							
1. Food At Home	138.67	27.03	37.48	24.05	33.35	21.30	29.54
2. Food Away From Home	114.54	13.43	15.38	14.18	16.24	14.87	17.03
3. Tobacco	125.05	2.82	3.53	2.34	2.93	1.90	2.38
4. Alcohol	104.12	2.33	2.43	2.40	2.50	2.47	2.57
5. Furnishings and Household Operations	107.66	15.36	16.54	16.64	17.91	17.82	19.19
6. Clothing	109.30	13.02	14.23	13.50	14.76	13.94	15.24
7. Domestic Services	114.65	1.73	1.98	1.95	2.24	2.15	2.46
8. Professional Services	106.15	7.09	7.53	6.82	7.24	6.57	6.97
9. Personal Care	106.17	3.91	4.15	3.77	4.00	3.64	3.86
10. Recreation	110.47	13.27	14.66	14.35	15.85	15.34	16.95
Total Weights	.....	100.00	.....	100.00	.....	100.00	.....
Total Indexes:							
Lower	.....	.....	117.91	.....	.....	.....	.....
Middle	.....	.....	.....	.....	117.02		
Upper	.....	.....	.....	.....	.....	.....	116.19
Kauai County, HI:							
1. Food At Home	158.55	27.03	42.86	24.05	38.13	21.30	33.77
2. Food Away From Home	111.51	13.43	14.98	14.18	15.81	14.87	16.58
3. Tobacco	123.62	2.82	3.49	2.34	2.89	1.90	2.35
4. Alcohol	96.92	2.33	2.26	2.40	2.33	2.47	2.39
5. Furnishings and Household Operations	120.85	15.36	18.56	16.64	20.11	17.82	21.54

Categories	Category indexes	Lower income		Middle income		Upper income	
		Weights*	Subtotal	Weights*	Subtotal	Weights*	Subtotal
6. Clothing	103.95	13.02	13.53	13.50	14.03	13.94	14.49
7. Domestic Services	83.64	1.73	1.45	1.95	1.63	2.15	1.80
8. Professional Services	101.86	7.09	7.22	6.82	6.95	6.57	6.69
9. Personal Care	118.62	3.91	4.64	3.77	4.47	3.64	4.32
10. Recreation	115.83	13.27	15.37	14.35	16.62	15.34	17.77
Total Weights		100.00		100.00		100.00	
Total Indexes:							
Lower			124.36				
Middle					122.97		
Upper							121.70
Maui County, HI:							
1. Food at Home	150.10	27.03	40.57	24.05	36.10	21.30	31.97
2. Food Away From Home	115.59	13.43	15.52	14.18	16.39	14.87	17.19
3. Tobacco	121.17	2.82	3.42	2.34	2.84	1.90	2.30
4. Alcohol	103.03	2.33	2.40	2.40	2.47	2.47	2.54
5. Furnishings and Household Operations	117.89	15.36	18.11	16.64	19.62	17.82	21.01
6. Clothing	109.61	13.02	14.27	13.50	14.80	13.94	15.28
7. Domestic Services	87.16	1.73	1.51	1.95	1.70	2.15	1.87
8. Professional Services	105.42	7.09	7.47	6.82	7.19	6.57	6.93
9. Personal Care	102.40	3.91	4.00	3.77	3.86	3.64	3.73
10. Recreation	129.32	13.27	17.16	14.35	18.56	15.34	19.847
Total Weights		100.00		100.00		100.00	
Total Indexes:							
Lower			124.43				
Middle					123.53		
Upper							122.66
Guam:							
1. Food At Home	134.59	27.03	36.38	24.05	32.37	21.30	28.67
2. Food Away From Home	120.67	13.43	16.21	14.18	17.11	14.87	17.94
3. Tobacco	64.70	2.82	1.82	2.34	1.51	1.90	1.23
4. Alcohol	84.25	2.33	1.96	2.40	2.02	2.47	2.08
5. Furnishings and Household Operations.	136.07	15.36	20.90	16.64	22.64	17.82	24.25
6. Clothing	110.96	13.02	14.45	13.50	14.98	13.94	15.47
7. Domestic Services	77.30	1.73	1.34	1.95	1.51	2.15	1.66
8. Professional Services	99.36	7.09	7.04	6.82	6.78	6.57	6.53
9. Personal Care	110.81	3.91	4.33	3.77	4.18	3.64	4.03
10. Recreation	120.06	13.27	15.93	14.35	17.23	15.34	18.42
Total Weights		100.00		100.00		100.00	
Total Indexes:							
Lower			120.36				
Middle					120.33		
Upper							120.28
Guam Blend:**							
1. Food At Home	101.83	27.03	27.52	24.05	24.49	21.30	21.69
2. Food Away From Home	120.67	13.43	16.21	14.18	17.11	14.87	17.94
3. Tobacco	64.70	2.82	1.82	2.34	1.51	1.90	1.23
4. Alcohol	84.25	2.33	1.96	2.40	2.02	2.47	2.08
5. Furnishings and Household Operations	129.21	15.36	19.85	16.64	21.50	17.82	23.03
6. Clothing	108.56	13.02	14.13	13.50	14.66	13.94	15.13
7. Domestic Services	77.30	1.73	1.34	1.95	1.51	2.15	1.66
8. Professional Services	99.36	7.09	7.04	6.82	6.78	6.57	6.53
9. Personal Care	99.33	3.91	3.88	3.77	3.74	3.64	3.62
10. Recreation	111.73	13.27	14.83	14.35	16.03	15.34	17.14
Total Weights		100.00		100.00		100.00	
Total Indexes:							
Lower			108.58				
Middle					109.35		
Upper							110.05
Puerto Rico:							
1. Food At Home	116.37	27.03	31.45	24.05	27.99	21.30	24.79

Categories	Category indexes	Lower income		Middle income		Upper income	
		Weights*	Subtotal	Weights*	Subtotal	Weights*	Subtotal
2. Food Away From Home	113.32	13.43	15.22	14.18	16.07	14.87	16.85
3. Tobacco	74.87	2.82	2.11	2.34	1.75	1.90	1.42
4. Alcohol	109.87	2.33	2.56	2.40	2.64	2.47	2.71
5. Furnishings and Household Operations	109.16	15.36	16.77	16.64	18.16	17.82	19.45
6. Clothing	104.21	13.02	13.57	13.50	14.07	13.94	14.53
7. Domestic Services	57.76	1.73	1.00	1.95	1.13	2.15	1.24
8. Professional Services	103.09	7.09	7.31	6.82	7.03	6.57 6.77	
9. Personal Care	106.65	3.91	4.17	3.77	4.02	3.64	3.88
10. Recreation	114.33	13.27	15.17	14.35	16.41	15.34	17.54
Total Weights		100.00		100.00		100.00	
Total Indexes:							
Lower			109.33				
Middle					109.27		
Upper							109.18
St. Croix, VI:							
1. Food At Home	127.69	27.03	34.51	24.05	30.71	21.30	27.20
2. Food Away From Home	122.82	13.43	16.49	14.18	17.42	14.87	18.26
3. Tobacco	53.92	2.82	1.52	2.34	1.26	1.90	1.02
4. Alcohol	102.26	2.33	2.38	2.40	2.45	2.47	2.53
5. Furnishings and Household Operations	134.22	15.36	20.62	16.64	22.33	17.82	23.92
6. Clothing	103.59	13.02	13.49	13.50	13.98	13.94	14.44
7. Domestic Services	53.37	1.73	0.92	1.95	1.04	2.15	1.15
8. Professional Services	121.62	7.09	8.62	6.82	8.29	6.57	7.99
9. Personal Care	113.40	3.91	4.43	3.77	4.28	3.64	4.13
10. Recreation	118.08	13.27	15.67	14.35	16.94	15.34	18.11
Total Weights		100.00		100.00		100.00	
Total Indexes:							
Lower			118.65				
Middle					118.70		
Upper							118.75
St. Thomas, VI:							
1. Food At Home	138.12	27.03	37.33	24.05	33.22	21.30	29.42
2. Food Away From Home	114.63	13.43	15.39	14.18	16.25	14.87	17.05
3. Tobacco	62.90	2.82	1.77	2.34	1.47	1.90	1.20
4. Alcohol	93.07	2.33	2.17	2.40	2.23	2.47	2.30
5. Furnishings and Household Operations	125.64	15.36	19.30	16.64	20.91	17.82	22.39
6. Clothing	100.85	13.02	13.13	13.50	13.61	13.94	14.06
7. Domestic Services	58.97	1.73	1.02	1.95	1.15	2.15	1.27
8. Professional Services	131.69	7.09	9.34	6.82	8.98	6.57	8.65
9. Personal Care	111.77	3.91	4.37	3.77	4.21	3.64	4.07
10. Recreation	112.32	13.27	14.90	14.35	16.12	15.34	17.23
Total Weights		100.00		100.00		100.00	
Total Indexes:							
Lower			118.72				
Middle					118.15		
Upper							117.64

*Numbers might not add to 100 due to rounding.
**Local Retail and Commissary/Exchange.

CONSUMPTION GOODS AND SERVICES ANALYSIS—COMPOSITES

Location	Weights	Total indexes		
		Lower income	Middle income	Upper income
Hilo, HI	75.81	114.12	113.08	112.09
Kailua Kona, HI	24.19	117.91	117.02	116.19
Total weight	100.00			

CONSUMPTION GOODS AND SERVICES ANALYSIS—COMPOSITES—Continued

Location	Weights	Total indexes		
		Lower income	Middle income	Upper income
Hawaii County, HI	.....	115.04	114.03	113.08
St. Croix, VI	48.26	118.65	118.70	118.75
St. Thomas, VI	51.74	118.72	118.15	117.64
Total weight	100.00	.....	.....	.....
Virgin Islands	.....	118.69	118.42	118.18

Appendix 8—OPM Living Community List

	Low	Middle	High
Anchorage, AK:			
Homeowner	North Anchorage*	North Anchorage*	South Anchorage*.
Renter	North Anchorage*	North Anchorage*	South Anchorage*.
Fairbanks, AK:			
Homeowner	Fairbanks	Fairbanks	Fairbanks.
Renter	Fairbanks	Fairbanks	Fairbanks.
Juneau, AK:			
Homeowner	Juneau/Mendenhall	Juneau/Mendenhall	Juneau/Mendenhall.
Renter	Juneau/Mendenhall	Juneau/Mendenhall	Juneau/Mendenhall.
Nome, AK:			
Homeowner	Nome	Nome	Nome.
Renter	Nome	Nome	Nome.
Honolulu:			
Homeowner	Pearl City	Kailua	Aina Haina.
	Waipahu	Kanehoe	Hawaii Kai.
		Mililani Town	Kaimuki.
			Manoa.
Renter	Kalihi	Aiea	Aina Haina.
	Pearl Harbor Area	Kailua	Hawaii Kai.
		Kanehoe	Kaimuki.
		Mililani Town	Manoa.
Hawaii County—Hilo:			
Homeowner	Hilo	Hilo	Hilo.
Renter	Hilo	Hilo	Hilo.
Hawaii County—Kailua Kona:			
Homeowner	Kailua Kona Area	Kailua Kona Area	Kailua Kona Area.
Renter	Kailua Kona Area	Kailua Kona Area	Kailua Kona Area.
Kauai:			
Homeowner	Kauai	Kauai	Kauai.
Renter	Kauai	Kauai	Kauai.
Maui:			
Homeowner	Maui	Maui	Maui.
Renter	Maui	Maui	Maui.
Guam:			
Homeowner	Guam	Guam	Guam.
Renter	Guam	Guam	Guam.
Puerto Rico:			
Homeowner	Bayamon	Rio Piedras including VA Hospital Area.	Guaynabo.
	Carolina		
Renter	Bayamon	Isla Verde	Condado.
	Carolina	Rio Piedras excluding VA Hospital Area.	Guaynabo.
	Rio Piedras excluding VA Hospital Area.		
St. Croix:			
Homeowner	St. Croix	St. Croix	St. Croix.
Renter	St. Croix	St. Croix	St. Croix.
St. Thomas:			
Homeowner	St. Thomas	St. Thomas	St. Thomas.
Renter	St. Thomas	St. Thomas	St. Thomas.
Washington, DC—DC:			
Homeowner	Southeast DC	Northeast DC	Northwest DC**.
Renter	Southeast DC	Northeast DC	Northwest DC**.
Washington, DC—MD:			
Homeowner	Capitol Heights/Suitland	Gaithersburg/Silver Spring	Rockville.

	Low	Middle	High
Renter	Capitol Heights/Suitland	Hyattsville/College Park	Rockville.
Washington, DC—VA:			
Homeowner	Woodbridge/Dale City	Springfield	Alexandria.
Renter	Woodbridge/Dale City	Alexandria	Arlington.

*Dividing line between North and South Anchorage is Tudor Road.
**Excludes Georgetown, but includes Dupont Circle, Cleveland Park, and Adams Morgan.

Appendix 9—Historical Home Market Values and Interest Rates

Area	Year	Interest rate (percent)	Income level	Market value	Annual P & I*
Anchorage, AK	1988	10.500	Lower	$74,218	$6,517.44
			Middle	101,300	8,895.60
			Upper	117,190	10,291.08
	1989	11.125	Lower	67,538	6,235.80
			Middle	93,454	8,628.72
			Upper	112,532	10,390.20
	1990	10.250	Lower	60,784	5,229.00
			Middle	87,071	7,490.40
			Upper	114,783	9,874.32
	1992	9.000	Lower	65,700	5,074.92
			Middle	96,200	7,430.88
			Upper	139,400	10,767.84
	1993	8.125	Lower	70,902	5,053.92
			Middle	99,073	7,061.88
			Upper	130,815	9,324.48
	1994	7.625	Lower	72,216	4,906.92
			Middle	99,099	6,733.56
			Upper	124,780	8,478.60
	1995	8.625	Lower	83,286	6,218.76
			Middle	102,089	7,622.76
			Upper	134,580	10,048.80
	1996	7.125	Lower	83,646	5,409.96
			Middle	112,671	7,287.24
			Upper	139,689	9,034.68
	1997	7.792	Lower	86,859	5,997.96
			Middle	119,561	8,256.24
			Upper	149,073	10,294.20
	1998	6.875	Lower	92,484	5,832.48
			Middle	123,136	7,765.56
			Upper	154,139	9,720.84
Fairbanks, AK	1988	10.500	Lower	64,696	5,681.28
			Middle	93,191	8,183.52
			Upper	123,467	10,842.24
	1989	11.125	Lower	57,553	5,313.96
			Middle	88,424	8,164.32
			Upper	115,101	10,627.44
	1990	10.250	Lower	50,604	4,353.24
			Middle	83,619	7,193.40
			Upper	107,143	9,217.08
	1992	9.000	Lower	70,851	5,472.84
			Middle	101,400	7,832.52
			Upper	137,000	10,582.44
	1993	8.125	Lower	69,498	4,953.84
			Middle	101,478	7,233.36
			Upper	115,787	8,253.24
	1994	7.625	Lower	76,302	5,184.60
			Middle	112,580	7,649.64
			Upper	127,829	8,685.72
	1995	8.708	Lower	68,940	5,186.76
			Middle	84,240	6,337.80
			Upper	108,426	8,157.48
	1996	7.125	Lower	72,918	4,716.12
			Middle	92,625	5,990.76
			Upper	115,855	7,493.16
	1997	8.183	Lower	78,804	5,647.92
			Middle	97,110	6,959.88
			Upper	122,196	8,757.72
	1998	6.938	Lower	79,200	5,026.80
			Middle	110,903	7,038.96
			Upper		

Area	Year	Interest rate (percent)	Income level	Market value	Annual P & I*
Juneau, AK	1988	10.500	Lower	76,441	6,712.68
			Middle	93,787	8,235.96
			Upper	113,874	9,999.84
	1989	11.125	Lower	68,797	6,352.08
			Middle	86,284	7,966.68
			Upper	106,131	9,799.20
	1990	10.250	Lower	78,429	6,746.88
			Middle	99,227	8,536.08
			Upper	123,324	10,609.08
	1992	9.000	Lower	89,470	6,911.04
			Middle	114,400	8,836.68
			Upper	146,300	11,300.76
	1993	8.125	Lower	87,570	6,241.92
			Middle	115,518	8,234.04
			Upper	134,232	9,568.08
	1994	7.625	Lower	92,826	6,307.32
			Middle	117,364	7,974.72
			Upper	140,760	9,564.36
	1995	8.625	Lower	102,879	7,681.80
			Middle	138,723	10,358.16
			Upper	163,812	12,231.48
	1996	7.125	Lower	114,255	7,389.72
			Middle	143,767	9,298.44
			Upper	169,507	10,963.20
	1997	7.792	Lower	130,266	8,995.44
			Middle	162,955	11,252.76
			Upper	185,011	12,775.80
	1998	6.958	Lower	126,783	8,063.16
			Middle	160,927	10,234.68
			Upper	188,003	11,956.68
Nome, AK	1988	10.500	Lower	78,763	6,916.56
			Middle	104,159	9,146.76
			Upper	125,312	11,004.24
	1989	11.125	Lower	76,243	7,039.56
			Middle	100,826	9,309.36
			Upper	121,302	11,199.96
	1990	10.250	Lower	73,803	6,348.96
			Middle	97,600	8,396.16
			Upper	117,420	10,101.12
	1992	9.000	Lower	71,100	5,492.04
			Middle	97,500	7,531.32
			Upper	122,400	9,454.68
	1993	8.125	Lower	56,453	4,023.96
			Middle	77,415	5,518.08
			Upper	97,186	6,927.36
	1994	7.625	Lower	82,365	5,596.56
			Middle	112,948	7,674.60
			Upper	141,794	9,634.68
	1995	8.625	Lower	81,711	6,101.16
			Middle	118,027	8,812.80
			Upper	154,343	11,524.44
	1996	7.125	Lower	80,856	5,229.48
			Middle	119,171	7,707.60
			Upper	139,213	9,003.84
	1997	8.183	Lower	99,324	7,118.52
			Middle	143,468	10,282.32
			Upper	187,612	13,446.12
	1998	8.250	Lower	86,479	6,237.00
			Middle	124,914	9,009.00
			Upper	163,350	11,781.00
Honolulu, HI	1988	11.000	Lower	134,388	12,286.20
			Middle	173,823	15,891.48
			Upper	335,274	30,651.72
	1989	10.500	Lower	182,268	16,005.84
			Middle	231,218	20,304.36
			Upper	410,550	36,052.44
	1990	10.250	Lower	248,571	21,383.52
			Middle	299,702	25,782.12
			Upper	510,714	43,934.42
	1991	9.125	Lower	258,300	20,175.48
			Middle	320,866	25,062.48
			Upper	501,701	39,187.20

Area	Year	Interest rate (percent)	Income level	Market value	Annual P & I*
	1992	8.125	Lower	192,168	13,697.64
			Middle	323,752	23,076.96
			Upper	483,820	34,486.56
	1993	7.125	Lower	243,072	15,721.20
			Middle	331,006	21,408.48
			Upper	470,730	30,445.44
	1994	9.333	Lower	257,814	20,510.40
			Middle	340,392	27,079.80
			Upper	466,242	37,091.88
	1996	7.025	Lower	220,896	14,144.04
			Middle	303,849	19,455.60
			Upper	417,095	26,706.72
	1997	7.875	Lower	213,003	14,826.48
			Middle	278,759	19,403.52
			Upper	401,642	27,957.00
	1998	7.250	Lower	190,800	12,495.24
			Middle	266,955	17,482.56
			Upper	399,092	26,136.12
Hilo, HI	1988	11.000	Lower	68,410	6,254.28
			Middle	92,371	8,444.88
			Upper	114,412	10,459.92
	1989	10.500	Lower	77,386	6,795.60
			Middle	102,559	9,006.24
			Upper	122,727	10,777.32
	1990	10.250	Lower	121,688	10,468.32
			Middle	108,821	9,361.44
			Upper	164,283	14,132.52
	1991	9.125	Lower	134,100	10,474.44
			Middle	180,700	14,114.28
			Upper	204,000	15,934.20
	1992	8.125	Lower	130,743	9,319.32
			Middle	162,903	11,611.68
			Upper	197,863	14,103.60
	1993	7.125	Lower	127,854	8,269.20
			Middle	173,095	11,195.28
			Upper	202,018	13,065.96
	1994	9.333	Lower	114,696	9,124.92
			Middle	162,500	12,927.96
			Upper	196,146	15,604.80
	1996	7.000	Lower	115,750	7,392.84
			Middle	164,711	10,519.92
			Upper	183,841	11,741.76
	1997	7.792	Lower	89,064	6,150.24
			Middle	139,191	9,611.76
			Upper	186,983	12,912.00
	1998	7.125	Lower	90,000	5,820.96
			Middle	137,436	8,889.00
			Upper	163,489	10,573.92
Kailua Kona, HI	1988	11.000	Lower	100,662	9,202.80
			Middle	137,180	12,541.44
			Upper	160,692	14,691.00
	1989	10.500	Lower	112,444	9,874.32
			Middle	151,973	13,345.56
			Upper	181,087	15,902.16
	1990	10.250	Lower	134,609	11,579.88
			Middle	189,900	16,336.32
			Upper	225,100	19,364.40
	1991	9.130	Lower	154,800	12,096.60
			Middle	204,100	15,949.08
			Upper	256,700	20,059.44
	1992	8.125	Lower	159,867	11,395.32
			Middle	222,950	15,891.84
			Upper	261,018	18,605.28
	1993	7.125	Lower	153,666	9,938.64
			Middle	219,902	14,180.16
			Upper	261,902	16,939.08
	1994	9.333	Lower	152,235	12,111.36
			Middle	215,826	17,170.44
			Upper	224,128	17,830.92
	1996	6.958	Lower	144,434	9,186.12
			Middle	191,923	12,206.40
			Upper	220,752	14,039.88

Area	Year	Interest rate (percent)	Income level	Market value	Annual P & I*
	1997	8.042	Lower	141,552	10,010.88
			Middle	186,056	13,158.36
			Upper	219,674	15,535.92
	1998	7.375	Lower	156,699	10,389.84
			Middle	180,557	11,971.80
			Upper	225,284	14,937.36
Kauai County, HI	1988	11.000	Lower	91,046	8,323.68
			Middle	124,556	11,387.28
			Upper	145,581	13,309.44
	1989	10.500	Lower	103,516	9,090.24
			Middle	142,818	12,541.56
			Upper	177,900	15,622.32
	1990	10.250	Lower	177,351	15,256.80
			Middle	233,846	20,116.80
			Upper	295,854	25,451.04
	1991	9.125	Lower	174,336	13,617.12
			Middle	229,900	17,957.16
			Upper	290,800	22,714.08
	1992	8.125	Lower	171,792	12,245.28
			Middle	221,624	15,797.28
			Upper	273,921	19,524.96
	1993	7.125	Lower	171,964	11,122.08
			Middle	221,858	14,349.12
			Upper	274,195	17,734.08
	1994	9.333	Lower	163,350	12,995.64
			Middle	222,196	17,677.20
			Upper	255,000	20,287.08
	1996	6.958	Lower	176,907	11,251.32
			Middle	228,147	14,510.28
			Upper	265,084	16,859.40
	1997	8.042	Lower	151,551	10,718.04
			Middle	209,781	14,836.32
			Upper	235,688	16,668.48
	1998	7.292	Lower	150,885	9,922.56
			Middle	191,646	12,603.12
			Upper	229,534	15,094.80
Maui County, HI	1988	11.000	Lower	121,107	11,071.92
			Middle	160,693	14,691.00
			Upper	202,081	18,474.84
	1989	10.500	Lower	151,384	13,293.84
			Middle	200,866	17,639.04
			Upper	252,601	22,182.12
	1990	10.250	Lower	174,092	14,976.36
			Middle	230,996	19,871.64
			Upper	290,491	24,989.64
	1991	9.125	Lower	210,651	16,453.68
			Middle	279,500	21,831.36
			Upper	351,494	27,454.80
	1992	8.125	Lower	207,913	14,820.00
			Middle	275,925	19,667.88
			Upper	346,925	24,728.76
	1993	7.125	Lower	180,099	11,648.28
			Middle	255,476	16,523.40
			Upper	310,845	20,104.56
	1994	9.333	Lower	180,000	14,320.32
			Middle	250,588	19,936.08
			Upper	278,443	22,152.12
	1996	7.000	Lower	192,575	12,299.64
			Middle	260,593	16,643.88
			Upper	283,138	18,083.76
	1997	7.417	Lower	182,448	12,147.36
			Middle	234,429	15,608.28
			Upper	274,074	18,247.80
	1998	7.292	Lower	192,636	12,668.28
			Middle	233,779	15,373.92
			Upper	263,653	17,338.56
Guam	1988	11.000	Lower	84,271	7,704.36
			Middle	103,920	9,500.64
			Upper	207,287	18,950.76
	1989	10.375	Lower	93,709	8,145.12
			Middle	116,079	10,089.48
			Upper	225,735	19,620.72

Area	Year	Interest rate (percent)	Income level	Market value	Annual P & I*
	1990	10.500	Lower	103,174	9,060.24
			Middle	128,151	11,253.60
			Upper	244,245	21,448.32
	1991	10.125	Lower	113,491	9,662.04
			Middle	140,966	12,001.08
			Upper	268,670	22,873.20
	1992	9.491	Lower	130,855	10,554.60
			Middle	162,534	13,109.88
			Upper	309,777	24,986.28
	1993	7.750	Lower	144,738	9,954.48
			Middle	189,280	13,017.84
			Upper	258,978	17,811.36
	1994	10.050	Lower	133,452	11,290.32
			Middle	188,240	15,925.44
			Upper	244,375	20,674.56
	1996	7.875	Lower	130,746	9,100.80
			Middle	180,074	12,534.36
			Upper	224,347	15,616.08
	1997	7.917	Lower	149,292	10,433.52
			Middle	162,500	11,356.56
			Upper	212,500	14,850.96
	1998	7.500	Lower	121,500	8,155.68
			Middle	162,500	10,907.76
			Upper	204,000	13,693.44
Puerto Rico	1988	10.875	Lower	64,485	5,837.04
			Middle	78,985	7,149.48
			Upper	114,326	10,348.44
	1989	10.375	Lower	70,934	6,165.48
			Middle	86,884	7,551.84
			Upper	122,329	10,632.72
	1990	10.375	Lower	78,027	6,782.04
			Middle	95,572	8,307.00
			Upper	134,562	11,696.04
	1991	8.875	Lower	82,800	6,324.48
			Middle	100,255	7,657.68
			Upper	141,100	10,777.44
	1992	8.125	Lower	62,271	4,438.68
			Middle	84,721	6,038.88
			Upper	151,946	10,830.72
	1993	7.125	Lower	61,389	3,970.44
			Middle	84,084	5,438.28
			Upper	151,878	9,822.96
	1994	8.750	Lower	66,843	5,048.16
			Middle	102,232	7,720.92
			Upper	143,633	10,847.64
	1996	7.792	Lower	69,714	4,814.04
			Middle	107,367	7,414.20
			Upper	168,385	11,627.76
	1997	7.770	Lower	73,683	5,077.32
			Middle	108,849	7,500.60
			Upper	172,244	11,869.08
	1998	6.500	Lower	77,859	4,724.40
			Middle	118,937	7,216.92
			Upper	175,032	10,620.72
St. Croix, VI	1988	12,000	Lower	66,051	6,522.36
			Middle	85,592	8,451.96
			Upper	145,231	14,341.08
	1989	11.750	Lower	64,730	6,272.52
			Middle	83,880	8,128.20
			Upper	142,326	13,791.84
	1990	11.250	Lower	80,912	7,544.28
			Middle	104,850	9,776.28
			Upper	177,908	16,588.32
	1991	10.250	Lower	85,281	7,336.32
			Middle	110,500	9,505.80
			Upper	187,500	16,129.80
	1992	9,500	Lower	103,635	8,365.68
			Middle	151,866	12,258.96
			Upper	188,037	15,178.68
	1993	8,375	Lower	112,962	8,242.44
			Middle	174,161	12,708.00
			Upper	194,004	14,155.92

Area	Year	Interest rate (percent)	Income level	Market value	Annual P & I*
	1994	9.083	Lower	77,409	6,024.00
			Middle	128,076	9,966.84
			Upper	210,035	16,344.96
	1996	9.042	Lower	86,304	6,691.32
			Middle	124,863	9,680.88
			Upper	180,796	14,017.44
	1997	9.250	Lower	78,489	6,198.84
			Middle	128,076	10,115.04
			Upper	152,099	12,012.24
	1998	8.420	Lower	62,793	4,600.92
			Middle	98,020	7,182.12
			Upper	193,188	14,155.32
St. Thomas, VI	1988	12.000	Lower	121,129	11,961.12
			Middle	153,265	15,134.40
			Upper	182,929	18,063.60
	1989	11.750	Lower	126,943	12,301.20
			Middle	160,622	15,564.84
			Upper	191,710	18,577.32
	1990	11.250	Lower	122,500	11,422.08
			Middle	155,000	14,452.32
			Upper	185,000	17,249.64
	1991	10.250	Lower	126,900	10,916.64
			Middle	180,700	15,544.80
			Upper	210,800	18,134.28
	1992	9.000	Lower	128,930	9,959.04
			Middle	183,591	14,181.24
			Upper	214,173	16,543.56
	1993	8.250	Lower	139,680	10,074.00
			Middle	198,829	14,339.88
			Upper	231,949	16,728.48
	1994	9.083	Lower	106,533	8,290.44
			Middle	190,164	14,798.52
			Upper	195,381	15,204.60
	1996	8.292	Lower	137,936	9,987.00
			Middle	197,134	14,273.16
			Upper	187,673	13,588.08
	1997	8.333	Lower	137,936	10,025.52
			Middle	197,134	14,328.24
			Upper	187,673	13,640.52
	1998	7.000	Lower	223,632	14,283.12
			Middle	193,388	12,351.48
			Upper	261,902	16,727.40
Washington, DC (DC)	1988	10.500	Lower	76,327	6,702.60
			Middle	126,817	11,136.48
			Upper	202,310	17,765.88
	1989	9.625	Lower	82,128	6,701.52
			Middle	140,619	11,474.40
			Upper	218,495	17,829.00
	1990	9.875	Lower	87,877	7,325.52
			Middle	140,974	11,751.84
			Upper	235,975	19,671.24
	1991	9.250	Lower	90,104	7,116.12
			Middle	144,550	11,416.08
			Upper	242,000	19,112.40
	1992	8.313	Lower	90,828	6,589.32
			Middle	127,270	9,233.04
			Upper	241,230	17,500.56
	1993	7.375	Lower	93,369	6,190.80
			Middle	115,021	7,626.48
			Upper	286,564	19,000.56
	1994	8.677	Lower	82,242	6,170.04
			Middle	104,657	7,851.72
			Upper	305,541	22,922.64
	1996	7.625	Lower	73,177	4,972.20
			Middle	110,425	7,503.12
			Upper	290,563	19,743.24
	1997	7.823	Lower	56,115	3,886.56
			Middle	82,940	5,744.52
			Upper	220,779	15,291.24
	1998	6.938	Lower	64,827	4,114.56
			Middle	91,585	5,812.92
			Upper	236,640	15,019.44

Area	Year	Interest rate (percent)	Income level	Market value	Annual P & I*
Washington, DC (MD)	1988	10.375	Lower	73,295	6,370.68
			Middle	113,498	9,865.20
			Upper	135,043	11,737.80
	1989	10.000	Lower	81,357	6,854.04
			Middle	125,983	10,613.64
			Upper	149,898	12,628.44
	1990	9.875	Lower	89,493	7,460.28
			Middle	138,581	11,552.28
			Upper	164,888	13,745.28
	1991	8.750	Lower	93,475	7,059.48
			Middle	144,748	10,931.88
			Upper	169,958	12,835.80
	1992	8.313	Lower	104,198	7,559.28
			Middle	131,118	9,512.28
			Upper	207,502	15,053.64
	1993	7.375	Lower	92,655	6,143.52
			Middle	118,911	7,884.36
			Upper	204,264	13,543.68
	1994	8.688	Lower	90,963	6,831.24
			Middle	167,349	12,567.72
			Upper	214,030	16,073.40
	1996	6.896	Lower	109,369	6,912.12
			Middle	222,845	14,083.80
			Upper	224,792	14,206.80
	1997	7.920	Lower	94,536	6,608.76
			Middle	160,823	11,242.56
			Upper	199,648	13,956.72
	1998	6.969	Lower	94,779	6,034.56
			Middle	166,049	10,572.24
			Upper	173,162	11,025.12
Washington, DC (VA)	1988	10.500	Lower	83,413	7,324.92
			Middle	94,122	8,265.36
			Upper	156,059	13,704.36
	1989	9,500	Lower	90,086	7,271.88
			Middle	101,652	8,205.60
			Upper	168,544	13,605.24
	1990	10.000	Lower	97,293	8,196.60
			Middle	109,784	9,249.00
			Upper	182,028	15,335.28
	1991	8.938	Lower	103,462	7,947.48
			Middle	117,650	9,037.44
			Upper	187,000	14,364.60
	1992	8.250	Lower	100,103	7,219.56
			Middle	126,315	9,110.04
			Upper	182,810	13,184.52
	1993	7.500	Lower	94,905	6,370.44
			Middle	126,874	8,516.40
			Upper	181,705	12,196.92
	1994	8.698	Lower	99,657	7,490.88
			Middle	167,876	12,618.72
			Upper	228,191	17,152.44
	1996	7.083	Lower	108,327	6,976.80
			Middle	169,472	10,914.84
			Upper	206,918	13,326.60
	1997	7.858	Lower	104,364	7,252.56
			Middle	160,706	11,168.04
			Upper	229,925	15,978.24
	1998	6.948	Lower	103,662	6,586.08
			Middle	160,849	10,219.44
			Upper	229,024	14,550.84

Appendix 10—Historical Housing Data

Year	Weights	Lower amounts	Subtotal	Middle amounts	Subtotal	Upper amounts	Subtotal
Anchorage, AK:							
1988	6.31	6,517.44	411.25	8,895.60	561.31	10,291.08	649.37
1989	6.77	6,235.80	422.16	8,628.72	584.16	10,390.20	703.42
1990	8.19	5,229.00	428.26	7,490.40	613.46	9,874.32	808.71
1992	7.03	5,074.92	356.77	7,430.88	522.39	10,767.84	756.98
1993	7.72	5,053.92	390.16	7,061.88	545.18	9,324.48	719.85
1994	8.32	4,906.92	408.26	6,733.56	560.23	8,478.60	705.42

Year	Weights	Lower amounts	Subtotal	Middle amounts	Subtotal	Upper amounts	Subtotal
1995	10.08	6,218.76	626.85	7,622.76	768.37	10,048.80	1,012.92
1996	12.92	5,409.96	698.97	7,287.24	941.51	9,034.68	1,167.28
1997	13.78	5,997.96	826.52	8,256.24	1,137.71	10,294.20	1,418.54
1998	18.88	5,832.48	1,101.17	7,765.56	1,466.14	9,720.84	1,835.29
Totals	100.00		5,670.37		7,700.46		9,777.78
Fairbanks, AK:							
1988	6.31	5,681.28	358.49	8,183.52	516.38	10,842.24	684.15
1989	6.77	5,313.96	359.76	8,164.32	552.72	10,627.44	719.48
1990	8.19	4,353.24	356.53	7,193.40	589.14	9,217.08	754.88
1992	7.03	5,472.84	384.74	7,832.52	550.63	10,582.44	743.95
1993	7.72	4,953.84	382.44	7,233.36	558.42	8,253.24	637.15
1994	8.32	5,184.60	431.36	7,649.64	636.45	8,685.72	722.65
1995	10.08	5,186.76	522.83	6,337.80	638.85	8,157.48	822.27
1996	12.92	4,716.12	609.32	5,990.76	774.01	7,493.16	968.12
1997	13.78	5,647.92	778.28	6,959.88	959.07	8,757.72	1,206.81
1998	18.88	5,026.80	949.06	7,038.96	1,328.96	7,803.24	1,473.25
Totals	100.00		5,132.81		7,104.63		8,732.71
Juneau, AK:							
1988	6.31	6,712.68	423.57	8,235.96	519.69	9,999.84	630.99
1989	6.77	6,352.08	430.04	7,966.68	539.34	9,799.20	663.41
1990	8.19	6,746.88	552.57	8,536.08	699.10	10,609.08	868.88
1992	7.03	6,911.04	485.85	8,836.68	621.22	11,300.76	794.44
1993	7.72	6,241.92	481.88	8,234.04	635.67	9,568.08	738.66
1994	8.32	6,307.32	524.77	7,974.72	663.50	9,564.36	795.75
1995	10.08	7,681.80	774.33	10,358.16	1,044.10	12,231.48	1,232.93
1996	12.92	7,389.72	954.75	9,298.44	1,201.36	10,963.20	1,416.45
1997	13.78	8,995.44	1,239.57	11,252.76	1,550.63	12,775.80	1,760.51
1998	18.88	8,063.16	1,522.32	10,234.68	1,932.31	11,956.68	2,257.42
Totals	100.00		7,389.65		9,406.92		11,159.44
Nome, AK:							
1988	6.31	6,916.56	436.43	9,146.76	577.16	11,004.24	694.37
1989	6.77	7,039.56	476.58	9,309.36	630.24	11,199.96	758.24
1990	8.19	6,348.96	519.98	8,396.16	687.65	10,101.12	827.28
1992	7.03	5,492.04	386.09	7,531.32	529.45	9,454.68	664.66
1993	7.72	4,023.96	310.65	5,518.08	426.00	6,927.36	534.79
1994	8.32	5,596.56	465.63	7,674.60	638.53	9,634.68	801.61
1995	10.08	6,101.16	615.00	8,812.80	888.33	11,524.44	1,161.66
1996	12.92	5,229.48	675.65	7,707.60	995.82	9,003.84	1,163.30
1997	13.78	7,118.52	980.93	10,282.32	1,416.90	13,446.12	1,852.88
1998	18.88	6,237.00	1,177.55	9,009.00	1,700.90	11,781.00	2,224.25
Totals	100.00		6,044.49		8,490.98		10,683.04
Honolulu, HI:							
1988	6.31	12,286.20	775.26	15,891.48	1,002.75	30,651.72	1,934.12
1989	6.77	16,005.84	1,083.60	20,304.36	1,374.61	36,052.44	2,440.75
1990	8.19	21,383.52	1,751.31	25,782.12	2,111.56	43,934.52	3,598.24
1991	7.03	20,175.48	1,418.34	25,062.48	1,761.89	39,187.20	2,754.86
1992	7.72	13,697.64	1,057.46	23,076.96	1,781.54	34,486.56	2,662.36
1993	8.32	15,721.20	1,308.00	21,408.48	1,781.19	30,445.44	2,533.06
1994	10.08	20,510.40	2,067.45	27,079.80	2,729.64	37,091.88	3,738.86
1996	12.92	14,144.04	1,827.41	19,455.60	2,513.66	26,706.72	3,450.51
1997	13.78	14,826.48	2,043.09	19,403.52	2,673.81	27,957.00	3,852.47
1998	18.88	12,495.24	2,359.10	17,482.56	3,300.71	26,136.12	4,934.50
Totals	100.00		15,691.02		21,031.36		31,899.73
Hilo, HI:							
1988	6.31	6,254.28	394.65	8,444.88	532.87	10,459.92	660.02
1989	6.77	6,795.60	460.06	9,006.24	609.72	10,777.32	729.62
1990	8.19	10,468.32	857.36	9,361.44	766.70	14,132.52	1,157.45
1991	7.03	10,474.44	736.35	14,114.28	992.23	15,934.20	1,120.17
1992	7.72	9,319.32	719.45	11,611.68	896.42	14,103.60	1,088.80
1993	8.32	8,269.20	688.00	11,195.28	931.45	13,065.96	1,087.09
1994	10.08	9,124.92	919.79	12,927.96	1,303.14	15,604.80	1,572.96
1996	12.92	7,392.84	955.15	10,519.92	1,359.17	11,741.76	1,517.04
1997	13.78	6,150.24	847.50	9,611.76	1,324.50	12,912.00	1,779.27

Year	Weights	Lower amounts	Subtotal	Middle amounts	Subtotal	Upper amounts	Subtotal
1998	18.88	5,820.96	1,099.00	8,889.00	1,678.24	10,573.92	1,996.36
Totals	100.00		7,677.31		10,394.44		12,708.78
Kailua Kona, HI:							
1988	6.31	9,202.80	580.70	12,541.44	791.36	14,691.00	927.00
1989	6.77	9,874.32	668.49	13,345.56	903.49	15,902.16	1,076.58
1990	8.19	11,579.88	948.39	16,336.32	1,337.94	19,364.40	1,585.94
1991	7.03	12,096.60	850.39	15,949.08	1,121.22	20,059.44	1,410.18
1992	7.72	11,395.32	879.72	15,891.84	1,226.85	18,605.28	1,436.33
1993	8.32	9,938.64	826.89	14,180.16	1,179.79	16,939.08	1,409.33
1994	10.08	12,111.36	1,220.83	17,170.44	1,730.78	17,830.92	1,797.36
1996	12.92	9,186.12	1,186.85	12,206.40	1,577.07	14,039.88	1,813.95
1997	13.78	10,010.88	1,379.50	13,158.36	1,813.22	15,535.92	2,140.85
1998	18.88	10,389.84	1,961.60	11,971.80	2,260.28	14,937.36	2,820.17
Totals	100.00		10,503.36		13,942.00		16,417.69
Kauai, HI:							
1988	6.31	8,323.68	525.22	11,387.28	718.54	13,309.44	839.83
1989	6.77	9,090.24	615.41	12,541.56	849.06	15,622.32	1,057.63
1990	8.19	15,256.80	1,249.53	20,116.80	1,647.57	25,451.04	2,084.44
1991	7.03	13,617.12	957.28	17,957.16	1,262.39	22,714.08	1,596.80
1992	7.72	12,245.28	945.34	15,797.28	1,219.55	19,524.96	1,507.33
1993	8.32	11,122.08	925.36	14,349.12	1,193.85	17,734.08	1,475.48
1994	10.08	12,995.64	1,309.96	17,677.20	1,781.86	20,287.08	2,044.94
1996	12.92	11,251.32	1,453.67	14,510.28	1,874.73	16,859.40	2,178.23
1997	13.78	10,718.04	1,476.95	14,836.32	2,044.44	16,668.48	2,296.92
1998	18.88	9,922.56	1,873.38	12,603.12	2,379.47	15,094.80	2,849.90
Totals	100.00		11,332.10		14,971.46		17,931.50
Maui, HI:							
1988	6.31	11,071.92	698.64	14,691.00	927.00	18,474.84	1,165.76
1989	6.77	13,293.84	899.99	17,639.04	1,194.16	22,182.12	1,501.73
1990	8.19	14,976.36	1,226.56	19,871.64	1,627.49	24,989.64	2,046.65
1991	7.03	16,453.68	1,156.69	21,831.36	1,534.74	27,454.80	1,930.07
1992	7.72	14,820.00	1,144.10	19,667.88	1,518.36	24,728.76	1,909.06
1993	8.32	11,648.28	969.14	16,523.40	1,374.75	20,104.56	1,672.70
1994	10.08	14,320.32	1,443.49	19,936.08	2,009.56	22,152.12	2,232.93
1996	12.92	12,299.64	1,589.11	16,643.88	2,150.39	18,083.76	2,336.42
1997	13.78	12,147.36	1,673.91	15,608.28	2,150.82	18,247.80	2,514.55
1998	18.88	12,668.28	2,391.77	15,373.92	2,902.60	17,338.56	3,273.52
Totals	100.00		13,193.40		17,389.87		20,583.39
Guam:							
1988	6.31	7,704.36	486.15	9,500.64	599.49	18,950.76	1,195.79
1989	6.77	8,145.12	551.42	10,089.48	683.06	19,620.72	1,328.32
1990	8.19	9,060.24	742.03	11,253.60	921.67	21,448.32	1,756.62
1991	7.03	9,662.04	679.24	12,001.08	843.68	22,873.20	1,607.99
1992	7.72	10,554.60	814.82	13,109.88	1,012.08	24,986.28	1,928.94
1993	8.32	9,954.48	828.21	13,017.84	1,083.08	17,811.36	1,481.91
1994	10.08	11,290.32	1,138.06	15,925.44	1,605.28	20,674.56	2,084.00
1996	12.92	9,100.80	1,175.82	12,534.36	1,619.44	15,616.08	2,017.60
1997	13.78	10,433.52	1,437.74	11,356.56	1,564.93	14,850.96	2,046.46
1998	18.88	8,155.68	1,539.79	10,907.76	2,059.39	13,693.44	2,585.32
Totals	100.00		9,393.28		11,992.10		18,032.95
Puerto Rico:							
1988	6.31	5,837.04	368.32	7,149.48	451.13	10,348.44	652.99
1989	6.77	6,165.48	417.40	7,551.84	511.26	10,632.72	719.84
1990	8.19	6,782.04	555.45	8,307.00	680.34	11,696.04	957.91
1991	7.03	6,324.48	444.61	7,657.68	538.33	10,777.44	757.65
1992	7.72	4,438.68	342.67	6,038.88	466.20	10,830.72	836.13
1993	8.32	3,970.44	330.34	5,438.28	452.46	9,822.96	817.27
1994	10.08	5,048.16	508.85	7,720.92	778.27	10,847.64	1,093.44
1996	12.92	4,814.04	621.97	7,414.20	957.91	11,627.76	1,502.31
1997	13.78	5,077.32	699.65	7,500.60	1,033.58	11,869.08	1,635.56
1998	18.88	4,724.40	891.97	7,216.92	1,362.55	10,620.72	2,005.19
Totals	100.00		5,181.23		7,232.03		10,978.29

Year	Weights	Lower amounts	Subtotal	Middle amounts	Subtotal	Upper amounts	Subtotal
St. Croix, VI:							
1988	6.31	6,522.36	411.56	8,451.96	533.32	14,341.08	904.92
1989	6.77	6,272.52	424.65	8,128.20	550.28	13,791.84	933.71
1990	8.19	7,544.28	617.88	9,776.28	800.68	16,588.32	1,358.58
1991	7.03	7,336.32	515.74	9,505.80	668.26	16,129.80	1,133.92
1992	7.72	8,365.68	645.83	12,258.96	946.39	15,178.68	1,171.79
1993	8.32	8,242.44	685.77	12,708.00	1,057.31	14,155.92	1,177.77
1994	10.08	6,024.00	607.22	9,966.84	1,004.66	16,344.96	1,647.57
1996	12.92	6,691.32	864.52	9,680.88	1,250.77	14,017.44	1,811.05
1997	13.78	6,198.84	854.20	10,115.04	1,393.85	12,012.24	1,655.29
1998	18.88	4,600.92	868.65	7,182.12	1,355.98	14,155.32	2,672.52
Totals	100.00	.....	6,496.02	.....	9,561.50	.....	14,467.12
St. Thomas, VI:							
1988	6.31	11,961.12	754.75	15,134.40	954.98	18,063.60	1,139.81
1989	6.77	12,301.20	832.79	15,564.84	1,053.74	18,577.32	1,257.68
1990	8.19	11,422.08	935.47	14,452.32	1,183.65	17,249.64	1,412.75
1991	7.03	10,916.64	767.44	15,544.80	1,092.80	18,134.28	1,274.84
1992	7.72	9,959.04	768.84	14,181.24	1,094.79	16,543.56	1,277.16
1993	8.32	10,074.00	838.16	14,339.88	1,193.08	16,728.48	1,391.81
1994	10.08	8,290.44	835.68	14,798.52	1,491.69	15,204.60	1,532.62
1996	12.92	9,987.00	1,290.32	14,273.16	1,844.09	13,588.08	1,755.58
1997	13.78	10,025.52	1,381.52	14,328.24	1,974.43	13,640.52	1,879.66
1998	18.88	14,283.12	2,696.65	12,351.48	2,331.96	16,727.40	3,158.13
Totals	100.00	.....	11,101.62	.....	14,215.21	.....	16,080.04
Washington, DC (DC):							
1988	6.31	6,702.60	422.93	11,136.48	702.71	17,765.88	1,121.03
1989	6.77	6,701.52	453.69	11,474.40	776.82	17,829.00	1,207.02
1990	8.19	7,325.52	599.96	11,751.84	962.48	19,671.24	1,611.07
1991	7.03	7,116.12	500.26	11,416.08	802.55	19,112.40	1,343.60
1992	7.72	6,589.32	508.70	9,233.04	712.79	17,500.56	1,351.04
1993	8.32	6,190.80	515.07	7,626.48	634.52	19,000.56	1,580.85
1994	10.08	6,170.04	621.94	7,851.72	791.45	22,922.64	2,310.60
1996	12.92	4,972.20	642.41	7,503.12	969.40	19,743.24	2,550.83
1997	13.78	3,886.56	535.57	5,744.52	791.59	15,291.24	2,107.13
1998	18.88	4,114.56	776.83	5,812.92	1,097.48	15,019.44	2,835.67
Totals	100.00	.....	5,577.36	.....	8,241.79	.....	18,018.84
Washington, DC (MD):							
1988	6.31	6,370.68	401.99	9,865.20	622.49	11,737.80	740.66
1989	6.77	6,854.04	464.02	10,613.64	718.54	12,628.44	854.95
1990	8.19	7,460.28	611.00	11,552.28	946.13	13,745.28	1,125.74
1991	7.03	7,059.48	496.28	10,931.88	768.51	12,835.80	902.36
1992	7.72	7,559.28	583.58	9,512.28	734.35	15,053.64	1,162.14
1993	8.32	6,143.52	511.14	7,884.36	655.98	13,543.68	1,126.83
1994	10.08	6,831.24	688.59	12,567.72	1,266.83	16,073.40	1,620.20
1996	12.92	6,912.12	893.05	14,083.80	1,819.63	14,206.80	1,835.52
1997	13.78	6,608.76	910.69	11,242.56	1,549.22	13,956.72	1,923.24
1998	18.88	6,034.56	1,139.32	10,572.24	1,996.04	11,025.12	2,081.54
Totals	100.00	.....	6,699.66	.....	11,077.72	.....	13,373.18
Washington, DC (VA):							
1988	6.31	7,324.92	462.20	8,265.36	521.54	13,704.36	864.75
1989	6.77	7,271.88	492.31	8,205.60	555.52	13,605.24	921.07
1990	8.19	8,196.60	671.30	9,249.00	757.49	15,335.28	1,255.96
1991	7.03	7,947.48	558.71	9,037.44	635.33	14,364.60	1,009.83
1992	7.72	7,219.56	557.35	9,110.04	703.30	13,184.52	1,017.84
1993	8.32	6,370.44	530.02	8,516.40	708.56	12,196.92	1,014.78
1994	10.08	7,490.88	755.08	12,618.72	1,271.97	17,152.44	1,728.97
1996	12.92	6,976.80	901.40	10,914.84	1,410.20	13,326.60	1,721.80
1997	13.78	7,252.56	999.40	11,168.04	1,538.96	15,978.24	2,201.80
1998	18.88	6,586.08	1,243.45	10,219.44	1,929.43	14,550.84	2,747.20
Totals	100.00	.....	7,171.22	.....	10,032.30	.....	14,484.00

Appendix 11—Summary of Rental Analyses

	1998 data medians					
	Broker & non-broker		Non-Broker		Broker	
	#	$	#	$	#	$
Anchorage, AK:						
Low	22	$563	15	$575	7	$550
Middle	18	668	12	698	6	638
High	30	1,013	23	1,175	7	850
Fairbanks, AK:						
Low	9	520	6	505	3	535
Middle	14	698	9	695	5	700
High	10	888	9	1,000	1	775
Juneau, AK:						
Low	7	750	3	725	4	775
Middle	15	890	8	930	7	850
High	11	1,225	5	1,350	6	1,100
*Nome, AK:						
Low	2	750	2	750	0	750
Middle	4	869	4	913	0	825
High	0	988	0	0	0	988
Honolulu, HI:						
Low	130	723	119	695	11	750
Middle	205	900	192	850	13	950
High	310	1,373	302	1,395	8	1,350
Hilo, HI:						
Low	65	441	65	375	0	506
Middle	44	575	39	450	5	700
High	207	698	201	695	6	700
Kailua Kona, HI:						
Low	62	569	60	550	2	588
Middle	24	713	21	625	3	800
High	126	1,038	124	975	2	1,100
Kauai, HI:						
Low	54	588	48	525	6	650
Middle	24	669	12	638	12	700
High	74	875	72	850	2	900
Maui, HI:						
Low	157	675	142	650	15	700
Middle	39	800	26	725	13	875
High	400	1,035	388	950	12	1,119
Guam:						
Low	8	700	3	500	5	900
Middle	26	900	17	800	9	1,000
High	14	1,100	9	1,200	5	1,000
**Puerto Rico:						
Low	31	613	18	425	13	800
Middle	24	775	10	600	14	950
High	11	1,238	11	975	0	1,500
St. Croix, VI:						
Low	8	494	4	438	4	550
Middle	9	694	4	638	5	750
High	8	850	5	700	3	1,000
St. Thomas, VI:						
Low	25	663	13	625	12	700
Middle	21	900	9	800	12	1,000
High	22	1,213	11	1,200	11	1,225
***Washington, DC (DC):						
Low	16	489	10	438	6	540
Middle	13	695	4	645	9	745
High	13	1,275	13	1,000	0	1,550
Washington, DC (MD):						
Low	12	589	6	553	6	624
Middle	18	739	10	689	8	788
High	25	1,275	12	1,300	13	1,250
****Washington, DC (VA):						
Low	5	628	5	665	0	590
Middle	31	979	14	798	17	1,159
High	68	1,425	49	1,200	19	1,650

* Used 1997 broker rental values at all income levels because this year's data were unavailable.

** Used broker quote data for all communities in the greater San Juan area except at the upper income level, for which 1997 broker rental value was used because this year's data reflected incomplete rental information.

*** Used 1997 broker rental at the upper income level because this year's data reflected incomplete rental information.

**** Used 1997 broker rental value at the lower income level because this year's data were unavailable.

Appendix 12—Housing Cost Analysis

Category	Annual costs					
	Lower income		Middle income		Upper income	
	Owner	Renter	Owner	Renter	Owner	Renter
Anchorage, AK:						
Maintenance	$796	$62	$936	$73	$1,077	$78
Insurance	390	117	472	$129	560	$141
Utilities	2,094	1,840	2,411	2,094	2,728	2,242
Real estate taxes	1,710	.....	2,277	.....	2,580	.....
Housing	5,670	6,756	7,700	8,016	9,778	12,156
Total annual cost	10,660	8,775	13,796	10,312	16,723	14,617
Fairbanks, AK:						
Maintenance	764	60	898	70	1,033	75
Insurance	374	150	472	168	511	180
Utilities	2,814	2,466	3,250	2,814	3,685	3,018
Real estate taxes	1,368	.....	1,995	.....	2,233	.....
Housing	5,133	6,240	7,105	8,376	8,733	10,656
Total annual cost	10,453	8,916	13,720	11,428	16,195	13,929
Juneau, AK:						
Maintenance	814	64	958	74	1,101	80
Insurance	412	127	493	139	567	152
Utilities	2,245	1,976	2,583	2,245	2,920	2,403
Real estate taxes	1,524	.....	1,934	.....	2,260	.....
Housing	7,390	9,000	9,407	10,680	11,159	14,700
Total annual cost	12,385	11,167	15,375	13,138	18,007	17,335
Nome, AK:						
Maintenance	736	58	866	67	995	73
Insurance	511	250	663	250	701	250
Utilities	3,633	3,174	4,206	3,633	4,780	3,901
Real estate taxes	961	.....	1,388	.....	1,815	.....
Housing	6,044	9,000	8,491	10,428	10,683	11,856
Total annual cost	11,885	12,482	15,614	14,378	18,974	16,080
Honolulu, HI:						
Maintenance	695	54	817	63	940	69
Insurance	580	319	682	364	907	412
Utilities	1,776	1,585	2,015	1,776	2,253	1,887
Real estate taxes	526	.....	792	.....	1,253	.....
Housing	15,691	8,676	21,031	10,800	31,900	16,476
Total annual cost	19,268	10,634	25,337	13,003	37,253	18,844
Hilo, HI:						
Maintenance	784	61	922	71	1,060	77
Insurance	423	276	487	314	548	351
Utilities	2,314	2,041	2,654	2,314	2,994	2,472
Real estate taxes	425	.....	828	.....	1,050	.....
Housing	7,677	5,292	10,394	6,900	12,709	8,376
Total annual cost	11,623	7,670	15,285	9,599	18,361	11,276
Kailua Kona, HI:						
Maintenance	737	58	867	67	997	73
Insurance	531	145	587	161	676	351
Utilities	2,308	2,036	2,648	2,308	2,989	2,467
Real estate taxes	992	.....	1,195	.....	1,575	.....
Housing	10,503	6,828	13,942	8,556	16,418	12,456
Total annual cost	15,071	9,067	19,239	11,092	22,655	15,347
Kauai County, HI:						
Maintenance	1,103	86	1,297	100	1,492	109
Insurance	517	329	609	365	716	416
Utilities	1,876	1,657	2,151	1,876	2,425	2,004

Category	Annual costs					
	Lower income		Middle income		Upper income	
	Owner	Renter	Owner	Renter	Owner	Renter
Real estate taxes	582	.....	795	.....	994	.....
Housing	11,332	7,056	14,971	8,028	17,932	10,500
Total annual cost	15,410	9,128	19,823	10,369	23,559	13,029
Maui County, HI:						
Maintenance	1,074	84	1,263	98	1,452	106
Insurance	629	307	711	349	723	390
Utilities	1,679	1,495	1,908	1,679	2,137	1,786
Real estate taxes	725	.....	920	.....	1,062	.....
Housing	13,193	8,100	17,390	9,600	20,583	12,420
Total annual cost	17,300	9,986	22,192	11,726	25,957	14,702
Guam:						
Maintenance	963	75	1,133	88	1,303	95
Insurance	1,429	329	1,912	394	2,400	460
Utilities	3,103	2,720	3,582	3,103	4,061	3,327
Real estate taxes	330	.....	459	.....	590	.....
Housing	9,393	8,400	11,992	10,800	18,033	13,200
Total annual cost	15,218	11,524	19,078	14,385	26,387	17,082
Puerto Rico:						
Maintenance	538	42	633	49	728	53
Insurance	497	247	778	297	1,163	323
Utilities	2,031	1,797	2,325	2,031	2,618	2,168
Real estate taxes	46	.....	708	.....	1,611	.....
Housing	5,181	7,356	7,232	9,300	10,978	14,856
Total annual cost	8,293	9,442	11,676	11,677	17,098	17,400
St. Croix, VI:						
Maintenance	491	38	577	45	664	48
Insurance	1,195	684	1,472	772	2,797	890
Utilities	1,371	1,237	1,539	1,371	1,707	1,449
Real estate taxes	283	.....	548	.....	1,261	.....
Housing	6,496	5,928	9,562	8,328	14,467	10,200
Total annual cost	9,836	7,887	13,698	10,516	20,896	12,587
St. Thomas, VI:						
Maintenance	542	42	638	49	733	53
Insurance	3,213	700	2,777	822	3,759	890
Utilities	1,372	1,237	1,539	1,372	1,707	1,450
Real estate taxes	1,490	.....	1,188	.....	1,777	.....
Housing	11,102	7,956	14,215	10,800	16,080	14,556
Total annual cost	17,719	9,935	20,357	13,043	24,056	16,949
Washington, DC (DC):						
Maintenance	611	48	719	56	827	60
Insurance	252	127	350	161	800	136
Utilities	2,432	2,144	2,791	2,432	3,151	2,599
Real estate taxes	334	.....	591	.....	1,984	.....
Housing	5,577	5,868	8,242	8,340	18,019	15,300
Total annual cost	9,206	8,187	12,693	10,989	24,781	18,095
Washington, DC (MD):						
Maintenance	611	48	719	56	827	60
Insurance	212	145	294	159	302	148
Utilities	2,040	1,800	2,340	2,040	2,641	2,180
Real estate taxes	1,175	.....	2,059	.....	2,147	.....
Housing	6,700	7,068	11,078	8,868	13,373	15,300
Total annual cost	10,738	9,061	16,490	11,123	19,290	17,688
Washington, DC (VA):						
Maintenance	611	48	719	56	827	60
Insurance	226	126	282	141	358	156

Category	Annual costs					
	Lower income		Middle income		Upper income	
	Owner	Renter	Owner	Renter	Owner	Renter
Utilities	2,401	2,122	2,749	2,401	3,097	2,563
Real estate taxes	1,410	.....	1,978	.....	2,462	.....
Housing	7,171	7,536	10,032	11,748	14,484	17,100
Total annual cost	11,819	9,832	15,760	14,346	21,228	19,879

HOUSING COST ANALYSIS—COMPOSITES

Location	Weights	Annual costs					
		Lower income		Middle income		Upper income	
		Owner	Renter	Owner	Renter	Owner	Renter
Hilo, HI	75.81	$11,623	$7,670	$15,285	$9,599	$18,361	$11,276
Kailua Kona, HI	24.19	15,071	9,067	19,239	11,092	22,655	15,347
Total weight	100.00	.....	.....	.....	.....	.....	.....
Hawaii County, HI	.....	12,457	8,008	16,241	9,960	19,400	12,261
St. Croix, VI	48.26	9,836	7,887	13,698	10,516	20,896	12,587
St. Thomas, VI	51.74	17,719	9,935	20,357	13,043	24,056	16,949
Total weight	100.00	.....	.....	.....	.....	.....	.....
Virgin Islands	.....	13,915	8,947	17,143	11,823	22,531	14,844
Washington, DC, DC	33.34	9,206	8,187	12,693	10,989	24,781	18,095
Washington, DC, MD	33.33	10,738	9,061	16,490	11,123	19,290	17,688
Washington, DC, VA	33.33	11,819	9,832	15,760	14,346	21,228	19,879
Total weight	100.00	.....	.....	.....	.....	.....	.....
DC area		10,588	9,027	14,981	12,153	21,767	18,554

Appendix 13—Housing Analysis

	Owners			Renters		
	Total annual cost	Total cost DC area	Index	Total annual cost	Total cost DC area	Index
Anchorage, AK:						
Lower income	$10,660	$10,588	100.68	$8,775	$9,027	97.21
Middle income	13,796	14,981	92.09	10,312	12,153	84.85
Upper income	16,723	21,767	76.83	14,617	18,554	78.78
Fairbanks, AK:						
Lower income	10,453	10,588	98.72	8,916	9,027	98.77
Middle income	13,720	14,981	91.58	11,428	12,153	94.03
Upper income	16,195	21,767	74.40	13,929	18,554	75.07
Juneau, AK:						
Lower income	12,385	10,588	116.97	11,167	9,027	123.71
Middle income	15,375	14,981	102.63	13,138	12,153	108.10
Upper income	18,007	21,767	82.73	17,335	18,554	93.43
Nome, AK:						
Lower income	11,885	10,588	112.25	12,482	9,027	138.27
Middle income	15,614	14,981	104.23	14,378	12,153	118.31
Upper income	18,974	21,767	87.17	16,080	18,554	86.67
Honolulu, HI:						
Lower income	19,268	10,588	181.98	10,634	9,027	117.80
Middle income	25,337	14,981	169.13	13,003	12,153	106.99
Upper income	37,253	21,767	171.14	18,844	18,554	101.56
Hawaii County, HI:						
Lower income	12,457	10,588	117.65	8,008	9,027	88.71
Middle income	16,241	14,981	108.41	9,960	12,153	81.96
Upper income	19,400	21,767	89.13	12,261	18,554	66.08
Kauai County, HI:						
Lower income	15,410	10,588	145.54	9,128	9,027	101.12
Middle income	19,823	14,981	132.32	10,369	12,153	85.32
Upper income	23,559	21,767	108.23	13,029	18,554	70.22

	Owners			Renters		
	Total annual cost	Total cost DC area	Index	Total annual cost	Total cost DC area	Index
Maui County, HI:						
Lower income	17,300	10,588	163.39	9,986	9,027	110.62
Middle income	22,192	14,981	148.13	11,726	12,153	96.49
Upper income	25,957	21,767	119.25	14,702	18,554	79.24
Guam:						
Lower income	15,218	10,588	143.73	11,524	9,027	127.66
Middle income	19,078	14,981	127.35	14,385	12,153	118.37
Upper income	26,387	21,767	121.22	17,082	18,554	92.07
Puerto Rico:						
Lower income	8,293	10,588	78.32	9,442	9,027	104.60
Middle income	11,676	14,981	77.94	11,677	12,153	96.08
Upper income	17,098	21,767	78.55	17,400	18,554	93.78
Virgin Islands:						
Lower income	13,915	10,588	131.42	8,947	9,027	99.11
Middle income	17,143	14,981	114.43	11,823	12,153	97.28
Upper income	22,531	21,767	103.51	14,844	18,554	80.00

Appendix 14—Private Transportation Cost Analysis

Category	Annual costs		
	Honda Civic 1.5L 4 cyl DX 4 dr sedan	Ford Taurus 3.0L 6 cyl GL 4 dr sedan	Chevrolet S10 Blazer 4.3L 6 cyl 4 WD 2 dr
Anchorage, AK:			
Fuel	$762	$1,143	$1,429
Maintenance/oil	728	695	657
Tires	123	163	152
License and registration	69	69	74
Miscellaneous tax	50	50	50
Depreciation	2,167	3,595	4,111
Finance expense	687	875	1,023
Insurance	1,321	1,247	1,491
Total annual cost	5,907	7,837	8,987
Fairbanks, AK:			
Fuel	739	1,109	1,386
Maintenance/oil	915	916	829
Tires	97	131	160
License and registration	74	74	79
Miscellaneous tax	0	0	0
Depreciation	2,457	3,556	4,535
Finance expense	724	861	1,078
Insurance	1,336	1,271	1,477
Total annual cost	6,342	7,918	9,544
Juneau, AK:			
Fuel	813	1,220	1,525
Maintenance/oil	756	758	771
Tires	112	151	154
License and registration	44	44	49
Miscellaneous tax	0	0	0
Depreciation	1,954	3,390	4,043
Finance expense	636	821	985
Insurance	981	966	1,064
Total annual cost	5,296	7,350	8,591
Nome, AK:			
Fuel	1,264	1,897	2,371
Maintenance/oil	796	774	708
Tires	124	159	169
License and registration	44	44	49
Miscellaneous tax	0	0	0
Depreciation	3,013	4,190	5,218
Finance expense	784	928	1,145
Insurance	1,202	1,244	1,656

Category	Annual costs		
	Honda Civic 1.5L 4 cyl DX 4 dr sedan	Ford Taurus 3.0L 6 cyl GL 4 dr sedan	Chevrolet S10 Blazer 4.3L 6 cyl 4 WD 2 dr
Total annual cost	7,227	9,236	11,316
Honolulu, HI:			
Fuel	802	1,202	1,503
Maintenance/oil	626	581	571
Tires	112	147	0
License and registration	103	118	128
Miscellaneous tax	0	0	0
Depreciation	2,665	3,871	5,194
Finance expense	947	1,139	1,476
Insurance	1,197	1,146	1,326
Total annual cost	6,452	8,204	10,198
Hilo, HI:			
Fuel	955	1,433	1,791
Maintenance/oil	513	500	505
Tires	85	163	175
License and registration	75	86	110
Miscellaneous tax	0	0	0
Depreciation	2,415	3,261	4,790
Finance expense	967	1,099	1,503
Insurance	1,189	1,226	1,455
Total annual cost	6,199	7,768	10,329
Kailua Kona, HI:			
Fuel	928	1,393	1,741
Maintenance/oil	660	662	666
Tires	100	154	131
License and registration	95	105	129
Miscellaneous tax	0	0	0
Depreciation	2,353	3,660	4,855
Finance expense	921	1,140	1,464
Insurance	1,684	1,663	1,783
Total annual cost	6,741	8,777	10,769
Kauai, HI:			
Fuel	866	1,299	1,623
Maintenance/oil	674	710	615
Tires	123	160	204
License and registration	72	82	87
Miscellaneous tax	0	0	0
Depreciation	2,634	3,559	4,984
Finance expense	1,027	1,178	1,566
Insurance	1,110	1,141	1,279
Total annual cost	6,506	8,129	10,358
Maui, HI:			
Fuel	893	1,339	1,674
Maintenance/oil	685	714	612
Tires	138	183	181
License and registration	82	97	105
Miscellaneous tax	0	0	0
Depreciation	1,989	3,366	5,242
Finance expense	880	1,120	1,595
Insurance	1,115	1,151	1,369
Total annual cost	5,782	7,970	10,778
Guam:			
Fuel	956	1,434	1,792
Maintenance/oil	472	501	569
Tires	112	195	134
License and registration	36	41	43
Miscellaneous tax	0	0	0
Depreciation	2,228	4,047	4,552
Finance expense	928	1,259	1,454

Category	Annual costs		
	Honda Civic 1.5L 4 cyl DX 4 dr sedan	Ford Taurus 3.0L 6 cyl GL 4 dr sedan	Chevrolet S10 Blazer 4.3L 6 cyl 4 WD 2 dr
Insurance	1,326	1,794	1,763
Total annual cost	6,058	9,271	10,307
Puerto Rico:			
Fuel	534	800	1,000
Maintenance/oil	334	351	450
Tires	111	159	152
License and registration	304	329	342
Miscellaneous tax	0	0	0
Depreciation	2,215	4,002	5,804
Finance expense	858	1,158	1,584
Insurance	1,482	1,702	2,024
Total annual cost	5,838	8,501	11,356
St. Croix, VI:			
Fuel	688	1,031	1,289
Maintenance/oil	447	409	485
Tires	80	160	142
License and registration	69	78	90
Miscellaneous tax	0	0	0
Depreciation	2,198	3,565	4,629
Finance expense	899	1,132	1,434
Insurance	1,754	1,723	1,998
Total annual cost	6,135	8,098	10,067
St. Thomas, VI:			
Fuel	739	1,108	1,385
Maintenance/oil	558	561	614
Tires	102	146	126
License and registration	69	78	90
Miscellaneous tax	0	0	0
Depreciation	2,749	3,537	5,463
Finance expense	930	1,038	1,474
Insurance	1,810	1,728	1,877
Total annual cost	6,957	8,196	11,029
Washington, DC (DC):			
Fuel	545	817	1,021
Maintenance/oil	404	379	346
Tires	133	115	81
License and registration	109	109	142
Miscellaneous tax	0	0	0
Depreciation	1,866	3,243	4,143
Finance expense	599	767	960
Insurance	1,409	1,296	1,508
Total annual cost	5,065	6,726	8,201
Washington, DC (MD):			
Fuel	537	805	1,006
Maintenance/oil	409	387	340
Tires	86	112	111
License and registration	83	83	97
Miscellaneous tax	0	0	0
Depreciation	1,865	3,248	4,845
Finance expense	587	753	1,040
Insurance	1,171	1,120	1,348
Total annual cost	4,738	6,508	8,787
Washington, DC (VA):			
Fuel	506	760	949
Maintenance/oil	386	386	385
Tires	64	94	110
License and registration	37	37	37
Miscellaneous tax	556	626	878

Category	Annual costs		
	Honda Civic 1.5L 4 cyl DX 4 dr sedan	Ford Taurus 3.0L 6 cyl GL 4 dr sedan	Chevrolet S10 Blazer 4.3L 6 cyl 4 WD 2 dr
Depreciation	1,892	3,173	3,969
Finance expense	609	766	946
Insurance	827	740	922
Total annual cost	4,877	6,582	8,196

PRIVATE TRANSPORTATION COST ANALYSIS—COMPOSITES

Location	Weights	Annual costs		
		Honda Civic 1.5L 4 cyl DX 4 dr sedan	Ford Taurus 3.0L 6 cyl GL 4 dr sedan	Chevrolet S10 Blazer 4.3L 6 cyl 4 WD 2 dr
Hilo, HI	75.81	$6,199	$7,768	$10,329
Kailua Kona, HI	24.19	6,741	8,777	10,769
Total weight	100.00	.....	.....	.....
Hawaii County, HI	N/A	6,330	8,012	10,435
St. Croix, VI	48.26	6,135	8,098	10,067
St. Thomas, VI	51.74	6,957	8,196	11,029
Total weight	100.00	.....	.....	.....
Virgin Islands	N/A	6,560	8,149	10,565
Washington, DC, DC	33.34	5,065	6,726	8,201
Washington, DC, MD	33.33	4,738	6,508	8,787
Washington, DC, VA	33.33	4,877	6,582	8,196
Total weight	100.00	.....	.....	.....
DC area	N/A	4,893	6,605	8,395

Appendix 15—Auto Insurance Calculation Worksheet—Special Limits Adjustments

	Honda	Ford	Chevy
Guam:			
Average Local Insurance Price	1,288.67	1,739.33	1,718.67
Price of Equivalent Reference Area Coverage	1,113.04	1,030.85	1,255.59
Index	115.78	168.73	136.88
Price of Reference Area UM 100/300 Coverage	32.57	32.57	32.57
Estimated Local Equivalent UM Coverage	37.71	54.96	44.58
Adjusted Local Insurance Price	1,326.38	1,794.29	1,763.25
Puerto Rico:			
Average Local Insurance Price	1,439.67	1,650.00	1,972.40
Price of Equivalent Reference Area Coverage	1,113.04	1,030.85	1,255.59
Index	129.35	160.06	157.09
Price of Reference Area UM 100/300 Coverage	32.57	32.57	32.57
Estimated Local Equivalent UM Coverage	42.13	52.13	51.16
Adjusted Local Insurance Price	1,481.80	1,702.13	2,023.56
St. Croix:			
Average Local Insurance Price	1,516.68	1,484.76	1,746.28
Price of Equivalent Reference Area Coverage	990.67	916.48	1,125.90
Index	153.10	162.01	155.10
Price of Specified Reference Area Coverage	1,145.61	1,063.42	1,288.16
Adjusted Local Insurance Price	1,753.93	1,722.85	1,997.94
St. Thomas:			
Average Local Insurance Price	1,565.09	1,489.16	1,640.52
Price of Equivalent Reference Area Coverage	990.67	916.48	1125.90
Index	157.98	162.49	145.71
Price of Specified Reference Area Coverage	1,145.61	1,063.42	1,288.16

	Honda	Ford	Chevy
Adjusted Local Insurance Price	1,809.83	1,727.95	1,876.98

Note: Special adjustments were required for Guam, Puerto Rico, and U.S. Virgin Islands automobile insurance prices because the coverage available was significantly less than that surveyed in the other locations. In Guam and Puerto Rico, uninsured motorist (UM) coverage had significantly lower coverage or was not available. For both areas, we compared the average price of the local policy with the average price of equivalent coverage in the DC area and computed an index. We used that index to adjust the price of the DC area specified UM coverage, which we then added to the average local prices. In the U.S. Virgin Islands, all coverage (bodily injury, property damage, medical, collision, and comprehensive) was significantly less than that priced elsewhere. For these areas, we compared the average price of the local policy with equivalent coverage in the DC area and computed an index. We used that index to adjust the price of the DC specified coverage.

Appendix 16—Air Fares Cost Analysis

Location	Average allowance area air fares	Average DC area air fares	Index
Anchorage, AK	$519	$240	216.25
Fairbanks, AK	691	240	287.92
Juneau, AK	663	240	276.25
Nome, AK	1,161	240	483.75
Honolulu, HI	727	240	302.92
Hawaii County, HI	907	240	377.92
Kauai, HI	907	240	377.92
Maui, HI	859	240	357.92
Guam	1,277	240	532.08
Puerto Rico	448	240	186.67
Virgin Islands	685	240	285.42

AIR FARES—COMPOSITES

Location	Weights	Costs
Hilo, HI	75.81	$907
Kailua Kona, HI	24.19	907
Total	100.00	
Hawaii County, HI cost		907
St. Croix, VI	48.26	682
St. Thomas, VI	51.74	688
Total	100.00	
Virgin Islands cost		685

Appendix 17—Transportation Analysis

	Total annual cost	Total cost DC area	Index
Anchorage, AK:			
1. Honda Civic DX 4 dr sdn 1.5L 4 cyl	$5,907	$4,893	120.72
2. Ford Taurus GL 4 dr sedan 3.0L 6 cyl	7,837	6,605	118.65
3. Chevy S10 Blazer 4WD 2 dr 4.3L 6 cyl	8,987	8,395	107.05
Average index			115.47
Fairbanks, AK:			
1. Honda Civic DX 4 dr sdn 1.5L 4 cyl	6,342	4,893	129.61
2. Ford Taurus GL 4 dr sedan 3.0L 6 cyl	7,918	6,605	119.88
3. Chevy S10 Blazer 4WD 2 dr 4.3L 6 cyl	9,544	8,395	113.69
Average index			121.06
Juneau, AK:			
1. Honda Civic DX 4 dr sdn 1.5L 4 cyl	5,296	4,893	108.24
2. Ford Taurus GL 4 dr sedan 3.0L 6 cyl	7,350	6,605	111.28
3. Chevy S10 Blazer 4WD 2 dr 4.3L 6 cyl	8,591	8,395	102.33
Average index			107.28
Nome, AK:			
1. Honda Civic DX 4 dr sdn 1.5L 4 cyl	7,227	4,893	147.70

	Total annual cost	Total cost DC area	Index
2. Ford Taurus GL 4 dr sedan 3.0L 6 cyl	9,236	6,605	139.83
3. Chevy S10 Blazer 4WD 2 dr 4.3L 6 cyl	11,316	8,395	134.79
Average index			140.77
Honolulu, HI:			
1. Honda Civic DX 4 dr sdn 1.5L 4 cyl	6,452	4,893	131.86
2. Ford Taurus GL 4 dr sedan 3.0L 6 cyl	8,204	6,605	124.21
3. Chevy S10 Blazer 4WD 2 dr 4.3L 6 cyl	10,198	8,395	121.48
Average index			1125.85
Hawaii County, HI:			
1. Honda Civic DX 4 dr sdn 1.5L 4 cyl	6,330	4,893	129.37
2. Ford Taurus GL 4 dr sedan 3.0L 6 cyl	8,012	6,605	121.30
3. Chevy S10 Blazer 4WD 2 dr 4.3L 6 cyl	10,435	8,395	124.30
Average index			124.99
Kauai County, HI:			
1. Honda Civic DX 4 dr sdn 1.5L 4 cyl	6,506	4,893	132.97
2. Ford Taurus GL 4 dr sedan 3.0L 6 cyl	8,129	6,605	123.07
3. Chevy S10 Blazer 4WD 2 dr 4.3L 6 cyl	10,358	8,395	123.38
Average index			126.47
Maui County, HI:			
1. Honda Civic DX 4 dr sdn 1.5L 4 cyl	5,782	4,893	118.17
2. Ford Taurus GL 4 dr sedan 3.0L 6 cyl	7,970	6,605	120.67
3. Chevy S10 Blazer 4WD 2 dr 4.3L 6 cyl	10,778	8,395	128.39
Average index			122.41
Guam:			
1. Honda Civic DX 4 dr sdn 1.5L 4 cyl	6,058	4,893	123.82
2. Ford Taurus GL 4 dr sedan 3.0L 6 cyl	9,271	6,605	140.37
3. Chevy S10 Blazer 4WD 2 dr 4.3L 6 cyl	10,307	8,395	122.78
Average index			128.99
Puerto Rico:			
1. Honda Civic DX 4 dr sdn 1.5L 4 cyl	5,838	4,893	119.31
2. Ford Taurus GL 4 dr sedan 3.0L 6 cyl	8,501	6,605	128.71
3. Chevy S10 Blazer 4WD 2 dr 4.3L 6 cyl	11,356	8,395	135.27
Average index			127.76
Virgin Islands:			
1. Honda Civic DX 4 dr sdn 1.5L 4 cyl	6,560	4,893	134.07
2. Ford Taurus GL 4 dr sedan 3.0L 6 cyl	8,149	6,605	123.38
3. Chevy S10 Blazer 4WD 2 dr 4.3L 6 cyl	10,565	8,395	125.85
Average index			127.77

Appendix 18—Transportation Summary

	Category indexes	Lower income		Middle income		Upper income	
		Weights	Subtotal	Weights	Subtotal	Weights	Subtotal
Anchorage, AK:							
Private transportation	115.47	95.22	109.95	94.57	109.20	93.97	108.51
Air fares and other transportation expenses	216.25	4.78	10.34	5.43	11.74	6.03	13.04
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			120.29				
Middle					120.94		
Upper							121.55
Fairbanks, AK:							
Private transportation	121.06	95.22	115.27	94.57	114.49	93.97	113.76

	Category indexes	Lower income		Middle income		Upper income	
		Weights	Subtotal	Weights	Subtotal	Weights	Subtotal
Air fares and other transportation expenses	287.92	4.78	13.76	5.43	15.63	6.03	17.36
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			129.03				
Middle					130.12		
Upper							131.12
Juneau, AK:							
Private transportation	107.28	95.22	102.15	94.57	101.45	93.97	100.81
Air fares and other transportation expenses	276.25	4.78	13.20	5.43	15.00	6.03	16.66
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			115.35				
Middle					116.45		
Upper							117.47
Nome, AK:							
Private transportation	140.77	95.22	134.04	94.57	133.13	93.97	132.28
Air fares and other transportation expenses	483.75	4.78	23.12	5.43	26.27	6.03	29.17
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			157.16				
Middle					159.40		
Upper							161.45
Honolulu, HI:							
Private transportation	125.85	95.22	119.83	94.57	119.02	93.97	118.26
Air fares and other transportation expenses	302.92	4.78	14.48	5.43	16.45	6.03	18.27
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			134.31				
Middle					135.47		
Upper							136.53
Hawaii County, HI:							
Private transportation	124.99	95.22	119.02	94.57	118.20	93.97	117.45
Air fares and other transportation expenses	377.92	4.78	18.06	5.43	20.52	6.03	22.79
Total weights		100.00		100.00		100.00	
Total indexes:.							
Lower			137.08				
Middle					138.72		
Upper							140.24
Kauai County, HI:							
Private transportation	126.47	95.22	120.42	94.57	119.60	93.97	118.84
Air fares and other transportation expenses	377.92	4.78	18.06	5.43	20.52	6.03	22.79
Total weights		100.00		100.00		100.00	
Total indexes:.							
Lower			138.48				
Middle					140.12		
Upper							141.63
Maui County, HI:							
Private transportation	122.41	95.22	116.56	94.57	115.76	93.97	115.03

	Category indexes	Lower income		Middle income		Upper income	
		Weights	Subtotal	Weights	Subtotal	Weights	Subtotal
Air fares and other transportation expenses	357.92	4.78	17.11	5.43	19.44	6.03	21.58
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			133.67				
Middle					135.20		
Upper							136.61
Guam:							
Private transportation	128.99	95.22	122.82	94.57	121.99	93.97	121.21
Air fares and other transportation expenses	532.08	4.78	25.43	5.43	28.89	6.03	32.08
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			148.25				
Middle					150.88		
Upper							153.29
Puerto Rico:							
Private transportation	127.76	95.22	121.65	94.57	120.82	93.97	120.06
Air fares and other transportation expenses	186.67	4.78	8.92	5.43	10.14	6.03	11.26
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			130.57				
Middle					130.96		
Upper							131.32
Virgin Islands:							
Private transportation	127.77	95.22	121.66	94.57	120.83	93.97	120.07
Air fares and other transportation expenses	285.42	4.78	13.64	5.43	15.50	6.03	17.21
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			135.30				
Middle					136.33		
Upper							137.28

Appendix 19—Miscellaneous Expense Analysis—Category Development

Category/item	Price	Price DC area	Ratio	Weights	Subtotal	Index
Anchorage, AK:						
Medicalcare						113.31
Non-aspirin pain reliever	$7.35	$6.95	1.06	5.34	5.65	
Tetracycline	7.91	7.03	1.13	11.83	13.31	
Dentist clean/check	158.33	103.26	1.53	15.51	23.78	
Doctor office visit	66.67	58.86	1.13	11.39	12.90	
Hospital room	748.00	625.35	1.20	2.89	3.46	
Health Insurance	1,275.77	1,232.98	1.03	47.72	49.38	
Contact Lenses	167.33	185.77	0.90	5.32	4.79	
Fairbanks, AK:						
Medical care						116.20
Non-aspirin pain reliever	6.70	6.95	0.96	5.34	5.15	
Tetracycline	8.55	7.03	1.22	11.83	14.38	
Dentist clean/check	173.67	103.26	1.68	15.51	26.09	
Doctor office visit	71.67	58.86	1.22	11.39	13.87	
Hospital room	637.00	625.35	1.02	2.89	2.94	
Health Insurance	1,250.20	1,232.98	1.01	47.72	48.39	
Contact Lenses	188.00	185.77	1.01	5.32	5.38	
Juneau, AK:						
Medical care		ENT				118.83
Non-aspirin pain reliever	9.41	6.95	1.35	5.34	7.23	
Tetracycline	7.72	7.03	1.10	11.83	12.99	

Category/item	Price	Price DC area	Ratio	Weights	Subtotal	Index
Dentist clean/check	183.33	103.26	1.78	15.51	27.54	.....
Doctor office visit	73.50	58.86	1.25	11.39	14.22	.....
Hospital room	656.97	625.35	1.05	2.89	3.04	.....
Health Insurance	1,252.03	1,232.98	1.02	47.72	48.46	.....
Contact Lenses	1186.67	185.77	1.00	5.32	5.35	.....
Nome, AK:						
Medical care	.....	.....	.....	.....	.....	134.92
Non-aspirin pain reliever	10.46	6.95	1.51	5.34	8.04	.....
Tetracycline	14.75	7.03	2.10	11.83	24.83	.....
Dentist clean/check	153.50	103.26	1.49	15.51	23.06	.....
Doctor office visit	94.00	58.86	1.60	11.39	18.19	.....
Hospital room	1,100.00	625.35	1.76	2.89	5.08	.....
Health Insurance	1,260.90	1,232.98	1.02	47.72	48.80	.....
Contact Lenses	240.00	185.77	1.29	5.32	6.87	.....
Honolulu, HI:						
Medical care	.....	.....	.....	.....	.....	104.33
Non-aspirin pain reliever	9.10	6.95	1.31	5.34	7.00	.....
Tetracycline	7.74	7.03	1.10	11.83	13.03	.....
Dentist clean/check	123.92	103.26	1.20	15.51	18.61	.....
Doctor office visit	59.76	58.86	1.02	11.39	11.56	.....
Hospital room	675.99	625.35	1.08	2.89	3.12	.....
Health Insurance	1,170.63	1,232.98	0.95	47.72	45.31	.....
Contact Lenses	197.92	185.77	1.07	5.32	5.67	.....
Hilo, HI:						
Medical care	.....	.....	.....	.....	.....	99.48
Non-aspirin pain reliever	9.67	6.95	1.39	5.34	7.43	.....
Tetracycline	5.79	7.03	0.82	11.83	9.74	.....
Dentist clean/check	127.99	103.26	1.24	15.51	19.23	.....
Doctor office visit	66.93	58.86	1.14	11.39	12.95	.....
Hospital room	558.50	625.35	0.89	2.89	2.58	.....
Health Insurance	1,085.58	1,232.98	0.88	47.72	42.02	.....
Contact Lenses	192.49	185.77	1.04	5.32	5.51	.....
Kailua Kona, HI:						
Medical care	.....	.....	.....	.....	.....	99.97
Non-aspirin pain reliever	8.67	6.95	1.25	5.34	6.67	.....
Tetracycline	6.23	7.03	0.89	11.83	10.48	.....
Dentist clean/check	154.51	103.26	1.50	15.51	23.21	.....
Doctor office visit	49.82	58.86	0.85	11.39	9.64	.....
Hospital room	558.33	625.35	0.89	2.89	2.58	.....
Health Insurance	1,085.58	1,232.98	0.88	47.72	42.02	.....
Contact Lenses	187.35	185.77	1.01	5.32	5.37	.....
Kauai County, HI:						
Medical care	.....	.....	.....	.....	.....	96.07
Non-aspirin pain reliever	9.26	6.95	1.33	5.34	7.12	.....
Tetracycline	6.60	7.03	0.94	11.83	11.11	.....
Dentist clean/check	143.75	103.26	1.39	15.51	21.59	.....
Doctor office visit	40.68	58.86	0.69	11.39	7.87	.....
Hospital room	605.04	625.35	0.97	2.89	2.80	.....
Health Insurance	1,015.92	1,232.98	0.82	47.72	39.32	.....
Contact Lenses	218.17	185.77	1.17	5.32	6.25	.....
Maui County, HI:						
Medical care	.....	.....	.....	.....	.....	110.26
Non-aspirin pain reliever	7.85	6.95	1.13	5.34	6.03	.....
Tetracycline	6.53	7.03	0.93	11.83	10.98	.....
Dentist clean/check	162.50	103.26	1.57	15.51	24.41	.....
Doctor office visit	65.95	58.86	1.12	11.39	12.76	.....
Hospital room	558.50	625.35	0.89	2.89	2.58	.....
Health Insurance	1,206.89	1,232.98	0.98	47.72	46.71	.....
Contact Lenses	236.11	185.77	1.27	5.32	6.76	.....
Guam:						
Medical care	.....	.....	.....	.....	.....	124.85
Non-aspirin pain reliever	9.32	6.95	1.34	5.34	7.16	.....
Tetracycline	4.00	7.03	0.57	11.83	6.73	.....
Dentist clean/check	166.50	103.26	1.61	15.51	25.01	.....
Doctor office visit	49.00	58.86	0.83	11.39	9.48	.....
Hospital room	289.50	625.35	0.46	2.89	1.34	.....
Health Insurance	1,635.28	1,232.98	1.33	47.72	63.29	.....
Contact Lenses	413.33	185.77	2.23	5.32	11.84	.....
Puerto Rico:						
Medical care	.....	.....	.....	.....	.....	80.01
Non-aspirin pain reliever	6.65	6.95	0.96	5.34	5.11	.....
Tetracycline	4.00	7.03	0.57	11.83	6.73	.....
Dentist clean/check	95.33	103.26	0.92	15.51	14.32	.....

Category/item	Price	Price DC area	Ratio	Weights	Subtotal	Index
Doctor office visit	31.67	58.86	0.54	11.39	6.13	.....
Hospital room	510.92	625.35	0.82	2.89	2.36	.....
Health Insurance	923.04	1,232.98	0.75	47.72	35.72	.....
Contact Lenses	336.67	185.77	1.81	5.32	9.64	.....
St. Croix, VI:						
Medical care	.....	.....	.....	.....	.....	111.69
Non-aspirin pain reliever	7.97	6.95	1.15	5.34	6.13	.....
Tetracycline	6.13	7.03	0.87	11.83	10.32	.....
Dentist clean/check	91.67	103.26	0.89	15.51	13.77	.....
Doctor office visit	45.83	58.86	0.78	11.39	8.87	.....
Hospital room	650.00	625.35	1.04	2.89	3.00	.....
Health Insurance	1,636.82	1,232.98	1.33	47.72	63.35	.....
Contact Lenses	217.23	185.77	1.17	5.32	6.22	.....
St. Thomas, VI:						
Medical care	.....	.....	.....	.....	.....	118.59
Non-aspirin pain reliever	7.89	6.95	1.14	5.34	6.06	.....
Tetracycline	9.80	7.03	1.39	11.83	16.50	.....
Dentist clean/check	77.00	103.26	0.75	15.51	11.57	.....
Doctor office visit	61.25	58.86	1.04	11.39	11.85	.....
Hospital room	512.50	625.35	0.82	2.89	2.37	.....
Health Insurance	1,636.82	1,232.98	1.33	47.72	63.35	.....
Contact Lenses	240.00	185.77	1.29	5.32	6.87	.....

Appendix 20—Miscellaneous Expense Analysis—Total Index Development

	Category indexes	Lower income		Middle income		Upper income	
		Weights*	Subtotal	Weights*	Subtotal	Weights*	Subtotal
Anchorage, AK:							
1. Medical care	113.31	40.96	46.41	31.24	35.40	24.27	27.50
2. Cash contributions:							
Lower income	112.60	16.63	18.73	.....	.....	.....	.....
Middle income	112.33	.....	.....	16.27	18.28	.....	.....
Upper income	112.02	.....	.....	.....	.....	16.01	17.93
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27
4. Education	35.35	0.98	0.35	1.26	0.45	1.45	0.51
Total weights	.....	100.00	.....	100.00	.....	100.00	.....
Total indexes:							
Lower	.....	.....	106.93	.....	.....	.....	.....
Middle	.....	.....	.....	.....	105.37	.....	.....
Upper	.....	.....	.....	.....	.....	.....	104.21
Fairbanks, AK:							
1. Medical care	116.20	40.96	47.60	31.24	36.30	24.27	28.20
2. Cash contributions:							
Lower income	114.97	16.63	19.12	.....	.....	.....	.....
Middle income	114.84	.....	.....	16.27	18.68	.....	.....
Upper income	114.69	.....	.....	.....	.....	16.01	18.36
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27
4. Education	20.41	0.98	0.20	1.26	0.26	1.45	0.30
Total weights	.....	100.00	.....	100.00	.....	100.00	.....
Total indexes:							
Lower	.....	.....	108.36	.....	.....	.....	.....
Middle	.....	.....	.....	.....	106.48	.....	.....
Upper	.....	.....	.....	.....	.....	.....	105.13
Juneau, AK:							
1. Medical care	118.83	40.96	48.67	31.24	37.12	24.27	28.84
2. Cash contributions:							
Lower income	118.75	16.63	19.75	.....	.....	.....	.....
Middle income	118.56	.....	.....	16.27	19.29	.....	.....
Upper income	118.37	.....	.....	.....	.....	16.01	18.95
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27
4. Education	39.18	0.98	0.38	1.26	0.49	1.45	0.57
Total weights	.....	100.00	.....	100.00	.....	100.00	.....
Total indexes:							
Lower	.....	.....	110.24	.....	.....	.....	

	Category indexes	Lower income		Middle income		Upper income	
		Weights*	Subtotal	Weights*	Subtotal	Weights*	Subtotal
Middle	.....	.....	.....	.....	108.14	.....	.....
Upper	.....	.....	.....	.....	.....	.....	106.63
Nome, AK:							
1. Medical care	134.92	40.96	55.26	31.24	42.15	24.27	32.75
2. Cash contributions:							
Lower income	143.76	16.63	23.91	.....	.....	.....	.....
Middle income	143.15	.....	.....	16.27	23.29	.....	
Upper income	142.57	.....	.....	.....	.....	16.01	22.83
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27
4. Education	17.44	0.98	0.17	1.26	0.22	1.45	0.25
Total weights	.....	100.00	.....	100.00	.....	100.00	.....
Total indexes:							
Lower	.....	.....	120.78	.....	.....	.....	.....
Middle	.....	.....	.....	.....	116.90	.....	.....
Upper	.....	.....	.....	.....	.....	.....	114.10
Honolulu, HI:							
1. Medical care	104.33	40.96	42.73	31.24	32.59	24.27	25.32
2. Cash contributions:							
Lower income	118.38	16.63	19.69	.....	.....	.....	.....
Middle income	117.72	.....	.....	16.27	19.15	.....	.....
Upper income	117.10	.....	.....	.....	.....	16.01	18.75
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27
4. Education	177.14	0.98	1.74	1.26	2.23	1.45	2.57
Total weights	.....	100.00	.....	100.00	.....	100.00	.....
Total indexes:							
Lower	.....	.....	105.60	.....	.....	.....	.....
Middle	.....	.....	.....	.....	105.21	.....	.....
Upper	.....	.....	.....	.....	.....	.....	104.91
Hilo, HI:							
1. Medical care	99.48	40.96	40.75	31.24	31.08	24.27	24.14
2. Cash contributions:							
Lower income	114.12	16.63	18.98	.....	.....	.....	.....
Middle income	113.08	.....	.....	16.27	18.40	.....	.....
Upper income	112.09	.....	.....	.....	.....	16.01	17.95
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27
4. Education	173.58	0.98	1.70	1.26	2.19	1.45	2.52
Total weights	.....	100.00	.....	100.00	.....	100.00	.....
Total indexes:							
Lower	.....	.....	102.87	.....	.....	.....	.....
Middle	.....	.....	.....	.....	102.91	.....	.....
Upper	.....	.....	.....	.....	.....	.....	102.88
Kailua Kona, HI:							
1. Medical care	99.97	40.96	40.95	31.24	31.23	24.27	24.26
2. Cash contributions:							
Lower income	117.91	16.63	19.61	.....	.....	.....	.....
Middle income	117.02	.....	.....	16.27	19.04	.....	.....
Upper income	116.19	.....	.....	.....	.....	16.01	18.60
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27
4. Education	135.21	0.98	1.33	1.26	1.70	1.45	1.96
Total weights	.....	100.00	.....	100.00	.....	100.00	.....
Total indexes:							
Lower	.....	.....	103.33	.....	.....	.....	.....
Middle	.....	.....	.....	.....	103.21	.....	.....
Upper	.....	.....	.....	.....	.....	.....	103.09
Kauai County, HI:							
1. Medical care	96.07	40.96	39.35	31.24	30.01	24.27	23.32
2. Cash contributions:							
Lower income	124.36	16.63	20.68	.....	.....	.....	.....
Middle income	122.97	.....	.....	16.27	20.01	.....	.....
Upper income	121.70	.....	.....	.....	.....	16.01	19.48
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27

	Category indexes	Lower income		Middle income		Upper income	
		Weights*	Subtotal	Weights*	Subtotal	Weights*	Subtotal
4. Education	132.28	0.98	1.30	1.26	1.67	1.45	1.92
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			102.77				
Middle					102.93		
Upper							102.99
Maui County, HI:							
1. Medical care	110.26	40.96	45.16	31.24	34.45	24.27	26.76
2. Cash contributions:							
Lower income	124.43	16.63	20.69				
Middle income	123.53			16.27	20.10		
Upper income	122.66					16.01	19.64
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27
4. Education	73.39	0.98	0.72	1.26	0.92	1.45	1.06
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			108.01				
Middle					106.71		
Upper							105.73
Guam:							
1. Medical care	124.85	40.96	51.14	31.24	39.00	24.27	30.30
2. Cash contributions:							
Lower income	120.36	16.63	20.02				
Middle income	120.33			16.27	19.58		
Upper income	120.28					16.01	19.26
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27
4. Education	242.12	0.98	2.37	1.26	3.05	1.45	3.51
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			114.97				
Middle					112.87		
Upper							111.34
Puerto Rico:							
1. Medical care	80.01	40.96	32.77	31.24	25.00	24.27	19.42
2.Cash contributions:							
Lower income	109.33	16.63	18.18				
Middle income	109.27			16.27	17.78		
Upper income	109.18					16.01	17.48
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27
4. Education	211.32	0.98	2.07	1.26	2.66	1.45	3.06
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			94.46				
Middle					96.68		
Upper							98.23
St. Croix, VI:							
1. Medical care	111.69	40.96	45.75	31.24	34.89	24.27	27.11
2. Cash contributions:							
Lower income	118.65	16.63	19.73				
Middle	118.70			16.27	19.31		
Upper income	118.75					16.01	19.01
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27
4. Education	245.79	0.98	2.41	1.26	3.10	1.45	3.56
Total weights		100.00		100.00		100.00	
Total indexes:							
Lower			109.33				
Middle					108.54		
Upper							107.95

	Category indexes	Lower income		Middle income		Upper income	
		Weights*	Subtotal	Weights*	Subtotal	Weights*	Subtotal
St. Thomas, VI:							
1. Medical care	118.59	40.96	48.57	31.24	37.05	24.27	28.78
2. Cash contributions:							
Lower income	118.72	16.63	19.74	.....	.....	.....	.....
Middle income	118.15	.....	.....	16.27	19.22	.....	.....
Upper income	117.64	.....	.....	.....	.....	16.01	18.83
3. Personal insurance/pensions	100.00	41.44	41.44	51.24	51.24	58.27	58.27
4. Education	274.01	0.98	2.69	1.26	3.45	1.45	3.97
Total weights	.....	100.00	.....	100.00	.....	100.00	.....
Total indexes:							
Lower	.....	.....	112.44	.....	.....	.....	.....
Middle	.....	.....	.....	.....	110.96	.....	.....
Upper	.....	.....	.....	.....	.....	.....	109.85

*Numbers might not add to 100 due to rounding.

MISCELLANEOUS EXPENSE ANALYSIS—COMPOSITES

Location	Weights	Total Indexes		
		Lower income	Middle income	Upper income
Hilo, HI	75.81	102.87	102.91	102.88
Kailua Kona, HI	24.19	103.33	103.21	103.09
Total weight	100.00			
Hawaii County, HI	N/A	102.98	102.98	102.93
St. Croix, VI	48.26	109.33	108.54	107.95
St. Thomas, VI	51.74	112.44	110.96	109.85
Total weight	100.00			
Virgin Islands	N/A	110.94	109.79	108.93

Appendix 21—Component Expenditure Amounts

	Incomes	Indexes					Amounts				
		CG&S	Own	Rent	Transp	Misc	CG&S	Own	Rent	Transp	Misc
Reference Wts/Amts	23,300	38.07	26.42	26.42	19.24	16.27	$8,870	$6,156	$6,156	$4,483	$3,791
	35,300	37.48	25.00	25.00	19.12	18.40	13,230	8,825	8,825	6,749	6,495
	52,700	36.96	23.72	23.72	19.01	20.32	19,478	12,500	12,500	10,018	10,709
Anchorage, AK	Lower	112.60	100.68	97.21	120.29	106.93	9,988	6,198	5,984	5,393	4,054
	Middle	112.33	92.09	84.85	120.94	105.37	14,861	8,127	7,488	8,162	6,844
	Upper	112.02	76.83	78.78	121.55	104.21	21,819	9,604	9,848	12,177	11,160
Fairbanks, AK	Lower	114.97	98.72	98.77	129.03	108.36	10,198	6,077	6,080	5,784	4,108
	Middle	114.84	91.58	94.03	130.12	106.48	15,193	8,082	8,298	8,782	6,916
	Upper	114.69	74.40	75.07	131.12	105.13	22,339	9,300	9,384	13,136	11,258
Juneau, AK	Lower	118.75	116.97	123.71	115.35	110.24	10,533	7,201	7,616	5,171	4,179
	Middle	118.56	102.63	108.10	116.45	108.14	15,685	9,057	9,540	7,859	7,024
	Upper	118.37	82.73	93.43	117.47	106.63	23,056	10,341	11,679	11,768	11,419
Nome, AK	Lower	143.76	112.25	138.27	157.16	120.78	12,752	6,910	8,512	7,045	4,579
	Middle	143.15	104.23	118.31	159.40	116.90	18,939	9,198	10,441	10,758	7,593
	Upper	142.57	87.17	86.67	161.45	114.10	27,770	10,896	10,834	16,174	12,219
Honolulu, HI	Lower	118.38	181.98	117.80	134.31	105.60	10,500	11,203	7,252	6,021	4,003
	Middle	117.72	169.13	106.99	135.47	105.21	15,574	14,926	9,442	9,143	6,833
	Upper	117.10	171.14	101.56	136.53	104.91	22,809	21,393	12,695	13,678	11,235
Hawaii County, HI	Lower	115.04	117.65	88.71	137.08	102.98	10,204	7,243	5,461	6,145	3,904
	Middle	114.03	108.41	81.96	138.72	102.98	15,086	9,567	7,233	9,362	6,689
	Upper	113.08	89.13	66.08	140.24	102.93	22,026	11,141	8,260	14,049	11,023
Kauai County, HI	Lower	124.36	145.54	101.12	138.48	102.77	11,031	8,959	6,225	6,208	3,896
	Middle	122.97	132.32	85.32	140.12	102.93	16,269	11,677	7,529	9,457	6,685

	Incomes	Indexes					Amounts				
		CG&S	Own	Rent	Transp	Misc	CG&S	Own	Rent	Transp	Misc
	Upper	121.70	108.23	70.22	141.63	102.99	23,705	13,529	8,778	14,188	11,029
Maui County, HI	Lower	124.43	163.39	110.62	133.67	108.01	11,037	10,058	6,810	5,992	4,095
	Middle	123.53	148.13	96.49	135.20	106.71	16,343	13,072	8,515	9,125	6,931
	Upper	122.66	119.25	79.24	136.61	105.73	23,892	14,906	9,905	13,686	11,323
Guam (Local Retail)	Lower	120.36	143.73	127.66	148.25	114.97	10,676	8,848	7,859	6,646	4,359
	Middle	120.33	127.35	118.37	150.88	112.87	15,920	11,239	10,446	10,183	7,331
	Upper	120.28	121.22	92.07	153.29	111.34	23,428	15,153	11,509	15,357	11,923
Guam (Comm.&Exch.)	Lower	108.58	143.73	127.66	148.25	114.97	9,631	8,848	7,859	6,646	4,359
	Middle	109.35	127.35	118.37	150.88	112.87	14,467	11,239	10,446	10,183	7,331
	Upper	110.05	121.22	92.07	153.29	111.34	21,436	15,153	11,509	15,357	11,923
Puerto Rico	Lower	109.33	78.32	104.60	130.57	94.46	9,698	4,821	6,439	5,853	3,581
	Middle	109.27	77.94	96.08	130.96	96.68	14,456	6,878	8,479	8,838	6,279
	Upper	109.18	78.55	93.78	131.32	98.23	21,266	9,819	11,723	13,156	10,519
Virgin Islands	Lower	118.69	131.42	99.11	135.30	110.94	10,528	8,090	6,101	6,065	4,206
	Middle	118.42	114.43	97.28	136.33	109.79	15,667	10,098	8,585	9,201	7,131
	Upper	118.18	103.51	80.00	137.28	108.93	23,019	12,939	10,000	13,753	11,665

Appendix 22—Total Comparative Cost Indexes

	Income	Income weights	Own	Rent	Total	WDC	Index
	Lower	23,300	37.96	62.04	.....	.....	.....
	Middle	35,300	47.26	52.74	.....	.....	.....
	Upper	52,700	60.70	39.30			
Anchorage, AK	Lower	27.02	$25,633	$25,419	$25,500	$23,300	.....
	Middle	30.64	37,994	37,355	37,657	35,300	.....
	Upper	42.34	54,760	55,004	54,856	52,700	.....
	.....	100.00	.....	.....	41,654	39,425	105.65
Fairbanks, AK	Lower	35.20	26,167	26,170	26,169	23,300	.....
	Middle	34.79	38,973	39,189	39,087	35,300	.....
	Upper	30.01	56,033	56,117	56,066	52,700	.....
	.....	100.00	.....	.....	39,635	36,298	109.19
Juneau, AK	Lower	18.91	27,084	27,499	27,341	23,300	.....
	Middle	29.77	39,625	40,108	39,880	35,300	.....
	Upper	51.32	56,584	57,922	57,110	52,700	.....
	.....	100.00	.....	.....	46,351	41,960	110.46
Nome, AK	Lower	23.96	31,286	32,888	32,280	23,300	.....
	Middle	45.51	46,488	47,731	47,144	35,300	.....
	Upper	30.53	67,059	66,997	67,035	52,700	.....
	.....	100.00	.....	.....	49,655	37,737	131.58
Honolulu, HI	Lower	33.01	31,727	27,776	29,276	23,300	.....
	Middle	31.19	46,476	40,992	43,584	35,300	.....
	Upper	35.80	69,115	60,417	65,697	52,700	.....
	.....	100.00	.....	.....	46,777	37,568	124.51
Hawaii County, HI	Lower	35.40	27,496	25,714	26,390	23,300	.....
	Middle	40.10	40,704	38,370	39,473	35,300;	
	Upper	24.50	58,239	55,358	57,107	52,700	.....
	.....	100.00	.....	.....	39,162	35,315	110.89
Kauai County, HI	Lower	27.23	30,094	27,360	28,398	23,300	.....
	Middle	32.59	44,088	39,940	41,900	35,300	.....
	Upper	40.18	62,451	57,700	60,584	52,700	.....
	.....	100.00	.....	.....	45,731	39,024	117.19
Maui County, HI	Lower	22.79	31,182	27,934	29,167	23,300	.....
	Middle	44.12	45,471	40,914	43,068	35,300	.....
	Upper	33.09	63,807	58,806	61,842	52,700	.....
	.....	100.00	.....	.....	46,112	38,323	120.32
Guam (Local Retail)	Lower	45.15	30,529	29,540	29,915	23,300	.....
	Middle	32.67	44,673	43,880	44,255	35,300	.....
	Upper	22.18	65,861	62,217	64,429	52,700	.....

	Income	Income weights	Own	Rent	Total	WDC	Index
	.....	100.00	.....	.....	42,255	33,741	125.23
Guam (Comm.&Exch.)	Lower	45.15	29,484	28,495	28,870	23,300	.....
	Middle	32.67	43,220	42,427	42,802	35,300	.....
	Upper	22.18	63,869	60,225	62,437	52,700	.....
	.....	100.00	.....	.....	40,867	33,741	121.12
Puerto Rico	Lower	39.89	23,953	25,571	24,957	23,300	.....
	Middle	37.34	36,451	38,052	37,295	35,300	.....
	Upper	22.77	54,760	56,664	55,508	52,700	.....
	.....	100.00	.....	.....	36,520	34,475	105.93
Virgin Islands	Lower	32.49	28,889	26,900	27,655	23,300	.....
	Middle	41.96	42,097	40,584	41,299	35,300	.....
	Upper	25.55	61,376	58,437	60,221	52,700	.....
	.....	100.00	.....	.....	41,701	35,847	116.33

[FR Doc. 00–17570 Filed 7–14–00; 8:45 am]

BILLING CODE 6325–01–P

Federal Register

Monday,
July 17, 2000

Part III

Department of Health and Human Services

Health Care Financing Administration

42 CFR Parts 410 and 414

Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2001; Proposed Rule

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

42 CFR Parts 410 and 414

[HCFA–1120–P]

RIN 0938–AK11

Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2001

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: Proposed rule.

SUMMARY: This proposed rule would make several changes affecting Medicare Part B payment. The changes include: Refinement of resource-based practice expense relative value units (RVUs); changes to the geographic practice cost indices; resource-based malpractice RVUs; critical care RVUs; care plan oversight and physician certification/recertification; observation care codes; ocular photodynamic therapy and other ophthalmological treatments; electrical bioimpedance; the global period for insertion, removal, and replacement of pacemakers and cardioverter defibrillators; antigen supply; low intensity ultrasound; and the implantation of ventricular assist devices. This proposed rule also discusses or clarifies the payment policy for incomplete medical direction, pulse oximetry services, outpatient therapy supervision, outpatient therapy caps, and the second 5-year refinement of work RVUs for services furnished beginning January 1, 2002. We are proposing these changes to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services. We solicit comments on the proposed policy changes.

DATES: To be assured of consideration, we must receive comments at the appropriate address, as provided below, no later than 5 p.m. on September 15, 2000.

ADDRESSES: Mail written comments (1 original and 3 copies) to the following address only: Health Care Financing Administration, Department of Health and Human Services, Attention: HCFA–1120–P, P.O. Box 8013, Baltimore, MD 21244–8013.

Please allow sufficient time for mailed comments to be timely received in the event of delivery delays. If you prefer, you may deliver your written comments by courier (1 original and 3 copies) to one of the following addresses: Room 443–G, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201 or Room C5–14–03, 7500 Security Boulevard, Baltimore, MD 21244.

Comments mailed to the two above addresses may be delayed and received too late to be considered.

Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission. In commenting, please refer to file code HCFA–1120–P. Comments received timely will be available for public inspection as they are received, generally beginning approximately 3 weeks after publication of a document, in Room 443–G of the Department's office at 200 Independence Avenue, SW., Washington, DC, on Monday through Friday of each week from 8:30 to 5 p.m. (phone: (202) 690–7890).

FOR FURTHER INFORMATION CONTACT:

Bob Ulikowski, (410) 786–5721 (for issues related to resource-based malpractice relative value units and geographic practice cost index changes).

Carolyn Mullen, (410) 786–4589 or Marc Hartstein, (410) 786–4539, (for issues related to resource-based practice expense relative value units).

Rick Ensor, (410) 786–5617 (for issues related to care plan oversight and physician certification/recertification).

Jim Menas, (410) 786–4507 (for issues related to incomplete medical direction and the 5-year review).

Roberta Epps, (410) 786–1858 (for outpatient therapy-related issues).

Cathleen Scally, (410) 786–5714 (for issues related to observation care codes).

Diane Milstead, (410) 786–3355 (for all other issues).

SUPPLEMENTARY INFORMATION:

Copies: To order copies of the **Federal Register** containing this document, send your request to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250–7954. Specify the date of the issue requested and enclose a check or money order payable to the Superintendent of Documents, or enclose your Visa or Master Card number and expiration date. Credit card orders can also be placed by calling the order desk at (202) 512–1800 or by faxing to (202) 512–2250. The cost for each copy is $8. As an alternative, you can view and photocopy the **Federal Register** document at most libraries designated as Federal Depository Libraries and at many other public and academic libraries throughout the country that receive the **Federal Register**. This **Federal Register** document is also available from the Federal Register online database through GPO Access, a service of the U.S. Government Printing Office. The Website address is: http://www.access.gpo.gov/nara/index.html.

Information on the Lewin report referenced in the preamble can be found on our homepage. This data can be accessed by using the following directions:

1. Go to the HCFA homepage (http://www.hcfa.gov).
2. Click on ''Medicare.''
3. Click on ''Professional/Technical Information.''
4. Select Medicare Payment Systems.
5. Select Physician Fee Schedule.

Or, you can go directly to the Physician Fee Schedule page by typing the following: http://www.hcfa.gov/medicare/pfsmain.htm.

To assist readers in referencing sections contained in this preamble, we are providing the following table of contents. Some of the issues discussed in this preamble affect the payment policies but do not require changes to the regulations in the Code of Federal Regulations.

Table of Contents

I. Background
- A. Legislative History
- B. Published Changes to the Fee Schedule

II. Specific Proposals for Calendar Year 2001
- A. Resource-Based Practice Expense Relative Value Units
- B. Geographic Practice Cost Index Changes
- C. Resource-Based Malpractice Relative Value Units
- D. Critical Care Relative Value Units
- E. Care Plan Oversight and Physician Certification/Recertification
- F. Observation Care Codes
- G. Ocular Photodynamic Therapy and Other Ophthalmalogical Treatments
- H. Electrical Bioimpedance
- I. Global Period for Insertion, Removal, and Replacement of Pacemakers and Cardioverter Defibrillators
- J. Antigen Supply
- K. Low Intensity Ultrasound
- L. Implantation of Ventricular Assist Devices

III. Other Issues
- A. Incomplete Medical Direction
- B. Payment for Pulse Oximetry Services
- C. Outpatient Therapy Supervision
- D. Outpatient Therapy Caps

IV. Five Year Refinement of Relative Value Units

V. Collection of Information Requirements

VI. Response to Comments

VII. Regulatory Impact Analysis

VIII. Federalism

Addendum A—Explanation and Use of Addendum B

Addendum B—2001 Relative Value Units and Related Information Used in Determining Medicare Payments for 2001

Addendum C—Clinical Staff Times for Selected Codes

Addendum D—Comparison of 1999 and Proposed 2002 Office Rent Index By Fee Schedule Area

Addendum E—Comparison of 1999 and Proposed 2002 Malpractice GPCIs By Fee Schedule Area
Addendum F—2002 Geographic Practice Cost Indices by Medicare Carrier and Locality
Addendum G—2001 Geographic Practice Cost Indices by Medicare Carrier and Locality
Addendum H—Proposed 2002 Versus 1999 Geographic Adjustment Factors (GAF)

In addition, because of the many organizations and terms to which we refer by acronym in this proposed rule, we are listing these acronyms and their corresponding terms in alphabetical order below:

AMA American Medical Association
BBA Balanced Budget Act of 1997
BBRA Balanced Budget Refinement Act
CF Conversion factor
CFR Code of Federal Regulations
CPT [Physicians'] Current Procedural Terminology [4th Edition, 1997, copyrighted by the American Medical Association]
CPEP Clinical Practice Expert Panel
CRNA Certified Registered Nurse Anesthetist
E/M Evaluation and management
EB Electrical bioimpedance
FMR Fair market rental
GAF Geographic adjustment factor
GPCI Geographic practice cost index
HCFA Health Care Financing Administration
HCPCS HCFA Common Procedure Coding System
HHA Home health agency
HHS [Department of] Health and Human Services
IDTFs Independent Diagnostic Testing Facilities
MCM Medicare Carrier Manual
MEDPAC Medicare Payment Advisory Commission
MEI Medicare Economic Index
MGMA Medical Group Management Association
MSA Metropolitan Statistical Area
NAMCS National Ambulatory Medical Care Survey
OBRA Omnibus Budget Reconciliation Act
PC Professional component
PEAC Practice Expense Advisory Committee
PPAC Practicing Physicians Advisory Council
PPS Prospective payment system
RUC [AMA's Specialty Society] Relative [Value] Update Committee
RVU Relative value unit
SGR Standard growth rate
SMS [AMA's] Socioeconomic Monitoring System
TC Technical component

I. Background

A. *Legislative History*

Since January 1, 1992, Medicare has paid for physician services under section 1848 of the Social Security Act (the Act), ''Payment for Physicians' Services.'' This section contains three major elements—(1) a fee schedule for the payment of physicians' services; (2) a sustainable growth rate for the rates of increase in Medicare expenditures for physicians' services; and (3) limits on the amounts that nonparticipating physicians can charge beneficiaries. The Act requires that payments under the fee schedule be based on national uniform relative value units (RVUs) based on the resources used in furnishing a service. Section 1848(c) of the Act requires that national RVUs be established for physician work, practice expense, and malpractice expense.

Section 1848(c)(2)(B)(ii)(II) of the Act provides that adjustments in RVUs may not cause total physician fee schedule payments to differ by more than $20 million from what they would have been had the adjustments not been made. If adjustments to RVUs cause expenditures to change by more than $20 million, we must make adjustments to the conversion factors (CFs) to preserve budget neutrality.

B. *Published Changes to the Fee Schedule*

We published a final rule on November 25, 1991 (56 FR 59502) to implement section 1848 of the Act by establishing a fee schedule for physicians' services furnished on or after January 1, 1992. In the November 1991 final rule (56 FR 59511), we stated our intention to update RVUs for new and revised codes in the American Medical Association's (AMA's) Physicians' Current Procedural Terminology (CPT) through an ''interim RVU'' process every year. We published the updates to the RVUs and fee schedule policies are as follows:

- November 25, 1992, a final notice with comment period on new and revised RVUs only (57 FR 55914).
- December 2, 1993, a final rule with comment period (58 FR 63626) revised the refinement process used to establish physician work RVUs and to revise payment policies for specific physicians' services and supplies. (We solicited comments on new and revised RVUs only.)
- December 8, 1994, a final rule with comment period (59 FR 63410) revised the geographic adjustment factor (GAF) values, fee schedule payment areas, and payment policies for specific physicians' services. The final rule also discussed the process for periodic review and adjustment of RVUs not less frequently than every 5 years as required by section 1848(c)(2)(B)(i) of the Act.
- December 8, 1995, a final rule with comment period (60 FR 63124) revised various policies affecting payment for physicians' services including Medicare payment for physicians' services in teaching settings, the RVUs for certain existing procedure codes, and established interim RVUs for new and revised procedure codes. The rule also included the final revised 1996 geographic practice cost indices (GPCIs).
- November 22, 1996, a final rule with comment period (61 FR 59490) revised the policy for payment for diagnostic services, transportation in connection with furnishing diagnostic tests, changes in geographic payment areas (localities), and changes in the procedure status codes for a variety of services.
- October 31, 1997, a final rule with comment period (62 FR 59048) revised the GPCIs, physician supervision of diagnostic tests, establishment of independent diagnostic testing facilities, the methodology used to develop reasonable compensation equivalent limits, payment to participating and nonparticipating suppliers, global surgical services, caloric vestibular testing, and clinical consultations. It also implemented certain provisions of the Balanced Budget Act of 1997 (BBA) (Public Law 105–33), enacted on August 5, 1997, and implemented the RVUs for certain existing procedure codes and established interim RVUs for new and revised procedure codes.
- November 2, 1998, a final rule with comment period (63 FR 58814) revised the policy for resource-based practice expense RVUs, medical direction rules for anesthesia services, and payment for abnormal Pap smears. We also rebased the Medicare economic index (MEI) from a 1989 base year to a 1996 base year. Under the law, we were also required to develop a resource-based system for determining practice expense RVUs. The BBA delayed, for 1 year, implementation of the resource-based practice expense RVUs until January 1, 1999. Also, the BBA revised our payment policy for nonphysician practitioners, for outpatient rehabilitation services, and for drugs and biologicals not paid on a cost or prospective payment basis. In addition, the BBA permitted certain physicians and practitioners to opt out of Medicare and furnish covered services to Medicare beneficiaries through private contracts and permits payment for professional consultations via

interactive telecommunication systems. Furthermore, we finalized the 1998 interim RVUs and issued interim RVUs for new and revised codes for 1999. The final rule also announced the CY 1999 Medicare physician fee schedule CF under the Medicare Supplementary Medical Insurance (Part B) program as required by section 1848(d) of the Act. The 1999 Medicare physician fee schedule CF was $34.7315.

• November 2, 1999, a final rule with comment period (64 FR 59380) made several changes affecting Medicare Part B payment. The changes included: implementation of resource-based malpractice insurance RVUs; refinement of resource-based practice expense RVUs; payment for physician pathology and independent laboratory services; discontinuous anesthesia time; diagnostic tests; prostate screening; use of CPT modifier -25; qualifications for nurse practitioners; an increase in the work RVUs for pediatric services; adjustments to the practice expense RVUs for physician interpretation of Pap smears; and a number of other changes relating to coding and payment. Furthermore, we finalized the 1999 interim physician work RVUs and issued interim RVUs for new and revised codes for 2000. The final rule solicited public comments on the second 5-year refinement of work RVUs for services furnished beginning January 1, 2002 and requested public comments on potentially misvalued work RVUs for all services in the CY 2000 physician fee schedule. The final rule conformed the regulations to existing law and policy regarding: removal of the x-ray as a prerequisite for chiropractic manipulation; the exclusion of payment for assisted suicide; and optometrist services. The final rule also announced the CY 2000 Medicare physician fee schedule CF under the Medicare Supplementary Medical Insurance (Part B) program as required by section 1848(d) of the Act. The 2000 Medicare physician fee schedule CF was $36.6137.

This proposed rule would affect the regulations set forth at Part 410, Supplementary medical insurance (SMI) benefits and Part 414, Payment for Part B medical and other services.

II. Specific Proposals for Calendar Year 2001

A. Resource-Based Practice Expense Relative Value Units

1. Resource-Based Practice Expense Legislation

Section 121 of the Social Security Act Amendments of 1994 (Public Law 103–432), enacted on October 31, 1994, required us to develop a methodology for a resource-based system for determining practice expense RVUs for each physician's service beginning in 1998. In developing the methodology, we were to consider the staff, equipment, and supplies used in providing medical and surgical services in various settings. The legislation specifically required that, in implementing the new system of practice expense RVUs, we must apply the same budget-neutrality provisions that we apply to other adjustments under the physician fee schedule.

Section 4505(a) of the BBA delayed the effective date of the resource-based practice expense RVU system until January 1, 1999. In addition, section 4505(b) of the BBA provided for a 4-year transition period from charge-based practice expense RVUs to resource-based RVUs. The practice expense RVUs for CY 1999 were the product of 75 percent of charge-based RVUs and 25 percent of the resource-based RVUs. For CY 2000, the RVUs were 50 percent charge-based and 50 percent resource-based. For CY 2001, the RVUs will be 25 percent charge-based and 75 percent resource-based. After CY 2001, the RVUs will be totally resource-based.

Section 4505(e) of the BBA provided that, in 1998, the practice expense RVUs be adjusted for certain services in anticipation of implementation of resource-based practice expenses beginning in 1999. As a result, we increased practice expense RVUs for office visits. For other services in which practice expense RVUs exceeded 110 percent of the work RVUs and were furnished less than 75 percent of the time in an office setting, we reduced the 1998 practice expense RVUs to a number equal to 110 percent of the work RVUs. This limitation did not apply to services that had proposed resource-based practice expense RVUs that increased from their 1997 practice expense RVUs as reflected in the June 18, 1997 proposed rule (62 FR 33196). The services affected, and the final RVUs for 1998, were published in the October 1997 final rule (62 FR 59103).

The most recent legislation affecting resource-based practice expense was included in the Balanced Budget Refinement Act of 1999 (BBRA) (Public Law 106–113). Section 212 of the BBRA stated that we must establish a process under which we accept and use, to the maximum extent practicable and consistent with sound data practices, data collected or developed by entities and organizations. These data would supplement the data we normally collect in determining the practice expense component of the physician fee schedule for payments in CY 2001 and CY 2002.

2. Current Methodology for Computing Practice Expense Relative Value Unit System

Effective with services on or after January 1, 1999, we established a new methodology for computing resource-based practice expense RVUs that used the two significant sources of actual practice expense data we have available: the Clinical Practice Expert Panel (CPEP) data and the AMA's Socioeconomic Monitoring System (SMS) data. The methodology was based on an assumption that current aggregate specialty practice costs are a reasonable way to establish initial estimates of relative resource costs of physicians' services across specialties. The methodology allocated these aggregate specialty practice costs to specific procedures and, thus, can be seen as a ''top-down'' approach. The methodology can be summarized as follows:

(a) Practice Expense Cost Pools. We used actual practice expense data by specialty, derived from the 1995 through 1997 SMS survey data, to create six cost pools—administrative labor, clinical labor, medical supplies, medical equipment, office supplies, and all other expenses. There were three steps in the creation of the cost pools.

• Step (1) We used the AMA's SMS survey of actual cost data to determine practice expenses per hour by cost category. The practice expenses per hour for each physician respondent's practice was calculated as the practice expenses for the practice divided by the total number of hours spent in patient care activities. The practice expenses per hour for the specialty were an average of the practice expenses per hour for the respondent physicians in that specialty. In addition, for the CY 2000 physician fee schedule, we used data from a survey submitted by the Society of Thoracic Surgeons in calculating the thoracic and cardiac surgery's practice expense per hour. (See the November 1999 final rule (64 FR 59391) for additional information concerning acceptance of this data.)

• Step (2) We determined the total number of physician hours (by specialty) spent treating Medicare patients. This was calculated from physician time data for each procedure code and from Medicare claims data.

• Step (3) We calculated the practice expense pools by specialty and by cost category by multiplying the specialty practice expenses per hour for each category by the total physician hours.

For services with work RVUs equal to zero (including the technical component (TC) of services with a TC and professional component (PC)), we created a separate practice expense pool using the average clinical staff time from the CPEP data (since these codes by definition do not have physician time), and the ''all physicians'' practice expense per hour.

(b) Cost Allocation Methodology. For each specialty, we separated the six practice expense pools into two groups and used a different allocation basis for each group.

(1) Direct Costs

For direct costs (including clinical labor, medical supplies, and medical equipment), we used the CPEP data as the allocation basis. The CPEP data for clinical labor, medical supplies, and medical equipment were used to allocate the clinical labor, medical supplies, and medical equipment cost pools, respectively.

For the separate practice expense pool for services with work RVUs equal to zero, we used 1998 practice expense RVUs to allocate the direct cost pools (clinical labor, medical supplies, and medical equipment cost pools) as an interim measure. Also, for all radiology services that are assigned work RVUs, we used the 1998 practice expense relative values for radiology services as an interim measure to allocate the direct practice expense cost pool for radiology. For all other specialties that perform radiology services, we used the CPEP data for radiology services in the allocation of that specialty's direct practice expense cost pools.

(2) Indirect Costs

To allocate the cost pools for indirect costs, including administrative labor, office expenses, and all other expenses, we used the total direct costs, as described above, in combination with the physician fee schedule work RVUs. We converted the work RVUs to dollars using the Medicare CF (expressed in 1995 dollars for consistency with the SMS survey years).

The SMS pool was divided by the CPEP pool for each specialty to produce a scaling factor that was applied to the CPEP direct cost inputs. This was intended to match costs counted as practice expenses in the SMS survey with items counted as practice expense in the CPEP process. When the specialty specific scaling factor exceeds the average scaling factor by more than three standard deviations, we used the average scaling factor. (See the November 1999 final rule (64 FR 59390) for further discussion of this issue).

For procedures performed by more than one specialty, the final procedure code allocation was a weighted average of allocations for the specialties that perform the procedure, with the weights being the frequency with which each specialty performs the procedure on Medicare patients.

(c) Other Methodological Issues.

(1) Global Practice Expense Relative Value Units

For services with the PC and TC paid under the physician fee schedule, the global practice expense RVUs were set equal to the sum of the PC and TC.

(2) Practice Expenses Per Hour Adjustments and Specialty Crosswalks

Since many specialties identified in our claims data did not correspond exactly to the specialties included in the practice expense tables from the SMS survey data, it was necessary to crosswalk these specialties to the most appropriate SMS specialty category. We also made the following adjustments to the practice expense per hour data (for the rationale for these adjustments to the practice expense per hour see the November 1998 final rule (63 FR 58841):

- We set the medical materials and supplies practice expenses per hour for the specialty of ''oncology'' equal to the ''all physician'' medical materials and supplies practice expenses per hour.
- We based the administrative payroll, office, and other practice expenses per hour for the specialties of ''physical therapy'' and ''occupational therapy'' on data used to develop the salary equivalency guidelines for these specialties. We set the remaining practice expense per hour categories equal to the ''all physician'' practice expenses per hour from the SMS survey data.
- Due to uncertainty concerning the appropriate crosswalk and time data for the nonphysician specialty ''audiologist,'' we derived the resource-based practice expense RVUs for codes performed by audiologists from the practice expenses per hour of the other specialties that perform these codes.
- For the specialty of ''emergency medicine,'' we used the ''all physician'' practice expense per hour to create practice expense cost pools for the categories ''clerical payroll'' and ''other expenses.''
- For the specialty of ''podiatry,'' we used the ''all physician'' practice expense per hour to create the practice expense pool.
- For the specialty of ''pathology,'' we removed the supervision and autopsy hours reimbursed through Part A of the Medicare program from the practice expense per hour calculation.
- For the specialty ''maxillofacial prosthetics,'' we used the ''all physician'' practice expense per hour to create practice expense cost pools and, as an interim measure, allocated these pools using the 1998 practice expense RVUs.
- We split the practice expenses per hour for the specialty ''radiology'' into ''radiation oncology'' and ''radiology other than radiation oncology'' and used this split practice expense per hour to create practice expense cost pools for these specialties.

(3) Time Associated With the Work RVUs

The time data resulting from the refinement of the work RVUs have been, on average, 25 percent greater than the time data obtained by the Harvard study for the same services. We increased the Harvard research team's time data to ensure consistency between these data sources.

For services with no assigned physician time (such as, dialysis, physical therapy, psychology, and many radiology and other diagnostic services), we calculated estimated total physician time based on work RVUs, maximum clinical staff time for each service as shown in the CPEP data, or the judgment of our clinical staff.

We calculated the time for CPT codes 00100 through 01996 using the base and time units from the anesthesia fee schedule and the Medicare allowed claims data.

3. Refinement

(a) Background. Section 4505(d)(1)(C) of the BBA required us to develop a refinement process to be used during each of the 4 years of the transition period. We did not propose a specific long-term refinement process in the June 1998 proposed rule (63 FR 30835). Rather, we set out the parameters for an acceptable refinement process for practice expense RVUs and solicited comments on our proposal. We received a large variety of comments about broad methodology issues, practice expense per hour data, and detailed code level data. We made some adjustments to our proposal when we were convinced an adjustment was appropriate. We also indicated that we would consider other comments for possible refinement and that the values of all codes would be considered interim for 1999 and for future years during the transition period.

We outlined in the November 1998 final rule (63 FR 58832) the steps we were undertaking as part of the initial

refinement process. These steps included—

- Establishment of a mechanism to receive independent advice for dealing with broad practice expense RVU technical and methodological issues;
- Evaluation of any additional recommendations from the General Accounting Office, the Medicare Payment Advisory Commission (MedPAC), and the Practicing Physicians Advisory Council (PPAC); and
- Consultation with physician and other groups about these issues.

We also discussed a proposal submitted by the AMA's Specialty Society Relative Value Update Committee (RUC) for development of a new advisory committee, the Practice Expense Advisory Committee (PEAC), to review comments and recommendations on the code-specific CPEP data during the refinement period. In addition, we solicited comments and suggestions about our practice expense methodology from organizations that have a broad range of interests and expertise in practice expense and survey issues.

In the July 22, 1999 proposed rule and the November 1999 final rule, we provided further information on refinement activities underway, including the formation of the PEAC and the support contract that we awarded to focus on methodologic issues. The following is an update on activities with respect to these initiatives, as well as the status of refinement with respect to other areas of concern such as the SMS data and CPEP inputs.

(b) SMS Data. We have received many comments on both our 1998 and 1999 proposed and final rules from a number of medical specialty societies expressing concerns regarding the accuracy of the SMS data. Some commenters stated their belief that the sample size for their specialty was not large enough to yield reliable data. Other specialties not represented in the SMS survey objected that the crosswalk used for their practice expense per hour was not appropriate and requested that their own data be used instead. Commenters also raised questions about whether the direct patient care hours for their specialty were overstated by the SMS to the specialty's disadvantage.

We consider dealing with these issues to be one of the major priorities of the refinement effort. Therefore, we have undertaken the following activities:

(1) Interim Final Rule on Supplemental Practice Expense Survey Data

On May 3, 2000, we published an interim final rule (65 FR 25664) that set forth the criteria for physician and non-physician specialty groups to submit supplemental practice expense survey data for use in determining payments under the physician fee schedule. Section 212 of the BBRA required us to establish a process under which we will accept and use, to the maximum extent practicable and consistent with sound data practices, data collected or developed by entities and organizations to supplement the data we normally collect in determining the practice expense component of the physician fee schedule for payments in CY 2001 and CY 2002.

To obtain data that could be used in computing practice expense RVUs beginning January 1, 2001, we published the criteria in the May 2000 interim final rule (65 FR 25666) that we will apply to supplemental survey data submitted to us by August 1, 2000. We also provided a 60-day period for submission of comments on the criteria that we will consider for survey data submitted between August 2, 2000 and August 1, 2001 for use in computing the practice expense RVUs for the CY 2002 physician fee schedule. (See the May 2000 interim final rule for further information on the criteria and process). We intend to respond to comments received on this interim final rule in the physician fee schedule final rule to be published this fall. We believe this is an important step in addressing the concerns of those specialties that believe they are underrepresented in the SMS survey data or believe they have not been surveyed by the SMS.

(2) Proposals for SMS Refinement

As we indicated in the November 1999 final rule, we awarded a contract to The Lewin Group to obtain independent advice dealing with broad practice expense RVU technical and methodological issues. Specific activities we requested the contractor to evaluate included the following:

- Evaluation of SMS data for validity and reliability.
- Identification and evaluation of alternative and supplementary data sources from specialty and multi-specialty societies.
- Development of options for validating the Harvard/RUC physician procedure time data.
- Evaluation of the indirect cost allocation methodology.
- Advice on developing a process for the 5-year review of practice expense RVUs.

The Lewin Group issued their first draft report, ''Practice Expense Methodology,'' dated September 24, 1999. We have placed this report on our homepage under the title ''Practice Expense Methodology Report.'' (Access to our homepage is discussed under the ''Supplementary Information'' section above.) The report contains various recommendations aimed at increasing the validity and reliability of the AMA's SMS survey. As we discuss below, the AMA will no longer be collecting data through the SMS survey. However, the AMA is currently pilot-testing an alternative practice expense survey of physician practices. Although The Lewin Group's recommendations were made specifically to address improving the SMS survey for calculating practice expense RVUs, we believe the recommendations will be useful in making refinements to the practice level survey or designing any other survey instrument that may be used in calculating practice expense RVUs. The recommendations fell into the three following areas:

- The use of data supplementary to the SMS survey.
- Suggested changes to the survey instrument.
- Recommendations for using the data in calculating the specialty-specific practice expense per hour.

The report recognized the need for additional data obtained either through oversampling or additional surveys. We would welcome the receipt of additional objective and valid data that would help ensure that our specialty-specific practice expense per hour calculations are as accurate as possible. However, to ensure consistency of the data across specialties, the report also stressed the need for any supplementary data to adhere to the same format, survey instrument, sample frame, and definitions as the SMS survey. We share this concern, and in the May 2000 interim final rule we identified the specific criteria that all supplementary surveys must meet to ensure that data are valid, reliable, and consistent with the SMS data already in use.

In line with the report's recommendations on the use of the SMS data, we are proposing to do the following:

- The Lewin Group recommended that we update the SMS survey data currently being used for practice expense per hour with new SMS data. They also recommended using a rolling 3-year average to determine practice expense per hour values. We are currently using data from the 1995 through 1997 SMS survey (1994 through 1996 practice expense data). The latest data available is from the 1998 SMS survey and we have incorporated this data into our practice expense per hour calculations. Although The Lewin

Group has recommended using a rolling 3-year average, we have decided to base the practice expense per hour calculations on a 4-year average. We are concerned that substituting data from the 1998 SMS for data from the 1999 SMS may exacerbate changes in the practice expense per hour calculations that may be explained by sampling error. We believe that using an additional year of SMS data will have the advantage of minimizing changes in the practice expense per hour data that result from sampling error, while allowing our calculations to be based on more survey data.

• The Lewin Group recommended that we standardize survey data from the SMS so that it reflects a common base year. They raised a concern that variations in sample size for a given specialty across the 3 years may produce a different result than if the survey response were standardized to reflect a common year. This could disadvantage those specialties that were more heavily sampled in the early years. We evaluated this recommendation and found that standardizing the SMS data we are currently using to reflect a 1995 cost year has virtually no impact on the practice expense per hour calculations. However, this issue will be more of a concern in using the later SMS data because response rates were lower in the 1998 SMS survey than in prior years. For this reason, we are standardizing the practice expense data so that it reflects a common base year. Using the MEI, we standardized the practice expense data so that it reflects a 1995 cost year consistent with the pricing information that we are using for the estimates of practice expense inputs for individual procedures.

The table below reflects the practice expense per hour calculations we are using in determining the CY 2001 practice expense RVUs.

BILLING CODE 4120–01–P

SPECIALTY	NON-PHYS PAYROLL PER HOUR	CLERICAL* PAYROLL PER HOUR	OFFICE EXPENSE PER HOUR	SUPPLIES EXPENSE PER HOUR	EQUIPMENT EXPENSE PER HOUR	OTHER EXPENSE PER HOUR	TOTAL** EXPENSE PER HOUR
ALL PHYSICIANS	27.4	15.1	19.5	7.3	3.1	11.5	68.6
GENERAL/FAMILY PRACTICE	29.7	15	17.9	7.9	3.3	8.5	67.2
GENERAL INTERNAL MEDICINE	23.7	14.2	18	6.2	2.1	6.6	56.6
CARDIOVASCULAR DISEASE	29.9	15.1	20.9	6.4	6.2	19.8	83.2
GASTROENTEROLOGY	24.8	16.4	18.7	3	1.9	11.7	60.1
ALLERGY/IMMUNOLOGY	64.3	27.1	31.4	17.1	3.1	16.6	132.5
PULMONARY DISEASE	18	11.5	14.9	2.4	1.5	6.5	43.4
ONCOLOGY	50.2	23.1	27.4	7.3	4.8	9.1	98.8
GENERAL SURGERY	22.2	15.3	17	3	1.8	10	54.1
OTOLARYNGOLOGY	43.1	24.6	32.8	7.5	5.7	18.1	107.2
ORTHOPEDIC SURGERY	45.2	27.9	29.9	10.4	3.7	19	108.3
OPHTHALMOLOGY	52.6	26.7	35.3	10.5	8.3	21.4	128.1
UROLOGICAL SURGERY	30	17.6	23.8	24.9	5.7	11.1	95.6
PLASTIC SURGERY	32.4	19.5	32.9	19.1	5	25.4	114.8
NEUROLOGICAL SURGERY	33.9	24.5	29.1	1.7	1.2	16.7	82.6
CARDIAC/THORACIC SURGERY	35.1	16.9	16.8	1.8	2.2	13.3	69.2
PEDIATRICS	25.4	13	19.5	10.5	1.6	8.2	65.2
OBSTETRICS/GYNECOLOGY	34	17.3	23.2	7.2	3.2	11.2	78.9
RADIATION ONCOLOGY	24	9.4	12.1	5.7	10.2	16	68
RADIOLOGY	19.8	10.5	14.2	4.6	7	21.8	67.4
PSYCHIATRY	6.9	5.1	10.5	0.4	0.3	7.3	25.5
ANESTHESIOLOGY	14.1	3.7	6.1	0.3	0.4	6	26.9
PATHOLOGY	21.2	10.4	11.4	6.4	2.1	21.5	62.8
DERMATOLOGY	51	28.3	31.8	12.5	4.6	16.6	116.4
EMERGENCY MEDICINE	6	15.1	1.8	0.8	0.1	11.5	32.7
NEUROLOGY	29.3	22.8	17.9	4.8	4.3	8.6	64.9
PHYS MED/RHEUMATOLOGY	39.2	24.1	32	5.8	4.7	12.2	93.9
OTHER SPECIALTY	23.1	13.6	20.5	4.4	1.8	9.5	59.3

*Clerical payroll is included in total non-physician payroll.

**Total expenses exclude professional liability insurance premiums and employee physician payroll.

Notes:

(1) Only self-employed non-federal non-resident patient care physicians who responded to all relevant expense questions are included.

Self-employed physician respondents with no practice expenses for the year are excluded.

(2) Physicians whose typical number of hours worked in patient care activities per week is missing, less than 20, or equal to 168 are excluded.

Physicians whose number of weeks worked the previous year is missing or less than 26 are excluded.

(3) For each respondent, total practice expense and expense components per hour are calculated as (4) / (5) below.

(4) Expenses adjusted for practice size = self-employed respondent expenses X # physician owners

(5) Hours adjusted for practice size = (respondent hours * # physician owners) + (employee physician hours (see (6) below) * # employee physicians)

(6) The typical number of hours worked in patient care activities for the employee physician(s) of a self-employed physician's practice is not known.

Mean hours worked in patient care activities for employee physicians of each specialty are used as an estimate of employee physician hours.

(7) As described earlier in this proposed rule, the practice expense per hour shown above reflect:

- the "All Physician" supplies expense per hour for Oncology
- use of supplemental practice expense data for Cardiac and Thoracic Surgery
- removal of hours spent in Part A activities for Pathology.
- Using the "All Physician" administration and other practice expense data for Emergency Medicine.

BILLING CODE 4120–01–C

• The Lewin Group also recommended that we revise edits and trims to the SMS survey data, both practice expenses and hours, to exclude data that fall outside set acceptable ranges (for example, three standard deviations from the geometric mean). We asked the AMA about their reaction to The Lewin Group's recommendation and the AMA replied:

> Trimming outlier values will further reduce sample size. Trimming expense values can also be problematic because high expense responses on the SMS are often justified when practice size and structure are taken into account. A trim may also disproportionately impact specialties with highly skewed distributions of PE–HR.

For this reason, we are not taking action in response to The Lewin Group's recommendation at this time.

• In addition, The Lewin Group recommended that we account for item non-response to questions related to practice expenses and patient care hours. We asked the AMA for their reaction to this recommendation as well. The AMA replied that they would need more information and added that there is no evidence that a pattern of non-response bias exists for practice expense, although it is a possibility. We are considering whether to study this issue further but, at this time, are not making any adjustments in response to this recommendation.

The report also makes suggestions on changes to the survey instrument used to collect practice expense data from practitioners. Though the original SMS survey does collect some information on practice expenses, it was not designed as a vehicle to calculate a specialty-specific practice expense per hour. We, and the contractor, have held several meetings with the AMA's SMS staff to discuss revisions to the survey that would help make our calculations more precise.

We understand that the AMA is currently piloting a new practice-level survey designed to address some of the limitations of the SMS. If the pilot of the survey is successful, we earlier understood that the AMA plans were to conduct the practice survey initially in CY 2000 and, in alternate years thereafter, the practice expense survey and the SMS survey. The AMA has recently indicated that its plans about the future of the SMS and collection of practice level survey data are unclear at this time. While the AMA has not made a final decision at this time about whether the practice level survey will be done, they have indicated concern to us about low response rates from the pilot test. Nevertheless, we are proceeding to make recommendations to the AMA regarding collection of practice expense data through the practice level survey. We will continue our discussion with the AMA regarding its plans for future practice expense data collection following completion of the practice level survey. And, as we stated earlier, we believe these recommendations will be useful in the design of the practice level survey or any other survey of practice expenses used in developing RVUs for practice expenses.

The use of this practice level survey, as it is currently contemplated, responds to several of our contractor's recommendations. For example, it would address the recommendation that information be collected on each physician's percent share of practice expense and hours within the practice by collecting information at the total practice, rather than the individual physician owner level. The practice level survey also currently contains, as requested, questions on the number of hours the physician's office is open in a typical week and on the salaries for the mid-level practitioners used by the practice (that is, physician assistants, nurse practitioners, clinical nurse specialists, nurse mid-wives, certified registered nurse anesthetists, and physical and occupational therapists).

We are also suggesting additional changes in the survey questions or directions, generally reflecting our contractor's recommendations. We believe that the following changes would give more precise and reliable data on which to base our practice expense calculations:

• Emphasize the benefit of involving the practice manager or accountant in the completion of the survey and the need to link the practice expense data to the practice's tax information whenever possible.

• Include a question concerning how many patient care hours are spent on uncompensated care, that is, care that the law requires one to provide, but for which one is not compensated. This would not include charity care that is voluntarily provided.

• Add a question concerning the amount or percentage of revenue generated by mid-level practitioners.

• Add a question concerning the amount or percentage of supply costs that relates to separately billable supplies (for example, drugs, casting supplies, and laboratory supplies).

• In addition, we are recommending that the survey include more specific questions on patient care hours and that separately billed mid-level practitioner hours be included.

The Lewin Group also recommended that the survey include questions about a typical week, rather than the most recent week. We are not adopting this suggestion because we believe that questions about the most recent week are likely to yield more concrete, accurate answers, whereas questions about a typical week are more likely based on estimates. As we have already stated, the AMA will no longer be collecting data through the SMS and the AMA has also expressed concern about low response rates from the pilot of the practice level survey. At this time, we are unclear as to the AMA's plans with regard to future practice expense data collection efforts.

As we indicated earlier, we are currently proposing to use data from the 1998 SMS in developing the 2001 practice expense relative value units. Furthermore, data from the 1999 SMS will become available later this year. In addition, section 1848(c)(2)(B) of the Act requires that not less often than every 5 years, we review and make adjustments to RVUs. Thus, by law we are required to review and make adjustments to the practice expense RVUs no later than 2007. Regardless of whether the AMA continues to collect data on practice expenses, we will be developing plans for making refinements to practice expense RVUs beyond 2002.

We welcome comments on long-term strategies for refining the practice expense RVUs and any suggestions for how to collect practice expense data in the event it is no longer collected by the AMA. We will consider these comments and any further decisions by the AMA with regard to its practice expense data collection efforts in developing our refinement strategy beyond 2002.

(3) Direct Patient Care Hours

We have received many comments from specialty societies concerning our calculation of direct patient care hours. This is a major issue because the patient care hours are one half of the ratio used to determine the practice expense per hour for each specialty. (The practice expenses of practitioners in a specialty are divided by the direct patient care hours in order to calculate the practice expense per hour). If the reported hours do not reflect the actual average billable hours for a specialty, the practice expense per hour will be over-or understated.

Several commenters representing surgical specialty societies have raised concern that the hours computed for their specialties have been overstated. This may be a result of SMS survey respondents including non-billable

hours (such as stand-by time) when asked how many hours they worked each week. If this is the case, this would decrease the practice expense per hour for these specialties. In addition, commenters representing emergency room physicians raised the issue that the hours spent on uncompensated care were probably also included in the survey responses to the detriment of this specialty.

We agree with the commenters that there is a need to increase the level of confidence in the direct patient care hour data. We are already taking steps to improve the future accuracy of these data. As mentioned above, we are recommending that the future survey questions be worded more precisely so that only the appropriate practitioner hours are included. In addition, we have asked our contractor to give priority to recommendations on steps we can take to improve the accuracy of the patient care hours.

As a first step in accomplishing this, The Lewin Group issued their second draft report on December 6, 1999, entitled ''Validating Patient Care Hours Used in HCFA's Practice Expense Methodology.'' This report explores alternative methods that we might use to validate the time data collected by the SMS survey. The validation techniques attempt to achieve two goals: (1) Identifying inaccurate existing data and (2) identifying inconsistencies in new data to be derived from future survey efforts.

The Lewin Group developed the following four validation techniques to analyze the SMS data used in computing the specialty-specific patient care hours:

- Method 1: Compare the patient care hour data reported at the beginning of the SMS survey (that asks for the total hours worked in a week) to responses from the detailed questions on patient care hours appearing later in the SMS survey.
- Method 2: Calculate ratios of SMS time pools to Harvard/RUC time pools by specialty, using Harvard/RUC procedure time data and Medicare claims data.
- Method 3: Compare newly reported SMS data to historical SMS data to identify outliers.
- Method 4: Compare SMS data on annual hours worked with annual hours data reported in the Medical Group Management Association's (MGMA) ''Physician Compensation and Production Survey''.

We have placed this report on our homepage under the title ''Validating Patient Care Hours.''

We agree with our contractor that no single validation approach exists that can be used to validate both existing and new data on patient care hours with a high level of confidence. However, the approaches described above, when used together, could be effective tools that will help to ensure the accuracy and reliability of existing and future data used in the calculation of practice expense RVUs. These validation efforts would allow us, and the medical community, to be more confident in the use of future data to update practice expense RVUs. Therefore, we extended The Lewin Group's contract so that, among other refinement tasks, the above analyses can be carried out. We are aware that even with the above initiatives, it might not be possible to address all concerns regarding refinement of the patient care hours in the short term. Therefore, we welcome any comments and suggestions as to other steps we could take to verify and improve the accuracy of the specialty-specific patient care hours.

(c) CPEP Data.

(1) Relative Value Update Committee's Practice Expense Advisory Committee

The PEAC, a subcommittee of the RUC, held its initial meetings last year and the RUC made recommendations on CPEP inputs for clinical staff times, supplies, and equipment on approximately 65 CPT codes. We discussed our actions with regard to these recommendations in the November 1999 final rule. The PEAC continues to meet to refine the CPEP direct cost inputs, and we anticipate that we will receive additional RUC recommendations in July. We will address these recommendations in this year's physician fee schedule final rule.

In the November 1999 final rule, we deferred action on the RUC recommendations for a few groups of CPT codes on which we had significant questions. We are now proposing to accept the RUC recommendations with the revisions noted below:

Prostate Procedures

52647 Non-contact laser coagulation of prostate, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included)

53850 Transurethral destruction of prostate tissue; by microwave thermotherapy

53852 Transurethral destruction of prostate tissue; by radiofrequency thermotherapy

We are accepting the total clinical staff time recommended for the in-office setting, but are moving 60 minutes from post to intra-service time for each of the above procedures because the staff time for observation of the patient during recovery from anesthesia belongs in the intra-service period. We are reducing the out of office preservice clinical staff time for CPT codes 52647 and 53852 to 30 minutes to match the RUC recommendation for CPT code 53850 and the time allotted in the office for each service and are making the out-of-office postservice time equal to the in-office postservice time because we believe there is no reason that these times should differ.

The supplies for all three procedures were adjusted to reflect three postoperative visits and to conform with the overall adjustment to supplies made in the November 1999 final rule. For CPT code 52647, we deleted the flexible cystoscope from the equipment because only one scope is required for the procedure. We also deleted the sterilizer because it is not typically used. For CPT code 53850, the RUC recommendations included the inputs for two different scenarios using two different devices. We chose what we believe to be the most typically used device and the inputs that accompany this. For CPT code 53852, we deleted the cystoscopes and sterilizer from the equipment because we believe that they are not typically used.

Chemotherapy Procedures

96408 Chemotherapy administration, intravenous; push technique

96410 Chemotherapy administration, intravenous; infusion technique, up to one hour

The RUC had recommended 102 minutes of clinical staff time for CPT code 96408 and 121 minutes for CPT code 96410. In the November 1999 final rule, we solicited comments on these codes to assist us in our review. In response, the American Society of Clinical Oncology provided a breakdown by specific tasks of the above staff times. Included in this breakdown were 20 minutes for pre- and postprocedure education and 15 minutes for three phone calls after each visit.

Because we believe that the times for patient education and phone calls should be averaged over the whole course of chemotherapy treatment, and because there appeared to be some duplication in the pre- and postprocedure education tasks, we reduced both the patient education and phone call times by 5 minutes. Therefore, we are proposing 92 minutes

of clinical staff time for CPT code 96408 and 111 minutes for CPT code 96410. For supplies, the specialty society agreed that we should delete the silver nitrate stick and HEPA filters from both procedures and the infusion pump cassette from CPT code 96408.

(2) Clinical Staff Time

In the November 1999 final rule, we removed estimates of all clinical staff time allotted to the use of clinical staff in the facility setting from the CPEP data. Commenters have since noted that the clinical staff times reported by some CPEP panels for pre- and postservice times for 0-day global services performed in the office were recorded in the intra-service field in the CPEP database. These times were, therefore, deleted along with the times for the use of clinical staff in the facility setting, unlike the pre- and postservice times for 10 and 90-day global services that were entered into the separate pre and post data fields. The commenters argued that these pre- and postservice staff times for the relevant 0-day global services should be reinstated because these times are for staff in the office before and after the patient is in the facility.

We agree that these data are not comparable to the data we excluded for clinical staff used in the facility setting. We reviewed the ''CPEP Recorders' Notes Files'' compiled for each CPEP panel by Abt Associates, Inc., the contractor managing the CPEP panels. When the notes indicate that clinical staff estimates were for activities performed in physicians' offices, we are proposing to reinstate the time data for 0-day global services. The fact that we have reinstated these time data does not mean that we necessarily agree that the amount of time assigned is correct. Like all the other raw CPEP data, these time data are subject to refinement and possible revision.

The entire recorders' notes file is available on our website and is entitled ''CPEP Recorders' Notes Files.'' Addendum C shows a list of the codes for which pre- or postclinical staff time has been added, as well as the times that are now assigned.

(3) Supplies

In the November 1999 final rule (64 FR 59392), we indicated that casting materials are bundled into the payment for the initial fracture management procedures and that separate billing for the supplies is not allowed. However, commenters noted that our policy has been to allow separate payment for splints, casts, and other devices used for the reduction of all fractures and dislocations under section 1861(s)(5) of the Act. Since we provide separate payment for splints and casting supplies, we are now proposing to remove these types of expenses from practice expense inputs for all applicable fracture management and cast/strapping application procedure codes under the physician fee schedule.

In the November 1999 final rule, we deleted certain casting supplies (fiberglass roll, cast padding, and cast shoe) from the list of supplies for the casting and strapping CPT codes 29000 through 29750. We have identified additional CPT codes for the treatment of fractures/dislocations that have these supplies included in the CPEP data. Since these supplies are currently separately billable, we are proposing to remove the fiberglass roll, cast padding, and cast shoe from the following CPT codes: 23500 through 23680; 24500 through 24685; 25500 through 25695; 26600 through 26785; 27500 through 27566; 27750 through 27848; and 28400 through 28675.

In addition, we are also proposing to remove additional casting and splinting supplies from all the CPT codes referenced above because these supplies are also currently separately billable under section 1861(s)(5) of the Act. The list of supplies is as follows: stockingnet/stockinette; plaster bandage; Denver splint; dome paste bandage; cast sole; elastoplast roll; fiberglass splint; Ace wrap; Kerlix; Webril; Malleable Archbars; and elastics.

We welcome comments on whether these supplies should be deleted from additional procedures outside the code ranges referenced above, and whether we have appropriately identified all the casting supplies in our supply list.

(4) Equipment

We are currently using the original CPEP definitions for equipment that distinguish between ''procedure specific equipment'' and ''overhead'' equipment. The main distinction between the two categories is that procedure specific equipment is used only for a limited number of procedures, while overhead equipment is used over a wide range of services. In terms of actual application, we assume a 50-percent utilization rate for procedure specific equipment, but a 100-percent rate for all overhead equipment. In addition, the methodology assumes that the procedure specific equipment is used only during the intraservice period, while it assumes that the overhead equipment is used for the entire service. We believe this distinction was more important under our original ''bottom-up'' methodology when the accuracy of the practice expense RVUs was almost totally dependent on the precision of the CPEP inputs. Under our current ''top-down'' methodology, however, when the CPEP inputs are used only as allocators of the specialty-specific practice expense pools, the distinction has served to hinder the process of refining the CPEP inputs while not leading to a substantive distinction in how we value services.

We are proposing to combine both categories of equipment into a single ''equipment'' category, assuming an average 50-percent utilization for all equipment. We believe that this will be beneficial to our refinement process for the following reasons:

- The current definition of the two categories of equipment necessitates many subjective decisions. While it might be obvious that an examination table is used for a wide range of services and, therefore, would be overhead equipment, it is somewhat more arbitrary to classify equipment such as cystoscopes or specific x-ray machines as overhead or procedure specific.
- The various CPEP panels were not consistent in their application of the distinction between the two categories. Most of the items that were classified by some of the CPEP panels as overhead equipment were classified by another panel as procedure specific. In addition, equipment that would seem to be very similar was sometimes treated in different ways. For example, an examination table or a stretcher were considered to be overhead, but an electric table or a wheelchair were considered procedure-specific.
- It would simplify the refinement process to have only one category of equipment to consider rather than having to decide for all 7000 codes to which category each piece of equipment belongs.

We are also proposing to delete from the CPEP data equipment that is not used typically with any service, but is on ''standby'' for many services, or that is used for multiple services at the same time. In either of these cases, it is difficult to allocate the cost of this equipment appropriately to individual CPT codes. Examples of ''standby'' equipment are crash carts, defibrillators, wheelchairs, and stretchers. Examples of equipment used for multiple procedures at the same time are cabinets, refrigerators, and autoclaves.

Following is the list of equipment that we are proposing to delete at this time from the CPEP inputs of all services: autoclave, wheelchair, refrigerator, film file cabinet, hazard material spill kit, embryo freezer, water system, flammable reagent cabinet, utility freezer, ultra low temperature freezer,

acid cabinet, bulk storage refrigerator, abortion clinic security system, abortion clinic security guard, gomco suction machine, doppler, laser printer, lead shielding, defibrillator with cardiac monitor, blood pressure/pulseox monitor, blood pressure monitor, printer, crash cart—no defibrillator, and smoke evacuator.

The following is a list of equipment that we are proposing to delete as ''standby'' equipment for most codes, but that we believe typically may be used with a designated subset of procedures:

- X-ray view box—four panel (retain when currently in the CPEP data for codes in the range CPT codes 70010 through 79999).
- ECG machine—3 channel (retain when currently in the CPEP data for CPT codes 93000 through 93221).
- Pulse oximeter (retain when currently in the CPEP data for CPT codes 94620, 94621, 94680, 94681 and 94690; 94760 through 94770, 95807 through 95811 and 95819).
- ECG/blood pressure monitor—3 channel (retain when currently in the CPEP data for CPT codes 43200 through 43202 and 43234 through 43239).
- Cardiac monitor (retain when currently in the CPEP data for CPT codes 31615 through 31628).
- ECG-Burdick (except for HCPCS code G0166).

We welcome comments on this proposal and on any additional equipment that should not be considered a direct expense because the cost cannot appropriately be allocated to an individual service. Neither of these proposals to improve the CPEP equipment data have a significant impact on any specialty.

(5) CPEP Anomalies

In the November 1999 final rule, we made corrections to the CPEP data for a number of codes that we learned contained errors and anomalies that we could easily correct. Since that time, we have discovered some additional anomalies, and we are proposing to correct them at this time. As we stated in the final rule, though certain revisions may be made now, all practice expense inputs for these codes are still subject to further comment, refinement, and potential PEAC and RUC review and recommendations.

- We have identified several CPT codes that were not costed by the CPEP panels and were not assigned CPEP inputs. We are now crosswalking these services to the CPEP inputs of the most appropriate other service. The CPEP inputs for these codes are subject to refinement. We welcome comments on the crosswalks that we have chosen. The codes and their crosswalks are shown below:

CPT and HCPCS code	Crosswalk
27347 Remove knee cyst	27345 Removal of knee cyst.
28289 Repair hallux rigidus	28288 Partial removal of foot bone.
31643 Diag bronchoscope/catheter	31629 Bronchoscopy with biopsy.
36831 Av fistula excision	34111 Removal of arm artery clot.
36833 Av fistula revision	36832 Av fistula revision.
45126 Pelvic exenteration	58240 Removal of pelvis contents.
57106 Remove vagina wall, partial	57110 Removal of vagina wall, complete.
57107 Remove vagina tissue, part	57111 Remove vagina tissue, complete.
59610 Vbac delivery	59400 Obstetrical care.
59612 Vbac delivery only	59409 Obstetrical care.
59614 Vbac care after delivery	59410 Obstetrical care.
59618 Attempted vbac delivery	59410 Obstetrical care.
59620 Attempted vbac delivery only	59514 Cesarean delivery only.
59622 Attempted vbac after care	59515 Cesarean delivery.
67220 Treatment of choroid lesion	67208 Treatment of retinal lesion.
76831 Echo exam, uterus	76830 Echo exam, transvaginal.
78206 Liver image (3d) w/flow	78205 Liver imaging (3D).

- The following services can be performed in the office, but either have no CPEP data for the office setting or have been assigned the same inputs as for the facility setting. Until these codes can be refined, we are proposing the following crosswalks for the in-office practice expense inputs so that costs in the office setting are appropriately reflected.

CPT code	Crosswalk
20225 Bone biopsy, trocar/needle	20220 Bone biopsy, trocar/needle.
57105 Biopsy of vagina	57100 Biopsy of vagina (for intraservice period)

- Because the following either are not performed in the office setting or because we do not have appropriate CPEP inputs for the in-office setting for these services, we are designating the following CPT and HCPCS codes as ''N/A'' in the office setting: 99183 (Hyperbaric oxygen therapy); 21493 (Treatment of hyoid bone fracture); 21494 (Treatment of hyoid bone fracture with manipulation); 32997 (Total lung lavage); 33968 (Remove aortic assist device); 66830 (Removal of lens lesion); 69990 (Micro-surgery add-on); 92961 (Cardioversion, electric, internal) and we are designating G0167 (Hyperbaric oxygen treatment; no physician required) as carrier priced.
- The TC for CPT code 93660 (Tilt table evaluation) is carrier priced, but we are proposing to price it nationally. Therefore, we are reinstating the original CPEP data.
- We are crosswalking all CPEP inputs for CPT code 44201 (Laparascopy, jejunostomy) from the inputs for CPT code 44200 (Laparoscopy, enterolysis) to reflect that it is a 90-day global service.
- We are adjusting the CPEP inputs for CPT codes 15001 (Skin graft add-on); 15351 (Skin hemograft add-on); and 15401 (Skin heterograft add-on) to reflect that these are ZZZ services.
- CPT code 00103 (Anesthesia for blepharoplasty), which was not costed by the anesthesia CPEP panel, was inadvertently crosswalked to the CPEP inputs of two different CPT codes. We are deleting the crosswalk to the procedure CPT code 21450 and will

retain the crosswalk to the anesthesia CPT code 00140 (Anesthesia for procedures on eye).

• We believe that the supply inputs for the retrobulbar injection codes (CPT codes 67500, 67505, and 67515) have been inappropriately crosswalked by the CPEP panel from adjacent surgical procedure codes. After consultation with an ophthalmology specialty society, we have adjusted the supplies so that the list now includes one alcohol swab, one pair of nonsterile gloves, one 5-cc syringe, and one 25-gauge needle.

• In several of the in-office ophthalmology codes, the supply list includes the costs for 50 to 100 sterile towels. The specialty society has confirmed that this is a typographical error and that the quantity should not exceed five for any one visit or procedure. We have made the appropriate adjustments.

• The supply list for CPT code 68761 (Close tear duct opening by plug), currently does not include the costs of a punctal plug. We have received a comment from the specialty society representing optometrists requesting that we add this supply because it is typically used for this procedure. We agree with this comment and are proposing the addition of a punctal plug to the CPEP supplies. We have also deleted the inappropriate inputs from HCPCS code A4263, permanent tear duct plug.

• We have discovered a calculation error that affects the total cost of supplies for some of the codes for which the RUC made recommendations in 1999. We have made the appropriate corrections and are using the corrected values for this rule.

• We have adjusted the clinical staff and supply inputs for HCPCS code G0170, skin biograft, to reflect that it is a 10-day global service with one postprocedure visit.

After consultation with the specialty society, we have also adjusted the supplies for CPT code 53040, drainage of deep periurethral abscess, to correct for anomalies in the quantity of supplies between the in and out of office settings.

(d) Calculation of Practice Expense Pools—Other Issues.

(1) Technical Refinement to Practice Expense Pools

The Act requires payment of some practitioner services (services of certified registered nurse anesthetists, nurse practitioners, clinical nurse specialists, physician assistants, and certified nurse mid-wives) based on a percentage of the physician fee schedule payment amount. Since the payment under the physician fee schedule for a service performed by a midlevel practitioner is required to be based on a percentage of the amount paid to a physician for a service, we are proposing using only physician practice expense data in determining the practice expense RVUs for each practitioner service. Removal of the services performed by midlevel practitioners from the practice expense calculations would assist in simplifying the methodology and would also be consistent with the statutory requirement that we pay for their services based on a percentage of the fee schedule amount.

(2) Medicare Utilization Data

We have received comments from several surgical specialties urging us to evaluate the Medicare claims data to eliminate potential errors. (For example, claims for non-surgeons performing complex surgeries that are generally performed by surgical specialties only.) These commenters were concerned that incorrect specialty utilization will decrease a specialty's practice expense pool and recommended that these claims should either be reassigned to the appropriate specialty or excluded during refinement. To determine whether potential errors in the claim data have an adverse impact on any specialty or merely represent ''noise'' that creates no significant effect, we ran the following analyses:

First, we analyzed the utilization for CPT codes 63045 through 63048, the highest volume neurosurgical procedures performed by neurosurgeons. Our utilization data indicates that 91 percent of allowed services for these codes are performed by neurosurgeons and orthopedic surgeons. Of the 9 percent of allowed services when the utilization data indicates another specialty, 3 percent are attributed to general surgeons. An additional 2 percent are attributed to the HCFA specialty code for a clinic or other group practice, when it is likely that a surgeon who is a member of a multispecialty clinic is providing the surgical service. Of the remaining 4 percent of allowed services, the data indicates a specialty of general practice, family practice, or neurology.

For the utilization attributed to general and family practitioners, the data indicate that, in most cases, these physicians are serving as assistants-at-surgery. With respect to neurology (2 percent of the allowed services), we believe it is possible that a physician may practice as both a neurologist and neurosurgeon and designate neurology as the specialty for reporting on Medicare claims. For an insignificant percentage of the allowed services (under 1 percent of the allowed services for all remaining specialties combined), our data indicate a specialty that would not be expected to perform the neurosurgical procedure. In these cases, the incorrect CPT code might have been transcribed on the Medicare claim or the incorrect specialty code may have been reported. There was a similar pattern for services associated with other surgical specialties.

We then tested the impact of reassigning to the dominant specialty this small proportion of allowed services associated with specialties not expected to perform them. We selected three of the specialties that commented on the possibility of erroneous utilization data and identified the complete range of specialized codes associated with each specialty. We reassigned to each dominant specialty the utilization currently assigned to other specialties not expected to perform the services. In addition, to test the ''worst-case'' scenario, we then crosswalked all frequencies for their complete range of codes to the selected individual specialty.

Neurosurgery

When we recoded CPT codes 61000 through 64999 to neurosurgery only, the impact on neurosurgery was a 0.55-percent increase. When we recoded the specialty for only those specialties that would not be expected to provide CPT codes 61000 through 64999 (specialties other than neurosurgery, orthopedic surgery, group practice or physician assistant) to neurosurgery, the resulting impact on neurosurgery was a 0.69-percent increase. In reviewing the utilization data for this code range, we found services that are predominantly performed by radiologists and anesthesiologists (such as CPT code 62311). When we recoded only those services predominantly performed by neurosurgeons, the impact was even less.

Ophthalmology

When we recoded the specialty for all utilization in the range of CPT codes 65091 through 68899 to ophthalmology only, the impact on ophthalmology was 0.31 percent. When we recoded the specialty for only those specialties that would not be expected to provide CPT codes 65091 through 68899 to ophthalmology, the resulting impact on ophthalmology was a 0.32-percent increase.

Otolaryngology

When we recoded the specialty for all utilization in the range of CPT codes

69000 through 69979 to otolaryngology, the impact on otolaryngology was a −0.36 percent. When we recoded the specialty for only those specialties that would be expected to provide CPT codes 69000 through 69979 to otolaryngology, the resulting impact on otolaryngology was −0.35 percent.

We believe that these simulations exaggerate the potential impact of possible errors in the utilization data because, as discussed in the above analysis of CPT codes 63045 to 63048, our simulations likely reassigned the specialty in situations in which the specialty was correctly coded. In any case, in no scenario did the impacts even approach a 1-percent increase or decrease.

We also believe these simulations demonstrate that the small percentage of potential errors in our very large database have no adverse effect on specialty-specific practice expense RVUs. Therefore, we are not proposing any further action at this time.

(3) Allocation of Practice Expense Pools to Codes

The Lewin Group has recently begun the third phase of the project. This phase will concentrate specifically on evaluating the indirect cost allocation methodology. They will evaluate the validity of our current methodology that allocates indirect costs using direct costs and work RVUs and consider alternatives to allocating indirect costs by the current method. The Lewin Group will perform a variety of tasks during this phase of the project to evaluate the advantages and shortcomings of our current indirect cost allocation methodology, as well as of any alternative methodologies. The preliminary tasks for Phase III include—

- Analyzing the current indirect cost allocation methodology to identify its advantages and shortcomings;
- Considering alternate ways in which our methodology might weight direct costs and work RVUs in the allocation of indirect costs and predicting the effects of these alternatives;
- Evaluating the impact and value of changing the methodology to use time rather than work measurements to allocate indirect costs;
- Interviewing experts in the field on potential alternatives to the current indirect cost allocation methodology; and
- Reviewing other relevant efforts to allocate indirect costs associated with physician and non-physician practice expenses.

The Lewin Group's draft final report will present the findings from all three phases of The Lewin Group's analysis of our practice expense methodology. As mentioned above, we are planning to extend The Lewin Group's contract for another year to obtain additional assistance on issues related to practice expense refinement.

(e) Site of Service. Clarifying the Definition of Facility/Nonfacility.

For purposes of practice expense calculations, we make a distinction between services performed in a non-facility and a facility setting. This distinction takes into account the higher expenses of the practitioner in the non-facility setting when the practitioner typically bears the cost of the resources (for example, clinical staff, supplies, and equipment) associated with the services. In the facility setting, because these costs are not incurred by the physician, Medicare payment to the facility includes the cost of the resources for the services furnished. The purpose of the distinction in the site-of-service is to ensure that Medicare does not duplicate payment, to the physician and the facility, for any of the practice expenses incurred in performing a service for a Medicare patient.

For purposes of applying the site-of-service differential, we are defining hospitals, skilled nursing facilities, and ambulatory surgical centers as facilities because they will receive a facility payment for their provision of services. We have been advised that community mental health centers (CMHCs) should also be defined as a facility setting since CMHCs also receive a separate facility payment for their services. Therefore, we are proposing to revise § 414.22(b)(5)(i) (Practice expense RVUs) to add CMHCs to the settings listed in which we would apply the facility practice expense RVUs.

In addition, while we have indicated in previously published rules that the non-facility practice expense RVUs are applicable to outpatient therapy services (physical therapy, occupational therapy, and speech language pathology) furnished by comprehensive outpatient rehabilitation facilities or outpatient rehabilitation providers, there is confusion about this issue. Only the facility can bill for therapy services furnished to hospital and SNF patients. Because this facility payment must include amounts reflecting practice expenses, the higher nonfacility RVUs are used to pay for therapy services even in the facility setting. Therefore, we would amend § 414.22(b)(5)(i) to specifically provide that the nonfacility practice expense RVUs are applicable to outpatient therapy services regardless of the actual setting.

B. Geographic Practice Cost Index Changes

1. Background

The Act requires that payments vary among fee schedule areas according to the extent that relative costs vary as measured by the GPCIs. Generally, the fee schedule areas that existed under the prior reasonable charge system were retained under the fee schedule from calendar years 1992 to 1996. We implemented a comprehensive revision in fee schedule payment areas (localities) in 1997, reducing the number of localities from 210 to 89. A detailed discussion of fee schedule areas can be found in the July 2, 1996 proposed rule (61 FR 34615) and the November 1996 final rule (61 FR 59494). We are required by section 1848(e)(1)(A) of the Act to develop separate indices to measure relative cost differences among fee schedule areas compared to the national average for each of the three fee schedule components. While requiring that the practice expense and malpractice indices reflect the full relative cost differences, the Act requires that the work index reflect only one-quarter of the relative cost differences compared to the national average.

Section 1848(e)(1)(C) requires us to review and, if necessary, adjust the GPCIs at least every 3 years. This section of the Act also requires us to phase in the adjustment over 2 years and implement only one-half of any adjustment in the first year if more than 1 year has elapsed since the last GPCI revision.

The GPCIs were first implemented in 1992. The first review and revision was implemented in 1995, and the second review was implemented in 1998. This constitutes the third GPCI review and revision and will be implemented in 2001.

2. Development of the Geographic Practice Cost Indices

The GPCIs were developed by a joint effort of researchers at the Urban Institute and the Center for Health Economics Research under contract to HCFA. Indices were developed that measured the relative cost differences among areas compared to the national average in a ''market basket'' of goods. In this case, the market basket consists of the resources involved with operating a private medical practice. The resource inputs are physician work or net income; employee wages; office rents; medical equipment, supplies; malpractice insurance; and other miscellaneous expenses. Employee wages, rents, medical equipment,

supplies, and other miscellaneous expenses are combined to comprise the practice expense component of the GPCI. The weights of these components in the original GPCIs (from 1992 through 1994), the first (1995 through 1997) and second (1998 through 2000) GPCI revisions, and the new weights for the third proposed GPCI revision (2001 through 2003) are as follows:

GPCI COMPONENT WEIGHTS

	1992–1994 GPCIs	1995–2000 GPCIs	2001–2003 GPCIs
Physician Work	54.2	54.2	54.5
Practice Expense	40.2	41.0	42.3
(Employee Wages)	(15.7)	(16.3)	(16.8)
(Rent)	(11.1)	(10.3)	(11.6)
(Miscellaneous)	(13.4)	(14.4)	(13.9)
Malpractice	5.6	4.8	3.2
	100.0	100.0	100.0

The resource inputs and their weights were obtained from the AMA's Socioeconomic Characteristics of Medical Practice Survey. The weights for the 1992 through 1994 GPCIs were from the AMA's 1987 survey, the latest available when the original GPCIs were being developed. The weights for the 1995 through 1997 and 1998 through 2000 GPCIs were from the 1989 survey. The 1989 weights are those used in the revised Medicare Economic Index (MEI) discussed in the November 25, 1992 final rule (Medicare Program; Revision of the Medicare Economic Index) (57 FR 55899). The weights in the proposed 2001 through 2003 GPCIs are from the 1997 AMA survey and were used in the MEI revision discussed in November 2, 1998 final rule (Medicare Program; Revisions to Payment Policies and Adjustments to the Relative Value Units Under the Physician Fee Schedule for Calendar Year 1999) (63 FR 58846).

The MEI is a measure of annual increases in the cost of operating a private medical practice and is used in the annual update of the physician fee schedule CFs. Because the GPCIs and the MEI use the same resource inputs to measure the costs of a private medical practice (the GPCIs measure relative costs among areas while the MEI measures the national annual rate of increase in costs), we believe the same weights should be used.

Once the components and their weights were determined, data sources had to be found that were widely and consistently available in all physician fee schedule areas to measure costs. After examining many sources, the following proxies were selected as the best available sources for measuring each component of the original 1992 through 1994 GPCIs:

• Physician work—The median hourly earnings, based on a 20 percent sample of 1980 census data, of workers in six professional specialty occupation categories (engineers, surveyors, and architects; natural scientists and mathematicians; teachers, counselors, and librarians; social scientists, social workers, and lawyers; registered nurses and pharmacists; writers, artists, and editors) with 5 or more years of college. Adjustments were made to produce a standard occupational mix in each area. The actual reported earnings of physicians were not used to adjust geographical differences in fees because these fees are, in large part, the determinants of the earnings. We believe that the earnings of physicians will vary among areas to the same degree that the earnings of other professionals vary.

• Employee wages—Median hourly wages of clerical workers, registered nurses, licensed practical nurses, and health technicians were also based on a 20-percent sample of 1980 census data.

• Office rents—Residential apartment rental data produced annually by the Department of Housing and Urban Development (HUD) were used because there were insufficient data on commercial rents across all physician fee schedule areas.

• Miscellaneous expenses—The Urban Institute and the Center for Health Economics Research assumed that this component is represented by a national market and that costs do not vary appreciably among areas. This component's index is 1.000 for all areas to indicate no variation from the national average.

• Malpractice—Premiums in 1985 and 1986 for a mature ''claims made'' policy (a policy that covers malpractice claims made during the covered period) providing $100,000 to $300,000 of coverage were used. Adjustments were made to incorporate the costs of $1 million to $3 million coverage and mandatory patient compensation fund requirements. Premium data were collected for physicians in three risk classes—low-risk (general practitioners who do not perform surgery), moderate risk (general surgeons), and high-risk (orthopedic surgeons).

The areas selected for measurement purposes were the Metropolitan Statistical Areas (MSAs). Non-MSA areas within a State were aggregated into one residual area. Using MSAs for measurement satisfied the criteria of (1) homogeneity in resource input prices within the area, and (2) a size large enough so that market areas are self-contained to minimize border crossing; that is, physicians would not move their offices a few miles to secure higher payments and patients would tend to receive services within their area.

The Act requires, however, that the GPCIs reflect cost differences among fee schedule areas. Thus, it was necessary to map Medicare localities to the MSA and non-MSA aggregation of GPCI data. Where localities crossed MSA boundaries, MSA indices were converted to Medicare locality indices by population weights.

Detailed discussions of the methodology and data sources of the 1992 through 1994 GPCIs can be obtained by requesting the following studies from the National Technical Information Service by calling 1–800–553–NTIS or, for residents of Springfield, Virginia, (703) 487–4650.

• The Urban Institute report ''The Geographic Medicare Index: Alternative Approaches,'' NTIS PB89–216592.

• The supplement to ''The Geographic Medicare Index: Alternative Approaches,'' NTIS PB91–113506. This was published in the September 4, 1990 notice for the model fee schedule (55 FR 36238).

• The Urban Institute report, ''Refining the Malpractice Geographic Practice Cost Index,'' February 1991, NTIS PB91–155218. The related diskette is NTIS PB91–507491. This is the final version of the 1992 through 1994 GPCIs

as published in the November 1991 final rule (56 FR 59785).

3. Revised 1995 Through 1997 Geographic Practice Cost Indices

The main criticism of the original GPCIs was that they were outdated because they were based on old data; for example, 1980 census data and 1985 and 1986 malpractice premiums. This was, however, the most recent data available when the GPCIs were established. The revised 1995 through 1997 GPCIs were based on the most current data available when they were developed in 1993 and 1994.

We made some minor changes from the original GPCI methodology in calculating some of the revised 1995 through 1997 indices. One methodological change was made that applied across all indices. As mentioned earlier, under the original GPCIs, where Medicare localities crossed MSA boundaries, MSA indices were converted to locality indices by population weights. Medicare expenditure weights were not used because the expenditures under the reasonable charge system contained large differences unrelated to relative cost differences among areas. In calculating the revised GPCIs, where localities crossed MSA boundaries, locality indices were calculated by weights based on the proportion of localities' RVUs provided in each MSA to reflect relative cost differences among areas. Full fee schedule RVUS were used rather than actual 1993 payments because 1993 fee schedule payments still reflected some reasonable charge payment levels. The advantages of RVU weighting are (1) the GPCIs more closely reflect physician practice costs in the area where the services are provided rather than where the population lives, and (2) budget neutrality is preserved when we combine multiple localities into larger areas, such as statewide localities.

a. Work Geographic Practice Cost Indices. Data from the 20-percent sample of census data of median hourly earnings for the same six categories of professional specialty occupations as used in the 1992 through 1994 work GPCIs were used in calculating the 1995 through 1997 work GPCIs. The 1992 through 1994 work GPCIs were calculated using 1980 census data of earnings for professionals with 5 or more years of college. That sample was no longer available with the 1990 census. The 1990 census educational classifications were by highest degree earned and not by years of schooling as in the 1980 census. Thus, it was not possible to obtain earnings data that exactly compared to the 1980 data.

For 1990, data were available for all-education and advanced-degree samples, but not for 5 or more years of college. We elected to use the all-education sample because its larger sample sizes made it more stable and accurate in the less populous areas. Although it could be argued that physicians' earnings might more closely approximate the earnings of professionals with advanced degrees, the differences between the all-education and advanced-degree indices were negligible in all but a few of the smallest localities. We believed that the small sample sizes of advanced-degree occupations in these small localities may produce inaccurate results.

The 1992 through 1994 work GPCIs used metropolitan-wide median wages for each county within an MSA. That is, all counties within an MSA were assigned the MSA-wide median wage even if there were wage variations within the MSA. We believed that this was appropriate for all but Consolidated Metropolitan Statistical Areas (CMSAs), the largest of the MSAs, such as New York. In these CMSAs, we replaced metropolitan-wide earnings with county-specific earnings. We believed this change was appropriate because costs were, in fact, higher in central city areas (for example, Manhattan and San Francisco) than in the rest of the CMSA. County earnings better account for cost variation within these large metropolitan areas.

b. Practice Expense Geographic Practice Cost Indices. (1) Employee Wage Indices. Data from the 20-percent sample of census data of median hourly earnings for the same categories of medical and clerical occupations used in the 1992 through 1994 practice expense GPCIs were used in the 1995 through 1997 practice expense GPCIs. The 1995 through 1997 practice expense GPCIs used 1990 rather than 1980 census data. As with the work GPCIs, county level data were used for CMSAs to better reflect the cost variations within these large metropolitan areas.

(2) Rent Indices. As with the original rent indices, the HUD fair market rental (FMR) data for residential rents were again used as the proxy for physician office rents. The 1995 through 1997 practice expense GPCIs reflect 1994 HUD FMRs. Like the work GPCI and the employee wage index of the practice expense GPCIs, county level data were used in CMSAs to recognize the variations within the CMSA.

The major criticism of the rent indices was that residential rather than commercial rent data were used. As mentioned earlier, for constructing the GPCIs, we needed data that were widely and consistently available across all physician fee schedule areas. As with the original GPCIs, we again searched for private sources of commercial rent data that were widely and consistently available.

The private sources we found were not adequate. None of the sources collected data for nonmetropolitan areas, nor did any collect data for all metropolitan areas. The sources did not reflect the average commercial space in the area, but rather the particular type of space most relevant to the needs of a particular source's clients. In addition, the sample sizes were small. A comparison of the average rental for any particular city showed significant variation depending upon the source. Also, the private commercial rent data tended to be for very high priced real estate of the type likely to be used by large institutions such as banks, insurance companies, or financial firms and not for the type of office space used by physicians.

Among the sources of commercial rent data available, the most promising were data from the Building Owners and Managers Association, the General Services Administration, and the U.S. Postal Service. These data were analyzed in depth. We did not use data from the Building Owners and Managers Association and the General Services Administration because of poor geographic coverage, especially outside of large metropolitan areas. That is, data were not widely and consistently available for all physician fee schedule areas. The U.S. Postal Service data had much better geographic coverage, but sample sizes in many areas were unacceptably small and could have led to erroneous results.

No acceptable national commercial rent data are readily available for physician office rents. Thus, some proxy must be used for this portion of the index. In addition, commercial rent data are not available for all areas from published statistical sources.

We believe that the HUD FMR data remain the best available data for constructing the office rental index. They are available for all areas, are updated on an annual basis, and are consistent among areas and from year to year. Moreover, physicians are frequently located in areas and office space that are residential rather than commercial (for example, in apartment complexes and small strip commercial centers adjacent to residential areas).

(3) Medical Equipment, Supplies, and Miscellaneous Expenses. As mentioned earlier, the GPCI assumes that this

component has a national market and that input prices do not vary among geographic areas. We were unable to find any data sources that demonstrated price differences by geographic area. Anecdotal and interview data from suppliers and manufacturers were inconclusive. While some price differences may exist, they are more likely to be based on volume discounts rather than on geographic areas. Generally, it appears that manufacturers' prices do not vary among areas except for shipping costs. Since manufacturers and suppliers are located all over the country, shipping costs on the mainland do not vary significantly.

We did consider an add-on for shipping costs to Alaska, Hawaii, and Puerto Rico to recognize the added shipping distance. We decided against the add-on because there were no data to indicate how much the costs of shipping medical equipment and supplies to these areas increased their total costs. We were able to ascertain that commercial shippers like United Parcel Service and Federal Express generally charge about 10 percent more to ship to Puerto Rico and about 20 percent more to ship to Alaska and Hawaii from the mainland.

Medical equipment and supplies represent about 7 percent of physician practice costs. Even assuming that shipping costs represent 5 percent of total equipment and supply costs, which we believe to be a high estimate, recognizing a 20 percent increase in shipping costs would only increase payment levels by 0.07 percent or 0.0007 ($.20 \times .05 \times .07 = .0007$). The medical equipment, supplies, and miscellaneous expense index for all areas continued to be 1.000 in the revised 1995 through 1997 GPCIs.

c. Malpractice Geographic Practice Cost Indices. Again, malpractice premium data for a $1 million to $3 million mature ''claims made'' policy were collected, with mandatory patient compensation funds considered. However, more recent and more comprehensive malpractice insurance data were used in calculating the 1995 through 1997 malpractice GPCIs. The 1995 through 1997 malpractice GPCIs were based on 1990 through 1992 premium data. Malpractice premiums are very volatile and may change significantly from year to year. We decided to use the most recent 3-year average available rather than just the most recent single year to smooth out this volatility and present a more accurate indication of malpractice premium trends over time.

We collected data on more specialties and from more insurers. We collected data on 20 specialties, rather than on only three as in the 1992 through 1994 malpractice GPCIs. The 1992 through 1994 malpractice GPCI data were largely drawn from a single nationwide insurer (St. Paul Fire and Marine) and were supplemented by several State-specific carriers in States in which St. Paul did not offer coverage. Subsequent analyses suggest that these data were not representative of insurers operating in many States. For the revised malpractice GPCI, data were collected from insurers that, on average, represented 82 percent of the market in each State, with the lowest State market share being 60 percent. We believe that the more recent and much more comprehensive data greatly improved the accuracy of the malpractice GPCIs for 1995 through 1997.

Detailed discussions of the methodology and data sources of the 1995 through 1997 GPCIs can be obtained by requesting the following studies from NTIS by calling 1–800–553–NTIS, or (703) 487–4650 in Springfield, Virginia:

- ''Updating the Geographic Practice Cost Index: Revised Cost Shares.'' Debra A. Dayhoff, John E. Schneider, and Gregory C. Pope. NTIS PB94–161072.
- ''Updating the Geographic Practice Cost Index: The Physician Work GPCI.'' Gregory C. Pope and Deborah A. Dayhoff. NTIS PB94–161080.
- ''Updating the Geographic Practice Cost Index: The Practice Expense GPCI.'' Gregory C. Pope, Deborah A. Dayhoff, Angella R. Merrill, and Killard W. Adamache. NTIS PB94–161098.
- ''Updating the Geographic Practice Cost Index: The Malpractice GPCI.'' Stephen Zuckerman and Stephen Norton. NTIS PB94–161106.

4. Revised 1998 Through 2000 Geographic Practice Cost Indices

The same data sources and methodology used for the 1995 through 1997 GPCIs were used for the revised 1998 through 2000 GPCIs with a few very minor modifications. No acceptable additional data sources were found. The cost shares were the same as in the 1995 through 1997 GPCIs because no changes were made in the MEI weights.

Indices for fee schedule areas are based on the indices for the individual counties within the fee schedule area. Fee schedule RVUs are again used to weight the county indices (to reflect volumes of services within counties) when mapping to fee schedule areas and in constructing the national average indices. However, we used more recent data, 1994 rather than 1992 RVUs, in the county, locality, and national mapping in the proposed GPCIs. The payment effect of this is negligible in most cases and generally results in changes at the third decimal point if at all.

a. Work Geographic Practice Cost Indices. The work GPCIs are based on the decennial census. The 1992 through 1994 work GPCIs were based on 1980 census data because 1990 census data were not yet available. The work GPCIs were revised in 1995 with new data from the 1990 census. New census data will not be available again until after the 2000 census. We searched for other data that would enable us to update the work GPCIs between the decennial censuses but no acceptable data sources were found. The most promising sources of data were the hospital wage data that we collected to calculate the prospective payment system (PPS) hospital wage index and the payroll per worker data collected by the U.S. Bureau of Labor Statistics from State unemployment insurance agencies (''the ES–202 data'').

The PPS hospital wage data were examined when we constructed the original GPCIs. They were rejected in favor of census data because of their lack of an occupation mix adjustment and their unrepresentative occupational composition (hospital employees rather than professionals or physician office employees). ES–202 data consist of total payroll divided by counts of wage and salary workers. Their major disadvantages were that they did not measure hourly earnings, only payroll per employee, and no occupational detail is available. Also, they did not adjust for part-time or full-time and hours worked, and the numbers of workers are small for certain States, leading to unstable estimates of payroll per worker. We compared the changes by State from 1989 to 1993 in the PPS wage data and the ES–202 data to see if there was any correlation between the two series. The correlation between the two was only moderate: 0.55. The changes indicated by both series were generally small, for example, a few percentage points. The difference between the two series by State was in many cases as large as, or greater than, the change indicated by either series. The average difference between the two series (2.1 percent) is as large as the change indicated by either series. In addition, changes for particular States were substantially different between the two series. For example, Indiana relative wages rose by 1.9 percent according to the PPS data, but fell 5.7 percent according to the ES–202 data.

Since we were unable to find an acceptable data source for updating the work GPCIs, we examined the

consequences of not updating the work GPCIs between the decennial censuses. We compared the changes between the 1992 through 1994 work GPCIs, based on the 1980 census and the 1995 through 1997 GPCIs, based on the 1990 census. On average, the full variation State work GPCIs changed by about 5 percent. This translates to about a 1.2 percent change in the quarter work GPCI required by law. Since work makes up about one-half of the GPCI cost shares, this translates into an average payment change per State of about 0.6 percent from updating the work GPCI based on the 10-year change in relative wages indicated by the census data. Even the maximum change in the full variation State work GPCIs from the 1992 through 1994 to the 1995 through 1997 GPCIs of 14 percent translates into only about a 1.8 percent change in payments. The largest full work GPCI changes for individual payment areas were from 16 to 20 percent, or about a 4 to 5 percent change in the quarter work GPCI, or about a 2.4 percent change in payments. However, 80 percent of payment areas experienced payment changes of less than 1 percent, and 50 percent of payment localities experienced payment changes of less than 0.5 percent as a result of changes in the census data from 1980 to 1990.

We, therefore, made no changes in the 1998 through 2000 work GPCIs from the 1995 through 1997 work GPCIs, other than the generally negligible changes resulting from using 1994, rather than 1992, RVUs for this GPCI update because we were unable to find acceptable data for use between the decennial censuses. We believe that making no changes is preferable to making inaccurate changes based on unacceptable data. We believe that this is a reasonable position given the generally small magnitude of the changes in payments resulting from the changes in the work GPCIs from the 1980 to the 1990 census data.

b. Practice Expense Geographic Practice Cost Indices. (1) Employee Wage Indices. As with the work GPCIs, the employee wage portion of the practice expense GPCIs is based on decennial census data. For the same reasons discussed above pertaining to the work GPCIs, we made no changes in the employee wage indices during the 1998 through 2000 GPCI update. The average change from the 1992 through 1994 to the 1995 through 1997 employee wage indices across States was about 6 percent. Since the employee wage index had a weight of about 16 percent in the GPCI cost shares, this translated into a 1 percent average change in payments. The maximum payment change in any payment area resulting from changes from the 1992 through 1994 to the 1995 through 1997 employee wage indices was about 3.2 percent. Payment changes in over two-thirds of the payment areas were less than 1 percent.

(2) Rent Indices. The office rental indices were again based on HUD residential rent data. The rental indices were based on 1996 HUD data as opposed to the 1994 HUD data in the 1995 through 1997 GPCIs. HUD made two small methodological changes in developing the data. First, HUD used the 40th percentile of area rents rather than the 45th percentile. This did not materially affect the GPCIs, which measure relative rents among areas. Second, HUD established a rental floor for rural counties at the statewide rural average. This had the effect of raising the office rental indices slightly in rural areas.

We made one methodological change in the rent indices. HUD publishes FMRs only for metropolitan areas as a whole. For the 1995 through 1997 GPCIs, HUD used a special tabulation of the 1990 census data to allocate rents by county within CMSAs. In some metropolitan areas, this had the effect of reducing the central city index below the suburban index, probably because of lower unmeasured housing quality in central cities than in suburbs. This may not have been the best indicator of relative physician rents, since the GPCIs are intended to measure rental costs for offices of similar quality in different areas. The metropolitan-wide rent is most appropriate for measuring the cost of space of an average quality across the metropolitan area, which is why HUD publishes only metropolitan-wide FMRs. Also, the census county adjustments can be updated only once every 10 years. For this reason, we believed that the county-specific adjustment should not be made for all large metropolitan areas, but should be retained only for the New York City Primary MSA. Available evidence suggested that rents vary substantially among the boroughs of New York City and that, given the current locality configuration, the county-specific rental adjustment appropriately reflected these patterns in the New York City area, especially the higher rents in Manhattan.

(3) Medical Equipment, Supplies, and Miscellaneous Expenses. As with the 1992 through 1994 and 1995 through 1997 GPCIs, this component was given a national value of 1.000, indicating no measurable difference among areas in costs.

c. Malpractice Geographic Practice Cost Indices. Again, malpractice premium data were collected for a mature ''claims made'' policy with $1 million to $3 million limits of coverage, with adjustments made for mandatory patient compensation funds. As with the 1995 through 1997 GPCIs, data were collected for the 20 largest Medicare-billing physician specialties. The premium data represent at least 50 percent of the market in each State. Again, we used an average of the 3 most recent premium years to smooth out the considerable year-to-year fluctuations that can occur in malpractice premiums. The revised 1998 through 2000 malpractice indices were based on 1992 through 1994 premium data, the latest years available when the Health Economics Research (HER) GPCI study was being conducted in 1995 through 1996. Another change from the 1995 through 1997 indices is that we weighted the specialty shares of the 20 specialties by fee schedule RVUs rather than allowed charges.

Detailed discussions of the methodology and data sources of the 1998 through 2000 GPCIs may be obtained by requesting the following study from NTIS by calling 1–800–533–NTIS, or, for residents of Springfield, Virginia, (703) 487–4650: ''Second Update of the Geographic Practice Cost Index.'' Gregory C. Pope and Killard W. Adamache.

5. Proposed 2001 Through 2003 Geographic Practice Cost Indices

We propose using the same data sources and methodology used for the 1998 through 2000 GPCIs for the 2001 through 2003 GPCIs (hereafter referred to as proposed GPCIs). No acceptable additional data sources were found. The only differences between the 1998 through 2000 GPCIs and the proposed GPCIs are in the cost shares and RVU weighting. As shown in the cost share table in the discussion of the development of the GPCIs, the cost shares have been changed to reflect the revisions in the MEI. This does not affect the work or malpractice GPCIs since they are stand-alone indices. The change has a small effect on the practice expense GPCIs because it changes slightly the weights among the employee wage, rents and miscellaneous components of the practice expense index. We used more recent RVU data—1998 rather than 1994—in the county, locality, and national mapping in the proposed GPCIs. The payment effect of this is generally negligible.

a. Work Geographic Practice Cost Indices. For the same reasons discussed

in the section on the 1998 through 2000 work GPCIs, no significant changes are being proposed in the 2001 through 2003 work GPCIs because we were unable to find acceptable data for use between the decennial censuses. There are general negligible changes resulting from the use of 1998 rather than 1994 RVUs for weighting.

b. Practice Expense Geographic Practice Cost Indices. (1) Employee Wage Indices. As with the work GPCIs, the employee wage indices are based on decennial census data. For the same reasons discussed above pertaining to the work GPCIs, we are proposing no changes in the employee wage indices during this GPCI update.

(2) Rent Indices. The office rental indices are again based on HUD residential rent data. No changes have been made in the methodology. The proposed rental indices are based on 2000 rather than 1994 HUD data.

The proposed rental indices are compared to the current rental indices in Addendum D. A reduction in an area's rent index does not necessarily mean that rents have gone down in that area since the last GPCI update. Since the GPCIs measure area costs compared to the national average, a decrease in an area's rent index means that an area's rental costs have decreased when compared to the change in national average rental costs. The indices are arranged in descending order of change. The rental index has a cost share of about 12 percent of the GPCI. This means that the actual effect on payments will be about 12 percent of the change in the rental indices. While the new rental indices show significant changes in a few areas, primarily in the San Francisco Bay area, 80 of the 89 areas change by less than 10 percent, which translates into about a 1 percent change in payments.

(3) Medical Equipment, Supplies, and Miscellaneous Expenses. As with all previous GPCIs, this component would be given a national value of 1.000, indicating no measurable differences among areas in costs.

c. Malpractice Geographic Practice Cost Indices. We propose using the same methodology described in the 1998 through 2000 malpractice GPCI section in the proposed malpractice GPCIs for 2001 through 2003. The only difference is that we used more recent data. The proposed malpractice indices are based on 1996 through 1998 data compared to the 1992 through 1994 data used in the previous GPCI update.

Addendum E shows the changes from the 1998 through 2000 indices to the proposed malpractice GPCIs. A change in an area's malpractice GPCI does not mean that absolute malpractice premiums have changed by that amount. It, rather, reflects the area's new position compared to the national average. As with past GPCI revisions, the changes in the proposed malpractice GPCIs are relatively large in some cases, reflecting the significant changes in malpractice premiums that occur from year to year. As Addendum E shows, two-thirds of the payment areas experience changes of less than 12 percent. It should be noted, however, that the weight of the malpractice GPCI is only about 3 percent of the total GPCI. Therefore, a 12 percent change in the malpractice GPCI translates into only a 0.4 percent change in payments. Even the largest 42 percent change in the malpractice GPCI translates into only a 1.3 percent change in payments. The mean change in the malpractice GPCIs is 11 percent, or about a 0.4 percent change in payments.

The proposed 2002 fully-effective revised GPCIs and the transitional 2001 revised GPCIs can be found at Addendum F and Addendum G, respectively. Since the proposed revised GPCIs could result in total payments either greater or less than payments that would have been made if the GPCIs were not revised, it was necessary to adjust the GPCIs for budget neutrality as required by law. Therefore, we adjusted the 2001 through 2002 GPCIs as follows: work by 0.99699; practice expense by 0.99235; and malpractice by 1.00215.

C. Resource-Based Malpractice Relative Value Units

In the July 1999 proposed rule (64 FR 39610) and the November 1999 final rule (64 FR 59383) for the CY 2000 physician fee schedule, we discussed the methodology used to calculate resource based malpractice RVUs and proposed interim RVUs effective January 1, 2000. (See ''Legislative History'' section for dates and **Federal Register** citations for these rules.) The methodology can be briefly summarized as follows:

- Actual malpractice premium data were collected for the top 20 Medicare physician specialties.
- All Medicare specialties were mapped to insurer rating classes (ISO codes).
- A national average premium was calculated for every specialty.
- Specialty risk factors showing the relative malpractice costs among specialties were created by dividing each specialty national average premium by the lowest average premium.
- Specialty-weighted malpractice RVUs were calculated for each procedure by summing, for all specialties providing the procedure, the product of each specialty's risk factor times the proportion of total service count for that procedure provided by the specialty.
- This number was multiplied by the procedure's work RVUs to account for differences in risk-of-service among procedures.
- The new malpractice RVUs were adjusted by the appropriate factor to attain budget neutrality.

The malpractice RVUs were based on 1993 through 1995 premium data, the most recent premium data readily available. In last year's proposed and final rules we stated that we planned to collect more recent data, but did not expect that newer data would change the values significantly since malpractice premiums have been remarkably stable in recent years.

We have now obtained, and are currently examining, malpractice premium data for 1996 through 1998. The malpractice RVUs in the fall final rule will reflect the newer data. While we have not yet completed the proposed malpractice RVU calculations, the table below compares the 1993 through 1995 average premiums (that were used to calculate the 2000 malpractice RVUs) with the 1996 through 1998 average premiums (that will be used to calculate the 2001 malpractice RVUs). As the table below shows, there was very little change in the national average premiums from 1993 through 1995 to 1996 through 1998. We, therefore, anticipate minimal changes in malpractice RVUs from use of the more recent data.

National Average Premiums By Surveyed Specialties

ISO	Specialty	1996 avg	1997 avg	1998 avg	93-95	96-98	Trend
80114	Ophthalmology	11,304	11,377	10,945	10,960	11,209	0.75%
80143	General surgery	27,667	28,116	27,694	27,020	27,825	0.98%
80144	Thoracic surgery	39,056	39,020	38,359	38,789	38,812	0.02%
80145	Urology	16,799	17,163	16,911	15,817	16,958	2.35%
80151	Anesthesiology	15,708	15,468	14,904	17,231	15,360	-3.75%
80152	Neurosurgery	58,104	58,263	56,735	54,610	57,701	1.85%
80154	Orthopedic surgery	39,182	38,882	37,688	38,877	38,584	-0.25%
80156	Plastic surgery	31,670	31,708	31,062	30,599	31,480	0.95%
80159	Otolaryngology	20,603	19,845	19,521	19,748	19,990	0.41%
80244	Gynecology	8,445	8,690	8,790	n/a	8,642	n/a
80249	Psychiatry	6,645	6,533	6,664	7,240	6,614	-2.96%
80269	Pulmonary disease	9,352	9,553	9,620	8,594	9,508	3.42%
80274	Gastroenterology	11,691	11,890	11,655	11,008	11,745	2.18%
80280	Diagnostic radiology	12,099	12,651	12,365	10,783	12,372	4.68%
80281	Cardiology	13,265	13,367	12,980	12,465	13,204	1.94%
80282	Dermatology	10,690	10,865	10,394	10,946	10,650	-0.91%
80284	Internal medicine	11,770	11,941	11,798	11,491	11,836	0.99%
80288	Neurology	14,000	13,758	13,421	12,396	13,726	3.45%
80292	Pathology	9,633	9,690	9,439	8,913	9,587	2.46%
80423	General practice	11,181	11,354	11,167	10,465	11,234	2.39%
n/a -data not available							

In addition, in response to comments received on last year's rules, we are proposing to accept a comment regarding crosswalking specialties. We are proposing to crosswalk surgical oncology to general surgery rather than to all physicians. The malpractice values to be included in the final rule reflecting the updated data will remain interim.

D. Critical Care Relative Value Units

In the November 1999 final rule (64 FR 59423), we established interim work RVUs for CPT codes 99291 and 99292 (critical care services) of 3.6 and 1.8, respectively, which were decreased from the previous RVUs for these services. These work RVUs were established because of the change in the CPT definition of critical care services in CPT 2000. We also discussed in detail what changes in the definition most concerned us. We received many comments on the interim work RVUs for critical care.

This year we proposed new coding language to the AMA CPT Editorial Panel (the Panel) to resolve physician concerns. The Panel, with input from various specialty societies, accepted the language that we proposed with some modifications. The AMA has given us copyright permission to publish the introduction for CPT codes 99291 and 99292 as it will appear in CPT 2001. For CPT 2001, the introduction for critical care services will be as follows (new language in italics):

Critical care is the direct delivery by a physician(s) of medical care for a critically ill or *critically* injured patient. A critical illness or injury acutely impairs one or more vital organ systems such that *there is a high probability of imminent or life threatening deterioration in the patient's condition.* Critical care involves decision making of high complexity, to assess, manipulate, and support *vital system function(s) to treat single or multiple vital organ system failure and/or to prevent further life threatening deterioration of the patient's condition. Examples of vital organ system failure include, but are not limited to:* central nervous system failure, circulatory failure, shock, renal, hepatic, metabolic *and/or* respiratory failure. *Although critical care typically requires* interpretation of multiple *physiologic parameters and/or* application of advanced technology*(s), critical care may be provided in life threatening situations when these elements are not present.* Critical care may be provided on multiple days, even if no changes are made in the treatment rendered to the patient, provided that the patient's condition continues to require the level of physician attention described above.

Providing medical care to a critically ill, injured, or post-operative patient qualifies as a critical care service only if both the illness or injury and the treatment being provided meet the above requirements. Critical care is usually, but not always, given in a critical care area, such as the coronary care unit, intensive care unit, pediatric intensive care unit, respiratory care unit, or the emergency care facility. Critical care services provided to infants older * * * [no change to this paragraph]

Services for a patient who is not critically ill but happens to be in a critical care unit are reported using other appropriate E/M codes.

Critical care and other E/M services may be provided to the same patient on the same date by the same physician.

The following services are included in reporting critical care when performed during the critical period by the physician(s) providing critical care: the interpretation of cardiac output measurements (93561,93562), chest x-rays (71010, 71015, 71020), *pulse oximetry (94760, 94761, 94762),* blood gases, and information data stored in computers (eg, ECGs, blood pressures, hematologic data (99090); gastric intubation (*43762,* 91105); temporary transcutaneous pacing (92953); ventilator management (94656, 94657, 94660, and 94662); and vascular access procedures (36000, 36410, 36415, *36540* and 36600). Any services performed which are not listed above should be reported separately.

The critical care codes 99291 and 99292 are used to report the total duration of time spent by a physician providing critical care services to a critically ill or critically injured patient, even if the time spent by the physician on that date is not continuous. For any given period of time spent providing critical care services, the physician must devote his or her full attention to the patient and, therefore, cannot provide services to any other patient during the same period of time.

Time spent with the individual patient should be recorded in the patient's record.

The time that can be reported as critical care is the time spent engaged in work directly related to the individual patient's care whether the time was spent at the immediate bedside or elsewhere on the floor or unit. For example, time spent on the unit or at the nursing station on the floor reviewing test results or imaging studies, discussing the critically ill patient's care with other medical staff or documenting critical care services in the medical record would be reported as critical care, even though it does not occur at the bedside. Also, when the patient is unable or clinically incompetent to participate in discussions, time spent on the floor or unit with family members or surrogate decision makers obtaining a medical history, reviewing the patients condition or prognosis, or discussing treatment or limitation(s) of treatment may be reported as critical care, provided that the conversation *bears directly on the management of the patient.*

Time spent in activities that occur outside of the unit or off the floor (eg, telephone calls, whether taken at home, in the office, or elsewhere in the hospital) may not be reported as critical care since the physician is not immediately available to the patient. Time spent in activities that do not directly contribute to the treatment of the patient may not be reported as critical care, even if they are performed in the critical care unit (eg, participation in administrative meetings or telephone calls to discuss other patients). *Time spent performing separately reportable procedures or services should not be included in the time reported as critical care time.*

The remainder of the introduction as published in CPT 2000, as well as the descriptors for the two CPT codes (99290 and 99291), remains unchanged.

Adoption of this revised introduction for the critical care CPT codes 99291 and 99292 is consistent with our view of the appropriate intensity of these services and addresses the concerns we had raised in the November 1999 final rule. Therefore, based on implementation of this revised introduction for critical care services for CY 2001, we are proposing to value the physician work at 4.0 RVUs for CPT code 99291 and 2.0 RVUs for CPT code 99292.

In addition, consistent with our discussion in the proposal for electrical bioimpedance (EB) (see section II.H), we are proposing to not allow separate Medicare payment for EB when provided in conjunction with critical care services (CPT codes 99291 and 99292).

E. Care Plan Oversight and Physician Certification/Recertification

The Panel considered changes to the definition of care plan oversight for 2001. After analyzing the definition changes, we are concerned that these codes (CPT codes 99375 and 99378) will no longer be consistent with our coverage criteria.

In anticipation of the likely CPT revisions, we would establish two new HCPCS codes for care plan oversight that are consistent with our coverage criteria. For the 2001 physician fee schedule, we would establish a new HCPCS code Gxxx1, that will use the CPT 2000 definition associated with CPT code 99375 and a new HCPCS code Gxxx2, that will use the CPT 2000 definition associated with CPT code 99378. The current policy guidance that applied to CPT codes 99375 and 99378, including our past responses to questions on care plan oversight, will continue to apply to these G codes. The current payments for CPT codes 99375 and 99378 will be maintained in Gxxx1 and Gxxx2.

In addition, we would establish two new HCPCS codes (Gxxx3 and Gxxx4) to describe the services involved in physician certification (and recertification) and development of a plan of care for a patient for whom the physician has prescribed Medicare-covered home health services. The proposed text of the new codes will read as follows:

Gxxx3 ..... Physician services for initial certification of Medicare-covered services by a home health agency, per patient's home health certification period.

This code would be used when the patient has not received Medicare-covered home health services for at least 60 days.

Gxxx4 ..... Physician services for recertification of Medicare-covered services by a home health agency, per patient's home health certification period

This code would be used after a patient has received services for at least 60 days (or one certification period) when the physician signs the certification after the initial certification period.

The use of these HCPCS codes (Gxxx3 and Gxxx4) would be restricted to physicians who are permitted to certify that home health services are required by a patient pursuant to section 1814(a)(2)(C) and section 1835(a)(2)(A) of the Act. The Gxxx3 code would be billed only once every 60 days, except in the rare situation when the patient starts a new episode before 60 days elapses and requires a new plan of care to start a new episode. Consistent with section 1835(a)(2) of the Act, a physician who has a significant ownership interest in, or a significant financial or contractual relationship with a home health agency (HHA), generally cannot bill this code for patients served by that HHA.

For services within the episode (generally beyond the first week or two of care plan implementation) that are consistent with the definition of care plan oversight (HCPCS code Gxxx1), the care plan oversight code (CPT code 99375) would be used.

Because we believe that the physician work associated with HCPCS code Gxxx3 equates to that of a level 3 established patient office visit (CPT code 99213), we are proposing a value of .67 for the work RVUs. For Gxxx4, because we believe the work equates to a level 2 established patient office visit (CPT code 99212), we are proposing a value of .45 for the work RVUs. For practice expense RVUs, we are proposing to crosswalk both Gxxx3 and Gxxx4 to the practice expense inputs currently used for care plan oversight (CPT code 99375).

F. Observation Care Codes

In 1998, the AMA added new CPT codes 99234 to 99236, Observation or inpatient hospital care services (including the admission and discharge services) for a patient on the same date. We accepted the RUC recommendations for work RVUs for these new codes. The work RVUs for each code are the sum of the applicable admission work for CPT codes 99218 to 99220 (or CPT codes 99221 to 99223) plus the discharge work (CPT codes 99217 or 99238). For example, CPT code 99234 has 2.56 work RVUs, which is the sum of the work RVUs for CPT code 99221 (1.28) plus the work RVUs for CPT code 99217 (1.28). However, it has come to our attention that allowing payment for these CPT codes conflicts with two policies currently in the Medicare Carrier Manual (MCM).

Section 15505.1(c) of the MCM states that we will pay for only the initial hospital care service code when a patient is admitted as an inpatient and discharged on the same day. Physicians are not paid for both an inpatient hospital admission and hospital discharge management on the same day. In addition, section 15504.b of the MCM instructs that CPT codes 99218 to 99220 (Initial observation care) should be used if the patient is discharged on the same day as the admission for observation because each of these codes represents a full day of care and, thus, paying for a code representing both admission and discharge on the same day would be duplicative. CPT code 99217 (Observation care discharge) may be billed only on the second or subsequent days in observation.

These two payment policies result in different payments for patients whose inpatient stay is less than 24 hours based solely on whether they were in the hospital at midnight. For example, a physician who admits a patient to observation or to inpatient care at 8 a.m. and then discharges the patient at 8 p.m. the same day, would be allowed payment for only the admission service. On the other hand, a physician who admits a patient to observation or to inpatient care at 8 p.m. and then discharges the patient at 8 a.m. the next day, would be allowed payment for both the admission and discharge services.

In response to these concerns, and to clarify our payment policy, we are proposing the following:

Inpatient stay of 24 hours or more—We would pay for both inpatient hospital admission services (CPT codes 99221 to 99223) and hospital discharge services (CPT codes 99238 to 99239) when a patient is a hospital inpatient for a period of 24 hours or more. The medical record must document that the patient was an inpatient for at least 24 hours for both of these services to be paid.

Inpatient or observation stay of less than 8 hours—If a patient is admitted as a hospital inpatient or an observation patient for less than 8 hours, we would pay for only the admission service (CPT codes 99221 to 99223 or 99218 to 99220) on that day. The discharge service is not considered to be a separately billable service.

Inpatient or observation stay of 8 or more hours, but less than 24 hours—If a patient is admitted as a hospital inpatient or an observation patient for a period of 8 or more hours, but less than 24 hours, we would pay for both the admission and discharge services under CPT codes 99234 to 99236 with the following proposed physician work RVUs and documentation requirements:

Physician Work RVUs—To properly value both the admission and discharge work of these services, we are proposing to continue valuing the admission portion of the physician work as equivalent to CPT codes 99218 to 99220 (or CPT codes 99221 to 99223), but to reduce the discharge work RVUs from 1.28 to 0.67. This would make the discharge portion of the work equal to the work for CPT code 99213 (Office or other outpatient visits) instead of CPT code 99217 (or CPT code 99238). Thus, the proposed work RVUs would be as follows: CPT code 99234—1.95 RVUs; CPT code 99235—2.81 RVUs; CPT code 99236—3.66 RVUs. We would not pay CPT codes 99217, 99238, and 99239 for hospital inpatient or observation admissions between 8 and 24 hours in length.

Our reasoning for these proposed RVUs is that we believe that the physician work typically required for discharging an inpatient or observation admission patient after a period of at least 8 hours, but less than 24 hours, is less than that required for an admission of 24 hours or more. The typical work (for example, history, physical examination, and medical decision making) and the typical face to face time required to discharge such a patient is comparable to the requirements for CPT code 99213. Moreover, the typical time for CPT code 99238 is up to 30 minutes and the physician work is 1.28 RVUs, so a clear work anomaly would be created if we made the work value of discharging a patient with a stay of less than 24 hours identical to the work of discharging a patient with a length of stay of 24 hours or more.

Our proposal would avoid creating such a rank order anomaly and would place admission and discharge valuation in proper order. For example, for observation stays of less than 8 hours, we would pay only the admission portion and would not pay separately for the discharge because the extra work is minimal. For observation stays of more than 8 hours, but less than 24 hours, we would recognize the discharge component since there is significant extra work involved, but not as much as a discharge for a 24 hour or longer admission for which we would pay the full value of CPT code 99238. Our proposal would allow payment for CPT codes 99234 through 99236 only for stays of equal to or greater than 8 hours, but less than 24 hours.

In addition to the documentation guidelines for history, physical examination, and medical decision making described in CPT 2000 for CPT codes 99234 to 99236, we would require the following to be documented in the medical record:

- A stay involving 8 hours, but less than 24 hours.
- That the billing physician was present and personally performed the services.
- Admission and discharge notes written by the billing physician.

We believe this policy would harmonize current policy on hospital admissions and discharges and also accommodate the observation codes as they are described in CPT 2000. The policy would not be tied to the ''midnight'' time frame of the hospital inpatient census.

If these proposals are adopted in the final rule, the work RVUs for CPT codes 99234 to 99236 would be considered interim for 2001.

G. Ocular Photodynamic Therapy and Other Ophthalmological Treatments

Ocular photodynamic therapy is a treatment recently approved by the Food and Drug Administration for age-related macular degeneration, the most common cause of blindness in the elderly. For CPT 2000, ocular photodynamic therapy was added to CPT code 67220, which was formerly limited to photocoagulation by laser.

We believe that ocular photodynamic therapy is significantly different from laser photocoagulation and, therefore, we are proposing to establish new HCPCS codes that specifically identify these procedures. A discussion of each of these codes follows:

Gxxx5 ..... Destruction of localized lesion of choroid (*e.g.*, choroidal neovascularization); photocoagulation (*e.g.*, by laser), one or more sessions

This code would be used in place of CPT code 67220. We would maintain the work and malpractice RVUs and the CPEP inputs presently used for CPT code 67220 for payment of this new ''G'' code.

Gxxx6 ..... Destruction of localized lesion of choroid (*e.g.*, choroidal neovascularization); ocular photodynamic therapy (includes intravenous infusion)

We are proposing a value of 0.55 work RVUs for Gxxx6. This value is half the physician work value for CPT code 96570 (Photodynamic therapy by endoscopic application of light to ablate abnormal tissue via activation of photosensitive drug(s); first 30 minutes), and it is identical to the physician work value for CPT code 96571 (Photodynamic therapy by endoscopic application of light to ablate abnormal tissue via activation of photosensitive drug(s); each additional 15 minutes). We note that the total time of laser light application for ocular photodynamic therapy is 83 seconds, which is considerably shorter than the time of laser light application for CPT codes 96570 and 96571.

We are also proposing that the global period for Gxxx6 be ''XXX.'' Because of the global designation, significant, separately identifiable evaluation and management (E/M) services may be billed on the same day as Gxxx6 with the use of the –25 modifier. Patients will, typically, have fluorescein angiography as well as an E/M service before ocular photodynamic therapy to determine whether they will benefit from the therapy and to discuss the

treatment. Any E/M services performed after the treatment may be billed separately.

For Gxxx6 we are proposing the following practice expense inputs for non-facility settings:

- Clinical Staff Time: Registered nurse/ophthalmology technician—40 minutes.
- Supplies: Ophthaine, mydriacil, myolfrin, gonisol, post myd spectacles, verteporfin and also infusion supplies including sterile and non-sterile gloves, butterfly needle, syringe, band aid, alcohol swab, staff gown, iv infusion set, and infusion pump cassette.
- *Equipment:* Laser, infusion pump, and exam lane.

For the malpractice component of Gxxx6, we are proposing 0.52 RVUs (the value assigned to CPT code 67220, Destruction of localized lesion of choroid). Although we are establishing procedure codes for ocular photodynamic therapy, coverage of the procedure is at the discretion of the local carrier.

In instances where both eyes are treated the same day, we are proposing the use of the following HCPCS add-on code:

Gxxx7 Destruction of localized lesion of choroid (for example, choroidal neovascularization); ocular photodynamic therapy (includes intravenous infusion)—other eye (List separately in addition to Gxxx6)

For this add-on code we are proposing a ''ZZZ'' global period, with .28 work RVUs (half of that proposed for Gxxx6) and .52 malpractice RVUs (identical to that proposed for Gxxx6). The practice expense inputs for services in the non-facility setting would be as follows:

- *Clinical Staff Time:* Registered nurse/ophthalmology technician—5 minutes.
- *Supplies:* Ophthaine, mydriacil, myolfrin, gonisol.

In addition, we have identified several other specific ophthalmological treatments that are not distinctly identified in CPT 2000. We are proposing to establish specific HCPCS codes for these procedures.

Gxxx8 Destruction of localized lesion of choroid (*e.g.*, choroidal neovascularization); transpupillary thermotherapy, one or more sessions

Gxxx9 Destruction of localized lesion of choroid (*e.g.*, choroidal neovascularization); photocoagulation, feeder vessel technique, one or more sessions

Gxx10 Destruction of macular drusen, photocoagulation, one or more sessions

We are not proposing RVUs for HCPCS codes Gxxx8 through Gxx10. These codes are being established for tracking purposes only. These procedures are considered experimental in nature at this time and, therefore, are not covered under Medicare.

H. Electrical Bioimpedance

Electrical bioimpedance (EB), a noninvasive method of measuring cardiac input, is a covered procedure under Medicare, if medically necessary. Performance of this procedure is reported by the Level 2 HCPCS code M0302, and the procedure is currently carrier priced. We are proposing the following RVUs for this procedure:

1. Practice Expense

We are proposing the following direct inputs for determining practice expense RVUs. (We note, however, that a final determination of the practice expense RVUS will depend on how we value physician work.) The practice expense RVU in Addendum B reflects the value for the technical portion of the service. If the service is given physician work, a separate PC will be established with an additional practice expense RVU.

- *Clinical staff:* Registered nurse—15 minutes.
- *Supplies:* Four disposable sensors, patient gown, exam table paper, and pillowcase.
- *Equipment:* Cardiac output monitor and exam table.

2. Malpractice

We are proposing 0.02 RVUs for this procedure. This value is equivalent to the TC of an EKG, which is a similar procedure.

3. Physician Work

The uses for which this procedure are covered (for example, differentiating cardiogenic from pulmonary causes of acute dyspnea, the need for intravenous inotropic therapy, fluid management, and the uses indicated in section 50–54 of the Coverage Issues Manual, HCFA Pub. 6) require a clinical evaluation of the patient on the same day that EB is performed. The procedure reports measurements that can not be interpreted without other clinical information.

With respect to proposed RVUs for physician work, we have insufficient information to propose a work value. We are collecting information and invite comments on this subject as well as on the proposed inputs for practice expense and malpractice. In your comments, please be sure to compare your proposed value for the physician work component for this service to other similar services with established physician work values. Please also include the reason why you believe the physician work is similar. At this time, we have received comments proposing no physician work values, proposing physician work values similar to that for the interpretation of an EKG (CPT code 93010—0.17 work RVUs), proposing work values similar to total body plethysmography (CPT code 93720—0.17 work RVUs), and similar to interpretation of cardiovascular stress test (CPT code 93018—0.30 work RVUs).

We also are proposing that the payment for this procedure be included in reporting critical care. Therefore, separate payment would not be made for this procedure when provided in conjunction with critical care services (CPT codes 99291 and 99292).

I. Global Period for Insertion, Removal, and Replacement of Pacemakers and Cardioverter Defibrillators

Currently, there is a 90-day global period in the physician fee schedule for all CPT codes involving the insertion, removal, and replacement of pacemakers or cardioverter defibrillators. During the global surgical period, no separate payment may be made for any E/M service furnished by the surgeon, unless the visit is: (1) Unrelated to the diagnosis for which the surgical procedure was performed; (2) for treating the underlying condition; or (3) an added course of treatment that is not part of normal recovery from surgery.

In these situations, the surgeon must use CPT modifier -24 that attests that the E/M service provided, although performed during the postoperative period, was for a reason unrelated to the original procedure. Services submitted with a -24 modifier must be sufficiently documented to establish that the visit was unrelated to the surgery. An ICD–9–CM code that clearly indicates that the reason for the encounter was unrelated to the surgery is acceptable documentation.

Many patients receiving pacemakers or cardioverter defibrillators have clinically serious cardiac diseases (related to the reason for the procedure) that require significant postoperative care. In these cases, it is difficult to separate care during the postoperative period for the related cardiac problem(s) from the postoperative care for the pacemaker or cardioverter defibrillator procedure. As medical practice has changed, cardiologists predominantly perform pacemaker or cardioverter defibrillator procedures. Thus, the physician performing the pacemaker or cardioverter defibrillator procedure now is typically the same physician who is expected to furnish care for the patient's

related cardiac disease. Therefore, a single physician is providing postoperative care for both the pacemaker or cardioverter defibrillator insertion and the related medical problem(s), but can be paid only for the insertion because of the global period policy.

We believe it is common for patients undergoing pacemaker and cardioverter defibrillator procedures to require significant care for related cardiac disease during the postoperative period. This care overlaps substantially with the care furnished for the pacemaker or cardioverter defibrillator procedure and may be coded with the same ICD–9–CM diagnosis code; therefore, using the -24 modifier is inadequate to allow appropriate payment for the physician performing both postoperative care and care for the patient's other cardiac conditions.

We are proposing to change the global period for CPT codes 33206, 33207, 33208, 33212, 33213, 33214, 33216, 33217, 33218, 33220, 33233, 33234, 33235, 33240, 33241, 33244, 33249, 33282, and 33284 from 90 days to 0 days. This would permit separate payment for any care furnished during the postoperative period by the physician who performed the pacemaker or cardioverter defibrillator procedure.

We are soliciting comments on whether it is appropriate to reduce the global period for these CPT codes. We are also proposing to ask the RUC to revise the RVUs for these CPT codes. If RUC recommendations are not received in time for our consideration for the CY 2001 physician fee schedule final rule, we propose to implement interim work RVUs, as listed below.

CPT code	2000 work RVUs	Proposed work RVUs
33206	6.67	3.11
33207	8.04	3.30
33208	8.13	2.64
33212	5.52	3.32
33213	6.37	4.92
33214	7.75	4.27
33216	5.39	3.21
33217	5.75	3.57
33218	5.44	3.26
33220	5.52	2.90
33233	3.29	1.11
33234	7.82	5.64
33235	9.40	4.58
33240	7.50	5.13
33241	3.24	1.51
33244	13.76	9.85
33249	14.23	11.41
33282	4.17	2.83
33284	2.50	1.16

In calculating the proposed interim RVUs, we have subtracted the work RVUs of all postoperative visits after the day of surgery from the total work RVUs. We used our database to calculate the number of postoperative visits. Where our database did not contain the number of postoperative visits, we crosswalked a number from the most clinically similar procedure. We have included an example to illustrate the calculation.

Example: For CPT code 33206, the 2000 work relative value is 6.67 units. The proposed work value is 3.11 (6.67 minus 3.56). The 3.56 units represents the work based on the pattern of E/M services in the global period.

E/M	Frequency	Work	Total
99213	1.5	.67	1.00
99231	2.0	.4	1.28
99238	1.0	1.28	1.28
Total E/M Work			3.56

We would also adjust practice expense inputs for supplies, staff time, and equipment to account for the change in the global period. Because these would be 0-day global services only priced in the facility setting, there would be no direct CPEP inputs associated with them. The adjusted practice expense RVUs are reflected in Addendum B.

We welcome comments on our proposed calculation of interim RVUs and request that commenters recommending RVUs include the methodology employed so that we can appropriately evaluate the recommended RVUs. As an alternative to applying a 0-day global period as discussed above, we are interested in other suggestions that might address the issue of assuring appropriate payment for these services (for example, adjusting the global period to 10 days for these services). We invite public comment on such alternatives.

J. Antigen Supply

Section 410.68(b), Antigens: Scope and conditions, provides for beneficiaries to receive a supply of antigen for no more than 12 weeks at one time. A specialty society has indicated that this limitation is not reflective of current industry standards and guidelines (for example, duration of potency for allergy extracts has changed since the policy was implemented.) Therefore, we are proposing to change this limitation from 12 weeks to 12 months and would revise the regulations to reflect this change. We are requesting comments on this proposal.

K. Low Intensity Ultrasound

In the November 1999 (64 FR 59419) final rule, we assigned RVUs to CPT code 20979, low intensity ultrasound stimulation to aid bone healing. Commenters expressed concern about the RVUs assigned to this service. Because of the concerns raised by commenters, and because CPT code 20979 is a noncovered service under Medicare, we are proposing to remove the RVUs that were assigned to this code at this time. We may reconsider this at a future date.

L. Implantation of Ventricular Assist Devices

In the April 11, 2000 correction notice (65 FR 19332) to the November 1999 final rule, we inadvertently published practice expense RVUs based on the work RVUs associated with a 90-day global period for CPT codes 33975 and 33976 (implantation of ventricular assist devices). However, in the same notice, the global periods and associated work RVUs for CPT codes 33975 and 33976 were revised to reflect an ''XXX'' (the global concept does not apply). In calculating the practice expense RVUs, we reflected changes made in CPEP data that result from changes in the global period. However, the practice expense RVUs are also a function, in part, of the physician work RVUs. In calculating the revised practice expense RVUs, we did not use the work RVUs that reflected the global period change. Effective January 1, 2001, we would revise the practice expense RVUs associated with these CPT codes to reflect the revision in the global periods and work RVUs.

III. Other Issues

A. Incomplete Medical Direction

Under current policy, medical supervision by an anesthesiologist occurs if the anesthesiologist is involved in furnishing more than four concurrent procedures or is performing other services while directing fewer than four concurrent procedures. Payment is based on three base units plus one unit for induction if the physician is present at induction.

Under current policy, medical direction by an anesthesiologist occurs if the anesthesiologist is involved in two to four concurrent anesthesia procedures or a single anesthesia procedure with a qualified anesthetist. For each anesthesia procedure, the anesthesiologist must—

- Perform a pre-anesthesia examination and evaluation;
- Prescribe the anesthesia plan;
- Personally participate in the most demanding procedures of the anesthesia plan, including emergence and induction;
- Ensure that any procedures in the anesthesia plan that he or she does not perform are performed by a qualified anesthetist;
- Monitor the course of anesthesia administration at frequent intervals;
- Remain physically present and available for immediate diagnosis and treatment of emergencies; and
- Provide indicated post anesthesia care.

We currently do not have a national policy that instructs the carriers how to pay for a service when the anesthesiologist does not fulfill all the medical direction requirements. One option carriers may use is to instruct the anesthesiologist to report this service as a reduced or unusual service and determine appropriate payment. We are considering clarifying this policy and making other revisions to the medical supervision payment policy. We are considering the following:

1. To specify that the physician furnishing medical supervision must perform, at a minimum, the preoperative evaluation, participate in induction, remain available for consultation, and provide a minimum level of monitoring.
2. To establish payment for medical supervision at 40 percent of the payment amount for the service performed by the physician alone.
3. To apply the proposed medical supervision payment amounts to incompletely medically-directed cases.
4. To limit the number of concurrent cases the physician can supervise to five concurrent cases.

Payment for medical supervision is payment for the physician service. In addition, the certified registered nurse anesthetist (CRNA) service furnished under medical supervision is paid at 50 percent of the amount that would have been paid if the service had been performed by the physician alone.

We invite comments from the public, but in particular, the physicians and practitioners most affected by this policy. We are not proposing a change at this time, but will consider the comments we receive should we develop a future proposal.

B. Payment for Pulse Oximetry Services

In the November 1999 final rule (64 FR 59413), we indicated that we would adopt our proposal to bundle payment for certain diagnostic codes, including pulse oximetry CPT codes 94760 and 94761, into the payment for other services. We believe that continuing to pay separately for these codes duplicates amounts included in both facility payments and practice expense RVUs. However, we did not address how we would treat situations when these services are performed without any other billable service and, thus, are not reflected in facility payments or other practice expense RVUs. We will continue to pay separately for these services (CPT codes 94760 and 94761) when they are medically necessary and there are no other services payable under the physician fee schedule billed on the same date by the same supplier.

C. Outpatient Therapy Supervision

In the November 1998 final rule (63 FR 58868), we stated that we were maintaining our current requirement that therapy assistants of therapists in private practice (formerly known as therapists in independent practice (PTIP)) must be personally supervised by the therapist and be employed directly by the therapist; employed by the partnership or group to which the therapist belongs; or employed by the same practice. Personal supervision requires that the therapist be in the same room during the performance of the service. Levels of supervision are defined at § 410.32 (Diagnostic X-ray tests, diagnostic laboratory, and other diagnostic tests: Conditions.)

The November 1998 final rule did not change pre-existing regulations at § 410.60(c)(2) (Supervision of physical therapy services) for therapy assistants in a private practice setting. In that final rule, we codified the statutory requirements for coverage of outpatient occupational therapy services by establishing § 410.59 (Outpatient occupational therapy services: Conditions). Section 410.59 parallels the requirements in § 410.60 for outpatient physical therapy, as revised in the November 1998 final rule. We also made conforming changes in § 410.61 (Plan of treatment requirements for outpatient rehabilitation services) to include occupational therapy.

The personal supervision requirements for therapy assistants and aides in a private practice setting are long-standing. The outpatient physical therapy benefit, enacted in 1972, applied to PTIP (that is, individual therapists in independent practice in their own offices). Services performed by employees of a PTIP were covered if furnished under the direct personal supervision of the PTIP. This requirement was necessary to assure beneficiary health and safety and quality of care.

In 1981, in response to the conference committee report (H.R. 96–1479) accompanying the Omnibus Reconciliation Act of 1980 (Public Law 96–499), we revised our Medicare Carriers Manual instructions (see section 2215F, HCFA Pub. 6). These revised instructions stated that the services of employees of a PTIP who are not qualified physical therapists must be furnished under the direct personal supervision of a supervising therapist who must be the employer or on the employer's staff. Therefore, a licensed physical therapist had to directly and personally supervise the services of assistants and aides. Thus, even before the November 1998 final rule, the regulations and manuals clearly stated that the PTIP must directly and personally supervise all services for which he or she bills.

As noted above, pre-existing supervision requirements for therapy assistants in a private practice setting were not affected by the November 1998 final rule. However, we received comments from the therapy industry and other interested parties who erroneously believed that we had either misinterpreted the supervision requirement or had established a new requirement for therapy assistants in the private practice setting.

These comments and the confusion possibly resulted from the one revision in supervision requirements made in the final rule. This revision related not to therapy assistants, but to qualified therapists in a private practice setting. As referenced in the November 1998 final rule (63 FR 58868), the Congress was concerned about the requirement for therapists in independent practice to directly supervise all services performed by their employees, even if those employees were fully-licensed

therapists. The therapist in independent practice had to be on the premises whenever services were furnished to Medicare beneficiaries, including services furnished by a licensed therapist. Therefore, a therapist in independent practice could not have more than one office open at the same time because he or she could not be on both premises at once. Congressional statements in both the House and Senate committee reports associated with our fiscal year 1997 appropriations process addressed this issue. The House committee report urged us to modify the regulations so that certified therapists need not be on the premises to supervise other licensed therapists. We were also urged by the Senate to review this concern and recommend changes in our regulations or instructions. To address this concern expressed in both the 1997 House and Senate Appropriations Committee reports, we revised the regulations at § 410.59(c)(2) and § 410.60(c)(2).

Accordingly, effective January 1, 1999, as specified in the November 1998 final rule, the revised regulations permit legally authorized (see § 410.59(c)(1)(i) and § 410.60(c)(1)(i)) therapists who own the practice to be off the premises when other legally authorized therapists are present to furnish supervision for therapy assistants. These regulations also restated which practitioners are qualified as therapists under section 1861(p) of the Act. In accordance with the November 1998 final rule, the term ''independent'' was removed from the description of a therapist in independent practice. In its place, the term ''private'' was added. The benefit is now described in terms of an individual physical therapist or occupational therapist in private practice.

This change did not affect the required degree of supervision for physical therapist assistants. Assistants still must be personally supervised by the therapist in private practice and employed directly by the therapist, by the partnership, or group to which the therapist belongs.

D. Outpatient Therapy Caps

Section 221 of the BBRA placed a 2-year moratorium on Medicare Part B outpatient therapy caps (the $1500 cap on outpatient physical therapy services including speech language-pathology services and the $1500 cap on outpatient occupational therapy services in all nonhospital settings). The two $1500 caps were implemented in 1999 as required by the BBA.

The BBRA also requires us to submit to the Congress a report by January 1, 2001 that includes recommendations on—(1) the establishment of a mechanism for assuring appropriate utilization of outpatient therapy services; (2) the establishment of an alternative payment policy for these services based on classifications of individuals by diagnostic category, functional status, prior use of services (in both inpatient and outpatient settings), and other criteria, in place of uniform dollar limitations; and (3) how to do this in a budget-neutral manner.

We are gathering information on alternatives or options that we can use to achieve these objectives. We have received the following informal recommendations for legislation:

- Institute a cap per diagnosis rather than per year.
- Establish payment based on patient groupings by primary diagnosis and average number of treatments, with options for variants.
- Base payment on an episode of occurrence of illness or injury, with a cap amount adjusted to address geographic differences in the cost of furnishing services.
- Develop a sustainable growth rate (SGR) for outpatient therapy services to control growth in the volume of services.

The outpatient therapy cap was also a topic of discussion at the PPAC meeting in December 1999. As a result of these discussions, the PPAC recommended continuation of the current moratorium with focused medical review, indicating that such a review could lead to the desired budget-neutral outcome.

We would like comments from the public on additional alternatives that we could consider in developing a payment policy for outpatient therapy services. We will consider this information as we prepare our report to the Congress on outpatient therapy services.

IV. Five-Year Refinement of Relative Value Units

Section 1848(c)(2)(B)(i) of the Act requires that we review all RVUs for services in the physician fee schedule no less often than every 5 years. The first 5-year review was undertaken as part of the final rule published December 1994 (59 FR 63140), with the resulting changes effective for services furnished beginning January 1, 1997. In the final rule published November 1999 (64 FR 59427), we included a discussion of the first 5-year refinement and outlined our plans for the second 5-year refinement of work RVUs. We also solicited comments on potentially misvalued work RVUs as well as data sources and methodologies to assist us in identifying misvalued services. We received comments from approximately 30 specialty groups, organizations, and individuals. While some of the comments were on the proposed process, comments also included requests for evaluating over 900 codes.

As we had discussed in the November 1999 final rule, in addition to performing internal review and analysis, we will be sharing these comments with the RUC, which currently makes recommendations to us on the assignment of RVUs to new and revised CPT codes. The RUC's perspective will be helpful because of its experience in recommending RVUs for the codes that have been added to the CPT, or revised by the CPT panel, since we implemented the physician fee schedule in 1992. We emphasize, however, as we reiterated for the first 5-year review, we have the responsibility for analyzing the comments concerning the 5-year review and deciding whether to revise RVUs. We are not delegating this responsibility to the RUC or any other organization.

Current initiatives underway (see discussion that follows on physician time) will assist us in our identification of misvalued codes. However, we will not be able to identify those codes that we believe have misvalued work RVUs before late in the year 2000 or early in the year 2001. We propose to perform the 5-year review in two phases. The first phase will take place in CY 2000 with consideration of public comments. The second phase will occur in CY 2001 when we use the contracted research to identify misvalued codes. We will work with the RUC and the medical community to minimize work duplication. For example, we will ask the RUC to defer action in CY 2000 on those codes that were identified by public comments and that our research later indicates might be misvalued. Furthermore, to focus on each phase of the review and prevent duplicative work, we propose to concentrate on intraspecialty issues and anomalies in CY 2000 and consider cross specialty misvaluations and issues in CY 2001. This is because we believe that validation of time across a wide range of services will allow direct comparison of pre-, intra-, and postservice work RVUs across specialties with the potential to identify a large number of misvalued codes. Again, we will work closely with the medical community to analyze and interpret the data as well as to organize the review in an efficient manner.

Physician Time Data

We currently have initiatives underway to validate the physician time

data and identify potentially misvalued codes to be considered during the 5-year review. A discussion of these activities follows.

Under a contract with HCFA, Health Economics Research (HER) is reviewing secondary data sources to validate time estimates for physicians' services. Physician time estimates are a factor used in the calculation of the practice expense RVUs and one of the primary determinates of physician work. These secondary data sources are as follows:

- The National Ambulatory Medical Care Survey (NAMCS).
- D.J. Sullivan Associates Hospital Data.
- MGMA Practice Cost Survey Data.

The NAMCS is a survey conducted by the Center for Disease Control that collects self-reported information on over 20,000 office visits annually including physician face-to-face time (called the duration of the visit). Various comparative analyses, both at the physician specialty level and for all physicians, can be made between projected E/M codes in the NAMCS data and with the actual E/M codes reported in the Medicare Part B National Claims History. (E/M codes are not captured in the NAMCS data. However, a method is used to map the time of the physician visit to an appropriate E/M code. This represents the ''projected'' E/M code.) The analysis was performed on the 1997 NAMCS.

The D.J. Sullivan database groups approximately 495,000 inpatient and outpatient records into 177 small clinically similar classes. The database captures information from the hospital record such as the procedure, time the patient enters the operating room, time of incision, time of wound closure, and time the patient exits the operating room. Data are presented for all hospitals and for all hospitals by categories: community hospitals, teaching hospitals, and university-based hospitals.

HER is analyzing a sample of the D.J. Sullivan database to determine whether it can be used for validating skin-to-skin time for selected surgical procedures. The selected procedures are high volume procedures or procedures on the RUC multispecialty list.

The MGMA Physician Profiling Database contains information at the physician practice level on the number of services by CPT code, physician specialty, and clinical work week. The database contains information on almost 4,000 physicians, primarily from Florida, Minnesota, New York, and Washington. Analysis will focus on comparing expected clinical times based on current time estimates attributable to CPT codes to total practice hours worked.

V. Collection of Information Requirements

This document does not impose information collection and recordkeeping requirements. Consequently, it need not be reviewed by the Office of Management and Budget under the authority of the Paperwork Reduction Act of 1995.

VI. Response to Comments

Because of the large number of items of correspondence we normally receive on **Federal Register** documents published for comment, we are not able to acknowledge or respond to them individually. We will consider all comments we receive by the date and time specified in the **DATES** section of this preamble, and we will respond to the major comments in the final rule.

VII. Regulatory Impact Analysis

We have examined the impacts of this proposed rule as required by Executive Order of 1993 (EO) 12866, the Unfunded Mandates Reform Act of 1995 (EO) 12875 (UMRA) (Public Law 104–4), the Regulatory Flexibility Act of 1980 (RFA) (Public Law 96–354) and the Federalism Executive Order of 1999 (EO) 13132.

EO 12866 directs agencies to assess costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). A regulatory impact analysis (RIA) must be prepared for major rules with economically significant effects ($100 million or more annually). While the changes in the Medicare physician fee schedule are for the most part, budget neutral, they do involve redistribution of Medicare spending among procedures and physician specialties and geographic areas. However, the redistributive effect of this rule on any particular specialty or geographic area is, in our estimate, unlikely to exceed $100 million. The effect of the practice expense changes are estimated to increase payments to one specialty by about $90 million and decrease payments to another specialty by approximately $45 million. All other physician specialties will be affected by less than these amounts. The GPCI changes are expected to increase payments by less than $10 million in one locality and decrease payments by about $20 million in another locality. The effect on all other payment localities are likely to be less than these amounts. Since we estimate that these changes are unlikely to redistribute more than $100 million in Medicare allowed charges, we are not considering this proposed rule to be a major rule. However, we will reconsider this decision for the final rule if our estimates based on new data exceed $100 million.

The UMRA also requires (in section 202) that agencies prepare an assessment of anticipated costs and benefits before developing any rule that may result in expenditure in any one year by State, local, or tribal governments, in the aggregate, or by the private sector, of $100 million or more. We have determined that this proposed rule will have no consequential effect on State, local, or tribal governments. We believe the private sector cost of this rule falls below the above stated threshold as well.

The RFA requires that we analyze regulatory options for small businesses and other small entities. We prepare a Regulatory Flexibility Analysis unless we certify that a rule would not have a significant economic impact on a substantial number of small entities. The analysis must include a justification of why action is being taken, the kinds and number of small entities the rule affects, and an explanation of any meaningful options that achieve the objectives and lessen significant adverse economic impact on the small entities.

In addition, section 1102(b) of the Act requires us to prepare a regulatory impact analysis if a rule may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 603 of the RFA. For purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside of a Metropolitan Statistical Area and has fewer than 50 beds.

For purposes of the RFA, all physicians are considered to be small entities. There are about 700,000 physicians and other practitioners who receive Medicare payment under the physician fee schedule. We have prepared the following analysis, which, together with the rest of this preamble, meets all four assessment requirements. It explains the rationale for and purpose of the rule, details the costs and benefits of the rule, analyzes alternatives, and presents the measures we considered to minimize the burden on small entities.

A. Resource-Based Practice Expense Relative Value Units

Revisions in resource-based practice expense RVUs for physicians' services are calculated to be budget neutral, that

is, the total practice expense RVUs for calendar year 2001 are calculated to be the same as the total practice expense RVUs that we estimate would have occurred without the changes proposed in this regulation. This also means that increases in practice expense RVUs for some services will necessarily be offset by corresponding decreases in values for other services.

Table 1 shows the impact on total allowed charges by specialty of this proposed rule's practice expense changes. There are six changes that we made that have on effect on payment for practice expenses. We show the impact of each individual provision and the combined impact on the practice expense RVUs.

BILLING CODE 4120–01–P

Table 1 -- Impact of Specific Practice Expense Changes on Total Allowed Charges by Specialty

Specialty	Allowed Charges	Clinical Staff	Overhead Equipment	"Standby Equipment	Midlevel Practitioners	New SMS Data	Other	Total
ANESTHESIOLOGY	1.5	0%	-0%	0%	-1%	0%	-0%	-1%
CARDIAC SURGERY	0.3	-0	0	-0	-1	-2	0	-3
CARDIOLOGY	3.9	-0	-0	0	0	-0	-0	-0
CLINICS	1.5	-0	0	-0	0	0	-0	0
DERMATOLOGY	1.3	-0	1	-1	0	-0	0	-0
EMERGENCY MEDICINE	0.9	0	-0	0	0	-0	0	0
FAMILY PRACTICE	3.2	-0	0	-0	0	-0	-0	-0
GASTROENTEROLOGY	1.1	2	-0	-0	0	0	0	2
GENERAL PRACTICE	1.0	-0	0	-0	0	0	-0	0
GENERAL SURGERY	1.9	0	0	-0	-0	-0	-0	-1
HEMATOLOGY ONCOLOGY	0.6	-0	-0	-0	0	-0	-0	-1
INTERNAL MEDICINE	6.7	-0	-0	-0	0	-0	-0	-0
NEPHROLOGY	0.9	0	0	0	0	1	0	2
NEUROLOGY	0.8	-0	-1	-0	0	0	0	-0
NEUROSURGERY	0.3	-0	-0	-0	-0	-1	0	-1
OBSTETRICS/GYNECOLOGY	0.4	-0	-1	-0	0	-0	0	-1
OPHTHALMOLOGY	3.7	-0	0	0	0	-2	0	-1
ORTHOPEDIC SURGERY	2.2	-0	0	-0	-0	0	-0	-0
OTHER PHYSICIAN	1.3	-0	-0	-0	0	1	-0	1
OTOLARYNGOLOGY	0.6	-0	-0	-0	0	-1	-0	-1
PATHOLOGY	0.6	0	-1	1	0	-2	1	-1
PLASTIC SURGERY	0.2	-0	0	-0	0	0	-0	0
PSYCHIATRY	1.1	0	0	-0	0	-1	-0	-1
PULMONARY	1.0	0	-0	-0	0	-0	-0	-0
RADIATION ONCOLOGY	0.6	0	-0	0	0	0	0	1
RADIOLOGY	2.9	0	-0	0	0	3	-0	3
RHEUMATOLOGY	0.3	-0	-0	-0	0	0	-0	-1
THORACIC SURGERY	0.5	-0	0	-0	-1	-1	-0	-2
UROLOGY	1.3	-0	0	-0	0	-0	-0	-0
VASCULAR SURGERY	0.3	-0	-0	-0	-0	-0	-0	-1
OTHERS:								
CHIROPRACTOR	0.4	0	-0	-0	1	1	-0	1
NONPHYSICIAN PRACTITIONER	0.9	-0	0	0	0	3	-0	4
OPTOMETRIST	0.5	-0	0	0	0	-2	0	-2
PODIATRY	1.1	-0	0	-0	0	-0	0	0
SUPPLIERS	0.5	0	-3	2	0	-1	0	-1
Note: Total may not add due to rounding.								

BILLING CODE 4120–01–C

The column labeled ''Clinical Staff'' refers to the proposal discussed earlier with respect to clinical staff times and 0-day global surgical services. As we indicated, clinical staff times for pre- and postsurgical services provided in the office were reinstated to the estimates of practice expense inputs for individual procedures. This change has nearly a 2.0 percent increase in payments for gastroenterology and small positive or negative impacts for all other specialties. The negative impacts on some specialties offset the positive impact for other specialties.

The column labeled ''Overhead Equipment'' refers to the provision described earlier to remove the distinction between procedure specific and overhead equipment. As we indicated, this change is largely designed to simplify the refinement process and remove a distinction that was more relevant under the ''bottom-up'' rather than the ''top-down'' methodology for determining the practice expense RVUs. This proposal has some small impacts on a few specialties.

The column labeled ''Standby Equipment'' refers to our proposal to remove certain types of equipment from equipment inputs that are used to value individual procedure codes. These types of equipment are not typically used with any individual service, but are on ''standby'' or used for multiple services at the same time. This proposal also has some small impact on payments to a few specialties.

The column labeled ''Midlevel Practitioners'' refers to the provision we described earlier to remove utilization data associated with the provision of services by midlevel practitioners that are paid a percentage of the physician fee schedule amount. This change to the model would mean that we would no longer create separate practice expense pools for midlevel practitioners. It would also mean that specialty-specific practice expense RVUs for midlevel practitioners determined after the scaling factor adjustments are made would no longer be used in the weight averaging step.

The greater the extent that allowed services for midlevel practitioners represent a higher proportion of the total number of allowed services for a given code, the more likely this change will have an impact on the practice expense RVU for the service. In some cases, this change would mean that we are no longer weight averaging specialty-specific practice expense RVUs that are higher in value than the RVUs determined for the remaining physician specialties. This would cause the practice expense value for the service to decline in value from what would result from including higher specialty-specific practice expense RVUs for the midlevel practitioner. In general, the impact of this provision would be small for most specialties. The impact on specialty level payments are more likely for specialties that frequently perform services in conjunction with midlevel practitioners.

The column labeled ''New SMS Data'' refers to our proposal to recalculate the practice expense per hour data based on data from the 1995 through 1998 SMS. (We refer to the SMS based on its publication year. The practice expense data is actually from surveys performed the year prior to publication. For example, the 1998 SMS includes 1997 cost data.) As indicated in the table, this change would have an impact on specialty level payments. These changes in payment would be in the same direction as relative changes in the practice expense per hour. That is, an increase in practice expense per hour for a specialty relative to other specialties would result in increased payments for that specialty. For cardiac and thoracic surgery, there is an additional factor influencing the impact. As we indicated in the November 1999 final rule (64 FR 59391), we weight averaged 1998 SMS data from an oversample for cardiac and thoracic surgery with data from the 1996 and 1997 SMS. At that time, we did not use data from the 1995 SMS in determining the practice expense per hour. Since we are using 1995 through 1998 SMS data for all other physician specialties, we recalculated the practice expense per hour for cardiac and thoracic surgery using data from the 1995 through 1998 SMS. In addition, we are continuing to use 1998 SMS data from the oversample in this calculation.

The total impact column shows the product of each individual provision for the years 2001 and 2002 relative to continuing with our current policy. The figures may not add due to rounding. Table 2 shows the total impact over the 2001 and 2002 period of these changes and the 2001 impact. The difference between the two columns reflects the effect of the transition to fully implemented practice expense RVUs. That is, the impact in the 2001 column will reflect 75 percent of the impact on the fully implemented RVUs. These impacts are in addition to the impacts announced in previous rules related to the adoption of resource-based practice relative value units.

BILLING CODE 4120–01–P

Table 2 -- Impact of Practice Expense Changes Transition and 2001-2002 Impact

Specialty	Allowed Charges	Year 2001 Impact	2001-2002 Impact
ANESTHESIOLOGY	1.5	-1%	-1%
CARDIAC SURGERY	0.3	-2	-3
CARDIOLOGY	3.9	-0	-0
CLINICS	1.5	0	0
DERMATOLOGY	1.3	-0	-0
EMERGENCY MEDICINE	0.8	0	0
FAMILY PRACTICE	3.2	-0	-0
GASTROENTEROLOGY	1.1	2	2
GENERAL PRACTICE	1.0	0	0
GENERAL SURGERY	1.9	-0	-1
HEMATOLOGY ONCOLOGY	0.6	-0	-1
INTERNAL MEDICINE	6.7	-0	-0
NEPHROLOGY	0.9	1	2
NEUROLOGY	0.8	-0	-0
NEUROSURGERY	0.3	-1	-1
OBSTETRICS/GYNECOLOGY	0.4	-1	-1
OPHTHALMOLOGY	3.8	-1	-1
ORTHOPEDIC SURGERY	2.2	-0	-0
OTHER PHYSICIAN	1.3	0	1
OTOLARYNGOLOGY	0.6	-1	-1
PATHOLOGY	0.6	-0	-1
PLASTIC SURGERY	0.2	0	0
PSYCHIATRY	1.1	-0	-1
PULMONARY	1.0	-0	-0
RADIATION ONCOLOGY	0.6	1	1
RADIOLOGY	2.9	2	3
RHEUMATOLOGY	0.3	-1	-1
THORACIC SURGERY	0.5	-2	-2
UROLOGY	1.3	-0	-0
VASCULAR SURGERY	0.3	-1	-1
OTHERS:			
CHIROPRACTOR	0.4	1	1
NONPHYSICIAN PRACTITIONER	0.9	3	4
OPTOMETRIST	0.5	-1	-2
PODIATRY	1.1	0	0
SUPPLIERS	0.5	-1	-1

Table 3 shows the impact on payments for selected high volume procedures of all of the practice expense changes previously discussed. This table isolates the impact of the practice expense changes only on payments. It does not show what actual payments for these procedures will be in 2001 because the payment calculations do not include the effect of the transition or the impact of the physician fee schedule update which is unknown at this time.

Table 3 -- Total Payment for Selected Procedures

Code	Mod	Description	Old Non-facility	New Non-facility	Percent Change	Old Facility	New Facility	Percent Change
11721		Debride nail, 6 or more	39.542796	39.908933	0.009	28.924823	28.924823	0
17000		Destroy benign/premal lesion	60.046468	58.948057	-1.8293	32.586193	32.586193	0
27130		Total hip replacement	NA	NA	NA	1448.0718	1435.9893	-0.834
27236		Treat thigh fracture	NA	NA	NA	1082.6671	1079.3719	-0.304
27244		Treat thigh fracture	NA	NA	NA	1098.411	1097.3126	-0.1
27447		Total knee replacement	NA	NA	NA	1518.3701	1505.5553	-0.844
33533		CABG, arterial, single	NA	NA	NA	1853.7516	1803.957	-2.686
35301		Rechanneling of artery	NA	NA	NA	1126.2374	1112.3242	-1.235
43239		Upper GI endoscopy, biopsy	250.071571	288.149819	15.2269	142.06116	152.31299	7.2165
45385		Lesion removal colonoscopy	465.726264	482.934703	3.69497	278.63026	291.44505	4.5992
66821		After cataract laser surgery	203.938309	208.69809	2.33393	177.94258	185.63146	4.321
66984		Remove cataract/insert lens	NA	NA	NA	665.27093	665.27093	0
67210		Treatment of retinal lesion	603.027639	602.661502	-0.061	551.03619	550.67005	-0.07
71010	26	Chest x-ray	8.787288	9.153425	4.16667	8.787288	9.153425	4.1667
71020		Chest x-ray	34.416878	35.149152	2.12766	NA	NA	NA
71020	26	Chest x-ray	10.617973	11.350247	6.89655	10.617973	11.350247	6.8966
77430		Weekly radiation therapy	189.292829	190.757377	0.77369	189.29283	190.75738	0.7737
78465		Heart image (3d), multiple	528.335691	533.461609	0.9702	NA	NA	NA
88305		Tissue exam by pathologist	82.014688	87.140606	6.25	NA	NA	NA
88305	26	Tissue exam by pathologist	41.007344	40.641207	-0.8929	41.007344	40.641207	-0.893
90801		Psy dx interview	146.088663	144.990252	-0.7519	138.76592	138.39979	-0.264
90806		Psytx, off, 45-50 min	98.124716	97.392442	-0.7463	94.097209	93.731072	-0.389
90807		Psytx, off, 45-50 min w/e&m	103.982908	103.250634	-0.7042	99.589264	99.223127	-0.368
90862		Medication management	51.625317	50.893043	-1.4184	47.231673	46.865536	-0.775
90921		ESRD related services, month	259.95727	260.689544	0.28169	259.95727	260.68954	0.2817
90935		Hemodialysis, one evaluation	NA	NA	NA	62.24329	74.325811	19.412
92004		Eye exam, new patient	123.022032	116.797703	-5.0595	87.140606	86.774469	-0.42
92012		Eye exam established pat	63.707838	64.440112	1.14943	36.6137	36.247563	-1
92014		Eye exam & treatment	90.435839	91.53425	1.21457	58.948057	58.58192	-0.621
92980		Insert intracoronary stent	NA	NA	NA	809.52891	809.89504	0.045
92982		Coronary artery dilation	NA	NA	NA	608.15356	608.88583	0.1204
93000		Electrocardiogram, complete	26.361864	26.361864	0	NA	NA	NA
93010		Electrocardiogram report	8.787288	9.153425	4.16667	8.787288	9.153425	4.1667
93015		Cardiovascular stress test	105.081319	105.447456	0.34843	NA	NA	NA
93307		Echo exam of heart	199.910802	200.643076	0.3663	NA	NA	NA
93307	26	Echo exam of heart	50.160769	50.160769	0	50.160769	50.160769	0
93510	26	Left heart catheterization	232.130858	232.130858	0	232.13086	232.13086	0
98941		Chiropractic manipulation	34.783015	35.515289	2.10526	30.389371	30.755508	1.2048
99202		Office/outpatient visit, new	72.495126	69.932167	-3.5354	45.400988	45.400988	0
99203		Office/outpatient visit, new	101.786086	98.490853	-3.2374	68.833756	68.833756	0
99204		Office/outpatient visit, new	144.257978	139.13206	-3.5533	101.78609	102.15222	0.3597
99205		Office/outpatient visit, new	177.942582	170.619842	-4.1152	134.37228	134.73842	0.2725
99211		Office/outpatient visit, est	25.62959	26.728001	4.28571	9.153425	9.153425	0
99212		Office/outpatient visit, est	38.810522	39.176659	0.9434	23.066631	23.066631	0
99213		Office/outpatient visit, est	51.625317	51.991454	0.70922	33.684604	34.050741	1.087
99214		Office/outpatient visit, est	80.55014	76.88877	-4.5455	55.652824	56.018961	0.6579
99215		Office/outpatient visit, est	114.967018	112.037922	-2.5478	89.703565	89.703565	0
99221		Initial hospital care	NA	NA	NA	65.172386	65.538523	0.5618

Code	Mod	Description	Old Non-facility	New Non-facility	Percent Change	Old Facility	New Facility	Percent Change
99222		Initial hospital care	NA	NA	NA	108.01042	108.37655	0.339
99223		Initial hospital care	NA	NA	NA	149.3839	149.75003	0.2451
99231		Subsequent hospital care	NA	NA	NA	32.586193	32.586193	0
99232		Subsequent hospital care	NA	NA	NA	53.456002	53.456002	0
99233		Subsequent hospital care	NA	NA	NA	75.790359	76.156496	0.4831
99236		Observ/hosp same date	NA	NA	NA	212.35946	212.7256	0.1724
99238		Hospital discharge day	NA	NA	NA	64.073975	64.073975	0
99239		Hospital discharge day	NA	NA	NA	87.140606	87.506743	0.4202
99241		Office consultation	61.877153	58.58192	-5.3254	33.684604	34.050741	1.087
99242		Office consultation	101.419949	96.660168	-4.6931	67.003071	67.369208	0.5464
99243		Office consultation	128.14795	121.191347	-5.4286	89.337428	89.703565	0.4098
99244		Office consultation	175.74576	169.155294	-3.75	131.44318	132.17546	0.5571
99245		Office consultation	221.879022	216.386967	-2.4752	175.37962	176.47803	0.6263
99251		Initial inpatient consult	NA	NA	NA	36.979837	36.979837	0
99252		Initial inpatient consult	NA	NA	NA	71.396715	71.396715	0
99253		Initial inpatient consult	NA	NA	NA	97.026305	97.026305	0
99254		Initial inpatient consult	NA	NA	NA	138.03365	138.39979	0.2653
99255		Initial inpatient consult	NA	NA	NA	188.92669	189.65897	0.3876
99261		Follow-up inpatient consult	NA	NA	NA	23.432768	23.432768	0
99262		Follow-up inpatient consult	NA	NA	NA	45.400988	45.400988	0
99263		Follow-up inpatient consult	NA	NA	NA	66.270797	66.270797	0
99282		Emergency dept visit	NA	NA	NA	26.361864	26.361864	0
99283		Emergency dept visit	NA	NA	NA	58.215783	58.215783	0
99284		Emergency dept visit	NA	NA	NA	90.801976	91.168113	0.4032
99285		Emergency dept visit	NA	NA	NA	140.96275	141.32888	0.2597
99291		Critical care, first hour	185.631459	185.997596	0.19724	177.21031	177.94258	0.4132
99292		Critical care, addl 30 min	94.829483	94.829483	0	87.87288	88.239017	0.4167
99301		Nursing facility care	NA	NA	NA	59.680331	59.680331	0
99302		Nursing facility care	NA	NA	NA	79.817866	80.184003	0.4587
99303		Nursing facility care	NA	NA	NA	99.589264	99.955401	0.3676
99311		Nursing fac care, subseq	NA	NA	NA	30.023234	30.023234	0
99312		Nursing fac care, subseq	NA	NA	NA	49.428495	49.428495	0
99313		Nursing fac care, subseq	NA	NA	NA	70.298304	70.664441	0.5208
99348		Home visit, est patient	72.128989	71.762852	-0.5076	66.270797	66.270797	0
99350		Home visit, est patient	162.564828	162.198691	-0.2252	153.04527	153.4114	0.2392

BILLING CODE 4120–01–C

B. Geographic Practice Cost Index Changes

Section 1848(e)(1)(A) of the Act requires that payments under the Medicare physician fee schedule vary among payment areas only to the extent that area costs vary as reflected by the area GPCIs. The GPCIs measure area cost differences in the three components of the physician fee schedule: physician work, practice expenses (employee wages, rent, medical supplies, and equipment), and malpractice insurance. Section 1848(e)(1)(C) of the Act requires that the GPCIs be reviewed and, if necessary, revised at least every 3 years. The first GPCI revision was implemented in 1995. The second revision was implemented in 1998, and the next revision will be implemented in 2001. Section 1848(e)(1)(C) of the Act also requires that the GPCI revisions be phased in equally over a 2-year period if more than one year has elapsed since the last adjustment.

An estimate of the overall effects of proposed GPCI changes on fee schedule area payments can be demonstrated by a comparison of area geographic adjustment factors (GAFs). The GAFs are a weighted composite of each area's work, practice expense, and malpractice expense GPCIs using the national GPCI cost share weights. While not actually used in computing the fee schedule payment for a specific service, the GAFs are useful in comparing overall area costs and payments. The actual effect on payment for any actual service will deviate from the GAF to the extent that the service's proportions of work, practice expense, and malpractice expense RVUs differ from those of the GAF. Addendum H shows the estimated effects of the proposed GPCIs on area GAFs in descending order.

Only 14 of the 89 fee schedule areas would change by at least 2 percent. Only 16 areas would change by from 1 to 1.9 percent. The remaining 59 areas are estimated to experience payment changes of less than 1 percent under the proposed changes. These are very minor changes that would be expected in that we are revising only the rent indices, comprising 11.6 percent of the total GPCI, and the malpractice expense indices, comprising 3.2 percent of the GPCI. Thus, only about 15 percent of the GPCI would be subject to change. The effects in the transition year 2001, would only be one-half of these amounts as the proposed revised GPCIs would be phased in over a 2-year period as required by law.

C. Resource-Based Malpractice Relative Value Units

As indicated earlier, we are currently examining the more recent malpractice data. The malpractice RVUs in the fall final rule will reflect the newer data and the refinements made as a result of comments made on last year's rules.

While we anticipate there would be little impact, this would be fully discussed in the final rule.

D. Critical Care Relative Value Units

As we explained earlier in the preamble in the November 1999 final rule, we established interim work RVUs for 2000 for CPT codes 99291 and 99292 (critical care services). These RVUs were decreased due to concerns about changes in the CPT definition for these services. In this proposed rule, based on changes the Panel is making to the definition for critical care for CY 2001, we are proposing to increase the work RVUs for critical care services and value the physician work at 4.0 RVUs for CPT code 99291 and 2.0 RVUs for CPT code 99292. Any impact of this proposal would be incorporated in the physician fee budget neutrality calculation.

E. Care Plan Oversight

We are proposing to establish two new HCPCS codes for care plan oversight that are consistent with our coverage criteria. We would also establish two new HCPCS codes to describe the services involved in physician certification or recertification and development of a plan of care for a patient for whom the physician has prescribed Medicare-covered home health services.

We are assuming there would be no additional cost or savings as a result of the two new HCPCS codes for care plan oversight. We are merely instituting these codes for consistency with our coverage criteria, and they would be used in place of the CPT codes when these services are provided.

For the new HCPCS codes for physician certification or recertification and development of a plan of care, the payment for these services is currently included in the payment for a variety of services such as E/M that are provided independently to patients as part of a global surgical service. Under this proposal, we would instead pay separately. Since we are proposing to pay separately for a service that is currently included in our payment for other services, this proposal would increase Medicare expenditures for physicians' services without an adjustment to the physician fee schedule CF. For this reason, we are proposing to adjust the physician fee schedule CF to ensure that Medicare payments for physicians' services do not increase as a result of this proposal.

F. Observation Care Codes

Our proposal is budget-neutral. We believe physicians have not been billing for the discharge component of a hospital or observation stay of less than 24 hours so those physicians would be seeing an increase in payment. However, physicians who have been billing 99234 to 99236 and physicians who have been billing 99238 or 99217 for stays less than 24 hours in length (for example, where the patient was in the hospital at the time of the midnight census) would see a small reduction in payment. This policy clarification will give clear guidance to physicians and Medicare contractors in reviewing medical records and would assure consistent payment across contractors.

G. Ocular Photodynamic Therapy and Other Ophthalmological Treatments

As previously stated, we would establish national HCPCS codes and payment amounts for ocular photodynamic therapy. If we did not establish national codes and pricing for this procedure, carriers that determined that this procedure is covered would use unlisted codes and determine pricing locally. There will be no budget effects associated with establishing national codes and payment amounts for this service since national pricing would substitute for use of unlisted codes and carrier pricing.

H. Electrical Bioimpedance

As stated earlier, we are establishing a national payment amount for electrical bioimpedance. This change will have little impact on the Medicare program costs. It establishes national pricing amounts for a service currently priced by carriers.

I. Global Period for Insertion, Removal, and Replacement of Pacemakers and Cardioverter Defibrillators

We are proposing to change the global period for certain CPT codes involving the insertion, removal, and replacement of pacemakers and cardioverter defibrillators from 90 days to 0 days. We would also implement interim RVUs to account for the change in the global period from 90 to 0 days. Since we are making RVU adjustments to accommodate the change in global period, we do not anticipate any costs or savings. There is no redistributive impact of this proposal since it only affects physicians that insert, remove or replace pacemakers or cardioverter defibrillators.

J. Antigen Supply

Our proposal to change from a 12-week to a 12-month supply of antigen could benefit beneficiaries since they could obtain a year's supply of medication in a single visit. We anticipate that this proposed change would have no impact on program costs. There is no redistributive impact of this proposal since it only aggregates four prescriptions into one and the cost to the beneficiary remains the same.

Other issues mentioned in the preamble are merely discussions or clarifications and, therefore, have no budgetary impact.

Budget-Neutrality

Each year since the fee schedule has been implemented, our actuaries have determined any adjustments needed to meet the budget-neutrality requirement of the statute. A component of the actuarial determination of budget-neutrality involves estimating the impact of changes in the volume-and-intensity of physicians' services provided to Medicare beneficiaries as a result of the proposed changes. Consistent with the provision in the November 1998 final rule, the actuaries would use a model that assumes a 30 percent volume-and-intensity response to price reductions.

Impact on Beneficiaries

Although changes in physicians' payments when the physician fee schedule was implemented in 1992 were large, we detected no problems with beneficiary access to care. Furthermore, since beginning our transition to a resource-based practice expense system in 1999, we have not found that there are problems with beneficiary access to care.

VIII. Federalism

We have reviewed this proposed rule under the threshold criteria of EO 13132, Federalism, and we have determined that the proposed rule does not significantly affect the rights, roles, and responsibilities of States.

List of Subjects

42 CFR Part 410

Health facilities, Health professions, Kidney diseases, Laboratories, Medicare, Rural areas, X-rays.

42 CFR Part 414

Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medicare,

Reporting and recordkeeping requirements, Rural areas, X-rays.

For the reasons set forth in the preamble, HCFA proposes to amend 42 CFR chapter IV as follows:

PART 410—SUPPLEMENTARY MEDICAL INSURANCE (SMI) BENEFITS

1. The authority citation for part 410 continues to read as follows:

Authority: Secs. 1102, and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

2. In § 410.68, republish the introductory text and revise the introductory text for paragraph (b) to read as follows:

§ 410.68 Antigens: Scope and conditions.

Medicare Part B pays for—

* * * * *

(b) A supply of antigen sufficient for not more than 12 months that is—

* * * * *

PART 414—PAYMENT FOR PART B MEDICAL AND OTHER HEALTH SERVICES

1. The authority citation for part 414 continues to read as follows:

Authority: Secs. 1102, 1871, and 1881(b)(1) of the Social Security Act (42 U.S.C. 1302, 1395(hh), and 1395rr(b)(1).

2. Revise § 414.22(b)(5)(i) to read as follows:

§ 414.22 Relative value units (RVUs).

* * * * *

(b) * * *

(5) * * *

(i) Usually there are two levels of practice expense RVUs that correspond to each code.

(A) *Facility practice expense RVUs.* The lower facility practice expense RVUs apply to services furnished to patients in the hospital, skilled nursing facility, community mental health center, or in an ambulatory surgical center when the physician performs procedures on the ASC approved procedures list. (The facility practice expense RVUs for a particular code may not be greater than the non-facility RVUs for the code.)

(B) *Non-facility practice expense RVUs.* The higher non-facility practice expense RVUs apply to services performed in the following settings: a physician's office, a patient's home, an ASC if the physician is performing a procedure not on the ASC approved procedures list, a nursing facility, or a facility or institution other than a hospital or skilled nursing facility.

(C) *Outpatient therapy services.* Outpatient therapy services billed under the physician fee schedule are paid using the non-facility practice expense RVU component.

* * * * *

(Catalog of Federal Domestic Assistance Program No. 93.778, Medical Assistance Program)

(Catalog of Federal Domestic Assistance Program No. 93.773, Medicare—Hospital Insurance; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: May 25, 2000.

Nancy-Ann Min DeParle,

Administrator, Health Care Financing Administration.

Dated: June 26, 2000.

Donna E. Shalala,

Secretary.

Note: These addenda will not appear in the Code of Federal Regulations.

Addendum A—Explanation and Use of Addendum B

The addenda on the following pages provide various data pertaining to the Medicare fee schedule for physicians' services furnished in 2001. Addendum B contains the RVUs for work, non-facility practice expense, facility practice expense, and malpractice expense, and other information for all services included in the physician fee schedule.

Addendum B—2001 Relative Value Units and Related Information Used in Determining Medicare Payments for 2001

This addendum contains the following information for each CPT code and alphanumeric HCPCS code, except for alphanumeric codes beginning with B (enteral and parenteral therapy), E (durable medical equipment), K (temporary codes for nonphysicians' services or items), or L (orthotics), and codes for anesthesiology.

1. *CPT/HCPCS code.* This is the CPT or alphanumeric HCPCS number for the service. Alphanumeric HCPCS codes are included at the end of this addendum.

2. *Modifier.* A modifier is shown if there is a technical component (modifier TC) and a professional component (PC) (modifier –26) for the service. If there is a PC and TC for the service, Addendum B contains three entries for the code: One for the global values (both professional and technical); one for modifier –26 (PC); and one for modifier TC. The global service is not designated by a modifier, and physicians must bill using the code without a modifier if the physician furnishes both the PC and the TC of the service.

Modifier –53 is shown for a discontinued procedure. There will be RVUs for the code (CPT code 45378) with this modifier.

3. *Status indicator.* This indicator shows whether the CPT/HCPCS code is in the physician fee schedule and whether it is separately payable if the service is covered.

A = Active code. These codes are separately payable under the fee schedule if covered. There will be RVUs for codes with this status. The presence of an ''A'' indicator does not mean that Medicare has made a national decision regarding the coverage of the service. Carriers remain responsible for coverage decisions in the absence of a national Medicare policy.

B = Bundled code. Payment for covered services is always bundled into payment for other services not specified. If RVUs are shown, they are not used for Medicare payment. If these services are covered, payment for them is subsumed by the payment for the services to which they are incident. (An example is a telephone call from a hospital nurse regarding care of a patient.)

C = Carrier-priced code. Carriers will establish RVUs and payment amounts for these services, generally on a case-by-case basis following review of documentation, such as an operative report.

D = Deleted code. These codes are deleted effective with the beginning of the calendar year.

E = Excluded from physician fee schedule by regulation. These codes are for items or services that we chose to exclude from the physician fee schedule payment by regulation. No RVUs are shown, and no payment may be made under the physician fee schedule for these codes. Payment for them, if they are covered, continues under reasonable charge or other payment procedures.

G = Code not valid for Medicare purposes. Medicare does not recognize codes assigned this status. Medicare uses another code for reporting of, and payment for, these services.

N = Noncovered service. These codes are noncovered services. Medicare payment may not be made for these codes. If RVUs are shown, they are not used for Medicare payment.

P= Bundled or excluded code. There are no RVUs for these services. No separate payment should be made for them under the physician fee schedule.

—If the item or service is covered as incident to a physician's service and is furnished on the same day as a physician's service, payment for it is bundled into the payment for the physician's service to which it is

incident (an example is an elastic bandage furnished by a physician incident to a physician's service).

—If the item or service is covered as other than incident to a physician's service, it is excluded from the physician fee schedule (for example, colostomy supplies) and is paid under the other payment provisions of the Act.

R = Restricted coverage. Special coverage instructions apply. If the service is covered and no RVUs are shown, it is carrier-priced.

T = Injections. There are RVUs for these services, but they are only paid if there are no other services payable under the physician fee schedule billed on the same date by the same provider. If any other services payable under the physician fee schedule are billed on the same date by the same provider, these services are bundled into the service(s) for which payment is made.

X = Exclusion by law. These codes represent an item or service that is not within the definition of ''physicians' services'' for physician fee schedule payment purposes. No RVUs are shown for these codes, and no payment may be made under the physician fee schedule. (Examples are ambulance services and clinical diagnostic laboratory services.)

4. *Description of code.* This is an abbreviated version of the narrative description of the code.

5. *Physician work RVUs.* These are the RVUs for the physician work for this service in 2001. Codes that are not used for Medicare payment are identified with a ''+.''

6. *Fully implemented non-facility practice expense RVUs.* These are the fully implemented resource-based practice expense RVUs for non-facility settings.

7. *Year 2001 Transition non-facility practice expense RVUs.* Blended non-facility practice expense RVUs for use in 2001.

8. *Fully implemented facility practice expense RVUs.* These are the fully implemented resource-based practice expense RVUs for facility settings.

9. *Year 2001 transition facility practice expense RVUs.* Blended facility practice expense RVUs for use in 2001.

10. *Malpractice expense RVUs.* These are the RVUs for the malpractice expense for the service for 2001.

11. *Fully implemented non-facility total.* This is the sum of the work, fully implemented non-facility practice expense, and malpractice expense RVUs.

12. *Year 2001 transition non-facility total.* This is the sum of the work, transition non-facility practice expense, and malpractice expense RVUs for use in 2001.

13. *Fully implemented facility total.* This is the sum of the work, fully implemented facility practice expense, and malpractice expense RVUs.

14. *Year 2001 transition facility total.* This is the sum of the work, transition facility practice expense, and malpractice expense RVUs for use in 2001.

15. *Global period.* This indicator shows the number of days in the global period for the code (0, 10, or 90 days). An explanation of the alpha codes follows:

MMM = The code describes a service furnished in uncomplicated maternity cases including antepartum care, delivery, and postpartum care. The usual global surgical concept does not apply. See the 1999 Physicians' Current Procedural Terminology for specific definitions.

XXX = The global concept does not apply.

YYY = The global period is to be set by the carrier (for example, unlisted surgery codes).

ZZZ = The code is part of another service and falls within the global period for the other service.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
10120		A	Remove foreign body	1.22	1.67	1.38	0.67	0.63	0.10	2.99	2.70	1.99	1.95	010
10121		A	Remove foreign body	2.69	2.61	2.23	1.70	1.55	0.24	5.54	5.16	4.63	4.48	010
10140		A	Drainage of hematoma/fluid	1.53	1.32	1.12	0.82	0.75	0.11	2.96	2.76	2.46	2.39	010
10160		A	Puncture drainage of lesion	1.20	1.45	1.19	0.73	0.65	0.09	2.74	2.48	2.02	1.94	010
10180		A	Complex drainage, wound	2.25	1.32	1.28	1.24	1.22	0.23	3.80	3.76	3.72	3.70	010
11000		A	Debride infected skin	0.60	0.52	0.50	0.24	0.29	0.04	1.16	1.14	0.88	0.93	000
11001		A	Debride infected skin add-on	0.30	0.29	0.29	0.12	0.16	0.02	0.61	0.61	0.44	0.48	ZZZ
11010		A	Debride skin, fx	4.20	2.39	2.87	2.10	2.65	0.36	6.95	7.43	6.66	7.21	010
11011		A	Debride skin/muscle, fx	4.95	3.67	4.03	2.61	3.24	0.48	9.10	9.46	8.04	8.67	000
11012		A	Debride skin/muscle/bone, fx	6.88	4.94	5.49	4.14	4.89	0.71	12.53	13.08	11.73	12.48	000
11040		A	Debride skin, partial	0.50	0.45	0.45	0.21	0.27	0.03	0.98	0.98	0.74	0.80	000
11041		A	Debride skin, full	0.82	0.61	0.61	0.33	0.40	0.06	1.49	1.49	1.21	1.28	000
11042		A	Debride skin/tissue	1.12	0.85	0.82	0.46	0.52	0.09	2.06	2.03	1.67	1.73	000
11043		A	Debride tissue/muscle	2.38	2.41	2.30	1.38	1.53	0.22	5.01	4.90	3.98	4.13	010
11044		A	Debride tissue/muscle/bone	3.06	3.11	3.10	1.81	2.12	0.30	6.47	6.46	5.17	5.48	010
11055		R	Trim skin lesion	0.27	0.34	0.33	0.12	0.16	0.02	0.63	0.62	0.41	0.45	000
11056		R	Trim skin lesions, 2 to 4	0.39	0.38	0.38	0.16	0.22	0.03	0.80	0.80	0.58	0.64	000
11057		R	Trim skin lesions, over 4	0.50	0.42	0.39	0.21	0.23	0.03	0.95	0.92	0.74	0.76	000
11100		A	Biopsy of skin lesion	0.81	1.47	1.24	0.38	0.42	0.04	2.32	2.09	1.23	1.27	000
11101		A	Biopsy, skin add-on	0.41	0.68	0.59	0.20	0.23	0.02	1.11	1.02	0.63	0.66	ZZZ
11200		A	Removal of skin tags	0.77	1.03	0.89	0.31	0.35	0.04	1.84	1.70	1.12	1.16	010
11201		A	Remove skin tags add-on	0.29	0.42	0.36	0.12	0.14	0.02	0.73	0.67	0.43	0.45	ZZZ
11300		A	Shave skin lesion	0.51	0.98	0.88	0.22	0.31	0.03	1.52	1.42	0.76	0.85	000
11301		A	Shave skin lesion	0.85	1.08	0.99	0.40	0.48	0.04	1.97	1.88	1.29	1.37	000
11302		A	Shave skin lesion	1.05	1.18	1.13	0.48	0.60	0.05	2.28	2.23	1.58	1.70	000
11303		A	Shave skin lesion	1.24	1.29	1.34	0.56	0.79	0.06	2.59	2.64	1.86	2.09	000
11305		A	Shave skin lesion	0.67	0.78	0.73	0.29	0.36	0.04	1.49	1.44	1.00	1.07	000
11306		A	Shave skin lesion	0.99	1.03	0.97	0.44	0.52	0.05	2.07	2.01	1.48	1.56	000
11307		A	Shave skin lesion	1.14	1.13	1.10	0.51	0.64	0.05	2.32	2.29	1.70	1.83	000
11308		A	Shave skin lesion	1.41	1.21	1.29	0.62	0.85	0.07	2.69	2.77	2.10	2.33	000
11310		A	Shave skin lesion	0.73	1.08	1.00	0.34	0.44	0.04	1.85	1.77	1.11	1.21	000
11311		A	Shave skin lesion	1.05	1.19	1.12	0.51	0.61	0.05	2.29	2.22	1.61	1.71	000
11312		A	Shave skin lesion	1.20	1.27	1.26	0.58	0.74	0.05	2.52	2.51	1.83	1.99	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
11313		A	Shave skin lesion	1.62	1.51	1.54	0.76	0.98	0.08	3.21	3.24	2.46	2.68	000
11400		A	Removal of skin lesion	0.91	2.30	1.87	0.71	0.68	0.07	3.28	2.85	1.69	1.66	010
11401		A	Removal of skin lesion	1.32	2.34	1.94	0.87	0.84	0.10	3.76	3.36	2.29	2.26	010
11402		A	Removal of skin lesion	1.61	2.42	2.06	0.95	0.96	0.11	4.14	3.78	2.67	2.68	010
11403		A	Removal of skin lesion	1.92	2.63	2.29	1.08	1.13	0.15	4.70	4.36	3.15	3.20	010
11404		A	Removal of skin lesion	2.20	2.78	2.46	1.17	1.25	0.18	5.16	4.84	3.55	3.63	010
11406		A	Removal of skin lesion	2.76	3.07	2.81	1.39	1.55	0.25	6.08	5.82	4.40	4.56	010
11420		A	Removal of skin lesion	1.06	1.92	1.58	0.76	0.71	0.08	3.06	2.72	1.90	1.85	010
11421		A	Removal of skin lesion	1.53	2.25	1.88	0.97	0.92	0.11	3.89	3.52	2.61	2.56	010
11422		A	Removal of skin lesion	1.76	2.44	2.09	1.04	1.04	0.12	4.32	3.97	2.92	2.92	010
11423		A	Removal of skin lesion	2.17	2.73	2.40	1.21	1.26	0.17	5.07	4.74	3.55	3.60	010
11424		A	Removal of skin lesion	2.62	2.87	2.53	1.38	1.41	0.20	5.69	5.35	4.20	4.23	010
11426		A	Removal of skin lesion	3.78	3.51	3.13	1.85	1.89	0.32	7.61	7.23	5.95	5.99	010
11440		A	Removal of skin lesion	1.15	2.45	2.03	0.92	0.88	0.08	3.68	3.26	2.15	2.11	010
11441		A	Removal of skin lesion	1.61	2.59	2.17	1.14	1.09	0.11	4.31	3.89	2.86	2.81	010
11442		A	Removal of skin lesion	1.87	2.66	2.30	1.24	1.24	0.13	4.66	4.30	3.24	3.24	010
11443		A	Removal of skin lesion	2.49	3.12	2.73	1.54	1.55	0.18	5.79	5.40	4.21	4.22	010
11444		A	Removal of skin lesion	3.42	3.55	3.06	1.93	1.85	0.25	7.22	6.73	5.60	5.52	010
11446		A	Removal of skin lesion	4.49	4.02	3.50	2.45	2.32	0.32	8.83	8.31	7.26	7.13	010
11450		A	Removal, sweat gland lesion	2.73	3.83	3.60	1.08	1.54	0.24	6.80	6.57	4.05	4.51	090
11451		A	Removal, sweat gland lesion	3.95	4.79	4.38	1.56	1.96	0.37	9.11	8.70	5.88	6.28	090
11462		A	Removal, sweat gland lesion	2.51	3.82	3.52	1.01	1.41	0.23	6.56	6.26	3.75	4.15	090
11463		A	Removal, sweat gland lesion	3.95	5.26	4.49	1.63	1.77	0.39	9.60	8.83	5.97	6.11	090
11470		A	Removal, sweat gland lesion	3.25	4.28	3.97	1.30	1.73	0.31	7.84	7.53	4.86	5.29	090
11471		A	Removal, sweat gland lesion	4.41	5.38	4.70	1.81	2.03	0.42	10.21	9.53	6.64	6.86	090
11600		A	Removal of skin lesion	1.41	2.47	2.16	0.97	1.04	0.09	3.97	3.66	2.47	2.54	010
11601		A	Removal of skin lesion	1.93	2.56	2.30	1.09	1.20	0.11	4.60	4.34	3.13	3.24	010
11602		A	Removal of skin lesion	2.09	2.62	2.46	1.29	1.46	0.12	4.83	4.67	3.50	3.67	010
11603		A	Removal of skin lesion	2.35	2.79	2.70	1.36	1.63	0.15	5.29	5.20	3.86	4.13	010
11604		A	Removal of skin lesion	2.58	2.96	2.92	1.44	1.78	0.18	5.72	5.68	4.20	4.54	010
11606		A	Removal of skin lesion	3.43	3.50	3.47	1.75	2.16	0.28	7.21	7.18	5.46	5.87	010
11620		A	Removal of skin lesion	1.34	2.44	2.19	0.99	1.11	0.09	3.87	3.62	2.42	2.54	010
11621		A	Removal of skin lesion	1.97	2.59	2.42	1.24	1.41	0.11	4.67	4.50	3.32	3.49	010
11622		A	Removal of skin lesion	2.34	2.75	2.66	1.45	1.69	0.14	5.23	5.14	3.93	4.17	010
11623		A	Removal of skin lesion	2.93	2.70	2.73	1.69	1.97	0.20	5.83	5.86	4.82	5.10	010
11624		A	Removal of skin lesion	3.43	3.01	3.13	1.91	2.30	0.25	6.69	6.81	5.59	5.98	010
11626		A	Removal of skin lesion	4.30	3.96	3.90	2.29	2.64	0.34	8.60	8.54	6.93	7.28	010
11640		A	Removal of skin lesion	1.53	2.53	2.35	1.16	1.32	0.10	4.16	3.98	2.79	2.95	010
11641		A	Removal of skin lesion	2.44	2.88	2.73	1.61	1.78	0.14	5.46	5.31	4.19	4.36	010
11642		A	Removal of skin lesion	2.93	2.79	2.79	1.82	2.06	0.18	5.90	5.90	4.93	5.17	010
11643		A	Removal of skin lesion	3.50	3.12	3.16	2.10	2.39	0.24	6.86	6.90	5.84	6.13	010
11644		A	Removal of skin lesion	4.55	3.74	3.76	2.60	2.90	0.32	8.61	8.63	7.47	7.77	010
11646		A	Removal of skin lesion	5.95	4.94	4.88	3.31	3.66	0.46	11.35	11.29	9.72	10.07	010
11719		R	Trim nail(s)	0.11	0.48	0.43	0.04	0.10	0.01	0.60	0.55	0.16	0.22	000
11720		A	Debride nail, 1–5	0.32	0.40	0.39	0.13	0.19	0.02	0.74	0.73	0.47	0.53	000
11721		A	Debride nail, 6 or more	0.54	0.51	0.53	0.21	0.31	0.04	1.09	1.11	0.79	0.89	000
11730		A	Removal of nail plate	1.13	0.72	0.66	0.45	0.46	0.07	1.92	1.86	1.65	1.66	000
11732		A	Remove nail plate, add-on	0.57	0.28	0.28	0.23	0.24	0.04	0.89	0.89	0.84	0.85	ZZZ
11740		A	Drain blood from under nail	0.37	0.64	0.59	0.14	0.21	0.03	1.04	0.99	0.54	0.61	000
11750		A	Removal of nail bed	1.86	1.49	1.69	0.78	1.16	0.12	3.47	3.67	2.76	3.14	010
11752		A	Remove nail bed/finger tip	2.67	1.84	2.15	1.65	2.00	0.20	4.71	5.02	4.52	4.87	010
11755		A	Biopsy, nail unit	1.31	0.97	1.00	0.57	0.70	0.08	2.36	2.39	1.96	2.09	000
11760		A	Repair of nail bed	1.58	1.54	1.41	1.13	1.10	0.13	3.25	3.12	2.84	2.81	010
11762		A	Reconstruction of nail bed	2.89	1.97	2.18	1.75	2.01	0.20	5.06	5.27	4.84	5.10	010
11765		A	Excision of nail fold, toe	0.69	0.93	0.84	0.42	0.45	0.05	1.67	1.58	1.16	1.19	010
11770		A	Removal of pilonidal lesion	2.61	2.77	2.80	1.27	1.68	0.24	5.62	5.65	4.12	4.53	010
11771		A	Removal of pilonidal lesion	5.74	5.00	4.98	3.95	4.19	0.55	11.29	11.27	10.24	10.48	090
11772		A	Removal of pilonidal lesion	6.98	5.85	5.70	4.45	4.65	0.70	13.53	13.38	12.13	12.33	090
11900		A	Injection into skin lesions	0.52	0.69	0.59	0.22	0.23	0.02	1.23	1.13	0.76	0.77	000
11901		A	Added skin lesions injection	0.80	0.82	0.73	0.37	0.39	0.03	1.65	1.56	1.20	1.22	000
11920		R	Correct skin color defects	1.61	2.01	1.83	0.78	0.91	0.17	3.79	3.61	2.56	2.69	000
11921		R	Correct skin color defects	1.93	2.21	2.04	1.00	1.13	0.20	4.34	4.17	3.13	3.26	000
11922		R	Correct skin color defects	0.49	0.36	0.37	0.26	0.29	0.05	0.90	0.91	0.80	0.83	ZZZ
11950		R	Therapy for contour defects	0.84	1.01	1.08	0.35	0.59	0.06	1.91	1.98	1.25	1.49	000
11951		R	Therapy for contour defects	1.19	1.34	1.33	0.53	0.72	0.09	2.62	2.61	1.81	2.00	000
11952		R	Therapy for contour defects	1.69	2.09	1.89	0.80	0.92	0.11	3.89	3.69	2.60	2.72	000
11954		R	Therapy for contour defects	1.85	2.36	2.09	0.71	0.86	0.20	4.41	4.14	2.76	2.91	000
11960		A	Insert tissue expander(s)	9.08	NA	NA	10.01	9.61	0.89	NA	NA	19.98	19.58	090
11970		A	Replace tissue expander	7.06	NA	NA	4.89	5.78	0.75	NA	NA	12.70	13.59	090
11971		A	Remove tissue expander(s)	2.13	5.96	5.10	3.56	3.30	0.22	8.31	7.45	5.91	5.65	090
11975		N	Insert contraceptive cap	1.48	1.46	1.38	0.59	0.73	0.11	3.05	2.97	2.18	2.32	XXX
11976		R	Removal of contraceptive cap	1.78	1.52	1.49	0.65	0.84	0.13	3.43	3.40	2.56	2.75	XXX
11977		N	Removal/reinsert contra cap	3.30	2.19	2.28	1.31	1.62	0.25	5.74	5.83	4.86	5.17	XXX
11980		A	Implant hormone pellet(s)	1.48	1.46	1.46	0.59	0.59	0.11	3.05	3.05	2.18	2.18	000
12001		A	Repair superficial wound(s)	1.70	2.17	1.78	0.78	0.74	0.15	4.02	3.63	2.63	2.59	010
12002		A	Repair superficial wound(s)	1.86	2.26	1.91	0.82	0.83	0.16	4.28	3.93	2.84	2.85	010
12004		A	Repair superficial wound(s)	2.24	2.45	2.15	0.94	1.02	0.20	4.89	4.59	3.38	3.46	010
12005		A	Repair superficial wound(s)	2.86	2.84	2.53	1.17	1.28	0.26	5.96	5.65	4.29	4.40	010
12006		A	Repair superficial wound(s)	3.67	3.97	3.46	1.74	1.79	0.34	7.98	7.47	5.75	5.80	010
12007		A	Repair superficial wound(s)	4.12	4.29	3.71	2.04	2.02	0.38	8.79	8.21	6.54	6.52	010
12011		A	Repair superficial wound(s)	1.76	2.27	1.90	0.79	0.79	0.16	4.19	3.82	2.71	2.71	010
12013		A	Repair superficial wound(s)	1.99	2.38	2.07	0.84	0.91	0.18	4.55	4.24	3.01	3.08	010

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
12014		A	Repair superficial wound(s)	2.46	2.68	2.33	1.01	1.08	0.22	5.36	5.01	3.69	3.76	010
12015		A	Repair superficial wound(s)	3.19	3.09	2.76	1.20	1.34	0.29	6.57	6.24	4.68	4.82	010
12016		A	Repair superficial wound(s)	3.93	3.35	3.13	1.50	1.74	0.36	7.64	7.42	5.79	6.03	010
12017		A	Repair superficial wound(s)	4.71	5.03	4.69	2.11	2.50	0.44	10.18	9.84	7.26	7.65	010
12018		A	Repair superficial wound(s)	5.53	5.66	5.64	2.54	3.30	0.46	11.65	11.63	8.53	9.29	010
12020		A	Closure of split wound	2.62	2.59	2.27	1.51	1.46	0.23	5.44	5.12	4.36	4.31	010
12021		A	Closure of split wound	1.84	2.00	1.67	1.11	1.00	0.15	3.99	3.66	3.10	2.99	010
12031		A	Layer closure of wound(s)	2.15	2.66	2.19	1.16	1.07	0.14	4.95	4.48	3.45	3.36	010
12032		A	Layer closure of wound(s)	2.47	2.74	2.34	1.23	1.21	0.15	5.36	4.96	3.85	3.83	010
12034		A	Layer closure of wound(s)	2.92	2.97	2.63	1.39	1.44	0.24	6.13	5.79	4.55	4.60	010
12035		A	Layer closure of wound(s)	3.43	2.98	2.76	1.62	1.74	0.32	6.73	6.51	5.37	5.49	010
12036		A	Layer closure of wound(s)	4.05	4.89	4.30	2.34	2.39	0.40	9.34	8.75	6.79	6.84	010
12037		A	Layer closure of wound(s)	4.67	5.11	4.67	2.81	2.95	0.44	10.22	9.78	7.92	8.06	010
12041		A	Layer closure of wound(s)	2.37	2.95	2.44	1.19	1.12	0.17	5.49	4.98	3.73	3.66	010
12042		A	Layer closure of wound(s)	2.74	2.93	2.52	1.36	1.34	0.18	5.85	5.44	4.28	4.26	010
12044		A	Layer closure of wound(s)	3.14	2.99	2.68	1.54	1.60	0.26	6.39	6.08	4.94	5.00	010
12045		A	Layer closure of wound(s)	3.64	3.33	3.08	1.80	1.93	0.32	7.29	7.04	5.76	5.89	010
12046		A	Layer closure of wound(s)	4.25	4.95	4.48	2.40	2.57	0.37	9.57	9.10	7.02	7.19	010
12047		A	Layer closure of wound(s)	4.65	4.99	4.83	2.79	3.18	0.44	10.08	9.92	7.88	8.27	010
12051		A	Layer closure of wound(s)	2.47	2.91	2.46	1.35	1.29	0.17	5.55	5.10	3.99	3.93	010
12052		A	Layer closure of wound(s)	2.77	2.88	2.56	1.30	1.38	0.17	5.82	5.50	4.24	4.32	010
12053		A	Layer closure of wound(s)	3.12	3.03	2.75	1.45	1.57	0.23	6.38	6.10	4.80	4.92	010
12054		A	Layer closure of wound(s)	3.46	3.36	3.23	1.57	1.88	0.29	7.11	6.98	5.32	5.63	010
12055		A	Layer closure of wound(s)	4.43	4.12	3.97	2.09	2.45	0.39	8.94	8.79	6.91	7.27	010
12056		A	Layer closure of wound(s)	5.24	5.87	5.69	2.89	3.45	0.43	11.54	11.36	8.56	9.12	010
12057		A	Layer closure of wound(s)	5.96	5.55	5.67	3.52	4.15	0.49	12.00	12.12	9.97	10.60	010
13100		A	Repair of wound or lesion	3.12	3.25	2.75	1.83	1.68	0.22	6.59	6.09	5.17	5.02	010
13101		A	Repair of wound or lesion	3.92	3.54	3.22	2.28	2.28	0.23	7.69	7.37	6.43	6.43	010
13102		A	Repair wound/lesion add-on	1.24	0.72	0.72	0.57	0.57	0.08	2.04	2.04	1.89	1.89	ZZZ
13120		A	Repair of wound or lesion	3.30	3.39	2.91	1.82	1.73	0.25	6.94	6.46	5.37	5.28	010
13121		A	Repair of wound or lesion	4.33	3.76	3.54	2.32	2.46	0.27	8.36	8.14	6.92	7.06	010
13122		A	Repair wound/lesion add-on	1.44	0.84	0.84	0.66	0.66	0.09	2.37	2.37	2.19	2.19	ZZZ
13131		A	Repair of wound or lesion	3.79	3.64	3.27	2.17	2.17	0.26	7.69	7.32	6.22	6.22	010
13132		A	Repair of wound or lesion	5.95	4.50	4.62	3.19	3.63	0.34	10.79	10.91	9.48	9.92	010
13133		A	Repair wound/lesion add-on	2.19	1.19	1.19	1.01	1.01	0.12	3.50	3.50	3.32	3.32	ZZZ
13150		A	Repair of wound or lesion	3.81	4.97	4.21	2.50	2.35	0.29	9.07	8.31	6.60	6.45	010
13151		A	Repair of wound or lesion	4.45	4.98	4.40	2.95	2.88	0.30	9.73	9.15	7.70	7.63	010
13152		A	Repair of wound or lesion	6.33	5.64	5.62	3.85	4.28	0.40	12.37	12.35	10.58	11.01	010
13153		A	Repair wound/lesion add-on	2.38	1.32	1.32	1.09	1.09	0.15	3.85	3.85	3.62	3.62	ZZZ
13160		A	Late closure of wound	10.48	NA	NA	6.26	5.60	1.08	NA	NA	17.82	17.16	090
13300		D	Repair of wound or lesion	5.27	2.09	3.12	2.09	3.12	0.44	7.80	8.83	7.80	8.83	010
14000		A	Skin tissue rearrangement	5.89	7.03	6.20	4.52	4.32	0.46	13.38	12.55	10.87	10.67	090
14001		A	Skin tissue rearrangement	8.47	8.26	7.48	5.82	5.65	0.67	17.40	16.62	14.96	14.79	090
14020		A	Skin tissue rearrangement	6.59	7.45	6.92	5.13	5.18	0.51	14.55	14.02	12.23	12.28	090
14021		A	Skin tissue rearrangement	10.06	8.94	8.39	6.89	6.85	0.73	19.73	19.18	17.68	17.64	090
14040		A	Skin tissue rearrangement	7.87	7.82	7.70	5.80	6.19	0.53	16.22	16.10	14.20	14.59	090
14041		A	Skin tissue rearrangement	11.49	9.68	9.40	7.65	7.88	0.69	21.86	21.58	19.83	20.06	090
14060		A	Skin tissue rearrangement	8.50	8.34	8.36	6.60	7.05	0.60	17.44	17.46	15.70	16.15	090
14061		A	Skin tissue rearrangement	12.29	10.66	10.84	8.55	9.26	0.75	23.70	23.88	21.59	22.30	090
14300		A	Skin tissue rearrangement	11.76	9.70	10.34	8.10	9.14	0.92	22.38	23.02	20.78	21.82	090
14350		A	Skin tissue rearrangement	9.61	NA	NA	5.92	6.09	0.90	NA	NA	16.43	16.60	090
15000		A	Skin graft	0.04	2.40	2.38	1.93	2.03	0.36	2.80	2.78	2.33	2.43	000
15001		A	Skin graft add-on	0.01	0.60	0.60	0.48	0.48	0.09	0.70	0.70	0.58	0.58	ZZZ
15050		A	Skin pinch graft	4.30	4.82	4.10	3.66	3.23	0.41	9.53	8.81	8.37	7.94	090
15100		A	Skin split graft	9.05	6.17	5.86	6.01	5.74	0.94	16.16	15.85	16.00	15.73	090
15101		A	Skin split graft add-on	1.72	1.15	1.30	0.77	1.01	0.18	3.05	3.20	2.67	2.91	ZZZ
15120		A	Skin split graft	9.83	8.00	7.64	6.56	6.56	0.80	18.63	18.27	17.19	17.19	090
15121		A	Skin split graft add-on	2.67	1.69	2.06	1.29	1.76	0.26	4.62	4.99	4.22	4.69	ZZZ
15200		A	Skin full graft	8.03	8.74	7.68	5.43	5.19	0.72	17.49	16.43	14.18	13.94	090
15201		A	Skin full graft add-on	1.32	1.08	1.27	0.66	0.95	0.13	2.53	2.72	2.11	2.40	ZZZ
15220		A	Skin full graft	7.87	9.02	8.08	5.95	5.78	0.68	17.57	16.63	14.50	14.33	090
15221		A	Skin full graft add-on	1.19	0.86	1.08	0.58	0.87	0.11	2.16	2.38	1.88	2.17	ZZZ
15240		A	Skin full graft	9.04	8.62	8.12	6.69	6.67	0.77	18.43	17.93	16.50	16.48	090
15241		A	Skin full graft add-on	1.86	1.40	1.70	0.95	1.36	0.17	3.43	3.73	2.98	3.39	ZZZ
15260		A	Skin full graft	10.06	8.73	8.57	7.27	7.48	0.65	19.44	19.28	17.98	18.19	090
15261		A	Skin full graft add-on	2.23	1.52	1.91	1.15	1.64	0.17	3.92	4.31	3.55	4.04	ZZZ
15350		A	Skin homograft	0.04	7.54	6.24	4.12	3.67	0.40	7.98	6.68	4.56	4.11	090
15351		A	Skin homograft add-on	0.01	0.80	0.80	0.46	0.46	0.09	0.90	0.90	0.56	0.56	ZZZ
15400		A	Skin heterograft	0.04	4.25	3.48	4.25	3.48	0.34	4.63	3.86	4.63	3.86	090
15401		A	Skin heterograft add-on	0.01	0.80	0.80	0.46	0.46	0.09	0.90	0.90	0.56	0.56	ZZZ
15570		A	Form skin pedicle flap	9.21	8.32	7.73	5.85	5.88	0.91	18.44	17.85	15.97	16.00	090
15572		A	Form skin pedicle flap	9.27	7.55	7.12	5.21	5.37	0.87	17.69	17.26	15.35	15.51	090
15574		A	Form skin pedicle flap	9.88	8.04	7.50	6.45	6.30	0.86	18.78	18.24	17.19	17.04	090
15576		A	Form skin pedicle flap	8.69	8.41	7.16	6.13	5.45	0.71	17.81	16.56	15.53	14.85	090
15580		D	Attach skin pedicle graft	9.46	3.75	3.98	3.75	3.98	0.98	14.19	14.42	14.19	14.42	090
15600		A	Skin graft	1.91	5.35	4.69	2.20	2.33	0.19	7.45	6.79	4.30	4.43	090
15610		A	Skin graft	2.42	2.39	2.56	2.39	2.56	0.25	5.06	5.23	5.06	5.23	090
15620		A	Skin graft	2.94	6.16	5.55	3.12	3.27	0.27	9.37	8.76	6.33	6.48	090
15625		D	Skin graft	1.91	0.76	1.14	0.76	1.14	0.20	2.87	3.25	2.87	3.25	090
15630		A	Skin graft	3.27	5.77	5.31	3.38	3.51	0.29	9.33	8.87	6.94	7.07	090
15650		A	Transfer skin pedicle flap	3.97	6.52	6.08	3.51	3.82	0.33	10.82	10.38	7.81	8.12	090
15732		A	Muscle-skin graft, head/neck	17.84	NA	NA	11.13	12.55	1.47	NA	NA	30.44	31.86	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
15734		A	Muscle-skin graft, trunk	17.79	NA	NA	11.07	13.46	1.88	NA	NA	30.74	33.13	090
15736		A	Muscle-skin graft, arm	16.27	NA	NA	10.44	12.23	1.72	NA	NA	28.43	30.22	090
15738		A	Muscle-skin graft, leg	17.92	NA	NA	11.01	11.76	1.91	NA	NA	30.84	31.59	090
15740		A	Island pedicle flap graft	10.25	8.51	9.20	6.82	7.94	0.64	19.40	20.09	17.71	18.83	090
15750		A	Neurovascular pedicle graft	11.41	NA	NA	8.03	9.27	1.17	NA	NA	20.61	21.85	090
15756		A	Free muscle flap, microvasc	35.23	NA	NA	21.45	24.25	3.62	NA	NA	60.30	63.10	090
15757		A	Free skin flap, microvasc	35.23	NA	NA	21.62	24.38	3.37	NA	NA	60.22	62.98	090
15758		A	Free fascial flap, microvasc	35.10	NA	NA	21.39	24.21	3.40	NA	NA	59.89	62.71	090
15760		A	Composite skin graft	8.74	8.14	8.08	6.03	6.50	0.72	17.60	17.54	15.49	15.96	090
15770		A	Derma-fat-fascia graft	7.52	NA	NA	5.73	6.32	0.81	NA	NA	14.06	14.65	090
15775		R	Hair transplant punch grafts	3.96	2.92	2.97	1.58	1.97	0.42	7.30	7.35	5.96	6.35	000
15776		R	Hair transplant punch grafts	5.54	5.40	5.14	2.20	2.74	0.59	11.53	11.27	8.33	8.87	000
15780		A	Abrasion treatment of skin	7.29	6.57	5.34	6.57	5.34	0.54	14.40	13.17	14.40	13.17	090
15781		A	Abrasion treatment of skin	4.85	4.69	4.54	4.41	4.33	0.29	9.83	9.68	9.55	9.47	090
15782		A	Abrasion treatment of skin	4.32	4.04	3.35	3.73	3.12	0.27	8.63	7.94	8.32	7.71	090
15783		A	Abrasion treatment of skin	4.29	4.43	3.83	3.12	2.84	0.26	8.98	8.38	7.67	7.39	090
15786		A	Abrasion, lesion, single	2.03	1.69	1.44	1.24	1.10	0.11	3.83	3.58	3.38	3.24	010
15787		A	Abrasion, lesions, add-on	0.33	0.28	0.27	0.18	0.20	0.02	0.63	0.62	0.53	0.55	ZZZ
15788		R	Chemical peel, face, epiderm	2.09	2.82	2.52	1.04	1.18	0.10	5.01	4.71	3.23	3.37	090
15789		R	Chemical peel, face, dermal	4.92	5.69	4.67	3.38	2.94	0.30	10.91	9.89	8.60	8.16	090
15792		R	Chemical peel, nonfacial	1.86	2.68	2.15	1.62	1.35	0.11	4.65	4.12	3.59	3.32	090
15793		A	Chemical peel, nonfacial	3.74	NA	NA	3.42	2.70	0.16	NA	NA	7.32	6.60	090
15810		A	Salabrasion	4.74	3.80	3.88	3.80	3.88	0.38	8.92	9.00	8.92	9.00	090
15811		A	Salabrasion	5.39	3.94	3.97	3.94	3.97	0.57	9.90	9.93	9.90	9.93	090
15819		A	Plastic surgery, neck	9.38	NA	NA	6.41	6.98	0.83	NA	NA	16.62	17.19	090
15820		A	Revision of lower eyelid	5.15	7.27	6.99	6.76	6.61	0.30	12.72	12.44	12.21	12.06	090
15821		A	Revision of lower eyelid	5.72	7.76	7.53	6.87	6.86	0.30	13.78	13.55	12.89	12.88	090
15822		A	Revision of upper eyelid	4.45	7.00	6.58	6.08	5.89	0.23	11.68	11.26	10.76	10.57	090
15823		A	Revision of upper eyelid	7.05	8.32	8.33	7.20	7.49	0.33	15.70	15.71	14.58	14.87	090
15824		R	Removal of forehead wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15825		R	Removal of neck wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15826		R	Removal of brow wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15828		R	Removal of face wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15829		R	Removal of skin wrinkles	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15831		A	Excise excessive skin tissue	12.40	NA	NA	7.24	8.10	1.24	NA	NA	20.88	21.74	090
15832		A	Excise excessive skin tissue	11.59	NA	NA	7.78	8.09	1.20	NA	NA	20.57	20.88	090
15833		A	Excise excessive skin tissue	10.64	NA	NA	7.42	7.25	1.31	NA	NA	19.37	19.20	090
15834		A	Excise excessive skin tissue	10.85	NA	NA	6.16	6.57	1.23	NA	NA	18.24	18.65	090
15835		A	Excise excessive skin tissue	11.67	NA	NA	5.60	6.10	1.36	NA	NA	18.63	19.13	090
15836		A	Excise excessive skin tissue	9.34	NA	NA	6.08	6.13	0.95	NA	NA	16.37	16.42	090
15837		A	Excise excessive skin tissue	8.43	6.36	6.39	6.36	6.39	0.82	15.61	15.64	15.61	15.64	090
15838		A	Excise excessive skin tissue	7.13	NA	NA	5.41	5.65	0.53	NA	NA	13.07	13.31	090
15839		A	Excise excessive skin tissue	9.38	6.10	5.24	5.57	4.84	0.80	16.28	15.42	15.75	15.02	090
15840		A	Graft for face nerve palsy	13.26	NA	NA	9.46	11.05	1.06	NA	NA	23.78	25.37	090
15841		A	Graft for face nerve palsy	23.26	NA	NA	14.47	15.43	2.51	NA	NA	40.24	41.20	090
15842		A	Graft for face nerve palsy	37.96	NA	NA	22.96	25.09	5.53	NA	NA	66.45	68.58	090
15845		A	Skin and muscle repair, face	12.57	NA	NA	8.67	10.26	0.87	NA	NA	22.11	23.70	090
15850		B	Removal of sutures	0.78	1.32	1.09	0.31	0.33	0.05	2.15	1.92	1.14	1.16	XXX
15851		A	Removal of sutures	0.86	1.48	1.19	0.34	0.34	0.06	2.40	2.11	1.26	1.26	000
15852		A	Dressing change,not for burn	0.86	1.63	1.34	0.35	0.38	0.07	2.56	2.27	1.28	1.31	000
15860		A	Test for blood flow in graft	1.95	1.11	1.20	0.87	1.02	0.19	3.25	3.34	3.01	3.16	000
15876		R	Suction assisted lipectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15877		R	Suction assisted lipectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15878		R	Suction assisted lipectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15879		R	Suction assisted lipectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
15920		A	Removal of tail bone ulcer	7.95	NA	NA	5.38	4.84	0.75	NA	NA	14.08	13.54	090
15922		A	Removal of tail bone ulcer	9.90	NA	NA	6.94	6.83	1.03	NA	NA	17.87	17.76	090
15931		A	Remove sacrum pressure sore	9.24	NA	NA	5.52	4.94	0.95	NA	NA	15.71	15.13	090
15933		A	Remove sacrum pressure sore	10.85	NA	NA	7.87	7.78	1.13	NA	NA	19.85	19.76	090
15934		A	Remove sacrum pressure sore	12.69	NA	NA	8.16	8.15	1.34	NA	NA	22.19	22.18	090
15935		A	Remove sacrum pressure sore	14.57	NA	NA	9.76	10.37	1.53	NA	NA	25.86	26.47	090
15936		A	Remove sacrum pressure sore	12.38	NA	NA	8.76	9.36	1.30	NA	NA	22.44	23.04	090
15937		A	Remove sacrum pressure sore	14.21	NA	NA	9.97	11.13	1.49	NA	NA	25.67	26.83	090
15940		A	Remove hip pressure sore	9.34	NA	NA	5.84	5.34	0.96	NA	NA	16.14	15.64	090
15941		A	Remove hip pressure sore	11.43	NA	NA	9.32	8.90	1.20	NA	NA	21.95	21.53	090
15944		A	Remove hip pressure sore	11.46	NA	NA	8.41	8.82	1.19	NA	NA	21.06	21.47	090
15945		A	Remove hip pressure sore	12.69	NA	NA	9.35	10.04	1.33	NA	NA	23.37	24.06	090
15946		A	Remove hip pressure sore	21.57	NA	NA	13.99	15.00	2.15	NA	NA	37.71	38.72	090
15950		A	Remove thigh pressure sore	7.54	NA	NA	5.21	4.73	0.77	NA	NA	13.52	13.04	090
15951		A	Remove thigh pressure sore	10.72	NA	NA	7.94	8.03	1.11	NA	NA	19.77	19.86	090
15952		A	Remove thigh pressure sore	11.39	NA	NA	7.10	7.26	1.19	NA	NA	19.68	19.84	090
15953		A	Remove thigh pressure sore	12.63	NA	NA	8.66	8.96	1.31	NA	NA	22.60	22.90	090
15956		A	Remove thigh pressure sore	15.52	NA	NA	10.36	12.40	1.61	NA	NA	27.49	29.53	090
15958		A	Remove thigh pressure sore	15.48	NA	NA	10.45	12.46	1.59	NA	NA	27.52	29.53	090
15999		C	Removal of pressure sore	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
16000		A	Initial treatment of burn(s)	0.89	0.91	0.78	0.26	0.29	0.07	1.87	1.74	1.22	1.25	000
16010		A	Treatment of burn(s)	0.87	1.01	0.85	0.36	0.36	0.07	1.95	1.79	1.30	1.30	000
16015		A	Treatment of burn(s)	2.35	1.62	1.77	0.99	1.30	0.21	4.18	4.33	3.55	3.86	000
16020		A	Treatment of burn(s)	0.80	0.99	0.84	0.25	0.28	0.06	1.85	1.70	1.11	1.14	000
16025		A	Treatment of burn(s)	1.85	1.58	1.31	0.67	0.63	0.16	3.59	3.32	2.68	2.64	000
16030		A	Treatment of burn(s)	2.08	2.51	2.02	0.89	0.81	0.19	4.78	4.29	3.16	3.08	000
16035		A	Incision of burn scab	4.82	2.82	2.63	2.09	2.08	0.48	8.12	7.93	7.39	7.38	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
17000		A	Destroy benign/premal lesion	0.60	0.99	0.86	0.27	0.32	0.03	1.62	1.49	0.90	0.95	010
17003		A	Destroy lesions, 2–14	0.15	0.24	0.22	0.07	0.09	0.01	0.40	0.38	0.23	0.25	ZZZ
17004		A	Destroy lesions, 15 or more	2.79	2.34	2.37	1.28	1.57	0.11	5.24	5.27	4.18	4.47	010
17106		A	Destruction of skin lesions	4.59	4.03	3.55	2.68	2.53	0.27	8.89	8.41	7.54	7.39	090
17107		A	Destruction of skin lesions	9.16	6.56	5.93	4.90	4.68	0.51	16.23	15.60	14.57	14.35	090
17108		A	Destruction of skin lesions	13.20	8.58	8.96	7.14	7.88	0.76	22.54	22.92	21.10	21.84	090
17110		A	Destruct lesion, 1–14	0.65	0.93	0.81	0.26	0.30	0.04	1.62	1.50	0.95	0.99	010
17111		A	Destruct lesion, 15 or more	0.92	1.13	1.01	0.38	0.45	0.05	2.10	1.98	1.35	1.42	010
17250		A	Chemical cautery, tissue	0.50	0.62	0.56	0.20	0.24	0.04	1.16	1.10	0.74	0.78	000
17260		A	Destruction of skin lesions	0.91	1.22	1.22	0.41	0.62	0.04	2.17	2.17	1.36	1.57	010
17261		A	Destruction of skin lesions	1.17	1.34	1.38	0.55	0.79	0.05	2.56	2.60	1.77	2.01	010
17262		A	Destruction of skin lesions	1.58	1.54	1.65	0.75	1.06	0.06	3.18	3.29	2.39	2.70	010
17263		A	Destruction of skin lesions	1.79	1.65	1.85	0.84	1.24	0.07	3.51	3.71	2.70	3.10	010
17264		A	Destruction of skin lesions	1.94	1.72	1.99	0.90	1.38	0.08	3.74	4.01	2.92	3.40	010
17266		A	Destruction of skin lesions	2.34	1.92	2.29	0.99	1.59	0.11	4.37	4.74	3.44	4.04	010
17270		A	Destruction of skin lesions	1.32	1.41	1.42	0.60	0.81	0.06	2.79	2.80	1.98	2.19	010
17271		A	Destruction of skin lesions	1.49	1.50	1.60	0.71	1.01	0.06	3.05	3.15	2.26	2.56	010
17272		A	Destruction of skin lesions	1.77	1.64	1.83	0.85	1.24	0.07	3.48	3.67	2.69	3.08	010
17273		A	Destruction of skin lesions	2.05	1.78	2.04	0.97	1.43	0.08	3.91	4.17	3.10	3.56	010
17274		A	Destruction of skin lesions	2.59	2.04	2.40	1.24	1.80	0.11	4.74	5.10	3.94	4.50	010
17276		A	Destruction of skin lesions	3.20	2.35	2.69	1.59	2.12	0.15	5.70	6.04	4.94	5.47	010
17280		A	Destruction of skin lesions	1.17	1.25	1.39	0.54	0.85	0.05	2.47	2.61	1.76	2.07	010
17281		A	Destruction of skin lesions	1.72	1.61	1.78	0.82	1.18	0.07	3.40	3.57	2.61	2.97	010
17282		A	Destruction of skin lesions	2.04	1.77	2.03	0.98	1.43	0.08	3.89	4.15	3.10	3.55	010
17283		A	Destruction of skin lesions	2.64	2.07	2.37	1.24	1.75	0.11	4.82	5.12	3.99	4.50	010
17284		A	Destruction of skin lesions	3.21	2.35	2.72	1.51	2.09	0.13	5.69	6.06	4.85	5.43	010
17286		A	Destruction of skin lesions	4.44	2.93	3.37	2.45	3.01	0.21	7.58	8.02	7.10	7.66	010
17304		A	Chemosurgery of skin lesion	7.60	7.45	6.68	3.67	3.84	0.31	15.36	14.59	11.58	11.75	000
17305		A	2nd stage chemosurgery	2.85	3.44	3.19	1.38	1.65	0.11	6.40	6.15	4.34	4.61	000
17306		A	3rd stage chemosurgery	2.85	3.47	2.98	1.40	1.43	0.11	6.43	5.94	4.36	4.39	000
17307		A	Followup skin lesion therapy	2.85	3.27	2.85	1.41	1.46	0.11	6.23	5.81	4.37	4.42	000
17310		A	Extensive skin chemosurgery	0.95	1.37	1.06	0.48	0.40	0.05	2.37	2.06	1.48	1.40	000
17340		A	Cryotherapy of skin	0.76	1.30	1.05	0.26	0.27	0.05	2.11	1.86	1.07	1.08	010
17360		A	Skin peel therapy	1.43	1.46	1.17	0.76	0.64	0.06	2.95	2.66	2.25	2.13	010
17380		R	Hair removal by electrolysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
17999		C	Skin tissue procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
19000		A	Drainage of breast lesion	0.84	1.15	0.97	0.30	0.33	0.07	2.06	1.88	1.21	1.24	000
19001		A	Drain breast lesion add-on	0.42	0.78	0.65	0.15	0.18	0.03	1.23	1.10	0.60	0.63	ZZZ
19020		A	Incision of breast lesion	3.57	6.16	5.00	3.17	2.76	0.34	10.07	8.91	7.08	6.67	090
19030		A	Injection for breast x-ray	1.53	9.87	7.54	0.53	0.53	0.06	11.46	9.13	2.12	2.12	000
19100		A	Biopsy of breast	1.27	3.14	2.53	0.45	0.51	0.09	4.50	3.89	1.81	1.87	000
19101		A	Biopsy of breast	3.18	9.36	7.66	2.82	2.75	0.23	12.77	11.07	6.23	6.16	010
19110		A	Nipple exploration	4.30	7.17	6.05	4.16	3.79	0.42	11.89	10.77	8.88	8.51	090
19112		A	Excise breast duct fistula	3.67	6.51	5.52	2.91	2.82	0.35	10.53	9.54	6.93	6.84	090
19120		A	Removal of breast lesion	5.56	4.14	3.89	3.43	3.36	0.55	10.25	10.00	9.54	9.47	090
19125		A	Excision, breast lesion	6.06	4.75	4.35	3.61	3.50	0.60	11.41	11.01	10.27	10.16	090
19126		A	Excision, addl breast lesion	2.93	NA	NA	1.10	1.22	0.30	NA	NA	4.33	4.45	ZZZ
19140		A	Removal of breast tissue	5.14	8.52	7.56	3.50	3.79	0.52	14.18	13.22	9.16	9.45	090
19160		A	Removal of breast tissue	5.99	NA	NA	4.32	4.36	0.59	NA	NA	10.90	10.94	090
19162		A	Remove breast tissue, nodes	13.53	NA	NA	7.73	8.34	1.33	NA	NA	22.59	23.20	090
19180		A	Removal of breast	8.80	NA	NA	5.68	5.78	0.87	NA	NA	15.35	15.45	090
19182		A	Removal of breast	7.73	NA	NA	4.85	5.29	0.77	NA	NA	13.35	13.79	090
19200		A	Removal of breast	15.49	NA	NA	8.87	9.43	1.51	NA	NA	25.87	26.43	090
19220		A	Removal of breast	15.72	NA	NA	8.85	9.55	1.49	NA	NA	26.06	26.76	090
19240		A	Removal of breast	0.16	NA	NA	8.61	9.02	1.58	NA	NA	10.35	10.76	090
19260		A	Removal of chest wall lesion	15.44	NA	NA	10.02	8.89	1.68	NA	NA	27.14	26.01	090
19271		A	Revision of chest wall	18.90	NA	NA	13.36	13.81	2.13	NA	NA	34.39	34.84	090
19272		A	Extensive chest wall surgery	21.55	NA	NA	13.92	13.86	2.52	NA	NA	37.99	37.93	090
19290		A	Place needle wire, breast	1.27	4.76	3.69	0.44	0.45	0.05	6.08	5.01	1.76	1.77	000
19291		A	Place needle wire, breast	0.63	1.64	1.30	0.22	0.23	0.03	2.30	1.96	0.88	0.89	ZZZ
19316		A	Suspension of breast	10.69	NA	NA	7.28	8.65	1.13	NA	NA	19.10	20.47	090
19318		A	Reduction of large breast	15.62	NA	NA	10.09	11.42	1.65	NA	NA	27.36	28.69	090
19324		A	Enlarge breast	5.85	NA	NA	3.58	3.58	0.61	NA	NA	10.04	10.04	090
19325		A	Enlarge breast with implant	8.45	NA	NA	5.03	5.37	0.90	NA	NA	14.38	14.72	090
19328		A	Removal of breast implant	5.68	NA	NA	4.38	4.31	0.60	NA	NA	10.66	10.59	090
19330		A	Removal of implant material	7.59	NA	NA	5.11	4.89	0.80	NA	NA	13.50	13.28	090
19340		A	Immediate breast prosthesis	6.33	NA	NA	3.25	4.33	0.67	NA	NA	10.25	11.33	ZZZ
19342		A	Delayed breast prosthesis	11.20	NA	NA	7.61	8.64	1.19	NA	NA	20.00	21.03	090
19350		A	Breast reconstruction	8.92	12.18	11.06	6.56	6.84	0.95	22.05	20.93	16.43	16.71	090
19355		A	Correct inverted nipple(s)	7.57	12.61	10.80	4.45	4.68	0.75	20.93	19.12	12.77	13.00	090
19357		A	Breast reconstruction	18.16	NA	NA	13.19	13.19	1.92	NA	NA	33.27	33.27	090
19361		A	Breast reconstruction	19.26	NA	NA	11.68	14.22	2.04	NA	NA	32.98	35.52	090
19364		A	Breast reconstruction	0.41	NA	NA	24.19	22.67	4.22	NA	NA	28.82	27.30	090
19366		A	Breast reconstruction	21.28	NA	NA	11.78	13.29	2.15	NA	NA	35.21	36.72	090
19367		A	Breast reconstruction	25.73	NA	NA	15.11	16.80	2.72	NA	NA	43.56	45.25	090
19368		A	Breast reconstruction	32.42	NA	NA	17.88	18.87	3.46	NA	NA	53.76	54.75	090
19369		A	Breast reconstruction	29.82	NA	NA	17.95	18.93	3.17	NA	NA	50.94	51.92	090
19370		A	Surgery of breast capsule	8.05	NA	NA	5.86	6.07	0.86	NA	NA	14.77	14.98	090
19371		A	Removal of breast capsule	9.35	NA	NA	6.90	7.32	0.99	NA	NA	17.24	17.66	090
19380		A	Revise breast reconstruction	9.14	NA	NA	7.07	7.50	0.97	NA	NA	17.18	17.61	090
19396		A	Design custom breast implant	2.17	4.88	4.09	1.15	1.29	0.23	7.28	6.49	3.55	3.69	000
19499		C	Breast surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
20000		A	Incision of abscess	2.12	1.92	1.67	1.16	1.10	0.15	4.19	3.94	3.43	3.37	010
20005		A	Incision of deep abscess	3.42	2.69	2.52	2.14	2.10	0.31	6.42	6.25	5.87	5.83	010
20100		A	Explore wound, neck	10.08	5.57	5.53	4.71	4.88	0.94	16.59	16.55	15.73	15.90	010
20101		A	Explore wound, chest	3.22	3.07	2.73	1.87	1.83	0.30	6.59	6.25	5.39	5.35	010
20102		A	Explore wound, abdomen	3.94	3.50	3.15	1.88	1.93	0.39	7.83	7.48	6.21	6.26	010
20103		A	Explore wound, extremity	5.30	3.96	3.67	3.01	2.96	0.53	9.79	9.50	8.84	8.79	010
20150		A	Excise epiphyseal bar	13.69	NA	NA	9.58	10.55	1.03	NA	NA	24.30	25.27	090
20200		A	Muscle biopsy	1.46	1.56	1.48	0.62	0.77	0.17	3.19	3.11	2.25	2.40	000
20205		A	Deep muscle biopsy	2.35	3.53	3.16	0.99	1.25	0.28	6.16	5.79	3.62	3.88	000
20206		A	Needle biopsy, muscle	0.99	2.80	2.36	0.36	0.53	0.06	3.85	3.41	1.41	1.58	000
20220		A	Bone biopsy, trocar/needle	1.27	4.00	3.36	2.50	2.23	0.06	5.33	4.69	3.83	3.56	000
20225		A	Bone biopsy, trocar/needle	1.87	3.63	3.37	2.72	2.69	0.10	5.60	5.34	4.69	4.66	000
20240		A	Bone biopsy, excisional	3.23	NA	NA	3.80	3.36	0.27	NA	NA	7.30	6.86	010
20245		A	Bone biopsy, excisional	3.95	NA	NA	4.18	4.11	0.36	NA	NA	8.49	8.42	010
20250		A	Open bone biopsy	5.03	NA	NA	3.92	4.32	0.46	NA	NA	9.41	9.81	010
20251		A	Open bone biopsy	5.56	NA	NA	4.43	4.91	0.67	NA	NA	10.66	11.14	010
20500		A	Injection of sinus tract	1.23	4.92	3.79	3.48	2.71	0.09	6.24	5.11	4.80	4.03	010
20501		A	Inject sinus tract for x-ray	0.76	10.92	8.27	0.26	0.28	0.03	11.71	9.06	1.05	1.07	000
20520		A	Removal of foreign body	1.85	4.52	3.58	2.81	2.30	0.15	6.52	5.58	4.81	4.30	010
20525		A	Removal of foreign body	3.50	5.52	4.75	3.82	3.47	0.34	9.36	8.59	7.66	7.31	010
20550		A	Inject tendon/ligament/cyst	0.86	1.79	1.45	0.22	0.27	0.06	2.71	2.37	1.14	1.19	000
20600		A	Drain/inject, joint/bursa	0.66	1.23	1.05	0.27	0.33	0.05	1.94	1.76	0.98	1.04	000
20605		A	Drain/inject, joint/bursa	0.68	1.53	1.27	0.27	0.33	0.05	2.26	2.00	1.00	1.06	000
20610		A	Drain/inject, joint/bursa	0.79	1.90	1.55	0.51	0.51	0.06	2.75	2.40	1.36	1.36	000
20615		A	Treatment of bone cyst	2.28	3.83	3.01	2.41	1.94	0.16	6.27	5.45	4.85	4.38	010
20650		A	Insert and remove bone pin	2.23	3.81	3.15	2.75	2.36	0.17	6.21	5.55	5.15	4.76	010
20660		A	Apply,remove fixation device	2.51	NA	NA	1.42	1.49	0.45	NA	NA	4.38	4.45	000
20661		A	Application of head brace	4.89	NA	NA	6.04	5.57	0.83	NA	NA	11.76	11.29	090
20662		A	Application of pelvis brace	6.07	NA	NA	4.96	5.50	0.64	NA	NA	11.67	12.21	090
20663		A	Application of thigh brace	5.43	NA	NA	4.17	4.39	0.55	NA	NA	10.15	10.37	090
20664		A	Halo brace application	8.06	NA	NA	7.71	6.82	1.38	NA	NA	17.15	16.26	090
20665		A	Removal of fixation device	1.31	2.16	1.76	1.13	0.98	0.17	3.64	3.24	2.61	2.46	010
20670		A	Removal of support implant	1.74	5.07	4.00	3.24	2.63	0.17	6.98	5.91	5.15	4.54	010
20680		A	Removal of support implant	3.35	4.28	4.11	4.28	4.11	0.33	7.96	7.79	7.96	7.79	090
20690		A	Apply bone fixation device	3.52	NA	NA	1.90	2.42	0.33	NA	NA	5.75	6.27	090
20692		A	Apply bone fixation device	6.41	NA	NA	3.39	4.04	0.64	NA	NA	10.44	11.09	090
20693		A	Adjust bone fixation device	5.86	NA	NA	10.52	8.57	0.66	NA	NA	17.04	15.09	090
20694		A	Remove bone fixation device	4.16	7.47	6.31	5.40	4.76	0.43	12.06	10.90	9.99	9.35	090
20802		A	Replantation, arm, complete	41.15	NA	NA	22.58	27.17	3.51	NA	NA	67.24	71.83	090
20805		A	Replant, forearm, complete	0.50	NA	NA	39.31	42.01	3.56	NA	NA	43.37	46.07	090
20808		A	Replantation hand, complete	61.65	NA	NA	47.48	51.18	5.46	NA	NA	114.59	118.29	090
20816		A	Replantation digit, complete	30.94	NA	NA	43.71	40.46	3.20	NA	NA	77.85	74.60	090
20822		A	Replantation digit, complete	25.59	NA	NA	34.68	32.36	2.64	NA	NA	62.91	60.59	090
20824		A	Replantation thumb, complete	30.94	NA	NA	41.90	39.10	3.26	NA	NA	76.10	73.30	090
20827		A	Replantation thumb, complete	26.41	NA	NA	39.21	35.93	2.72	NA	NA	68.34	65.06	090
20838		A	Replantation foot, complete	41.41	NA	NA	24.36	28.51	4.99	NA	NA	70.76	74.91	090
20900		A	Removal of bone for graft	5.58	5.46	4.86	5.46	4.86	0.55	11.59	10.99	11.59	10.99	090
20902		A	Removal of bone for graft	7.55	NA	NA	7.80	7.19	0.78	NA	NA	16.13	15.52	090
20910		A	Remove cartilage for graft	5.34	7.05	5.50	6.05	4.75	0.43	12.82	11.27	11.82	10.52	090
20912		A	Remove cartilage for graft	6.35	NA	NA	6.46	6.10	0.55	NA	NA	13.36	13.00	090
20920		A	Removal of fascia for graft	5.31	NA	NA	5.07	4.87	0.51	NA	NA	10.89	10.69	090
20922		A	Removal of fascia for graft	6.61	9.82	8.56	5.79	5.53	0.84	17.27	16.01	13.24	12.98	090
20924		A	Removal of tendon for graft	6.48	NA	NA	6.30	6.20	0.68	NA	NA	13.46	13.36	090
20926		A	Removal of tissue for graft	5.53	NA	NA	5.49	4.82	0.73	NA	NA	11.75	11.08	090
20930		B	Spinal bone allograft	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
20931		A	Spinal bone allograft	1.81	NA	NA	0.95	1.18	0.31	NA	NA	3.07	3.30	ZZZ
20936		B	Spinal bone autograft	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
20937		A	Spinal bone autograft	2.79	NA	NA	1.48	1.83	0.34	NA	NA	4.61	4.96	ZZZ
20938		A	Spinal bone autograft	3.02	NA	NA	1.58	1.97	0.44	NA	NA	5.04	5.43	ZZZ
20950		A	Fluid pressure, muscle	1.26	NA	NA	1.89	1.71	0.13	NA	NA	3.28	3.10	000
20955		A	Fibula bone graft, microvasc	39.21	NA	NA	27.44	30.31	3.88	NA	NA	70.53	73.40	090
20956		A	Iliac bone graft, microvasc	39.27	NA	NA	26.61	27.26	4.68	NA	NA	70.56	71.21	090
20957		A	Mt bone graft, microvasc	40.65	NA	NA	18.71	21.60	4.84	NA	NA	64.20	67.09	090
20962		A	Other bone graft, microvasc	39.27	NA	NA	25.96	26.77	4.28	NA	NA	69.51	70.32	090
20969		A	Bone/skin graft, microvasc	43.92	NA	NA	29.77	33.22	4.12	NA	NA	77.81	81.26	090
20970		A	Bone/skin graft, iliac crest	43.06	NA	NA	28.35	31.93	4.49	NA	NA	75.90	79.48	090
20972		A	Bone/skin graft, metatarsal	42.99	NA	NA	18.95	24.96	3.89	NA	NA	65.83	71.84	090
20973		A	Bone/skin graft, great toe	45.76	NA	NA	27.76	32.28	4.73	NA	NA	78.25	82.77	090
20974		A	Electrical bone stimulation	0.62	0.39	1.22	0.31	1.16	0.04	1.05	1.88	0.97	1.82	000
20975		A	Electrical bone stimulation	2.60	NA	NA	1.38	1.81	0.31	NA	NA	4.29	4.72	000
20979		N	Us bone stimulation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
20999		C	Musculoskeletal surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
21010		A	Incision of jaw joint	10.14	NA	NA	6.91	7.96	0.50	NA	NA	17.55	18.60	090
21015		A	Resection of facial tumor	5.29	NA	NA	6.39	6.37	0.52	NA	NA	12.20	12.18	090
21025		A	Excision of bone, lower jaw	10.06	6.87	6.28	6.28	5.83	0.77	17.70	17.11	17.11	16.66	090
21026		A	Excision of facial bone(s)	4.85	4.92	4.54	4.62	4.32	0.38	10.15	9.77	9.85	9.55	090
21029		A	Contour of face bone lesion	7.71	5.99	6.79	5.61	6.51	0.62	14.32	15.12	13.94	14.84	090
21030		A	Removal of face bone lesion	6.46	5.03	4.68	4.36	4.18	0.47	11.96	11.61	11.29	11.11	090
21031		A	Remove exostosis, mandible	3.24	3.11	3.33	2.04	2.53	0.24	6.59	6.81	5.52	6.01	090
21032		A	Remove exostosis, maxilla	3.24	3.09	3.37	2.13	2.65	0.25	6.58	6.86	5.62	6.14	090
21034		A	Removal of face bone lesion	16.17	9.33	8.89	9.33	8.89	1.32	26.82	26.38	26.82	26.38	090
21040		A	Removal of jaw bone lesion	2.11	2.75	2.81	1.67	2.00	0.16	5.02	5.08	3.94	4.27	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
21041		A	Removal of jaw bone lesion	6.71	5.21	5.47	4.15	4.68	0.49	12.41	12.67	11.35	11.88	090
21044		A	Removal of jaw bone lesion	11.86	NA	NA	7.44	8.17	0.89	NA	NA	20.19	20.92	090
21045		A	Extensive jaw surgery	16.17	NA	NA	9.67	11.01	1.25	NA	NA	27.09	28.43	090
21050		A	Removal of jaw joint	10.77	NA	NA	10.66	11.21	0.74	NA	NA	22.17	22.72	090
21060		A	Remove jaw joint cartilage	10.23	NA	NA	10.05	10.59	0.77	NA	NA	21.05	21.59	090
21070		A	Remove coronoid process	8.20	NA	NA	5.61	6.06	0.71	NA	NA	14.52	14.97	090
21076		A	Prepare face/oral prosthesis	13.42	9.51	11.14	7.16	9.38	0.94	23.87	25.50	21.52	23.74	010
21077		A	Prepare face/oral prosthesis	33.75	23.92	28.02	18.00	23.58	2.44	60.11	64.21	54.19	59.77	090
21079		A	Prepare face/oral prosthesis	22.34	16.90	20.25	12.45	16.92	1.51	40.75	44.10	36.30	40.77	090
21080		A	Prepare face/oral prosthesis	25.10	18.99	22.76	13.99	19.01	1.74	45.83	49.60	40.83	45.85	090
21081		A	Prepare face/oral prosthesis	22.88	17.31	20.74	12.75	17.32	1.60	41.79	45.22	37.23	41.80	090
21082		A	Prepare face/oral prosthesis	20.87	14.79	17.32	11.13	14.58	1.47	37.13	39.66	33.47	36.92	090
21083		A	Prepare face/oral prosthesis	19.30	14.60	17.50	10.76	14.62	1.31	35.21	38.11	31.37	35.23	090
21084		A	Prepare face/oral prosthesis	22.51	17.03	20.41	12.54	17.04	1.61	41.15	44.53	36.66	41.16	090
21085		A	Prepare face/oral prosthesis	0.09	6.38	7.47	4.80	6.29	0.66	7.13	8.22	5.55	7.04	010
21086		A	Prepare face/oral prosthesis	24.92	18.85	22.59	13.89	18.87	1.84	45.61	49.35	40.65	45.63	090
21087		A	Prepare face/oral prosthesis	24.92	17.66	20.68	13.29	17.41	1.81	44.39	47.41	40.02	44.14	090
21088		C	Prepare face/oral prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	090
21089		C	Prepare face/oral prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	090
21100		A	Maxillofacial fixation	4.22	4.63	3.76	3.57	2.97	0.24	9.09	8.22	8.03	7.43	090
21110		A	Interdental fixation	5.21	4.87	5.15	3.78	4.34	0.34	10.42	10.70	9.33	9.89	090
21116		A	Injection, jaw joint x-ray	0.81	6.59	5.14	0.30	0.42	0.05	7.45	6.00	1.16	1.28	000
21120		A	Reconstruction of chin	4.93	10.09	8.54	36	5.00	0.40	15.42	13.87	10.69	10.33	090
21121		A	Reconstruction of chin	7.64	7.18	6.92	5.67	5.79	0.60	15.42	15.16	13.91	14.03	090
21122		A	Reconstruction of chin	8.52	NA	NA	6.54	6.60	0.72	NA	NA	15.78	15.84	090
21123		A	Reconstruction of chin	11.16	NA	NA	8.28	8.42	0.90	NA	NA	20.34	20.48	090
21125		A	Augmentation, lower jaw bone	10.62	7.83	7.15	7.23	6.70	0.81	19.26	18.58	18.66	18.13	090
21127		A	Augmentation, lower jaw bone	11.12	8.80	8.75	6.67	7.15	0.92	20.84	20.79	18.71	19.19	090
21137		A	Reduction of forehead	9.82	NA	NA	7.56	7.60	0.88	NA	NA	18.26	18.30	090
21138		A	Reduction of forehead	12.19	NA	NA	7.64	8.14	1.06	NA	NA	20.89	21.39	090
21139		A	Reduction of forehead	14.61	NA	NA	9.69	10.16	1.27	NA	NA	25.57	26.04	090
21141		A	Reconstruct midface, lefort	18.10	NA	NA	10.87	12.04	1.42	NA	NA	30.39	31.56	090
21142		A	Reconstruct midface, lefort	18.81	NA	NA	12.55	13.44	1.77	NA	NA	33.13	34.02	090
21143		A	Reconstruct midface, lefort	19.58	NA	NA	10.42	11.99	1.21	NA	NA	31.21	32.78	090
21145		A	Reconstruct midface, lefort	19.94	NA	NA	10.50	11.77	1.46	NA	NA	31.90	33.17	090
21146		A	Reconstruct midface, lefort	20.71	NA	NA	10.73	12.08	1.61	NA	NA	33.05	34.40	090
21147		A	Reconstruct midface, lefort	21.77	NA	NA	11.27	12.63	1.53	NA	NA	34.57	35.93	090
21150		A	Reconstruct midface, lefort	25.24	NA	NA	12.53	14.41	1.85	NA	NA	39.62	41.50	090
21151		A	Reconstruct midface, lefort	28.30	NA	NA	18.33	19.36	3.25	NA	NA	49.88	50.91	090
21154		A	Reconstruct midface, lefort	30.52	NA	NA	16.26	18.21	3.14	NA	NA	49.92	51.87	090
21155		A	Reconstruct midface, lefort	34.45	NA	NA	16.97	19.54	3.54	NA	NA	54.96	57.53	090
21159		A	Reconstruct midface, lefort	42.38	NA	NA	24.58	26.85	3.77	NA	NA	70.73	73.00	090
21160		A	Reconstruct midface, lefort	46.44	NA	NA	22.57	26.14	3.51	NA	NA	72.52	76.09	090
21172		A	Reconstruct orbit/forehead	27.80	NA	NA	14.67	16.51	1.92	NA	NA	44.39	46.23	090
21175		A	Reconstruct orbit/forehead	33.17	NA	NA	18.18	20.25	3.75	NA	NA	55.10	57.17	090
21179		A	Reconstruct entire forehead	22.25	NA	NA	16.07	16.46	2.52	NA	NA	40.84	41.23	090
21180		A	Reconstruct entire forehead	25.19	NA	NA	18.29	18.73	2.21	NA	NA	45.69	46.13	090
21181		A	Contour cranial bone lesion	9.90	NA	NA	7.67	7.68	1.04	NA	NA	18.61	18.62	090
21182		A	Reconstruct cranial bone	32.19	NA	NA	21.35	22.42	2.77	NA	NA	56.31	57.38	090
21183		A	Reconstruct cranial bone	35.31	NA	NA	20.50	22.39	3.14	NA	NA	58.95	60.84	090
21184		A	Reconstruct cranial bone	38.24	NA	NA	23.46	25.21	6.52	NA	NA	68.22	69.97	090
21188		A	Reconstruction of midface	22.46	NA	NA	14.77	15.48	1.87	NA	NA	39.10	39.81	090
21193		A	Reconstruct lower jaw bone	17.15	NA	NA	10.11	10.92	1.42	NA	NA	28.68	29.49	090
21194		A	Reconstruct lower jaw bone	19.84	NA	NA	11.79	12.71	1.64	NA	NA	33.27	34.19	090
21195		A	Reconstruct lower jaw bone	17.24	NA	NA	11.58	12.03	1.34	NA	NA	30.16	30.61	090
21196		A	Reconstruct lower jaw bone	18.91	NA	NA	12.33	12.94	1.50	NA	NA	32.74	33.35	090
21198		A	Reconstruct lower jaw bone	14.16	NA	NA	10.93	12.22	1.03	NA	NA	26.12	27.41	090
21206		A	Reconstruct upper jaw bone	14.10	NA	NA	9.40	9.80	1.02	NA	NA	24.52	24.92	090
21208		A	Augmentation of facial bones	10.23	8.98	9.79	7.88	8.96	0.79	20.00	20.81	18.90	19.98	090
21209		A	Reduction of facial bones	6.72	6.89	6.41	5.19	5.14	0.55	14.16	13.68	12.46	12.41	090
21210		A	Face bone graft	10.23	8.24	9.23	7.69	8.82	0.75	19.22	20.21	18.67	19.80	090
21215		A	Lower jaw bone graft	10.77	8.20	9.37	6.51	8.10	0.78	19.75	20.92	18.06	19.65	090
21230		A	Rib cartilage graft	10.77	NA	NA	9.26	9.76	0.96	NA	NA	20.99	21.49	090
21235		A	Ear cartilage graft	6.72	10.51	9.89	7.24	7.44	0.53	17.76	17.14	14.49	14.69	090
21240		A	Reconstruction of jaw joint	14.05	NA	NA	11.16	12.57	1.09	NA	NA	26.30	27.71	090
21242		A	Reconstruction of jaw joint	12.95	NA	NA	11.56	12.54	1.09	NA	NA	25.60	26.58	090
21243		A	Reconstruction of jaw joint	20.79	NA	NA	13.46	14.00	1.53	NA	NA	35.78	36.32	090
21244		A	Reconstruction of lower jaw	11.86	NA	NA	8.38	9.83	0.95	NA	NA	21.19	22.64	090
21245		A	Reconstruction of jaw	11.86	9.40	10.16	9.40	10.16	0.91	22.17	22.93	22.17	22.93	090
21246		A	Reconstruction of jaw	12.47	9.52	9.54	9.52	9.54	0.96	22.95	22.97	22.95	22.97	090
21247		A	Reconstruct lower jaw bone	22.63	NA	NA	15.57	18.43	1.62	NA	NA	39.82	42.68	090
21248		A	Reconstruction of jaw	11.48	8.26	9.62	7.35	8.94	0.85	20.59	21.95	19.68	21.27	090
21249		A	Reconstruction of jaw	17.52	10.88	13.39	9.72	12.52	1.33	29.73	32.24	28.57	31.37	090
21255		A	Reconstruct lower jaw bone	16.72	NA	NA	9.49	12.11	1.66	NA	NA	27.87	30.49	090
21256		A	Reconstruction of orbit	16.19	NA	NA	12.52	14.22	1.38	NA	NA	30.09	31.79	090
21260		A	Revise eye sockets	16.52	NA	NA	9.95	12.39	0.67	NA	NA	27.14	29.58	090
21261		A	Revise eye sockets	31.49	NA	NA	19.07	19.13	2.38	NA	NA	52.94	53.00	090
21263		A	Revise eye sockets	28.42	NA	NA	14.51	19.37	1.12	NA	NA	44.05	48.91	090
21267		A	Revise eye sockets	18.90	NA	NA	14.03	14.49	1.12	NA	NA	34.05	34.51	090
21268		A	Revise eye sockets	24.48	NA	NA	14.81	15.27	3.89	NA	NA	43.18	43.64	090
21270		A	Augmentation, cheek bone	10.23	7.86	8.50	7.86	8.50	0.89	18.98	19.62	18.98	19.62	090
21275		A	Revision, orbitofacial bones	11.24	NA	NA	9.88	9.84	1.05	NA	NA	22.17	22.13	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
21280		A	Revision of eyelid	6.03	NA	NA	5.99	6.29	0.29	NA	NA	12.31	12.61	090
21282		A	Revision of eyelid	3.49	NA	NA	4.96	4.76	0.20	NA	NA	8.65	8.45	090
21295		A	Revision of jaw muscle/bone	1.53	NA	NA	4.26	3.46	0.11	NA	NA	5.90	5.10	090
21296		A	Revision of jaw muscle/bone	4.25	NA	NA	4.31	4.22	0.35	NA	NA	8.91	8.82	090
21299		C	Cranio/maxillofacial surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
21300		A	Treatment of skull fracture	0.72	2.35	2.01	0.28	0.46	0.08	3.15	2.81	1.08	1.26	000
21310		A	Treatment of nose fracture	0.58	2.28	1.91	0.16	0.32	0.06	2.92	2.55	0.80	0.96	000
21315		A	Treatment of nose fracture	1.51	2.88	2.65	1.15	1.35	0.12	4.51	4.28	2.78	2.98	010
21320		A	Treatment of nose fracture	1.85	4.06	3.68	1.87	2.04	0.14	6.05	5.67	3.86	4.03	010
21325		A	Treatment of nose fracture	3.77	NA	NA	3.39	3.65	0.31	NA	NA	7.47	7.73	090
21330		A	Treatment of nose fracture	5.38	NA	NA	5.02	5.37	0.47	NA	NA	10.87	11.22	090
21335		A	Treatment of nose fracture	8.61	NA	NA	6.57	7.50	0.65	NA	NA	15.83	16.76	090
21336		A	Treat nasal septal fracture	5.72	NA	NA	4.95	4.82	0.47	NA	NA	11.14	11.01	090
21337		A	Treat nasal septal fracture	2.70	4.90	4.44	2.92	2.96	0.23	7.83	7.37	5.85	5.89	090
21338		A	Treat nasoethmoid fracture	6.46	NA	NA	5.95	5.82	0.53	NA	NA	12.94	12.81	090
21339		A	Treat nasoethmoid fracture	8.09	NA	NA	6.31	6.66	0.65	NA	NA	15.05	15.40	090
21340		A	Treatment of nose fracture	10.77	NA	NA	9.24	9.35	0.69	NA	NA	20.70	20.81	090
21343		A	Treatment of sinus fracture	12.95	NA	NA	9.34	9.49	1.20	NA	NA	23.49	23.64	090
21344		A	Treatment of sinus fracture	19.72	NA	NA	12.80	12.09	1.78	NA	NA	34.30	33.59	090
21345		A	Treat nose/jaw fracture	8.16	7.45	7.73	7.41	7.70	0.64	16.25	16.53	16.21	16.50	090
21346		A	Treat nose/jaw fracture	10.61	NA	NA	8.90	9.23	0.83	NA	NA	20.34	20.67	090
21347		A	Treat nose/jaw fracture	12.69	NA	NA	9.02	9.58	1.08	NA	NA	22.79	23.35	090
21348		A	Treat nose/jaw fracture	16.69	NA	NA	9.60	10.28	1.44	NA	NA	27.73	28.41	090
21355		A	Treat cheek bone fracture	3.77	3.49	3.04	2.04	1.95	0.32	7.58	7.13	6.13	6.04	010
21356		A	Treat cheek bone fracture	4.15	NA	NA	3.02	3.51	0.34	NA	NA	7.51	8.00	010
21360		A	Treat cheek bone fracture	6.46	NA	NA	5.24	5.86	0.52	NA	NA	12.22	12.84	090
21365		A	Treat cheek bone fracture	14.95	NA	NA	10.72	11.39	1.28	NA	NA	26.95	27.62	090
21366		A	Treat cheek bone fracture	17.77	NA	NA	11.76	12.10	1.52	NA	NA	31.05	31.39	090
21385		A	Treat eye socket fracture	9.16	NA	NA	6.79	7.70	0.67	NA	NA	16.62	17.53	090
21386		A	Treat eye socket fracture	9.16	NA	NA	7.48	8.07	0.75	NA	NA	17.39	17.98	090
21387		A	Treat eye socket fracture	9.70	NA	NA	7.82	7.89	0.78	NA	NA	18.30	18.37	090
21390		A	Treat eye socket fracture	10.13	NA	NA	8.15	9.14	0.74	NA	NA	19.02	20.01	090
21395		A	Treat eye socket fracture	12.68	NA	NA	9.36	9.63	1.16	NA	NA	23.20	23.47	090
21400		A	Treat eye socket fracture	1.40	2.87	2.61	0.92	1.14	0.12	4.39	4.13	2.44	2.66	090
21401		A	Treat eye socket fracture	3.26	4.25	3.89	2.99	2.94	0.25	7.76	7.40	6.50	6.45	090
21406		A	Treat eye socket fracture	7.01	NA	NA	5.96	5.88	0.60	NA	NA	13.57	13.49	090
21407		A	Treat eye socket fracture	8.61	NA	NA	7.39	7.47	0.70	NA	NA	16.70	16.78	090
21408		A	Treat eye socket fracture	12.38	NA	NA	10.01	9.81	1.21	NA	NA	23.60	23.40	090
21421		A	Treat mouth roof fracture	5.14	6.39	6.46	5.27	5.62	0.38	11.91	11.98	10.79	11.14	090
21422		A	Treat mouth roof fracture	8.32	NA	NA	7.00	7.73	0.69	NA	NA	16.01	16.74	090
21423		A	Treat mouth roof fracture	10.40	NA	NA	7.66	8.41	0.82	NA	NA	18.88	19.63	090
21431		A	Treat craniofacial fracture	7.05	NA	NA	5.51	5.77	0.54	NA	NA	13.10	13.36	090
21432		A	Treat craniofacial fracture	8.61	NA	NA	7.63	7.56	0.94	NA	NA	17.18	17.11	090
21433		A	Treat craniofacial fracture	25.35	NA	NA	15.99	16.87	2.11	NA	NA	43.45	44.33	090
21435		A	Treat craniofacial fracture	17.25	NA	NA	12.27	12.80	1.36	NA	NA	30.88	31.41	090
21436		A	Treat craniofacial fracture	28.04	NA	NA	17.76	17.30	1.88	NA	NA	47.68	47.22	090
21440		A	Treat dental ridge fracture	2.70	5.00	4.58	3.20	3.23	0.20	7.90	7.48	6.10	6.13	090
21445		A	Treat dental ridge fracture	5.38	6.14	6.26	4.89	5.33	0.42	11.94	12.06	10.69	11.13	090
21450		A	Treat lower jaw fracture	2.97	5.56	4.94	2.21	2.43	0.23	8.76	8.14	5.41	5.63	090
21451		A	Treat lower jaw fracture	4.87	5.91	6.02	4.91	5.27	0.37	11.15	11.26	10.15	10.51	090
21452		A	Treat lower jaw fracture	1.98	7.04	5.66	3.86	3.27	0.15	9.17	7.79	5.99	5.40	090
21453		A	Treat lower jaw fracture	5.54	6.56	6.72	5.62	6.02	0.44	12.54	12.70	11.60	12.00	090
21454		A	Treat lower jaw fracture	6.46	NA	NA	5.14	5.79	0.48	NA	NA	12.08	12.73	090
21461		A	Treat lower jaw fracture	8.09	8.05	8.45	7.27	7.87	0.65	16.79	17.19	16.01	16.61	090
21462		A	Treat lower jaw fracture	9.79	8.97	9.65	7.50	8.55	0.76	19.52	20.20	18.05	19.10	090
21465		A	Treat lower jaw fracture	11.91	NA	NA	7.31	7.77	0.95	NA	NA	20.17	20.63	090
21470		A	Treat lower jaw fracture	15.34	NA	NA	9.27	11.53	1.21	NA	NA	25.82	28.08	090
21480		A	Reset dislocated jaw	0.61	1.47	1.32	0.18	0.35	0.05	2.13	1.98	0.84	1.01	000
21485		A	Reset dislocated jaw	3.99	3.51	3.23	3.01	2.85	0.27	7.77	7.49	7.27	7.11	090
21490		A	Repair dislocated jaw	11.86	NA	NA	7.14	7.07	0.84	NA	NA	19.84	19.77	090
21493		A	Treat hyoid bone fracture	1.27	NA	NA	2.96	2.63	0.10	NA	NA	4.33	4.00	090
21494		A	Treat hyoid bone fracture	6.28	NA	NA	4.95	5.75	0.45	NA	NA	11.68	12.48	090
21495		A	Treat hyoid bone fracture	5.69	NA	NA	5.11	5.14	0.41	NA	NA	11.21	11.24	090
21497		A	Interdental wiring	3.86	4.17	4.21	3.45	3.67	0.30	8.33	8.37	7.61	7.83	090
21499		C	Head surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
21501		A	Drain neck/chest lesion	3.81	3.83	3.37	3.38	3.03	0.37	8.01	7.55	7.56	7.21	090
21502		A	Drain chest lesion	7.12	NA	NA	7.34	6.65	0.78	NA	NA	15.24	14.55	090
21510		A	Drainage of bone lesion	5.74	NA	NA	7.54	6.69	0.63	NA	NA	13.91	13.06	090
21550		A	Biopsy of neck/chest	2.06	2.16	1.85	1.24	1.16	0.12	4.34	4.03	3.42	3.34	010
21555		A	Remove lesion, neck/chest	4.35	4.09	3.50	2.48	2.30	0.39	8.83	8.24	7.22	7.04	090
21556		A	Remove lesion, neck/chest	5.57	NA	NA	3.20	3.43	0.52	NA	NA	9.29	9.52	090
21557		A	Remove tumor, neck/chest	8.88	NA	NA	7.42	7.87	0.81	NA	NA	17.11	17.56	090
21600		A	Partial removal of rib	6.89	NA	NA	8.46	7.57	0.79	NA	NA	16.14	15.25	090
21610		A	Partial removal of rib	14.61	NA	NA	10.21	9.06	1.99	NA	NA	26.81	25.66	090
21615		A	Removal of rib	9.87	NA	NA	8.99	9.49	1.30	NA	NA	20.16	20.66	090
21616		A	Removal of rib and nerves	12.04	NA	NA	12.12	11.06	1.45	NA	NA	25.61	24.55	090
21620		A	Partial removal of sternum	6.79	NA	NA	8.80	8.46	0.78	NA	NA	16.37	16.03	090
21627		A	Sternal debridement	6.81	NA	NA	14.79	12.46	0.84	NA	NA	22.44	20.11	090
21630		A	Extensive sternum surgery	17.38	NA	NA	13.86	13.89	1.95	NA	NA	33.19	33.22	090
21632		A	Extensive sternum surgery	18.14	NA	NA	15.27	14.58	2.27	NA	NA	35.68	34.99	090
21700		A	Revision of neck muscle	6.19	7.62	6.84	7.24	6.56	0.74	14.55	13.77	14.17	13.49	090
21705		A	Revision of neck muscle/rib	9.60	NA	NA	6.97	6.54	1.27	NA	NA	17.84	17.41	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
21720		A	Revision of neck muscle	5.68	6.76	6.11	6.06	5.59	0.82	13.26	12.61	12.56	12.09	090
21725		A	Revision of neck muscle	6.99	NA	NA	6.21	5.97	0.68	NA	NA	13.88	13.64	090
21740		A	Reconstruction of sternum	16.80	NA	NA	15.15	13.80	1.95	NA	NA	33.90	32.55	090
21750		A	Repair of sternum separation	10.77	NA	NA	13.25	11.93	1.35	NA	NA	25.37	24.05	090
21800		A	Treatment of rib fracture	0.96	1.80	1.56	0.79	0.80	0.09	2.85	2.61	1.84	1.85	090
21805		A	Treatment of rib fracture	2.75	NA	NA	6.10	4.94	0.29	NA	NA	9.14	7.98	090
21810		A	Treatment of rib fracture(s)	6.86	NA	NA	7.31	7.47	0.56	NA	NA	14.73	14.89	090
21820		A	Treat sternum fracture	1.28	2.18	2.01	1.14	1.23	0.12	3.58	3.41	2.54	2.63	090
21825		A	Treat sternum fracture	7.41	NA	NA	11.97	10.85	0.95	NA	NA	20.33	19.21	090
21899		C	Neck/chest surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
21920		A	Biopsy soft tissue of back	2.06	2.26	1.91	0.81	0.82	0.10	4.42	4.07	2.97	2.98	010
21925		A	Biopsy soft tissue of back	4.49	10.40	8.33	4.30	3.76	0.43	15.32	13.25	9.22	8.68	090
21930		A	Remove lesion, back or flank	0.05	4.41	4.05	2.66	2.73	0.47	4.93	4.57	3.18	3.25	090
21935		A	Remove tumor, back	17.96	NA	NA	11.85	10.68	1.79	NA	NA	31.60	30.43	090
22100		A	Remove part of neck vertebra	9.73	NA	NA	8.02	8.09	1.34	NA	NA	19.09	19.16	090
22101		A	Remove part, thorax vertebra	9.81	NA	NA	8.02	8.19	1.23	NA	NA	19.06	19.23	090
22102		A	Remove part, lumbar vertebra	9.81	NA	NA	8.21	7.38	1.37	NA	NA	19.39	18.56	090
22103		A	Remove extra spine segment	2.34	NA	NA	1.21	1.51	0.33	NA	NA	3.88	4.18	ZZZ
22110		A	Remove part of neck vertebra	12.74	NA	NA	10.11	10.22	1.88	NA	NA	24.73	24.84	090
22112		A	Remove part, thorax vertebra	12.81	NA	NA	10.01	10.19	1.57	NA	NA	24.39	24.57	090
22114		A	Remove part, lumbar vertebra	12.81	NA	NA	9.71	9.25	1.37	NA	NA	23.89	23.43	090
22116		A	Remove extra spine segment	2.32	NA	NA	1.18	1.49	0.32	NA	NA	3.82	4.13	ZZZ
22210		A	Revision of neck spine	23.82	NA	NA	15.82	15.62	3.46	NA	NA	43.10	42.90	090
22212		A	Revision of thorax spine	19.42	NA	NA	14.23	15.36	1.99	NA	NA	35.64	36.77	090
22214		A	Revision of lumbar spine	19.45	NA	NA	13.92	14.54	2.35	NA	NA	35.72	36.34	090
22216		A	Revise, extra spine segment	6.04	NA	NA	3.18	3.76	0.81	NA	NA	10.03	10.61	ZZZ
22220		A	Revision of neck spine	21.37	NA	NA	14.41	15.32	3.15	NA	NA	38.93	39.84	090
22222		A	Revision of thorax spine	21.52	NA	NA	13.17	13.57	1.01	NA	NA	35.70	36.10	090
22224		A	Revision of lumbar spine	21.52	NA	NA	14.80	15.08	2.43	NA	NA	38.75	39.03	090
22226		A	Revise, extra spine segment	6.04	NA	NA	3.14	3.73	0.73	NA	NA	9.91	10.50	ZZZ
22305		A	Treat spine process fracture	2.05	2.74	2.67	1.69	1.88	0.21	5.00	4.93	3.95	4.14	090
22310		A	Treat spine fracture	2.61	3.91	3.62	2.98	2.92	0.27	6.79	6.50	5.86	5.80	090
22315		A	Treat spine fracture	8.84	NA	NA	8.43	7.82	1.14	NA	NA	18.41	17.80	090
22318		A	Treat odontoid fx w/o graft	21.50	NA	NA	14.06	14.06	3.89	NA	NA	39.45	39.45	090
22319		A	Treat odontoid fx w/graft	0.24	NA	NA	16.20	16.20	4.34	NA	NA	20.78	20.78	090
22325		A	Treat spine fracture	18.30	NA	NA	13.71	12.54	2.29	NA	NA	34.30	33.13	090
22326		A	Treat neck spine fracture	19.59	NA	NA	14.47	15.18	3.18	NA	NA	37.24	37.95	090
22327		A	Treat thorax spine fracture	19.20	NA	NA	14.25	15.02	2.64	NA	NA	36.09	36.86	090
22328		A	Treat each add spine fx	4.61	NA	NA	2.40	3.00	0.68	NA	NA	7.69	8.29	ZZZ
22505		A	Manipulation of spine	1.87	3.92	3.30	2.67	2.36	0.13	5.92	5.30	4.67	4.36	010
22548		A	Neck spine fusion	25.82	NA	NA	17.04	18.95	4.66	NA	NA	47.52	49.43	090
22554		A	Neck spine fusion	18.62	NA	NA	12.91	15.06	3.14	NA	NA	34.67	36.82	090
22556		A	Thorax spine fusion	23.46	NA	NA	16.15	18.00	3.20	NA	NA	42.81	44.66	090
22558		A	Lumbar spine fusion	22.28	NA	NA	14.70	16.50	2.62	NA	NA	39.60	41.40	090
22585		A	Additional spinal fusion	5.53	NA	NA	2.86	3.61	0.85	NA	NA	9.24	9.99	ZZZ
22590		A	Spine & skull spinal fusion	20.51	NA	NA	14.50	16.73	3.38	NA	NA	38.39	40.62	090
22595		A	Neck spinal fusion	19.39	NA	NA	13.54	15.94	3.23	NA	NA	36.16	38.56	090
22600		A	Neck spine fusion	16.14	NA	NA	11.95	13.78	2.53	NA	NA	30.62	32.45	090
22610		A	Thorax spine fusion	16.02	NA	NA	11.94	13.74	2.22	NA	NA	30.18	31.98	090
22612		A	Lumbar spine fusion	0.21	NA	NA	14.60	16.54	2.62	NA	NA	17.43	19.37	090
22614		A	Spine fusion, extra segment	6.44	NA	NA	3.43	4.11	0.82	NA	NA	10.69	11.37	ZZZ
22630		A	Lumbar spine fusion	20.84	NA	NA	14.78	16.09	3.05	NA	NA	38.67	39.98	090
22632		A	Spine fusion, extra segment	5.23	NA	NA	2.75	3.42	0.72	NA	NA	8.70	9.37	ZZZ
22800		A	Fusion of spine	18.25	NA	NA	12.94	15.15	2.09	NA	NA	33.28	35.49	090
22802		A	Fusion of spine	30.88	NA	NA	20.27	22.89	3.38	NA	NA	54.53	57.15	090
22804		A	Fusion of spine	36.27	NA	NA	23.15	25.05	3.82	NA	NA	63.24	65.14	090
22808		A	Fusion of spine	26.27	NA	NA	17.62	18.21	3.79	NA	NA	47.68	48.27	090
22810		A	Fusion of spine	30.27	NA	NA	19.42	19.56	3.51	NA	NA	53.20	53.34	090
22812		A	Fusion of spine	32.70	NA	NA	20.84	22.67	3.60	NA	NA	57.14	58.97	090
22818		A	Kyphectomy, 1–2 segments	31.83	NA	NA	19.46	22.26	4.31	NA	NA	55.60	58.40	090
22819		A	Kyphectomy, 3 or more	36.44	NA	NA	21.62	23.88	4.93	NA	NA	62.99	65.25	090
22830		A	Exploration of spinal fusion	10.85	NA	NA	9.03	10.01	1.31	NA	NA	21.19	22.17	090
22840		A	Insert spine fixation device	12.54	NA	NA	7.83	7.50	1.61	NA	NA	21.98	21.65	ZZZ
22841		B	Insert spine fixation device	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
22842		A	Insert spine fixation device	12.58	NA	NA	6.66	6.86	1.63	NA	NA	20.87	21.07	ZZZ
22843		A	Insert spine fixation device	13.46	NA	NA	7.13	7.67	1.64	NA	NA	22.23	22.77	ZZZ
22844		A	Insert spine fixation device	16.44	NA	NA	10.23	10.51	1.76	NA	NA	28.43	28.71	ZZZ
22845		A	Insert spine fixation device	11.96	NA	NA	7.53	7.20	1.95	NA	NA	21.44	21.11	ZZZ
22846		A	Insert spine fixation device	12.42	NA	NA	7.82	8.01	0.02	NA	NA	20.26	20.45	ZZZ
22847		A	Insert spine fixation device	13.80	NA	NA	8.46	8.73	1.63	NA	NA	23.89	24.16	ZZZ
22848		A	Insert pelv fixation device	0.06	NA	NA	4.50	4.93	0.64	NA	NA	5.20	5.63	ZZZ
22849		A	Reinsert spinal fixation	18.51	NA	NA	12.98	12.93	2.25	NA	NA	33.74	33.69	090
22850		A	Remove spine fixation device	9.52	NA	NA	7.91	8.42	1.19	NA	NA	18.62	19.13	090
22851		A	Apply spine prosth device	6.71	NA	NA	4.78	5.32	0.93	NA	NA	12.42	12.96	ZZZ
22852		A	Remove spine fixation device	9.01	NA	NA	7.70	8.44	1.09	NA	NA	17.80	18.54	090
22855		A	Remove spine fixation device	15.13	NA	NA	10.71	10.06	2.35	NA	NA	28.19	27.54	090
22899		C	Spine surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
22900		A	Remove abdominal wall lesion	5.80	NA	NA	4.20	3.97	0.57	NA	NA	10.57	10.34	090
22999		C	Abdomen surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
23000		A	Removal of calcium deposits	4.36	7.21	6.29	6.05	5.42	0.40	11.97	11.05	10.81	10.18	090
23020		A	Release shoulder joint	8.93	NA	NA	9.25	8.91	0.93	NA	NA	19.11	18.77	090
23030		A	Drain shoulder lesion	3.43	5.16	4.46	3.87	3.49	0.33	8.92	8.22	7.63	7.25	010

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
23031		A	Drain shoulder bursa	2.74	5.07	3.94	3.59	2.83	0.26	8.07	6.94	6.59	5.83	010
23035		A	Drain shoulder bone lesion	8.61	NA	NA	13.34	11.69	0.88	NA	NA	22.83	21.18	090
23040		A	Exploratory shoulder surgery	9.20	NA	NA	10.17	10.14	0.95	NA	NA	20.32	20.29	090
23044		A	Exploratory shoulder surgery	7.12	NA	NA	8.88	8.54	0.74	NA	NA	16.74	16.40	090
23065		A	Biopsy shoulder tissues	2.27	2.51	2.06	1.35	1.19	0.11	4.89	4.44	3.73	3.57	010
23066		A	Biopsy shoulder tissues	4.16	6.46	5.17	5.60	4.52	0.41	11.03	9.74	10.17	9.09	090
23075		A	Removal of shoulder lesion	2.39	4.55	3.87	2.82	2.57	0.23	7.17	6.49	5.44	5.19	010
23076		A	Removal of shoulder lesion	7.63	NA	NA	7.40	6.51	0.78	NA	NA	15.81	14.92	090
23077		A	Remove tumor of shoulder	16.09	NA	NA	12.87	11.66	1.58	NA	NA	30.54	29.33	090
23100		A	Biopsy of shoulder joint	6.03	NA	NA	7.77	7.63	0.60	NA	NA	14.40	14.26	090
23101		A	Shoulder joint surgery	5.58	NA	NA	7.56	7.34	0.57	NA	NA	13.71	13.49	090
23105		A	Remove shoulder joint lining	8.23	NA	NA	8.88	9.12	0.85	NA	NA	17.96	18.20	090
23106		A	Incision of collarbone joint	5.96	NA	NA	7.72	7.08	0.64	NA	NA	14.32	13.68	090
23107		A	Explore treat shoulder joint	8.62	NA	NA	9.11	9.41	0.88	NA	NA	18.61	18.91	090
23120		A	Partial removal, collar bone	7.11	NA	NA	8.29	7.47	0.73	NA	NA	16.13	15.31	090
23125		A	Removal of collar bone	9.39	NA	NA	9.53	9.45	0.97	NA	NA	19.89	19.81	090
23130		A	Remove shoulder bone, part	7.55	NA	NA	8.46	8.26	0.77	NA	NA	16.78	16.58	090
23140		A	Removal of bone lesion	6.89	NA	NA	7.59	6.82	0.68	NA	NA	15.16	14.39	090
23145		A	Removal of bone lesion	9.09	NA	NA	9.27	9.16	0.84	NA	NA	19.20	19.09	090
23146		A	Removal of bone lesion	7.83	NA	NA	9.24	8.35	0.82	NA	NA	17.89	17.00	090
23150		A	Removal of humerus lesion	8.48	NA	NA	8.56	8.22	0.85	NA	NA	17.89	17.55	090
23155		A	Removal of humerus lesion	10.35	NA	NA	11.00	10.64	1.08	NA	NA	22.43	22.07	090
23156		A	Removal of humerus lesion	8.68	NA	NA	8.91	8.76	0.89	NA	NA	18.48	18.33	090
23170		A	Remove collar bone lesion	6.86	NA	NA	9.29	8.27	0.72	NA	NA	16.87	15.85	090
23172		A	Remove shoulder blade lesion	6.90	NA	NA	8.46	7.75	0.72	NA	NA	16.08	15.37	090
23174		A	Remove humerus lesion	9.51	NA	NA	10.19	9.96	0.94	NA	NA	20.64	20.41	090
23180		A	Remove collar bone lesion	8.53	NA	NA	13.76	11.49	0.88	NA	NA	23.17	20.90	090
23182		A	Remove shoulder blade lesion	8.15	NA	NA	15.56	13.45	0.84	NA	NA	24.55	22.44	090
23184		A	Remove humerus lesion	9.38	NA	NA	13.89	12.81	0.95	NA	NA	24.22	23.14	090
23190		A	Partial removal of scapula	7.24	NA	NA	7.41	7.21	0.74	NA	NA	15.39	15.19	090
23195		A	Removal of head of humerus	9.81	NA	NA	9.72	9.71	1.02	NA	NA	20.55	20.54	090
23200		A	Removal of collar bone	12.08	NA	NA	13.47	12.59	1.22	NA	NA	26.77	25.89	090
23210		A	Removal of shoulder blade	12.49	NA	NA	12.91	2.13	1.25	NA	NA	26.65	25.87	090
23220		A	Partial removal of humerus	14.56	NA	NA	13.24	13.20	1.47	NA	NA	29.27	29.23	090
23221		A	Partial removal of humerus	17.74	NA	NA	13.30	14.90	1.26	NA	NA	32.30	33.90	090
23222		A	Partial removal of humerus	23.92	NA	NA	18.68	18.09	2.43	NA	NA	45.03	44.44	090
23330		A	Remove shoulder foreign body	1.85	4.49	3.52	3.23	2.57	0.18	6.52	5.55	5.26	4.60	010
23331		A	Remove shoulder foreign body	7.38	NA	NA	8.38	6.90	0.76	NA	NA	16.52	15.04	090
23332		A	Remove shoulder foreign body	11.62	NA	NA	10.68	10.65	1.19	NA	NA	23.49	23.46	090
23350		A	Injection for shoulder x-ray	0.01	9.23	7.06	0.35	0.40	0.04	9.28	7.11	0.40	0.45	000
23395		A	Muscle transfer,shoulder/arm	16.85	NA	NA	12.97	12.75	1.74	NA	NA	31.56	31.34	090
23397		A	Muscle transfers	16.13	NA	NA	13.20	13.69	1.68	NA	NA	31.01	31.50	090
23400		A	Fixation of shoulder blade	13.54	NA	NA	12.60	12.12	1.42	NA	NA	27.56	27.08	090
23405		A	Incision of tendon & muscle	8.37	NA	NA	9.54	9.19	0.86	NA	NA	18.77	18.42	090
23406		A	Incise tendon(s) & muscle(s)	10.79	NA	NA	10.12	10.14	1.13	NA	NA	22.04	22.06	090
23410		A	Repair of tendon(s)	12.45	NA	NA	11.14	11.32	1.27	NA	NA	24.86	25.04	090
23412		A	Repair of tendon(s)	13.31	NA	NA	11.64	12.36	1.36	NA	NA	26.31	27.03	090
23415		A	Release of shoulder ligament	9.97	NA	NA	9.04	8.19	1.02	NA	NA	20.03	19.18	090
23420		A	Repair of shoulder	13.30	NA	NA	12.33	13.22	1.36	NA	NA	26.99	27.88	090
23430		A	Repair biceps tendon	9.98	NA	NA	9.86	9.39	1.02	NA	NA	20.86	20.39	090
23440		A	Remove/transplant tendon	10.48	NA	NA	10.08	9.51	1.08	NA	NA	21.64	21.07	090
23450		A	Repair shoulder capsule	13.40	NA	NA	11.50	12.09	1.37	NA	NA	26.27	26.86	090
23455		A	Repair shoulder capsule	14.37	NA	NA	12.18	13.36	1.47	NA	NA	28.02	29.20	090
23460		A	Repair shoulder capsule	15.37	NA	NA	12.93	13.52	1.56	NA	NA	29.86	30.45	090
23462		A	Repair shoulder capsule	15.30	NA	NA	12.51	13.49	1.50	NA	NA	29.31	30.29	090
23465		A	Repair shoulder capsule	15.85	NA	NA	13.04	13.62	1.63	NA	NA	30.52	31.10	090
23466		A	Repair shoulder capsule	14.22	NA	NA	12.07	13.30	1.47	NA	NA	27.76	28.99	090
23470		A	Reconstruct shoulder joint	17.15	NA	NA	13.68	14.81	1.76	NA	NA	32.59	33.72	090
23472		A	Reconstruct shoulder joint	16.92	NA	NA	13.56	15.22	1.74	NA	NA	32.22	33.88	090
23480		A	Revision of collar bone	11.18	NA	NA	10.44	9.62	1.16	NA	NA	22.78	21.96	090
23485		A	Revision of collar bone	13.43	NA	NA	11.62	11.80	1.37	NA	NA	26.42	26.60	090
23490		A	Reinforce clavicle	11.86	NA	NA	10.42	10.52	1.24	NA	NA	23.52	23.62	090
23491		A	Reinforce shoulder bones	14.21	NA	NA	11.99	12.44	1.48	NA	NA	27.68	28.13	090
23500		A	Treat clavicle fracture	2.08	3.25	2.89	1.98	1.93	0.21	5.54	5.18	4.27	4.22	090
23505		A	Treat clavicle fracture	3.69	5.01	4.46	3.42	3.26	0.37	9.07	8.52	7.48	7.32	090
23515		A	Treat clavicle fracture	7.41	NA	NA	7.20	7.28	0.76	NA	NA	15.37	15.45	090
23520		A	Treat clavicle dislocation	2.16	3.36	2.90	2.24	2.06	0.21	5.73	5.27	4.61	4.43	090
23525		A	Treat clavicle dislocation	3.60	4.33	3.79	3.22	2.95	0.37	8.30	7.76	7.19	6.92	090
23530		A	Treat clavicle dislocation	7.31	NA	NA	6.84	6.92	0.74	NA	NA	14.89	14.97	090
23532		A	Treat clavicle dislocation	8.01	NA	NA	7.06	7.26	0.84	NA	NA	15.91	16.11	090
23540		A	Treat clavicle dislocation	2.23	3.76	3.24	1.95	1.88	0.21	6.20	5.68	4.39	4.32	090
23545		A	Treat clavicle dislocation	3.25	4.21	3.70	3.06	2.83	0.32	7.78	7.27	6.63	6.40	090
23550		A	Treat clavicle dislocation	7.24	NA	NA	7.13	7.51	0.73	NA	NA	15.10	15.48	090
23552		A	Treat clavicle dislocation	8.45	NA	NA	7.82	7.84	0.84	NA	NA	17.11	17.13	090
23570		A	Treat shoulder blade fx	2.23	3.27	2.91	2.24	2.14	0.23	5.73	5.37	4.70	4.60	090
23575		A	Treat shoulder blade fx	4.06	5.31	4.73	3.84	3.63	0.41	9.78	9.20	8.31	8.10	090
23585		A	Treat scapula fracture	8.96	NA	NA	8.31	8.32	0.92	NA	NA	18.19	18.20	090
23600		A	Treat humerus fracture	2.93	5.05	4.58	3.13	3.14	0.30	8.28	7.81	6.36	6.37	090
23605		A	Treat humerus fracture	4.87	7.53	6.94	5.92	5.73	0.51	12.91	12.32	11.30	11.11	090
23615		A	Treat humerus fracture	9.35	NA	NA	8.98	9.53	0.96	NA	NA	19.29	19.84	090
23616		A	Treat humerus fracture	21.27	NA	NA	14.89	17.22	2.19	NA	NA	38.35	40.68	090
23620		A	Treat humerus fracture	2.40	4.75	4.35	2.84	2.91	0.25	7.40	7.00	5.49	5.56	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
23625		A	Treat humerus fracture	3.93	6.64	6.02	4.91	4.72	0.41	10.98	10.36	9.25	9.06	090
23630		A	Treat humerus fracture	7.35	NA	NA	7.19	7.59	0.75	NA	NA	15.29	15.69	090
23650		A	Treat shoulder dislocation	3.39	4.63	4.04	2.59	2.51	0.32	8.34	7.75	6.30	6.22	090
23655		A	Treat shoulder dislocation	4.57	NA	NA	3.53	3.44	0.46	NA	NA	8.56	8.47	090
23660		A	Treat shoulder dislocation	7.49	NA	NA	6.92	7.43	0.69	NA	NA	15.10	15.61	090
23665		A	Treat dislocation/fracture	4.47	6.69	5.93	5.19	4.80	0.46	11.62	10.86	10.12	9.73	090
23670		A	Treat dislocation/fracture	7.90	NA	NA	7.60	8.06	0.81	NA	NA	16.31	16.77	090
23675		A	Treat dislocation/fracture	6.05	7.64	6.80	6.07	5.62	0.62	14.31	13.47	12.74	12.29	090
23680		A	Treat dislocation/fracture	10.06	NA	NA	8.81	9.61	1.03	NA	NA	19.90	20.70	090
23700		A	Fixation of shoulder	2.52	NA	NA	3.01	2.83	0.26	NA	NA	5.79	5.61	010
23800		A	Fusion of shoulder joint	14.16	NA	NA	12.61	13.69	1.41	NA	NA	28.18	29.26	090
23802		A	Fusion of shoulder joint	16.60	NA	NA	10.43	11.64	1.70	NA	NA	28.73	29.94	090
23900		A	Amputation of arm & girdle	19.72	NA	NA	14.47	14.26	1.86	NA	NA	36.05	35.84	090
23920		A	Amputation at shoulder joint	14.61	NA	NA	12.09	12.83	1.52	NA	NA	28.22	28.96	090
23921		A	Amputation follow-up surgery	5.49	6.18	5.79	6.17	5.79	0.50	12.17	11.78	12.16	11.78	090
23929		C	Shoulder surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
23930		A	Drainage of arm lesion	2.94	4.99	4.18	3.53	3.09	0.29	8.22	7.41	6.76	6.32	010
23931		A	Drainage of arm bursa	1.79	4.71	3.74	3.09	2.52	0.17	6.67	5.70	5.05	4.48	010
23935		A	Drain arm/elbow bone lesion	6.09	NA	NA	10.72	9.31	0.62	NA	NA	17.43	16.02	090
24000		A	Exploratory elbow surgery	5.82	NA	NA	5.39	5.78	0.58	NA	NA	11.79	12.18	090
24006		A	Release elbow joint	9.31	NA	NA	7.69	7.71	0.96	NA	NA	17.96	17.98	090
24065		A	Biopsy arm/elbow soft tissue	2.08	4.92	3.91	2.84	2.35	0.11	7.11	6.10	5.03	4.54	010
24066		A	Biopsy arm/elbow soft tissue	5.21	7.51	6.37	5.97	5.21	0.55	13.27	12.13	11.73	10.97	090
24075		A	Remove arm/elbow lesion	3.92	6.99	5.78	5.32	4.53	0.38	11.29	10.08	9.62	8.83	090
24076		A	Remove arm/elbow lesion	6.30	NA	NA	6.39	5.79	0.64	NA	NA	13.33	12.73	090
24077		A	Remove tumor of arm/elbow	11.76	NA	NA	12.18	11.79	1.17	NA	NA	25.11	24.72	090
24100		A	Biopsy elbow joint lining	4.93	NA	NA	5.70	5.42	0.46	NA	NA	11.09	10.81	090
24101		A	Explore/treat elbow joint	6.13	NA	NA	6.01	6.34	0.63	NA	NA	12.77	13.10	090
24102		A	Remove elbow joint lining	8.03	NA	NA	7.06	7.69	0.83	NA	NA	15.92	16.55	090
24105		A	Removal of elbow bursa	3.61	NA	NA	4.48	4.38	0.37	NA	NA	8.46	8.36	090
24110		A	Remove humerus lesion	7.39	NA	NA	8.52	8.48	0.78	NA	NA	16.69	16.65	090
24115		A	Remove/graft bone lesion	9.63	NA	NA	9.29	9.05	0.85	NA	NA	19.77	19.53	090
24116		A	Remove/graft bone lesion	11.81	NA	NA	10.82	10.75	1.20	NA	NA	23.83	23.76	090
24120		A	Remove elbow lesion	6.65	NA	NA	6.03	6.16	0.68	NA	NA	13.36	13.49	090
24125		A	Remove/graft bone lesion	7.89	NA	NA	6.68	6.58	0.76	NA	NA	15.33	15.23	090
24126		A	Remove/graft bone lesion	8.31	NA	NA	7.03	7.28	0.87	NA	NA	16.21	16.46	090
24130		A	Removal of head of radius	6.25	NA	NA	6.08	6.38	0.65	NA	NA	12.98	13.28	090
24134		A	Removal of arm bone lesion	9.73	NA	NA	13.90	12.78	0.94	NA	NA	24.57	23.45	090
24136		A	Remove radius bone lesion	7.99	NA	NA	5.71	6.67	0.80	NA	NA	14.50	15.46	090
24138		A	Remove elbow bone lesion	8.05	NA	NA	7.08	7.04	0.84	NA	NA	15.97	15.93	090
24140		A	Partial removal of arm bone	9.18	NA	NA	14.49	13.25	0.95	NA	NA	24.62	23.38	090
24145		A	Partial removal of radius	7.58	NA	NA	9.69	9.00	0.77	NA	NA	18.04	17.35	090
24147		A	Partial removal of elbow	7.54	NA	NA	9.78	9.13	0.80	NA	NA	18.12	17.47	090
24149		A	Radical resection of elbow	14.20	NA	NA	10.47	11.28	1.46	NA	NA	26.13	26.94	090
24150		A	Extensive humerus surgery	13.27	NA	NA	13.12	13.66	1.34	NA	NA	27.73	28.27	090
24151		A	Extensive humerus surgery	15.58	NA	NA	13.96	14.22	1.50	NA	NA	31.04	31.30	090
24152		A	Extensive radius surgery	10.06	NA	NA	8.75	8.41	0.95	NA	NA	19.76	19.42	090
24153		A	Extensive radius surgery	11.54	NA	NA	6.76	7.90	0.67	NA	NA	18.97	20.11	090
24155		A	Removal of elbow joint	11.73	NA	NA	8.75	9.48	1.18	NA	NA	21.66	22.39	090
24160		A	Remove elbow joint implant	7.83	NA	NA	6.94	6.52	0.78	NA	NA	15.55	15.13	090
24164		A	Remove radius head implant	6.23	NA	NA	6.05	6.04	0.65	NA	NA	12.93	12.92	090
24200		A	Removal of arm foreign body	1.76	4.50	3.53	2.68	2.16	0.14	6.40	5.43	4.58	4.06	010
24201		A	Removal of arm foreign body	4.56	7.24	6.26	5.90	5.26	0.48	12.28	11.30	10.94	10.30	090
24220		A	Injection for elbow x-ray	1.31	10.07	7.69	0.46	0.48	0.07	11.45	9.07	1.84	1.86	000
24301		A	Muscle/tendon transfer	10.20	NA	NA	8.30	8.37	1.04	NA	NA	19.54	19.61	090
24305		A	Arm tendon lengthening	7.45	NA	NA	6.79	5.93	0.75	NA	NA	14.99	14.13	090
24310		A	Revision of arm tendon	5.98	NA	NA	7.11	6.13	0.63	NA	NA	13.72	12.74	090
24320		A	Repair of arm tendon	10.56	NA	NA	8.99	9.24	0.98	NA	NA	20.53	20.78	090
24330		A	Revision of arm muscles	9.60	NA	NA	7.94	8.33	1.03	NA	NA	18.57	18.96	090
24331		A	Revision of arm muscles	10.65	NA	NA	8.36	8.88	1.11	NA	NA	20.12	20.64	090
24340		A	Repair of biceps tendon	7.89	NA	NA	6.92	7.09	0.81	NA	NA	15.62	15.79	090
24341		A	Repair arm tendon/muscle	7.90	NA	NA	6.92	7.09	0.82	NA	NA	15.64	15.81	090
24342		A	Repair of ruptured tendon	10.62	NA	NA	8.47	9.17	1.10	NA	NA	20.19	20.89	090
24350		A	Repair of tennis elbow	5.25	NA	NA	5.42	5.21	0.54	NA	NA	11.21	11.00	090
24351		A	Repair of tennis elbow	5.91	NA	NA	5.92	5.68	0.62	NA	NA	12.45	12.21	090
24352		A	Repair of tennis elbow	6.43	NA	NA	6.28	6.26	0.66	NA	NA	13.37	13.35	090
24354		A	Repair of tennis elbow	6.48	NA	NA	6.15	6.14	0.68	NA	NA	13.31	13.30	090
24356		A	Revision of tennis elbow	6.68	NA	NA	6.36	6.75	0.70	NA	NA	13.74	14.13	090
24360		A	Reconstruct elbow joint	12.34	NA	NA	9.30	10.66	1.27	NA	NA	22.91	24.27	090
24361		A	Reconstruct elbow joint	14.08	NA	NA	10.11	11.15	1.46	NA	NA	25.65	26.69	090
24362		A	Reconstruct elbow joint	14.99	NA	NA	10.56	11.49	1.34	NA	NA	26.89	27.82	090
24363		A	Replace elbow joint	18.49	NA	NA	12.70	15.04	1.91	NA	NA	33.10	35.44	090
24365		A	Reconstruct head of radius	8.39	NA	NA	7.30	7.52	0.87	NA	NA	16.56	16.78	090
24366		A	Reconstruct head of radius	9.13	NA	NA	7.66	8.47	0.95	NA	NA	17.74	18.55	090
24400		A	Revision of humerus	11.06	NA	NA	11.09	10.61	1.13	NA	NA	23.28	22.80	090
24410		A	Revision of humerus	14.82	NA	NA	12.58	13.25	1.37	NA	NA	28.77	29.44	090
24420		A	Revision of humerus	13.44	NA	NA	15.22	14.75	1.36	NA	NA	30.02	29.55	090
24430		A	Repair of humerus	12.81	NA	NA	11.39	12.37	1.32	NA	NA	25.52	26.50	090
24435		A	Repair humerus with graft	13.17	NA	NA	12.30	13.16	1.36	NA	NA	26.83	27.69	090
24470		A	Revision of elbow joint	8.74	NA	NA	7.50	7.78	0.92	NA	NA	17.16	17.44	090
24495		A	Decompression of forearm	8.12	NA	NA	9.76	8.88	0.91	NA	NA	18.79	17.91	090
24498		A	Reinforce humerus	11.92	NA	NA	11.03	11.09	1.23	NA	NA	24.18	24.24	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
24500		A	Treat humerus fracture	3.21	4.58	4.13	2.80	2.79	0.32	8.11	7.66	6.33	6.32	090
24505		A	Treat humerus fracture	5.17	8.00	7.22	6.14	5.83	0.53	13.70	12.92	11.84	11.53	090
24515		A	Treat humerus fracture	11.65	NA	NA	10.15	10.23	1.16	NA	NA	22.96	23.04	090
24516		A	Treat humerus fracture	11.65	NA	NA	10.54	10.52	1.20	NA	NA	23.39	23.37	090
24530		A	Treat humerus fracture	3.50	5.56	4.91	4.12	3.83	0.35	9.41	8.76	7.97	7.68	090
24535		A	Treat humerus fracture	6.87	8.06	7.36	6.18	5.95	0.72	15.65	14.95	13.77	13.54	090
24538		A	Treat humerus fracture	9.43	NA	NA	9.30	9.14	0.96	NA	NA	19.69	19.53	090
24545		A	Treat humerus fracture	10.46	NA	NA	9.07	9.51	1.08	NA	NA	20.61	21.05	090
24546		A	Treat humerus fracture	15.69	NA	NA	12.32	11.95	1.62	NA	NA	29.63	29.26	090
24560		A	Treat humerus fracture	2.80	4.38	3.87	2.51	2.47	0.28	7.46	6.95	5.59	5.55	090
24565		A	Treat humerus fracture	5.56	6.97	6.16	5.29	4.90	0.57	13.10	12.29	11.42	11.03	090
24566		A	Treat humerus fracture	7.79	NA	NA	8.61	8.10	0.78	NA	NA	17.18	16.67	090
24575		A	Treat humerus fracture	10.66	NA	NA	7.58	7.80	1.10	NA	NA	19.34	19.56	090
24576		A	Treat humerus fracture	2.86	4.16	3.71	2.79	2.68	0.29	7.31	6.86	5.94	5.83	090
24577		A	Treat humerus fracture	5.79	7.36	6.61	5.60	5.29	0.60	13.75	13.00	11.99	11.68	090
24579		A	Treat humerus fracture	11.60	NA	NA	9.20	9.17	1.19	NA	NA	21.99	21.96	090
24582		A	Treat humerus fracture	8.55	NA	NA	9.11	8.63	0.88	NA	NA	18.54	18.06	090
24586		A	Treat elbow fracture	15.21	NA	NA	10.30	11.72	1.56	NA	NA	27.07	28.49	090
24587		A	Treat elbow fracture	15.16	NA	NA	10.15	11.34	1.46	NA	NA	26.77	27.96	090
24600		A	Treat elbow dislocation	4.23	6.17	5.16	4.11	3.61	0.42	10.82	9.81	8.76	8.26	090
24605		A	Treat elbow dislocation	5.42	NA	NA	4.37	3.90	0.56	NA	NA	10.35	9.88	090
24615		A	Treat elbow dislocation	9.42	NA	NA	7.21	7.93	0.98	NA	NA	17.61	18.33	090
24620		A	Treat elbow fracture	6.98	NA	NA	5.96	5.50	0.70	NA	NA	13.64	13.18	090
24635		A	Treat elbow fracture	13.19	NA	NA	14.41	13.81	1.37	NA	NA	28.97	28.37	090
24640		A	Treat elbow dislocation	1.20	2.98	2.51	1.33	1.27	0.11	4.29	3.82	2.64	2.58	010
24650		A	Treat radius fracture	2.16	4.07	3.66	2.31	2.34	0.22	6.45	6.04	4.69	4.72	090
24655		A	Treat radius fracture	4.40	6.56	5.74	4.70	4.34	0.45	11.41	10.59	9.55	9.19	090
24665		A	Treat radius fracture	8.14	NA	NA	8.26	8.13	0.84	NA	NA	17.24	17.11	090
24666		A	Treat radius fracture	9.49	NA	NA	9.03	9.56	0.98	NA	NA	19.50	20.03	090
24670		A	Treat ulnar fracture	2.54	4.01	3.54	2.60	2.48	0.26	6.81	6.34	5.40	5.28	090
24675		A	Treat ulnar fracture	4.72	6.71	5.99	5.01	4.71	0.49	11.92	11.20	10.22	9.92	090
24685		A	Treat ulnar fracture	8.80	NA	NA	8.61	8.74	0.91	NA	NA	18.32	18.45	090
24800		A	Fusion of elbow joint	11.20	NA	NA	8.79	9.47	1.13	NA	NA	21.12	21.80	090
24802		A	Fusion/graft of elbow joint	13.69	NA	NA	10.59	11.25	1.37	NA	NA	25.65	26.31	090
24900		A	Amputation of upper arm	9.60	NA	NA	9.51	9.22	0.01	NA	NA	19.12	18.83	090
24920		A	Amputation of upper arm	9.54	NA	NA	10.71	9.87	0.95	NA	NA	21.20	20.36	090
24925		A	Amputation follow-up surgery	7.07	NA	NA	7.99	7.69	0.71	NA	NA	15.77	15.47	090
24930		A	Amputation follow-up surgery	10.25	NA	NA	10.57	10.14	0.99	NA	NA	21.81	21.38	090
24931		A	Amputate upper arm & implant	12.72	NA	NA	8.32	9.27	1.29	NA	NA	22.33	23.28	090
24935		A	Revision of amputation	15.56	NA	NA	11.27	12.17	1.58	NA	NA	28.41	29.31	090
24940		C	Revision of upper arm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	090
24999		C	Upper arm/elbow surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
25000		A	Incision of tendon sheath	3.38	NA	NA	6.31	5.74	0.35	NA	NA	10.04	9.47	090
25020		A	Decompression of forearm	5.92	NA	NA	9.90	8.61	0.66	NA	NA	16.48	15.19	090
25023		A	Decompression of forearm	12.96	NA	NA	15.26	12.92	1.34	NA	NA	29.56	27.22	090
25028		A	Drainage of forearm lesion	5.25	NA	NA	9.03	7.33	0.53	NA	NA	14.81	13.11	090
25031		A	Drainage of forearm bursa	4.14	NA	NA	8.88	6.84	0.36	NA	NA	13.38	11.34	090
25035		A	Treat forearm bone lesion	7.36	NA	NA	14.13	12.31	0.74	NA	NA	22.23	20.41	090
25040		A	Explore/treat wrist joint	7.18	NA	NA	8.10	7.62	0.74	NA	NA	16.02	15.54	090
25065		A	Biopsy forearm soft tissues	1.99	2.38	1.99	2.38	1.99	0.10	4.47	4.08	4.47	4.08	010
25066		A	Biopsy forearm soft tissues	4.13	NA	NA	7.02	5.68	0.42	NA	NA	11.57	10.23	090
25075		A	Removal of forearm lesion	3.74	NA	NA	6.64	5.58	0.36	NA	NA	10.74	9.68	090
25076		A	Removal of forearm lesion	4.92	NA	NA	11.14	9.38	0.51	NA	NA	16.57	14.81	090
25077		A	Remove tumor, forearm/wrist	9.76	NA	NA	13.92	12.74	0.97	NA	NA	24.65	23.47	090
25085		A	Incision of wrist capsule	5.50	NA	NA	9.05	8.04	0.57	NA	NA	15.12	14.11	090
25100		A	Biopsy of wrist joint	3.90	NA	NA	6.23	5.84	0.41	NA	NA	10.54	10.15	090
25101		A	Explore/treat wrist joint	4.69	NA	NA	6.87	6.55	0.49	NA	NA	12.05	11.73	090
25105		A	Remove wrist joint lining	5.85	NA	NA	9.39	8.79	0.60	NA	NA	15.84	15.24	090
25107		A	Remove wrist joint cartilage	6.43	NA	NA	9.68	8.69	0.67	NA	NA	16.78	15.79	090
25110		A	Remove wrist tendon lesion	3.92	NA	NA	7.29	6.23	0.39	NA	NA	11.60	10.54	090
25111		A	Remove wrist tendon lesion	3.39	NA	NA	5.61	5.08	0.34	NA	NA	9.34	8.81	090
25112		A	Reremove wrist tendon lesion	4.53	NA	NA	6.48	5.87	0.47	NA	NA	11.48	10.87	090
25115		A	Remove wrist/forearm lesion	8.82	NA	NA	14.82	13.05	0.92	NA	NA	24.56	22.79	090
25116		A	Remove wrist/forearm lesion	7.11	NA	NA	13.57	12.30	0.74	NA	NA	21.42	20.15	090
25118		A	Excise wrist tendon sheath	4.37	NA	NA	6.82	6.42	0.46	NA	NA	11.65	11.25	090
25119		A	Partial removal of ulna	6.04	NA	NA	9.52	8.94	0.62	NA	NA	16.18	15.60	090
25120		A	Removal of forearm lesion	6.10	NA	NA	13.04	11.55	0.64	NA	NA	19.78	18.29	090
25125		A	Remove/graft forearm lesion	7.48	NA	NA	13.71	12.14	0.77	NA	NA	21.96	20.39	090
25126		A	Remove/graft forearm lesion	7.55	NA	NA	12.31	11.08	0.77	NA	NA	20.63	19.40	090
25130		A	Removal of wrist lesion	5.26	NA	NA	7.11	6.48	0.54	NA	NA	12.91	12.28	090
25135		A	Remove & graft wrist lesion	6.89	NA	NA	7.85	7.37	0.73	NA	NA	15.47	14.99	090
25136		A	Remove & graft wrist lesion	5.97	NA	NA	6.73	6.33	0.62	NA	NA	13.32	12.92	090
25145		A	Remove forearm bone lesion	6.37	NA	NA	13.10	11.44	0.66	NA	NA	20.13	18.47	090
25150		A	Partial removal of ulna	7.09	NA	NA	10.39	9.60	0.72	NA	NA	18.20	17.41	090
25151		A	Partial removal of radius	7.39	NA	NA	13.68	11.82	0.77	NA	NA	21.84	19.98	090
25170		A	Extensive forearm surgery	11.09	NA	NA	15.34	14.16	1.16	NA	NA	27.59	26.41	090
25210		A	Removal of wrist bone	5.95	NA	NA	7.52	6.97	0.62	NA	NA	14.09	13.54	090
25215		A	Removal of wrist bones	7.89	NA	NA	10.54	10.26	0.81	NA	NA	19.24	18.96	090
25230		A	Partial removal of radius	5.23	NA	NA	6.97	6.74	0.53	NA	NA	12.73	12.50	090
25240		A	Partial removal of ulna	5.17	NA	NA	9.08	8.25	0.53	NA	NA	14.78	13.95	090
25246		A	Injection for wrist x-ray	1.45	9.41	7.19	0.51	0.52	0.06	10.92	8.70	2.02	2.03	000
25248		A	Remove forearm foreign body	5.14	NA	NA	9.35	7.61	0.51	NA	NA	15.00	13.26	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
25250		A	Removal of wrist prosthesis	6.60	NA	NA	7.76	7.35	0.68	NA	NA	15.04	14.63	090
25251		A	Removal of wrist prosthesis	9.57	NA	NA	11.62	10.95	0.98	NA	NA	22.17	21.50	090
25260		A	Repair forearm tendon/muscle	7.80	NA	NA	14.75	12.31	0.81	NA	NA	23.36	20.92	090
25263		A	Repair forearm tendon/muscle	7.82	NA	NA	15.68	13.33	0.81	NA	NA	24.31	21.96	090
25265		A	Repair forearm tendon/muscle	9.88	NA	NA	15.12	13.49	1.02	NA	NA	26.02	24.39	090
25270		A	Repair forearm tendon/muscle	0.06	NA	NA	13.71	11.20	0.62	NA	NA	14.39	11.88	090
25272		A	Repair forearm tendon/muscle	7.04	NA	NA	14.21	11.59	0.74	NA	NA	21.99	19.37	090
25274		A	Repair forearm tendon/muscle	8.75	NA	NA	14.57	12.72	0.91	NA	NA	24.23	22.38	090
25280		A	Revise wrist/forearm tendon	7.22	NA	NA	13.53	11.29	0.74	NA	NA	21.49	19.25	090
25290		A	Incise wrist/forearm tendon	5.29	NA	NA	15.56	12.34	0.55	NA	NA	21.40	18.18	090
25295		A	Release wrist/forearm tendon	6.55	NA	NA	13.48	10.94	0.68	NA	NA	20.71	18.17	090
25300		A	Fusion of tendons at wrist	8.80	NA	NA	8.84	8.63	0.87	NA	NA	18.51	18.30	090
25301		A	Fusion of tendons at wrist	8.40	NA	NA	8.59	8.28	0.83	NA	NA	17.82	17.51	090
25310		A	Transplant forearm tendon	8.14	NA	NA	13.96	12.41	0.84	NA	NA	22.94	21.39	090
25312		A	Transplant forearm tendon	9.57	NA	NA	14.54	12.98	0.98	NA	NA	25.09	23.53	090
25315		A	Revise palsy hand tendon(s)	10.20	NA	NA	15.39	13.73	1.10	NA	NA	26.69	25.03	090
25316		A	Revise palsy hand tendon(s)	12.33	NA	NA	17.72	16.16	1.23	NA	NA	31.28	29.72	090
25320		A	Repair/revise wrist joint	10.77	NA	NA	10.08	9.89	1.11	NA	NA	21.96	21.77	090
25332		A	Revise wrist joint	11.41	NA	NA	10.55	10.62	1.16	NA	NA	23.12	23.19	090
25335		A	Realignment of hand	12.88	NA	NA	12.61	12.55	1.36	NA	NA	26.85	26.79	090
25337		A	Reconstruct ulna/radioulnar	10.17	NA	NA	11.84	11.21	1.06	NA	NA	23.07	22.44	090
25350		A	Revision of radius	8.78	NA	NA	14.38	12.85	0.91	NA	NA	24.07	22.54	090
25355		A	Revision of radius	10.17	NA	NA	14.58	13.41	1.05	NA	NA	25.80	24.63	090
25360		A	Revision of ulna	8.43	NA	NA	14.20	12.39	0.90	NA	NA	23.53	21.72	090
25365		A	Revise radius & ulna	12.40	NA	NA	15.38	14.33	1.20	NA	NA	28.98	27.93	090
25370		A	Revise radius or ulna	13.36	NA	NA	13.22	13.11	1.30	NA	NA	27.88	27.77	090
25375		A	Revise radius & ulna	13.04	NA	NA	15.79	15.47	1.27	NA	NA	30.10	29.78	090
25390		A	Shorten radius or ulna	10.40	NA	NA	15.26	13.84	1.07	NA	NA	26.73	25.31	090
25391		A	Lengthen radius or ulna	13.65	NA	NA	17.57	16.23	1.42	NA	NA	32.64	31.30	090
25392		A	Shorten radius & ulna	13.95	NA	NA	15.11	14.71	1.46	NA	NA	30.52	30.12	090
25393		A	Lengthen radius & ulna	15.87	NA	NA	17.48	16.97	1.62	NA	NA	34.97	34.46	090
25400		A	Repair radius or ulna	10.92	NA	NA	15.57	14.60	1.13	NA	NA	27.62	26.65	090
25405		A	Repair/graft radius or ulna	14.38	NA	NA	17.81	16.73	1.48	NA	NA	33.67	32.59	090
25415		A	Repair radius & ulna	13.35	NA	NA	16.86	15.74	1.39	NA	NA	31.60	30.48	090
25420		A	Repair/graft radius & ulna	16.33	NA	NA	18.39	17.78	1.69	NA	NA	36.41	35.80	090
25425		A	Repair/graft radius or ulna	13.21	NA	NA	23.60	20.96	1.33	NA	NA	38.14	35.50	090
25426		A	Repair/graft radius & ulna	15.82	NA	NA	18.25	16.87	1.33	NA	NA	35.40	34.02	090
25440		A	Repair/graft wrist bone	10.44	NA	NA	9.94	9.91	1.09	NA	NA	21.47	21.44	090
25441		A	Reconstruct wrist joint	12.90	NA	NA	11.18	11.47	1.35	NA	NA	25.43	25.72	090
25442		A	Reconstruct wrist joint	10.85	NA	NA	10.12	9.51	1.13	NA	NA	22.10	21.49	090
25443		A	Reconstruct wrist joint	10.39	NA	NA	11.43	11.12	1.09	NA	NA	22.91	22.60	090
25444		A	Reconstruct wrist joint	11.15	NA	NA	11.68	11.51	1.16	NA	NA	23.99	23.82	090
25445		A	Reconstruct wrist joint	9.69	NA	NA	11.68	11.57	0.01	NA	NA	21.38	21.27	090
25446		A	Wrist replacement	16.55	NA	NA	13.37	14.97	1.70	NA	NA	31.62	33.22	090
25447		A	Repair wrist joint(s)	10.37	NA	NA	9.93	10.07	1.07	NA	NA	21.37	21.51	090
25449		A	Remove wrist joint implant	14.49	NA	NA	14.15	12.74	1.50	NA	NA	30.14	28.73	090
25450		A	Revision of wrist joint	7.87	NA	NA	12.13	11.08	0.65	NA	NA	20.65	19.60	090
25455		A	Revision of wrist joint	9.49	NA	NA	10.71	10.40	0.72	NA	NA	20.92	20.61	090
25490		A	Reinforce radius	9.54	NA	NA	13.69	12.63	0.99	NA	NA	24.22	23.16	090
25491		A	Reinforce ulna	9.96	NA	NA	14.89	13.64	1.04	NA	NA	25.89	24.64	090
25492		A	Reinforce radius and ulna	12.33	NA	NA	13.65	13.28	1.29	NA	NA	27.27	26.90	090
25500		A	Treat fracture of radius	2.45	3.72	3.42	2.31	2.37	0.23	6.40	6.10	4.99	5.05	090
25505		A	Treat fracture of radius	5.21	6.95	6.18	5.06	4.76	0.53	12.69	11.92	10.80	10.50	090
25515		A	Treat fracture of radius	9.18	NA	NA	8.77	8.65	0.86	NA	NA	18.81	18.69	090
25520		A	Treat fracture of radius	6.26	7.20	6.96	5.77	5.89	0.64	14.10	13.86	12.67	12.79	090
25525		A	Treat fracture of radius	12.24	NA	NA	10.45	10.86	1.28	NA	NA	23.97	24.38	090
25526		A	Treat fracture of radius	12.98	NA	NA	13.57	13.39	1.34	NA	NA	27.89	27.71	090
25530		A	Treat fracture of ulna	2.09	3.73	3.46	2.38	2.45	0.21	6.03	5.76	4.68	4.75	090
25535		A	Treat fracture of ulna	5.14	6.75	6.03	5.19	4.86	0.51	12.40	11.68	10.84	10.51	090
25545		A	Treat fracture of ulna	8.90	NA	NA	8.68	8.57	0.92	NA	NA	18.50	18.39	090
25560		A	Treat fracture radius & ulna	2.44	3.76	3.44	2.24	2.30	0.23	6.43	6.11	4.91	4.97	090
25565		A	Treat fracture radius & ulna	5.63	7.23	6.69	5.24	5.20	0.57	13.43	12.89	11.44	11.40	090
25574		A	Treat fracture radius & ulna	7.01	NA	NA	7.62	7.81	0.73	NA	NA	15.36	15.55	090
25575		A	Treat fracture radius/ulna	10.45	NA	NA	9.50	10.03	1.08	NA	NA	21.03	21.56	090
25600		A	Treat fracture radius/ulna	2.63	4.06	3.82	2.50	2.65	0.27	6.96	6.72	5.40	5.55	090
25605		A	Treat fracture radius/ulna	5.81	7.43	6.65	5.58	5.26	0.60	13.84	13.06	11.99	11.67	090
25611		A	Treat fracture radius/ulna	7.77	NA	NA	8.73	8.18	0.80	NA	NA	17.30	16.75	090
25620		A	Treat fracture radius/ulna	8.55	NA	NA	8.32	8.18	0.88	NA	NA	17.75	17.61	090
25622		A	Treat wrist bone fracture	2.61	4.01	3.63	2.44	2.45	0.27	6.89	6.51	5.32	5.33	090
25624		A	Treat wrist bone fracture	4.53	6.71	6.03	4.70	4.52	0.47	11.71	11.03	9.70	9.52	090
25628		A	Treat wrist bone fracture	8.43	NA	NA	8.42	8.25	0.89	NA	NA	17.74	17.57	090
25630		A	Treat wrist bone fracture	2.88	4.17	3.72	2.44	2.43	0.29	7.34	6.89	5.61	5.60	090
25635		A	Treat wrist bone fracture	4.39	6.59	5.86	4.42	4.23	0.45	11.43	10.70	9.26	9.07	090
25645		A	Treat wrist bone fracture	7.25	NA	NA	7.67	7.57	0.75	NA	NA	15.67	15.57	090
25650		A	Treat wrist bone fracture	3.05	4.16	3.84	2.59	2.67	0.31	7.52	7.20	5.95	6.03	090
25660		A	Treat wrist dislocation	4.76	NA	NA	4.48	3.86	0.48	NA	NA	9.72	9.10	090
25670		A	Treat wrist dislocation	7.92	NA	NA	8.33	8.17	0.82	NA	NA	17.07	16.91	090
25675		A	Treat wrist dislocation	4.67	6.25	5.31	4.56	4.04	0.47	11.39	10.45	9.70	9.18	090
25676		A	Treat wrist dislocation	8.04	NA	NA	8.36	8.26	0.81	NA	NA	17.21	17.11	090
25680		A	Treat wrist fracture	5.99	NA	NA	5.67	4.92	0.53	NA	NA	12.19	11.44	090
25685		A	Treat wrist fracture	9.78	NA	NA	9.16	9.26	0.98	NA	NA	19.92	20.02	090
25690		A	Treat wrist dislocation	5.50	NA	NA	6.22	5.99	0.56	NA	NA	12.28	12.05	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
25695		A	Treat wrist dislocation	8.34	NA	NA	8.42	8.23	0.87	NA	NA	17.63	17.44	090
25800		A	Fusion of wrist joint	9.76	NA	NA	9.55	10.08	0.01	NA	NA	19.32	19.85	090
25805		A	Fusion/graft of wrist joint	11.28	NA	NA	10.41	11.18	1.17	NA	NA	22.86	23.63	090
25810		A	Fusion/graft of wrist joint	10.57	NA	NA	9.98	10.64	1.08	NA	NA	21.63	22.29	090
25820		A	Fusion of hand bones	7.45	NA	NA	8.42	8.54	0.74	NA	NA	16.61	16.73	090
25825		A	Fuse hand bones with graft	9.27	NA	NA	9.25	9.71	0.95	NA	NA	19.47	19.93	090
25830		A	Fusion, radioulnar jnt/ulna	10.06	NA	NA	14.63	13.31	1.03	NA	NA	25.72	24.40	090
25900		A	Amputation of forearm	9.01	NA	NA	12.78	11.51	0.95	NA	NA	22.74	21.47	090
25905		A	Amputation of forearm	9.12	NA	NA	14.20	12.58	0.95	NA	NA	24.27	22.65	090
25907		A	Amputation follow-up surgery	7.80	NA	NA	14.07	12.11	0.82	NA	NA	22.69	20.73	090
25909		A	Amputation follow-up surgery	8.96	NA	NA	13.79	11.85	0.96	NA	NA	23.71	21.77	090
25915		A	Amputation of forearm	17.08	NA	NA	14.03	14.82	1.83	NA	NA	32.94	33.73	090
25920		A	Amputate hand at wrist	8.68	NA	NA	8.72	8.44	0.92	NA	NA	18.32	18.04	090
25922		A	Amputate hand at wrist	7.42	NA	NA	8.81	8.11	0.77	NA	NA	17.00	16.30	090
25924		A	Amputation follow-up surgery	8.46	NA	NA	9.23	8.96	0.61	NA	NA	18.30	18.03	090
25927		A	Amputation of hand	8.80	NA	NA	12.32	10.95	0.93	NA	NA	22.05	20.68	090
25929		A	Amputation follow-up surgery	7.59	NA	NA	7.83	7.16	0.76	NA	NA	16.18	15.51	090
25931		A	Amputation follow-up surgery	7.81	NA	NA	13.10	11.06	0.79	NA	NA	21.70	19.66	090
25999		C	Forearm or wrist surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
26010		A	Drainage of finger abscess	1.54	4.47	3.48	3.06	2.43	0.12	6.13	5.14	4.72	4.09	010
26011		A	Drainage of finger abscess	2.19	6.18	5.05	5.27	4.37	0.22	8.59	7.46	7.68	6.78	010
26020		A	Drain hand tendon sheath	4.67	NA	NA	10.75	9.07	0.49	NA	NA	15.91	14.23	090
26025		A	Drainage of palm bursa	4.82	NA	NA	10.69	9.24	0.50	NA	NA	16.01	14.56	090
26030		A	Drainage of palm bursa(s)	5.93	NA	NA	11.55	10.22	0.62	NA	NA	18.10	16.77	090
26034		A	Treat hand bone lesion	6.23	NA	NA	12.79	10.74	0.64	NA	NA	19.66	17.61	090
26035		A	Decompress fingers/hand	9.51	NA	NA	14.74	12.46	0.97	NA	NA	25.22	22.94	090
26037		A	Decompress fingers/hand	7.25	NA	NA	11.30	10.20	0.75	NA	NA	19.30	18.20	090
26040		A	Release palm contracture	3.33	NA	NA	10.46	8.62	0.34	NA	NA	14.13	12.29	090
26045		A	Release palm contracture	5.56	NA	NA	11.77	10.14	0.57	NA	NA	17.90	16.27	090
26055		A	Incise finger tendon sheath	2.69	6.79	5.98	6.46	5.74	0.28	9.76	8.95	9.43	8.71	090
26060		A	Incision of finger tendon	2.81	NA	NA	6.76	5.38	0.30	NA	NA	9.87	8.49	090
26070		A	Explore/treat hand joint	3.69	NA	NA	9.24	7.68	0.32	NA	NA	13.25	11.69	090
26075		A	Explore/treat finger joint	3.79	NA	NA	10.07	8.58	0.35	NA	NA	14.21	12.72	090
26080		A	Explore/treat finger joint	4.24	NA	NA	10.91	9.04	0.43	NA	NA	15.58	13.71	090
26100		A	Biopsy hand joint lining	3.67	NA	NA	7.50	6.44	0.36	NA	NA	11.53	10.47	090
26105		A	Biopsy finger joint lining	3.71	NA	NA	10.99	9.38	0.38	NA	NA	15.08	13.47	090
26110		A	Biopsy finger joint lining	3.53	NA	NA	10.26	8.49	0.36	NA	NA	14.15	12.38	090
26115		A	Removal of hand lesion	3.86	6.64	5.53	6.64	5.53	0.39	10.89	9.78	10.89	9.78	090
26116		A	Removal of hand lesion	5.53	NA	NA	11.69	9.78	0.57	NA	NA	17.79	15.88	090
26117		A	Remove tumor, hand/finger	8.55	NA	NA	13.40	11.43	0.88	NA	NA	22.83	20.86	090
26121		A	Release palm contracture	7.54	NA	NA	13.48	12.36	0.78	NA	NA	21.80	20.68	090
26123		A	Release palm contracture	9.29	NA	NA	14.43	13.29	0.97	NA	NA	24.69	23.55	090
26125		A	Release palm contracture	4.61	NA	NA	2.51	2.59	0.49	NA	NA	7.61	7.69	ZZZ
26130		A	Remove wrist joint lining	5.42	NA	NA	13.13	11.21	0.56	NA	NA	19.11	17.19	090
26135		A	Revise finger joint, each	6.96	NA	NA	14.52	12.21	0.73	NA	NA	22.21	19.90	090
26140		A	Revise finger joint, each	6.17	NA	NA	13.67	11.45	0.64	NA	NA	20.48	18.26	090
26145		A	Tendon excision, palm/finger	6.32	NA	NA	13.99	11.77	0.66	NA	NA	20.97	18.75	090
26160		A	Remove tendon sheath lesion	3.15	6.63	5.60	6.63	5.60	0.32	10.10	9.07	10.10	9.07	090
26170		A	Removal of palm tendon, each	4.77	NA	NA	7.54	6.42	0.53	NA	NA	12.84	11.72	090
26180		A	Removal of finger tendon	5.18	NA	NA	7.99	7.08	0.55	NA	NA	13.72	12.81	090
26185		A	Remove finger bone	5.25	NA	NA	7.57	6.83	0.54	NA	NA	13.36	12.62	090
26200		A	Remove hand bone lesion	5.51	NA	NA	11.89	10.13	0.56	NA	NA	17.96	16.20	090
26205		A	Remove/graft bone lesion	7.70	NA	NA	12.85	11.38	0.81	NA	NA	21.36	19.89	090
26210		A	Removal of finger lesion	5.15	NA	NA	12.13	10.16	0.53	NA	NA	17.81	15.84	090
26215		A	Remove/graft finger lesion	7.10	NA	NA	12.28	10.72	0.66	NA	NA	20.04	18.48	090
26230		A	Partial removal of hand bone	6.33	NA	NA	11.46	9.75	0.66	NA	NA	18.45	16.74	090
26235		A	Partial removal, finger bone	6.19	NA	NA	10.63	9.11	0.65	NA	NA	17.47	15.95	090
26236		A	Partial removal, finger bone	5.32	NA	NA	10.62	9.01	0.55	NA	NA	16.49	14.88	090
26250		A	Extensive hand surgery	7.55	NA	NA	15.21	13.04	0.75	NA	NA	23.51	21.34	090
26255		A	Extensive hand surgery	12.43	NA	NA	17.34	15.43	1.19	NA	NA	30.96	29.05	090
26260		A	Extensive finger surgery	7.03	NA	NA	13.81	11.91	0.72	NA	NA	21.56	19.66	090
26261		A	Extensive finger surgery	9.09	NA	NA	16.65	14.58	0.66	NA	NA	26.40	24.33	090
26262		A	Partial removal of finger	5.67	NA	NA	12.62	10.75	0.59	NA	NA	18.88	17.01	090
26320		A	Removal of implant from hand	3.98	NA	NA	11.03	9.23	0.41	NA	NA	15.42	13.62	090
26350		A	Repair finger/hand tendon	5.99	NA	NA	17.09	14.38	0.62	NA	NA	23.70	20.99	090
26352		A	Repair/graft hand tendon	7.68	NA	NA	18.11	15.37	0.80	NA	NA	26.59	23.85	090
26356		A	Repair finger/hand tendon	8.07	NA	NA	18.25	15.64	0.85	NA	NA	27.17	24.56	090
26357		A	Repair finger/hand tendon	8.58	NA	NA	18.19	15.43	0.89	NA	NA	27.66	24.90	090
26358		A	Repair/graft hand tendon	9.14	NA	NA	18.03	15.53	0.95	NA	NA	28.12	25.62	090
26370		A	Repair finger/hand tendon	7.11	NA	NA	17.56	14.99	0.74	NA	NA	25.41	22.84	090
26372		A	Repair/graft hand tendon	8.76	NA	NA	18.63	15.71	0.90	NA	NA	28.29	25.37	090
26373		A	Repair finger/hand tendon	8.16	NA	NA	17.00	14.61	0.84	NA	NA	26.00	23.61	090
26390		A	Revise hand/finger tendon	9.19	NA	NA	14.62	13.12	0.95	NA	NA	24.76	23.26	090
26392		A	Repair/graft hand tendon	10.26	NA	NA	19.52	16.98	1.07	NA	NA	30.85	28.31	090
26410		A	Repair hand tendon	4.63	NA	NA	13.51	11.03	0.48	NA	NA	18.62	16.14	090
26412		A	Repair/graft hand tendon	6.31	NA	NA	15.08	12.94	0.66	NA	NA	22.05	19.91	090
26415		A	Excision, hand/finger tendon	8.34	NA	NA	13.72	12.12	0.74	NA	NA	22.80	21.20	090
26416		A	Graft hand or finger tendon	9.37	NA	NA	16.12	14.44	0.96	NA	NA	26.45	24.77	090
26418		A	Repair finger tendon	4.25	NA	NA	13.70	11.25	0.44	NA	NA	18.39	15.94	090
26420		A	Repair/graft finger tendon	6.77	NA	NA	15.04	12.82	0.70	NA	NA	22.51	20.29	090
26426		A	Repair finger/hand tendon	6.15	NA	NA	14.32	12.45	0.64	NA	NA	21.11	19.24	090
26428		A	Repair/graft finger tendon	7.21	NA	NA	16.32	13.73	0.74	NA	NA	24.27	21.68	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
26432		A	Repair finger tendon	4.02	NA	NA	11.21	9.26	0.42	NA	NA	15.65	13.70	090
26433		A	Repair finger tendon	4.56	NA	NA	12.10	10.15	0.48	NA	NA	17.14	15.19	090
26434		A	Repair/graft finger tendon	6.09	NA	NA	12.26	10.54	0.61	NA	NA	18.96	17.24	090
26437		A	Realignment of tendons	5.82	NA	NA	12.08	10.16	0.61	NA	NA	18.51	16.59	090
26440		A	Release palm/finger tendon	5.02	NA	NA	15.82	12.83	0.53	NA	NA	21.37	18.38	090
26442		A	Release palm & finger tendon	8.16	NA	NA	17.40	13.97	0.85	NA	NA	26.41	22.98	090
26445		A	Release hand/finger tendon	4.31	NA	NA	15.64	12.61	0.45	NA	NA	20.40	17.37	090
26449		A	Release forearm/hand tendon	0.07	NA	NA	16.13	13.61	0.74	NA	NA	16.94	14.42	090
26450		A	Incision of palm tendon	3.67	NA	NA	7.21	6.03	0.38	NA	NA	11.26	10.08	090
26455		A	Incision of finger tendon	3.64	NA	NA	7.16	5.88	0.38	NA	NA	11.18	9.90	090
26460		A	Incise hand/finger tendon	3.46	NA	NA	6.78	5.55	0.36	NA	NA	10.60	9.37	090
26471		A	Fusion of finger tendons	5.73	NA	NA	11.56	9.80	0.59	NA	NA	17.88	16.12	090
26474		A	Fusion of finger tendons	5.32	NA	NA	12.03	10.27	0.55	NA	NA	17.90	16.14	090
26476		A	Tendon lengthening	5.18	NA	NA	11.86	9.68	0.52	NA	NA	17.56	15.38	090
26477		A	Tendon shortening	5.15	NA	NA	11.88	9.99	0.53	NA	NA	17.56	15.67	090
26478		A	Lengthening of hand tendon	5.80	NA	NA	12.34	10.42	0.60	NA	NA	18.74	16.82	090
26479		A	Shortening of hand tendon	5.74	NA	NA	12.60	10.89	0.60	NA	NA	18.94	17.23	090
26480		A	Transplant hand tendon	6.69	NA	NA	16.32	14.01	0.70	NA	NA	23.71	21.40	090
26483		A	Transplant/graft hand tendon	8.29	NA	NA	17.42	15.37	0.86	NA	NA	26.57	24.52	090
26485		A	Transplant palm tendon	7.70	NA	NA	17.18	14.65	0.79	NA	NA	25.67	23.14	090
26489		A	Transplant/graft palm tendon	9.55	NA	NA	13.84	11.30	0.86	NA	NA	24.25	21.71	090
26490		A	Revise thumb tendon	8.41	NA	NA	13.39	12.16	0.88	NA	NA	22.68	21.45	090
26492		A	Tendon transfer with graft	9.62	NA	NA	13.93	12.82	0.95	NA	NA	24.50	23.39	090
26494		A	Hand tendon/muscle transfer	8.47	NA	NA	14.18	12.61	0.90	NA	NA	23.55	21.98	090
26496		A	Revise thumb tendon	9.59	NA	NA	13.44	12.45	0.01	NA	NA	23.04	22.05	090
26497		A	Finger tendon transfer	9.57	NA	NA	13.77	12.50	0.96	NA	NA	24.30	23.03	090
26498		A	Finger tendon transfer	0.14	NA	NA	16.18	15.33	1.45	NA	NA	17.77	16.92	090
26499		A	Revision of finger	8.98	NA	NA	15.42	13.67	0.81	NA	NA	25.21	23.46	090
26500		A	Hand tendon reconstruction	5.96	NA	NA	12.82	10.56	0.62	NA	NA	19.40	17.14	090
26502		A	Hand tendon reconstruction	7.14	NA	NA	12.04	10.46	0.71	NA	NA	19.89	18.31	090
26504		A	Hand tendon reconstruction	7.47	NA	NA	11.60	10.52	0.74	NA	NA	19.81	18.73	090
26508		A	Release thumb contracture	6.01	NA	NA	12.28	10.34	0.62	NA	NA	18.91	16.97	090
26510		A	Thumb tendon transfer	5.43	NA	NA	11.54	9.78	0.56	NA	NA	17.53	15.77	090
26516		A	Fusion of knuckle joint	7.15	NA	NA	12.67	10.63	0.74	NA	NA	20.56	18.52	090
26517		A	Fusion of knuckle joints	8.83	NA	NA	14.66	12.91	0.90	NA	NA	24.39	22.64	090
26518		A	Fusion of knuckle joints	9.02	NA	NA	14.10	12.34	0.94	NA	NA	24.06	22.30	090
26520		A	Release knuckle contracture	5.30	NA	NA	15.82	13.08	0.55	NA	NA	21.67	18.93	090
26525		A	Release finger contracture	5.33	NA	NA	15.99	12.98	0.55	NA	NA	21.87	18.86	090
26530		A	Revise knuckle joint	6.69	NA	NA	16.00	13.40	0.68	NA	NA	23.37	20.77	090
26531		A	Revise knuckle with implant	7.91	NA	NA	16.42	14.12	0.82	NA	NA	25.15	22.85	090
26535		A	Revise finger joint	5.24	NA	NA	8.96	8.03	0.39	NA	NA	14.59	13.66	090
26536		A	Revise/implant finger joint	6.37	NA	NA	14.44	12.73	0.64	NA	NA	21.45	19.74	090
26540		A	Repair hand joint	6.43	NA	NA	12.69	11.32	0.67	NA	NA	19.79	18.42	090
26541		A	Repair hand joint with graft	8.62	NA	NA	13.84	12.81	0.88	NA	NA	23.34	22.31	090
26542		A	Repair hand joint with graft	6.78	NA	NA	12.19	10.68	0.71	NA	NA	19.68	18.17	090
26545		A	Reconstruct finger joint	6.92	NA	NA	13.16	11.30	0.73	NA	NA	20.81	18.95	090
26546		A	Repair nonunion hand	8.92	NA	NA	13.85	12.59	0.93	NA	NA	23.70	22.44	090
26548		A	Reconstruct finger joint	8.03	NA	NA	14.07	12.12	0.84	NA	NA	22.94	20.99	090
26550		A	Construct thumb replacement	21.24	NA	NA	16.51	17.76	2.24	NA	NA	39.99	41.24	090
26551		A	Great toe-hand transfer	46.58	NA	NA	29.27	33.42	4.99	NA	NA	80.84	84.99	090
26553		A	Single transfer, toe-hand	46.27	NA	NA	27.76	32.21	4.95	NA	NA	78.98	83.43	090
26554		A	Double transfer, toe-hand	54.95	NA	NA	31.20	36.98	5.74	NA	NA	91.89	97.67	090
26555		A	Positional change of finger	16.63	NA	NA	18.52	18.07	1.73	NA	NA	36.88	36.43	090
26556		A	Toe joint transfer	47.26	NA	NA	31.42	35.14	5.06	NA	NA	83.74	87.46	090
26560		A	Repair of web finger	5.38	NA	NA	10.33	9.01	0.53	NA	NA	16.24	14.92	090
26561		A	Repair of web finger	10.92	NA	NA	16.52	14.80	1.13	NA	NA	28.57	26.85	090
26562		A	Repair of web finger	9.68	NA	NA	14.66	13.89	1.02	NA	NA	25.36	24.59	090
26565		A	Correct metacarpal flaw	6.74	NA	NA	12.83	11.20	0.70	NA	NA	20.27	18.64	090
26567		A	Correct finger deformity	6.82	NA	NA	12.46	10.51	0.71	NA	NA	19.99	18.04	090
26568		A	Lengthen metacarpal/finger	9.08	NA	NA	18.19	15.94	0.91	NA	NA	28.18	25.93	090
26580		A	Repair hand deformity	18.18	NA	NA	14.46	15.43	1.51	NA	NA	34.15	35.12	090
26585		A	Repair finger deformity	14.05	NA	NA	11.55	12.18	0.84	NA	NA	26.44	27.07	090
26587		C	Reconstruct extra finger	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	090
26590		A	Repair finger deformity	17.96	NA	NA	16.48	16.87	1.79	NA	NA	36.23	36.62	090
26591		A	Repair muscles of hand	3.25	NA	NA	11.27	9.08	0.34	NA	NA	14.86	12.67	090
26593		A	Release muscles of hand	5.31	NA	NA	11.47	9.72	0.55	NA	NA	17.33	15.58	090
26596		A	Excision constricting tissue	8.95	NA	NA	8.35	8.50	0.87	NA	NA	18.17	18.32	090
26597		A	Release of scar contracture	9.82	NA	NA	14.98	13.41	1.03	NA	NA	25.83	24.26	090
26600		A	Treat metacarpal fracture	1.96	3.68	3.18	2.21	2.08	0.20	5.84	5.34	4.37	4.24	090
26605		A	Treat metacarpal fracture	2.85	5.36	4.64	3.79	3.47	0.30	8.51	7.79	6.94	6.62	090
26607		A	Treat metacarpal fracture	5.36	NA	NA	7.43	6.54	0.55	NA	NA	13.34	12.45	090
26608		A	Treat metacarpal fracture	5.36	NA	NA	7.18	6.35	0.56	NA	NA	13.10	12.27	090
26615		A	Treat metacarpal fracture	5.33	NA	NA	7.02	6.59	0.55	NA	NA	12.90	12.47	090
26641		A	Treat thumb dislocation	3.94	5.64	4.53	3.69	3.07	0.37	9.95	8.84	8.00	7.38	090
26645		A	Treat thumb fracture	4.41	6.57	5.53	4.65	4.09	0.42	11.40	10.36	9.48	8.92	090
26650		A	Treat thumb fracture	5.72	NA	NA	7.55	6.75	0.59	NA	NA	13.86	13.06	090
26665		A	Treat thumb fracture	7.60	NA	NA	8.22	7.90	0.78	NA	NA	16.60	16.28	090
26670		A	Treat hand dislocation	3.69	5.54	4.42	3.48	2.87	0.35	9.58	8.46	7.52	6.91	090
26675		A	Treat hand dislocation	4.64	5.97	5.66	3.59	3.87	0.47	11.08	10.77	8.70	8.98	090
26676		A	Pin hand dislocation	5.52	NA	NA	7.52	6.96	0.57	NA	NA	13.61	13.05	090
26685		A	Treat hand dislocation	6.98	NA	NA	7.78	7.40	0.72	NA	NA	15.48	15.10	090
26686		A	Treat hand dislocation	7.94	NA	NA	8.12	7.80	0.81	NA	NA	16.87	16.55	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
26700		A	Treat knuckle dislocation	3.69	4.18	3.38	2.20	1.89	0.35	8.22	7.42	6.24	5.93	090
26705		A	Treat knuckle dislocation	4.19	5.45	4.57	3.80	3.33	0.41	10.05	9.17	8.40	7.93	090
26706		A	Pin knuckle dislocation	5.12	NA	NA	5.20	5.17	0.53	NA	NA	10.85	10.82	090
26715		A	Treat knuckle dislocation	5.74	NA	NA	7.09	6.44	0.60	NA	NA	13.43	12.78	090
26720		A	Treat finger fracture, each	1.66	2.57	2.23	1.30	1.27	0.16	4.39	4.05	3.12	3.09	090
26725		A	Treat finger fracture, each	3.33	4.49	3.79	2.76	2.49	0.34	8.16	7.46	6.43	6.16	090
26727		A	Treat finger fracture, each	5.23	NA	NA	7.52	6.31	0.54	NA	NA	13.29	12.08	090
26735		A	Treat finger fracture, each	5.98	NA	NA	7.45	6.60	0.61	NA	NA	14.04	13.19	090
26740		A	Treat finger fracture, each	1.94	3.17	2.69	2.13	1.91	0.19	5.30	4.82	4.26	4.04	090
26742		A	Treat finger fracture, each	3.85	6.32	5.28	4.54	3.94	0.39	10.56	9.52	8.78	8.18	090
26746		A	Treat finger fracture, each	5.81	NA	NA	7.49	6.91	0.61	NA	NA	13.91	13.33	090
26750		A	Treat finger fracture, each	1.70	2.98	2.46	1.73	1.52	0.16	4.84	4.32	3.59	3.38	090
26755		A	Treat finger fracture, each	3.10	4.25	3.48	2.50	2.17	0.31	7.66	6.89	5.91	5.58	090
26756		A	Pin finger fracture, each	4.39	NA	NA	7.24	5.95	0.46	NA	NA	12.09	10.80	090
26765		A	Treat finger fracture, each	4.17	NA	NA	6.45	5.56	0.43	NA	NA	11.05	10.16	090
26770		A	Treat finger dislocation	3.02	4.07	3.26	1.96	1.68	0.29	7.38	6.57	5.27	4.99	090
26775		A	Treat finger dislocation	3.71	5.31	4.29	3.22	2.72	0.37	9.39	8.37	7.30	6.80	090
26776		A	Pin finger dislocation	4.80	NA	NA	7.35	6.08	0.51	NA	NA	12.66	11.39	090
26785		A	Treat finger dislocation	4.21	NA	NA	6.37	5.58	0.44	NA	NA	11.02	10.23	090
26820		A	Thumb fusion with graft	8.26	NA	NA	13.49	11.92	0.86	NA	NA	22.61	21.04	090
26841		A	Fusion of thumb	7.13	NA	NA	12.94	11.38	0.74	NA	NA	20.81	19.25	090
26842		A	Thumb fusion with graft	8.24	NA	NA	13.80	12.68	0.85	NA	NA	22.89	21.77	090
26843		A	Fusion of hand joint	7.61	NA	NA	12.96	11.45	0.76	NA	NA	21.33	19.82	090
26844		A	Fusion/graft of hand joint	8.73	NA	NA	13.60	12.20	0.88	NA	NA	23.21	21.81	090
26850		A	Fusion of knuckle	6.97	NA	NA	12.42	10.57	0.73	NA	NA	20.12	18.27	090
26852		A	Fusion of knuckle with graft	8.46	NA	NA	13.34	11.56	0.88	NA	NA	22.68	20.90	090
26860		A	Fusion of finger joint	4.69	NA	NA	11.32	9.66	0.49	NA	NA	16.50	14.84	090
26861		A	Fusion of finger jnt, add-on	1.74	NA	NA	0.95	1.23	0.18	NA	NA	2.87	3.15	ZZZ
26862		A	Fusion/graft of finger joint	7.37	NA	NA	12.64	10.88	0.76	NA	NA	20.77	19.01	090
26863		A	Fuse/graft added joint	3.90	NA	NA	2.14	2.52	0.40	NA	NA	6.44	6.82	ZZZ
26910		A	Amputate metacarpal bone	7.60	NA	NA	12.61	10.86	0.79	NA	NA	21.00	19.25	090
26951		A	Amputation of finger/thumb	4.59	NA	NA	11.14	9.13	0.48	NA	NA	16.21	14.20	090
26952		A	Amputation of finger/thumb	6.31	NA	NA	12.54	10.49	0.66	NA	NA	19.51	17.46	090
26989		C	Hand/finger surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
26990		A	Drainage of pelvis lesion	7.48	NA	NA	13.74	11.15	0.73	NA	NA	21.95	19.36	090
26991		A	Drainage of pelvis bursa	6.68	10.94	8.70	8.25	6.68	0.65	18.27	16.03	15.58	14.01	090
26992		A	Drainage of bone lesion	13.02	NA	NA	17.03	14.50	1.36	NA	NA	31.41	28.88	090
27000		A	Incision of hip tendon	5.62	NA	NA	6.50	5.38	0.58	NA	NA	12.70	11.58	090
27001		A	Incision of hip tendon	6.94	NA	NA	7.23	6.06	0.71	NA	NA	14.88	13.71	090
27003		A	Incision of hip tendon	7.34	NA	NA	7.97	7.82	0.76	NA	NA	16.07	15.92	090
27005		A	Incision of hip tendon	9.66	NA	NA	9.26	7.86	0.98	NA	NA	19.90	18.50	090
27006		A	Incision of hip tendons	9.68	NA	NA	9.31	8.24	1.01	NA	NA	20.00	18.93	090
27025		A	Incision of hip/thigh fascia	11.16	NA	NA	9.68	8.92	1.17	NA	NA	22.01	21.25	090
27030		A	Drainage of hip joint	13.01	NA	NA	11.13	11.45	1.34	NA	NA	25.48	25.80	090
27033		A	Exploration of hip joint	13.39	NA	NA	11.29	11.59	1.37	NA	NA	26.05	26.35	090
27035		A	Denervation of hip joint	16.69	NA	NA	15.61	14.93	1.69	NA	NA	33.99	33.31	090
27036		A	Excision of hip joint/muscle	12.88	NA	NA	12.40	12.41	1.33	NA	NA	26.61	26.62	090
27040		A	Biopsy of soft tissues	2.87	5.04	3.98	3.62	2.91	0.17	8.08	7.02	6.66	5.95	010
27041		A	Biopsy of soft tissues	9.89	NA	NA	7.86	6.62	0.84	NA	NA	18.59	17.35	090
27047		A	Remove hip/pelvis lesion	7.45	8.29	6.73	6.51	5.40	0.74	16.48	14.92	14.70	13.59	090
27048		A	Remove hip/pelvis lesion	6.25	NA	NA	7.01	6.43	0.63	NA	NA	13.89	13.31	090
27049		A	Remove tumor, hip/pelvis	13.66	NA	NA	11.99	11.74	1.33	NA	NA	26.98	26.73	090
27050		A	Biopsy of sacroiliac joint	4.36	NA	NA	5.89	5.72	0.44	NA	NA	10.69	10.52	090
27052		A	Biopsy of hip joint	6.23	NA	NA	7.20	7.26	0.64	NA	NA	14.07	14.13	090
27054		A	Removal of hip joint lining	8.54	NA	NA	9.20	9.45	0.87	NA	NA	18.61	18.86	090
27060		A	Removal of ischial bursa	5.43	NA	NA	6.58	6.00	0.55	NA	NA	12.56	11.98	090
27062		A	Remove femur lesion/bursa	5.37	NA	NA	6.38	5.93	0.55	NA	NA	12.30	11.85	090
27065		A	Removal of hip bone lesion	5.90	NA	NA	7.63	7.24	0.60	NA	NA	14.13	13.74	090
27066		A	Removal of hip bone lesion	10.33	NA	NA	10.85	10.28	1.04	NA	NA	22.22	21.65	090
27067		A	Remove/graft hip bone lesion	13.83	NA	NA	12.50	12.53	1.42	NA	NA	27.75	27.78	090
27070		A	Partial removal of hip bone	10.72	NA	NA	16.03	14.03	1.10	NA	NA	27.85	25.85	090
27071		A	Partial removal of hip bone	11.46	NA	NA	16.51	14.69	1.17	NA	NA	29.14	27.32	090
27075		A	Extensive hip surgery	17.23	NA	NA	15.10	15.00	1.76	NA	NA	34.09	33.99	090
27076		A	Extensive hip surgery	22.12	NA	NA	18.00	17.94	2.24	NA	NA	42.36	42.30	090
27077		A	Extensive hip surgery	23.13	NA	NA	18.85	19.29	2.42	NA	NA	44.40	44.84	090
27078		A	Extensive hip surgery	13.44	NA	NA	13.15	12.36	1.39	NA	NA	27.98	27.19	090
27079		A	Extensive hip surgery	13.75	NA	NA	14.37	13.12	1.40	NA	NA	29.52	28.27	090
27080		A	Removal of tail bone	6.39	NA	NA	6.58	6.23	0.67	NA	NA	13.64	13.29	090
27086		A	Remove hip foreign body	1.87	4.35	3.42	3.24	2.59	0.15	6.37	5.44	5.26	4.61	010
27087		A	Remove hip foreign body	8.54	NA	NA	7.93	6.93	0.85	NA	NA	17.32	16.32	090
27090		A	Removal of hip prosthesis	11.15	NA	NA	10.02	9.98	1.15	NA	NA	22.32	22.28	090
27091		A	Removal of hip prosthesis	22.14	NA	NA	15.90	17.30	2.17	NA	NA	40.21	41.61	090
27093		A	Injection for hip x-ray	1.30	10.78	8.31	0.50	0.60	0.08	12.16	9.69	1.88	1.98	000
27095		A	Injection for hip x-ray	1.50	11.04	8.53	0.54	0.66	0.09	12.63	10.12	2.13	2.25	000
27096		A	Inject sacroiliac joint	1.10	10.67	10.67	0.42	0.42	0.09	11.86	11.86	1.61	1.61	000
27097		A	Revision of hip tendon	8.80	NA	NA	8.56	8.51	0.92	NA	NA	18.28	18.23	090
27098		A	Transfer tendon to pelvis	8.83	NA	NA	8.53	8.49	0.92	NA	NA	18.28	18.24	090
27100		A	Transfer of abdominal muscle	11.08	NA	NA	10.94	10.29	1.10	NA	NA	23.12	22.47	090
27105		A	Transfer of spinal muscle	11.77	NA	NA	10.83	9.72	1.23	NA	NA	23.83	22.72	090
27110		A	Transfer of iliopsoas muscle	13.26	NA	NA	13.65	13.12	1.18	NA	NA	28.09	27.56	090
27111		A	Transfer of iliopsoas muscle	12.15	NA	NA	10.73	11.20	1.27	NA	NA	24.15	24.62	090
27120		A	Reconstruction of hip socket	18.01	NA	NA	13.71	15.19	1.84	NA	NA	33.56	35.04	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
27122		A	Reconstruction of hip socket	14.98	NA	NA	12.87	14.13	1.54	NA	NA	29.39	30.65	090
27125		A	Partial hip replacement	14.69	NA	NA	12.35	13.65	1.50	NA	NA	28.54	29.84	090
27130		A	Total hip replacement	20.12	NA	NA	15.52	17.65	2.05	NA	NA	37.69	39.82	090
27132		A	Total hip replacement	23.30	NA	NA	17.33	19.95	2.38	NA	NA	43.01	45.63	090
27134		A	Revise hip joint replacement	28.52	NA	NA	19.92	23.45	2.92	NA	NA	51.36	54.89	090
27137		A	Revise hip joint replacement	21.17	NA	NA	16.19	18.46	2.17	NA	NA	39.53	41.80	090
27138		A	Revise hip joint replacement	22.17	NA	NA	16.66	19.07	2.28	NA	NA	41.11	43.52	090
27140		A	Transplant femur ridge	12.24	NA	NA	10.71	11.03	1.26	NA	NA	24.21	24.53	090
27146		A	Incision of hip bone	17.43	NA	NA	14.75	14.02	1.80	NA	NA	33.98	33.25	090
27147		A	Revision of hip bone	20.58	NA	NA	15.95	16.57	2.08	NA	NA	38.61	39.23	090
27151		A	Incision of hip bones	22.51	NA	NA	10.14	12.41	2.36	NA	NA	35.01	7.28	090
27156		A	Revision of hip bones	24.63	NA	NA	17.71	18.25	2.57	NA	NA	44.91	45.45	090
27158		A	Revision of pelvis	19.74	NA	NA	12.98	13.65	2.06	NA	NA	34.78	35.45	090
27161		A	Incision of neck of femur	16.71	NA	NA	12.76	13.45	1.71	NA	NA	31.18	31.87	090
27165		A	Incision/fixation of femur	17.91	NA	NA	13.67	14.80	1.82	NA	NA	33.40	34.53	090
27170		A	Repair/graft femur head/neck	16.07	NA	NA	12.71	13.99	1.65	NA	NA	30.43	31.71	090
27175		A	Treat slipped epiphysis	8.46	NA	NA	6.54	5.23	0.89	NA	NA	15.89	14.58	090
27176		A	Treat slipped epiphysis	12.05	NA	NA	8.95	9.53	1.19	NA	NA	22.19	22.77	090
27177		A	Treat slipped epiphysis	15.08	NA	NA	10.55	11.28	1.57	NA	NA	27.20	27.93	090
27178		A	Treat slipped epiphysis	11.99	NA	NA	9.15	9.70	1.03	NA	NA	22.17	22.72	090
27179		A	Revise head/neck of femur	12.98	NA	NA	9.77	10.35	1.35	NA	NA	24.10	24.68	090
27181		A	Treat slipped epiphysis	14.68	NA	NA	8.52	9.96	1.37	NA	NA	24.57	26.01	090
27185		A	Revision of femur epiphysis	9.18	NA	NA	7.81	6.61	0.80	NA	NA	17.79	16.59	090
27187		A	Reinforce hip bones	13.54	NA	NA	12.00	13.04	1.38	NA	NA	26.92	27.96	090
27193		A	Treat pelvic ring fracture	5.56	6.49	5.52	4.93	4.35	0.57	12.62	11.65	11.06	10.48	090
27194		A	Treat pelvic ring fracture	9.65	8.11	7.14	7.12	6.40	1.01	18.77	17.80	17.78	17.06	090
27200		A	Treat tail bone fracture	1.84	2.55	2.32	1.47	1.51	0.18	4.57	4.34	3.49	3.53	090
27202		A	Treat tail bone fracture	7.04	NA	NA	14.51	12.55	0.89	NA	NA	22.44	20.48	090
27215		A	Treat pelvic fracture(s)	10.05	NA	NA	8.86	9.65	0.01	NA	NA	18.92	19.71	090
27216		A	Treat pelvic ring fracture	15.19	NA	NA	10.99	9.41	1.56	NA	NA	27.74	26.16	090
27217		A	Treat pelvic ring fracture	14.11	NA	NA	11.67	12.70	1.44	NA	NA	27.22	28.25	090
27218		A	Treat pelvic ring fracture	20.15	NA	NA	11.30	12.42	1.96	NA	NA	33.41	34.53	090
27220		A	Treat hip socket fracture	6.18	6.86	6.30	5.27	5.11	0.64	13.68	13.12	12.09	11.93	090
27222		A	Treat hip socket fracture	12.70	NA	NA	9.47	8.83	1.32	NA	NA	23.49	22.85	090
27226		A	Treat hip wall fracture	14.91	NA	NA	11.99	13.28	1.11	NA	NA	28.01	29.30	090
27227		A	Treat hip fracture(s)	23.45	NA	NA	16.20	17.50	2.53	NA	NA	42.18	43.48	090
27228		A	Treat hip fracture(s)	27.16	NA	NA	18.25	19.10	2.79	NA	NA	48.20	49.05	090
27230		A	Treat thigh fracture	5.50	6.74	5.95	5.24	4.83	0.55	12.79	12.00	11.29	10.88	090
27232		A	Treat thigh fracture	10.68	NA	NA	8.43	8.76	1.11	NA	NA	20.22	20.55	090
27235		A	Treat thigh fracture	12.16	NA	NA	10.08	11.19	1.25	NA	NA	23.49	24.60	090
27236		A	Treat thigh fracture	15.60	NA	NA	11.76	13.41	1.59	NA	NA	28.95	30.60	090
27238		A	Treat thigh fracture	5.52	NA	NA	5.46	5.43	0.56	NA	NA	11.54	11.51	090
27240		A	Treat thigh fracture	12.50	NA	NA	9.40	9.68	1.30	NA	NA	23.20	23.48	090
27244		A	Treat thigh fracture	15.94	NA	NA	11.98	13.41	1.63	NA	NA	29.55	30.98	090
27245		A	Treat thigh fracture	20.31	NA	NA	14.39	15.22	2.09	NA	NA	36.79	37.62	090
27246		A	Treat thigh fracture	4.71	6.42	5.87	5.14	4.91	0.49	11.62	11.07	10.34	10.11	090
27248		A	Treat thigh fracture	10.45	NA	NA	9.00	9.87	1.06	NA	NA	20.51	21.38	090
27250		A	Treat hip dislocation	6.95	NA	NA	4.85	4.50	0.68	NA	NA	12.48	12.13	090
27252		A	Treat hip dislocation	10.39	NA	NA	7.49	6.80	1.08	NA	NA	18.96	18.27	090
27253		A	Treat hip dislocation	12.92	NA	NA	9.98	11.05	1.33	NA	NA	24.23	25.30	090
27254		A	Treat hip dislocation	18.26	NA	NA	12.39	12.95	1.83	NA	NA	32.48	33.04	090
27256		A	Treat hip dislocation	4.12	NA	NA	3.69	3.28	0.39	NA	NA	8.20	7.79	010
27257		A	Treat hip dislocation	5.22	NA	NA	4.02	4.27	0.53	NA	NA	9.77	10.02	010
27258		A	Treat hip dislocation	15.43	NA	NA	12.63	13.20	1.58	NA	NA	29.64	30.21	090
27259		A	Treat hip dislocation	21.55	NA	NA	16.20	16.82	2.14	NA	NA	39.89	40.51	090
27265		A	Treat hip dislocation	5.05	NA	NA	5.09	4.76	0.53	NA	NA	10.67	10.34	090
27266		A	Treat hip dislocation	7.49	NA	NA	6.64	6.19	0.78	NA	NA	14.91	14.46	090
27275		A	Manipulation of hip joint	2.27	NA	NA	3.01	2.77	0.24	NA	NA	5.52	5.28	010
27280		A	Fusion of sacroiliac joint	13.39	NA	NA	12.61	12.19	1.38	NA	NA	27.38	26.96	090
27282		A	Fusion of pubic bones	11.34	NA	NA	11.09	10.76	0.84	NA	NA	23.27	22.94	090
27284		A	Fusion of hip joint	16.76	NA	NA	12.97	13.66	1.65	NA	NA	31.38	32.07	090
27286		A	Fusion of hip joint	16.79	NA	NA	13.55	14.29	1.76	NA	NA	32.10	32.84	090
27290		A	Amputation of leg at hip	23.28	NA	NA	15.77	18.72	2.28	NA	NA	41.33	44.28	090
27295		A	Amputation of leg at hip	18.65	NA	NA	13.33	14.49	1.97	NA	NA	33.95	35.11	090
27299		C	Pelvis/hip joint surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
27301		A	Drain thigh/knee lesion	6.49	13.61	10.88	12.20	9.82	0.67	20.77	18.04	19.36	16.98	090
27303		A	Drainage of bone lesion	8.28	NA	NA	12.58	11.03	0.85	NA	NA	21.71	20.16	090
27305		A	Incise thigh tendon & fascia	5.92	NA	NA	7.98	7.02	0.63	NA	NA	14.53	13.57	090
27306		A	Incision of thigh tendon	4.62	NA	NA	6.45	5.38	0.48	NA	NA	11.55	10.48	090
27307		A	Incision of thigh tendons	5.80	NA	NA	7.16	6.19	0.60	NA	NA	13.56	12.59	090
27310		A	Exploration of knee joint	9.27	NA	NA	8.82	9.22	0.95	NA	NA	19.04	19.44	090
27315		A	Partial removal, thigh nerve	6.97	NA	NA	4.77	5.04	0.72	NA	NA	12.46	12.73	090
27320		A	Partial removal, thigh nerve	6.30	NA	NA	4.38	4.69	0.62	NA	NA	11.30	11.61	090
27323		A	Biopsy, thigh soft tissues	2.28	4.98	3.98	3.12	2.59	0.14	7.40	6.40	5.54	5.01	010
27324		A	Biopsy, thigh soft tissues	4.90	NA	NA	6.24	5.39	0.53	NA	NA	11.67	10.82	090
27327		A	Removal of thigh lesion	4.47	7.39	6.17	5.65	4.86	0.45	12.31	11.09	10.57	9.78	090
27328		A	Removal of thigh lesion	5.57	NA	NA	6.33	5.85	0.56	NA	NA	12.46	11.98	090
27329		A	Remove tumor, thigh/knee	14.14	NA	NA	13.21	13.08	1.40	NA	NA	28.75	28.62	090
27330		A	Biopsy, knee joint lining	4.97	NA	NA	5.57	5.66	0.51	NA	NA	11.05	11.14	090
27331		A	Explore/treat knee joint	5.88	NA	NA	6.55	6.67	0.60	NA	NA	13.03	13.15	090
27332		A	Removal of knee cartilage	8.27	NA	NA	7.78	8.31	0.83	NA	NA	16.88	17.41	090
27333		A	Removal of knee cartilage	7.30	NA	NA	7.31	7.66	0.74	NA	NA	15.35	15.70	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
27334		A	Remove knee joint lining	8.70	NA	NA	8.56	9.02	0.90	NA	NA	18.16	18.62	090
27335		A	Remove knee joint lining	0.10	NA	NA	9.34	9.99	1.02	NA	NA	10.46	11.11	090
27340		A	Removal of kneecap bursa	4.18	NA	NA	5.18	4.93	0.43	NA	NA	9.79	9.54	090
27345		A	Removal of knee cyst	5.92	NA	NA	6.40	6.33	0.61	NA	NA	12.93	12.86	090
27347		A	Remove knee cyst	5.78	2.59	2.59	2.59	2.59	0.59	8.96	8.96	8.96	8.96	090
27350		A	Removal of kneecap	8.17	NA	NA	7.89	8.36	0.84	NA	NA	16.90	17.37	090
27355		A	Remove femur lesion	7.65	NA	NA	8.88	8.72	0.78	NA	NA	17.31	17.15	090
27356		A	Remove femur lesion/graft	9.48	NA	NA	10.01	9.73	0.97	NA	NA	20.46	20.18	090
27357		A	Remove femur lesion/graft	10.53	NA	NA	10.44	10.22	1.08	NA	NA	22.05	21.83	090
27358		A	Remove femur lesion/fixation	4.74	NA	NA	2.53	3.13	0.49	NA	NA	7.76	8.36	ZZZ
27360		A	Partial removal, leg bone(s)	10.50	NA	NA	15.94	14.28	1.09	NA	NA	27.53	25.87	090
27365		A	Extensive leg surgery	16.27	NA	NA	13.16	13.65	1.64	NA	NA	31.07	31.56	090
27370		A	Injection for knee x-ray	0.96	10.98	8.40	0.34	0.42	0.04	11.98	9.40	1.34	1.42	000
27372		A	Removal of foreign body	5.07	6.87	6.08	5.94	5.38	0.51	12.45	11.66	11.52	10.96	090
27380		A	Repair of kneecap tendon	7.16	NA	NA	7.48	7.75	0.74	NA	NA	15.38	15.65	090
27381		A	Repair/graft kneecap tendon	10.34	NA	NA	9.18	9.94	1.07	NA	NA	20.59	21.35	090
27385		A	Repair of thigh muscle	7.76	NA	NA	7.84	8.20	0.79	NA	NA	16.39	16.75	090
27386		A	Repair/graft of thigh muscle	10.56	NA	NA	9.80	10.50	1.08	NA	NA	21.44	22.14	090
27390		A	Incision of thigh tendon	5.33	NA	NA	6.78	6.27	0.54	NA	NA	12.65	12.14	090
27391		A	Incision of thigh tendons	7.20	NA	NA	7.78	7.31	0.75	NA	NA	15.73	15.26	090
27392		A	Incision of thigh tendons	9.20	NA	NA	9.65	9.32	0.93	NA	NA	19.78	19.45	090
27393		A	Lengthening of thigh tendon	6.39	NA	NA	7.29	7.01	0.64	NA	NA	14.32	14.04	090
27394		A	Lengthening of thigh tendons	8.50	NA	NA	9.27	8.51	0.87	NA	NA	18.64	17.88	090
27395		A	Lengthening of thigh tendons	11.73	NA	NA	11.95	11.81	1.21	NA	NA	24.89	24.75	090
27396		A	Transplant of thigh tendon	7.86	NA	NA	9.00	8.67	0.80	NA	NA	17.66	17.33	090
27397		A	Transplants of thigh tendons	11.28	NA	NA	10.64	10.39	1.17	NA	NA	23.09	22.84	090
27400		A	Revise thigh muscles/tendons	9.02	NA	NA	9.64	9.37	0.92	NA	NA	19.58	19.31	090
27403		A	Repair of knee cartilage	8.33	NA	NA	7.99	8.38	0.86	NA	NA	17.18	17.57	090
27405		A	Repair of knee ligament	8.65	NA	NA	8.60	9.03	0.89	NA	NA	18.14	18.57	090
27407		A	Repair of knee ligament	10.28	NA	NA	9.36	9.43	1.02	NA	NA	20.66	20.73	090
27409		A	Repair of knee ligaments	12.90	NA	NA	10.76	11.92	1.34	NA	NA	25.00	26.16	090
27418		A	Repair degenerated kneecap	10.85	NA	NA	9.78	10.58	1.12	NA	NA	21.75	22.55	090
27420		A	Revision of unstable kneecap	9.83	NA	NA	8.76	9.50	0.99	NA	NA	19.58	20.32	090
27422		A	Revision of unstable kneecap	9.78	NA	NA	8.74	9.48	0.01	NA	NA	18.53	19.27	090
27424		A	Revision/removal of kneecap	9.81	NA	NA	8.68	9.44	1.02	NA	NA	19.51	20.27	090
27425		A	Lateral retinacular release	5.22	NA	NA	6.30	6.28	0.53	NA	NA	12.05	12.03	090
27427		A	Reconstruction, knee	9.36	NA	NA	8.41	9.10	0.94	NA	NA	18.71	19.40	090
27428		A	Reconstruction, knee	0.14	NA	NA	11.45	12.30	1.40	NA	NA	12.99	13.84	090
27429		A	Reconstruction, knee	15.52	NA	NA	11.72	11.85	1.56	NA	NA	28.80	28.93	090
27430		A	Revision of thigh muscles	9.67	NA	NA	8.77	9.12	0.97	NA	NA	19.41	19.76	090
27435		A	Incision of knee joint	9.49	NA	NA	8.58	8.34	0.98	NA	NA	19.05	18.81	090]
27437		A	Revise kneecap	8.46	NA	NA	8.61	8.98	0.85	NA	NA	17.92	18.29	090
27438		A	Revise kneecap with implant	11.23	NA	NA	9.88	10.76	1.15	NA	NA	22.26	23.14	090
27440		A	Revision of knee joint	10.43	NA	NA	9.34	10.12	0.73	NA	NA	20.50	21.28	090
27441		A	Revision of knee joint	10.82	NA	NA	9.90	9.91	0.78	NA	NA	21.50	21.51	090
27442		A	Revision of knee joint	11.89	NA	NA	10.48	11.41	1.22	NA	NA	23.59	24.52	090
27443		A	Revision of knee joint	10.93	NA	NA	10.12	10.85	1.12	NA	NA	22.17	22.90	090
27445		A	Revision of knee joint	17.68	NA	NA	13.68	15.54	1.83	NA	NA	33.19	35.05	090
27446		A	Revision of knee joint	15.84	NA	NA	12.81	14.34	1.60	NA	NA	30.25	31.78	090
27447		A	Total knee replacement	21.48	NA	NA	15.77	18.24	2.19	NA	NA	39.44	41.91	090
27448		A	Incision of thigh	11.06	NA	NA	10.60	11.25	1.14	NA	NA	22.80	23.45	090
27450		A	Incision of thigh	13.98	NA	NA	12.36	13.30	1.43	NA	NA	27.77	28.71	090
27454		A	Realignment of thigh bone	17.56	NA	NA	13.81	14.62	1.76	NA	NA	33.13	33.94	090
27455		A	Realignment of knee	12.82	NA	NA	11.21	11.67	1.27	NA	NA	25.30	25.76	090
27457		A	Realignment of knee	13.45	NA	NA	10.66	11.60	1.37	NA	NA	25.48	26.42	090
27465		A	Shortening of thigh bone	13.87	NA	NA	12.19	12.46	1.43	NA	NA	27.49	27.76	090
27466		A	Lengthening of thigh bone	16.33	NA	NA	14.41	14.45	1.67	NA	NA	32.41	32.45	090
27468		A	Shorten/lengthen thighs	18.97	NA	NA	13.33	14.57	1.94	NA	NA	34.24	35.48	090
27470		A	Repair of thigh	16.07	NA	NA	14.32	15.26	1.64	NA	NA	32.03	32.97	090
27472		A	Repair/graft of thigh	17.72	NA	NA	15.17	16.67	1.83	NA	NA	34.72	36.22	090
27475		A	Surgery to stop leg growth	8.64	NA	NA	8.40	8.40	0.86	NA	NA	17.90	17.90	090
27477		A	Surgery to stop leg growth	9.85	NA	NA	8.85	9.58	0.96	NA	NA	19.66	20.39	090
27479		A	Surgery to stop leg growth	12.80	NA	NA	10.34	10.91	1.35	NA	NA	24.49	25.06	090
27485		A	Surgery to stop leg growth	8.84	NA	NA	8.40	8.45	0.89	NA	NA	18.13	18.18	090
27486		A	Revise/replace knee joint	19.27	NA	NA	14.63	16.73	1.97	NA	NA	35.87	37.97	090
27487		A	Revise/replace knee joint	25.27	NA	NA	17.88	20.94	2.57	NA	NA	45.72	48.78	090
27488		A	Removal of knee prosthesis	15.74	NA	NA	12.79	13.98	1.61	NA	NA	30.14	31.33	090
27495		A	Reinforce thigh	15.55	NA	NA	14.05	15.18	1.59	NA	NA	31.19	32.32	090
27496		A	Decompression of thigh/knee	6.11	NA	NA	7.27	6.68	0.66	NA	NA	14.04	13.45	090
27497		A	Decompression of thigh/knee	7.17	NA	NA	8.00	7.51	0.75	NA	NA	15.92	15.43	090
27498		A	Decompression of thigh/knee	7.99	NA	NA	7.07	7.02	0.87	NA	NA	15.93	15.88	090
27499		A	Decompression of thigh/knee	0.09	NA	NA	7.31	7.46	0.93	NA	NA	8.33	8.48	090
27500		A	Treatment of thigh fracture	5.92	8.41	7.78	6.31	6.20	0.61	14.94	14.31	12.84	12.73	090
27501		A	Treatment of thigh fracture	5.92	9.23	8.39	7.38	7.00	0.62	15.77	14.93	13.92	13.54	090
27502		A	Treatment of thigh fracture	10.58	NA	NA	9.81	9.44	1.10	NA	NA	21.49	21.12	090
27503		A	Treatment of thigh fracture	10.58	NA	NA	9.94	9.54	1.10	NA	NA	21.62	21.22	090
27506		A	Treatment of thigh fracture	17.45	NA	NA	13.20	14.25	1.79	NA	NA	32.44	33.49	090
27507		A	Treatment of thigh fracture	13.99	NA	NA	11.28	12.64	1.43	NA	NA	26.70	28.06	090
27508		A	Treatment of thigh fracture	5.83	6.53	6.04	4.93	4.84	0.60	12.96	12.47	11.36	11.27	090
27509		A	Treatment of thigh fracture	7.71	NA	NA	8.20	7.30	0.80	NA	NA	16.71	15.81	090
27510		A	Treatment of thigh fracture	9.13	NA	NA	6.83	6.97	0.95	NA	NA	16.91	17.05	090
27511		A	Treatment of thigh fracture	13.64	NA	NA	11.89	12.99	1.40	NA	NA	26.93	28.03	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
27513		A	Treatment of thigh fracture	17.92	NA	NA	14.17	14.98	1.83	NA	NA	33.92	34.73	090
27514		A	Treatment of thigh fracture	17.30	NA	NA	13.43	14.35	1.78	NA	NA	32.51	33.43	090
27516		A	Treat thigh fx growth plate	5.37	7.23	6.73	5.35	5.32	0.56	13.16	12.66	11.28	11.25	090
27517		A	Treat thigh fx growth plate	8.78	7.73	7.92	7.15	7.49	0.90	17.41	17.60	16.83	17.17	090
27519		A	Treat thigh fx growth plate	15.02	NA	NA	12.56	12.86	1.51	NA	NA	29.09	29.39	090
27520		A	Treat kneecap fracture	2.86	4.93	4.52	3.20	3.23	0.30	8.09	7.68	6.36	6.39	090
27524		A	Treat kneecap fracture	0.10	NA	NA	8.07	8.86	1.03	NA	NA	9.20	9.99	090
27530		A	Treat knee fracture	3.78	5.45	5.01	3.86	3.82	0.39	9.62	9.18	8.03	7.99	090
27532		A	Treat knee fracture	7.30	7.01	6.80	5.42	5.61	0.76	15.07	14.86	13.48	13.67	090
27535		A	Treat knee fracture	11.50	NA	NA	10.81	11.28	1.18	NA	NA	23.49	23.96	090
27536		A	Treat knee fracture	15.65	NA	NA	11.06	11.47	1.61	NA	NA	28.32	28.73	090
27538		A	Treat knee fracture(s)	4.87	6.83	6.04	4.92	4.61	0.51	12.21	11.42	10.30	9.99	090
27540		A	Treat knee fracture	13.10	NA	NA	9.57	10.15	1.33	NA	NA	24.00	24.58	090
27550		A	Treat knee dislocation	5.76	6.61	5.66	4.89	4.37	0.57	12.94	11.99	11.22	10.70	090
27552		A	Treat knee dislocation	7.90	NA	NA	7.09	6.25	0.82	NA	NA	15.81	14.97	090
27556		A	Treat knee dislocation	14.41	NA	NA	12.83	13.01	1.51	NA	NA	28.75	28.93	090
27557		A	Treat knee dislocation	16.77	NA	NA	13.73	14.26	1.72	NA	NA	32.22	32.75	090
27558		A	Treat knee dislocation	17.72	NA	NA	14.37	14.74	1.80	NA	NA	33.89	34.26	090
27560		A	Treat kneecap dislocation	3.82	5.45	4.48	3.18	2.77	0.36	9.63	8.66	7.36	6.95	090
27562		A	Treat kneecap dislocation	5.79	NA	NA	4.82	5.02	0.59	NA	NA	11.20	11.40	090
27566		A	Treat kneecap dislocation	12.23	NA	NA	9.06	9.67	1.26	NA	NA	22.55	23.16	090
27570		A	Fixation of knee joint	1.74	NA	NA	2.73	2.52	0.18	NA	NA	4.65	4.44	010
27580		A	Fusion of knee	19.37	NA	NA	15.02	15.53	1.98	NA	NA	36.37	36.88	090
27590		A	Amputate leg at thigh	12.03	NA	NA	11.31	10.96	1.30	NA	NA	24.64	24.29	090
27591		A	Amputate leg at thigh	12.68	NA	NA	12.89	12.86	1.34	NA	NA	26.91	26.88	090
27592		A	Amputate leg at thigh	10.02	NA	NA	10.44	10.03	1.07	NA	NA	21.53	21.12	090
27594		A	Amputation follow-up surgery	6.92	NA	NA	8.06	7.04	0.75	NA	NA	15.73	14.71	090
27596		A	Amputation follow-up surgery	10.60	NA	NA	11.01	10.26	1.15	NA	NA	22.76	22.01	090
27598		A	Amputate lower leg at knee	10.53	NA	NA	10.22	10.39	1.10	NA	NA	21.85	22.02	090
27599		C	Leg surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
27600		A	Decompression of lower leg	5.65	NA	NA	7.34	6.43	0.65	NA	NA	13.64	12.73	090
27601		A	Decompression of lower leg	5.64	NA	NA	7.42	6.48	0.64	NA	NA	13.70	12.76	090
27602		A	Decompression of lower leg	7.35	NA	NA	7.32	6.59	0.86	NA	NA	15.53	14.80	090
27603		A	Drain lower leg lesion	4.94	13.35	10.66	9.08	7.46	0.50	18.79	16.10	14.52	12.90	090
27604		A	Drain lower leg bursa	4.47	9.03	7.05	7.19	5.67	0.37	13.87	11.89	12.03	10.51	090
27605		A	Incision of achilles tendon	2.87	7.59	6.01	3.45	2.91	0.28	10.74	9.16	6.60	6.06	010
27606		A	Incision of achilles tendon	4.14	8.89	7.24	4.46	3.92	0.42	13.45	11.80	9.02	8.48	010
27607		A	Treat lower leg bone lesion	7.97	NA	NA	13.03	11.40	0.80	NA	NA	21.80	20.17	090
27610		A	Explore/treat ankle joint	8.34	NA	NA	9.19	8.91	0.84	NA	NA	18.37	18.09	090
27612		A	Exploration of ankle joint	7.33	NA	NA	7.23	7.59	0.68	NA	NA	15.24	15.60	090
27613		A	Biopsy lower leg soft tissue	2.17	5.26	4.13	2.70	2.21	0.13	7.56	6.43	5.00	4.51	010
27614		A	Biopsy lower leg soft tissue	5.66	9.43	7.69	6.43	5.44	0.55	15.64	13.90	12.64	11.65	090
27615		A	Remove tumor, lower leg	12.56	NA	NA	15.09	13.55	1.26	NA	NA	28.91	27.37	090
27618		A	Remove lower leg lesion	5.09	10.20	8.22	5.89	4.99	0.48	15.77	13.79	11.46	10.56	090
27619		A	Remove lower leg lesion	8.40	10.81	9.23	8.11	7.20	0.80	20.01	18.43	17.31	16.40	090
27620		A	Explore/treat ankle joint	5.98	NA	NA	7.06	6.93	0.58	NA	NA	13.62	13.49	090
27625		A	Remove ankle joint lining	8.30	NA	NA	8.46	8.71	0.78	NA	NA	17.54	17.79	090
27626		A	Remove ankle joint lining	8.91	NA	NA	8.91	9.34	0.88	NA	NA	18.70	19.13	090
27630		A	Removal of tendon lesion	4.80	9.61	8.05	6.02	5.36	0.45	14.86	13.30	11.27	10.61	090
27635		A	Remove lower leg bone lesion	7.78	NA	NA	9.47	9.29	0.78	NA	NA	18.03	17.85	090
27637		A	Remove/graft leg bone lesion	9.85	NA	NA	10.80	10.40	1.01	NA	NA	21.66	21.26	090
27638		A	Remove/graft leg bone lesion	10.57	NA	NA	11.24	10.91	1.06	NA	NA	22.87	22.54	090
27640		A	Partial removal of tibia	11.37	NA	NA	15.60	14.36	1.14	NA	NA	28.11	26.87	090
27641		A	Partial removal of fibula	9.24	NA	NA	14.09	12.50	0.92	NA	NA	24.25	22.66	090
27645		A	Extensive lower leg surgery	14.17	NA	NA	15.60	14.86	1.46	NA	NA	31.23	30.49	090
27646		A	Extensive lower leg surgery	12.66	NA	NA	15.38	14.45	1.24	NA	NA	29.28	28.35	090
27647		A	Extensive ankle/heel surgery	12.24	NA	NA	10.41	10.51	1.02	NA	NA	23.67	23.77	090
27648		A	Injection for ankle x-ray	0.96	8.42	6.46	0.34	0.40	0.05	9.43	7.47	1.35	1.41	000
27650		A	Repair achilles tendon	9.69	NA	NA	8.44	8.77	0.95	NA	NA	19.08	19.41	090
27652		A	Repair/graft achilles tendon	10.33	NA	NA	8.66	9.32	0.98	NA	NA	19.97	20.63	090
27654		A	Repair of achilles tendon	10.02	NA	NA	8.93	9.66	0.90	NA	NA	19.85	20.58	090
27656		A	Repair leg fascia defect	4.57	12.05	9.90	6.14	5.47	0.44	17.06	14.91	11.15	10.48	090
27658		A	Repair of leg tendon, each	4.98	8.99	7.83	7.53	6.74	0.46	14.43	13.27	12.97	12.18	090
27659		A	Repair of leg tendon, each	6.81	12.60	11.04	8.15	7.71	0.61	20.02	18.46	15.57	15.13	090
27664		A	Repair of leg tendon, each	4.59	9.19	7.82	7.94	6.88	0.45	14.23	12.86	12.98	11.92	090
27665		A	Repair of leg tendon, each	5.40	12.76	10.91	7.88	7.25	0.53	18.69	16.84	13.81	13.18	090
27675		A	Repair lower leg tendons	7.18	NA	NA	7.18	7.12	0.69	NA	NA	15.05	14.99	090
27676		A	Repair lower leg tendons	8.42	NA	NA	8.29	8.27	0.74	NA	NA	17.45	17.43	090
27680		A	Release of lower leg tendon	5.74	NA	NA	6.93	6.32	0.54	NA	NA	13.21	12.60	090
27681		A	Release of lower leg tendons	6.82	NA	NA	7.58	7.31	0.68	NA	NA	15.08	14.81	090
27685		A	Revision of lower leg tendon	6.50	7.33	6.54	7.29	6.51	0.56	14.39	13.60	14.35	13.57	090
27686		A	Revise lower leg tendons	7.46	8.98	8.52	8.58	8.22	0.74	17.18	16.72	16.78	16.42	090
27687		A	Revision of calf tendon	6.24	NA	NA	7.22	6.89	0.56	NA	NA	14.02	13.69	090
27690		A	Revise lower leg tendon	8.71	NA	NA	8.15	7.94	0.76	NA	NA	17.62	17.41	090
27691		A	Revise lower leg tendon	9.96	NA	NA	9.62	9.36	0.95	NA	NA	20.53	20.27	090
27692		A	Revise additional leg tendon	1.87	NA	NA	0.90	1.23	0.19	NA	NA	2.96	3.29	ZZZ
27695		A	Repair of ankle ligament	6.51	NA	NA	7.91	7.88	0.63	NA	NA	15.05	15.02	090
27696		A	Repair of ankle ligaments	8.27	NA	NA	8.64	8.40	0.76	NA	NA	17.67	17.43	090
27698		A	Repair of ankle ligament	9.36	NA	NA	8.47	9.15	0.84	NA	NA	18.67	19.35	090
27700		A	Revision of ankle joint	9.29	NA	NA	7.03	8.05	0.68	NA	NA	17.00	18.02	090
27702		A	Reconstruct ankle joint	13.67	NA	NA	11.57	12.76	1.41	NA	NA	26.65	27.84	090
27703		A	Reconstruction, ankle joint	15.87	NA	NA	11.62	12.47	1.32	NA	NA	28.81	29.66	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
27704		A	Removal of ankle implant	7.62	NA	NA	8.28	7.80	0.67	NA	NA	16.57	16.09	090
27705		A	Incision of tibia	10.38	NA	NA	10.17	10.54	1.06	NA	NA	21.61	21.98	090
27707		A	Incision of fibula	4.37	NA	NA	7.01	6.55	0.45	NA	NA	11.83	11.37	090
27709		A	Incision of tibia & fibula	9.95	NA	NA	10.05	10.51	1.02	NA	NA	21.02	21.48	090
27712		A	Realignment of lower leg	14.25	NA	NA	12.30	12.21	1.46	NA	NA	28.01	27.92	090
27715		A	Revision of lower leg	14.39	NA	NA	13.32	13.41	1.47	NA	NA	29.18	29.27	090
27720		A	Repair of tibia	11.79	NA	NA	11.93	12.47	1.21	NA	NA	24.93	25.47	090
27722		A	Repair/graft of tibia	11.82	NA	NA	11.76	11.67	1.21	NA	NA	24.79	24.70	090
27724		A	Repair/graft of tibia	14.99	NA	NA	13.71	14.49	1.54	NA	NA	30.24	31.02	090
27725		A	Repair of lower leg	15.59	NA	NA	13.93	13.28	1.58	NA	NA	31.10	30.45	090
27727		A	Repair of lower leg	14.01	NA	NA	12.63	12.02	1.41	NA	NA	28.05	27.44	090
27730		A	Repair of tibia epiphysis	7.41	13.48	11.09	8.85	7.61	0.74	21.63	19.24	17.00	15.76	090
27732		A	Repair of fibula epiphysis	5.32	12.65	10.80	7.02	6.58	0.53	18.50	16.65	12.87	12.43	090
27734		A	Repair lower leg epiphyses	8.48	NA	NA	8.27	8.25	0.76	NA	NA	17.51	17.49	090
27740		A	Repair of leg epiphyses	9.30	20.08	17.33	8.60	8.72	0.97	30.35	27.60	18.87	18.99	090
27742		A	Repair of leg epiphyses	10.30	14.63	13.49	9.00	9.27	0.93	25.86	24.72	20.23	20.50	090
27745		A	Reinforce tibia	10.07	NA	NA	10.23	10.11	1.02	NA	NA	21.32	21.20	090
27750		A	Treatment of tibia fracture	3.19	5.08	4.75	3.49	3.55	0.32	8.59	8.26	7.00	7.06	090
27752		A	Treatment of tibia fracture	5.84	7.42	6.95	5.66	5.63	0.61	13.87	13.40	12.11	12.08	090
27756		A	Treatment of tibia fracture	6.78	NA	NA	9.22	8.94	0.70	NA	NA	16.70	16.42	090
27758		A	Treatment of tibia fracture	11.67	NA	NA	10.82	11.60	1.19	NA	NA	23.68	24.46	090
27759		A	Treatment of tibia fracture	13.76	NA	NA	11.97	12.71	1.41	NA	NA	27.14	27.88	090
27760		A	Treatment of ankle fracture	3.01	4.87	4.35	3.19	3.09	0.31	8.19	7.67	6.51	6.41	090
27762		A	Treatment of ankle fracture	5.25	6.98	6.15	5.19	4.81	0.53	12.76	11.93	10.97	10.59	090
27766		A	Treatment of ankle fracture	8.36	NA	NA	7.54	7.79	0.86	NA	NA	16.76	17.01	090
27780		A	Treatment of fibula fracture	2.65	4.78	4.12	3.01	2.79	0.26	7.69	7.03	5.92	5.70	090
27781		A	Treatment of fibula fracture	4.40	5.98	5.38	4.28	4.10	0.45	10.83	10.23	9.13	8.95	090
27784		A	Treatment of fibula fracture	7.11	NA	NA	7.50	7.14	0.73	NA	NA	15.34	14.98	090
27786		A	Treatment of ankle fracture	2.84	4.83	4.31	3.12	3.02	0.29	7.96	7.44	6.25	6.15	090
27788		A	Treatment of ankle fracture	4.45	5.99	5.38	4.20	4.04	0.46	10.90	10.29	9.11	8.95	090
27792		A	Treatment of ankle fracture	7.66	NA	NA	7.21	7.41	0.78	NA	NA	15.65	15.85	090
27808		A	Treatment of ankle fracture	2.83	5.74	5.06	3.79	3.60	0.29	8.86	8.18	6.91	6.72	090
27810		A	Treatment of ankle fracture	5.13	6.97	6.60	5.17	5.25	0.53	12.63	12.26	10.83	10.91	090
27814		A	Treatment of ankle fracture	10.68	NA	NA	9.69	9.98	1.10	NA	NA	21.47	21.76	090
27816		A	Treatment of ankle fracture	2.89	5.27	4.90	3.77	3.77	0.29	8.45	8.08	6.95	6.95	090
27818		A	Treatment of ankle fracture	5.50	7.19	7.04	5.29	5.61	0.56	13.25	13.10	11.35	11.67	090
27822		A	Treatment of ankle fracture	9.20	NA	NA	10.68	10.76	0.95	NA	NA	20.83	20.91	090
27823		A	Treatment of ankle fracture	11.80	NA	NA	12.04	12.50	1.21	NA	NA	25.05	25.51	090
27824		A	Treat lower leg fracture	2.89	5.71	5.23	3.86	3.84	0.29	8.89	8.41	7.04	7.02	090
27825		A	Treat lower leg fracture	6.19	7.68	7.53	5.83	6.14	0.64	14.51	14.36	12.66	12.97	090
27826		A	Treat lower leg fracture	8.54	NA	NA	10.34	10.30	0.88	NA	NA	19.76	19.72	090
27827		A	Treat lower leg fracture	14.06	NA	NA	13.38	13.21	1.44	NA	NA	28.88	28.71	090
27828		A	Treat lower leg fracture	16.23	NA	NA	14.48	14.33	1.67	NA	NA	32.38	32.23	090
27829		A	Treat lower leg joint	5.49	NA	NA	7.46	7.23	0.56	NA	NA	13.51	13.28	090
27830		A	Treat lower leg dislocation	3.79	5.32	4.87	3.48	3.49	0.38	9.49	9.04	7.65	7.66	090
27831		A	Treat lower leg dislocation	4.56	NA	NA	4.35	4.34	0.46	NA	NA	9.37	9.36	090
27832		A	Treat lower leg dislocation	6.49	NA	NA	7.25	6.99	0.68	NA	NA	14.42	14.16	090
27840		A	Treat ankle dislocation	4.58	NA	NA	4.37	3.79	0.45	NA	NA	9.40	8.82	090
27842		A	Treat ankle dislocation	6.21	NA	NA	4.42	3.92	0.64	NA	NA	11.27	10.77	090
27846		A	Treat ankle dislocation	9.79	NA	NA	9.17	9.21	0.96	NA	NA	19.92	19.96	090
27848		A	Treat ankle dislocation	11.20	NA	NA	10.48	10.13	1.15	NA	NA	22.83	22.48	090
27860		A	Fixation of ankle joint	2.34	NA	NA	3.05	2.67	0.23	NA	NA	5.62	5.24	010
27870		A	Fusion of ankle joint	13.91	NA	NA	12.27	12.82	1.40	NA	NA	27.58	28.13	090
27871		A	Fusion of tibiofibular joint	9.17	NA	NA	9.43	9.19	0.92	NA	NA	19.52	19.28	090
27880		A	Amputation of lower leg	11.85	NA	NA	10.61	10.23	1.27	NA	NA	23.73	23.35	090
27881		A	Amputation of lower leg	12.34	NA	NA	11.70	11.71	1.31	NA	NA	25.35	25.36	090
27882		A	Amputation of lower leg	8.94	NA	NA	11.10	10.32	0.98	NA	NA	21.02	20.24	090
27884		A	Amputation follow-up surgery	8.21	NA	NA	9.64	8.15	0.89	NA	NA	18.74	17.25	090
27886		A	Amputation follow-up surgery	9.32	NA	NA	9.71	9.23	1.01	NA	NA	20.04	19.56	090
27888		A	Amputation of foot at ankle	9.67	NA	NA	9.73	9.87	1.01	NA	NA	20.41	20.55	090
27889		A	Amputation of foot at ankle	9.98	NA	NA	8.85	8.93	1.10	NA	NA	19.93	20.01	090
27892		A	Decompression of leg	7.39	NA	NA	7.49	6.54	0.80	NA	NA	15.68	14.73	090
27893		A	Decompression of leg	7.35	NA	NA	6.92	6.11	0.69	NA	NA	14.96	14.15	090
27894		A	Decompression of leg	10.49	NA	NA	8.68	7.61	1.12	NA	NA	20.29	19.22	090
27899		C	Leg/ankle surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
28001		A	Drainage of bursa of foot	2.73	4.44	3.47	2.80	2.24	0.18	7.35	6.38	5.71	5.15	010
28002		A	Treatment of foot infection	4.62	5.68	4.87	3.86	3.51	0.37	10.67	9.86	8.85	8.50	010
28003		A	Treatment of foot infection	8.41	8.93	7.65	8.93	7.65	0.66	18.00	16.72	18.00	16.72	090
28005		A	Treat foot bone lesion	8.68	NA	NA	9.06	7.90	0.74	NA	NA	18.48	17.32	090
28008		A	Incision of foot fascia	4.45	6.25	5.42	5.32	4.72	0.31	11.01	10.18	10.08	9.48	090
28010		A	Incision of toe tendon	2.84	5.83	5.36	4.08	4.04	0.19	8.86	8.39	7.11	7.07	090
28011		A	Incision of toe tendons	4.14	7.19	5.87	5.81	4.84	0.33	11.66	10.34	10.28	9.31	090
28020		A	Exploration of foot joint	5.01	7.63	6.92	5.57	5.37	0.41	13.05	12.34	10.99	10.79	090
28022		A	Exploration of foot joint	4.67	6.36	5.51	5.09	4.56	0.35	11.38	10.53	10.11	9.58	090
28024		A	Exploration of toe joint	4.38	6.15	5.26	4.94	4.35	0.32	10.85	9.96	9.64	9.05	090
28030		A	Removal of foot nerve	6.15	NA	NA	3.22	3.48	0.42	NA	NA	9.79	10.05	090
28035		A	Decompression of tibia nerve	5.09	6.67	6.68	4.89	5.35	0.42	12.18	12.19	10.40	10.86	090
28043		A	Excision of foot lesion	3.54	5.87	4.87	4.26	3.67	0.27	9.68	8.68	8.07	7.48	090
28045		A	Excision of foot lesion	4.72	6.46	5.93	4.88	4.74	0.36	11.54	11.01	9.96	9.82	090
28046		A	Resection of tumor, foot	10.18	9.50	8.58	9.50	8.58	0.82	20.50	19.58	20.50	19.58	090
28050		A	Biopsy of foot joint lining	4.25	5.67	5.30	4.71	4.58	0.33	10.25	9.88	9.29	9.16	090
28052		A	Biopsy of foot joint lining	3.94	5.86	5.43	5.04	4.82	0.32	10.12	9.69	9.30	9.08	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
28054		A	Biopsy of toe joint lining	3.45	5.92	5.05	5.53	4.76	0.29	9.66	8.79	9.27	8.50	090
28060		A	Partial removal, foot fascia	5.23	6.92	6.34	5.56	5.32	0.38	12.53	11.95	11.17	10.93	090
28062		A	Removal of foot fascia	6.52	8.48	8.28	5.39	5.96	0.45	15.45	15.25	12.36	12.93	090
28070		A	Removal of foot joint lining	5.10	6.01	5.72	5.15	5.08	0.37	11.48	11.19	10.62	10.55	090
28072		A	Removal of foot joint lining	4.58	6.92	6.06	5.78	5.21	0.41	11.91	11.05	10.77	10.20	090
28080		A	Removal of foot lesion	3.58	5.96	5.58	4.51	4.49	0.26	9.80	9.42	8.35	8.33	090
28086		A	Excise foot tendon sheath	4.78	8.96	7.57	6.38	5.63	0.47	14.21	12.82	11.63	10.88	090
28088		A	Excise foot tendon sheath	3.86	6.57	5.91	5.66	5.23	0.35	10.78	10.12	9.87	9.44	090
28090		A	Removal of foot lesion	4.41	6.26	5.52	4.67	4.32	0.32	10.99	10.25	9.40	9.05	090
28092		A	Removal of toe lesions	3.64	6.95	5.76	5.01	4.31	0.28	10.87	9.68	8.93	8.23	090
28100		A	Removal of ankle/heel lesion	5.66	8.94	7.95	6.41	6.05	0.49	15.09	14.10	12.56	12.20	090
28102		A	Remove/graft foot lesion	7.73	NA	NA	7.70	7.63	0.72	NA	NA	16.15	16.08	090
28103		A	Remove/graft foot lesion	6.50	13.01	11.28	5.70	5.80	0.52	20.03	18.30	12.72	12.82	090
28104		A	Removal of foot lesion	5.12	6.78	6.26	5.75	5.49	0.38	12.28	11.76	11.25	10.99	090
28106		A	Remove/graft foot lesion	7.16	NA	NA	5.96	6.21	0.53	NA	NA	13.65	13.90	090
28107		A	Remove/graft foot lesion	5.56	6.52	6.21	6.03	5.84	0.40	12.48	12.17	11.99	11.80	090
28108		A	Removal of toe lesions	4.16	5.74	5.45	4.42	4.46	0.28	10.18	9.89	8.86	8.90	090
28110		A	Part removal of metatarsal	4.08	6.83	6.07	5.66	5.19	0.31	11.22	10.46	10.05	9.58	090
28111		A	Part removal of metatarsal	5.01	8.32	7.61	6.41	6.18	0.42	13.75	13.04	11.84	11.61	090
28112		A	Part removal of metatarsal	4.49	7.09	6.39	6.11	5.66	0.35	11.93	11.23	10.95	10.50	090
28113		A	Part removal of metatarsal	4.79	7.03	6.48	5.93	5.65	0.36	12.18	11.63	11.08	10.80	090
28114		A	Removal of metatarsal heads	9.79	9.64	9.72	9.27	9.44	0.82	20.25	20.33	19.88	20.05	090
28116		A	Revision of foot	7.75	7.07	6.79	5.89	5.91	0.56	15.38	15.10	14.20	14.22	090
28118		A	Removal of heel bone	5.96	6.95	6.76	5.99	6.04	0.48	13.39	13.20	12.43	12.48	090
28119		A	Removal of heel spur	5.39	6.61	6.43	5.11	5.31	0.37	12.37	12.19	10.87	11.07	090
28120		A	Part removal of ankle/heel	5.40	10.73	9.42	8.00	7.37	0.47	16.60	15.29	13.87	13.24	090
28122		A	Partial removal of foot bone	7.29	8.78	7.80	7.92	7.16	0.56	16.63	15.65	15.77	15.01	090
28124		A	Partial removal of toe	4.81	7.35	6.63	6.29	5.83	0.32	12.48	11.76	11.42	10.96	090
28126		A	Partial removal of toe	3.52	6.27	5.78	5.70	5.36	0.24	10.03	9.54	9.46	9.12	090
28130		A	Removal of ankle bone	8.11	NA	NA	7.88	7.82	0.75	NA	NA	16.74	16.68	090
28140		A	Removal of metatarsal	6.91	7.66	7.08	6.70	6.36	0.59	15.16	14.58	14.20	13.86	090
28150		A	Removal of toe	4.09	6.78	5.98	5.87	5.30	0.32	11.19	10.39	10.28	9.71	090
28153		A	Partial removal of toe	3.66	6.30	5.81	4.54	4.49	0.24	10.20	9.71	8.44	8.39	090
28160		A	Partial removal of toe	3.74	6.47	5.97	5.95	5.58	0.27	10.48	9.98	9.96	9.59	090
28171		A	Extensive foot surgery	9.60	NA	NA	6.92	7.36	0.62	NA	NA	17.14	17.58	090
28173		A	Extensive foot surgery	8.80	9.04	8.34	7.65	7.30	0.71	18.55	17.85	17.16	16.81	090
28175		A	Extensive foot surgery	6.05	7.41	7.02	5.84	5.84	0.41	13.87	13.48	12.30	12.30	090
28190		A	Removal of foot foreign body	1.96	5.06	3.94	2.52	2.03	0.13	7.15	6.03	4.61	4.12	010
28192		A	Removal of foot foreign body	4.64	6.70	5.56	4.66	4.03	0.36	11.70	10.56	9.66	9.03	090
28193		A	Removal of foot foreign body	5.73	6.90	5.82	5.51	4.78	0.42	13.05	11.97	11.66	10.93	090
28200		A	Repair of foot tendon	4.60	6.57	6.30	5.38	5.41	0.33	11.50	11.23	10.31	10.34	090
28202		A	Repair/graft of foot tendon	6.84	7.03	6.85	5.91	6.01	0.53	14.40	14.22	13.28	13.38	090
28208		A	Repair of foot tendon	4.37	6.29	5.48	4.84	4.39	0.31	10.97	10.16	9.52	9.07	090
28210		A	Repair/graft of foot tendon	6.35	8.04	7.55	5.64	5.75	0.46	14.85	14.36	12.45	12.56	090
28220		A	Release of foot tendon	4.53	6.13	5.65	5.12	4.89	0.30	10.96	10.48	9.95	9.72	090
28222		A	Release of foot tendons	5.62	6.54	6.64	6.05	6.28	0.36	12.52	12.62	12.03	12.26	090
28225		A	Release of foot tendon	3.66	5.90	5.07	4.71	4.18	0.25	9.81	8.98	8.62	8.09	090
28226		A	Release of foot tendons	4.53	6.11	5.50	5.33	4.92	0.33	10.97	10.36	10.19	9.78	090
28230		A	Incision of foot tendon(s)	4.24	6.24	5.34	5.64	4.89	0.31	10.79	9.89	10.19	9.44	090
28232		A	Incision of toe tendon	3.39	6.44	5.27	5.38	4.47	0.25	10.08	8.91	9.02	8.11	090
28234		A	Incision of foot tendon	3.37	6.52	5.31	4.80	4.02	0.24	10.13	8.92	8.41	7.63	090
28238		A	Revision of foot tendon	7.73	7.38	7.50	6.40	6.76	0.56	15.67	15.79	14.69	15.05	090
28240		A	Release of big toe	4.36	6.09	5.15	5.29	4.55	0.32	10.77	9.83	9.97	9.23	090
28250		A	Revision of foot fascia	5.92	7.01	6.47	6.17	5.84	0.42	13.35	12.81	12.51	12.18	090
28260		A	Release of midfoot joint	7.96	7.47	6.81	6.37	5.98	0.57	16.00	15.34	14.90	14.51	090
28261		A	Revision of foot tendon	11.73	9.37	8.63	8.39	7.90	0.84	21.94	21.20	20.96	20.47	090
28262		A	Revision of foot and ankle	15.83	15.10	14.56	13.41	13.29	1.48	32.41	31.87	30.72	30.60	090
28264		A	Release of midfoot joint	10.35	8.87	9.25	8.87	9.25	0.86	20.08	20.46	20.08	20.46	090
28270		A	Release of foot contracture	4.76	6.73	5.76	6.01	5.22	0.32	11.81	10.84	11.09	10.30	090
28272		A	Release of toe joint, each	3.80	5.84	4.93	4.49	3.92	0.24	9.88	8.97	8.53	7.96	090
28280		A	Fusion of toes	5.19	6.73	5.65	5.93	5.05	0.45	12.37	11.29	11.57	10.69	090
28285		A	Repair of hammertoe	4.59	6.72	6.23	5.48	5.30	0.32	11.63	11.14	10.39	10.21	090
28286		A	Repair of hammertoe	4.56	6.64	5.95	5.30	4.95	0.32	11.52	10.83	10.18	9.83	090
28288		A	Partial removal of foot bone	4.74	6.58	5.95	6.58	5.95	0.38	11.70	11.07	11.70	11.07	090
28289		A	Repair hallux rigidus	7.04	8.05	8.05	7.23	7.23	0.55	15.64	15.64	14.82	14.82	090
28290		A	Correction of bunion	5.66	7.57	7.13	7.47	7.06	0.46	13.69	13.25	13.59	13.18	090
28292		A	Correction of bunion	7.04	7.75	7.73	6.41	6.72	0.50	15.29	15.27	13.95	14.26	090
28293		A	Correction of bunion	9.15	8.84	9.22	6.78	7.68	0.61	18.60	18.98	16.54	17.44	090
28294		A	Correction of bunion	8.56	8.28	8.70	6.60	7.44	0.55	17.39	17.81	15.71	16.55	090
28296		A	Correction of bunion	9.18	8.83	9.01	7.42	7.96	0.66	18.67	18.85	17.26	17.80	090
28297		A	Correction of bunion	9.18	8.75	9.01	8.75	9.01	0.74	18.67	18.93	18.67	18.93	090
28298		A	Correction of bunion	7.94	8.15	8.48	7.09	7.69	0.54	16.63	16.96	15.57	16.17	090
28299		A	Correction of bunion	8.88	8.35	8.91	7.05	7.94	0.61	17.84	18.40	16.54	17.43	090
28300		A	Incision of heel bone	9.54	9.20	8.67	8.19	7.91	0.87	19.61	19.08	18.60	18.32	090
28302		A	Incision of ankle bone	9.55	12.77	11.99	8.55	8.83	0.78	23.10	22.32	18.88	19.16	090
28304		A	Incision of midfoot bones	9.16	8.77	8.33	7.06	7.04	0.68	18.61	18.17	16.90	16.88	090
28305		A	Incise/graft midfoot bones	10.50	13.32	12.66	9.03	9.45	0.61	24.43	23.77	20.14	20.56	090
28306		A	Incision of metatarsal	5.86	6.76	6.31	5.35	5.25	0.45	13.07	12.62	11.66	11.56	090
28307		A	Incision of metatarsal	6.33	7.90	7.52	7.43	7.17	0.51	14.74	14.36	14.27	14.01	090
28308		A	Incision of metatarsal	5.29	6.16	6.17	4.45	4.89	0.35	11.80	11.81	10.09	10.53	090
28309		A	Incision of metatarsals	12.78	NA	NA	9.49	8.98	0.99	NA	NA	23.26	22.75	090
28310		A	Revision of big toe	5.43	7.09	6.45	5.65	5.37	0.37	12.89	12.25	11.45	11.17	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
28312		A	Revision of toe	4.55	6.86	6.38	6.10	5.81	0.33	11.74	11.26	10.98	10.69	090
28313		A	Repair deformity of toe	5.01	7.38	6.23	7.38	6.23	0.45	12.84	11.69	12.84	11.69	090
28315		A	Removal of sesamoid bone	4.86	6.23	5.82	4.73	4.70	0.33	11.42	11.01	9.92	9.89	090
28320		A	Repair of foot bones	9.18	NA	NA	8.07	8.41	0.82	NA	NA	18.07	18.41	090
28322		A	Repair of metatarsals	8.34	7.30	6.74	7.24	6.70	0.74	16.38	15.82	16.32	15.78	090
28340		A	Resect enlarged toe tissue	6.98	7.81	7.58	5.73	6.02	0.52	15.31	15.08	13.23	13.52	090
28341		A	Resect enlarged toe	8.41	8.27	8.28	6.18	6.71	0.55	17.23	17.24	15.14	15.67	090
28344		A	Repair extra toe(s)	4.26	5.68	5.27	5.15	4.87	0.38	10.32	9.91	9.79	9.51	090
28345		A	Repair webbed toe(s)	5.92	6.98	6.69	6.46	6.30	0.48	13.38	13.09	12.86	12.70	090
28360		A	Reconstruct cleft foot	13.34	NA	NA	12.26	12.43	1.39	NA	NA	26.99	27.16	090
28400		A	Treatment of heel fracture	2.16	5.13	4.55	3.91	3.63	0.21	7.50	6.92	6.28	6.00	090
28405		A	Treatment of heel fracture	4.57	5.88	5.47	5.33	5.06	0.44	10.89	10.48	10.34	10.07	090
28406		A	Treatment of heel fracture	6.31	NA	NA	7.65	7.39	0.65	NA	NA	14.61	14.35	090
28415		A	Treat heel fracture	15.97	NA	NA	13.83	12.82	1.58	NA	NA	31.38	30.37	090
28420		A	Treat/graft heel fracture	16.64	NA	NA	14.33	13.70	1.67	NA	NA	32.64	32.01	090
28430		A	Treatment of ankle fracture	2.09	4.67	4.17	3.30	3.14	0.20	6.96	6.46	5.59	5.43	090
28435		A	Treatment of ankle fracture	3.40	5.18	4.80	4.24	4.09	0.31	8.89	8.51	7.95	7.80	090
28436		A	Treatment of ankle fracture	4.71	NA	NA	6.25	5.83	0.50	NA	NA	11.46	11.04	090
28445		A	Treat ankle fracture	9.33	NA	NA	9.36	9.41	0.90	NA	NA	19.59	19.64	090
28450		A	Treat midfoot fracture, each	1.90	4.55	3.92	3.18	2.89	0.18	6.63	6.00	5.26	4.97	090
28455		A	Treat midfoot fracture, each	3.09	4.22	3.86	4.11	3.77	0.25	7.56	7.20	7.45	7.11	090
28456		A	Treat midfoot fracture	2.68	NA	NA	4.98	4.35	0.26	NA	NA	7.92	7.29	090
28465		A	Treat midfoot fracture, each	7.01	NA	NA	7.40	7.05	0.65	NA	NA	15.06	14.71	090
28470		A	Treat metatarsal fracture	1.99	4.00	3.49	2.69	2.51	0.19	6.18	5.67	4.87	4.69	090
28475		A	Treat metatarsal fracture	2.97	4.48	4.00	3.93	3.58	0.26	7.71	7.23	7.16	6.81	090
28476		A	Treat metatarsal fracture	3.38	NA	NA	5.64	5.15	0.32	NA	NA	9.34	8.85	090
28485		A	Treat metatarsal fracture	5.71	NA	NA	6.80	6.37	0.48	NA	NA	12.99	12.56	090
28490		A	Treat big toe fracture	1.09	2.18	1.88	1.53	1.39	0.10	3.37	3.07	2.72	2.58	090
28495		A	Treat big toe fracture	1.58	2.24	1.99	1.74	1.61	0.12	3.94	3.69	3.44	3.31	090
28496		A	Treat big toe fracture	2.33	7.03	5.84	4.40	3.86	0.23	9.59	8.40	6.96	6.42	090
28505		A	Treat big toe fracture	3.81	9.21	7.72	5.77	5.14	0.34	13.36	11.87	9.92	9.29	090
28510		A	Treatment of toe fracture	1.09	1.93	1.69	1.46	1.34	0.09	3.11	2.87	2.64	2.52	090
28515		A	Treatment of toe fracture	1.46	2.13	1.90	1.66	1.55	0.11	3.70	3.47	3.23	3.12	090
28525		A	Treat toe fracture	3.32	8.37	6.84	5.44	4.64	0.30	11.99	10.46	9.06	8.26	090
28530		A	Treat sesamoid bone fracture	1.06	2.75	2.34	2.31	2.01	0.08	3.89	3.48	3.45	3.15	090
28531		A	Treat sesamoid bone fracture	2.35	8.01	6.53	3.15	2.88	0.17	10.53	9.05	5.67	5.40	090
28540		A	Treat foot dislocation	2.04	3.30	2.64	3.27	2.62	0.15	5.49	4.83	5.46	4.81	090
28545		A	Treat foot dislocation	2.45	3.17	2.73	3.17	2.73	0.22	5.84	5.40	5.84	5.40	090
28546		A	Treat foot dislocation	3.20	4.91	4.43	4.91	4.43	0.30	8.41	7.93	8.41	7.93	090
28555		A	Repair foot dislocation	6.30	6.33	6.26	6.33	6.26	0.59	13.22	13.15	13.22	13.15	090
28570		A	Treat foot dislocation	1.66	3.68	3.19	3.32	2.92	0.14	5.48	4.99	5.12	4.72	090
28575		A	Treat foot dislocation	3.31	3.36	3.27	3.36	3.27	0.32	6.99	6.90	6.99	6.90	090
28576		A	Treat foot dislocation	4.17	5.30	4.73	5.30	4.73	0.41	9.88	9.31	9.88	9.31	090
28585		A	Repair foot dislocation	7.99	8.58	7.78	7.12	6.69	0.71	17.28	16.48	15.82	15.39	090
28600		A	Treat foot dislocation	1.89	4.01	3.19	3.52	2.83	0.16	6.06	5.24	5.57	4.88	090
28605		A	Treat foot dislocation	2.71	4.63	4.09	3.98	3.60	0.26	7.60	7.06	6.95	6.57	090
28606		A	Treat foot dislocation	4.90	14.59	11.89	6.15	5.56	0.50	19.99	17.29	11.55	10.96	090
28615		A	Repair foot dislocation	7.77	NA	NA	8.27	7.55	0.77	NA	NA	16.81	16.09	090
28630		A	Treat toe dislocation	1.70	1.84	1.66	1.76	1.60	0.14	3.68	3.50	3.60	3.44	010
28635		A	Treat toe dislocation	1.91	2.15	2.01	2.15	2.01	0.15	4.21	4.07	4.21	4.07	010
28636		A	Treat toe dislocation	2.77	5.54	4.85	2.57	2.62	0.26	8.57	7.88	5.60	5.65	010
28645		A	Repair toe dislocation	4.22	5.25	4.82	3.81	3.74	0.31	9.78	9.35	8.34	8.27	090
28660		A	Treat toe dislocation	1.23	2.48	2.03	1.70	1.45	0.11	3.82	3.37	3.04	2.79	010
28665		A	Treat toe dislocation	1.92	2.21	1.92	2.21	1.92	0.14	4.27	3.98	4.27	3.98	010
28666		A	Treat toe dislocation	2.66	8.41	6.97	2.58	2.60	0.26	11.33	9.89	5.50	5.52	010
28675		A	Repair of toe dislocation	2.92	6.74	5.87	4.12	3.91	0.28	9.94	9.07	7.32	7.11	090
28705		A	Fusion of foot bones	15.21	NA	NA	11.91	13.03	1.40	NA	NA	28.52	29.64	090
28715		A	Fusion of foot bones	13.10	NA	NA	11.12	11.69	1.28	NA	NA	25.50	26.07	090
28725		A	Fusion of foot bones	11.61	NA	NA	10.22	10.23	1.06	NA	NA	22.89	22.90	090
28730		A	Fusion of foot bones	10.76	NA	NA	9.42	9.51	0.01	NA	NA	20.19	20.28	090
28735		A	Fusion of foot bones	10.85	NA	NA	9.22	9.56	0.96	NA	NA	21.03	21.37	090
28737		A	Revision of foot bones	9.64	NA	NA	8.25	8.60	0.86	NA	NA	18.75	19.10	090
28740		A	Fusion of foot bones	8.02	10.13	8.99	7.76	7.22	0.70	18.85	17.71	16.48	15.94	090
28750		A	Fusion of big toe joint	7.30	10.13	9.04	8.01	7.45	0.70	18.13	17.04	16.01	15.45	090
28755		A	Fusion of big toe joint	4.74	7.26	6.45	5.46	5.10	0.38	12.38	11.57	10.58	10.22	090
28760		A	Fusion of big toe joint	7.75	7.39	7.01	6.62	6.43	0.59	15.73	15.35	14.96	14.77	090
28800		A	Amputation of midfoot	8.21	NA	NA	8.02	7.82	0.82	NA	NA	17.05	16.85	090
28805		A	Amputation thru metatarsal	8.39	NA	NA	7.92	7.66	0.89	NA	NA	17.20	16.94	090
28810		A	Amputation toe & metatarsal	6.21	NA	NA	6.82	6.18	0.65	NA	NA	13.68	13.04	090
28820		A	Amputation of toe	4.41	8.78	7.29	6.11	5.28	0.44	13.63	12.14	10.96	10.13	090
28825		A	Partial amputation of toe	3.59	8.11	6.73	5.74	4.96	0.35	12.05	10.67	9.68	8.90	090
28899		C	Foot/toes surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
29000		A	Application of body cast	2.25	2.42	2.32	1.26	1.45	0.34	5.01	4.91	3.85	4.04	000
29010		A	Application of body cast	2.06	2.14	2.24	1.24	1.56	0.26	4.46	4.56	3.56	3.88	000
29015		A	Application of body cast	2.41	2.85	2.77	1.18	1.52	0.14	5.40	5.32	3.73	4.07	000
29020		A	Application of body cast	2.11	2.55	2.41	1.03	1.27	0.12	4.78	4.64	3.26	3.50	000
29025		A	Application of body cast	2.40	2.44	2.03	1.34	1.21	0.27	5.11	4.70	4.01	3.88	000
29035		A	Application of body cast	1.77	2.33	2.28	0.95	1.24	0.19	4.29	4.24	2.91	3.20	000
29040		A	Application of body cast	2.22	1.83	1.92	0.90	1.22	0.18	4.23	4.32	3.30	3.62	000
29044		A	Application of body cast	2.12	2.53	2.47	1.30	1.54	0.23	4.88	4.82	3.65	3.89	000
29046		A	Application of body cast	2.41	2.02	2.12	1.45	1.69	0.25	4.68	4.78	4.11	4.35	000
29049		A	Application of figure eight	0.89	1.46	1.21	0.36	0.39	0.09	2.44	2.19	1.34	1.37	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
29055		A	Application of shoulder cast	1.78	2.07	1.88	1.03	1.10	0.18	4.03	3.84	2.99	3.06	000
29058		A	Application of shoulder cast	1.31	1.69	1.45	0.66	0.67	0.12	3.12	2.88	2.09	2.10	000
29065		A	Application of long arm cast	0.87	1.20	1.12	0.52	0.61	0.09	2.16	2.08	1.48	1.57	000
29075		A	Application of forearm cast	0.77	1.15	1.03	0.45	0.50	0.08	2.00	1.88	1.30	1.35	000
29085		A	Apply hand/wrist cast	0.87	1.18	1.02	0.46	0.48	0.09	2.14	1.98	1.42	1.44	000
29105		A	Apply long arm splint	0.87	1.19	1.03	0.37	0.41	0.09	2.15	1.99	1.33	1.37	000
29125		A	Apply forearm splint	0.59	1.03	0.87	0.25	0.29	0.06	1.68	1.52	0.90	0.94	000
29126		A	Apply forearm splint	0.77	1.46	1.20	0.38	0.39	0.07	2.30	2.04	1.22	1.23	000
29130		A	Application of finger splint	0.50	0.79	0.64	0.22	0.21	0.05	1.34	1.19	0.77	0.76	000
29131		A	Application of finger splint	0.55	1.30	1.08	0.33	0.35	0.05	1.90	1.68	0.93	0.95	000
29200		A	Strapping of chest	0.65	0.99	0.82	0.25	0.26	0.06	1.70	1.53	0.96	0.97	000
29220		A	Strapping of low back	0.64	0.90	0.78	0.33	0.35	0.05	1.59	1.47	1.02	1.04	000
29240		A	Strapping of shoulder	0.71	1.09	0.89	0.27	0.28	0.07	1.87	1.67	1.05	1.06	000
29260		A	Strapping of elbow or wrist	0.55	0.90	0.74	0.23	0.24	0.05	1.50	1.34	0.83	0.84	000
29280		A	Strapping of hand or finger	0.51	0.98	0.79	0.22	0.22	0.05	1.54	1.35	0.78	0.78	000
29305		A	Application of hip cast	2.03	2.25	2.20	1.23	1.43	0.21	4.49	4.44	3.47	3.67	000
29325		A	Application of hip casts	2.32	2.10	2.10	1.35	1.54	0.24	4.66	4.66	3.91	4.10	000
29345		A	Application of long leg cast	1.40	1.57	1.46	0.80	0.88	0.14	3.11	3.00	2.34	2.42	000
29355		A	Application of long leg cast	1.53	1.58	1.48	0.85	0.94	0.15	3.26	3.16	2.53	2.62	000
29358		A	Apply long leg cast brace	1.43	1.71	1.71	0.90	1.10	0.14	3.28	3.28	2.47	2.67	000
29365		A	Application of long leg cast	1.18	1.42	1.30	0.69	0.75	0.12	2.72	2.60	1.99	2.05	000
29405		A	Apply short leg cast	0.86	1.12	1.06	0.49	0.58	0.09	2.07	2.01	1.44	1.53	000
29425		A	Apply short leg cast	1.01	1.10	1.09	0.55	0.68	0.10	2.21	2.20	1.66	1.79	000
29435		A	Apply short leg cast	1.18	1.63	1.54	0.75	0.88	0.11	2.92	2.83	2.04	2.17	000
29440		A	Addition of walker to cast	0.57	0.85	0.70	0.30	0.29	0.06	1.48	1.33	0.93	0.92	000
29445		A	Apply rigid leg cast	1.78	1.85	1.85	0.85	1.10	0.16	3.79	3.79	2.79	3.04	000
29450		A	Application of leg cast	1.02	1.06	0.90	0.54	0.51	0.08	2.16	2.00	1.64	1.61	000
29505		A	Application, long leg splint	0.69	1.34	1.16	0.35	0.42	0.07	2.10	1.92	1.11	1.18	000
29515		A	Application lower leg splint	0.73	1.01	0.89	0.35	0.39	0.06	1.80	1.68	1.14	1.18	000
29520		A	Strapping of hip	0.54	1.06	0.89	0.36	0.37	0.03	1.63	1.46	0.93	0.94	000
29530		A	Strapping of knee	0.57	0.97	0.82	0.24	0.28	0.05	1.59	1.44	0.86	0.90	000
29540		A	Strapping of ankle	0.51	0.46	0.43	0.23	0.26	0.03	1.00	0.97	0.77	0.80	000
29550		A	Strapping of toes	0.47	0.44	0.41	0.22	0.24	0.03	0.94	0.91	0.72	0.74	000
29580		A	Application of paste boot	0.57	0.76	0.79	0.29	0.43	0.05	1.38	1.41	0.91	1.05	000
29590		A	Application of foot splint	0.76	0.67	0.58	0.37	0.35	0.05	1.48	1.39	1.18	1.16	000
29700		A	Removal/revision of cast	0.57	0.72	0.63	0.29	0.31	0.06	1.35	1.26	0.92	0.94	000
29705		A	Removal/revision of cast	0.76	0.89	0.76	0.39	0.39	0.08	1.73	1.60	1.23	1.23	000
29710		A	Removal/revision of cast	1.34	1.50	1.25	0.76	0.69	0.12	2.96	2.71	2.22	2.15	000
29715		A	Removal/revision of cast	0.94	1.16	1.10	0.40	0.53	0.10	2.20	2.14	1.44	1.57	000
29720		A	Repair of body cast	0.68	1.34	1.07	0.47	0.42	0.07	2.09	1.82	1.22	1.17	000
29730		A	Windowing of cast	0.75	0.86	0.72	0.37	0.35	0.08	1.69	1.55	1.20	1.18	000
29740		A	Wedging of cast	1.12	1.26	1.05	0.51	0.49	0.11	2.49	2.28	1.74	1.72	000
29750		A	Wedging of clubfoot cast	1.26	1.19	1.03	0.69	0.65	0.11	2.56	2.40	2.06	2.02	000
29799		C	Casting/strapping procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
29800		A	Jaw arthroscopy/surgery	6.43	NA	NA	7.69	6.86	0.59	NA	NA	14.71	13.88	090
29804		A	Jaw arthroscopy/surgery	8.14	NA	NA	8.18	8.56	0.62	NA	NA	16.94	17.32	090
29815		A	Shoulder arthroscopy	5.89	NA	NA	6.70	6.34	0.58	NA	NA	13.17	12.81	090
29819		A	Shoulder arthroscopy/surgery	7.62	NA	NA	8.57	8.70	0.78	NA	NA	16.97	17.10	090
29820		A	Shoulder arthroscopy/surgery	7.07	NA	NA	8.28	8.32	0.73	NA	NA	16.08	16.12	090
29821		A	Shoulder arthroscopy/surgery	7.72	NA	NA	8.60	8.75	0.78	NA	NA	17.10	17.25	090
29822		A	Shoulder arthroscopy/surgery	7.43	NA	NA	8.51	8.60	0.76	NA	NA	16.70	16.79	090
29823		A	Shoulder arthroscopy/surgery	8.17	NA	NA	8.92	9.13	0.83	NA	NA	17.92	18.13	090
29825		A	Shoulder arthroscopy/surgery	7.62	NA	NA	8.63	8.75	0.78	NA	NA	17.03	17.15	090
29826		A	Shoulder arthroscopy/surgery	8.99	NA	NA	9.34	9.69	0.93	NA	NA	19.26	19.61	090
29830		A	Elbow arthroscopy	5.76	NA	NA	5.44	5.52	0.62	NA	NA	11.82	11.90	090
29834		A	Elbow arthroscopy/surgery	6.28	NA	NA	6.10	6.16	0.64	NA	NA	13.02	13.08	090
29835		A	Elbow arthroscopy/surgery	6.48	NA	NA	6.15	6.25	0.66	NA	NA	13.29	13.39	090
29836		A	Elbow arthroscopy/surgery	7.55	NA	NA	6.84	7.04	0.77	NA	NA	15.16	15.36	090
29837		A	Elbow arthroscopy/surgery	6.87	NA	NA	6.34	6.49	0.71	NA	NA	13.92	14.07	090
29838		A	Elbow arthroscopy/surgery	7.71	NA	NA	6.91	7.10	0.80	NA	NA	15.42	15.61	090
29840		A	Wrist arthroscopy	5.54	NA	NA	7.35	6.41	0.57	NA	NA	13.46	12.52	090
29843		A	Wrist arthroscopy/surgery	6.01	NA	NA	7.45	7.11	0.66	NA	NA	14.12	13.78	090
29844		A	rist arthroscopy/surgery	6.37	NA	NA	7.70	7.29	0.67	NA	NA	14.74	14.33	090
29845		A	Wrist arthroscopy/surgery	7.52	NA	NA	7.72	7.69	0.77	NA	NA	16.01	15.98	090
29846		A	Wrist arthroscopy/surgery	6.75	NA	NA	9.98	9.50	0.71	NA	NA	17.44	16.96	090
29847		A	Wrist arthroscopy/surgery	7.08	NA	NA	9.84	9.22	0.74	NA	NA	17.66	17.04	090
29848		A	Wrist endoscopy/surgery	5.44	NA	NA	7.30	6.52	0.58	NA	NA	13.32	12.54	090
29850		A	Knee arthroscopy/surgery	8.19	NA	NA	6.68	7.46	0.71	NA	NA	15.58	16.36	090
29851		A	Knee arthroscopy/surgery	13.10	NA	NA	10.43	10.79	1.37	NA	NA	24.90	25.26	090
29855		A	Tibial arthroscopy/surgery	10.62	NA	NA	9.42	10.24	1.09	NA	NA	21.13	21.95	090
29856		A	Tibial arthroscopy/surgery	14.14	NA	NA	11.36	11.69	1.47	NA	NA	26.97	27.30	090
29860		A	Hip arthroscopy, dx	8.05	NA	NA	7.10	6.64	0.77	NA	NA	15.92	15.46	090
29861		A	Hip arthroscopy/surgery	9.15	NA	NA	8.23	8.72	0.88	NA	NA	18.26	18.75	090
29862		A	Hip arthroscopy/surgery	9.90	NA	NA	8.63	9.21	0.95	NA	NA	19.48	20.06	090
29863		A	Hip arthroscopy/surgery	9.90	NA	NA	8.97	9.09	0.95	NA	NA	19.82	19.94	090
29870		A	Knee arthroscopy, dx	5.07	NA	NA	5.50	5.22	0.52	NA	NA	11.09	10.81	090
29871		A	Knee arthroscopy/drainage	6.55	NA	NA	7.26	7.28	0.59	NA	NA	14.40	14.42	090
29874		A	Knee arthroscopy/surgery	7.05	NA	NA	7.02	7.37	0.68	NA	NA	14.75	15.10	090
29875		A	Knee arthroscopy/surgery	6.31	NA	NA	6.72	6.92	0.66	NA	NA	13.69	13.89	090
29876		A	Knee arthroscopy/surgery	7.92	NA	NA	8.07	8.42	0.80	NA	NA	16.79	17.14	090
29877		A	Knee arthroscopy/surgery	7.35	NA	NA	7.30	7.67	0.76	NA	NA	15.41	15.78	090
29879		A	Knee arthroscopy/surgery	8.04	NA	NA	7.67	8.15	0.84	NA	NA	16.55	17.03	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
29880		A	Knee arthroscopy/surgery	8.50	NA	NA	7.93	8.49	0.89	NA	NA	17.32	17.88	090
29881		A	Knee arthroscopy/surgery	7.76	NA	NA	7.53	7.97	0.80	NA	NA	16.09	16.53	090
29882		A	Knee arthroscopy/surgery	8.65	NA	NA	7.96	8.55	0.90	NA	NA	17.51	18.10	090
29883		A	Knee arthroscopy/surgery	9.46	NA	NA	8.45	9.16	0.98	NA	NA	18.89	19.60	090
29884		A	Knee arthroscopy/surgery	7.33	NA	NA	7.74	7.99	0.75	NA	NA	15.82	16.07	090
29885		A	Knee arthroscopy/surgery	9.09	NA	NA	8.72	8.77	0.95	NA	NA	18.76	18.81	090
29886		A	Knee arthroscopy/surgery	7.54	NA	NA	7.89	7.76	0.78	NA	NA	16.21	16.08	090
29887		A	Knee arthroscopy/surgery	9.04	NA	NA	8.69	9.22	0.94	NA	NA	18.67	19.20	090
29888		A	Knee arthroscopy/surgery	13.90	NA	NA	11.22	12.56	1.41	NA	NA	26.53	27.87	090
29889		A	Knee arthroscopy/surgery	15.13	NA	NA	12.34	12.04	1.56	NA	NA	29.03	28.73	090
29891		A	Ankle arthroscopy/surgery	8.40	NA	NA	8.15	8.52	0.81	NA	NA	17.36	17.73	090
29892		A	Ankle arthroscopy/surgery	0.09	NA	NA	8.53	8.80	0.87	NA	NA	9.49	9.76	090
29893		A	Scope, plantar fasciotomy	5.22	NA	NA	4.74	4.97	0.37	NA	NA	10.33	10.56	090
29894		A	Ankle arthroscopy/surgery	7.21	NA	NA	7.25	7.59	0.65	NA	NA	15.11	15.45	090
29895		A	Ankle arthroscopy/surgery	6.99	NA	NA	7.16	7.46	0.65	NA	NA	14.80	15.10	090
29897		A	Ankle arthroscopy/surgery	7.18	NA	NA	7.69	7.91	0.68	NA	NA	15.55	15.77	090
29898		A	Ankle arthroscopy/surgery	8.32	NA	NA	7.47	8.09	0.74	NA	NA	16.53	17.15	090
29909		C	Arthroscopy of joint	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
30000		A	Drainage of nose lesion	1.43	2.14	1.76	1.31	1.14	0.11	3.68	3.30	2.85	2.68	010
30020		A	Drainage of nose lesion	1.43	2.30	1.89	1.36	1.18	0.07	3.80	3.39	2.86	2.68	010
30100		A	Intranasal biopsy	0.94	1.12	1.03	0.51	0.57	0.07	2.13	2.04	1.52	1.58	000
30110		A	Removal of nose polyp(s)	1.63	2.28	2.06	0.85	0.99	0.11	4.02	3.80	2.59	2.73	010
30115		A	Removal of nose polyp(s)	4.35	NA	NA	3.92	3.70	0.31	NA	NA	8.58	8.36	090
30117		A	Removal of intranasal lesion	3.16	3.90	3.70	2.79	2.86	0.23	7.29	7.09	6.18	6.25	090
30118		A	Removal of intranasal lesion	9.69	NA	NA	7.57	7.85	0.71	NA	NA	17.97	18.25	090
30120		A	Revision of nose	5.27	5.38	5.61	5.38	5.61	0.40	11.05	11.28	11.05	11.28	090
30124		A	Removal of nose lesion	3.10	NA	NA	2.98	2.60	0.21	NA	NA	6.29	5.91	090
30125		A	Removal of nose lesion	7.16	NA	NA	5.89	5.92	0.48	NA	NA	13.53	13.56	090
30130		A	Removal of turbinate bones	3.38	NA	NA	3.45	3.04	0.23	NA	NA	7.06	6.65	090
30140		A	Removal of turbinate bones	3.43	NA	NA	3.87	3.73	0.25	NA	NA	7.55	7.41	090
30150		A	Partial removal of nose	9.14	NA	NA	7.75	7.96	0.77	NA	NA	17.66	17.87	090
30160		A	Removal of nose	9.58	NA	NA	7.80	8.71	0.75	NA	NA	18.13	19.04	090
30200		A	Injection treatment of nose	0.78	1.02	0.87	0.42	0.42	0.06	1.86	1.71	1.26	1.26	000
30210		A	Nasal sinus therapy	1.08	1.75	1.38	0.60	0.52	0.08	2.91	2.54	1.76	1.68	010
30220		A	Insert nasal septal button	1.54	2.09	1.98	0.84	1.04	0.11	3.74	3.63	2.49	2.69	010
30300		A	Remove nasal foreign body	1.04	2.18	1.76	0.38	0.41	0.08	3.30	2.88	1.50	1.53	010
30310		A	Remove nasal foreign body	1.96	NA	NA	1.72	1.73	0.14	NA	NA	3.82	3.83	010
30320		A	Remove nasal foreign body	4.52	NA	NA	4.79	4.76	0.33	NA	NA	9.64	9.61	090
30400		R	Reconstruction of nose	9.83	NA	NA	7.94	8.66	0.84	NA	NA	18.61	19.33	090
30410		R	Reconstruction of nose	12.98	NA	NA	9.79	11.22	1.14	NA	NA	23.91	25.34	090
30420		R	Reconstruction of nose	15.88	NA	NA	11.32	13.23	1.25	NA	NA	28.45	30.36	090
30430		R	Revision of nose	7.21	NA	NA	6.40	6.45	0.62	NA	NA	14.23	14.28	090
30435		R	Revision of nose	11.71	NA	NA	9.22	9.68	1.03	NA	NA	21.96	22.42	090
30450		R	Revision of nose	18.65	NA	NA	13.02	12.82	1.65	NA	NA	33.32	33.12	090
30460		A	Revision of nose	9.96	NA	NA	8.39	8.62	0.87	NA	NA	19.22	19.45	090
30462		A	Revision of nose	19.57	NA	NA	13.07	14.46	1.90	NA	NA	34.54	35.93	090
30520		A	Repair of nasal septum	5.70	NA	NA	5.13	5.55	0.41	NA	NA	11.24	11.66	090
30540		A	Repair nasal defect	7.75	NA	NA	5.44	5.88	0.54	NA	NA	13.73	14.17	090
30545		A	Repair nasal defect	11.38	NA	NA	8.13	9.04	0.88	NA	NA	20.39	21.30	090
30560		A	Release of nasal adhesions	1.26	1.92	1.59	1.30	1.13	0.09	3.27	2.94	2.65	2.48	010
30580		A	Repair upper jaw fistula	6.69	4.64	5.17	4.64	5.17	0.49	11.82	12.35	11.82	12.35	090
30600		A	Repair mouth/nose fistula	6.02	4.17	4.15	4.17	4.15	0.47	10.66	10.64	10.66	10.64	090
30620		A	Intranasal reconstruction	5.97	NA	NA	5.72	6.07	0.45	NA	NA	12.14	12.49	090
30630		A	Repair nasal septum defect	7.12	NA	NA	6.25	6.38	0.53	NA	NA	13.90	14.03	090
30801		A	Cauterization, inner nose	1.09	2.14	1.73	1.88	1.54	0.08	3.31	2.90	3.05	2.71	010
30802		A	Cauterization, inner nose	2.03	2.62	2.22	2.41	2.06	0.14	4.79	4.39	4.58	4.23	010
30901		A	Control of nosebleed	1.21	1.84	1.53	0.40	0.45	0.10	3.15	2.84	1.71	1.76	000
30903		A	Control of nosebleed	1.54	2.18	1.87	0.58	0.67	0.12	3.84	3.53	2.24	2.33	000
30905		A	Control of nosebleed	1.97	3.88	3.40	0.85	1.12	0.15	6.00	5.52	2.97	3.24	000
30906		A	Repeat control of nosebleed	2.45	4.16	3.41	1.29	1.26	0.18	6.79	6.04	3.92	3.89	000
30915		A	Ligation, nasal sinus artery	7.20	NA	NA	6.04	5.87	0.52	NA	NA	13.76	13.59	090
30920		A	Ligation, upper jaw artery	9.83	NA	NA	7.56	8.26	0.70	NA	NA	18.09	18.79	090
30930		A	Therapy, fracture of nose	1.26	NA	NA	1.77	1.52	0.09	NA	NA	3.12	2.87	010
30999		C	Nasal surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
31000		A	Irrigation, maxillary sinus	1.15	2.00	1.62	0.62	0.58	0.08	3.23	2.85	1.85	1.81	010
31002		A	Irrigation, sphenoid sinus	1.91	NA	NA	1.76	1.45	0.13	NA	NA	3.80	3.49	010
31020		A	Exploration, maxillary sinus	2.94	3.60	3.42	3.15	3.09	0.21	6.75	6.57	6.30	6.24	090
31030		A	Exploration, maxillary sinus	5.92	4.44	5.10	4.24	4.95	0.43	10.79	11.45	10.59	11.30	090
31032		A	Explore sinus,remove polyps	6.57	NA	NA	5.41	6.02	0.48	NA	NA	12.46	13.07	090
31040		A	Exploration behind upper jaw	9.42	NA	NA	6.21	6.82	0.69	NA	NA	16.32	16.93	090
31050		A	Exploration, sphenoid sinus	5.28	NA	NA	4.47	4.93	0.39	NA	NA	10.14	10.60	090
31051		A	Sphenoid sinus surgery	7.11	NA	NA	5.79	6.47	0.55	NA	NA	13.45	14.13	090
31070		A	Exploration of frontal sinus	4.28	NA	NA	4.30	4.50	0.31	NA	NA	8.89	9.09	090
31075		A	Exploration of frontal sinus	9.16	NA	NA	7.33	8.23	0.63	NA	NA	17.12	18.02	090
31080		A	Removal of frontal sinus	11.42	NA	NA	8.36	8.77	0.81	NA	NA	20.59	21.00	090
31081		A	Removal of frontal sinus	12.75	NA	NA	8.91	9.48	1.86	NA	NA	23.52	24.09	090
31084		A	Removal of frontal sinus	13.51	NA	NA	9.56	11.18	1.03	NA	NA	24.10	25.72	090
31085		A	Removal of frontal sinus	14.20	NA	NA	9.85	11.63	1.35	NA	NA	25.40	27.18	090
31086		A	Removal of frontal sinus	12.86	NA	NA	9.37	9.98	0.96	NA	NA	23.19	23.80	090
31087		A	Removal of frontal sinus	13.10	NA	NA	9.24	9.75	0.93	NA	NA	23.27	23.78	090
31090		A	Exploration of sinuses	9.53	NA	NA	7.89	8.76	0.68	NA	NA	18.10	18.97	090
31200		A	Removal of ethmoid sinus	4.97	NA	NA	5.43	5.33	0.28	NA	NA	10.68	10.58	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
31201		A	Removal of ethmoid sinus	8.37	NA	NA	6.87	7.06	0.59	NA	NA	15.83	16.02	090
31205		A	Removal of ethmoid sinus	10.24	NA	NA	8.10	8.25	0.61	NA	NA	18.95	19.10	090
31225		A	Removal of upper jaw	19.23	NA	NA	13.72	15.57	1.41	NA	NA	34.36	36.21	090
31230		A	Removal of upper jaw	21.94	NA	NA	15.38	17.43	1.67	NA	NA	38.99	41.04	090
31231		A	Nasal endoscopy, dx	1.10	1.68	1.63	0.58	0.81	0.08	2.86	2.81	1.76	1.99	000
31233		A	Nasal/sinus endoscopy, dx	2.18	2.28	2.47	1.20	1.66	0.15	4.61	4.80	3.53	3.99	000
31235		A	Nasal/sinus endoscopy, dx	2.64	2.54	2.55	1.45	1.74	0.18	5.36	5.37	4.27	4.56	000
31237		A	Nasal/sinus endoscopy, surg	2.98	2.80	2.99	1.60	2.09	0.21	5.99	6.18	4.79	5.28	000
31238		A	Nasal/sinus endoscopy, surg	3.26	3.21	3.38	1.79	2.32	0.23	6.70	6.87	5.28	5.81	000
31239		A	Nasal/sinus endoscopy, surg	8.70	NA	NA	6.28	7.31	0.44	NA	NA	15.42	16.45	010
31240		A	Nasal/sinus endoscopy, surg	2.61	NA	NA	1.47	1.88	0.18	NA	NA	4.26	4.67	000
31254		A	Revision of ethmoid sinus	4.65	NA	NA	2.65	3.38	0.32	NA	NA	7.62	8.35	000
31255		A	Removal of ethmoid sinus	6.96	NA	NA	3.92	5.02	0.50	NA	NA	11.38	12.48	000
31256		A	Exploration maxillary sinus	3.29	NA	NA	1.89	2.40	0.23	NA	NA	5.41	5.92	000
31267		A	Endoscopy, maxillary sinus	5.46	NA	NA	3.09	3.74	0.39	NA	NA	8.94	9.59	000
31276		A	Sinus endoscopy, surgical	8.85	NA	NA	4.88	5.48	0.63	NA	NA	14.36	14.96	000
31287		A	Nasal/sinus endoscopy, surg	3.92	NA	NA	2.24	2.85	0.28	NA	NA	6.44	7.05	000
31288		A	Nasal/sinus endoscopy, surg	4.58	NA	NA	2.61	3.33	0.32	NA	NA	7.51	8.23	000
31290		A	Nasal/sinus endoscopy, surg	17.24	NA	NA	10.95	12.68	1.28	NA	NA	29.47	31.20	010
31291		A	Nasal/sinus endoscopy, surg	18.19	NA	NA	11.31	13.18	1.73	NA	NA	31.23	33.10	010
31292		A	Nasal/sinus endoscopy, surg	14.76	NA	NA	9.54	10.79	1.03	NA	NA	25.33	26.58	010
31293		A	Nasal/sinus endoscopy, surg	16.21	NA	NA	10.18	11.61	1.09	NA	NA	27.48	28.91	010
31294		A	Nasal/sinus endoscopy, surg	19.06	NA	NA	11.83	13.41	1.71	NA	NA	32.60	34.18	010
31299		C	Sinus surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
31300		A	Removal of larynx lesion	14.29	NA	NA	14.94	14.35	1.02	NA	NA	30.25	29.66	090
31320		A	Diagnostic incision, larynx	5.26	NA	NA	11.08	9.36	0.39	NA	NA	16.73	15.01	090
31360		A	Removal of larynx	17.08	NA	NA	16.69	17.62	1.24	NA	NA	35.01	35.94	090
31365		A	Removal of larynx	24.16	NA	NA	20.46	22.56	1.77	NA	NA	46.39	48.49	090
31367		A	Partial removal of larynx	21.86	NA	NA	21.00	20.42	1.59	NA	NA	44.45	43.87	090
31368		A	Partial removal of larynx	27.09	NA	NA	24.85	25.90	1.98	NA	NA	53.92	54.97	090
31370		A	Partial removal of larynx	21.38	NA	NA	20.88	20.32	1.60	NA	NA	43.86	43.30	090
31375		A	Partial removal of larynx	20.21	NA	NA	18.41	17.84	1.41	NA	NA	40.03	39.46	090
31380		A	Partial removal of larynx	20.21	NA	NA	18.61	18.64	1.44	NA	NA	40.26	40.29	090
31382		A	Partial removal of larynx	20.52	NA	NA	20.08	19.42	1.51	NA	NA	42.11	41.45	090
31390		A	Removal of larynx & pharynx	27.53	NA	NA	25.18	26.23	1.99	NA	NA	54.70	55.75	090
31395		A	Reconstruct larynx & pharynx	31.09	NA	NA	29.74	31.40	2.25	NA	NA	63.08	64.74	090
31400		A	Revision of larynx	10.31	NA	NA	13.34	12.13	0.74	NA	NA	24.39	23.18	090
31420		A	Removal of epiglottis	10.22	NA	NA	13.25	12.13	0.74	NA	NA	24.21	23.09	090
31500		A	Insert emergency airway	2.33	NA	NA	0.64	0.79	0.17	NA	NA	3.14	3.29	000
31502		A	Change of windpipe airway	0.65	1.59	1.35	0.26	0.35	0.04	2.28	2.04	0.95	1.04	000
31505		A	Diagnostic laryngoscopy	0.61	1.49	1.24	0.31	0.35	0.05	2.15	1.90	0.97	1.01	000
31510		A	Laryngoscopy with biopsy	1.92	2.37	1.93	0.96	0.87	0.14	4.43	3.99	3.02	2.93	000
31511		A	Remove foreign body, larynx	2.16	2.56	2.18	0.78	0.85	0.18	4.90	4.52	3.12	3.19	000
31512		A	Removal of larynx lesion	2.07	2.49	2.35	1.07	1.29	0.19	4.75	4.61	3.33	3.55	000
31513		A	Injection into vocal cord	2.10	NA	NA	1.24	1.56	0.15	NA	NA	3.49	3.81	000
31515		A	Laryngoscopy for aspiration	1.80	2.18	1.94	0.81	0.92	0.12	4.10	3.86	2.73	2.84	000
31520		A	Diagnostic laryngoscopy	2.56	NA	NA	1.34	1.45	0.18	NA	NA	4.08	4.19	000
31525		A	Diagnostic laryngoscopy	2.63	2.54	2.50	1.44	1.68	0.18	5.35	5.31	4.25	4.49	000
31526		A	Diagnostic laryngoscopy	2.57	NA	NA	1.49	1.89	0.18	NA	NA	4.24	4.64	000
31527		A	Laryngoscopy for treatment	3.27	NA	NA	1.66	2.06	0.23	NA	NA	5.16	5.56	000
31528		A	Laryngoscopy and dilatation	2.37	NA	NA	1.28	1.67	0.18	NA	NA	3.83	4.22	000
31529		A	Laryngoscopy and dilatation	2.68	NA	NA	1.46	1.76	0.19	NA	NA	4.33	4.63	000
31530		A	Operative laryngoscopy	3.39	NA	NA	1.72	2.28	0.23	NA	NA	5.34	5.90	000
31531		A	Operative laryngoscopy	3.59	NA	NA	2.07	2.63	0.26	NA	NA	5.92	6.48	000
31535		A	Operative laryngoscopy	3.16	NA	NA	1.78	2.28	0.23	NA	NA	5.17	5.67	000
31536		A	Operative laryngoscopy	3.56	NA	NA	2.04	2.59	0.26	NA	NA	5.86	6.41	000
31540		A	Operative laryngoscopy	4.13	NA	NA	2.34	2.99	0.30	NA	NA	6.77	7.42	000
31541		A	Operative laryngoscopy	4.53	NA	NA	2.56	3.16	0.32	NA	NA	7.41	8.01	000
31560		A	Operative laryngoscopy	5.46	NA	NA	3.02	3.62	0.39	NA	NA	8.87	9.47	000
31561		A	Operative laryngoscopy	0.06	NA	NA	3.33	4.20	0.43	NA	NA	3.82	4.69	000
31570		A	Laryngoscopy with injection	3.87	3.80	4.01	2.16	2.78	0.29	7.96	8.17	6.32	6.94	000
31571		A	Laryngoscopy with injection	4.27	NA	NA	2.40	3.02	0.31	NA	NA	6.98	7.60	000
31575		A	Diagnostic laryngoscopy	1.10	1.81	1.78	0.60	0.87	0.08	2.99	2.96	1.78	2.05	000
31576		A	Laryngoscopy with biopsy	1.97	1.95	2.05	1.03	1.36	0.13	4.05	4.15	3.13	3.46	000
31577		A	Remove foreign body, larynx	2.47	2.26	2.43	1.26	1.68	0.18	4.91	5.08	3.91	4.33	000
31578		A	Removal of larynx lesion	2.84	2.57	2.78	0.94	1.55	0.20	5.61	5.82	3.98	4.59	000
31579		A	Diagnostic laryngoscopy	2.26	2.52	2.52	1.19	1.53	0.16	4.94	4.94	3.61	3.95	000
31580		A	Revision of larynx	12.38	NA	NA	13.61	13.90	0.88	NA	NA	26.87	27.16	090
31582		A	Revision of larynx	21.62	NA	NA	19.32	19.34	1.54	NA	NA	42.48	42.50	090
31584		A	Treat larynx fracture	19.64	NA	NA	16.79	16.04	1.54	NA	NA	37.97	37.22	090
31585		A	Treat larynx fracture	4.64	NA	NA	7.46	6.62	0.32	NA	NA	12.42	11.58	090
31586		A	Treat larynx fracture	8.03	NA	NA	10.88	9.94	0.57	NA	NA	19.48	18.54	090
31587		A	Revision of larynx	11.99	NA	NA	12.34	11.21	0.88	NA	NA	25.21	24.08	090
31588		A	Revision of larynx	13.11	NA	NA	14.69	13.92	0.94	NA	NA	28.74	27.97	090
31590		A	Reinnervate larynx	6.97	NA	NA	10.11	9.15	0.47	NA	NA	17.55	16.59	090
31595		A	Larynx nerve surgery	8.34	NA	NA	9.68	9.12	0.61	NA	NA	18.63	18.07	090
31599		C	Larynx surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
31600		A	Incision of windpipe	3.62	NA	NA	1.61	2.29	0.34	NA	NA	5.57	6.25	000
31601		A	Incision of windpipe	4.45	NA	NA	2.16	2.95	0.36	NA	NA	6.97	7.76	000
31603		A	Incision of windpipe	4.15	NA	NA	1.86	2.54	0.38	NA	NA	6.39	7.07	000
31605		A	Incision of windpipe	3.58	NA	NA	1.31	2.05	0.36	NA	NA	5.25	5.99	000
31610		A	Incision of windpipe	8.76	NA	NA	9.71	9.09	0.70	NA	NA	19.17	18.55	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
31611		A	Surgery/speech prosthesis	5.64	NA	NA	8.30	7.98	0.41	NA	NA	14.35	14.03	090
31612		A	Puncture/clear windpipe	0.91	1.24	1.25	0.40	0.62	0.06	2.21	2.22	1.37	1.59	000
31613		A	Repair windpipe opening	4.59	NA	NA	8.03	6.62	0.37	NA	NA	12.99	11.58	090
31614		A	Repair windpipe opening	7.12	NA	NA	10.28	9.54	0.53	NA	NA	17.93	17.19	090
31615		A	Visualization of windpipe	2.09	2.90	2.71	1.10	1.36	0.14	5.13	4.94	3.33	3.59	000
31622		A	Dx bronchoscope/wash	2.78	3.12	3.18	1.12	1.68	0.13	6.03	6.09	4.03	4.59	000
31623		A	Dx bronchoscope/brush	2.88	3.16	3.21	1.16	1.71	0.15	6.19	6.24	4.19	4.74	000
31624		A	Dx bronchoscope/lavage	2.88	2.68	2.85	1.16	1.71	0.15	5.71	5.88	4.19	4.74	000
31625		A	Bronchoscopy with biopsy	3.37	2.68	3.02	1.27	1.96	0.16	6.21	6.55	4.80	5.49	000
31628		A	Bronchoscopy with biopsy	3.81	3.13	3.49	1.33	2.14	0.13	7.07	7.43	5.27	6.08	000
31629		A	Bronchoscopy with biopsy	3.37	NA	NA	1.20	1.91	0.11	NA	NA	4.68	5.39	000
31630		A	Bronchoscopy with repair	3.82	NA	NA	2.06	2.56	0.34	NA	NA	6.22	6.72	000
31631		A	Bronchoscopy with dilation	4.37	NA	NA	2.07	2.62	0.31	NA	NA	6.75	7.30	000
31635		A	Remove foreign body, airway	3.68	NA	NA	1.64	2.33	0.23	NA	NA	5.55	6.24	000
31640		A	Bronchoscopy & remove lesion	4.94	NA	NA	2.47	3.22	0.37	NA	NA	7.78	8.53	000
31641		A	Bronchoscopy, treat blockage	5.03	NA	NA	2.09	3.07	0.28	NA	NA	7.40	8.38	000
31643		A	Diag bronchoscope/catheter	3.50	1.73	2.13	1.47	1.94	0.20	5.43	5.83	5.17	5.64	000
31645		A	Bronchoscopy, clear airways	3.16	NA	NA	1.17	1.82	0.13	NA	NA	4.46	5.11	000
31646		A	Bronchoscopy, reclear airway	2.72	NA	NA	1.04	1.59	0.12	NA	NA	3.88	4.43	000
31656		A	Bronchoscopy, inj for xray	2.17	NA	NA	0.91	1.33	0.10	NA	NA	3.18	3.60	000
31700		A	Insertion of airway catheter	1.34	1.69	1.64	0.61	0.83	0.08	3.11	3.06	2.03	2.25	000
31708		A	Instill airway contrast dye	1.41	NA	NA	0.59	0.65	0.06	NA	NA	2.06	2.12	000
31710		A	Insertion of airway catheter	1.30	NA	NA	0.70	0.77	0.05	NA	NA	2.05	2.12	000
31715		A	Injection for bronchus x-ray	1.11	NA	NA	0.71	0.66	0.04	NA	NA	1.86	1.81	000
31717		A	Bronchial brush biopsy	2.12	2.92	2.39	0.82	0.81	0.08	5.12	4.59	3.02	3.01	000
31720		A	Clearance of airways	1.06	1.74	1.51	0.33	0.45	0.06	2.86	2.63	1.45	1.57	000
31725		A	Clearance of airways	1.96	NA	NA	0.64	0.86	0.08	NA	NA	2.68	2.90	000
31730		A	Intro, windpipe wire/tube	2.85	2.27	2.37	1.07	1.47	0.15	5.27	5.37	4.07	4.47	000
31750		A	Repair of windpipe	13.02	NA	NA	14.19	13.05	0.01	NA	NA	27.22	26.08	090
31755		A	Repair of windpipe	15.93	NA	NA	16.14	15.71	1.20	NA	NA	33.27	32.84	090
31760		A	Repair of windpipe	22.35	NA	NA	13.56	13.13	2.09	NA	NA	38.00	37.57	090
31766		A	Reconstruction of windpipe	30.43	NA	NA	16.74	17.55	3.73	NA	NA	50.90	51.71	090
31770		A	Repair/graft of bronchus	22.51	NA	NA	16.73	16.64	2.06	NA	NA	41.30	41.21	090
31775		A	Reconstruct bronchus	23.54	NA	NA	18.57	18.37	2.80	NA	NA	44.91	44.71	090
31780		A	Reconstruct windpipe	17.72	NA	NA	13.24	14.63	1.70	NA	NA	32.66	34.05	090
31781		A	Reconstruct windpipe	23.53	NA	NA	16.29	16.79	2.83	NA	NA	42.65	43.15	090
31785		A	Remove windpipe lesion	17.23	NA	NA	12.42	11.74	1.35	NA	NA	31.00	30.32	090
31786		A	Remove windpipe lesion	23.98	NA	NA	17.54	16.76	1.99	NA	NA	43.51	42.73	090
31800		A	Repair of windpipe injury	7.43	NA	NA	6.72	6.37	0.74	NA	NA	14.89	14.54	090
31805		A	Repair of windpipe injury	13.13	NA	NA	12.40	11.97	1.72	NA	NA	27.25	26.82	090
31820		A	Closure of windpipe lesion	4.49	7.10	6.30	7.10	6.30	0.34	11.93	11.13	11.93	11.13	090
31825		A	Repair of windpipe defect	6.81	9.62	8.57	9.62	8.57	0.52	16.95	15.90	16.95	15.90	090
31830		A	Revise windpipe scar	4.50	6.87	6.15	6.87	6.15	0.36	11.73	11.01	11.73	11.01	090
31899		C	Airways surgical procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
32000		A	Drainage of chest	1.54	3.01	2.50	0.50	0.62	0.07	4.62	4.11	2.11	2.23	000
32001		D	Total lung lavage	0.06	2.38	2.38	2.38	2.38	0.60	3.04	3.04	3.04	3.04	000
32002		A	Treatment of collapsed lung	2.19	NA	NA	0.84	0.99	0.11	NA	NA	3.14	3.29	000
32005		A	Treat lung lining chemically	2.19	NA	NA	0.93	0.99	0.18	NA	NA	3.30	3.36	000
32020		A	Insertion of chest tube	3.98	NA	NA	1.57	1.89	0.37	NA	NA	5.92	6.24	000
32035		A	Exploration of chest	8.67	NA	NA	10.06	9.38	1.05	NA	NA	19.78	19.10	090
32036		A	Exploration of chest	9.68	NA	NA	11.25	10.37	1.19	NA	NA	22.12	21.24	090
32095		A	Biopsy through chest wall	8.36	NA	NA	10.17	9.87	0.98	NA	NA	19.51	19.21	090
32100		A	Exploration/biopsy of chest	11.84	NA	NA	11.45	11.64	1.45	NA	NA	24.74	24.93	090
32110		A	Explore/repair chest	13.62	NA	NA	11.89	12.04	1.67	NA	NA	27.18	27.33	090
32120		A	Re-exploration of chest	11.54	NA	NA	12.00	11.57	1.45	NA	NA	24.99	24.56	090
32124		A	Explore chest free adhesions	12.72	NA	NA	11.18	11.35	1.57	NA	NA	25.47	25.64	090
32140		A	Removal of lung lesion(s)	13.93	NA	NA	12.89	13.02	1.68	NA	NA	28.50	28.63	090
32141		A	Remove/treat lung lesions	0.14	NA	NA	10.96	11.86	1.74	NA	NA	12.84	13.74	090
32150		A	Removal of lung lesion(s)	14.15	NA	NA	12.31	12.04	1.71	NA	NA	28.17	27.90	090
32151		A	Remove lung foreign body	14.21	NA	NA	13.42	12.55	1.76	NA	NA	29.39	28.52	090
32160		A	Open chest heart massage	9.30	NA	NA	7.25	7.92	1.07	NA	NA	17.62	18.29	090
32200		A	Drain, open, lung lesion	15.29	NA	NA	11.18	10.26	1.25	NA	NA	27.72	26.80	090
32201		A	Drain, percut, lung lesion	0.04	NA	NA	6.43	5.65	0.32	NA	NA	6.79	6.01	000
32215		A	Treat chest lining	11.33	NA	NA	12.10	11.14	1.37	NA	NA	24.80	23.84	090
32220		A	Release of lung	19.27	NA	NA	15.25	15.73	2.28	NA	NA	36.80	37.28	090
32225		A	Partial release of lung	13.96	NA	NA	12.48	12.57	1.74	NA	NA	28.18	28.27	090
32310		A	Removal of chest lining	13.44	NA	NA	12.13	12.26	1.65	NA	NA	27.22	27.35	090
32320		A	Free/remove chest lining	20.54	NA	NA	14.86	16.06	2.50	NA	NA	37.90	39.10	090
32400		A	Needle biopsy chest lining	1.76	1.69	1.67	0.57	0.83	0.07	3.52	3.50	2.40	2.66	000
32402		A	Open biopsy chest lining	7.56	NA	NA	10.48	9.92	0.94	NA	NA	18.98	18.42	090
32405		A	Biopsy, lung or mediastinum	1.93	2.45	2.41	0.67	1.08	0.08	4.46	4.42	2.68	3.09	000
32420		A	Puncture/clear lung	2.18	NA	NA	0.83	1.03	0.10	NA	NA	3.11	3.31	000
32440		A	Removal of lung	21.02	NA	NA	15.28	16.50	2.60	NA	NA	38.90	40.12	090
32442		A	Sleeve pneumonectomy	26.24	NA	NA	16.28	17.08	3.28	NA	NA	45.80	46.60	090
32445		A	Removal of lung	25.09	NA	NA	16.11	17.63	3.09	NA	NA	44.29	45.81	090
32480		A	Partial removal of lung	18.32	NA	NA	13.25	14.59	2.25	NA	NA	33.82	35.16	090
32482		A	Bilobectomy	19.71	NA	NA	14.24	15.33	2.38	NA	NA	36.33	37.42	090
32484		A	Segmentectomy	20.69	NA	NA	14.81	15.76	2.54	NA	NA	38.04	38.99	090
32486		A	Sleeve lobectomy	23.92	NA	NA	17.05	17.28	3.04	NA	NA	44.01	44.24	090
32488		A	Completion pneumonectomy	25.71	NA	NA	17.26	17.76	3.19	NA	NA	46.16	46.66	090
32491		R	Lung volume reduction	21.25	NA	NA	15.68	15.95	2.84	NA	NA	39.77	40.04	090
32500		A	Partial removal of lung	14.30	NA	NA	12.90	13.33	1.79	NA	NA	28.99	29.42	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
32501		A	Repair bronchus add-on	4.69	NA	NA	1.86	2.57	0.53	NA	NA	7.08	7.79	ZZZ
32520		A	Remove lung & revise chest	21.68	NA	NA	15.82	17.47	2.75	NA	NA	40.25	41.90	090
32522		A	Remove lung & revise chest	24.20	NA	NA	16.66	18.44	3.03	NA	NA	43.89	45.67	090
32525		A	Remove lung & revise chest	26.50	NA	NA	17.13	19.22	3.29	NA	NA	46.92	49.01	090
32540		A	Removal of lung lesion	14.64	NA	NA	13.15	13.03	1.81	NA	NA	29.60	29.48	090
32601		A	Thoracoscopy, diagnostic	5.46	NA	NA	4.52	4.33	0.68	NA	NA	10.66	10.47	000
32602		A	Thoracoscopy, diagnostic	5.96	NA	NA	4.71	4.58	0.74	NA	NA	11.41	11.28	000
32603		A	Thoracoscopy, diagnostic	7.81	NA	NA	5.26	4.89	0.78	NA	NA	13.85	13.48	000
32604		A	Thoracoscopy, diagnostic	8.78	NA	NA	6.02	5.57	1.07	NA	NA	15.87	15.42	000
32605		A	Thoracoscopy, diagnostic	6.93	NA	NA	5.50	5.07	0.86	NA	NA	13.29	12.86	000
32606		A	Thoracoscopy, diagnostic	8.40	NA	NA	5.71	5.33	1.04	NA	NA	15.15	14.77	000
32650		A	Thoracoscopy, surgical	10.75	NA	NA	10.60	10.02	1.26	NA	NA	22.61	22.03	090
32651		A	Thoracoscopy, surgical	12.91	NA	NA	10.60	11.16	1.55	NA	NA	25.06	25.62	090
32652		A	Thoracoscopy, surgical	18.66	NA	NA	13.59	14.48	2.30	NA	NA	34.55	35.44	090
32653		A	Thoracoscopy, surgical	12.87	NA	NA	11.41	11.36	1.55	NA	NA	25.83	25.78	090
32654		A	Thoracoscopy, surgical	12.44	NA	NA	8.98	9.86	1.48	NA	NA	22.90	23.78	090
32655		A	Thoracoscopy, surgical	13.10	NA	NA	10.70	11.67	1.54	NA	NA	25.34	26.31	090
32656		A	Thoracoscopy, surgical	12.91	NA	NA	11.57	12.30	1.61	NA	NA	26.09	26.82	090
32657		A	Thoracoscopy, surgical	13.65	NA	NA	11.49	12.27	1.65	NA	NA	26.79	27.57	090
32658		A	Thoracoscopy, surgical	11.63	NA	NA	11.47	12.07	1.45	NA	NA	24.55	25.15	090
32659		A	Thoracoscopy, surgical	11.59	NA	NA	11.18	11.85	1.46	NA	NA	24.23	24.90	090
32660		A	Thoracoscopy, surgical	17.43	NA	NA	15.53	16.85	2.29	NA	NA	35.25	36.57	090
32661		A	Thoracoscopy, surgical	13.25	NA	NA	12.02	11.53	1.65	NA	NA	26.92	26.43	090
32662		A	Thoracoscopy, surgical	16.44	NA	NA	12.76	13.52	2.03	NA	NA	31.23	31.99	090
32663		A	Thoracoscopy, surgical	18.47	NA	NA	13.50	14.78	2.25	NA	NA	34.22	35.50	090
32664		A	Thoracoscopy, surgical	14.20	NA	NA	10.80	10.96	1.64	NA	NA	26.64	26.80	090
32665		A	Thoracoscopy, surgical	15.54	NA	NA	11.27	12.34	1.80	NA	NA	28.61	29.68	090
32800		A	Repair lung hernia	13.69	NA	NA	13.17	12.13	1.41	NA	NA	28.27	27.23	090
32810		A	Close chest after drainage	13.05	NA	NA	12.42	11.08	1.66	NA	NA	27.13	25.79	090
32815		A	Close bronchial fistula	23.15	NA	NA	17.73	17.43	2.94	NA	NA	43.82	43.52	090
32820		A	Reconstruct injured chest	21.48	NA	NA	15.97	17.14	2.40	NA	NA	39.85	41.02	090
32850		X	Donor pneumonectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
32851		A	Lung transplant, single	38.63	NA	NA	24.89	25.60	5.21	NA	NA	68.73	69.44	090
32852		A	Lung transplant with bypass	41.80	NA	NA	25.98	27.00	5.81	NA	NA	73.59	74.61	090
32853		A	Lung transplant, double	47.81	NA	NA	28.44	30.00	6.43	NA	NA	82.68	84.24	090
32854		A	Lung transplant with bypass	50.98	NA	NA	30.44	32.08	6.75	NA	NA	88.17	89.81	090
32900		A	Removal of rib(s)	20.27	NA	NA	14.63	13.27	2.40	NA	NA	37.30	35.94	090
32905		A	Revise & repair chest wall	20.75	NA	NA	14.48	14.32	2.55	NA	NA	37.78	37.62	090
32906		A	Revise & repair chest wall	26.77	NA	NA	17.44	17.26	3.34	NA	NA	47.55	47.37	090
32940		A	Revision of lung	19.43	NA	NA	14.32	13.83	2.37	NA	NA	36.12	35.63	090
32960		A	Therapeutic pneumothorax	1.84	1.90	1.68	0.55	0.67	0.13	3.87	3.65	2.52	2.64	000
32997		A	Total lung lavage	0.06	NA	NA	2.28	2.28	0.58	NA	NA	2.92	2.92	000
32999		C	Chest surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
33010		A	Drainage of heart sac	2.24	NA	NA	0.99	1.16	0.27	NA	NA	3.50	3.67	000
33011		A	Repeat drainage of heart sac	2.24	NA	NA	1.02	1.07	0.26	NA	NA	3.52	3.57	000
33015		A	Incision of heart sac	6.80	NA	NA	5.20	5.06	0.88	NA	NA	12.88	12.74	090
33020		A	Incision of heart sac	12.61	NA	NA	10.08	11.16	1.63	NA	NA	24.32	25.40	090
33025		A	Incision of heart sac	12.09	NA	NA	10.01	11.12	1.55	NA	NA	23.65	24.76	090
33030		A	Partial removal of heart sac	18.71	NA	NA	15.79	17.43	2.41	NA	NA	36.91	38.55	090
33031		A	Partial removal of heart sac	21.79	NA	NA	17.76	16.92	2.90	NA	NA	42.45	41.61	090
33050		A	Removal of heart sac lesion	14.36	NA	NA	12.85	12.15	1.77	NA	NA	28.98	28.28	090
33120		A	Removal of heart lesion	24.56	NA	NA	21.22	23.25	3.19	NA	NA	48.97	51.00	090
33130		A	Removal of heart lesion	21.39	NA	NA	15.50	15.29	2.42	NA	NA	39.31	39.10	090
33140		A	Heart revascularize (tmr)	0.20	NA	NA	12.66	12.66	2.56	NA	NA	15.42	15.42	090
33200		A	Insertion of heart pacemaker	12.48	NA	NA	11.57	12.01	1.45	NA	NA	25.50	25.94	090
33201		A	Insertion of heart pacemaker	10.18	NA	NA	12.09	12.10	1.34	NA	NA	23.61	23.62	090
33206		A	Insertion of heart pacemaker	3.11	NA	NA	1.28	2.95	0.84	NA	NA	5.23	6.90	000
33207		A	Insertion of heart pacemaker	3.30	NA	NA	1.36	3.42	1.03	NA	NA	5.69	7.75	000
33208		A	Insertion of heart pacemaker	2.64	NA	NA	1.10	3.25	1.07	NA	NA	4.81	6.96	000
33210		A	Insertion of heart electrode	3.30	NA	NA	1.35	1.91	0.42	NA	NA	5.07	5.63	000
33211		A	Insertion of heart electrode	3.40	NA	NA	1.44	1.98	0.44	NA	NA	5.28	5.82	000
33212		A	Insertion of pulse generator	3.32	NA	NA	1.36	2.48	0.71	NA	NA	5.39	6.51	000
33213		A	Insertion of pulse generator	4.92	NA	NA	2.03	2.98	0.82	NA	NA	7.77	8.72	000
33214		A	Upgrade of pacemaker system	4.27	NA	NA	1.75	2.78	0.99	NA	NA	7.01	8.04	000
33216		A	Revise eltrd pacing-defib	3.21	NA	NA	1.33	2.36	0.70	NA	NA	5.24	6.27	000
33217		A	Revise eltrd pacing-defib	3.57	NA	NA	1.48	2.47	0.76	NA	NA	5.81	6.80	000
33218		A	Revise eltrd pacing-defib	3.26	NA	NA	1.34	2.25	0.70	NA	NA	5.30	6.21	000
33220		A	Revise eltrd pacing-defib	2.90	NA	NA	1.19	2.14	0.71	NA	NA	4.80	5.75	000
33222		A	Revise pocket, pacemaker	4.96	NA	NA	4.21	4.64	0.62	NA	NA	9.79	10.22	090
33223		A	Revise pocket, pacing-defib	6.46	NA	NA	5.63	5.77	0.88	NA	NA	12.97	13.11	090
33233		A	Removal of pacemaker system	1.11	NA	NA	0.46	1.06	0.44	NA	NA	2.01	2.61	000
33234		A	Removal of pacemaker system	5.64	NA	NA	2.35	2.53	1.05	NA	NA	9.04	9.22	000
33235		A	Removal pacemaker electrode	4.58	NA	NA	1.91	2.29	1.26	NA	NA	7.75	8.13	000
33236		A	Remove electrode/thoracotomy	12.60	NA	NA	11.19	9.47	1.63	NA	NA	25.42	23.70	090
33237		A	Remove electrode/thoracotomy	13.71	NA	NA	12.01	11.61	1.77	NA	NA	27.49	27.09	090
33238		A	Remove electrode/thoracotomy	15.22	NA	NA	11.41	11.35	1.41	NA	NA	28.04	27.98	090
33240		A	Insert pulse generator	5.13	NA	NA	2.14	3.07	1.03	NA	NA	8.30	9.23	000
33241		A	Remove pulse generator	1.51	NA	NA	0.63	1.06	0.44	NA	NA	2.58	3.01	000
33242		D	Repair pulse generator/leads	6.17	2.45	3.68	2.45	3.68	0.83	9.45	10.68	9.45	10.68	090
33243		A	Remove eltrd/thoracotomy	22.64	NA	NA	13.53	12.60	3.03	NA	NA	39.20	38.27	090
33244		A	Remove eltrd, transven	9.85	NA	NA	4.11	5.53	1.83	NA	NA	15.79	17.21	000
33245		A	Insert epic eltrd pace-defib	14.30	NA	NA	13.63	14.49	1.83	NA	NA	29.76	30.62	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
33246		A	Insert epic eltrd/generator	20.71	NA	NA	17.00	18.39	2.74	NA	NA	40.45	41.84	090
33247		D	Insert/replace leads	10.21	4.05	6.09	4.05	6.09	1.27	15.53	17.57	15.53	17.57	090
33249		A	Eltrd/insert pace-defib	11.41	NA	NA	4.80	7.57	1.79	NA	NA	18.00	20.77	000
33250		A	Ablate heart dysrhythm focus	21.85	NA	NA	14.28	13.85	2.97	NA	NA	39.10	38.67	090
33251		A	Ablate heart dysrhythm focus	24.88	NA	NA	18.57	18.38	3.26	NA	NA	46.71	46.52	090
33253		A	Reconstruct atria	31.06	NA	NA	21.60	22.12	4.12	NA	NA	56.78	57.30	090
33261		A	Ablate heart dysrhythm focus	24.88	NA	NA	18.92	17.98	2.94	NA	NA	46.74	45.80	090
33282		A	Implant pat-active ht record	2.83	NA	NA	1.15	1.15	0.53	NA	NA	4.51	4.51	000
33284		A	Remove pat-active ht record	1.16	NA	NA	0.47	0.47	0.33	NA	NA	1.96	1.96	000
33300		A	Repair of heart wound	17.92	NA	NA	14.78	14.98	2.33	NA	NA	35.03	35.23	090
33305		A	Repair of heart wound	21.44	NA	NA	17.53	17.87	2.81	NA	NA	41.78	42.12	090
33310		A	Exploratory heart surgery	18.51	NA	NA	16.72	15.60	2.48	NA	NA	37.71	36.59	090
33315		A	Exploratory heart surgery	22.37	NA	NA	17.98	17.41	0.03	NA	NA	40.38	39.81	090
33320		A	Repair major blood vessel(s)	16.79	NA	NA	13.62	14.05	2.14	NA	NA	32.55	32.98	090
33321		A	Repair major vessel	20.20	NA	NA	16.08	17.96	2.36	NA	NA	38.64	40.52	090
33322		A	Repair major blood vessel(s)	20.62	NA	NA	16.85	18.54	2.70	NA	NA	40.17	41.86	090
33330		A	Insert major vessel graft	21.43	NA	NA	15.66	15.18	2.79	NA	NA	39.88	39.40	090
33332		A	Insert major vessel graft	23.96	NA	NA	15.85	15.98	3.29	NA	NA	43.10	43.23	090
33335		A	Insert major vessel graft	30.01	NA	NA	20.81	19.70	3.99	NA	NA	54.81	53.70	090
33400		A	Repair of aortic valve	25.34	NA	NA	22.27	23.81	3.34	NA	NA	50.95	52.49	090
33401		A	Valvuloplasty, open	23.91	NA	NA	18.29	20.83	3.19	NA	NA	45.39	47.93	090
33403		A	Valvuloplasty, w/cp bypass	24.89	NA	NA	21.83	23.48	3.47	NA	NA	50.19	51.84	090
33404		A	Prepare heart-aorta conduit	28.54	NA	NA	23.34	25.98	3.68	NA	NA	55.56	58.20	090
33405		A	Replacement of aortic valve	30.61	NA	NA	21.23	24.19	3.97	NA	NA	55.81	58.77	090
33406		A	Replacement of aortic valve	32.30	NA	NA	22.08	26.20	4.18	NA	NA	58.56	62.68	090
33410		A	Replacement of aortic valve	32.46	NA	NA	21.99	21.99	4.21	NA	NA	58.66	58.66	090
33411		A	Replacement of aortic valve	32.47	NA	NA	22.05	26.23	4.21	NA	NA	58.73	62.91	090
33412		A	Replacement of aortic valve	34.79	NA	NA	25.59	29.58	4.18	NA	NA	64.56	68.55	090
33413		A	Replacement of aortic valve	35.24	NA	NA	26.30	30.24	4.59	NA	NA	66.13	70.07	090
33414		A	Repair of aortic valve	30.35	NA	NA	26.14	28.67	3.88	NA	NA	60.37	62.90	090
33415		A	Revision, subvalvular tissue	27.15	NA	NA	22.75	25.17	2.84	NA	NA	52.74	55.16	090
33416		A	Revise ventricle muscle	30.35	NA	NA	21.71	23.92	0.04	NA	NA	52.10	54.31	090
33417		A	Repair of aortic valve	28.53	NA	NA	25.47	27.62	3.72	NA	NA	57.72	59.87	090
33420		A	Revision of mitral valve	22.70	NA	NA	11.43	13.95	1.58	NA	NA	35.71	38.23	090
33422		A	Revision of mitral valve	25.94	NA	NA	19.74	22.55	3.34	NA	NA	49.02	51.83	090
33425		A	Repair of mitral valve	0.27	NA	NA	19.58	22.74	3.47	NA	NA	23.32	26.48	090
33426		A	Repair of mitral valve	31.03	NA	NA	21.42	24.74	4.03	NA	NA	56.48	59.80	090
33427		A	Repair of mitral valve	33.72	NA	NA	22.50	26.29	4.42	NA	NA	60.64	64.43	090
33430		A	Replacement of mitral valve	31.43	NA	NA	21.56	25.55	4.09	NA	NA	57.08	61.07	090
33460		A	Revision of tricuspid valve	23.60	NA	NA	18.32	20.78	0.03	NA	NA	41.95	44.41	090
33463		A	Valvuloplasty, tricuspid	25.62	NA	NA	19.22	22.06	3.34	NA	NA	48.18	51.02	090
33464		A	Valvuloplasty, tricuspid	27.33	NA	NA	20.03	23.18	3.57	NA	NA	50.93	54.08	090
33465		A	Replace tricuspid valve	28.79	NA	NA	20.61	24.05	3.65	NA	NA	53.05	56.49	090
33468		A	Revision of tricuspid valve	30.12	NA	NA	28.69	30.51	3.93	NA	NA	62.74	64.56	090
33470		A	Revision of pulmonary valve	20.81	NA	NA	11.28	13.84	2.50	NA	NA	34.59	37.15	090
33471		A	Valvotomy, pulmonary valve	22.25	NA	NA	13.15	16.51	1.75	NA	NA	37.15	40.51	090
33472		A	Revision of pulmonary valve	22.25	NA	NA	14.81	17.75	2.53	NA	NA	39.59	42.53	090
33474		A	Revision of pulmonary valve	23.04	NA	NA	19.11	21.21	2.62	NA	NA	44.77	46.87	090
33475		A	Replacement, pulmonary valve	28.41	NA	NA	22.03	25.00	3.73	NA	NA	54.17	57.14	090
33476		A	Revision of heart chamber	25.77	NA	NA	16.56	20.06	2.38	NA	NA	44.71	48.21	090
33478		A	Revision of heart chamber	26.74	NA	NA	22.18	24.62	3.68	NA	NA	52.60	55.04	090
33496		A	Repair, prosth valve clot	27.25	NA	NA	22.69	25.15	3.63	NA	NA	53.57	56.03	090
33500		A	Repair heart vessel fistula	25.55	NA	NA	19.25	22.07	3.10	NA	NA	47.90	50.72	090
33501		A	Repair heart vessel fistula	17.78	NA	NA	14.32	14.58	2.09	NA	NA	34.19	34.45	090
33502		A	Coronary artery correction	21.04	NA	NA	23.68	21.60	2.86	NA	NA	47.58	45.50	090
33503		A	Coronary artery graft	21.78	NA	NA	14.97	17.73	2.70	NA	NA	39.45	42.21	090
33504		A	Coronary artery graft	24.66	NA	NA	23.84	25.24	2.63	NA	NA	51.13	52.53	090
33505		A	Repair artery w/tunnel	26.84	NA	NA	15.91	19.94	3.16	NA	NA	45.91	49.94	090
33506		A	Repair artery, translocation	26.71	NA	NA	19.83	22.84	2.94	NA	NA	49.48	52.49	090
33510		A	CABG, vein, single	25.12	NA	NA	18.98	21.73	3.27	NA	NA	47.37	50.12	090
33511		A	CABG, vein, two	27.40	NA	NA	19.87	23.08	3.56	NA	NA	50.83	54.04	090
33512		A	CABG, vein, three	29.67	NA	NA	20.57	24.28	3.79	NA	NA	54.03	57.74	090
33513		A	CABG, vein, four	31.95	NA	NA	21.68	25.80	4.11	NA	NA	57.74	61.86	090
33514		A	CABG, vein, five	0.35	NA	NA	23.07	27.75	4.49	NA	NA	27.91	32.59	090
33516		A	Cabg, vein, six or more	37.40	NA	NA	24.08	29.22	4.78	NA	NA	66.26	71.40	090
33517		A	CABG, artery-vein, single	2.57	NA	NA	1.05	1.56	0.33	NA	NA	3.95	4.46	ZZZ
33518		A	CABG, artery-vein, two	4.85	NA	NA	1.98	2.94	0.63	NA	NA	7.46	8.42	ZZZ
33519		A	CABG, artery-vein, three	7.12	NA	NA	2.91	4.31	0.92	NA	NA	10.95	12.35	ZZZ
33521		A	CABG, artery-vein, four	9.40	NA	NA	3.84	5.69	1.21	NA	NA	14.45	16.30	ZZZ
33522		A	CABG, artery-vein, five	11.67	NA	NA	4.78	7.07	1.49	NA	NA	17.94	20.23	ZZZ
33523		A	Cabg, art-vein, six or more	13.95	NA	NA	5.73	8.46	1.78	NA	NA	21.46	24.19	ZZZ
33530		A	Coronary artery, bypass/reop	5.86	NA	NA	2.39	3.54	0.76	NA	NA	9.01	10.16	ZZZ
33533		A	CABG, arterial, single	25.83	NA	NA	19.25	22.15	3.33	NA	NA	48.41	51.31	090
33534		A	CABG, arterial, two	28.82	NA	NA	19.86	23.50	3.68	NA	NA	52.36	56.00	090
33535		A	CABG, arterial, three	31.81	NA	NA	20.88	25.15	3.96	NA	NA	56.65	60.92	090
33536		A	Cabg, arterial, four or more	34.79	NA	NA	21.59	26.58	4.39	NA	NA	60.77	65.76	090
33542		A	Removal of heart lesion	28.85	NA	NA	22.46	25.18	3.76	NA	NA	55.07	57.79	090
33545		A	Repair of heart damage	36.78	NA	NA	25.43	28.55	4.80	NA	NA	67.01	70.13	090
33572		A	Open coronary endarterectomy	4.45	NA	NA	1.82	2.24	0.58	NA	NA	6.85	7.27	ZZZ
33600		A	Closure of valve	29.51	NA	NA	20.23	23.98	2.58	NA	NA	52.32	56.07	090
33602		A	Closure of valve	28.54	NA	NA	20.00	23.27	2.84	NA	NA	51.38	54.65	090
33606		A	Anastomosis/artery-aorta	30.74	NA	NA	22.08	25.73	3.97	NA	NA	56.79	60.44	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
33608		A	Repair anomaly w/conduit	31.09	NA	NA	24.35	27.54	4.27	NA	NA	59.71	62.90	090
33610		A	Repair by enlargement	30.61	NA	NA	25.44	28.22	3.64	NA	NA	59.69	62.47	090
33611		A	Repair double ventricle	32.30	NA	NA	23.19	27.03	4.44	NA	NA	59.93	63.77	090
33612		A	Repair double ventricle	33.26	NA	NA	26.76	30.00	4.51	NA	NA	64.53	67.77	090
33615		A	Repair, simple fontan	32.06	NA	NA	26.81	29.68	3.88	NA	NA	62.75	65.62	090
33617		A	Repair, modified fontan	34.03	NA	NA	28.98	31.89	4.75	NA	NA	67.76	70.67	090
33619		A	Repair single ventricle	37.57	NA	NA	34.35	36.98	5.03	NA	NA	76.95	79.58	090
33641		A	Repair heart septum defect	21.39	NA	NA	15.27	17.84	2.78	NA	NA	39.44	42.01	090
33645		A	Revision of heart veins	24.82	NA	NA	20.05	22.45	3.32	NA	NA	48.19	50.59	090
33647		A	Repair heart septum defects	28.73	NA	NA	23.71	26.36	3.81	NA	NA	56.25	58.90	090
33660		A	Repair of heart defects	25.54	NA	NA	22.37	24.40	3.13	NA	NA	51.04	53.07	090
33665		A	Repair of heart defects	28.60	NA	NA	23.01	25.74	0.04	NA	NA	51.65	54.38	090
33670		A	Repair of heart chambers	32.73	NA	NA	16.81	22.38	3.35	NA	NA	52.89	58.46	090
33681		A	Repair heart septum defect	27.67	NA	NA	23.93	26.21	3.60	NA	NA	55.20	57.48	090
33684		A	Repair heart septum defect	29.65	NA	NA	22.11	25.43	3.63	NA	NA	55.39	58.71	090
33688		A	Repair heart septum defect	30.62	NA	NA	13.26	19.08	3.74	NA	NA	47.62	53.44	090
33690		A	Reinforce pulmonary artery	19.55	NA	NA	17.97	19.31	2.38	NA	NA	39.90	41.24	090
33692		A	Repair of heart defects	30.75	NA	NA	21.05	24.97	4.22	NA	NA	56.02	59.94	090
33694		A	Repair of heart defects	31.73	NA	NA	21.44	25.55	3.36	NA	NA	56.53	60.64	090
33697		A	Repair of heart defects	33.71	NA	NA	22.24	26.74	4.52	NA	NA	60.47	64.97	090
33702		A	Repair of heart defects	26.54	NA	NA	22.68	24.93	3.55	NA	NA	52.77	55.02	090
33710		A	Repair of heart defects	29.71	NA	NA	20.63	24.34	4.15	NA	NA	54.49	58.20	090
33720		A	Repair of heart defect	26.56	NA	NA	21.31	23.91	3.56	NA	NA	51.43	54.03	090
33722		A	Repair of heart defect	28.41	NA	NA	24.35	26.53	3.97	NA	NA	56.73	58.91	090
33730		A	Repair heart-vein defect(s)	31.67	NA	NA	18.46	23.30	4.24	NA	NA	54.37	59.21	090
33732		A	Repair heart-vein defect	28.16	NA	NA	19.98	23.39	3.93	NA	NA	52.07	55.48	090
33735		A	Revision of heart chamber	21.39	NA	NA	16.06	19.02	2.21	NA	NA	39.66	42.62	090
33736		A	Revision of heart chamber	23.52	NA	NA	21.57	23.15	3.03	NA	NA	48.12	49.70	090
33737		A	Revision of heart chamber	21.76	NA	NA	18.24	20.18	0.86	NA	NA	40.86	42.80	090
33750		A	Major vessel shunt	21.41	NA	NA	13.17	15.87	2.72	NA	NA	37.30	40.00	090
33755		A	Major vessel shunt	21.79	NA	NA	12.97	15.72	1.37	NA	NA	36.13	38.88	090
33762		A	Major vessel shunt	21.79	NA	NA	12.97	15.72	2.95	NA	NA	37.71	40.46	090
33764		A	Major vessel shunt & graft	21.79	NA	NA	14.29	16.71	2.07	NA	NA	38.15	40.57	090
33766		A	Major vessel shunt	22.76	NA	NA	20.06	21.04	3.08	NA	NA	45.90	46.88	090
33767		A	Major vessel shunt	24.50	NA	NA	15.20	18.37	3.49	NA	NA	43.19	46.36	090
33770		A	Repair great vessels defect	33.29	NA	NA	22.08	26.50	2.76	NA	NA	58.13	62.55	090
33771		A	Repair great vessels defect	34.65	NA	NA	16.38	22.63	2.87	NA	NA	53.90	60.15	090
33774		A	Repair great vessels defect	30.98	NA	NA	23.14	25.84	1.18	NA	NA	55.30	58.00	090
33775		A	Repair great vessels defect	32.20	NA	NA	17.10	21.31	2.67	NA	NA	51.97	56.18	090
33776		A	Repair great vessels defect	34.04	NA	NA	17.83	22.85	2.82	NA	NA	54.69	59.71	090
33777		A	Repair great vessels defect	33.46	NA	NA	17.60	21.69	2.77	NA	NA	53.83	57.92	090
33778		A	Repair great vessels defect	35.82	NA	NA	24.62	29.16	2.97	NA	NA	63.41	67.95	090
33779		A	Repair great vessels defect	36.21	NA	NA	16.37	23.09	4.72	NA	NA	57.30	64.02	090
33780		A	Repair great vessels defect	36.94	NA	NA	18.98	25.26	5.08	NA	NA	61.00	67.28	090
33781		A	Repair great vessels defect	36.45	NA	NA	16.86	23.53	3.02	NA	NA	56.33	63.00	090
33786		A	Repair arterial trunk	34.84	NA	NA	18.14	24.00	2.88	NA	NA	55.86	61.72	090
33788		A	Revision of pulmonary artery	26.62	NA	NA	14.64	18.93	2.21	NA	NA	43.47	47.76	090
33800		A	Aortic suspension	16.24	NA	NA	17.96	17.31	1.95	NA	NA	36.15	35.50	090
33802		A	Repair vessel defect	17.66	NA	NA	17.86	18.67	2.40	NA	NA	37.92	38.73	090
33803		A	Repair vessel defect	19.60	NA	NA	12.10	14.93	2.35	NA	NA	34.05	36.88	090
33813		A	Repair septal defect	20.65	NA	NA	16.34	18.25	2.92	NA	NA	39.91	41.82	090
33814		A	Repair septal defect	25.77	NA	NA	21.49	23.81	3.47	NA	NA	50.73	53.05	090
33820		A	Revise major vessel	16.29	NA	NA	16.46	17.21	2.05	NA	NA	34.80	35.55	090
33822		A	Revise major vessel	17.32	NA	NA	11.20	13.57	2.19	NA	NA	30.71	33.08	090
33824		A	Revise major vessel	19.52	NA	NA	17.41	18.88	2.45	NA	NA	39.38	40.85	090
33840		A	Remove aorta constriction	20.63	NA	NA	19.94	21.11	2.89	NA	NA	43.46	44.63	090
33845		A	Remove aorta constriction	22.12	NA	NA	18.65	20.59	3.10	NA	NA	43.87	45.81	090
33851		A	Remove aorta constriction	21.27	NA	NA	22.24	23.03	2.92	NA	NA	46.43	47.22	090
33852		A	Repair septal defect	23.71	NA	NA	21.42	23.14	3.07	NA	NA	48.20	49.92	090
33853		A	Repair septal defect	31.72	NA	NA	28.53	30.86	4.07	NA	NA	64.32	66.65	090
33860		A	Ascending aortic graft	33.96	NA	NA	22.70	26.44	4.46	NA	NA	61.12	64.86	090
33861		A	Ascending aortic graft	34.52	NA	NA	22.46	26.26	4.58	NA	NA	61.56	65.36	090
33863		A	Ascending aortic graft	36.47	NA	NA	23.38	26.95	4.77	NA	NA	64.62	68.19	090
33870		A	Transverse aortic arch graft	40.31	NA	NA	25.09	30.84	5.38	NA	NA	70.78	76.53	090
33875		A	Thoracic aortic graft	33.06	NA	NA	21.33	24.48	4.27	NA	NA	58.66	61.81	090
33877		A	Thoracoabdominal graft	42.60	NA	NA	26.55	31.88	5.48	NA	NA	74.63	79.96	090
33910		A	Remove lung artery emboli	24.59	NA	NA	17.98	17.46	3.12	NA	NA	45.69	45.17	090
33915		A	Remove lung artery emboli	21.02	NA	NA	13.96	13.73	2.26	NA	NA	37.24	37.01	090
33916		A	Surgery of great vessel	25.83	NA	NA	17.22	17.68	3.27	NA	NA	46.32	46.78	090
33917		A	Repair pulmonary artery	24.50	NA	NA	20.89	22.98	3.30	NA	NA	48.69	50.78	090
33918		A	Repair pulmonary atresia	26.45	NA	NA	14.82	19.01	3.77	NA	NA	45.04	49.23	090
33919		A	Repair pulmonary atresia	32.67	NA	NA	17.28	22.71	4.56	NA	NA	54.51	59.94	090
33920		A	Repair pulmonary atresia	31.95	NA	NA	23.86	27.43	4.47	NA	NA	60.28	63.85	090
33922		A	Transect pulmonary artery	23.52	NA	NA	20.14	22.13	2.40	NA	NA	46.06	48.05	090
33924		A	Remove pulmonary shunt	5.50	NA	NA	2.25	2.77	0.77	NA	NA	8.52	9.04	ZZZ
33930		X	Removal of donor heart/lung	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
33935		R	Transplantation, heart/lung	60.96	NA	NA	33.84	43.58	8.06	NA	NA	102.86	112.60	090
33940		X	Removal of donor heart	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
33945		R	Transplantation of heart	42.10	NA	NA	26.76	32.64	5.60	NA	NA	74.46	80.34	090
33960		A	External circulation assist	19.36	NA	NA	6.06	6.45	1.59	NA	NA	27.01	27.40	XXX
33961		A	External circulation assist	10.93	NA	NA	4.16	5.02	1.35	NA	NA	16.44	17.30	ZZZ
33968		A	Remove aortic assist device	0.64	NA	NA	0.25	0.25	0.27	NA	NA	1.16	1.16	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
33970		A	Aortic circulation assist	6.75	NA	NA	2.77	4.09	0.91	NA	NA	10.43	11.75	000
33971		A	Aortic circulation assist	9.69	NA	NA	9.64	8.63	1.29	NA	NA	20.62	19.61	090
33973		A	Insert balloon device	9.76	NA	NA	3.98	5.03	1.32	NA	NA	15.06	16.11	000
33974		A	Remove intra-aortic balloon	14.41	NA	NA	12.73	11.06	1.94	NA	NA	29.08	27.41	090
33975		A	Implant ventricular device	0.21	NA	NA	8.53	10.25	2.86	NA	NA	11.60	13.32	XXX
33976		A	Implant ventricular device	0.23	NA	NA	9.36	12.27	3.91	NA	NA	13.50	16.41	XXX
33977		A	Remove ventricular device	19.29	NA	NA	13.26	13.31	2.56	NA	NA	35.11	35.16	090
33978		A	Remove ventricular device	21.73	NA	NA	14.17	14.48	2.89	NA	NA	38.79	39.10	090
33999		C	Cardiac surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
34001		A	Removal of artery clot	12.91	NA	NA	6.36	7.37	1.56	NA	NA	20.83	21.84	090
34051		A	Removal of artery clot	15.21	NA	NA	7.77	8.22	1.85	NA	NA	24.83	25.28	090
34101		A	Removal of artery clot	9.97	NA	NA	5.04	6.04	1.13	NA	NA	16.14	17.14	090
34111		A	Removal of arm artery clot	8.07	NA	NA	4.36	5.33	0.84	NA	NA	13.27	14.24	090
34151		A	Removal of artery clot	16.86	NA	NA	7.91	9.18	1.87	NA	NA	26.64	27.91	090
34201		A	Removal of artery clot	9.13	NA	NA	5.09	6.23	1.06	NA	NA	15.28	16.42	090
34203		A	Removal of leg artery clot	12.21	NA	NA	6.34	7.10	1.43	NA	NA	19.98	20.74	090
34401		A	Removal of vein clot	12.86	NA	NA	6.31	6.92	1.25	NA	NA	20.42	21.03	090
34421		A	Removal of vein clot	9.93	NA	NA	5.56	6.19	0.97	NA	NA	16.46	17.09	090
34451		A	Removal of vein clot	14.44	NA	NA	6.90	8.08	1.60	NA	NA	22.94	24.12	090
34471		A	Removal of vein clot	10.18	NA	NA	4.96	4.67	0.01	NA	NA	15.15	14.86	090
34490		A	Removal of vein clot	7.60	NA	NA	5.56	6.14	0.76	NA	NA	13.92	14.50	090
34501		A	Repair valve, femoral vein	10.93	NA	NA	8.35	8.26	1.43	NA	NA	20.71	20.62	090
34502		A	Reconstruct vena cava	26.95	NA	NA	12.48	14.42	2.97	NA	NA	42.40	44.34	090
34510		A	Transposition of vein valve	13.25	NA	NA	10.63	10.39	1.64	NA	NA	25.52	25.28	090
34520		A	Cross-over vein graft	13.74	NA	NA	7.91	8.47	1.64	NA	NA	23.29	23.85	090
34530		A	Leg vein fusion	17.61	NA	NA	9.52	10.49	0.02	NA	NA	27.15	28.12	090
35001		A	Repair defect of artery	19.64	NA	NA	9.31	11.30	2.51	NA	NA	31.46	33.45	090
35002		A	Repair artery rupture, neck	0.21	NA	NA	9.42	10.50	2.43	NA	NA	12.06	13.14	090
35005		A	Repair defect of artery	18.12	NA	NA	8.19	8.93	1.40	NA	NA	27.71	28.45	090
35011		A	Repair defect of artery	11.65	NA	NA	5.72	7.77	1.36	NA	NA	18.73	20.78	090
35013		A	Repair artery rupture, arm	17.40	NA	NA	7.73	9.79	0.02	NA	NA	25.15	27.21	090
35021		A	Repair defect of artery	19.65	NA	NA	10.14	12.53	2.42	NA	NA	32.21	34.60	090
35022		A	Repair artery rupture, chest	23.18	NA	NA	9.78	11.35	2.15	NA	NA	35.11	6.68	090
35045		A	Repair defect of arm artery	11.26	NA	NA	6.68	8.36	1.26	NA	NA	19.20	20.88	090
35081		A	Repair defect of artery	28.01	NA	NA	12.65	15.31	3.30	NA	NA	43.96	46.62	090
35082		A	Repair artery rupture, aorta	36.35	NA	NA	14.91	17.40	4.14	NA	NA	55.40	57.89	090
35091		A	Repair defect of artery	35.40	NA	NA	15.36	17.67	4.28	NA	NA	55.04	57.35	090
35092		A	Repair artery rupture, aorta	38.39	NA	NA	16.08	19.19	4.48	NA	NA	58.95	62.06	090
35102		A	Repair defect of artery	30.76	NA	NA	13.47	16.11	3.65	NA	NA	47.88	50.52	090
35103		A	Repair artery rupture, groin	33.57	NA	NA	14.15	17.71	3.84	NA	NA	51.56	55.12	090
35111		A	Repair defect of artery	16.43	NA	NA	7.76	10.60	1.82	NA	NA	26.01	28.85	090
35112		A	Repair artery rupture,spleen	18.69	NA	NA	8.32	9.08	2.14	NA	NA	29.15	29.91	090
35121		A	Repair defect of artery	25.99	NA	NA	11.71	13.97	3.10	NA	NA	40.80	43.06	090
35122		A	Repair artery rupture, belly	33.45	NA	NA	14.23	15.54	3.69	NA	NA	51.37	52.68	090
35131		A	Repair defect of artery	18.55	NA	NA	8.94	11.01	2.20	NA	NA	29.69	31.76	090
35132		A	Repair artery rupture, groin	21.95	NA	NA	9.94	12.52	2.47	NA	NA	34.36	36.94	090
35141		A	Repair defect of artery	14.46	NA	NA	7.31	9.47	1.73	NA	NA	23.50	25.66	090
35142		A	Repair artery rupture, thigh	15.86	NA	NA	7.63	10.09	1.92	NA	NA	25.41	27.87	090
35151		A	Repair defect of artery	0.17	NA	NA	8.20	10.32	2.01	NA	NA	10.38	12.50	090
35152		A	Repair artery rupture, knee	16.70	NA	NA	8.18	8.65	2.01	NA	NA	26.89	27.36	090
35161		A	Repair defect of artery	18.76	NA	NA	9.56	11.48	2.19	NA	NA	30.51	32.43	090
35162		A	Repair artery rupture	19.78	NA	NA	9.78	12.40	2.26	NA	NA	31.82	34.44	090
35180		A	Repair blood vessel lesion	13.62	NA	NA	6.97	7.23	1.53	NA	NA	22.12	22.38	090
35182		A	Repair blood vessel lesion	17.74	NA	NA	8.93	9.59	2.19	NA	NA	28.86	29.52	090
35184		A	Repair blood vessel lesion	12.25	NA	NA	6.22	7.31	1.45	NA	NA	19.92	21.01	090
35188		A	Repair blood vessel lesion	14.28	NA	NA	6.78	7.29	1.70	NA	NA	22.76	23.27	090
35189		A	Repair blood vessel lesion	18.43	NA	NA	9.10	9.90	2.17	NA	NA	29.70	30.50	090
35190		A	Repair blood vessel lesion	12.75	NA	NA	6.37	7.58	1.48	NA	NA	20.60	21.81	090
35201		A	Repair blood vessel lesion	9.99	NA	NA	5.28	6.69	1.23	NA	NA	16.50	17.91	090
35206		A	Repair blood vessel lesion	9.25	NA	NA	6.15	7.37	1.06	NA	NA	16.46	17.68	090
35207		A	Repair blood vessel lesion	10.15	NA	NA	8.67	9.43	1.06	NA	NA	19.88	20.64	090
35211		A	Repair blood vessel lesion	22.12	NA	NA	17.68	16.89	2.91	NA	NA	42.71	41.92	090
35216		A	Repair blood vessel lesion	18.75	NA	NA	13.90	13.32	2.24	NA	NA	34.89	34.31	090
35221		A	Repair blood vessel lesion	16.42	NA	NA	7.89	8.93	1.81	NA	NA	26.12	27.16	090
35226		A	Repair blood vessel lesion	9.06	NA	NA	6.96	7.93	1.15	NA	NA	17.17	18.14	090
35231		A	Repair blood vessel lesion	0.12	NA	NA	6.65	8.57	1.38	NA	NA	8.15	10.07	090
35236		A	Repair blood vessel lesion	10.54	NA	NA	6.73	8.19	1.23	NA	NA	18.50	19.96	090
35241		A	Repair blood vessel lesion	23.12	NA	NA	19.86	18.56	2.84	NA	NA	45.82	44.52	090
35246		A	Repair blood vessel lesion	19.84	NA	NA	14.12	15.19	2.42	NA	NA	36.38	37.45	090
35251		A	Repair blood vessel lesion	17.49	NA	NA	8.01	8.61	1.87	NA	NA	27.37	27.97	090
35256		A	Repair blood vessel lesion	11.38	NA	NA	7.05	8.65	1.37	NA	NA	19.80	21.40	090
35261		A	Repair blood vessel lesion	11.63	NA	NA	5.81	7.83	1.38	NA	NA	18.82	20.84	090
35266		A	Repair blood vessel lesion	10.30	NA	NA	6.37	7.85	1.24	NA	NA	17.91	19.39	090
35271		A	Repair blood vessel lesion	22.12	NA	NA	17.64	16.63	2.95	NA	NA	42.71	41.70	090
35276		A	Repair blood vessel lesion	18.75	NA	NA	15.11	14.28	2.50	NA	NA	36.36	35.53	090
35281		A	Repair blood vessel lesion	16.48	NA	NA	7.93	10.64	1.84	NA	NA	26.25	28.96	090
35286		A	Repair blood vessel lesion	11.87	NA	NA	7.52	8.82	1.39	NA	NA	20.78	22.08	090
35301		A	Rechanneling of artery	18.70	NA	NA	9.48	11.03	2.29	NA	NA	30.47	32.02	090
35311		A	Rechanneling of artery	23.85	NA	NA	12.09	15.05	3.12	NA	NA	39.06	42.02	090
35321		A	Rechanneling of artery	11.97	NA	NA	5.92	7.96	1.40	NA	NA	19.29	21.33	090
35331		A	Rechanneling of artery	23.52	NA	NA	10.77	11.70	2.88	NA	NA	37.17	38.10	090
35341		A	Rechanneling of artery	25.11	NA	NA	11.34	13.22	3.07	NA	NA	39.52	41.40	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
35351		A	Rechanneling of artery	20.11	NA	NA	9.40	11.11	2.33	NA	NA	31.84	33.55	090
35355		A	Rechanneling of artery	16.09	NA	NA	7.85	10.07	1.86	NA	NA	25.80	28.02	090
35361		A	Rechanneling of artery	23.59	NA	NA	10.70	13.28	2.74	NA	NA	37.03	39.61	090
35363		A	Rechanneling of artery	24.66	NA	NA	11.26	14.62	2.81	NA	NA	38.73	42.09	090
35371		A	Rechanneling of artery	11.64	NA	NA	5.94	7.85	1.37	NA	NA	18.95	20.86	090
35372		A	Rechanneling of artery	13.56	NA	NA	6.68	8.05	1.59	NA	NA	21.83	23.20	090
35381		A	Rechanneling of artery	15.81	NA	NA	7.75	9.52	1.85	NA	NA	25.41	27.18	090
35390		A	Reoperation, carotid add-on	3.19	NA	NA	1.22	1.37	0.40	NA	NA	4.81	4.96	ZZZ
35400		A	Angioscopy	0.03	NA	NA	1.14	1.47	0.27	NA	NA	1.44	1.77	ZZZ
35450		A	Repair arterial blockage	10.07	NA	NA	4.51	6.39	1.17	NA	NA	15.75	17.63	000
35452		A	Repair arterial blockage	6.91	NA	NA	3.31	3.66	0.83	NA	NA	11.05	11.40	000
35454		A	Repair arterial blockage	6.04	NA	NA	2.87	3.96	0.71	NA	NA	9.62	10.71	000
35456		A	Repair arterial blockage	7.35	NA	NA	3.42	4.76	0.87	NA	NA	11.64	12.98	000
35458		A	Repair arterial blockage	9.49	NA	NA	4.26	5.94	1.13	NA	NA	14.88	16.56	000
35459		A	Repair arterial blockage	8.63	NA	NA	3.85	5.46	0.99	NA	NA	13.47	15.08	000
35460		A	Repair venous blockage	6.04	NA	NA	2.71	2.89	0.64	NA	NA	9.39	9.57	000
35470		A	Repair arterial blockage	8.63	NA	NA	4.00	5.58	0.68	NA	NA	13.31	14.89	000
35471		A	Repair arterial blockage	10.07	NA	NA	4.60	6.46	0.82	NA	NA	15.49	17.35	000
35472		A	Repair arterial blockage	6.91	NA	NA	3.34	3.49	0.55	NA	NA	10.80	10.95	000
35473		A	Repair arterial blockage	6.04	NA	NA	2.97	4.03	0.41	NA	NA	9.42	10.48	000
35474		A	Repair arterial blockage	7.36	NA	NA	3.48	4.81	0.53	NA	NA	11.37	12.70	000
35475		R	Repair arterial blockage	9.49	NA	NA	4.15	5.86	0.51	NA	NA	14.15	15.86	000
35476		A	Repair venous blockage	6.04	NA	NA	2.87	3.01	0.26	NA	NA	9.17	9.31	000
35480		A	Atherectomy, open	11.08	NA	NA	4.78	6.89	1.16	NA	NA	17.02	19.13	000
35481		A	Atherectomy, open	7.61	NA	NA	3.77	4.01	0.95	NA	NA	12.33	12.57	000
35482		A	Atherectomy, open	6.65	NA	NA	3.27	4.44	0.83	NA	NA	10.75	11.92	000
35483		A	Atherectomy, open	8.10	NA	NA	3.70	5.19	0.98	NA	NA	12.78	14.27	000
35484		A	Atherectomy, open	10.44	NA	NA	4.65	6.24	1.11	NA	NA	16.20	17.79	000
35485		A	Atherectomy, open	9.49	NA	NA	4.26	4.42	1.15	NA	NA	14.90	15.06	000
35490		A	Atherectomy, percutaneous	11.08	NA	NA	4.91	6.99	1.03	NA	NA	17.02	19.10	000
35491		A	Atherectomy, percutaneous	7.61	NA	NA	3.51	3.81	0.77	NA	NA	11.89	12.19	000
35492		A	Atherectomy, percutaneous	6.65	NA	NA	3.22	4.40	0.71	NA	NA	10.58	11.76	000
35493		A	Atherectomy, percutaneous	8.10	NA	NA	4.06	5.46	0.91	NA	NA	13.07	14.47	000
35494		A	Atherectomy, percutaneous	10.44	NA	NA	4.53	6.15	0.50	NA	NA	15.47	17.09	000
35495		A	Atherectomy, percutaneous	9.49	NA	NA	4.74	4.78	1.09	NA	NA	15.32	15.36	000
35500		A	Harvest vein for bypass	6.45	NA	NA	2.42	2.42	0.73	NA	NA	9.60	9.60	ZZZ
35501		A	Artery bypass graft	19.19	NA	NA	7.22	10.67	2.39	NA	NA	28.80	32.25	090
35506		A	Artery bypass graft	19.67	NA	NA	9.22	12.12	2.41	NA	NA	31.30	34.20	090
35507		A	Artery bypass graft	19.67	NA	NA	9.17	11.74	2.43	NA	NA	31.27	33.84	090
35508		A	Artery bypass graft	18.65	NA	NA	9.04	11.69	2.42	NA	NA	30.11	32.76	090
35509		A	Artery bypass graft	18.07	NA	NA	8.17	11.26	2.21	NA	NA	28.45	31.54	090
35511		A	Artery bypass graft	16.83	NA	NA	8.06	8.87	0.02	NA	NA	24.91	25.72	090
35515		A	Artery bypass graft	18.65	NA	NA	8.73	9.60	2.39	NA	NA	29.77	30.64	090
35516		A	Artery bypass graft	16.32	NA	NA	7.60	10.41	0.02	NA	NA	23.94	26.75	090
35518		A	Artery bypass graft	15.42	NA	NA	6.88	9.76	1.74	NA	NA	24.04	26.92	090
35521		A	Artery bypass graft	16.17	NA	NA	7.91	10.69	1.88	NA	NA	25.96	28.74	090
35526		A	Artery bypass graft	0.20	NA	NA	10.05	11.05	2.48	NA	NA	12.73	13.73	090
35531		A	Artery bypass graft	25.61	NA	NA	11.45	14.08	3.04	NA	NA	40.10	42.73	090
35533		A	Artery bypass graft	20.52	NA	NA	9.51	12.84	2.27	NA	NA	32.30	35.63	090
35536		A	Artery bypass graft	23.11	NA	NA	10.45	13.64	2.90	NA	NA	36.46	39.65	090
35541		A	Artery bypass graft	25.80	NA	NA	11.88	14.22	3.08	NA	NA	40.76	43.10	090
35546		A	Artery bypass graft	25.54	NA	NA	11.51	14.44	2.91	NA	NA	39.96	42.89	090
35548		A	Artery bypass graft	21.57	NA	NA	10.11	12.89	2.34	NA	NA	34.02	36.80	090
35549		A	Artery bypass graft	23.35	NA	NA	10.99	14.05	2.69	NA	NA	37.03	40.09	090
35551		A	Artery bypass graft	26.67	NA	NA	12.32	14.46	2.85	NA	NA	41.84	43.98	090
35556		A	Artery bypass graft	21.76	NA	NA	10.06	12.62	2.57	NA	NA	34.39	36.95	090
35558		A	Artery bypass graft	14.04	NA	NA	7.06	9.49	1.61	NA	NA	22.71	25.14	090
35560		A	Artery bypass graft	23.56	NA	NA	11.13	13.83	2.84	NA	NA	37.53	40.23	090
35563		A	Artery bypass graft	15.14	NA	NA	7.86	8.15	1.71	NA	NA	24.71	25.00	090
35565		A	Artery bypass graft	15.14	NA	NA	7.51	10.15	1.78	NA	NA	24.43	27.07	090
35566		A	Artery bypass graft	26.92	NA	NA	15.00	16.85	3.22	NA	NA	45.14	46.99	090
35571		A	Artery bypass graft	18.58	NA	NA	10.37	13.03	2.22	NA	NA	31.17	33.83	090
35582		A	Vein bypass graft	27.13	NA	NA	11.64	15.17	3.14	NA	NA	41.91	45.44	090
35583		A	Vein bypass graft	22.37	NA	NA	11.14	13.90	2.63	NA	NA	36.14	38.90	090
35585		A	Vein bypass graft	28.39	NA	NA	14.75	17.29	3.33	NA	NA	46.47	49.01	090
35587		A	Vein bypass graft	19.05	NA	NA	11.39	14.23	2.23	NA	NA	32.67	35.51	090
35601		A	Artery bypass graft	17.50	NA	NA	7.99	11.10	2.16	NA	NA	27.65	30.76	090
35606		A	Artery bypass graft	18.71	NA	NA	8.65	11.25	2.27	NA	NA	29.63	32.23	090
35612		A	Artery bypass graft	15.76	NA	NA	7.68	10.31	1.90	NA	NA	25.34	27.97	090
35616		A	Artery bypass graft	15.70	NA	NA	7.35	10.07	1.93	NA	NA	24.98	27.70	090
35621		A	Artery bypass graft	14.54	NA	NA	7.40	9.89	1.74	NA	NA	23.68	26.17	090
35623		A	Bypass graft, not vein	16.62	NA	NA	8.02	8.20	0.02	NA	NA	24.66	24.84	090
35626		A	Artery bypass graft	23.63	NA	NA	11.33	14.06	2.98	NA	NA	37.94	40.67	090
35631		A	Artery bypass graft	24.60	NA	NA	11.14	13.20	0.03	NA	NA	35.77	37.83	090
35636		A	Artery bypass graft	22.46	NA	NA	10.15	11.28	2.70	NA	NA	35.31	36.44	090
35641		A	Artery bypass graft	24.57	NA	NA	11.55	14.24	0.03	NA	NA	36.15	38.84	090
35642		A	Artery bypass graft	17.98	NA	NA	7.79	8.65	2.16	NA	NA	27.93	28.79	090
35645		A	Artery bypass graft	17.47	NA	NA	7.99	9.02	1.85	NA	NA	27.31	28.34	090
35646		A	Artery bypass graft	25.81	NA	NA	11.76	15.27	3.08	NA	NA	40.65	44.16	090
35650		A	Artery bypass graft	14.36	NA	NA	6.73	9.34	1.71	NA	NA	22.80	25.41	090
35651		A	Artery bypass graft	25.04	NA	NA	11.42	15.10	2.81	NA	NA	39.27	42.95	090
35654		A	Artery bypass graft	18.61	NA	NA	8.81	12.16	2.20	NA	NA	29.62	32.97	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
35656		A	Artery bypass graft	19.53	NA	NA	9.10	11.64	2.27	NA	NA	30.90	33.44	090
35661		A	Artery bypass graft	13.18	NA	NA	6.64	8.92	1.55	NA	NA	21.37	23.65	090
35663		A	Artery bypass graft	14.17	NA	NA	7.32	9.72	1.72	NA	NA	23.21	25.61	090
35665		A	Artery bypass graft	15.40	NA	NA	7.58	10.28	1.84	NA	NA	24.82	27.52	090
35666		A	Artery bypass graft	19.19	NA	NA	11.41	14.00	2.28	NA	NA	32.88	35.47	090
35671		A	Artery bypass graft	14.80	NA	NA	9.43	11.31	1.75	NA	NA	25.98	27.86	090
35681		A	Composite bypass graft	1.60	NA	NA	2.45	4.24	0.19	NA	NA	4.24	6.03	ZZZ
35682		A	Composite bypass graft	7.20	2.71	4.44	2.70	4.43	0.85	10.76	12.49	10.75	12.48	ZZZ
35683		A	Composite bypass graft	8.50	3.20	4.81	3.18	4.79	1.01	12.71	14.32	12.69	14.30	ZZZ
35691		A	Arterial transposition	18.05	NA	NA	8.23	11.50	2.27	NA	NA	28.55	31.82	090
35693		A	Arterial transposition	15.36	NA	NA	7.00	7.80	1.94	NA	NA	24.30	25.10	090
35694		A	Arterial transposition	19.16	NA	NA	8.26	8.73	2.33	NA	NA	29.75	30.22	090
35695		A	Arterial transposition	19.16	NA	NA	8.42	8.85	2.16	NA	NA	29.74	30.17	090
35700		A	Reoperation, bypass graft	3.08	NA	NA	3.17	2.82	0.38	NA	NA	6.63	6.28	ZZZ
35701		A	Exploration, carotid artery	5.55	NA	NA	3.58	4.27	0.64	NA	NA	9.77	10.46	090
35721		A	Exploration, femoral artery	5.28	NA	NA	4.73	5.06	0.62	NA	NA	10.63	10.96	090
35741		A	Exploration popliteal artery	5.37	NA	NA	4.39	4.85	0.62	NA	NA	10.38	10.84	090
35761		A	Exploration of artery/vein	5.37	NA	NA	4.30	4.80	0.61	NA	NA	10.28	10.78	090
35800		A	Explore neck vessels	7.02	NA	NA	4.16	4.55	0.82	NA	NA	12.00	12.39	090
35820		A	Explore chest vessels	12.88	NA	NA	5.28	6.11	1.70	NA	NA	19.86	20.69	090
35840		A	Explore abdominal vessels	9.77	NA	NA	5.36	5.98	1.08	NA	NA	16.21	16.83	090
35860		A	Explore limb vessels	5.55	NA	NA	3.71	4.36	0.65	NA	NA	9.91	10.56	090
35870		A	Repair vessel graft defect	22.17	NA	NA	10.63	10.86	2.63	NA	NA	35.43	35.66	090
35875		A	Removal of clot in graft	10.13	NA	NA	6.31	6.96	1.08	NA	NA	17.52	18.17	090
35876		A	Removal of clot in graft	0.17	NA	NA	9.03	9.00	1.92	NA	NA	11.12	11.09	090
35879		A	Revise graft w/vein	0.16	NA	NA	8.30	8.30	1.97	NA	NA	10.43	10.43	090
35881		A	Revise graft w/vein	0.18	NA	NA	8.83	8.83	2.21	NA	NA	11.22	11.22	090
35901		A	Excision, graft, neck	8.19	NA	NA	5.91	6.38	0.97	NA	NA	15.07	15.54	090
35903		A	Excision, graft, extremity	9.39	NA	NA	8.10	8.02	1.08	NA	NA	18.57	18.49	090
35905		A	Excision, graft, thorax	18.19	NA	NA	12.25	11.14	2.15	NA	NA	32.59	31.48	090
35907		A	Excision, graft, abdomen	19.24	NA	NA	9.67	9.20	2.29	NA	NA	31.20	30.73	090
36000		A	Place needle in vein	0.18	0.55	0.48	0.05	0.10	0.01	0.74	0.67	0.24	0.29	XXX
36005		A	Injection, venography	0.95	15.60	11.83	0.33	0.38	0.05	16.60	12.83	1.33	1.38	000
36010		A	Place catheter in vein	2.43	NA	NA	0.87	1.23	0.16	NA	NA	3.46	3.82	XXX
36011		A	Place catheter in vein	3.14	NA	NA	1.13	1.36	0.20	NA	NA	4.47	4.70	XXX
36012		A	Place catheter in vein	3.52	NA	NA	1.26	1.67	0.15	NA	NA	4.93	5.34	XXX
36013		A	Place catheter in artery	2.52	NA	NA	0.83	1.20	0.21	NA	NA	3.56	3.93	XXX
36014		A	Place catheter in artery	3.02	NA	NA	1.09	1.44	0.12	NA	NA	4.23	4.58	XXX
36015		A	Place catheter in artery	3.52	NA	NA	1.26	1.67	0.15	NA	NA	4.93	5.34	XXX
36100		A	Establish access to artery	3.02	NA	NA	1.23	1.63	0.32	NA	NA	4.57	4.97	XXX
36120		A	Establish access to artery	2.01	NA	NA	0.73	1.15	0.12	NA	NA	2.86	3.28	XXX
36140		A	Establish access to artery	2.01	NA	NA	0.72	0.92	0.13	NA	NA	2.86	3.06	XXX
36145		A	Artery to vein shunt	2.01	NA	NA	0.73	1.15	0.09	NA	NA	2.83	3.25	XXX
36160		A	Establish access to aorta	2.52	NA	NA	0.97	1.36	0.23	NA	NA	3.72	4.11	XXX
36200		A	Place catheter in aorta	3.02	NA	NA	1.08	1.55	0.16	NA	NA	4.26	4.73	XXX
36215		A	Place catheter in artery	4.68	NA	NA	1.71	2.04	0.28	NA	NA	6.67	7.00	XXX
36216		A	Place catheter in artery	5.28	NA	NA	1.90	2.32	0.25	NA	NA	7.43	7.85	XXX
36217		A	Place catheter in artery	6.30	NA	NA	2.32	2.80	0.36	NA	NA	8.98	9.46	XXX
36218		A	Place catheter in artery	1.01	NA	NA	0.40	0.47	0.06	NA	NA	1.47	1.54	ZZZ
36245		A	Place catheter in artery	4.68	NA	NA	1.80	2.21	0.35	NA	NA	6.83	7.24	XXX
36246		A	Place catheter in artery	5.28	NA	NA	1.95	2.36	0.33	NA	NA	7.56	7.97	XXX
36247		A	Place catheter in artery	6.30	NA	NA	2.28	2.77	0.35	NA	NA	8.93	9.42	XXX
36248		A	Place catheter in artery	1.01	NA	NA	0.41	0.48	0.07	NA	NA	1.49	1.56	ZZZ
36260		A	Insertion of infusion pump	9.71	NA	NA	5.40	5.88	0.93	NA	NA	16.04	16.52	090
36261		A	Revision of infusion pump	5.45	NA	NA	3.05	2.89	0.53	NA	NA	9.03	8.87	090
36262		A	Removal of infusion pump	4.02	NA	NA	2.50	2.40	0.41	NA	NA	6.93	6.83	090
36299		C	Vessel injection procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
36400		A	Drawing blood	0.18	0.56	0.45	0.05	0.06	0.02	0.76	0.65	0.25	0.26	XXX
36405		A	Drawing blood	0.18	0.44	0.45	0.05	0.16	0.01	0.63	0.64	0.24	0.35	XXX
36406		A	Drawing blood	0.18	0.50	0.42	0.05	0.08	0.01	0.69	0.61	0.24	0.27	XXX
36410		A	Drawing blood	0.18	0.43	0.38	0.05	0.10	0.01	0.62	0.57	0.24	0.29	XXX
36415		I	Drawing blood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
36420		A	Establish access to vein	1.01	NA	NA	0.34	0.39	0.10	NA	NA	1.45	1.50	XXX
36425		A	Establish access to vein	0.76	2.63	2.00	0.18	0.16	0.06	3.45	2.82	1.00	0.98	XXX
36430		A	Blood transfusion service	0.00	1.02	1.03	1.02	1.03	0.05	1.07	1.08	1.07	1.08	XXX
36440		A	Blood transfusion service	1.03	NA	NA	0.28	0.47	0.10	NA	NA	1.41	1.60	XXX
36450		A	Exchange transfusion service	2.23	NA	NA	0.70	1.04	0.14	NA	NA	3.07	3.41	XXX
36455		A	Exchange transfusion service	2.43	NA	NA	0.91	1.30	0.14	NA	NA	3.48	3.87	XXX
36460		A	Transfusion service, fetal	6.59	NA	NA	2.32	3.02	0.60	NA	NA	9.51	10.21	XXX
36468		R	Injection(s), spider veins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
36469		R	Injection(s), spider veins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
36470		A	Injection therapy of vein	1.09	2.65	2.06	0.41	0.38	0.11	3.85	3.26	1.61	1.58	010
36471		A	Injection therapy of veins	1.57	3.07	2.41	0.58	0.54	0.14	4.78	4.12	2.29	2.25	010
36481		A	Insertion of catheter, vein	6.99	NA	NA	2.84	3.57	0.40	NA	NA	10.23	10.96	000
36488		A	Insertion of catheter, vein	1.35	NA	NA	0.67	0.77	0.11	NA	NA	2.13	2.23	000
36489		A	Insertion of catheter, vein	1.22	3.56	2.98	0.62	0.77	0.09	4.87	4.29	1.93	2.08	000
36490		A	Insertion of catheter, vein	1.67	NA	NA	0.81	0.98	0.13	NA	NA	2.61	2.78	000
36491		A	Insertion of catheter, vein	1.43	NA	NA	0.73	0.97	0.13	NA	NA	2.29	2.53	000
36493		A	Repositioning of cvc	1.21	NA	NA	0.82	0.79	0.06	NA	NA	2.09	2.06	000
36500		A	Insertion of catheter, vein	3.52	NA	NA	1.28	0.98	0.17	NA	NA	4.97	4.67	000
36510		A	Insertion of catheter, vein	1.09	NA	NA	0.65	0.58	0.07	NA	NA	1.81	1.74	000
36520		A	Plasma and/or cell exchange	1.74	NA	NA	0.96	1.24	0.10	NA	NA	2.80	3.08	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
36521		A	Apheresis w/ adsorp/reinfuse	1.74	NA	NA	0.96	0.96	0.09	NA	NA	2.79	2.79	000
36522		A	Photopheresis	1.67	6.96	5.89	1.08	1.48	0.06	8.69	7.62	2.81	3.21	000
36530		R	Insertion of infusion pump	6.20	NA	NA	3.49	3.93	0.63	NA	NA	10.32	10.76	010
36531		R	Revision of infusion pump	4.87	NA	NA	3.26	3.63	0.49	NA	NA	8.62	8.99	010
36532		R	Removal of infusion pump	3.30	NA	NA	1.58	1.67	0.33	NA	NA	5.21	5.30	010
36533		A	Insertion of access device	5.32	4.17	4.29	3.32	3.66	0.52	10.01	10.13	9.16	9.50	010
36534		A	Revision of access device	2.80	NA	NA	1.43	1.91	0.22	NA	NA	4.45	4.93	010
36535		A	Removal of access device	2.27	2.66	2.49	1.90	1.92	0.23	5.16	4.99	4.40	4.42	010
36550		A	Declot vascular device	0.00	0.54	0.54	0.06	0.06	0.32	0.86	0.86	0.38	0.38	XXX
36600		A	Withdrawal of arterial blood	0.32	0.36	0.35	0.09	0.14	0.02	0.70	0.69	0.43	0.48	XXX
36620		A	Insertion catheter, artery	1.15	NA	NA	0.25	0.37	0.08	NA	NA	1.48	1.60	000
36625		A	Insertion catheter, artery	2.11	NA	NA	0.56	0.65	0.17	NA	NA	2.84	2.93	000
36640		A	Insertion catheter, artery	2.10	NA	NA	0.77	1.21	0.19	NA	NA	3.06	3.50	000
36660		A	Insertion catheter, artery	1.40	NA	NA	0.45	0.47	0.07	NA	NA	1.92	1.94	000
36680		A	Insert needle, bone cavity	1.20	NA	NA	0.51	0.72	0.11	NA	NA	1.82	2.03	000
36800		A	Insertion of cannula	2.43	NA	NA	1.55	1.77	0.21	NA	NA	4.19	4.41	000
36810		A	Insertion of cannula	3.97	NA	NA	2.27	2.89	0.39	NA	NA	6.63	7.25	000
36815		A	Insertion of cannula	2.62	NA	NA	1.81	2.14	0.27	NA	NA	4.70	5.03	000
36819		A	Av fusion by basilic vein	0.14	NA	NA	6.63	6.63	1.55	NA	NA	8.32	8.32	090
36821		A	Av fusion direct any site	8.93	NA	NA	4.95	5.68	0.99	NA	NA	14.87	15.60	090
36822		A	Insertion of cannula(s)	5.42	NA	NA	9.86	8.92	0.70	NA	NA	15.98	15.04	090
36823		A	Insertion of cannula(s)	0.21	NA	NA	11.62	11.62	0.67	NA	NA	12.50	12.50	090
36825		A	Artery-vein graft	9.84	NA	NA	5.64	7.17	1.10	NA	NA	16.58	18.11	090
36830		A	Artery-vein graft	0.12	NA	NA	6.26	7.40	1.36	NA	NA	7.74	8.88	090
36831		A	Av fistula excision	0.08	2.77	2.77	2.77	2.77	0.85	3.70	3.70	3.70	3.70	090
36832		A	Av fistula revision	10.50	NA	NA	5.63	6.15	1.16	NA	NA	17.29	17.81	090
36833		A	Av fistula revision	11.95	4.44	4.44	4.44	4.44	1.33	17.72	17.72	17.72	17.72	090
36834		A	Repair A-V aneurysm	9.93	NA	NA	3.95	5.08	1.13	NA	NA	15.01	16.14	090
36835		A	Artery to vein shunt	7.15	NA	NA	4.94	4.63	0.80	NA	NA	12.89	12.58	090
36860		A	External cannula declotting	2.01	1.97	2.18	1.58	1.88	0.13	4.11	4.32	3.72	4.02	000
36861		A	Cannula declotting	2.52	NA	NA	1.72	2.04	0.22	NA	NA	4.46	4.78	000
37140		A	Revision of circulation	23.60	NA	NA	10.40	12.22	1.06	NA	NA	35.06	36.88	090
37145		A	Revision of circulation	24.61	NA	NA	9.22	11.56	0.95	NA	NA	34.78	37.12	090
37160		A	Revision of circulation	21.60	NA	NA	9.43	11.89	2.29	NA	NA	33.32	35.78	090
37180		A	Revision of circulation	24.61	NA	NA	10.80	11.95	2.45	NA	NA	37.86	39.01	090
37181		A	Splice spleen/kidney veins	26.68	NA	NA	11.53	13.10	2.56	NA	NA	40.77	42.34	090
37195		A	Thrombolytic therapy, stroke	0.00	8.14	8.19	8.14	8.19	0.39	8.53	8.58	8.53	8.58	XXX
37200		A	Transcatheter biopsy	4.56	NA	NA	1.62	1.65	0.25	NA	NA	6.43	6.46	000
37201		A	Transcatheter therapy infuse	0.05	NA	NA	2.52	3.38	0.25	NA	NA	2.82	3.68	000
37202		A	Transcatheter therapy infuse	5.68	NA	NA	3.08	3.48	0.74	NA	NA	9.50	9.90	000
37203		A	Transcatheter retrieval	5.03	NA	NA	2.56	2.96	0.25	NA	NA	7.84	8.24	000
37204		A	Transcatheter occlusion	18.14	NA	NA	6.41	8.54	0.77	NA	NA	25.32	27.45	000
37205		A	Transcatheter stent	8.28	NA	NA	3.84	4.28	0.61	NA	NA	12.73	13.17	000
37206		A	Transcatheter stent add-on	4.13	NA	NA	1.58	1.89	0.32	NA	NA	6.03	6.34	ZZZ
37207		A	Transcatheter stent	8.28	NA	NA	3.72	4.19	0.97	NA	NA	12.97	13.44	000
37208		A	Transcatheter stent add-on	4.13	NA	NA	1.57	1.88	0.49	NA	NA	6.19	6.50	ZZZ
37209		A	Exchange arterial catheter	2.27	NA	NA	0.83	1.01	0.11	NA	NA	3.21	3.39	000
37250		A	Iv us first vessel add-on	2.10	NA	NA	0.88	0.97	0.24	NA	NA	3.22	3.31	ZZZ
37251		A	Iv us each add vessel add-on	1.60	NA	NA	0.68	0.75	0.19	NA	NA	2.47	2.54	ZZZ
37565		A	Ligation of neck vein	4.44	NA	NA	2.61	2.99	0.44	NA	NA	7.49	7.87	090
37600		A	Ligation of neck artery	4.57	NA	NA	3.29	3.82	0.42	NA	NA	8.28	8.81	090
37605		A	Ligation of neck artery	6.19	NA	NA	3.72	4.30	0.75	NA	NA	10.66	11.24	090
37606		A	Ligation of neck artery	6.28	NA	NA	4.11	4.69	1.11	NA	NA	11.50	12.08	090
37607		A	Ligation of a-v fistula	6.16	NA	NA	3.66	3.58	0.69	NA	NA	10.51	10.43	090
37609		A	Temporal artery procedure	2.30	6.02	5.12	2.13	2.20	0.22	8.54	7.64	4.65	4.72	010
37615		A	Ligation of neck artery	5.73	NA	NA	3.72	4.32	0.58	NA	NA	10.03	10.63	090
37616		A	Ligation of chest artery	16.49	NA	NA	12.76	10.71	1.70	NA	NA	30.95	28.90	090
37617		A	Ligation of abdomen artery	15.95	NA	NA	7.53	7.82	1.61	NA	NA	25.09	25.38	090
37618		A	Ligation of extremity artery	4.84	NA	NA	3.47	3.95	0.54	NA	NA	8.85	9.33	090
37620		A	Revision of major vein	10.56	NA	NA	5.50	6.52	0.78	NA	NA	16.84	17.86	090
37650		A	Revision of major vein	5.13	NA	NA	3.72	3.88	0.60	NA	NA	9.45	9.61	090
37660		A	Revision of major vein	10.61	NA	NA	6.05	6.10	1.19	NA	NA	17.85	17.90	090
37700		A	Revise leg vein	3.73	NA	NA	3.00	3.24	0.41	NA	NA	7.14	7.38	090
37720		A	Removal of leg vein	5.66	NA	NA	3.59	4.08	0.62	NA	NA	9.87	10.36	090
37730		A	Removal of leg veins	7.33	NA	NA	4.50	5.26	0.80	NA	NA	12.63	13.39	090
37735		A	Removal of leg veins/lesion	10.53	NA	NA	5.92	6.70	1.16	NA	NA	17.61	18.39	090
37760		A	Revision of leg veins	10.47	NA	NA	5.64	6.26	1.08	NA	NA	17.19	17.81	090
37780		A	Revision of leg vein	3.84	NA	NA	3.03	2.79	0.43	NA	NA	7.30	7.06	090
37785		A	Revise secondary varicosity	3.88	6.63	5.24	2.84	2.40	0.40	10.91	9.52	7.12	6.68	090
37788		A	Revascularization, penis	22.01	NA	NA	11.76	12.93	1.43	NA	NA	35.20	36.37	090
37790		A	Penile venous occlusion	8.34	NA	NA	7.25	6.99	0.53	NA	NA	16.12	15.86	090
37799		C	Vascular surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
38100		A	Removal of spleen, total	13.01	NA	NA	6.20	6.97	1.30	NA	NA	20.51	21.28	090
38101		A	Removal of spleen, partial	13.74	NA	NA	6.39	6.69	1.39	NA	NA	21.52	21.82	090
38102		A	Removal of spleen, total	4.80	NA	NA	1.80	2.03	0.48	NA	NA	7.08	7.31	ZZZ
38115		A	Repair of ruptured spleen	14.19	NA	NA	6.68	7.08	1.43	NA	NA	22.30	22.70	090
38120		A	Laparoscopy, splenectomy	0.17	NA	NA	7.66	7.66	1.04	NA	NA	8.87	8.87	090
38129		C	Laparoscope proc, spleen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
38200		A	Injection for spleen x-ray	2.64	NA	NA	0.97	1.19	0.12	NA	NA	3.73	3.95	000
38230		R	Bone marrow collection	4.54	NA	NA	2.39	2.55	0.23	NA	NA	7.16	7.32	010
38231		R	Stem cell collection	1.50	NA	NA	0.59	0.82	0.06	NA	NA	2.15	2.38	000
38240		R	Bone marrow/stem transplant	2.24	NA	NA	0.82	1.18	0.11	NA	NA	3.17	3.53	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
38241		R	Bone marrow/stem transplant	2.24	NA	NA	0.85	1.19	0.10	NA	NA	3.19	3.53	XXX
38300		A	Drainage, lymph node lesion	1.53	3.69	2.93	2.21	1.82	0.14	5.36	4.60	3.88	3.49	010
38305		A	Drainage, lymph node lesion	4.61	6.96	5.75	5.53	4.68	0.36	11.93	10.72	10.50	9.65	090
38308		A	Incision of lymph channels	4.95	NA	NA	4.88	4.58	0.43	NA	NA	10.26	9.96	090
38380		A	Thoracic duct procedure	7.46	NA	NA	7.35	6.72	0.60	NA	NA	15.41	14.78	090
38381		A	Thoracic duct procedure	12.88	NA	NA	11.92	10.99	1.66	NA	NA	26.46	25.53	090
38382		A	Thoracic duct procedure	10.08	NA	NA	8.65	7.80	1.06	NA	NA	19.79	18.94	090
38500		A	Biopsy/removal, lymph nodes	2.88	2.47	2.29	2.11	2.02	0.28	5.63	5.45	5.27	5.18	010
38505		A	Needle biopsy, lymph nodes	1.14	2.75	2.37	1.05	1.09	0.09	3.98	3.60	2.28	2.32	000
38510		A	Biopsy/removal, lymph nodes	4.14	NA	NA	4.00	3.69	0.38	NA	NA	8.52	8.21	090
38520		A	Biopsy/removal, lymph nodes	5.12	NA	NA	4.95	4.52	0.53	NA	NA	10.60	10.17	090
38525		A	Biopsy/removal, lymph nodes	4.66	NA	NA	3.67	3.46	0.47	NA	NA	8.80	8.59	090
38530		A	Biopsy/removal, lymph nodes	6.13	NA	NA	5.96	5.33	0.66	NA	NA	12.75	12.12	090
38542		A	Explore deep node(s), neck	5.91	NA	NA	5.46	5.25	0.50	NA	NA	11.87	11.66	090
38550		A	Removal, neck/armpit lesion	6.92	NA	NA	5.22	4.79	0.50	NA	NA	12.64	12.21	090
38555		A	Removal, neck/armpit lesion	14.14	NA	NA	10.98	10.21	1.53	NA	NA	26.65	25.88	090
38562		A	Removal, pelvic lymph nodes	10.49	NA	NA	6.19	6.51	0.84	NA	NA	17.52	17.84	090
38564		A	Removal, abdomen lymph nodes	10.83	NA	NA	6.04	6.54	0.01	NA	NA	16.88	17.38	090
38570		A	Laparoscopy, lymph node biop	9.25	NA	NA	4.49	5.10	0.81	NA	NA	14.55	15.16	010
38571		A	Laparoscopy, lymphadenectomy	12.38	NA	NA	5.27	6.28	0.78	NA	NA	18.43	19.44	010
38572		A	Laparoscopy, lymphadenectomy	14.32	NA	NA	6.18	7.35	1.04	NA	NA	21.54	22.71	010
38589		C	Laparoscope proc, lymphatic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
38700		A	Removal of lymph nodes, neck	8.24	NA	NA	11.93	11.41	0.63	NA	NA	20.80	20.28	090
38720		A	Removal of lymph nodes, neck	13.61	NA	NA	14.13	14.66	1.03	NA	NA	28.77	29.30	090
38724		A	Removal of lymph nodes, neck	14.54	NA	NA	14.51	14.78	1.11	NA	NA	30.16	30.43	090
38740		A	Remove armpit lymph nodes	6.77	NA	NA	4.44	4.61	0.67	NA	NA	11.88	12.05	090
38745		A	Remove armpit lymph nodes	8.84	NA	NA	6.35	7.01	0.86	NA	NA	16.05	16.71	090
38746		A	Remove thoracic lymph nodes	4.39	NA	NA	1.76	1.94	0.56	NA	NA	6.71	6.89	ZZZ
38747		A	Remove abdominal lymph nodes	4.89	NA	NA	1.82	2.06	0.45	NA	NA	7.16	7.40	ZZZ
38760		A	Remove groin lymph nodes	8.74	NA	NA	5.38	5.84	0.83	NA	NA	14.95	15.41	090
38765		A	Remove groin lymph nodes	16.06	NA	NA	9.64	10.67	1.34	NA	NA	27.04	28.07	090
38770		A	Remove pelvis lymph nodes	13.23	NA	NA	6.48	8.81	0.85	NA	NA	20.56	22.89	090
38780		A	Remove abdomen lymph nodes	16.59	NA	NA	8.63	10.83	1.26	NA	NA	26.48	28.68	090
38790		A	Inject for lymphatic x-ray	1.29	21.16	16.32	0.48	0.81	0.09	22.54	17.70	1.86	2.19	000
38792		A	Identify sentinel node	0.52	NA	NA	0.21	0.21	0.01	NA	NA	0.74	0.74	000
38794		A	Access thoracic lymph duct	4.45	NA	NA	1.51	1.90	0.17	NA	NA	6.13	6.52	090
38999		C	Blood/lymph system procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
39000		A	Exploration of chest	6.10	NA	NA	9.45	8.73	0.75	NA	NA	16.30	15.58	090
39010		A	Exploration of chest	11.79	NA	NA	12.37	12.39	1.52	NA	NA	25.68	25.70	090
39200		A	Removal chest lesion	13.62	NA	NA	12.96	12.86	1.65	NA	NA	28.23	28.13	090
39220		A	Removal chest lesion	17.42	NA	NA	14.12	14.64	2.16	NA	NA	33.70	34.22	090
39400		A	Visualization of chest	5.61	NA	NA	9.32	8.38	0.72	NA	NA	15.65	14.71	010
39499		C	Chest procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
39501		A	Repair diaphragm laceration	13.19	NA	NA	8.29	9.11	1.35	NA	NA	22.83	23.65	090
39502		A	Repair paraesophageal hernia	16.33	NA	NA	8.51	9.62	1.64	NA	NA	26.48	27.59	090
39503		A	Repair of diaphragm hernia	37.54	NA	NA	15.86	18.73	3.26	NA	NA	56.66	59.53	090
39520		A	Repair of diaphragm hernia	16.10	NA	NA	11.26	11.85	1.82	NA	NA	29.18	29.77	090
39530		A	Repair of diaphragm hernia	15.41	NA	NA	9.17	10.69	1.68	NA	NA	26.26	27.78	090
39531		A	Repair of diaphragm hernia	16.42	NA	NA	9.08	9.52	1.79	NA	NA	27.29	27.73	090
39540		A	Repair of diaphragm hernia	13.32	NA	NA	8.75	9.81	1.39	NA	NA	23.46	24.52	090
39541		A	Repair of diaphragm hernia	14.41	NA	NA	8.37	9.58	1.47	NA	NA	24.25	25.46	090
39545		A	Revision of diaphragm	13.37	NA	NA	11.21	10.55	1.59	NA	NA	26.17	25.51	090
39560		A	Resect diaphragm, simple	0.12	NA	NA	8.66	8.66	1.22	NA	NA	10.00	10.00	090
39561		A	Resect diaphragm, complex	17.50	NA	NA	10.85	10.85	1.79	NA	NA	30.14	30.14	090
39599		C	Diaphragm surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
40490		A	Biopsy of lip	1.22	1.56	1.37	0.61	0.66	0.06	2.84	2.65	1.89	1.94	000
40500		A	Partial excision of lip	4.28	5.19	5.17	5.07	5.08	0.31	9.78	9.76	9.66	9.67	090
40510		A	Partial excision of lip	4.70	5.84	5.78	5.76	5.72	0.37	10.91	10.85	10.83	10.79	090
40520		A	Partial excision of lip	4.67	6.77	6.30	6.05	5.76	0.41	11.85	11.38	11.13	10.84	090
40525		A	Reconstruct lip with flap	7.55	NA	NA	7.43	7.83	0.69	NA	NA	15.67	16.07	090
40527		A	Reconstruct lip with flap	9.13	NA	NA	8.34	8.98	0.79	NA	NA	18.26	18.90	090
40530		A	Partial removal of lip	5.40	5.98	5.87	5.54	5.54	0.45	11.83	11.72	11.39	11.39	090
40650		A	Repair lip	3.64	4.89	4.75	3.95	4.05	0.32	8.85	8.71	7.91	8.01	090
40652		A	Repair lip	4.26	6.11	5.86	5.73	5.57	0.40	10.77	10.52	10.39	10.23	090
40654		A	Repair lip	5.31	6.68	6.60	6.48	6.45	0.48	12.47	12.39	12.27	12.24	090
40700		A	Repair cleft lip/nasal	12.79	NA	NA	9.72	9.59	0.98	NA	NA	23.49	23.36	090
40701		A	Repair cleft lip/nasal	15.85	NA	NA	10.38	13.03	1.38	NA	NA	27.61	30.26	090
40702		A	Repair cleft lip/nasal	13.04	NA	NA	8.77	9.12	0.95	NA	NA	22.76	23.11	090
40720		A	Repair cleft lip/nasal	13.55	NA	NA	10.71	10.64	1.31	NA	NA	25.57	25.50	090
40761		A	Repair cleft lip/nasal	14.72	NA	NA	11.41	11.50	1.31	NA	NA	27.44	27.53	090
40799		C	Lip surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
40800		A	Drainage of mouth lesion	1.17	1.68	1.46	0.48	0.56	0.09	2.94	2.72	1.74	1.82	010
40801		A	Drainage of mouth lesion	2.53	2.22	2.13	1.69	1.73	0.18	4.93	4.84	4.40	4.44	010
40804		A	Removal, foreign body, mouth	1.24	2.27	1.86	1.85	1.55	0.09	3.60	3.19	3.18	2.88	010
40805		A	Removal, foreign body, mouth	2.69	2.72	2.72	2.34	2.43	0.19	5.60	5.60	5.22	5.31	010
40806		A	Incision of lip fold	0.31	0.70	0.62	0.51	0.48	0.03	1.04	0.96	0.85	0.82	000
40808		A	Biopsy of mouth lesion	0.96	1.77	1.53	1.76	1.53	0.07	2.80	2.56	2.79	2.56	010
40810		A	Excision of mouth lesion	1.31	2.31	2.05	1.97	1.80	0.10	3.72	3.46	3.38	3.21	010
40812		A	Excise/repair mouth lesion	2.31	2.60	2.36	2.48	2.27	0.17	5.08	4.84	4.96	4.75	010
40814		A	Excise/repair mouth lesion	3.42	3.66	3.62	3.66	3.62	0.25	7.33	7.29	7.33	7.29	090
40816		A	Excision of mouth lesion	3.67	3.95	3.84	3.95	3.84	0.26	7.88	7.77	7.88	7.77	090
40818		A	Excise oral mucosa for graft	2.41	3.82	3.48	3.82	3.48	0.14	6.37	6.03	6.37	6.03	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
40819		A	Excise lip or cheek fold	2.41	3.18	2.72	3.05	2.62	0.17	5.76	5.30	5.63	5.20	090
40820		A	Treatment of mouth lesion	1.28	2.07	1.70	1.90	1.57	0.09	3.44	3.07	3.27	2.94	010
40830		A	Repair mouth laceration	1.76	2.20	1.83	1.89	1.60	0.15	4.11	3.74	3.80	3.51	010
40831		A	Repair mouth laceration	2.46	2.28	2.24	2.28	2.24	0.21	4.95	4.91	4.95	4.91	010
40840		R	Reconstruction of mouth	8.73	5.72	6.00	5.72	6.00	0.66	15.11	15.39	15.11	15.39	090
40842		R	Reconstruction of mouth	8.73	5.44	5.79	5.44	5.79	0.71	14.88	15.23	14.88	15.23	090
40843		R	Reconstruction of mouth	12.10	8.08	8.45	6.31	7.12	0.63	20.81	21.18	19.04	19.85	090
40844		R	Reconstruction of mouth	16.01	8.60	9.61	8.60	9.61	1.44	26.05	27.06	26.05	27.06	090
40845		R	Reconstruction of mouth	18.58	10.03	13.07	10.03	13.07	1.56	30.17	33.21	30.17	33.21	090
40899		C	Mouth surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
41000		A	Drainage of mouth lesion	1.30	2.00	1.71	1.27	1.16	0.10	3.40	3.11	2.67	2.56	010
41005		A	Drainage of mouth lesion	1.26	1.83	1.54	1.28	1.13	0.10	3.19	2.90	2.64	2.49	010
41006		A	Drainage of mouth lesion	3.24	3.56	2.95	3.01	2.53	0.24	7.04	6.43	6.49	6.01	090
41007		A	Drainage of mouth lesion	3.10	3.24	3.22	2.80	2.89	0.16	6.50	6.48	6.06	6.15	090
41008		A	Drainage of mouth lesion	3.37	3.12	2.63	2.99	2.53	0.24	6.73	6.24	6.60	6.14	090
41009		A	Drainage of mouth lesion	3.59	3.26	3.34	2.79	2.99	0.27	7.12	7.20	6.65	6.85	090
41010		A	Incision of tongue fold	1.06	2.80	2.20	2.80	2.20	0.06	3.92	3.32	3.92	3.32	010
41015		A	Drainage of mouth lesion	3.96	3.74	3.04	2.98	2.47	0.29	7.99	7.29	7.23	6.72	090
41016		A	Drainage of mouth lesion	4.07	3.55	3.66	3.00	3.25	0.32	7.94	8.05	7.39	7.64	090
41017		A	Drainage of mouth lesion	4.07	3.74	3.19	3.05	2.67	0.32	8.13	7.58	7.44	7.06	090
41018		A	Drainage of mouth lesion	5.10	4.17	4.20	3.46	3.66	0.34	9.61	9.64	8.90	9.10	090
41100		A	Biopsy of tongue	1.63	2.26	1.91	2.18	1.85	0.11	4.00	3.65	3.92	3.59	010
41105		A	Biopsy of tongue	1.42	2.04	1.81	2.04	1.81	0.11	3.57	3.34	3.57	3.34	010
41108		A	Biopsy of floor of mouth	1.05	1.96	1.70	1.88	1.64	0.08	3.09	2.83	3.01	2.77	010
41110		A	Excision of tongue lesion	1.51	2.60	2.30	2.17	1.98	0.11	4.22	3.92	3.79	3.60	010
41112		A	Excision of tongue lesion	2.73	3.15	3.01	3.15	3.01	0.20	6.08	5.94	6.08	5.94	090
41113		A	Excision of tongue lesion	3.19	3.13	3.27	3.13	3.27	0.23	6.55	6.69	6.55	6.69	090
41114		A	Excision of tongue lesion	8.47	NA	NA	5.85	6.12	0.62	NA	NA	14.94	15.21	090
41115		A	Excision of tongue fold	1.74	2.37	2.26	2.15	2.10	0.12	4.23	4.12	4.01	3.96	010
41116		A	Excision of mouth lesion	2.44	3.06	2.97	3.02	2.94	0.18	5.68	5.59	5.64	5.56	090
41120		A	Partial removal of tongue	9.77	NA	NA	7.88	7.89	0.73	NA	NA	18.38	18.39	090
41130		A	Partial removal of tongue	11.15	NA	NA	8.64	8.94	0.82	NA	NA	20.61	20.91	090
41135		A	Tongue and neck surgery	23.09	NA	NA	14.89	16.13	1.71	NA	NA	39.69	40.93	090
41140		A	Removal of tongue	25.50	NA	NA	15.51	16.76	1.90	NA	NA	42.91	44.16	090
41145		A	Tongue removal, neck surgery	30.06	NA	NA	19.45	20.77	2.20	NA	NA	51.71	53.03	090
41150		A	Tongue, mouth, jaw surgery	23.04	NA	NA	15.76	16.97	1.70	NA	NA	40.50	41.71	090
41153		A	Tongue, mouth, neck surgery	23.77	NA	NA	16.30	19.01	1.79	NA	NA	41.86	44.57	090
41155		A	Tongue, jaw, & neck surgery	27.72	NA	NA	18.54	22.03	2.03	NA	NA	48.29	51.78	090
41250		A	Repair tongue laceration	1.91	2.35	2.05	1.44	1.37	0.16	4.42	4.12	3.51	3.44	010
41251		A	Repair tongue laceration	2.27	2.15	2.18	1.72	1.85	0.17	4.59	4.62	4.16	4.29	010
41252		A	Repair tongue laceration	2.97	2.95	2.85	2.12	2.23	0.24	6.16	6.06	5.33	5.44	010
41500		A	Fixation of tongue	3.71	NA	NA	3.72	3.68	0.25	NA	NA	7.68	7.64	090
41510		A	Tongue to lip surgery	3.42	NA	NA	4.55	4.10	0.21	NA	NA	8.18	7.73	090
41520		A	Reconstruction, tongue fold	2.73	2.62	2.75	2.62	2.75	0.20	5.55	5.68	5.55	5.68	090
41599		C	Tongue and mouth surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
41800		A	Drainage of gum lesion	1.17	1.69	1.46	1.06	0.98	0.10	2.96	2.73	2.33	2.25	010
41805		A	Removal foreign body, gum	1.24	1.68	1.49	1.68	1.49	0.09	3.01	2.82	3.01	2.82	010
41806		A	Removal foreign body,jawbone	2.69	2.33	2.19	2.13	2.04	0.20	5.22	5.08	5.02	4.93	010
41820		R	Excision, gum, each quadrant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
41821		R	Excision of gum flap	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
41822		R	Excision of gum lesion	2.31	2.52	2.71	0.97	1.55	0.18	5.01	5.20	3.46	4.04	010
41823		R	Excision of gum lesion	3.30	3.19	3.38	2.69	3.00	0.23	6.72	6.91	6.22	6.53	090
41825		A	Excision of gum lesion	1.31	2.10	1.98	1.92	1.85	0.10	3.51	3.39	3.33	3.26	010
41826		A	Excision of gum lesion	2.31	2.39	2.36	2.36	2.33	0.17	4.87	4.84	4.84	4.81	010
41827		A	Excision of gum lesion	3.42	3.22	3.44	3.22	3.44	0.25	6.89	7.11	6.89	7.11	090
41828		R	Excision of gum lesion	3.09	2.77	3.18	2.16	2.73	0.21	6.07	6.48	5.46	6.03	010
41830		R	Removal of gum tissue	3.35	2.96	3.22	2.57	2.93	0.24	6.55	6.81	6.16	6.52	010
41850		R	Treatment of gum lesion	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
41870		R	Gum graft	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
41872		R	Repair gum	2.59	2.77	2.85	2.15	2.39	0.19	5.55	5.63	4.93	5.17	090
41874		R	Repair tooth socket	3.09	2.64	2.90	2.18	2.56	0.24	5.97	6.23	5.51	5.89	090
41899		C	Dental surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
42000		A	Drainage mouth roof lesion	1.23	2.11	1.75	1.32	1.16	0.09	3.43	3.07	2.64	2.48	010
42100		A	Biopsy roof of mouth	1.31	2.05	1.75	2.03	1.74	0.10	3.46	3.16	3.44	3.15	010
42104		A	Excision lesion, mouth roof	1.64	2.11	2.02	2.11	2.02	0.11	3.86	3.77	3.86	3.77	010
42106		A	Excision lesion, mouth roof	2.10	2.37	2.38	2.37	2.38	0.15	4.62	4.63	4.62	4.63	010
42107		A	Excision lesion, mouth roof	4.44	3.76	4.15	3.76	4.15	0.32	8.52	8.91	8.52	8.91	090
42120		A	Remove palate/lesion	6.17	NA	NA	5.39	5.89	0.45	NA	NA	12.01	12.51	090
42140		A	Excision of uvula	1.62	3.07	2.67	2.69	2.39	0.11	4.80	4.40	4.42	4.12	090
42145		A	Repair palate, pharynx/uvula	8.05	NA	NA	6.65	7.39	0.57	NA	NA	15.27	16.01	090
42160		A	Treatment mouth roof lesion	1.80	2.62	2.38	2.20	2.07	0.13	4.55	4.31	4.13	4.00	010
42180		A	Repair palate	2.50	2.35	2.37	1.86	2.00	0.18	5.03	5.05	4.54	4.68	010
42182		A	Repair palate	3.83	2.74	3.00	2.74	3.00	0.29	6.86	7.12	6.86	7.12	010
42200		A	Reconstruct cleft palate	0.12	NA	NA	9.18	8.84	1.03	NA	NA	10.33	9.99	090
42205		A	Reconstruct cleft palate	9.59	NA	NA	6.94	8.07	0.85	NA	NA	17.38	18.51	090
42210		A	Reconstruct cleft palate	14.50	NA	NA	8.56	9.82	1.15	NA	NA	24.21	25.47	090
42215		A	Reconstruct cleft palate	8.82	NA	NA	7.61	7.79	0.76	NA	NA	17.19	17.37	090
42220		A	Reconstruct cleft palate	7.02	NA	NA	5.90	5.89	0.49	NA	NA	13.41	13.40	090
42225		A	Reconstruct cleft palate	9.54	NA	NA	8.73	8.42	0.80	NA	NA	19.07	18.76	090
42226		A	Lengthening of palate	10.01	NA	NA	8.28	8.35	0.79	NA	NA	19.08	19.15	090
42227		A	Lengthening of palate	9.52	NA	NA	6.01	6.52	0.78	NA	NA	16.31	16.82	090
42235		A	Repair palate	7.87	NA	NA	5.85	5.89	0.59	NA	NA	14.31	14.35	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
42260		A	Repair nose to lip fistula	9.80	6.88	6.24	6.88	6.24	0.76	17.44	16.80	17.44	16.80	090
42280		A	Preparation, palate mold	1.54	1.31	1.52	0.73	1.09	0.10	2.95	3.16	2.37	2.73	010
42281		A	Insertion, palate prosthesis	1.93	1.58	1.59	0.95	1.11	0.13	3.64	3.65	3.01	3.17	010
42299		C	Palate/uvula surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
42300		A	Drainage of salivary gland	1.93	2.27	1.96	1.69	1.53	0.14	4.34	4.03	3.76	3.60	010
42305		A	Drainage of salivary gland	6.07	NA	NA	4.81	4.20	0.46	NA	NA	11.34	10.73	090
42310		A	Drainage of salivary gland	1.56	2.04	1.81	1.39	1.32	0.11	3.71	3.48	3.06	2.99	010
42320		A	Drainage of salivary gland	2.35	2.43	2.32	1.97	1.98	0.17	4.95	4.84	4.49	4.50	010
42325		A	Create salivary cyst drain	2.75	2.87	2.73	1.02	1.34	0.22	5.84	5.70	3.99	4.31	090
42326		A	Create salivary cyst drain	3.78	4.10	4.20	1.55	2.29	0.27	8.15	8.25	5.60	6.34	090
42330		A	Removal of salivary stone	2.21	2.40	2.10	1.13	1.15	0.16	4.77	4.47	3.50	3.52	010
42335		A	Removal of salivary stone	3.31	3.13	3.02	3.13	3.02	0.24	6.68	6.57	6.68	6.57	090
42340		A	Removal of salivary stone	4.60	4.26	4.35	4.26	4.35	0.32	9.18	9.27	9.18	9.27	090
42400		A	Biopsy of salivary gland	0.78	2.06	1.76	0.39	0.51	0.06	2.90	2.60	1.23	1.35	000
42405		A	Biopsy of salivary gland	3.29	2.95	2.63	2.92	2.61	0.24	6.48	6.16	6.45	6.14	010
42408		A	Excision of salivary cyst	4.54	3.84	3.76	3.84	3.76	0.34	8.72	8.64	8.72	8.64	090
42409		A	Drainage of salivary cyst	2.81	3.00	3.01	3.00	3.01	0.20	6.01	6.02	6.01	6.02	090
42410		A	Excise parotid gland/lesion	9.34	NA	NA	7.15	6.98	0.78	NA	NA	17.27	17.10	090
42415		A	Excise parotid gland/lesion	16.89	NA	NA	11.50	12.07	1.30	NA	NA	29.69	30.26	090
42420		A	Excise parotid gland/lesion	19.59	NA	NA	13.03	13.79	1.48	NA	NA	34.10	34.86	090
42425		A	Excise parotid gland/lesion	13.02	NA	NA	9.62	10.23	0.99	NA	NA	23.63	24.24	090
42426		A	Excise parotid gland/lesion	21.26	NA	NA	13.97	16.82	1.60	NA	NA	36.83	39.68	090
42440		A	Excise submaxillary gland	6.97	NA	NA	5.37	6.11	0.53	NA	NA	12.87	3.61	090
42450		A	Excise sublingual gland	4.62	4.28	4.14	4.28	4.14	0.34	9.24	9.10	9.24	9.10	090
42500		A	Repair salivary duct	4.30	4.26	4.45	4.26	4.45	0.32	8.88	9.07	8.88	9.07	090
42505		A	Repair salivary duct	6.18	4.72	5.39	4.72	5.39	0.47	11.37	12.04	11.37	12.04	090
42507		A	Parotid duct diversion	6.11	NA	NA	5.60	5.46	0.46	NA	NA	12.17	12.03	090
42508		A	Parotid duct diversion	9.10	NA	NA	6.93	7.26	0.68	NA	NA	16.71	17.04	090
42509		A	Parotid duct diversion	11.54	NA	NA	8.74	8.54	0.82	NA	NA	21.10	20.90	090
42510		A	Parotid duct diversion	8.15	NA	NA	6.60	7.03	0.81	NA	NA	15.56	15.99	090
42550		A	Injection for salivary x-ray	1.25	11.98	9.11	0.44	0.45	0.05	13.28	10.41	1.74	1.75	000
42600		A	Closure of salivary fistula	4.82	5.56	5.23	4.93	4.75	0.37	10.75	10.42	10.12	9.94	090
42650		A	Dilation of salivary duct	0.77	0.94	0.81	0.39	0.40	0.06	1.77	1.64	1.22	1.23	000
42660		A	Dilation of salivary duct	1.13	1.08	0.95	1.08	0.95	0.07	2.28	2.15	2.28	2.15	000
42665		A	Ligation of salivary duct	2.53	3.15	2.92	3.02	2.82	0.18	5.86	5.63	5.73	5.53	090
42699		C	Salivary surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
42700		A	Drainage of tonsil abscess	1.62	2.57	2.16	1.62	1.45	0.11	4.30	3.89	3.35	3.18	010
42720		A	Drainage of throat abscess	5.42	4.43	3.84	4.26	3.71	0.39	10.24	9.65	10.07	9.52	010
42725		A	Drainage of throat abscess	10.72	NA	NA	7.92	7.15	0.84	NA	NA	19.48	18.71	090
42800		A	Biopsy of throat	1.39	2.43	2.02	2.13	1.80	0.10	3.92	3.51	3.62	3.29	010
42802		A	Biopsy of throat	1.54	2.49	2.15	2.20	1.93	0.11	4.14	3.80	3.85	3.58	010
42804		A	Biopsy of upper nose/throat	1.24	2.37	2.07	2.05	1.83	0.09	3.70	3.40	3.38	3.16	010
42806		A	Biopsy of upper nose/throat	1.58	2.74	2.44	2.25	2.07	0.11	4.43	4.13	3.94	3.76	010
42808		A	Excise pharynx lesion	2.30	3.89	3.60	2.64	2.66	0.16	6.35	6.06	5.10	5.12	010
42809		A	Remove pharynx foreign body	1.81	2.77	2.30	1.49	1.34	0.14	4.72	4.25	3.44	3.29	010
42810		A	Excision of neck cyst	3.25	4.76	4.42	3.81	3.71	0.27	8.28	7.94	7.33	7.23	090
42815		A	Excision of neck cyst	7.07	NA	NA	5.89	6.58	0.55	NA	NA	13.51	14.20	090
42820		A	Remove tonsils and adenoids	3.91	NA	NA	3.48	3.47	0.26	NA	NA	7.65	7.64	090
42821		A	Remove tonsils and adenoids	4.29	NA	NA	3.68	3.83	0.31	NA	NA	8.28	8.43	090
42825		A	Removal of tonsils	3.42	NA	NA	3.27	3.17	0.25	NA	NA	6.94	6.84	090
42826		A	Removal of tonsils	3.38	NA	NA	3.22	3.43	0.24	NA	NA	6.84	7.05	090
42830		A	Removal of adenoids	2.57	NA	NA	2.16	2.13	0.18	NA	NA	4.91	4.88	090
42831		A	Removal of adenoids	2.71	NA	NA	2.26	2.34	0.19	NA	NA	5.16	5.24	090
42835		A	Removal of adenoids	2.30	NA	NA	2.53	2.40	0.16	NA	NA	4.99	4.86	090
42836		A	Removal of adenoids	3.18	NA	NA	3.13	3.11	0.23	NA	NA	6.54	6.52	090
42842		A	Extensive surgery of throat	8.76	NA	NA	6.93	7.01	0.63	NA	NA	16.32	16.40	090
42844		A	Extensive surgery of throat	14.31	NA	NA	10.50	10.82	1.07	NA	NA	25.88	26.20	090
42845		A	Extensive surgery of throat	24.29	NA	NA	16.02	17.07	1.82	NA	NA	42.13	43.18	090
42860		A	Excision of tonsil tags	2.22	NA	NA	2.59	2.46	0.16	NA	NA	4.97	4.84	090
42870		A	Excision of lingual tonsil	5.40	NA	NA	5.28	4.59	0.38	NA	NA	11.06	10.37	090
42890		A	Partial removal of pharynx	12.94	NA	NA	9.75	9.75	0.94	NA	NA	23.63	23.63	090
42892		A	Revision of pharyngeal walls	15.83	NA	NA	11.21	11.37	1.15	NA	NA	28.19	28.35	090
42894		A	Revision of pharyngeal walls	22.88	NA	NA	15.71	16.14	1.69	NA	NA	40.28	40.71	090
42900		A	Repair throat wound	5.25	NA	NA	3.50	3.78	0.39	NA	NA	9.14	9.42	010
42950		A	Reconstruction of throat	8.10	NA	NA	6.67	7.42	0.62	NA	NA	15.39	16.14	090
42953		A	Repair throat, esophagus	8.96	NA	NA	8.11	7.80	0.75	NA	NA	17.82	17.51	090
42955		A	Surgical opening of throat	7.39	NA	NA	5.88	5.31	0.59	NA	NA	13.86	13.29	090
42960		A	Control throat bleeding	2.33	NA	NA	1.87	1.70	0.17	NA	NA	4.37	4.20	010
42961		A	Control throat bleeding	5.59	NA	NA	4.66	3.97	0.40	NA	NA	10.65	9.96	090
42962		A	Control throat bleeding	7.14	NA	NA	5.44	5.70	0.52	NA	NA	13.10	13.36	090
42970		A	Control nose/throat bleeding	5.43	NA	NA	3.38	2.82	0.34	NA	NA	9.15	8.59	090
42971		A	Control nose/throat bleeding	6.21	NA	NA	4.91	4.47	0.45	NA	NA	11.57	11.13	090
42972		A	Control nose/throat bleeding	7.20	NA	NA	5.08	5.05	0.53	NA	NA	12.81	12.78	090
42999		C	Throat surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43020		A	Incision of esophagus	8.09	NA	NA	6.52	6.68	0.76	NA	NA	15.37	15.53	090
43030		A	Throat muscle surgery	7.69	NA	NA	6.15	6.91	0.62	NA	NA	14.46	15.22	090
43045		A	Incision of esophagus	20.12	NA	NA	12.89	13.05	2.34	NA	NA	35.35	35.51	090
43100		A	Excision of esophagus lesion	9.19	NA	NA	6.75	6.74	0.87	NA	NA	16.81	16.80	090
43101		A	Excision of esophagus lesion	16.24	NA	NA	10.02	10.09	1.88	NA	NA	28.14	28.21	090
43107		A	Removal of esophagus	28.79	NA	NA	16.57	18.53	3.29	NA	NA	48.65	50.61	090
43108		A	Removal of esophagus	34.19	NA	NA	16.97	19.58	3.79	NA	NA	54.95	57.56	090
43112		A	Removal of esophagus	31.22	NA	NA	18.51	19.76	3.63	NA	NA	53.36	54.61	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
43113		A	Removal of esophagus	35.27	NA	NA	18.53	20.75	4.18	NA	NA	57.98	60.20	090
43116		A	Partial removal of esophagus	31.22	NA	NA	17.68	20.12	3.01	NA	NA	51.91	54.35	090
43117		A	Partial removal of esophagus	30.02	NA	NA	17.24	19.79	3.45	NA	NA	50.71	53.26	090
43118		A	Partial removal of esophagus	33.20	NA	NA	17.18	19.74	3.39	NA	NA	53.77	56.33	090
43121		A	Partial removal of esophagus	29.19	NA	NA	17.78	19.13	3.40	NA	NA	50.37	51.72	090
43122		A	Parital removal of esophagus	29.11	NA	NA	15.73	17.59	3.21	NA	NA	48.05	49.91	090
43123		A	Partial removal of esophagus	33.20	NA	NA	19.23	21.28	3.58	NA	NA	56.01	58.06	090
43124		A	Removal of esophagus	27.32	NA	NA	16.53	18.50	2.94	NA	NA	46.79	48.76	090
43130		A	Removal of esophagus pouch	11.75	NA	NA	8.86	9.50	1.06	NA	NA	21.67	22.31	090
43135		A	Removal of esophagus pouch	16.10	NA	NA	11.12	11.52	1.90	NA	NA	29.12	29.52	090
43200		A	Esophagus endoscopy	1.59	5.33	4.55	1.09	1.37	0.11	7.03	6.25	2.79	3.07	000
43202		A	Esophagus endoscopy, biopsy	1.89	4.72	4.20	1.04	1.44	0.13	6.74	6.22	3.06	3.46	000
43204		A	Esophagus endoscopy & inject	3.77	NA	NA	1.58	2.31	0.24	NA	NA	5.59	6.32	000
43205		A	Esophagus endoscopy/ligation	3.79	NA	NA	1.57	1.91	0.23	NA	NA	5.59	5.93	000
43215		A	Esophagus endoscopy	2.60	NA	NA	1.20	1.68	0.19	NA	NA	3.99	4.47	000
43216		A	Esophagus endoscopy/lesion	2.40	NA	NA	1.11	1.55	0.17	NA	NA	3.68	4.12	000
43217		A	Esophagus endoscopy	2.90	NA	NA	1.28	1.83	0.19	NA	NA	4.37	4.92	000
43219		A	Esophagus endoscopy	2.80	NA	NA	1.36	1.86	0.20	NA	NA	4.36	4.86	000
43220		A	Esoph endoscopy, dilation	2.10	NA	NA	1.03	1.40	0.13	NA	NA	3.26	3.63	000
43226		A	Esoph endoscopy, dilation	2.34	NA	NA	1.09	1.52	0.15	NA	NA	3.58	4.01	000
43227		A	Esoph endoscopy, repair	3.60	NA	NA	1.51	2.21	0.23	NA	NA	5.34	6.04	000
43228		A	Esoph endoscopy, ablation	3.77	NA	NA	1.66	2.37	0.26	NA	NA	5.69	6.40	000
43234		A	Upper GI endoscopy, exam	2.01	3.50	3.32	0.98	1.43	0.14	5.65	5.47	3.13	3.58	000
43235		A	Uppr gi endoscopy, diagnosis	2.39	4.70	4.36	1.11	1.67	0.15	7.24	6.90	3.65	4.21	000
43239		A	Upper GI endoscopy, biopsy	2.69	4.92	4.62	1.21	1.84	0.17	7.78	7.48	4.07	4.70	000
43241		A	Upper GI endoscopy with tube	2.59	NA	NA	1.16	1.64	0.17	NA	NA	3.92	4.40	000
43243		A	Upper gi endoscopy & inject	4.57	NA	NA	1.86	2.76	0.28	NA	NA	6.71	7.61	000
43244		A	Upper GI endoscopy/ligation	4.59	NA	NA	1.86	2.34	0.28	NA	NA	6.73	7.21	000
43245		A	Operative upper GI endoscopy	3.39	NA	NA	1.44	2.09	0.22	NA	NA	5.05	5.70	000
43246		A	Place gastrostomy tube	4.33	NA	NA	1.74	2.60	0.30	NA	NA	6.37	7.23	000
43247		A	Operative upper GI endoscopy	3.39	NA	NA	1.44	2.09	0.22	NA	NA	5.05	5.70	000
43248		A	Uppr gi endoscopy/guide wire	3.15	NA	NA	1.36	1.96	0.20	NA	NA	4.71	5.31	000
43249		A	Esoph endoscopy, dilation	2.90	NA	NA	1.26	1.81	0.18	NA	NA	4.34	4.89	000
43250		A	Upper GI endoscopy/tumor	3.20	NA	NA	1.37	1.98	0.21	NA	NA	4.78	5.39	000
43251		A	Operative upper GI endoscopy	3.70	NA	NA	1.54	2.26	0.24	NA	NA	5.48	6.20	000
43255		A	Operative upper GI endoscopy	4.40	NA	NA	1.71	2.60	0.27	NA	NA	6.38	7.27	000
43258		A	Operative upper GI endoscopy	4.55	NA	NA	1.85	2.75	0.29	NA	NA	6.69	7.59	000
43259		A	Endoscopic ultrasound exam	4.89	NA	NA	2.03	2.61	0.30	NA	NA	7.22	7.80	000
43260		A	Endo cholangiopancreatograph	5.96	NA	NA	2.34	3.38	0.36	NA	NA	8.66	9.70	000
43261		A	Endo cholangiopancreatograph	6.27	NA	NA	2.45	3.46	0.38	NA	NA	9.10	10.11	000
43262		A	Endo cholangiopancreatograph	7.39	NA	NA	2.85	4.34	0.46	NA	NA	10.70	12.19	000
43263		A	Endo cholangiopancreatograph	6.19	NA	NA	2.42	3.40	0.38	NA	NA	8.99	9.97	000
43264		A	Endo cholangiopancreatograph	8.90	NA	NA	3.39	4.96	0.54	NA	NA	12.83	14.40	000
43265		A	Endo cholangiopancreatograph	8.90	NA	NA	3.38	4.39	0.54	NA	NA	12.82	13.83	000
43267		A	Endo cholangiopancreatograph	7.39	NA	NA	2.85	4.15	0.46	NA	NA	10.70	12.00	000
43268		A	Endo cholangiopancreatograph	7.39	NA	NA	2.85	4.34	0.46	NA	NA	10.70	12.19	000
43269		A	Endo cholangiopancreatograph	6.04	NA	NA	2.37	3.58	0.37	NA	NA	8.78	9.99	000
43271		A	Endo cholangiopancreatograph	7.39	NA	NA	2.84	4.20	0.44	NA	NA	10.67	12.03	000
43272		A	Endo cholangiopancreatograph	7.39	NA	NA	2.85	3.66	0.44	NA	NA	10.68	11.49	000
43280		A	Laparoscopy, fundoplasty	17.25	NA	NA	8.58	9.66	1.72	NA	NA	27.55	28.63	090
43289		C	Laparoscope proc, esoph	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43300		A	Repair of esophagus	9.14	NA	NA	6.78	7.81	0.88	NA	NA	16.80	17.83	090
43305		A	Repair esophagus and fistula	17.39	NA	NA	12.11	12.80	1.32	NA	NA	30.82	31.51	090
43310		A	Repair of esophagus	27.47	NA	NA	17.92	18.05	3.07	NA	NA	48.46	48.59	090
43312		A	Repair esophagus and fistula	30.50	NA	NA	22.78	20.81	3.46	NA	NA	56.74	54.77	090
43320		A	Fuse esophagus & stomach	16.07	NA	NA	10.44	11.00	1.69	NA	NA	28.20	28.76	090
43324		A	Revise esophagus & stomach	16.58	NA	NA	8.54	9.63	1.66	NA	NA	26.78	27.87	090
43325		A	Revise esophagus & stomach	16.17	NA	NA	8.91	9.83	1.66	NA	NA	26.74	27.66	090
43326		A	Revise esophagus & stomach	15.91	NA	NA	10.41	9.85	1.84	NA	NA	28.16	27.60	090
43330		A	Repair of esophagus	15.94	NA	NA	8.50	9.46	1.54	NA	NA	25.98	26.94	090
43331		A	Repair of esophagus	16.23	NA	NA	10.62	11.85	1.72	NA	NA	28.57	29.80	090
43340		A	Fuse esophagus & intestine	15.81	NA	NA	10.01	10.88	1.70	NA	NA	27.52	28.39	090
43341		A	Fuse esophagus & intestine	16.81	NA	NA	14.01	13.19	1.33	NA	NA	32.15	31.33	090
43350		A	Surgical opening, esophagus	12.72	NA	NA	8.22	8.30	1.19	NA	NA	22.13	22.21	090
43351		A	Surgical opening, esophagus	14.79	NA	NA	10.69	10.40	1.76	NA	NA	27.24	26.95	090
43352		A	Surgical opening, esophagus	12.30	NA	NA	9.57	9.58	1.29	NA	NA	23.16	23.17	090
43360		A	Gastrointestinal repair	28.78	NA	NA	16.03	17.82	2.97	NA	NA	47.78	49.57	090
43361		A	Gastrointestinal repair	32.65	NA	NA	18.56	20.78	3.21	NA	NA	54.42	56.64	090
43400		A	Ligate esophagus veins	17.09	NA	NA	8.46	9.28	1.39	NA	NA	26.94	27.76	090
43401		A	Esophagus surgery for veins	17.81	NA	NA	9.27	9.56	1.76	NA	NA	28.84	29.13	090
43405		A	Ligate/staple esophagus	16.13	NA	NA	8.97	10.62	1.77	NA	NA	26.87	28.52	090
43410		A	Repair esophagus wound	10.86	NA	NA	8.91	9.10	1.16	NA	NA	20.93	21.12	090
43415		A	Repair esophagus wound	17.06	NA	NA	10.65	11.45	1.90	NA	NA	29.61	30.41	090
43420		A	Repair esophagus opening	11.57	NA	NA	7.50	7.22	0.85	NA	NA	19.92	19.64	090
43425		A	Repair esophagus opening	16.95	NA	NA	11.60	11.40	0.02	NA	NA	28.57	28.37	090
43450		A	Dilate esophagus	1.38	1.22	1.10	0.59	0.63	0.09	2.69	2.57	2.06	2.10	000
43453		A	Dilate esophagus	1.51	NA	NA	0.63	0.88	0.10	NA	NA	2.24	2.49	000
43456		A	Dilate esophagus	2.57	NA	NA	1.01	1.43	0.16	NA	NA	3.74	4.16	000
43458		A	Dilate esophagus	3.06	NA	NA	1.20	1.31	0.20	NA	NA	4.46	4.57	000
43460		A	Pressure treatment esophagus	3.80	NA	NA	1.46	1.55	0.28	NA	NA	5.54	5.63	000
43496		C	Free jejunum flap, microvasc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	090
43499		C	Esophagus surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
43500		A	Surgical opening of stomach	8.44	NA	NA	4.25	4.85	0.82	NA	NA	13.51	14.11	090
43501		A	Surgical repair of stomach	15.31	NA	NA	7.11	7.66	1.53	NA	NA	23.95	24.50	090
43502		A	Surgical repair of stomach	17.67	NA	NA	8.22	8.49	1.80	NA	NA	27.69	27.96	090
43510		A	Surgical opening of stomach	9.99	NA	NA	5.93	6.70	0.77	NA	NA	16.69	17.46	090
43520		A	Incision of pyloric muscle	7.63	NA	NA	5.17	5.09	0.88	NA	NA	13.68	13.60	090
43600		A	Biopsy of stomach	1.91	NA	NA	0.93	0.83	0.12	NA	NA	2.96	2.86	000
43605		A	Biopsy of stomach	9.15	NA	NA	4.55	5.02	0.90	NA	NA	14.60	15.07	090
43610		A	Excision of stomach lesion	11.15	NA	NA	5.60	6.42	1.11	NA	NA	17.86	18.68	090
43611		A	Excision of stomach lesion	13.63	NA	NA	6.59	7.16	1.33	NA	NA	21.55	22.12	090
43620		A	Removal of stomach	22.54	NA	NA	10.41	11.98	2.25	NA	NA	35.20	36.77	090
43621		A	Removal of stomach	23.06	NA	NA	10.53	12.07	2.29	NA	NA	35.88	37.42	090
43622		A	Removal of stomach	24.41	NA	NA	11.08	12.48	2.44	NA	NA	37.93	39.33	090
43631		A	Removal of stomach, partial	19.66	NA	NA	8.75	9.93	1.96	NA	NA	30.37	31.55	090
43632		A	Removal of stomach, partial	19.66	NA	NA	8.72	9.91	1.95	NA	NA	30.33	31.52	090
43633		A	Removal of stomach, partial	20.10	NA	NA	8.87	10.02	0.02	NA	NA	28.99	30.14	090
43634		A	Removal of stomach, partial	21.86	NA	NA	9.57	12.83	2.21	NA	NA	33.64	36.90	090
43635		A	Removal of stomach, partial	2.06	NA	NA	0.77	0.87	0.20	NA	NA	3.03	3.13	ZZZ
43638		A	Removal of stomach, partial	21.76	NA	NA	9.67	10.71	2.19	NA	NA	33.62	34.66	090
43639		A	Removal of stomach, partial	22.25	NA	NA	9.92	10.90	2.25	NA	NA	34.42	35.40	090
43640		A	Vagotomy & pylorus repair	14.81	NA	NA	6.93	8.00	1.47	NA	NA	23.21	24.28	090
43641		A	Vagotomy & pylorus repair	15.03	NA	NA	7.26	8.25	1.50	NA	NA	23.79	24.78	090
43651		A	Laparoscopy, vagus nerve	10.15	NA	NA	4.70	4.90	1.01	NA	NA	15.86	16.06	090
43652		A	Laparoscopy, vagus nerve	12.15	NA	NA	5.44	5.73	1.03	NA	NA	18.62	18.91	090
43653		A	Laparoscopy, gastrostomy	7.73	NA	NA	4.27	4.88	0.74	NA	NA	12.74	13.35	090
43659		C	Laparoscope proc, stom	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
43750		A	Place gastrostomy tube	4.49	NA	NA	2.51	3.06	0.34	NA	NA	7.34	7.89	010
43760		A	Change gastrostomy tube	1.10	1.24	1.12	0.44	0.52	0.08	2.42	2.30	1.62	1.70	000
43761		A	Reposition gastrostomy tube	2.01	NA	NA	0.80	0.89	0.10	NA	NA	2.91	3.00	000
43800		A	Reconstruction of pylorus	10.46	NA	NA	5.44	5.94	1.04	NA	NA	16.94	17.44	090
43810		A	Fusion of stomach and bowel	11.19	NA	NA	5.57	6.25	1.07	NA	NA	17.83	18.51	090
43820		A	Fusion of stomach and bowel	11.74	NA	NA	5.78	6.59	1.16	NA	NA	18.68	19.49	090
43825		A	Fusion of stomach and bowel	14.68	NA	NA	6.87	8.16	1.45	NA	NA	23.00	24.29	090
43830		A	Place gastrostomy tube	7.28	NA	NA	4.12	4.77	0.70	NA	NA	12.10	12.75	090
43831		A	Place gastrostomy tube	7.84	NA	NA	4.28	4.62	0.74	NA	NA	12.86	13.20	090
43832		A	Place gastrostomy tube	11.92	NA	NA	6.20	6.81	1.14	NA	NA	19.26	19.87	090
43840		A	Repair of stomach lesion	11.89	NA	NA	5.83	6.50	1.18	NA	NA	18.90	19.57	090
43842		A	Gastroplasty for obesity	14.71	NA	NA	9.81	11.08	1.49	NA	NA	26.01	27.28	090
43843		A	Gastroplasty for obesity	14.85	NA	NA	9.14	10.58	1.47	NA	NA	25.46	26.90	090
43846		A	Gastric bypass for obesity	19.15	NA	NA	11.04	12.30	1.90	NA	NA	32.09	33.35	090
43847		A	Gastric bypass for obesity	21.44	NA	NA	12.44	13.35	2.06	NA	NA	35.94	36.85	090
43848		A	Revision gastroplasty	23.41	NA	NA	13.40	14.07	2.34	NA	NA	39.15	39.82	090
43850		A	Revise stomach-bowel fusion	19.69	NA	NA	8.65	9.65	1.91	NA	NA	30.25	31.25	090
43855		A	Revise stomach-bowel fusion	20.83	NA	NA	9.19	9.73	1.92	NA	NA	31.94	32.48	090
43860		A	Revise stomach-bowel fusion	19.91	NA	NA	8.82	9.73	1.98	NA	NA	30.71	31.62	090
43865		A	Revise stomach-bowel fusion	21.12	NA	NA	9.32	10.62	2.12	NA	NA	32.56	33.86	090
43870		A	Repair stomach opening	7.40	NA	NA	4.20	4.72	0.72	NA	NA	12.32	12.84	090
43880		A	Repair stomach-bowel fistula	19.63	NA	NA	9.10	9.06	1.97	NA	NA	30.70	30.66	090
43999		C	Stomach surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
44005		A	Freeing of bowel adhesion	13.84	NA	NA	6.49	7.12	1.37	NA	NA	21.70	22.33	090
44010		A	Incision of small bowel	10.68	NA	NA	5.65	6.11	1.06	NA	NA	17.39	17.85	090
44015		A	Insert needle cath bowel	2.62	NA	NA	0.97	1.51	0.25	NA	NA	3.84	4.38	ZZZ
44020		A	Exploration of small bowel	11.93	NA	NA	5.74	6.43	1.15	NA	NA	18.82	19.51	090
44021		A	Decompress small bowel	12.01	NA	NA	6.17	6.53	1.17	NA	NA	19.35	19.71	090
44025		A	Incision of large bowel	12.18	NA	NA	5.84	6.48	1.20	NA	NA	19.22	19.86	090
44050		A	Reduce bowel obstruction	11.40	NA	NA	5.56	6.28	1.13	NA	NA	18.09	18.81	090
44055		A	Correct malrotation of bowel	13.14	NA	NA	6.14	6.68	1.28	NA	NA	20.56	21.10	090
44100		A	Biopsy of bowel	2.01	NA	NA	0.99	1.12	0.14	NA	NA	3.14	3.27	000
44110		A	Excision of bowel lesion(s)	10.07	NA	NA	5.10	5.91	0.97	NA	NA	16.14	16.95	090
44111		A	Excision of bowel lesion(s)	12.19	NA	NA	6.31	7.36	1.17	NA	NA	19.67	20.72	090
44120		A	Removal of small intestine	14.50	NA	NA	6.72	7.61	1.43	NA	NA	22.65	23.54	090
44121		A	Removal of small intestine	4.45	NA	NA	1.67	1.88	0.44	NA	NA	6.56	6.77	ZZZ
44125		A	Removal of small intestine	14.96	NA	NA	6.91	8.10	1.48	NA	NA	23.35	24.54	090
44130		A	Bowel to bowel fusion	12.36	NA	NA	5.92	6.79	1.22	NA	NA	19.50	20.37	090
44139		A	Mobilization of colon	2.23	NA	NA	0.83	0.94	0.22	NA	NA	3.28	3.39	ZZZ
44140		A	Partial removal of colon	18.35	NA	NA	8.53	9.48	1.81	NA	NA	28.69	29.64	090
44141		A	Partial removal of colon	19.51	NA	NA	11.51	11.85	1.94	NA	NA	32.96	33.30	090
44143		A	Partial removal of colon	20.17	NA	NA	11.77	12.16	0.02	NA	NA	31.96	32.35	090
44144		A	Partial removal of colon	18.89	NA	NA	10.59	11.22	1.88	NA	NA	31.36	31.99	090
44145		A	Partial removal of colon	23.18	NA	NA	10.67	11.60	2.30	NA	NA	36.15	37.08	090
44146		A	Partial removal of colon	24.16	NA	NA	13.81	14.42	2.40	NA	NA	40.37	40.98	090
44147		A	Partial removal of colon	18.17	NA	NA	9.06	10.96	1.81	NA	NA	29.04	30.94	090
44150		A	Removal of colon	21.01	NA	NA	12.63	13.50	2.11	NA	NA	35.75	36.62	090
44151		A	Removal of colon/ileostomy	20.04	NA	NA	12.85	12.41	1.98	NA	NA	34.87	34.43	090
44152		A	Removal of colon/ileostomy	24.41	NA	NA	14.96	15.41	2.39	NA	NA	41.76	42.21	090
44153		A	Removal of colon/ileostomy	26.83	NA	NA	15.33	16.75	2.72	NA	NA	44.88	46.30	090
44155		A	Removal of colon/ileostomy	24.44	NA	NA	13.60	14.72	2.44	NA	NA	40.48	41.60	090
44156		A	Removal of colon/ileostomy	23.01	NA	NA	14.36	13.86	2.33	NA	NA	39.70	39.20	090
44160		A	Removal of colon	15.88	NA	NA	7.58	9.06	1.58	NA	NA	25.04	26.52	090
44200		A	Laparoscopy, enterolysis	14.44	NA	NA	6.71	7.28	1.41	NA	NA	22.56	23.13	090
44201		A	Laparoscopy, jejunostomy	9.78	NA	NA	5.28	5.28	1.35	NA	NA	16.41	16.41	090
44202		A	Laparo, resect intestine	22.04	NA	NA	9.89	11.01	2.17	NA	NA	34.10	35.22	090
44209		C	Laparoscope proc, intestine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
44300		A	Open bowel to skin	8.88	NA	NA	5.48	5.75	0.88	NA	NA	15.24	15.51	090
44310		A	Ileostomy/jejunostomy	11.70	NA	NA	8.53	8.54	1.16	NA	NA	21.39	21.40	090
44312		A	Revision of ileostomy	5.88	NA	NA	4.39	4.13	0.53	NA	NA	10.80	10.54	090
44314		A	Revision of ileostomy	11.04	NA	NA	8.64	8.29	1.05	NA	NA	20.73	20.38	090
44316		A	Devise bowel pouch	15.47	NA	NA	11.30	11.09	1.47	NA	NA	28.24	28.03	090
44320		A	Colostomy	12.94	NA	NA	9.77	9.35	1.28	NA	NA	23.99	23.57	090
44322		A	Colostomy with biopsies	11.98	NA	NA	9.54	9.62	1.18	NA	NA	22.70	22.78	090
44340		A	Revision of colostomy	5.66	NA	NA	3.91	3.39	0.55	NA	NA	10.12	9.60	090
44345		A	Revision of colostomy	11.32	NA	NA	6.66	6.31	1.12	NA	NA	19.10	18.75	090
44346		A	Revision of colostomy	12.46	NA	NA	7.06	7.10	1.23	NA	NA	20.75	20.79	090
44360		A	Small bowel endoscopy	2.92	NA	NA	1.36	1.89	0.18	NA	NA	4.46	4.99	000
44361		A	Small bowel endoscopy/biopsy	3.23	NA	NA	1.45	2.05	0.19	NA	NA	4.87	5.47	000
44363		A	Small bowel endoscopy	3.94	NA	NA	1.67	2.06	0.23	NA	NA	5.84	6.23	000
44364		A	Small bowel endoscopy	4.22	NA	NA	1.81	2.62	0.27	NA	NA	6.30	7.11	000
44365		A	Small bowel endoscopy	3.73	NA	NA	1.66	2.36	0.24	NA	NA	5.63	6.33	000
44366		A	Small bowel endoscopy	4.97	NA	NA	2.08	3.05	0.31	NA	NA	7.36	8.33	000
44369		A	Small bowel endoscopy	5.09	NA	NA	2.13	3.12	0.32	NA	NA	7.54	8.53	000
44372		A	Small bowel endoscopy	4.97	NA	NA	2.11	3.07	0.33	NA	NA	7.41	8.37	000
44373		A	Small bowel endoscopy	3.94	NA	NA	1.75	2.49	0.25	NA	NA	5.94	6.68	000
44376		A	Small bowel endoscopy	5.69	NA	NA	2.33	2.85	0.37	NA	NA	8.39	8.91	000
44377		A	Small bowel endoscopy/biopsy	5.98	NA	NA	2.46	3.00	0.37	NA	NA	8.81	9.35	000
44378		A	Small bowel endoscopy	7.71	NA	NA	3.08	3.74	0.50	NA	NA	11.29	11.95	000
44380		A	Small bowel endoscopy	1.51	NA	NA	0.83	1.07	0.10	NA	NA	2.44	2.68	000
44382		A	Small bowel endoscopy	1.82	NA	NA	0.95	1.26	0.11	NA	NA	2.88	3.19	000
44385		A	Endoscopy of bowel pouch	1.82	3.11	2.97	0.89	1.30	0.13	5.06	4.92	2.84	3.25	000
44386		A	Endoscopy, bowel pouch/biop	2.12	4.25	3.61	1.06	1.21	0.17	6.54	5.90	3.35	3.50	000
44388		A	Colon endoscopy	2.82	4.27	4.18	1.31	1.96	0.22	7.31	7.22	4.35	5.00	000
44389		A	Colonoscopy with biopsy	3.13	4.68	4.60	1.43	2.16	0.22	8.03	7.95	4.78	5.51	000
44390		A	Colonoscopy for foreign body	3.83	5.47	4.82	1.64	1.94	0.31	9.61	8.96	5.78	6.08	000
44391		A	Colonoscopy for bleeding	4.32	5.14	5.28	1.69	2.70	0.29	9.75	9.89	6.30	7.31	000
44392		A	Colonoscopy & polypectomy	3.82	5.07	5.20	1.67	2.65	0.28	9.17	9.30	5.77	6.75	000
44393		A	Colonoscopy, lesion removal	4.84	5.39	5.51	2.03	2.99	0.34	10.57	10.69	7.21	8.17	000
44394		A	Colonoscopy w/snare	4.43	6.60	6.35	1.90	2.83	0.32	11.35	11.10	6.65	7.58	000
44500		A	Intro, gastrointestinal tube	0.49	NA	NA	0.34	0.35	0.02	NA	NA	0.85	0.86	000
44602		A	Suture, small intestine	10.61	NA	NA	5.30	6.05	1.05	NA	NA	16.96	17.71	090
44603		A	Suture, small intestine	0.14	NA	NA	6.56	7.39	1.38	NA	NA	8.08	8.91	090
44604		A	Suture, large intestine	14.28	NA	NA	6.64	7.12	1.39	NA	NA	22.31	22.79	090
44605		A	Repair of bowel lesion	15.37	NA	NA	7.32	8.03	1.50	NA	NA	24.19	24.90	090
44615		A	Intestinal stricturoplasty	14.19	NA	NA	6.60	6.78	1.39	NA	NA	22.18	22.36	090
44620		A	Repair bowel opening	10.87	NA	NA	5.31	5.60	1.08	NA	NA	17.26	17.55	090
44625		A	Repair bowel opening	13.41	NA	NA	6.26	7.30	1.33	NA	NA	21.00	22.04	090
44626		A	Repair bowel opening	22.59	NA	NA	9.70	10.36	2.23	NA	NA	34.52	35.18	090
44640		A	Repair bowel-skin fistula	14.83	NA	NA	7.19	7.17	1.48	NA	NA	23.50	23.48	090
44650		A	Repair bowel fistula	15.25	NA	NA	7.31	7.47	1.50	NA	NA	24.06	24.22	090
44660		A	Repair bowel-bladder fistula	14.63	NA	NA	6.83	7.39	1.24	NA	NA	22.70	23.26	090
44661		A	Repair bowel-bladder fistula	16.99	NA	NA	7.85	9.67	1.57	NA	NA	26.41	28.23	090
44680		A	Surgical revision, intestine	13.72	NA	NA	6.82	7.75	1.37	NA	NA	21.91	22.84	090
44700		A	Suspend bowel w/prosthesis	14.35	NA	NA	7.02	8.35	1.25	NA	NA	22.62	23.95	090
44799		C	Intestine surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
44800		A	Excision of bowel pouch	11.23	NA	NA	5.53	5.57	1.09	NA	NA	17.85	17.89	090
44820		A	Excision of mesentery lesion	10.31	NA	NA	5.32	5.56	1.01	NA	NA	16.64	16.88	090
44850		A	Repair of mesentery	9.57	NA	NA	4.96	5.24	0.95	NA	NA	15.48	15.76	090
44899		C	Bowel surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
44900		A	Drain app abscess, open	8.82	NA	NA	5.13	5.01	0.81	NA	NA	14.76	14.64	090
44901		A	Drain app abscess, percut	3.38	NA	NA	4.22	3.86	0.32	NA	NA	7.92	7.56	000
44950		A	Appendectomy	8.70	NA	NA	4.70	4.85	0.86	NA	NA	14.26	14.41	090
44955		A	Appendectomy add-on	1.53	NA	NA	0.57	0.88	0.14	NA	NA	2.24	2.55	ZZZ
44960		A	Appendectomy	10.74	NA	NA	5.75	5.91	1.07	NA	NA	17.56	17.72	090
44970		A	Laparoscopy, appendectomy	8.70	NA	NA	4.18	4.46	0.86	NA	NA	13.74	14.02	090
44979		C	Laparoscope proc, app	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
45000		A	Drainage of pelvic abscess	4.52	NA	NA	3.55	3.10	0.38	NA	NA	8.45	8.00	090
45005		A	Drainage of rectal abscess	1.99	4.11	3.43	1.45	1.44	0.19	6.29	5.61	3.63	3.62	010
45020		A	Drainage of rectal abscess	4.72	NA	NA	3.39	3.25	0.45	NA	NA	8.56	8.42	090
45100		A	Biopsy of rectum	3.68	4.47	3.86	1.98	2.00	0.35	8.50	7.89	6.01	6.03	090
45108		A	Removal of anorectal lesion	4.76	5.51	4.86	3.01	2.98	0.48	10.75	10.10	8.25	8.22	090
45110		A	Removal of rectum	23.80	NA	NA	11.62	13.14	2.33	NA	NA	37.75	39.27	090
45111		A	Partial removal of rectum	16.48	NA	NA	8.49	9.56	1.63	NA	NA	26.60	27.67	090
45112		A	Removal of rectum	25.96	NA	NA	11.93	13.31	2.55	NA	NA	40.44	41.82	090
45113		A	Partial proctectomy	25.99	NA	NA	11.18	12.74	2.48	NA	NA	39.65	41.21	090
45114		A	Partial removal of rectum	23.22	NA	NA	10.86	12.32	2.29	NA	NA	36.37	37.83	090
45116		A	Partial removal of rectum	20.89	NA	NA	9.88	10.33	2.04	NA	NA	32.81	33.26	090
45119		A	Remove rectum w/reservoir	26.21	NA	NA	11.68	13.12	2.58	NA	NA	40.47	41.91	090
45120		A	Removal of rectum	0.25	NA	NA	11.47	13.05	2.31	NA	NA	14.03	15.61	090
45121		A	Removal of rectum and colon	27.51	NA	NA	12.98	12.66	2.65	NA	NA	43.14	42.82	090
45123		A	Partial proctectomy	14.20	NA	NA	6.99	8.44	1.41	NA	NA	22.60	24.05	090
45126		A	Pelvic exenteration	38.39	14.50	14.50	14.50	14.50	2.73	55.62	55.62	55.62	55.62	090
45130		A	Excision of rectal prolapse	13.97	NA	NA	6.76	7.49	1.41	NA	NA	22.14	22.87	090
45135		A	Excision of rectal prolapse	16.39	NA	NA	8.01	10.34	1.62	NA	NA	26.02	28.35	090
45150		A	Excision of rectal stricture	5.67	5.23	4.84	3.05	3.21	0.56	11.46	11.07	9.28	9.44	090
45160		A	Excision of rectal lesion	13.02	NA	NA	6.28	6.74	1.30	NA	NA	20.60	21.06	090
45170		A	Excision of rectal lesion	9.77	NA	NA	5.01	5.01	0.98	NA	NA	15.76	15.76	090
45190		A	Destruction, rectal tumor	8.28	NA	NA	4.45	4.72	0.83	NA	NA	13.56	13.83	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
45300		A	Proctosigmoidoscopy	0.70	1.27	1.10	0.33	0.40	0.06	2.03	1.86	1.09	1.16	000
45303		A	Proctosigmoidoscopy	0.80	1.46	1.27	0.37	0.45	0.07	2.33	2.14	1.24	1.32	000
45305		A	Proctosigmoidoscopy & biopsy	1.01	1.43	1.30	0.45	0.57	0.10	2.54	2.41	1.56	1.68	000
45307		A	Proctosigmoidoscopy	1.71	2.57	2.27	0.69	0.86	0.16	4.44	4.14	2.56	2.73	000
45308		A	Proctosigmoidoscopy	1.51	1.62	1.52	0.64	0.79	0.14	3.27	3.17	2.29	2.44	000
45309		A	Proctosigmoidoscopy	2.01	2.19	1.95	0.81	0.92	0.19	4.39	4.15	3.01	3.12	000
45315		A	Proctosigmoidoscopy	2.54	2.66	2.32	1.00	1.07	0.23	5.43	5.09	3.77	3.84	000
45317		A	Proctosigmoidoscopy	2.73	2.08	1.90	1.08	1.15	0.25	5.06	4.88	4.06	4.13	000
45320		A	Proctosigmoidoscopy	2.88	2.07	2.06	1.13	1.36	0.26	5.21	5.20	4.27	4.50	000
45321		A	Proctosigmoidoscopy	2.12	NA	NA	0.85	1.04	0.18	NA	NA	3.15	3.34	000
45330		A	Diagnostic sigmoidoscopy	0.96	1.68	1.59	0.42	0.65	0.07	2.71	2.62	1.45	1.68	000
45331		A	Sigmoidoscopy and biopsy	1.26	1.93	1.89	0.53	0.84	0.09	3.28	3.24	1.88	2.19	000
45332		A	Sigmoidoscopy	1.96	3.39	3.02	0.78	1.06	0.14	5.49	5.12	2.88	3.16	000
45333		A	Sigmoidoscopy & polypectomy	1.96	3.04	2.89	0.78	1.19	0.14	5.14	4.99	2.88	3.29	000
45334		A	Sigmoidoscopy for bleeding	2.99	NA	NA	1.15	1.60	0.20	NA	NA	4.34	4.79	000
45337		A	Sigmoidoscopy & decompress	2.36	NA	NA	0.93	1.40	0.17	NA	NA	3.46	3.93	000
45338		A	Sigmoidoscopy	2.57	3.29	3.08	1.01	1.37	0.18	6.04	5.83	3.76	4.12	000
45339		A	Sigmoidoscopy	3.14	2.36	2.65	1.20	1.78	0.22	5.72	6.01	4.56	5.14	000
45355		A	Surgical colonoscopy	3.52	NA	NA	1.26	1.26	0.28	NA	NA	5.06	5.06	000
45378		A	Diagnostic colonoscopy	3.70	5.39	5.16	1.63	2.34	0.26	9.35	9.12	5.59	6.30	000
45378	53	A	Diagnostic colonoscopy	0.96	1.68	1.59	0.42	0.65	0.07	2.71	2.62	1.45	1.68	000
45379		A	Colonoscopy	4.72	5.92	5.89	1.99	2.94	0.34	10.98	10.95	7.05	8.00	000
45380		A	Colonoscopy and biopsy	4.01	5.61	5.51	1.74	2.61	0.26	9.88	9.78	6.01	6.88	000
45382		A	Colonoscopy/control bleeding	5.73	6.72	6.63	2.18	3.23	0.36	12.81	12.72	8.27	9.32	000
45383		A	Lesion removal colonoscopy	5.87	6.47	6.46	2.40	3.41	0.40	12.74	12.73	8.67	9.68	000
45384		A	Colonoscopy	4.70	7.26	6.85	1.98	2.89	0.32	12.28	11.87	7.00	7.91	000
45385		A	Lesion removal colonoscopy	5.31	7.43	7.38	2.20	3.46	0.35	13.09	13.04	7.86	9.12	000
45500		A	Repair of rectum	7.29	NA	NA	3.96	4.59	0.73	NA	NA	11.98	12.61	090
45505		A	Repair of rectum	6.02	NA	NA	3.07	4.01	0.60	NA	NA	9.69	10.63	090
45520		A	Treatment of rectal prolapse	0.55	0.65	0.65	0.19	0.31	0.06	1.26	1.26	0.80	0.92	000
45540		A	Correct rectal prolapse	12.92	NA	NA	6.67	7.69	1.26	NA	NA	20.85	21.87	090
45541		A	Correct rectal prolapse	10.64	NA	NA	5.78	7.10	1.07	NA	NA	17.49	18.81	090
45550		A	Repair rectum/remove sigmoid	18.26	NA	NA	8.56	9.54	1.82	NA	NA	28.64	29.62	090
45560		A	Repair of rectocele	8.40	NA	NA	4.74	4.86	0.68	NA	NA	13.82	13.94	090
45562		A	Exploration/repair of rectum	12.21	NA	NA	6.06	6.74	1.14	NA	NA	19.41	20.09	090
45563		A	Exploration/repair of rectum	18.63	NA	NA	9.22	10.38	1.80	NA	NA	29.65	30.81	090
45800		A	Repair rect/bladder fistula	14.11	NA	NA	6.53	7.56	1.11	NA	NA	21.75	22.78	090
45805		A	Repair fistula w/colostomy	16.50	NA	NA	8.45	9.68	1.49	NA	NA	26.44	27.67	090
45820		A	Repair rectourethral fistula	14.67	NA	NA	6.76	7.51	1.28	NA	NA	22.71	23.46	090
45825		A	Repair fistula w/colostomy	16.87	NA	NA	8.91	9.36	1.49	NA	NA	27.27	27.72	090
45900		A	Reduction of rectal prolapse	1.83	NA	NA	0.76	0.73	0.18	NA	NA	2.77	2.74	010
45905		A	Dilation of anal sphincter	1.61	2.85	2.33	0.70	0.72	0.15	4.61	4.09	2.46	2.48	010
45910		A	Dilation of rectal narrowing	1.96	3.89	3.15	0.82	0.85	0.16	6.01	5.27	2.94	2.97	010
45915		A	Remove rectal obstruction	2.20	3.90	3.14	0.78	0.80	0.19	6.29	5.53	3.17	3.19	010
45999		C	Rectum surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
46030		A	Removal of rectal marker	1.23	2.61	2.07	1.08	0.92	0.12	3.96	3.42	2.43	2.27	010
46040		A	Incision of rectal abscess	4.96	5.00	4.21	2.94	2.66	0.50	10.46	9.67	8.40	8.12	090
46045		A	Incision of rectal abscess	4.32	NA	NA	2.64	2.48	0.43	NA	NA	7.39	7.23	090
46050		A	Incision of anal abscess	1.19	3.17	2.54	1.12	1.00	0.11	4.47	3.84	2.42	2.30	010
46060		A	Incision of rectal abscess	5.69	NA	NA	3.51	4.09	0.57	NA	NA	9.77	10.35	090
46070		A	Incision of anal septum	2.71	NA	NA	2.56	2.29	0.28	NA	NA	5.55	5.28	090
46080		A	Incision of anal sphincter	2.49	3.29	3.05	1.55	1.74	0.25	6.03	5.79	4.29	4.48	010
46083		A	Incise external hemorrhoid	1.40	4.20	3.32	1.23	1.09	0.11	5.71	4.83	2.74	2.60	010
46200		A	Removal of anal fissure	3.42	3.38	3.43	2.19	2.54	0.34	7.14	19	5.95	6.30	090
46210		A	Removal of anal crypt	2.67	4.94	3.92	2.01	1.72	0.25	7.86	6.84	4.93	4.64	090
46211		A	Removal of anal crypts	4.25	4.53	3.91	2.65	2.50	0.41	9.19	8.57	7.31	7.16	090
46220		A	Removal of anal tab	1.56	1.22	1.09	0.58	0.61	0.15	2.93	2.80	2.29	2.32	010
46221		A	Ligation of hemorrhoid(s)	1.43	2.79	2.27	0.53	0.58	0.14	4.36	3.84	2.10	2.15	010
46230		A	Removal of anal tabs	2.57	3.87	3.13	1.59	1.42	0.25	6.69	5.95	4.41	4.24	010
46250		A	Hemorrhoidectomy	4.53	5.02	4.54	2.77	2.85	0.44	9.99	9.51	7.74	7.82	090
46255		A	Hemorrhoidectomy	5.36	5.69	5.55	3.05	3.57	0.53	11.58	11.44	8.94	9.46	090
46257		A	Remove hemorrhoids & fissure	6.28	NA	NA	3.35	3.93	0.63	NA	NA	10.26	10.84	090
46258		A	Remove hemorrhoids & fistula	6.67	NA	NA	3.43	4.17	0.66	NA	NA	10.76	11.50	090
46260		A	Hemorrhoidectomy	7.42	NA	NA	4.17	4.78	0.74	NA	NA	12.33	12.94	090
46261		A	Remove hemorrhoids & fissure	8.24	NA	NA	4.39	5.09	0.83	NA	NA	13.46	14.16	090
46262		A	Remove hemorrhoids & fistula	8.73	NA	NA	4.61	5.28	0.87	NA	NA	14.21	14.88	090
46270		A	Removal of anal fistula	3.72	4.65	4.00	2.44	2.34	0.37	8.74	8.09	6.53	6.43	090
46275		A	Removal of anal fistula	4.56	4.41	4.67	2.65	3.35	0.46	9.43	9.69	7.67	8.37	090
46280		A	Removal of anal fistula	5.98	NA	NA	3.54	4.31	0.61	NA	NA	10.13	10.90	090
46285		A	Removal of anal fistula	4.09	3.61	3.33	2.45	2.46	0.41	8.11	7.83	6.95	6.96	090
46288		A	Repair anal fistula	7.13	NA	NA	4.06	4.01	0.71	NA	NA	11.90	11.85	090
46320		A	Removal of hemorrhoid clot	1.61	3.45	2.78	1.26	1.14	0.15	5.21	4.54	3.02	2.90	010
46500		A	Injection into hemorrhoids	1.61	2.33	1.84	0.59	0.53	0.16	4.10	3.61	2.36	2.30	010
46600		A	Diagnostic anoscopy	0.50	0.70	0.60	0.15	0.19	0.04	1.24	1.14	0.69	0.73	000
46604		A	Anoscopy and dilation	1.31	0.90	0.78	0.48	0.46	0.11	2.32	2.20	1.90	1.88	000
46606		A	Anoscopy and biopsy	0.81	0.79	0.69	0.30	0.32	0.08	1.68	1.58	1.19	1.21	000
46608		A	Anoscopy/ remove for body	1.51	1.72	1.58	0.49	0.66	0.13	3.36	3.22	2.13	2.30	000
46610		A	Anoscopy/remove lesion	1.32	1.34	1.24	0.49	0.60	0.11	2.77	2.67	1.92	2.03	000
46611		A	Anoscopy	1.81	1.86	1.63	0.67	0.73	0.16	3.83	3.60	2.64	2.70	000
46612		A	Anoscopy/ remove lesions	2.34	2.23	2.05	0.87	1.03	0.20	4.77	4.59	3.41	3.57	000
46614		A	Anoscopy/control bleeding	2.01	1.56	1.59	0.72	0.96	0.17	3.74	3.77	2.90	3.14	000
46615		A	Anoscopy	2.68	1.63	1.64	1.00	1.17	0.23	4.54	4.55	3.91	4.08	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
46700		A	Repair of anal stricture	7.25	NA	NA	3.89	4.58	0.74	NA	NA	11.88	12.57	090
46705		A	Repair of anal stricture	7.17	NA	NA	4.16	4.10	0.73	NA	NA	12.06	12.00	090
46715		A	Repair of anovaginal fistula	7.46	NA	NA	4.26	4.15	0.86	NA	NA	12.58	12.47	090
46716		A	Repair of anovaginal fistula	12.85	NA	NA	6.75	6.71	1.21	NA	NA	20.81	20.77	090
46730		A	Construction of absent anus	22.39	NA	NA	12.17	12.04	1.91	NA	NA	36.47	36.34	090
46735		A	Construction of absent anus	27.02	NA	NA	12.49	12.91	2.59	NA	NA	42.10	42.52	090
46740		A	Construction of absent anus	24.19	NA	NA	10.81	11.24	2.31	NA	NA	37.31	37.74	090
46742		A	Repair of imperforated anus	29.67	NA	NA	15.06	16.65	0.03	NA	NA	44.76	46.35	090
46744		A	Repair of cloacal anomaly	33.21	NA	NA	14.24	16.70	2.51	NA	NA	49.96	52.42	090
46746		A	Repair of cloacal anomaly	36.74	NA	NA	17.86	19.98	3.23	NA	NA	57.83	59.95	090
46748		A	Repair of cloacal anomaly	40.52	NA	NA	19.36	21.85	1.94	NA	NA	61.82	64.31	090
46750		A	Repair of anal sphincter	8.14	NA	NA	4.60	5.08	0.74	NA	NA	13.48	13.96	090
46751		A	Repair of anal sphincter	8.77	NA	NA	5.63	5.33	0.86	NA	NA	15.26	14.96	090
46753		A	Reconstruction of anus	6.58	NA	NA	3.36	3.85	0.67	NA	NA	10.61	11.10	090
46754		A	Removal of suture from anus	1.54	4.61	3.86	1.07	1.21	0.13	6.28	5.53	2.74	2.88	010
46760		A	Repair of anal sphincter	11.46	NA	NA	5.98	6.33	1.08	NA	NA	18.52	18.87	090
46761		A	Repair of anal sphincter	10.99	NA	NA	5.34	5.86	1.06	NA	NA	17.39	17.91	090
46762		A	Implant artificial sphincter	10.09	NA	NA	4.91	5.24	0.93	NA	NA	15.93	16.26	090
46900		A	Destruction, anal lesion(s)	1.91	3.10	2.43	0.76	0.68	0.16	5.17	4.50	2.83	2.75	010
46910		A	Destruction, anal lesion(s)	1.86	3.34	2.68	1.34	1.18	0.15	5.35	4.69	3.35	3.19	010
46916		A	Cryosurgery, anal lesion(s)	1.86	3.17	2.56	1.55	1.35	0.09	5.12	4.51	3.50	3.30	010
46917		A	Laser surgery, anal lesions	1.86	4.07	3.58	1.37	1.56	0.16	6.09	5.60	3.39	3.58	010
46922		A	Excision of anal lesion(s)	1.86	3.38	2.88	1.35	1.36	0.18	5.42	4.92	3.39	3.40	010
46924		A	Destruction, anal lesion(s)	2.76	4.63	4.17	1.62	1.91	0.22	7.61	7.15	4.60	4.89	010
46934		A	Destruction of hemorrhoids	4.08	5.46	4.42	3.21	2.73	0.33	9.87	8.83	7.62	7.14	090
46935		A	Destruction of hemorrhoids	2.43	3.74	3.25	0.88	1.10	0.22	6.39	5.90	3.53	3.75	010
46936		A	Destruction of hemorrhoids	4.30	5.01	4.38	3.22	3.04	0.37	9.68	9.05	7.89	7.71	090
46937		A	Cryotherapy of rectal lesion	2.69	3.86	3.53	1.69	1.91	0.12	6.67	6.34	4.50	4.72	010
46938		A	Cryotherapy of rectal lesion	4.66	5.32	4.67	2.92	2.87	0.47	10.45	9.80	8.05	8.00	090
46940		A	Treatment of anal fissure	2.32	2.67	2.14	0.85	0.78	0.23	5.22	4.69	3.40	3.33	010
46942		A	Treatment of anal fissure	2.04	2.43	1.95	0.70	0.65	0.21	4.68	4.20	2.95	2.90	010
46945		A	Ligation of hemorrhoids	2.14	3.51	2.80	1.93	1.62	0.20	5.85	5.14	4.27	3.96	090
46946		A	Ligation of hemorrhoids	0.03	4.40	3.56	2.21	1.91	0.27	4.70	3.86	2.51	2.21	090
46999		C	Anus surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
47000		A	Needle biopsy of liver	1.90	8.42	6.70	0.66	0.88	0.09	10.41	8.69	2.65	2.87	000
47001		A	Needle biopsy, liver add-on	1.90	NA	NA	0.71	0.91	0.18	NA	NA	2.79	2.99	ZZZ
47010		A	Open drainage, liver lesion	10.28	NA	NA	7.57	7.51	0.54	NA	NA	18.39	18.33	090
47011		A	Percut drain, liver lesion	3.70	NA	NA	5.55	4.92	0.20	NA	NA	9.45	8.82	000
47015		A	Inject/aspirate liver cyst	9.70	NA	NA	5.96	6.30	0.85	NA	NA	16.51	16.85	090
47100		A	Wedge biopsy of liver	7.49	NA	NA	4.82	4.51	0.74	NA	NA	13.05	12.74	090
47120		A	Partial removal of liver	22.79	NA	NA	12.23	12.43	2.21	NA	NA	37.23	37.43	090
47122		A	Extensive removal of liver	35.39	NA	NA	16.94	17.48	3.39	NA	NA	55.72	56.26	090
47125		A	Partial removal of liver	31.58	NA	NA	15.59	16.42	3.05	NA	NA	50.22	51.05	090
47130		A	Partial removal of liver	34.25	NA	NA	16.58	17.64	3.31	NA	NA	54.14	55.20	090
47133		X	Removal of donor liver	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
47134		R	Partial removal, donor liver	39.15	NA	NA	15.52	17.20	3.78	NA	NA	58.45	60.13	XXX
47135		R	Transplantation of liver	81.52	NA	NA	41.25	45.72	8.02	NA	NA	130.79	135.26	090
47136		R	Transplantation of liver	68.60	NA	NA	39.63	38.81	6.62	NA	NA	114.85	114.03	090
47300		A	Surgery for liver lesion	9.68	NA	NA	5.63	6.30	0.95	NA	NA	16.26	16.93	090
47350		A	Repair liver wound	12.56	NA	NA	6.89	7.19	1.23	NA	NA	20.68	20.98	090
47360		A	Repair liver wound	17.28	NA	NA	9.41	10.02	1.70	NA	NA	28.39	29.00	090
47361		A	Repair liver wound	30.25	NA	NA	14.23	14.65	2.96	NA	NA	47.44	47.86	090
47362		A	Repair liver wound	11.88	NA	NA	6.85	6.56	1.12	NA	NA	19.85	19.56	090
47399		C	Liver surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
47400		A	Incision of liver duct	20.86	NA	NA	10.64	10.30	1.96	NA	NA	33.46	33.12	090
47420		A	Incision of bile duct	16.72	NA	NA	8.24	8.75	1.67	NA	NA	26.63	27.14	090
47425		A	Incision of bile duct	16.68	NA	NA	8.53	9.58	1.63	NA	NA	26.84	27.89	090
47460		A	Incise bile duct sphincter	15.17	NA	NA	7.83	10.09	1.26	NA	NA	24.26	26.52	090
47480		A	Incision of gallbladder	9.10	NA	NA	5.92	6.50	0.89	NA	NA	15.91	16.49	090
47490		A	Incision of gallbladder	7.23	NA	NA	7.41	6.53	0.30	NA	NA	14.94	14.06	090
47500		A	Injection for liver x-rays	1.96	NA	NA	0.68	0.92	0.08	NA	NA	2.72	2.96	000
47505		A	Injection for liver x-rays	0.76	14.95	11.48	0.26	0.46	0.03	15.74	12.27	1.05	1.25	000
47510		A	Insert catheter, bile duct	7.83	NA	NA	8.28	6.99	0.32	NA	NA	16.43	15.14	090
47511		A	Insert bile duct drain	10.50	NA	NA	9.50	7.90	0.41	NA	NA	20.41	18.81	090
47525		A	Change bile duct catheter	5.55	NA	NA	3.24	2.86	0.22	NA	NA	9.01	8.63	010
47530		A	Revise/reinsert bile tube	5.85	NA	NA	4.84	4.04	0.28	NA	NA	10.97	10.17	090
47550		A	Bile duct endoscopy add-on	3.02	NA	NA	1.13	1.27	0.30	NA	NA	4.45	4.59	ZZZ
47552		A	Biliary endoscopy thru skin	6.04	NA	NA	2.51	2.25	0.49	NA	NA	9.04	8.78	000
47553		A	Biliary endoscopy thru skin	6.35	NA	NA	2.67	3.03	0.28	NA	NA	9.30	9.66	000
47554		A	Biliary endoscopy thru skin	9.06	NA	NA	3.58	3.75	0.74	NA	NA	13.38	13.55	000
47555		A	Biliary endoscopy thru skin	7.56	NA	NA	3.09	3.03	0.31	NA	NA	10.96	10.90	000
47556		A	Biliary endoscopy thru skin	8.56	NA	NA	3.44	3.29	0.33	NA	NA	12.33	12.18	000
47560		A	Laparoscopy w/cholangio	4.89	NA	NA	1.94	2.21	0.46	NA	NA	7.29	7.56	000
47561		A	Laparo w/cholangio/biopsy	5.18	NA	NA	2.17	2.70	0.47	NA	NA	7.82	8.35	000
47562		A	Laparoscopic cholecystectomy	11.09	NA	NA	4.91	5.85	1.09	NA	NA	17.09	18.03	090
47563		A	Laparo cholecystectomy/graph	11.94	NA	NA	5.39	6.33	1.17	NA	NA	18.50	19.44	090
47564		A	Laparo cholecystectomy/explr	14.23	NA	NA	6.97	7.77	1.37	NA	NA	22.57	23.37	090
47570		A	Laparo cholecystoenterostomy	12.58	NA	NA	6.01	6.99	1.27	NA	NA	19.86	20.84	090
47579		C	Laparoscope proc, biliary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
47600		A	Removal of gallbladder	11.42	NA	NA	6.01	6.55	1.14	NA	NA	18.57	19.11	090
47605		A	Removal of gallbladder	12.36	NA	NA	6.32	6.95	1.22	NA	NA	19.90	20.53	090
47610		A	Removal of gallbladder	15.83	NA	NA	7.71	8.33	1.57	NA	NA	25.11	25.73	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
47612		A	Removal of gallbladder	15.80	NA	NA	7.59	9.55	1.58	NA	NA	24.97	26.93	090
47620		A	Removal of gallbladder	17.36	NA	NA	8.26	9.24	1.73	NA	NA	27.35	28.33	090
47630		A	Remove bile duct stone	9.11	NA	NA	3.19	3.41	0.47	NA	NA	12.77	12.99	090
47700		A	Exploration of bile ducts	15.62	NA	NA	8.29	8.29	1.37	NA	NA	25.28	25.28	090
47701		A	Bile duct revision	29.55	NA	NA	13.79	12.57	2.87	NA	NA	46.21	44.99	090
47711		A	Excision of bile duct tumor	19.37	NA	NA	9.86	10.67	1.86	NA	NA	31.09	31.90	090
47712		A	Excision of bile duct tumor	25.44	NA	NA	12.03	12.30	2.67	NA	NA	40.14	40.41	090
47715		A	Excision of bile duct cyst	15.81	NA	NA	8.14	8.34	1.55	NA	NA	25.50	25.70	090
47716		A	Fusion of bile duct cyst	13.83	NA	NA	7.50	7.41	1.30	NA	NA	22.63	22.54	090
47720		A	Fuse gallbladder & bowel	13.38	NA	NA	7.62	8.20	1.33	NA	NA	22.33	22.91	090
47721		A	Fuse upper gi structures	16.08	NA	NA	8.58	9.53	1.58	NA	NA	26.24	27.19	090
47740		A	Fuse gallbladder & bowel	15.54	NA	NA	8.50	9.15	1.57	NA	NA	25.61	26.26	090
47741		A	Fuse gallbladder & bowel	17.95	NA	NA	9.26	10.84	1.78	NA	NA	28.99	30.57	090
47760		A	Fuse bile ducts and bowel	21.74	NA	NA	10.66	11.15	2.17	NA	NA	34.57	35.06	090
47765		A	Fuse liver ducts & bowel	20.93	NA	NA	10.91	12.15	2.07	NA	NA	33.91	35.15	090
47780		A	Fuse bile ducts and bowel	22.29	NA	NA	10.93	11.74	2.21	NA	NA	35.43	36.24	090
47785		A	Fuse bile ducts and bowel	26.23	NA	NA	12.90	13.22	2.63	NA	NA	41.76	42.08	090
47800		A	Reconstruction of bile ducts	19.60	NA	NA	10.05	11.13	1.91	NA	NA	31.56	32.64	090
47801		A	Placement, bile duct support	12.76	NA	NA	9.29	8.46	0.74	NA	NA	22.79	21.96	090
47802		A	Fuse liver duct & intestine	18.13	NA	NA	10.16	10.41	1.85	NA	NA	30.14	30.39	090
47900		A	Suture bile duct injury	16.74	NA	NA	8.90	10.26	1.68	NA	NA	27.32	28.68	090
47999		C	Bile tract surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
48000		A	Drainage of abdomen	14.91	NA	NA	7.96	7.88	1.32	NA	NA	24.19	24.11	090
48001		A	Placement of drain, pancreas	18.83	NA	NA	8.88	8.87	1.85	NA	NA	29.56	29.55	090
48005		A	Resect/debride pancreas	22.40	NA	NA	10.42	10.31	2.21	NA	NA	35.03	34.92	090
48020		A	Removal of pancreatic stone	14.22	NA	NA	6.90	7.02	1.02	NA	NA	22.14	22.26	090
48100		A	Biopsy of pancreas	11.08	NA	NA	6.40	5.94	1.08	NA	NA	18.56	18.10	090
48102		A	Needle biopsy, pancreas	4.68	8.18	6.79	2.36	2.43	0.19	13.05	11.66	7.23	7.30	010
48120		A	Removal of pancreas lesion	14.36	NA	NA	6.86	7.78	1.42	NA	NA	22.64	23.56	090
48140		A	Partial removal of pancreas	20.78	NA	NA	9.96	11.08	2.05	NA	NA	32.79	33.91	090
48145		A	Partial removal of pancreas	21.76	NA	NA	10.48	12.12	2.16	NA	NA	34.40	36.04	090
48146		A	Pancreatectomy	23.91	NA	NA	12.41	13.78	2.44	NA	NA	38.76	40.13	090
48148		A	Removal of pancreatic duct	15.71	NA	NA	8.55	8.65	1.54	NA	NA	25.80	25.90	090
48150		A	Partial removal of pancreas	43.48	NA	NA	20.63	21.59	4.28	NA	NA	68.39	69.35	090
48152		A	Pancreatectomy	39.63	NA	NA	19.18	20.50	4.06	NA	NA	62.87	64.19	090
48153		A	Pancreatectomy	43.38	NA	NA	20.61	21.57	4.31	NA	NA	68.30	69.26	090
48154		A	Pancreatectomy	39.95	NA	NA	18.95	20.33	3.99	NA	NA	62.89	64.27	090
48155		A	Removal of pancreas	22.32	NA	NA	12.72	15.08	2.20	NA	NA	37.24	39.60	090
48160		N	Pancreas removal/transplant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
48180		A	Fuse pancreas and bowel	22.39	NA	NA	10.26	11.11	2.22	NA	NA	34.87	35.72	090
48400		A	Injection, intraop add-on	1.95	NA	NA	0.70	0.81	0.10	NA	NA	2.75	2.86	ZZZ
48500		A	Surgery of pancreas cyst	13.84	NA	NA	6.28	7.03	1.23	NA	NA	21.35	22.10	090
48510		A	Drain pancreatic pseudocyst	12.96	NA	NA	7.05	7.33	0.92	NA	NA	20.93	21.21	090
48511		A	Drain pancreatic pseudocyst	0.04	NA	NA	4.03	3.85	0.29	NA	NA	4.36	4.18	000
48520		A	Fuse pancreas cyst and bowel	14.12	NA	NA	6.77	8.14	1.38	NA	NA	22.27	23.64	090
48540		A	Fuse pancreas cyst and bowel	17.86	NA	NA	8.20	9.59	1.80	NA	NA	27.86	29.25	090
48545		A	Pancreatorrhaphy	16.47	NA	NA	8.27	8.28	1.76	NA	NA	26.50	26.51	090
48547		A	Duodenal exclusion	23.40	NA	NA	10.30	10.73	2.42	NA	NA	36.12	36.55	090
48550		X	Donor pancreatectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
48554		R	Transpl allograft pancreas	34.17	NA	NA	13.55	15.01	3.26	NA	NA	50.98	52.44	090
48556		A	Removal, allograft pancreas	15.71	NA	NA	8.37	8.25	1.50	NA	NA	25.58	25.46	090
48999		C	Pancreas surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
49000		A	Exploration of abdomen	11.68	NA	NA	6.06	6.39	1.14	NA	NA	18.88	19.21	090
49002		A	Reopening of abdomen	10.49	NA	NA	5.89	6.06	1.03	NA	NA	17.41	17.58	090
49010		A	Exploration behind abdomen	12.28	NA	NA	6.94	7.09	1.22	NA	NA	20.44	20.59	090
49020		A	Drain abdominal abscess	16.79	NA	NA	9.33	8.31	1.12	NA	NA	27.24	26.22	090
49021		A	Drain abdominal abscess	3.38	NA	NA	5.05	4.80	0.20	NA	NA	8.63	8.38	000
49040		A	Drain, open, abdom abscess	9.94	NA	NA	6.76	6.85	0.67	NA	NA	17.37	17.46	090
49041		A	Drain, percut, abdom abscess	0.04	NA	NA	5.31	4.81	0.27	NA	NA	5.62	5.12	000
49060		A	Drain, open, retrop abscess	11.66	NA	NA	7.76	7.32	0.65	NA	NA	20.07	19.63	090
49061		A	Drain, percut, retroper absc	3.70	NA	NA	5.44	4.84	0.21	NA	NA	9.35	8.75	000
49062		A	Drain to peritoneal cavity	11.36	NA	NA	6.91	7.37	1.07	NA	NA	19.34	19.80	090
49080		A	Puncture, peritoneal cavity	1.35	2.99	2.48	0.59	0.68	0.08	4.42	3.91	2.02	2.11	000
49081		A	Removal of abdominal fluid	1.26	2.80	2.30	0.55	0.62	0.08	4.14	3.64	1.89	1.96	000
49085		A	Remove abdomen foreign body	8.93	NA	NA	5.26	4.88	0.90	NA	NA	15.09	14.71	090
49180		A	Biopsy, abdominal mass	1.73	6.65	5.48	0.60	0.95	0.08	8.46	7.29	2.41	2.76	000
49200		A	Removal of abdominal lesion	10.25	NA	NA	6.01	6.78	0.92	NA	NA	17.18	17.95	090
49201		A	Removal of abdominal lesion	14.84	NA	NA	8.23	9.46	1.28	NA	NA	24.35	25.58	090
49215		A	Excise sacral spine tumor	23.20	NA	NA	10.76	10.38	2.18	NA	NA	36.14	35.76	090
49220		A	Multiple surgery, abdomen	14.88	NA	NA	7.69	9.11	1.45	NA	NA	24.02	25.44	090
49250		A	Excision of umbilicus	8.35	NA	NA	5.00	4.98	0.79	NA	NA	14.14	14.12	090
49255		A	Removal of omentum	11.14	NA	NA	6.28	6.11	1.04	NA	NA	18.46	18.29	090
49320		A	Diag laparo separate proc	5.10	NA	NA	2.89	3.38	0.47	NA	NA	8.46	8.95	010
49321		A	Laparoscopy, biopsy	5.40	NA	NA	2.95	3.54	0.49	NA	NA	8.84	9.43	010
49322		A	Laparoscopy, aspiration	5.70	NA	NA	3.23	3.75	0.49	NA	NA	9.42	9.94	010
49323		A	Laparo drain lymphocele	9.48	NA	NA	4.25	5.01	0.90	NA	NA	14.63	15.39	090
49329		C	Laparo proc, abdm/per/oment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
49400		A	Air injection into abdomen	1.88	NA	NA	0.81	0.91	0.11	NA	NA	2.80	2.90	000
49420		A	Insert abdominal drain	2.22	NA	NA	0.94	1.13	0.16	NA	NA	3.32	3.51	000
49421		A	Insert abdominal drain	5.54	NA	NA	3.81	3.98	0.56	NA	NA	9.91	10.08	090
49422		A	Remove perm cannula/catheter	6.25	NA	NA	2.98	3.36	0.63	NA	NA	9.86	10.24	010
49423		A	Exchange drainage catheter	1.46	NA	NA	0.67	0.80	0.15	NA	NA	2.28	2.41	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
49424		A	Assess cyst, contrast inject	0.76	NA	NA	0.43	0.48	0.05	NA	NA	1.24	1.29	000
49425		A	Insert abdomen-venous drain	11.37	NA	NA	7.00	7.55	1.21	NA	NA	19.58	20.13	090
49426		A	Revise abdomen-venous shunt	9.63	NA	NA	5.77	5.79	0.99	NA	NA	16.39	16.41	090
49427		A	Injection, abdominal shunt	0.89	NA	NA	0.47	0.49	0.04	NA	NA	1.40	1.42	000
49428		A	Ligation of shunt	2.38	NA	NA	1.88	1.69	0.29	NA	NA	4.55	4.36	010
49429		A	Removal of shunt	7.40	NA	NA	3.71	3.68	0.79	NA	NA	11.90	11.87	010
49495		A	Repair inguinal hernia, init	5.84	NA	NA	3.22	3.77	0.56	NA	NA	9.62	10.17	090
49496		A	Repair inguinal hernia, init	8.79	NA	NA	6.12	5.96	0.85	NA	NA	15.76	15.60	090
49500		A	Repair inguinal hernia	4.68	NA	NA	3.04	3.63	0.43	NA	NA	8.15	8.74	090
49501		A	Repair inguinal hernia, init	7.58	NA	NA	3.99	4.36	0.75	NA	NA	12.32	12.69	090
49505		A	Repair inguinal hernia	6.49	3.90	4.15	3.58	3.91	0.64	11.03	11.28	10.71	11.04	090
49507		A	Repair inguinal hernia	8.17	NA	NA	5.30	5.34	0.81	NA	NA	14.28	14.32	090
49520		A	Rerepair inguinal hernia	8.22	NA	NA	4.75	4.98	0.82	NA	NA	13.79	14.02	090
49521		A	Repair inguinal hernia, rec	10.22	NA	NA	5.09	5.19	1.02	NA	NA	16.33	16.43	090
49525		A	Repair inguinal hernia	7.32	NA	NA	4.28	4.72	0.73	NA	NA	12.33	12.77	090
49540		A	Repair lumbar hernia	8.87	NA	NA	5.01	5.17	0.89	NA	NA	14.77	14.93	090
49550		A	Repair femoral hernia	7.37	NA	NA	3.95	4.21	0.74	NA	NA	12.06	12.32	090
49553		A	Repair femoral hernia, init	8.06	NA	NA	4.32	4.49	0.80	NA	NA	13.18	13.35	090
49555		A	Repair femoral hernia	7.71	NA	NA	4.59	5.09	0.77	NA	NA	13.07	13.57	090
49557		A	Repair femoral hernia, recur	9.52	NA	NA	4.85	5.29	0.95	NA	NA	15.32	15.76	090
49560		A	Repair abdominal hernia	9.88	NA	NA	5.33	5.53	0.99	NA	NA	16.20	16.40	090
49561		A	Repair incisional hernia	12.17	NA	NA	5.87	5.94	1.21	NA	NA	19.25	19.32	090
49565		A	Rerepair abdominal hernia	9.88	NA	NA	5.44	5.82	0.98	NA	NA	16.30	16.68	090
49566		A	Repair incisional hernia	12.30	NA	NA	5.91	6.17	1.22	NA	NA	19.43	19.69	090
49568		A	Hernia repair w/mesh	4.89	NA	NA	1.84	2.08	0.49	NA	NA	7.22	7.46	ZZZ
49570		A	Repair epigastric hernia	4.86	NA	NA	3.11	3.52	0.49	NA	NA	8.46	8.87	090
49572		A	Repair epigastric hernia	5.75	NA	NA	3.47	4.12	0.57	NA	NA	9.79	10.44	090
49580		A	Repair umbilical hernia	3.34	NA	NA	2.52	2.94	0.34	NA	NA	6.20	6.62	090
49582		A	Repair umbilical hernia	5.68	NA	NA	4.23	4.42	0.57	NA	NA	10.48	10.67	090
49585		A	Repair umbilical hernia	5.32	NA	NA	3.55	3.86	0.53	NA	NA	9.40	9.71	090
49587		A	Repair umbilical hernia	6.46	NA	NA	3.68	3.96	0.64	NA	NA	10.78	11.06	090
49590		A	Repair abdominal hernia	7.29	NA	NA	4.29	4.75	0.73	NA	NA	12.31	12.77	090
49600		A	Repair umbilical lesion	10.96	NA	NA	5.89	5.85	0.95	NA	NA	17.80	17.76	090
49605		A	Repair umbilical lesion	24.94	NA	NA	12.12	11.42	2.20	NA	NA	39.26	38.56	090
49606		A	Repair umbilical lesion	21.31	NA	NA	9.86	9.65	1.91	NA	NA	33.08	32.87	090
49610		A	Repair umbilical lesion	10.50	NA	NA	6.57	6.42	1.05	NA	NA	18.12	17.97	090
49611		A	Repair umbilical lesion	8.92	NA	NA	6.05	6.98	0.68	NA	NA	15.65	16.58	090
49650		A	Laparo hernia repair initial	6.27	NA	NA	3.26	3.67	0.62	NA	NA	10.15	10.56	090
49651		A	Laparo hernia repair recur	8.24	NA	NA	4.34	4.67	0.82	NA	NA	13.40	13.73	090
49659		C	Laparo proc, hernia repair	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
49900		A	Repair of abdominal wall	12.28	NA	NA	6.77	6.07	1.20	NA	NA	20.25	19.55	090
49905		A	Omental flap	6.55	NA	NA	2.52	2.82	0.64	NA	NA	9.71	10.01	ZZZ
49906		C	Free omental flap, microvasc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	090
49999		C	Abdomen surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
50010		A	Exploration of kidney	10.98	NA	NA	6.47	7.44	0.75	NA	NA	18.20	19.17	090
50020		A	Renal abscess, open drain	14.66	NA	NA	12.90	11.52	0.68	NA	NA	28.24	26.86	090
50021		A	Renal abscess, percut drain	3.38	NA	NA	10.51	8.58	0.15	NA	NA	14.04	12.11	000
50040		A	Drainage of kidney	14.94	NA	NA	10.67	9.95	0.79	NA	NA	26.40	25.68	090
50045		A	Exploration of kidney	15.46	NA	NA	7.82	8.53	1.13	NA	NA	24.41	25.12	090
50060		A	Removal of kidney stone	19.30	NA	NA	9.13	10.17	1.14	NA	NA	29.57	30.61	090
50065		A	Incision of kidney	20.79	NA	NA	9.72	11.07	1.17	NA	NA	31.68	33.03	090
50070		A	Incision of kidney	20.32	NA	NA	9.53	10.64	1.44	NA	NA	31.29	32.40	090
50075		A	Removal of kidney stone	25.34	NA	NA	11.47	13.18	1.50	NA	NA	38.31	40.02	090
50080		A	Removal of kidney stone	14.71	NA	NA	9.85	10.70	0.81	NA	NA	25.37	26.22	090
50081		A	Removal of kidney stone	21.80	NA	NA	12.02	13.08	1.23	NA	NA	35.05	36.11	090
50100		A	Revise kidney blood vessels	16.09	NA	NA	9.23	9.73	1.74	NA	NA	27.06	27.56	090
50120		A	Exploration of kidney	15.91	NA	NA	8.04	8.99	0.95	NA	NA	24.90	25.85	090
50125		A	Explore and drain kidney	16.52	NA	NA	8.39	9.26	1.24	NA	NA	26.15	27.02	090
50130		A	Removal of kidney stone	17.29	NA	NA	8.52	9.86	1.05	NA	NA	26.86	28.20	090
50135		A	Exploration of kidney	19.18	NA	NA	9.15	11.49	1.18	NA	NA	29.51	31.85	090
50200		A	Biopsy of kidney	2.63	NA	NA	0.92	1.40	0.14	NA	NA	3.69	4.17	000
50205		A	Biopsy of kidney	11.31	NA	NA	6.15	6.14	0.88	NA	NA	18.34	18.33	090
50220		A	Removal of kidney	17.15	NA	NA	8.57	10.04	1.18	NA	NA	26.90	28.37	090
50225		A	Removal of kidney	20.23	NA	NA	9.50	11.61	1.26	NA	NA	30.99	33.10	090
50230		A	Removal of kidney	22.07	NA	NA	10.07	12.55	1.37	NA	NA	33.51	35.99	090
50234		A	Removal of kidney & ureter	22.40	NA	NA	10.18	12.15	1.38	NA	NA	33.96	35.93	090
50236		A	Removal of kidney & ureter	24.86	NA	NA	12.99	14.56	1.51	NA	NA	39.36	40.93	090
50240		A	Partial removal of kidney	0.22	NA	NA	11.95	13.30	1.37	NA	NA	13.54	14.89	090
50280		A	Removal of kidney lesion	15.67	NA	NA	7.90	8.87	0.01	NA	NA	23.58	24.55	090
50290		A	Removal of kidney lesion	14.73	NA	NA	7.49	8.03	1.16	NA	NA	23.38	23.92	090
50300		X	Removal of donor kidney	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
50320		A	Removal of donor kidney	22.21	NA	NA	10.33	12.22	1.74	NA	NA	34.28	36.17	090
50340		A	Removal of kidney	12.15	NA	NA	9.28	10.35	1.03	NA	NA	22.46	23.53	090
50360		A	Transplantation of kidney	31.53	NA	NA	17.33	19.63	2.91	NA	NA	51.77	54.07	090
50365		A	Transplantation of kidney	36.81	NA	NA	20.38	23.62	3.32	NA	NA	60.51	63.75	090
50370		A	Remove transplanted kidney	13.72	NA	NA	9.07	9.81	1.24	NA	NA	24.03	24.77	090
50380		A	Reimplantation of kidney	20.76	NA	NA	12.42	12.06	1.79	NA	NA	34.97	34.61	090
50390		A	Drainage of kidney lesion	1.96	NA	NA	0.68	0.97	0.08	NA	NA	2.72	3.01	000
50392		A	Insert kidney drain	3.38	NA	NA	1.17	1.52	0.13	NA	NA	4.68	5.03	000
50393		A	Insert ureteral tube	4.16	NA	NA	1.43	1.89	0.16	NA	NA	5.75	6.21	000
50394		A	Injection for kidney x-ray	0.76	13.48	10.26	0.26	0.35	0.03	14.27	11.05	1.05	1.14	000
50395		A	Create passage to kidney	3.38	NA	NA	1.16	1.77	0.13	NA	NA	4.67	5.28	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
50396		A	Measure kidney pressure	2.09	NA	NA	0.87	0.79	0.09	NA	NA	3.05	2.97	000
50398		A	Change kidney tube	1.46	0.94	0.85	0.50	0.52	0.06	2.46	2.37	2.02	2.04	000
50400		A	Revision of kidney/ureter	19.50	NA	NA	9.19	10.60	1.17	NA	NA	29.86	31.27	090
50405		A	Revision of kidney/ureter	23.93	NA	NA	12.24	13.87	1.48	NA	NA	37.65	39.28	090
50500		A	Repair of kidney wound	19.57	NA	NA	10.73	11.43	1.54	NA	NA	31.84	32.54	090
50520		A	Close kidney-skin fistula	17.23	NA	NA	10.77	10.88	1.08	NA	NA	29.08	29.19	090
50525		A	Repair renal-abdomen fistula	22.27	NA	NA	12.53	12.82	0.02	NA	NA	34.82	35.11	090
50526		A	Repair renal-abdomen fistula	24.02	NA	NA	15.04	13.29	2.40	NA	NA	41.46	39.71	090
50540		A	Revision of horseshoe kidney	19.93	NA	NA	9.46	10.73	1.37	NA	NA	30.76	32.03	090
50541		A	Laparo ablate renal cyst	0.16	NA	NA	6.40	6.40	1.03	NA	NA	7.59	7.59	090
50544		A	Laparoscopy, pyeloplasty	22.40	NA	NA	8.49	8.49	1.36	NA	NA	32.25	32.25	090
50546		A	Laparoscopic nephrectomy	20.48	NA	NA	8.03	8.03	1.41	NA	NA	29.92	29.92	090
50547		A	Laparo removal donor kidney	25.50	NA	NA	11.10	11.10	1.98	NA	NA	38.58	38.58	090
50548		A	Laparo-asst remove k/ureter	24.40	NA	NA	9.19	9.19	1.52	NA	NA	35.11	35.11	090
50549		C	Laparoscope proc, renal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
50551		A	Kidney endoscopy	5.60	4.47	3.95	1.82	1.96	0.32	10.39	9.87	7.74	7.88	000
50553		A	Kidney endoscopy	5.99	16.44	12.78	2.02	1.97	0.33	22.76	19.10	8.34	8.29	000
50555		A	Kidney endoscopy & biopsy	6.53	12.06	10.32	2.15	2.89	0.34	18.93	17.19	9.02	9.76	000
50557		A	Kidney endoscopy & treatment	6.62	18.22	14.94	2.16	2.90	0.37	25.21	21.93	9.15	9.89	000
50559		A	Renal endoscopy/radiotracer	6.78	NA	NA	2.44	2.19	0.30	NA	NA	9.52	9.27	000
50561		A	Kidney endoscopy & treatment	7.59	16.47	13.74	2.50	3.27	0.42	24.48	21.75	10.51	11.28	000
50570		A	Kidney endoscopy	9.54	NA	NA	3.10	2.72	0.54	NA	NA	13.18	12.80	000
50572		A	Kidney endoscopy	10.35	NA	NA	3.42	4.53	0.56	NA	NA	4.33	15.44	000
50574		A	Kidney endoscopy & biopsy	11.02	NA	NA	3.67	4.67	0.62	NA	NA	15.31	16.31	000
50575		A	Kidney endoscopy	13.98	NA	NA	4.56	6.12	0.79	NA	NA	19.33	20.89	000
50576		A	Kidney endoscopy & treatment	10.99	NA	NA	3.60	5.06	0.64	NA	NA	15.23	16.69	000
50578		A	Renal endoscopy/radiotracer	11.35	NA	NA	4.50	4.40	0.57	NA	NA	16.42	16.32	000
50580		A	Kidney endoscopy & treatment	11.86	NA	NA	3.86	3.87	0.68	NA	NA	16.40	16.41	000
50590		A	Fragmenting of kidney stone	9.09	9.63	9.94	4.74	6.27	0.52	19.24	19.55	14.35	15.88	090
50600		A	Exploration of ureter	15.84	NA	NA	8.00	8.63	0.99	NA	NA	24.83	25.46	090
50605		A	Insert ureteral support	15.46	NA	NA	8.13	7.76	1.10	NA	NA	24.69	24.32	090
50610		A	Removal of ureter stone	15.92	NA	NA	8.35	9.46	0.99	NA	NA	25.26	26.37	090
50620		A	Removal of ureter stone	15.16	NA	NA	7.68	8.88	0.90	NA	NA	23.74	24.94	090
50630		A	Removal of ureter stone	14.94	NA	NA	7.54	9.10	0.92	NA	NA	23.40	24.96	090
50650		A	Removal of ureter	17.41	NA	NA	8.68	9.79	1.06	NA	NA	27.15	28.26	090
50660		A	Removal of ureter	19.55	NA	NA	9.71	10.67	1.20	NA	NA	30.46	31.42	090
50684		A	Injection for ureter x-ray	0.76	12.30	9.36	0.25	0.32	0.04	13.10	10.16	1.05	1.12	000
50686		A	Measure ureter pressure	1.51	4.53	3.50	0.70	0.63	0.09	6.13	5.10	2.30	2.23	000
50688		A	Change of ureter tube	1.17	NA	NA	1.68	1.37	0.05	NA	NA	2.90	2.59	010
50690		A	Injection for ureter x-ray	1.16	13.98	10.57	0.39	0.38	0.06	15.20	11.79	1.61	1.60	000
50700		A	Revision of ureter	15.21	NA	NA	8.84	10.04	0.94	NA	NA	24.99	26.19	090
50715		A	Release of ureter	18.90	NA	NA	10.86	11.20	1.38	NA	NA	31.14	31.48	090
50722		A	Release of ureter	16.35	NA	NA	8.85	9.44	1.17	NA	NA	26.37	26.96	090
50725		A	Release/revise ureter	18.49	NA	NA	9.63	10.49	1.34	NA	NA	29.46	30.32	090
50727		A	Revise ureter	8.18	NA	NA	5.83	5.83	0.52	NA	NA	14.53	14.53	090
50728		A	Revise ureter	12.02	NA	NA	7.31	7.63	0.91	NA	NA	20.24	20.56	090
50740		A	Fusion of ureter & kidney	18.42	NA	NA	9.01	10.29	1.49	NA	NA	28.92	30.20	090
50750		A	Fusion of ureter & kidney	19.51	NA	NA	9.68	11.07	1.13	NA	NA	30.32	31.71	090
50760		A	Fusion of ureters	18.42	NA	NA	9.26	10.60	1.19	NA	NA	28.87	30.21	090
50770		A	Splicing of ureters	19.51	NA	NA	9.50	11.26	1.19	NA	NA	30.20	31.96	090
50780		A	Reimplant ureter in bladder	18.36	NA	NA	9.14	10.59	1.18	NA	NA	28.68	30.13	090
50782		A	Reimplant ureter in bladder	19.54	NA	NA	9.98	11.22	1.29	NA	NA	30.81	32.05	090
50783		A	Reimplant ureter in bladder	20.55	NA	NA	10.13	11.34	1.32	NA	NA	32.00	33.21	090
50785		A	Reimplant ureter in bladder	20.52	NA	NA	9.91	11.62	1.30	NA	NA	31.73	33.44	090
50800		A	Implant ureter in bowel	14.52	NA	NA	8.88	10.64	0.92	NA	NA	24.32	26.08	090
50810		A	Fusion of ureter & bowel	20.05	NA	NA	11.82	12.28	1.62	NA	NA	33.49	33.95	090
50815		A	Urine shunt to bowel	19.93	NA	NA	10.71	13.39	1.28	NA	NA	31.92	34.60	090
50820		A	Construct bowel bladder	21.89	NA	NA	11.13	13.50	1.46	NA	NA	34.48	36.85	090
50825		A	Construct bowel bladder	28.18	NA	NA	13.90	18.71	1.71	NA	NA	43.79	48.60	090
50830		A	Revise urine flow	31.28	NA	NA	14.48	16.54	2.15	NA	NA	47.91	49.97	090
50840		A	Replace ureter by bowel	0.20	NA	NA	10.89	11.78	1.25	NA	NA	12.34	13.23	090
50845		A	Appendico-vesicostomy	20.89	NA	NA	9.44	10.84	1.26	NA	NA	31.59	32.99	090
50860		A	Transplant ureter to skin	15.36	NA	NA	8.30	9.19	1.01	NA	NA	24.67	25.56	090
50900		A	Repair of ureter	13.62	NA	NA	7.39	8.25	0.97	NA	NA	21.98	22.84	090
50920		A	Closure ureter/skin fistula	14.33	NA	NA	7.86	8.48	1.03	NA	NA	23.22	23.84	090
50930		A	Closure ureter/bowel fistula	18.72	NA	NA	9.15	10.26	1.34	NA	NA	29.21	30.32	090
50940		A	Release of ureter	14.51	NA	NA	7.70	8.46	0.95	NA	NA	23.16	23.92	090
50945		A	Laparoscopy ureterolithotomy	0.17	NA	NA	7.00	7.00	1.07	NA	NA	8.24	8.24	090
50951		A	Endoscopy of ureter	5.84	4.70	3.98	1.91	1.89	0.34	10.88	10.16	8.09	8.07	000
50953		A	Endoscopy of ureter	6.24	16.67	12.95	2.04	1.98	0.36	23.27	19.55	8.64	8.58	000
50955		A	Ureter endoscopy & biopsy	6.75	11.95	9.66	2.21	2.35	0.37	19.07	16.78	9.33	9.47	000
50957		A	Ureter endoscopy & treatment	6.79	12.00	9.68	2.24	2.36	0.38	19.17	16.85	9.41	9.53	000
50959		A	Ureter endoscopy & tracer	4.40	NA	NA	1.41	1.98	0.25	NA	NA	6.06	6.63	000
50961		A	Ureter endoscopy & treatment	6.05	22.24	17.39	1.98	2.20	0.33	28.62	23.77	8.36	8.58	000
50970		A	Ureter endoscopy	7.14	NA	NA	2.36	3.17	0.41	NA	NA	9.91	10.72	000
50972		A	Ureter endoscopy & catheter	6.89	NA	NA	2.27	2.12	0.40	NA	NA	9.56	9.41	000
50974		A	Ureter endoscopy & biopsy	9.17	NA	NA	3.02	4.17	0.50	NA	NA	12.69	13.84	000
50976		A	Ureter endoscopy & treatment	9.04	NA	NA	2.99	3.98	0.51	NA	NA	12.54	13.53	000
50978		A	Ureter endoscopy & tracer	5.10	NA	NA	2.02	2.62	0.33	NA	NA	7.45	8.05	000
50980		A	Ureter endoscopy & treatment	6.85	NA	NA	2.24	2.53	0.38	NA	NA	9.47	9.76	000
51000		A	Drainage of bladder	0.78	1.70	1.41	0.25	0.32	0.05	2.53	2.24	1.08	1.15	000
51005		A	Drainage of bladder	1.02	2.85	2.26	0.35	0.39	0.08	3.95	3.36	1.45	1.49	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
51010		A	Drainage of bladder	3.53	6.54	5.17	1.74	1.57	0.22	10.29	8.92	5.49	5.32	010
51020		A	Incise & treat bladder	6.71	NA	NA	5.06	5.65	0.42	NA	NA	12.19	12.78	090
51030		A	Incise & treat bladder	6.77	NA	NA	5.30	5.21	0.40	NA	NA	12.47	12.38	090
51040		A	Incise & drain bladder	4.40	NA	NA	3.88	4.22	0.27	NA	NA	8.55	8.89	090
51045		A	Incise bladder/drain ureter	6.77	NA	NA	5.03	5.12	0.43	NA	NA	12.23	12.32	090
51050		A	Removal of bladder stone	6.92	NA	NA	4.59	5.38	0.41	NA	NA	11.92	12.71	090
51060		A	Removal of ureter stone	8.85	NA	NA	5.53	6.79	0.53	NA	NA	14.91	16.17	090
51065		A	Removal of ureter stone	8.85	NA	NA	5.62	6.14	0.52	NA	NA	14.99	15.51	090
51080		A	Drainage of bladder abscess	5.96	NA	NA	5.17	5.28	0.36	NA	NA	11.49	11.60	090
51500		A	Removal of bladder cyst	10.14	NA	NA	6.01	6.37	0.82	NA	NA	16.97	17.33	090
51520		A	Removal of bladder lesion	9.29	NA	NA	5.81	6.67	0.57	NA	NA	15.67	16.53	090
51525		A	Removal of bladder lesion	13.97	NA	NA	7.33	8.39	0.85	NA	NA	22.15	23.21	090
51530		A	Removal of bladder lesion	12.38	NA	NA	6.96	7.73	0.85	NA	NA	20.19	20.96	090
51535		A	Repair of ureter lesion	12.57	NA	NA	7.28	7.54	0.84	NA	NA	20.69	20.95	090
51550		A	Partial removal of bladder	15.66	NA	NA	8.00	8.91	1.10	NA	NA	24.76	25.67	090
51555		A	Partial removal of bladder	21.23	NA	NA	10.20	10.98	1.38	NA	NA	32.81	33.59	090
51565		A	Revise bladder & ureter(s)	21.62	NA	NA	10.54	12.20	1.37	NA	NA	33.53	35.19	090
51570		A	Removal of bladder	24.24	NA	NA	11.55	12.91	1.50	NA	NA	37.29	38.65	090
51575		A	Removal of bladder & nodes	30.45	NA	NA	14.21	16.86	1.90	NA	NA	46.56	49.21	090
51580		A	Remove bladder/revise tract	31.08	NA	NA	14.62	16.38	1.93	NA	NA	47.63	49.39	090
51585		A	Removal of bladder & nodes	35.23	NA	NA	15.82	18.68	2.21	NA	NA	53.26	56.12	090
51590		A	Remove bladder/revise tract	32.66	NA	NA	14.75	17.72	2.03	NA	NA	49.44	52.41	090
51595		A	Remove bladder/revise tract	37.14	NA	NA	16.05	21.21	2.21	NA	NA	55.40	60.56	090
51596		A	Remove bladder/create pouch	39.52	NA	NA	17.23	22.39	2.37	NA	NA	59.12	64.28	090
51597		A	Removal of pelvic structures	38.35	NA	NA	17.07	21.11	2.53	NA	NA	57.95	61.99	090
51600		A	Injection for bladder x-ray	0.88	13.95	10.54	0.30	0.30	0.04	14.87	11.46	1.22	1.22	000
51605		A	Preparation for bladder xray	0.64	12.73	9.63	0.22	0.25	0.03	13.40	10.30	0.89	0.92	000
51610		A	Injection for bladder x-ray	1.05	14.61	11.03	0.35	0.34	0.05	15.71	12.13	1.45	1.44	000
51700		A	Irrigation of bladder	0.88	3.59	2.75	0.31	0.29	0.05	4.52	3.68	1.24	1.22	000
51705		A	Change of bladder tube	1.02	2.41	1.91	1.19	1.00	0.06	3.49	2.99	2.27	2.08	010
51710		A	Change of bladder tube	1.49	4.56	3.58	1.33	1.15	0.09	6.14	5.16	2.91	2.73	010
51715		A	Endoscopic injection/implant	3.74	3.88	3.63	1.23	1.64	0.22	7.84	7.59	5.19	5.60	000
51720		A	Treatment of bladder lesion	1.96	3.79	2.97	0.64	0.60	0.11	5.86	5.04	2.71	2.67	000
51725		A	Simple cystometrogram	1.51	0.90	0.95	NA	NA	0.12	2.53	2.58	NA	NA	000
51725	26	A	Simple cystometrogram	1.51	0.50	0.55	0.50	0.55	0.09	2.10	2.15	2.10	2.15	000
51725	TC	A	Simple cystometrogram	0.00	0.40	0.40	NA	NA	0.03	0.43	0.43	NA	NA	000
51726		A	Complex cystometrogram	1.71	1.08	1.16	NA	NA	0.14	2.93	3.01	NA	NA	000
51726	26	A	Complex cystometrogram	1.71	0.57	0.65	0.57	0.65	0.10	2.38	2.46	2.38	2.46	000
51726	TC	A	Complex cystometrogram	0.00	0.51	0.51	NA	NA	0.04	0.55	0.55	NA	NA	000
51736		A	Urine flow measurement	0.61	0.36	0.38	NA	NA	0.05	1.02	1.04	NA	NA	000
51736	26	A	Urine flow measurement	0.61	0.20	0.22	0.20	0.22	0.04	0.85	0.87	0.85	0.87	000
51736	TC	A	Urine flow measurement	0.00	0.16	0.16	NA	NA	0.01	0.17	0.17	NA	NA	000
51741		A	Electro-uroflowmetry, first	1.14	0.60	0.60	NA	NA	0.09	1.83	1.83	NA	NA	000
51741	26	A	Electro-uroflowmetry, first	1.14	0.38	0.38	0.38	0.38	0.07	1.59	1.59	1.59	1.59	000
51741	TC	A	Electro-uroflowmetry, first	0.00	0.22	0.22	NA	NA	0.02	0.24	0.24	NA	NA	000
51772		A	Urethra pressure profile	1.61	1.00	1.00	NA	NA	0.14	2.75	2.75	NA	NA	000
51772	26	A	Urethra pressure profile	1.61	0.55	0.55	0.55	0.55	0.10	2.26	2.26	2.26	2.26	000
51772	TC	A	Urethra pressure profile	0.00	0.45	0.45	NA	NA	0.04	0.49	0.49	NA	NA	000
51784		A	Anal/urinary muscle study	1.53	0.92	0.97	NA	NA	0.13	2.58	2.63	NA	NA	000
51784	26	A	Anal/urinary muscle study	1.53	0.51	0.56	0.51	0.56	0.10	2.14	2.19	2.14	2.19	000
51784	TC	A	Anal/urinary muscle study	0.00	0.41	0.41	NA	NA	0.03	0.44	0.44	NA	NA	000
51785		A	Anal/urinary muscle study	1.53	0.92	0.97	NA	NA	0.12	2.57	2.62	NA	NA	000
51785	26	A	Anal/urinary muscle study	1.53	0.51	0.56	0.51	0.56	0.09	2.13	2.18	2.13	2.18	000
51785	TC	A	Anal/urinary muscle study	0.00	0.41	0.41	NA	NA	0.03	0.44	0.44	NA	NA	000
51792		A	Urinary reflex study	1.10	1.86	1.92	NA	NA	0.17	3.13	3.19	NA	NA	000
51792	26	A	Urinary reflex study	1.10	0.44	0.49	0.44	0.49	0.06	1.60	1.65	1.60	1.65	000
51792	TC	A	Urinary reflex study	0.00	1.42	1.43	NA	NA	0.11	1.53	1.54	NA	NA	000
51795		A	Urine voiding pressure study	1.53	1.43	1.47	NA	NA	0.17	3.13	3.17	NA	NA	000
51795	26	A	Urine voiding pressure study	1.53	0.51	0.54	0.51	0.54	0.09	2.13	2.16	2.13	2.16	000
51795	TC	A	Urine voiding pressure study	0.00	0.92	0.93	NA	NA	0.08	1.00	1.01	NA	NA	000
51797		A	Intraabdominal pressure test	1.60	1.02	1.02	NA	NA	0.14	2.76	2.76	NA	NA	000
51797	26	A	Intraabdominal pressure test	1.60	0.54	0.54	0.54	0.54	0.10	2.24	2.24	2.24	2.24	000
51797	TC	A	Intraabdominal pressure test	0.00	0.48	0.48	NA	NA	0.04	0.52	0.52	NA	NA	000
51800		A	Revision of bladder/urethra	17.42	NA	NA	8.67	9.76	1.09	NA	NA	27.18	28.27	090
51820		A	Revision of urinary tract	17.89	NA	NA	9.70	9.28	1.37	NA	NA	28.96	28.54	090
51840		A	Attach bladder/urethra	10.71	NA	NA	6.15	7.12	0.74	NA	NA	17.60	18.57	090
51841		A	Attach bladder/urethra	13.03	NA	NA	7.54	8.64	0.90	NA	NA	21.47	22.57	090
51845		A	Repair bladder neck	9.73	NA	NA	6.06	7.45	0.59	NA	NA	16.38	17.77	090
51860		A	Repair of bladder wound	12.02	NA	NA	7.20	7.47	0.93	NA	NA	20.15	20.42	090
51865		A	Repair of bladder wound	15.04	NA	NA	8.04	9.00	1.05	NA	NA	24.13	25.09	090
51880		A	Repair of bladder opening	7.66	NA	NA	5.11	5.18	0.53	NA	NA	13.30	13.37	090
51900		A	Repair bladder/vagina lesion	12.97	NA	NA	7.39	8.70	0.89	NA	NA	21.25	22.56	090
51920		A	Close bladder-uterus fistula	11.81	NA	NA	6.58	6.97	0.85	NA	NA	19.24	19.63	090
51925		A	Hysterectomy/bladder repair	15.58	NA	NA	8.84	9.36	1.17	NA	NA	25.59	26.11	090
51940		A	Correction of bladder defect	28.43	NA	NA	14.08	15.70	1.90	NA	NA	44.41	46.03	090
51960		A	Revision of bladder & bowel	23.01	NA	NA	11.95	14.77	1.39	NA	NA	36.35	39.17	090
51980		A	Construct bladder opening	11.36	NA	NA	6.52	6.92	0.73	NA	NA	18.61	19.01	090
51990		A	Laparo urethral suspension	12.50	NA	NA	5.95	5.95	0.87	NA	NA	19.32	19.32	090
51992		A	Laparo sling operation	14.01	NA	NA	6.10	6.10	0.86	NA	NA	20.97	20.97	090
52000		A	Cystoscopy	2.01	3.01	2.62	0.66	0.86	0.11	5.13	4.74	2.78	2.98	000
52005		A	Cystoscopy & ureter catheter	2.37	4.72	4.14	0.77	1.18	0.13	7.22	6.64	3.27	3.68	000
52007		A	Cystoscopy and biopsy	3.02	NA	NA	0.99	1.51	0.17	NA	NA	4.18	4.70	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
52010		A	Cystoscopy & duct catheter	3.02	4.94	4.22	0.99	1.26	0.17	8.13	7.41	4.18	4.45	000
52204		A	Cystoscopy	2.37	5.46	4.74	0.77	1.22	0.13	7.96	7.24	3.27	3.72	000
52214		A	Cystoscopy and treatment	3.71	5.82	5.13	1.21	1.67	0.21	9.74	9.05	5.13	5.59	000
52224		A	Cystoscopy and treatment	3.14	5.67	5.04	1.02	1.55	0.18	8.99	8.36	4.34	4.87	000
52234		A	Cystoscopy and treatment	4.63	6.55	6.19	1.51	2.41	0.26	11.44	11.08	6.40	7.30	000
52235		A	Cystoscopy and treatment	5.45	6.82	6.74	1.78	2.96	0.31	12.58	12.50	7.54	8.72	000
52240		A	Cystoscopy and treatment	9.72	8.23	9.06	3.17	5.27	0.55	18.50	19.33	13.44	15.54	000
52250		A	Cystoscopy and radiotracer	4.50	NA	NA	1.47	1.88	0.26	NA	NA	6.23	6.64	000
52260		A	Cystoscopy and treatment	3.92	NA	NA	1.28	1.53	0.22	NA	NA	5.42	5.67	000
52265		A	Cystoscopy and treatment	2.94	3.39	2.91	0.96	1.09	0.17	6.50	6.02	4.07	4.20	000
52270		A	Cystoscopy & revise urethra	3.37	6.14	5.55	1.10	1.77	0.19	9.70	9.11	4.66	5.33	000
52275		A	Cystoscopy & revise urethra	4.70	6.65	5.92	1.53	2.08	0.27	11.62	10.89	6.50	7.05	000
52276		A	Cystoscopy and treatment	0.05	6.76	6.31	1.63	2.47	0.29	7.10	6.65	1.97	2.81	000
52277		A	Cystoscopy and treatment	6.17	NA	NA	2.03	2.83	0.36	NA	NA	8.56	9.36	000
52281		A	Cystoscopy and treatment	2.80	3.39	3.17	0.91	1.31	0.16	6.35	6.13	3.87	4.27	000
52282		A	Cystoscopy, implant stent	6.40	6.97	6.47	2.09	2.81	0.36	13.73	13.23	8.85	9.57	000
52283		A	Cystoscopy and treatment	3.74	6.06	4.96	1.22	1.33	0.21	10.01	8.91	5.17	5.28	000
52285		A	Cystoscopy and treatment	3.61	6.27	5.50	1.18	1.68	0.21	10.09	9.32	5.00	5.50	000
52290		A	Cystoscopy and treatment	4.59	NA	NA	1.50	1.76	0.26	NA	NA	6.35	6.61	000
52300		A	Cystoscopy and treatment	5.31	NA	NA	1.73	2.24	0.31	NA	NA	7.35	7.86	000
52301		A	Cystoscopy and treatment	5.51	NA	NA	1.73	2.24	0.40	NA	NA	7.64	8.15	000
52305		A	Cystoscopy and treatment	5.31	NA	NA	1.73	2.25	0.31	NA	NA	7.35	7.87	000
52310		A	Cystoscopy and treatment	2.81	13.88	11.22	0.92	1.50	0.16	16.85	14.19	3.89	4.47	000
52315		A	Cystoscopy and treatment	5.21	14.82	12.22	1.70	2.38	0.30	20.33	17.73	7.21	7.89	000
52317		A	Remove bladder stone	6.72	23.00	18.93	2.19	3.32	0.38	30.10	26.03	9.29	10.42	000
52318		A	Remove bladder stone	9.19	NA	NA	2.99	4.38	0.52	NA	NA	12.70	14.09	000
52320		A	Cystoscopy and treatment	4.70	NA	NA	1.52	2.46	0.27	NA	NA	6.49	7.43	000
52325		A	Cystoscopy, stone removal	6.16	NA	NA	2.00	3.34	0.35	NA	NA	8.51	9.85	000
52327		A	Cystoscopy, inject material	5.19	NA	NA	1.72	2.29	0.30	NA	NA	7.21	7.78	000
52330		A	Cystoscopy and treatment	5.04	18.80	15.04	1.64	2.17	0.29	24.13	20.37	6.97	7.50	000
52332		A	Cystoscopy and treatment	2.83	28.16	21.99	0.92	1.56	0.16	31.15	24.98	3.91	4.55	000
52334		A	Create passage to kidney	4.83	NA	NA	1.57	2.08	0.28	NA	NA	6.68	7.19	000
52335		A	Endoscopy of urinary tract	5.86	NA	NA	1.91	2.71	0.33	NA	NA	8.10	8.90	000
52336		A	Cystoscopy, stone removal	6.88	NA	NA	2.23	3.73	0.39	NA	NA	9.50	11.00	000
52337		A	Cystoscopy, stone removal	7.97	NA	NA	2.58	4.32	0.45	NA	NA	11.00	12.74	000
52338		A	Cystoscopy and treatment	7.34	NA	NA	2.39	3.40	0.42	NA	NA	10.15	11.16	000
52339		A	Cystoscopy and treatment	8.82	NA	NA	2.89	3.77	0.51	NA	NA	12.22	13.10	000
52340		A	Cystoscopy and treatment	9.68	NA	NA	5.10	5.22	0.55	NA	NA	15.33	15.45	090
52450		A	Incision of prostate	7.64	NA	NA	5.85	5.74	0.43	NA	NA	13.92	13.81	090
52500		A	Revision of bladder neck	8.47	NA	NA	6.08	6.58	0.48	NA	NA	15.03	15.53	090
52510		A	Dilation prostatic urethra	6.72	NA	NA	5.24	5.94	0.38	NA	NA	12.34	13.04	090
52601		A	Prostatectomy (TURP)	12.37	NA	NA	7.37	8.75	0.70	NA	NA	20.44	21.82	090
52606		A	Control postop bleeding	8.13	NA	NA	5.63	5.12	0.47	NA	NA	14.23	13.72	090
52612		A	Prostatectomy, first stage	7.98	NA	NA	5.95	6.85	0.46	NA	NA	14.39	15.29	090
52614		A	Prostatectomy, second stage	6.84	NA	NA	5.69	6.19	0.39	NA	NA	12.92	13.42	090
52620		A	Remove residual prostate	6.61	NA	NA	5.50	5.57	0.37	NA	NA	12.48	12.55	090
52630		A	Remove prostate regrowth	7.26	NA	NA	5.73	6.47	0.41	NA	NA	13.40	14.14	090
52640		A	Relieve bladder contracture	6.62	NA	NA	5.12	5.59	0.37	NA	NA	12.11	12.58	090
52647		A	Laser surgery of prostate	10.36	54.31	43.83	4.50	6.47	0.58	65.25	54.77	15.44	17.41	090
52648		A	Laser surgery of prostate	11.21	NA	NA	6.94	8.43	0.64	NA	NA	18.79	20.28	090
52700		A	Drainage of prostate abscess	6.80	NA	NA	5.58	5.08	0.40	NA	NA	12.78	12.28	090
53000		A	Incision of urethra	2.28	6.48	5.34	2.26	2.17	0.14	8.90	7.76	4.68	4.59	010
53010		A	Incision of urethra	3.64	NA	NA	3.59	3.65	0.30	NA	NA	7.53	7.59	090
53020		A	Incision of urethra	1.77	3.92	3.16	0.63	0.70	0.11	5.80	5.04	2.51	2.58	000
53025		A	Incision of urethra	1.13	4.23	3.39	0.42	0.53	0.07	5.43	4.59	1.62	1.73	000
53040		A	Drainage of urethra abscess	6.40	12.20	9.65	7.34	6.01	0.38	18.98	16.43	14.12	12.79	090
53060		A	Drainage of urethra abscess	2.63	5.75	4.45	2.39	1.93	0.18	8.56	7.26	5.20	4.74	010
53080		A	Drainage of urinary leakage	6.29	NA	NA	8.27	7.28	0.36	NA	NA	14.92	13.93	090
53085		A	Drainage of urinary leakage	10.27	NA	NA	8.94	8.54	0.61	NA	NA	19.82	19.42	090
53200		A	Biopsy of urethra	2.59	4.96	4.02	0.91	0.98	0.15	7.70	6.76	3.65	3.72	000
53210		A	Removal of urethra	12.57	NA	NA	7.18	7.19	0.80	NA	NA	20.55	20.56	090
53215		A	Removal of urethra	15.58	NA	NA	7.90	8.64	0.94	NA	NA	24.42	25.16	090
53220		A	Treatment of urethra lesion	0.07	NA	NA	4.93	4.99	0.41	NA	NA	5.41	5.47	090
53230		A	Removal of urethra lesion	9.58	NA	NA	5.69	6.42	0.56	NA	NA	15.83	16.56	090
53235		A	Removal of urethra lesion	10.14	NA	NA	5.87	5.77	0.59	NA	NA	16.60	16.50	090
53240		A	Surgery for urethra pouch	6.45	NA	NA	4.60	4.63	0.42	NA	NA	11.47	11.50	090
53250		A	Removal of urethra gland	5.89	NA	NA	4.14	4.21	0.38	NA	NA	10.41	10.48	090
53260		A	Treatment of urethra lesion	2.98	5.36	4.33	2.10	1.88	0.19	8.53	7.50	5.27	5.05	010
53265		A	Treatment of urethra lesion	3.12	5.80	4.86	2.09	2.08	0.19	9.11	8.17	5.40	5.39	010
53270		A	Removal of urethra gland	3.09	5.44	4.31	2.23	1.90	0.21	8.74	7.61	5.53	5.20	010
53275		A	Repair of urethra defect	4.53	NA	NA	2.98	2.88	0.26	NA	NA	7.77	7.67	010
53400		A	Revise urethra, stage 1	12.77	NA	NA	7.06	7.32	0.74	NA	NA	20.57	20.83	090
53405		A	Revise urethra, stage 2	14.48	NA	NA	7.59	8.51	0.82	NA	NA	22.89	23.81	090
53410		A	Reconstruction of urethra	16.44	NA	NA	8.26	8.52	0.95	NA	NA	25.65	25.91	090
53415		A	Reconstruction of urethra	19.41	NA	NA	8.73	9.77	1.19	NA	NA	29.33	30.37	090
53420		A	Reconstruct urethra, stage 1	14.08	NA	NA	7.84	8.83	0.84	NA	NA	22.76	23.75	090
53425		A	Reconstruct urethra, stage 2	15.98	NA	NA	8.55	8.92	0.90	NA	NA	25.43	25.80	090
53430		A	Reconstruction of urethra	16.34	NA	NA	8.36	8.21	0.97	NA	NA	25.67	25.52	090
53440		A	Correct bladder function	12.34	NA	NA	7.20	8.97	0.72	NA	NA	20.26	22.03	090
53442		A	Remove perineal prosthesis	8.27	NA	NA	5.29	5.55	0.47	NA	NA	14.03	14.29	090
53443		A	Reconstruction of urethra	19.89	NA	NA	9.18	9.61	1.25	NA	NA	30.32	30.75	090
53445		A	Correct urine flow control	14.06	NA	NA	7.78	10.03	0.82	NA	NA	22.66	24.91	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
53447		A	Remove artificial sphincter	13.17	NA	NA	7.14	7.84	0.75	NA	NA	21.06	21.76	090
53449		A	Correct artificial sphincter	9.70	NA	NA	6.03	6.81	0.55	NA	NA	16.28	17.06	090
53450		A	Revision of urethra	6.14	NA	NA	4.45	4.08	0.34	NA	NA	10.93	10.56	090
53460		A	Revision of urethra	7.12	NA	NA	4.78	4.25	0.42	NA	NA	12.32	11.79	090
53502		A	Repair of urethra injury	7.63	NA	NA	5.28	5.31	0.48	NA	NA	13.39	13.42	090
53505		A	Repair of urethra injury	7.63	NA	NA	4.91	5.09	0.45	NA	NA	12.99	13.17	090
53510		A	Repair of urethra injury	10.11	NA	NA	6.38	6.68	0.68	NA	NA	17.17	17.47	090
53515		A	Repair of urethra injury	13.31	NA	NA	6.88	7.61	0.78	NA	NA	20.97	21.70	090
53520		A	Repair of urethra defect	8.68	NA	NA	5.33	5.60	0.52	NA	NA	14.53	14.80	090
53600		A	Dilate urethra stricture	1.21	3.77	2.92	0.48	0.45	0.07	5.05	4.20	1.76	1.73	000
53601		A	Dilate urethra stricture	0.98	3.70	2.85	0.40	0.38	0.06	4.74	3.89	1.44	1.42	000
53605		A	Dilate urethra stricture	1.28	NA	NA	0.42	0.44	0.08	NA	NA	1.78	1.80	000
53620		A	Dilate urethra stricture	1.62	5.61	4.34	0.53	0.53	0.10	7.33	6.06	2.25	2.25	000
53621		A	Dilate urethra stricture	1.35	5.61	4.31	0.44	0.43	0.08	7.04	5.74	1.87	1.86	000
53660		A	Dilation of urethra	0.71	3.54	2.73	0.32	0.32	0.04	4.29	3.48	1.07	1.07	000
53661		A	Dilation of urethra	0.72	3.61	2.78	0.24	0.25	0.04	4.37	3.54	1.00	1.01	000
53665		A	Dilation of urethra	0.76	NA	NA	0.26	0.29	0.05	NA	NA	1.07	1.10	000
53670		A	Insert urinary catheter	0.50	3.33	2.56	0.19	0.20	0.03	3.86	3.09	0.72	0.73	000
53675		A	Insert urinary catheter	1.47	4.46	3.47	0.47	0.48	0.09	6.02	5.03	2.03	2.04	000
53850		A	Prostatic microwave thermotx	9.45	12.11	10.90	4.17	4.95	0.53	22.09	20.88	14.15	14.93	090
53852		A	Prostatic rf thermotx	9.88	67.86	52.80	4.28	5.11	0.56	78.30	63.24	14.72	15.55	090
53899		C	Urology surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
54000		A	Slitting of prepuce	1.54	5.16	4.04	1.30	1.15	0.09	6.79	5.67	2.93	2.78	010
54001		A	Slitting of prepuce	2.19	5.51	4.36	1.80	1.58	0.13	7.83	6.68	4.12	3.90	010
54015		A	Drain penis lesion	5.32	6.48	5.09	2.83	2.35	0.32	12.12	10.73	8.47	7.99	010
54050		A	Destruction, penis lesion(s)	1.24	2.28	1.81	0.49	0.47	0.07	3.59	3.12	1.80	1.78	010
54055		A	Destruction, penis lesion(s)	1.22	5.92	4.61	1.28	1.13	0.07	7.21	5.90	2.57	2.42	010
54056		A	Cryosurgery, penis lesion(s)	1.24	2.75	2.21	0.53	0.54	0.05	4.04	3.50	1.82	1.83	010
54057		A	Laser surg, penis lesion(s)	1.24	2.67	2.42	1.19	1.31	0.07	3.98	3.73	2.50	2.62	010
54060		A	Excision of penis lesion(s)	1.93	4.98	4.05	1.43	1.39	0.11	7.02	6.09	3.47	3.43	010
54065		A	Destruction, penis lesion(s)	2.42	5.01	4.43	1.92	2.11	0.13	7.56	6.98	4.47	4.66	010
54100		A	Biopsy of penis	1.90	3.38	2.71	0.71	0.71	0.10	5.38	4.71	2.71	2.71	000
54105		A	Biopsy of penis	3.50	5.83	4.65	1.94	1.73	0.20	9.53	8.35	5.64	5.43	010
54110		A	Treatment of penis lesion	10.13	NA	NA	7.28	7.10	0.60	NA	NA	18.01	17.83	090
54111		A	Treat penis lesion, graft	13.57	NA	NA	8.38	8.78	0.78	NA	NA	22.73	23.13	090
54112		A	Treat penis lesion, graft	15.86	NA	NA	9.30	9.92	0.96	NA	NA	26.12	26.74	090
54115		A	Treatment of penis lesion	6.15	10.08	8.70	5.98	5.62	0.36	16.59	15.21	12.49	12.13	090
54120		A	Partial removal of penis	9.97	NA	NA	7.21	7.16	0.57	NA	NA	17.75	17.70	090
54125		A	Removal of penis	13.53	NA	NA	8.44	9.47	0.79	NA	NA	22.76	23.79	090
54130		A	Remove penis & nodes	20.14	NA	NA	10.99	12.22	1.20	NA	NA	32.33	33.56	090
54135		A	Remove penis & nodes	26.36	NA	NA	13.30	14.79	1.54	NA	NA	41.20	42.69	090
54150		A	Circumcision	1.81	5.36	4.17	1.64	1.38	0.12	7.29	6.10	3.57	3.31	010
54152		A	Circumcision	2.31	NA	NA	1.57	1.67	0.15	NA	NA	4.03	4.13	010
54160		A	Circumcision	2.48	5.57	4.63	1.64	1.68	0.17	8.22	7.28	4.29	4.33	010
54161		A	Circumcision	3.27	NA	NA	1.86	1.99	0.19	NA	NA	5.32	5.45	010
54200		A	Treatment of penis lesion	1.06	2.36	1.86	0.37	0.37	0.06	3.48	2.98	1.49	1.49	010
54205		A	Treatment of penis lesion	7.93	NA	NA	6.51	6.27	0.46	NA	NA	14.90	14.66	090
54220		A	Treatment of penis lesion	2.42	1.79	1.77	0.94	1.13	0.14	4.35	4.33	3.50	3.69	000
54230		A	Prepare penis study	1.34	NA	NA	0.44	0.69	0.08	NA	NA	1.86	2.11	000
54231		A	Dynamic cavernosometry	2.04	1.92	1.83	0.79	0.98	0.14	4.10	4.01	2.97	3.16	000
54235		A	Penile injection	1.19	1.02	0.88	0.39	0.41	0.07	2.28	2.14	1.65	1.67	000
54240		A	Penis study	1.31	0.95	0.98	NA	NA	0.14	2.40	2.43	NA	NA	000
54240	26	A	Penis study	1.31	0.44	0.47	0.44	0.47	0.09	1.84	1.87	1.84	1.87	000
54240	TC	A	Penis study	0.00	0.51	0.51	NA	NA	0.05	0.56	0.56	NA	NA	000
54250		A	Penis study	2.22	1.05	1.00	NA	NA	0.15	3.42	3.37	NA	NA	000
54250	26	A	Penis study	2.22	0.72	0.68	0.72	0.68	0.13	3.07	3.03	3.07	3.03	000
54250	TC	A	Penis study	0.00	0.32	0.32	NA	NA	0.02	0.34	0.34	NA	NA	000
54300		A	Revision of penis	10.41	NA	NA	8.03	7.89	0.61	NA	NA	19.05	18.91	090
54304		A	Revision of penis	12.49	NA	NA	9.06	9.15	0.78	NA	NA	22.33	22.42	090
54308		A	Reconstruction of urethra	11.83	NA	NA	8.59	8.03	0.77	NA	NA	21.19	20.63	090
54312		A	Reconstruction of urethra	13.57	NA	NA	9.81	9.90	0.69	NA	NA	24.07	24.16	090
54316		A	Reconstruction of urethra	16.82	NA	NA	12.01	12.09	0.95	NA	NA	29.78	29.86	090
54318		A	Reconstruction of urethra	11.25	NA	NA	8.97	8.77	0.64	NA	NA	20.86	20.66	090
54322		A	Reconstruction of urethra	13.01	NA	NA	8.63	8.54	0.74	NA	NA	22.38	22.29	090
54324		A	Reconstruction of urethra	16.31	NA	NA	10.48	10.84	1.18	NA	NA	27.97	28.33	090
54326		A	Reconstruction of urethra	15.72	NA	NA	9.95	10.32	1.11	NA	NA	26.78	27.15	090
54328		A	Revise penis/urethra	15.65	NA	NA	9.77	10.24	0.88	NA	NA	26.30	26.77	090
54332		A	Revise penis/urethra	17.08	NA	NA	10.52	11.29	1.03	NA	NA	28.63	29.40	090
54336		A	Revise penis/urethra	20.04	NA	NA	12.59	14.54	1.47	NA	NA	34.10	36.05	090
54340		A	Secondary urethral surgery	8.91	NA	NA	7.43	7.22	0.63	NA	NA	16.97	16.76	090
54344		A	Secondary urethral surgery	15.94	NA	NA	9.85	11.90	1.03	NA	NA	26.82	28.87	090
54348		A	Secondary urethral surgery	17.15	NA	NA	10.71	11.19	1.15	NA	NA	29.01	29.49	090
54352		A	Reconstruct urethra/penis	24.74	NA	NA	13.45	14.48	1.11	NA	NA	39.30	40.33	090
54360		A	Penis plastic surgery	11.93	NA	NA	7.82	7.77	0.70	NA	NA	20.45	20.40	090
54380		A	Repair penis	13.18	NA	NA	9.50	9.68	0.86	NA	NA	23.54	23.72	090
54385		A	Repair penis	15.39	NA	NA	11.18	11.22	0.99	NA	NA	27.56	27.60	090
54390		A	Repair penis and bladder	21.61	NA	NA	13.64	13.91	1.39	NA	NA	36.64	36.91	090
54400		A	Insert semi-rigid prosthesis	8.99	NA	NA	5.75	7.00	0.53	NA	NA	15.27	16.52	090
54401		A	Insert self-contd prosthesis	10.28	NA	NA	6.51	7.95	0.61	NA	NA	17.40	18.84	090
54402		A	Remove penis prosthesis	9.21	NA	NA	5.83	6.00	0.54	NA	NA	15.58	15.75	090
54405		A	Insert multi-comp prosthesis	13.43	NA	NA	7.57	9.69	0.78	NA	NA	21.78	23.90	090
54407		A	Remove multi-comp prosthesis	13.34	NA	NA	7.18	8.43	0.77	NA	NA	21.29	22.54	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
54409		A	Revise penis prosthesis	12.20	NA	NA	6.84	7.56	0.71	NA	NA	19.75	20.47	090
54420		A	Revision of penis	11.42	NA	NA	8.37	8.38	0.67	NA	NA	20.46	20.47	090
54430		A	Revision of penis	10.15	NA	NA	7.24	7.33	0.60	NA	NA	17.99	18.08	090
54435		A	Revision of penis	6.12	NA	NA	5.44	5.21	0.34	NA	NA	11.90	11.67	090
54440		C	Repair of penis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	090
54450		A	Preputial stretching	1.12	0.91	0.87	0.44	0.52	0.07	2.10	2.06	1.63	1.71	000
54500		A	Biopsy of testis	1.31	5.27	4.07	0.43	0.44	0.08	6.66	5.46	1.82	1.83	000
54505		A	Biopsy of testis	3.46	NA	NA	2.43	2.33	0.21	NA	NA	6.10	6.00	010
54510		A	Removal of testis lesion	5.45	NA	NA	3.27	3.28	0.34	NA	NA	9.06	9.07	090
54520		A	Removal of testis	5.23	NA	NA	3.37	3.97	0.32	NA	NA	8.92	9.52	090
54530		A	Removal of testis	8.58	NA	NA	4.87	5.64	0.53	NA	NA	13.98	14.75	090
54535		A	Extensive testis surgery	12.16	NA	NA	6.67	7.32	0.79	NA	NA	19.62	20.27	090
54550		A	Exploration for testis	7.78	NA	NA	4.41	4.73	0.47	NA	NA	12.66	12.98	090
54560		A	Exploration for testis	11.13	NA	NA	6.54	6.87	0.75	NA	NA	18.42	18.75	090
54600		A	Reduce testis torsion	7.01	NA	NA	3.98	4.24	0.41	NA	NA	11.40	11.66	090
54620		A	Suspension of testis	4.90	NA	NA	2.99	3.14	0.29	NA	NA	8.18	8.33	010
54640		A	Suspension of testis	6.90	NA	NA	4.00	5.06	0.47	NA	NA	11.37	12.43	090
54650		A	Orchiopexy (Fowler-Stephens)	11.45	NA	NA	6.40	6.92	0.63	NA	NA	18.48	19.00	090
54660		A	Revision of testis	5.11	NA	NA	3.74	3.73	0.29	NA	NA	9.14	9.13	090
54670		A	Repair testis injury	6.41	NA	NA	3.70	3.94	0.42	NA	NA	10.53	10.77	090
54680		A	Relocation of testis(es)	12.65	NA	NA	7.35	7.74	0.86	NA	NA	20.86	21.25	090
54690		A	Laparoscopy, orchiectomy	10.96	NA	NA	6.35	6.73	0.69	NA	NA	18.00	18.38	090
54692		A	Laparoscopy, orchiopexy	12.88	NA	NA	5.50	5.50	0.87	NA	NA	19.25	19.25	090
54699		C	Laparoscope proc, testis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
54700		A	Drainage of scrotum	3.43	7.72	6.04	3.15	2.61	0.22	11.37	9.69	6.80	6.26	010
54800		A	Biopsy of epididymis	2.33	5.30	4.51	0.81	1.14	0.14	7.77	6.98	3.28	3.61	000
54820		A	Exploration of epididymis	5.14	NA	NA	3.38	3.25	0.36	NA	NA	8.88	8.75	090
54830		A	Remove epididymis lesion	5.38	NA	NA	3.43	3.53	0.33	NA	NA	9.14	9.24	090
54840		A	Remove epididymis lesion	5.20	NA	NA	3.36	3.83	0.31	NA	NA	8.87	9.34	090
54860		A	Removal of epididymis	6.32	NA	NA	3.91	4.34	0.36	NA	NA	10.59	11.02	090
54861		A	Removal of epididymis	8.90	NA	NA	4.74	5.54	0.51	NA	NA	14.15	14.95	090
54900		A	Fusion of spermatic ducts	13.20	NA	NA	6.43	7.25	0.74	NA	NA	20.37	21.19	090
54901		A	Fusion of spermatic ducts	17.94	NA	NA	9.45	10.42	1.18	NA	NA	28.57	29.54	090
55000		A	Drainage of hydrocele	1.43	1.76	1.43	0.48	0.47	0.10	3.29	2.96	2.01	2.00	000
55040		A	Removal of hydrocele	5.36	NA	NA	3.22	3.74	0.35	NA	NA	8.93	9.45	090
55041		A	Removal of hydroceles	7.74	NA	NA	4.19	5.17	0.50	NA	NA	12.43	13.41	090
55060		A	Repair of hydrocele	5.52	NA	NA	3.28	3.58	0.37	NA	NA	9.17	9.47	090
55100		A	Drainage of scrotum abscess	2.13	8.89	6.84	3.34	2.68	0.13	11.15	9.10	5.60	4.94	010
55110		A	Explore scrotum	5.70	NA	NA	3.35	3.46	0.35	NA	NA	9.40	9.51	090
55120		A	Removal of scrotum lesion	5.09	NA	NA	3.17	2.86	0.30	NA	NA	8.56	8.25	090
55150		A	Removal of scrotum	7.22	NA	NA	4.26	4.67	0.46	NA	NA	11.94	12.35	090
55175		A	Revision of scrotum	5.24	NA	NA	3.37	3.75	0.31	NA	NA	8.92	9.30	090
55180		A	Revision of scrotum	10.72	NA	NA	5.97	6.33	0.72	NA	NA	17.41	17.77	090
55200		A	Incision of sperm duct	4.24	NA	NA	2.93	2.73	0.27	NA	NA	7.44	7.24	090
55250		A	Removal of sperm duct(s)	3.29	8.34	6.97	2.79	2.81	0.20	11.83	10.46	6.28	6.30	090
55300		A	Prepare, sperm duct x-ray	3.51	NA	NA	1.44	1.82	0.19	NA	NA	5.14	5.52	000
55400		A	Repair of sperm duct	8.49	NA	NA	4.84	5.41	0.52	NA	NA	13.85	14.42	090
55450		A	Ligation of sperm duct	4.12	7.19	6.10	2.26	2.40	0.31	11.62	10.53	6.69	6.83	010
55500		A	Removal of hydrocele	5.59	NA	NA	3.46	3.77	0.43	NA	NA	9.48	9.79	090
55520		A	Removal of sperm cord lesion	6.03	NA	NA	3.59	3.54	0.57	NA	NA	10.19	10.14	090
55530		A	Revise spermatic cord veins	5.66	NA	NA	3.53	4.06	0.36	NA	NA	9.55	10.08	090
55535		A	Revise spermatic cord veins	6.56	NA	NA	3.82	4.06	0.41	NA	NA	10.79	11.03	090
55540		A	Revise hernia & sperm veins	7.67	NA	NA	4.23	4.41	0.73	NA	NA	12.63	12.81	090
55550		A	Laparo ligate spermatic vein	6.57	NA	NA	3.31	3.68	0.41	NA	NA	10.29	10.66	090
55559		C	Laparo proc, spermatic cord	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
55600		A	Incise sperm duct pouch	6.38	NA	NA	3.91	4.10	0.36	NA	NA	10.65	10.84	090
55605		A	Incise sperm duct pouch	7.96	NA	NA	4.62	4.99	0.52	NA	NA	13.10	13.47	090
55650		A	Remove sperm duct pouch	11.80	NA	NA	5.95	6.42	0.70	NA	NA	18.45	18.92	090
55680		A	Remove sperm pouch lesion	5.19	NA	NA	4.11	4.29	0.30	NA	NA	9.60	9.78	090
55700		A	Biopsy of prostate	1.57	3.49	3.03	0.51	0.79	0.09	5.15	4.69	2.17	2.45	000
55705		A	Biopsy of prostate	4.57	NA	NA	3.47	3.52	0.25	NA	NA	8.29	8.34	010
55720		A	Drainage of prostate abscess	7.64	NA	NA	5.38	4.99	0.44	NA	NA	13.46	13.07	090
55725		A	Drainage of prostate abscess	8.68	NA	NA	5.97	6.00	0.52	NA	NA	15.17	15.20	090
55801		A	Removal of prostate	17.80	NA	NA	8.80	10.06	1.09	NA	NA	27.69	28.95	090
55810		A	Extensive prostate surgery	22.58	NA	NA	10.48	12.71	1.32	NA	NA	34.38	36.61	090
55812		A	Extensive prostate surgery	27.51	NA	NA	12.82	14.41	1.65	NA	NA	41.98	43.57	090
55815		A	Extensive prostate surgery	30.46	NA	NA	13.67	17.09	1.88	NA	NA	46.01	49.43	090
55821		A	Removal of prostate	14.25	NA	NA	7.43	9.26	0.85	NA	NA	22.53	24.36	090
55831		A	Removal of prostate	15.62	NA	NA	7.90	9.88	0.94	NA	NA	24.46	26.44	090
55840		A	Extensive prostate surgery	22.69	NA	NA	11.18	12.89	1.37	NA	NA	35.24	36.95	090
55842		A	Extensive prostate surgery	24.38	NA	NA	11.79	14.04	1.50	NA	NA	37.67	39.92	090
55845		A	Extensive prostate surgery	28.55	NA	NA	13.05	16.60	1.69	NA	NA	43.29	46.84	090
55859		A	Percut/needle insert, pros	12.52	NA	NA	6.97	6.83	0.69	NA	NA	20.18	20.04	090
55860		A	Surgical exposure, prostate	14.45	NA	NA	7.90	7.86	0.78	NA	NA	23.13	23.09	090
55862		A	Extensive prostate surgery	18.39	NA	NA	9.50	10.30	1.19	NA	NA	29.08	29.88	090
55865		A	Extensive prostate surgery	22.87	NA	NA	10.55	14.57	1.40	NA	NA	34.82	38.84	090
55870		A	Electroejaculation	2.58	1.65	1.74	0.91	1.18	0.14	4.37	4.46	3.63	3.90	000
55899		C	Genital surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
55970		N	Sex transformation, M to F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
55980		N	Sex transformation, F to M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
56300		D	Laparoscopy; diagnostic	5.10	2.02	2.72	2.02	2.72	0.47	7.59	8.29	7.59	8.29	010
56301		D	Laparoscopy; tubal cautery	5.60	2.22	2.94	2.22	2.94	0.43	8.25	8.97	8.25	8.97	010

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
56302		D	Laparoscopy; tubal block	5.60	2.22	3.09	2.22	3.09	0.43	8.25	9.12	8.25	9.12	010
56303		D	Laparoscopy; excise lesions	11.79	4.67	5.00	4.67	5.00	0.93	17.39	17.72	17.39	17.72	090
56304		D	Laparoscopy; lysis	11.29	4.48	4.88	4.48	4.88	1.04	16.81	17.21	16.81	17.21	090
56305		D	Laparoscopy; biopsy	5.40	2.14	2.94	2.14	2.94	0.50	8.04	8.84	8.04	8.84	010
56306		D	Laparoscopy; aspiration	5.70	2.26	3.02	2.26	3.02	0.48	8.44	9.20	8.44	9.20	010
56307		D	Laparoscopy; remove adnexa	11.05	4.38	5.23	4.38	5.23	0.86	16.29	17.14	16.29	17.14	010
56308		D	Laparoscopy; hysterectomy	14.19	5.63	6.77	5.63	6.77	1.09	20.91	22.05	20.91	22.05	010
56309		D	Laparoscopy; remove myoma	14.21	5.63	5.52	5.63	5.52	1.13	20.97	20.86	20.97	20.86	010
56310		D	Laparoscopic enterolysis	14.44	5.72	6.54	5.72	6.54	1.42	21.58	22.40	21.58	22.40	090
56311		D	Laparoscopic lymph node biop	9.25	3.67	4.48	3.67	4.48	0.82	13.74	14.55	13.74	14.55	010
56312		D	Laparoscopic lymphadenectomy	12.38	4.91	6.01	4.91	6.01	0.77	18.06	19.16	18.06	19.16	010
56313		D	Laparoscopic lymphadenectomy	14.32	5.68	6.98	5.68	6.98	1.02	21.02	22.32	21.02	22.32	010
56314		D	Lapar; drain lymphocele	9.48	3.76	4.65	3.76	4.65	0.91	14.15	15.04	14.15	15.04	090
56315		D	Laparoscopic appendectomy	8.70	3.45	3.92	3.45	3.92	0.86	13.01	13.48	13.01	13.48	090
56316		D	Laparoscopic hernia repair	6.27	2.49	3.09	2.49	3.09	0.62	9.38	9.98	9.38	9.98	090
56317		D	Laparoscopic hernia repair	8.24	3.27	3.87	3.27	3.87	0.83	12.34	12.94	12.34	12.94	090
56318		D	Laparoscopic orchiectomy	10.96	4.34	5.22	4.34	5.22	0.69	15.99	16.87	15.99	16.87	090
56320		D	Laparoscopy, spermatic veins	6.57	2.60	3.15	2.60	3.15	0.41	9.58	10.13	9.58	10.13	090
56321		D	Laparoscopy; adrenalectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
56322		D	Laparoscopy, vagus nerves	10.15	4.02	4.39	4.02	4.39	1.01	15.18	15.55	15.18	15.55	090
56323		D	Laparoscopy, vagus nerves	12.15	4.82	5.27	4.82	5.27	1.16	18.13	18.58	18.13	18.58	090
56324		D	Laparoscopy, cholecystoenter	12.58	4.99	6.23	4.99	6.23	1.26	18.83	20.07	18.83	20.07	090
56340		D	Laparoscopic cholecystectomy	11.09	4.40	5.47	4.40	5.47	1.10	16.59	17.66	16.59	17.66	090
56341		D	Laparoscopic cholecystectomy	11.94	4.73	5.84	4.73	5.84	1.18	17.85	18.96	17.85	18.96	090
56342		D	Laparoscopic cholecystectomy	14.23	5.64	6.77	5.64	6.77	1.38	21.25	22.38	21.25	22.38	090
56343		D	Laparoscopic salpingostomy	13.74	5.45	5.52	5.45	5.52	1.11	20.30	20.37	20.30	20.37	090
56344		D	Laparoscopic fimbrioplasty	12.88	5.11	5.22	5.11	5.22	1.11	19.10	19.21	19.10	19.21	090
56345		D	Laparoscopic splenectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
56346		D	Laparoscopic gastrostomy	7.73	3.06	3.98	3.06	3.98	0.74	11.53	12.45	11.53	12.45	090
56347		D	Laparoscopic jejunostomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
56348		D	Laparo; resect intestine	22.04	8.74	10.15	8.74	10.15	2.19	32.97	34.38	32.97	34.38	090
56349		D	Laparoscopy; fundoplasty	17.25	6.84	8.35	6.84	8.35	1.73	25.82	27.33	25.82	27.33	090
56350		D	Hysteroscopy; diagnostic	3.33	1.32	1.53	1.32	1.53	0.25	4.90	5.11	4.90	5.11	000
56351		D	Hysteroscopy; biopsy	4.75	1.88	1.95	1.88	1.95	0.36	6.99	7.06	6.99	7.06	000
56352		D	Hysteroscopy; lysis	6.17	2.45	2.86	2.45	2.86	0.47	9.09	9.50	9.09	9.50	000
56353		D	Hysteroscopy; resect septum	0.07	2.78	3.11	2.78	3.11	0.53	3.38	3.71	3.38	3.71	000
56354		D	Hysteroscopy; remove myoma	0.10	3.96	4.31	3.96	4.31	0.75	4.81	5.16	4.81	5.16	000
56355		D	Hysteroscopy; remove impact	5.21	2.07	2.09	2.07	2.09	0.39	7.67	7.69	7.67	7.69	000
56356		D	Hysteroscopy; ablation	6.17	2.45	3.03	2.45	3.03	0.47	9.09	9.67	9.09	9.67	000
56362		D	Laparoscopy w/cholangio	4.89	1.94	2.21	1.94	2.21	0.47	7.30	7.57	7.30	7.57	000
56363		D	Laparoscopy w/biopsy	5.18	2.05	2.61	2.05	2.61	0.47	7.70	8.26	7.70	8.26	000
56399		D	Laparoscopy procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
56405		A	I & D of vulva/perineum	1.44	2.15	1.82	1.20	1.11	0.11	3.70	3.37	2.75	2.66	010
56420		A	Drainage of gland abscess	1.39	2.15	1.83	1.11	1.05	0.11	3.65	3.33	2.61	2.55	010
56440		A	Surgery for vulva lesion	2.84	3.29	3.18	2.12	2.30	0.22	6.35	6.24	5.18	5.36	010
56441		A	Lysis of labial lesion(s)	1.97	2.35	2.21	1.89	1.87	0.13	4.45	4.31	3.99	3.97	010
56501		A	Destruction, vulva lesion(s)	1.53	2.12	1.74	1.24	1.08	0.11	3.76	3.38	2.88	2.72	010
56515		A	Destruction, vulva lesion(s)	1.88	2.50	2.52	1.81	2.00	0.13	4.51	4.53	3.82	4.01	010
56605		A	Biopsy of vulva/perineum	1.10	1.64	1.42	0.46	0.53	0.09	2.83	2.61	1.65	1.72	000
56606		A	Biopsy of vulva/perineum	0.55	1.41	1.15	0.21	0.25	0.04	2.00	1.74	0.80	0.84	ZZZ
56620		A	Partial removal of vulva	7.47	NA	NA	4.57	5.18	0.56	NA	NA	12.60	13.21	090
56625		A	Complete removal of vulva	8.40	NA	NA	5.37	6.54	0.63	NA	NA	14.40	15.57	090
56630		A	Extensive vulva surgery	12.36	NA	NA	7.07	8.96	0.94	NA	NA	20.37	22.26	090
56631		A	Extensive vulva surgery	16.20	NA	NA	9.56	12.01	1.21	NA	NA	26.97	29.42	090
56632		A	Extensive vulva surgery	20.29	NA	NA	8.00	11.79	1.52	NA	NA	29.81	33.60	090
56633		A	Extensive vulva surgery	16.47	NA	NA	8.68	10.84	1.24	NA	NA	26.39	28.55	090
56634		A	Extensive vulva surgery	17.88	NA	NA	10.18	12.97	1.34	NA	NA	29.40	32.19	090
56637		A	Extensive vulva surgery	21.97	NA	NA	11.79	14.66	1.64	NA	NA	35.40	38.27	090
56640		A	Extensive vulva surgery	22.17	NA	NA	11.69	14.18	1.64	NA	NA	35.50	37.99	090
56700		A	Partial removal of hymen	2.52	2.87	2.65	1.88	1.91	0.18	5.57	5.35	4.58	4.61	010
56720		A	Incision of hymen	0.68	1.48	1.24	0.62	0.60	0.05	2.21	1.97	1.35	1.33	000
56740		A	Remove vagina gland lesion	3.76	3.30	3.25	2.45	2.62	0.31	7.37	7.32	6.52	6.69	010
56800		A	Repair of vagina	3.89	NA	NA	2.54	2.70	0.29	NA	NA	6.72	6.88	010
56805		A	Repair clitoris	18.86	NA	NA	8.80	9.79	1.08	NA	NA	28.74	29.73	090
56810		A	Repair of perineum	4.13	NA	NA	2.60	2.66	0.32	NA	NA	7.05	7.11	010
57000		A	Exploration of vagina	2.97	NA	NA	2.21	2.21	0.22	NA	NA	5.40	5.40	010
57010		A	Drainage of pelvic abscess	6.03	NA	NA	3.64	3.45	0.48	NA	NA	10.15	9.96	090
57020		A	Drainage of pelvic fluid	1.50	1.46	1.27	0.59	0.62	0.11	3.07	2.88	2.20	2.23	000
57061		A	Destruction vagina lesion(s)	1.25	2.05	1.76	1.16	1.09	0.10	3.40	3.11	2.51	2.44	010
57065		A	Destruction vagina lesion(s)	2.61	2.68	2.79	2.10	2.35	0.20	5.49	5.60	4.91	5.16	010
57100		A	Biopsy of vagina	0.97	1.32	1.16	0.40	0.47	0.08	2.37	2.21	1.45	1.52	000
57105		A	Biopsy of vagina	1.69	2.01	1.93	2.01	1.93	0.12	3.82	3.74	3.82	3.74	010
57106		A	Remove vagina wall, partial	6.36	2.46	2.46	2.46	2.46	0.51	9.33	9.33	9.33	9.33	090
57107		A	Remove vagina tissue, part	0.23	NA	NA	10.00	10.00	1.75	NA	NA	11.98	11.98	090
57109		A	Vaginectomy partial w/nodes	0.27	NA	NA	11.68	11.68	1.81	NA	NA	13.76	13.76	090
57110		A	Remove vagina wall, complete	14.29	NA	NA	6.89	7.31	1.07	NA	NA	22.25	22.67	090
57111		A	Remove vagina tissue, compl	0.27	NA	NA	11.75	11.75	2.03	NA	NA	14.05	14.05	090
57112		A	Vaginectomy w/nodes, compl	0.29	NA	NA	12.28	12.28	1.89	NA	NA	14.46	14.46	090
57120		A	Closure of vagina	7.41	NA	NA	4.32	5.14	0.56	NA	NA	12.29	13.11	090
57130		A	Remove vagina lesion	2.43	NA	NA	1.94	2.17	0.19	NA	NA	4.56	4.79	010
57135		A	Remove vagina lesion	2.67	2.67	2.53	2.07	2.08	0.20	5.54	5.40	4.94	4.95	010
57150		A	Treat vagina infection	0.55	0.87	0.71	0.21	0.21	0.04	1.46	1.30	0.80	0.80	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
57160		A	Insert pessary/other device	0.89	1.25	1.01	0.34	0.32	0.07	2.21	1.97	1.30	1.28	000
57170		A	Fitting of diaphragm/cap	0.91	1.27	1.04	0.34	0.34	0.07	2.25	2.02	1.32	1.32	000
57180		A	Treat vaginal bleeding	1.58	2.07	1.70	1.34	1.16	0.12	3.77	3.40	3.04	2.86	010
57200		A	Repair of vagina	3.94	NA	NA	2.80	2.84	0.31	NA	NA	7.05	7.09	090
57210		A	Repair vagina/perineum	5.17	NA	NA	3.25	3.33	0.40	NA	NA	8.82	8.90	090
57220		A	Revision of urethra	4.31	NA	NA	3.12	3.55	0.32	NA	NA	7.75	8.18	090
57230		A	Repair of urethral lesion	5.64	NA	NA	3.87	3.95	0.40	NA	NA	9.91	9.99	090
57240		A	Repair bladder & vagina	6.07	NA	NA	4.08	4.87	0.44	NA	NA	10.59	11.38	090
57250		A	Repair rectum & vagina	5.53	NA	NA	3.57	4.33	0.42	NA	NA	9.52	10.28	090
57260		A	Repair of vagina	8.27	NA	NA	4.62	5.81	0.63	NA	NA	13.52	14.71	090
57265		A	Extensive repair of vagina	11.34	NA	NA	6.36	7.33	0.86	NA	NA	18.56	19.53	090
57268		A	Repair of bowel bulge	6.76	NA	NA	4.02	4.92	0.52	NA	NA	11.30	12.20	090
57270		A	Repair of bowel pouch	12.11	NA	NA	5.94	6.31	0.92	NA	NA	18.97	19.34	090
57280		A	Suspension of vagina	15.04	NA	NA	7.07	7.62	1.13	NA	NA	23.24	23.79	090
57282		A	Repair of vaginal prolapse	8.86	NA	NA	4.88	6.03	0.67	NA	NA	14.41	15.56	090
57284		A	Repair paravaginal defect	12.70	NA	NA	6.65	7.32	0.93	NA	NA	20.28	20.95	090
57288		A	Repair bladder defect	13.02	NA	NA	6.52	7.80	0.80	NA	NA	20.34	21.62	090
57289		A	Repair bladder & vagina	11.58	NA	NA	6.26	6.92	0.78	NA	NA	18.62	19.28	090
57291		A	Construction of vagina	7.95	NA	NA	5.54	5.61	0.62	NA	NA	14.11	14.18	090
57292		A	Construct vagina with graft	13.09	NA	NA	6.67	6.78	1.08	NA	NA	20.84	20.95	090
57300		A	Repair rectum-vagina fistula	7.61	NA	NA	4.49	5.51	0.69	NA	NA	12.79	13.81	090
57305		A	Repair rectum-vagina fistula	13.77	NA	NA	6.74	7.10	1.34	NA	NA	21.85	22.21	090
57307		A	Fistula repair & colostomy	15.93	NA	NA	7.55	7.32	1.57	NA	NA	25.05	24.82	090
57308		A	Fistula repair, transperine	9.94	NA	NA	5.53	6.11	0.86	NA	NA	16.33	16.91	090
57310		A	Repair urethrovaginal lesion	6.78	NA	NA	4.40	4.47	0.43	NA	NA	11.61	11.68	090
57311		A	Repair urethrovaginal lesion	7.98	NA	NA	5.06	5.31	0.41	NA	NA	13.45	13.70	090
57320		A	Repair bladder-vagina lesion	8.01	NA	NA	4.91	6.07	0.51	NA	NA	13.43	14.59	090
57330		A	Repair bladder-vagina lesion	12.35	NA	NA	6.37	7.03	0.78	NA	NA	19.50	20.16	090
57335		A	Repair vagina	18.73	NA	NA	8.67	8.38	1.37	NA	NA	28.77	28.48	090
57400		A	Dilation of vagina	2.27	NA	NA	1.24	1.02	0.16	NA	NA	3.67	3.45	000
57410		A	Pelvic examination	1.75	2.48	1.96	1.02	0.86	0.11	4.34	3.82	2.88	2.72	000
57415		A	Remove vaginal foreign body	2.17	3.13	2.45	1.92	1.54	0.16	5.46	4.78	4.25	3.87	010
57452		A	Examination of vagina	0.99	1.52	1.32	0.36	0.45	0.08	2.59	2.39	1.43	1.52	000
57454		A	Vagina examination & biopsy	1.27	1.60	1.53	0.48	0.69	0.10	2.97	2.90	1.85	2.06	000
57460		A	Cervix excision	2.83	1.89	1.97	1.10	1.37	0.21	4.93	5.01	4.14	4.41	000
57500		A	Biopsy of cervix	0.97	1.29	1.12	0.41	0.46	0.08	2.34	2.17	1.46	1.51	000
57505		A	Endocervical curettage	1.14	1.76	1.49	1.16	1.04	0.09	2.99	2.72	2.39	2.27	010
57510		A	Cauterization of cervix	1.90	2.87	2.29	1.45	1.23	0.14	4.91	4.33	3.49	3.27	010
57511		A	Cryocautery of cervix	1.90	2.21	1.89	0.72	0.77	0.14	4.25	3.93	2.76	2.81	010
57513		A	Laser surgery of cervix	1.90	2.37	2.35	1.44	1.65	0.14	4.41	4.39	3.48	3.69	010
57520		A	Conization of cervix	4.04	3.87	3.84	2.63	2.91	0.31	8.22	8.19	6.98	7.26	090
57522		A	Conization of cervix	3.36	3.44	3.52	2.35	2.70	0.26	7.06	7.14	5.97	6.32	090
57530		A	Removal of cervix	4.79	NA	NA	3.32	3.47	0.37	NA	NA	8.48	8.63	090
57531		A	Removal of cervix, radical	0.28	NA	NA	13.09	14.64	2.16	NA	NA	15.53	17.08	090
57540		A	Removal of residual cervix	12.22	NA	NA	6.01	6.34	0.01	NA	NA	18.24	18.57	090
57545		A	Remove cervix/repair pelvis	13.03	NA	NA	6.27	5.95	1.02	NA	NA	20.32	20.00	090
57550		A	Removal of residual cervix	5.53	NA	NA	3.58	4.34	0.43	NA	NA	9.54	10.30	090
57555		A	Remove cervix/repair vagina	8.95	NA	NA	5.28	6.63	0.70	NA	NA	14.93	16.28	090
57556		A	Remove cervix, repair bowel	8.37	NA	NA	4.61	5.96	0.64	NA	NA	13.62	14.97	090
57700		A	Revision of cervix	3.55	NA	NA	2.43	2.47	0.26	NA	NA	6.24	6.28	090
57720		A	Revision of cervix	4.13	NA	NA	3.05	3.04	0.31	NA	NA	7.49	7.48	090
57800		A	Dilation of cervical canal	0.77	1.06	0.93	0.33	0.38	0.06	1.89	1.76	1.16	1.21	000
57820		A	D & c of residual cervix	1.67	2.36	2.34	2.02	2.08	0.13	4.16	4.14	3.82	3.88	010
58100		A	Biopsy of uterus lining	0.71	1.91	1.61	0.27	0.38	0.06	2.68	2.38	1.04	1.15	000
58120		A	Dilation and curettage	3.27	3.48	3.34	2.26	2.43	0.25	7.00	6.86	5.78	5.95	010
58140		A	Removal of uterus lesion	14.60	NA	NA	6.86	7.41	1.24	NA	NA	22.70	23.25	090
58145		A	Removal of uterus lesion	8.04	NA	NA	4.58	5.67	0.60	NA	NA	13.22	14.31	090
58150		A	Total hysterectomy	15.24	NA	NA	7.21	8.01	1.19	NA	NA	23.64	24.44	090
58152		A	Total hysterectomy	15.09	NA	NA	7.16	8.62	1.16	NA	NA	23.41	24.87	090
58180		A	Partial hysterectomy	15.29	NA	NA	7.22	8.06	1.23	NA	NA	23.74	24.58	090
58200		A	Extensive hysterectomy	21.59	NA	NA	10.53	11.42	1.65	NA	NA	33.77	34.66	090
58210		A	Extensive hysterectomy	28.85	NA	NA	13.32	14.81	2.18	NA	NA	44.35	45.84	090
58240		A	Removal of pelvis contents	38.39	NA	NA	17.96	21.27	2.98	NA	NA	59.33	62.64	090
58260		A	Vaginal hysterectomy	12.20	NA	NA	5.65	6.79	0.94	NA	NA	18.79	19.93	090
58262		A	Vaginal hysterectomy	13.99	NA	NA	6.41	7.36	1.06	NA	NA	21.46	22.41	090
58263		A	Vaginal hysterectomy	15.28	NA	NA	6.89	7.97	1.16	NA	NA	23.33	24.41	090
58267		A	Hysterectomy & vagina repair	0.15	NA	NA	6.76	8.20	1.15	NA	NA	8.06	9.50	090
58270		A	Hysterectomy & vagina repair	13.48	NA	NA	6.19	7.44	1.03	NA	NA	20.70	21.95	090
58275		A	Hysterectomy/revise vagina	14.98	NA	NA	6.76	8.06	1.17	NA	NA	22.91	24.21	090
58280		A	Hysterectomy/revise vagina	15.41	NA	NA	6.92	8.04	1.18	NA	NA	23.51	24.63	090
58285		A	Extensive hysterectomy	18.57	NA	NA	9.33	10.15	1.42	NA	NA	29.32	30.14	090
58300		N	Insert intrauterine device	1.01	1.31	1.19	0.40	0.51	0.08	2.40	2.28	1.49	1.60	XXX
58301		A	Remove intrauterine device	1.27	1.41	1.18	0.48	0.48	0.10	2.78	2.55	1.85	1.85	000
58321		A	Artificial insemination	0.92	0.90	0.87	0.36	0.46	0.07	1.89	1.86	1.35	1.45	000
58322		A	Artificial insemination	1.10	0.94	0.90	0.42	0.51	0.08	2.12	2.08	1.60	1.69	000
58323		A	Sperm washing	0.23	0.46	0.39	0.09	0.11	0.02	0.71	0.64	0.34	0.36	000
58340		A	Catheter for hysterography	0.88	8.09	6.22	0.32	0.40	0.06	9.03	7.16	1.26	1.34	000
58345		A	Reopen fallopian tube	4.66	NA	NA	1.72	2.24	0.26	NA	NA	6.64	7.16	010
58350		A	Reopen fallopian tube	1.01	1.81	1.55	1.02	0.95	0.08	2.90	2.64	2.11	2.04	010
58400		A	Suspension of uterus	6.36	NA	NA	3.79	4.37	0.49	NA	NA	10.64	11.22	090
58410		A	Suspension of uterus	12.73	NA	NA	6.43	6.32	0.94	NA	NA	20.10	19.99	090
58520		A	Repair of ruptured uterus	11.92	NA	NA	5.93	5.60	1.03	NA	NA	18.88	18.55	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
58540		A	Revision of uterus	14.64	NA	NA	5.92	6.10	1.11	NA	NA	21.67	21.85	090
58550		A	Laparo-asst vag hysterectomy	14.19	NA	NA	6.44	7.38	1.11	NA	NA	21.74	22.68	010
58551		A	Laparoscopy, remove myoma	14.21	NA	NA	6.35	6.06	1.15	NA	NA	21.71	21.42	010
58555		A	Hysteroscopy, dx, sep proc	3.33	2.58	2.48	1.39	1.58	0.26	6.17	6.07	4.98	5.17	000
58558		A	Hysteroscopy, biopsy	4.75	3.14	2.90	1.95	2.00	0.36	8.25	8.01	7.06	7.11	000
58559		A	Hysteroscopy, lysis	6.17	2.43	2.85	2.43	2.85	0.48	9.08	9.50	9.08	9.50	000
58560		A	Hysteroscopy, resect septum	0.07	2.76	3.09	2.76	3.09	0.54	3.37	3.70	3.37	3.70	000
58561		A	Hysteroscopy, remove myoma	0.10	3.94	4.29	3.94	4.29	0.77	4.81	5.16	4.81	5.16	000
58562		A	Hysteroscopy, remove fb	5.21	NA	NA	2.12	2.13	0.40	A	NA	7.73	7.74	000
58563		A	Hysteroscopy, ablation	6.17	2.41	3.00	2.41	3.00	0.48	9.06	9.65	9.06	9.65	000
58578		C	Laparo proc, uterus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
58579		C	Hysteroscope procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
58600		A	Division of fallopian tube	3.84	NA	NA	2.44	2.98	0.30	NA	NA	6.58	7.12	090
58605		A	Division of fallopian tube	3.34	NA	NA	2.36	2.77	0.26	NA	NA	5.96	6.37	090
58611		A	Ligate oviduct(s) add-on	0.63	NA	NA	0.24	0.31	0.05	NA	NA	0.92	0.99	ZZZ
58615		A	Occlude fallopian tube(s)	3.90	NA	NA	3.03	3.06	0.30	NA	NA	7.23	7.26	010
58660		A	Laparoscopy, lysis	11.29	NA	NA	5.31	5.50	1.04	NA	NA	17.64	17.83	090
58661		A	Laparoscopy, remove adnexa	11.05	NA	NA	5.00	5.69	0.87	NA	NA	16.92	17.61	010
58662		A	Laparoscopy, excise lesions	11.79	NA	NA	5.26	5.45	0.94	NA	NA	17.99	18.18	090
58670		A	Laparoscopy, tubal cautery	5.60	NA	NA	3.32	3.77	0.43	NA	NA	9.35	9.80	090
58671		A	Laparoscopy, tubal block	5.60	NA	NA	3.38	3.96	0.43	NA	NA	9.41	9.99	090
58672		A	Laparoscopy, fimbrioplasty	12.88	NA	NA	6.14	5.99	1.10	NA	NA	20.12	19.97	090
58673		A	Laparoscopy, salpingostomy	13.74	NA	NA	6.54	6.34	1.12	NA	NA	21.40	21.20	090
58679		C	Laparo proc, oviduct-ovary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
58700		A	Removal of fallopian tube	6.49	NA	NA	3.66	4.46	0.58	NA	NA	10.73	11.53	090
58720		A	Removal of ovary/tube(s)	11.36	NA	NA	5.60	6.24	0.95	NA	NA	17.91	18.55	090
58740		A	Revise fallopian tube(s)	5.83	NA	NA	3.55	4.40	0.46	NA	NA	9.84	10.69	090
58750		A	Repair oviduct	14.84	NA	NA	7.02	6.98	1.20	NA	NA	23.06	23.02	090
58752		A	Revise ovarian tube(s)	14.84	NA	NA	6.85	6.97	1.09	NA	NA	22.78	22.90	090
58760		A	Remove tubal obstruction	13.13	NA	NA	6.39	6.18	0.99	NA	NA	20.51	20.30	090
58770		A	Create new tubal opening	13.97	NA	NA	6.66	6.43	1.14	NA	NA	21.77	21.54	090
58800		A	Drainage of ovarian cyst(s)	4.14	3.80	3.58	3.80	3.58	0.28	8.22	8.00	8.22	8.00	090
58805		A	Drainage of ovarian cyst(s)	5.88	NA	NA	3.39	4.27	0.52	NA	NA	9.79	10.67	090
58820		A	Drain ovary abscess, open	4.22	NA	NA	3.23	3.17	0.25	NA	NA	7.70	7.64	090
58822		A	Drain ovary abscess, percut	10.13	NA	NA	5.20	4.86	0.85	NA	NA	16.18	15.84	090
58823		A	Drain pelvic abscess, percut	3.38	NA	NA	3.02	2.96	0.23	NA	NA	6.63	6.57	000
58825		A	Transposition, ovary(s)	6.13	NA	NA	3.72	3.88	0.48	NA	NA	10.33	10.49	090
58900		A	Biopsy of ovary(s)	5.99	NA	NA	3.50	4.03	0.51	NA	NA	10.00	10.53	090
58920		A	Partial removal of ovary(s)	6.78	NA	NA	3.78	4.68	0.60	NA	NA	11.16	12.06	090
58925		A	Removal of ovarian cyst(s)	11.36	NA	NA	5.51	5.91	0.01	NA	NA	16.88	17.28	090
58940		A	Removal of ovary(s)	7.29	NA	NA	3.90	4.69	0.66	NA	NA	11.85	12.64	090
58943		A	Removal of ovary(s)	18.43	NA	NA	9.10	10.11	1.53	NA	NA	29.06	30.07	090
58950		A	Resect ovarian malignancy	15.27	NA	NA	7.94	9.01	1.24	NA	NA	24.45	25.52	090
58951		A	Resect ovarian malignancy	21.81	NA	NA	10.57	12.90	1.70	NA	NA	34.08	36.41	090
58952		A	Resect ovarian malignancy	25.01	NA	NA	11.83	13.79	1.94	NA	NA	38.78	40.74	090
58960		A	Exploration of abdomen	14.65	NA	NA	7.72	9.31	1.16	NA	NA	23.53	25.12	090
58970		A	Retrieval of oocyte	3.53	7.26	6.13	1.70	1.96	0.25	11.04	9.91	5.48	5.74	000
58974		C	Transfer of embryo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	000
58976		A	Transfer of embryo	3.83	2.20	2.39	1.52	1.88	0.29	6.32	6.51	5.64	6.00	000
58999		C	Genital surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
59000		A	Amniocentesis	1.30	1.49	1.38	0.50	0.64	0.19	2.98	2.87	1.99	2.13	000
59012		A	Fetal cord puncture,prenatal	3.45	NA	NA	1.64	1.94	0.51	NA	NA	5.60	5.90	000
59015		A	Chorion biopsy	2.20	1.25	1.26	0.87	0.98	0.32	3.77	3.78	3.39	3.50	000
59020		A	Fetal contract stress test	0.66	0.79	0.92	NA	NA	0.21	1.66	1.79	NA	NA	000
59020	26	A	Fetal contract stress test	0.66	0.26	0.39	0.26	0.39	0.13	1.05	1.18	1.05	1.18	000
59020	TC	A	Fetal contract stress test	0.00	0.53	0.53	NA	NA	0.08	0.61	0.61	NA	NA	000
59025		A	Fetal non-stress test	0.53	0.44	0.49	NA	NA	0.10	1.07	1.12	NA	NA	000
59025	26	A	Fetal non-stress test	0.53	0.21	0.26	0.21	0.26	0.08	0.82	0.87	0.82	0.87	000
59025	TC	A	Fetal non-stress test	0.00	0.23	0.23	NA	NA	0.02	0.25	0.25	NA	NA	000
59030		A	Fetal scalp blood sample	1.99	NA	NA	1.02	1.19	0.30	NA	NA	3.31	3.48	000
59050		A	Fetal monitor w/report	0.89	NA	NA	0.34	0.48	0.12	NA	NA	1.35	1.49	XXX
59051		A	Fetal monitor/interpret only	0.74	NA	NA	0.28	0.43	0.10	NA	NA	1.12	1.27	XXX
59100		A	Remove uterus lesion	12.35	NA	NA	6.08	5.68	1.80	NA	NA	20.23	19.83	090
59120		A	Treat ectopic pregnancy	11.49	NA	NA	5.77	6.46	1.67	NA	NA	18.93	19.62	090
59121		A	Treat ectopic pregnancy	11.67	NA	NA	5.90	5.89	1.70	NA	NA	19.27	19.26	090
59130		A	Treat ectopic pregnancy	14.22	NA	NA	6.97	6.85	2.07	NA	NA	23.26	23.14	090
59135		A	Treat ectopic pregnancy	13.88	NA	NA	6.83	7.80	2.01	NA	NA	22.72	23.69	090
59136		A	Treat ectopic pregnancy	13.18	NA	NA	6.55	6.60	1.92	NA	NA	21.65	21.70	090
59140		A	Treat ectopic pregnancy	5.46	NA	NA	3.41	3.82	0.79	NA	NA	9.66	10.07	090
59150		A	Treat ectopic pregnancy	6.89	NA	NA	4.06	4.28	0.01	NA	NA	10.96	11.18	090
59151		A	Treat ectopic pregnancy	7.86	NA	NA	4.07	5.39	1.15	NA	NA	13.08	14.40	090
59160		A	D & c after delivery	2.71	3.24	3.23	2.06	2.34	0.39	6.34	6.33	5.16	5.44	010
59200		A	Insert cervical dilator	0.79	1.21	1.06	0.30	0.37	0.11	2.11	1.96	1.20	1.27	000
59300		A	Episiotomy or vaginal repair	2.41	1.57	1.45	0.96	0.99	0.34	4.32	4.20	3.71	3.74	000
59320		A	Revision of cervix	2.48	NA	NA	1.36	1.50	0.36	NA	NA	4.20	4.34	000
59325		A	Revision of cervix	4.07	NA	NA	1.99	2.28	0.59	NA	NA	6.65	6.94	000
59350		A	Repair of uterus	4.95	NA	NA	1.96	2.43	0.73	NA	NA	7.64	8.11	000
59400		A	Obstetrical care	23.06	NA	NA	13.43	14.14	3.35	NA	NA	39.84	40.55	MMM
59409		A	Obstetrical care	13.50	NA	NA	5.14	6.43	1.97	NA	NA	20.61	21.90	MMM
59410		A	Obstetrical care	14.78	NA	NA	6.05	7.34	2.15	NA	NA	22.98	24.27	MMM
59412		A	Antepartum manipulation	1.71	1.19	1.22	0.66	0.83	0.25	3.15	3.18	2.62	2.79	MMM
59414		A	Deliver placenta	1.61	NA	NA	1.14	1.17	0.24	NA	NA	2.99	3.02	MMM

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
59425		A	Antepartum care only	4.81	4.65	4.27	4.65	4.27	0.71	10.17	9.79	10.17	9.79	MMM
59426		A	Antepartum care only	8.28	7.95	7.30	7.93	7.29	1.20	17.43	16.78	17.41	16.77	MMM
59430		A	Care after delivery	2.13	1.16	0.97	1.15	0.97	0.32	3.61	3.42	3.60	3.42	MMM
59510		A	Cesarean delivery	26.22	NA	NA	15.65	16.32	3.82	NA	NA	45.69	46.36	MMM
59514		A	Cesarean delivery only	15.97	NA	NA	6.06	7.53	2.32	NA	NA	24.35	25.82	MMM
59515		A	Cesarean delivery	17.37	NA	NA	7.63	8.93	2.53	NA	NA	27.53	28.83	MMM
59525		A	Remove uterus after cesarean	8.54	NA	NA	3.23	3.46	1.24	NA	NA	13.01	13.24	ZZZ
59610		A	Vbac delivery	24.62	NA	NA	14.37	14.85	3.58	NA	NA	42.57	43.05	MMM
59612		A	Vbac delivery only	15.06	NA	NA	5.85	6.96	2.20	NA	NA	23.11	24.22	MMM
59614		A	Vbac care after delivery	16.34	NA	NA	7.07	8.10	2.38	NA	NA	25.79	26.82	MMM
59618		A	Attempted vbac delivery	27.78	NA	NA	11.46	13.18	4.05	NA	NA	43.29	45.01	MMM
59620		A	Attempted vbac delivery only	17.53	NA	NA	6.75	8.05	2.55	NA	NA	26.83	28.13	MMM
59622		A	Attempted vbac after care	18.93	NA	NA	8.55	9.62	2.76	NA	NA	30.24	31.31	MMM
59812		A	Treatment of miscarriage	3.25	2.94	3.19	2.23	2.65	0.48	6.67	6.92	5.96	6.38	090
59820		A	Care of miscarriage	4.01	3.22	3.43	2.50	2.89	0.59	7.82	8.03	7.10	7.49	090
59821		A	Treatment of miscarriage	4.47	3.48	3.35	2.69	2.76	0.66	8.61	8.48	7.82	7.89	090
59830		A	Treat uterus infection	6.11	NA	NA	3.65	3.97	0.89	NA	NA	10.65	10.97	090
59840		R	Abortion	3.01	3.26	3.32	2.12	2.46	0.44	6.71	6.77	5.57	5.91	010
59841		R	Abortion	5.24	4.80	4.62	3.34	3.52	0.75	10.79	10.61	9.33	9.51	010
59850		R	Abortion	5.91	NA	NA	2.50	2.96	0.86	NA	NA	9.27	9.73	090
59851		R	Abortion	5.93	NA	NA	2.90	3.34	0.86	NA	NA	9.69	10.13	090
59852		R	Abortion	8.24	NA	NA	4.36	4.77	1.19	NA	NA	13.79	14.20	090
59855		R	Abortion	6.12	NA	NA	3.18	3.51	0.89	NA	NA	10.19	10.52	090
59856		R	Abortion	7.48	NA	NA	3.58	4.07	1.09	NA	NA	12.15	12.64	090
59857		R	Abortion	9.29	NA	NA	4.34	4.94	1.36	NA	NA	14.99	15.59	090
59866		R	Abortion (mpr)	0.04	NA	NA	1.59	1.97	0.58	NA	NA	2.21	2.59	000
59870		A	Evacuate mole of uterus	4.28	NA	NA	2.85	2.93	0.62	NA	NA	7.75	7.83	090
59871		A	Remove cerclage suture	2.13	1.89	1.90	0.85	1.12	0.32	4.34	4.35	3.30	3.57	000
59898		C	Laparo proc, ob care/deliver	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
59899		C	Maternity care procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
60000		A	Drain thyroid/tongue cyst	1.76	2.10	1.74	1.80	1.51	0.11	3.97	3.61	3.67	3.38	010
60001		A	Aspirate/inject thyriod cyst	0.97	1.51	1.42	0.36	0.56	0.07	2.55	2.46	1.40	1.60	000
60100		A	Biopsy of thyroid	0.97	2.09	1.85	0.35	0.55	0.06	3.12	2.88	1.38	1.58	000
60200		A	Remove thyroid lesion	9.55	NA	NA	6.22	6.30	0.87	NA	NA	16.64	16.72	090
60210		A	Partial thyroid excision	10.88	NA	NA	6.24	7.04	1.01	NA	NA	18.13	18.93	090
60212		A	Parital thyroid excision	16.03	NA	NA	8.05	8.49	1.54	NA	NA	25.62	26.06	090
60220		A	Partial removal of thyroid	10.53	NA	NA	6.21	6.98	0.97	NA	NA	17.71	18.48	090
60225		A	Partial removal of thyroid	14.19	NA	NA	7.67	8.60	1.30	NA	NA	23.16	24.09	090
60240		A	Removal of thyroid	16.06	NA	NA	8.92	9.56	1.49	NA	NA	26.47	27.11	090
60252		A	Removal of thyroid	18.20	NA	NA	10.11	11.29	1.64	NA	NA	29.95	31.13	090
60254		A	Extensive thyroid surgery	23.88	NA	NA	13.75	15.53	1.99	NA	NA	39.62	41.40	090
60260		A	Repeat thyroid surgery	15.46	NA	NA	8.98	7.59	1.42	NA	NA	25.86	24.47	090
60270		A	Removal of thyroid	17.94	NA	NA	11.42	12.36	1.86	NA	NA	31.22	32.16	090
60271		A	Removal of thyroid	14.89	NA	NA	8.95	10.01	1.39	NA	NA	25.23	26.29	090
60280		A	Remove thyroid duct lesion	5.87	NA	NA	4.56	5.24	0.48	NA	NA	10.91	11.59	090
60281		A	Remove thyroid duct lesion	8.53	NA	NA	6.21	6.03	0.74	NA	NA	15.48	15.30	090
60500		A	Explore parathyroid glands	16.23	NA	NA	7.86	8.98	1.58	NA	NA	25.67	26.79	090
60502		A	Re-explore parathyroids	20.35	NA	NA	9.85	10.48	1.97	NA	NA	32.17	32.80	090
60505		A	Explore parathyroid glands	21.49	NA	NA	12.26	12.76	2.20	NA	NA	35.95	36.45	090
60512		A	Autotransplant parathyroid	4.45	NA	NA	1.77	1.96	0.44	NA	NA	6.66	6.85	ZZZ
60520		A	Removal of thymus gland	16.81	NA	NA	11.17	12.05	1.90	NA	NA	29.88	30.76	090
60521		A	Removal of thymus gland	18.87	NA	NA	14.18	14.31	2.43	NA	NA	35.48	35.61	090
60522		A	Removal of thymus gland	23.09	NA	NA	15.47	15.28	2.88	NA	NA	41.44	41.25	090
60540		A	Explore adrenal gland	17.03	NA	NA	7.84	9.15	1.40	NA	NA	26.27	27.58	090
60545		A	Explore adrenal gland	19.88	NA	NA	9.60	11.07	1.68	NA	NA	31.16	32.63	090
60600		A	Remove carotid body lesion	17.93	NA	NA	14.06	13.66	1.95	NA	NA	33.94	33.54	090
60605		A	Remove carotid body lesion	20.24	NA	NA	17.41	15.96	1.89	NA	NA	39.54	38.09	090
60650		A	Laparoscopy adrenalectomy	0.20	NA	NA	9.24	9.24	1.35	NA	NA	10.79	10.79	090
60659		C	Laparo proc, endocrine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
60699		C	Endocrine surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
61000		A	Remove cranial cavity fluid	1.58	1.54	1.45	1.39	1.33	0.13	3.25	3.16	3.10	3.04	000
61001		A	Remove cranial cavity fluid	1.49	1.53	1.39	1.35	1.25	0.13	3.15	3.01	2.97	2.87	000
61020		A	Remove brain cavity fluid	1.51	1.96	1.81	1.38	1.38	0.28	3.75	3.60	3.17	3.17	000
61026		A	Injection into brain canal	1.69	1.96	1.98	1.50	1.63	0.24	3.89	3.91	3.43	3.56	000
61050		A	Remove brain canal fluid	1.51	NA	NA	1.43	1.41	0.16	NA	NA	3.10	3.08	000
61055		A	Injection into brain canal	2.10	NA	NA	1.55	1.67	0.12	NA	NA	3.77	3.89	000
61070		A	Brain canal shunt procedure	0.89	6.07	4.69	1.07	0.94	0.09	7.05	5.67	2.05	1.92	000
61105		A	Twist drill hole	5.14	NA	NA	3.47	4.14	1.03	NA	NA	9.64	10.31	090
61107		A	Drill skull for implantation	0.05	NA	NA	3.03	3.77	0.01	NA	NA	3.09	3.83	000
61108		A	Drill skull for drainage	10.19	NA	NA	6.74	8.10	2.04	NA	NA	18.97	20.33	090
61120		A	Burr hole for puncture	8.76	NA	NA	5.61	5.82	1.78	NA	NA	16.15	16.36	090
61140		A	Pierce skull for biopsy	15.90	NA	NA	9.47	10.94	3.06	NA	NA	28.43	29.90	090
61150		A	Pierce skull for drainage	17.57	NA	NA	10.72	12.02	3.40	NA	NA	31.69	32.99	090
61151		A	Pierce skull for drainage	12.42	NA	NA	7.98	6.56	2.51	NA	NA	22.91	21.49	090
61154		A	Pierce skull & remove clot	14.99	NA	NA	9.72	11.77	2.94	NA	NA	27.65	29.70	090
61156		A	Pierce skull for drainage	16.32	NA	NA	9.90	11.82	3.25	NA	NA	29.47	31.39	090
61210		A	Pierce skull, implant device	5.84	NA	NA	3.46	4.23	1.15	NA	NA	10.45	11.22	000
61215		A	Insert brain-fluid device	4.89	NA	NA	3.95	4.42	0.95	NA	NA	9.79	10.26	090
61250		A	Pierce skull & explore	10.42	NA	NA	6.47	7.03	2.07	NA	NA	18.96	19.52	090
61253		A	Pierce skull & explore	12.36	NA	NA	7.27	8.06	2.40	NA	NA	22.03	22.82	090
61304		A	Open skull for exploration	21.96	NA	NA	12.11	15.64	4.20	NA	NA	38.27	41.80	090
61305		A	Open skull for exploration	26.61	NA	NA	14.68	18.91	0.05	NA	NA	41.34	45.57	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
61312		A	Open skull for drainage	24.57	NA	NA	14.00	17.05	4.77	NA	NA	43.34	46.39	090
61313		A	Open skull for drainage	24.93	NA	NA	14.21	17.18	4.81	NA	NA	43.95	46.92	090
61314		A	Open skull for drainage	24.23	NA	NA	13.79	17.29	4.73	NA	NA	42.75	46.25	090
61315		A	Open skull for drainage	27.68	NA	NA	15.59	18.32	5.37	NA	NA	48.64	51.37	090
61320		A	Open skull for drainage	25.62	NA	NA	14.44	15.90	4.90	NA	NA	44.96	46.42	090
61321		A	Open skull for drainage	28.50	NA	NA	15.58	17.07	5.28	NA	NA	49.36	50.85	090
61330		A	Decompress eye socket	23.32	NA	NA	15.92	15.46	2.77	NA	NA	42.01	41.55	090
61332		A	Explore/biopsy eye socket	27.28	NA	NA	18.15	19.24	4.31	NA	NA	49.74	50.83	090
61333		A	Explore orbit/remove lesion	27.95	NA	NA	16.54	17.96	3.08	NA	NA	47.57	48.99	090
61334		A	Explore orbit/remove object	18.27	NA	NA	11.69	12.74	2.49	NA	NA	32.45	33.50	090
61340		A	Relieve cranial pressure	18.66	NA	NA	11.26	12.46	3.47	NA	NA	33.39	34.59	090
61343		A	Incise skull (press relief)	29.77	NA	NA	17.15	21.02	5.80	NA	NA	52.72	56.59	090
61345		A	Relieve cranial pressure	27.20	NA	NA	16.05	17.24	5.29	NA	NA	48.54	49.73	090
61440		A	Incise skull for surgery	26.63	NA	NA	13.99	16.12	2.95	NA	NA	43.57	45.70	090
61450		A	Incise skull for surgery	25.95	NA	NA	14.08	16.10	5.14	NA	NA	45.17	47.19	090
61458		A	Incise skull for brain wound	27.29	NA	NA	15.32	18.89	5.28	NA	NA	47.89	51.46	090
61460		A	Incise skull for surgery	28.39	NA	NA	16.16	18.92	4.73	NA	NA	49.28	52.04	090
61470		A	Incise skull for surgery	26.06	NA	NA	14.01	14.27	4.30	NA	NA	44.37	44.63	090
61480		A	Incise skull for surgery	26.49	NA	NA	14.70	15.11	4.97	NA	NA	46.16	46.57	090
61490		A	Incise skull for surgery	25.66	NA	NA	14.23	13.85	4.81	NA	NA	44.70	44.32	090
61500		A	Removal of skull lesion	17.92	NA	NA	10.53	13.25	3.14	NA	NA	31.59	34.31	090
61501		A	Remove infected skull bone	14.84	NA	NA	8.90	11.10	2.53	NA	NA	26.27	28.47	090
61510		A	Removal of brain lesion	28.45	NA	NA	15.99	19.33	5.53	NA	NA	49.97	53.31	090
61512		A	Remove brain lining lesion	35.09	NA	NA	19.46	22.47	6.83	NA	NA	61.38	64.39	090
61514		A	Removal of brain abscess	25.26	NA	NA	14.44	17.76	4.82	NA	NA	44.52	47.84	090
61516		A	Removal of brain lesion	24.61	NA	NA	14.35	17.95	4.78	NA	NA	43.74	47.34	090
61518		A	Removal of brain lesion	37.32	NA	NA	21.33	24.14	7.20	NA	NA	65.85	68.66	090
61519		A	Remove brain lining lesion	41.39	NA	NA	23.33	25.97	8.02	NA	NA	72.74	75.38	090
61520		A	Removal of brain lesion	54.84	NA	NA	30.85	32.32	9.62	NA	NA	95.31	96.78	090
61521		A	Removal of brain lesion	44.48	NA	NA	24.54	27.35	8.18	NA	NA	77.20	80.01	090
61522		A	Removal of brain abscess	29.45	NA	NA	16.97	18.14	5.79	NA	NA	52.21	53.38	090
61524		A	Removal of brain lesion	27.86	NA	NA	16.22	19.61	5.32	NA	NA	49.40	52.79	090
61526		A	Removal of brain lesion	52.17	NA	NA	29.68	31.49	6.38	NA	NA	88.23	90.04	090
61530		A	Removal of brain lesion	43.86	NA	NA	25.95	28.69	6.16	NA	NA	75.97	78.71	090
61531		A	Implant brain electrodes	14.63	NA	NA	9.29	11.03	2.88	NA	NA	26.80	28.54	090
61533		A	Implant brain electrodes	19.71	NA	NA	11.78	13.45	3.88	NA	NA	35.37	37.04	090
61534		A	Removal of brain lesion	20.97	NA	NA	12.50	11.11	3.84	NA	NA	37.31	35.92	090
61535		A	Remove brain electrodes	11.63	NA	NA	7.51	7.71	2.13	NA	NA	21.27	21.47	090
61536		A	Removal of brain lesion	35.52	NA	NA	20.13	21.06	7.13	NA	NA	62.78	63.71	090
61538		A	Removal of brain tissue	26.81	NA	NA	15.73	19.69	5.27	NA	NA	47.81	51.77	090
61539		A	Removal of brain tissue	32.08	NA	NA	18.32	19.97	6.37	NA	NA	56.77	58.42	090
61541		A	Incision of brain tissue	28.85	NA	NA	16.71	17.91	5.40	NA	NA	50.96	52.16	090
61542		A	Removal of brain tissue	31.02	NA	NA	18.34	19.16	6.27	NA	NA	55.63	56.45	090
61543		A	Removal of brain tissue	29.22	NA	NA	16.60	17.13	5.25	NA	NA	51.07	51.60	090
61544		A	Remove & treat brain lesion	25.50	NA	NA	13.80	17.96	3.85	NA	NA	43.15	47.31	090
61545		A	Excision of brain tumor	43.80	NA	NA	24.49	25.33	8.32	NA	NA	76.61	77.45	090
61546		A	Removal of pituitary gland	31.30	NA	NA	18.13	20.93	5.86	NA	NA	55.29	58.09	090
61548		A	Removal of pituitary gland	21.53	NA	NA	13.00	16.18	3.48	NA	NA	38.01	41.19	090
61550		A	Release of skull seams	14.65	NA	NA	8.48	9.57	0.57	NA	NA	23.70	24.79	090
61552		A	Release of skull seams	19.56	NA	NA	9.50	10.88	1.48	NA	NA	30.54	31.92	090
61556		A	Incise skull/sutures	22.26	NA	NA	11.57	12.89	3.45	NA	NA	37.28	38.60	090
61557		A	Incise skull/sutures	22.38	NA	NA	12.04	13.27	4.12	NA	NA	38.54	39.77	090
61558		A	Excision of skull/sutures	25.58	NA	NA	13.85	15.20	5.17	NA	NA	44.60	45.95	090
61559		A	Excision of skull/sutures	32.79	NA	NA	18.43	20.07	6.63	NA	NA	57.85	59.49	090
61563		A	Excision of skull tumor	26.83	NA	NA	15.39	16.65	4.50	NA	NA	46.72	47.98	090
61564		A	Excision of skull tumor	33.83	NA	NA	14.31	17.17	0.05	NA	NA	48.19	51.05	090
61570		A	Remove foreign body, brain	24.60	NA	NA	13.36	14.50	4.45	NA	NA	42.41	43.55	090
61571		A	Incise skull for brain wound	26.39	NA	NA	14.48	15.83	4.79	NA	NA	45.66	47.01	090
61575		A	Skull base/brainstem surgery	34.36	NA	NA	20.37	24.23	5.12	NA	NA	59.85	63.71	090
61576		A	Skull base/brainstem surgery	52.43	NA	NA	30.84	30.79	6.55	NA	NA	89.82	89.77	090
61580		A	Craniofacial approach, skull	30.35	NA	NA	18.00	19.20	2.98	NA	NA	51.33	52.53	090
61581		A	Craniofacial approach, skull	34.60	NA	NA	0.50	21.84	2.46	NA	NA	57.56	58.90	090
61582		A	Craniofacial approach, skull	31.66	NA	NA	18.04	19.41	5.44	NA	NA	55.14	56.51	090
61583		A	Craniofacial approach, skull	36.21	NA	NA	21.39	22.75	6.91	NA	NA	64.51	65.87	090
61584		A	Orbitocranial approach/skull	34.65	NA	NA	19.94	21.44	6.45	NA	NA	61.04	62.54	090
61585		A	Orbitocranial approach/skull	38.61	NA	NA	21.82	23.62	7.01	NA	NA	67.44	69.24	090
61586		A	Resect nasopharynx, skull	25.10	NA	NA	15.15	17.16	3.10	NA	NA	43.35	45.36	090
61590		A	Infratemporal approach/skull	41.78	NA	NA	24.15	26.01	4.74	NA	NA	70.67	72.53	090
61591		A	Infratemporal approach/skull	43.68	NA	NA	25.73	27.58	5.52	NA	NA	74.93	76.78	090
61592		A	Orbitocranial approach/skull	39.64	NA	NA	22.75	24.57	7.30	NA	NA	69.69	71.51	090
61595		A	Transtemporal approach/skull	29.57	NA	NA	18.42	19.36	3.03	NA	NA	51.02	51.96	090
61596		A	Transcochlear approach/skull	35.63	NA	NA	21.17	22.62	4.03	NA	NA	60.83	62.28	090
61597		A	Transcondylar approach/skull	37.96	NA	NA	21.90	23.55	5.65	NA	NA	65.51	67.16	090
61598		A	Transpetrosal approach/skull	33.41	NA	NA	19.41	20.83	5.09	NA	NA	57.91	59.33	090
61600		A	Resect/excise cranial lesion	25.85	NA	NA	15.58	16.50	2.80	NA	NA	44.23	45.15	090
61601		A	Resect/excise cranial lesion	27.89	NA	NA	16.37	17.44	5.14	NA	NA	49.40	50.47	090
61605		A	Resect/excise cranial lesion	29.33	NA	NA	17.76	18.77	2.67	NA	NA	49.76	50.77	090
61606		A	Resect/excise cranial lesion	38.83	NA	NA	22.70	24.32	7.06	NA	NA	68.59	70.21	090
61607		A	Resect/excise cranial lesion	36.27	NA	NA	20.76	22.39	6.59	NA	NA	63.62	65.25	090
61608		A	Resect/excise cranial lesion	42.10	NA	NA	23.94	25.89	8.11	NA	NA	74.15	76.10	090
61609		A	Transect artery, sinus	9.89	NA	NA	4.59	5.39	0.02	NA	NA	14.50	15.30	ZZZ
61610		A	Transect artery, sinus	29.67	NA	NA	14.59	16.80	4.63	NA	NA	48.89	51.10	ZZZ

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
61611		A	Transect artery, sinus	7.42	NA	NA	2.94	3.67	1.50	NA	NA	11.86	12.59	ZZZ
61612		A	Transect artery, sinus	27.88	NA	NA	14.12	16.09	4.21	NA	NA	46.21	48.18	ZZZ
61613		A	Remove aneurysm, sinus	40.86	NA	NA	23.29	25.25	8.27	NA	NA	72.42	74.38	090
61615		A	Resect/excise lesion, skull	32.07	NA	NA	19.39	20.53	4.42	NA	NA	55.88	57.02	090
61616		A	Resect/excise lesion, skull	43.33	NA	NA	25.79	27.49	7.27	NA	NA	76.39	78.09	090
61618		A	Repair dura	16.99	NA	NA	10.79	11.17	2.83	NA	NA	30.61	30.99	090
61619		A	Repair dura	20.71	NA	NA	12.44	13.18	3.40	NA	NA	36.55	37.29	090
61624		A	Occlusion/embolization cath	20.15	NA	NA	7.28	9.61	1.04	NA	NA	28.47	30.80	000
61626		A	Occlusion/embolization cath	16.62	NA	NA	5.88	7.83	0.74	NA	NA	23.24	25.19	000
61680		A	Intracranial vessel surgery	30.71	NA	NA	17.66	21.67	5.90	NA	NA	54.27	58.28	090
61682		A	Intracranial vessel surgery	61.57	NA	NA	33.18	34.47	11.84	NA	NA	106.59	107.88	090
61684		A	Intracranial vessel surgery	39.81	NA	NA	22.68	25.09	8.05	NA	NA	70.54	72.95	090
61686		A	Intracranial vessel surgery	64.49	NA	NA	35.15	36.13	12.87	NA	NA	112.51	113.49	090
61690		A	Intracranial vessel surgery	29.31	NA	NA	16.43	19.77	5.46	NA	NA	51.20	54.54	090
61692		A	Intracranial vessel surgery	51.87	NA	NA	28.24	28.99	9.05	NA	NA	89.16	89.91	090
61700		A	Inner skull vessel surgery	50.52	NA	NA	27.43	29.17	9.86	NA	NA	87.81	89.55	090
61702		A	Inner skull vessel surgery	48.41	NA	NA	26.43	29.68	9.56	NA	NA	84.40	87.65	090
61703		A	Clamp neck artery	17.47	NA	NA	10.57	11.24	3.28	NA	NA	31.32	31.99	090
61705		A	Revise circulation to head	36.20	NA	NA	19.36	22.77	6.67	NA	NA	62.23	65.64	090
61708		A	Revise circulation to head	35.30	NA	NA	15.57	18.52	2.42	NA	NA	53.29	56.24	090
61710		A	Revise circulation to head	29.67	NA	NA	13.92	14.95	3.62	NA	NA	47.21	48.24	090
61711		A	Fusion of skull arteries	36.33	NA	NA	20.00	23.97	7.04	NA	NA	63.37	67.34	090
61720		A	Incise skull/brain surgery	16.77	NA	NA	10.36	12.78	3.29	NA	NA	30.42	32.84	090
61735		A	Incise skull/brain surgery	20.43	NA	NA	12.35	12.78	3.98	NA	NA	36.76	37.19	090
61750		A	Incise skull/brain biopsy	18.20	NA	NA	10.57	11.60	3.52	NA	NA	32.29	33.32	090
61751		A	Brain biopsy w/ ct/mr guide	17.62	NA	NA	10.41	13.07	3.47	NA	NA	31.50	34.16	090
61760		A	Implant brain electrodes	22.27	NA	NA	6.98	9.30	4.18	NA	NA	33.43	35.75	090
61770		A	Incise skull for treatment	21.44	NA	NA	12.86	14.90	3.85	NA	NA	38.15	40.19	090
61790		A	Treat trigeminal nerve	10.86	NA	NA	5.06	7.04	1.75	NA	NA	17.67	19.65	090
61791		A	Treat trigeminal tract	14.61	NA	NA	8.91	9.33	2.90	NA	NA	26.42	26.84	090
61793		A	Focus radiation beam	17.24	NA	NA	10.48	13.01	3.31	NA	NA	31.03	33.56	090
61795		A	Brain surgery using computer	4.04	NA	NA	2.08	2.77	0.80	NA	NA	6.92	7.61	ZZZ
61850		A	Implant neuroelectrodes	12.39	NA	NA	7.71	8.94	2.10	NA	NA	22.20	23.43	090
61855		D	Implant neuroelectrodes	13.39	5.31	6.80	5.31	6.80	2.63	21.33	22.82	21.33	22.82	090
61860		A	Implant neuroelectrodes	20.87	NA	NA	12.64	11.69	4.22	NA	NA	37.73	36.78	090
61862		A	Implant neurostimul, subcort	19.34	NA	NA	11.59	11.59	3.89	NA	NA	34.82	34.82	090
61865		D	Implant neuroelectrodes	22.97	9.11	11.12	9.11	11.12	4.65	36.73	38.74	36.73	38.74	090
61870		A	Implant neuroelectrodes	14.94	NA	NA	8.59	7.58	3.03	NA	NA	26.56	25.55	090
61875		A	Implant neuroelectrodes	15.06	NA	NA	8.64	8.30	3.05	NA	NA	26.75	26.41	090
61880		A	Revise/remove neuroelectrode	6.29	NA	NA	4.94	5.01	1.25	NA	NA	12.48	12.55	090
61885		A	Implant neurostim one array	5.85	NA	NA	4.03	3.56	1.18	NA	NA	11.06	10.59	090
61886		A	Implant neurostim arrays	0.08	NA	NA	5.82	5.82	1.43	NA	NA	7.33	7.33	090
61888		A	Revise/remove neuroreceiver	5.07	NA	NA	3.74	3.42	1.02	NA	NA	9.83	9.51	010
62000		A	Treat skull fracture	12.53	NA	NA	5.31	5.54	0.90	NA	NA	18.74	18.97	090
62005		A	Treat skull fracture	16.17	NA	NA	8.46	9.35	2.61	NA	NA	27.24	28.13	090
62010		A	Treatment of head injury	19.81	NA	NA	11.42	13.78	3.72	NA	NA	34.95	37.31	090
62100		A	Repair brain fluid leakage	22.03	NA	NA	13.45	15.95	3.82	NA	NA	39.30	41.80	090
62115		A	Reduction of skull defect	21.66	NA	NA	11.16	12.58	2.96	NA	NA	35.78	37.20	090
62116		A	Reduction of skull defect	23.59	NA	NA	12.76	14.18	4.47	NA	NA	40.82	42.24	090
62117		A	Reduction of skull defect	26.60	NA	NA	15.26	16.66	5.38	NA	NA	47.24	48.64	090
62120		A	Repair skull cavity lesion	23.35	NA	NA	13.79	14.93	3.46	NA	NA	40.60	41.74	090
62121		A	Incise skull repair	21.58	NA	NA	13.05	14.54	3.52	NA	NA	38.15	39.64	090
62140		A	Repair of skull defect	13.51	NA	NA	8.29	9.86	2.56	NA	NA	24.36	25.93	090
62141		A	Repair of skull defect	14.91	NA	NA	9.38	11.49	2.80	NA	NA	27.09	29.20	090
62142		A	Remove skull plate/flap	10.79	NA	NA	7.00	8.47	2.06	NA	NA	19.85	21.32	090
62143		A	Replace skull plate/flap	13.05	NA	NA	8.43	8.81	2.47	NA	NA	23.95	24.33	090
62145		A	Repair of skull & brain	18.82	NA	NA	11.28	12.03	3.76	NA	NA	33.86	34.61	090
62146		A	Repair of skull with graft	16.12	NA	NA	9.96	10.45	2.93	NA	NA	29.01	29.50	090
62147		A	Repair of skull with graft	19.34	NA	NA	11.52	12.21	3.22	NA	NA	34.08	34.77	090
62180		A	Establish brain cavity shunt	21.06	NA	NA	12.49	13.22	0.04	NA	NA	33.59	34.32	090
62190		A	Establish brain cavity shunt	11.07	NA	NA	7.06	8.60	2.21	NA	NA	20.34	21.88	090
62192		A	Establish brain cavity shunt	12.25	NA	NA	8.00	9.66	2.28	NA	NA	22.53	24.19	090
62194		A	Replace/irrigate catheter	5.03	NA	NA	1.94	1.97	0.47	NA	NA	7.44	7.47	010
62200		A	Establish brain cavity shunt	18.32	NA	NA	11.14	12.96	3.67	NA	NA	33.13	34.95	090
62201		A	Establish brain cavity shunt	14.86	NA	NA	9.34	9.39	2.71	NA	NA	26.91	26.96	090
62220		A	Establish brain cavity shunt	0.13	NA	NA	8.26	10.08	2.52	NA	NA	10.91	12.73	090
62223		A	Establish brain cavity shunt	12.87	NA	NA	8.15	9.96	2.43	NA	NA	23.45	25.26	090
62225		A	Replace/irrigate catheter	5.41	NA	NA	3.91	4.24	1.07	NA	NA	10.39	10.72	090
62230		A	Replace/revise brain shunt	10.54	NA	NA	6.44	7.50	2.02	NA	NA	19.00	20.06	090
62256		A	Remove brain cavity shunt	6.60	NA	NA	5.08	5.54	1.30	NA	NA	12.98	13.44	090
62258		A	Replace brain cavity shunt	14.54	NA	NA	8.43	10.33	2.80	NA	NA	25.77	27.67	090
62263		A	Lysis epidural adhesions	6.02	5.33	5.33	2.27	2.27	0.88	12.23	12.23	9.17	9.17	010
62268		A	Drain spinal cord cyst	4.74	NA	NA	2.52	2.70	0.42	NA	NA	7.68	7.86	000
62269		A	Needle biopsy, spinal cord	5.02	NA	NA	2.42	2.29	0.28	NA	NA	7.72	7.59	000
62270		A	Spinal fluid tap, diagnostic	1.13	3.10	2.52	0.45	0.53	0.14	4.37	3.79	1.72	1.80	000
62272		A	Drain spinal fluid	1.35	2.97	2.50	0.61	0.73	0.19	4.51	4.04	2.15	2.27	000
62273		A	Treat epidural spine lesion	2.15	1.27	1.26	1.06	1.10	0.14	3.56	3.55	3.35	3.39	000
62274		D	Inject spinal anesthetic	1.78	0.71	0.73	0.71	0.73	0.12	2.61	2.63	2.61	2.63	000
62275		D	Inject spinal anesthetic	1.79	0.71	0.69	0.71	0.69	0.12	2.62	2.60	2.62	2.60	000
62276		D	Inject spinal anesthetic	2.04	0.81	0.94	0.81	0.94	0.14	2.99	3.12	2.99	3.12	000
62277		D	Inject spinal anesthetic	2.15	0.85	0.87	0.85	0.87	0.14	3.14	3.16	3.14	3.16	000
62278		D	Inject spinal anesthetic	1.51	0.60	0.72	0.60	0.72	0.11	2.22	2.34	2.22	2.34	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
62279		D	Inject spinal anesthetic	1.58	0.63	0.70	0.63	0.70	0.11	2.32	2.39	2.32	2.39	000
62280		A	Treat spinal cord lesion	2.63	4.36	3.46	0.71	0.73	0.17	7.16	6.26	3.51	3.53	010
62281		A	Treat spinal cord lesion	2.66	3.46	2.83	0.58	0.67	0.18	6.30	5.67	3.42	3.51	010
62282		A	Treat spinal canal lesion	2.33	5.32	4.45	0.59	0.90	0.15	7.80	6.93	3.07	3.38	010
62284		A	Injection for myelogram	1.54	4.00	3.54	0.67	1.04	0.11	5.65	5.19	2.32	2.69	000
62287		A	Percutaneous diskectomy	8.08	NA	NA	4.88	5.55	0.83	NA	NA	13.79	14.46	090
62288		D	Injection into spinal canal	1.74	0.69	0.82	0.69	0.82	0.14	2.57	2.70	2.57	2.70	000
62289		D	Injection into spinal canal	1.64	0.65	0.78	0.65	0.78	0.11	2.40	2.53	2.40	2.53	000
62290		A	Inject for spine disk x-ray	0.03	4.16	3.63	1.30	1.48	0.21	4.40	3.87	1.54	1.72	000
62291		A	Inject for spine disk x-ray	2.91	5.21	4.39	1.13	1.33	0.21	8.33	7.51	4.25	4.45	000
62292		A	Injection into disk lesion	7.86	NA	NA	3.98	5.33	0.71	NA	NA	12.55	13.90	090
62294		A	Injection into spinal artery	11.83	NA	NA	6.37	6.36	0.68	NA	NA	18.88	18.87	090
62298		D	Injection into spinal canal	2.20	0.87	0.94	0.87	0.94	0.14	3.21	3.28	3.21	3.28	000
62310		A	Inject spine c/t	1.91	3.22	3.22	0.42	0.42	0.26	5.39	5.39	2.59	2.59	000
62311		A	Inject spine l/s (cd)	1.54	3.71	3.71	0.36	0.36	0.25	5.50	5.50	2.15	2.15	000
62318		A	Inject spine w/cath, c/t	2.04	3.28	3.28	0.45	0.45	0.32	5.64	5.64	2.81	2.81	000
62319		A	Inject spine w/cath l/s (cd)	1.87	3.26	3.26	0.39	0.39	0.28	5.41	5.41	2.54	2.54	000
62350		A	Implant spinal canal cath	6.87	NA	NA	3.38	3.48	0.67	NA	NA	10.92	11.02	090
62351		A	Implant spinal canal cath	0.10	NA	NA	6.49	6.27	1.61	NA	NA	8.20	7.98	090
62355		A	Remove spinal canal catheter	5.45	NA	NA	2.58	2.88	0.51	NA	NA	8.54	8.84	090
62360		A	Insert spine infusion device	2.62	NA	NA	1.93	1.75	0.23	NA	NA	4.78	4.60	090
62361		A	Implant spine infusion pump	5.42	NA	NA	2.93	2.93	0.54	NA	NA	8.89	8.89	090
62362		A	Implant spine infusion pump	7.04	NA	NA	3.83	3.83	0.86	NA	NA	11.73	11.73	090
62365		A	Remove spine infusion device	5.42	NA	NA	2.95	3.16	0.72	NA	NA	9.09	9.30	090
62367		C	Analyze spine infusion pump	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
62367	26	A	Analyze spine infusion pump	0.48	0.13	0.19	0.13	0.19	0.05	0.66	0.72	0.66	0.72	XXX
62367	TC	C	Analyze spine infusion pump	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
62368		C	Analyze spine infusion pump	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
62368	26	A	Analyze spine infusion pump	0.75	0.20	0.30	0.20	0.30	0.06	1.01	1.11	1.01	1.11	XXX
62368	TC	C	Analyze spine infusion pump	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
63001		A	Removal of spinal lamina	15.82	NA	NA	10.93	12.92	2.62	NA	NA	29.37	31.36	090
63003		A	Removal of spinal lamina	15.95	NA	NA	11.15	13.13	2.70	NA	NA	29.80	31.78	090
63005		A	Removal of spinal lamina	14.92	NA	NA	10.68	12.46	2.29	NA	NA	27.89	29.67	090
63011		A	Removal of spinal lamina	14.52	NA	NA	8.83	9.33	1.74	NA	NA	25.09	25.59	090
63012		A	Removal of spinal lamina	15.40	NA	NA	9.82	11.96	2.25	NA	NA	27.47	29.61	090
63015		A	Removal of spinal lamina	19.35	NA	NA	12.81	15.37	3.59	NA	NA	35.75	38.31	090
63016		A	Removal of spinal lamina	19.20	NA	NA	12.92	15.42	3.29	NA	NA	35.41	37.91	090
63017		A	Removal of spinal lamina	15.94	NA	NA	11.19	13.15	2.55	NA	NA	29.68	31.64	090
63020		A	Neck spine disk surgery	14.81	NA	NA	10.52	12.24	2.69	NA	NA	28.02	29.74	090
63030		A	Low back disk surgery	0.12	NA	NA	9.13	10.43	1.95	NA	NA	11.20	12.50	090
63035		A	Spinal disk surgery add-on	3.15	NA	NA	1.63	2.17	0.51	NA	NA	5.29	5.83	ZZZ
63040		A	Neck spine disk surgery	18.81	NA	NA	12.60	15.06	3.09	NA	NA	34.50	36.96	090
63042		A	Low back disk surgery	17.47	NA	NA	11.98	14.20	2.69	NA	NA	32.14	34.36	090
63045		A	Removal of spinal lamina	16.50	NA	NA	11.36	13.45	2.91	NA	NA	30.77	32.86	090
63046		A	Removal of spinal lamina	15.80	NA	NA	11.12	13.06	2.63	NA	NA	29.55	31.49	090
63047		A	Removal of spinal lamina	14.61	NA	NA	10.50	12.24	2.22	NA	NA	27.33	29.07	090
63048		A	Remove spinal lamina add-on	3.26	NA	NA	1.70	2.25	0.51	NA	NA	5.47	6.02	ZZZ
63055		A	Decompress spinal cord	21.99	NA	NA	14.25	17.13	3.94	NA	NA	40.18	43.06	090
63056		A	Decompress spinal cord	20.36	NA	NA	13.44	16.01	3.01	NA	NA	36.81	39.38	090
63057		A	Decompress spine cord add-on	5.26	NA	NA	2.65	3.03	0.86	NA	NA	8.77	9.15	ZZZ
63064		A	Decompress spinal cord	24.61	NA	NA	15.92	18.41	4.26	NA	NA	44.79	47.28	090
63066		A	Decompress spine cord add-on	3.26	NA	NA	1.65	1.91	0.53	NA	NA	5.44	5.70	ZZZ
63075		A	Neck spine disk surgery	19.41	NA	NA	12.94	14.47	3.38	NA	NA	35.73	37.26	090
63076		A	Neck spine disk surgery	4.05	NA	NA	2.09	2.78	0.70	NA	NA	6.84	7.53	ZZZ
63077		A	Spine disk surgery, thorax	21.44	NA	NA	14.55	15.91	2.72	NA	NA	38.71	40.07	090
63078		A	Spine disk surgery, thorax	3.28	NA	NA	1.69	1.98	0.40	NA	NA	5.37	5.66	ZZZ
63081		A	Removal of vertebral body	23.73	NA	NA	15.60	18.78	4.08	NA	NA	43.41	46.59	090
63082		A	Remove vertebral body add-on	4.37	NA	NA	2.27	3.01	0.74	NA	NA	7.38	8.12	ZZZ
63085		A	Removal of vertebral body	26.92	NA	NA	17.62	20.65	4.10	NA	NA	48.64	51.67	090
63086		A	Remove vertebral body add-on	3.19	NA	NA	1.63	2.18	0.49	NA	NA	5.31	5.86	ZZZ
63087		A	Removal of vertebral body	35.57	NA	NA	21.82	24.03	4.66	NA	NA	62.05	64.26	090
63088		A	Remove vertebral body add-on	4.33	NA	NA	2.25	2.98	0.61	NA	NA	7.19	7.92	ZZZ
63090		A	Removal of vertebral body	28.16	NA	NA	17.58	21.11	3.66	NA	NA	49.40	52.93	090
63091		A	Remove vertebral body add-on	3.03	NA	NA	1.54	1.90	0.37	NA	NA	4.94	5.30	ZZZ
63170		A	Incise spinal cord tract(s)	19.83	NA	NA	13.14	14.98	3.84	NA	NA	36.81	38.65	090
63172		A	Drainage of spinal cyst	17.66	NA	NA	12.50	14.65	3.36	NA	NA	33.52	35.67	090
63173		A	Drainage of spinal cyst	21.99	NA	NA	14.53	15.10	4.25	NA	NA	40.77	41.34	090
63180		A	Revise spinal cord ligaments	18.27	NA	NA	12.60	12.60	2.76	NA	NA	33.63	33.63	090
63182		A	Revise spinal cord ligaments	20.50	NA	NA	12.26	13.66	3.22	NA	NA	35.98	37.38	090
63185		A	Incise spinal column/nerves	15.04	NA	NA	9.08	11.03	2.43	NA	NA	26.55	28.50	090
63190		A	Incise spinal column/nerves	17.45	NA	NA	11.60	13.91	2.84	NA	NA	31.89	34.20	090
63191		A	Incise spinal column/nerves	17.54	NA	NA	10.76	11.61	2.78	NA	NA	31.08	31.93	090
63194		A	Incise spinal column & cord	19.19	NA	NA	12.06	12.58	3.89	NA	NA	35.14	35.66	090
63195		A	Incise spinal column & cord	18.84	NA	NA	12.39	13.05	3.71	NA	NA	34.94	35.60	090
63196		A	Incise spinal column & cord	22.30	NA	NA	11.82	13.10	4.52	NA	NA	38.64	39.92	090
63197		A	Incise spinal column & cord	21.11	NA	NA	12.24	13.08	4.27	NA	NA	37.62	38.46	090
63198		A	Incise spinal column & cord	25.38	NA	NA	10.42	12.24	5.14	NA	NA	40.94	42.76	090
63199		A	Incise spinal column & cord	26.89	NA	NA	16.23	17.98	4.52	NA	NA	47.64	49.39	090
63200		A	Release of spinal cord	19.18	NA	NA	12.71	12.92	3.23	NA	NA	35.12	35.33	090
63250		A	Revise spinal cord vessels	40.76	NA	NA	21.25	23.53	5.30	NA	NA	67.31	69.59	090
63251		A	Revise spinal cord vessels	41.20	NA	NA	22.47	23.02	7.84	NA	NA	71.51	72.06	090
63252		A	Revise spinal cord vessels	41.19	NA	NA	22.29	24.38	7.47	NA	NA	70.95	73.04	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
63265		A	Excise intraspinal lesion	21.56	NA	NA	12.65	15.46	4.01	NA	NA	38.22	41.03	090
63266		A	Excise intraspinal lesion	22.30	NA	NA	13.25	16.59	4.17	NA	NA	39.72	43.06	090
63267		A	Excise intraspinal lesion	17.95	NA	NA	10.97	13.59	3.14	NA	NA	32.06	34.68	090
63268		A	Excise intraspinal lesion	18.52	NA	NA	9.47	10.51	3.31	NA	NA	31.30	32.34	090
63270		A	Excise intraspinal lesion	26.80	NA	NA	15.44	16.50	5.33	NA	NA	47.57	48.63	090
63271		A	Excise intraspinal lesion	26.92	NA	NA	15.53	18.87	5.19	NA	NA	47.64	50.98	090
63272		A	Excise intraspinal lesion	25.32	NA	NA	14.59	17.22	4.72	NA	NA	44.63	47.26	090
63273		A	Excise intraspinal lesion	24.29	NA	NA	14.34	15.52	4.53	NA	NA	43.16	44.34	090
63275		A	Biopsy/excise spinal tumor	23.68	NA	NA	13.69	17.34	4.31	NA	NA	41.68	45.33	090
63276		A	Biopsy/excise spinal tumor	23.45	NA	NA	13.66	17.11	4.29	NA	NA	41.40	44.85	090
63277		A	Biopsy/excise spinal tumor	20.83	NA	NA	12.43	15.54	3.64	NA	NA	36.90	40.01	090
63278		A	Biopsy/excise spinal tumor	20.56	NA	NA	12.29	15.36	3.52	NA	NA	36.37	39.44	090
63280		A	Biopsy/excise spinal tumor	28.35	NA	NA	16.18	19.75	5.51	NA	NA	50.04	53.61	090
63281		A	Biopsy/excise spinal tumor	28.05	NA	NA	15.97	19.49	5.42	NA	NA	49.44	52.96	090
63282		A	Biopsy/excise spinal tumor	26.39	NA	NA	15.33	18.04	4.95	NA	NA	46.67	49.38	090
63283		A	Biopsy/excise spinal tumor	0.25	NA	NA	13.15	14.96	4.52	NA	NA	17.92	19.73	090
63285		A	Biopsy/excise spinal tumor	0.36	NA	NA	20.07	21.70	7.01	NA	NA	27.44	29.07	090
63286		A	Biopsy/excise spinal tumor	35.63	NA	NA	19.65	22.54	6.85	NA	NA	62.13	65.02	090
63287		A	Biopsy/excise spinal tumor	36.70	NA	NA	20.64	22.46	7.13	NA	NA	64.47	66.29	090
63290		A	Biopsy/excise spinal tumor	37.38	NA	NA	20.76	22.94	6.99	NA	NA	65.13	67.31	090
63300		A	Removal of vertebral body	24.43	NA	NA	14.23	15.36	4.35	NA	NA	43.01	44.14	090
63301		A	Removal of vertebral body	27.60	NA	NA	15.56	16.68	4.63	NA	NA	47.79	48.91	090
63302		A	Removal of vertebral body	27.81	NA	NA	15.88	17.71	4.56	NA	NA	48.25	50.08	090
63303		A	Removal of vertebral body	30.50	NA	NA	16.81	17.63	4.47	NA	NA	51.78	52.60	090
63304		A	Removal of vertebral body	30.33	NA	NA	17.38	18.82	6.14	NA	NA	53.85	55.29	090
63305		A	Removal of vertebral body	32.03	NA	NA	17.54	19.26	5.24	NA	NA	54.81	56.53	090
63306		A	Removal of vertebral body	32.22	NA	NA	17.96	19.65	5.44	NA	NA	55.62	57.31	090
63307		A	Removal of vertebral body	31.63	NA	NA	16.57	19.05	4.17	NA	NA	52.37	54.85	090
63308		A	Remove vertebral body add-on	5.25	NA	NA	2.63	3.07	0.86	NA	NA	8.74	9.18	ZZZ
63600		A	Remove spinal cord lesion	14.02	NA	NA	5.67	7.16	1.51	NA	NA	21.20	22.69	090
63610		A	Stimulation of spinal cord	8.73	NA	NA	3.15	4.19	0.54	NA	NA	12.42	13.46	000
63615		A	Remove lesion of spinal cord	16.28	NA	NA	9.65	10.37	3.14	NA	NA	29.07	29.79	090
63650		A	Implant neuroelectrodes	6.74	NA	NA	3.62	4.73	0.55	NA	NA	10.91	12.02	090
63655		A	Implant neuroelectrodes	10.29	NA	NA	6.79	8.17	1.75	NA	NA	18.83	20.21	090
63660		A	Revise/remove neuroelectrode	6.16	NA	NA	3.54	4.50	0.71	NA	NA	10.41	11.37	090
63685		A	Implant neuroreceiver	7.04	NA	NA	3.95	4.97	0.89	NA	NA	11.88	12.90	090
63688		A	Revise/remove neuroreceiver	5.39	NA	NA	3.23	4.03	0.73	NA	NA	9.35	10.15	090
63700		A	Repair of spinal herniation	16.53	NA	NA	10.18	10.72	2.48	NA	NA	29.19	29.73	090
63702		A	Repair of spinal herniation	18.48	NA	NA	11.60	12.17	3.04	NA	NA	33.12	33.69	090
63704		A	Repair of spinal herniation	21.18	NA	NA	12.09	12.92	3.87	NA	NA	37.14	37.97	090
63706		A	Repair of spinal herniation	24.11	NA	NA	13.90	14.86	2.61	NA	NA	40.62	41.58	090
63707		A	Repair spinal fluid leakage	11.26	NA	NA	7.60	9.06	1.78	NA	NA	20.64	22.10	090
63709		A	Repair spinal fluid leakage	14.32	NA	NA	9.24	11.20	2.18	NA	NA	25.74	27.70	090
63710		A	Graft repair of spine defect	14.07	NA	NA	8.98	9.38	2.49	NA	NA	25.54	25.94	090
63740		A	Install spinal shunt	11.36	NA	NA	7.38	8.93	2.15	NA	NA	20.89	22.44	090
63741		A	Install spinal shunt	8.25	NA	NA	4.63	5.94	1.28	NA	NA	14.16	15.47	090
63744		A	Revision of spinal shunt	8.10	NA	NA	5.35	6.22	1.41	NA	NA	14.86	15.73	090
63746		A	Removal of spinal shunt	6.43	NA	NA	3.61	4.21	0.73	NA	NA	10.77	11.37	090
64400		A	Injection for nerve block	1.11	2.10	1.71	0.26	0.33	0.09	3.30	2.91	1.46	1.53	000
64402		A	Injection for nerve block	1.25	3.65	2.91	0.45	0.51	0.08	4.98	4.24	1.78	1.84	000
64405		A	Injection for nerve block	1.32	2.26	1.87	0.30	0.40	0.12	3.70	3.31	1.74	1.84	000
64408		A	Injection for nerve block	1.41	2.39	2.08	0.59	0.73	0.13	3.93	3.62	2.13	2.27	000
64410		A	Injection for nerve block	1.43	2.32	1.93	0.30	0.42	0.09	3.84	3.45	1.82	1.94	000
64412		A	Injection for nerve block	1.18	2.63	2.14	0.25	0.36	0.10	3.91	3.42	1.53	1.64	000
64413		A	Injection for nerve block	1.40	2.47	2.05	0.37	0.48	0.11	3.98	3.56	1.88	1.99	000
64415		A	Injection for nerve block	1.48	2.66	2.07	0.31	0.30	0.11	4.25	3.66	1.90	1.89	000
64417		A	Injection for nerve block	1.44	2.26	1.87	0.32	0.41	0.11	3.81	3.42	1.87	1.96	000
64418		A	Injection for nerve block	1.32	2.13	1.83	0.28	0.44	0.10	3.55	3.25	1.70	1.86	000
64420		A	Injection for nerve block	1.18	2.18	1.81	0.27	0.38	0.08	3.44	3.07	1.53	1.64	000
64421		A	Injection for nerve block	1.68	2.51	2.11	0.37	0.50	0.11	4.30	3.90	2.16	2.29	000
64425		A	Injection for nerve block	1.75	2.15	1.77	0.40	0.46	0.12	4.02	3.64	2.27	2.33	000
64430		A	Injection for nerve block	1.46	2.58	2.13	0.42	0.51	0.10	4.14	3.69	1.98	2.07	000
64435		A	Injection for nerve block	1.45	2.71	2.16	0.52	0.52	0.11	4.27	3.72	2.08	2.08	000
64440		D	Injection for nerve block	1.34	0.53	0.61	0.53	0.61	0.10	1.97	2.05	1.97	2.05	000
64441		D	Injection for nerve block	1.79	0.71	0.81	0.71	0.81	0.12	2.62	2.72	2.62	2.72	000
64442		D	Injection for nerve block	1.41	0.56	0.74	0.56	0.74	0.11	2.08	2.26	2.08	2.26	000
64443		D	Inject, nerve block add-on	0.98	0.39	0.46	0.39	0.46	0.07	1.44	1.51	1.44	1.51	ZZZ
64445		A	Injection for nerve block	1.48	2.98	2.37	0.34	0.39	0.10	4.56	3.95	1.92	1.97	000
64450		A	Injection for nerve block	1.27	1.54	1.30	0.33	0.39	0.09	2.90	2.66	1.69	1.75	000
64470		A	Inj paravertebral c/t	1.85	3.62	3.62	0.50	0.50	0.12	5.59	5.59	2.47	2.47	000
64472		A	Inj paravertebral c/t add-on	1.29	3.29	3.29	0.37	0.37	0.09	4.67	4.67	1.75	1.75	ZZZ
64475		A	Inj paravertebral l/s	1.41	3.45	3.45	0.38	0.38	0.10	4.96	4.96	1.89	1.89	000
64476		A	Inj paravertebral l/s add-on	0.98	3.58	3.58	0.26	0.26	0.07	4.63	4.63	1.31	1.31	ZZZ
64479		A	Inj foramen epidural c/t	2.20	3.71	3.71	0.61	0.61	0.15	6.06	6.06	2.96	2.96	000
64480		A	Inj foramen epidural add-on	1.54	3.77	3.77	0.39	0.39	0.11	5.42	5.42	2.04	2.04	ZZZ
64483		A	Inj foramen epidural l/s	1.90	3.59	3.59	0.52	0.52	0.10	5.59	5.59	2.52	2.52	000
64484		A	Inj foramen epidural add-on	1.33	3.69	3.69	0.34	0.34	0.10	5.12	5.12	1.77	1.77	ZZZ
64505		A	Injection for nerve block	1.36	2.06	1.71	0.35	0.43	0.09	3.51	3.16	1.80	1.88	000
64508		A	Injection for nerve block	1.12	1.93	1.73	0.40	0.58	0.13	3.18	2.98	1.65	1.83	000
64510		A	Injection for nerve block	1.22	2.16	1.81	0.26	0.39	0.08	3.46	3.11	1.56	1.69	000
64520		A	Injection for nerve block	1.35	3.35	2.71	0.29	0.41	0.10	4.80	4.16	1.74	1.86	000
64530		A	Injection for nerve block	1.58	2.63	2.29	0.36	0.59	0.11	4.32	3.98	2.05	2.28	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
64550		A	Apply neurostimulator	0.18	0.47	0.47	0.05	0.16	0.01	0.66	0.66	0.24	0.35	000
64553		A	Implant neuroelectrodes	2.31	1.58	1.46	1.21	1.19	0.06	3.95	3.83	3.58	3.56	010
64555		A	Implant neuroelectrodes	2.27	2.10	1.69	0.52	0.51	0.16	4.53	4.12	2.95	2.94	010
64560		A	Implant neuroelectrodes	2.36	2.11	1.98	0.85	1.03	0.17	4.64	4.51	3.38	3.56	010
64565		A	Implant neuroelectrodes	1.76	2.27	1.91	0.56	0.63	0.13	4.16	3.80	2.45	2.52	010
64573		A	Implant neuroelectrodes	7.50	NA	NA	5.19	4.75	0.84	NA	NA	13.53	13.09	090
64575		A	Implant neuroelectrodes	4.35	NA	NA	3.30	3.31	0.68	NA	NA	8.33	8.34	090
64577		A	Implant neuroelectrodes	4.62	NA	NA	3.51	3.38	0.74	NA	NA	8.87	8.74	090
64580		A	Implant neuroelectrodes	4.12	NA	NA	3.50	3.42	0.38	NA	NA	8.00	7.92	090
64585		A	Revise/remove neuroelectrode	2.06	4.14	3.37	1.89	1.68	0.26	6.46	5.69	4.21	4.00	010
64590		A	Implant neuroreceiver	2.40	NA	NA	2.27	2.20	0.37	NA	NA	5.04	4.97	010
64595		A	Revise/remove neuroreceiver	1.73	NA	NA	1.95	1.77	0.14	NA	NA	3.82	3.64	010
64600		A	Injection treatment of nerve	3.45	3.01	2.72	1.92	1.90	0.34	6.80	6.51	5.71	5.69	010
64605		A	Injection treatment of nerve	5.61	3.48	3.03	2.44	2.25	0.43	9.52	9.07	8.48	8.29	010
64610		A	Injection treatment of nerve	7.16	NA	NA	4.01	4.98	1.28	NA	NA	12.45	13.42	010
64612		A	Destroy nerve, face muscle	1.96	2.62	2.36	1.58	1.58	0.14	4.72	4.46	3.68	3.68	010
64613		A	Destroy nerve, spine muscle	1.96	1.48	1.50	1.25	1.33	0.36	3.80	3.82	3.57	3.65	010
64620		A	Injection treatment of nerve	2.84	2.78	2.36	0.63	0.75	0.20	5.82	5.40	3.67	3.79	010
64622		A	Destr paravertebrl nerve l/s	0.03	4.03	3.52	0.73	1.04	0.21	4.27	3.76	0.97	1.28	010
64623		A	Destr paravertebral n add-on	0.99	3.01	2.49	0.24	0.41	0.07	4.07	3.55	1.30	1.47	ZZZ
64626		A	Destr paravertebrl nerve c/t	3.28	3.64	3.64	0.94	0.94	0.22	7.14	7.14	4.44	4.44	010
64627		A	Destr paravertebral n add-on	1.16	3.00	3.00	0.33	0.33	0.08	4.24	4.24	1.57	1.57	ZZZ
64630		A	Injection treatment of nerve	0.03	2.79	2.57	0.72	1.01	0.25	3.07	2.85	1.00	1.29	010
64640		A	Injection treatment of nerve	2.76	4.44	3.58	0.93	0.95	0.20	7.40	6.54	3.89	3.91	010
64680		A	Injection treatment of nerve	2.62	2.46	2.27	0.69	0.94	0.16	5.24	5.05	3.47	3.72	010
64702		A	Revise finger/toe nerve	4.23	NA	NA	3.63	3.87	0.44	NA	NA	8.30	8.54	090
64704		A	Revise hand/foot nerve	4.57	NA	NA	2.95	3.58	0.36	NA	NA	7.88	8.51	090
64708		A	Revise arm/leg nerve	6.12	NA	NA	4.69	5.34	0.66	NA	NA	11.47	12.12	090
64712		A	Revision of sciatic nerve	7.75	NA	NA	4.63	5.79	0.74	NA	NA	13.12	14.28	090
64713		A	Revision of arm nerve(s)	0.11	NA	NA	5.02	6.32	1.14	NA	NA	6.27	7.57	090
64714		A	Revise low back nerve(s)	10.33	NA	NA	3.77	4.49	0.78	NA	NA	14.88	15.60	090
64716		A	Revision of cranial nerve	6.31	NA	NA	4.65	4.80	0.59	NA	NA	11.55	11.70	090
64718		A	Revise ulnar nerve at elbow	5.99	NA	NA	4.81	5.40	0.74	NA	NA	11.54	12.13	090
64719		A	Revise ulnar nerve at wrist	4.85	NA	NA	4.28	4.55	0.53	NA	NA	9.66	9.93	090
64721		A	Carpal tunnel surgery	4.29	5.58	5.47	5.31	5.26	0.49	10.36	10.25	10.09	10.04	090
64722		A	Relieve pressure on nerve(s)	4.70	NA	NA	2.81	3.51	0.40	NA	NA	7.91	8.61	090
64726		A	Release foot/toe nerve	4.18	NA	NA	2.85	2.33	0.31	NA	NA	7.34	6.82	090
64727		A	Internal nerve revision	3.10	NA	NA	1.49	2.00	0.33	NA	NA	4.92	5.43	ZZZ
64732		A	Incision of brow nerve	4.41	NA	NA	3.36	3.69	0.75	NA	NA	8.52	8.85	090
64734		A	Incision of cheek nerve	4.92	NA	NA	3.30	3.73	0.72	NA	NA	8.94	9.37	090
64736		A	Incision of chin nerve	4.60	NA	NA	2.77	3.29	0.39	NA	NA	7.76	8.28	090
64738		A	Incision of jaw nerve	5.73	NA	NA	3.28	3.84	0.58	NA	NA	9.59	10.15	090
64740		A	Incision of tongue nerve	5.59	NA	NA	3.39	3.95	0.38	NA	NA	9.36	9.92	090
64742		A	Incision of facial nerve	6.22	NA	NA	4.51	4.74	0.53	NA	NA	11.26	11.49	090
64744		A	Incise nerve, back of head	5.24	NA	NA	3.50	4.19	0.92	NA	NA	9.66	10.35	090
64746		A	Incise diaphragm nerve	5.93	NA	NA	4.98	4.76	0.68	NA	NA	11.59	11.37	090
64752		A	Incision of vagus nerve	7.06	NA	NA	5.30	5.04	0.67	NA	NA	13.03	12.77	090
64755		A	Incision of stomach nerves	13.52	NA	NA	6.15	7.45	1.22	NA	NA	20.89	22.19	090
64760		A	Incision of vagus nerve	6.96	NA	NA	3.39	4.35	0.64	NA	NA	10.99	11.95	090
64761		A	Incision of pelvis nerve	6.41	NA	NA	3.68	4.03	0.44	NA	NA	10.53	10.88	090
64763		A	Incise hip/thigh nerve	6.93	NA	NA	5.18	5.19	0.71	NA	NA	12.82	12.83	090
64766		A	Incise hip/thigh nerve	8.67	NA	NA	5.11	5.64	1.34	NA	NA	15.12	15.65	090
64771		A	Sever cranial nerve	7.35	NA	NA	5.17	5.62	0.86	NA	NA	13.38	13.83	090
64772		A	Incision of spinal nerve	7.21	NA	NA	4.72	5.38	1.14	NA	NA	13.07	13.73	090
64774		A	Remove skin nerve lesion	5.17	NA	NA	3.54	3.40	0.52	NA	NA	9.23	9.09	090
64776		A	Remove digit nerve lesion	5.12	NA	NA	3.70	3.53	0.44	NA	NA	9.26	9.09	090
64778		A	Digit nerve surgery add-on	3.11	NA	NA	1.45	1.83	0.34	NA	NA	4.90	5.28	ZZZ
64782		A	Remove limb nerve lesion	6.23	NA	NA	3.47	3.88	0.45	NA	NA	10.15	10.56	090
64783		A	Limb nerve surgery add-on	3.72	NA	NA	1.85	2.27	0.37	NA	NA	5.94	6.36	ZZZ
64784		A	Remove nerve lesion	9.82	NA	NA	6.37	6.31	1.06	NA	NA	17.25	17.19	090
64786		A	Remove sciatic nerve lesion	15.46	NA	NA	9.79	10.78	1.93	NA	NA	27.18	28.17	090
64787		A	Implant nerve end	4.30	NA	NA	2.20	2.59	0.43	NA	NA	6.93	7.32	ZZZ
64788		A	Remove skin nerve lesion	4.61	NA	NA	3.22	3.40	0.49	NA	NA	8.32	8.50	090
64790		A	Removal of nerve lesion	11.31	NA	NA	6.84	7.06	1.47	NA	NA	19.62	19.84	090
64792		A	Removal of nerve lesion	14.92	NA	NA	8.43	8.76	1.97	NA	NA	25.32	25.65	090
64795		A	Biopsy of nerve	3.01	NA	NA	1.77	1.97	0.43	NA	NA	5.21	5.41	000
64802		A	Remove sympathetic nerves	9.15	NA	NA	6.02	5.98	1.03	NA	NA	16.20	16.16	090
64804		A	Remove sympathetic nerves	14.64	NA	NA	7.75	9.28	1.83	NA	NA	24.22	25.75	090
64809		A	Remove sympathetic nerves	13.67	NA	NA	6.71	7.90	1.68	NA	NA	22.06	23.25	090
64818		A	Remove sympathetic nerves	10.30	NA	NA	6.01	6.83	1.16	NA	NA	17.47	18.29	090
64820		A	Remove sympathetic nerves	10.37	NA	NA	7.51	7.61	1.08	NA	NA	18.96	19.06	090
64831		A	Repair of digit nerve	9.44	NA	NA	6.77	6.00	0.99	NA	NA	17.20	16.43	090
64832		A	Repair nerve add-on	5.66	NA	NA	3.03	2.65	0.59	NA	NA	9.28	8.90	ZZZ
64834		A	Repair of hand or foot nerve	10.19	NA	NA	6.82	6.07	1.06	NA	NA	18.07	17.32	090
64835		A	Repair of hand or foot nerve	10.94	NA	NA	7.51	7.25	1.14	NA	NA	19.59	19.33	090
64836		A	Repair of hand or foot nerve	10.94	NA	NA	7.50	7.44	1.17	NA	NA	19.61	19.55	090
64837		A	Repair nerve add-on	6.26	NA	NA	3.16	3.58	0.65	NA	NA	10.07	10.49	ZZZ
64840		A	Repair of leg nerve	13.02	NA	NA	8.76	9.38	1.03	NA	NA	22.81	23.43	090
64856		A	Repair/transpose nerve	13.80	NA	NA	8.98	8.96	1.52	NA	NA	24.30	24.28	090
64857		A	Repair arm/leg nerve	14.49	NA	NA	9.50	9.71	1.54	NA	NA	25.53	25.74	090
64858		A	Repair sciatic nerve	16.49	NA	NA	9.97	10.46	2.38	NA	NA	28.84	29.33	090
64859		A	Nerve surgery	4.26	NA	NA	2.27	2.65	0.45	NA	NA	6.98	7.36	ZZZ

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
64861		A	Repair of arm nerves	19.24	NA	NA	12.35	12.90	1.68	NA	NA	33.27	33.82	090
64862		A	Repair of low back nerves	19.44	NA	NA	11.27	14.30	3.93	NA	NA	34.64	37.67	090
64864		A	Repair of facial nerve	12.55	NA	NA	9.35	9.15	1.12	NA	NA	23.02	22.82	090
64865		A	Repair of facial nerve	15.24	NA	NA	10.71	11.38	1.37	NA	NA	27.32	27.99	090
64866		A	Fusion of facial/other nerve	15.74	NA	NA	10.98	11.27	1.42	NA	NA	28.14	28.43	090
64868		A	Fusion of facial/other nerve	14.04	NA	NA	10.55	10.95	1.62	NA	NA	26.21	26.61	090
64870		A	Fusion of facial/other nerve	15.99	NA	NA	9.58	10.96	1.71	NA	NA	27.28	28.66	090
64872		A	Subsequent repair of nerve	1.99	NA	NA	1.11	1.22	0.22	NA	NA	3.32	3.43	ZZZ
64874		A	Repair & revise nerve add-on	2.98	NA	NA	1.47	1.69	0.32	NA	NA	4.77	4.99	ZZZ
64876		A	Repair nerve/shorten bone	3.38	NA	NA	1.34	1.67	0.37	NA	NA	5.09	5.42	ZZZ
64885		A	Nerve graft, head or neck	17.53	NA	NA	11.23	11.87	1.47	NA	NA	30.23	30.87	090
64886		A	Nerve graft, head or neck	20.75	NA	NA	13.47	14.21	1.74	NA	NA	35.96	36.70	090
64890		A	Nerve graft, hand or foot	15.15	NA	NA	11.58	12.01	1.57	NA	NA	28.30	28.73	090
64891		A	Nerve graft, hand or foot	16.14	NA	NA	11.15	11.19	1.54	NA	NA	28.83	28.87	090
64892		A	Nerve graft, arm or leg	14.65	NA	NA	9.04	9.78	1.74	NA	NA	25.43	26.17	090
64893		A	Nerve graft, arm or leg	15.60	NA	NA	9.64	11.01	2.41	NA	NA	27.65	29.02	090
64895		A	Nerve graft, hand or foot	19.25	NA	NA	13.16	13.44	1.81	NA	NA	34.22	34.50	090
64896		A	Nerve graft, hand or foot	20.49	NA	NA	13.13	14.60	2.18	NA	NA	35.80	37.27	090
64897		A	Nerve graft, arm or leg	18.24	NA	NA	11.21	11.84	1.91	NA	NA	31.36	31.99	090
64898		A	Nerve graft, arm or leg	19.50	NA	NA	12.61	13.37	1.97	NA	NA	34.08	34.84	090
64901		A	Nerve graft add-on	10.22	NA	NA	5.56	6.93	1.02	NA	NA	16.80	18.17	ZZZ
64902		A	Nerve graft add-on	11.83	NA	NA	5.81	7.59	1.07	NA	NA	18.71	20.49	ZZZ
64905		A	Nerve pedicle transfer	14.02	NA	NA	8.70	9.08	1.02	NA	NA	23.74	24.12	090
64907		A	Nerve pedicle transfer	18.83	NA	NA	11.86	12.43	1.97	NA	NA	32.66	33.23	090
64999		C	Nervous system surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
65091		A	Revise eye	6.46	NA	NA	9.51	9.06	0.27	NA	NA	16.24	15.79	090
65093		A	Revise eye with implant	6.87	NA	NA	9.66	9.30	0.28	NA	NA	16.81	16.45	090
65101		A	Removal of eye	7.03	NA	NA	9.87	9.50	0.30	NA	NA	17.20	16.83	090
65103		A	Remove eye/insert implant	7.57	NA	NA	9.90	9.69	0.30	NA	NA	17.77	17.56	090
65105		A	Remove eye/attach implant	8.49	NA	NA	10.42	10.35	0.33	NA	NA	19.24	19.17	090
65110		A	Removal of eye	13.95	NA	NA	13.21	14.07	0.68	NA	NA	27.84	28.70	090
65112		A	Remove eye/revise socket	16.38	NA	NA	15.27	14.75	1.19	NA	NA	32.84	32.32	090
65114		A	Remove eye/revise socket	17.53	NA	NA	15.13	14.89	0.82	NA	NA	33.48	33.24	090
65125		A	Revise ocular implant	3.12	4.76	4.24	1.53	1.82	0.16	8.04	7.52	4.81	5.10	090
65130		A	Insert ocular implant	7.15	NA	NA	9.61	9.34	0.30	NA	NA	17.06	16.79	090
65135		A	Insert ocular implant	7.33	NA	NA	9.42	8.54	0.31	NA	NA	17.06	16.18	090
65140		A	Attach ocular implant	8.02	NA	NA	10.08	9.25	0.32	NA	NA	18.42	17.59	090
65150		A	Revise ocular implant	6.26	NA	NA	8.93	8.57	0.25	NA	NA	15.44	15.08	090
65155		A	Reinsert ocular implant	8.66	NA	NA	10.99	10.83	0.40	NA	NA	20.05	19.89	090
65175		A	Removal of ocular implant	6.28	NA	NA	9.04	8.66	0.25	NA	NA	15.57	15.19	090
65205		A	Remove foreign body from eye	0.71	5.10	3.93	0.20	0.25	0.04	5.85	4.68	0.95	1.00	000
65210		A	Remove foreign body from eye	0.84	5.26	4.07	0.30	0.35	0.04	6.14	4.95	1.18	1.23	000
65220		A	Remove foreign body from eye	0.71	6.81	5.25	0.19	0.28	0.06	7.58	6.02	0.96	1.05	000
65222		A	Remove foreign body from eye	0.93	5.21	4.06	0.27	0.36	0.04	6.18	5.03	1.24	1.33	000
65235		A	Remove foreign body from eye	7.57	NA	NA	6.79	6.62	0.32	NA	NA	14.68	14.51	090
65260		A	Remove foreign body from eye	10.96	NA	NA	11.60	11.04	0.42	NA	NA	22.98	22.42	090
65265		A	Remove foreign body from eye	12.59	NA	NA	13.36	12.75	0.50	NA	NA	26.45	25.84	090
65270		A	Repair of eye wound	1.90	3.47	2.92	2.06	1.86	0.08	5.45	4.90	4.04	3.84	010
65272		A	Repair of eye wound	3.82	5.06	4.24	4.10	3.52	0.15	9.03	8.21	8.07	7.49	090
65273		A	Repair of eye wound	4.36	NA	NA	4.48	4.23	0.17	NA	NA	9.01	8.76	090
65275		A	Repair of eye wound	5.34	4.96	3.90	4.39	3.47	0.27	10.57	9.51	10.00	9.08	090
65280		A	Repair of eye wound	7.66	NA	NA	7.28	7.75	0.30	NA	NA	15.24	15.71	090
65285		A	Repair of eye wound	12.90	NA	NA	13.49	13.45	0.51	NA	NA	26.90	26.86	090
65286		A	Repair of eye wound	5.51	7.87	7.20	6.72	6.34	0.22	13.60	12.93	12.45	12.07	090
65290		A	Repair of eye socket wound	5.41	NA	NA	6.06	6.16	0.22	NA	NA	11.69	11.79	090
65400		A	Removal of eye lesion	6.06	7.21	7.16	6.02	6.27	0.24	13.51	13.46	12.32	12.57	090
65410		A	Biopsy of cornea	1.47	1.71	1.72	0.70	0.96	0.06	3.24	3.25	2.23	2.49	000
65420		A	Removal of eye lesion	4.17	7.11	6.49	6.03	5.68	0.16	11.44	10.82	10.36	10.01	090
65426		A	Removal of eye lesion	5.25	7.24	7.00	6.14	6.17	0.21	12.70	12.46	11.60	11.63	090
65430		A	Corneal smear	1.47	5.77	4.48	0.70	0.67	0.06	7.30	6.01	2.23	2.20	000
65435		A	Curette/treat cornea	0.92	1.34	1.22	0.42	0.53	0.04	2.30	2.18	1.38	1.49	000
65436		A	Curette/treat cornea	4.19	5.20	4.32	4.27	3.62	0.16	9.55	8.67	8.62	7.97	090
65450		A	Treatment of corneal lesion	3.27	6.87	6.04	5.61	5.10	0.12	10.26	9.43	9.00	8.49	090
65600		A	Revision of cornea	3.40	4.82	4.33	1.54	1.87	0.14	8.36	7.87	5.08	5.41	090
65710		A	Corneal transplant	12.35	NA	NA	12.32	12.62	0.49	NA	NA	25.16	25.46	090
65730		A	Corneal transplant	14.25	NA	NA	13.79	14.45	0.55	NA	NA	28.59	29.25	090
65750		A	Corneal transplant	0.15	NA	NA	14.19	15.01	0.58	NA	NA	14.92	15.74	090
65755		A	Corneal transplant	14.89	NA	NA	12.87	14.02	0.58	NA	NA	28.34	29.49	090
65760		N	Revision of cornea	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
65765		N	Revision of cornea	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
65767		N	Corneal tissue transplant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
65770		A	Revise cornea with implant	17.56	NA	NA	15.04	15.03	0.69	NA	NA	33.29	33.28	090
65771		N	Radial keratotomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
65772		A	Correction of astigmatism	4.29	5.92	5.72	5.32	5.27	0.17	10.38	10.18	9.78	9.73	090
65775		A	Correction of astigmatism	5.79	NA	NA	7.37	7.26	0.23	NA	NA	13.39	13.28	090
65800		A	Drainage of eye	1.91	2.04	2.00	1.39	1.51	0.08	4.03	3.99	3.38	3.50	000
65805		A	Drainage of eye	1.91	2.04	2.02	1.39	1.53	0.08	4.03	4.01	3.38	3.52	000
65810		A	Drainage of eye	4.87	NA	NA	7.40	7.01	0.19	NA	NA	12.46	12.07	090
65815		A	Drainage of eye	5.05	8.08	7.28	6.93	6.42	0.20	13.33	12.53	12.18	11.67	090
65820		A	Relieve inner eye pressure	8.13	NA	NA	9.40	9.64	0.32	NA	NA	17.85	18.09	090
65850		A	Incision of eye	10.52	NA	NA	9.59	10.33	0.41	NA	NA	20.52	21.26	090
65855		A	Laser surgery of eye	4.30	4.31	4.86	3.28	4.09	0.17	8.78	9.33	7.75	8.56	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
65860		A	Incise inner eye adhesions	3.55	3.83	3.93	2.99	3.30	0.14	7.52	7.62	6.68	6.99	090
65865		A	Incise inner eye adhesions	5.60	NA	NA	6.28	6.38	0.22	NA	NA	12.10	12.20	090
65870		A	Incise inner eye adhesions	6.27	NA	NA	6.62	6.56	0.25	NA	NA	13.14	13.08	090
65875		A	Incise inner eye adhesions	6.54	NA	NA	6.74	6.76	0.26	NA	NA	13.54	13.56	090
65880		A	Incise inner eye adhesions	7.09	NA	NA	6.98	7.09	0.28	NA	NA	14.35	14.46	090
65900		A	Remove eye lesion	10.93	NA	NA	11.68	10.91	0.48	NA	NA	23.09	22.32	090
65920		A	Remove implant from eye	8.40	NA	NA	7.63	7.99	0.33	NA	NA	16.36	16.72	090
65930		A	Remove blood clot from eye	7.44	NA	NA	8.12	8.17	0.29	NA	NA	15.85	15.90	090
66020		A	Injection treatment of eye	1.59	2.30	2.20	1.49	1.59	0.07	3.96	3.86	3.15	3.25	010
66030		A	Injection treatment of eye	1.25	2.13	1.75	1.32	1.14	0.05	3.43	3.05	2.62	2.44	010
66130		A	Remove eye lesion	7.69	6.85	6.57	5.97	5.91	0.31	14.85	14.57	13.97	13.91	090
66150		A	Glaucoma surgery	8.30	NA	NA	8.55	8.89	0.32	NA	NA	17.17	17.51	090
66155		A	Glaucoma surgery	8.29	NA	NA	8.49	8.84	0.32	NA	NA	17.10	17.45	090
66160		A	Glaucoma surgery	10.17	NA	NA	9.99	10.42	0.41	NA	NA	20.57	21.00	090
66165		A	Glaucoma surgery	8.01	NA	NA	8.86	9.04	0.32	NA	NA	17.19	17.37	090
66170		A	Glaucoma surgery	12.16	NA	NA	11.02	11.56	0.48	NA	NA	23.66	24.20	090
66172		A	Incision of eye	15.04	NA	NA	12.79	12.89	0.59	NA	NA	28.42	28.52	090
66180		A	Implant eye shunt	14.55	NA	NA	12.25	13.53	0.57	NA	NA	27.37	28.65	090
66185		A	Revise eye shunt	8.14	NA	NA	8.41	8.74	0.32	NA	NA	16.87	17.20	090
66220		A	Repair eye lesion	7.77	NA	NA	10.07	9.17	0.32	NA	NA	18.16	17.26	090
66225		A	Repair/graft eye lesion	11.05	NA	NA	9.69	10.57	0.43	NA	NA	21.17	22.05	090
66250		A	Follow-up surgery of eye	5.98	7.20	7.19	5.98	6.27	0.24	13.42	13.41	12.20	12.49	090
66500		A	Incision of iris	3.71	NA	NA	4.07	4.16	0.14	NA	NA	7.92	8.01	090
66505		A	Incision of iris	4.08	NA	NA	4.18	4.02	0.16	NA	NA	8.42	8.26	090
66600		A	Remove iris and lesion	8.68	NA	NA	9.15	9.40	0.34	NA	NA	18.17	18.42	090
66605		A	Removal of iris	12.79	NA	NA	12.30	12.45	0.53	NA	NA	25.62	25.77	090
66625		A	Removal of iris	5.13	7.37	7.06	6.97	6.76	0.20	12.70	12.39	12.30	12.09	090
66630		A	Removal of iris	6.16	NA	NA	8.01	7.85	0.24	NA	NA	14.41	14.25	090
66635		A	Removal of iris	6.25	NA	NA	6.13	6.47	0.25	NA	NA	12.63	12.97	090
66680		A	Repair iris & ciliary body	5.44	NA	NA	5.71	5.91	0.21	NA	NA	11.36	11.56	090
66682		A	Repair iris & ciliary body	6.21	NA	NA	8.04	7.88	0.24	NA	NA	14.49	14.33	090
66700		A	Destruction, ciliary body	4.78	7.63	7.15	6.35	6.19	0.20	12.61	12.13	11.33	11.17	090
66710		A	Destruction, ciliary body	4.78	7.66	7.17	6.35	6.19	0.19	12.63	12.14	11.32	11.16	090
66720		A	Destruction, ciliary body	4.78	7.40	6.98	6.32	6.17	0.20	12.38	11.96	11.30	11.15	090
66740		A	Destruction, ciliary body	4.78	NA	NA	5.89	5.85	0.19	NA	NA	10.86	10.82	090
66761		A	Revision of iris	4.07	4.37	4.49	3.59	3.91	0.16	8.60	8.72	7.82	8.14	090
66762		A	Revision of iris	4.58	4.49	4.74	3.77	4.20	0.18	9.25	9.50	8.53	8.96	090
66770		A	Removal of inner eye lesion	5.18	4.77	5.13	4.06	4.59	0.20	10.15	10.51	9.44	9.97	090
66820		A	Incision, secondary cataract	3.89	NA	NA	6.90	6.34	0.15	NA	NA	10.94	10.38	090
66821		A	After cataract laser surgery	2.35	3.06	3.00	2.43	2.53	0.10	5.51	5.45	4.88	4.98	090
66825		A	Reposition intraocular lens	8.23	NA	NA	9.01	8.75	0.32	NA	NA	17.56	17.30	090
66830		A	Removal of lens lesion	8.20	NA	NA	6.37	6.86	0.32	NA	NA	14.89	15.38	090
66840		A	Removal of lens material	7.91	NA	NA	6.26	7.06	0.32	NA	NA	14.49	15.29	090
66850		A	Removal of lens material	9.11	NA	NA	6.80	7.82	0.36	NA	NA	16.27	17.29	090
66852		A	Removal of lens material	9.97	NA	NA	7.29	8.45	0.39	NA	NA	17.65	18.81	090
66920		A	Extraction of lens	8.86	NA	NA	6.71	7.68	0.35	NA	NA	15.92	16.89	090
66930		A	Extraction of lens	10.18	NA	NA	8.73	9.39	0.40	NA	NA	19.31	19.97	090
66940		A	Extraction of lens	8.93	NA	NA	8.11	8.75	0.35	NA	NA	17.39	18.03	090
66983		A	Remove cataract/insert lens	8.99	NA	NA	5.17	6.56	0.49	NA	NA	14.65	16.04	090
66984		A	Remove cataract/insert lens	10.28	NA	NA	7.15	8.43	0.43	NA	NA	17.86	19.14	090
66985		A	Insert lens prosthesis	8.39	NA	NA	6.37	7.28	0.34	NA	NA	15.10	16.01	090
66986		A	Exchange lens prosthesis	12.28	NA	NA	8.37	9.59	0.49	NA	NA	21.14	22.36	090
66999		C	Eye surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
67005		A	Partial removal of eye fluid	5.70	NA	NA	2.77	3.78	0.22	NA	NA	8.69	9.70	090
67010		A	Partial removal of eye fluid	6.87	NA	NA	3.35	4.56	0.27	NA	NA	10.49	11.70	090
67015		A	Release of eye fluid	6.92	NA	NA	7.77	7.58	0.27	NA	NA	14.96	14.77	090
67025		A	Replace eye fluid	6.84	14.66	12.83	7.24	7.26	0.27	21.77	19.94	14.35	14.37	090
67027		A	Implant eye drug system	10.85	16.52	14.84	9.18	9.34	0.42	27.79	26.11	20.45	20.61	090
67028		A	Injection eye drug	2.52	7.78	6.71	1.22	1.79	0.10	10.40	9.33	3.84	4.41	000
67030		A	Incise inner eye strands	4.84	NA	NA	6.85	6.58	0.19	NA	NA	11.88	11.61	090
67031		A	Laser surgery, eye strands	3.67	3.91	4.03	3.07	3.40	0.14	7.72	7.84	6.88	7.21	090
67036		A	Removal of inner eye fluid	11.89	NA	NA	8.19	9.69	0.47	NA	NA	20.55	22.05	090
67038		A	Strip retinal membrane	21.24	NA	NA	14.31	17.07	0.83	NA	NA	36.38	39.14	090
67039		A	Laser treatment of retina	14.52	NA	NA	11.69	13.10	0.56	NA	NA	26.77	28.18	090
67040		A	Laser treatment of retina	17.23	NA	NA	13.01	14.90	0.68	NA	NA	30.92	32.81	090
67101		A	Repair detached retina	7.53	10.72	10.29	8.67	8.75	0.30	18.55	18.12	16.50	16.58	090
67105		A	Repair detached retina	7.41	7.49	8.10	5.58	6.67	0.29	15.19	15.80	13.28	14.37	090
67107		A	Repair detached retina	14.84	NA	NA	13.04	14.21	0.58	NA	NA	28.46	29.63	090
67108		A	Repair detached retina	20.82	NA	NA	17.33	19.21	0.81	NA	NA	38.96	40.84	090
67110		A	Repair detached retina	8.81	18.21	16.29	10.08	10.19	0.34	27.36	25.44	19.23	19.34	090
67112		A	Rerepair detached retina	16.86	NA	NA	15.40	16.03	0.66	NA	NA	32.92	33.55	090
67115		A	Release encircling material	4.99	NA	NA	6.45	6.33	0.19	NA	NA	11.63	11.51	090
67120		A	Remove eye implant material	5.98	14.12	12.38	6.82	6.90	0.24	20.34	18.60	13.04	13.12	090
67121		A	Remove eye implant material	10.67	NA	NA	11.58	11.24	0.42	NA	NA	22.67	22.33	090
67141		A	Treatment of retina	5.20	7.65	7.29	6.60	6.50	0.20	13.05	12.69	12.00	11.90	090
67145		A	Treatment of retina	5.37	5.24	5.69	4.18	4.90	0.21	10.82	11.27	9.76	10.48	090
67208		A	Treatment of retinal lesion	6.70	8.03	8.02	6.84	7.13	0.26	14.99	14.98	13.80	14.09	090
67210		A	Treatment of retinal lesion	8.82	7.27	7.90	5.85	6.84	0.34	16.43	17.06	15.01	16.00	090
67218		A	Treatment of retinal lesion	13.52	NA	NA	12.19	12.75	0.53	NA	NA	26.24	26.80	090
67220		N	Treatment of choroid lesion	13.13	6.66	6.66	6.60	6.60	0.52	20.31	20.31	20.25	20.25	090
67227		A	Treatment of retinal lesion	6.58	8.46	8.31	6.86	7.11	0.27	15.31	15.16	13.71	13.96	090
67228		A	Treatment of retinal lesion	12.74	9.91	9.98	7.40	8.10	0.50	23.15	23.22	20.64	21.34	090

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
67250		A	Reinforce eye wall	8.66	NA	NA	10.24	9.58	0.39	NA	NA	19.29	18.63	090
67255		A	Reinforce/graft eye wall	8.90	NA	NA	9.83	10.03	0.35	NA	NA	19.08	19.28	090
67299		C	Eye surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
67311		A	Revise eye muscle	6.65	NA	NA	6.39	6.78	0.27	NA	NA	13.31	13.70	090
67312		A	Revise two eye muscles	8.54	NA	NA	7.34	8.05	0.33	NA	NA	16.21	16.92	090
67314		A	Revise eye muscle	7.52	NA	NA	6.81	7.35	0.30	NA	NA	14.63	15.17	090
67316		A	Revise two eye muscles	9.66	NA	NA	7.38	8.32	0.38	NA	NA	17.42	18.36	090
67318		A	Revise eye muscle(s)	7.85	NA	NA	7.22	7.10	0.31	NA	NA	15.38	15.26	090
67320		A	Revise eye muscle(s) add-on	4.33	NA	NA	6.84	7.72	0.17	NA	NA	11.34	12.22	ZZZ
67331		A	Eye surgery follow-up add-on	4.06	NA	NA	5.18	6.31	0.16	NA	NA	9.40	10.53	ZZZ
67332		A	Rerevise eye muscles add-on	4.49	NA	NA	5.90	7.11	0.18	NA	NA	10.57	11.78	ZZZ
67334		A	Revise eye muscle w/suture	3.98	NA	NA	5.45	5.80	0.15	NA	NA	9.58	9.93	ZZZ
67335		A	Eye suture during surgery	2.49	NA	NA	1.20	1.64	0.10	NA	NA	3.79	4.23	ZZZ
67340		A	Revise eye muscle add-on	4.93	NA	NA	6.30	6.86	0.20	NA	NA	11.43	11.99	ZZZ
67343		A	Release eye tissue	7.35	NA	NA	7.13	6.93	0.29	NA	NA	14.77	14.57	090
67345		A	Destroy nerve of eye muscle	2.96	4.01	3.61	1.42	1.67	0.27	7.24	6.84	4.65	4.90	010
67350		A	Biopsy eye muscle	2.87	NA	NA	2.49	2.52	0.12	NA	NA	5.48	5.51	000
67399		C	Eye muscle surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
67400		A	Explore/biopsy eye socket	9.76	NA	NA	10.99	11.16	0.43	NA	NA	21.18	21.35	090
67405		A	Explore/drain eye socket	7.93	NA	NA	9.58	9.55	0.39	NA	NA	17.90	17.87	090
67412		A	Explore/treat eye socket	9.50	NA	NA	12.32	12.08	0.41	NA	NA	22.23	21.99	090
67413		A	Explore/treat eye socket	0.10	NA	NA	10.94	10.40	0.49	NA	NA	11.53	10.99	090
67414		A	Explr/decompress eye socket	11.13	NA	NA	13.25	12.22	0.52	NA	NA	24.90	23.87	090
67415		A	Aspiration, orbital contents	1.76	NA	NA	0.80	1.13	0.09	NA	NA	2.65	2.98	000
67420		A	Explore/treat eye socket	20.06	NA	NA	17.90	17.98	1.07	NA	NA	39.03	39.11	090
67430		A	Explore/treat eye socket	13.39	NA	NA	15.11	14.22	0.59	NA	NA	29.09	28.20	090
67440		A	Explore/drain eye socket	13.09	NA	NA	13.67	14.16	0.54	NA	NA	27.30	27.79	090
67445		A	Explr/decompress eye socket	14.42	NA	NA	14.50	13.90	0.61	NA	NA	29.53	28.93	090
67450		A	Explore/biopsy eye socket	13.51	NA	NA	14.35	14.80	0.66	NA	NA	28.52	28.97	090
67500		A	Inject/treat eye socket	0.79	2.24	1.88	0.20	0.35	0.05	3.08	2.72	1.04	1.19	000
67505		A	Inject/treat eye socket	0.82	0.91	0.97	0.21	0.44	0.04	1.77	1.83	1.07	1.30	000
67515		A	Inject/treat eye socket	0.61	0.70	0.68	0.30	0.38	0.03	1.34	1.32	0.94	1.02	000
67550		A	Insert eye socket implant	10.19	NA	NA	10.23	10.28	0.49	NA	NA	20.91	20.96	090
67560		A	Revise eye socket implant	10.60	NA	NA	10.48	10.11	0.48	NA	NA	21.56	21.19	090
67570		A	Decompress optic nerve	13.58	NA	NA	13.96	12.52	0.81	NA	NA	28.35	26.91	090
67599		C	Orbit surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
67700		A	Drainage of eyelid abscess	35	5.11	3.97	0.60	0.58	0.06	6.52	5.38	2.01	1.99	010
67710		A	Incision of eyelid	1.02	5.22	4.19	0.50	0.65	0.04	6.28	5.25	1.56	1.71	010
67715		A	Incision of eyelid fold	1.22	NA	NA	0.60	0.81	0.05	NA	NA	1.87	2.08	010
67800		A	Remove eyelid lesion	1.38	5.25	4.19	0.67	0.76	0.06	6.69	5.63	2.11	2.20	010
67801		A	Remove eyelid lesions	1.88	5.47	4.48	0.92	1.07	0.08	7.43	6.44	2.88	3.03	010
67805		A	Remove eyelid lesions	2.22	5.74	4.68	1.08	1.19	0.09	8.05	6.99	3.39	3.50	010
67808		A	Remove eyelid lesion(s)	3.80	NA	NA	3.41	3.14	0.16	NA	NA	7.37	7.10	090
67810		A	Biopsy of eyelid	1.48	4.18	3.36	0.72	0.76	0.06	5.72	4.90	2.26	2.30	000
67820		A	Revise eyelashes	0.89	1.43	1.18	0.38	0.39	0.04	2.36	2.11	1.31	1.32	000
67825		A	Revise eyelashes	1.38	6.51	5.13	1.51	1.38	0.06	7.95	6.57	2.95	2.82	010
67830		A	Revise eyelashes	1.70	7.77	6.40	1.77	1.90	0.07	9.54	8.17	3.54	3.67	010
67835		A	Revise eyelashes	5.56	NA	NA	4.07	4.71	0.23	NA	NA	9.86	10.50	090
67840		A	Remove eyelid lesion	2.04	5.51	4.46	0.99	1.07	0.09	7.64	6.59	3.12	3.20	010
67850		A	Treat eyelid lesion	1.69	6.87	5.38	1.83	1.60	0.07	8.63	7.14	3.59	3.36	010
67875		A	Closure of eyelid by suture	1.35	7.38	6.00	1.58	1.65	0.06	8.79	7.41	2.99	3.06	000
67880		A	Revision of eyelid	3.80	8.92	7.76	2.83	3.19	0.15	12.87	11.71	6.78	7.14	090
67882		A	Revision of eyelid	5.07	11.35	10.03	4.05	4.55	0.21	16.63	15.31	9.33	9.83	090
67900		A	Repair brow defect	6.14	8.86	7.67	6.58	5.96	0.30	15.30	14.11	13.02	12.40	090
67901		A	Repair eyelid defect	6.97	NA	NA	8.46	8.43	0.34	NA	NA	15.77	15.74	090
67902		A	Repair eyelid defect	7.03	NA	NA	6.60	7.05	0.32	NA	NA	13.95	14.40	090
67903		A	Repair eyelid defect	6.37	9.22	8.82	9.22	8.82	0.40	15.99	15.59	15.99	15.59	090
67904		A	Repair eyelid defect	6.26	12.49	11.24	7.32	7.36	0.27	19.02	17.77	13.85	13.89	090
67906		A	Repair eyelid defect	6.79	8.77	8.06	8.39	7.78	0.27	15.83	15.12	15.45	14.84	090
67908		A	Repair eyelid defect	5.13	8.37	7.81	6.10	6.11	0.20	13.70	13.14	11.43	11.44	090
67909		A	Revise eyelid defect	5.40	8.13	7.71	6.00	6.11	0.24	13.77	13.35	11.64	11.75	090
67911		A	Revise eyelid defect	5.27	NA	NA	6.46	6.42	0.24	NA	NA	11.97	11.93	090
67914		A	Repair eyelid defect	3.68	8.93	7.80	3.03	3.37	0.15	12.76	11.63	6.86	7.20	090
67915		A	Repair eyelid defect	3.18	7.86	6.24	1.53	1.49	0.12	11.16	9.54	4.83	4.79	090
67916		A	Repair eyelid defect	5.31	12.81	11.19	4.98	5.32	0.23	18.35	16.73	10.52	10.86	090
67917		A	Repair eyelid defect	6.02	9.21	8.70	6.31	6.53	0.26	15.49	14.98	12.59	12.81	090
67921		A	Repair eyelid defect	3.40	8.59	7.46	2.80	3.12	0.13	12.12	10.99	6.33	6.65	090
67922		A	Repair eyelid defect	3.06	7.91	6.26	2.64	2.30	0.12	11.09	9.44	5.82	5.48	090
67923		A	Repair eyelid defect	5.88	12.25	10.94	4.89	5.42	0.24	18.37	17.06	11.01	11.54	090
67924		A	Repair eyelid defect	5.79	8.01	7.74	5.80	6.08	0.24	14.04	13.77	11.83	12.11	090
67930		A	Repair eyelid wound	3.61	9.17	7.22	2.63	2.32	0.16	12.94	10.99	6.40	6.09	010
67935		A	Repair eyelid wound	6.22	13.33	11.03	5.17	4.91	0.30	19.85	17.55	11.69	11.43	090
67938		A	Remove eyelid foreign body	1.33	6.15	4.75	0.52	0.53	0.07	7.55	6.15	1.92	1.93	010
67950		A	Revision of eyelid	5.82	7.80	7.59	7.00	6.99	0.28	13.90	13.69	13.10	13.09	090
67961		A	Revision of eyelid	5.69	7.62	7.41	7.62	7.41	0.26	13.57	13.36	13.57	13.36	090
67966		A	Revision of eyelid	6.57	7.04	7.24	6.19	6.61	0.31	13.92	14.12	13.07	13.49	090
67971		A	Reconstruction of eyelid	9.79	NA	NA	7.89	8.82	0.41	NA	NA	18.09	19.02	090
67973		A	Reconstruction of eyelid	12.87	NA	NA	9.93	11.12	0.58	NA	NA	23.38	24.57	090
67974		A	Reconstruction of eyelid	12.84	NA	NA	10.47	11.67	0.59	NA	NA	23.90	25.10	090
67975		A	Reconstruction of eyelid	9.13	NA	NA	9.76	8.45	0.37	NA	NA	19.26	17.95	090
67999		C	Revision of eyelid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
68020		A	Incise/drain eyelid lining	1.37	5.19	4.03	0.66	0.63	0.06	6.62	5.46	2.09	2.06	010

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
68040		A	Treatment of eyelid lesions	0.85	5.00	3.87	0.38	0.41	0.04	5.89	4.76	1.27	1.30	000
68100		A	Biopsy of eyelid lining	1.35	5.39	4.31	0.65	0.76	0.06	6.80	5.72	2.06	2.17	000
68110		A	Remove eyelid lining lesion	1.77	6.10	4.91	1.36	1.36	0.07	7.94	6.75	3.20	3.20	010
68115		A	Remove eyelid lining lesion	2.36	5.91	4.96	1.14	1.38	0.10	8.37	7.42	3.60	3.84	010
68130		A	Remove eyelid lining lesion	4.93	NA	NA	2.40	2.91	0.19	NA	NA	7.52	8.03	090
68135		A	Remove eyelid lining lesion	1.84	5.47	4.30	0.89	0.87	0.08	7.39	6.22	2.81	2.79	010
68200		A	Treat eyelid by injection	0.49	5.17	4.02	0.24	0.32	0.02	5.68	4.53	0.75	0.83	000
68320		A	Revise/graft eyelid lining	5.37	5.28	5.56	5.28	5.56	0.22	10.87	11.15	10.87	11.15	090
68325		A	Revise/graft eyelid lining	7.36	NA	NA	8.48	8.56	0.34	NA	NA	16.18	16.26	090
68326		A	Revise/graft eyelid lining	7.15	NA	NA	7.76	7.96	0.31	NA	NA	15.22	15.42	090
68328		A	Revise/graft eyelid lining	8.18	NA	NA	7.63	8.17	0.40	NA	NA	16.21	16.75	090
68330		A	Revise eyelid lining	4.83	6.45	6.28	5.11	5.27	0.19	11.47	11.30	10.13	10.29	090
68335		A	Revise/graft eyelid lining	7.19	NA	NA	5.23	6.07	0.30	NA	NA	12.72	13.56	090
68340		A	Separate eyelid adhesions	4.17	11.25	9.29	3.83	3.73	0.17	15.59	13.63	8.17	8.07	090
68360		A	Revise eyelid lining	4.37	6.19	5.95	4.84	4.94	0.17	10.73	10.49	9.38	9.48	090
68362		A	Revise eyelid lining	7.34	NA	NA	7.65	7.91	0.29	NA	NA	15.28	15.54	090
68399		C	Eyelid lining surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
68400		A	Incise/drain tear gland	1.69	8.04	6.30	1.91	1.71	0.07	9.80	8.06	3.67	3.47	010
68420		A	Incise/drain tear sac	2.30	8.48	6.64	2.16	1.90	0.10	10.88	9.04	4.56	4.30	010
68440		A	Incise tear duct opening	0.94	5.14	4.06	0.46	0.55	0.04	6.12	5.04	1.44	1.53	010
68500		A	Removal of tear gland	11.02	NA	NA	8.72	8.61	0.52	NA	NA	20.26	20.15	090
68505		A	Partial removal, tear gland	10.94	NA	NA	9.97	9.84	0.65	NA	NA	21.56	21.43	090
68510		A	Biopsy of tear gland	4.61	9.83	8.37	2.27	2.70	0.18	14.62	13.16	7.06	7.49	000
68520		A	Removal of tear sac	7.51	NA	NA	6.63	7.21	0.32	NA	NA	14.46	15.04	090
68525		A	Biopsy of tear sac	4.43	NA	NA	2.13	2.60	0.18	NA	NA	6.74	7.21	000
68530		A	Clearance of tear duct	3.66	10.17	8.40	2.54	2.68	0.15	13.98	12.21	6.35	6.49	010
68540		A	Remove tear gland lesion	10.60	NA	NA	7.73	8.05	0.53	NA	NA	18.86	19.18	090
68550		A	Remove tear gland lesion	13.26	NA	NA	8.92	9.77	0.95	NA	NA	23.13	23.98	090
68700		A	Repair tear ducts	6.60	NA	NA	5.59	4.92	0.27	NA	NA	12.46	11.79	090
68705		A	Revise tear duct opening	2.06	5.70	4.55	1.00	1.03	0.09	7.85	6.70	3.15	3.18	010
68720		A	Create tear sac drain	8.96	NA	NA	6.65	7.66	0.38	NA	NA	15.99	17.00	090
68745		A	Create tear duct drain	8.63	NA	NA	6.39	6.57	0.35	NA	NA	15.37	15.55	090
68750		A	Create tear duct drain	8.66	NA	NA	6.92	7.78	0.36	NA	NA	15.94	16.80	090
68760		A	Close tear duct opening	1.73	5.34	4.26	0.84	0.88	0.07	7.14	6.06	2.64	2.68	010
68761		A	Close tear duct opening	1.36	6.11	4.83	0.61	0.71	0.07	7.54	6.26	2.04	2.14	010
68770		A	Close tear system fistula	7.02	11.88	10.06	5.03	4.92	0.31	19.21	17.39	12.36	12.25	090
68801		A	Dilate tear duct opening	0.94	5.95	4.58	0.44	0.45	0.04	6.93	5.56	1.42	1.43	010
68810		A	Probe nasolacrimal duct	1.90	7.39	5.69	1.74	1.46	0.08	9.37	7.67	3.72	3.44	010
68811		A	Probe nasolacrimal duct	2.35	NA	NA	2.00	1.91	0.10	NA	NA	4.45	4.36	010
68815		A	Probe nasolacrimal duct	3.20	8.35	6.79	2.42	2.34	0.14	11.69	10.13	5.76	5.68	010
68840		A	Explore/irrigate tear ducts	1.25	6.56	5.05	0.54	0.54	0.05	7.86	6.35	1.84	1.84	010
68850		A	Injection for tear sac x-ray	0.80	12.29	9.36	0.31	0.37	0.03	13.12	10.19	1.14	1.20	000
68899		C	Tear duct system surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69000		A	Drain external ear lesion	1.45	1.78	1.43	0.53	0.49	0.10	3.33	2.98	2.08	2.04	010
69005		A	Drain external ear lesion	2.11	2.17	1.94	1.82	1.68	0.15	4.43	4.20	4.08	3.94	010
69020		A	Drain outer ear canal lesion	1.48	1.86	1.52	0.72	0.66	0.11	3.45	3.11	2.31	2.25	010
69090		N	Pierce earlobes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
69100		A	Biopsy of external ear	0.81	1.43	1.25	0.40	0.48	0.04	2.28	2.10	1.25	1.33	000
69105		A	Biopsy of external ear canal	0.85	1.25	1.16	0.84	0.85	0.06	2.16	2.07	1.75	1.76	000
69110		A	Remove external ear, partial	3.44	3.23	3.14	2.52	2.60	0.25	6.92	6.83	6.21	6.29	090
69120		A	Removal of external ear	4.05	NA	NA	3.88	3.12	0.32	NA	NA	8.25	7.49	090
69140		A	Remove ear canal lesion(s)	7.97	NA	NA	7.00	7.42	0.56	NA	NA	15.53	15.95	090
69145		A	Remove ear canal lesion(s)	2.62	2.89	2.85	2.19	2.32	0.19	5.70	5.66	5.00	5.13	090
69150		A	Extensive ear canal surgery	13.43	NA	NA	10.15	10.45	1.01	NA	NA	24.59	24.89	090
69155		A	Extensive ear/neck surgery	20.80	NA	NA	13.90	14.75	1.65	NA	NA	36.35	37.20	090
69200		A	Clear outer ear canal	0.77	1.20	1.02	0.55	0.53	0.06	2.03	1.85	1.38	1.36	000
69205		A	Clear outer ear canal	1.20	NA	NA	1.29	1.26	0.09	NA	NA	2.58	2.55	010
69210		A	Remove impacted ear wax	0.61	1.11	0.90	0.24	0.24	0.04	1.76	1.55	0.89	0.89	000
69220		A	Clean out mastoid cavity	0.83	1.25	1.07	0.42	0.45	0.06	2.14	1.96	1.31	1.34	000
69222		A	Clean out mastoid cavity	1.40	1.83	1.57	1.42	1.27	0.10	3.33	3.07	2.92	2.77	010
69300		R	Revise external ear	6.36	NA	NA	4.14	4.54	0.51	NA	NA	11.01	11.41	YYY
69310		A	Rebuild outer ear canal	10.79	NA	NA	8.63	9.14	0.77	NA	NA	20.19	20.70	090
69320		A	Rebuild outer ear canal	16.96	NA	NA	12.58	13.41	1.21	NA	NA	30.75	31.58	090
69399		C	Outer ear surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69400		A	Inflate middle ear canal	0.83	1.24	1.05	0.43	0.45	0.06	2.13	1.94	1.32	1.34	000
69401		A	Inflate middle ear canal	0.63	1.14	0.92	0.35	0.33	0.05	1.82	1.60	1.03	1.01	000
69405		A	Catheterize middle ear canal	2.63	2.61	2.09	1.41	1.19	0.18	5.42	4.90	4.22	4.00	010
69410		A	Inset middle ear (baffle)	0.33	1.10	0.99	0.15	0.28	0.02	1.45	1.34	0.50	0.63	000
69420		A	Incision of eardrum	1.33	1.89	1.61	0.70	0.71	0.10	3.32	3.04	2.13	2.14	010
69421		A	Incision of eardrum	1.73	2.14	1.92	1.60	1.51	0.12	3.99	3.77	3.45	3.36	010
69424		A	Remove ventilating tube	0.85	1.35	1.18	0.70	0.69	0.06	2.26	2.09	1.61	1.60	000
69433		A	Create eardrum opening	1.52	1.91	1.79	0.83	0.98	0.11	3.54	3.42	2.46	2.61	010
69436		A	Create eardrum opening	1.96	NA	NA	1.74	1.88	0.14	NA	NA	3.84	3.98	010
69440		A	Exploration of middle ear	7.57	NA	NA	6.41	7.07	0.53	NA	NA	14.51	15.17	090
69450		A	Eardrum revision	5.57	NA	NA	5.22	5.58	0.40	NA	NA	11.19	11.55	090
69501		A	Mastoidectomy	9.07	NA	NA	7.18	8.09	0.66	NA	NA	16.91	17.82	090
69502		A	Mastoidectomy	12.38	NA	NA	9.54	10.78	0.89	NA	NA	22.81	24.05	090
69505		A	Remove mastoid structures	12.99	NA	NA	9.81	11.24	0.94	NA	NA	23.74	25.17	090
69511		A	Extensive mastoid surgery	13.52	NA	NA	10.10	11.61	0.96	NA	NA	24.58	26.09	090
69530		A	Extensive mastoid surgery	19.19	NA	NA	13.64	14.76	1.43	NA	NA	34.26	35.38	090
69535		A	Remove part of temporal bone	36.14	NA	NA	22.50	23.73	2.61	NA	NA	61.25	62.48	090
69540		A	Remove ear lesion	1.20	1.82	1.71	1.31	1.33	0.09	3.11	3.00	2.60	2.62	010

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
69550		A	Remove ear lesion	10.99	NA	NA	8.56	9.70	0.77	NA	NA	20.32	21.46	090
69552		A	Remove ear lesion	19.46	NA	NA	13.33	14.54	1.38	NA	NA	34.17	35.38	090
69554		A	Remove ear lesion	33.16	NA	NA	20.30	21.43	2.94	NA	NA	56.40	57.53	090
69601		A	Mastoid surgery revision	13.24	NA	NA	10.43	11.63	0.95	NA	NA	24.62	25.82	090
69602		A	Mastoid surgery revision	13.58	NA	NA	10.11	11.64	0.96	NA	NA	24.65	26.18	090
69603		A	Mastoid surgery revision	14.02	NA	NA	10.43	12.01	0.01	NA	NA	24.46	26.04	090
69604		A	Mastoid surgery revision	14.02	NA	NA	10.34	11.94	0.01	NA	NA	24.37	25.97	090
69605		A	Mastoid surgery revision	18.49	NA	NA	13.31	14.04	1.24	NA	NA	33.04	33.77	090
69610		A	Repair of eardrum	4.43	3.67	3.01	3.08	2.56	0.31	8.41	7.75	7.82	7.30	010
69620		A	Repair of eardrum	5.89	5.78	6.09	3.28	4.22	0.42	12.09	12.40	9.59	10.53	090
69631		A	Repair eardrum structures	9.86	NA	NA	8.16	9.07	0.70	NA	NA	18.72	19.63	090
69632		A	Rebuild eardrum structures	12.75	NA	NA	10.21	11.47	0.91	NA	NA	23.87	25.13	090
69633		A	Rebuild eardrum structures	12.10	NA	NA	9.88	11.02	0.86	NA	NA	22.84	23.98	090
69635		A	Repair eardrum structures	13.33	NA	NA	10.10	11.55	0.95	NA	NA	24.38	25.83	090
69636		A	Rebuild eardrum structures	15.22	NA	NA	11.65	13.28	1.09	NA	NA	27.96	29.59	090
69637		A	Rebuild eardrum structures	15.11	NA	NA	11.53	13.16	1.08	NA	NA	27.72	29.35	090
69641		A	Revise middle ear & mastoid	12.71	NA	NA	9.75	11.11	0.91	NA	NA	23.37	24.73	090
69642		A	Revise middle ear & mastoid	16.84	NA	NA	12.51	14.41	1.19	NA	NA	30.54	32.44	090
69643		A	Revise middle ear & mastoid	15.32	NA	NA	11.67	13.33	1.10	NA	NA	28.09	29.75	090
69644		A	Revise middle ear & mastoid	16.97	NA	NA	12.53	14.46	1.20	NA	NA	30.70	32.63	090
69645		A	Revise middle ear & mastoid	16.38	NA	NA	12.23	14.06	1.16	NA	NA	29.77	31.60	090
69646		A	Revise middle ear & mastoid	17.99	NA	NA	13.16	15.24	1.29	NA	NA	32.44	34.52	090
69650		A	Release middle ear bone	9.66	NA	NA	7.50	8.51	0.69	NA	NA	17.85	18.86	090
69660		A	Revise middle ear bone	11.90	NA	NA	8.73	10.10	0.85	NA	NA	21.48	22.85	090
69661		A	Revise middle ear bone	15.74	NA	NA	11.29	13.17	1.14	NA	NA	28.17	30.05	090
69662		A	Revise middle ear bone	15.44	NA	NA	11.11	12.94	1.10	NA	NA	27.65	29.48	090
69666		A	Repair middle ear structures	9.75	NA	NA	7.59	8.60	0.69	NA	NA	18.03	19.04	090
69667		A	Repair middle ear structures	9.76	NA	NA	7.59	8.61	0.69	NA	NA	18.04	19.06	090
69670		A	Remove mastoid air cells	11.51	NA	NA	9.03	9.54	0.79	NA	NA	21.33	21.84	090
69676		A	Remove middle ear nerve	9.52	NA	NA	7.94	8.27	0.66	NA	NA	18.12	18.45	090
69700		A	Close mastoid fistula	8.23	NA	NA	5.44	6.21	0.62	NA	NA	14.29	15.06	090
69710		N	Implant/replace hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
69711		A	Remove/repair hearing aid	10.44	NA	NA	8.24	8.47	0.73	NA	NA	19.41	19.64	090
69720		A	Release facial nerve	14.38	NA	NA	11.15	12.66	1.03	NA	NA	26.56	28.07	090
69725		A	Release facial nerve	25.38	NA	NA	16.53	16.37	1.62	NA	NA	43.53	43.37	090
69740		A	Repair facial nerve	15.96	NA	NA	10.68	11.22	1.11	NA	NA	27.75	28.29	090
69745		A	Repair facial nerve	16.69	NA	NA	11.02	12.59	1.80	NA	NA	29.51	31.08	090
69799		C	Middle ear surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69801		A	Incise inner ear	8.56	NA	NA	6.68	7.57	0.61	NA	NA	15.85	16.74	090
69802		A	Incise inner ear	13.10	NA	NA	9.55	10.21	1.04	NA	NA	23.69	24.35	090
69805		A	Explore inner ear	13.82	NA	NA	9.50	10.69	0.97	NA	NA	24.29	25.48	090
69806		A	Explore inner ear	12.35	NA	NA	9.21	10.60	0.88	NA	NA	22.44	23.83	090
69820		A	Establish inner ear window	10.34	NA	NA	7.91	8.33	0.55	NA	NA	18.80	19.22	090
69840		A	Revise inner ear window	10.26	NA	NA	8.49	8.67	0.40	NA	NA	19.15	19.33	090
69905		A	Remove inner ear	11.10	NA	NA	8.48	9.67	0.77	NA	NA	20.35	21.54	090
69910		A	Remove inner ear & mastoid	13.63	NA	NA	9.74	11.37	0.97	NA	NA	24.34	25.97	090
69915		A	Incise inner ear nerve	21.23	NA	NA	14.11	15.39	1.50	NA	NA	36.84	38.12	090
69930		A	Implant cochlear device	16.81	NA	NA	11.34	13.52	1.21	NA	NA	29.36	31.54	090
69949		C	Inner ear surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69950		A	Incise inner ear nerve	25.64	NA	NA	15.46	16.48	2.34	NA	NA	43.44	44.46	090
69955		A	Release facial nerve	27.04	NA	NA	17.99	19.00	2.31	NA	NA	47.34	48.35	090
69960		A	Release inner ear canal	27.04	NA	NA	16.77	17.42	2.52	NA	NA	46.33	46.98	090
69970		A	Remove inner ear lesion	30.04	NA	NA	18.13	18.94	2.13	NA	NA	50.30	51.11	090
69979		C	Temporal bone surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
69990		R	Microsurgery add-on	3.47	NA	NA	1.79	1.79	0.64	NA	NA	5.90	5.90	ZZZ
70010		A	Contrast x-ray of brain	1.19	4.79	4.86	NA	NA	0.24	6.22	6.29	NA	NA	XXX
70010	26	A	Contrast x-ray of brain	1.19	0.41	0.45	0.41	0.45	0.05	1.65	1.69	1.65	1.69	XXX
70010	TC	A	Contrast x-ray of brain	0.00	4.38	4.41	NA	NA	0.19	4.57	4.60	NA	NA	XXX
70015		A	Contrast x-ray of brain	1.19	1.77	1.82	NA	NA	0.12	3.08	3.13	NA	NA	XXX
70015	26	A	Contrast x-ray of brain	1.19	0.40	0.44	0.40	0.44	0.05	1.64	1.68	1.64	1.68	XXX
70015	TC	A	Contrast x-ray of brain	0.00	1.37	1.38	NA	NA	0.07	1.44	1.45	NA	NA	XXX
70030		A	X-ray eye for foreign body	0.17	0.48	0.49	NA	NA	0.03	0.68	0.69	NA	NA	XXX
70030	26	A	X-ray eye for foreign body	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
70030	TC	A	X-ray eye for foreign body	0.00	0.42	0.42	NA	NA	0.02	0.44	0.44	NA	NA	XXX
70100		A	X-ray exam of jaw	0.18	0.59	0.60	NA	NA	0.03	0.80	0.81	NA	NA	XXX
70100	26	A	X-ray exam of jaw	0.18	0.06	0.07	0.06	0.07	0.01	0.25	0.26	0.25	0.26	XXX
70100	TC	A	X-ray exam of jaw	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
70110		A	X-ray exam of jaw	0.25	0.72	0.73	NA	NA	0.04	1.01	1.02	NA	NA	XXX
70110	26	A	X-ray exam of jaw	0.25	0.09	0.10	0.09	0.10	0.01	0.35	0.36	0.35	0.36	XXX
70110	TC	A	X-ray exam of jaw	0.00	0.63	0.63	NA	NA	0.03	0.66	0.66	NA	NA	XXX
70120		A	X-ray exam of mastoids	0.18	0.69	0.70	NA	NA	0.04	0.91	0.92	NA	NA	XXX
70120	26	A	X-ray exam of mastoids	0.18	0.06	0.07	0.06	0.07	0.01	0.25	0.26	0.25	0.26	XXX
70120	TC	A	X-ray exam of mastoids	0.00	0.63	0.63	NA	NA	0.03	0.66	0.66	NA	NA	XXX
70130		A	X-ray exam of mastoids	0.34	0.91	0.93	NA	NA	0.05	1.30	1.32	NA	NA	XXX
70130	26	A	X-ray exam of mastoids	0.34	0.12	0.13	0.12	0.13	0.01	0.47	0.48	0.47	0.48	XXX
70130	TC	A	X-ray exam of mastoids	0.00	0.79	0.80	NA	NA	0.04	0.83	0.84	NA	NA	XXX
70134		A	X-ray exam of middle ear	0.34	0.86	0.88	NA	NA	0.05	1.25	1.27	NA	NA	XXX
70134	26	A	X-ray exam of middle ear	0.34	0.12	0.13	0.12	0.13	0.01	0.47	0.48	0.47	0.48	XXX
70134	TC	A	X-ray exam of middle ear	0.00	0.74	0.75	NA	NA	0.04	0.78	0.79	NA	NA	XXX
70140		A	X-ray exam of facial bones	0.19	0.70	0.71	NA	NA	0.04	0.93	0.94	NA	NA	XXX
70140	26	A	X-ray exam of facial bones	0.19	0.07	0.08	0.07	0.08	0.01	0.27	0.28	0.27	0.28	XXX
70140	TC	A	X-ray exam of facial bones	0.00	0.63	0.63	NA	NA	0.03	0.66	0.66	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
70150	.....	A	X-ray exam of facial bones	0.26	0.88	0.90	NA	NA	0.05	1.19	1.21	NA	NA	XXX
70150	26	A	X-ray exam of facial bones	0.26	0.09	0.10	0.09	0.10	0.01	0.36	0.37	0.36	0.37	XXX
70150	TC	A	X-ray exam of facial bones	0.00	0.79	0.80	NA	NA	0.04	0.83	0.84	NA	NA	XXX
70160	.....	A	X-ray exam of nasal bones	0.17	0.59	0.60	NA	NA	0.03	0.79	0.80	NA	NA	XXX
70160	26	A	X-ray exam of nasal bones	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
70160	TC	A	X-ray exam of nasal bones	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
70170	.....	A	X-ray exam of tear duct	0.30	1.07	1.09	NA	NA	0.06	1.43	1.45	NA	NA	XXX
70170	26	A	X-ray exam of tear duct	0.30	0.11	0.12	0.11	0.12	0.01	0.42	0.43	0.42	0.43	XXX
70170	TC	A	X-ray exam of tear duct	0.00	0.96	0.97	NA	NA	0.05	1.01	1.02	NA	NA	XXX
70190	.....	A	X-ray exam of eye sockets	0.21	0.70	0.71	NA	NA	0.04	0.95	0.96	NA	NA	XXX
70190	26	A	X-ray exam of eye sockets	0.21	0.07	0.08	0.07	0.08	0.01	0.29	0.30	0.29	0.30	XXX
70190	TC	A	X-ray exam of eye sockets	0.00	0.63	0.63	NA	NA	0.03	0.66	0.66	NA	NA	XXX
70200	.....	A	X-ray exam of eye sockets	0.28	0.89	0.91	NA	NA	0.05	1.22	1.24	NA	NA	XXX
70200	26	A	X-ray exam of eye sockets	0.28	0.10	0.11	0.10	0.11	0.01	0.39	0.40	0.39	0.40	XXX
70200	TC	A	X-ray exam of eye sockets	0.00	0.79	0.80	NA	NA	0.04	0.83	0.84	NA	NA	XXX
70210	.....	A	X-ray exam of sinuses	0.17	0.69	0.70	NA	NA	0.04	0.90	0.91	NA	NA	XXX
70210	26	A	X-ray exam of sinuses	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
70210	TC	A	X-ray exam of sinuses	0.00	0.63	0.63	NA	NA	0.03	0.66	0.66	NA	NA	XXX
70220	.....	A	X-ray exam of sinuses	0.25	0.88	0.90	NA	NA	0.05	1.18	1.20	NA	NA	XXX
70220	26	A	X-ray exam of sinuses	0.25	0.09	0.10	0.09	0.10	0.01	0.35	0.36	0.35	0.36	XXX
70220	TC	A	X-ray exam of sinuses	0.00	0.79	0.80	NA	NA	0.04	0.83	0.84	NA	NA	XXX
70240	.....	A	X-ray exam, pituitary saddle	0.19	0.49	0.50	NA	NA	0.03	0.71	0.72	NA	NA	XXX
70240	26	A	X-ray exam, pituitary saddle	0.19	0.07	0.08	0.07	0.08	0.01	0.27	0.28	0.27	0.28	XXX
70240	TC	A	X-ray exam, pituitary saddle	0.00	0.42	0.42	NA	NA	0.02	0.44	0.44	NA	NA	XXX
70250	.....	A	X-ray exam of skull	0.24	0.71	0.72	NA	NA	0.04	0.99	1.00	NA	NA	XXX
70250	26	A	X-ray exam of skull	0.24	0.08	0.09	0.08	0.09	0.01	0.33	0.34	0.33	0.34	XXX
70250	TC	A	X-ray exam of skull	0.00	0.63	0.63	NA	NA	0.03	0.66	0.66	NA	NA	XXX
70260	.....	A	X-ray exam of skull	0.34	1.02	1.04	NA	NA	0.06	1.42	1.44	NA	NA	XXX
70260	26	A	X-ray exam of skull	0.34	0.12	0.13	0.12	0.13	0.01	0.47	0.48	0.47	0.48	XXX
70260	TC	A	X-ray exam of skull	0.00	0.90	0.91	NA	NA	0.05	0.95	0.96	NA	NA	XXX
70300	.....	A	X-ray exam of teeth	0.10	0.30	0.30	NA	NA	0.03	0.43	0.43	NA	NA	XXX
70300	26	A	X-ray exam of teeth	0.10	0.04	0.04	0.04	0.04	0.01	0.15	0.15	0.15	0.15	XXX
70300	TC	A	X-ray exam of teeth	0.00	0.26	0.26	NA	NA	0.02	0.28	0.28	NA	NA	XXX
70310	.....	A	X-ray exam of teeth	0.16	0.48	0.49	NA	NA	0.03	0.67	0.68	NA	NA	XXX
70310	26	A	X-ray exam of teeth	0.16	0.06	0.07	0.06	0.07	0.01	0.23	0.24	0.23	0.24	XXX
70310	TC	A	X-ray exam of teeth	0.00	0.42	0.42	NA	NA	0.02	0.44	0.44	NA	NA	XXX
70320	.....	A	Full mouth x-ray of teeth	0.22	0.87	0.89	NA	NA	0.05	1.14	1.16	NA	NA	XXX
70320	26	A	Full mouth x-ray of teeth	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
70320	TC	A	Full mouth x-ray of teeth	0.00	0.79	0.80	NA	NA	0.04	0.83	0.84	NA	NA	XXX
70328	.....	A	X-ray exam of jaw joint	0.18	0.56	0.57	NA	NA	0.03	0.77	0.78	NA	NA	XXX
70328	26	A	X-ray exam of jaw joint	0.18	0.06	0.07	0.06	0.07	0.01	0.25	0.26	0.25	0.26	XXX
70328	TC	A	X-ray exam of jaw joint	0.00	0.50	0.50	NA	NA	0.02	0.52	0.52	NA	NA	XXX
70330	.....	A	X-ray exam of jaw joints	0.24	0.93	0.95	NA	NA	0.05	1.22	1.24	NA	NA	XXX
70330	26	A	X-ray exam of jaw joints	0.24	0.08	0.09	0.08	0.09	0.01	0.33	0.34	0.33	0.34	XXX
70330	TC	A	X-ray exam of jaw joints	0.00	0.85	0.86	NA	NA	0.04	0.89	0.90	NA	NA	XXX
70332	.....	A	X-ray exam of jaw joint	0.54	2.31	2.34	NA	NA	0.12	2.97	3.00	NA	NA	XXX
70332	26	A	X-ray exam of jaw joint	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
70332	TC	A	X-ray exam of jaw joint	0.00	2.12	2.13	NA	NA	0.10	2.22	2.23	NA	NA	XXX
70336	.....	A	Magnetic image, jaw joint	1.48	11.85	11.91	NA	NA	0.56	13.89	13.95	NA	NA	XXX
70336	26	A	Magnetic image, jaw joint	1.48	0.52	0.51	0.52	0.51	0.06	2.06	2.05	2.06	2.05	XXX
70336	TC	A	Magnetic image, jaw joint	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
70350	.....	A	X-ray head for orthodontia	0.17	0.44	0.45	NA	NA	0.03	0.64	0.65	NA	NA	XXX
70350	26	A	X-ray head for orthodontia	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
70350	TC	A	X-ray head for orthodontia	0.00	0.38	0.38	NA	NA	0.02	0.40	0.40	NA	NA	XXX
70355	.....	A	Panoramic x-ray of jaws	0.20	0.65	0.66	NA	NA	0.04	0.89	0.90	NA	NA	XXX
70355	26	A	Panoramic x-ray of jaws	0.20	0.07	0.08	0.07	0.08	0.01	0.28	0.29	0.28	0.29	XXX
70355	TC	A	Panoramic x-ray of jaws	0.00	0.58	0.58	NA	NA	0.03	0.61	0.61	NA	NA	XXX
70360	.....	A	X-ray exam of neck	0.17	0.48	0.49	NA	NA	0.03	0.68	0.69	NA	NA	XXX
70360	26	A	X-ray exam of neck	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
70360	TC	A	X-ray exam of neck	0.00	0.42	0.42	NA	NA	0.02	0.44	0.44	NA	NA	XXX
70370	.....	A	Throat x-ray & fluoroscopy	0.32	1.43	1.45	NA	NA	0.07	1.82	1.84	NA	NA	XXX
70370	26	A	Throat x-ray & fluoroscopy	0.32	0.11	0.12	0.11	0.12	0.01	0.44	0.45	0.44	0.45	XXX
70370	TC	A	Throat x-ray & fluoroscopy	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
70371	.....	A	Speech evaluation, complex	0.84	2.41	2.45	NA	NA	0.13	3.38	3.42	NA	NA	XXX
70371	26	A	Speech evaluation, complex	0.84	0.29	0.32	0.29	0.32	0.03	1.16	1.19	1.16	1.19	XXX
70371	TC	A	Speech evaluation, complex	0.00	2.12	2.13	NA	NA	0.10	2.22	2.23	NA	NA	XXX
70373	.....	A	Contrast x-ray of larynx	0.44	1.95	1.98	NA	NA	0.11	2.50	2.53	NA	NA	XXX
70373	26	A	Contrast x-ray of larynx	0.44	0.15	0.17	0.15	0.17	0.02	0.61	0.63	0.61	0.63	XXX
70373	TC	A	Contrast x-ray of larynx	0.00	1.80	1.81	NA	NA	0.09	1.89	1.90	NA	NA	XXX
70380	.....	A	X-ray exam of salivary gland	0.17	0.73	0.75	NA	NA	0.04	0.94	0.96	NA	NA	XXX
70380	26	A	X-ray exam of salivary gland	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
70380	TC	A	X-ray exam of salivary gland	0.00	0.67	0.68	NA	NA	0.03	0.70	0.71	NA	NA	XXX
70390	.....	A	X-ray exam of salivary duct	0.38	1.93	1.95	NA	NA	0.11	2.42	2.44	NA	NA	XXX
70390	26	A	X-ray exam of salivary duct	0.38	0.13	0.14	0.13	0.14	0.02	0.53	0.54	0.53	0.54	XXX
70390	TC	A	X-ray exam of salivary duct	0.00	1.80	1.81	NA	NA	0.09	1.89	1.90	NA	NA	XXX
70450	.....	A	CAT scan of head or brain	0.85	5.07	5.13	NA	NA	0.25	6.17	6.23	NA	NA	XXX
70450	26	A	CAT scan of head or brain	0.85	0.30	0.33	0.30	0.33	0.03	1.18	1.21	1.18	1.21	XXX
70450	TC	A	CAT scan of head or brain	0.00	4.77	4.80	NA	NA	0.22	4.99	5.02	NA	NA	XXX
70460	.....	A	Contrast CAT scan of head	1.13	6.11	6.18	NA	NA	0.31	7.55	7.62	NA	NA	XXX
70460	26	A	Contrast CAT scan of head	1.13	0.39	0.43	0.39	0.43	0.05	1.57	1.61	1.57	1.61	XXX
70460	TC	A	Contrast CAT scan of head	0.00	5.72	5.75	NA	NA	0.26	5.98	6.01	NA	NA	XXX
70470	.....	A	Contrast CAT scans of head	1.27	7.59	7.67	NA	NA	0.37	9.23	9.31	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
70470	26	A	Contrast CAT scans of head	1.27	0.44	0.48	0.44	0.48	0.05	1.76	1.80	1.76	1.80	XXX
70470	TC	A	Contrast CAT scans of head	0.00	7.15	7.19	NA	NA	0.32	7.47	7.51	NA	NA	XXX
70480		A	CAT scan of skull	1.28	5.22	5.29	NA	NA	0.27	6.77	6.84	NA	NA	XXX
70480	26	A	CAT scan of skull	1.28	0.45	0.49	0.45	0.49	0.05	1.78	1.82	1.78	1.82	XXX
70480	TC	A	CAT scan of skull	0.00	4.77	4.80	NA	NA	0.22	4.99	5.02	NA	NA	XXX
70481		A	Contrast CAT scan of skull	1.38	6.20	6.28	NA	NA	0.31	7.89	7.97	NA	NA	XXX
70481	26	A	Contrast CAT scan of skull	1.38	0.48	0.53	0.48	0.53	0.05	1.91	1.96	1.91	1.96	XXX
70481	TC	A	Contrast CAT scan of skull	0.00	5.72	5.75	NA	NA	0.26	5.98	6.01	NA	NA	XXX
70482		A	Contrast CAT scans of skull	1.45	7.66	7.75	7.50	0.56	0.38	9.49	9.58	9.33	2.39	XXX
70482	26	A	Contrast CAT scans of skull	1.45	0.51	0.56	0.51	0.56	0.06	2.02	2.07	2.02	2.07	XXX
70482	TC	A	Contrast CAT scans of skull	0.00	7.15	7.19	NA	NA	0.32	7.47	7.51	NA	NA	XXX
70486		A	Cat scan of face/jaw	1.14	5.17	5.24	5.05	0.44	0.27	6.58	6.65	6.46	1.85	XXX
70486	26	A	Cat scan of face/jaw	1.14	0.40	0.44	0.40	0.44	0.05	1.59	1.63	1.59	1.63	XXX
70486	TC	A	Cat scan of face/jaw	0.00	4.77	4.80	NA	NA	0.22	4.99	5.02	NA	NA	XXX
70487		A	Contrast CAT scan, face/jaw	1.30	6.17	6.24	6.04	0.49	0.31	7.78	7.85	7.65	2.10	XXX
70487	26	A	Contrast CAT scan, face/jaw	1.30	0.45	0.49	0.45	0.49	0.05	1.80	1.84	1.80	1.84	XXX
70487	TC	A	Contrast CAT scan, face/jaw	0.00	5.72	5.75	NA	NA	0.26	5.98	6.01	NA	NA	XXX
70488		A	Contrast cat scans, face/jaw	1.42	7.64	7.73	7.49	0.54	0.38	9.44	9.53	9.29	2.34	XXX
70488	26	A	Contrast cat scans, face/jaw	1.42	0.49	0.54	0.49	0.54	0.06	1.97	2.02	1.97	2.02	XXX
70488	TC	A	Contrast cat scans, face/jaw	0.00	7.15	7.19	NA	NA	0.32	7.47	7.51	NA	NA	XXX
70490		A	CAT scan of neck tissue	1.28	5.22	5.29	5.09	0.49	0.27	6.77	6.84	6.64	2.04	XXX
70490	26	A	CAT scan of neck tissue	1.28	0.45	0.49	0.45	0.49	0.05	1.78	1.82	1.78	1.82	XXX
70490	TC	A	CAT scan of neck tissue	0.00	4.77	4.80	NA	NA	0.22	4.99	5.02	NA	NA	XXX
70491		A	Contrast CAT of neck tissue	1.38	6.20	6.28	6.06	0.53	0.31	7.89	7.97	7.75	2.22	XXX
70491	26	A	Contrast CAT of neck tissue	1.38	0.48	0.53	0.48	0.53	0.05	1.91	1.96	1.91	1.96	XXX
70491	TC	A	Contrast CAT of neck tissue	0.00	5.72	5.75	NA	NA	0.26	5.98	6.01	NA	NA	XXX
70492		A	Contrast CAT of neck tissue	1.45	7.65	7.74	7.49	0.55	0.38	9.48	9.57	9.32	2.38	XXX
70492	26	A	Contrast CAT of neck tissue	1.45	0.50	0.55	0.50	0.55	0.06	2.01	2.06	2.01	2.06	XXX
70492	TC	A	Contrast CAT of neck tissue	0.00	7.15	7.19	NA	NA	0.32	7.47	7.51	NA	NA	XXX
70540		A	Magnetic image, face/neck	1.48	11.85	11.97	NA	NA	0.56	13.89	14.01	NA	NA	XXX
70540	26	A	Magnetic image, face/neck	1.48	0.52	0.57	0.52	0.57	0.06	2.06	2.11	2.06	2.11	XXX
70540	TC	A	Magnetic image, face/neck	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
70541		R	Magnetic image, head (MRA)	1.81	11.96	12.05	NA	NA	0.57	14.34	14.43	NA	NA	XXX
70541	26	R	Magnetic image, head (MRA)	1.81	0.63	0.65	0.63	0.65	0.07	2.51	2.53	2.51	2.53	XXX
70541	TC	R	Magnetic image, head (MRA)	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
70551		A	Magnetic image, brain (MRI)	1.48	11.85	11.97	NA	NA	0.56	13.89	14.01	NA	NA	XXX
70551	26	A	Magnetic image, brain (MRI)	1.48	0.52	0.57	0.52	0.57	0.06	2.06	2.11	2.06	2.11	XXX
70551	TC	A	Magnetic image, brain (MRI)	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
70552		A	Magnetic image, brain (MRI)	1.78	14.22	14.36	NA	NA	0.67	16.67	16.81	NA	NA	XXX
70552	26	A	Magnetic image, brain (MRI)	1.78	0.63	0.69	0.63	0.69	0.07	2.48	2.54	2.48	2.54	XXX
70552	TC	A	Magnetic image, brain (MRI)	0.00	13.59	13.67	NA	NA	0.60	14.19	14.27	NA	NA	XXX
70553		A	Magnetic image, brain (mri)	2.36	25.98	26.22	NA	NA	1.21	29.55	29.79	NA	NA	XXX
70553	26	A	Magnetic image, brain (mri)	2.36	0.82	0.91	0.82	0.91	0.09	3.27	3.36	3.27	3.36	XXX
70553	TC	A	Magnetic image, brain (mri)	0.00	25.16	25.31	NA	NA	1.12	26.28	26.43	NA	NA	XXX
71010		A	Chest x-ray	0.18	0.54	0.55	NA	NA	0.03	0.75	0.76	NA	NA	XXX
71010	26	A	Chest x-ray	0.18	0.06	0.07	0.06	0.07	0.01	0.25	0.26	0.25	0.26	XXX
71010	TC	A	Chest x-ray	0.00	0.48	0.48	NA	NA	0.02	0.50	0.50	NA	NA	XXX
71015		A	Chest x-ray	0.21	0.60	0.61	NA	NA	0.03	0.84	0.85	NA	NA	XXX
71015	26	A	Chest x-ray	0.21	0.07	0.08	0.07	0.08	0.01	0.29	0.30	0.29	0.30	XXX
71015	TC	A	Chest x-ray	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
71020		A	Chest x-ray	0.22	0.71	0.72	NA	NA	0.04	0.97	0.98	NA	NA	XXX
71020	26	A	Chest x-ray	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
71020	TC	A	Chest x-ray	0.00	0.63	0.63	NA	NA	0.03	0.66	0.66	NA	NA	XXX
71021		A	Chest x-ray	0.27	0.83	0.85	NA	NA	0.05	1.15	1.17	NA	NA	XXX
71021	26	A	Chest x-ray	0.27	0.09	0.10	0.09	0.10	0.01	0.37	0.38	0.37	0.38	XXX
71021	TC	A	Chest x-ray	0.00	0.74	0.75	NA	NA	0.04	0.78	0.79	NA	NA	XXX
71022		A	Chest x-ray	0.31	0.85	0.87	NA	NA	0.05	1.21	1.23	NA	NA	XXX
71022	26	A	Chest x-ray	0.31	0.11	0.12	0.11	0.12	0.01	0.43	0.44	0.43	0.44	XXX
71022	TC	A	Chest x-ray	0.00	0.74	0.75	NA	NA	0.04	0.78	0.79	NA	NA	XXX
71023		A	Chest x-ray and fluoroscopy	0.38	0.93	0.95	NA	NA	0.05	1.36	1.38	NA	NA	XXX
71023	26	A	Chest x-ray and fluoroscopy	0.38	0.14	0.15	0.14	0.15	0.01	0.53	0.54	0.53	0.54	XXX
71023	TC	A	Chest x-ray and fluoroscopy	0.00	0.79	0.80	NA	NA	0.04	0.83	0.84	NA	NA	XXX
71030		A	Chest x-ray	0.31	0.90	0.92	NA	NA	0.05	1.26	1.28	NA	NA	XXX
71030	26	A	Chest x-ray	0.31	0.11	0.12	0.11	0.12	0.01	0.43	0.44	0.43	0.44	XXX
71030	TC	A	Chest x-ray	0.00	0.79	0.80	NA	NA	0.04	0.83	0.84	NA	NA	XXX
71034		A	Chest x-ray and fluoroscopy	0.46	1.63	1.66	NA	NA	0.09	2.18	2.21	NA	NA	XXX
71034	26	A	Chest x-ray and fluoroscopy	0.46	0.17	0.19	0.17	0.19	0.02	0.65	0.67	0.65	0.67	XXX
71034	TC	A	Chest x-ray and fluoroscopy	0.00	1.46	1.47	NA	NA	0.07	1.53	1.54	NA	NA	XXX
71035		A	Chest x-ray	0.18	0.59	0.60	NA	NA	0.03	0.80	0.81	NA	NA	XXX
71035	26	A	Chest x-ray	0.18	0.06	0.07	0.06	0.07	0.01	0.25	0.26	0.25	0.26	XXX
71035	TC	A	Chest x-ray	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
71036		A	X-ray guidance for biopsy	0.54	1.77	1.80	NA	NA	0.10	2.41	2.44	NA	NA	XXX
71036	26	A	X-ray guidance for biopsy	0.54	0.18	0.20	0.18	0.20	0.02	0.74	0.76	0.74	0.76	XXX
71036	TC	A	X-ray guidance for biopsy	0.00	1.59	1.60	NA	NA	0.08	1.67	1.68	NA	NA	XXX
71040		A	Contrast x-ray of bronchi	0.58	1.68	1.71	NA	NA	0.09	2.35	2.38	NA	NA	XXX
71040	26	A	Contrast x-ray of bronchi	0.58	0.20	0.22	0.20	0.22	0.02	0.80	0.82	0.80	0.82	XXX
71040	TC	A	Contrast x-ray of bronchi	0.00	1.48	1.49	NA	NA	0.07	1.55	1.56	NA	NA	XXX
71060		A	Contrast x-ray of bronchi	0.74	2.49	2.53	NA	NA	0.14	3.37	3.41	NA	NA	XXX
71060	26	A	Contrast x-ray of bronchi	0.74	0.26	0.29	0.26	0.29	0.03	1.03	1.06	1.03	1.06	XXX
71060	TC	A	Contrast x-ray of bronchi	0.00	2.23	2.24	NA	NA	0.11	2.34	2.35	NA	NA	XXX
71090		A	X-ray & pacemaker insertion	0.54	1.92	1.94	NA	NA	0.11	2.57	2.59	NA	NA	XXX
71090	26	A	X-ray & pacemaker insertion	0.54	0.22	0.23	0.22	0.23	0.02	0.78	0.79	0.78	0.79	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
71090	TC	A	X-ray & pacemaker insertion	0.00	1.70	1.71	NA	NA	0.09	1.79	1.80	NA	NA	XXX
71100		A	X-ray exam of ribs	0.22	0.66	0.67	NA	NA	0.04	0.92	0.93	NA	NA	XXX
71100	26	A	X-ray exam of ribs	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
71100	TC	A	X-ray exam of ribs	0.00	0.58	0.58	NA	NA	0.03	0.61	0.61	NA	NA	XXX
71101		A	X-ray exam of ribs/chest	0.27	0.76	0.78	NA	NA	0.04	1.07	1.09	NA	NA	XXX
71101	26	A	X-ray exam of ribs/chest	0.27	0.09	0.10	0.09	0.10	0.01	0.37	0.38	0.37	0.38	XXX
71101	TC	A	X-ray exam of ribs/chest	0.00	0.67	0.68	NA	NA	0.03	0.70	0.71	NA	NA	XXX
71110		A	X-ray exam of ribs	0.27	0.88	0.90	NA	NA	0.05	1.20	1.22	NA	NA	XXX
71110	26	A	X-ray exam of ribs	0.27	0.09	0.10	0.09	0.10	0.01	0.37	0.38	0.37	0.38	XXX
71110	TC	A	X-ray exam of ribs	0.00	0.79	0.80	NA	NA	0.04	0.83	0.84	NA	NA	XXX
71111		A	X-ray exam of ribs/ chest	0.32	1.01	1.03	NA	NA	0.06	1.39	1.41	NA	NA	XXX
71111	26	A	X-ray exam of ribs/ chest	0.32	0.11	0.12	0.11	0.12	0.01	0.44	0.45	0.44	0.45	XXX
71111	TC	A	X-ray exam of ribs/ chest	0.00	0.90	0.91	NA	NA	0.05	0.95	0.96	NA	NA	XXX
71120		A	X-ray exam of breastbone	0.20	0.72	0.74	NA	NA	0.04	0.96	0.98	NA	NA	XXX
71120	26	A	X-ray exam of breastbone	0.20	0.07	0.08	0.07	0.08	0.01	0.28	0.29	0.28	0.29	XXX
71120	TC	A	X-ray exam of breastbone	0.00	0.65	0.66	NA	NA	0.03	0.68	0.69	NA	NA	XXX
71130		A	X-ray exam of breastbone	0.22	0.79	0.81	NA	NA	0.04	1.05	1.07	NA	NA	XXX
71130	26	A	X-ray exam of breastbone	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
71130	TC	A	X-ray exam of breastbone	0.00	0.71	0.72	NA	NA	0.03	0.74	0.75	NA	NA	XXX
71250		A	Cat scan of chest	1.16	6.37	6.45	NA	NA	0.32	7.85	7.93	NA	NA	XXX
71250	26	A	Cat scan of chest	1.16	0.40	0.44	0.40	0.44	0.05	1.61	1.65	1.61	1.65	XXX
71250	TC	A	Cat scan of chest	0.00	5.97	6.01	NA	NA	0.27	6.24	6.28	NA	NA	XXX
71260		A	Contrast CAT scan of chest	1.24	7.58	7.66	NA	NA	0.37	9.19	9.27	NA	NA	XXX
71260	26	A	Contrast CAT scan of chest	1.24	0.43	0.47	0.43	0.47	0.05	1.72	1.76	1.72	1.76	XXX
71260	TC	A	Contrast CAT scan of chest	0.00	7.15	7.19	NA	NA	0.32	7.47	7.51	NA	NA	XXX
71270		A	Contrast CAT scans of chest	1.38	9.42	9.52	NA	NA	0.44	11.24	11.34	NA	NA	XXX
71270	26	A	Contrast CAT scans of chest	1.38	0.48	0.53	0.48	0.53	0.05	1.91	1.96	1.91	1.96	XXX
71270	TC	A	Contrast CAT scans of chest	0.00	8.94	8.99	NA	NA	0.39	9.33	9.38	NA	NA	XXX
71550		A	Magnetic image, chest (mri)	1.60	11.89	12.02	NA	NA	0.56	14.05	14.18	NA	NA	XXX
71550	26	A	Magnetic image, chest (mri)	1.60	0.56	0.62	0.56	0.62	0.06	2.22	2.28	2.22	2.28	XXX
71550	TC	A	Magnetic image, chest (mri)	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
71555		R	Magnetic image, chest (mra)	1.81	11.96	12.07	NA	NA	0.57	14.34	14.45	NA	NA	XXX
71555	26	R	Magnetic image, chest (mra)	1.81	0.63	0.67	0.63	0.67	0.07	2.51	2.55	2.51	2.55	XXX
71555	TC	R	Magnetic image, chest (mra)	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
72010		A	X-ray exam of spine	0.45	1.20	1.23	NA	NA	0.07	1.72	1.75	NA	NA	XXX
72010	26	A	X-ray exam of spine	0.45	0.16	0.18	0.16	0.18	0.02	0.63	0.65	0.63	0.65	XXX
72010	TC	A	X-ray exam of spine	0.00	1.04	1.05	NA	NA	0.05	1.09	1.10	NA	NA	XXX
72020		A	X-ray exam of spine	0.15	0.47	0.48	NA	NA	0.03	0.65	0.66	NA	NA	XXX
72020	26	A	X-ray exam of spine	0.15	0.05	0.06	0.05	0.06	0.01	0.21	0.22	0.21	0.22	XXX
72020	TC	A	X-ray exam of spine	0.00	0.42	0.42	NA	NA	0.02	0.44	0.44	NA	NA	XXX
72040		A	X-ray exam of neck spine	0.22	0.69	0.70	NA	NA	0.04	0.95	0.96	NA	NA	XXX
72040	26	A	X-ray exam of neck spine	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
72040	TC	A	X-ray exam of neck spine	0.00	0.61	0.61	NA	NA	0.03	0.64	0.64	NA	NA	XXX
72050		A	X-ray exam of neck spine	0.31	1.01	1.03	NA	NA	0.06	1.38	1.40	NA	NA	XXX
72050	26	A	X-ray exam of neck spine	0.31	0.11	0.12	0.11	0.12	0.01	0.43	0.44	0.43	0.44	XXX
72050	TC	A	X-ray exam of neck spine	0.00	0.90	0.91	NA	NA	0.05	0.95	0.96	NA	NA	XXX
72052		A	X-ray exam of neck spine	0.36	1.27	1.29	NA	NA	0.06	1.69	1.71	NA	NA	XXX
72052	26	A	X-ray exam of neck spine	0.36	0.13	0.14	0.13	0.14	0.01	0.50	0.51	0.50	0.51	XXX
72052	TC	A	X-ray exam of neck spine	0.00	1.14	1.15	NA	NA	0.05	1.19	1.20	NA	NA	XXX
72069		A	X-ray exam of trunk spine	0.22	0.58	0.59	NA	NA	0.03	0.83	0.84	NA	NA	XXX
72069	26	A	X-ray exam of trunk spine	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
72069	TC	A	X-ray exam of trunk spine	0.00	0.50	0.50	NA	NA	0.02	0.52	0.52	NA	NA	XXX
72070		A	X-ray exam of thoracic spine	0.22	0.73	0.75	NA	NA	0.04	0.99	1.01	NA	NA	XXX
72070	26	A	X-ray exam of thoracic spine	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
72070	TC	A	X-ray exam of thoracic spine	0.00	0.65	0.66	NA	NA	0.03	0.68	0.69	NA	NA	XXX
72072		A	X-ray exam of thoracic spine	0.22	0.82	0.84	NA	NA	0.05	1.09	1.11	NA	NA	XXX
72072	26	A	X-ray exam of thoracic spine	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
72072	TC	A	X-ray exam of thoracic spine	0.00	0.74	0.75	NA	NA	0.04	0.78	0.79	NA	NA	XXX
72074		A	X-ray exam of thoracic spine	0.22	1.00	1.02	NA	NA	0.06	1.28	1.30	NA	NA	XXX
72074	26	A	X-ray exam of thoracic spine	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
72074	TC	A	X-ray exam of thoracic spine	0.00	0.92	0.93	NA	NA	0.05	0.97	0.98	NA	NA	XXX
72080		A	X-ray exam of trunk spine	0.22	0.75	0.77	NA	NA	0.04	1.01	1.03	NA	NA	XXX
72080	26	A	X-ray exam of trunk spine	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
72080	TC	A	X-ray exam of trunk spine	0.00	0.67	0.68	NA	NA	0.03	0.70	0.71	NA	NA	XXX
72090		A	X-ray exam of trunk spine	0.28	0.77	0.79	NA	NA	0.04	1.09	1.11	NA	NA	XXX
72090	26	A	X-ray exam of trunk spine	0.28	0.10	0.11	0.10	0.11	0.01	0.39	0.40	0.39	0.40	XXX
72090	TC	A	X-ray exam of trunk spine	0.00	0.67	0.68	NA	NA	0.03	0.70	0.71	NA	NA	XXX
72100		A	X-ray exam of lower spine	0.22	0.75	0.77	NA	NA	0.04	1.01	1.03	NA	NA	XXX
72100	26	A	X-ray exam of lower spine	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
72100	TC	A	X-ray exam of lower spine	0.00	0.67	0.68	NA	NA	0.03	0.70	0.71	NA	NA	XXX
72110		A	X-ray exam of lower spine	0.31	1.03	1.05	NA	NA	0.06	1.40	1.42	NA	NA	XXX
72110	26	A	X-ray exam of lower spine	0.31	0.11	0.12	0.11	0.12	0.01	0.43	0.44	0.43	0.44	XXX
72110	TC	A	X-ray exam of lower spine	0.00	0.92	0.93	NA	NA	0.05	0.97	0.98	NA	NA	XXX
72114		A	X-ray exam of lower spine	0.36	1.33	1.35	NA	NA	0.07	1.76	1.78	NA	NA	XXX
72114	26	A	X-ray exam of lower spine	0.36	0.13	0.14	0.13	0.14	0.02	0.51	0.52	0.51	0.52	XXX
72114	TC	A	X-ray exam of lower spine	0.00	1.20	1.21	NA	NA	0.05	1.25	1.26	NA	NA	XXX
72120		A	X-ray exam of lower spine	0.22	0.98	1.00	NA	NA	0.06	1.26	1.28	NA	NA	XXX
72120	26	A	X-ray exam of lower spine	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
72120	TC	A	X-ray exam of lower spine	0.00	0.90	0.91	NA	NA	0.05	0.95	0.96	NA	NA	XXX
72125		A	CAT scan of neck spine	1.16	6.37	6.45	NA	NA	0.32	7.85	7.93	NA	NA	XXX
72125	26	A	CAT scan of neck spine	1.16	0.40	0.44	0.40	0.44	0.05	1.61	1.65	1.61	1.65	XXX
72125	TC	A	CAT scan of neck spine	0.00	5.97	6.01	NA	NA	0.27	6.24	6.28	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
72126	.....	A	Contrast CAT scan of neck	1.22	7.57	7.65	NA	NA	0.37	9.16	9.24	NA	NA	XXX
72126	26	A	Contrast CAT scan of neck	1.22	0.42	0.46	0.42	0.46	0.05	1.69	1.73	1.69	1.73	XXX
72126	TC	A	Contrast CAT scan of neck	0.00	7.15	7.19	NA	NA	0.32	7.47	7.51	NA	NA	XXX
72127	.....	A	Contrast CAT scans of neck	1.27	9.38	9.47	NA	NA	0.44	11.09	11.18	NA	NA	XXX
72127	26	A	Contrast CAT scans of neck	1.27	0.44	0.48	0.44	0.48	0.05	1.76	1.80	1.76	1.80	XXX
72127	TC	A	Contrast CAT scans of neck	0.00	8.94	8.99	NA	NA	0.39	9.33	9.38	NA	NA	XXX
72128	.....	A	CAT scan of thorax spine	1.16	6.37	6.45	NA	NA	0.32	7.85	7.93	NA	NA	XXX
72128	26	A	CAT scan of thorax spine	1.16	0.40	0.44	0.40	0.44	0.05	1.61	1.65	1.61	1.65	XXX
72128	TC	A	CAT scan of thorax spine	0.00	5.97	6.01	NA	NA	0.27	6.24	6.28	NA	NA	XXX
72129	.....	A	Contrast CAT scan of thorax	1.22	7.57	7.65	NA	NA	0.37	9.16	9.24	NA	NA	XXX
72129	26	A	Contrast CAT scan of thorax	1.22	0.42	0.46	0.42	0.46	0.05	1.69	1.73	1.69	1.73	XXX
72129	TC	A	Contrast CAT scan of thorax	0.00	7.15	7.19	NA	NA	0.32	7.47	7.51	NA	NA	XXX
72130	.....	A	Contrast CAT scans of thorax	1.27	9.38	9.47	NA	NA	0.44	11.09	11.18	NA	NA	XXX
72130	26	A	Contrast CAT scans of thorax	1.27	0.44	0.48	0.44	0.48	0.05	1.76	1.80	1.76	1.80	XXX
72130	TC	A	Contrast CAT scans of thorax	0.00	8.94	8.99	NA	NA	0.39	9.33	9.38	NA	NA	XXX
72131	.....	A	CAT scan of lower spine	1.16	6.37	6.45	NA	NA	0.32	7.85	7.93	NA	NA	XXX
72131	26	A	CAT scan of lower spine	1.16	0.40	0.44	0.40	0.44	0.05	1.61	1.65	1.61	1.65	XXX
72131	TC	A	CAT scan of lower spine	0.00	5.97	6.01	NA	NA	0.27	6.24	6.28	NA	NA	XXX
72132	.....	A	Contrast CAT of lower spine	1.22	7.57	7.65	NA	NA	0.37	9.16	9.24	NA	NA	XXX
72132	26	A	Contrast CAT of lower spine	1.22	0.42	0.46	0.42	0.46	0.05	1.69	1.73	1.69	1.73	XXX
72132	TC	A	Contrast CAT of lower spine	0.00	7.15	7.19	NA	NA	0.32	7.47	7.51	NA	NA	XXX
72133	.....	A	Contrst cat scans, low spine	1.27	9.39	9.48	NA	NA	0.44	11.10	11.19	NA	NA	XXX
72133	26	A	Contrst cat scans, low spine	1.27	0.45	0.49	0.45	0.49	0.05	1.77	1.81	1.77	1.81	XXX
72133	TC	A	Contrst cat scans, low spine	0.00	8.94	8.99	NA	NA	0.39	9.33	9.38	NA	NA	XXX
72141	.....	A	Magnetic image, neck spine	1.60	11.89	12.02	NA	NA	0.56	14.05	14.18	NA	NA	XXX
72141	26	A	Magnetic image, neck spine	1.60	0.56	0.62	0.56	0.62	0.06	2.22	2.28	2.22	2.28	XXX
72141	TC	A	Magnetic image, neck spine	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
72142	.....	A	Magnetic image, neck spine	1.92	14.27	14.41	NA	NA	0.68	16.87	17.01	NA	NA	XXX
72142	26	A	Magnetic image, neck spine	1.92	0.68	0.74	0.68	0.74	0.08	2.68	2.74	2.68	2.74	XXX
72142	TC	A	Magnetic image, neck spine	0.00	13.59	13.67	NA	NA	0.60	14.19	14.27	NA	NA	XXX
72146	.....	A	Magnetic image, chest spine	1.60	13.14	13.27	NA	NA	0.61	15.35	15.48	NA	NA	XXX
72146	26	A	Magnetic image, chest spine	1.60	0.56	0.62	0.56	0.62	0.06	2.22	2.28	2.22	2.28	XXX
72146	TC	A	Magnetic image, chest spine	0.00	12.58	12.65	NA	NA	0.55	13.13	13.20	NA	NA	XXX
72147	.....	A	Magnetic image, chest spine	1.92	14.26	14.41	NA	NA	0.68	16.86	17.01	NA	NA	XXX
72147	26	A	Magnetic image, chest spine	1.92	0.67	0.74	0.67	0.74	0.08	2.67	2.74	2.67	2.74	XXX
72147	TC	A	Magnetic image, chest spine	0.00	13.59	13.67	NA	NA	0.60	14.19	14.27	NA	NA	XXX
72148	.....	A	Magnetic image, lumbar spine	1.48	13.10	13.22	NA	NA	0.61	15.19	15.31	NA	NA	XXX
72148	26	A	Magnetic image, lumbar spine	1.48	0.52	0.57	0.52	0.57	0.06	2.06	2.11	2.06	2.11	XXX
72148	TC	A	Magnetic image, lumbar spine	0.00	12.58	12.65	NA	NA	0.55	13.13	13.20	NA	NA	XXX
72149	.....	A	Magnetic image, lumbar spine	1.78	14.22	14.36	NA	NA	0.67	16.67	16.81	NA	NA	XXX
72149	26	A	Magnetic image, lumbar spine	1.78	0.63	0.69	0.63	0.69	0.07	2.48	2.54	2.48	2.54	XXX
72149	TC	A	Magnetic image, lumbar spine	0.00	13.59	13.67	NA	NA	0.60	14.19	14.27	NA	NA	XXX
72156	.....	A	Magnetic image, neck spine	2.57	26.06	26.30	NA	NA	1.22	29.85	30.09	NA	NA	XXX
72156	26	A	Magnetic image, neck spine	2.57	0.90	0.99	0.90	0.99	0.10	3.57	3.66	3.57	3.66	XXX
72156	TC	A	Magnetic image, neck spine	0.00	25.16	25.31	NA	NA	1.12	26.28	26.43	NA	NA	XXX
72157	.....	A	Magnetic image, chest spine	2.57	26.06	26.30	NA	NA	1.22	29.85	30.09	NA	NA	XXX
72157	26	A	Magnetic image, chest spine	2.57	0.90	0.99	0.90	0.99	0.10	3.57	3.66	3.57	3.66	XXX
72157	TC	A	Magnetic image, chest spine	0.00	25.16	25.31	NA	NA	1.12	26.28	26.43	NA	NA	XXX
72158	.....	A	Magnetic image, lumbar spine	2.36	25.98	26.22	NA	NA	1.21	29.55	29.79	NA	NA	XXX
72158	26	A	Magnetic image, lumbar spine	2.36	0.82	0.91	0.82	0.91	0.09	3.27	3.36	3.27	3.36	XXX
72158	TC	A	Magnetic image, lumbar spine	0.00	25.16	25.31	NA	NA	1.12	26.28	26.43	NA	NA	XXX
72159	.....	N	Magnetic image, spine (mra)	1.80	13.29	13.36	NA	NA	0.62	15.71	15.78	NA	NA	XXX
72159	26	N	Magnetic image, spine (mra)	1.80	0.71	0.71	0.71	0.71	0.07	2.58	2.58	2.58	2.58	XXX
72159	TC	N	Magnetic image, spine (mra)	0.00	12.58	12.65	NA	NA	0.55	13.13	13.20	NA	NA	XXX
72170	.....	A	X-ray exam of pelvis	0.17	0.59	0.60	NA	NA	0.03	0.79	0.80	NA	NA	XXX
72170	26	A	X-ray exam of pelvis	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
72170	TC	A	X-ray exam of pelvis	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
72190	.....	A	X-ray exam of pelvis	0.21	0.74	0.76	NA	NA	0.04	0.99	1.01	NA	NA	XXX
72190	26	A	X-ray exam of pelvis	0.21	0.07	0.08	0.07	0.08	0.01	0.29	0.30	0.29	0.30	XXX
72190	TC	A	X-ray exam of pelvis	0.00	0.67	0.68	NA	NA	0.03	0.70	0.71	NA	NA	XXX
72192	.....	A	CAT scan of pelvis	1.09	6.35	6.43	NA	NA	0.31	7.75	7.83	NA	NA	XXX
72192	26	A	CAT scan of pelvis	1.09	0.38	0.42	0.38	0.42	0.04	1.51	1.55	1.51	1.55	XXX
72192	TC	A	CAT scan of pelvis	0.00	5.97	6.01	NA	NA	0.27	6.24	6.28	NA	NA	XXX
72193	.....	A	Contrast CAT scan of pelvis	1.16	7.32	7.40	NA	NA	0.36	8.84	8.92	NA	NA	XXX
72193	26	A	Contrast CAT scan of pelvis	1.16	0.40	0.44	0.40	0.44	0.05	1.61	1.65	1.61	1.65	XXX
72193	TC	A	Contrast CAT scan of pelvis	0.00	6.92	6.96	NA	NA	0.31	7.23	7.27	NA	NA	XXX
72194	.....	A	Contrast CAT scans of pelvis	1.22	9.00	9.09	NA	NA	0.42	10.64	10.73	NA	NA	XXX
72194	26	A	Contrast CAT scans of pelvis	1.22	0.42	0.46	0.42	0.46	0.05	1.69	1.73	1.69	1.73	XXX
72194	TC	A	Contrast CAT scans of pelvis	0.00	8.58	8.63	NA	NA	0.37	8.95	9.00	NA	NA	XXX
72196	.....	A	Magnetic image, pelvis	1.60	11.89	12.02	NA	NA	0.56	14.05	14.18	NA	NA	XXX
72196	26	A	Magnetic image, pelvis	1.60	0.56	0.62	0.56	0.62	0.06	2.22	2.28	2.22	2.28	XXX
72196	TC	A	Magnetic image, pelvis	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
72198	.....	N	Magnetic image, pelvis (mra)	1.80	12.04	12.13	NA	NA	0.57	14.41	14.50	NA	NA	XXX
72198	26	N	Magnetic image, pelvis (mra)	1.80	0.71	0.73	0.71	0.73	0.07	2.58	2.60	2.58	2.60	XXX
72198	TC	N	Magnetic image, pelvis (mra)	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
72200	.....	A	X-ray exam sacroiliac joints	0.17	0.59	0.60	NA	NA	0.03	0.79	0.80	NA	NA	XXX
72200	26	A	X-ray exam sacroiliac joints	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
72200	TC	A	X-ray exam sacroiliac joints	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
72202	.....	A	X-ray exam sacroiliac joints	0.19	0.70	0.71	NA	NA	0.04	0.93	0.94	NA	NA	XXX
72202	26	A	X-ray exam sacroiliac joints	0.19	0.07	0.08	0.07	0.08	0.01	0.27	0.28	0.27	0.28	XXX
72202	TC	A	X-ray exam sacroiliac joints	0.00	0.63	0.63	NA	NA	0.03	0.66	0.66	NA	NA	XXX
72220	.....	A	X-ray exam of tailbone	0.17	0.64	0.65	NA	NA	0.04	0.85	0.86	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
72220	26	A	X-ray exam of tailbone	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
72220	TC	A	X-ray exam of tailbone	0.00	0.58	0.58	NA	NA	0.03	0.61	0.61	NA	NA	XXX
72240		A	Contrast x-ray of neck spine	0.91	5.10	5.17	NA	NA	0.26	6.27	6.34	NA	NA	XXX
72240	26	A	Contrast x-ray of neck spine	0.91	0.30	0.34	0.30	0.34	0.04	1.25	1.29	1.25	1.29	XXX
72240	TC	A	Contrast x-ray of neck spine	0.00	4.80	4.83	NA	NA	0.22	5.02	5.05	NA	NA	XXX
72255		A	Contrast x-ray, thorax spine	0.91	4.66	4.73	NA	NA	0.23	5.80	5.87	NA	NA	XXX
72255	26	A	Contrast x-ray, thorax spine	0.91	0.28	0.32	0.28	0.32	0.04	1.23	1.27	1.23	1.27	XXX
72255	TC	A	Contrast x-ray, thorax spine	0.00	4.38	4.41	NA	NA	0.19	4.57	4.60	NA	NA	XXX
72265		A	Contrast x-ray, lower spine	0.83	4.38	4.44	NA	NA	0.23	5.44	5.50	NA	NA	XXX
72265	26	A	Contrast x-ray, lower spine	0.83	0.26	0.30	0.26	0.30	0.04	1.13	1.17	1.13	1.17	XXX
72265	TC	A	Contrast x-ray, lower spine	0.00	4.12	4.14	NA	NA	0.19	4.31	4.33	NA	NA	XXX
72270		A	Contrast x-ray of spine	1.33	6.61	6.70	NA	NA	0.34	8.28	8.37	NA	NA	XXX
72270	26	A	Contrast x-ray of spine	1.33	0.44	0.49	0.44	0.49	0.06	1.83	1.88	1.83	1.88	XXX
72270	TC	A	Contrast x-ray of spine	0.00	6.17	6.21	NA	NA	0.28	6.45	6.49	NA	NA	XXX
72275		A	Epidurography	0.54	2.23	2.24	NA	NA	0.24	3.01	3.02	NA	NA	XXX
72275	26	A	Epidurography	0.54	0.17	0.17	0.17	0.17	0.05	0.76	0.76	0.76	0.76	XXX
72275	TC	A	Epidurography	0.00	2.06	2.07	NA	NA	0.19	2.25	2.26	NA	NA	XXX
72285		A	X-ray c/t spine disk	1.16	8.88	8.93	NA	NA	0.41	10.45	10.50	NA	NA	XXX
72285	26	A	X-ray c/t spine disk	1.16	0.41	0.41	0.41	0.41	0.04	1.61	1.61	1.61	1.61	XXX
72285	TC	A	X-ray c/t spine disk	0.00	8.47	8.52	NA	NA	0.37	8.84	8.89	NA	NA	XXX
72295		A	X-ray of lower spine disk	0.83	8.24	8.32	NA	NA	0.38	9.45	9.53	NA	NA	XXX
72295	26	A	X-ray of lower spine disk	0.83	0.29	0.32	0.29	0.32	0.04	1.16	1.19	1.16	1.19	XXX
72295	TC	A	X-ray of lower spine disk	0.00	7.95	8.00	NA	NA	0.34	8.29	8.34	NA	NA	XXX
73000		A	X-ray exam of collar bone	0.16	0.59	0.60	NA	NA	0.03	0.78	0.79	NA	NA	XXX
73000	26	A	X-ray exam of collar bone	0.16	0.06	0.07	0.06	0.07	0.01	0.23	0.24	0.23	0.24	XXX
73000	TC	A	X-ray exam of collar bone	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
73010		A	X-ray exam of shoulder blade	0.17	0.59	0.60	NA	NA	0.03	0.79	0.80	NA	NA	XXX
73010	26	A	X-ray exam of shoulder blade	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
73010	TC	A	X-ray exam of shoulder blade	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
73020		A	X-ray exam of shoulder	0.15	0.53	0.54	NA	NA	0.03	0.71	0.72	NA	NA	XXX
73020	26	A	X-ray exam of shoulder	0.15	0.05	0.06	0.05	0.06	0.01	0.21	0.22	0.21	0.22	XXX
73020	TC	A	X-ray exam of shoulder	0.00	0.48	0.48	NA	NA	0.02	0.50	0.50	NA	NA	XXX
73030		A	X-ray exam of shoulder	0.18	0.64	0.65	NA	NA	0.04	0.86	0.87	NA	NA	XXX
73030	26	A	X-ray exam of shoulder	0.18	0.06	0.07	0.06	0.07	0.01	0.25	0.26	0.25	0.26	XXX
73030	TC	A	X-ray exam of shoulder	0.00	0.58	0.58	NA	NA	0.03	0.61	0.61	NA	NA	XXX
73040		A	Contrast x-ray of shoulder	0.54	2.31	2.34	NA	NA	0.12	2.97	3.00	NA	NA	XXX
73040	26	A	Contrast x-ray of shoulder	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
73040	TC	A	Contrast x-ray of shoulder	0.00	2.12	2.13	NA	NA	0.10	2.22	2.23	NA	NA	XXX
73050		A	X-ray exam of shoulders	0.20	0.74	0.76	NA	NA	0.04	0.98	1.00	NA	NA	XXX
73050	26	A	X-ray exam of shoulders	0.20	0.07	0.08	0.07	0.08	0.01	0.28	0.29	0.28	0.29	XXX
73050	TC	A	X-ray exam of shoulders	0.00	0.67	0.68	NA	NA	0.03	0.70	0.71	NA	NA	XXX
73060		A	X-ray exam of humerus	0.17	0.64	0.65	NA	NA	0.04	0.85	0.86	NA	NA	XXX
73060	26	A	X-ray exam of humerus	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
73060	TC	A	X-ray exam of humerus	0.00	0.58	0.58	NA	NA	0.03	0.61	0.61	NA	NA	XXX
73070		A	X-ray exam of elbow	15	0.58	0.59	NA	NA	0.03	0.76	0.77	NA	NA	XXX
73070	26	A	X-ray exam of elbow	0.15	0.05	0.06	0.05	0.06	0.01	0.21	0.22	0.21	0.22	XXX
73070	TC	A	X-ray exam of elbow	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
73080		A	X-ray exam of elbow	0.17	0.64	0.65	NA	NA	0.04	0.85	0.86	NA	NA	XXX
73080	26	A	X-ray exam of elbow	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
73080	TC	A	X-ray exam of elbow	0.00	0.58	0.58	NA	NA	0.03	0.61	0.61	NA	NA	XXX
73085		A	Contrast x-ray of elbow	0.54	2.32	2.35	NA	NA	0.12	2.98	3.01	NA	NA	XXX
73085	26	A	Contrast x-ray of elbow	0.54	0.20	0.22	0.20	0.22	0.02	0.76	0.78	0.76	0.78	XXX
73085	TC	A	Contrast x-ray of elbow	0.00	2.12	2.13	NA	NA	0.10	2.22	2.23	NA	NA	XXX
73090		A	X-ray exam of forearm	0.16	0.59	0.60	NA	NA	0.03	0.78	0.79	NA	NA	XXX
73090	26	A	X-ray exam of forearm	0.16	0.06	0.07	0.06	0.07	0.01	0.23	0.24	0.23	0.24	XXX
73090	TC	A	X-ray exam of forearm	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
73092		A	X-ray exam of arm, infant	0.16	0.56	0.57	NA	NA	0.03	0.75	0.76	NA	NA	XXX
73092	26	A	X-ray exam of arm, infant	0.16	0.06	0.07	0.06	0.07	0.01	0.23	0.24	0.23	0.24	XXX
73092	TC	A	X-ray exam of arm, infant	0.00	0.50	0.50	NA	NA	0.02	0.52	0.52	NA	NA	XXX
73100		A	X-ray exam of wrist	0.16	0.56	0.57	NA	NA	0.03	0.75	0.76	NA	NA	XXX
73100	26	A	X-ray exam of wrist	0.16	0.06	0.07	0.06	0.07	0.01	0.23	0.24	0.23	0.24	XXX
73100	TC	A	X-ray exam of wrist	0.00	0.50	0.50	NA	NA	0.02	0.52	0.52	NA	NA	XXX
73110		A	X-ray exam of wrist	0.17	0.60	0.61	NA	NA	0.03	0.80	0.81	NA	NA	XXX
73110	26	A	X-ray exam of wrist	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
73110	TC	A	X-ray exam of wrist	0.00	0.54	0.54	NA	NA	0.02	0.56	0.56	NA	NA	XXX
73115		A	Contrast x-ray of wrist	0.54	1.79	1.82	NA	NA	0.10	2.43	2.46	NA	NA	XXX
73115	26	A	Contrast x-ray of wrist	0.54	0.20	0.22	0.20	0.22	0.02	0.76	0.78	0.76	0.78	XXX
73115	TC	A	Contrast x-ray of wrist	0.00	1.59	1.60	NA	NA	0.08	1.67	1.68	NA	NA	XXX
73120		A	X-ray exam of hand	0.16	0.56	0.57	NA	NA	0.03	0.75	0.76	NA	NA	XXX
73120	26	A	X-ray exam of hand	0.16	0.06	0.07	0.06	0.07	0.01	0.23	0.24	0.23	0.24	XXX
73120	TC	A	X-ray exam of hand	0.00	0.50	0.50	NA	NA	0.02	0.52	0.52	NA	NA	XXX
73130		A	X-ray exam of hand	0.17	0.60	0.61	NA	NA	0.03	0.80	0.81	NA	NA	XXX
73130	26	A	X-ray exam of hand	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
73130	TC	A	X-ray exam of hand	0.00	0.54	0.54	NA	NA	0.02	0.56	0.56	NA	NA	XXX
73140		A	X-ray exam of finger(s)	0.13	0.47	0.48	NA	NA	0.03	0.63	0.64	NA	NA	XXX
73140	26	A	X-ray exam of finger(s)	0.13	0.05	0.06	0.05	0.06	0.01	0.19	0.20	0.19	0.20	XXX
73140	TC	A	X-ray exam of finger(s)	0.00	0.42	0.42	NA	NA	0.02	0.44	0.44	NA	NA	XXX
73200		A	CAT scan of arm	1.09	5.39	5.46	NA	NA	0.26	6.74	6.81	NA	NA	XXX
73200	26	A	CAT scan of arm	1.09	0.38	0.42	0.38	0.42	0.04	1.51	1.55	1.51	1.55	XXX
73200	TC	A	CAT scan of arm	0.00	5.01	5.04	NA	NA	0.22	5.23	5.26	NA	NA	XXX
73201		A	Contrast CAT scan of arm	1.16	6.37	6.45	NA	NA	0.32	7.85	7.93	NA	NA	XXX
73201	26	A	Contrast CAT scan of arm	1.16	0.40	0.44	0.40	0.44	0.05	1.61	1.65	1.61	1.65	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
73201	TC	A	Contrast CAT scan of arm	0.00	5.97	6.01	NA	NA	0.27	6.24	6.28	NA	NA	XXX
73202		A	Contrast CAT scans of arm	1.22	7.94	8.02	NA	NA	0.38	9.54	9.62	NA	NA	XXX
73202	26	A	Contrast CAT scans of arm	1.22	0.43	0.47	0.43	0.47	0.05	1.70	1.74	1.70	1.74	XXX
73202	TC	A	Contrast CAT scans of arm	0.00	7.51	7.55	NA	NA	0.33	7.84	7.88	NA	NA	XXX
73220		A	Magnetic image, arm/hand	1.48	11.85	11.97	NA	NA	0.56	13.89	14.01	NA	NA	XXX
73220	26	A	Magnetic image, arm/hand	1.48	0.52	0.57	0.52	0.57	0.06	2.06	2.11	2.06	2.11	XXX
73220	TC	A	Magnetic image, arm/hand	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
73221		A	Magnetic image, joint of arm	1.48	11.85	11.91	NA	NA	0.56	13.89	13.95	NA	NA	XXX
73221	26	A	Magnetic image, joint of arm	1.48	0.52	0.51	0.52	0.51	0.06	2.06	2.05	2.06	2.05	XXX
73221	TC	A	Magnetic image, joint of arm	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
73225		N	Magnetic image, upper (mra)	1.73	12.02	12.10	NA	NA	0.57	14.32	14.40	NA	NA	XXX
73225	26	N	Magnetic image, upper (mra)	1.73	0.69	0.70	0.69	0.70	0.07	2.49	2.50	2.49	2.50	XXX
73225	TC	N	Magnetic image, upper (mra)	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
73500		A	X-ray exam of hip	0.17	0.54	0.55	NA	NA	0.03	0.74	0.75	NA	NA	XXX
73500	26	A	X-ray exam of hip	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
73500	TC	A	X-ray exam of hip	0.00	0.48	0.48	NA	NA	0.02	0.50	0.50	NA	NA	XXX
73510		A	X-ray exam of hip	0.21	0.65	0.66	NA	NA	0.04	0.90	0.91	NA	NA	XXX
73510	26	A	X-ray exam of hip	0.21	0.07	0.08	0.07	0.08	0.01	0.29	0.30	0.29	0.30	XXX
73510	TC	A	X-ray exam of hip	0.00	0.58	0.58	NA	NA	0.03	0.61	0.61	NA	NA	XXX
73520		A	X-ray exam of hips	0.26	0.76	0.78	NA	NA	0.04	1.06	1.08	NA	NA	XXX
73520	26	A	X-ray exam of hips	0.26	0.09	0.10	0.09	0.10	0.01	0.36	0.37	0.36	0.37	XXX
73520	TC	A	X-ray exam of hips	0.00	0.67	0.68	NA	NA	0.03	0.70	0.71	NA	NA	XXX
73525		A	Contrast x-ray of hip	0.54	2.31	2.34	NA	NA	0.12	2.97	3.00	NA	NA	XXX
73525	26	A	Contrast x-ray of hip	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
73525	TC	A	Contrast x-ray of hip	0.00	2.12	2.13	NA	NA	0.10	2.22	2.23	NA	NA	XXX
73530		A	X-ray exam of hip	0.29	0.63	0.64	NA	NA	0.03	0.95	0.96	NA	NA	XXX
73530	26	A	X-ray exam of hip	0.29	0.10	0.11	0.10	0.11	0.01	0.40	0.41	0.40	0.41	XXX
73530	TC	A	X-ray exam of hip	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
73540		A	X-ray exam of pelvis & hips	0.20	0.65	0.66	NA	NA	0.04	0.89	0.90	NA	NA	XXX
73540	26	A	X-ray exam of pelvis & hips	0.20	0.07	0.08	0.07	0.08	0.01	0.28	0.29	0.28	0.29	XXX
73540	TC	A	X-ray exam of pelvis & hips	0.00	0.58	0.58	NA	NA	0.03	0.61	0.61	NA	NA	XXX
73542		A	X-ray exam, sacroiliac joint	0.54	2.25	2.26	NA	NA	0.14	2.93	2.94	NA	NA	XXX
73542	26	A	X-ray exam, sacroiliac joint	0.54	0.19	0.19	0.19	0.19	0.04	0.77	0.77	0.77	0.77	XXX
73542	TC	A	X-ray exam, sacroiliac joint	0.00	2.06	2.07	NA	NA	0.10	2.16	2.17	NA	NA	XXX
73550		A	X-ray exam of thigh	0.17	0.64	0.65	NA	NA	0.04	0.85	0.86	NA	NA	XXX
73550	26	A	X-ray exam of thigh	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
73550	TC	A	X-ray exam of thigh	0.00	0.58	0.58	NA	NA	0.03	0.61	0.61	NA	NA	XXX
73560		A	X-ray exam of knee, 1 or 2	0.17	0.59	0.60	NA	NA	0.03	0.79	0.80	NA	NA	XXX
73560	26	A	X-ray exam of knee, 1 or 2	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
73560	TC	A	X-ray exam of knee, 1 or 2	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
73562		A	X-ray exam of knee, 3	0.18	0.64	0.65	NA	NA	0.04	0.86	0.87	NA	NA	XXX
73562	26	A	X-ray exam of knee, 3	0.18	0.06	0.07	0.06	0.07	0.01	0.25	0.26	0.25	0.26	XXX
73562	TC	A	X-ray exam of knee, 3	0.00	0.58	0.58	NA	NA	0.03	0.61	0.61	NA	NA	XXX
73564		A	X-ray exam, knee, 4 or more	0.22	0.71	0.72	NA	NA	0.04	0.97	0.98	NA	NA	XXX
73564	26	A	X-ray exam, knee, 4 or more	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
73564	TC	A	X-ray exam, knee, 4 or more	0.00	0.63	0.63	NA	NA	0.03	0.66	0.66	NA	NA	XXX
73565		A	X-ray exam of knees	0.17	0.56	0.57	NA	NA	0.03	0.76	0.77	NA	NA	XXX
73565	26	A	X-ray exam of knees	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
73565	TC	A	X-ray exam of knees	0.00	0.50	0.50	NA	NA	0.02	0.52	0.52	NA	NA	XXX
73580		A	Contrast x-ray of knee joint	0.54	2.83	2.87	NA	NA	0.14	3.51	3.55	NA	NA	XXX
73580	26	A	Contrast x-ray of knee joint	0.54	0.18	0.20	0.18	0.20	0.02	0.74	0.76	0.74	0.76	XXX
73580	TC	A	Contrast x-ray of knee joint	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
73590		A	X-ray exam of lower leg	0.17	0.59	0.60	NA	NA	0.03	0.79	0.80	NA	NA	XXX
73590	26	A	X-ray exam of lower leg	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
73590	TC	A	X-ray exam of lower leg	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
73592		A	X-ray exam of leg, infant	0.16	0.56	0.57	NA	NA	0.03	0.75	0.76	NA	NA	XXX
73592	26	A	X-ray exam of leg, infant	0.16	0.06	0.07	0.06	0.07	0.01	0.23	0.24	0.23	0.24	XXX
73592	TC	A	X-ray exam of leg, infant	0.00	0.50	0.50	NA	NA	0.02	0.52	0.52	NA	NA	XXX
73600		A	X-ray exam of ankle	0.16	0.56	0.57	NA	NA	0.03	0.75	0.76	NA	NA	XXX
73600	26	A	X-ray exam of ankle	0.16	0.06	0.07	0.06	0.07	0.01	0.23	0.24	0.23	0.24	XXX
73600	TC	A	X-ray exam of ankle	0.00	0.50	0.50	NA	NA	0.02	0.52	0.52	NA	NA	XXX
73610		A	X-ray exam of ankle	0.17	0.60	0.61	NA	NA	0.03	0.80	0.81	NA	NA	XXX
73610	26	A	X-ray exam of ankle	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
73610	TC	A	X-ray exam of ankle	0.00	0.54	0.54	NA	NA	0.02	0.56	0.56	NA	NA	XXX
73615		A	Contrast x-ray of ankle	0.54	2.31	2.34	NA	NA	0.12	2.97	3.00	NA	NA	XXX
73615	26	A	Contrast x-ray of ankle	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
73615	TC	A	Contrast x-ray of ankle	0.00	2.12	2.13	NA	NA	0.10	2.22	2.23	NA	NA	XXX
73620		A	X-ray exam of foot	0.16	0.56	0.57	NA	NA	0.03	0.75	0.76	NA	NA	XXX
73620	26	A	X-ray exam of foot	0.16	0.06	0.07	0.06	0.07	0.01	0.23	0.24	0.23	0.24	XXX
73620	TC	A	X-ray exam of foot	0.00	0.50	0.50	NA	NA	0.02	0.52	0.52	NA	NA	XXX
73630		A	X-ray exam of foot	0.17	0.60	0.61	NA	NA	0.03	0.80	0.81	NA	NA	XXX
73630	26	A	X-ray exam of foot	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
73630	TC	A	X-ray exam of foot	0.00	0.54	0.54	NA	NA	0.02	0.56	0.56	NA	NA	XXX
73650		A	X-ray exam of heel	0.16	0.54	0.55	NA	NA	0.03	0.73	0.74	NA	NA	XXX
73650	26	A	X-ray exam of heel	0.16	0.06	0.07	0.06	0.07	0.01	0.23	0.24	0.23	0.24	XXX
73650	TC	A	X-ray exam of heel	0.00	0.48	0.48	NA	NA	0.02	0.50	0.50	NA	NA	XXX
73660		A	X-ray exam of toe(s)	0.13	0.47	0.48	NA	NA	0.03	0.63	0.64	NA	NA	XXX
73660	26	A	X-ray exam of toe(s)	0.13	0.05	0.06	0.05	0.06	0.01	0.19	0.20	0.19	0.20	XXX
73660	TC	A	X-ray exam of toe(s)	0.00	0.42	0.42	NA	NA	0.02	0.44	0.44	NA	NA	XXX
3700		A	CAT scan of leg	1.09	5.39	5.46	NA	NA	0.26	6.74	6.81	NA	NA	XXX
73700	26	A	CAT scan of leg	1.09	0.38	0.42	0.38	0.42	0.04	1.51	1.55	1.51	1.55	XXX
73700	TC	A	CAT scan of leg	0.00	5.01	5.04	NA	NA	0.22	5.23	5.26	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
73701	.....	A	Contrast CAT scan of leg	1.16	6.37	6.45	NA	NA	0.32	7.85	7.93	NA	NA	XXX
73701	26	A	Contrast CAT scan of leg	1.16	0.40	0.44	0.40	0.44	0.05	1.61	1.65	1.61	1.65	XXX
73701	TC	A	Contrast CAT scan of leg	0.00	5.97	6.01	NA	NA	0.27	6.24	6.28	NA	NA	XXX
73702	.....	A	Contrast CAT scans of leg	1.22	7.93	8.01	NA	NA	0.38	9.53	9.61	NA	NA	XXX
73702	26	A	Contrast CAT scans of leg	1.22	0.42	0.46	0.42	0.46	0.05	1.69	1.73	1.69	1.73	XXX
73702	TC	A	Contrast CAT scans of leg	0.00	7.51	7.55	NA	NA	0.33	7.84	7.88	NA	NA	XXX
73720	.....	A	Magnetic image, leg/foot	1.48	11.85	11.97	NA	NA	0.56	13.89	14.01	NA	NA	XXX
73720	26	A	Magnetic image, leg/foot	1.48	0.52	0.57	0.52	0.57	0.06	2.06	2.11	2.06	2.11	XXX
73720	TC	A	Magnetic image, leg/foot	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
73721	.....	A	Magnetic image, joint of leg	1.48	11.85	11.91	NA	NA	0.56	13.89	13.95	NA	NA	XXX
73721	26	A	Magnetic image, joint of leg	1.48	0.52	0.51	0.52	0.51	0.06	2.06	2.05	2.06	2.05	XXX
73721	TC	A	Magnetic image, joint of leg	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
73725	.....	R	Magnetic image/lower (mra)	1.82	11.96	12.05	NA	NA	0.57	14.35	14.44	NA	NA	XXX
73725	26	R	Magnetic image/lower (mra)	1.82	0.63	0.65	0.63	0.65	0.07	2.52	2.54	2.52	2.54	XXX
73725	TC	R	Magnetic image/lower (mra)	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
74000	.....	A	X-ray exam of abdomen	0.18	0.59	0.60	NA	NA	0.03	0.80	0.81	NA	NA	XXX
74000	26	A	X-ray exam of abdomen	0.18	0.06	0.07	0.06	0.07	0.01	0.25	0.26	0.25	0.26	XXX
74000	TC	A	X-ray exam of abdomen	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
74010	.....	A	X-ray exam of abdomen	0.23	0.66	0.67	NA	NA	0.04	0.93	0.94	NA	NA	XXX
74010	26	A	X-ray exam of abdomen	0.23	0.08	0.09	0.08	0.09	0.01	0.32	0.33	0.32	0.33	XXX
74010	TC	A	X-ray exam of abdomen	0.00	0.58	0.58	NA	NA	0.03	0.61	0.61	NA	NA	XXX
74020	.....	A	X-ray exam of abdomen	0.27	0.72	0.73	NA	NA	0.04	1.03	1.04	NA	NA	XXX
74020	26	A	X-ray exam of abdomen	0.27	0.09	0.10	0.09	0.10	0.01	0.37	0.38	0.37	0.38	XXX
74020	TC	A	X-ray exam of abdomen	0.00	0.63	0.63	NA	NA	0.03	0.66	0.66	NA	NA	XXX
74022	.....	A	X-ray exam series, abdomen	0.32	0.85	0.87	NA	NA	0.05	1.22	1.24	NA	NA	XXX
74022	26	A	X-ray exam series, abdomen	0.32	0.11	0.12	0.11	0.12	0.01	0.44	0.45	0.44	0.45	XXX
74022	TC	A	X-ray exam series, abdomen	0.00	0.74	0.75	NA	NA	0.04	0.78	0.79	NA	NA	XXX
74150	.....	A	CAT scan of abdomen	1.19	6.13	6.20	NA	NA	0.31	7.63	7.70	NA	NA	XXX
74150	26	A	CAT scan of abdomen	1.19	0.41	0.45	0.41	0.45	0.05	1.65	1.69	1.65	1.69	XXX
74150	TC	A	CAT scan of abdomen	0.00	5.72	5.75	NA	NA	0.26	5.98	6.01	NA	NA	XXX
74160	.....	A	Contrast CAT scan of abdomen	1.27	7.36	7.44	NA	NA	0.36	8.99	9.07	NA	NA	XXX
74160	26	A	Contrast CAT scan of abdomen	1.27	0.44	0.48	0.44	0.48	0.05	1.76	1.80	1.76	1.80	XXX
74160	TC	A	Contrast CAT scan of abdomen	0.00	6.92	6.96	NA	NA	0.31	7.23	7.27	NA	NA	XXX
74170	.....	A	Contrast CAT scans, abdomen	1.40	9.07	9.17	NA	NA	0.43	10.90	11.00	NA	NA	XXX
74170	26	A	Contrast CAT scans, abdomen	1.40	0.49	0.54	0.49	0.54	0.06	1.95	2.00	1.95	2.00	XXX
74170	TC	A	Contrast CAT scans, abdomen	0.00	8.58	8.63	NA	NA	0.37	8.95	9.00	NA	NA	XXX
74181	.....	A	Magnetic image/abdomen (mri)	1.60	11.89	12.02	NA	NA	0.56	14.05	14.18	NA	NA	XXX
74181	26	A	Magnetic image/abdomen (mri)	1.60	0.56	0.62	0.56	0.62	0.06	2.22	2.28	2.22	2.28	XXX
74181	TC	A	Magnetic image/abdomen (mri)	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
74185	.....	R	Magnetic image/abdomen (MRA)	1.80	11.96	12.07	NA	NA	0.57	14.33	14.44	NA	NA	XXX
74185	26	R	Magnetic image/abdomen (MRA)	1.80	0.63	0.67	0.63	0.67	0.07	2.50	2.54	2.50	2.54	XXX
74185	TC	R	Magnetic image/abdomen (MRA)	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
74190	.....	A	X-ray exam of peritoneum	0.48	1.49	1.49	NA	NA	0.08	2.05	2.05	NA	NA	XXX
74190	26	A	X-ray exam of peritoneum	0.48	0.17	0.16	0.17	0.16	0.02	0.67	0.66	0.67	0.66	XXX
74190	TC	A	X-ray exam of peritoneum	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
74210	.....	A	Contrst x-ray exam of throat	0.36	1.33	1.35	NA	NA	0.06	1.75	1.77	NA	NA	XXX
74210	26	A	Contrst x-ray exam of throat	0.36	0.13	0.14	0.13	0.14	0.01	0.50	0.51	0.50	0.51	XXX
74210	TC	A	Contrst x-ray exam of throat	0.00	1.20	1.21	NA	NA	0.05	1.25	1.26	NA	NA	XXX
74220	.....	A	Contrast x-ray, esophagus	0.46	1.36	1.39	NA	NA	0.07	1.89	1.92	NA	NA	XXX
74220	26	A	Contrast x-ray, esophagus	0.46	0.16	0.18	0.16	0.18	0.02	0.64	0.66	0.64	0.66	XXX
74220	TC	A	Contrast x-ray, esophagus	0.00	1.20	1.21	NA	NA	0.05	1.25	1.26	NA	NA	XXX
74230	.....	A	Cinema x-ray, throat/esoph	0.53	1.51	1.54	NA	NA	0.08	2.12	2.15	NA	NA	XXX
74230	26	A	Cinema x-ray, throat/esoph	0.53	0.19	0.21	0.19	0.21	0.02	0.74	0.76	0.74	0.76	XXX
74230	TC	A	Cinema x-ray, throat/esoph	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
74235	.....	A	Remove esophagus obstruction	1.19	3.06	3.12	NA	NA	0.17	4.42	4.48	NA	NA	XXX
74235	26	A	Remove esophagus obstruction	1.19	0.41	0.45	0.41	0.45	0.05	1.65	1.69	1.65	1.69	XXX
74235	TC	A	Remove esophagus obstruction	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
74240	.....	A	X-ray exam, upper gi tract	0.69	1.72	1.76	NA	NA	0.10	2.51	2.55	NA	NA	XXX
74240	26	A	X-ray exam, upper gi tract	0.69	0.24	0.27	0.24	0.27	0.03	0.96	0.99	0.96	0.99	XXX
74240	TC	A	X-ray exam, upper gi tract	0.00	1.48	1.49	NA	NA	0.07	1.55	1.56	NA	NA	XXX
74241	.....	A	X-ray exam, upper gi tract	0.69	1.75	1.79	NA	NA	0.10	2.54	2.58	NA	NA	XXX
74241	26	A	X-ray exam, upper gi tract	0.69	0.24	0.27	0.24	0.27	0.03	0.96	0.99	0.96	0.99	XXX
74241	TC	A	X-ray exam, upper gi tract	0.00	1.51	1.52	NA	NA	0.07	1.58	1.59	NA	NA	XXX
74245	.....	A	X-ray exam, upper gi tract	0.91	2.72	2.77	NA	NA	0.15	3.78	3.83	NA	NA	XXX
74245	26	A	X-ray exam, upper gi tract	0.91	0.32	0.35	0.32	0.35	0.04	1.27	1.30	1.27	1.30	XXX
74245	TC	A	X-ray exam, upper gi tract	0.00	2.40	2.42	NA	NA	0.11	2.51	2.53	NA	NA	XXX
74246	.....	A	Contrst x-ray uppr gi tract	0.69	1.90	1.94	NA	NA	0.11	2.70	2.74	NA	NA	XXX
74246	26	A	Contrst x-ray uppr gi tract	0.69	0.24	0.27	0.24	0.27	0.03	0.96	0.99	0.96	0.99	XXX
74246	TC	A	Contrst x-ray uppr gi tract	0.00	1.66	1.67	NA	NA	0.08	1.74	1.75	NA	NA	XXX
74247	.....	A	Contrst x-ray uppr gi tract	0.69	1.94	1.98	NA	NA	0.12	2.75	2.79	NA	NA	XXX
74247	26	A	Contrst x-ray uppr gi tract	0.69	0.24	0.27	0.24	0.27	0.03	0.96	0.99	0.96	0.99	XXX
74247	TC	A	Contrst x-ray uppr gi tract	0.00	1.70	1.71	NA	NA	0.09	1.79	1.80	NA	NA	XXX
74249	.....	A	Contrst x-ray uppr gi tract	0.91	2.92	2.97	NA	NA	0.16	3.99	4.04	NA	NA	XXX
74249	26	A	Contrst x-ray uppr gi tract	0.91	0.32	0.35	0.32	0.35	0.04	1.27	1.30	1.27	1.30	XXX
74249	TC	A	Contrst x-ray uppr gi tract	0.00	2.60	2.62	NA	NA	0.12	2.72	2.74	NA	NA	XXX
74250	.....	A	X-ray exam of small bowel	0.47	1.48	1.51	NA	NA	0.08	2.03	2.06	NA	NA	XXX
74250	26	A	X-ray exam of small bowel	0.47	0.16	0.18	0.16	0.18	0.02	0.65	0.67	0.65	0.67	XXX
74250	TC	A	X-ray exam of small bowel	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
74251	.....	A	X-ray exam of small bowel	0.69	1.56	1.57	NA	NA	0.09	2.34	2.35	NA	NA	XXX
74251	26	A	X-ray exam of small bowel	0.69	0.24	0.24	0.24	0.24	0.03	0.96	0.96	0.96	0.96	XXX
74251	TC	A	X-ray exam of small bowel	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
74260	.....	A	X-ray exam of small bowel	0.50	1.68	1.71	NA	NA	0.09	2.27	2.30	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
74260	26	A	X-ray exam of small bowel	0.50	0.17	0.19	0.17	0.19	0.02	0.69	0.71	0.69	0.71	XXX
74260	TC	A	X-ray exam of small bowel	0.00	1.51	1.52	NA	NA	0.07	1.58	1.59	NA	NA	XXX
74270		A	Contrast x-ray exam of colon	0.69	1.96	2.00	NA	NA	0.12	2.77	2.81	NA	NA	XXX
74270	26	A	Contrast x-ray exam of colon	0.69	0.24	0.27	0.24	0.27	0.03	0.96	0.99	0.96	0.99	XXX
74270	TC	A	Contrast x-ray exam of colon	0.00	1.72	1.73	NA	NA	0.09	1.81	1.82	NA	NA	XXX
74280		A	Contrast x-ray exam of colon	0.99	2.60	2.65	NA	NA	0.15	3.74	3.79	NA	NA	XXX
74280	26	A	Contrast x-ray exam of colon	0.99	0.34	0.38	0.34	0.38	0.04	1.37	1.41	1.37	1.41	XXX
74280	TC	A	Contrast x-ray exam of colon	0.00	2.26	2.27	NA	NA	0.11	2.37	2.38	NA	NA	XXX
74283		A	Contrast x-ray exam of colon	2.02	3.29	3.38	NA	NA	0.20	5.51	5.60	NA	NA	XXX
74283	26	A	Contrast x-ray exam of colon	2.02	0.70	0.77	0.70	0.77	0.08	2.80	2.87	2.80	2.87	XXX
74283	TC	A	Contrast x-ray exam of colon	0.00	2.59	2.61	NA	NA	0.12	2.71	2.73	NA	NA	XXX
74290		A	Contrast x-ray, gallbladder	0.32	0.85	0.87	NA	NA	0.05	1.22	1.24	NA	NA	XXX
74290	26	A	Contrast x-ray, gallbladder	0.32	0.11	0.12	0.11	0.12	0.01	0.44	0.45	0.44	0.45	XXX
74290	TC	A	Contrast x-ray, gallbladder	0.00	0.74	0.75	NA	NA	0.04	0.78	0.79	NA	NA	XXX
74291		A	Contrast x-rays, gallbladder	0.20	0.49	0.50	NA	NA	0.03	0.72	0.73	NA	NA	XXX
74291	26	A	Contrast x-rays, gallbladder	0.20	0.07	0.08	0.07	0.08	0.01	0.28	0.29	0.28	0.29	XXX
74291	TC	A	Contrast x-rays, gallbladder	0.00	0.42	0.42	NA	NA	0.02	0.44	0.44	NA	NA	XXX
74300		C	X-ray bile ducts/pancreas	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
74300	26	A	X-ray bile ducts/pancreas	0.36	0.13	0.14	0.13	0.14	0.01	0.50	0.51	0.50	0.51	XXX
74300	TC	C	X-ray bile ducts/pancreas	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
74301		C	X-rays at surgery add-on	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	ZZZ
74301	26	A	X-rays at surgery add-on	0.21	0.07	0.08	0.07	0.08	0.01	0.29	0.30	0.29	0.30	ZZZ
74301	TC	C	X-rays at surgery add-on	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	ZZZ
74305		A	X-ray bile ducts/pancreas	0.42	0.94	0.97	NA	NA	0.06	1.42	1.45	NA	NA	XXX
74305	26	A	X-ray bile ducts/pancreas	0.42	0.15	0.17	0.15	0.17	0.02	0.59	0.61	0.59	0.61	XXX
74305	TC	A	X-ray bile ducts/pancreas	0.00	0.79	0.80	NA	NA	0.04	0.83	0.84	NA	NA	XXX
74320		A	Contrast x-ray of bile ducts	0.54	3.38	3.42	NA	NA	0.16	4.08	4.12	NA	NA	XXX
74320	26	A	Contrast x-ray of bile ducts	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
74320	TC	A	Contrast x-ray of bile ducts	0.00	3.19	3.21	NA	NA	0.14	3.33	3.35	NA	NA	XXX
74327		A	X-ray bile stone removal	0.70	2.02	2.06	NA	NA	0.12	2.84	2.88	NA	NA	XXX
74327	26	A	X-ray bile stone removal	0.70	0.24	0.27	0.24	0.27	0.03	0.97	1.00	0.97	1.00	XXX
74327	TC	A	X-ray bile stone removal	0.00	1.78	1.79	NA	NA	0.09	1.87	1.88	NA	NA	XXX
74328		A	Xray bile duct endoscopy	0.70	3.43	3.48	NA	NA	0.17	4.30	4.35	NA	NA	XXX
74328	26	A	Xray bile duct endoscopy	0.70	0.24	0.27	0.24	0.27	0.03	0.97	1.00	0.97	1.00	XXX
74328	TC	A	Xray bile duct endoscopy	0.00	3.19	3.21	NA	NA	0.14	3.33	3.35	NA	NA	XXX
74329		A	X-ray for pancreas endoscopy	0.70	3.43	3.48	NA	NA	0.17	4.30	4.35	NA	NA	XXX
74329	26	A	X-ray for pancreas endoscopy	0.70	0.24	0.27	0.24	0.27	0.03	0.97	1.00	0.97	1.00	XXX
74329	TC	A	X-ray for pancreas endoscopy	0.00	3.19	3.21	NA	NA	0.14	3.33	3.35	NA	NA	XXX
74330		A	X-ray bile/panc endoscopy	0.90	3.50	3.53	NA	NA	0.18	4.58	4.61	NA	NA	XXX
74330	26	A	X-ray bile/panc endoscopy	0.90	0.31	0.32	0.31	0.32	0.04	1.25	1.26	1.25	1.26	XXX
74330	TC	A	X-ray bile/panc endoscopy	0.00	3.19	3.21	NA	NA	0.14	3.33	3.35	NA	NA	XXX
74340		A	X-ray guide for GI tube	0.54	2.84	2.88	NA	NA	0.14	3.52	3.56	NA	NA	XXX
74340	26	A	X-ray guide for GI tube	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
74340	TC	A	X-ray guide for GI tube	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
74350		A	X-ray guide, stomach tube	0.76	3.45	3.50	NA	NA	0.17	4.38	4.43	NA	NA	XXX
74350	26	A	X-ray guide, stomach tube	0.76	0.26	0.29	0.26	0.29	0.03	1.05	1.08	1.05	1.08	XXX
74350	TC	A	X-ray guide, stomach tube	0.00	3.19	3.21	NA	NA	0.14	3.33	3.35	NA	NA	XXX
74355		A	X-ray guide, intestinal tube	0.76	2.91	2.96	NA	NA	0.15	3.82	3.87	NA	NA	XXX
74355	26	A	X-ray guide, intestinal tube	0.76	0.26	0.29	0.26	0.29	0.03	1.05	1.08	1.05	1.08	XXX
74355	TC	A	X-ray guide, intestinal tube	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
74360		A	X-ray guide, GI dilation	0.54	3.38	3.42	NA	NA	0.16	4.08	4.12	NA	NA	XXX
74360	26	A	X-ray guide, GI dilation	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
74360	TC	A	X-ray guide, GI dilation	0.00	3.19	3.21	NA	NA	0.14	3.33	3.35	NA	NA	XXX
74363		A	X-ray, bile duct dilation	0.88	6.47	6.54	NA	NA	0.32	7.67	7.74	NA	NA	XXX
74363	26	A	X-ray, bile duct dilation	0.88	0.30	0.33	0.30	0.33	0.04	1.22	1.25	1.22	1.25	XXX
74363	TC	A	X-ray, bile duct dilation	0.00	6.17	6.21	NA	NA	0.28	6.45	6.49	NA	NA	XXX
74400		A	Contrst x-ray, urinary tract	0.49	1.87	1.90	NA	NA	0.11	2.47	2.50	NA	NA	XXX
74400	26	A	Contrst x-ray, urinary tract	0.49	0.17	0.19	0.17	0.19	0.02	0.68	0.70	0.68	0.70	XXX
74400	TC	A	Contrst x-ray, urinary tract	0.00	1.70	1.71	NA	NA	0.09	1.79	1.80	NA	NA	XXX
74410		A	Contrst x-ray, urinary tract	0.49	2.14	2.17	NA	NA	0.11	2.74	2.77	NA	NA	XXX
74410	26	A	Contrst x-ray, urinary tract	0.49	0.17	0.19	0.17	0.19	0.02	0.68	0.70	0.68	0.70	XXX
74410	TC	A	Contrst x-ray, urinary tract	0.00	1.97	1.98	NA	NA	0.09	2.06	2.07	NA	NA	XXX
74415		A	Contrst x-ray, urinary tract	0.49	2.31	2.34	NA	NA	0.12	2.92	2.95	NA	NA	XXX
74415	26	A	Contrst x-ray, urinary tract	0.49	0.17	0.19	0.17	0.19	0.02	0.68	0.70	0.68	0.70	XXX
74415	TC	A	Contrst x-ray, urinary tract	0.00	2.14	2.15	NA	NA	0.10	2.24	2.25	NA	NA	XXX
74420		A	Contrst x-ray, urinary tract	0.36	2.77	2.80	NA	NA	0.14	3.27	3.30	NA	NA	XXX
74420	26	A	Contrst x-ray, urinary tract	0.36	0.12	0.13	0.12	0.13	0.02	0.50	0.51	0.50	0.51	XXX
74420	TC	A	Contrst x-ray, urinary tract	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
74425		A	Contrst x-ray, urinary tract	0.36	1.44	1.46	NA	NA	0.07	1.87	1.89	NA	NA	XXX
74425	26	A	Contrst x-ray, urinary tract	0.36	0.12	0.13	0.12	0.13	0.01	0.49	0.50	0.49	0.50	XXX
74425	TC	A	Contrst x-ray, urinary tract	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
74430		A	Contrast x-ray, bladder	0.32	1.18	1.20	NA	NA	0.06	1.56	1.58	NA	NA	XXX
74430	26	A	Contrast x-ray, bladder	0.32	0.11	0.12	0.11	0.12	0.01	0.44	0.45	0.44	0.45	XXX
74430	TC	A	Contrast x-ray, bladder	0.00	1.07	1.08	NA	NA	0.05	1.12	1.13	NA	NA	XXX
74440		A	X-ray, male genital tract	0.38	1.27	1.29	NA	NA	0.07	1.72	1.74	NA	NA	XXX
74440	26	A	X-ray, male genital tract	0.38	0.13	0.14	0.13	0.14	0.02	0.53	0.54	0.53	0.54	XXX
74440	TC	A	X-ray, male genital tract	0.00	1.14	1.15	NA	NA	0.05	1.19	1.20	NA	NA	XXX
74445		A	X-ray exam of penis	1.14	1.53	1.58	NA	NA	0.11	2.78	2.83	NA	NA	XXX
74445	26	A	X-ray exam of penis	1.14	0.39	0.43	0.39	0.43	0.06	1.59	1.63	1.59	1.63	XXX
74445	TC	A	X-ray exam of penis	0.00	1.14	1.15	NA	NA	0.05	1.19	1.20	NA	NA	XXX
74450		A	X-ray, urethra/bladder	0.33	1.59	1.61	NA	NA	0.08	2.00	2.02	NA	NA	XXX
74450	26	A	X-ray, urethra/bladder	0.33	0.11	0.12	0.11	0.12	0.01	0.45	0.46	0.45	0.46	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
74450	TC	A	X-ray, urethra/bladder	0.00	1.48	1.49	NA	NA	0.07	1.55	1.56	NA	NA	XXX
74455		A	X-ray, urethra/bladder	0.33	1.70	1.72	NA	NA	0.09	2.12	2.14	NA	NA	XXX
74455	26	A	X-ray, urethra/bladder	0.33	0.11	0.12	0.11	0.12	0.01	0.45	0.46	0.45	0.46	XXX
74455	TC	A	X-ray, urethra/bladder	0.00	1.59	1.60	NA	NA	0.08	1.67	1.68	NA	NA	XXX
74470		A	X-ray exam of kidney lesion	0.54	1.45	1.48	NA	NA	0.08	2.07	2.10	NA	NA	XXX
74470	26	A	X-ray exam of kidney lesion	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
74470	TC	A	X-ray exam of kidney lesion	0.00	1.26	1.27	NA	NA	0.06	1.32	1.33	NA	NA	XXX
74475		A	X-ray control, cath insert	0.54	4.31	4.35	NA	NA	0.21	5.06	5.10	NA	NA	XXX
74475	26	A	X-ray control, cath insert	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
74475	TC	A	X-ray control, cath insert	0.00	4.12	4.14	NA	NA	0.19	4.31	4.33	NA	NA	XXX
74480		A	X-ray control, cath insert	0.54	4.31	4.35	NA	NA	0.21	5.06	5.10	NA	NA	XXX
74480	26	A	X-ray control, cath insert	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
74480	TC	A	X-ray control, cath insert	0.00	4.12	4.14	NA	NA	0.19	4.31	4.33	NA	NA	XXX
74485		A	X-ray guide, GU dilation	0.54	3.37	3.41	NA	NA	0.16	4.07	4.11	NA	NA	XXX
74485	26	A	X-ray guide, GU dilation	0.54	0.18	0.20	0.18	0.20	0.02	0.74	0.76	0.74	0.76	XXX
74485	TC	A	X-ray guide, GU dilation	0.00	3.19	3.21	NA	NA	0.14	3.33	3.35	NA	NA	XXX
74710		A	X-ray measurement of pelvis	0.34	1.19	1.21	NA	NA	0.06	1.59	1.61	NA	NA	XXX
74710	26	A	X-ray measurement of pelvis	0.34	0.12	0.13	0.12	0.13	0.01	0.47	0.48	0.47	0.48	XXX
74710	TC	A	X-ray measurement of pelvis	0.00	1.07	1.08	NA	NA	0.05	1.12	1.13	NA	NA	XXX
74740		A	X-ray, female genital tract	0.38	1.45	1.47	NA	NA	0.08	1.91	1.93	NA	NA	XXX
74740	26	A	X-ray, female genital tract	0.38	0.13	0.14	0.13	0.14	0.02	0.53	0.54	0.53	0.54	XXX
74740	TC	A	X-ray, female genital tract	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
74742		A	X-ray, fallopian tube	0.61	3.40	3.44	NA	NA	0.16	4.17	4.21	NA	NA	XXX
74742	26	A	X-ray, fallopian tube	0.61	0.21	0.23	0.21	0.23	0.02	0.84	0.86	0.84	0.86	XXX
74742	TC	A	X-ray, fallopian tube	0.00	3.19	3.21	NA	NA	0.14	3.33	3.35	NA	NA	XXX
74775		A	X-ray exam of perineum	0.62	1.70	1.73	NA	NA	0.10	2.42	2.45	NA	NA	XXX
74775	26	A	X-ray exam of perineum	0.62	0.22	0.24	0.22	0.24	0.03	0.87	0.89	0.87	0.89	XXX
74775	TC	A	X-ray exam of perineum	0.00	1.48	1.49	NA	NA	0.07	1.55	1.56	NA	NA	XXX
75552		A	Magnetic image, myocardium	1.60	11.89	12.02	NA	NA	0.56	14.05	14.18	NA	NA	XXX
75552	26	A	Magnetic image, myocardium	1.60	0.56	0.62	0.56	0.62	0.06	2.22	2.28	2.22	2.28	XXX
75552	TC	A	Magnetic image, myocardium	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
75553		A	Magnetic image, myocardium	0.02	12.03	12.12	NA	NA	0.58	12.63	12.72	NA	NA	XXX
75553	26	A	Magnetic image, myocardium	0.02	0.70	0.72	0.70	0.72	0.08	0.80	0.82	0.80	0.82	XXX
75553	TC	A	Magnetic image, myocardium	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
75554		A	Cardiac MRI/function	1.83	12.01	12.11	NA	NA	0.57	14.41	14.51	NA	NA	XXX
75554	26	A	Cardiac MRI/function	1.83	0.68	0.71	0.68	0.71	0.07	2.58	2.61	2.58	2.61	XXX
75554	TC	A	Cardiac MRI/function	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
75555		A	Cardiac MRI/limited study	1.74	12.02	12.11	NA	NA	0.56	14.32	14.41	NA	NA	XXX
75555	26	A	Cardiac MRI/limited study	1.74	0.69	0.71	0.69	0.71	0.06	2.49	2.51	2.49	2.51	XXX
75555	TC	A	Cardiac MRI/limited study	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
75556		N	Cardiac MRI/flow mapping	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
75600		A	Contrast x-ray exam of aorta	0.49	12.94	13.02	NA	NA	0.58	14.01	14.09	NA	NA	XXX
75600	26	A	Contrast x-ray exam of aorta	0.49	0.20	0.21	0.20	0.21	0.02	0.71	0.72	0.71	0.72	XXX
75600	TC	A	Contrast x-ray exam of aorta	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75605		A	Contrast x-ray exam of aorta	1.14	13.17	13.27	NA	NA	0.60	14.91	15.01	NA	NA	XXX
75605	26	A	Contrast x-ray exam of aorta	1.14	0.43	0.46	0.43	0.46	0.04	1.61	1.64	1.61	1.64	XXX
75605	TC	A	Contrast x-ray exam of aorta	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75625		A	Contrast x-ray exam of aorta	1.14	13.14	13.25	NA	NA	0.61	14.89	15.00	NA	NA	XXX
75625	26	A	Contrast x-ray exam of aorta	1.14	0.40	0.44	0.40	0.44	0.05	1.59	1.63	1.59	1.63	XXX
75625	TC	A	Contrast x-ray exam of aorta	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75630		A	X-ray aorta, leg arteries	1.79	13.92	14.00	NA	NA	0.66	16.37	16.45	NA	NA	XXX
75630	26	A	X-ray aorta, leg arteries	1.79	0.65	0.65	0.65	0.65	0.07	2.51	2.51	2.51	2.51	XXX
75630	TC	A	X-ray aorta, leg arteries	0.00	13.27	13.35	NA	NA	0.59	13.86	13.94	NA	NA	XXX
75650		A	Artery x-rays, head & neck	1.49	13.26	13.38	NA	NA	0.62	15.37	15.49	NA	NA	XXX
75650	26	A	Artery x-rays, head & neck	1.49	0.52	0.57	0.52	0.57	0.06	2.07	2.12	2.07	2.12	XXX
75650	TC	A	Artery x-rays, head & neck	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75658		A	Artery x-rays, arm	1.31	13.25	13.35	NA	NA	0.61	15.17	15.27	NA	NA	XXX
75658	26	A	Artery x-rays, arm	1.31	0.51	0.54	0.51	0.54	0.05	1.87	1.90	1.87	1.90	XXX
75658	TC	A	Artery x-rays, arm	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75660		A	Artery x-rays, head & neck	1.31	13.21	13.32	NA	NA	0.61	15.13	15.24	NA	NA	XXX
75660	26	A	Artery x-rays, head & neck	1.31	0.47	0.51	0.47	0.51	0.05	1.83	1.87	1.83	1.87	XXX
75660	TC	A	Artery x-rays, head & neck	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75662		A	Artery x-rays, head & neck	1.66	13.37	13.48	NA	NA	0.62	15.65	15.76	NA	NA	XXX
75662	26	A	Artery x-rays, head & neck	1.66	0.63	0.67	0.63	0.67	0.06	2.35	2.39	2.35	2.39	XXX
75662	TC	A	Artery x-rays, head & neck	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75665		A	Artery x-rays, head & neck	1.31	13.21	13.32	NA	NA	0.62	15.14	15.25	NA	NA	XXX
75665	26	A	Artery x-rays, head & neck	1.31	0.47	0.51	0.47	0.51	0.06	1.84	1.88	1.84	1.88	XXX
75665	TC	A	Artery x-rays, head & neck	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75671		A	Artery x-rays, head & neck	1.66	13.32	13.45	NA	NA	0.63	15.61	15.74	NA	NA	XXX
75671	26	A	Artery x-rays, head & neck	1.66	0.58	0.64	0.58	0.64	0.07	2.31	2.37	2.31	2.37	XXX
75671	TC	A	Artery x-rays, head & neck	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75676		A	Artery x-rays, neck	1.31	13.21	13.32	NA	NA	0.62	15.14	15.25	NA	NA	XXX
75676	26	A	Artery x-rays, neck	1.31	0.47	0.51	0.47	0.51	0.06	1.84	1.88	1.84	1.88	XXX
75676	TC	A	Artery x-rays, neck	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75680		A	Artery x-rays, neck	1.66	13.32	13.45	NA	NA	0.63	15.61	15.74	NA	NA	XXX
75680	26	A	Artery x-rays, neck	1.66	0.58	0.64	0.58	0.64	0.07	2.31	2.37	2.31	2.37	XXX
75680	TC	A	Artery x-rays, neck	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75685		A	Artery x-rays, spine	1.31	13.20	13.31	NA	NA	0.61	15.12	15.23	NA	NA	XXX
75685	26	A	Artery x-rays, spine	1.31	0.46	0.50	0.46	0.50	0.05	1.82	1.86	1.82	1.86	XXX
75685	TC	A	Artery x-rays, spine	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75705		A	Artery x-rays, spine	2.18	13.51	13.65	NA	NA	0.65	16.34	16.48	NA	NA	XXX
75705	26	A	Artery x-rays, spine	2.18	0.77	0.84	0.77	0.84	0.09	3.04	3.11	3.04	3.11	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
75705	TC	A	Artery x-rays, spine	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75710		A	Artery x-rays, arm/leg	1.14	13.15	13.25	NA	NA	0.61	14.90	15.00	NA	NA	XXX
75710	26	A	Artery x-rays, arm/leg	1.14	0.41	0.44	0.41	0.44	0.05	1.60	1.63	1.60	1.63	XXX
75710	TC	A	Artery x-rays, arm/leg	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75716		A	Artery x-rays, arms/legs	1.31	13.20	13.31	NA	NA	0.61	15.12	15.23	NA	NA	XXX
75716	26	A	Artery x-rays, arms/legs	1.31	0.46	0.50	0.46	0.50	0.05	1.82	1.86	1.82	1.86	XXX
75716	TC	A	Artery x-rays, arms/legs	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75722		A	Artery x-rays, kidney	1.14	13.17	13.27	NA	NA	0.60	14.91	15.01	NA	NA	XXX
75722	26	A	Artery x-rays, kidney	1.14	0.43	0.46	0.43	0.46	0.04	1.61	1.64	1.61	1.64	XXX
75722	TC	A	Artery x-rays, kidney	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75724		A	Artery x-rays, kidneys	1.49	13.34	13.44	NA	NA	0.61	15.44	15.54	NA	NA	XXX
75724	26	A	Artery x-rays, kidneys	1.49	0.60	0.63	0.60	0.63	0.05	2.14	2.17	2.14	2.17	XXX
75724	TC	A	Artery x-rays, kidneys	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75726		A	Artery x-rays, abdomen	1.14	13.14	13.25	NA	NA	0.61	14.89	15.00	NA	NA	XXX
75726	26	A	Artery x-rays, abdomen	1.14	0.40	0.44	0.40	0.44	0.05	1.59	1.63	1.59	1.63	XXX
75726	TC	A	Artery x-rays, abdomen	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75731		A	Artery x-rays, adrenal gland	1.14	13.14	13.25	NA	NA	0.61	14.89	15.00	NA	NA	XXX
75731	26	A	Artery x-rays, adrenal gland	1.14	0.40	0.44	0.40	0.44	0.05	1.59	1.63	1.59	1.63	XXX
75731	TC	A	Artery x-rays, adrenal gland	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75733		A	Artery x-rays, adrenals	1.31	13.21	13.32	NA	NA	0.61	15.13	15.24	NA	NA	XXX
75733	26	A	Artery x-rays, adrenals	1.31	0.47	0.51	0.47	0.51	0.05	1.83	1.87	1.83	1.87	XXX
75733	TC	A	Artery x-rays, adrenals	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75736		A	Artery x-rays, pelvis	1.14	13.14	13.25	NA	NA	0.61	14.89	15.00	NA	NA	XXX
75736	26	A	Artery x-rays, pelvis	1.14	0.40	0.44	0.40	0.44	0.05	1.59	1.63	1.59	1.63	XXX
75736	TC	A	Artery x-rays, pelvis	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75741		A	Artery x-rays, lung	1.31	13.19	13.31	NA	NA	0.61	15.11	15.23	NA	NA	XXX
75741	26	A	Artery x-rays, lung	1.31	0.45	0.50	0.45	0.50	0.05	1.81	1.86	1.81	1.86	XXX
75741	TC	A	Artery x-rays, lung	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75743		A	Artery x-rays, lungs	1.66	13.32	13.45	NA	NA	0.63	15.61	15.74	NA	NA	XXX
75743	26	A	Artery x-rays, lungs	1.66	0.58	0.64	0.58	0.64	0.07	2.31	2.37	2.31	2.37	XXX
75743	TC	A	Artery x-rays, lungs	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75746		A	Artery x-rays, lung	1.14	13.14	13.25	NA	NA	0.60	14.88	14.99	NA	NA	XXX
75746	26	A	Artery x-rays, lung	1.14	0.40	0.44	0.40	0.44	0.04	1.58	1.62	1.58	1.62	XXX
75746	TC	A	Artery x-rays, lung	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75756		A	Artery x-rays, chest	1.14	13.22	13.31	NA	NA	0.60	14.96	15.05	NA	NA	XXX
75756	26	A	Artery x-rays, chest	1.14	0.48	0.50	0.48	0.50	0.04	1.66	1.68	1.66	1.68	XXX
75756	TC	A	Artery x-rays, chest	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75774		A	Artery x-ray, each vessel	0.36	12.87	12.95	NA	NA	0.57	13.80	13.88	NA	NA	ZZZ
75774	26	A	Artery x-ray, each vessel	0.36	0.13	0.14	0.13	0.14	0.01	0.50	0.51	0.50	0.51	ZZZ
75774	TC	A	Artery x-ray, each vessel	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	ZZZ
75790		A	Visualize A-V shunt	1.84	2.01	2.09	NA	NA	0.15	4.00	4.08	NA	NA	XXX
75790	26	A	Visualize A-V shunt	1.84	0.64	0.71	0.64	0.71	0.08	2.56	2.63	2.56	2.63	XXX
75790	TC	A	Visualize A-V shunt	0.00	1.37	1.38	NA	NA	0.07	1.44	1.45	NA	NA	XXX
75801		A	Lymph vessel x-ray, arm/leg	0.81	5.75	5.81	NA	NA	0.29	6.85	6.91	NA	NA	XXX
75801	26	A	Lymph vessel x-ray, arm/leg	0.81	0.28	0.31	0.28	0.31	0.04	1.13	1.16	1.13	1.16	XXX
75801	TC	A	Lymph vessel x-ray, arm/leg	0.00	5.47	5.50	NA	NA	0.25	5.72	5.75	NA	NA	XXX
75803		A	Lymph vessel x-ray,arms/legs	1.17	5.87	5.94	NA	NA	0.30	7.34	7.41	NA	NA	XXX
75803	26	A	Lymph vessel x-ray,arms/legs	1.17	0.40	0.44	0.40	0.44	0.05	1.62	1.66	1.62	1.66	XXX
75803	TC	A	Lymph vessel x-ray,arms/legs	0.00	5.47	5.50	NA	NA	0.25	5.72	5.75	NA	NA	XXX
75805		A	Lymph vessel x-ray, trunk	0.81	6.46	6.53	NA	NA	0.31	7.58	7.65	NA	NA	XXX
75805	26	A	Lymph vessel x-ray, trunk	0.81	0.29	0.32	0.29	0.32	0.03	1.13	1.16	1.13	1.16	XXX
75805	TC	A	Lymph vessel x-ray, trunk	0.00	6.17	6.21	NA	NA	0.28	6.45	6.49	NA	NA	XXX
75807		A	Lymph vessel x-ray, trunk	1.17	6.57	6.65	NA	NA	0.33	8.07	8.15	NA	NA	XXX
75807	26	A	Lymph vessel x-ray, trunk	1.17	0.40	0.44	0.40	0.44	0.05	1.62	1.66	1.62	1.66	XXX
75807	TC	A	Lymph vessel x-ray, trunk	0.00	6.17	6.21	NA	NA	0.28	6.45	6.49	NA	NA	XXX
75809		A	Nonvascular shunt, x-ray	0.47	0.95	0.97	NA	NA	0.06	1.48	1.50	NA	NA	XXX
75809	26	A	Nonvascular shunt, x-ray	0.47	0.16	0.17	0.16	0.17	0.02	0.65	0.66	0.65	0.66	XXX
75809	TC	A	Nonvascular shunt, x-ray	0.00	0.79	0.80	NA	NA	0.04	0.83	0.84	NA	NA	XXX
75810		A	Vein x-ray, spleen/liver	1.14	13.13	13.24	NA	NA	0.61	14.88	14.99	NA	NA	XXX
75810	26	A	Vein x-ray, spleen/liver	1.14	0.39	0.43	0.39	0.43	0.05	1.58	1.62	1.58	1.62	XXX
75810	TC	A	Vein x-ray, spleen/liver	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75820		A	Vein x-ray, arm/leg	0.70	1.20	1.24	NA	NA	0.08	1.98	2.02	NA	NA	XXX
75820	26	A	Vein x-ray, arm/leg	0.70	0.24	0.27	0.24	0.27	0.03	0.97	1.00	0.97	1.00	XXX
75820	TC	A	Vein x-ray, arm/leg	0.00	0.96	0.97	NA	NA	0.05	1.01	1.02	NA	NA	XXX
75822		A	Vein x-ray, arms/legs	1.06	1.87	1.92	NA	NA	0.11	3.04	3.09	NA	NA	XXX
75822	26	A	Vein x-ray, arms/legs	1.06	0.37	0.41	0.37	0.41	0.04	1.47	1.51	1.47	1.51	XXX
75822	TC	A	Vein x-ray, arms/legs	0.00	1.50	1.51	NA	NA	0.07	1.57	1.58	NA	NA	XXX
75825		A	Vein x-ray, trunk	1.14	13.14	13.25	NA	NA	0.61	14.89	15.00	NA	NA	XXX
75825	26	A	Vein x-ray, trunk	1.14	0.40	0.44	0.40	0.44	0.05	1.59	1.63	1.59	1.63	XXX
75825	TC	A	Vein x-ray, trunk	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75827		A	Vein x-ray, chest	1.14	13.13	13.24	NA	NA	0.61	14.88	14.99	NA	NA	XXX
75827	26	A	Vein x-ray, chest	1.14	0.39	0.43	0.39	0.43	0.05	1.58	1.62	1.58	1.62	XXX
75827	TC	A	Vein x-ray, chest	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75831		A	Vein x-ray, kidney	1.14	13.14	13.25	NA	NA	0.61	14.89	15.00	NA	NA	XXX
75831	26	A	Vein x-ray, kidney	1.14	0.40	0.44	0.40	0.44	0.05	1.59	1.63	1.59	1.63	XXX
75831	TC	A	Vein x-ray, kidney	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75833		A	Vein x-ray, kidneys	1.49	13.26	13.38	NA	NA	0.62	15.37	15.49	NA	NA	XXX
75833	26	A	Vein x-ray, kidneys	1.49	0.52	0.57	0.52	0.57	0.06	2.07	2.12	2.07	2.12	XXX
75833	TC	A	Vein x-ray, kidneys	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75840		A	Vein x-ray, adrenal gland	1.14	13.14	13.25	NA	NA	0.61	14.89	15.00	NA	NA	XXX
75840	26	A	Vein x-ray, adrenal gland	1.14	0.40	0.44	0.40	0.44	0.05	1.59	1.63	1.59	1.63	XXX
75840	TC	A	Vein x-ray, adrenal gland	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
75842	.....	A	Vein x-ray, adrenal glands	1.49	13.26	13.38	NA	NA	0.62	15.37	15.49	NA	NA	XXX
75842	26	A	Vein x-ray, adrenal glands	1.49	0.52	0.57	0.52	0.57	0.06	2.07	2.12	2.07	2.12	XXX
75842	TC	A	Vein x-ray, adrenal glands	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75860	.....	A	Vein x-ray, neck	1.14	13.14	13.25	NA	NA	0.61	14.89	15.00	NA	NA	XXX
75860	26	A	Vein x-ray, neck	1.14	0.40	0.44	0.40	0.44	0.05	1.59	1.63	1.59	1.63	XXX
75860	TC	A	Vein x-ray, neck	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75870	.....	A	Vein x-ray, skull	1.14	13.14	13.25	NA	NA	0.61	14.89	15.00	NA	NA	XXX
75870	26	A	Vein x-ray, skull	1.14	0.40	0.44	0.40	0.44	0.05	1.59	1.63	1.59	1.63	XXX
75870	TC	A	Vein x-ray, skull	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75872	.....	A	Vein x-ray, skull	1.14	13.13	13.24	NA	NA	0.61	14.88	14.99	NA	NA	XXX
75872	26	A	Vein x-ray, skull	1.14	0.39	0.43	0.39	0.43	0.05	1.58	1.62	1.58	1.62	XXX
75872	TC	A	Vein x-ray, skull	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75880	.....	A	Vein x-ray, eye socket	0.70	1.20	1.24	NA	NA	0.08	1.98	2.02	NA	NA	XXX
75880	26	A	Vein x-ray, eye socket	0.70	0.24	0.27	0.24	0.27	0.03	0.97	1.00	0.97	1.00	XXX
75880	TC	A	Vein x-ray, eye socket	0.00	0.96	0.97	NA	NA	0.05	1.01	1.02	NA	NA	XXX
75885	.....	A	Vein x-ray, liver	1.44	13.24	13.36	NA	NA	0.62	15.30	15.42	NA	NA	XXX
75885	26	A	Vein x-ray, liver	1.44	0.50	0.55	0.50	0.55	0.06	2.00	2.05	2.00	2.05	XXX
75885	TC	A	Vein x-ray, liver	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75887	.....	A	Vein x-ray, liver	1.44	13.24	13.36	NA	NA	0.62	15.30	15.42	NA	NA	XXX
75887	26	A	Vein x-ray, liver	1.44	0.50	0.55	0.50	0.55	0.06	2.00	2.05	2.00	2.05	XXX
75887	TC	A	Vein x-ray, liver	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75889	.....	A	Vein x-ray, liver	1.14	13.13	13.24	NA	NA	0.61	14.88	14.99	NA	NA	XXX
75889	26	A	Vein x-ray, liver	1.14	0.39	0.43	0.39	0.43	0.05	1.58	1.62	1.58	1.62	XXX
75889	TC	A	Vein x-ray, liver	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75891	.....	A	Vein x-ray, liver	1.14	13.13	13.24	NA	NA	0.61	14.88	14.99	NA	NA	XXX
75891	26	A	Vein x-ray, liver	1.14	0.39	0.43	0.39	0.43	0.05	1.58	1.62	1.58	1.62	XXX
75891	TC	A	Vein x-ray, liver	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75893	.....	A	Venous sampling by catheter	0.54	12.93	13.02	NA	NA	0.58	14.05	14.14	NA	NA	XXX
75893	26	A	Venous sampling by catheter	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
75893	TC	A	Venous sampling by catheter	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75894	.....	A	X-rays, transcath therapy	1.31	24.86	25.04	NA	NA	1.13	27.30	27.48	NA	NA	XXX
75894	26	A	X-rays, transcath therapy	1.31	0.46	0.50	0.46	0.50	0.05	1.82	1.86	1.82	1.86	XXX
75894	TC	A	X-rays, transcath therapy	0.00	24.40	24.54	NA	NA	1.08	25.48	25.62	NA	NA	XXX
75896	.....	A	X-rays, transcath therapy	1.31	21.70	21.86	NA	NA	0.99	24.00	24.16	NA	NA	XXX
75896	26	A	X-rays, transcath therapy	1.31	0.48	0.52	0.48	0.52	0.05	1.84	1.88	1.84	1.88	XXX
75896	TC	A	X-rays, transcath therapy	0.00	21.22	21.34	NA	NA	0.94	22.16	22.28	NA	NA	XXX
75898	.....	A	Follow-up angiogram	1.65	1.66	1.72	NA	NA	0.12	3.43	3.49	NA	NA	XXX
75898	26	A	Follow-up angiogram	1.65	0.59	0.64	0.59	0.64	0.07	2.31	2.36	2.31	2.36	XXX
75898	TC	A	Follow-up angiogram	0.00	1.07	1.08	NA	NA	0.05	1.12	1.13	NA	NA	XXX
75900	.....	A	Arterial catheter exchange	0.49	21.37	21.51	NA	NA	0.97	22.83	22.97	NA	NA	XXX
75900	26	A	Arterial catheter exchange	0.49	0.17	0.19	0.17	0.19	0.02	0.68	0.70	0.68	0.70	XXX
75900	TC	A	Arterial catheter exchange	0.00	21.20	21.32	NA	NA	0.95	22.15	22.27	NA	NA	XXX
75940	.....	A	X-ray placement, vein filter	0.54	12.93	13.02	NA	NA	0.58	14.05	14.14	NA	NA	XXX
75940	26	A	X-ray placement, vein filter	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
75940	TC	A	X-ray placement, vein filter	0.00	12.74	12.81	NA	NA	0.56	13.30	13.37	NA	NA	XXX
75945	.....	A	Intravascular us	0.40	4.76	4.81	NA	NA	0.24	5.40	5.45	NA	NA	XXX
75945	26	A	Intravascular us	0.40	0.15	0.17	0.15	0.17	0.03	0.58	0.60	0.58	0.60	XXX
75945	TC	A	Intravascular us	0.00	4.61	4.64	NA	NA	0.21	4.82	4.85	NA	NA	XXX
75946	.....	A	Intravascular us add-on	0.40	2.47	2.50	NA	NA	0.13	3.00	3.03	NA	NA	ZZZ
75946	26	A	Intravascular us add-on	0.40	0.15	0.17	0.15	0.17	0.02	0.57	0.59	0.57	0.59	ZZZ
75946	TC	A	Intravascular us add-on	0.00	2.32	2.33	NA	NA	0.11	2.43	2.44	NA	NA	ZZZ
75960	.....	A	Transcatheter intro, stent	0.82	15.36	15.48	NA	NA	0.70	16.88	17.00	NA	NA	XXX
75960	26	A	Transcatheter intro, stent	0.82	0.30	0.33	0.30	0.33	0.04	1.16	1.19	1.16	1.19	XXX
75960	TC	A	Transcatheter intro, stent	0.00	15.06	15.15	NA	NA	0.66	15.72	15.81	NA	NA	XXX
75961	.....	A	Retrieval, broken catheter	4.25	12.10	12.31	NA	NA	0.63	16.98	17.19	NA	NA	XXX
75961	26	A	Retrieval, broken catheter	4.25	1.48	1.63	1.48	1.63	0.16	5.89	6.04	5.89	6.04	XXX
75961	TC	A	Retrieval, broken catheter	0.00	10.62	10.68	NA	NA	0.47	11.09	11.15	NA	NA	XXX
75962	.....	A	Repair arterial blockage	0.54	16.11	16.22	NA	NA	0.73	17.38	17.49	NA	NA	XXX
75962	26	A	Repair arterial blockage	0.54	0.20	0.22	0.20	0.22	0.02	0.76	0.78	0.76	0.78	XXX
75962	TC	A	Repair arterial blockage	0.00	15.91	16.00	NA	NA	0.71	16.62	16.71	NA	NA	XXX
75964	.....	A	Repair artery blockage, each	0.36	8.61	8.67	NA	NA	0.39	9.36	9.42	NA	NA	ZZZ
75964	26	A	Repair artery blockage, each	0.36	0.13	0.14	0.13	0.14	0.02	0.51	0.52	0.51	0.52	ZZZ
75964	TC	A	Repair artery blockage, each	0.00	8.48	8.53	NA	NA	0.37	8.85	8.90	NA	NA	ZZZ
75966	.....	A	Repair arterial blockage	1.31	16.40	16.53	NA	NA	0.76	18.47	18.60	NA	NA	XXX
75966	26	A	Repair arterial blockage	1.31	0.49	0.53	0.49	0.53	0.05	1.85	1.89	1.85	1.89	XXX
75966	TC	A	Repair arterial blockage	0.00	15.91	16.00	NA	NA	0.71	16.62	16.71	NA	NA	XXX
75968	.....	A	Repair artery blockage, each	0.36	8.62	8.68	NA	NA	0.38	9.36	9.42	NA	NA	ZZZ
75968	26	A	Repair artery blockage, each	0.36	0.14	0.15	0.14	0.15	0.01	0.51	0.52	0.51	0.52	ZZZ
75968	TC	A	Repair artery blockage, each	0.00	8.48	8.53	NA	NA	0.37	8.85	8.90	NA	NA	ZZZ
75970	.....	A	Vascular biopsy	0.83	11.97	12.07	NA	NA	0.55	13.35	13.45	NA	NA	XXX
75970	26	A	Vascular biopsy	0.83	0.30	0.33	0.30	0.33	0.03	1.16	1.19	1.16	1.19	XXX
75970	TC	A	Vascular biopsy	0.00	11.67	11.74	NA	NA	0.52	12.19	12.26	NA	NA	XXX
75978	.....	A	Repair venous blockage	0.54	16.10	16.27	NA	NA	0.73	17.37	17.54	NA	NA	XXX
75978	26	A	Repair venous blockage	0.54	0.19	0.27	0.19	0.27	0.02	0.75	0.83	0.75	0.83	XXX
75978	TC	A	Repair venous blockage	0.00	15.91	16.00	NA	NA	0.71	16.62	16.71	NA	NA	XXX
75980	.....	A	Contrast xray exam bile duct	1.44	5.97	6.05	NA	NA	0.31	7.72	7.80	NA	NA	XXX
75980	26	A	Contrast xray exam bile duct	1.44	0.50	0.55	0.50	0.55	0.06	2.00	2.05	2.00	2.05	XXX
75980	TC	A	Contrast xray exam bile duct	0.00	5.47	5.50	NA	NA	0.25	5.72	5.75	NA	NA	XXX
75982	.....	A	Contrast xray exam bile duct	1.44	6.67	6.76	NA	NA	0.34	8.45	8.54	NA	NA	XXX
75982	26	A	Contrast xray exam bile duct	1.44	0.50	0.55	0.50	0.55	0.06	2.00	2.05	2.00	2.05	XXX
75982	TC	A	Contrast xray exam bile duct	0.00	6.17	6.21	NA	NA	0.28	6.45	6.49	NA	NA	XXX
75984	.....	A	Xray control catheter change	0.72	2.22	.26	NA	NA	0.12	3.06	3.10	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
75984	26	A	Xray control catheter change	0.72	0.25	0.28	0.25	0.28	0.03	1.00	1.03	1.00	1.03	XXX
75984	TC	A	Xray control catheter change	0.00	1.97	1.98	NA	NA	0.09	2.06	2.07	NA	NA	XXX
75989		A	Abscess drainage under x-ray	1.19	3.60	3.66	NA	NA	0.19	4.98	5.04	NA	NA	XXX
75989	26	A	Abscess drainage under x-ray	1.19	0.41	0.45	0.41	0.45	0.05	1.65	1.69	1.65	1.69	XXX
75989	TC	A	Abscess drainage under x-ray	0.00	3.19	3.21	NA	NA	0.14	3.33	3.35	NA	NA	XXX
75992		A	Atherectomy, x-ray exam	0.54	16.12	16.23	NA	NA	0.73	17.39	17.50	NA	NA	XXX
75992	26	A	Atherectomy, x-ray exam	0.54	0.21	0.23	0.21	0.23	0.02	0.77	0.79	0.77	0.79	XXX
75992	TC	A	Atherectomy, x-ray exam	0.00	15.91	16.00	NA	NA	0.71	16.62	16.71	NA	NA	XXX
75993		A	Atherectomy, x-ray exam	0.36	8.63	8.69	NA	NA	0.38	9.37	9.43	NA	NA	ZZZ
75993	26	A	Atherectomy, x-ray exam	0.36	0.15	0.16	0.15	0.16	0.01	0.52	0.53	0.52	0.53	ZZZ
75993	TC	A	Atherectomy, x-ray exam	0.00	8.48	8.53	NA	NA	0.37	8.85	8.90	NA	NA	ZZZ
75994		A	Atherectomy, x-ray exam	1.31	16.41	16.53	NA	NA	0.77	18.49	18.61	NA	NA	XXX
75994	26	A	Atherectomy, x-ray exam	1.31	0.50	0.53	0.50	0.53	0.06	1.87	1.90	1.87	1.90	XXX
75994	TC	A	Atherectomy, x-ray exam	0.00	15.91	16.00	NA	NA	0.71	16.62	16.71	NA	NA	XXX
75995		A	Atherectomy, x-ray exam	1.31	16.38	16.51	NA	NA	0.75	18.44	18.57	NA	NA	XXX
75995	26	A	Atherectomy, x-ray exam	1.31	0.47	0.51	0.47	0.51	0.04	1.82	1.86	1.82	1.86	XXX
75995	TC	A	Atherectomy, x-ray exam	0.00	15.91	16.00	NA	NA	0.71	16.62	16.71	NA	NA	XXX
75996		A	Atherectomy, x-ray exam	0.36	8.61	8.67	NA	NA	0.38	9.35	9.41	NA	NA	ZZZ
75996	26	A	Atherectomy, x-ray exam	0.36	0.13	0.14	0.13	0.14	0.01	0.50	0.51	0.50	0.51	ZZZ
75996	TC	A	Atherectomy, x-ray exam	0.00	8.48	8.53	NA	NA	0.37	8.85	8.90	NA	NA	ZZZ
76000		A	Fluoroscope examination	0.17	1.38	1.40	NA	NA	0.07	1.62	1.64	NA	NA	XXX
76000	26	A	Fluoroscope examination	0.17	0.06	0.07	0.06	0.07	0.01	0.24	0.25	0.24	0.25	XXX
76000	TC	A	Fluoroscope examination	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
76001		A	Fluoroscope exam, extensive	0.67	2.88	2.93	NA	NA	0.15	3.70	3.75	NA	NA	XXX
76001	26	A	Fluoroscope exam, extensive	0.67	0.23	0.26	0.23	0.26	0.03	0.93	0.96	0.93	0.96	XXX
76001	TC	A	Fluoroscope exam, extensive	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
76003		A	Needle localization by x-ray	0.54	1.50	1.53	NA	NA	0.08	2.12	2.15	NA	NA	XXX
76003	26	A	Needle localization by x-ray	0.54	0.18	0.20	0.18	0.20	0.02	0.74	0.76	0.74	0.76	XXX
76003	TC	A	Needle localization by x-ray	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
76005		A	Fluoroguide for spine inject	0.60	1.48	1.49	NA	NA	0.09	2.17	2.18	NA	NA	XXX
76005	26	A	Fluoroguide for spine inject	0.60	0.20	0.20	0.20	0.20	0.03	0.83	0.83	0.83	0.83	XXX
76005	TC	A	Fluoroguide for spine inject	0.00	1.28	1.29	NA	NA	0.06	1.34	1.35	NA	NA	XXX
76006		A	X-ray stress view	0.41	0.14	0.14	NA	NA	0.02	0.57	0.57	NA	NA	XXX
76010		A	X-ray, nose to rectum	0.18	0.59	0.60	NA	NA	0.03	0.80	0.81	NA	NA	XXX
76010	26	A	X-ray, nose to rectum	0.18	0.06	0.07	0.06	0.07	0.01	0.25	0.26	0.25	0.26	XXX
76010	TC	A	X-ray, nose to rectum	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
76020		A	X-rays for bone age	0.19	0.60	0.61	NA	NA	0.03	0.82	0.83	NA	NA	XXX
76020	26	A	X-rays for bone age	0.19	0.07	0.08	0.07	0.08	0.01	0.27	0.28	0.27	0.28	XXX
76020	TC	A	X-rays for bone age	0.00	0.53	0.53	NA	NA	0.02	0.55	0.55	NA	NA	XXX
76040		A	X-rays, bone evaluation	0.27	0.89	0.91	NA	NA	0.05	1.21	1.23	NA	NA	XXX
76040	26	A	X-rays, bone evaluation	0.27	0.10	0.11	0.10	0.11	0.01	0.38	0.39	0.38	0.39	XXX
76040	TC	A	X-rays, bone evaluation	0.00	0.79	0.80	NA	NA	0.04	0.83	0.84	NA	NA	XXX
76061		A	X-rays, bone survey	0.45	1.17	1.20	NA	NA	0.07	1.69	1.72	NA	NA	XXX
76061	26	A	X-rays, bone survey	0.45	0.16	0.18	0.16	0.18	0.02	0.63	0.65	0.63	0.65	XXX
76061	TC	A	X-rays, bone survey	0.00	1.01	1.02	NA	NA	0.05	1.06	1.07	NA	NA	XXX
76062		A	X-rays, bone survey	0.54	1.65	1.68	NA	NA	0.09	2.28	2.31	NA	NA	XXX
76062	26	A	X-rays, bone survey	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
76062	TC	A	X-rays, bone survey	0.00	1.46	1.47	NA	NA	0.07	1.53	1.54	NA	NA	XXX
76065		A	X-rays, bone evaluation	0.28	0.84	0.86	NA	NA	0.05	1.17	1.19	NA	NA	XXX
76065	26	A	X-rays, bone evaluation	0.28	0.10	0.11	0.10	0.11	0.01	0.39	0.40	0.39	0.40	XXX
76065	TC	A	X-rays, bone evaluation	0.00	0.74	0.75	NA	NA	0.04	0.78	0.79	NA	NA	XXX
76066		A	Joint(s) survey, single film	0.31	1.23	1.25	NA	NA	0.06	1.60	1.62	NA	NA	XXX
76066	26	A	Joint(s) survey, single film	0.31	0.11	0.12	0.11	0.12	0.01	0.43	0.44	0.43	0.44	XXX
76066	TC	A	Joint(s) survey, single film	0.00	1.12	1.13	NA	NA	0.05	1.17	1.18	NA	NA	XXX
76070		I	CT scan, bone density study	0.25	3.08	3.11	NA	NA	0.14	3.47	3.50	NA	NA	XXX
76070	26	I	CT scan, bone density study	0.25	0.10	0.11	0.10	0.11	0.01	0.36	0.37	0.36	0.37	XXX
76070	TC	I	CT scan, bone density study	0.00	2.98	3.00	NA	NA	0.13	3.11	3.13	NA	NA	XXX
76075		A	Dual energy x-ray study	0.30	3.24	3.27	NA	NA	0.15	3.69	3.72	NA	NA	XXX
76075	26	A	Dual energy x-ray study	0.30	0.11	0.12	0.11	0.12	0.01	0.42	0.43	0.42	0.43	XXX
76075	TC	A	Dual energy x-ray study	0.00	3.13	3.15	NA	NA	0.14	3.27	3.29	NA	NA	XXX
76076		A	Dual energy x-ray study	0.22	0.84	0.86	NA	NA	0.05	1.11	1.13	NA	NA	XXX
76076	26	A	Dual energy x-ray study	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
76076	TC	A	Dual energy x-ray study	0.00	0.76	0.77	NA	NA	0.04	0.80	0.81	NA	NA	XXX
76078		A	Photodensitometry	0.20	0.83	0.85	NA	NA	0.05	1.08	1.10	NA	NA	XXX
76078	26	A	Photodensitometry	0.20	0.07	0.08	0.07	0.08	0.01	0.28	0.29	0.28	0.29	XXX
76078	TC	A	Photodensitometry	0.00	0.76	0.77	NA	NA	0.04	0.80	0.81	NA	NA	XXX
76080		A	X-ray exam of fistula	0.54	1.26	1.29	NA	NA	0.07	1.87	1.90	NA	NA	XXX
76080	26	A	X-ray exam of fistula	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
76080	TC	A	X-ray exam of fistula	0.00	1.07	1.08	NA	NA	0.05	1.12	1.13	NA	NA	XXX
76086		A	X-ray of mammary duct	0.36	2.78	2.81	NA	NA	0.13	3.27	3.30	NA	NA	XXX
76086	26	A	X-ray of mammary duct	0.36	0.13	0.14	0.13	0.14	0.01	0.50	0.51	0.50	0.51	XXX
76086	TC	A	X-ray of mammary duct	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
76088		A	X-ray of mammary ducts	0.45	3.86	3.90	NA	NA	0.18	4.49	4.53	NA	NA	XXX
76088	26	A	X-ray of mammary ducts	0.45	0.16	0.18	0.16	0.18	0.02	0.63	0.65	0.63	0.65	XXX
76088	TC	A	X-ray of mammary ducts	0.00	3.70	3.72	NA	NA	0.16	3.86	3.88	NA	NA	XXX
76090		A	Mammogram, one breast	0.58	1.27	1.26	NA	NA	0.07	1.92	1.91	NA	NA	XXX
76090	26	A	Mammogram, one breast	0.58	0.20	0.18	0.20	0.18	0.02	0.80	0.78	0.80	0.78	XXX
76090	TC	A	Mammogram, one breast	0.00	1.07	1.08	NA	NA	0.05	1.12	1.13	NA	NA	XXX
76091		A	Mammogram, both breasts	0.69	1.56	1.56	NA	NA	0.09	2.34	2.34	NA	NA	XXX
76091	26	A	Mammogram, both breasts	0.69	0.24	0.23	0.24	0.23	0.03	0.96	0.95	0.96	0.95	XXX
76091	TC	A	Mammogram, both breasts	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
76092		X	Mamm0gram, screening	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
76093		A	Magnetic image, breast	1.63	18.39	18.54	NA	NA	0.84	20.86	21.01	NA	NA	XXX
76093	26	A	Magnetic image, breast	1.63	0.57	0.62	0.57	0.62	0.06	2.26	2.31	2.26	2.31	XXX
76093	TC	A	Magnetic image, breast	0.00	17.82	17.92	NA	NA	0.78	18.60	18.70	NA	NA	XXX
76094		A	Magnetic image, both breasts	1.63	24.74	24.93	NA	NA	1.12	27.49	27.68	NA	NA	XXX
76094	26	A	Magnetic image, both breasts	1.63	0.57	0.62	0.57	0.62	0.06	2.26	2.31	2.26	2.31	XXX
76094	TC	A	Magnetic image, both breasts	0.00	24.17	24.31	NA	NA	1.06	25.23	25.37	NA	NA	XXX
76095		A	Stereotactic breast biopsy	1.59	7.80	7.89	NA	NA	0.40	9.79	9.88	NA	NA	XXX
76095	26	A	Stereotactic breast biopsy	1.59	0.56	0.61	0.56	0.61	0.08	2.23	2.28	2.23	2.28	XXX
76095	TC	A	Stereotactic breast biopsy	0.00	7.24	7.28	NA	NA	0.32	7.56	7.60	NA	NA	XXX
76096		A	X-ray of needle wire, breast	0.56	1.52	1.55	NA	NA	0.08	2.16	2.19	NA	NA	XXX
76096	26	A	X-ray of needle wire, breast	0.56	0.20	0.22	0.20	0.22	0.02	0.78	0.80	0.78	0.80	XXX
76096	TC	A	X-ray of needle wire, breast	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
76098		A	X-ray exam, breast specimen	0.16	0.48	0.49	NA	NA	0.03	0.67	0.68	NA	NA	XXX
76098	26	A	X-ray exam, breast specimen	0.16	0.06	0.07	0.06	0.07	0.01	0.23	0.24	0.23	0.24	XXX
76098	TC	A	X-ray exam, breast specimen	0.00	0.42	0.42	NA	NA	0.02	0.44	0.44	NA	NA	XXX
76100		A	X-ray exam of body section	0.58	1.46	1.49	NA	NA	0.08	2.12	2.15	NA	NA	XXX
76100	26	A	X-ray exam of body section	0.58	0.20	0.22	0.20	0.22	0.02	0.80	0.82	0.80	0.82	XXX
76100	TC	A	X-ray exam of body section	0.00	1.26	1.27	NA	NA	0.06	1.32	1.33	NA	NA	XXX
76101		A	Complex body section x-ray	0.58	1.64	1.67	NA	NA	0.09	2.31	2.34	NA	NA	XXX
76101	26	A	Complex body section x-ray	0.58	0.20	0.22	0.20	0.22	0.02	0.80	0.82	0.80	0.82	XXX
76101	TC	A	Complex body section x-ray	0.00	1.44	1.45	NA	NA	0.07	1.51	1.52	NA	NA	XXX
76102		A	Complex body section x-rays	0.58	1.95	1.98	NA	NA	0.11	2.64	2.67	NA	NA	XXX
76102	26	A	Complex body section x-rays	0.58	0.20	0.22	0.20	0.22	0.02	0.80	0.82	0.80	0.82	XXX
76102	TC	A	Complex body section x-rays	0.00	1.75	1.76	NA	NA	0.09	1.84	1.85	NA	NA	XXX
76120		A	Cinematic x-rays	0.38	1.21	1.23	NA	NA	0.07	1.66	1.68	NA	NA	XXX
76120	26	A	Cinematic x-rays	0.38	0.14	0.15	0.14	0.15	0.02	0.54	0.55	0.54	0.55	XXX
76120	TC	A	Cinematic x-rays	0.00	1.07	1.08	NA	NA	0.05	1.12	1.13	NA	NA	XXX
76125		A	Cinematic x-rays add-on	0.27	0.89	0.91	NA	NA	0.05	1.21	1.23	NA	NA	ZZZ
76125	26	A	Cinematic x-rays add-on	0.27	0.10	0.11	0.10	0.11	0.01	0.38	0.39	0.38	0.39	ZZZ
76125	TC	A	Cinematic x-rays add-on	0.00	0.79	0.80	NA	NA	0.04	0.83	0.84	NA	NA	ZZZ
76140		I	X-ray consultation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
76150		A	X-ray exam, dry process	0.00	0.42	0.42	NA	NA	0.02	0.44	0.44	NA	NA	XXX
76350		C	Special x-ray contrast study	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
76355		A	CAT scan for localization	1.21	8.77	8.86	NA	NA	0.41	10.39	10.48	NA	NA	XXX
76355	26	A	CAT scan for localization	1.21	0.42	0.46	0.42	0.46	0.05	1.68	1.72	1.68	1.72	XXX
76355	TC	A	CAT scan for localization	0.00	8.35	8.40	NA	NA	0.36	8.71	8.76	NA	NA	XXX
76360		A	CAT scan for needle biopsy	1.16	8.75	8.84	NA	NA	0.41	10.32	10.41	NA	NA	XXX
76360	26	A	CAT scan for needle biopsy	1.16	0.40	0.44	0.40	0.44	0.05	1.61	1.65	1.61	1.65	XXX
76360	TC	A	CAT scan for needle biopsy	0.00	8.35	8.40	NA	NA	0.36	8.71	8.76	NA	NA	XXX
76365		A	CAT scan for cyst aspiration	1.16	8.75	8.84	NA	NA	0.41	10.32	10.41	NA	NA	XXX
76365	26	A	CAT scan for cyst aspiration	1.16	0.40	0.44	0.40	0.44	0.05	1.61	1.65	1.61	1.65	XXX
76365	TC	A	CAT scan for cyst aspiration	0.00	8.35	8.40	NA	NA	0.36	8.71	8.76	NA	NA	XXX
76370		A	CAT scan for therapy guide	0.85	3.27	3.32	NA	NA	0.16	4.28	4.33	NA	NA	XXX
76370	26	A	CAT scan for therapy guide	0.85	0.29	0.32	0.29	0.32	0.03	1.17	1.20	1.17	1.20	XXX
76370	TC	A	CAT scan for therapy guide	0.00	2.98	3.00	NA	NA	0.13	3.11	3.13	NA	NA	XXX
76375		A	3d/holograph reconstr add-on	0.16	3.64	3.67	NA	NA	0.16	3.96	3.99	NA	NA	XXX
76375	26	A	3d/holograph reconstr add-on	0.16	0.06	0.07	0.06	0.07	0.01	0.23	0.24	0.23	0.24	XXX
76375	TC	A	3d/holograph reconstr add-on	0.00	3.58	3.60	NA	NA	0.15	3.73	3.75	NA	NA	XXX
76380		A	CAT scan follow-up study	0.98	3.88	3.94	NA	NA	0.19	5.05	5.11	NA	NA	XXX
76380	26	A	CAT scan follow-up study	0.98	0.34	0.38	0.34	0.38	0.04	1.36	1.40	1.36	1.40	XXX
76380	TC	A	CAT scan follow-up study	0.00	3.54	3.56	NA	NA	0.15	3.69	3.71	NA	NA	XXX
76390		A	Mr spectroscopy	1.40	11.82	11.95	NA	NA	0.56	13.78	13.91	NA	NA	XXX
76390	26	A	Mr spectroscopy	1.40	0.49	0.55	0.49	0.55	0.06	1.95	2.01	1.95	2.01	XXX
76390	TC	A	Mr spectroscopy	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
76400		A	Magnetic image, bone marrow	1.60	11.89	12.02	NA	NA	0.56	14.05	14.18	NA	NA	XXX
76400	26	A	Magnetic image, bone marrow	1.60	0.56	0.62	0.56	0.62	0.06	2.22	2.28	2.22	2.28	XXX
76400	TC	A	Magnetic image, bone marrow	0.00	11.33	11.40	NA	NA	0.50	11.83	11.90	NA	NA	XXX
76499		C	Radiographic procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
76499	26	C	Radiographic procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
76499	TC	C	Radiographic procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
76506		A	Echo exam of head	0.63	1.68	1.71	NA	NA	0.10	2.41	2.44	NA	NA	XXX
76506	26	A	Echo exam of head	0.63	0.24	0.26	0.24	0.26	0.03	0.90	0.92	0.90	0.92	XXX
76506	TC	A	Echo exam of head	0.00	1.44	1.45	NA	NA	0.07	1.51	1.52	NA	NA	XXX
76511		A	Echo exam of eye	0.94	1.69	1.66	NA	NA	0.09	2.72	2.69	NA	NA	XXX
76511	26	A	Echo exam of eye	0.94	0.43	0.39	0.43	0.39	0.03	1.40	1.36	1.40	1.36	XXX
76511	TC	A	Echo exam of eye	0.00	1.26	1.27	NA	NA	0.06	1.32	1.33	NA	NA	XXX
76512		A	Echo exam of eye	0.66	1.84	1.86	NA	NA	0.10	2.60	2.62	NA	NA	XXX
76512	26	A	Echo exam of eye	0.66	0.31	0.32	0.31	0.32	0.02	0.99	1.00	0.99	1.00	XXX
76512	TC	A	Echo exam of eye	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76513		A	Echo exam of eye, water bath	0.66	1.83	1.85	NA	NA	0.10	2.59	2.61	NA	NA	XXX
76513	26	A	Echo exam of eye, water bath	0.66	0.30	0.31	0.30	0.31	0.02	0.98	0.99	0.98	0.99	XXX
76513	TC	A	Echo exam of eye, water bath	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76516		A	Echo exam of eye	0.54	1.52	1.53	NA	NA	0.08	2.14	2.15	NA	NA	XXX
76516	26	A	Echo exam of eye	0.54	0.26	0.26	0.26	0.26	0.02	0.82	0.82	0.82	0.82	XXX
76516	TC	A	Echo exam of eye	0.00	1.26	1.27	NA	NA	0.06	1.32	1.33	NA	NA	XXX
76519		A	Echo exam of eye	0.54	1.52	1.53	NA	NA	0.08	2.14	2.15	NA	NA	XXX
76519	26	A	Echo exam of eye	0.54	0.26	0.26	0.26	0.26	0.02	0.82	0.82	0.82	0.82	XXX
76519	TC	A	Echo exam of eye	0.00	1.26	1.27	NA	NA	0.06	1.32	1.33	NA	NA	XXX
76529		A	Echo exam of eye	0.57	1.65	1.66	NA	NA	0.09	2.31	2.32	NA	NA	XXX
76529	26	A	Echo exam of eye	0.57	0.27	0.27	0.27	0.27	0.02	0.86	0.86	0.86	0.86	XXX
76529	TC	A	Echo exam of eye	0.00	1.38	1.39	NA	NA	0.07	1.45	1.46	NA	NA	XXX
76536		A	Echo exam of head and neck	0.56	1.64	1.67	NA	NA	0.09	2.29	2.32	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
76536	26	A	Echo exam of head and neck	0.56	0.20	0.22	0.20	0.22	0.02	0.78	0.80	0.78	0.80	XXX
76536	TC	A	Echo exam of head and neck	0.00	1.44	1.45	NA	NA	0.07	1.51	1.52	NA	NA	XXX
76604		A	Echo exam of chest	0.55	1.51	1.54	NA	NA	0.08	2.14	2.17	NA	NA	XXX
76604	26	A	Echo exam of chest	0.55	0.19	0.21	0.19	0.21	0.02	0.76	0.78	0.76	0.78	XXX
76604	TC	A	Echo exam of chest	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
76645		A	Echo exam of breast(s)	0.54	1.26	1.29	NA	NA	0.07	1.87	1.90	NA	NA	XXX
76645	26	A	Echo exam of breast(s)	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
76645	TC	A	Echo exam of breast(s)	0.00	1.07	1.08	NA	NA	0.05	1.12	1.13	NA	NA	XXX
76700		A	Echo exam of abdomen	0.81	2.27	2.31	NA	NA	0.12	3.20	3.24	NA	NA	XXX
76700	26	A	Echo exam of abdomen	0.81	0.28	0.31	0.28	0.31	0.03	1.12	1.15	1.12	1.15	XXX
76700	TC	A	Echo exam of abdomen	0.00	1.99	2.00	NA	NA	0.09	2.08	2.09	NA	NA	XXX
76705		A	Echo exam of abdomen	0.59	1.65	1.68	NA	NA	0.09	2.33	2.36	NA	NA	XXX
76705	26	A	Echo exam of abdomen	0.59	0.21	0.23	0.21	0.23	0.02	0.82	0.84	0.82	0.84	XXX
76705	TC	A	Echo exam of abdomen	0.00	1.44	1.45	NA	NA	0.07	1.51	1.52	NA	NA	XXX
76770		A	Echo exam abdomen back wall	0.74	2.25	2.29	NA	NA	0.12	3.11	3.15	NA	NA	XXX
76770	26	A	Echo exam abdomen back wall	0.74	0.26	0.29	0.26	0.29	0.03	1.03	1.06	1.03	1.06	XXX
76770	TC	A	Echo exam abdomen back wall	0.00	1.99	2.00	NA	NA	0.09	2.08	2.09	NA	NA	XXX
76775		A	Echo exam abdomen back wall	0.58	1.64	1.67	NA	NA	0.09	2.31	2.34	NA	NA	XXX
76775	26	A	Echo exam abdomen back wall	0.58	0.20	0.22	0.20	0.22	0.02	0.80	0.82	0.80	0.82	XXX
76775	TC	A	Echo exam abdomen back wall	0.00	1.44	1.45	NA	NA	0.07	1.51	1.52	NA	NA	XXX
76778		A	Echo exam kidney transplant	0.74	2.25	2.29	NA	NA	0.12	3.11	3.15	NA	NA	XXX
76778	26	A	Echo exam kidney transplant	0.74	0.26	0.29	0.26	0.29	0.03	1.03	1.06	1.03	1.06	XXX
76778	TC	A	Echo exam kidney transplant	0.00	1.99	2.00	NA	NA	0.09	2.08	2.09	NA	NA	XXX
76800		A	Echo exam spinal canal	1.13	1.81	1.86	NA	NA	0.12	3.06	3.11	NA	NA	XXX
76800	26	A	Echo exam spinal canal	1.13	0.37	0.41	0.37	0.41	0.05	1.55	1.59	1.55	1.59	XXX
76800	TC	A	Echo exam spinal canal	0.00	1.44	1.45	NA	NA	0.07	1.51	1.52	NA	NA	XXX
76805		A	Echo exam of pregnant uterus	0.99	2.47	2.52	NA	NA	0.14	3.60	3.65	NA	NA	XXX
76805	26	A	Echo exam of pregnant uterus	0.99	0.35	0.39	0.35	0.39	0.04	1.38	1.42	1.38	1.42	XXX
76805	TC	A	Echo exam of pregnant uterus	0.00	2.12	2.13	NA	NA	0.10	2.22	2.23	NA	NA	XXX
76810		A	Echo exam of pregnant uterus	1.97	4.95	5.04	NA	NA	0.26	7.18	7.27	NA	NA	XXX
76810	26	A	Echo exam of pregnant uterus	1.97	0.71	0.77	0.71	0.77	0.07	2.75	2.81	2.75	2.81	XXX
76810	TC	A	Echo exam of pregnant uterus	0.00	4.24	4.27	NA	NA	0.19	4.43	4.46	NA	NA	XXX
76815		A	Echo exam of pregnant uterus	0.65	1.68	1.71	NA	NA	0.09	2.42	2.45	NA	NA	XXX
76815	26	A	Echo exam of pregnant uterus	0.65	0.24	0.26	0.24	0.26	0.02	0.91	0.93	0.91	0.93	XXX
76815	TC	A	Echo exam of pregnant uterus	0.00	1.44	1.45	NA	NA	0.07	1.51	1.52	NA	NA	XXX
76816		A	Echo exam follow-up/repeat	0.57	1.33	1.36	NA	NA	0.07	1.97	2.00	NA	NA	XXX
76816	26	A	Echo exam follow-up/repeat	0.57	0.21	0.23	0.21	0.23	0.02	0.80	0.82	0.80	0.82	XXX
76816	TC	A	Echo exam follow-up/repeat	0.00	1.12	1.13	NA	NA	0.05	1.17	1.18	NA	NA	XXX
76818		A	Fetal biophysical profile	0.77	1.92	1.95	NA	NA	0.11	2.80	2.83	NA	NA	XXX
76818	26	A	Fetal biophysical profile	0.77	0.29	0.31	0.29	0.31	0.03	1.09	1.11	1.09	1.11	XXX
76818	TC	A	Fetal biophysical profile	0.00	1.63	1.64	NA	NA	0.08	1.71	1.72	NA	NA	XXX
76825		A	Echo exam of fetal heart	1.67	2.63	2.58	NA	NA	0.15	4.45	4.40	NA	NA	XXX
76825	26	A	Echo exam of fetal heart	1.67	0.64	0.58	0.64	0.58	0.06	2.37	2.31	2.37	2.31	XXX
76825	TC	A	Echo exam of fetal heart	0.00	1.99	2.00	NA	NA	0.09	2.08	2.09	NA	NA	XXX
76826		A	Echo exam of fetal heart	0.83	1.03	1.15	NA	NA	0.07	1.93	2.05	NA	NA	XXX
76826	26	A	Echo exam of fetal heart	0.83	0.32	0.43	0.32	0.43	0.03	1.18	1.29	1.18	1.29	XXX
76826	TC	A	Echo exam of fetal heart	0.00	0.71	0.72	NA	NA	0.04	0.75	0.76	NA	NA	XXX
76827		A	Echo exam of fetal heart	0.58	1.96	2.09	NA	NA	0.12	2.66	2.79	NA	NA	XXX
76827	26	A	Echo exam of fetal heart	0.58	0.22	0.34	0.22	0.34	0.02	0.82	0.94	0.82	0.94	XXX
76827	TC	A	Echo exam of fetal heart	0.00	1.74	1.75	NA	NA	0.10	1.84	1.85	NA	NA	XXX
76828		A	Echo exam of fetal heart	0.56	1.34	1.37	NA	NA	0.09	1.99	2.02	NA	NA	XXX
76828	26	A	Echo exam of fetal heart	0.56	0.22	0.24	0.22	0.24	0.02	0.80	0.82	0.80	0.82	XXX
76828	TC	A	Echo exam of fetal heart	0.00	1.12	1.13	NA	NA	0.07	1.19	1.20	NA	NA	XXX
76830		A	Echo exam, transvaginal	0.69	1.77	1.81	NA	NA	0.11	2.57	2.61	NA	NA	XXX
76830	26	A	Echo exam, transvaginal	0.69	0.24	0.27	0.24	0.27	0.03	0.96	0.99	0.96	0.99	XXX
76830	TC	A	Echo exam, transvaginal	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76831		A	Echo exam, uterus	0.72	1.79	1.82	NA	NA	0.11	2.62	2.65	NA	NA	XXX
76831	26	A	Echo exam, uterus	0.72	0.26	0.28	0.26	0.28	0.03	1.01	1.03	1.01	1.03	XXX
76831	TC	A	Echo exam, uterus	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76856		A	Echo exam of pelvis	0.69	1.77	1.81	NA	NA	0.11	2.57	2.61	NA	NA	XXX
76856	26	A	Echo exam of pelvis	0.69	0.24	0.27	0.24	0.27	0.03	0.96	0.99	0.96	0.99	XXX
76856	TC	A	Echo exam of pelvis	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76857		A	Echo exam of pelvis	0.38	1.20	1.22	NA	NA	0.07	1.65	1.67	NA	NA	XXX
76857	26	A	Echo exam of pelvis	0.38	0.13	0.14	0.13	0.14	0.02	0.53	0.54	0.53	0.54	XXX
76857	TC	A	Echo exam of pelvis	0.00	1.07	1.08	NA	NA	0.05	1.12	1.13	NA	NA	XXX
76870		A	Echo exam of scrotum	0.64	1.75	1.78	NA	NA	0.11	2.50	2.53	NA	NA	XXX
76870	26	A	Echo exam of scrotum	0.64	0.22	0.24	0.22	0.24	0.03	0.89	0.91	0.89	0.91	XXX
76870	TC	A	Echo exam of scrotum	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76872		A	Echo exam, transrectal	0.69	1.76	1.80	NA	NA	0.11	2.56	2.60	NA	NA	XXX
76872	26	A	Echo exam, transrectal	0.69	0.23	0.26	0.23	0.26	0.03	0.95	0.98	0.95	0.98	XXX
76872	TC	A	Echo exam, transrectal	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76873		A	Echograp trans r, pros study	1.38	2.53	2.54	NA	NA	0.20	4.11	4.12	NA	NA	XXX
76873	26	A	Echograp trans r, pros study	1.38	0.47	0.47	0.47	0.47	0.07	1.92	1.92	1.92	1.92	XXX
76873	TC	A	Echograp trans r, pros study	0.00	2.06	2.07	NA	NA	0.13	2.19	2.20	NA	NA	XXX
76880		A	Echo exam of extremity	0.59	1.65	1.68	NA	NA	0.09	2.33	2.36	NA	NA	XXX
76880	26	A	Echo exam of extremity	0.59	0.21	0.23	0.21	0.23	0.02	0.82	0.84	0.82	0.84	XXX
76880	TC	A	Echo exam of extremity	0.00	1.44	1.45	NA	NA	0.07	1.51	1.52	NA	NA	XXX
76885		A	Echo exam, infant hips	0.74	1.79	1.82	NA	NA	0.11	2.64	2.67	NA	NA	XXX
76885	26	A	Echo exam, infant hips	0.74	0.26	0.28	0.26	0.28	0.03	1.03	1.05	1.03	1.05	XXX
76885	TC	A	Echo exam, infant hips	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76886		A	Echo exam, infant hips	0.62	1.66	1.69	NA	NA	0.09	2.37	2.40	NA	NA	XXX
76886	26	A	Echo exam, infant hips	0.62	0.22	0.24	0.22	0.24	0.02	0.86	0.88	0.86	0.88	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
76886	TC	A	Echo exam, infant hips	0.00	1.44	1.45	NA	NA	0.07	1.51	1.52	NA	NA	XXX
76930		A	Echo guide for heart sac tap	0.67	1.80	1.83	NA	NA	0.10	2.57	2.60	NA	NA	XXX
76930	26	A	Echo guide for heart sac tap	0.67	0.27	0.29	0.27	0.29	0.02	0.96	0.98	0.96	0.98	XXX
76930	TC	A	Echo guide for heart sac tap	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76932		A	Echo guide for heart biopsy	0.67	1.80	1.83	NA	NA	0.10	2.57	2.60	NA	NA	XXX
76932	26	A	Echo guide for heart biopsy	0.67	0.27	0.29	0.27	0.29	0.02	0.96	0.98	0.96	0.98	XXX
76932	TC	A	Echo guide for heart biopsy	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76934		A	Echo guide for chest tap	0.67	1.76	1.80	NA	NA	0.11	2.54	2.58	NA	NA	XXX
76934	26	A	Echo guide for chest tap	0.67	0.23	0.26	0.23	0.26	0.03	0.93	0.96	0.93	0.96	XXX
76934	TC	A	Echo guide for chest tap	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76936		A	Echo guide for artery repair	1.99	7.07	7.27	NA	NA	0.40	9.46	9.66	NA	NA	XXX
76936	26	A	Echo guide for artery repair	1.99	0.71	0.87	0.71	0.87	0.11	2.81	2.97	2.81	2.97	XXX
76936	TC	A	Echo guide for artery repair	0.00	6.36	6.40	NA	NA	0.29	6.65	6.69	NA	NA	XXX
76938		A	Echo exam for drainage	0.67	1.76	1.80	NA	NA	0.11	2.54	2.58	NA	NA	XXX
76938	26	A	Echo exam for drainage	0.67	0.23	0.26	0.23	0.26	0.03	0.93	0.96	0.93	0.96	XXX
76938	TC	A	Echo exam for drainage	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76941		A	Echo guide for transfusion	1.34	2.07	2.11	NA	NA	0.12	3.53	3.57	NA	NA	XXX
76941	26	A	Echo guide for transfusion	1.34	0.53	0.56	0.53	0.56	0.05	1.92	1.95	1.92	1.95	XXX
76941	TC	A	Echo guide for transfusion	0.00	1.54	1.55	NA	NA	0.07	1.61	1.62	NA	NA	XXX
76942		A	Echo guide for biopsy	0.67	1.76	1.80	NA	NA	0.11	2.54	2.58	NA	NA	XXX
76942	26	A	Echo guide for biopsy	0.67	0.23	0.26	0.23	0.26	0.03	0.93	0.96	0.93	0.96	XXX
76942	TC	A	Echo guide for biopsy	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76945		A	Echo guide, villus sampling	0.67	1.77	1.89	NA	NA	0.10	2.54	2.66	NA	NA	XXX
76945	26	A	Echo guide, villus sampling	0.67	0.23	0.34	0.23	0.34	0.03	0.93	1.04	0.93	1.04	XXX
76945	TC	A	Echo guide, villus sampling	0.00	1.54	1.55	NA	NA	0.07	1.61	1.62	NA	NA	XXX
76946		A	Echo guide for amniocentesis	0.38	1.67	1.69	NA	NA	0.09	2.14	2.16	NA	NA	XXX
76946	26	A	Echo guide for amniocentesis	0.38	0.14	0.15	0.14	0.15	0.01	0.53	0.54	0.53	0.54	XXX
76946	TC	A	Echo guide for amniocentesis	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76948		A	Echo guide, ova aspiration	0.38	1.66	1.68	NA	NA	0.10	2.14	2.16	NA	NA	XXX
76948	26	A	Echo guide, ova aspiration	0.38	0.13	0.14	0.13	0.14	0.02	0.53	0.54	0.53	0.54	XXX
76948	TC	A	Echo guide, ova aspiration	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76950		A	Echo guidance radiotherapy	0.58	1.52	1.55	NA	NA	0.09	2.19	2.22	NA	NA	XXX
76950	26	A	Echo guidance radiotherapy	0.58	0.20	0.22	0.20	0.22	0.03	0.81	0.83	0.81	0.83	XXX
76950	TC	A	Echo guidance radiotherapy	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
76960		A	Echo guidance radiotherapy	0.58	1.52	1.55	NA	NA	0.09	2.19	2.22	NA	NA	XXX
76960	26	A	Echo guidance radiotherapy	0.58	0.20	0.22	0.20	0.22	0.03	0.81	0.83	0.81	0.83	XXX
76960	TC	A	Echo guidance radiotherapy	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
76965		A	Echo guidance radiotherapy	1.34	6.08	6.40	NA	NA	0.32	7.74	8.06	NA	NA	XXX
76965	26	A	Echo guidance radiotherapy	1.34	0.45	0.74	0.45	0.74	0.07	1.86	2.15	1.86	2.15	XXX
76965	TC	A	Echo guidance radiotherapy	0.00	5.63	5.66	NA	NA	0.25	5.88	5.91	NA	NA	XXX
76970		A	Ultrasound exam follow-up	0.40	1.21	1.24	NA	NA	0.07	1.68	1.71	NA	NA	XXX
76970	26	A	Ultrasound exam follow-up	0.40	0.14	0.16	0.14	0.16	0.02	0.56	0.58	0.56	0.58	XXX
76970	TC	A	Ultrasound exam follow-up	0.00	1.07	1.08	NA	NA	0.05	1.12	1.13	NA	NA	XXX
76975		A	GI endoscopic ultrasound	0.81	1.81	1.84	NA	NA	0.11	2.73	2.76	NA	NA	XXX
76975	26	A	GI endoscopic ultrasound	0.81	0.28	0.30	0.28	0.30	0.03	1.12	1.14	1.12	1.14	XXX
76975	TC	A	GI endoscopic ultrasound	0.00	1.53	1.54	NA	NA	0.08	1.61	1.62	NA	NA	XXX
76977		A	Us bone density measure	0.05	0.86	0.87	NA	NA	0.05	0.96	0.97	NA	NA	XXX
76977	26	A	Us bone density measure	0.05	0.02	0.02	0.02	0.02	0.01	0.08	0.08	0.08	0.08	XXX
76977	TC	A	Us bone density measure	0.00	0.84	0.85	NA	NA	0.04	0.88	0.89	NA	NA	XXX
76986		A	Echo exam at surgery	1.20	3.08	3.14	NA	NA	0.18	4.46	4.52	NA	NA	XXX
76986	26	A	Echo exam at surgery	1.20	0.43	0.47	0.43	0.47	0.06	1.69	1.73	1.69	1.73	XXX
76986	TC	A	Echo exam at surgery	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
76999		C	Echo examination procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
76999	26	C	Echo examination procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
76999	TC	C	Echo examination procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77261		A	Radiation therapy planning	1.39	0.55	0.58	0.55	0.58	0.05	1.99	2.02	1.99	2.02	XXX
77262		A	Radiation therapy planning	2.11	0.81	0.86	0.81	0.86	0.08	3.00	3.05	3.00	3.05	XXX
77263		A	Radiation therapy planning	3.14	1.20	1.28	1.20	1.28	0.12	4.46	4.54	4.46	4.54	XXX
77280		A	Set radiation therapy field	0.70	3.75	3.80	NA	NA	0.18	4.63	4.68	NA	NA	XXX
77280	26	A	Set radiation therapy field	0.70	0.24	0.27	0.24	0.27	0.03	0.97	1.00	0.97	1.00	XXX
77280	TC	A	Set radiation therapy field	0.00	3.51	3.53	NA	NA	0.15	3.66	3.68	NA	NA	XXX
77285		A	Set radiation therapy field	1.05	5.99	6.06	NA	NA	0.30	7.34	7.41	NA	NA	XXX
77285	26	A	Set radiation therapy field	1.05	0.36	0.40	0.36	0.40	0.04	1.45	1.49	1.45	1.49	XXX
77285	TC	A	Set radiation therapy field	0.00	5.63	5.66	NA	NA	0.26	5.89	5.92	NA	NA	XXX
77290		A	Set radiation therapy field	1.56	7.12	7.22	NA	NA	0.36	9.04	9.14	NA	NA	XXX
77290	26	A	Set radiation therapy field	1.56	0.54	0.60	0.54	0.60	0.06	2.16	2.22	2.16	2.22	XXX
77290	TC	A	Set radiation therapy field	0.00	6.58	6.62	NA	NA	0.30	6.88	6.92	NA	NA	XXX
77295		A	Set radiation therapy field	4.57	29.82	30.15	NA	NA	1.44	35.83	36.16	NA	NA	XXX
77295	26	A	Set radiation therapy field	4.57	1.58	1.75	1.58	1.75	0.17	6.32	6.49	6.32	6.49	XXX
77295	TC	A	Set radiation therapy field	0.00	28.24	28.40	NA	NA	1.27	29.51	29.67	NA	NA	XXX
77299		C	Radiation therapy planning	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77299	26	C	Radiation therapy planning	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77299	TC	C	Radiation therapy planning	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77300		A	Radiation therapy dose plan	0.62	1.57	1.60	NA	NA	0.08	2.27	2.30	NA	NA	XXX
77300	26	A	Radiation therapy dose plan	0.62	0.21	0.23	0.21	0.23	0.02	0.85	0.87	0.85	0.87	XXX
77300	TC	A	Radiation therapy dose plan	0.00	1.36	1.37	NA	NA	0.06	1.42	1.43	NA	NA	XXX
77305		A	Radiation therapy dose plan	0.70	2.12	2.16	NA	NA	0.12	2.94	2.98	NA	NA	XXX
77305	26	A	Radiation therapy dose plan	0.70	0.24	0.27	0.24	0.27	0.03	0.97	1.00	0.97	1.00	XXX
77305	TC	A	Radiation therapy dose plan	0.00	1.88	1.89	NA	NA	0.09	1.97	1.98	NA	NA	XXX
77310		A	Radiation therapy dose plan	1.05	2.72	2.77	NA	NA	0.15	3.92	3.97	NA	NA	XXX
77310	26	A	Radiation therapy dose plan	1.05	0.36	0.40	0.36	0.40	0.04	1.45	1.49	1.45	1.49	XXX
77310	TC	A	Radiation therapy dose plan	0.00	2.36	2.37	NA	NA	0.11	2.47	2.48	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
77315		A	Radiation therapy dose plan	1.56	3.23	3.31	NA	NA	0.18	4.97	5.05	NA	NA	XXX
77315	26	A	Radiation therapy dose plan	1.56	0.54	0.60	0.54	0.60	0.06	2.16	2.22	2.16	2.22	XXX
77315	TC	A	Radiation therapy dose plan	0.00	2.69	2.71	NA	NA	0.12	2.81	2.83	NA	NA	XXX
77321		A	Radiation therapy port plan	0.95	4.42	4.48	NA	NA	0.22	5.59	5.65	NA	NA	XXX
77321	26	A	Radiation therapy port plan	0.95	0.33	0.37	0.33	0.37	0.04	1.32	1.36	1.32	1.36	XXX
77321	TC	A	Radiation therapy port plan	0.00	4.09	4.11	NA	NA	0.18	4.27	4.29	NA	NA	XXX
77326		A	Radiation therapy dose plan	0.93	2.71	2.76	NA	NA	0.15	3.79	3.84	NA	NA	XXX
77326	26	A	Radiation therapy dose plan	0.93	0.32	0.36	0.32	0.36	0.04	1.29	1.33	1.29	1.33	XXX
77326	TC	A	Radiation therapy dose plan	0.00	2.39	2.40	NA	NA	0.11	2.50	2.51	NA	NA	XXX
77327		A	Radiation therapy dose plan	1.39	3.99	4.06	NA	NA	0.21	5.59	5.66	NA	NA	XXX
77327	26	A	Radiation therapy dose plan	1.39	0.48	0.53	0.48	0.53	0.06	1.93	1.98	1.93	1.98	XXX
77327	TC	A	Radiation therapy dose plan	0.00	3.51	3.53	NA	NA	0.15	3.66	3.68	NA	NA	XXX
77328		A	Radiation therapy dose plan	2.09	5.73	5.83	NA	NA	0.30	8.12	8.22	NA	NA	XXX
77328	26	A	Radiation therapy dose plan	2.09	0.72	0.79	0.72	0.79	0.08	2.89	2.96	2.89	2.96	XXX
77328	TC	A	Radiation therapy dose plan	0.00	5.01	5.04	NA	NA	0.22	5.23	5.26	NA	NA	XXX
77331		A	Special radiation dosimetry	0.87	0.81	0.84	NA	NA	0.05	1.73	1.76	NA	NA	XXX
77331	26	A	Special radiation dosimetry	0.87	0.30	0.33	0.30	0.33	0.03	1.20	1.23	1.20	1.23	XXX
77331	TC	A	Special radiation dosimetry	0.00	0.51	0.51	NA	NA	0.02	0.53	0.53	NA	NA	XXX
77332		A	Radiation treatment aid(s)	0.54	1.55	1.58	NA	NA	0.08	2.17	2.20	NA	NA	XXX
77332	26	A	Radiation treatment aid(s)	0.54	0.19	0.21	0.19	0.21	0.02	0.75	0.77	0.75	0.77	XXX
77332	TC	A	Radiation treatment aid(s)	0.00	1.36	1.37	NA	NA	0.06	1.42	1.43	NA	NA	XXX
77333		A	Radiation treatment aid(s)	0.84	2.21	2.25	NA	NA	0.12	3.17	3.21	NA	NA	XXX
77333	26	A	Radiation treatment aid(s)	0.84	0.29	0.32	0.29	0.32	0.03	1.16	1.19	1.16	1.19	XXX
77333	TC	A	Radiation treatment aid(s)	0.00	1.92	1.93	NA	NA	0.09	2.01	2.02	NA	NA	XXX
77334		A	Radiation treatment aid(s)	1.24	3.71	3.77	NA	NA	0.19	5.14	5.20	NA	NA	XXX
77334	26	A	Radiation treatment aid(s)	1.24	0.43	0.47	0.43	0.47	0.05	1.72	1.76	1.72	1.76	XXX
77334	TC	A	Radiation treatment aid(s)	0.00	3.28	3.30	NA	NA	0.14	3.42	3.44	NA	NA	XXX
77336		A	Radiation physics consult	0.00	3.01	3.03	NA	NA	0.13	3.14	3.16	NA	NA	XXX
77370		A	Radiation physics consult	0.00	3.53	3.55	NA	NA	0.15	3.68	3.70	NA	NA	XXX
77380		D	Proton beam delivery	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77380	26	D	Proton beam delivery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77380	TC	D	Proton beam delivery	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77381		D	Proton beam treatment	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77381	26	D	Proton beam treatment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77381	TC	D	Proton beam treatment	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77399		C	External radiation dosimetry	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77399	26	C	External radiation dosimetry	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77399	TC	C	External radiation dosimetry	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77401		A	Radiation treatment delivery	0.00	1.79	1.80	NA	NA	0.09	1.88	1.89	NA	NA	XXX
77402		A	Radiation treatment delivery	0.00	1.79	1.80	NA	NA	0.09	1.88	1.89	NA	NA	XXX
77403		A	Radiation treatment delivery	0.00	1.79	1.80	NA	NA	0.09	1.88	1.89	NA	NA	XXX
77404		A	Radiation treatment delivery	0.00	1.79	1.80	NA	NA	0.09	1.88	1.89	NA	NA	XXX
77406		A	Radiation treatment delivery	0.00	1.79	1.80	NA	NA	0.09	1.88	1.89	NA	NA	XXX
77407		A	Radiation treatment delivery	0.00	2.11	2.12	NA	NA	0.10	2.21	2.22	NA	NA	XXX
77408		A	Radiation treatment delivery	0.00	2.11	2.12	NA	NA	0.10	2.21	2.22	NA	NA	XXX
77409		A	Radiation treatment delivery	0.00	2.11	2.12	NA	NA	0.10	2.21	2.22	NA	NA	XXX
77411		A	Radiation treatment delivery	0.00	2.11	2.12	NA	NA	0.10	2.21	2.22	NA	NA	XXX
77412		A	Radiation treatment delivery	0.00	2.36	2.37	NA	NA	0.11	2.47	2.48	NA	NA	XXX
77413		A	Radiation treatment delivery	0.00	2.36	2.37	NA	NA	0.11	2.47	2.48	NA	NA	XXX
77414		A	Radiation treatment delivery	0.00	2.36	2.37	NA	NA	0.11	2.47	2.48	NA	NA	XXX
77416		A	Radiation treatment delivery	0.00	2.36	2.37	NA	NA	0.11	2.47	2.48	NA	NA	XXX
77417		A	Radiology port film(s)	0.00	0.60	0.60	NA	NA	0.03	0.63	0.63	NA	NA	XXX
77419		D	Weekly radiation therapy	3.60	1.43	1.51	1.43	1.51	0.13	5.16	5.24	5.16	5.24	XXX
77420		D	Weekly radiation therapy	1.61	0.64	0.68	0.64	0.68	0.06	2.31	2.35	2.31	2.35	XXX
77425		D	Weekly radiation therapy	2.44	0.97	1.03	0.97	1.03	0.10	3.51	3.57	3.51	3.57	XXX
77427		A	Radiation tx management, x5	3.31	1.14	1.14	1.14	1.14	0.11	4.56	4.56	4.56	4.56	XXX
77430		D	Weekly radiation therapy	3.60	1.43	1.51	1.43	1.51	0.13	5.16	5.24	5.16	5.24	XXX
77431		A	Radiation therapy management	1.81	0.73	0.77	0.73	0.77	0.07	2.61	2.65	2.61	2.65	XXX
77432		A	Stereotactic radiation trmt	7.93	3.10	3.67	3.10	3.67	0.31	11.34	11.91	11.34	11.91	XXX
77470		A	Special radiation treatment	2.09	11.99	12.13	NA	NA	0.58	14.66	14.80	NA	NA	XXX
77470	26	A	Special radiation treatment	2.09	0.72	0.79	0.72	0.79	0.08	2.89	2.96	2.89	2.96	XXX
77470	TC	A	Special radiation treatment	0.00	11.27	11.34	NA	NA	0.50	11.77	11.84	NA	NA	XXX
77499		C	Radiation therapy management	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77499	26	C	Radiation therapy management	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77499	TC	C	Radiation therapy management	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77520		C	Proton beam delivery	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77523		C	Proton beam delivery	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77600		R	Hyperthermia treatment	1.56	3.62	3.70	NA	NA	0.19	5.37	5.45	NA	NA	XXX
77600	26	R	Hyperthermia treatment	1.56	0.54	0.60	0.54	0.60	0.06	2.16	2.22	2.16	2.22	XXX
77600	TC	R	Hyperthermia treatment	0.00	3.08	3.10	NA	NA	0.13	3.21	3.23	NA	NA	XXX
77605		R	Hyperthermia treatment	2.09	4.85	4.94	NA	NA	0.28	7.22	7.31	NA	NA	XXX
77605	26	R	Hyperthermia treatment	2.09	0.74	0.81	0.74	0.81	0.09	2.92	2.99	2.92	2.99	XXX
77605	TC	R	Hyperthermia treatment	0.00	4.11	4.13	NA	NA	0.19	4.30	4.32	NA	NA	XXX
77610		R	Hyperthermia treatment	1.56	3.62	3.70	NA	NA	0.19	5.37	5.45	NA	NA	XXX
77610	26	R	Hyperthermia treatment	1.56	0.54	0.60	0.54	0.60	0.06	2.16	2.22	2.16	2.22	XXX
77610	TC	R	Hyperthermia treatment	0.00	3.08	3.10	NA	NA	0.13	3.21	3.23	NA	NA	XXX
77615		R	Hyperthermia treatment	2.09	4.83	4.92	NA	NA	0.27	7.19	7.28	NA	NA	XXX
77615	26	R	Hyperthermia treatment	2.09	0.72	0.79	0.72	0.79	0.08	2.89	2.96	2.89	2.96	XXX
77615	TC	R	Hyperthermia treatment	0.00	4.11	4.13	NA	NA	0.19	4.30	4.32	NA	NA	XXX
77620		R	Hyperthermia treatment	1.56	3.70	3.76	NA	NA	0.19	5.45	5.51	NA	NA	XXX
77620	26	R	Hyperthermia treatment	1.56	0.62	0.66	0.62	0.66	0.06	2.24	2.28	2.24	2.28	XXX
77620	TC	R	Hyperthermia treatment	0.00	3.08	3.10	NA	NA	0.13	3.21	3.23	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
77750		A	Infuse radioactive materials	4.91	3.05	3.19	NA	NA	0.24	8.20	8.34	NA	NA	090
77750	26	A	Infuse radioactive materials	4.91	1.70	1.83	1.70	1.83	0.18	6.79	6.92	6.79	6.92	090
77750	TC	A	Infuse radioactive materials	0.00	1.35	1.36	NA	NA	0.06	1.41	1.42	NA	NA	090
77761		A	Radioelement application	3.81	3.68	3.85	NA	NA	0.28	7.77	7.94	NA	NA	090
77761	26	A	Radioelement application	3.81	1.15	1.30	1.15	1.30	0.16	5.12	5.27	5.12	5.27	090
77761	TC	A	Radioelement application	0.00	2.53	2.55	NA	NA	0.12	2.65	2.67	NA	NA	090
77762		A	Radioelement application	5.72	5.66	5.83	NA	NA	0.40	11.78	11.95	NA	NA	090
77762	26	A	Radioelement application	5.72	2.01	2.16	2.01	2.16	0.24	7.97	8.12	7.97	8.12	090
77762	TC	A	Radioelement application	0.00	3.65	3.67	NA	NA	0.16	3.81	3.83	NA	NA	090
77763		A	Radioelement application	8.57	7.50	7.76	NA	NA	0.55	16.62	16.88	NA	NA	090
77763	26	A	Radioelement application	8.57	2.96	3.19	2.96	3.19	0.35	11.88	12.11	11.88	12.11	090
77763	TC	A	Radioelement application	0.00	4.54	4.57	NA	NA	0.20	4.74	4.77	NA	NA	090
77776		A	Radioelement application	4.66	3.16	3.50	NA	NA	0.31	8.13	8.47	NA	NA	XXX
77776	26	A	Radioelement application	4.66	0.96	1.29	0.96	1.29	0.20	5.82	6.15	5.82	6.15	XXX
77776	TC	A	Radioelement application	0.00	2.20	2.21	NA	NA	0.11	2.31	2.32	NA	NA	XXX
77777		A	Radioelement application	7.48	6.85	7.09	NA	NA	0.50	14.83	15.07	NA	NA	090
77777	26	A	Radioelement application	7.48	2.57	2.78	2.57	2.78	0.31	10.36	10.57	10.36	10.57	090
77777	TC	A	Radioelement application	0.00	4.28	4.31	NA	NA	0.19	4.47	4.50	NA	NA	090
77778		A	Radioelement application	11.19	9.04	9.38	NA	NA	0.67	20.90	21.24	NA	NA	090
77778	26	A	Radioelement application	11.19	3.85	4.16	3.85	4.16	0.44	15.48	15.79	15.48	15.79	090
77778	TC	A	Radioelement application	0.00	5.19	5.22	NA	NA	0.23	5.42	5.45	NA	NA	090
77781		A	High intensity brachytherapy	1.66	21.10	21.27	NA	NA	0.98	23.74	23.91	NA	NA	090
77781	26	A	High intensity brachytherapy	1.66	0.57	0.62	0.57	0.62	0.07	2.30	2.35	2.30	2.35	090
77781	TC	A	High intensity brachytherapy	0.00	20.53	20.65	NA	NA	0.91	21.44	21.56	NA	NA	090
77782		A	High intensity brachytherapy	2.49	21.39	21.58	NA	NA	1.01	24.89	25.08	NA	NA	090
77782	26	A	High intensity brachytherapy	2.49	0.86	0.93	0.86	0.93	0.10	3.45	3.52	3.45	3.52	090
77782	TC	A	High intensity brachytherapy	0.00	20.53	20.65	NA	NA	0.91	21.44	21.56	NA	NA	090
77783		A	High intensity brachytherapy	3.73	21.81	22.03	NA	NA	1.05	26.59	26.81	NA	NA	090
77783	26	A	High intensity brachytherapy	3.73	1.28	1.38	1.28	1.38	0.14	5.15	5.25	5.15	5.25	090
77783	TC	A	High intensity brachytherapy	0.00	20.53	20.65	NA	NA	0.91	21.44	21.56	NA	NA	090
77784		A	High intensity brachytherapy	5.61	22.46	22.73	NA	NA	1.12	29.19	29.46	NA	NA	090
77784	26	A	High intensity brachytherapy	5.61	1.93	2.08	1.93	2.08	0.21	7.75	7.90	7.75	7.90	090
77784	TC	A	High intensity brachytherapy	0.00	20.53	20.65	NA	NA	0.91	21.44	21.56	NA	NA	090
77789		A	Radioelement application	1.12	0.86	0.89	NA	NA	0.06	2.04	2.07	NA	NA	090
77789	26	A	Radioelement application	1.12	0.40	0.43	0.40	0.43	0.04	1.56	1.59	1.56	1.59	090
77789	TC	A	Radioelement application	0.00	0.46	0.46	NA	NA	0.02	0.48	0.48	NA	NA	090
77790		A	Radioelement handling	1.05	0.87	0.91	NA	NA	0.06	1.98	2.02	NA	NA	XXX
77790	26	A	Radioelement handling	1.05	0.36	0.40	0.36	0.40	0.04	1.45	1.49	1.45	1.49	XXX
77790	TC	A	Radioelement handling	0.00	0.51	0.51	NA	NA	0.02	0.53	0.53	NA	NA	XXX
77799		C	Radium/radioisotope therapy	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
77799	26	C	Radium/radioisotope therapy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
77799	TC	C	Radium/radioisotope therapy	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78000		A	Thyroid, single uptake	0.19	1.05	1.07	NA	NA	0.06	1.30	1.32	NA	NA	XXX
78000	26	A	Thyroid, single uptake	0.19	0.07	0.08	0.07	0.08	0.01	0.27	0.28	0.27	0.28	XXX
78000	TC	A	Thyroid, single uptake	0.00	0.98	0.99	NA	NA	0.05	1.03	1.04	NA	NA	XXX
78001		A	Thyroid, multiple uptakes	0.26	1.41	1.43	NA	NA	0.07	1.74	1.76	NA	NA	XXX
78001	26	A	Thyroid, multiple uptakes	0.26	0.09	0.10	0.09	0.10	0.01	0.36	0.37	0.36	0.37	XXX
78001	TC	A	Thyroid, multiple uptakes	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
78003		A	Thyroid suppress/stimul	0.33	1.10	1.12	NA	NA	0.06	1.49	1.51	NA	NA	XXX
78003	26	A	Thyroid suppress/stimul	0.33	0.12	0.13	0.12	0.13	0.01	0.46	0.47	0.46	0.47	XXX
78003	TC	A	Thyroid suppress/stimul	0.00	0.98	0.99	NA	NA	0.05	1.03	1.04	NA	NA	XXX
78006		A	Thyroid imaging with uptake	0.49	2.57	2.61	NA	NA	0.13	3.19	3.23	NA	NA	XXX
78006	26	A	Thyroid imaging with uptake	0.49	0.17	0.19	0.17	0.19	0.02	0.68	0.70	0.68	0.70	XXX
78006	TC	A	Thyroid imaging with uptake	0.00	2.40	2.42	NA	NA	0.11	2.51	2.53	NA	NA	XXX
78007		A	Thyroid image, mult uptakes	0.50	2.78	2.82	NA	NA	0.14	3.42	3.46	NA	NA	XXX
78007	26	A	Thyroid image, mult uptakes	0.50	0.18	0.20	0.18	0.20	0.02	0.70	0.72	0.70	0.72	XXX
78007	TC	A	Thyroid image, mult uptakes	0.00	2.60	2.62	NA	NA	0.12	2.72	2.74	NA	NA	XXX
78010		A	Thyroid imaging	0.39	1.98	2.00	NA	NA	0.11	2.48	2.50	NA	NA	XXX
78010	26	A	Thyroid imaging	0.39	0.14	0.15	0.14	0.15	0.02	0.55	0.56	0.55	0.56	XXX
78010	TC	A	Thyroid imaging	0.00	1.84	1.85	NA	NA	0.09	1.93	1.94	NA	NA	XXX
78011		A	Thyroid imaging with flow	0.45	2.59	2.63	NA	NA	0.13	3.17	3.21	NA	NA	XXX
78011	26	A	Thyroid imaging with flow	0.45	0.16	0.18	0.16	0.18	0.02	0.63	0.65	0.63	0.65	XXX
78011	TC	A	Thyroid imaging with flow	0.00	2.43	2.45	NA	NA	0.11	2.54	2.56	NA	NA	XXX
78015		A	Thyroid met imaging	0.67	2.84	2.89	NA	NA	0.15	3.66	3.71	NA	NA	XXX
78015	26	A	Thyroid met imaging	0.67	0.24	0.27	0.24	0.27	0.03	0.94	0.97	0.94	0.97	XXX
78015	TC	A	Thyroid met imaging	0.00	2.60	2.62	NA	NA	0.12	2.72	2.74	NA	NA	XXX
78016		A	Thyroid met imaging/studies	0.82	3.82	3.87	NA	NA	0.18	4.82	4.87	NA	NA	XXX
78016	26	A	Thyroid met imaging/studies	0.82	0.30	0.33	0.30	0.33	0.03	1.15	1.18	1.15	1.18	XXX
78016	TC	A	Thyroid met imaging/studies	0.00	3.52	3.54	NA	NA	0.15	3.67	3.69	NA	NA	XXX
78018		A	Thyroid met imaging, body	0.86	5.79	5.86	NA	NA	0.28	6.93	7.00	NA	NA	XXX
78018	26	A	Thyroid met imaging, body	0.86	0.31	0.35	0.31	0.35	0.03	1.20	1.24	1.20	1.24	XXX
78018	TC	A	Thyroid met imaging, body	0.00	5.48	5.51	NA	NA	0.25	5.73	5.76	NA	NA	XXX
78020		A	Thyroid met uptake	0.60	0.39	0.39	NA	NA	0.00	0.99	0.99	NA	NA	ZZZ
78020	26	A	Thyroid met uptake	0.60	0.24	0.24	0.24	0.24	0.00	0.84	0.84	0.84	0.84	ZZZ
78020	TC	A	Thyroid met uptake	0.00	0.15	0.15	NA	NA	0.00	0.15	0.15	NA	NA	ZZZ
78070		A	Parathyroid nuclear imaging	0.82	2.13	2.13	NA	NA	0.12	3.07	3.07	NA	NA	XXX
78070	26	A	Parathyroid nuclear imaging	0.82	0.29	0.28	0.29	0.28	0.03	1.14	1.13	1.14	1.13	XXX
78070	TC	A	Parathyroid nuclear imaging	0.00	1.84	1.85	NA	NA	0.09	1.93	1.94	NA	NA	XXX
78075		A	Adrenal nuclear imaging	0.74	5.76	5.81	NA	NA	0.28	6.78	6.83	NA	NA	XXX
78075	26	A	Adrenal nuclear imaging	0.74	0.28	0.30	0.28	0.30	0.03	1.05	1.07	1.05	1.07	XXX
78075	TC	A	Adrenal nuclear imaging	0.00	5.48	5.51	NA	NA	0.25	5.73	5.76	NA	NA	XXX
78099		C	Endocrine nuclear procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
78099	26	C	Endocrine nuclear procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78099	TC	C	Endocrine nuclear procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78102		A	Bone marrow imaging, ltd	0.55	2.26	2.29	NA	NA	0.12	2.93	2.96	NA	NA	XXX
78102	26	A	Bone marrow imaging, ltd	0.55	0.20	0.22	0.20	0.22	0.02	0.77	0.79	0.77	0.79	XXX
78102	TC	A	Bone marrow imaging, ltd	0.00	2.06	2.07	NA	NA	0.10	2.16	2.17	NA	NA	XXX
78103		A	Bone marrow imaging, mult	0.75	3.48	3.53	NA	NA	0.17	4.40	4.45	NA	NA	XXX
78103	26	A	Bone marrow imaging, mult	0.75	0.27	0.30	0.27	0.30	0.03	1.05	1.08	1.05	1.08	XXX
78103	TC	A	Bone marrow imaging, mult	0.00	3.21	3.23	NA	NA	0.14	3.35	3.37	NA	NA	XXX
78104		A	Bone marrow imaging, body	0.80	4.41	4.46	NA	NA	0.22	5.43	5.48	NA	NA	XXX
78104	26	A	Bone marrow imaging, body	0.80	0.29	0.32	0.29	0.32	0.03	1.12	1.15	1.12	1.15	XXX
78104	TC	A	Bone marrow imaging, body	0.00	4.12	4.14	NA	NA	0.19	4.31	4.33	NA	NA	XXX
78110		A	Plasma volume, single	0.19	1.03	1.05	NA	NA	0.06	1.28	1.30	NA	NA	XXX
78110	26	A	Plasma volume, single	0.19	0.07	0.08	0.07	0.08	0.01	0.27	0.28	0.27	0.28	XXX
78110	TC	A	Plasma volume, single	0.00	0.96	0.97	NA	NA	0.05	1.01	1.02	NA	NA	XXX
78111		A	Plasma volume, multiple	0.22	2.68	2.71	NA	NA	0.13	3.03	3.06	NA	NA	XXX
78111	26	A	Plasma volume, multiple	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
78111	TC	A	Plasma volume, multiple	0.00	2.60	2.62	NA	NA	0.12	2.72	2.74	NA	NA	XXX
78120		A	Red cell mass, single	0.23	1.83	1.85	NA	NA	0.10	2.16	2.18	NA	NA	XXX
78120	26	A	Red cell mass, single	0.23	0.08	0.09	0.08	0.09	0.01	0.32	0.33	0.32	0.33	XXX
78120	TC	A	Red cell mass, single	0.00	1.75	1.76	NA	NA	0.09	1.84	1.85	NA	NA	XXX
78121		A	Red cell mass, multiple	0.32	3.06	3.09	NA	NA	0.13	3.51	3.54	NA	NA	XXX
78121	26	A	Red cell mass, multiple	0.32	0.12	0.13	0.12	0.13	0.01	0.45	0.46	0.45	0.46	XXX
78121	TC	A	Red cell mass, multiple	0.00	2.94	2.96	NA	NA	0.12	3.06	3.08	NA	NA	XXX
78122		A	Blood volume	0.45	4.81	4.86	NA	NA	0.23	5.49	5.54	NA	NA	XXX
78122	26	A	Blood volume	0.45	0.16	0.18	0.16	0.18	0.02	0.63	0.65	0.63	0.65	XXX
78122	TC	A	Blood volume	0.00	4.65	4.68	NA	NA	0.21	4.86	4.89	NA	NA	XXX
78130		A	Red cell survival study	0.61	3.10	3.14	NA	NA	0.14	3.85	3.89	NA	NA	XXX
78130	26	A	Red cell survival study	0.61	0.22	0.24	0.22	0.24	0.02	0.85	0.87	0.85	0.87	XXX
78130	TC	A	Red cell survival study	0.00	2.88	2.90	NA	NA	0.12	3.00	3.02	NA	NA	XXX
78135		A	Red cell survival kinetics	0.64	5.16	5.21	NA	NA	0.24	6.04	6.09	NA	NA	XXX
78135	26	A	Red cell survival kinetics	0.64	0.23	0.25	0.23	0.25	0.02	0.89	0.91	0.89	0.91	XXX
78135	TC	A	Red cell survival kinetics	0.00	4.93	4.96	NA	NA	0.22	5.15	5.18	NA	NA	XXX
78140		A	Red cell sequestration	0.61	4.19	4.23	NA	NA	0.20	5.00	5.04	NA	NA	XXX
78140	26	A	Red cell sequestration	0.61	0.21	0.23	0.21	0.23	0.02	0.84	0.86	0.84	0.86	XXX
78140	TC	A	Red cell sequestration	0.00	3.98	4.00	NA	NA	0.18	4.16	4.18	NA	NA	XXX
78160		A	Plasma iron turnover	0.33	3.82	3.85	NA	NA	0.17	4.32	4.35	NA	NA	XXX
78160	26	A	Plasma iron turnover	0.33	0.12	0.13	0.12	0.13	0.01	0.46	0.47	0.46	0.47	XXX
78160	TC	A	Plasma iron turnover	0.00	3.70	3.72	NA	NA	0.16	3.86	3.88	NA	NA	XXX
78162		A	Iron absorption exam	0.45	3.42	3.45	NA	NA	0.15	4.02	4.05	NA	NA	XXX
78162	26	A	Iron absorption exam	0.45	0.18	0.19	0.18	0.19	0.01	0.64	0.65	0.64	0.65	XXX
78162	TC	A	Iron absorption exam	0.00	3.24	3.26	NA	NA	0.14	3.38	3.40	NA	NA	XXX
78170		A	Red cell iron utilization	0.41	5.52	5.56	NA	NA	0.26	6.19	6.23	NA	NA	XXX
78170	26	A	Red cell iron utilization	0.41	0.15	0.16	0.15	0.16	0.02	0.58	0.59	0.58	0.59	XXX
78170	TC	A	Red cell iron utilization	0.00	5.37	5.40	NA	NA	0.24	5.61	5.64	NA	NA	XXX
78172		C	Total body iron estimation	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78172	26	A	Total body iron estimation	0.53	0.19	0.21	0.19	0.21	0.02	0.74	0.76	0.74	0.76	XXX
78172	TC	C	Total body iron estimation	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78185		A	Spleen imaging	0.40	2.53	2.56	NA	NA	0.13	3.06	3.09	NA	NA	XXX
78185	26	A	Spleen imaging	0.40	0.14	0.16	0.14	0.16	0.02	0.56	0.58	0.56	0.58	XXX
78185	TC	A	Spleen imaging	0.00	2.39	2.40	NA	NA	0.11	2.50	2.51	NA	NA	XXX
78190		A	Platelet survival, kinetics	1.09	6.21	6.26	NA	NA	0.30	7.60	7.65	NA	NA	XXX
78190	26	A	Platelet survival, kinetics	1.09	0.43	0.45	0.43	0.45	0.04	1.56	1.58	1.56	1.58	XXX
78190	TC	A	Platelet survival, kinetics	0.00	5.78	5.81	NA	NA	0.26	6.04	6.07	NA	NA	XXX
78191		A	Platelet survival	0.61	7.64	7.70	NA	NA	0.34	8.59	8.65	NA	NA	XXX
78191	26	A	Platelet survival	0.61	0.22	0.24	0.22	0.24	0.02	0.85	0.87	0.85	0.87	XXX
78191	TC	A	Platelet survival	0.00	7.42	7.46	NA	NA	0.32	7.74	7.78	NA	NA	XXX
78195		A	Lymph system imaging	1.20	4.55	4.55	NA	NA	0.24	5.99	5.99	NA	NA	XXX
78195	26	A	Lymph system imaging	1.20	0.43	0.41	0.43	0.41	0.05	1.68	1.66	1.68	1.66	XXX
78195	TC	A	Lymph system imaging	0.00	4.12	4.14	NA	NA	0.19	4.31	4.33	NA	NA	XXX
78199		C	Blood/lymph nuclear exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78199	26	C	Blood/lymph nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78199	TC	C	Blood/lymph nuclear exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78201		A	Liver imaging	0.44	2.55	2.57	NA	NA	0.13	3.12	3.14	NA	NA	XXX
78201	26	A	Liver imaging	0.44	0.16	0.17	0.16	0.17	0.02	0.62	0.63	0.62	0.63	XXX
78201	TC	A	Liver imaging	0.00	2.39	2.40	NA	NA	0.11	2.50	2.51	NA	NA	XXX
78202		A	Liver imaging with flow	0.51	3.09	3.13	NA	NA	0.14	3.74	3.78	NA	NA	XXX
78202	26	A	Liver imaging with flow	0.51	0.18	0.20	0.18	0.20	0.02	0.71	0.73	0.71	0.73	XXX
78202	TC	A	Liver imaging with flow	0.00	2.91	2.93	NA	NA	0.12	3.03	3.05	NA	NA	XXX
78205		A	Liver imaging (3D)	0.71	6.22	6.29	NA	NA	0.30	7.23	7.30	NA	NA	XXX
78205	26	A	Liver imaging (3D)	0.71	0.25	0.28	0.25	0.28	0.03	0.99	1.02	0.99	1.02	XXX
78205	TC	A	Liver imaging (3D)	0.00	5.97	6.01	NA	NA	0.27	6.24	6.28	NA	NA	XXX
78206		A	Liver image (3d) w/flow	0.96	6.34	6.38	NA	NA	0.13	7.43	7.47	NA	NA	XXX
78206	26	A	Liver image (3d) w/flow	0.96	0.35	0.35	0.35	0.35	0.04	1.35	1.35	1.35	1.35	XXX
78206	TC	A	Liver image (3d) w/flow	0.00	5.99	6.03	NA	NA	0.09	6.08	6.12	NA	NA	XXX
78215		A	Liver and spleen imaging	0.49	3.14	3.18	NA	NA	0.14	3.77	3.81	NA	NA	XXX
78215	26	A	Liver and spleen imaging	0.49	0.17	0.19	0.17	0.19	0.02	0.68	0.70	0.68	0.70	XXX
78215	TC	A	Liver and spleen imaging	0.00	2.97	2.99	NA	NA	0.12	3.09	3.11	NA	NA	XXX
78216		A	Liver & spleen image/flow	0.57	3.72	3.76	NA	NA	0.17	4.46	4.50	NA	NA	XXX
78216	26	A	Liver & spleen image/flow	0.57	0.20	0.22	0.20	0.22	0.02	0.79	0.81	0.79	0.81	XXX
78216	TC	A	Liver & spleen image/flow	0.00	3.52	3.54	NA	NA	0.15	3.67	3.69	NA	NA	XXX
78220		A	Liver function study	0.49	3.93	3.97	NA	NA	0.18	4.60	4.64	NA	NA	XXX
78220	26	A	Liver function study	0.49	0.17	0.19	0.17	0.19	0.02	0.68	0.70	0.68	0.70	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
78220	TC	A	Liver function study	0.00	3.76	3.78	NA	NA	0.16	3.92	3.94	NA	NA	XXX
78223		A	Hepatobiliary imaging	0.84	4.00	4.05	NA	NA	0.19	5.03	5.08	NA	NA	XXX
78223	26	A	Hepatobiliary imaging	0.84	0.30	0.33	0.30	0.33	0.03	1.17	1.20	1.17	1.20	XXX
78223	TC	A	Hepatobiliary imaging	0.00	3.70	3.72	NA	NA	0.16	3.86	3.88	NA	NA	XXX
78230		A	Salivary gland imaging	0.45	2.35	2.38	NA	NA	0.13	2.93	2.96	NA	NA	XXX
78230	26	A	Salivary gland imaging	0.45	0.15	0.17	0.15	0.17	0.02	0.62	0.64	0.62	0.64	XXX
78230	TC	A	Salivary gland imaging	0.00	2.20	2.21	NA	NA	0.11	2.31	2.32	NA	NA	XXX
78231		A	Serial salivary imaging	0.52	3.40	3.44	NA	NA	0.16	4.08	4.12	NA	NA	XXX
78231	26	A	Serial salivary imaging	0.52	0.19	0.21	0.19	0.21	0.02	0.73	0.75	0.73	0.75	XXX
78231	TC	A	Serial salivary imaging	0.00	3.21	3.23	NA	NA	0.14	3.35	3.37	NA	NA	XXX
78232		A	Salivary gland function exam	0.47	3.75	3.79	NA	NA	0.17	4.39	4.43	NA	NA	XXX
78232	26	A	Salivary gland function exam	0.47	0.17	0.19	0.17	0.19	0.02	0.66	0.68	0.66	0.68	XXX
78232	TC	A	Salivary gland function exam	0.00	3.58	3.60	NA	NA	0.15	3.73	3.75	NA	NA	XXX
78258		A	Esophageal motility study	0.74	3.17	3.22	NA	NA	0.15	4.06	4.11	NA	NA	XXX
78258	26	A	Esophageal motility study	0.74	0.26	0.29	0.26	0.29	0.03	1.03	1.06	1.03	1.06	XXX
78258	TC	A	Esophageal motility study	0.00	2.91	2.93	NA	NA	0.12	3.03	3.05	NA	NA	XXX
78261		A	Gastric mucosa imaging	0.69	4.40	4.45	NA	NA	0.22	5.31	5.36	NA	NA	XXX
78261	26	A	Gastric mucosa imaging	0.69	0.26	0.28	0.26	0.28	0.03	0.98	1.00	0.98	1.00	XXX
78261	TC	A	Gastric mucosa imaging	0.00	4.14	4.17	NA	NA	0.19	4.33	4.36	NA	NA	XXX
78262		A	Gastroesophageal reflux exam	0.68	4.55	4.60	NA	NA	0.21	5.44	5.49	NA	NA	XXX
78262	26	A	Gastroesophageal reflux exam	0.68	0.25	0.27	0.25	0.27	0.02	0.95	0.97	0.95	0.97	XXX
78262	TC	A	Gastroesophageal reflux exam	0.00	4.30	4.33	NA	NA	0.19	4.49	4.52	NA	NA	XXX
78264		A	Gastric emptying study	0.78	4.45	4.51	NA	NA	0.22	5.45	5.51	NA	NA	XXX
78264	26	A	Gastric emptying study	0.78	0.28	0.31	0.28	0.31	0.03	1.09	1.12	1.09	1.12	XXX
78264	TC	A	Gastric emptying study	0.00	4.17	4.20	NA	NA	0.19	4.36	4.39	NA	NA	XXX
78267		X	Breath tst attain/anal c-14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78268		X	Breath test analysis, c-14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78270		A	Vit B-12 absorption exam	0.20	1.63	1.65	NA	NA	0.09	1.92	1.94	NA	NA	XXX
78270	26	A	Vit B-12 absorption exam	0.20	0.07	0.08	0.07	0.08	0.01	0.28	0.29	0.28	0.29	XXX
78270	TC	A	Vit B-12 absorption exam	0.00	1.56	1.57	NA	NA	0.08	1.64	1.65	NA	NA	XXX
78271		A	Vit B-12 absorp exam, IF	0.20	1.73	1.75	NA	NA	0.09	2.02	2.04	NA	NA	XXX
78271	26	A	Vit B-12 absorp exam, IF	0.20	0.07	0.08	0.07	0.08	0.01	0.28	0.29	0.28	0.29	XXX
78271	TC	A	Vit B-12 absorp exam, IF	0.00	1.66	1.67	NA	NA	0.08	1.74	1.75	NA	NA	XXX
78272		A	Vit B-12 absorp, combined	0.27	2.45	2.47	NA	NA	0.12	2.84	2.86	NA	NA	XXX
78272	26	A	Vit B-12 absorp, combined	0.27	0.10	0.11	0.10	0.11	0.01	0.38	0.39	0.38	0.39	XXX
78272	TC	A	Vit B-12 absorp, combined	0.00	2.35	2.36	NA	NA	0.11	2.46	2.47	NA	NA	XXX
78278		A	Acute GI blood loss imaging	0.99	5.28	5.35	NA	NA	0.26	6.53	6.60	NA	NA	XXX
78278	26	A	Acute GI blood loss imaging	0.99	0.35	0.39	0.35	0.39	0.04	1.38	1.42	1.38	1.42	XXX
78278	TC	A	Acute GI blood loss imaging	0.00	4.93	4.96	NA	NA	0.22	5.15	5.18	NA	NA	XXX
78282		C	GI protein loss exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78282	26	A	GI protein loss exam	0.38	0.14	0.15	0.14	0.15	0.01	0.53	0.54	0.53	0.54	XXX
78282	TC	C	GI protein loss exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78290		A	Meckel's divert exam	0.68	3.32	3.37	NA	NA	0.16	4.16	4.21	NA	NA	XXX
78290	26	A	Meckel's divert exam	0.68	0.24	0.27	0.24	0.27	0.03	0.95	0.98	0.95	0.98	XXX
78290	TC	A	Meckel's divert exam	0.00	3.08	3.10	NA	NA	0.13	3.21	3.23	NA	NA	XXX
78291		A	Leveen/shunt patency exam	0.88	3.42	3.47	NA	NA	0.16	4.46	4.51	NA	NA	XXX
78291	26	A	Leveen/shunt patency exam	0.88	0.32	0.35	0.32	0.35	0.03	1.23	1.26	1.23	1.26	XXX
78291	TC	A	Leveen/shunt patency exam	0.00	3.10	3.12	NA	NA	0.13	3.23	3.25	NA	NA	XXX
78299		C	GI nuclear procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78299	26	C	GI nuclear procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78299	TC	C	GI nuclear procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78300		A	Bone imaging, limited area	0.62	2.73	2.77	NA	NA	0.14	3.49	3.53	NA	NA	XXX
78300	26	A	Bone imaging, limited area	0.62	0.22	0.24	0.22	0.24	0.02	0.86	0.88	0.86	0.88	XXX
78300	TC	A	Bone imaging, limited area	0.00	2.51	2.53	NA	NA	0.12	2.63	2.65	NA	NA	XXX
78305		A	Bone imaging, multiple areas	0.83	3.99	4.04	NA	NA	0.19	5.01	5.06	NA	NA	XXX
78305	26	A	Bone imaging, multiple areas	0.83	0.29	0.32	0.29	0.32	0.03	1.15	1.18	1.15	1.18	XXX
78305	TC	A	Bone imaging, multiple areas	0.00	3.70	3.72	NA	NA	0.16	3.86	3.88	NA	NA	XXX
78306		A	Bone imaging, whole body	0.86	4.62	4.68	NA	NA	0.22	5.70	5.76	NA	NA	XXX
78306	26	A	Bone imaging, whole body	0.86	0.30	0.33	0.30	0.33	0.03	1.19	1.22	1.19	1.22	XXX
78306	TC	A	Bone imaging, whole body	0.00	4.32	4.35	NA	NA	0.19	4.51	4.54	NA	NA	XXX
78315		A	Bone imaging, 3 phase	1.02	5.19	5.25	NA	NA	0.26	6.47	6.53	NA	NA	XXX
78315	26	A	Bone imaging, 3 phase	1.02	0.36	0.39	0.36	0.39	0.04	1.42	1.45	1.42	1.45	XXX
78315	TC	A	Bone imaging, 3 phase	0.00	4.83	4.86	NA	NA	0.22	5.05	5.08	NA	NA	XXX
78320		A	Bone imaging (3D)	1.04	6.35	6.42	NA	NA	0.31	7.70	7.77	NA	NA	XXX
78320	26	A	Bone imaging (3D)	1.04	0.38	0.41	0.38	0.41	0.04	1.46	1.49	1.46	1.49	XXX
78320	TC	A	Bone imaging (3D)	0.00	5.97	6.01	NA	NA	0.27	6.24	6.28	NA	NA	XXX
78350		A	Bone mineral, single photon	0.22	0.84	0.86	NA	NA	0.05	1.11	1.13	NA	NA	XXX
78350	26	A	Bone mineral, single photon	0.22	0.08	0.09	0.08	0.09	0.01	0.31	0.32	0.31	0.32	XXX
78350	TC	A	Bone mineral, single photon	0.00	0.76	0.77	NA	NA	0.04	0.80	0.81	NA	NA	XXX
78351		N	Bone mineral, dual photon	0.30	1.45	1.14	0.12	0.14	0.01	1.76	1.45	0.43	0.45	XXX
78399		C	Musculoskeletal nuclear exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78399	26	C	Musculoskeletal nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78399	TC	C	Musculoskeletal nuclear exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78414		C	Non-imaging heart function	0.00	0.00	0.18	NA	NA	0.00	0.00	0.18	NA	NA	XXX
78414	26	A	Non-imaging heart function	0.45	0.17	0.18	0.17	0.18	0.02	0.64	0.65	0.64	0.65	XXX
78414	TC	C	Non-imaging heart function	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78428		A	Cardiac shunt imaging	0.78	2.59	2.62	NA	NA	0.14	3.51	3.54	NA	NA	XXX
78428	26	A	Cardiac shunt imaging	0.78	0.31	0.33	0.31	0.33	0.03	1.12	1.14	1.12	1.14	XXX
78428	TC	A	Cardiac shunt imaging	0.00	2.28	2.29	NA	NA	0.11	2.39	2.40	NA	NA	XXX
78445		A	Vascular flow imaging	0.49	2.06	2.09	NA	NA	0.11	2.66	2.69	NA	NA	XXX
78445	26	A	Vascular flow imaging	0.49	0.18	0.20	0.18	0.20	0.02	0.69	0.71	0.69	0.71	XXX
78445	TC	A	Vascular flow imaging	0.00	1.88	1.89	NA	NA	0.09	1.97	1.98	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
78455	.....	A	Venous thrombosis study	0.73	4.29	4.34	NA	NA	0.21	5.23	5.28	NA	NA	XXX
78455	26	A	Venous thrombosis study	0.73	0.26	0.29	0.26	0.29	0.03	1.02	1.05	1.02	1.05	XXX
78455	TC	A	Venous thrombosis study	0.00	4.03	4.05	NA	NA	0.18	4.21	4.23	NA	NA	XXX
78456	.....	A	Acute venous thrombus image	0.01	4.28	4.30	NA	NA	0.30	4.59	4.61	NA	NA	XXX
78456	26	A	Acute venous thrombus image	0.01	0.37	0.37	0.37	0.37	0.05	0.43	0.43	0.43	0.43	XXX
78456	TC	A	Acute venous thrombus image	0.00	3.91	3.93	NA	NA	0.25	4.16	4.18	NA	NA	XXX
78457	.....	A	Venous thrombosis imaging	0.77	2.96	3.01	NA	NA	0.15	3.88	3.93	NA	NA	XXX
78457	26	A	Venous thrombosis imaging	0.77	0.27	0.30	0.27	0.30	0.03	1.07	1.10	1.07	1.10	XXX
78457	TC	A	Venous thrombosis imaging	0.00	2.69	2.71	NA	NA	0.12	2.81	2.83	NA	NA	XXX
78458	.....	A	Ven thrombosis images, bilat	0.90	4.41	4.45	NA	NA	0.21	5.52	5.56	NA	NA	XXX
78458	26	A	Ven thrombosis images, bilat	0.90	0.34	0.36	0.34	0.36	0.03	1.27	1.29	1.27	1.29	XXX
78458	TC	A	Ven thrombosis images, bilat	0.00	4.07	4.09	NA	NA	0.18	4.25	4.27	NA	NA	XXX
78459	.....	I	Heart muscle imaging (PET)	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78459	26	I	Heart muscle imaging (PET)	1.88	0.75	0.93	0.75	0.93	0.07	2.70	2.88	2.70	2.88	XXX
78459	TC	I	Heart muscle imaging (PET)	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78460	.....	A	Heart muscle blood, single	0.86	2.70	2.74	NA	NA	0.14	3.70	3.74	NA	NA	XXX
78460	26	A	Heart muscle blood, single	0.86	0.31	0.34	0.31	0.34	0.03	1.20	1.23	1.20	1.23	XXX
78460	TC	A	Heart muscle blood, single	0.00	2.39	2.40	NA	NA	0.11	2.50	2.51	NA	NA	XXX
78461	.....	A	Heart muscle blood, multiple	1.23	5.23	5.29	NA	NA	0.26	6.72	6.78	NA	NA	XXX
78461	26	A	Heart muscle blood, multiple	1.23	0.46	0.49	0.46	0.49	0.04	1.73	1.76	1.73	1.76	XXX
78461	TC	A	Heart muscle blood, multiple	0.00	4.77	4.80	NA	NA	0.22	4.99	5.02	NA	NA	XXX
78464	.....	A	Heart image (3d), single	1.09	7.55	7.62	NA	NA	0.36	9.00	9.07	NA	NA	XXX
78464	26	A	Heart image (3d), single	1.09	0.40	0.43	0.40	0.43	0.04	1.53	1.56	1.53	1.56	XXX
78464	TC	A	Heart image (3d), single	0.00	7.15	7.19	NA	NA	0.32	7.47	7.51	NA	NA	XXX
78465	.....	A	Heart image (3d), multiple	1.46	12.49	12.60	NA	NA	0.58	14.53	14.64	NA	NA	XXX
78465	26	A	Heart image (3d), multiple	1.46	0.56	0.60	0.56	0.60	0.05	2.07	2.11	2.07	2.11	XXX
78465	TC	A	Heart image (3d), multiple	0.00	11.93	12.00	NA	NA	0.53	12.46	12.53	NA	NA	XXX
78466	.....	A	Heart infarct image	0.69	2.91	2.95	NA	NA	0.15	3.75	3.79	NA	NA	XXX
78466	26	A	Heart infarct image	0.69	0.26	0.28	0.26	0.28	0.03	0.98	1.00	0.98	1.00	XXX
78466	TC	A	Heart infarct image	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
78468	.....	A	Heart infarct image (ef)	0.80	3.99	4.04	NA	NA	0.19	4.98	5.03	NA	NA	XXX
78468	26	A	Heart infarct image (ef)	0.80	0.29	0.32	0.29	0.32	0.03	1.12	1.15	1.12	1.15	XXX
78468	TC	A	Heart infarct image (ef)	0.00	3.70	3.72	NA	NA	0.16	3.86	3.88	NA	NA	XXX
78469	.....	A	Heart infarct image (3D)	0.92	5.60	5.66	NA	NA	0.27	6.79	6.85	NA	NA	XXX
78469	26	A	Heart infarct image (3D)	0.92	0.32	0.35	0.32	0.35	0.03	1.27	1.30	1.27	1.30	XXX
78469	TC	A	Heart infarct image (3D)	0.00	5.28	5.31	NA	NA	0.24	5.52	5.55	NA	NA	XXX
78472	.....	A	Gated heart, planar, single	0.98	5.93	5.99	NA	NA	0.30	7.21	7.27	NA	NA	XXX
78472	26	A	Gated heart, planar, single	0.98	0.36	0.39	0.36	0.39	0.04	1.38	1.41	1.38	1.41	XXX
78472	TC	A	Gated heart, planar, single	0.00	5.57	5.60	NA	NA	0.26	5.83	5.86	NA	NA	XXX
78473	.....	A	Gated heart, multiple	1.47	8.89	8.98	NA	NA	0.41	10.77	10.86	NA	NA	XXX
78473	26	A	Gated heart, multiple	1.47	0.54	0.58	0.54	0.58	0.05	2.06	2.10	2.06	2.10	XXX
78473	TC	A	Gated heart, multiple	0.00	8.35	8.40	NA	NA	0.36	8.71	8.76	NA	NA	XXX
78478	.....	A	Heart wall motion add-on	0.62	1.81	1.84	NA	NA	0.10	2.53	2.56	NA	NA	ZZZ
78478	26	A	Heart wall motion add-on	0.62	0.24	0.26	0.24	0.26	0.02	0.88	0.90	0.88	0.90	ZZZ
78478	TC	A	Heart wall motion add-on	0.00	1.57	1.58	NA	NA	0.08	1.65	1.66	NA	NA	ZZZ
78480	.....	A	Heart function add-on	0.62	1.81	1.84	NA	NA	0.10	2.53	2.56	NA	NA	ZZZ
78480	26	A	Heart function add-on	0.62	0.24	0.26	0.24	0.26	0.02	0.88	0.90	0.88	0.90	ZZZ
78480	TC	A	Heart function add-on	0.00	1.57	1.58	NA	NA	0.08	1.65	1.66	NA	NA	ZZZ
78481	.....	A	Heart first pass, single	0.98	5.66	5.72	NA	NA	0.27	6.91	6.97	NA	NA	XXX
78481	26	A	Heart first pass, single	0.98	0.38	0.41	0.38	0.41	0.03	1.39	1.42	1.39	1.42	XXX
78481	TC	A	Heart first pass, single	0.00	5.28	5.31	NA	NA	0.24	5.52	5.55	NA	NA	XXX
78483	.....	A	Heart first pass, multiple	1.47	8.53	8.62	NA	NA	0.40	10.40	10.49	NA	NA	XXX
78483	26	A	Heart first pass, multiple	1.47	0.57	0.61	0.57	0.61	0.05	2.09	2.13	2.09	2.13	XXX
78483	TC	A	Heart first pass, multiple	0.00	7.96	8.01	NA	NA	0.35	8.31	8.36	NA	NA	XXX
78491	.....	I	Heart image (pet), single	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78491	26	I	Heart image (pet), single	1.50	0.59	0.81	0.59	0.81	0.05	2.14	2.36	2.14	2.36	XXX
78491	TC	I	Heart image (pet), single	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78492	.....	I	Heart image (pet), multiple	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78492	26	I	Heart image (pet), multiple	1.87	0.74	0.92	0.74	0.92	0.07	2.68	2.86	2.68	2.86	XXX
78492	TC	I	Heart image (pet), multiple	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78494	.....	A	Heart image, spect	1.19	6.02	6.05	NA	NA	0.30	7.51	7.54	NA	NA	XXX
78494	26	A	Heart image, spect	1.19	0.44	0.44	0.44	0.44	0.04	1.67	1.67	1.67	1.67	XXX
78494	TC	A	Heart image, spect	0.00	5.58	5.61	NA	NA	0.26	5.84	5.87	NA	NA	XXX
78496	.....	A	Heart first pass add-on	0.50	1.77	1.78	NA	NA	0.28	2.55	2.56	NA	NA	ZZZ
78496	26	A	Heart first pass add-on	0.50	0.20	0.20	0.20	0.20	0.02	0.72	0.72	0.72	0.72	ZZZ
78496	TC	A	Heart first pass add-on	0.00	1.57	1.58	NA	NA	0.26	1.83	1.84	NA	NA	ZZZ
78499	.....	C	Cardiovascular nuclear exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78499	26	C	Cardiovascular nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78499	TC	C	Cardiovascular nuclear exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78580	.....	A	Lung perfusion imaging	0.74	3.73	3.78	NA	NA	0.18	4.65	4.70	NA	NA	XXX
78580	26	A	Lung perfusion imaging	0.74	0.26	0.29	0.26	0.29	0.03	1.03	1.06	1.03	1.06	XXX
78580	TC	A	Lung perfusion imaging	0.00	3.47	3.49	NA	NA	0.15	3.62	3.64	NA	NA	XXX
78584	.....	A	Lung V/Q image single breath	0.99	3.59	3.65	NA	NA	0.18	4.76	4.82	NA	NA	XXX
78584	26	A	Lung V/Q image single breath	0.99	0.35	0.39	0.35	0.39	0.04	1.38	1.42	1.38	1.42	XXX
78584	TC	A	Lung V/Q image single breath	0.00	3.24	3.26	NA	NA	0.14	3.38	3.40	NA	NA	XXX
78585	.....	A	Lung V/Q imaging	1.09	6.08	6.15	NA	NA	0.30	7.47	7.54	NA	NA	XXX
78585	26	A	Lung V/Q imaging	1.09	0.38	0.42	0.38	0.42	0.04	1.51	1.55	1.51	1.55	XXX
78585	TC	A	Lung V/Q imaging	0.00	5.70	5.73	NA	NA	0.26	5.96	5.99	NA	NA	XXX
78586	.....	A	Aerosol lung image, single	0.40	2.76	2.80	NA	NA	0.14	3.30	3.34	NA	NA	XXX
78586	26	A	Aerosol lung image, single	0.40	0.14	0.16	0.14	0.16	0.02	0.56	0.58	0.56	0.58	XXX
78586	TC	A	Aerosol lung image, single	0.00	2.62	2.64	NA	NA	0.12	2.74	2.76	NA	NA	XXX
78587	.....	A	Aerosol lung image, multiple	0.49	3.00	3.04	NA	NA	0.14	3.63	3.67	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
78587	26	A	Aerosol lung image, multiple	0.49	0.17	0.19	0.17	0.19	0.02	0.68	0.70	0.68	0.70	XXX
78587	TC	A	Aerosol lung image, multiple	0.00	2.83	2.85	NA	NA	0.12	2.95	2.97	NA	NA	XXX
78588		A	Perfusion lung image	1.09	3.87	3.89	NA	NA	0.19	5.15	5.17	NA	NA	XXX
78588	26	A	Perfusion lung image	1.09	0.39	0.39	0.39	0.39	0.04	1.52	1.52	1.52	1.52	XXX
78588	TC	A	Perfusion lung image	0.00	3.48	3.50	NA	NA	0.15	3.63	3.65	NA	NA	XXX
78591		A	Vent image, 1 breath, 1 proj	0.40	3.02	3.06	NA	NA	0.14	3.56	3.60	NA	NA	XXX
78591	26	A	Vent image, 1 breath, 1 proj	0.40	0.14	0.16	0.14	0.16	0.02	0.56	0.58	0.56	0.58	XXX
78591	TC	A	Vent image, 1 breath, 1 proj	0.00	2.88	2.90	NA	NA	0.12	3.00	3.02	NA	NA	XXX
78593		A	Vent image, 1 proj, gas	0.49	3.66	3.70	NA	NA	0.17	4.32	4.36	NA	NA	XXX
78593	26	A	Vent image, 1 proj, gas	0.49	0.17	0.19	0.17	0.19	0.02	0.68	0.70	0.68	0.70	XXX
78593	TC	A	Vent image, 1 proj, gas	0.00	3.49	3.51	NA	NA	0.15	3.64	3.66	NA	NA	XXX
78594		A	Vent image, mult proj, gas	0.53	5.22	5.27	NA	NA	0.24	5.99	6.04	NA	NA	XXX
78594	26	A	Vent image, mult proj, gas	0.53	0.19	0.21	0.19	0.21	0.02	0.74	0.76	0.74	0.76	XXX
78594	TC	A	Vent image, mult proj, gas	0.00	5.03	5.06	NA	NA	0.22	5.25	5.28	NA	NA	XXX
78596		A	Lung differential function	1.27	7.60	7.68	NA	NA	0.37	9.24	9.32	NA	NA	XXX
78596	26	A	Lung differential function	1.27	0.45	0.49	0.45	0.49	0.05	1.77	1.81	1.77	1.81	XXX
78596	TC	A	Lung differential function	0.00	7.15	7.19	NA	NA	0.32	7.47	7.51	NA	NA	XXX
78599		C	Respiratory nuclear exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78599	26	C	Respiratory nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78599	TC	C	Respiratory nuclear exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78600		A	Brain imaging, ltd static	0.44	3.07	3.11	NA	NA	0.14	3.65	3.69	NA	NA	XXX
78600	26	A	Brain imaging, ltd static	0.44	0.16	0.18	0.16	0.18	0.02	0.62	0.64	0.62	0.64	XXX
78600	TC	A	Brain imaging, ltd static	0.00	2.91	2.93	NA	NA	0.12	3.03	3.05	NA	NA	XXX
78601		A	Brain imaging, ltd w/ flow	0.51	3.62	3.66	NA	NA	0.17	4.30	4.34	NA	NA	XXX
78601	26	A	Brain imaging, ltd w/ flow	0.51	0.18	0.20	0.18	0.20	0.02	0.71	0.73	0.71	0.73	XXX
78601	TC	A	Brain imaging, ltd w/ flow	0.00	3.44	3.46	NA	NA	0.15	3.59	3.61	NA	NA	XXX
78605		A	Brain imaging, complete	0.53	3.63	3.67	NA	NA	0.17	4.33	4.37	NA	NA	XXX
78605	26	A	Brain imaging, complete	0.53	0.19	0.21	0.19	0.21	0.02	0.74	0.76	0.74	0.76	XXX
78605	TC	A	Brain imaging, complete	0.00	3.44	3.46	NA	NA	0.15	3.59	3.61	NA	NA	XXX
78606		A	Brain imaging, compl w/flow	0.64	4.14	4.18	NA	NA	0.19	4.97	5.01	NA	NA	XXX
78606	26	A	Brain imaging, compl w/flow	0.64	0.23	0.25	0.23	0.25	0.02	0.89	0.91	0.89	0.91	XXX
78606	TC	A	Brain imaging, compl w/flow	0.00	3.91	3.93	NA	NA	0.17	4.08	4.10	NA	NA	XXX
78607		A	Brain imaging (3D)	1.23	7.08	7.16	NA	NA	0.35	8.66	8.74	NA	NA	XXX
78607	26	A	Brain imaging (3D)	1.23	0.45	0.49	0.45	0.49	0.05	1.73	1.77	1.73	1.77	XXX
78607	TC	A	Brain imaging (3D)	0.00	6.63	6.67	NA	NA	0.30	6.93	6.97	NA	NA	XXX
78608		N	Brain imaging (PET)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78609		N	Brain imaging (PET)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78610		A	Brain flow imaging only	0.30	1.70	1.72	NA	NA	0.09	2.09	2.11	NA	NA	XXX
78610	26	A	Brain flow imaging only	0.30	0.11	0.12	0.11	0.12	0.01	0.42	0.43	0.42	0.43	XXX
78610	TC	A	Brain flow imaging only	0.00	1.59	1.60	NA	NA	0.08	1.67	1.68	NA	NA	XXX
78615		A	Cerebral blood flow imaging	0.42	4.05	4.08	NA	NA	0.19	4.66	4.69	NA	NA	XXX
78615	26	A	Cerebral blood flow imaging	0.42	0.16	0.17	0.16	0.17	0.02	0.60	0.61	0.60	0.61	XXX
78615	TC	A	Cerebral blood flow imaging	0.00	3.89	3.91	NA	NA	0.17	4.06	4.08	NA	NA	XXX
78630		A	Cerebrospinal fluid scan	0.68	5.33	5.39	NA	NA	0.26	6.27	6.33	NA	NA	XXX
78630	26	A	Cerebrospinal fluid scan	0.68	0.24	0.27	0.24	0.27	0.03	0.95	0.98	0.95	0.98	XXX
78630	TC	A	Cerebrospinal fluid scan	0.00	5.09	5.12	NA	NA	0.23	5.32	5.35	NA	NA	XXX
78635		A	CSF ventriculography	0.61	2.83	2.86	NA	NA	0.14	3.58	3.61	NA	NA	XXX
78635	26	A	CSF ventriculography	0.61	0.26	0.27	0.26	0.27	0.02	0.89	0.90	0.89	0.90	XXX
78635	TC	A	CSF ventriculography	0.00	2.57	2.59	NA	NA	0.12	2.69	2.71	NA	NA	XXX
78645		A	CSF shunt evaluation	0.57	3.68	3.72	NA	NA	0.17	4.42	4.46	NA	NA	XXX
78645	26	A	CSF shunt evaluation	0.57	0.21	0.23	0.21	0.23	0.02	0.80	0.82	0.80	0.82	XXX
78645	TC	A	CSF shunt evaluation	0.00	3.47	3.49	NA	NA	0.15	3.62	3.64	NA	NA	XXX
78647		A	Cerebrospinal fluid scan	0.90	6.30	6.37	NA	NA	0.30	7.50	7.57	NA	NA	XXX
78647	26	A	Cerebrospinal fluid scan	0.90	0.33	0.36	0.33	0.36	0.03	1.26	1.29	1.26	1.29	XXX
78647	TC	A	Cerebrospinal fluid scan	0.00	5.97	6.01	NA	NA	0.27	6.24	6.28	NA	NA	XXX
78650		A	CSF leakage imaging	0.61	4.91	4.96	NA	NA	0.23	5.75	5.80	NA	NA	XXX
78650	26	A	CSF leakage imaging	0.61	0.22	0.24	0.22	0.24	0.02	0.85	0.87	0.85	0.87	XXX
78650	TC	A	CSF leakage imaging	0.00	4.69	4.72	NA	NA	0.21	4.90	4.93	NA	NA	XXX
78660		A	Nuclear exam of tear flow	0.53	2.33	2.36	NA	NA	0.12	2.98	3.01	NA	NA	XXX
78660	26	A	Nuclear exam of tear flow	0.53	0.19	0.21	0.19	0.21	0.02	0.74	0.76	0.74	0.76	XXX
78660	TC	A	Nuclear exam of tear flow	0.00	2.14	2.15	NA	NA	0.10	2.24	2.25	NA	NA	XXX
78699		C	Nervous system nuclear exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78699	26	C	Nervous system nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78699	TC	C	Nervous system nuclear exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78700		A	Kidney imaging, static	0.45	3.24	3.28	NA	NA	0.15	3.84	3.88	NA	NA	XXX
78700	26	A	Kidney imaging, static	0.45	0.16	0.18	0.16	0.18	0.02	0.63	0.65	0.63	0.65	XXX
78700	TC	A	Kidney imaging, static	0.00	3.08	3.10	NA	NA	0.13	3.21	3.23	NA	NA	XXX
78701		A	Kidney imaging with flow	0.49	3.77	3.81	NA	NA	0.17	4.43	4.47	NA	NA	XXX
78701	26	A	Kidney imaging with flow	0.49	0.17	0.19	0.17	0.19	0.02	0.68	0.70	0.68	0.70	XXX
78701	TC	A	Kidney imaging with flow	0.00	3.60	3.62	NA	NA	0.15	3.75	3.77	NA	NA	XXX
78704		A	Imaging renogram	0.74	4.26	4.31	NA	NA	0.21	5.21	5.26	NA	NA	XXX
78704	26	A	Imaging renogram	0.74	0.26	0.29	0.26	0.29	0.03	1.03	1.06	1.03	1.06	XXX
78704	TC	A	Imaging renogram	0.00	4.00	4.02	NA	NA	0.18	4.18	4.20	NA	NA	XXX
78707		A	Kidney flow/function image	0.96	4.86	4.92	NA	NA	0.24	6.06	6.12	NA	NA	XXX
78707	26	A	Kidney flow/function image	0.96	0.34	0.37	0.34	0.37	0.04	1.34	1.37	1.34	1.37	XXX
78707	TC	A	Kidney flow/function image	0.00	4.52	4.55	NA	NA	0.20	4.72	4.75	NA	NA	XXX
78708		A	Kidney flow/function image	1.21	4.95	4.99	NA	NA	0.25	6.41	6.45	NA	NA	XXX
78708	26	A	Kidney flow/function image	1.21	0.43	0.44	0.43	0.44	0.05	1.69	1.70	1.69	1.70	XXX
78708	TC	A	Kidney flow/function image	0.00	4.52	4.55	NA	NA	0.20	4.72	4.75	NA	NA	XXX
78709		A	Kidney flow/function image	1.41	5.02	5.04	NA	NA	0.25	6.68	6.70	NA	NA	XXX
78709	26	A	Kidney flow/function image	1.41	0.50	0.49	0.50	0.49	0.05	1.96	1.95	1.96	1.95	XXX
78709	TC	A	Kidney flow/function image	0.00	4.52	4.55	NA	NA	0.20	4.72	4.75	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
78710	.....	A	Kidney imaging (3D)	0.66	6.20	6.27	NA	NA	0.30	7.16	7.23	NA	NA	XXX
78710	26	A	Kidney imaging (3D)	0.66	0.23	0.26	0.23	0.26	0.03	0.92	0.95	0.92	0.95	XXX
78710	TC	A	Kidney imaging (3D)	0.00	5.97	6.01	NA	NA	0.27	6.24	6.28	NA	NA	XXX
78715	.....	A	Renal vascular flow exam	0.30	1.70	1.72	NA	NA	0.09	2.09	2.11	NA	NA	XXX
78715	26	A	Renal vascular flow exam	0.30	0.11	0.12	0.11	0.12	0.01	0.42	0.43	0.42	0.43	XXX
78715	TC	A	Renal vascular flow exam	0.00	1.59	1.60	NA	NA	0.08	1.67	1.68	NA	NA	XXX
78725	.....	A	Kidney function study	0.38	1.94	1.96	NA	NA	0.10	2.42	2.44	NA	NA	XXX
78725	26	A	Kidney function study	0.38	0.14	0.15	0.14	0.15	0.01	0.53	0.54	0.53	0.54	XXX
78725	TC	A	Kidney function study	0.00	1.80	1.81	NA	NA	0.09	1.89	1.90	NA	NA	XXX
78730	.....	A	Urinary bladder retention	0.36	1.61	1.63	NA	NA	0.09	2.06	2.08	NA	NA	XXX
78730	26	A	Urinary bladder retention	0.36	0.13	0.14	0.13	0.14	0.02	0.51	0.52	0.51	0.52	XXX
78730	TC	A	Urinary bladder retention	0.00	1.48	1.49	NA	NA	0.07	1.55	1.56	NA	NA	XXX
78740	.....	A	Ureteral reflux study	0.57	2.34	2.37	NA	NA	0.12	3.03	3.06	NA	NA	XXX
78740	26	A	Ureteral reflux study	0.57	0.20	0.22	0.20	0.22	0.02	0.79	0.81	0.79	0.81	XXX
78740	TC	A	Ureteral reflux study	0.00	2.14	2.15	NA	NA	0.10	2.24	2.25	NA	NA	XXX
78760	.....	A	Testicular imaging	0.66	2.94	2.99	NA	NA	0.15	3.75	3.80	NA	NA	XXX
78760	26	A	Testicular imaging	0.66	0.23	0.26	0.23	0.26	0.03	0.92	0.95	0.92	0.95	XXX
78760	TC	A	Testicular imaging	0.00	2.71	2.73	NA	NA	0.12	2.83	2.85	NA	NA	XXX
78761	.....	A	Testicular imaging/flow	0.71	3.49	3.54	NA	NA	0.17	4.37	4.42	NA	NA	XXX
78761	26	A	Testicular imaging/flow	0.71	0.25	0.28	0.25	0.28	0.03	0.99	1.02	0.99	1.02	XXX
78761	TC	A	Testicular imaging/flow	0.00	3.24	3.26	NA	NA	0.14	3.38	3.40	NA	NA	XXX
78799	.....	C	Genitourinary nuclear exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78799	26	C	Genitourinary nuclear exam	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78799	TC	C	Genitourinary nuclear exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78800	.....	A	Tumor imaging, limited area	0.66	3.67	3.72	NA	NA	0.18	4.51	4.56	NA	NA	XXX
78800	26	A	Tumor imaging, limited area	0.66	0.23	0.26	0.23	0.26	0.03	0.92	0.95	0.92	0.95	XXX
78800	TC	A	Tumor imaging, limited area	0.00	3.44	3.46	NA	NA	0.15	3.59	3.61	NA	NA	XXX
78801	.....	A	Tumor imaging, mult areas	0.79	4.55	4.61	NA	NA	0.22	5.56	5.62	NA	NA	XXX
78801	26	A	Tumor imaging, mult areas	0.79	0.28	0.31	0.28	0.31	0.03	1.10	1.13	1.10	1.13	XXX
78801	TC	A	Tumor imaging, mult areas	0.00	4.27	4.30	NA	NA	0.19	4.46	4.49	NA	NA	XXX
78802	.....	A	Tumor imaging, whole body	0.86	5.90	5.96	NA	NA	0.29	7.05	7.11	NA	NA	XXX
78802	26	A	Tumor imaging, whole body	0.86	0.31	0.34	0.31	0.34	0.03	1.20	1.23	1.20	1.23	XXX
78802	TC	A	Tumor imaging, whole body	0.00	5.59	5.62	NA	NA	0.26	5.85	5.88	NA	NA	XXX
78803	.....	A	Tumor imaging (3D)	1.09	7.03	7.10	NA	NA	0.34	8.46	8.53	NA	NA	XXX
78803	26	A	Tumor imaging (3D)	1.09	0.40	0.43	0.40	0.43	0.04	1.53	1.56	1.53	1.56	XXX
78803	TC	A	Tumor imaging (3D)	0.00	6.63	6.67	NA	NA	0.30	6.93	6.97	NA	NA	XXX
78805	.....	A	Abscess imaging, ltd area	0.73	3.70	3.75	NA	NA	0.18	4.61	4.66	NA	NA	XXX
78805	26	A	Abscess imaging, ltd area	0.73	0.26	0.29	0.26	0.29	0.03	1.02	1.05	1.02	1.05	XXX
78805	TC	A	Abscess imaging, ltd area	0.00	3.44	3.46	NA	NA	0.15	3.59	3.61	NA	NA	XXX
78806	.....	A	Abscess imaging, whole body	0.86	6.81	6.88	NA	NA	0.33	8.00	8.07	NA	NA	XXX
78806	26	A	Abscess imaging, whole body	0.86	0.31	0.34	0.31	0.34	0.03	1.20	1.23	1.20	1.23	XXX
78806	TC	A	Abscess imaging, whole body	0.00	6.50	6.54	NA	NA	0.30	6.80	6.84	NA	NA	XXX
78807	.....	A	Nuclear localization/abscess	1.09	7.04	7.11	NA	NA	0.34	8.47	8.54	NA	NA	XXX
78807	26	A	Nuclear localization/abscess	1.09	0.41	0.44	0.41	0.44	0.04	1.54	1.57	1.54	1.57	XXX
78807	TC	A	Nuclear localization/abscess	0.00	6.63	6.67	NA	NA	0.30	6.93	6.97	NA	NA	XXX
78810	.....	N	Tumor imaging (PET)	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78810	26	N	Tumor imaging (PET)	1.93	0.77	0.95	0.77	0.95	0.07	2.77	2.95	2.77	2.95	XXX
78810	TC	N	Tumor imaging (PET)	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78890	.....	B	Nuclear medicine data proc	0.05	1.34	1.35	NA	NA	0.06	1.45	1.46	NA	NA	XXX
78890	26	B	Nuclear medicine data proc	0.05	0.02	0.02	0.02	0.02	0.01	0.08	0.08	0.08	0.08	XXX
78890	TC	B	Nuclear medicine data proc	0.00	1.32	1.33	NA	NA	0.05	1.37	1.38	NA	NA	XXX
78891	.....	B	Nuclear med data proc	0.10	2.69	2.71	NA	NA	0.12	2.91	2.93	NA	NA	XXX
78891	26	B	Nuclear med data proc	0.10	0.04	0.04	0.04	0.04	0.01	0.15	0.15	0.15	0.15	XXX
78891	TC	B	Nuclear med data proc	0.00	2.65	2.67	NA	NA	0.11	2.76	2.78	NA	NA	XXX
78990	.....	I	Provide diag radionuclide(s)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78999	.....	C	Nuclear diagnostic exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
78999	26	C	Nuclear diagnostic exam	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
78999	TC	C	Nuclear diagnostic exam	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
79000	.....	A	Init hyperthyroid therapy	1.80	3.29	3.37	NA	NA	0.19	5.28	5.36	NA	NA	XXX
79000	26	A	Init hyperthyroid therapy	1.80	0.64	0.70	0.64	0.70	0.07	2.51	2.57	2.51	2.57	XXX
79000	TC	A	Init hyperthyroid therapy	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
79001	.....	A	Repeat hyperthyroid therapy	1.05	1.69	1.73	NA	NA	0.10	2.84	2.88	NA	NA	XXX
79001	26	A	Repeat hyperthyroid therapy	1.05	0.37	0.40	0.37	0.40	0.04	1.46	1.49	1.46	1.49	XXX
79001	TC	A	Repeat hyperthyroid therapy	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
79020	.....	A	Thyroid ablation	1.81	3.28	3.36	NA	NA	0.19	5.28	5.36	NA	NA	XXX
79020	26	A	Thyroid ablation	1.81	0.63	0.69	0.63	0.69	0.07	2.51	2.57	2.51	2.57	XXX
79020	TC	A	Thyroid ablation	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
79030	.....	A	Thyroid ablation, carcinoma	2.10	3.39	3.48	NA	NA	0.20	5.69	5.78	NA	NA	XXX
79030	26	A	Thyroid ablation, carcinoma	2.10	0.74	0.81	0.74	0.81	0.08	2.92	2.99	2.92	2.99	XXX
79030	TC	A	Thyroid ablation, carcinoma	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
79035	.....	A	Thyroid metastatic therapy	2.52	3.57	3.67	NA	NA	0.21	6.30	6.40	NA	NA	XXX
79035	26	A	Thyroid metastatic therapy	2.52	0.92	1.00	0.92	1.00	0.09	3.53	3.61	3.53	3.61	XXX
79035	TC	A	Thyroid metastatic therapy	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
79100	.....	A	Hematopoetic nuclear therapy	1.32	3.13	3.19	NA	NA	0.17	4.62	4.68	NA	NA	XXX
79100	26	A	Hematopoetic nuclear therapy	1.32	0.48	0.52	0.48	0.52	0.05	1.85	1.89	1.85	1.89	XXX
79100	TC	A	Hematopoetic nuclear therapy	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
79200	.....	A	Intracavitary nuclear trmt	1.99	3.37	3.45	NA	NA	0.19	5.55	5.63	NA	NA	XXX
79200	26	A	Intracavitary nuclear trmt	1.99	0.72	0.78	0.72	0.78	0.07	2.78	2.84	2.78	2.84	XXX
79200	TC	A	Intracavitary nuclear trmt	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
79300	.....	C	Interstitial nuclear therapy	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
79300	26	A	Interstitial nuclear therapy	1.60	0.58	0.63	0.58	0.63	0.06	2.24	2.29	2.24	2.29	XXX
79300	TC	C	Interstitial nuclear therapy	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
79400		A	Nonhemato nuclear therapy	1.96	3.36	3.44	NA	NA	0.19	5.51	5.59	NA	NA	XXX
79400	26	A	Nonhemato nuclear therapy	1.96	0.71	0.77	0.71	0.77	0.07	2.74	2.80	2.74	2.80	XXX
79400	TC	A	Nonhemato nuclear therapy	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
79420		C	Intravascular nuclear ther	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
79420	26	A	Intravascular nuclear ther	1.51	0.53	0.58	0.53	0.58	0.06	2.10	2.15	2.10	2.15	XXX
79420	TC	C	Intravascular nuclear ther	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
79440		A	Nuclear joint therapy	1.99	3.42	3.49	NA	NA	0.20	5.61	5.68	NA	NA	XXX
79440	26	A	Nuclear joint therapy	1.99	0.77	0.82	0.77	0.82	0.08	2.84	2.89	2.84	2.89	XXX
79440	TC	A	Nuclear joint therapy	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
79900		C	Provide ther radiopharm(s)	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
79999		C	Nuclear medicine therapy	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
79999	26	C	Nuclear medicine therapy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
79999	TC	C	Nuclear medicine therapy	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
80048		X	Basic metabolic panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80049		D	Metabolic panel, basic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80050		N	General health panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80051		X	Electrolyte panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80053		X	Comprehen metabolic panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80054		D	Comprehen metabolic panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80055		I	Obstetric panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80058		D	Hepatic function panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80059		D	Hepatitis panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80061		X	Lipid panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80069		X	Renal function panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80072		X	Arthritis panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80074		X	Acute hepatitis panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80076		X	Hepatic function panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80090		X	Torch antibody panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80091		D	Thyroid panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80092		D	Thyroid panel w/TSH	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80100		X	Drug screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80101		X	Drug screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80102		X	Drug confirmation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80103		X	Drug analysis, tissue prep	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80150		X	Assay of amikacin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80152		X	Assay of amitriptyline	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80154		X	Assay of benzodiazepines	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80156		X	Assay of carbamazepine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80158		X	Assay of cyclosporine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80160		X	Assay of desipramine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80162		X	Assay of digoxin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80164		X	Assay, dipropylacetic acid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80166		X	Assay of doxepin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80168		X	Assay of ethosuximide	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80170		X	Assay of gentamicin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80172		X	Assay of gold	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80174		X	Assay of imipramine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80176		X	Assay of lidocaine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80178		X	Assay of lithium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80182		X	Assay of nortriptyline	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80184		X	Assay of phenobarbital	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80185		X	Assay of phenytoin, total	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80186		X	Assay of phenytoin, free	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80188		X	Assay of primidone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80190		X	Assay of procainamide	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80192		X	Assay of procainamide	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80194		X	Assay of quinidine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80196		X	Assay of salicylate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80197		X	Assay of tacrolimus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80198		X	Assay of theophylline	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80200		X	Assay of tobramycin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80201		X	Assay of topiramate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80202		X	Assay of vancomycin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80299		X	Quantitative assay, drug	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80400		X	Acth stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80402		X	Acth stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80406		X	Acth stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80408		X	Aldosterone suppression eval	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80410		X	Calcitonin stimul panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80412		X	CRH stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80414		X	Testosterone response	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80415		X	Estradiol response panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80416		X	Renin stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80417		X	Renin stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80418		X	Pituitary evaluation panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80420		X	Dexamethasone panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80422		X	Glucagon tolerance panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80424		X	Glucagon tolerance panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80426		X	Gonadotropin hormone panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80428		X	Growth hormone panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80430		X	Growth hormone panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80432		X	Insulin suppression panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
80434		X	Insulin tolerance panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80435		X	Insulin tolerance panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80436		X	Metyrapone panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80438		X	TRH stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80439		X	TRH stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80440		X	TRH stimulation panel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
80500		A	Lab pathology consultation	0.37	0.19	0.20	0.16	0.18	0.01	0.57	0.58	0.54	0.56	XXX
80502		A	Lab pathology consultation	1.33	0.63	0.56	0.57	0.52	0.04	2.00	1.93	1.94	1.89	XXX
81000		X	Urinalysis, nonauto w/scope	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81001		X	Urinalysis, auto w/scope	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81002		X	Urinalysis nonauto w/o scope	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81003		X	Urinalysis, auto, w/o scope	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81005		X	Urinalysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81007		X	Urine screen for bacteria	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81015		X	Microscopic exam of urine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81020		X	Urinalysis, glass test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81025		X	Urine pregnancy test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81050		X	Urinalysis, volume measure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
81099		X	Urinalysis test procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82000		X	Assay of blood acetaldehyde	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82003		X	Assay of acetaminophen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82009		X	Test for acetone/ketones	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82010		X	Acetone assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82013		X	Acetylcholinesterase assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82016		X	Acylcarnitines, qual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82017		X	Acylcarnitines, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82024		X	Assay of acth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82030		X	Assay of adp & amp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82040		X	Assay of serum albumin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82042		X	Assay of urine albumin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82043		X	Microalbumin, quantitative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82044		X	Microalbumin, semiquant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82055		X	Assay of ethanol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82075		X	Assay of breath ethanol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82085		X	Assay of aldolase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82088		X	Assay of aldosterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82101		X	Assay of urine alkaloids	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82103		X	Alpha-1-antitrypsin, total	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82104		X	Alpha-1-antitrypsin, pheno	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82105		X	Alpha-fetoprotein, serum	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82106		X	Alpha-fetoprotein, amniotic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82108		X	Assay of aluminum	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82120		X	Amines, vaginal fluid qual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82127		X	Amino acid, single qual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82128		X	Amino acids, mult qual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82131		X	Amino acids, single quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82135		X	Assay, aminolevulinic acid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82136		X	Amino acids, quant, 2–5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82139		X	Amino acids, quan, 6 or more	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82140		X	Assay of ammonia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82143		X	Amniotic fluid scan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82145		X	Assay of amphetamines	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82150		X	Assay of amylase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82154		X	Androstanediol glucuronide	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82157		X	Assay of androstenedione	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82160		X	Assay of androsterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82163		X	Assay of angiotensin II	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82164		X	Angiotensin I enzyme test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82172		X	Assay of apolipoprotein	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82175		X	Assay of arsenic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82180		X	Assay of ascorbic acid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82190		X	Atomic absorption	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82205		X	Assay of barbiturates	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82232		X	Assay of beta-2 protein	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82239		X	Bile acids, total	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82240		X	Bile acids, cholylglycine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82247		X	Bilirubin, total	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82248		X	Bilirubin, direct	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82251		I	Assay of bilirubin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82252		X	Fecal bilirubin test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82261		X	Assay of biotinidase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82270		X	Test for blood, feces	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82273		X	Test for blood, other source	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82286		X	Assay of bradykinin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82300		X	Assay of cadmium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82306		X	Assay of vitamin D	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82307		X	Assay of vitamin D	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82308		X	Assay of calcitonin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82310		X	Assay of calcium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82330		X	Assay of calcium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82331		X	Calcium infusion test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82340		X	Assay of calcium in urine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
82355		X	Calculus (stone) analysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82360		X	Calculus (stone) assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82365		X	Calculus (stone) assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82370		X	X-ray assay, calculus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82374		X	Assay, blood carbon dioxide	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82375		X	Assay, blood carbon monoxide	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82376		X	Test for carbon monoxide	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82378		X	Carcinoembryonic antigen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82379		X	Assay of carnitine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82380		X	Assay of carotene	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82382		X	Assay, urine catecholamines	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82383		X	Assay, blood catecholamines	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82384		X	Assay, three catecholamines	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82387		X	Assay of cathepsin-d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82390		X	Assay of ceruloplasmin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82397		X	Chemiluminescent assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82415		X	Assay of chloramphenicol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82435		X	Assay of blood chloride	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82436		X	Assay of urine chloride	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82438		X	Assay, other fluid chlorides	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82441		X	Test for chlorohydrocarbons	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82465		X	Assay of serum cholesterol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82480		X	Assay, serum cholinesterase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82482		X	Assay, rbc cholinesterase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82485		X	Assay, chondroitin sulfate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82486		X	Gas/liquid chromatography	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82487		X	Paper chromatography	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82488		X	Paper chromatography	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82489		X	Thin layer chromatography	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82491		X	Chromotography, quant, sing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82492		X	Chromotography, quant, mult	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82495		X	Assay of chromium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82507		X	Assay of citrate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82520		X	Assay of cocaine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82523		X	Collagen crosslinks	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82525		X	Assay of copper	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82528		X	Assay of corticosterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82530		X	Cortisol, free	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82533		X	Total cortisol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82540		X	Assay of creatine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82541		X	Column chromotography, qual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82542		X	Column chromotography, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82543		X	Column chromotograph/isotope	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82544		X	Column chromotograph/isotope	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82550		X	Assay of ck (cpk)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82552		X	Assay of cpk in blood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82553		X	Creatine, MB fraction	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82554		X	Creatine, isoforms	0.00	0.00	0.00	0.00	0.00	0.00	00	0.00	0.00	0.00	XXX
82565		X	Assay of creatinine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82570		X	Assay of urine creatinine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82575		X	Creatinine clearance test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82585		X	Assay of cryofibrinogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82595		X	Assay of cryoglobulin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82600		X	Assay of cyanide	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82607		X	Vitamin B-12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82608		X	B-12 binding capacity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82615		X	Test for urine cystines	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82626		X	Dehydroepiandrosterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82627		X	Dehydroepiandrosterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82633		X	Desoxycorticosterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82634		X	Deoxycortisol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82638		X	Assay of dibucaine number	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82646		X	Assay of dihydrocodeinone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82649		X	Assay of dihydromorphinone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82651		X	Assay of dihydrotestosterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82652		X	Assay of dihydroxyvitamin d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82654		X	Assay of dimethadione	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82657		X	Enzyme cell activity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82658		X	Enzyme cell activity, ra	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82664		X	Electrophoretic test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82666		X	Assay of epiandrosterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82668		X	Assay of erythropoietin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82670		X	Assay of estradiol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82671		X	Assay of estrogens	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82672		X	Assay of estrogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82677		X	Assay of estriol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82679		X	Assay of estrone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82690		X	Assay of ethchlorvynol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82693		X	Assay of ethylene glycol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82696		X	Assay of etiocholanolone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82705		X	Fats/lipids, feces, qual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82710		X	Fats/lipids, feces, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
82715		X	Assay of fecal fat	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82725		X	Assay of blood fatty acids	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82726		X	Long chain fatty acids	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82728		X	Assay of ferritin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82731		X	Assay of fetal fibronectin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82735		X	Assay of fluoride	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82742		X	Assay of flurazepam	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82746		X	Blood folic acid serum	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82747		X	Assay of folic acid, rbc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82757		X	Assay of semen fructose	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82759		X	Assay of rbc galactokinase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82760		X	Assay of galactose	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82775		X	Assay galactose transferase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82776		X	Galactose transferase test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82784		X	Assay of gammaglobulin igm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82785		X	Assay of gammaglobulin ige	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82787		X	Igg 1, 2, 3 and 4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82800		X	Blood pH	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82803		X	Blood gases: pH, pO2 & pCO2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82805		X	Blood gases W/02 saturation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82810		X	Blood gases, O2 sat only	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82820		X	Hemoglobin-oxygen affinity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82926		X	Assay of gastric acid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82928		X	Assay of gastric acid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82938		X	Gastrin test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82941		X	Assay of gastrin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82943		X	Assay of glucagon	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82946		X	Glucagon tolerance test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82947		X	Assay of glucose, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82948		X	Reagent strip/blood glucose	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82950		X	Glucose test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82951		X	Glucose tolerance test (GTT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82952		X	GTT-added samples	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82953		X	Glucose-tolbutamide test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82955		X	Assay of g6pd enzyme	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82960		X	Test for G6PD enzyme	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82962		X	Glucose blood test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82963		X	Assay of glucosidase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82965		X	Assay of gdh enzyme	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82975		X	Assay of glutamine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82977		X	Assay of GGT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82978		X	Assay of glutathione	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82979		X	Assay, rbc glutathione	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82980		X	Assay of glutethimide	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
82985		X	Glycated protein	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83001		X	Gonadotropin (FSH)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83002		X	Gonadotropin (LH)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83003		X	Assay, growth hormone (hgh)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
?????		X	Assay of guanosine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83010		X	Assay of haptoglobin, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83012		X	Assay of haptoglobins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83013		X	H pylori breath tst analysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83014		X	H pylori drug admin/collect	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83015		X	Heavy metal screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83018		X	Quantitative screen, metals	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83020		X	Hemoglobin electrophoresis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83020	26	A	Hemoglobin electrophoresis	0.37	0.16	0.18	0.16	0.18	0.01	0.54	0.56	0.54	0.56	XXX
83021		X	Hemoglobin chromotography	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83026		X	Hemoglobin, copper sulfate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83030		X	Fetal hemoglobin assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83033		X	Fetal fecal hemoglobin assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83036		X	Glycated hemoglobin test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83045		X	Blood methemoglobin test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83050		X	Blood methemoglobin assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83051		X	Assay of plasma hemoglobin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83055		X	Blood sulfhemoglobin test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83060		X	Blood sulfhemoglobin assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83065		X	Assay of hemoglobin heat	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83068		X	Hemoglobin stability screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83069		X	Assay of urine hemoglobin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83070		X	Assay of hemosiderin, qual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83071		X	Assay of hemosiderin, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83080		X	Assay of b hexosaminidase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83088		X	Assay of histamine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83150		X	Assay of for hva	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83491		X	Assay of corticosteroids	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83497		X	Assay of 5-hiaa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83498		X	Assay of progesterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83499		X	Assay of progesterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83500		X	Assay, free hydroxyproline	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83505		X	Assay, total hydroxyproline	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83516		X	Immunoassay, nonantibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
83518		X	Immunoassay, dipstick	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83519		X	Immunoassay, nonantibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83520		X	Immunoassay, RIA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83525		X	Assay of insulin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83527		X	Assay of insulin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83528		X	Assay of intrinsic factor	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83540		X	Assay of iron	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83550		X	Iron binding test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83570		X	Assay of idh enzyme	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83582		X	Assay of ketogenic steroids	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83586		X	Assay 17-ketosteroids	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83593		X	Fractionation, ketosteroids	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83605		X	Assay of lactic acid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83615		X	Lactate (LD) (LDH) enzyme	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83625		X	Assay of ldh enzymes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83632		X	Placental lactogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83633		X	Test urine for lactose	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83634		X	Assay of urine for lactose	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83655		X	Assay of lead	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83661		X	Assay of l/s ratio	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83662		X	L/S ratio, foam stability	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83670		X	Assay of lap enzyme	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83690		X	Assay of lipase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83715		X	Assay of blood lipoproteins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83716		X	Assay of blood lipoproteins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83718		X	Assay of lipoprotein	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83719		X	Assay of blood lipoprotein	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83721		X	Assay of blood lipoprotein	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83727		X	Assay of lrh hormone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83735		X	Assay of magnesium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83775		X	Assay of md enzyme	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83785		X	Assay of manganese	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83788		X	Mass spectrometry qual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83789		X	Mass spectrometry quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83805		X	Assay of meprobamate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83825		X	Assay of mercury	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83835		X	Assay of metanephrines	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83840		X	Assay of methadone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83857		X	Assay of methemalbumin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83858		X	Assay of methsuximide	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83864		X	Mucopolysaccharides	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83866		X	Mucopolysaccharides screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83872		X	Assay synovial fluid mucin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83873		X	Assay of csf protein	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83874		X	Assay of myoglobin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83883		X	Assay, nephelometry not spec	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83885		X	Assay of nickel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83887		X	Assay of nicotine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83890		X	Molecule isolate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83891		X	Molecule isolate nucleic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83892		X	Molecular diagnostics	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83893		X	Molecule dot/slot/blot	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83894		X	Molecule gel electrophor	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83896		X	Molecular diagnostics	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83897		X	Molecule nucleic transfer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83898		X	Molecule nucleic ampli	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83901		X	Molecule nucleic ampli	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83902		X	Molecular diagnostics	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83903		X	Molecule mutation scan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83904		X	Molecule mutation identify	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83905		X	Molecule mutation identify	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83906		X	Molecule mutation identify	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83912		X	Genetic examination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83912	26	A	Genetic examination	0.37	0.18	0.19	0.16	0.18	0.01	0.56	0.57	0.54	0.56	XXX
83915		X	Assay of nucleotidase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83916		X	Oligoclonal bands	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83918		X	Assay, organic acids quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83919		X	Assay, organic acids qual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83925		X	Assay of opiates	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83930		X	Assay of blood osmolality	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83935		X	Assay of urine osmolality	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83937		X	Assay of osteocalcin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83945		X	Assay of oxalate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83970		X	Assay of parathormone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83986		X	Assay of body fluid acidity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
83992		X	Assay for phencyclidine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84022		X	Assay of phenothiazine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84030		X	Assay of blood pku	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84035		X	Assay of phenylketones	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84060		X	Assay acid phosphatase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84061		X	Phosphatase, forensic exam	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84066		X	Assay prostate phosphatase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
84075		X	Assay alkaline phosphatase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84078		X	Assay alkaline phosphatase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84080		X	Assay alkaline phosphatases	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84081		X	Amniotic fluid enzyme test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84085		X	Assay of rbc pg6d enzyme	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84087		X	Assay phosphohexose enzymes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84100		X	Assay of phosphorus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84105		X	Assay of urine phosphorus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84106		X	Test for porphobilinogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84110		X	Assay of porphobilinogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84119		X	Test urine for porphyrins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84120		X	Assay of urine porphyrins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84126		X	Assay of feces porphyrins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84127		X	Assay of feces porphyrins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84132		X	Assay of serum potassium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84133		X	Assay of urine potassium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84134		X	Assay of prealbumin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84135		X	Assay of pregnanediol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84138		X	Assay of pregnanetriol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84140		X	Assay of pregnenolone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84143		X	Assay of 17-hydroxypregneno	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84144		X	Assay of progesterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84146		X	Assay of prolactin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84150		X	Assay of prostaglandin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84153		X	Assay of psa, total	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84154		X	Assay of psa, free	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84155		X	Assay of protein	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84160		X	Assay of serum protein	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84165		X	Assay of serum proteins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84165	26	A	Assay of serum proteins	0.37	0.17	0.18	0.16	0.18	0.01	0.55	0.56	0.54	0.56	XXX
84181		X	Western blot test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84181	26	A	Western blot test	0.37	0.15	0.17	0.15	0.17	0.01	0.53	0.55	0.53	0.55	XXX
84182		X	Protein, western blot test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84182	26	A	Protein, western blot test	0.37	0.15	0.17	0.15	0.17	0.01	0.53	0.55	0.53	0.55	XXX
84202		X	Assay RBC protoporphyrin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84203		X	Test RBC protoporphyrin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84206		X	Assay of proinsulin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84207		X	Assay of vitamin b-6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84210		X	Assay of pyruvate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84220		X	Assay of pyruvate kinase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84228		X	Assay of quinine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84233		X	Assay of estrogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84234		X	Assay of progesterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84235		X	Assay of endocrine hormone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84238		X	Assay, nonendocrine receptor	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84244		X	Assay of renin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84252		X	Assay of vitamin b-2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84255		X	Assay of selenium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84260		X	Assay of serotonin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84270		X	Assay of sex hormone globul	0.00	00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84275		X	Assay of sialic acid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84285		X	Assay of silica	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84295		X	Assay of serum sodium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84300		X	Assay of urine sodium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84305		X	Assay of somatomedin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84307		X	Assay of somatostatin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84311		X	Spectrophotometry	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84315		X	Body fluid specific gravity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84375		X	Chromatogram assay, sugars	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84376		X	Sugars, single, qual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84377		X	Sugars, multiple, qual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84378		X	Sugars single quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84379		X	Sugars multiple quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84392		X	Assay of urine sulfate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84402		X	Assay of testosterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84403		X	Assay of total testosterone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84425		X	Assay of vitamin b-1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84430		X	Assay of thiocyanate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84432		X	Assay of thyroglobulin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84436		X	Assay of total thyroxine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84437		X	Assay of neonatal thyroxine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84439		X	Assay of free thyroxine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84442		X	Assay of thyroid activity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84443		X	Assay thyroid stim hormone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84445		X	Assay of tsi	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84446		X	Assay of vitamin e	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84449		X	Assay of transcortin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84450		X	Transferase (AST) (SGOT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84460		X	Alanine amino (ALT) (SGPT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84466		X	Assay of transferrin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84478		X	Assay of triglycerides	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84479		X	Assay of thyroid (t3 or t4)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
84480		X	Assay, triiodothyronine (t3)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84481		X	Free assay (FT-3)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84482		X	T3 reverse	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84484		X	Assay of troponin, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84485		X	Assay duodenal fluid trypsin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84488		X	Test feces for trypsin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84490		X	Assay of feces for trypsin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84510		X	Assay of tyrosine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84512		X	Assay of troponin, qual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84520		X	Assay of urea nitrogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84525		X	Urea nitrogen semi-quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84540		X	Assay of urine/urea-n	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84545		X	Urea-N clearance test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84550		X	Assay of blood/uric acid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84560		X	Assay of urine/uric acid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84577		X	Assay of feces/urobilinogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84578		X	Test urine urobilinogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84580		X	Assay of urine urobilinogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84583		X	Assay of urine urobilinogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84585		X	Assay of urine vma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84586		X	Assay of vip	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84588		X	Assay of vasopressin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84590		X	Assay of vitamin a	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84597		X	Assay of vitamin k	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84600		X	Assay of volatiles	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84620		X	Xylose tolerance test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84630		X	Assay of zinc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84681		X	Assay of c-peptide	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84702		X	Chorionic gonadotropin test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84703		X	Chorionic gonadotropin assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84830		X	Ovulation tests	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
84999		X	Clinical chemistry test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85002		X	Bleeding time test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85007		X	Differential WBC count	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85008		X	Nondifferential WBC count	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85009		X	Differential WBC count	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85013		X	Hematocrit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85014		X	Hematocrit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85018		X	Hemoglobin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85021		X	Automated hemogram	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85022		X	Automated hemogram	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85023		X	Automated hemogram	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85024		X	Automated hemogram	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85025		X	Automated hemogram	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85027		X	Automated hemogram	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85031		X	Manual hemogram, cbc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85041		X	Red blood cell (RBC) count	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85044		X	Reticulocyte count	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85045		X	Reticulocyte count	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85046		X	Reticyte/hgb concentrate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85048		X	White blood cell (WBC) count	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85060		A	Blood smear interpretation	0.45	0.20	0.21	0.19	0.20	0.01	0.66	0.67	0.65	0.66	XXX
85095		A	Bone marrow aspiration	1.08	4.30	3.41	0.42	0.50	0.03	5.41	4.52	1.53	1.61	XXX
85097		A	Bone marrow interpretation	0.94	0.40	0.43	0.40	0.43	0.03	1.37	1.40	1.37	1.40	XXX
85102		A	Bone marrow biopsy	1.37	4.41	3.53	0.53	0.62	0.04	5.82	4.94	1.94	2.03	XXX
85130		X	Chromogenic substrate assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85170		X	Blood clot retraction	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85175		X	Blood clot lysis time	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85210		X	Blood clot factor II test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85220		X	Blood clot factor V test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85230		X	Blood clot factor VII test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85240		X	Blood clot factor VIII test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85244		X	Blood clot factor VIII test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85245		X	Blood clot factor VIII test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85246		X	Blood clot factor VIII test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85247		X	Blood clot factor VIII test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85250		X	Blood clot factor IX test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85260		X	Blood clot factor X test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85270		X	Blood clot factor XI test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85280		X	Blood clot factor XII test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85290		X	Blood clot factor XIII test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85291		X	Blood clot factor XIII test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85292		X	Blood clot factor assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85293		X	Blood clot factor assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85300		X	Antithrombin III test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85301		X	Antithrombin III test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85302		X	Blood clot inhibitor antigen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85303		X	Blood clot inhibitor test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85305		X	Blood clot inhibitor assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85306		X	Blood clot inhibitor test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85335		X	Factor inhibitor test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85337		X	Thrombomodulin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
85345		X	Coagulation time	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85347		X	Coagulation time	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85348		X	Coagulation time	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85360		X	Euglobulin lysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85362		X	Fibrin degradation products	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85366		X	Fibrinogen test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85370		X	Fibrinogen test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85378		X	Fibrin degradation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85379		X	Fibrin degradation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85384		X	Fibrinogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85385		X	Fibrinogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85390		X	Fibrinolysins screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85390	26	A	Fibrinolysins screen	0.37	0.12	0.15	0.12	0.15	0.01	0.50	0.53	0.50	0.53	XXX
85400		X	Fibrinolytic plasmin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85410		X	Fibrinolytic antiplasmin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85415		X	Fibrinolytic plasminogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85420		X	Fibrinolytic plasminogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85421		X	Fibrinolytic plasminogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85441		X	Heinz bodies, direct	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85445		X	Heinz bodies, induced	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85460		X	Hemoglobin, fetal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85461		X	Hemoglobin, fetal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85475		X	Hemolysin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85520		X	Heparin assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85525		X	Heparin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85530		X	Heparin-protamine tolerance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85535		X	Iron stain, blood cells	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85540		X	Wbc alkaline phosphatase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85547		X	RBC mechanical fragility	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85549		X	Muramidase	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85555		X	RBC osmotic fragility	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85557		X	RBC osmotic fragility	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85576		X	Blood platelet aggregation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85576	26	A	Blood platelet aggregation	0.37	0.16	0.18	0.16	0.18	0.01	0.54	0.56	0.54	0.56	XXX
85585		X	Blood platelet estimation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85590		X	Platelet count, manual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85595		X	Platelet count, automated	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85597		X	Platelet neutralization	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85610		X	Prothrombin time	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85611		X	Prothrombin test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85612		X	Viper venom prothrombin time	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85613		X	Russell viper venom, diluted	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85635		X	Reptilase test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85651		X	Rbc sed rate, nonautomated	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85652		X	Rbc sed rate, automated	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85660		X	RBC sickle cell test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85670		X	Thrombin time, plasma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85675		X	Thrombin time, titer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85705		X	Thromboplastin inhibition	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85730		X	Thromboplastin time, partial	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85732		X	Thromboplastin time, partial	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85810		X	Blood viscosity examination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
85999		X	Hematology procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86000		X	Agglutinins, febrile	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86003		X	Allergen specific IgE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86005		X	Allergen specific IgE	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86021		X	WBC antibody identification	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86022		X	Platelet antibodies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86023		X	Immunoglobulin assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86038		X	Antinuclear antibodies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86039		X	Antinuclear antibodies (ANA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86060		X	Antistreptolysin o, titer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86063		X	Antistreptolysin o, screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86077		A	Physician blood bank service	0.94	0.50	0.46	0.40	0.38	0.03	1.47	1.43	1.37	1.35	XXX
86078		A	Physician blood bank service	0.94	0.52	0.48	0.40	0.39	0.02	1.48	1.44	1.36	1.35	XXX
86079		A	Physician blood bank service	0.94	0.51	0.47	0.40	0.39	0.02	1.47	1.43	1.36	1.35	XXX
86140		X	C-reactive protein	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86147		X	Cardiolipin antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86148		X	Phospholipid antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86155		X	Chemotaxis assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86156		X	Cold agglutinin, screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86157		X	Cold agglutinin, titer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86160		X	Complement, antigen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86161		X	Complement/function activity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86162		X	Complement, total (CH50)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86171		X	Complement fixation, each	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86185		X	Counterimmunoelectrophoresis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86215		X	Deoxyribonuclease, antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86225		X	DNA antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86226		X	DNA antibody, single strand	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86235		X	Nuclear antigen antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86243		X	Fc receptor	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
86255		X	Fluorescent antibody, screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86255	26	A	Fluorescent antibody, screen	0.37	0.18	0.19	0.16	0.18	0.01	0.56	0.57	0.54	0.56	XXX
86256		X	Fluorescent antibody, titer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86256	26	A	Fluorescent antibody, titer	0.37	0.16	0.18	0.16	0.18	0.01	0.54	0.56	0.54	0.56	XXX
86277		X	Growth hormone antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86280		X	Hemagglutination inhibition	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86308		X	Heterophile antibodies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86309		X	Heterophile antibodies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86310		X	Heterophile antibodies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86316		X	Immunoassay, tumor antigen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86317		X	Immunoassay,infectious agent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86318		X	Immunoassay,infectious agent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86320		X	Serum immunoelectrophoresis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86320	26	A	Serum immunoelectrophoresis	0.37	0.16	0.18	0.16	0.18	0.01	0.54	0.56	0.54	0.56	XXX
86325		X	Other immunoelectrophoresis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86325	26	A	Other immunoelectrophoresis	0.37	0.18	0.19	0.15	0.17	0.01	0.56	0.57	0.53	0.55	XXX
86327		X	Immunoelectrophoresis assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86327	26	A	Immunoelectrophoresis assay	0.42	0.17	0.18	0.17	0.18	0.01	0.60	0.61	0.60	0.61	XXX
86329		X	Immunodiffusion	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86331		X	Immunodiffusion ouchterlony	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86332		X	Immune complex assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86334		X	Immunofixation procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86334	26	A	Immunofixation procedure	0.37	0.16	0.18	0.16	0.18	0.01	0.54	0.56	0.54	0.56	XXX
86337		X	Insulin antibodies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86340		X	Intrinsic factor antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86341		X	Islet cell antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86343		X	Leukocyte histamine release	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86344		X	Leukocyte phagocytosis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86353		X	Lymphocyte transformation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86359		X	T cells, total count	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86360		X	T cell, absolute count/ratio	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86361		X	T cell, absolute count	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86376		X	Microsomal antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	.00	XXX
86378		X	Migration inhibitory factor	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86382		X	Neutralization test, viral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86384		X	Nitroblue tetrazolium dye	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86403		X	Particle agglutination test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86406		X	Particle agglutination test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86430		X	Rheumatoid factor test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86431		X	Rheumatoid factor, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86485		C	Skin test, candida	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
86490		A	Coccidioidomycosis skin test	0.00	0.29	0.29	NA	NA	0.02	0.31	0.31	NA	NA	XXX
86510		A	Histoplasmosis skin test	0.00	0.32	0.32	NA	NA	0.02	0.34	0.34	NA	NA	XXX
86580		A	TB intradermal test	0.00	0.25	0.25	NA	NA	0.02	0.27	0.27	NA	NA	XXX
86585		A	TB tine test	0.00	0.21	0.21	NA	NA	0.01	0.22	0.22	NA	NA	XXX
86586		C	Skin test, unlisted	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
86588		D	Streptocollus, direct screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86590		X	Streptokinase, antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86592		X	Blood serology, qualitative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86593		X	Blood serology, quantitative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86602		X	Antinomyces antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86603		X	Adenovirus antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86606		X	Aspergillus antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86609		X	Bacterium antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86612		X	Blastomyces antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86615		X	Bordetella antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86617		X	Lyme disease antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86618		X	Lyme disease antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86619		X	Borrelia antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86622		X	Brucella antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86625		X	Campylobacter antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86628		X	Candida antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86631		X	Chlamydia antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86632		X	Chlamydia igm antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86635		X	Coccidioides antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86638		X	Q fever antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86641		X	Cryptococcus antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86644		X	CMV antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86645		X	CMV antibody, IgM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86648		X	Diphtheria antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86651		X	Encephalitis antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86652		X	Encephalitis antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86653		X	Encephalitis antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86654		X	Encephalitis antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86658		X	Enterovirus antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86663		X	Epstein-barr antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86664		X	Epstein-barr antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86665		X	Epstein-barr antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86668		X	Francisella tularensis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86671		X	Fungus antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86674		X	Giardia lamblia antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86677		X	Helicobacter pylori	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
86682		X	Helminth antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86684		X	Hemophilus influenza	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86687		X	Htlv-i antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86688		X	Htlv-ii antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86689		X	HTLV/HIV confirmatory test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86692		X	Hepatitis, delta agent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86694		X	Herpes simplex test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86695		X	Herpes simplex test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86698		X	Histoplasma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86701		X	HIV-1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86702		X	HIV-2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86703		X	HIV-1/HIV-2, single assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86704		X	Hep b core antibody, igg/igm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86705		X	Hep b core antibody, igm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86706		X	Hep b surface antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86707		X	Hep be antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86708		X	Hep a antibody, igg/igm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86709		X	Hep a antibody, igm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86710		X	Influenza virus antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86713		X	Legionella antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86717		X	Leishmania antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86720		X	Leptospira antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86723		X	Listeria monocytogenes ab	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86727		X	Lymph choriomeningitis ab	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86729		X	Lympho venereum antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86732		X	Mucormycosis antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86735		X	Mumps antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86738		X	Mycoplasma antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86741		X	Neisseria meningitidis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86744		X	Nocardia antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86747		X	Parvovirus antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86750		X	Malaria antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86753		X	Protozoa antibody nos	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86756		X	Respiratory virus antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86759		X	Rotavirus antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86762		X	Rubella antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86765		X	Rubeola antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86768		X	Salmonella antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86771		X	Shigella antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86774		X	Tetanus antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86777		X	Toxoplasma antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86778		X	Toxoplasma antibody, igm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86781		X	Treponema pallidum, confirm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86784		X	Trichinella antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86787		X	Varicella-zoster antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86790		X	Virus antibody nos	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86793		X	Yersinia antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86800		X	Thyroglobulin antibody	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86803		X	Hepatitis c ab test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86804		X	Hep c ab test, confirm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86805		X	Lymphocytotoxicity assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86806		X	Lymphocytotoxicity assay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86807		X	Cytotoxic antibody screening	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86808		X	Cytotoxic antibody screening	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86812		X	HLA typing, A, B, or C	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86813		X	HLA typing, A, B, or C	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86816		X	HLA typing, DR/DQ	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86817		X	HLA typing, DR/DQ	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86821		X	Lymphocyte culture, mixed	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86822		X	Lymphocyte culture, primed	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86849		X	Immunology procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86850		X	RBC antibody screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86860		X	RBC antibody elution	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86870		X	RBC antibody identification	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86880		X	Coombs test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86885		X	Coombs test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86886		X	Coombs test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86890		X	Autologous blood process	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86891		X	Autologous blood, op salvage	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86900		X	Blood typing, ABO	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86901		X	Blood typing, Rh (D)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86903		X	Blood typing, antigen screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86904		X	Blood typing, patient serum	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86905		X	Blood typing, RBC antigens	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86906		X	Blood typing, Rh phenotype	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86910		N	Blood typing, paternity test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86911		N	Blood typing, antigen system	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86915		X	Bone marrow/stem cell prep	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86920		X	Compatibility test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86921		X	Compatibility test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86922		X	Compatibility test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86927		X	Plasma, fresh frozen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
86930		X	Frozen blood prep	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86931		X	Frozen blood thaw	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86932		X	Frozen blood freeze/thaw	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86940		X	Hemolysins/agglutinins, auto	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86941		X	Hemolysins/agglutinins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86945		X	Blood product/irradiation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86950		X	Leukacyte transfusion	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86965		X	Pooling blood platelets	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86970		X	RBC pretreatment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86971		X	RBC pretreatment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86972		X	RBC pretreatment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86975		X	RBC pretreatment, serum	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86976		X	RBC pretreatment, serum	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86977		X	RBC pretreatment, serum	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86978		X	RBC pretreatment, serum	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86985		X	Split blood or products	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
86999		X	Transfusion procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87001		X	Small animal inoculation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87003		X	Small animal inoculation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87015		X	Specimen concentration	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87040		X	Blood culture for bacteria	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87045		X	Stool culture for bacteria	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87060		X	Nose/throat culture, bact	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87070		X	Culture specimen, bacteria	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87072		X	Culture of specimen by kit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87075		X	Culture specimen, bacteria	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87076		X	Bacteria identification	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87081		X	Bacteria culture screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87082		X	Culture of specimen by kit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87083		X	Culture of specimen by kit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87084		X	Culture of specimen by kit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87085		X	Culture of specimen by kit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87086		X	Urine culture/colony count	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87087		X	Urine bacteria culture	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87088		X	Urine bacteria culture	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87101		X	Skin fungus culture	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87102		X	Fungus isolation culture	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87103		X	Blood fungus culture	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87106		X	Fungus identification	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87109		X	Mycoplasma culture	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87110		X	Culture, chlamydia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87116		X	Mycobacteria culture	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87117		X	Mycobacteria culture	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87118		X	Mycobacteria identification	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87140		X	Culture typing, fluorescent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87143		X	Culture typing, GLC method	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87145		X	Culture typing, phage method	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87147		X	Culture typing, serologic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87151		X	Culture typing, serologic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87155		X	Culture typing, precipitin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87158		X	Culture typing, added method	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87163		X	Special microbiology culture	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87164		X	Dark field examination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87164	26	A	Dark field examination	0.37	0.15	0.17	0.15	0.17	0.01	0.53	0.55	0.53	0.55	XXX
87166		X	Dark field examination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87174		X	Endotoxin, bacterial	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87175		X	Assay, endotoxin, bacterial	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87176		X	Endotoxin, bacterial	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87177		X	Ova and parasites smears	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87181		X	Antibiotic sensitivity, each	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87184		X	Antibiotic sensitivity, each	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87186		X	Antibiotic sensitivity, MIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87187		X	Antibiotic sensitivity, MBC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87188		X	Antibiotic sensitivity, each	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87190		X	TB antibiotic sensitivity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87192		X	Antibiotic sensitivity, each	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87197		X	Bactericidal level, serum	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87205		X	Smear, stain & interpret	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87206		X	Smear, stain & interpret	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87207		X	Smear, stain & interpret	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87207	26	A	Smear, stain & interpret	0.37	0.18	0.19	0.16	0.18	0.01	0.56	0.57	0.54	0.56	XXX
87208		X	Smear, stain & interpret	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87210		X	Smear, stain & interpret	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87211		X	Smear, stain & interpret	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87220		X	Tissue exam for fungi	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87230		X	Assay, toxin or antitoxin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87250		X	Virus inoculation for test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87252		X	Virus inoculation for test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87253		X	Virus inoculation for test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87260		X	Adenovirus ag, dfa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87265		X	Pertussis ag, dfa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87270		X	Chylmd trach ag, dfa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
87272		X	Cryptosporidum ag, dfa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87274		X	Herpes simplex ag, dfa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87276		X	Influenza ag, dfa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87278		X	Legion pneumo ag, dfa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87280		X	Resp syncytial ag, dfa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87285		X	Trepon pallidum ag, dfa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87290		X	Varicella ag, dfa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87299		X	Ag detection nos, dfa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87301		X	Adenovirus ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87320		X	Chylmd trach ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87324		X	Clostridium ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87328		X	Cryptospor ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87332		X	Cytomegalovirus ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87335		X	E coli 0157 ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87338		X	Hpylori, stool, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87340		X	Hepatitis b surface ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87350		X	Hepatitis be ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87380		X	Hepatitis delta ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87385		X	Histoplasma capsul ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87390		X	Hiv-1 ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87391		X	Hiv-2 ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87420		X	Resp syncytial ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87425		X	Rotavirus ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87430		X	Strep a ag, eia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87449		X	Ag detect nos, eia, mult	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87450		X	Ag detect nos, eia, single	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87470		X	Bartonella, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87471		X	Bartonella, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87472		X	Bartonella, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87475		X	Lyme dis, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87476		X	Lyme dis, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87477		X	Lyme dis, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87480		X	Candida, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87481		X	Candida, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87482		X	Candida, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87485		X	Chylmd pneum, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87486		X	Chylmd pneum, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87487		X	Chylmd pneum, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87490		X	Chylmd trach, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87491		X	Chylmd trach, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87492		X	Chylmd trach, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87495		X	Cytomeg, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87496		X	Cytomeg, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87497		X	Cytomeg, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87510		X	Gardner vag, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87511		X	Gardner vag, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87512		X	Gardner vag, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87515		X	Hepatitis b, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87516		X	Hepatitis b , dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87517		X	Hepatitis b , dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87520		X	Hepatitis c , rna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87521		X	Hepatitis c , rna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87522		X	Hepatitis c, rna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87525		X	Hepatitis g , dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87526		X	Hepatitis g, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87527		X	Hepatitis g, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87528		X	Hsv, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87529		X	Hsv, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87530		X	Hsv, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87531		X	Hhv-6, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87532		X	Hhv-6, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87533		X	Hhv-6, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87534		X	Hiv-1, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87535		X	Hiv-1, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87536		X	Hiv-1, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87537		X	Hiv-2, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87538		X	Hiv-2, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87539		X	Hiv-2, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87540		X	Legion pneumo, dna, dir prob	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87541		X	Legion pneumo, dna, amp prob	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87542		X	Legion pneumo, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87550		X	Mycobacteria, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87551		X	Mycobacteria, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87552		X	Mycobacteria, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87555		X	M.tuberculo, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87556		X	M.tuberculo, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87557		X	M.tuberculo, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87560		X	M.avium-intra, dna, dir prob	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87561		X	M.avium-intra, dna, amp prob	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87562		X	M.avium-intra, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87580		X	M.pneumon, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87581		X	M.pneumon, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
87582		X	M.pneumon, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87590		X	N.gonorrhoeae, dna, dir prob	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87591		X	N.gonorrhoeae, dna, amp prob	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87592		X	N.gonorrhoeae, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87620		X	Hpv, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87621		X	Hpv, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87622		X	Hpv, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87650		X	Strep a, dna, dir probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87651		X	Strep a, dna, amp probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87652		X	Strep a, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87797		X	Detect agent nos, dna, dir	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87798		X	Detect agent nos, dna, amp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87799		X	Detect agent nos, dna, quant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87810		X	Chylmd trach assay w/optic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87850		X	N. gonorrhoeae assay w/optic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87880		X	Strep a assay w/optic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87899		X	Agent nos assay w/optic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
87999		X	Microbiology procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88000		N	Autopsy (necropsy), gross	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88005		N	Autopsy (necropsy), gross	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88007		N	Autopsy (necropsy), gross	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88012		N	Autopsy (necropsy), gross	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88014		N	Autopsy (necropsy), gross	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88016		N	Autopsy (necropsy), gross	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88020		N	Autopsy (necropsy), complete	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88025		N	Autopsy (necropsy), complete	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88027		N	Autopsy (necropsy), complete	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88028		N	Autopsy (necropsy), complete	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88029		N	Autopsy (necropsy), complete	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88036		N	Limited autopsy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88037		N	Limited autopsy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88040		N	Forensic autopsy (necropsy)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88045		N	Coroner's autopsy (necropsy)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88099		N	Necropsy (autopsy) procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88104		A	Cytopathology, fluids	0.56	0.90	0.79	NA	NA	0.03	1.49	1.38	NA	NA	XXX
88104	26	A	Cytopathology, fluids	0.56	0.24	0.24	0.24	0.24	0.01	0.81	0.81	0.81	0.81	XXX
88104	TC	A	Cytopathology, fluids	0.00	0.66	0.55	NA	NA	0.02	0.68	0.57	NA	NA	XXX
88106		A	Cytopathology, fluids	0.56	0.56	0.53	NA	NA	0.03	1.15	1.12	NA	NA	XXX
88106	26	A	Cytopathology, fluids	0.56	0.24	0.24	0.24	0.24	0.01	0.81	0.81	0.81	0.81	XXX
88106	TC	A	Cytopathology, fluids	0.00	0.32	0.29	NA	NA	0.02	0.34	0.31	NA	NA	XXX
88107		A	Cytopathology, fluids	0.76	0.94	0.83	NA	NA	0.04	1.74	1.63	NA	NA	XXX
88107	26	A	Cytopathology, fluids	0.76	0.33	0.31	0.33	0.31	0.02	1.11	1.09	1.11	1.09	XXX
88107	TC	A	Cytopathology, fluids	0.00	0.61	0.52	NA	NA	0.02	0.63	0.54	NA	NA	XXX
88108		A	Cytopath, concentrate tech	0.56	0.81	0.74	NA	NA	0.03	1.40	1.33	NA	NA	XXX
88108	26	A	Cytopath, concentrate tech	0.56	0.24	0.25	0.24	0.25	0.01	0.81	0.82	0.81	0.82	XXX
88108	TC	A	Cytopath, concentrate tech	0.00	0.57	0.49	NA	NA	0.02	0.59	0.51	NA	NA	XXX
88125		A	Forensic cytopathology	0.26	0.30	0.25	NA	NA	0.02	0.58	0.53	NA	NA	XXX
88125	26	A	Forensic cytopathology	0.26	0.11	0.10	0.11	0.10	0.01	0.38	0.37	0.38	0.37	XXX
88125	TC	A	Forensic cytopathology	0.00	0.19	0.15	NA	NA	0.01	0.20	0.16	NA	NA	XXX
88130		X	Sex chromatin identification	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88140		X	Sex chromatin identification	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88141		A	Cytopath, c/v, interpret	0.42	0.19	0.23	0.19	0.23	0.01	0.62	0.66	0.62	0.66	XXX
88142		X	Cytopath, c/v, thin layer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88143		X	Cytopath c/v thin layer redo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88144		X	Cytopath, c/v thin lyr redo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88145		X	Cytopath, c/v thin lyr sel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88147		X	Cytopath, c/v, automated	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88148		X	Cytopath, c/v, auto rescreen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88150		X	Cytopath, c/v, manual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88152		X	Cytopath, c/v, auto redo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88153		X	Cytopath, c/v, redo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88154		X	Cytopath, c/v, select	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88155		X	Cytopath, c/v, index add-on	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88160		A	Cytopath smear, other source	0.50	1.08	0.90	NA	NA	0.03	1.61	1.43	NA	NA	XXX
88160	26	A	Cytopath smear, other source	0.50	0.21	0.20	0.21	0.20	0.01	0.72	0.71	0.72	0.71	XXX
88160	TC	A	Cytopath smear, other source	0.00	0.87	0.70	NA	NA	0.02	0.89	0.72	NA	NA	XXX
88161		A	Cytopath smear, other source	0.50	0.52	0.50	NA	NA	0.03	1.05	1.03	NA	NA	XXX
88161	26	A	Cytopath smear, other source	0.50	0.21	0.21	0.21	0.21	0.01	0.72	0.72	0.72	0.72	XXX
88161	TC	A	Cytopath smear, other source	0.00	0.31	0.29	NA	NA	0.02	0.33	0.31	NA	NA	XXX
88162		A	Cytopath smear, other source	0.76	0.94	0.92	NA	NA	0.04	1.74	1.72	NA	NA	XXX
88162	26	A	Cytopath smear, other source	0.76	0.33	0.36	0.33	0.36	0.02	1.11	1.14	1.11	1.14	XXX
88162	TC	A	Cytopath smear, other source	0.00	0.61	0.56	NA	NA	0.02	0.63	0.58	NA	NA	XXX
88164		X	Cytopath tbs, c/v, manual	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88165		X	Cytopath tbs, c/v, redo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88166		X	Cytopath tbs, c/v, auto redo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88167		X	Cytopath tbs, c/v, select	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88170		A	Fine needle aspiration	1.27	0.88	0.93	NA	NA	0.08	2.23	2.28	NA	NA	XXX
88170	26	A	Fine needle aspiration	1.27	0.53	0.54	0.53	0.54	0.05	1.85	1.86	1.85	1.86	XXX
88170	TC	A	Fine needle aspiration	0.00	0.35	0.39	NA	NA	0.03	0.38	0.42	NA	NA	XXX
88171		A	Fine needle aspiration	1.27	0.75	0.93	NA	NA	0.07	2.09	2.27	NA	NA	XXX
88171	26	A	Fine needle aspiration	1.27	0.48	0.55	0.48	0.55	0.04	1.79	1.86	1.79	1.86	XXX
88171	TC	A	Fine needle aspiration	0.00	0.27	0.38	NA	NA	0.03	0.30	0.41	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
88172		A	Evaluation of smear	0.60	1.13	1.04	NA	NA	0.04	1.77	1.68	NA	NA	XXX
88172	26	A	Evaluation of smear	0.60	0.26	0.29	0.26	0.29	0.02	0.88	0.91	0.88	0.91	XXX
88172	TC	A	Evaluation of smear	0.00	0.87	0.75	NA	NA	0.02	0.89	0.77	NA	NA	XXX
88173		A	Interpretation of smear	1.39	1.42	1.30	NA	NA	0.06	2.87	2.75	NA	NA	XXX
88173	26	A	Interpretation of smear	1.39	0.60	0.57	0.60	0.57	0.04	2.03	2.00	2.03	2.00	XXX
88173	TC	A	Interpretation of smear	0.00	0.82	0.73	NA	NA	0.02	0.84	0.75	NA	NA	XXX
88180		A	Cell marker study	0.36	0.76	0.66	NA	NA	0.03	1.15	1.05	NA	NA	XXX
88180	26	A	Cell marker study	0.36	0.15	0.16	0.15	0.16	0.01	0.52	0.53	0.52	0.53	XXX
88180	TC	A	Cell marker study	0.00	0.61	0.50	NA	NA	0.02	0.63	0.52	NA	NA	XXX
88182		A	Cell marker study	0.77	1.15	1.11	NA	NA	0.05	1.97	1.93	NA	NA	XXX
88182	26	A	Cell marker study	0.77	0.33	0.37	0.33	0.37	0.02	1.12	1.16	1.12	1.16	XXX
88182	TC	A	Cell marker study	0.00	0.82	0.74	NA	NA	0.03	0.85	0.77	NA	NA	XXX
88199		C	Cytopathology procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
88199	26	C	Cytopathology procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88199	TC	C	Cytopathology procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
88230		X	Tissue culture, lymphocyte	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88233		X	Tissue culture, skin/biopsy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88235		X	Tissue culture, placenta	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88237		X	Tissue culture, bone marrow	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88239		X	Tissue culture, tumor	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88240		X	Cell cryopreserve/storage	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88241		X	Frozen cell preparation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88245		X	Chromosome analysis, 20–25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88248		X	Chromosome analysis, 50–100	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88249		X	Chromosome analysis, 100	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88261		X	Chromosome analysis, 5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88262		X	Chromosome analysis, 15–20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88263		X	Chromosome analysis, 45	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88264		X	Chromosome analysis, 20–25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88267		X	Chromosome analys, placenta	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88269		X	Chromosome analys, amniotic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88271		X	Cytogenetics, dna probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88272		X	Cytogenetics, 3–5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88273		X	Cytogenetics, 10–30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88274		X	Cytogenetics, 25–99	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88275		X	Cytogenetics, 100–300	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88280		X	Chromosome karyotype study	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88283		X	Chromosome banding study	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88285		X	Chromosome count, additional	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88289		X	Chromosome study, additional	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88291		A	Cyto/molecular report	0.52	0.22	0.22	0.22	0.22	0.01	0.75	0.75	0.75	0.75	XXX
88299		C	Cytogenetic study	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88300		A	Surgical path, gross	0.08	0.40	0.36	NA	NA	0.02	0.50	0.46	NA	NA	XXX
88300	26	A	Surgical path, gross	0.08	0.03	0.05	0.03	0.05	0.01	0.12	0.14	0.12	0.14	XXX
88300	TC	A	Surgical path, gross	0.00	0.37	0.31	NA	NA	0.01	0.38	0.32	NA	NA	XXX
88302		A	Tissue exam by pathologist	0.13	1.29	1.08	NA	NA	0.03	1.45	1.24	NA	NA	XXX
88302	26	A	Tissue exam by pathologist	0.13	0.06	0.09	0.06	0.09	0.01	0.20	0.23	0.20	0.23	XXX
88302	TC	A	Tissue exam by pathologist	0.00	1.23	0.99	NA	NA	0.02	1.25	1.01	NA	NA	XXX
88304		A	Tissue exam by pathologist	0.22	0.82	0.77	NA	NA	0.03	1.07	1.02	NA	NA	XXX
88304	26	A	Tissue exam by pathologist	0.22	0.09	0.13	0.09	0.13	0.01	0.32	0.36	0.32	0.36	XXX
88304	TC	A	Tissue exam by pathologist	0.00	0.73	0.64	NA	NA	0.02	0.75	0.66	NA	NA	XXX
88305		A	Tissue exam by pathologist	0.75	1.57	1.46	NA	NA	0.05	2.37	2.26	NA	NA	XXX
88305	26	A	Tissue exam by pathologist	0.75	0.33	0.39	0.33	0.39	0.02	1.10	1.16	1.10	1.16	XXX
88305	TC	A	Tissue exam by pathologist	0.00	1.24	1.07	NA	NA	0.03	1.27	1.10	NA	NA	XXX
88307		A	Tissue exam by pathologist	1.59	2.92	2.60	NA	NA	0.09	4.60	4.28	NA	NA	XXX
88307	26	A	Tissue exam by pathologist	1.59	0.68	0.72	0.68	0.72	0.04	2.31	2.35	2.31	2.35	XXX
88307	TC	A	Tissue exam by pathologist	0.00	2.24	1.88	NA	NA	0.05	2.29	1.93	NA	NA	XXX
88309		A	Tissue exam by pathologist	2.28	3.90	3.44	NA	NA	0.11	6.29	5.83	NA	NA	XXX
88309	26	A	Tissue exam by pathologist	2.28	0.98	1.00	0.98	1.00	0.06	3.32	3.34	3.32	3.34	XXX
88309	TC	A	Tissue exam by pathologist	0.00	2.92	2.44	NA	NA	0.05	2.97	2.49	NA	NA	XXX
88311		A	Decalcify tissue	0.24	0.18	0.20	NA	NA	0.02	0.44	0.46	NA	NA	XXX
88311	26	A	Decalcify tissue	0.24	0.10	0.11	0.10	0.11	0.01	0.35	0.36	0.35	0.36	XXX
88311	TC	A	Decalcify tissue	0.00	0.08	0.09	NA	NA	0.01	0.09	0.10	NA	NA	XXX
88312		A	Special stains	0.54	1.62	1.29	NA	NA	0.02	2.18	1.85	NA	NA	XXX
88312	26	A	Special stains	0.54	0.23	0.21	0.23	0.21	0.01	0.78	0.76	0.78	0.76	XXX
88312	TC	A	Special stains	0.00	1.39	1.08	NA	NA	0.01	1.40	1.09	NA	NA	XXX
88313		A	Special stains	0.24	1.14	0.92	NA	NA	0.02	1.40	1.18	NA	NA	XXX
88313	26	A	Special stains	0.24	0.10	0.11	0.10	0.11	0.01	0.35	0.36	0.35	0.36	XXX
88313	TC	A	Special stains	0.00	1.04	0.81	NA	NA	0.01	1.05	0.82	NA	NA	XXX
88314		A	Histochemical stain	0.45	2.25	1.86	NA	NA	0.03	2.73	2.34	NA	NA	XXX
88314	26	A	Histochemical stain	0.45	0.19	0.24	0.19	0.24	0.01	0.65	0.70	0.65	0.70	XXX
88314	TC	A	Histochemical stain	0.00	2.06	1.62	NA	NA	0.02	2.08	1.64	NA	NA	XXX
88318		A	Chemical histochemistry	0.42	0.71	0.60	NA	NA	0.02	1.15	1.04	NA	NA	XXX
88318	26	A	Chemical histochemistry	0.42	0.18	0.17	0.18	0.17	0.01	0.61	0.60	0.61	0.60	XXX
88318	TC	A	Chemical histochemistry	0.00	0.53	0.43	NA	NA	0.01	0.54	0.44	NA	NA	XXX
88319		A	Enzyme histochemistry	0.53	2.16	1.75	NA	NA	0.03	2.72	2.31	NA	NA	XXX
88319	26	A	Enzyme histochemistry	0.53	0.23	0.24	0.23	0.24	0.01	0.77	0.78	0.77	0.78	XXX
88319	TC	A	Enzyme histochemistry	0.00	1.93	1.51	NA	NA	0.02	1.95	1.53	NA	NA	XXX
88321		A	Microslide consultation	1.30	0.62	0.58	0.56	0.53	0.04	1.96	1.92	1.90	1.87	XXX
88323		A	Microslide consultation	1.35	1.82	1.56	NA	NA	0.06	3.23	2.97	NA	NA	XXX
88323	26	A	Microslide consultation	1.35	0.59	0.55	0.59	0.55	0.04	1.98	1.94	1.98	1.94	XXX
88323	TC	A	Microslide consultation	0.00	1.23	1.01	NA	NA	0.02	1.25	1.03	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
88325		A	Comprehensive review of data	2.22	0.99	0.87	0.95	0.84	0.06	3.27	3.15	3.23	3.12	XXX
88329		A	Pathology consult in surgery	0.67	0.40	0.40	0.29	0.32	0.02	1.09	1.09	0.98	1.01	XXX
88331		A	Pathology consult in surgery	1.19	0.84	0.94	NA	NA	0.06	2.09	2.19	NA	NA	XXX
88331	26	A	Pathology consult in surgery	1.19	0.51	0.54	0.51	0.54	0.03	1.73	1.76	1.73	1.76	XXX
88331	TC	A	Pathology consult in surgery	0.00	0.33	0.40	NA	NA	0.03	0.36	0.43	NA	NA	XXX
88332		A	Pathology consult in surgery	0.59	0.47	0.51	NA	NA	0.04	1.10	1.14	NA	NA	XXX
88332	26	A	Pathology consult in surgery	0.59	0.25	0.27	0.25	0.27	0.02	0.86	0.88	0.86	0.88	XXX
88332	TC	A	Pathology consult in surgery	0.00	0.22	0.24	NA	NA	0.02	0.24	0.26	NA	NA	XXX
88342		A	Immunocytochemistry	0.85	1.34	1.18	NA	NA	0.04	2.23	2.07	NA	NA	XXX
88342	26	A	Immunocytochemistry	0.85	0.36	0.36	0.36	0.36	0.02	1.23	1.23	1.23	1.23	XXX
88342	TC	A	Immunocytochemistry	0.00	0.98	0.82	NA	NA	0.02	1.00	0.84	NA	NA	XXX
88346		A	Immunofluorescent study	0.86	1.60	1.36	NA	NA	0.04	2.50	2.26	NA	NA	XXX
88346	26	A	Immunofluorescent study	0.86	0.37	0.36	0.37	0.36	0.02	1.25	1.24	1.25	1.24	XXX
88346	TC	A	Immunofluorescent study	0.00	1.23	1.00	NA	NA	0.02	1.25	1.02	NA	NA	XXX
88347		A	Immunofluorescent study	0.86	1.17	0.99	NA	NA	0.04	2.07	1.89	NA	NA	XXX
88347	26	A	Immunofluorescent study	0.86	0.33	0.29	0.33	0.29	0.02	1.21	1.17	1.21	1.17	XXX
88347	TC	A	Immunofluorescent study	0.00	0.84	0.70	NA	NA	0.02	0.86	0.72	NA	NA	XXX
88348		A	Electron microscopy	1.51	9.91	8.05	NA	NA	0.10	11.52	9.66	NA	NA	XXX
88348	26	A	Electron microscopy	1.51	0.64	0.80	0.64	0.80	0.04	2.19	2.35	2.19	2.35	XXX
88348	TC	A	Electron microscopy	0.00	9.27	7.25	NA	NA	0.06	9.33	7.31	NA	NA	XXX
88349		A	Scanning electron microscopy	0.76	7.58	6.10	NA	NA	0.07	8.41	6.93	NA	NA	XXX
88349	26	A	Scanning electron microscopy	0.76	0.33	0.46	0.33	0.46	0.02	1.11	1.24	1.11	1.24	XXX
88349	TC	A	Scanning electron microscopy	0.00	7.25	5.64	NA	NA	0.05	7.30	5.69	NA	NA	XXX
88355		A	Analysis, skeletal muscle	1.85	2.74	2.53	NA	NA	0.10	4.69	4.48	NA	NA	XXX
88355	26	A	Analysis, skeletal muscle	1.85	0.80	0.85	0.80	0.85	0.05	2.70	2.75	2.70	2.75	XXX
88355	TC	A	Analysis, skeletal muscle	0.00	1.94	1.68	NA	NA	0.05	1.99	1.73	NA	NA	XXX
88356		A	Analysis, nerve	3.02	4.05	3.76	NA	NA	0.15	7.22	6.93	NA	NA	XXX
88356	26	A	Analysis, nerve	3.02	1.27	1.33	1.27	1.33	0.09	4.38	4.44	4.38	4.44	XXX
88356	TC	A	Analysis, nerve	0.00	2.78	2.43	NA	NA	0.06	2.84	2.49	NA	NA	XXX
88358		A	Analysis, tumor	2.82	2.17	2.26	NA	NA	0.13	5.12	5.21	NA	NA	XXX
88358	26	A	Analysis, tumor	2.82	1.22	1.23	1.22	1.23	0.07	4.11	4.12	4.11	4.12	XXX
88358	TC	A	Analysis, tumor	0.00	0.95	1.03	NA	NA	0.06	1.01	1.09	NA	NA	XXX
88362		A	Nerve teasing preparations	2.17	3.99	3.53	NA	NA	0.12	6.28	5.82	NA	NA	XXX
88362	26	A	Nerve teasing preparations	2.17	0.92	0.96	0.92	0.96	0.07	3.16	3.20	3.16	3.20	XXX
88362	TC	A	Nerve teasing preparations	0.00	3.07	2.57	NA	NA	0.05	3.12	2.62	NA	NA	XXX
88365		A	Tissue hybridization	0.93	2.17	1.84	NA	NA	0.04	3.14	2.81	NA	NA	XXX
88365	26	A	Tissue hybridization	0.93	0.39	0.40	0.39	0.40	0.02	1.34	1.35	1.34	1.35	XXX
88365	TC	A	Tissue hybridization	0.00	1.78	1.44	NA	NA	0.02	1.80	1.46	NA	NA	XXX
88371		X	Protein, western blot tissue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88371	26	A	Protein, western blot tissue	0.37	0.15	0.17	0.15	0.17	0.01	0.53	0.55	0.53	0.55	XXX
88372		X	Protein analysis w/probe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88372	26	A	Protein analysis w/probe	0.37	0.16	0.18	0.16	0.18	0.01	0.54	0.56	0.54	0.56	XXX
88399		C	Surgical pathology procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
88399	26	C	Surgical pathology procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
88399	TC	C	Surgical pathology procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
89050		X	Body fluid cell count	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89051		X	Body fluid cell count	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89060		X	Exam,synovial fluid crystals	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89060	26	A	Exam,synovial fluid crystals	0.37	0.17	0.18	0.16	0.18	0.01	0.55	0.56	0.54	0.56	XXX
89100		A	Sample intestinal contents	0.60	1.37	1.14	0.22	0.28	0.02	1.99	1.76	0.84	0.90	XXX
89105		A	Sample intestinal contents	0.50	2.37	1.88	0.17	0.23	0.02	2.89	2.40	0.69	0.75	XXX
89125		X	Specimen fat stain	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89130		A	Sample stomach contents	0.45	1.59	1.30	0.14	0.22	0.02	2.06	1.77	0.61	0.69	XXX
89132		A	Sample stomach contents	0.19	1.59	1.25	0.07	0.11	0.01	1.79	1.45	0.27	0.31	XXX
89135		A	Sample stomach contents	0.79	1.82	1.52	0.25	0.35	0.03	2.64	2.34	1.07	1.17	XXX
89136		A	Sample stomach contents	0.21	1.77	1.39	0.08	0.12	0.01	1.99	1.61	0.30	0.34	XXX
89140		A	Sample stomach contents	0.94	1.91	1.65	0.34	0.48	0.04	2.89	2.63	1.32	1.46	XXX
89141		A	Sample stomach contents	0.85	2.95	2.41	0.34	0.45	0.03	3.83	3.29	1.22	1.33	XXX
89160		X	Exam feces for meat fibers	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89190		X	Nasal smear for eosinophils	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89250		X	Fertilization of oocyte	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89251		X	Culture oocyte w/embryos	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89252		X	Assist oocyte fertilization	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89253		X	Embryo hatching	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89254		X	Oocyte identification	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89255		X	Prepare embryo for transfer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89256		X	Prepare cryopreserved embryo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89257		X	Sperm identification	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89258		X	Cryopreservation, embryo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89259		X	Cryopreservation, sperm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89260		X	Sperm isolation, simple	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89261		X	Sperm isolation, complex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89264		X	Identify sperm tissue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89300		X	Semen analysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89310		X	Semen analysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89320		X	Semen analysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89325		X	Sperm antibody test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89329		X	Sperm evaluation test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89330		X	Evaluation, cervical mucus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89350		A	Sputum specimen collection	0.00	0.41	0.41	NA	NA	0.02	0.43	0.43	NA	NA	XXX
89355		X	Exam feces for starch	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89360		A	Collect sweat for test	0.00	0.46	0.46	NA	NA	0.02	0.48	0.48	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
89365		X	Water load test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89399		C	Pathology lab procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
89399	26	C	Pathology lab procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
89399	TC	C	Pathology lab procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
90281		I	Human ig, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90283		I	Human ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90287		I	Botulinum antitoxin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90288		I	Botulism ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90291		I	Cmv ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90296		E	Diphtheria antitoxin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90371		E	Hep b ig, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90375		E	Rabies ig, im/sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90376		E	Rabies ig, heat treated	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90378		X	Rsv ig, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90379		E	Rsv ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90384		I	Rh ig, full-dose, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90385		E	Rh ig, minidose, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90386		I	Rh ig, iv	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90389		E	Tetanus ig, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90393		E	Vaccina ig, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90396		E	Varicella-zoster ig, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90399		I	Immune globulin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90471		X	Immunization admin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90472		X	Immunization admin, each add	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90476		E	Adenovirus vaccine, type 4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90477		E	Adenovirus vaccine, type 7	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90581		E	Anthrax vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90585		E	Bcg vaccine, percut	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90586		E	Bcg vaccine, intravesical	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90592		D	Cholera vaccine, oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90632		E	Hep a vaccine, adult im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90633		E	Hep a vacc, ped/adol, 2 dose	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90634		E	Hep a vacc, ped/adol, 3 dose	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90636		E	Hep a/hep b vacc, adult im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90645		E	Hib vaccine, hboc, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90646		E	Hib vaccine, prp-d, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90647		E	Hib vaccine, prp-omp, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90648		E	Hib vaccine, prp-t, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90657		X	Flu vaccine, 6–35 mo, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90658		X	Flu vaccine, 3 yrs, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90659		X	Flu vaccine, whole, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90660		X	Flu vaccine, nasal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90665		E	Lyme disease vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90669		N	Pneumococcal vaccine, ped	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90675		E	Rabies vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90676		E	Rabies vaccine, id	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90680		E	Rotovirus vaccine, oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90690		E	Typhoid vaccine, oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90691		E	Typhoid vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90692		E	Typhoid vaccine, h-p, sc/id	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90693		E	Typhoid vaccine, akd, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90700		E	Dtap vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90701		E	Dtp vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90702		E	Dt vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90703		E	Tetanus vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90704		E	Mumps vaccine, sc	0.00	0.00	.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90705		E	Measles vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90706		E	Rubella vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90707		E	Mmr vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90708		E	Measles-rubella vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90709		E	Rubella & mumps vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90710		E	Mmrv vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90712		E	Oral poliovirus vaccine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90713		E	Poliovirus, ipv, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90716		E	Chicken pox vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90717		E	Yellow fever vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90718		E	Td vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90719		E	Diphtheria vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90720		E	Dtp/hib vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90721		E	Dtap/hib vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90725		E	Cholera vaccine, injectable	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90727		E	Plague vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90732		X	Pneumococcal vaccine, adult	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90733		E	Meningococcal vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90735		E	Encephalitis vaccine, sc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90744		X	Hep b vaccine, ped/adol, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90745		D	Hepb vaccine, adol/risk, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90746		X	Hep b vaccine, adult, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90747		X	Hep b vaccine, ill pat, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90748		E	Hep b/hib vaccine, im	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90749		E	Vaccine toxoid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90780		A	IV infusion therapy, 1 hour	0.00	1.12	1.13	1.12	1.13	0.06	1.18	1.19	1.18	1.19	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
90781		A	IV infusion, additional hour	0.00	0.57	0.57	0.57	0.57	0.03	0.60	0.60	0.60	0.60	ZZZ
90782		T	Injection, sc/im	0.00	0.11	0.11	0.11	0.11	0.01	0.12	0.12	0.12	0.12	XXX
90783		T	Injection, ia	0.00	0.41	0.41	0.41	0.41	0.02	0.43	0.43	0.43	0.43	XXX
90784		T	Injection, iv	0.00	0.48	0.48	0.48	0.48	0.03	0.51	0.51	0.51	0.51	XXX
90788		T	Injection of antibiotic	0.00	0.12	0.12	0.12	0.12	0.01	0.13	0.13	0.13	0.13	XXX
90799		C	Ther/prophylactic/dx inject	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90801		A	Psy dx interview	2.80	1.09	1.00	0.91	0.87	0.07	3.96	3.87	3.78	3.74	XXX
90802		A	Intac psy dx interview	3.01	1.12	0.94	0.95	0.82	0.08	4.21	4.03	4.04	3.91	XXX
90804		A	Psytx, office, 20–30 min	1.21	0.50	0.47	0.40	0.40	0.03	1.74	1.71	1.64	1.64	XXX
90805		A	Psytx, off, 20–30 min w/e&m	1.37	0.55	0.51	0.42	0.41	0.04	1.96	1.92	1.83	1.82	XXX
90806		A	Psytx, off, 45–50 min	1.86	0.74	0.70	0.64	0.63	0.05	2.65	2.61	2.55	2.54	XXX
90807		A	Psytx, off, 45–50 min w/e&m	2.02	0.74	0.70	0.63	0.62	0.05	2.81	2.77	2.70	2.69	XXX
90808		A	Psytx, office, 75–80 min	2.79	1.08	1.10	0.97	1.01	0.07	3.94	3.96	3.83	3.87	XXX
90809		A	Psytx, off, 75–80, w/e&m	2.95	1.06	1.08	0.92	0.98	0.08	4.09	4.11	3.95	4.01	XXX
90810		A	Intac psytx, off, 20–30 min	1.32	0.52	0.55	0.42	0.48	0.03	1.87	1.90	1.77	1.83	XXX
90811		A	Intac psytx, 20–30, w/e&m	1.48	0.58	0.60	0.46	0.51	0.04	2.10	2.12	1.98	2.03	XXX
90812		A	Intac psytx, off, 45–50 min	1.97	0.81	0.77	0.67	0.66	0.05	2.83	2.79	2.69	2.68	XXX
90813		A	Intac psytx, 45–50 min w/e&m	2.13	0.80	0.76	0.66	0.66	0.05	2.98	2.94	2.84	2.84	XXX
90814		A	Intac psytx, off, 75–80 min	2.90	1.15	1.02	1.01	0.92	0.07	4.12	3.99	3.98	3.89	XXX
90815		A	Intac psytx, 75–80 w/e&m	3.06	1.15	1.02	0.94	0.87	0.08	4.29	4.16	4.08	4.01	XXX
90816		A	Psytx, hosp, 20–30 min	1.25	0.57	0.52	0.43	0.42	0.03	1.85	1.80	1.71	1.70	XXX
90817		A	Psytx, hosp, 20–30 min w/e&m	1.41	0.57	0.52	0.43	0.42	0.04	2.02	1.97	1.88	1.87	XXX
90818		A	Psytx, hosp, 45–50 min	1.89	0.79	0.74	0.65	0.64	0.05	2.73	2.68	2.59	2.58	XXX
90819		A	Psytx, hosp, 45–50 min w/e&m	2.05	0.78	0.73	0.63	0.62	0.05	2.88	2.83	2.73	2.72	XXX
90821		A	Psytx, hosp, 75–80 min	2.83	1.13	1.13	0.96	1.01	0.07	4.03	4.03	3.86	3.91	XXX
90822		A	Psytx, hosp, 75–80 min w/e&m	2.99	1.07	1.09	0.92	0.98	0.08	4.14	4.16	3.99	4.05	XXX
90823		A	Intac psytx, hosp, 20–30 min	1.36	0.65	0.65	0.44	0.49	0.03	2.04	2.04	1.83	1.88	XXX
90824		A	Intac psytx, hsp 20–30 w/e&m	1.52	0.64	0.64	0.47	0.51	0.04	2.20	2.20	2.03	2.07	XXX
90826		A	Intac psytx, hosp, 45–50 min	2.01	0.90	0.84	0.70	0.69	0.05	2.96	2.90	2.76	2.75	XXX
90827		A	Intac psytx, hsp 45–50 w/e&m	2.16	0.85	0.80	0.66	0.66	0.06	3.07	3.02	2.88	2.88	XXX
90828		A	Intac psytx, hosp, 75–80 min	2.94	1.25	1.10	1.04	0.94	0.08	4.27	4.12	4.06	3.96	XXX
90829		A	Intac psytx, hsp 75–80 w/e&m	3.10	1.14	1.02	0.96	0.88	0.08	4.32	4.20	4.14	4.06	XXX
90845		A	Psychoanalysis	1.79	0.66	0.61	0.56	0.53	0.05	2.50	2.45	2.40	2.37	XXX
90846		R	Family psytx w/o patient	1.83	0.72	0.71	0.62	0.63	0.05	2.60	2.59	2.50	2.51	XXX
90847		R	Family psytx w/patient	2.21	0.83	0.78	0.73	0.71	0.06	3.10	3.05	3.00	2.98	XXX
90849		R	Multiple family group psytx	0.59	0.31	0.30	0.21	0.23	0.02	0.92	0.91	0.82	0.84	XXX
90853		A	Group psychotherapy	0.59	0.33	0.32	0.20	0.22	0.02	0.94	0.93	0.81	0.83	XXX
90857		A	Intac group psytx	0.63	0.33	0.29	0.22	0.21	0.02	0.98	0.94	0.87	0.86	XXX
90862		A	Medication management	0.95	0.40	0.40	0.29	0.32	0.02	1.37	1.37	1.26	1.29	XXX
90865		A	Narcosynthesis	2.84	1.31	1.12	0.87	0.79	0.10	4.25	4.06	3.81	3.73	XXX
90870		A	Electroconvulsive therapy	1.88	0.68	0.66	0.68	0.66	0.05	2.61	2.59	2.61	2.59	000
90871		A	Electroconvulsive therapy	2.72	NA	NA	0.96	0.95	0.07	NA	NA	3.75	3.74	000
90875		N	Psychophysiological therapy	1.20	0.82	0.82	0.48	0.48	0.03	2.05	2.05	1.71	1.71	XXX
90876		N	Psychophysiological therapy	1.90	1.09	1.09	0.75	0.75	0.05	3.04	3.04	2.70	2.70	XXX
90880		A	Hypnotherapy	2.19	0.86	0.82	0.69	0.69	0.06	3.11	3.07	2.94	2.94	XXX
90882		N	Environmental manipulation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90885		B	Psy evaluation of records	0.97	0.38	0.37	0.38	0.37	0.02	1.37	1.36	1.37	1.36	XXX
90887		B	Consultation with family	1.48	0.78	0.68	0.59	0.53	0.04	2.30	2.20	2.11	2.05	XXX
90889		B	Preparation of report	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90899		C	Psychiatric service/therapy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90901		A	Biofeedback train, any meth	0.41	0.66	0.76	0.18	0.40	0.02	1.09	1.19	0.61	0.83	000
90911		A	Biofeedback peri/uro/rectal	0.89	0.74	0.86	0.37	0.59	0.05	1.68	1.80	1.31	1.53	000
90918		A	ESRD related services, month	11.18	5.18	4.48	5.18	4.48	0.48	16.84	16.14	16.84	16.14	XXX
90919		A	ESRD related services, month	8.54	4.20	3.75	4.20	3.75	0.39	13.13	12.68	13.13	12.68	XXX
90920		A	ESRD related services, month	7.27	3.61	3.30	3.61	3.30	0.38	11.26	10.95	11.26	10.95	XXX
90921		A	ESRD related services, month	4.47	2.54	2.50	2.54	2.50	0.26	7.27	7.23	7.27	7.23	XXX
90922		A	ESRD related services, day	0.37	0.15	0.13	0.15	0.13	0.02	0.54	0.52	0.54	0.52	XXX
90923		A	Esrd related services, day	0.28	0.14	0.13	0.14	0.13	0.01	0.43	0.42	0.43	0.42	XXX
90924		A	Esrd related services, day	0.24	0.12	0.11	0.12	0.11	0.01	0.37	0.36	0.37	0.36	XXX
90925		A	Esrd related services, day	0.15	0.09	0.09	0.09	0.09	0.01	0.25	0.25	0.25	0.25	XXX
90935		A	Hemodialysis, one evaluation	1.22	NA	NA	0.73	0.91	0.07	NA	NA	2.02	2.20	000
90937		A	Hemodialysis, repeated eval	2.11	NA	NA	1.04	1.41	0.11	NA	NA	3.26	3.63	000
90945		A	Dialysis, one evaluation	1.28	NA	NA	0.76	0.92	0.08	NA	NA	2.12	2.28	000
90947		A	Dialysis, repeated eval	2.16	NA	NA	1.06	1.36	0.12	NA	NA	3.34	3.64	000
90989		X	Dialysis training, complete	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90993		X	Dialysis training, incompl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
90997		A	Hemoperfusion	1.84	NA	NA	1.05	1.34	0.10	NA	NA	2.99	3.28	000
90999		C	Dialysis procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
91000		A	Esophageal intubation	0.73	0.34	0.44	NA	NA	0.03	1.10	1.20	NA	NA	000
91000	26	A	Esophageal intubation	0.73	0.26	0.36	0.26	0.36	0.02	1.01	1.11	1.01	1.11	000
91000	TC	A	Esophageal intubation	0.00	0.08	0.08	NA	NA	0.01	0.09	0.09	NA	NA	000
91010		A	Esophagus motility study	1.25	1.27	1.55	NA	NA	0.09	2.61	2.89	NA	NA	000
91010	26	A	Esophagus motility study	1.25	0.44	0.71	0.44	0.71	0.04	1.73	2.00	1.73	2.00	000
91010	TC	A	Esophagus motility study	0.00	0.83	0.84	NA	NA	0.05	0.88	0.89	NA	NA	000
91011		A	Esophagus motility study	1.50	1.58	1.90	NA	NA	0.10	3.18	3.50	NA	NA	000
91011	26	A	Esophagus motility study	1.50	0.54	0.85	0.54	0.85	0.05	2.09	2.40	2.09	2.40	000
91011	TC	A	Esophagus motility study	0.00	1.04	1.05	NA	NA	0.05	1.09	1.10	NA	NA	000
91012		A	Esophagus motility study	1.46	1.69	2.01	NA	NA	0.12	3.27	3.59	NA	NA	000
91012	26	A	Esophagus motility study	1.46	0.53	0.84	0.53	0.84	0.06	2.05	2.36	2.05	2.36	000
91012	TC	A	Esophagus motility study	0.00	1.16	1.17	NA	NA	0.06	1.22	1.23	NA	NA	000
91020		A	Gastric motility	1.44	1.27	1.58	NA	NA	0.11	2.82	3.13	NA	NA	000
91020	26	A	Gastric motility	1.44	0.50	0.80	0.50	0.80	0.06	2.00	2.30	2.00	2.30	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
91020	TC	A	Gastric motility	0.00	0.77	0.78	NA	NA	0.05	0.82	0.83	NA	NA	000
91030		A	Acid perfusion of esophagus	0.91	0.55	0.56	NA	NA	0.05	1.51	1.52	NA	NA	000
91030	26	A	Acid perfusion of esophagus	0.91	0.33	0.34	0.33	0.34	0.03	1.27	1.28	1.27	1.28	000
91030	TC	A	Acid perfusion of esophagus	0.00	0.22	0.22	NA	NA	0.02	0.24	0.24	NA	NA	000
91032		A	Esophagus, acid reflux test	1.21	1.18	1.42	NA	NA	0.09	2.48	2.72	NA	NA	000
91032	26	A	Esophagus, acid reflux test	1.21	0.43	0.66	0.43	0.66	0.04	1.68	1.91	1.68	1.91	000
91032	TC	A	Esophagus, acid reflux test	0.00	0.75	0.76	NA	NA	0.05	0.80	0.81	NA	NA	000
91033		A	Prolonged acid reflux test	1.30	1.82	2.10	NA	NA	0.14	3.26	3.54	NA	NA	000
91033	26	A	Prolonged acid reflux test	1.30	0.46	0.73	0.46	0.73	0.05	1.81	2.08	1.81	2.08	000
91033	TC	A	Prolonged acid reflux test	0.00	1.36	1.37	NA	NA	0.09	1.45	1.46	NA	NA	000
91052		A	Gastric analysis test	0.79	0.62	0.69	NA	NA	0.05	1.46	1.53	NA	NA	000
91052	26	A	Gastric analysis test	0.79	0.28	0.35	0.28	0.35	0.03	1.10	1.17	1.10	1.17	000
91052	TC	A	Gastric analysis test	0.00	0.34	0.34	NA	NA	0.02	0.36	0.36	NA	NA	000
91055		A	Gastric intubation for smear	0.94	0.58	0.65	NA	NA	0.07	1.59	1.66	NA	NA	000
91055	26	A	Gastric intubation for smear	0.94	0.28	0.35	0.28	0.35	0.05	1.27	1.34	1.27	1.34	000
91055	TC	A	Gastric intubation for smear	0.00	0.30	0.30	NA	NA	0.02	0.32	0.32	NA	NA	000
91060		A	Gastric saline load test	0.45	0.37	0.47	NA	NA	0.04	0.86	0.96	NA	NA	000
91060	26	A	Gastric saline load test	0.45	0.15	0.25	0.15	0.25	0.02	0.62	0.72	0.62	0.72	000
91060	TC	A	Gastric saline load test	0.00	0.22	0.22	NA	NA	0.02	0.24	0.24	NA	NA	000
91065		A	Breath hydrogen test	0.20	0.43	0.47	NA	NA	0.03	0.66	0.70	NA	NA	000
91065	26	A	Breath hydrogen test	0.20	0.07	0.11	0.07	0.11	0.01	0.28	0.32	0.28	0.32	000
91065	TC	A	Breath hydrogen test	0.00	0.36	0.36	NA	NA	0.02	0.38	0.38	NA	NA	000
91100		A	Pass intestine bleeding tube	1.08	NA	NA	0.39	0.45	0.07	NA	NA	1.54	1.60	000
91105		A	Gastric intubation treatment	0.37	NA	NA	0.16	0.23	0.02	NA	NA	0.55	0.62	000
91122		A	Anal pressure record	1.77	1.35	1.49	NA	NA	0.18	3.30	3.44	NA	NA	000
91122	26	A	Anal pressure record	1.77	0.64	0.77	0.64	0.77	0.11	2.52	2.65	2.52	2.65	000
91122	TC	A	Anal pressure record	0.00	0.71	0.72	NA	NA	0.07	0.78	0.79	NA	NA	000
91299		C	Gastroenterology procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
91299	26	C	Gastroenterology procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
91299	TC	C	Gastroenterology procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
92002		A	Eye exam, new patient	0.88	1.11	0.97	0.34	0.39	0.03	2.02	1.88	1.25	1.30	XXX
92004		A	Eye exam, new patient	1.67	1.50	1.28	0.68	0.67	0.06	3.23	3.01	2.41	2.40	XXX
92012		A	Eye exam established pat	0.67	1.07	0.92	0.30	0.35	0.02	1.76	1.61	0.99	1.04	XXX
92014		A	Eye exam & treatment	1.10	1.38	1.18	0.48	0.51	0.04	2.52	2.32	1.62	1.65	XXX
92015		N	Refraction	0.38	1.40	1.14	0.15	0.20	0.01	1.79	1.53	0.54	0.59	XXX
92018		A	New eye exam & treatment	1.51	NA	NA	0.69	0.65	0.05	NA	NA	2.25	2.21	XXX
92019		A	Eye exam & treatment	1.31	NA	NA	0.58	0.56	0.05	NA	NA	1.94	1.92	XXX
92020		A	Special eye evaluation	0.37	0.70	0.60	0.17	0.21	0.01	1.08	0.98	0.55	0.59	XXX
92060		A	Special eye evaluation	0.69	1.24	1.04	NA	NA	0.03	1.96	1.76	NA	NA	XXX
92060	26	A	Special eye evaluation	0.69	0.29	0.28	0.29	0.28	0.02	1.00	0.99	1.00	0.99	XXX
92060	TC	A	Special eye evaluation	0.00	0.95	0.76	NA	NA	0.01	0.96	0.77	NA	NA	XXX
92065		A	Orthoptic/pleoptic training	0.37	0.77	0.68	NA	NA	0.02	1.16	1.07	NA	NA	XXX
92065	26	A	Orthoptic/pleoptic training	0.37	0.15	0.17	0.15	0.17	0.01	0.53	0.55	0.53	0.55	XXX
92065	TC	A	Orthoptic/pleoptic training	0.00	0.62	0.51	NA	NA	0.01	0.63	0.52	NA	NA	XXX
92070		A	Fitting of contact lens	0.70	1.04	1.11	0.34	0.58	0.02	1.76	1.83	1.06	1.30	XXX
92081		A	Visual field examination(s)	0.36	1.34	1.10	NA	NA	0.02	1.72	1.48	NA	NA	XXX
92081	26	A	Visual field examination(s)	0.36	0.16	0.17	0.16	0.17	0.01	0.53	0.54	0.53	0.54	XXX
92081	TC	A	Visual field examination(s)	0.00	1.18	0.93	NA	NA	0.01	1.19	0.94	NA	NA	XXX
92082		A	Visual field examination(s)	0.44	1.32	1.12	NA	NA	0.02	1.78	1.58	NA	NA	XXX
92082	26	A	Visual field examination(s)	0.44	0.20	0.23	0.20	0.23	0.01	0.65	0.68	0.65	0.68	XXX
92082	TC	A	Visual field examination(s)	0.00	1.12	0.89	NA	NA	0.01	1.13	0.90	NA	NA	XXX
92083		A	Visual field examination(s)	0.50	1.09	1.04	NA	NA	0.03	1.62	1.57	NA	NA	XXX
92083	26	A	Visual field examination(s)	0.50	0.23	0.32	0.23	0.32	0.02	0.75	0.84	0.75	0.84	XXX
92083	TC	A	Visual field examination(s)	0.00	0.86	0.72	NA	NA	0.01	0.87	0.73	NA	NA	XXX
92100		A	Serial tonometry exam(s)	0.92	0.78	0.65	0.36	0.34	0.03	1.73	1.60	1.31	1.29	XXX
92120		A	Tonography & eye evaluation	0.81	0.76	0.66	0.31	0.32	0.03	1.60	1.50	1.15	1.16	XXX
92130		A	Water provocation tonography	0.81	0.87	0.79	0.32	0.37	0.03	1.71	1.63	1.16	1.21	XXX
92135		A	Opthalmic dx imaging	0.35	1.02	1.02	NA	NA	0.02	1.39	1.39	NA	NA	XXX
92135	26	A	Opthalmic dx imaging	0.35	0.16	0.16	0.16	0.16	0.01	0.52	0.52	0.52	0.52	XXX
92135	TC	A	Opthalmic dx imaging	0.00	0.86	0.86	NA	NA	0.01	0.87	0.87	NA	NA	XXX
92140		A	Glaucoma provocative tests	0.50	0.93	0.78	0.22	0.25	0.02	1.45	1.30	0.74	0.77	XXX
92225		A	Special eye exam, initial	0.38	1.64	1.35	0.16	0.24	0.01	2.03	1.74	0.55	0.63	XXX
92226		A	Special eye exam, subsequent	0.33	1.72	1.40	0.15	0.22	0.01	2.06	1.74	0.49	0.56	XXX
92230		A	Eye exam with photos	0.60	1.26	1.13	0.21	0.35	0.02	1.88	1.75	0.83	0.97	XXX
92235		A	Eye exam with photos	0.81	2.08	1.99	NA	NA	0.08	2.97	2.88	NA	NA	XXX
92235	26	A	Eye exam with photos	0.81	0.39	0.45	0.39	0.45	0.03	1.23	1.29	1.23	1.29	XXX
92235	TC	A	Eye exam with photos	0.00	1.69	1.54	NA	NA	0.05	1.74	1.59	NA	NA	XXX
92240		A	Icg angiography	1.10	2.72	2.47	NA	NA	0.08	3.90	3.65	NA	NA	XXX
92240	26	A	Icg angiography	1.10	0.53	0.56	0.53	0.56	0.03	1.66	1.69	1.66	1.69	XXX
92240	TC	A	Icg angiography	0.00	2.19	1.91	NA	NA	0.05	2.24	1.96	NA	NA	XXX
92250		A	Eye exam with photos	0.44	1.73	1.41	NA	NA	0.02	2.19	1.87	NA	NA	XXX
92250	26	A	Eye exam with photos	0.44	0.20	0.22	0.20	0.22	0.01	0.65	0.67	0.65	0.67	XXX
92250	TC	A	Eye exam with photos	0.00	1.53	1.19	NA	NA	0.01	1.54	1.20	NA	NA	XXX
92260		A	Ophthalmoscopy/dynamometry	0.20	0.21	0.31	0.09	0.22	0.01	0.42	0.52	0.30	0.43	XXX
92265		A	Eye muscle evaluation	0.81	1.89	1.50	NA	NA	0.05	2.75	2.36	NA	NA	XXX
92265	26	A	Eye muscle evaluation	0.81	0.31	0.25	0.31	0.25	0.03	1.15	1.09	1.15	1.09	XXX
92265	TC	A	Eye muscle evaluation	0.00	1.58	1.25	NA	NA	0.02	1.60	1.27	NA	NA	XXX
92270		A	Electro-oculography	0.81	1.37	1.22	NA	NA	0.05	2.23	2.08	NA	NA	XXX
92270	26	A	Electro-oculography	0.81	0.34	0.36	0.34	0.36	0.03	1.18	1.20	1.18	1.20	XXX
92270	TC	A	Electro-oculography	0.00	1.03	0.86	NA	NA	0.02	1.05	0.88	NA	NA	XXX
92275		A	Electroretinography	1.01	1.12	1.09	NA	NA	0.06	2.19	2.16	NA	NA	XXX
92275	26	A	Electroretinography	1.01	0.44	0.47	0.44	0.47	0.04	1.49	1.52	1.49	1.52	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
92275	TC	A	Electroretinography	0.00	0.68	0.62	NA	NA	0.02	0.70	0.64	NA	NA	XXX
92283		A	Color vision examination	0.17	0.86	0.73	NA	NA	0.02	1.05	0.92	NA	NA	XXX
92283	26	A	Color vision examination	0.17	0.08	0.11	0.08	0.11	0.01	0.26	0.29	0.26	0.29	XXX
92283	TC	A	Color vision examination	0.00	0.78	0.62	NA	NA	0.01	0.79	0.63	NA	NA	XXX
92284		A	Dark adaptation eye exam	0.24	1.50	1.24	NA	NA	0.02	1.76	1.50	NA	NA	XXX
92284	26	A	Dark adaptation eye exam	0.24	0.09	0.14	0.09	0.14	0.01	0.34	0.39	0.34	0.39	XXX
92284	TC	A	Dark adaptation eye exam	0.00	1.41	1.10	NA	NA	0.01	1.42	1.11	NA	NA	XXX
92285		A	Eye photography	0.20	1.90	1.51	NA	NA	0.02	2.12	1.73	NA	NA	XXX
92285	26	A	Eye photography	0.20	0.09	0.12	0.09	0.12	0.01	0.30	0.33	0.30	0.33	XXX
92285	TC	A	Eye photography	0.00	1.81	1.39	NA	NA	0.01	1.82	1.40	NA	NA	XXX
92286		A	Internal eye photography	0.66	1.95	1.80	NA	NA	0.04	2.65	2.50	NA	NA	XXX
92286	26	A	Internal eye photography	0.66	0.31	0.46	0.31	0.46	0.02	0.99	1.14	0.99	1.14	XXX
92286	TC	A	Internal eye photography	0.00	1.64	1.34	NA	NA	0.02	1.66	1.36	NA	NA	XXX
92287		A	Internal eye photography	0.81	1.84	1.79	0.36	0.68	0.03	2.68	2.63	1.20	1.52	XXX
92310		N	Contact lens fitting	1.17	0.90	1.03	0.46	0.70	0.00	2.07	2.20	1.63	1.87	XXX
92311		A	Contact lens fitting	1.08	0.92	0.94	0.39	0.54	0.04	2.04	2.06	1.51	1.66	XXX
92312		A	Contact lens fitting	1.26	0.91	1.00	0.63	0.79	0.04	2.21	2.30	1.93	2.09	XXX
92313		A	Contact lens fitting	0.92	0.84	0.87	0.27	0.44	0.03	1.79	1.82	1.22	1.39	XXX
92314		N	Prescription of contact lens	0.69	0.70	0.73	0.27	0.41	0.00	1.39	1.42	0.96	1.10	XXX
92315		A	Prescription of contact lens	0.45	0.63	0.65	0.18	0.32	0.02	1.10	1.12	0.65	0.79	XXX
92316		A	Prescription of contact lens	0.68	0.71	0.79	0.27	0.46	0.02	1.41	1.49	0.97	1.16	XXX
92317		A	Prescription of contact lens	0.45	0.79	0.70	0.18	0.24	0.01	1.25	1.16	0.64	0.70	XXX
92325		A	Modification of contact lens	0.00	0.30	0.33	0.12	0.19	0.01	0.31	0.34	0.13	0.20	XXX
92326		A	Replacement of contact lens	0.00	0.31	0.66	0.12	0.51	0.05	0.36	0.71	0.17	0.56	XXX
92330		A	Fitting of artificial eye	1.08	0.75	0.87	0.28	0.52	0.04	1.87	1.99	1.40	1.64	XXX
92335		A	Fitting of artificial eye	0.45	0.73	1.08	0.18	0.67	0.02	1.20	1.55	0.65	1.14	XXX
92340		N	Fitting of spectacles	0.37	0.52	0.51	0.15	0.23	0.00	0.89	0.88	0.52	0.60	XXX
92341		N	Fitting of spectacles	0.47	0.56	0.57	0.19	0.29	0.00	1.03	1.04	0.66	0.76	XXX
92342		N	Fitting of spectacles	0.53	0.58	0.60	0.21	0.32	0.00	1.11	1.13	0.74	0.85	XXX
92352		B	Special spectacles fitting	0.37	0.52	0.47	0.15	0.20	0.01	0.90	0.85	0.53	0.58	XXX
92353		B	Special spectacles fitting	0.50	0.57	0.54	0.20	0.26	0.02	1.09	1.06	0.72	0.78	XXX
92354		B	Special spectacles fitting	0.00	0.43	2.61	0.16	2.41	0.08	0.51	2.69	0.24	2.49	XXX
92355		B	Special spectacles fitting	0.00	0.43	1.44	0.16	1.24	0.01	0.44	1.45	0.17	1.25	XXX
92358		B	Eye prosthesis service	0.00	0.28	0.46	0.10	0.33	0.04	0.32	0.50	0.14	0.37	XXX
92370		N	Repair & adjust spectacles	0.32	0.41	0.41	0.13	0.20	0.00	0.73	0.73	0.45	0.52	XXX
92371		B	Repair & adjust spectacles	0.00	0.28	0.37	0.10	0.24	0.02	0.30	0.39	0.12	0.26	XXX
92390		N	Supply of spectacles	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92391		N	Supply of contact lenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92392		I	Supply of low vision aids	0.00	0.28	1.26	0.10	1.12	0.02	0.30	1.28	0.12	1.14	XXX
92393		I	Supply of artificial eye	0.00	0.28	3.46	0.10	3.32	0.48	0.76	3.94	0.58	3.80	XXX
92395		I	Supply of spectacles	0.00	0.28	0.57	0.10	0.43	0.08	0.36	0.65	0.18	0.51	XXX
92396		I	Supply of contact lenses	0.00	0.28	0.81	0.10	0.67	0.06	0.34	0.87	0.16	0.73	XXX
92499		C	Eye service or procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
92499	26	C	Eye service or procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92499	TC	C	Eye service or procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
92502		A	Ear and throat examination	1.51	NA	NA	1.16	1.18	0.05	NA	NA	2.72	2.74	000
92504		A	Ear microscopy examination	0.18	0.81	0.68	0.09	0.14	0.01	1.00	0.87	0.28	0.33	XXX
92506		A	Speech/hearing evaluation	0.86	1.20	1.04	0.40	0.44	0.03	2.09	1.93	1.29	1.33	XXX
92507		A	Speech/hearing therapy	0.52	1.11	0.92	0.25	0.28	0.02	1.65	1.46	0.79	0.82	XXX
92508		A	Speech/hearing therapy	0.26	0.94	0.76	0.15	0.16	0.01	1.21	1.03	0.42	0.43	XXX
92510		A	Rehab for ear implant	1.50	1.59	1.56	0.65	0.86	0.05	3.14	3.11	2.20	2.41	XXX
92511		A	Nasopharyngoscopy	0.84	1.04	1.01	0.42	0.55	0.03	1.91	1.88	1.29	1.42	000
92512		A	Nasal function studies	0.55	0.88	0.79	0.25	0.32	0.02	1.45	1.36	0.82	0.89	XXX
92516		A	Facial nerve function test	0.43	0.74	0.66	0.22	0.27	0.01	1.18	1.10	0.66	0.71	XXX
92520		A	Laryngeal function studies	0.76	0.51	0.53	0.43	0.47	0.03	1.30	1.32	1.22	1.26	XXX
92525		A	Oral function evaluation	1.50	1.76	1.60	0.74	0.83	0.05	3.31	3.15	2.29	2.38	XXX
92526		A	Oral function therapy	0.55	1.39	1.17	0.21	0.29	0.02	1.96	1.74	0.78	0.86	XXX
92531		B	Spontaneous nystagmus study	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92532		B	Positional nystagmus study	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92533		B	Caloric vestibular test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92534		B	Optokinetic nystagmus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92541		A	Spontaneous nystagmus test	0.40	0.42	0.50	NA	NA	0.03	0.85	0.93	NA	NA	XXX
92541	26	A	Spontaneous nystagmus test	0.40	0.19	0.27	0.19	0.27	0.01	0.60	0.68	0.60	0.68	XXX
92541	TC	A	Spontaneous nystagmus test	0.00	0.23	0.23	NA	NA	0.02	0.25	0.25	NA	NA	XXX
92542		A	Positional nystagmus test	0.33	0.42	0.48	NA	NA	0.03	0.78	0.84	NA	NA	XXX
92542	26	A	Positional nystagmus test	0.33	0.16	0.22	0.16	0.22	0.01	0.50	0.56	0.50	0.56	XXX
92542	TC	A	Positional nystagmus test	0.00	0.26	0.26	NA	NA	0.02	0.28	0.28	NA	NA	XXX
92543		A	Caloric vestibular test	0.10	0.16	0.18	NA	NA	0.02	0.28	0.30	NA	NA	XXX
92543	26	A	Caloric vestibular test	0.10	0.05	0.07	0.05	0.07	0.01	0.16	0.18	0.16	0.18	XXX
92543	TC	A	Caloric vestibular test	0.00	0.11	0.11	NA	NA	0.01	0.12	0.12	NA	NA	XXX
92544		A	Optokinetic nystagmus test	0.26	0.34	0.38	NA	NA	0.03	0.63	0.67	NA	NA	XXX
92544	26	A	Optokinetic nystagmus test	0.26	0.12	0.16	0.12	0.16	0.01	0.39	0.43	0.39	0.43	XXX
92544	TC	A	Optokinetic nystagmus test	0.00	0.22	0.22	NA	NA	0.02	0.24	0.24	NA	NA	XXX
92545		A	Oscillating tracking test	0.23	0.33	0.36	NA	NA	0.03	0.59	0.62	NA	NA	XXX
92545	26	A	Oscillating tracking test	0.23	0.11	0.14	0.11	0.14	0.01	0.35	0.38	0.35	0.38	XXX
92545	TC	A	Oscillating tracking test	0.00	0.22	0.22	NA	NA	0.02	0.24	0.24	NA	NA	XXX
92546		A	Sinusoidal rotational test	0.29	0.37	0.42	NA	NA	0.03	0.69	0.74	NA	NA	XXX
92546	26	A	Sinusoidal rotational test	0.29	0.13	0.18	0.13	0.18	0.01	0.43	0.48	0.43	0.48	XXX
92546	TC	A	Sinusoidal rotational test	0.00	0.24	0.24	NA	NA	0.02	0.26	0.26	NA	NA	XXX
92547		A	Supplemental electrical test	0.00	0.57	0.57	NA	NA	0.05	0.62	0.62	NA	NA	ZZZ
92548		A	Posturography	0.50	1.75	1.82	NA	NA	0.13	2.38	2.45	NA	NA	XXX
92548	26	A	Posturography	0.50	0.26	0.32	0.26	0.32	0.02	0.78	0.84	0.78	0.84	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
92548	TC	A	Posturography	0.00	1.49	1.50	NA	NA	0.11	1.60	1.61	NA	NA	XXX
92551		N	Pure tone hearing test, air	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92552		A	Pure tone audiometry, air	0.00	0.45	0.45	NA	NA	0.03	0.48	0.48	NA	NA	XXX
92553		A	Audiometry, air & bone	0.00	0.66	0.67	NA	NA	0.05	0.71	0.72	NA	NA	XXX
92555		A	Speech threshold audiometry	0.00	0.38	0.38	NA	NA	0.03	0.41	0.41	NA	NA	XXX
92556		A	Speech audiometry, complete	0.00	0.58	0.58	NA	NA	0.05	0.63	0.63	NA	NA	XXX
92557		A	Comprehensive hearing test	0.00	1.20	1.21	NA	NA	0.10	1.30	1.31	NA	NA	XXX
92559		N	Group audiometric testing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92560		N	Bekesy audiometry, screen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92561		A	Bekesy audiometry, diagnosis	0.00	0.72	0.73	NA	NA	0.05	0.77	0.78	NA	NA	XXX
92562		A	Loudness balance test	0.00	0.41	0.41	NA	NA	0.03	0.44	0.44	NA	NA	XXX
92563		A	Tone decay hearing test	0.00	0.38	0.38	NA	NA	0.03	0.41	0.41	NA	NA	XXX
92564		A	Sisi hearing test	0.00	0.48	0.48	NA	NA	0.04	0.52	0.52	NA	NA	XXX
92565		A	Stenger test, pure tone	0.00	0.40	0.40	NA	NA	0.03	0.43	0.43	NA	NA	XXX
92567		A	Tympanometry	0.00	0.53	0.53	NA	NA	0.05	0.58	0.58	NA	NA	XXX
92568		A	Acoustic reflex testing	0.00	0.38	0.38	NA	NA	0.03	0.41	0.41	NA	NA	XXX
92569		A	Acoustic reflex decay test	0.00	0.41	0.41	NA	NA	0.03	0.44	0.44	NA	NA	XXX
92571		A	Filtered speech hearing test	0.00	0.39	0.39	NA	NA	0.03	0.42	0.42	NA	NA	XXX
92572		A	Staggered spondaic word test	0.00	0.09	0.09	NA	NA	0.01	0.10	0.10	NA	NA	XXX
92573		A	Lombard test	0.00	0.35	0.35	NA	NA	0.03	0.38	0.38	NA	NA	XXX
92575		A	Sensorineural acuity test	0.00	0.30	0.30	NA	NA	0.02	0.32	0.32	NA	NA	XXX
92576		A	Synthetic sentence test	0.00	0.45	0.45	NA	NA	0.04	0.49	0.49	NA	NA	XXX
92577		A	Stenger test, speech	0.00	0.72	0.73	NA	NA	0.06	0.78	0.79	NA	NA	XXX
92579		A	Visual audiometry (vra)	0.00	0.73	0.74	NA	NA	0.05	0.78	0.79	NA	NA	XXX
92582		A	Conditioning play audiometry	0.00	0.73	0.74	NA	NA	0.05	0.78	0.79	NA	NA	XXX
92583		A	Select picture audiometry	0.00	0.90	0.91	NA	NA	0.07	0.97	0.98	NA	NA	XXX
92584		A	Electrocochleography	0.00	2.50	2.52	NA	NA	0.18	2.68	2.70	NA	NA	XXX
92585		A	Auditory evoked potential	0.50	2.09	2.45	NA	NA	0.14	2.73	3.09	NA	NA	XXX
92585	26	A	Auditory evoked potential	0.50	0.22	0.57	0.22	0.57	0.02	0.74	1.09	0.74	1.09	XXX
92585	TC	A	Auditory evoked potential	0.00	1.87	1.88	NA	NA	0.12	1.99	2.00	NA	NA	XXX
92587		A	Evoked auditory test	0.13	1.38	1.41	NA	NA	0.10	1.61	1.64	NA	NA	XXX
92587	26	A	Evoked auditory test	0.13	0.06	0.08	0.06	0.08	0.01	0.20	0.22	0.20	0.22	XXX
92587	TC	A	Evoked auditory test	0.00	1.32	1.33	NA	NA	0.09	1.41	1.42	NA	NA	XXX
92588		A	Evoked auditory test	0.36	1.65	1.70	NA	NA	0.12	2.13	2.18	NA	NA	XXX
92588	26	A	Evoked auditory test	0.36	0.16	0.20	0.16	0.20	0.01	0.53	0.57	0.53	0.57	XXX
92588	TC	A	Evoked auditory test	0.00	1.49	1.50	NA	NA	0.11	1.60	1.61	NA	NA	XXX
92589		A	Auditory function test(s)	0.00	0.54	0.54	NA	NA	0.05	0.59	0.59	NA	NA	XXX
92590		N	Hearing aid exam, one ear	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92591		N	Hearing aid exam, both ears	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92592		N	Hearing aid check, one ear	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92593		N	Hearing aid check, both ears	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92594		N	Electro hearng aid test, one	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92595		N	Electro hearng aid tst, both	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92596		A	Ear protector evaluation	0.00	0.60	0.60	NA	NA	0.05	0.65	0.65	NA	NA	XXX
92597		A	Oral speech device eval	1.35	1.48	1.39	0.73	0.82	0.04	2.87	2.78	2.12	2.21	XXX
92598		A	Modify oral speech device	0.99	0.85	0.82	0.51	0.56	0.03	1.87	1.84	1.53	1.58	XXX
92599		C	ENT procedure/service	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
92599	26	C	ENT procedure/service	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
92599	TC	C	ENT procedure/service	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
92950		A	Heart/lung resuscitation cpr	3.80	1.57	1.79	1.11	1.45	0.21	5.58	5.80	5.12	5.46	000
92953		A	Temporary external pacing	0.23	NA	NA	0.19	0.21	0.01	NA	NA	0.43	0.45	000
92960		A	Cardioversion electric, ext	2.25	2.03	2.03	0.90	1.19	0.08	4.36	4.36	3.23	3.52	000
92961		A	Cardioversion, electric, int	4.60	NA	NA	1.92	1.92	0.31	NA	NA	6.83	6.83	000
92970		A	Cardioassist, internal	3.52	NA	NA	1.09	1.76	0.17	NA	NA	4.78	5.45	000
92971		A	Cardioassist, external	1.77	NA	NA	0.89	0.97	0.06	NA	NA	2.72	2.80	000
92975		A	Dissolve clot, heart vessel	7.25	NA	NA	3.08	3.86	0.22	NA	NA	10.55	11.33	000
92977		A	Dissolve clot, heart vessel	0.00	NA	NA	8.14	8.19	0.39	NA	NA	8.53	8.58	XXX
92978		A	Intravasc us, heart add-on	1.80	5.37	5.50	NA	NA	0.27	7.44	7.57	NA	NA	ZZZ
92978	26	A	Intravasc us, heart add-on	1.80	0.76	0.86	0.76	0.86	0.06	2.62	2.72	2.62	2.72	ZZZ
92978	TC	A	Intravasc us, heart add-on	0.00	4.61	4.64	NA	NA	0.21	4.82	4.85	NA	NA	ZZZ
92979		A	Intravasc us, heart add-on	1.44	2.93	3.02	NA	NA	0.15	4.52	4.61	NA	NA	ZZZ
92979	26	A	Intravasc us, heart add-on	1.44	0.61	0.69	0.61	0.69	0.04	2.09	2.17	2.09	2.17	ZZZ
92979	TC	A	Intravasc us, heart add-on	0.00	2.32	2.33	NA	NA	0.11	2.43	2.44	NA	NA	ZZZ
92980		A	Insert intracoronary stent	14.84	NA	NA	6.33	9.18	0.02	NA	NA	21.19	24.04	000
92981		A	Insert intracoronary stent	4.17	NA	NA	1.77	2.57	0.56	NA	NA	6.50	7.30	ZZZ
92982		A	Coronary artery dilation	10.98	NA	NA	4.70	6.80	1.48	NA	NA	17.16	19.26	000
92984		A	Coronary artery dilation	2.97	NA	NA	1.26	1.83	0.40	NA	NA	4.63	5.20	ZZZ
92986		A	Revision of aortic valve	21.80	NA	NA	10.87	11.42	2.82	NA	NA	35.49	36.04	090
92987		A	Revision of mitral valve	22.70	NA	NA	11.23	11.73	2.99	NA	NA	36.92	37.42	090
92990		A	Revision of pulmonary valve	17.34	NA	NA	8.47	8.96	1.90	NA	NA	27.71	28.20	090
92992		C	Revision of heart chamber	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	090
92993		C	Revision of heart chamber	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	090
92995		A	Coronary atherectomy	12.09	NA	NA	5.16	7.48	1.63	NA	NA	18.88	21.20	000
92996		A	Coronary atherectomy add-on	3.26	NA	NA	1.43	2.05	0.44	NA	NA	5.13	5.75	ZZZ
92997		A	Pul art balloon repr, percut	0.12	NA	NA	5.12	7.42	1.45	NA	NA	6.69	8.99	000
92998		A	Pul art balloon repr, percut	0.06	NA	NA	2.48	2.89	0.73	NA	NA	3.27	3.68	ZZZ
93000		A	Electrocardiogram, complete	0.17	0.53	0.56	NA	NA	0.03	0.73	0.76	NA	NA	XXX
93005		A	Electrocardiogram, tracing	0.00	0.46	0.46	NA	NA	0.02	0.48	0.48	NA	NA	XXX
93010		A	Electrocardiogram report	0.17	0.07	0.10	0.07	0.10	0.01	0.25	0.28	0.25	0.28	XXX
93012		A	Transmission of ecg	0.00	2.39	2.40	NA	NA	0.15	2.54	2.55	NA	NA	XXX
93014		A	Report on transmitted ecg	0.52	0.20	0.26	0.20	0.26	0.02	0.74	0.80	0.74	0.80	XXX
93015		A	Cardiovascular stress test	0.75	2.00	2.13	NA	NA	0.11	2.86	2.99	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
93016	.....	A	Cardiovascular stress test	0.45	0.18	0.24	0.18	0.24	0.01	0.64	0.70	0.64	0.70	XXX
93017	.....	A	Cardiovascular stress test	0.00	1.70	1.71	NA	NA	0.09	1.79	1.80	NA	NA	XXX
93018	.....	A	Cardiovascular stress test	0.30	0.12	0.18	0.12	0.18	0.01	0.43	0.49	0.43	0.49	XXX
93024	.....	A	Cardiac drug stress test	1.17	1.61	1.85	NA	NA	0.11	2.89	3.13	NA	NA	XXX
93024	26	A	Cardiac drug stress test	1.17	0.48	0.71	0.48	0.71	0.04	1.69	1.92	1.69	1.92	XXX
93024	TC	A	Cardiac drug stress test	0.00	1.13	1.14	NA	NA	0.07	1.20	1.21	NA	NA	XXX
93040	.....	A	Rhythm ECG with report	0.16	0.20	0.22	NA	NA	0.02	0.38	0.40	NA	NA	XXX
93041	.....	A	Rhythm ECG, tracing	0.00	0.15	0.15	NA	NA	0.01	0.16	0.16	NA	NA	XXX
93042	.....	A	Rhythm ECG, report	0.16	0.05	0.07	0.05	0.07	0.01	0.22	0.24	0.22	0.24	XXX
93224	.....	A	ECG monitor/report, 24 hrs	0.52	3.67	3.79	NA	NA	0.21	4.40	4.52	NA	NA	XXX
93225	.....	A	ECG monitor/record, 24 hrs	0.00	1.25	1.26	NA	NA	0.07	1.32	1.33	NA	NA	XXX
93226	.....	A	ECG monitor/report, 24 hrs	0.00	2.21	2.22	NA	NA	0.12	2.33	2.34	NA	NA	XXX
93227	.....	A	ECG monitor/review, 24 hrs	0.52	0.21	0.31	0.21	0.31	0.02	0.75	0.85	0.75	0.85	XXX
93230	.....	A	ECG monitor/report, 24 hrs	0.52	3.94	4.06	NA	NA	0.22	4.68	4.80	NA	NA	XXX
93231	.....	A	Ecg monitor/record, 24 hrs	0.00	1.53	1.54	NA	NA	0.09	1.62	1.63	NA	NA	XXX
93232	.....	A	ECG monitor/report, 24 hrs	0.00	2.20	2.21	NA	NA	0.11	2.31	2.32	NA	NA	XXX
93233	.....	A	ECG monitor/review, 24 hrs	0.52	0.21	0.31	0.21	0.31	0.02	0.75	0.85	0.75	0.85	XXX
93235	.....	A	ECG monitor/report, 24 hrs	0.45	2.83	2.94	NA	NA	0.13	3.41	3.52	NA	NA	XXX
93236	.....	A	ECG monitor/report, 24 hrs	0.00	2.65	2.67	NA	NA	0.12	2.77	2.79	NA	NA	XXX
93237	.....	A	ECG monitor/review, 24 hrs	0.45	0.18	0.27	0.18	0.27	0.01	0.64	0.73	0.64	0.73	XXX
93268	.....	A	ECG record/review	0.52	3.84	3.92	NA	NA	0.24	4.60	4.68	NA	NA	XXX
93270	.....	A	ECG recording	0.00	1.25	1.26	NA	NA	0.07	1.32	1.33	NA	NA	XXX
93271	.....	A	Ecg/monitoring and analysis	0.00	2.39	2.40	NA	NA	0.15	2.54	2.55	NA	NA	XXX
93272	.....	A	Ecg/review,interpret only	0.52	0.20	0.26	0.20	0.26	0.02	0.74	0.80	0.74	0.80	XXX
93278	.....	A	ECG/signal-averaged	0.25	1.26	1.32	NA	NA	0.10	1.61	1.67	NA	NA	XXX
93278	26	A	ECG/signal-averaged	0.25	0.10	0.15	0.10	0.15	0.01	0.36	0.41	0.36	0.41	XXX
93278	TC	A	ECG/signal-averaged	0.00	1.16	1.17	NA	NA	0.09	1.25	1.26	NA	NA	XXX
93303	.....	A	Echo transthoracic	1.30	4.40	4.57	NA	NA	0.24	5.94	6.11	NA	NA	XXX
93303	26	A	Echo transthoracic	1.30	0.50	0.65	0.50	0.65	0.04	1.84	1.99	1.84	1.99	XXX
93303	TC	A	Echo transthoracic	0.00	3.90	3.92	NA	NA	0.20	4.10	4.12	NA	NA	XXX
93304	.....	A	Echo transthoracic	0.75	2.25	2.37	NA	NA	0.13	3.13	3.25	NA	NA	XXX
93304	26	A	Echo transthoracic	0.75	0.29	0.40	0.29	0.40	0.02	1.06	1.17	1.06	1.17	XXX
93304	TC	A	Echo transthoracic	0.00	1.96	1.97	NA	NA	0.11	2.07	2.08	NA	NA	XXX
93307	.....	A	Echo exam of heart	0.92	4.28	4.48	NA	NA	0.23	5.43	5.63	NA	NA	XXX
93307	26	A	Echo exam of heart	0.92	0.38	0.56	0.38	0.56	0.03	1.33	1.51	1.33	1.51	XXX
93307	TC	A	Echo exam of heart	0.00	3.90	3.92	NA	NA	0.20	4.10	4.12	NA	NA	XXX
93308	.....	A	Echo exam of heart	0.53	2.18	2.29	NA	NA	0.13	2.84	2.95	NA	NA	XXX
93308	26	A	Echo exam of heart	0.53	0.22	0.32	0.22	0.32	0.02	0.77	0.87	0.77	0.87	XXX
93308	TC	A	Echo exam of heart	0.00	1.96	1.97	NA	NA	0.11	2.07	2.08	NA	NA	XXX
93312	.....	A	Echo transesophageal	2.20	4.69	4.86	NA	NA	0.34	7.23	7.40	NA	NA	XXX
93312	26	A	Echo transesophageal	2.20	0.87	1.02	0.87	1.02	0.09	3.16	3.31	3.16	3.31	XXX
93312	TC	A	Echo transesophageal	0.00	3.82	3.84	NA	NA	0.25	4.07	4.09	NA	NA	XXX
93313	.....	A	Echo transesophageal	0.95	5.13	4.03	0.23	0.36	0.05	6.13	5.03	1.23	1.36	XXX
93314	.....	A	Echo transesophageal	1.25	4.32	4.40	NA	NA	0.29	5.86	5.94	NA	NA	XXX
93314	26	A	Echo transesophageal	1.25	0.50	0.56	0.50	0.56	0.04	1.79	1.85	1.79	1.85	XXX
93314	TC	A	Echo transesophageal	0.00	3.82	3.84	NA	NA	0.25	4.07	4.09	NA	NA	XXX
93315	.....	A	Echo transesophageal	2.78	4.90	5.02	NA	NA	0.36	8.04	8.16	NA	NA	XXX
93315	26	A	Echo transesophageal	2.78	1.08	1.18	1.08	1.18	0.11	3.97	4.07	3.97	4.07	XXX
93315	TC	A	Echo transesophageal	0.00	3.82	3.84	NA	NA	0.25	4.07	4.09	NA	NA	XXX
93316	.....	A	Echo transesophageal	0.95	1.66	1.43	0.28	0.39	0.05	2.66	2.43	1.28	1.39	XXX
93317	.....	A	Echo transesophageal	1.83	4.54	4.56	NA	NA	0.32	6.69	6.71	NA	NA	XXX
93317	26	A	Echo transesophageal	1.83	0.72	0.72	0.72	0.72	0.07	2.62	2.62	2.62	2.62	XXX
93317	TC	A	Echo transesophageal	0.00	3.82	3.84	NA	NA	0.25	4.07	4.09	NA	NA	XXX
93320	.....	A	Doppler echo exam, heart	0.38	1.89	1.98	NA	NA	0.11	2.38	2.47	NA	NA	ZZZ
93320	26	A	Doppler echo exam, heart	0.38	0.16	0.24	0.16	0.24	0.01	0.55	0.63	0.55	0.63	ZZZ
93320	TC	A	Doppler echo exam, heart	0.00	1.73	1.74	NA	NA	0.10	1.83	1.84	NA	NA	ZZZ
93321	.....	A	Doppler echo exam, heart	0.15	1.18	1.22	NA	NA	0.08	1.41	1.45	NA	NA	ZZZ
93321	26	A	Doppler echo exam, heart	0.15	0.06	0.09	0.06	0.09	0.01	0.22	0.25	0.22	0.25	ZZZ
93321	TC	A	Doppler echo exam, heart	0.00	1.12	1.13	NA	NA	0.07	1.19	1.20	NA	NA	ZZZ
93325	.....	A	Doppler color flow add-on	0.07	2.96	2.98	NA	NA	0.19	3.22	3.24	NA	NA	ZZZ
93325	26	A	Doppler color flow add-on	0.07	0.03	0.03	0.03	0.03	0.01	0.11	0.11	0.11	0.11	ZZZ
93325	TC	A	Doppler color flow add-on	0.00	2.93	2.95	NA	NA	0.18	3.11	3.13	NA	NA	ZZZ
93350	.....	A	Echo transthoracic	0.78	2.10	2.26	NA	NA	0.13	3.01	3.17	NA	NA	XXX
93350	26	A	Echo transthoracic	0.78	0.32	0.47	0.32	0.47	0.02	1.12	1.27	1.12	1.27	XXX
93350	TC	A	Echo transthoracic	0.00	1.78	1.79	NA	NA	0.11	1.89	1.90	NA	NA	XXX
93501	.....	A	Right heart catheterization	3.02	17.58	18.46	NA	NA	1.27	21.87	22.75	NA	NA	000
93501	26	A	Right heart catheterization	3.02	1.24	1.83	1.24	1.83	0.37	4.63	5.22	4.63	5.22	000
93501	TC	A	Right heart catheterization	0.00	16.34	16.63	NA	NA	0.90	17.24	17.53	NA	NA	000
93503	.....	A	Insert/place heart catheter	2.91	1.03	1.42	0.76	1.21	0.22	4.16	4.55	3.89	4.34	000
93505	.....	A	Biopsy of heart lining	4.38	3.74	4.15	NA	NA	0.70	8.82	9.23	NA	NA	000
93505	26	A	Biopsy of heart lining	4.38	1.83	2.20	1.83	2.20	0.57	6.78	7.15	6.78	7.15	000
93505	TC	A	Biopsy of heart lining	0.00	1.91	1.95	NA	NA	0.13	2.04	2.08	NA	NA	000
93508	.....	A	Cath placement, angiography	4.10	13.90	14.44	NA	NA	1.11	19.11	19.65	NA	NA	000
93508	26	A	Cath placement, angiography	4.10	1.72	2.05	1.72	2.05	0.55	6.37	6.70	6.37	6.70	000
93508	TC	A	Cath placement, angiography	0.00	12.18	12.39	NA	NA	0.56	12.74	12.95	NA	NA	000
93510	.....	A	Left heart catheterization	4.33	37.53	38.53	NA	NA	2.55	44.41	45.41	NA	NA	000
93510	26	A	Left heart catheterization	4.33	1.83	2.20	1.83	2.20	0.58	6.74	7.11	6.74	7.11	000
93510	TC	A	Left heart catheterization	0.00	35.70	36.33	NA	NA	1.97	37.67	38.30	NA	NA	000
93511	.....	A	Left heart catheterization	5.03	36.87	37.67	NA	NA	2.59	44.49	45.29	NA	NA	000
93511	26	A	Left heart catheterization	5.03	2.12	2.30	2.12	2.30	0.68	7.83	8.01	7.83	8.01	000
93511	TC	A	Left heart catheterization	0.00	34.75	35.37	NA	NA	1.91	36.66	37.28	NA	NA	000
93514	.....	A	Left heart catheterization	7.05	37.65	38.78	NA	NA	2.87	47.57	48.70	NA	NA	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
93514	26	A	Left heart catheterization	7.05	2.90	3.41	2.90	3.41	0.96	10.91	11.42	10.91	11.42	000
93514	TC	A	Left heart catheterization	0.00	34.75	35.37	NA	NA	1.91	36.66	37.28	NA	NA	000
93524		A	Left heart catheterization	6.95	48.31	49.66	NA	NA	3.45	58.71	60.06	NA	NA	000
93524	26	A	Left heart catheterization	6.95	2.91	3.45	2.91	3.45	0.95	10.81	11.35	10.81	11.35	000
93524	TC	A	Left heart catheterization	0.00	45.40	46.21	NA	NA	2.50	47.90	48.71	NA	NA	000
93526		A	Rt & Lt heart catheters	5.99	49.17	50.85	NA	NA	3.37	58.53	60.21	NA	NA	000
93526	26	A	Rt & Lt heart catheters	5.99	2.52	3.37	2.52	3.37	0.80	9.31	10.16	9.31	10.16	000
93526	TC	A	Rt & Lt heart catheters	0.00	46.65	47.48	NA	NA	2.57	49.22	50.05	NA	NA	000
93527		A	Rt & Lt heart catheters	7.28	48.47	50.45	NA	NA	3.47	59.22	61.20	NA	NA	000
93527	26	A	Rt & Lt heart catheters	7.28	3.07	4.24	3.07	4.24	0.97	11.32	12.49	11.32	12.49	000
93527	TC	A	Rt & Lt heart catheters	0.00	45.40	46.21	NA	NA	2.50	47.90	48.71	NA	NA	000
93528		A	Rt & Lt heart catheters	0.09	49.24	50.29	NA	NA	3.73	53.06	54.11	NA	NA	000
93528	26	A	Rt & Lt heart catheters	0.09	3.84	4.08	3.84	4.08	1.23	5.16	5.40	5.16	5.40	000
93528	TC	A	Rt & Lt heart catheters	0.00	45.40	46.21	NA	NA	2.50	47.90	48.71	NA	NA	000
93529		A	Rt, Lt heart catheterization	4.80	47.32	48.45	NA	NA	3.08	55.20	56.33	NA	NA	000
93529	26	A	Rt, Lt heart catheterization	4.80	1.92	2.24	1.92	2.24	0.58	7.30	7.62	7.30	7.62	000
93529	TC	A	Rt, Lt heart catheterization	0.00	45.40	46.21	NA	NA	2.50	47.90	48.71	NA	NA	000
93530		A	Rt heart cath, congenital	4.23	18.00	18.86	NA	NA	1.45	23.68	24.54	NA	NA	000
93530	26	A	Rt heart cath, congenital	4.23	1.66	2.23	1.66	2.23	0.55	6.44	7.01	6.44	7.01	000
93530	TC	A	Rt heart cath, congenital	0.00	16.34	16.63	NA	NA	0.90	17.24	17.53	NA	NA	000
93531		A	R & l heart cath, congenital	8.35	50.10	51.55	NA	NA	3.70	62.15	63.60	NA	NA	000
93531	26	A	R & l heart cath, congenital	8.35	3.45	4.07	3.45	4.07	1.13	12.93	13.55	12.93	13.55	000
93531	TC	A	R & l heart cath, congenital	0.00	46.65	47.48	NA	NA	2.57	49.22	50.05	NA	NA	000
93532		A	R & l heart cath, congenital	0.10	49.31	51.08	NA	NA	3.92	53.33	55.10	NA	NA	000
93532	26	A	R & l heart cath, congenital	0.10	3.91	4.87	3.91	4.87	1.42	5.43	6.39	5.43	6.39	000
93532	TC	A	R & l heart cath, congenital	0.00	45.40	46.21	NA	NA	2.50	47.90	48.71	NA	NA	000
93533		A	R & l heart cath, congenital	6.70	47.91	48.89	NA	NA	3.40	58.01	58.99	NA	NA	000
93533	26	A	R & l heart cath, congenital	6.70	2.51	2.68	2.51	2.68	0.90	10.11	10.28	10.11	10.28	000
93533	TC	A	R & l heart cath, congenital	0.00	45.40	46.21	NA	NA	2.50	47.90	48.71	NA	NA	000
93536		A	Insert circulation assi	4.85	NA	NA	2.08	3.01	0.65	NA	NA	7.58	8.51	000
93539		A	Injection, cardiac cath	0.40	0.74	0.80	0.17	0.37	0.01	1.15	1.21	0.58	0.78	000
93540		A	Injection, cardiac cath	0.43	0.77	0.82	0.18	0.38	0.01	1.21	1.26	0.62	0.82	000
93541		A	Injection for lung angiogram	0.29	NA	NA	0.12	0.18	0.01	NA	NA	0.42	0.48	000
93542		A	Injection for heart x-rays	0.29	NA	NA	0.12	0.18	0.01	NA	NA	0.42	0.48	000
93543		A	Injection for heart x-rays	0.29	0.49	0.52	0.12	0.25	0.01	0.79	0.82	0.42	0.55	000
93544		A	Injection for aortography	0.25	0.47	0.51	0.11	0.24	0.01	0.73	0.77	0.37	0.50	000
93545		A	Inject for coronary x-rays	0.40	0.76	0.69	0.17	0.25	0.01	1.17	1.10	0.58	0.66	000
93555		A	Imaging, cardiac cath	0.81	6.40	6.50	NA	NA	0.32	7.53	7.63	NA	NA	XXX
93555	26	A	Imaging, cardiac cath	0.81	0.34	0.33	0.34	0.33	0.03	1.18	1.17	1.18	1.17	XXX
93555	TC	A	Imaging, cardiac cath	0.00	6.06	6.17	NA	NA	0.29	6.35	6.46	NA	NA	XXX
93556		A	Imaging, cardiac cath	0.83	9.91	10.12	NA	NA	0.46	11.20	11.41	NA	NA	XXX
93556	26	A	Imaging, cardiac cath	0.83	0.35	0.39	0.35	0.39	0.03	1.21	1.25	1.21	1.25	XXX
93556	TC	A	Imaging, cardiac cath	0.00	9.56	9.73	NA	NA	0.43	9.99	10.16	NA	NA	XXX
93561		A	Cardiac output measurement	0.50	0.69	0.81	NA	NA	0.07	1.26	1.38	NA	NA	000
93561	26	A	Cardiac output measurement	0.50	0.17	0.28	0.17	0.28	0.02	0.69	0.80	0.69	0.80	000
93561	TC	A	Cardiac output measurement	0.00	0.52	0.53	NA	NA	0.05	0.57	0.58	NA	NA	000
93562		A	Cardiac output measurement	0.16	0.35	0.40	NA	NA	0.04	0.55	0.60	NA	NA	000
93562	26	A	Cardiac output measurement	0.16	0.05	0.09	0.05	0.09	0.01	0.22	0.26	0.22	0.26	000
93562	TC	A	Cardiac output measurement	0.00	0.30	0.31	NA	NA	0.03	0.33	0.34	NA	NA	000
93571		A	Heart flow reserve measure	1.80	5.33	5.36	NA	NA	0.27	7.40	7.43	NA	NA	ZZZ
93571	26	A	Heart flow reserve measure	1.80	0.71	0.71	0.71	0.71	0.06	2.57	2.57	2.57	2.57	ZZZ
93571	TC	A	Heart flow reserve measure	0.00	4.62	4.65	NA	NA	0.21	4.83	4.86	NA	NA	ZZZ
93572		A	Heart flow reserve measure	1.44	5.19	5.22	NA	NA	0.15	6.78	6.81	NA	NA	ZZZ
93572	26	A	Heart flow reserve measure	1.44	0.57	0.57	0.57	0.57	0.04	2.05	2.05	2.05	2.05	ZZZ
93572	TC	A	Heart flow reserve measure	0.00	4.62	4.65	NA	NA	0.11	4.73	4.76	NA	NA	ZZZ
93600		A	Bundle of His recording	2.12	2.87	3.29	NA	NA	0.18	5.17	5.59	NA	NA	000
93600	26	A	Bundle of His recording	2.12	0.90	1.31	0.90	1.31	0.07	3.09	3.50	3.09	3.50	000
93600	TC	A	Bundle of His recording	0.00	1.97	1.98	NA	NA	0.11	2.08	2.09	NA	NA	000
93602		A	Intra-atrial recording	2.12	2.02	2.29	NA	NA	0.15	4.29	4.56	NA	NA	000
93602	26	A	Intra-atrial recording	2.12	0.90	1.16	0.90	1.16	0.09	3.11	3.37	3.11	3.37	000
93602	TC	A	Intra-atrial recording	0.00	1.12	1.13	NA	NA	0.06	1.18	1.19	NA	NA	000
93603		A	Right ventricular recording	2.12	2.60	2.98	NA	NA	0.18	4.90	5.28	NA	NA	000
93603	26	A	Right ventricular recording	2.12	0.90	1.27	0.90	1.27	0.09	3.11	3.48	3.11	3.48	000
93603	TC	A	Right ventricular recording	0.00	1.70	1.71	NA	NA	0.09	1.79	1.80	NA	NA	000
93607		A	Left ventricular recording	3.26	2.91	3.17	NA	NA	0.19	6.36	6.62	NA	NA	000
93607	26	A	Left ventricular recording	3.26	1.40	1.65	1.40	1.65	0.10	4.76	5.01	4.76	5.01	000
93607	TC	A	Left ventricular recording	0.00	1.51	1.52	NA	NA	0.09	1.60	1.61	NA	NA	000
93609		A	Mapping of tachycardia	10.07	6.99	6.99	NA	NA	0.46	17.52	17.52	NA	NA	000
93609	26	A	Mapping of tachycardia	10.07	4.24	4.22	4.24	4.22	0.32	14.63	14.61	14.63	14.61	000
93609	TC	A	Mapping of tachycardia	0.00	2.75	2.77	NA	NA	0.14	2.89	2.91	NA	NA	000
93610		A	Intra-atrial pacing	3.02	2.64	2.96	NA	NA	0.19	5.85	6.17	NA	NA	000
93610	26	A	Intra-atrial pacing	3.02	1.27	1.58	1.27	1.58	0.11	4.40	4.71	4.40	4.71	000
93610	TC	A	Intra-atrial pacing	0.00	1.37	1.38	NA	NA	0.08	1.45	1.46	NA	NA	000
93612		A	Intraventricular pacing	3.02	2.90	3.23	NA	NA	0.21	6.13	6.46	NA	NA	000
93612	26	A	Intraventricular pacing	3.02	1.27	1.59	1.27	1.59	0.12	4.41	4.73	4.41	4.73	000
93612	TC	A	Intraventricular pacing	0.00	1.63	1.64	NA	NA	0.09	1.72	1.73	NA	NA	000
93615		A	Esophageal recording	0.99	0.65	0.66	NA	NA	0.08	1.72	1.73	NA	NA	000
93615	26	A	Esophageal recording	0.99	0.33	0.34	0.33	0.34	0.06	1.38	1.39	1.38	1.39	000
93615	TC	A	Esophageal recording	0.00	0.32	0.32	NA	NA	0.02	0.34	0.34	NA	NA	000
93616		A	Esophageal recording	1.49	0.71	0.98	NA	NA	0.10	2.30	2.57	NA	NA	000
93616	26	A	Esophageal recording	1.49	0.39	0.66	0.39	0.66	0.08	1.96	2.23	1.96	2.23	000
93616	TC	A	Esophageal recording	0.00	0.32	0.32	NA	NA	0.02	0.34	0.34	NA	NA	000

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
93618	.....	A	Heart rhythm pacing	4.26	5.82	6.66	NA	NA	0.33	10.41	11.25	NA	NA	000
93618	26	A	Heart rhythm pacing	4.26	1.81	2.63	1.81	2.63	0.12	6.19	7.01	6.19	7.01	000
93618	TC	A	Heart rhythm pacing	0.00	4.01	4.03	NA	NA	0.21	4.22	4.24	NA	NA	000
93619	.....	A	Electrophysiology evaluation	7.32	10.90	12.36	NA	NA	0.62	18.84	20.30	NA	NA	000
93619	26	A	Electrophysiology evaluation	7.32	3.11	4.52	3.11	4.52	0.22	10.65	12.06	10.65	12.06	000
93619	TC	A	Electrophysiology evaluation	0.00	7.79	7.84	NA	NA	0.40	8.19	8.24	NA	NA	000
93620	.....	A	Electrophysiology evaluation	11.59	13.90	16.20	NA	NA	0.79	26.28	28.58	NA	NA	000
93620	26	A	Electrophysiology evaluation	11.59	4.84	7.09	4.84	7.09	0.34	16.77	19.02	16.77	19.02	000
93620	TC	A	Electrophysiology evaluation	0.00	9.06	9.11	NA	NA	0.45	9.51	9.56	NA	NA	000
93621	.....	C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	000
93621	26	A	Electrophysiology evaluation	12.66	5.37	7.81	5.37	7.81	0.41	18.44	20.88	18.44	20.88	000
93621	TC	C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	000
93622	.....	C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	000
93622	26	A	Electrophysiology evaluation	12.74	5.25	7.74	5.25	7.74	0.39	18.38	20.87	18.38	20.87	000
93622	TC	C	Electrophysiology evaluation	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	000
93623	.....	C	Stimulation, pacing heart	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	ZZZ
93623	26	A	Stimulation, pacing heart	2.85	1.20	1.66	1.20	1.66	0.10	4.15	4.61	4.15	4.61	ZZZ
93623	TC	C	Stimulation, pacing heart	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	ZZZ
93624	.....	A	Electrophysiologic study	4.81	4.04	4.35	NA	NA	0.26	9.11	9.42	NA	NA	000
93624	26	A	Electrophysiologic study	4.81	2.04	2.34	2.04	2.34	0.15	7.00	7.30	7.00	7.30	000
93624	TC	A	Electrophysiologic study	0.00	2.00	2.01	NA	NA	0.11	2.11	2.12	NA	NA	000
93631	.....	A	Heart pacing, mapping	7.60	9.37	10.19	NA	NA	0.95	17.92	18.74	NA	NA	000
93631	26	A	Heart pacing, mapping	7.60	3.15	3.93	3.15	3.93	0.42	11.17	11.95	11.17	11.95	000
93631	TC	A	Heart pacing, mapping	0.00	6.22	6.26	NA	NA	0.53	6.75	6.79	NA	NA	000
93640	.....	A	Evaluation heart device	3.52	8.74	9.46	NA	NA	0.47	12.73	13.45	NA	NA	000
93640	26	A	Evaluation heart device	3.52	1.49	2.17	1.49	2.17	0.11	5.12	5.80	5.12	5.80	000
93640	TC	A	Evaluation heart device	0.00	7.25	7.29	NA	NA	0.36	7.61	7.65	NA	NA	000
93641	.....	A	Electrophysiology evaluation	5.93	9.75	10.94	NA	NA	0.54	16.22	17.41	NA	NA	000
93641	26	A	Electrophysiology evaluation	5.93	2.50	3.65	2.50	3.65	0.18	8.61	9.76	8.61	9.76	000
93641	TC	A	Electrophysiology evaluation	0.00	7.25	7.29	NA	NA	0.36	7.61	7.65	NA	NA	000
93642	.....	A	Electrophysiology evaluation	4.89	9.26	10.26	NA	NA	0.50	14.65	15.65	NA	NA	000
93642	26	A	Electrophysiology evaluation	4.89	2.01	2.97	2.01	2.97	0.14	7.04	8.00	7.04	8.00	000
93642	TC	A	Electrophysiology evaluation	0.00	7.25	7.29	NA	NA	0.36	7.61	7.65	NA	NA	000
93650	.....	A	Ablate heart dysrhythm focus	10.51	NA	NA	4.50	6.51	0.32	NA	NA	15.33	17.34	000
93651	.....	A	Ablate heart dysrhythm focus	16.25	NA	NA	6.86	9.98	0.50	NA	NA	23.61	26.73	000
93652	.....	A	Ablate heart dysrhythm focus	17.68	NA	NA	7.49	10.46	0.54	NA	NA	25.71	28.68	000
93660	.....	A	Tilt table evaluation	1.89	0.80	0.99	NA	NA	0.06	2.75	2.94	NA	NA	000
93660	26	A	Tilt table evaluation	1.89	0.80	0.99	0.80	0.99	0.06	2.75	2.94	2.75	2.94	000
93660	TC	C	Tilt table evaluation	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	000
93720	.....	A	Total body plethysmography	0.17	0.76	0.82	NA	NA	0.06	0.99	1.05	NA	NA	XXX
93721	.....	A	Plethysmography tracing	0.00	0.71	0.72	NA	NA	0.05	0.76	0.77	NA	NA	XXX
93722	.....	A	Plethysmography report	0.17	0.05	0.10	0.05	0.10	0.01	0.23	0.28	0.23	0.28	XXX
93724	.....	A	Analyze pacemaker system	4.89	6.09	6.37	NA	NA	0.35	11.33	11.61	NA	NA	000
93724	26	A	Analyze pacemaker system	4.89	2.08	2.34	2.08	2.34	0.14	7.11	7.37	7.11	7.37	000
93724	TC	A	Analyze pacemaker system	0.00	4.01	4.03	NA	NA	0.21	4.22	4.24	NA	NA	000
93727	.....	A	Analyze ilr system	0.52	0.21	0.21	0.21	0.21	0.02	0.75	0.75	0.75	0.75	XXX
93731	.....	A	Analyze pacemaker system	0.45	0.69	0.73	NA	NA	0.05	1.19	1.23	NA	NA	XXX
93731	26	A	Analyze pacemaker system	0.45	0.19	0.23	0.19	0.23	0.02	0.66	0.70	0.66	0.70	XXX
93731	TC	A	Analyze pacemaker system	0.00	0.50	0.50	NA	NA	0.03	0.53	0.53	NA	NA	XXX
93732	.....	A	Analyze pacemaker system	0.92	0.90	0.92	NA	NA	0.06	1.88	1.90	NA	NA	XXX
93732	26	A	Analyze pacemaker system	0.92	0.38	0.40	0.38	0.40	0.03	1.33	1.35	1.33	1.35	XXX
93732	TC	A	Analyze pacemaker system	0.00	0.52	0.52	NA	NA	0.03	0.55	0.55	NA	NA	XXX
93733	.....	A	Telephone analy, pacemaker	0.17	0.80	0.85	NA	NA	0.06	1.03	1.08	NA	NA	XXX
93733	26	A	Telephone analy, pacemaker	0.17	0.07	0.11	0.07	0.11	0.01	0.25	0.29	0.25	0.29	XXX
93733	TC	A	Telephone analy, pacemaker	0.00	0.73	0.74	NA	NA	0.05	0.78	0.79	NA	NA	XXX
93734	.....	A	Analyze pacemaker system	0.38	0.51	0.56	NA	NA	0.03	0.92	0.97	NA	NA	XXX
93734	26	A	Analyze pacemaker system	0.38	0.16	0.21	0.16	0.21	0.01	0.55	0.60	0.55	0.60	XXX
93734	TC	A	Analyze pacemaker system	0.00	0.35	0.35	NA	NA	0.02	0.37	0.37	NA	NA	XXX
93735	.....	A	Analyze pacemaker system	0.74	0.76	0.80	NA	NA	0.06	1.56	1.60	NA	NA	XXX
93735	26	A	Analyze pacemaker system	0.74	0.31	0.35	0.31	0.35	0.03	1.08	1.12	1.08	1.12	XXX
93735	TC	A	Analyze pacemaker system	0.00	0.45	0.45	NA	NA	0.03	0.48	0.48	NA	NA	XXX
93736	.....	A	Telephone analy, pacemaker	0.15	0.71	0.74	NA	NA	0.06	0.92	0.95	NA	NA	XXX
93736	26	A	Telephone analy, pacemaker	0.15	0.07	0.10	0.07	0.10	0.01	0.23	0.26	0.23	0.26	XXX
93736	TC	A	Telephone analy, pacemaker	0.00	0.64	0.64	NA	NA	0.05	0.69	0.69	NA	NA	XXX
93737	.....	A	Analyze cardio/defibrillator	0.45	0.69	0.72	NA	NA	0.04	1.18	1.21	NA	NA	XXX
93737	26	A	Analyze cardio/defibrillator	0.45	0.19	0.22	0.19	0.22	0.01	0.65	0.68	0.65	0.68	XXX
93737	TC	A	Analyze cardio/defibrillator	0.00	0.50	0.50	NA	NA	0.03	0.53	0.53	NA	NA	XXX
93738	.....	A	Analyze cardio/defibrillator	0.92	0.91	0.92	NA	NA	0.06	1.89	1.90	NA	NA	XXX
93738	26	A	Analyze cardio/defibrillator	0.92	0.39	0.40	0.39	0.40	0.03	1.34	1.35	1.34	1.35	XXX
93738	TC	A	Analyze cardio/defibrillator	0.00	0.52	0.52	NA	NA	0.03	0.55	0.55	NA	NA	XXX
93740	.....	B	Temperature gradient studies	0.16	0.21	0.28	NA	NA	0.02	0.39	0.46	NA	NA	XXX
93740	26	B	Temperature gradient studies	0.16	0.05	0.12	0.05	0.12	0.01	0.22	0.29	0.22	0.29	XXX
93740	TC	B	Temperature gradient studies	0.00	0.16	0.16	NA	NA	0.01	0.17	0.17	NA	NA	XXX
93741	.....	A	Analyze ht pace device sngl	0.64	1.16	1.17	NA	NA	0.05	1.85	1.86	NA	NA	XXX
93741	26	A	Analyze ht pace device sngl	0.64	0.25	0.25	0.25	0.25	0.02	0.91	0.91	0.91	0.91	XXX
93741	TC	A	Analyze ht pace device sngl	0.00	0.91	0.92	NA	NA	0.03	0.94	0.95	NA	NA	XXX
93742	.....	A	Analyze ht pace device sngl	0.73	1.54	1.55	NA	NA	0.05	2.32	2.33	NA	NA	XXX
93742	26	A	Analyze ht pace device sngl	0.73	0.29	0.29	0.29	0.29	0.02	1.04	1.04	1.04	1.04	XXX
93742	TC	A	Analyze ht pace device sngl	0.00	1.25	1.26	NA	NA	0.03	1.28	1.29	NA	NA	XXX
93743	.....	A	Analyze ht pace device dual	0.83	1.24	1.25	NA	NA	0.05	2.12	2.13	NA	NA	XXX
93743	26	A	Analyze ht pace device dual	0.83	0.33	0.33	0.33	0.33	0.02	1.18	1.18	1.18	1.18	XXX
93743	TC	A	Analyze ht pace device dual	0.00	0.91	0.92	NA	NA	0.03	0.94	0.95	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
93744		A	Analyze ht pace device dual	0.95	1.63	1.64	NA	NA	0.05	2.63	2.64	NA	NA	XXX
93744	26	A	Analyze ht pace device dual	0.95	0.38	0.38	0.38	0.38	0.02	1.35	1.35	1.35	1.35	XXX
93744	TC	A	Analyze ht pace device dual	0.00	1.25	1.26	NA	NA	0.03	1.28	1.29	NA	NA	XXX
93760		N	Cephalic thermogram	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93762		N	Peripheral thermogram	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93770		B	Measure venous pressure	0.16	0.08	0.11	NA	NA	0.02	0.26	0.29	NA	NA	XXX
93770	26	B	Measure venous pressure	0.16	0.05	0.08	0.05	0.08	0.01	0.22	0.25	0.22	0.25	XXX
93770	TC	B	Measure venous pressure	0.00	0.03	0.03	NA	NA	0.01	0.04	0.04	NA	NA	XXX
93784		N	Ambulatory BP monitoring	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93786		N	Ambulatory BP recording	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93788		N	Ambulatory BP analysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93790		N	Review/report BP recording	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93797		A	Cardiac rehab	0.18	0.34	0.31	0.07	0.11	0.01	0.53	0.50	0.26	0.30	000
93798		A	Cardiac rehab/monitor	0.28	0.43	0.45	0.11	0.21	0.01	0.72	0.74	0.40	0.50	000
93799		C	Cardiovascular procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
93799	26	C	Cardiovascular procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
93799	TC	C	Cardiovascular procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
93875		A	Extracranial study	0.22	1.19	1.25	NA	NA	0.10	1.51	1.57	NA	NA	XXX
93875	26	A	Extracranial study	0.22	0.08	0.13	0.08	0.13	0.01	0.31	0.36	0.31	0.36	XXX
93875	TC	A	Extracranial study	0.00	1.11	1.12	NA	NA	0.09	1.20	1.21	NA	NA	XXX
93880		A	Extracranial study	0.60	3.98	4.05	NA	NA	0.34	4.92	4.99	NA	NA	XXX
93880	26	A	Extracranial study	0.60	0.22	0.27	0.22	0.27	0.04	0.86	0.91	0.86	0.91	XXX
93880	TC	A	Extracranial study	0.00	3.76	3.78	NA	NA	0.30	4.06	4.08	NA	NA	XXX
93882		A	Extracranial study	0.40	2.65	2.70	NA	NA	0.22	3.27	3.32	NA	NA	XXX
93882	26	A	Extracranial study	0.40	0.15	0.18	0.15	0.18	0.03	0.58	0.61	0.58	0.61	XXX
93882	TC	A	Extracranial study	0.00	2.50	2.52	NA	NA	0.19	2.69	2.71	NA	NA	XXX
93886		A	Intracranial study	0.94	4.64	4.69	NA	NA	0.38	5.96	6.01	NA	NA	XXX
93886	26	A	Intracranial study	0.94	0.38	0.40	0.38	0.40	0.05	1.37	1.39	1.37	1.39	XXX
93886	TC	A	Intracranial study	0.00	4.26	4.29	NA	NA	0.33	4.59	4.62	NA	NA	XXX
93888		A	Intracranial study	0.62	3.08	3.12	NA	NA	0.27	3.97	4.01	NA	NA	XXX
93888	26	A	Intracranial study	0.62	0.24	0.26	0.24	0.26	0.04	0.90	0.92	0.90	0.92	XXX
93888	TC	A	Intracranial study	0.00	2.84	2.86	NA	NA	0.23	3.07	3.09	NA	NA	XXX
93922		A	Extremity study	0.25	1.25	1.31	NA	NA	0.13	1.63	1.69	NA	NA	XXX
93922	26	A	Extremity study	0.25	0.09	0.14	0.09	0.14	0.02	0.36	0.41	0.36	0.41	XXX
93922	TC	A	Extremity study	0.00	1.16	1.17	NA	NA	0.11	1.27	1.28	NA	NA	XXX
93923		A	Extremity study	0.45	2.38	2.48	NA	NA	0.23	3.06	3.16	NA	NA	XXX
93923	26	A	Extremity study	0.45	0.17	0.26	0.17	0.26	0.04	0.66	0.75	0.66	0.75	XXX
93923	TC	A	Extremity study	0.00	2.21	2.22	NA	NA	0.19	2.40	2.41	NA	NA	XXX
93924		A	Extremity study	0.50	2.57	2.70	NA	NA	0.27	3.34	3.47	NA	NA	XXX
93924	26	A	Extremity study	0.50	0.18	0.29	0.18	0.29	0.05	0.73	0.84	0.73	0.84	XXX
93924	TC	A	Extremity study	0.00	2.39	2.41	NA	NA	0.22	2.61	2.63	NA	NA	XXX
93925		A	Lower extremity study	0.58	3.99	4.06	NA	NA	0.34	4.91	4.98	NA	NA	XXX
93925	26	A	Lower extremity study	0.58	0.21	0.26	0.21	0.26	0.04	0.83	0.88	0.83	0.88	XXX
93925	TC	A	Lower extremity study	0.00	3.78	3.80	NA	NA	0.30	4.08	4.10	NA	NA	XXX
93926		A	Lower extremity study	0.39	2.66	2.72	NA	NA	0.23	3.28	3.34	NA	NA	XXX
93926	26	A	Lower extremity study	0.39	0.14	0.18	0.14	0.18	0.03	0.56	0.60	0.56	0.60	XXX
93926	TC	A	Lower extremity study	0.00	2.52	2.54	NA	NA	0.20	2.72	2.74	NA	NA	XXX
93930		A	Upper extremity study	0.46	4.19	4.27	NA	NA	0.35	5.00	5.08	NA	NA	XXX
93930	26	A	Upper extremity study	0.46	0.17	0.23	0.17	0.23	0.03	0.66	0.72	0.66	0.72	XXX
93930	TC	A	Upper extremity study	0.00	4.02	4.04	NA	NA	0.32	4.34	4.36	NA	NA	XXX
93931		A	Upper extremity study	0.31	2.78	2.84	NA	NA	0.23	3.32	3.38	NA	NA	XXX
93931	26	A	Upper extremity study	0.31	0.11	0.15	0.11	0.15	0.02	0.44	0.48	0.44	0.48	XXX
93931	TC	A	Upper extremity study	0.00	2.67	2.69	NA	NA	0.21	2.88	2.90	NA	NA	XXX
93965		A	Extremity study	0.35	1.23	1.31	NA	NA	0.12	1.70	1.78	NA	NA	XXX
93965	26	A	Extremity study	0.35	0.13	0.20	0.13	0.20	0.02	0.50	0.57	0.50	0.57	XXX
93965	TC	A	Extremity study	0.00	1.10	1.11	NA	NA	0.10	1.20	1.21	NA	NA	XXX
93970		A	Extremity study	0.68	4.42	4.50	NA	NA	0.39	5.49	5.57	NA	NA	XXX
93970	26	A	Extremity study	0.68	0.25	0.30	0.25	0.30	0.05	0.98	1.03	0.98	1.03	XXX
93970	TC	A	Extremity study	0.00	4.17	4.20	NA	NA	0.34	4.51	4.54	NA	NA	XXX
93971		A	Extremity study	0.45	2.94	2.99	NA	NA	0.26	3.65	3.70	NA	NA	XXX
93971	26	A	Extremity study	0.45	0.16	0.19	0.16	0.19	0.03	0.64	0.67	0.64	0.67	XXX
93971	TC	A	Extremity study	0.00	2.78	2.80	NA	NA	0.23	3.01	3.03	NA	NA	XXX
93975		A	Vascular study	1.80	5.39	5.38	NA	NA	0.47	7.66	7.65	NA	NA	XXX
93975	26	A	Vascular study	1.80	0.64	0.60	0.64	0.60	0.10	2.54	2.50	2.54	2.50	XXX
93975	TC	A	Vascular study	0.00	4.75	4.78	NA	NA	0.37	5.12	5.15	NA	NA	XXX
93976		A	Vascular study	1.21	3.60	3.59	NA	NA	0.32	5.13	5.12	NA	NA	XXX
93976	26	A	Vascular study	1.21	0.43	0.40	0.43	0.40	0.06	1.70	1.67	1.70	1.67	XXX
93976	TC	A	Vascular study	0.00	3.17	3.19	NA	NA	0.26	3.43	3.45	NA	NA	XXX
93978		A	Vascular study	0.65	4.13	4.20	NA	NA	0.37	5.15	5.22	NA	NA	XXX
93978	26	A	Vascular study	0.65	0.24	0.29	0.24	0.29	0.05	0.94	0.99	0.94	0.99	XXX
93978	TC	A	Vascular study	0.00	3.89	3.91	NA	NA	0.32	4.21	4.23	NA	NA	XXX
93979		A	Vascular study	0.44	2.76	2.81	NA	NA	0.24	3.44	3.49	NA	NA	XXX
93979	26	A	Vascular study	0.44	0.17	0.20	0.17	0.20	0.03	0.64	0.67	0.64	0.67	XXX
93979	TC	A	Vascular study	0.00	2.59	2.61	NA	NA	0.21	2.80	2.82	NA	NA	XXX
93980		A	Penile vascular study	1.25	3.96	4.10	NA	NA	0.37	5.58	5.72	NA	NA	XXX
93980	26	A	Penile vascular study	1.25	0.43	0.55	0.43	0.55	0.08	1.76	1.88	1.76	1.88	XXX
93980	TC	A	Penile vascular study	0.00	3.53	3.55	NA	NA	0.29	3.82	3.84	NA	NA	XXX
93981		A	Penile vascular study	0.44	3.40	3.49	NA	NA	0.30	4.14	4.23	NA	NA	XXX
93981	26	A	Penile vascular study	0.44	0.15	0.22	0.15	0.22	0.03	0.62	0.69	0.62	0.69	XXX
93981	TC	A	Penile vascular study	0.00	3.25	3.27	NA	NA	0.27	3.52	3.54	NA	NA	XXX
93990		A	Doppler flow testing	0.25	2.62	2.67	NA	NA	0.21	3.08	3.13	NA	NA	XXX
93990	26	A	Doppler flow testing	0.25	0.10	0.13	0.10	0.13	0.01	0.36	0.39	0.36	0.39	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
93990	TC	A	Doppler flow testing	0.00	2.52	2.54	NA	NA	0.20	2.72	2.74	NA	NA	XXX
94010		A	Breathing capacity test	0.17	0.47	0.53	NA	NA	0.03	0.67	0.73	NA	NA	XXX
94010	26	A	Breathing capacity test	0.17	0.05	0.11	0.05	0.11	0.01	0.23	0.29	0.23	0.29	XXX
94010	TC	A	Breathing capacity test	0.00	0.42	0.42	NA	NA	0.02	0.44	0.44	NA	NA	XXX
94014		A	Patient recorded spirometry	0.52	0.83	0.78	NA	NA	0.03	1.38	1.33	NA	NA	XXX
94015		A	Patient recorded spirometry	0.00	0.62	0.57	NA	NA	0.01	0.63	0.58	NA	NA	XXX
94016		A	Review patient spirometry	0.52	0.21	0.21	0.21	0.21	0.02	0.75	0.75	0.75	0.75	XXX
94060		A	Evaluation of wheezing	0.31	1.04	1.12	NA	NA	0.06	1.41	1.49	NA	NA	XXX
94060	26	A	Evaluation of wheezing	0.31	0.09	0.16	0.09	0.16	0.01	0.41	0.48	0.41	0.48	XXX
94060	TC	A	Evaluation of wheezing	0.00	0.95	0.96	NA	NA	0.05	1.00	1.01	NA	NA	XXX
94070		A	Evaluation of wheezing	0.60	1.66	1.73	NA	NA	0.10	2.36	2.43	NA	NA	XXX
94070	26	A	Evaluation of wheezing	0.60	0.18	0.24	0.18	0.24	0.02	0.80	0.86	0.80	0.86	XXX
94070	TC	A	Evaluation of wheezing	0.00	1.48	1.49	NA	NA	0.08	1.56	1.57	NA	NA	XXX
94150		B	Vital capacity test	0.07	0.12	0.14	NA	NA	0.02	0.21	0.23	NA	NA	XXX
94150	26	B	Vital capacity test	0.07	0.03	0.05	0.03	0.05	0.01	0.11	0.13	0.11	0.13	XXX
94150	TC	B	Vital capacity test	0.00	0.09	0.09	NA	NA	0.01	0.10	0.10	NA	NA	XXX
94200		A	Lung function test (MBC/MVV)	0.11	0.28	0.31	NA	NA	0.03	0.42	0.45	NA	NA	XXX
94200	26	A	Lung function test (MBC/MVV)	0.11	0.03	0.06	0.03	0.06	0.01	0.15	0.18	0.15	0.18	XXX
94200	TC	A	Lung function test (MBC/MVV)	0.00	0.25	0.25	NA	NA	0.02	0.27	0.27	NA	NA	XXX
94240		A	Residual lung capacity	0.26	0.77	0.82	NA	NA	0.05	1.08	1.13	NA	NA	XXX
94240	26	A	Residual lung capacity	0.26	0.08	0.12	0.08	0.12	0.01	0.35	0.39	0.35	0.39	XXX
94240	TC	A	Residual lung capacity	0.00	0.69	0.70	NA	NA	0.04	0.73	0.74	NA	NA	XXX
94250		A	Expired gas collection	0.11	0.17	0.20	NA	NA	0.02	0.30	0.33	NA	NA	XXX
94250	26	A	Expired gas collection	0.11	0.03	0.06	0.03	0.06	0.01	0.15	0.18	0.15	0.18	XXX
94250	TC	A	Expired gas collection	0.00	0.14	0.14	NA	NA	0.01	0.15	0.15	NA	NA	XXX
94260		A	Thoracic gas volume	0.13	0.59	0.62	NA	NA	0.04	0.76	0.79	NA	NA	XXX
94260	26	A	Thoracic gas volume	0.13	0.04	0.07	0.04	0.07	0.01	0.18	0.21	0.18	0.21	XXX
94260	TC	A	Thoracic gas volume	0.00	0.55	0.55	NA	NA	0.03	0.58	0.58	NA	NA	XXX
94350		A	Lung nitrogen washout curve	0.26	0.63	0.67	NA	NA	0.04	0.93	0.97	NA	NA	XXX
94350	26	A	Lung nitrogen washout curve	0.26	0.08	0.12	0.08	0.12	0.01	0.35	0.39	0.35	0.39	XXX
94350	TC	A	Lung nitrogen washout curve	0.00	0.55	0.55	NA	NA	0.03	0.58	0.58	NA	NA	XXX
94360		A	Measure airflow resistance	0.26	1.06	1.10	NA	NA	0.06	1.38	1.42	NA	NA	XXX
94360	26	A	Measure airflow resistance	0.26	0.08	0.11	0.08	0.11	0.01	0.35	0.38	0.35	0.38	XXX
94360	TC	A	Measure airflow resistance	0.00	0.98	0.99	NA	NA	0.05	1.03	1.04	NA	NA	XXX
94370		A	Breath airway closing volume	0.26	0.35	0.37	NA	NA	0.03	0.64	0.66	NA	NA	XXX
94370	26	A	Breath airway closing volume	0.26	0.08	0.10	0.08	0.10	0.01	0.35	0.37	0.35	0.37	XXX
94370	TC	A	Breath airway closing volume	0.00	0.27	0.27	NA	NA	0.02	0.29	0.29	NA	NA	XXX
94375		A	Respiratory flow volume loop	0.31	0.58	0.62	NA	NA	0.03	0.92	0.96	NA	NA	XXX
94375	26	A	Respiratory flow volume loop	0.31	0.09	0.13	0.09	0.13	0.01	0.41	0.45	0.41	0.45	XXX
94375	TC	A	Respiratory flow volume loop	0.00	0.49	0.49	NA	NA	0.02	0.51	0.51	NA	NA	XXX
94400		A	CO2 breathing response curve	0.40	0.45	0.55	NA	NA	0.07	0.92	1.02	NA	NA	XXX
94400	26	A	CO2 breathing response curve	0.40	0.13	0.23	0.13	0.23	0.02	0.55	0.65	0.55	0.65	XXX
94400	TC	A	CO2 breathing response curve	0.00	0.32	0.32	NA	NA	0.05	0.37	0.37	NA	NA	XXX
94450		A	Hypoxia response curve	0.40	0.52	0.55	NA	NA	0.03	0.95	0.98	NA	NA	XXX
94450	26	A	Hypoxia response curve	0.40	0.13	0.16	0.13	0.16	0.01	0.54	0.57	0.54	0.57	XXX
94450	TC	A	Hypoxia response curve	0.00	0.39	0.39	NA	NA	0.02	0.41	0.41	NA	NA	XXX
94620		A	Pulmonary stress test/simple	0.64	1.64	1.79	NA	NA	0.11	2.39	2.54	NA	NA	XXX
94620	26	A	Pulmonary stress test/simple	0.64	0.20	0.34	0.20	0.34	0.03	0.87	1.01	0.87	1.01	XXX
94620	TC	A	Pulmonary stress test/simple	0.00	1.44	1.45	NA	NA	0.08	1.52	1.53	NA	NA	XXX
94621		A	Pulm stress test/complex	1.42	1.88	1.97	NA	NA	0.11	3.41	3.50	NA	NA	XXX
94621	26	A	Pulm stress test/complex	1.42	0.44	0.52	0.44	0.52	0.03	1.89	1.97	1.89	1.97	XXX
94621	TC	A	Pulm stress test/complex	0.00	1.44	1.45	NA	NA	0.08	1.52	1.53	NA	NA	XXX
94640		A	Airway inhalation treatment	0.00	0.59	0.55	0.19	0.25	0.02	0.61	0.57	0.21	0.27	XXX
94642		C	Aerosol inhalation treatment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
94650		A	Pressure breathing (IPPB)	0.00	0.56	0.52	0.18	0.24	0.02	0.58	0.54	0.20	0.26	XXX
94651		A	Pressure breathing (IPPB)	0.00	0.51	0.48	0.17	0.23	0.02	0.53	0.50	0.19	0.25	XXX
94652		A	Pressure breathing (IPPB)	0.00	0.60	0.56	0.19	0.25	0.06	0.66	0.62	0.25	0.31	XXX
94656		A	Initial ventilator mgmt	1.22	NA	NA	0.33	0.56	0.06	NA	NA	1.61	1.84	XXX
94657		A	Continued ventilator mgmt	0.83	NA	NA	0.25	0.36	0.03	NA	NA	1.11	1.22	XXX
94660		A	Pos airway pressure, CPAP	0.76	0.57	0.62	0.23	0.37	0.03	1.36	1.41	1.02	1.16	XXX
94662		A	Neg press ventilation, cnp	0.76	NA	NA	0.24	0.26	0.02	NA	NA	1.02	1.04	XXX
94664		A	Aerosol or vapor inhalations	0.00	0.43	0.46	0.14	0.24	0.03	0.46	0.49	0.17	0.27	XXX
94665		A	Aerosol or vapor inhalations	0.00	0.46	0.47	0.15	0.24	0.04	0.50	0.51	0.19	0.28	XXX
94667		A	Chest wall manipulation	0.00	0.60	0.60	0.19	0.29	0.04	0.64	0.64	0.23	0.33	XXX
94668		A	Chest wall manipulation	0.00	0.59	0.54	0.18	0.23	0.02	0.61	0.56	0.20	0.25	XXX
94680		A	Exhaled air analysis, o2	0.26	0.61	0.67	NA	NA	0.06	0.93	0.99	NA	NA	XXX
94680	26	A	Exhaled air analysis, o2	0.26	0.09	0.15	0.09	0.15	0.01	0.36	0.42	0.36	0.42	XXX
94680	TC	A	Exhaled air analysis, o2	0.00	0.52	0.52	NA	NA	0.05	0.57	0.57	NA	NA	XXX
94681		A	Exhaled air analysis, o2/co2	0.20	1.46	1.52	NA	NA	0.11	1.77	1.83	NA	NA	XXX
94681	26	A	Exhaled air analysis, o2/co2	0.20	0.06	0.11	0.06	0.11	0.01	0.27	0.32	0.27	0.32	XXX
94681	TC	A	Exhaled air analysis, o2/co2	0.00	1.40	1.41	NA	NA	0.10	1.50	1.51	NA	NA	XXX
94690		A	Exhaled air analysis	0.07	0.56	0.57	NA	NA	0.04	0.67	0.68	NA	NA	XXX
94690	26	A	Exhaled air analysis	0.07	0.02	0.03	0.02	0.03	0.01	0.10	0.11	0.10	0.11	XXX
94690	TC	A	Exhaled air analysis	0.00	0.54	0.54	NA	NA	0.03	0.57	0.57	NA	NA	XXX
94720		A	Monoxide diffusing capacity	0.26	0.93	0.98	NA	NA	0.06	1.25	1.30	NA	NA	XXX
94720	26	A	Monoxide diffusing capacity	0.26	0.08	0.12	0.08	0.12	0.01	0.35	0.39	0.35	0.39	XXX
94720	TC	A	Monoxide diffusing capacity	0.00	0.85	0.86	NA	NA	0.05	0.90	0.91	NA	NA	XXX
94725		A	Membrane diffusion capacity	0.26	1.84	1.88	NA	NA	0.11	2.21	2.25	NA	NA	XXX
94725	26	A	Membrane diffusion capacity	0.26	0.08	0.11	0.08	0.11	0.01	0.35	0.38	0.35	0.38	XXX
94725	TC	A	Membrane diffusion capacity	0.00	1.76	1.77	NA	NA	0.10	1.86	1.87	NA	NA	XXX
94750		A	Pulmonary compliance study	0.23	0.66	0.71	NA	NA	0.04	0.93	0.98	NA	NA	XXX
94750	26	A	Pulmonary compliance study	0.23	0.07	0.12	0.07	0.12	0.01	0.31	0.36	0.31	0.36	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
94750	TC	A	Pulmonary compliance study	0.00	0.59	0.59	NA	NA	0.03	0.62	0.62	NA	NA	XXX
94760		T	Measure blood oxygen level	0.00	0.07	0.12	0.02	0.08	0.02	0.09	0.14	0.04	0.10	XXX
94761		T	Measure blood oxygen level	0.00	0.14	0.28	0.05	0.21	0.05	0.19	0.33	0.10	0.26	XXX
94762		A	Measure blood oxygen level	0.00	0.11	0.38	NA	NA	0.08	0.19	0.46	NA	NA	XXX
94770		A	Exhaled carbon dioxide test	0.15	0.34	0.36	NA	NA	0.07	0.56	0.58	NA	NA	XXX
94770	26	A	Exhaled carbon dioxide test	0.15	0.04	0.06	0.04	0.06	0.01	0.20	0.22	0.20	0.22	XXX
94770	TC	A	Exhaled carbon dioxide test	0.00	0.30	0.30	NA	NA	0.06	0.36	0.36	NA	NA	XXX
94772		C	Breath recording, infant	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
94772	26	C	Breath recording, infant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
94772	TC	C	Breath recording, infant	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
94799		C	Pulmonary service/procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
94799	26	C	Pulmonary service/procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
94799	TC	C	Pulmonary service/procedure	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
95004		A	Allergy skin tests	0.00	0.10	0.10	0.10	0.10	0.01	0.11	0.11	0.11	0.11	XXX
95010		A	Sensitivity skin tests	0.15	0.39	0.32	0.06	0.08	0.01	0.55	0.48	0.22	0.24	XXX
95015		A	Sensitivity skin tests	0.15	0.41	0.34	0.07	0.08	0.01	0.57	0.50	0.23	0.24	XXX
95024		A	Allergy skin tests	0.00	0.15	0.15	0.15	0.15	0.01	0.16	0.16	0.16	0.16	XXX
95027		A	Skin end point titration	0.00	0.15	0.15	NA	NA	0.01	0.16	0.16	NA	NA	XXX
95028		A	Allergy skin tests	0.00	0.23	0.23	NA	NA	0.01	0.24	0.24	NA	NA	XXX
95044		A	Allergy patch tests	0.00	0.21	0.21	0.21	0.21	0.01	0.22	0.22	0.22	0.22	XXX
95052		A	Photo patch test	0.00	0.25	0.25	0.25	0.25	0.01	0.26	0.26	0.26	0.26	XXX
95056		A	Photosensitivity tests	0.00	0.18	0.18	0.18	0.18	0.01	0.19	0.19	0.19	0.19	XXX
95060		A	Eye allergy tests	0.00	0.35	0.35	NA	NA	0.02	0.37	0.37	NA	NA	XXX
95065		A	Nose allergy test	0.00	0.21	0.21	NA	NA	0.01	0.22	0.22	NA	NA	XXX
95070		A	Bronchial allergy tests	0.00	2.31	2.32	NA	NA	0.02	2.33	2.34	NA	NA	XXX
95071		A	Bronchial allergy tests	0.00	2.95	2.97	NA	NA	0.02	2.97	2.99	NA	NA	XXX
95075		A	Ingestion challenge test	0.95	0.80	1.14	0.39	0.83	0.03	1.78	2.12	1.37	1.81	XXX
95078		A	Provocative testing	0.00	0.25	0.25	NA	NA	0.02	0.27	0.27	NA	NA	XXX
95115		A	Immunotherapy, one injection	0.00	0.39	0.39	0.39	0.39	0.02	0.41	0.41	0.41	0.41	000
95117		A	Immunotherapy injections	0.00	0.51	0.51	0.51	0.51	0.02	0.53	0.53	0.53	0.53	000
95120		I	Immunotherapy, one injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95125		I	Immunotherapy, many antigens	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95130		I	Immunotherapy, insect venom	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95131		I	Immunotherapy, insect venoms	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95132		I	Immunotherapy, insect venoms	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95133		I	Immunotherapy, insect venoms	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95134		I	Immunotherapy, insect venoms	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
95144		A	Antigen therapy services	0.06	0.22	0.20	0.03	0.06	0.01	0.29	0.27	0.10	0.13	000
95145		A	Antigen therapy services	0.06	0.45	0.43	0.03	0.12	0.01	0.52	0.50	0.10	0.19	000
95146		A	Antigen therapy services	0.06	0.60	0.62	0.03	0.19	0.01	0.67	0.69	0.10	0.26	000
95147		A	Antigen therapy services	0.06	0.74	0.80	0.02	0.26	0.01	0.81	0.87	0.09	0.33	000
95148		A	Antigen therapy services	0.06	0.75	0.81	0.02	0.26	0.01	0.82	0.88	0.09	0.33	000
95149		A	Antigen therapy services	0.06	0.92	1.00	0.02	0.33	0.01	0.99	1.07	0.09	0.40	000
95165		A	Antigen therapy services	0.06	0.23	0.20	0.02	0.04	0.01	0.30	0.27	0.09	0.11	000
95170		A	Antigen therapy services	0.06	0.23	0.27	0.02	0.11	0.01	0.30	0.34	0.09	0.18	000
95180		A	Rapid desensitization	2.01	1.50	1.16	0.87	0.69	0.06	3.57	3.23	2.94	2.76	000
95199		C	Allergy immunology services	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	000
95805		A	Multiple sleep latency test	1.88	9.74	8.80	NA	NA	0.35	11.97	11.03	NA	NA	XXX
95805	26	A	Multiple sleep latency test	1.88	0.66	0.65	0.66	0.65	0.06	2.60	2.59	2.60	2.59	XXX
95805	TC	A	Multiple sleep latency test	0.00	9.08	8.15	NA	NA	0.29	9.37	8.44	NA	NA	XXX
95806		A	Sleep study, unattended	1.66	2.21	3.60	NA	NA	0.32	4.19	5.58	NA	NA	XXX
95806	26	A	Sleep study, unattended	1.66	0.53	1.06	0.53	1.06	0.05	2.24	2.77	2.24	2.77	XXX
95806	TC	A	Sleep study, unattended	0.00	1.68	2.54	NA	NA	0.27	1.95	2.81	NA	NA	XXX
95807		A	Sleep study, attended	1.66	7.01	7.47	NA	NA	0.41	9.08	9.54	NA	NA	XXX
95807	26	A	Sleep study, attended	1.66	0.53	0.90	0.53	0.90	0.05	2.24	2.61	2.24	2.61	XXX
95807	TC	A	Sleep study, attended	0.00	6.48	6.57	NA	NA	0.36	6.84	6.93	NA	NA	XXX
95808		A	Polysomnography, 1–3	2.65	10.89	10.55	NA	NA	0.45	13.99	13.65	NA	NA	XXX
95808	26	A	Polysomnography, 1–3	2.65	0.92	1.36	0.92	1.36	0.09	3.66	4.10	3.66	4.10	XXX
95808	TC	A	Polysomnography, 1–3	0.00	9.97	9.19	NA	NA	0.36	10.33	9.55	NA	NA	XXX
95810		A	Polysomnography, 4 or more	3.53	17.47	15.48	NA	NA	0.47	21.47	19.48	NA	NA	XXX
95810	26	A	Polysomnography, 4 or more	3.53	1.18	1.55	1.18	1.55	0.11	4.82	5.19	4.82	19	XXX
95810	TC	A	Polysomnography, 4 or more	0.00	16.29	13.93	NA	NA	0.36	16.65	14.29	NA	NA	XXX
95811		A	Polysomnography w/cpap	3.80	14.75	13.56	NA	NA	0.49	19.04	17.85	NA	NA	XXX
95811	26	A	Polysomnography w/cpap	3.80	1.28	1.66	1.28	1.66	0.12	5.20	5.58	5.20	5.58	XXX
95811	TC	A	Polysomnography w/cpap	0.00	13.47	11.90	NA	NA	0.37	13.84	12.27	NA	NA	XXX
95812		A	Electroencephalogram (EEG)	1.08	3.00	2.75	NA	NA	0.13	4.21	3.96	NA	NA	XXX
95812	26	A	Electroencephalogram (EEG)	1.08	0.45	0.47	0.45	0.47	0.04	1.57	1.59	1.57	1.59	XXX
95812	TC	A	Electroencephalogram (EEG)	0.00	2.55	2.28	NA	NA	0.09	2.64	2.37	NA	NA	XXX
95813		A	Electroencephalogram (EEG)	1.73	4.41	3.82	NA	NA	0.16	6.30	5.71	NA	NA	XXX
95813	26	A	Electroencephalogram (EEG)	1.73	0.72	0.68	0.72	0.68	0.07	2.52	2.48	2.52	2.48	XXX
95813	TC	A	Electroencephalogram (EEG)	0.00	3.69	3.14	NA	NA	0.09	3.78	3.23	NA	NA	XXX
95816		A	Electroencephalogram (EEG)	1.08	3.06	2.71	NA	NA	0.12	4.26	3.91	NA	NA	XXX
95816	26	A	Electroencephalogram (EEG)	1.08	0.46	0.42	0.46	0.42	0.04	1.58	1.54	1.58	1.54	XXX
95816	TC	A	Electroencephalogram (EEG)	0.00	2.60	2.29	NA	NA	0.08	2.68	2.37	NA	NA	XXX
95819		A	Electroencephalogram (EEG)	1.08	3.24	2.92	NA	NA	0.12	4.44	4.12	NA	NA	XXX
95819	26	A	Electroencephalogram (EEG)	1.08	0.46	0.48	0.46	0.48	0.04	1.58	1.60	1.58	1.60	XXX
95819	TC	A	Electroencephalogram (EEG)	0.00	2.78	2.44	NA	NA	0.08	2.86	2.52	NA	NA	XXX
95822		A	Sleep electroencephalogram	1.08	2.07	2.18	NA	NA	0.15	3.30	3.41	NA	NA	XXX
95822	26	A	Sleep electroencephalogram	1.08	0.46	0.50	0.46	0.50	0.04	1.58	1.62	1.58	1.62	XXX
95822	TC	A	Sleep electroencephalogram	0.00	1.61	1.68	NA	NA	0.11	1.72	1.79	NA	NA	XXX
95824		A	Electroencephalography	0.74	0.69	1.12	NA	NA	0.05	1.48	1.91	NA	NA	XXX
95824	26	A	Electroencephalography	0.74	0.32	0.40	0.32	0.40	0.03	1.09	1.17	1.09	1.17	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
95824	TC	A	Electroencephalography	0.00	0.37	0.72	NA	NA	0.02	0.39	0.74	NA	NA	XXX
95827		A	Night electroencephalogram	1.08	2.71	2.86	NA	NA	0.16	3.95	4.10	NA	NA	XXX
95827	26	A	Night electroencephalogram	1.08	0.39	0.53	0.39	0.53	0.04	1.51	1.65	1.51	1.65	XXX
95827	TC	A	Night electroencephalogram	0.00	2.32	2.33	NA	NA	0.12	2.44	2.45	NA	NA	XXX
95829		A	Surgery electrocorticogram	6.21	7.49	5.78	NA	NA	0.26	13.96	12.25	NA	NA	XXX
95829	26	A	Surgery electrocorticogram	6.21	2.48	1.98	2.48	1.98	0.24	8.93	8.43	8.93	8.43	XXX
95829	TC	A	Surgery electrocorticogram	0.00	5.01	3.80	NA	NA	0.02	5.03	3.82	NA	NA	XXX
95830		A	Insert electrodes for EEG	1.70	2.80	2.31	0.74	0.77	0.07	4.57	4.08	2.51	2.54	XXX
95831		A	Limb muscle testing, manual	0.28	0.38	0.36	0.14	0.18	0.01	0.67	0.65	0.43	0.47	XXX
95832		A	Hand muscle testing, manual	0.29	0.33	0.32	0.14	0.17	0.01	0.63	0.62	0.44	0.47	XXX
95833		A	Body muscle testing, manual	0.47	0.49	0.47	0.23	0.28	0.02	0.98	0.96	0.72	0.77	XXX
95834		A	Body muscle testing, manual	0.60	0.58	0.60	0.29	0.38	0.02	1.20	1.22	0.91	1.00	XXX
95851		A	Range of motion measurements	0.16	0.43	0.39	0.08	0.13	0.01	0.60	0.56	0.25	0.30	XXX
95852		A	Range of motion measurements	0.11	0.36	0.31	0.06	0.09	0.01	0.48	0.43	0.18	0.21	XXX
95857		A	Tensilon test	0.53	0.57	0.56	0.23	0.31	0.02	1.12	1.11	0.78	0.86	XXX
95858		A	Tensilon test & myogram	1.56	1.07	1.08	NA	NA	0.09	2.72	2.73	NA	NA	XXX
95858	26	A	Tensilon test & myogram	1.56	0.67	0.68	0.67	0.68	0.06	2.29	2.30	2.29	2.30	XXX
95858	TC	A	Tensilon test & myogram	0.00	0.40	0.40	NA	NA	0.03	0.43	0.43	NA	NA	XXX
95860		A	Muscle test, one limb	0.96	0.81	0.90	NA	NA	0.06	1.83	1.92	NA	NA	XXX
95860	26	A	Muscle test, one limb	0.96	0.43	0.52	0.43	0.52	0.04	1.43	1.52	1.43	1.52	XXX
95860	TC	A	Muscle test, one limb	0.00	0.38	0.38	NA	NA	0.02	0.40	0.40	NA	NA	XXX
95861		A	Muscle test, two limbs	1.54	1.43	1.61	NA	NA	0.11	3.08	3.26	NA	NA	XXX
95861	26	A	Muscle test, two limbs	1.54	0.69	0.86	0.69	0.86	0.06	2.29	2.46	2.29	2.46	XXX
95861	TC	A	Muscle test, two limbs	0.00	0.74	0.75	NA	NA	0.05	0.79	0.80	NA	NA	XXX
95863		A	Muscle test, 3 limbs	1.87	1.76	1.95	NA	NA	0.12	3.75	3.94	NA	NA	XXX
95863	26	A	Muscle test, 3 limbs	1.87	0.81	0.99	0.81	0.99	0.07	2.75	2.93	2.75	2.93	XXX
95863	TC	A	Muscle test, 3 limbs	0.00	0.95	0.96	NA	NA	0.05	1.00	1.01	NA	NA	XXX
95864		A	Muscle test, 4 limbs	1.99	2.68	2.95	NA	NA	0.18	4.85	5.12	NA	NA	XXX
95864	26	A	Muscle test, 4 limbs	1.99	0.88	1.14	0.88	1.14	0.08	2.95	3.21	2.95	3.21	XXX
95864	TC	A	Muscle test, 4 limbs	0.00	1.80	1.81	NA	NA	0.10	1.90	1.91	NA	NA	XXX
95867		A	Muscle test, head or neck	0.79	0.93	1.00	NA	NA	0.06	1.78	1.85	NA	NA	XXX
95867	26	A	Muscle test, head or neck	0.79	0.34	0.41	0.34	0.41	0.03	1.16	1.23	1.16	1.23	XXX
95867	TC	A	Muscle test, head or neck	0.00	0.59	0.59	NA	NA	0.03	0.62	0.62	NA	NA	XXX
95868		A	Muscle test, head or neck	1.18	1.20	1.43	NA	NA	0.09	2.47	2.70	NA	NA	XXX
95868	26	A	Muscle test, head or neck	1.18	0.50	0.72	0.50	0.72	0.05	1.73	1.95	1.73	1.95	XXX
95868	TC	A	Muscle test, head or neck	0.00	0.70	0.71	NA	NA	0.04	0.74	0.75	NA	NA	XXX
95869		A	Muscle test, thor paraspinal	0.37	0.38	0.43	NA	NA	0.03	0.78	0.83	NA	NA	XXX
95869	26	A	Muscle test, thor paraspinal	0.37	0.16	0.21	0.16	0.21	0.01	0.54	0.59	0.54	0.59	XXX
95869	TC	A	Muscle test, thor paraspinal	0.00	0.22	0.22	NA	NA	0.02	0.24	0.24	NA	NA	XXX
95870		A	Muscle test, nonparaspinal	0.37	0.38	0.43	NA	NA	0.03	0.78	0.83	NA	NA	XXX
95870	26	A	Muscle test, nonparaspinal	0.37	0.16	0.21	0.16	0.21	0.01	0.54	0.59	0.54	0.59	XXX
95870	TC	A	Muscle test, nonparaspinal	0.00	0.22	0.22	NA	NA	0.02	0.24	0.24	NA	NA	XXX
95872		A	Muscle test, one fiber	1.50	1.25	1.28	NA	NA	0.10	2.85	2.88	NA	NA	XXX
95872	26	A	Muscle test, one fiber	1.50	0.64	0.67	0.64	0.67	0.06	2.20	2.23	2.20	2.23	XXX
95872	TC	A	Muscle test, one fiber	0.00	0.61	0.61	NA	NA	0.04	0.65	0.65	NA	NA	XXX
95875		A	Limb exercise test	1.34	1.25	1.10	NA	NA	0.10	2.69	2.54	NA	NA	XXX
95875	26	A	Limb exercise test	1.34	0.57	0.49	0.57	0.49	0.05	1.96	1.88	1.96	1.88	XXX
95875	TC	A	Limb exercise test	0.00	0.68	0.61	NA	NA	0.05	0.73	0.66	NA	NA	XXX
95900		A	Motor nerve conduction test	0.42	0.47	0.52	NA	NA	0.04	0.93	0.98	NA	NA	XXX
95900	26	A	Motor nerve conduction test	0.42	0.19	0.24	0.19	0.24	0.02	0.63	0.68	0.63	0.68	XXX
95900	TC	A	Motor nerve conduction test	0.00	0.28	0.28	NA	NA	0.02	0.30	0.30	NA	NA	XXX
95903		A	Motor nerve conduction test	0.60	0.51	0.54	NA	NA	0.04	1.15	1.18	NA	NA	XXX
95903	26	A	Motor nerve conduction test	0.60	0.26	0.29	0.26	0.29	0.02	0.88	0.91	0.88	0.91	XXX
95903	TC	A	Motor nerve conduction test	0.00	0.25	0.25	NA	NA	0.02	0.27	0.27	NA	NA	XXX
95904		A	Sense/mixed n conduction tst	0.34	0.37	0.43	NA	NA	0.03	0.74	0.80	NA	NA	XXX
95904	26	A	Sense/mixed n conduction tst	0.34	0.15	0.21	0.15	0.21	0.01	0.50	0.56	0.50	0.56	XXX
95904	TC	A	Sense/mixed n conduction tst	0.00	0.22	0.22	NA	NA	0.02	0.24	0.24	NA	NA	XXX
95920		A	Intraop nerve test add-on	2.11	2.26	2.42	NA	NA	0.15	4.52	4.68	NA	NA	ZZZ
95920	26	A	Intraop nerve test add-on	2.11	0.94	1.09	0.94	1.09	0.09	3.14	3.29	3.14	3.29	ZZZ
95920	TC	A	Intraop nerve test add-on	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	ZZZ
95921		A	Autonomic nerv function test	0.90	0.71	0.72	NA	NA	0.05	1.66	1.67	NA	NA	XXX
95921	26	A	Autonomic nerv function test	0.90	0.33	0.34	0.33	0.34	0.03	1.26	1.27	1.26	1.27	XXX
95921	TC	A	Autonomic nerv function test	0.00	0.38	0.38	NA	NA	0.02	0.40	0.40	NA	NA	XXX
95922		A	Autonomic nerv function test	0.96	0.78	0.77	NA	NA	0.06	1.80	1.79	NA	NA	XXX
95922	26	A	Autonomic nerv function test	0.96	0.40	0.39	0.40	0.39	0.04	1.40	1.39	1.40	1.39	XXX
95922	TC	A	Autonomic nerv function test	0.00	0.38	0.38	NA	NA	0.02	0.40	0.40	NA	NA	XXX
95923		A	Autonomic nerv function test	0.90	2.84	2.31	NA	NA	0.06	3.80	3.27	NA	NA	XXX
95923	26	A	Autonomic nerv function test	0.90	0.38	0.37	0.38	0.37	0.04	1.32	1.31	1.32	1.31	XXX
95923	TC	A	Autonomic nerv function test	0.00	2.46	1.94	NA	NA	0.02	2.48	1.96	NA	NA	XXX
95925		A	Somatosensory testing	0.54	1.15	1.28	NA	NA	0.07	1.76	1.89	NA	NA	XXX
95925	26	A	Somatosensory testing	0.54	0.23	0.35	0.23	0.35	0.02	0.79	0.91	0.79	0.91	XXX
95925	TC	A	Somatosensory testing	0.00	0.92	0.93	NA	NA	0.05	0.97	0.98	NA	NA	XXX
95926		A	Somatosensory testing	0.54	1.16	1.28	NA	NA	0.07	1.77	1.89	NA	NA	XXX
95926	26	A	Somatosensory testing	0.54	0.24	0.35	0.24	0.35	0.02	0.80	0.91	0.80	0.91	XXX
95926	TC	A	Somatosensory testing	0.00	0.92	0.93	NA	NA	0.05	0.97	0.98	NA	NA	XXX
95927		A	Somatosensory testing	0.54	1.18	1.30	NA	NA	0.07	1.79	1.91	NA	NA	XXX
95927	26	A	Somatosensory testing	0.54	0.26	0.37	0.26	0.37	0.02	0.82	0.93	0.82	0.93	XXX
95927	TC	A	Somatosensory testing	0.00	0.92	0.93	NA	NA	0.05	0.97	0.98	NA	NA	XXX
95930		A	Visual evoked potential test	0.35	0.94	0.93	NA	NA	0.02	1.31	1.30	NA	NA	XXX
95930	26	A	Visual evoked potential test	0.35	0.15	0.27	0.15	0.27	0.01	0.51	0.63	0.51	0.63	XXX
95930	TC	A	Visual evoked potential test	0.00	0.79	0.66	NA	NA	0.01	0.80	0.67	NA	NA	XXX
95933		A	Blink reflex test	0.59	1.02	1.11	NA	NA	0.07	1.68	1.77	NA	NA	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
95933	26	A	Blink reflex test	0.59	0.23	0.31	0.23	0.31	0.02	0.84	0.92	0.84	0.92	XXX
95933	TC	A	Blink reflex test	0.00	0.79	0.80	NA	NA	0.05	0.84	0.85	NA	NA	XXX
95934		A	H-reflex test	0.51	0.45	0.49	NA	NA	0.04	1.00	1.04	NA	NA	XXX
95934	26	A	H-reflex test	0.51	0.23	0.27	0.23	0.27	0.02	0.76	0.80	0.76	0.80	XXX
95934	TC	A	H-reflex test	0.00	0.22	0.22	NA	NA	0.02	0.24	0.24	NA	NA	XXX
95936		A	H-reflex test	0.55	0.46	0.49	NA	NA	0.04	1.05	1.08	NA	NA	XXX
95936	26	A	H-reflex test	0.55	0.24	0.27	0.24	0.27	0.02	0.81	0.84	0.81	0.84	XXX
95936	TC	A	H-reflex test	0.00	0.22	0.22	NA	NA	0.02	0.24	0.24	NA	NA	XXX
95937		A	Neuromuscular junction test	0.65	0.60	0.66	NA	NA	0.05	1.30	1.36	NA	NA	XXX
95937	26	A	Neuromuscular junction test	0.65	0.26	0.32	0.26	0.32	0.03	0.94	1.00	0.94	1.00	XXX
95937	TC	A	Neuromuscular junction test	0.00	0.34	0.34	NA	NA	0.02	0.36	0.36	NA	NA	XXX
95950		A	Ambulatory eeg monitoring	1.51	3.47	4.57	NA	NA	0.44	5.42	6.52	NA	NA	XXX
95950	26	A	Ambulatory eeg monitoring	1.51	0.63	0.80	0.63	0.80	0.07	2.21	2.38	2.21	2.38	XXX
95950	TC	A	Ambulatory eeg monitoring	0.00	2.84	3.77	NA	NA	0.37	3.21	4.14	NA	NA	XXX
95951		A	EEG monitoring/videorecord	0.06	21.00	18.15	NA	NA	0.63	21.69	18.84	NA	NA	XXX
95951	26	A	EEG monitoring/videorecord	0.06	2.55	2.32	2.55	2.32	0.24	2.85	2.62	2.85	2.62	XXX
95951	TC	A	EEG monitoring/videorecord	0.00	18.45	15.83	NA	NA	0.39	18.84	16.22	NA	NA	XXX
95953		A	EEG monitoring/computer	3.08	7.70	7.74	NA	NA	0.49	11.27	11.31	NA	NA	XXX
95953	26	A	EEG monitoring/computer	3.08	1.30	1.30	1.30	1.30	0.12	4.50	4.50	4.50	4.50	XXX
95953	TC	A	EEG monitoring/computer	0.00	6.40	6.44	NA	NA	0.37	6.77	6.81	NA	NA	XXX
95954		A	EEG monitoring/giving drugs	2.45	3.66	3.37	NA	NA	0.15	6.26	5.97	NA	NA	XXX
95954	26	A	EEG monitoring/giving drugs	2.45	1.06	1.30	1.06	1.30	0.10	3.61	3.85	3.61	3.85	XXX
95954	TC	A	EEG monitoring/giving drugs	0.00	2.60	2.07	NA	NA	0.05	2.65	2.12	NA	NA	XXX
95955		A	EEG during surgery	1.01	2.35	2.55	NA	NA	0.19	3.55	3.75	NA	NA	XXX
95955	26	A	EEG during surgery	1.01	0.37	0.56	0.37	0.56	0.05	1.43	1.62	1.43	1.62	XXX
95955	TC	A	EEG during surgery	0.00	1.98	1.99	NA	NA	0.14	2.12	2.13	NA	NA	XXX
95956		A	Eeg monitoring, cable/radio	3.08	23.17	19.43	NA	NA	0.49	26.74	23.00	NA	NA	XXX
95956	26	A	Eeg monitoring, cable/radio	3.08	1.32	1.40	1.32	1.40	0.12	4.52	4.60	4.52	4.60	XXX
95956	TC	A	Eeg monitoring, cable/radio	0.00	21.85	18.03	NA	NA	0.37	22.22	18.40	NA	NA	XXX
95957		A	EEG digital analysis	1.98	2.57	2.54	NA	NA	0.18	4.73	4.70	NA	NA	XXX
95957	26	A	EEG digital analysis	1.98	0.85	0.81	0.85	0.81	0.08	2.91	2.87	2.91	2.87	XXX
95957	TC	A	EEG digital analysis	0.00	1.72	1.73	NA	NA	0.10	1.82	1.83	NA	NA	XXX
95958		A	EEG monitoring/function test	4.25	3.51	3.96	NA	NA	0.27	8.03	8.48	NA	NA	XXX
95958	26	A	EEG monitoring/function test	4.25	1.75	2.19	1.75	2.19	0.16	6.16	6.60	6.16	6.60	XXX
95958	TC	A	EEG monitoring/function test	0.00	1.76	1.77	NA	NA	0.11	1.87	1.88	NA	NA	XXX
95961		A	Electrode stimulation, brain	2.97	2.64	2.71	NA	NA	0.17	5.78	5.85	NA	NA	XXX
95961	26	A	Electrode stimulation, brain	2.97	1.32	1.38	1.32	1.38	0.11	4.40	4.46	4.40	4.46	XXX
95961	TC	A	Electrode stimulation, brain	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	XXX
95962		A	Electrode stim, brain add-on	3.21	2.72	2.77	NA	NA	0.19	6.12	6.17	NA	NA	ZZZ
95962	26	A	Electrode stim, brain add-on	3.21	1.40	1.44	1.40	1.44	0.13	4.74	4.78	4.74	4.78	ZZZ
95962	TC	A	Electrode stim, brain add-on	0.00	1.32	1.33	NA	NA	0.06	1.38	1.39	NA	NA	ZZZ
95970		A	Analyze neurostim, no prog	0.45	0.15	0.15	0.13	0.13	0.03	0.63	0.63	0.61	0.61	XXX
95971		A	Analyze neurostim, simple	0.78	0.28	0.28	0.23	0.23	0.05	1.11	1.11	1.06	1.06	XXX
95972		A	Analyze neurostim, complex	1.50	0.54	0.54	0.45	0.45	0.09	2.13	2.13	2.04	2.04	XXX
95973		A	Analyze neurostim, complex	0.92	0.33	0.33	0.28	0.28	0.06	1.31	1.31	1.26	1.26	ZZZ
95974		A	Cranial neurostim, complex	0.03	1.07	1.07	0.95	0.95	0.16	1.26	1.26	1.14	1.14	XXX
95975		A	Cranial neurostim, complex	1.70	0.62	0.62	0.58	0.58	0.09	2.41	2.41	2.37	2.37	ZZZ
95999		C	Neurological procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
96100		A	Psychological testing	0.00	1.78	1.79	1.78	1.79	0.15	1.93	1.94	1.93	1.94	XXX
96105		A	Assessment of aphasia	0.00	1.78	1.79	1.78	1.79	0.15	1.93	1.94	1.93	1.94	XXX
96110		C	Developmental test, lim	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
96111		A	Developmental test, extend	0.00	1.78	1.79	1.78	1.79	0.15	1.93	1.94	1.93	1.94	XXX
96115		A	Neurobehavior status exam	0.00	1.78	1.79	1.78	1.79	0.15	1.93	1.94	1.93	1.94	XXX
96117		A	Neuropsych test battery	0.00	1.78	1.79	1.78	1.79	0.15	1.93	1.94	1.93	1.94	XXX
96400		A	Chemotherapy, sc/im	0.00	0.14	0.14	0.14	0.14	0.01	0.15	0.15	0.15	0.15	XXX
96405		A	Intralesional chemo admin	0.52	1.72	1.39	0.24	0.28	0.02	2.26	1.93	0.78	0.82	000
96406		A	Intralesional chemo admin	0.80	2.20	1.80	0.26	0.35	0.02	3.02	2.62	1.08	1.17	000
96408		A	Chemotherapy, push technique	0.00	0.98	0.99	0.98	0.99	0.05	1.03	1.04	1.03	1.04	XXX
96410		A	Chemotherapy,infusion method	0.00	1.56	1.57	1.56	1.57	0.07	1.63	1.64	1.63	1.64	XXX
96412		A	Chemo, infuse method add-on	0.00	1.16	1.17	1.16	1.17	0.06	1.22	1.23	1.22	1.23	ZZZ
96414		A	Chemo, infuse method add-on	0.00	1.35	1.36	1.35	1.36	0.07	1.42	1.43	1.42	1.43	XXX
96420		A	Chemotherapy, push technique	0.00	1.26	1.27	1.26	1.27	0.07	1.33	1.34	1.33	1.34	XXX
96422		A	Chemotherapy,infusion method	0.00	1.24	1.25	1.24	1.25	0.07	1.31	1.32	1.31	1.32	XXX
96423		A	Chemo, infuse method add-on	0.00	0.49	0.49	0.49	0.49	0.02	0.51	0.51	0.51	0.51	ZZZ
96425		A	Chemotherapy,infusion method	0.00	1.45	1.46	1.45	1.46	0.07	1.52	1.53	1.52	1.53	XXX
96440		A	Chemotherapy, intracavitary	2.37	7.24	5.65	0.99	0.96	0.09	9.70	8.11	3.45	3.42	000
96445		A	Chemotherapy, intracavitary	2.20	7.39	5.81	0.97	0.99	0.07	9.66	8.08	3.24	3.26	000
96450		A	Chemotherapy, into CNS	1.89	5.81	4.59	0.89	0.90	0.06	7.76	6.54	2.84	2.85	000
96520		A	Pump refilling, maintenance	0.00	0.90	0.91	0.90	0.91	0.05	0.95	0.96	0.95	0.96	XXX
96530		A	Pump refilling, maintenance	0.00	1.08	1.09	1.08	1.09	0.05	1.13	1.14	1.13	1.14	XXX
96542		A	Chemotherapy injection	1.42	3.54	2.95	0.54	0.70	0.04	5.00	4.41	2.00	2.16	XXX
96545		B	Provide chemotherapy agent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
96549		C	Chemotherapy, unspecified	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
96570		A	Photodynamic tx, 30 min	1.10	0.73	0.73	0.44	0.44	0.28	2.11	2.11	1.82	1.82	ZZZ
96571		A	Photodynamic tx, addl 15 min	0.55	0.31	0.31	0.22	0.22	0.28	1.14	1.14	1.05	1.05	ZZZ
96900		A	Ultraviolet light therapy	0.00	0.40	0.40	0.40	0.40	0.02	0.42	0.42	0.42	0.42	XXX
96902		B	Trichogram	0.41	0.23	0.25	0.16	0.20	0.01	0.65	0.67	0.58	0.62	XXX
96910		A	Photochemotherapy with UV–B	0.00	0.59	0.59	0.59	0.59	0.03	0.62	0.62	0.62	0.62	XXX
96912		A	Photochemotherapy with UV–A	0.00	0.66	0.67	0.66	0.67	0.04	0.70	0.71	0.70	0.71	XXX
96913		A	Photochemotherapy, UV–A or B	0.00	1.37	1.38	1.37	1.38	0.08	1.45	1.46	1.45	1.46	XXX
96999		C	Dermatological procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97001		A	Pt evaluation	1.20	0.80	0.70	0.51	0.48	0.05	2.05	1.95	1.76	1.73	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
97002		A	Pt re-evaluation	0.60	0.44	0.34	0.24	0.19	0.02	1.06	0.96	0.86	0.81	XXX
97003		A	Ot evaluation	1.20	0.78	0.68	0.39	0.39	0.05	2.03	1.93	1.64	1.64	XXX
97004		A	Ot re-evaluation	0.60	0.44	0.34	0.19	0.15	0.02	1.06	0.96	0.81	0.77	XXX
97010		B	Hot or cold packs therapy	0.06	0.24	0.24	0.03	0.08	0.01	0.31	0.31	0.10	0.15	XXX
97012		A	Mechanical traction therapy	0.25	0.32	0.29	0.12	0.14	0.01	0.58	0.55	0.38	0.40	XXX
97014		A	Electric stimulation therapy	0.18	0.29	0.27	0.09	0.12	0.01	0.48	0.46	0.28	0.31	XXX
97016		A	Vasopneumatic device therapy	0.18	0.29	0.29	0.09	0.14	0.01	0.48	0.48	0.28	0.33	XXX
97018		A	Paraffin bath therapy	0.06	0.22	0.23	0.03	0.09	0.01	0.29	0.30	0.10	0.16	XXX
97020		A	Microwave therapy	0.06	0.24	0.24	0.03	0.08	0.01	0.31	0.31	0.10	0.15	XXX
97022		A	Whirlpool therapy	0.17	0.43	0.38	0.08	0.11	0.01	0.61	0.56	0.26	0.29	XXX
97024		A	Diathermy treatment	0.06	0.24	0.24	0.03	0.08	0.01	0.31	0.31	0.10	0.15	XXX
97026		A	Infrared therapy	0.06	0.23	0.23	0.03	0.08	0.01	0.30	0.30	0.10	0.15	XXX
97028		A	Ultraviolet therapy	0.08	0.24	0.23	0.04	0.08	0.01	0.33	0.32	0.13	0.17	XXX
97032		A	Electrical stimulation	0.25	0.35	0.30	0.12	0.13	0.01	0.61	0.56	0.38	0.39	XXX
97033		A	Electric current therapy	0.26	0.37	0.32	0.13	0.14	0.01	0.64	0.59	0.40	0.41	XXX
97034		A	Contrast bath therapy	0.21	0.33	0.28	0.10	0.10	0.01	0.55	0.50	0.32	0.32	XXX
97035		A	Ultrasound therapy	0.21	0.21	0.19	0.10	0.11	0.01	0.43	0.41	0.32	0.33	XXX
97036		A	Hydrotherapy	0.28	0.43	0.38	0.14	0.16	0.01	0.72	0.67	0.43	0.45	XXX
97039		A	Physical therapy treatment	0.20	0.32	0.31	0.10	0.14	0.01	0.53	0.52	0.31	0.35	XXX
97110		A	Therapeutic exercises	0.45	0.32	0.28	0.22	0.20	0.02	0.79	0.75	0.69	0.67	XXX
97112		A	Neuromuscular reeducation	0.45	0.43	0.36	0.22	0.20	0.02	0.90	0.83	0.69	0.67	XXX
97113		A	Aquatic therapy/exercises	0.44	0.44	0.39	0.22	0.22	0.02	0.90	0.85	0.68	0.68	XXX
97116		A	Gait training therapy	0.40	0.41	0.34	0.20	0.18	0.01	0.82	0.75	0.61	0.59	XXX
97124		A	Massage therapy	0.35	0.38	0.32	0.17	0.16	0.01	0.74	0.68	0.53	0.52	XXX
97139		A	Physical medicine procedure	0.21	0.31	0.28	0.10	0.12	0.01	0.53	0.50	0.32	0.34	XXX
97140		A	Manual therapy	0.43	0.41	0.41	0.21	0.21	0.02	0.86	0.86	0.66	0.66	XXX
97150		A	Group therapeutic procedures	0.27	0.34	0.31	0.13	0.15	0.02	0.63	0.60	0.42	0.44	XXX
97504		A	Orthotic training	0.45	0.41	0.35	0.22	0.20	0.03	0.89	0.83	0.70	0.68	XXX
97520		A	Prosthetic training	0.45	0.43	0.36	0.22	0.21	0.02	0.90	0.83	0.69	0.68	XXX
97530		A	Therapeutic activities	0.44	0.30	0.27	0.22	0.21	0.02	0.76	0.73	0.68	0.67	XXX
97535		A	Self care mngment training	0.45	0.43	0.37	0.22	0.21	0.02	0.90	0.84	0.69	0.68	XXX
97537		A	Community/work reintegration	0.45	0.43	0.37	0.22	0.21	0.01	0.89	0.83	0.68	0.67	XXX
97542		A	Wheelchair mngment training	0.25	0.33	0.29	0.12	0.14	0.01	0.59	0.55	0.38	0.40	XXX
97545		R	Work hardening	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97546		R	Work hardening add-on	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
97703		A	Prosthetic checkout	0.25	0.21	0.21	0.12	0.14	0.01	0.47	0.47	0.38	0.40	XXX
97750		A	Physical performance test	0.45	0.35	0.33	0.22	0.23	0.02	0.82	0.80	0.69	0.70	XXX
97770		A	Cognitive skills development	0.44	0.38	0.36	0.22	0.24	0.01	0.83	0.81	0.67	0.69	XXX
97780		N	Acupuncture w/o stimul	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97781		N	Acupuncture w/stimul	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
97799		C	Physical medicine procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
98925		A	Osteopathic manipulation	0.45	0.32	0.31	0.15	0.18	0.02	0.79	0.78	0.62	0.65	000
98926		A	Osteopathic manipulation	0.65	0.39	0.40	0.25	0.30	0.02	1.06	1.07	0.92	0.97	000
98927		A	Osteopathic manipulation	0.87	0.50	0.48	0.30	0.33	0.03	1.40	1.38	1.20	1.23	000
98928		A	Osteopathic manipulation	1.03	0.54	0.52	0.34	0.37	0.03	1.60	1.58	1.40	1.43	000
98929		A	Osteopathic manipulation	1.19	0.63	0.58	0.37	0.38	0.04	1.86	1.81	1.60	1.61	000
98940		A	Chiropractic manipulation	0.45	0.24	0.26	0.12	0.17	0.01	0.70	0.72	0.58	0.63	000
98941		A	Chiropractic manipulation	0.65	0.31	0.31	0.18	0.21	0.02	0.98	0.98	0.85	0.88	000
98942		A	Chiropractic manipulation	0.87	0.36	0.35	0.24	0.26	0.03	1.26	1.25	1.14	1.16	000
98943		N	Chiropractic manipulation	0.40	0.33	0.33	0.16	0.20	0.01	0.74	0.74	0.57	0.61	XXX
99000		B	Specimen handling	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99001		B	Specimen handling	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99002		B	Device handling	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99024		B	Postop follow-up visit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99025		B	Initial surgical evaluation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99050		B	Medical services after hrs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99052		B	Medical services at night	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99054		B	Medical servcs, unusual hrs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99056		B	Non-office medical services	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99058		B	Office emergency care	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99070		B	Special supplies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99071		B	Patient education materials	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99075		N	Medical testimony	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	00	XXX
99078		B	Group health education	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99080		B	Special reports or forms	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99082		C	Unusual physician travel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99090		B	Computer data analysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99100		B	Special anesthesia service	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99116		B	Anesthesia with hypothermia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99135		B	Special anesthesia procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99140		B	Emergency anesthesia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99141		B	Sedation, iv/im or inhalant	0.80	1.69	1.49	0.32	0.47	0.05	2.54	2.34	1.17	1.32	XXX
99142		B	Sedation, oral/rectal/nasal	0.60	1.62	1.38	0.24	0.35	0.04	2.26	2.02	0.88	0.99	XXX
99170		A	Anogenital exam, child	1.75	1.75	1.75	0.69	0.69	0.11	3.61	3.61	2.55	2.55	000
99173		N	Visual screening test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99175		A	Induction of vomiting	0.00	1.41	1.42	1.41	1.42	0.08	1.49	1.50	1.49	1.50	XXX
99183		A	Hyperbaric oxygen therapy	2.34	NA	NA	0.74	1.01	0.12	NA	NA	3.20	3.47	XXX
99185		A	Regional hypothermia	0.00	NA	NA	0.65	0.65	0.03	NA	NA	0.68	0.68	XXX
99186		A	Total body hypothermia	0.00	NA	NA	1.80	1.81	0.38	NA	NA	2.18	2.19	XXX
99190		X	Special pump services	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99191		X	Special pump services	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99192		X	Special pump services	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
99195		A	Phlebotomy	0.00	0.45	0.45	0.45	0.45	0.02	0.47	0.47	0.47	0.47	XXX
99199		C	Special service/proc/report	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99201		A	Office/outpatient visit, new	0.45	0.75	0.68	0.16	0.24	0.02	1.22	1.15	0.63	0.71	XXX
99202		A	Office/outpatient visit, new	0.88	0.99	0.88	0.32	0.38	0.04	1.91	1.80	1.24	1.30	XXX
99203		A	Office/outpatient visit, new	1.34	1.30	1.14	0.49	0.53	0.07	2.71	2.55	1.90	1.94	XXX
99204		A	Office/outpatient visit, new	0.02	1.74	1.55	0.73	0.79	0.09	1.85	1.66	0.84	0.90	XXX
99205		A	Office/outpatient visit, new	2.67	1.92	1.70	0.94	0.97	0.11	4.70	4.48	3.72	3.75	XXX
99211		A	Office/outpatient visit, est	0.17	0.54	0.46	0.06	0.10	0.01	0.72	0.64	0.24	0.28	XXX
99212		A	Office/outpatient visit, est	0.45	0.60	0.54	0.16	0.21	0.02	1.07	1.01	0.63	0.68	XXX
99213		A	Office/outpatient visit, est	0.67	0.73	0.67	0.24	0.30	0.02	1.42	1.36	0.93	0.99	XXX
99214		A	Office/outpatient visit, est	1.10	0.97	0.88	0.40	0.46	0.04	2.11	2.02	1.54	1.60	XXX
99215		A	Office/outpatient visit, est	1.77	1.24	1.16	0.63	0.71	0.07	3.08	3.00	2.47	2.55	XXX
99217		A	Observation care discharge	1.28	NA	NA	0.44	0.47	0.05	NA	NA	1.77	1.80	XXX
99218		A	Observation care	1.28	NA	NA	0.44	0.52	0.05	NA	NA	1.77	1.85	XXX
99219		A	Observation care	2.14	NA	NA	0.73	0.83	0.08	NA	NA	2.95	3.05	XXX
99220		A	Observation care	2.99	NA	NA	1.03	1.08	0.11	NA	NA	4.13	4.18	XXX
99221		A	Initial hospital care	1.28	NA	NA	0.46	0.53	0.05	NA	NA	1.79	1.86	XXX
99222		A	Initial hospital care	2.14	NA	NA	0.75	0.85	0.08	NA	NA	2.97	3.07	XXX
99223		A	Initial hospital care	2.99	NA	NA	1.04	1.09	0.11	NA	NA	4.14	4.19	XXX
99231		A	Subsequent hospital care	0.64	NA	NA	0.23	0.28	0.02	NA	NA	0.89	0.94	XXX
99232		A	Subsequent hospital care	1.06	NA	NA	0.37	0.40	0.04	NA	NA	1.47	1.50	XXX
99233		A	Subsequent hospital care	1.51	NA	NA	0.53	0.56	0.05	NA	NA	2.09	2.12	XXX
99234		A	Observ/hosp same date	1.95	NA	NA	0.89	0.85	0.10	NA	NA	2.94	2.90	XXX
99235		A	Observ/hosp same date	2.81	NA	NA	1.17	1.16	0.12	NA	NA	4.10	4.09	XXX
99236		A	Observ/hosp same date	3.66	NA	NA	1.47	1.41	0.14	NA	NA	5.27	5.21	XXX
99238		A	Hospital discharge day	1.28	NA	NA	0.44	0.47	0.04	NA	NA	1.76	1.79	XXX
99239		A	Hospital discharge day	1.75	NA	NA	0.61	0.60	0.06	NA	NA	2.42	2.41	XXX
99241		A	Office consultation	0.64	0.90	0.85	0.23	0.35	0.04	1.58	1.53	0.91	1.03	XXX
99242		A	Office consultation	1.29	1.28	1.17	0.48	0.57	0.08	2.65	2.54	1.85	1.94	XXX
99243		A	Office consultation	1.72	1.51	1.40	0.65	0.75	0.09	3.32	3.21	2.46	2.56	XXX
99244		A	Office consultation	2.58	1.95	1.80	0.94	1.04	0.11	4.64	4.49	3.63	3.73	XXX
99245		A	Office consultation	3.43	2.35	2.22	1.26	1.40	0.14	5.92	5.79	4.83	4.97	XXX
99251		A	Initial inpatient consult	0.66	NA	NA	0.29	0.40	0.04	NA	NA	0.99	1.10	XXX
99252		A	Initial inpatient consult	1.32	NA	NA	0.56	0.63	0.08	NA	NA	1.96	2.03	XXX
99253		A	Initial inpatient consult	1.82	NA	NA	0.75	0.82	0.09	NA	NA	2.66	2.73	XXX
99254		A	Initial inpatient consult	2.64	NA	NA	1.05	1.11	0.11	NA	NA	3.80	3.86	XXX
99255		A	Initial inpatient consult	3.65	NA	NA	1.42	1.49	0.15	NA	NA	5.22	5.29	XXX
99261		A	Follow-up inpatient consult	0.42	NA	NA	0.20	0.24	0.02	NA	NA	0.64	0.68	XXX
99262		A	Follow-up inpatient consult	0.85	NA	NA	0.36	0.40	0.03	NA	NA	1.24	1.28	XXX
99263		A	Follow-up inpatient consult	1.27	NA	NA	0.51	0.57	0.05	NA	NA	1.83	1.89	XXX
99271		A	Confirmatory consultation	0.45	0.60	0.61	0.20	0.31	0.02	1.07	1.08	0.67	0.78	XXX
99272		A	Confirmatory consultation	0.84	0.83	0.82	0.36	0.46	0.05	1.72	1.71	1.25	1.35	XXX
99273		A	Confirmatory consultation	1.19	1.02	1.04	0.50	0.65	0.07	2.28	2.30	1.76	1.91	XXX
99274		A	Confirmatory consultation	1.73	1.33	1.33	0.71	0.86	0.09	3.15	3.15	2.53	2.68	XXX
99275		A	Confirmatory consultation	2.31	1.58	1.66	0.88	1.13	0.10	3.99	4.07	3.29	3.54	XXX
99281		A	Emergency dept visit	0.33	NA	NA	0.09	0.14	0.02	NA	NA	0.44	0.49	XXX
99282		A	Emergency dept visit	0.55	NA	NA	0.15	0.22	0.03	NA	NA	0.73	0.80	XXX
99283		A	Emergency dept visit	1.24	NA	NA	0.32	0.37	0.08	NA	NA	1.64	1.69	XXX
99284		A	Emergency dept visit	1.95	NA	NA	0.49	0.56	0.12	NA	NA	2.56	2.63	XXX
99285		A	Emergency dept visit	3.06	NA	NA	0.74	0.86	0.19	NA	NA	3.99	4.11	XXX
99288		B	Direct advanced life support	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99291		A	Critical care, first hour	0.04	1.39	1.43	1.17	1.27	0.14	1.57	1.61	1.35	1.45	XXX
99292		A	Critical care, addl 30 min	0.02	0.76	0.74	0.58	0.61	0.08	0.86	0.84	0.68	0.71	ZZZ
99295		A	Neonatal critical care	0.16	NA	NA	4.93	5.08	0.62	NA	NA	5.71	5.86	XXX
99296		A	Neonatal critical care	0.08	NA	NA	2.64	2.65	0.24	NA	NA	2.96	2.97	XXX
99297		A	Neonatal critical care	0.04	NA	NA	1.36	1.35	0.11	NA	NA	1.51	1.50	XXX
99298		A	Neonatal critical care	2.75	NA	NA	0.94	0.94	0.09	NA	NA	3.78	3.78	XXX
99301		A	Nursing facility care	1.20	NA	NA	0.41	0.43	0.04	NA	NA	1.65	1.67	XXX
99302		A	Nursing facility care	1.61	NA	NA	0.55	0.55	0.06	NA	NA	2.22	2.22	XXX
99303		A	Nursing facility care	2.01	NA	NA	0.67	0.76	0.07	NA	NA	2.75	2.84	XXX
99311		A	Nursing fac care, subseq	0.60	NA	NA	0.20	0.24	0.02	NA	NA	0.82	0.86	XXX
99312		A	Nursing fac care, subseq	0.01	NA	NA	0.33	0.36	0.03	NA	NA	0.37	0.40	XXX
99313		A	Nursing fac care, subseq	1.42	NA	NA	0.48	0.49	0.05	NA	NA	1.95	1.96	XXX
99315		A	Nursing fac discharge day	1.13	NA	NA	0.38	0.42	0.04	NA	NA	1.55	1.59	XXX
99316		A	Nursing fac discharge day	1.50	NA	NA	0.52	0.53	0.05	NA	NA	2.07	2.08	XXX
99321		A	Rest home visit, new patient	0.71	0.41	0.41	0.32	0.34	0.03	1.15	1.15	1.06	1.08	XXX
99322		A	Rest home visit, new patient	1.01	0.64	0.62	0.44	0.47	0.04	1.69	1.67	1.49	1.52	XXX
99323		A	Rest home visit, new patient	1.28	0.84	0.83	0.53	0.60	0.05	2.17	2.16	1.86	1.93	XXX
99331		A	Rest home visit, est pat	0.60	0.43	0.40	0.30	0.30	0.02	1.05	1.02	0.92	0.92	XXX
99332		A	Rest home visit, est pat	0.80	0.53	0.50	0.37	0.38	0.03	1.36	1.33	1.20	1.21	XXX
99333		A	Rest home visit, est pat	0.01	0.65	0.61	0.44	0.45	0.03	0.69	0.65	0.48	0.49	XXX
99341		A	Home visit, new patient	1.01	0.52	0.54	0.48	0.51	0.04	1.57	1.59	1.53	1.56	XXX
99342		A	Home visit, new patient	1.52	0.79	0.76	0.59	0.61	0.06	2.37	2.34	2.17	2.19	XXX
99343		A	Home visit, new patient	2.27	1.20	1.11	0.89	0.88	0.08	3.55	3.46	3.24	3.23	XXX
99344		A	Home visit, new patient	3.03	1.47	1.33	1.09	1.05	0.10	4.60	4.46	4.22	4.18	XXX
99345		A	Home visit, new patient	3.79	1.74	1.54	1.32	1.22	0.12	5.65	5.45	5.23	5.13	XXX
99347		A	Home visit, est patient	0.76	0.45	0.46	0.35	0.39	0.03	1.24	1.25	1.14	1.18	XXX
99348		A	Home visit, est patient	1.26	0.67	0.65	0.52	0.54	0.04	1.97	1.95	1.82	1.84	XXX
99349		A	Home visit, est patient	2.02	0.99	0.91	0.79	0.76	0.07	3.08	3.00	2.88	2.85	XXX
99350		A	Home visit, est patient	3.03	1.35	1.22	1.11	1.04	0.10	4.48	4.35	4.24	4.17	XXX
99354		A	Prolonged service, office	1.77	1.28	1.17	0.61	0.66	0.06	3.11	3.00	2.44	2.49	ZZZ
99355		A	Prolonged service, office	1.77	1.14	1.06	0.58	0.64	0.06	2.97	2.89	2.41	2.47	ZZZ

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
99356		A	Prolonged service, inpatient	1.71	NA	NA	0.59	0.67	0.06	NA	NA	2.36	2.44	ZZZ
99357		A	Prolonged service, inpatient	1.71	NA	NA	0.61	0.69	0.07	NA	NA	2.39	2.47	ZZZ
99358		B	Prolonged serv, w/o contact	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99359		B	Prolonged serv, w/o contact	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ
99360		X	Physician standby services	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99361		B	Physician/team conference	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99362		B	Physician/team conference	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99371		B	Physician phone consultation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99372		B	Physician phone consultation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99373		B	Physician phone consultation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99374		B	Home health care supervision	1.10	1.28	1.10	0.44	0.47	0.04	2.42	2.24	1.58	1.61	XXX
99375		N	Home health care supervision	1.73	1.30	0.93	0.60	0.58	0.06	3.09	2.72	2.39	2.37	XXX
99377		B	Hospice care supervision	1.10	1.29	1.11	0.44	0.47	0.04	2.43	2.25	1.58	1.61	XXX
99378		N	Hospice care supervision	1.73	1.50	1.03	0.58	0.57	0.06	3.29	2.82	2.37	2.36	XXX
99379		B	Nursing fac care supervision	1.10	1.27	1.09	0.44	0.47	0.04	2.41	2.23	1.58	1.61	XXX
99380		B	Nursing fac care supervision	1.73	1.54	1.29	0.69	0.66	0.06	3.33	3.08	2.48	2.45	XXX
99381		N	Prev visit, new, infant	1.19	1.33	1.33	0.47	0.69	0.18	2.70	2.70	1.84	2.06	XXX
99382		N	Prev visit, new, age 1–4	1.36	1.37	1.41	0.54	0.79	0.04	2.77	2.81	1.94	2.19	XXX
99383		N	Prev visit, new, age 5–11	1.36	1.31	1.37	0.54	0.79	0.04	2.71	2.77	1.94	2.19	XXX
99384		N	Prev visit, new, age 12–17	1.53	1.38	1.47	0.61	0.89	0.05	2.96	3.05	2.19	2.47	XXX
99385		N	Prev visit, new, age 18–39	1.53	1.38	1.42	0.61	0.84	0.05	2.96	3.00	2.19	2.42	XXX
99386		N	Prev visit, new, age 40–64	1.88	1.56	1.64	0.75	1.03	0.06	3.50	3.58	2.69	2.97	XXX
99387		N	Prev visit, new, 65 & over	2.06	1.69	1.78	0.82	1.13	0.06	3.81	3.90	2.94	3.25	XXX
99391		N	Prev visit, est, infant	1.02	0.91	0.97	0.40	0.59	0.15	2.08	2.14	1.57	1.76	XXX
99392		N	Prev visit, est, age 1–4	1.19	0.98	1.07	0.47	0.69	0.04	2.21	2.30	1.70	1.92	XXX
99393		N	Prev visit, est, age 5–11	1.19	0.96	1.05	0.47	0.69	0.04	2.19	2.28	1.70	1.92	XXX
99394		N	Prev visit, est, age 12–17	1.36	1.04	1.16	0.54	0.79	0.04	2.44	2.56	1.94	2.19	XXX
99395		N	Prev visit, est, age 18–39	1.36	1.06	1.14	0.54	0.75	0.04	2.46	2.54	1.94	2.15	XXX
99396		N	Prev visit, est, age 40–64	1.53	1.15	1.24	0.61	0.84	0.05	2.73	2.82	2.19	2.42	XXX
99397		N	Prev visit, est, 65 & over	1.71	1.25	1.36	0.68	0.93	0.05	3.01	3.12	2.44	2.69	XXX
99401		N	Preventive counseling, indiv	0.48	0.54	0.53	0.19	0.27	0.01	1.03	1.02	0.68	0.76	XXX
99402		N	Preventive counseling, indiv	0.98	0.78	0.83	0.39	0.54	0.03	1.79	1.84	1.40	1.55	XXX
99403		N	Preventive counseling, indiv	1.46	1.01	1.12	0.58	0.80	0.04	2.51	2.62	2.08	2.30	XXX
99404		N	Preventive counseling, indiv	1.95	1.24	1.41	0.77	1.06	0.05	3.24	3.41	2.77	3.06	XXX
99411		N	Preventive counseling, group	0.15	0.16	0.16	0.06	0.08	0.01	0.32	0.32	0.22	0.24	XXX
99412		N	Preventive counseling, group	0.25	0.22	0.23	0.10	0.14	0.01	0.48	0.49	0.36	0.40	XXX
99420		N	Health risk assessment test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99429		N	Unlisted preventive service	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99431		A	Initial care, normal newborn	1.17	NA	NA	0.39	0.62	0.04	NA	NA	1.60	1.83	XXX
99432		A	Newborn care, not in hosp	1.26	0.73	0.90	0.40	0.66	0.04	2.03	2.20	1.70	1.96	XXX
99433		A	Normal newborn care/hospital	0.62	NA	NA	0.22	0.34	0.02	NA	NA	0.86	0.98	XXX
99435		A	Newborn discharge day hosp	1.50	NA	NA	0.50	0.80	0.05	NA	NA	2.05	2.35	XXX
99436		A	Attendance, birth	1.50	0.48	0.78	0.48	0.78	0.05	2.03	2.33	2.03	2.33	XXX
99440		A	Newborn resuscitation	2.93	NA	NA	0.97	1.55	0.09	NA	NA	3.99	4.57	XXX
99450		N	Life/disability evaluation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99455		R	Disability examination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99456		R	Disability examination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
99499		C	Unlisted e&m service	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0021		I	Outside state ambulance serv	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0030		X	Air ambulance service	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0040		X	Helicopter ambulance service	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0050		X	Water amb service emergency	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0080		I	Noninterest escort in non er	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0090		I	Interest escort in non er	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0100		I	Nonemergency transport taxi	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0110		I	Nonemergency transport bus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0120		I	Noner transport mini-bus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0130		I	Noner transport wheelch van	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0140		I	Nonemergency transport air	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0160		I	Noner transport case worker	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0170		I	Noner transport parking fees	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0180		I	Noner transport lodgng recip	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0190		I	Noner transport meals recip	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0200		I	Noner transport lodgng escrt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0210		I	Noner transport meals escort	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0225		X	Neonatal emergency transport	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0300		X	Ambulance basic non-emer all	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0302		X	Ambulance basic emergeny all	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0304		X	Amb adv non-er no serv all	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0306		X	Amb adv non-er spec serv all	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0308		X	Amb adv er no spec serv all	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0310		X	Amb adv er spec serv all	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0320		X	Amb basic non-er + supplies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0322		X	Amb basic emerg + supplies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0324		X	Adv non-er serv sep mileage	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0326		X	Adv non-er no serv sep mile	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0328		X	Adv er no serv sep mileage	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0330		X	Adv er spec serv sep mile	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0340		X	Amb basic non-er + mileage	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0342		X	Ambul basic emer + mileage	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0344		X	Amb adv non-er no serv +mile	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0346		X	Amb adv non-er serv + mile	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
A0348		X	Adv emer no spec serv + mile	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0350		X	Adv emer spec serv + mileage	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0360		X	Basic non-er sep mile & supp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0362		X	Basic emer sep mile & supply	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0364		X	Adv non-er no serv sep mi&su	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0366		X	Adv non-er serv sep mil&supp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0368		X	Adv er no serv sep mile&supp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0370		X	Adv er spec serv sep mi&supp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0380		X	Basic life support mileage	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0382		X	Basic support routine suppls	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0384		X	Bls defibrillation supplies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0390		X	Advanced life support mileag	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0392		X	Als defibrillation supplies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0394		X	Als IV drug therapy supplies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0396		X	Als esophageal intub suppls	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0398		X	Als routine disposble suppls	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0420		X	Ambulance waiting 1/2 hr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0422		X	Ambulance 02 life sustaining	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0424		X	Extra ambulance attendant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0888		N	Noncovered ambulance mileage	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A0999		X	Unlisted ambulance service	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4206		I	1 CC sterile syringe&needle	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4207		I	2 CC sterile syringe&needle	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4208		I	3 CC sterile syringe&needle	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4209		I	5+ CC sterile syringe&needle	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4210		N	Nonneedle injection device	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4211		P	Supp for self-adm injections	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4212		P	Non coring needle or stylet	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4213		I	20+ CC syringe only	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4214		P	30 CC sterile water/saline	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4215		I	Sterile needle	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4220		P	Infusion pump refill kit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4221		X	Maint drug infus cath per wk	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4222		X	Drug infusion pump supplies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4230		X	Infus insulin pump non needl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4231		X	Infusion insulin pump needle	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4232		X	Syringe w/needle insulin 3cc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4244		I	Alcohol or peroxide per pint	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4245		I	Alcohol wipes per box	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4246		I	Betadine/phisohex solution	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4247		I	Betadine/iodine swabs/wipes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4250		N	Urine reagent strips/tablets	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4253		P	Blood glucose/reagent strips	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4254		X	Battery for glucose monitor	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4255		X	Glucose monitor platforms	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4256		P	Calibrator solution/chips	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4258		P	Lancet device each	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4259		P	Lancets per box	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4260		N	Levonorgestrel implant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4261		N	Cervical cap contraceptive	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4262		B	Temporary tear duct plug	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4263		A	Permanent tear duct plug	0.00	0.00	0.26	0.00	0.26	0.00	0.00	0.26	0.00	0.26	XXX
A4265		P	Paraffin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4270		B	Disposable endoscope sheath	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4280		X	Brst prsths adhsv attchmnt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4300		A	Cath impl vasc access portal	0.00	0.00	0.26	0.00	0.26	0.00	0.00	0.26	0.00	0.26	XXX
A4301		P	Implantable access syst perc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4305		P	Drug delivery system >=50 ML	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4306		P	Drug delivery system <=5 ML	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4310		P	Insert tray w/o bag/cath	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4311		P	Catheter w/o bag 2-way latex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4312		P	Cath w/o bag 2-way silicone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4313		P	Catheter w/bag 3-way	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4314		P	Cath w/drainage 2-way latex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4315		P	Cath w/drainage 2-way silcne	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4316		P	Cath w/drainage 3-way	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4320		P	Irrigation tray	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4321		X	Cath therapeutic irrig agent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4322		P	Irrigation syringe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4323		P	Saline irrigation solution	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4326		P	Male external catheter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4327		P	Fem urinary collect dev cup	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4328		P	Fem urinary collect pouch	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4329		P	External catheter start set	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4330		P	Stool collection pouch	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4335		P	Incontinence supply	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4338		P	Indwelling catheter latex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4340		P	Indwelling catheter special	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4344		P	Cath indw foley 2 way silicn	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4346		P	Cath indw foley 3 way	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4347		P	Male external catheter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4351		P	Straight tip urine catheter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
A4352		P	Coude tip urinary catheter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4353		X	Intermittent urinary cath	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4354		P	Cath insertion tray w/bag	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4355		P	Bladder irrigation tubing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4356		P	Ext ureth clmp or compr dvc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4357		P	Bedside drainage bag	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4358		P	Urinary leg bag	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4359		P	Urinary suspensory w/o leg b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4361		P	Ostomy face plate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4362		P	Solid skin barrier	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4363		D	Liquid skin barrier	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4364		P	Ostomy/cath adhesive	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4365		X	Ostomy adhesive remover wipe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4367		P	Ostomy belt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4368		X	Ostomy filter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4369		X	Skin barrier liquid per oz	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4370		X	Skin barrier paste per oz	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4371		X	Skin barrier powder per oz	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4372		X	Skin barrier solid 4x4 equiv	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4373		X	Skin barrier with flange	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4374		X	Skin barrier extended wear	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4375		X	Drainable plastic pch w fcpl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4376		X	Drainable rubber pch w fcplt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4377		X	Drainable plstic pch w/o fp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4378		X	Drainable rubber pch w/o fp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4379		X	Urinary plastic pouch w fcpl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4380		X	Urinary rubber pouch w fcplt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4381		X	Urinary plastic pouch w/o fp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4382		X	Urinary hvy plstc pch w/o fp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4383		X	Urinary rubber pouch w/o fp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4384		X	Ostomy faceplt/silicone ring	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4385		X	Ost skn barrier sld ext wear	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4386		X	Ost skn barrier w flng ex wr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4387		X	Ost clsd pouch w att st barr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4388		X	Drainable pch w ex wear barr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4389		X	Drainable pch w st wear barr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4390		X	Drainable pch ex wear convex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4391		X	Urinary pouch w ex wear barr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4392		X	Urinary pouch w st wear barr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4393		X	Urine pch w ex wear bar conv	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4394		X	Ostomy pouch liq deodorant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4395		X	Ostomy pouch solid deodorant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4397		P	Irrigation supply sleeve	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4398		P	Ostomy irrigation bag	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4399		P	Ostomy irrig cone/cath w brs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4400		P	Ostomy irrigation set	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4402		P	Lubricant per ounce	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4404		P	Ostomy ring each	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4421		P	Ostomy supply misc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4454		P	Tape all types all sizes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4455		P	Adhesive remover per ounce	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4460		P	Elastic compression bandage	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4462		X	Abdmnl drssng holder/binder	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4465		P	Non-elastic extremity binder	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4470		P	Gravlee jet washer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4480		P	Vabra aspirator	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4481		X	Tracheostoma filter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4483		X	Moisture exchanger	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4490		N	Above knee surgical stocking	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4495		N	Thigh length surg stocking	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4500		N	Below knee surgical stocking	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4510		N	Full length surg stocking	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4550		A	Surgical trays	0.00	0.00	0.26	0.00	0.26	0.00	0.00	0.26	0.00	0.26	XXX
A4554		N	Disposable underpads	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4556		P	Electrodes, pair	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4557		P	Lead wires, pair	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4558		P	Conductive paste or gel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4560		X	Pessary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4565		X	Slings	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4570		X	Splint	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4572		X	Rib belt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4575		N	Hyperbaric o2 chamber disps	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4580		X	Cast supplies (plaster)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4590		X	Special casting material	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4595		X	TENS suppl 2 lead per month	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4611		X	Heavy duty battery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4612		X	Battery cables	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4613		X	Battery charger	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4614		X	Hand-held PEFR meter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4615		X	Cannula nasal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4616		X	Tubing (oxygen) per foot	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4617		X	Mouth piece	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
A4618		X	Breathing circuits	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4619		X	Face tent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4620		X	Variable concentration mask	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4621		X	Tracheotomy mask or collar	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4622		X	Tracheostomy or larngectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4623		X	Tracheostomy inner cannula	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4624		X	Tracheal suction tube	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4625		X	Trach care kit for new trach	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4626		X	Tracheostomy cleaning brush	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4627		N	Spacer bag/reservoir	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4628		X	Oropharyngeal suction cath	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4629		X	Tracheostomy care kit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4630		X	Repl bat t.e.n.s. own by pt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4631		X	Wheelchair battery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4635		X	Underarm crutch pad	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4636		X	Handgrip for cane etc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4637		X	Repl tip cane/crutch/walker	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4640		X	Alternating pressure pad	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4641		E	Diagnostic imaging agent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4642		E	Satumomab pendetide per dose	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4643		E	High dose contrast MRI	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4644		E	Contrast 100–199 MGs iodine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4645		E	Contrast 200–299 MGs iodine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4646		E	Contrast 300–399 MGs iodine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4647		B	Supp- paramagnetic contr mat	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4649		P	Surgical supplies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4650		X	Supp esrd centrifuge	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4655		X	Esrd syringe/needle	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4660		X	Esrd blood pressure device	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4663		X	Esrd blood pressure cuff	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4670		N	Auto blood pressure monitor	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4680		X	Activated carbon filters	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4690		X	Dialyzers	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4700		X	Standard dialysate solution	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4705		X	Bicarb dialysate solution	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4712		X	Sterile water	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4714		X	Treated water for dialysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4730		X	Fistula cannulation set dial	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4735		X	Local/topical anesthetics	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4740		X	Esrd shunt accessory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4750		X	Arterial or venous tubing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4755		X	Arterial and venous tubing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4760		X	Standard testing solution	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4765		X	Dialysate concentrate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4770		X	Blood testing supplies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4771		X	Blood clotting time tube	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4772		X	Dextrostick/glucose strips	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4773		X	Hemostix	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4774		X	Ammonia test paper	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4780		X	Esrd sterilizing agent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4790		X	Esrd cleansing agents	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4800		X	Heparin/antidote dialysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4820		X	Supplies hemodialysis kit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4850		X	Rubber tipped hemostats	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4860		X	Disposable catheter caps	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4870		X	Plumbing/electrical work	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4880		X	Water storage tanks	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4890		R	Contracts/repair/maintenance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4900		X	Capd supply kit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4901		X	Ccpd supply kit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4905		X	Ipd supply kit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4910		X	Esrd nonmedical supplies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4912		X	Gomco drain bottle	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4913		X	Esrd supply	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4914		X	Preparation kit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4918		X	Venous pressure clamp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4919		X	Supp dialysis dialyzer holde	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4920		X	Harvard pressure clamp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4921		X	Measuring cylinder	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A4927		X	Gloves	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5051		P	Pouch clsd w barr attached	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5052		P	Clsd ostomy pouch w/o barr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5053		P	Clsd ostomy pouch faceplate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5054		P	Clsd ostomy pouch w/flange	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5055		P	Stoma cap	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5061		P	Pouch drainable w barrier at	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5062		P	Drnble ostomy pouch w/o barr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5063		P	Drain ostomy pouch w/flange	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5064		I	Drain ostomy pouch w/fceplte	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5065		I	Drain ostomy pouch on fcplte	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5071		P	Urinary pouch w/barrier	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5072		P	Urinary pouch w/o barrier	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUs) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
A5073		P	Urinary pouch on barr w/flng	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5074		I	Urinary pouch w/faceplate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5075		I	Urinary pouch on faceplate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5081		P	Continent stoma plug	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5082		P	Continent stoma catheter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5093		P	Ostomy accessory convex inse	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5102		P	Bedside drain btl w/wo tube	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5105		P	Urinary suspensory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5112		P	Urinary leg bag	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5113		P	Latex leg strap	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5114		P	Foam/fabric leg strap	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5119		P	Skin barrier wipes box pr 50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5121		P	Solid skin barrier 6x6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5122		P	Solid skin barrier 8x8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5123		P	Skin barrier with flange	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5126		P	Disk/foam pad +or- adhesive	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5131		P	Appliance cleaner	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5149		P	Incontinence/ostomy supply	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5200		X	Percutaneous catheter anchor	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5500		X	Diab shoe for density insert	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5501		X	Diabetic custom molded shoe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5502		X	Diabetic shoe density insert	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5503		X	Diabetic shoe w/roller/rockr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5504		X	Diabetic shoe with wedge	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5505		X	Diab shoe w/metatarsal bar	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5506		X	Diabetic shoe w/off set heel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5507		X	Modification diabetic shoe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A5508		X	Diabetic deluxe shoe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6020		P	Collagen wound dressing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6025		I	Silicone gel sheet, each	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6154		P	Wound pouch each	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6196		P	Alginate dressing <=16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6197		P	Alginate drsg >16 <=48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6198		P	alginate dressing > 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6199		P	Alginate drsg wound filler	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6200		X	Compos drsg <=16 no border	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6201		X	Compos drsg >16<=48 no bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6202		X	Compos drsg >48 no border	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6203		P	Composite drsg <= 16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6204		P	Composite drsg >16<=48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6205		P	Composite drsg > 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6206		P	Contact layer <= 16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6207		P	Contact layer >16<= 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6208		P	Contact layer > 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6209		P	Foam drsg <=16 sq in w/o bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6210		P	Foam drg >16<=48 sq in w/o b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6211		P	Foam drg > 48 sq in w/o brdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6212		P	Foam drg <=16 sq in w/border	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6213		P	Foam drg >16<=48 sq in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6214		P	Foam drg > 48 sq in w/border	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6215		P	Foam dressing wound filler	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6216		P	Non-sterile gauze<=16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6217		P	Non-sterile gauze≤16<=48 sq	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6218		P	Non-sterile gauze > 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6219		P	Gauze <= 16 sq in w/border	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6220		P	Gauze >16 <=48 sq in w/bordr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6221		P	Gauze > 48 sq in w/border	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6222		P	Gauze <=16 in no w/sal w/o b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6223		P	Gauze >16<=48 no w/sal w/o b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6224		P	Gauze > 48 in no w/sal w/o b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6228		P	Gauze <= 16 sq in water/sal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6229		P	Gauze >16<=48 sq in watr/sal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6230		P	Gauze > 48 sq in water/salne	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6234		P	Hydrocolld drg <=16 w/o bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6235		P	Hydrocolld drg >16<=48 w/o b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6236		P	Hydrocolld drg > 48 in w/o b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6237		P	Hydrocolld drg <=16 in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6238		P	Hydrocolld drg >16<=48 w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6239		P	Hydrocolld drg > 48 in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6240		P	Hydrocolld drg filler paste	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6241		P	Hydrocolloid drg filler dry	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6242		P	Hydrogel drg <=16 in w/o bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6243		P	Hydrogel drg >16<=48 w/o bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6244		P	Hydrogel drg >48 in w/o bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6245		P	Hydrogel drg <= 16 in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6246		P	Hydrogel drg >16<=48 in w/b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6247		P	Hydrogel drg > 48 sq in w/b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6248		P	Hydrogel drsg gel filler	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6250		P	Skin seal protect moisturizr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6251		P	Absorpt drg <=16 sq in w/o b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6252		P	Absorpt drg >16 <=48 w/o bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6253		P	Absorpt drg > 48 sq in w/o b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
A6254		P	Absorpt drg <=16 sq in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6255		P	Absorpt drg >16<=48 in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6256		P	Absorpt drg > 48 sq in w/bdr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6257		P	Transparent film <= 16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6258		P	Transparent film >16<=48 in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6259		P	Transparent film > 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6260		P	Wound cleanser any type/size	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6261		P	Wound filler gel/paste /oz	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6262		P	Wound filler dry form / gram	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6263		P	Non-sterile elastic gauze/yd	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6264		P	Non-sterile no elastic gauze	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6265		P	Tape per 18 sq inches	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6266		P	Impreg gauze no h20/sal/yard	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6402		P	Sterile gauze <= 16 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6403		P	Sterile gauze≤16 <= 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6404		P	Sterile gauze > 48 sq in	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6405		P	Sterile elastic gauze /yd	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A6406		P	Sterile non-elastic gauze/yd	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7000		X	Disposable canister for pump	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7001		X	Nondisposable pump canister	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7002		X	Tubing used w suction pump	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7003		X	Nebulizer administration set	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7004		X	Disposable nebulizer sml vol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7005		X	Nondisposable nebulizer set	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7006		X	Filtered nebulizer admin set	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7007		X	Lg vol nebulizer disposable	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7008		X	Disposable nebulizer prefill	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7009		X	Nebulizer reservoir bottle	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7010		X	Disposable corrugated tubing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7011		X	Nondispos corrugated tubing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7012		X	Nebulizer water collec devic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7013		X	Disposable compressor filter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7014		X	Compressor nondispos filter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7015		X	Aerosol mask used w nebulize	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7016		X	Nebulizer dome & mouthpiece	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A7017		X	Nebulizer not used w oxygen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9150		E	Misc/exper non-prescript dru	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9160		N	Podiatrist non-covered servi	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9170		N	Chiropractor non-covered ser	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9190		N	Misc/expe personal comfort i	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9270		N	Non-covered item or service	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9300		N	Exercise equipment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9500		E	Technetium TC 99m sestamibi	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9502		X	Technetium TC99M tetrofosmin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9503		E	Technetium TC 99m medronate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9504		X	Technetium tc 99m apcitide	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9505		E	Thallous chloride TL 201/mci	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9507		X	Indium/111 capromab pendetid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9600		X	Strontium-89 chloride	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9605		X	Samarium sm153 lexidronamm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9900		X	Supply/accessory/service	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
A9901		X	Delivery/set up/dispensing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0120		N	Periodic oral evaluation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0140		N	Limit oral eval problm focus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0150		R	Comprehensve oral evaluation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0160		N	Extensv oral eval prob focus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0170		N	Re-eval,est pt,problem focus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0210		I	Intraor complete film series	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0220		I	Intraoral periapical first f	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0230		I	Intraoral periapical ea add	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0240		R	Intraoral occlusal film	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0250		R	Extraoral first film	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0260		R	Extraoral ea additional film	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0270		R	Dental bitewing single film	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0272		R	Dental bitewings two films	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0274		R	Dental bitewings four films	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0277		R	Vert bitewings-sev to eight	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0290		I	Dental film skull/facial bon	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0310		I	Dental saliography	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0320		I	Dental tmj arthrogram incl i	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0321		I	Dental other tmj films	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0322		I	Dental tomographic survey	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0330		I	Dental panoramic film	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0340		I	Dental cephalometric film	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0350		I	Oral/facial images	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0415		N	Bacteriologic study	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0425		N	Caries susceptibility test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0460		R	Pulp vitality test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0470		N	Diagnostic casts	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0471		D	Diagnostic photographs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0472		R	Gross exam, prep & report	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0473		R	Micro exam, prep & report	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
D0474		R	Micro w exam of surg margins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0480		R	Cytopath smear prep & report	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D0501		R	Histopathologic examinations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0502		R	Other oral pathology procedu	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D0999		R	Unspecified diagnostic proce	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D1110		N	Dental prophylaxis adult	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1120		N	Dental prophylaxis child	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1201		N	Topical fluor w prophy child	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1203		N	Topical fluor w/o prophy chi	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1204		N	Topical fluor w/o prophy adu	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1205		N	Topical fluoride w/ prophy a	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1310		N	Nutri counsel-control caries	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1320		N	Tobacco counseling	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1330		N	Oral hygiene instruction	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1351		N	Dental sealant per tooth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D1510		R	Space maintainer fxd unilat	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D1515		R	Fixed bilat space maintainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D1520		R	Remove unilat space maintain	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D1525		R	Remove bilat space maintain	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D1550		R	Recement space maintainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D2110		N	Amalgam one surface primary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2120		N	Amalgam two surfaces primary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2130		N	Amalgam three surfaces prima	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2131		N	Amalgam four/more surf prima	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2140		N	Amalgam one surface permanen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2150		N	Amalgam two surfaces permane	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2160		N	Amalgam three surfaces perma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2161		N	Amalgam 4 or ≤ surfaces perm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2210		D	Silcate cement per restorat	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2330		N	Resin one surface-anterior	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2331		N	Resin two surfaces-anterior	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2332		N	Resin three surfaces-anterio	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2335		N	Resin 4/≤ surf or w incis an	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2336		N	Composite resin crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2337		N	Compo resin crown ant-perm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2380		N	Resin one surf poster primar	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2381		N	Resin two surf poster primar	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2382		N	Resin three/more surf post p	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2385		N	Resin one surf poster perman	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2386		N	Resin two surf poster perman	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2387		N	Resin three/more surf post p	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2388		N	Resin four/more, post perm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2410		N	Dental gold foil one surface	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2420		N	Dental gold foil two surface	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2430		N	Dental gold foil three surfa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2510		N	Dental inlay metalic 1 surf	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2520		N	Dental inlay metallic 2 surf	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2530		N	Dental inlay metl 3/more sur	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2542		N	Dental onlay metallic 2 surf	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2543		N	Dental onlay metallic 3 surf	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2544		N	Dental onlay metl 4/more sur	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2610		N	Inlay porcelain/ceramic 1 su	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2620		N	Inlay porcelain/ceramic 2 su	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2630		N	Dental onlay porc 3/more sur	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2642		N	Dental onlay porcelin 2 surf	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2643		N	Dental onlay porcelin 3 surf	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2644		N	Dental onlay porc 4/more sur	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2650		N	Inlay composite/resin one su	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2651		N	Inlay composite/resin two su	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2652		N	Dental inlay resin 3/mre sur	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2662		N	Dental onlay resin 2 surface	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2663		N	Dental onlay resin 3 surface	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2664		N	Dental onlay resin 4/mre sur	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2710		N	Crown resin laboratory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2720		N	Crown resin w/ high noble me	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2721		N	Crown resin w/ base metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2722		N	Crown resin w/ noble metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2740		N	Crown porcelain/ceramic subs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2750		N	Crown porcelain w/ h noble m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2751		N	Crown porcelain fused base m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2752		N	Crown porcelain w/ noble met	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2780		N	Crown 3/4 cast hi noble met	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2781		N	Crown 3/4 cast base metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2782		N	Crown 3/4 cast noble metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2783		N	Crown 3/4 porcelain/ceramic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2790		N	Crown full cast high noble m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2791		N	Crown full cast base metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2792		N	Crown full cast noble metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2799		N	Provisional crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2810		D	Crown 3/4 cast metallic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2910		N	Dental recement inlay	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2920		N	Dental recement crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
D2930		N	Prefab stnlss steel crwn pri	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2931		N	Prefab stnlss steel crown pe	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2932		N	Prefabricated resin crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2933		N	Prefab stainless steel crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2940		N	Dental sedative filling	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2950		N	Core build-up incl any pins	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2951		N	Tooth pin retention	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2952		N	Post and core cast + crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2953		N	Each addtnl cast post	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2954		N	Prefab post/core + crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2955		N	Post removal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2957		N	Each addtnl prefab post	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2960		N	Laminate labial veneer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2961		N	Lab labial veneer resin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2962		N	Lab labial veneer porcelain	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2970		R	Temporary-fractured tooth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D2980		N	Crown repair	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D2999		R	Dental unspec restorative pr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D3110		N	Pulp cap direct	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3120		N	Pulp cap indirect	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3220		N	Therapeutic pulpotomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3221		N	Gross pulpal debridement	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3230		N	Pulpal therapy anterior prim	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3240		N	Pulpal therapy posterior pri	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3310		N	Anterior	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3320		N	Root canal therapy 2 canals	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3330		N	Root canal therapy 3 canals	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3331		N	Non-surg tx root canal obs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3332		N	Incomplete endodontic tx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3333		N	Internal root repair	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3346		N	Retreat root canal anterior	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3347		N	Retreat root canal bicuspid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3348		N	Retreat root canal molar	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3351		N	Apexification/recalc initial	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3352		N	Apexification/recalc interim	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3353		N	Apexification/recalc final	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3410		N	Apicoect/perirad surg anter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3421		N	Root surgery bicuspid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3425		N	Root surgery molar	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3426		N	Root surgery ea add root	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3430		N	Retrograde filling	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3450		N	Root amputation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3460		R	Endodontic endosseous implan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D3470		N	Intentional replantation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3910		N	Isolation-tooth w rubb dam	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3920		N	Tooth splitting	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3950		N	Canal prep/fitting of dowel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3960		D	Bleaching of discolored toot	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D3999		R	Endodontic procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4210		I	Gingivectomy/plasty per quad	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4211		I	Gingivectomy/plasty per toot	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4220		N	Gingival curettage per quadr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4240		N	Gingival flap proc w/ planin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4245		N	Apically positioned flap	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4249		N	Crown lengthen hard tissue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4250		D	Mucogingival surg per quadra	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4260		R	Osseous surgery per quadrant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4263		R	Bone replce graft first site	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4264		R	Bone replce graft each add	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4266		N	Guided tiss regen resorble	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4267		N	Guided tiss regen nonresorb	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4268		R	Surgical revision procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4270		R	Pedicle soft tissue graft pr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4271		R	Free soft tissue graft proc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4273		R	Subepithelial tissue graft	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4274		N	Distal/proximal wedge proc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4320		N	Provision splnt intracoronal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4321		N	Provisional splint extracoro	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4341		N	Periodontal scaling & root	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4355		R	Full mouth debridement	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4381		R	Localized chemo delivery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D4910		N	Periodontal maint procedures	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4920		N	Unscheduled dressing change	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D4999		N	Unspecified periodontal proc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5110		N	Dentures complete maxillary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5120		N	Dentures complete mandible	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5130		N	Dentures immediat maxillary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5140		N	Dentures immediat mandible	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5211		N	Dentures maxill part resin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5212		N	Dentures mand part resin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5213		N	Dentures maxill part metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5214		N	Dentures mandibl part metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
D5281		N	Removable partial denture	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5410		N	Dentures adjust cmplt maxil	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5411		N	Dentures adjust cmplt mand	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5421		N	Dentures adjust part maxill	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5422		N	Dentures adjust part mandbl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5510		N	Dentur repr broken compl bas	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5520		N	Replace denture teeth complt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5610		N	Dentures repair resin base	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5620		N	Rep part denture cast frame	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5630		N	Rep partial denture clasp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5640		N	Replace part denture teeth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5650		N	Add tooth to partial denture	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5660		N	Add clasp to partial denture	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5710		N	Dentures rebase cmplt maxil	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5711		N	Dentures rebase cmplt mand	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5720		N	Dentures rebase part maxill	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5721		N	Dentures rebase part mandbl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5730		N	Denture reln cmplt maxil ch	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5731		N	Denture reln cmplt mand chr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5740		N	Denture reln part maxil chr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5741		N	Denture reln part mand chr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5750		N	Denture reln cmplt max lab	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5751		N	Denture reln cmplt mand lab	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5760		N	Denture reln part maxil lab	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5761		N	Denture reln part mand lab	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5810		N	Denture interm cmplt maxill	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5811		N	Denture interm cmplt mandbl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5820		N	Denture interm part maxill	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5821		N	Denture interm part mandbl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5850		N	Denture tiss conditn maxill	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5851		N	Denture tiss condtin mandbl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5860		N	Overdenture complete	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5861		N	Overdenture partial	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5862		N	Precision attachment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5867		N	Replacement of precision att	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5875		N	Prosthesis modification	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5899		N	Removable prosthodontic proc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5911		R	Facial moulage sectional	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5912		R	Facial moulage complete	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5913		I	Nasal prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5914		I	Auricular prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5915		I	Orbital prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5916		I	Ocular prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5919		I	Facial prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5922		I	Nasal septal prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5923		I	Ocular prosthesis interim	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5924		I	Cranial prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5925		I	Facial augmentation implant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5926		I	Replacement nasal prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5927		I	Auricular replacement	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5928		I	Orbital replacement	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5929		I	Facial replacement	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5931		I	Surgical obturator	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5932		I	Postsurgical obturator	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5933		I	Refitting of obturator	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5934		I	Mandibular flange prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5935		I	Mandibular denture prosth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5936		I	Temp obturator prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5937		I	Trismus appliance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5951		R	Feeding aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5952		I	Pediatric speech aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5953		I	Adult speech aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5954		I	Superimposed prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5955		I	Palatal lift prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5958		I	Intraoral con def inter plt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5959		I	Intraoral con def mod palat	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5960		I	Modify speech aid prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5982		I	Surgical stent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5983		R	Radiation applicator	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5984		R	Radiation shield	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5985		R	Radiation cone locator	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5986		N	Fluoride applicator	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5987		R	Commissure splint	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D5988		I	Surgical splint	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D5999		I	Maxillofacial prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6010		I	Odontics endosteal implant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6020		I	Odontics abutment placement	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6040		I	Odontics eposteal implant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6050		I	Odontics transosteal implnt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6055		I	Implant connecting bar	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6056		N	Prefabricated abutment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6057		N	Custom abutment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
D6058		N	Abutment supported crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6059		N	Abutment supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6060		N	Abutment supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6061		N	Abutment supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6062		N	Abutment supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6063		N	Abutment supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6064		N	Abutment supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6065		N	Implant supported crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6066		N	Implant supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6067		N	Implant supported mtl crown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6068		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6069		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6070		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6071		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6072		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6073		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6074		N	Abutment supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6075		N	Implant supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6076		N	Implant supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6077		N	Implant supported retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6078		N	Implnt/abut suprtd fixd dent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6079		N	Implnt/abut suprtd fixd dent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6080		I	Implant maintenance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6090		I	Repair implant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6095		I	Odontics repr abutment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6100		I	Removal of implant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6199		I	Implant procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6210		N	Prosthodont high noble metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6211		N	Bridge base metal cast	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6212		N	Bridge noble metal cast	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6240		N	Bridge porcelain high noble	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6241		N	Bridge porcelain base metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6242		N	Bridge porcelain nobel metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6245		N	Bridge porcelain/ceramic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6250		N	Bridge resin w/high noble	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6251		N	Bridge resin base metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6252		N	Bridge resin w/noble metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6519		N	Inlay/onlay porce/ceramic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6520		N	Dental retainer two surfaces	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6530		N	Retainer metallic 3+ surface	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6543		N	Dental retainr onlay 3 surf	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6544		N	Dental retainr onlay 4/more	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6545		N	Dental retainr cast metl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6548		N	Porcelain/ceramic retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6720		N	Retain crown resin w hi nble	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6721		N	Crown resin w/base metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6722		N	Crown resin w/noble metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6740		N	Crown porcelain/ceramic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6750		N	Crown porcelain high noble	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6751		N	Crown porcelain base metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6752		N	Crown porcelain noble metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6780		N	Crown 3/4 high noble metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6781		N	Crown 3/4 cast based metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6782		N	Crown 3/4 cast noble metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6783		N	Crown 3/4 porcelain/ceramic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6790		N	Crown full high noble metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6791		N	Crown full base metal cast	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6792		N	Crown full noble metal cast	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6920		R	Dental connector bar	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D6930		N	Dental recement bridge	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6940		N	Stress breaker	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6950		N	Precision attachment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6970		N	Post & core plus retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6971		N	Cast post bridge retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6972		N	Prefab post & core plus reta	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6973		N	Core build up for retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6975		N	Coping metal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6976		N	Each addtnl cast post	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6977		N	Each addtl prefab post	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6980		N	Bridge repair	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D6999		N	Fixed prosthodontic proc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7110		R	Oral surgery single tooth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7120		R	Each add tooth extraction	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7130		R	Tooth root removal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7210		R	Rem imp tooth w mucoper flp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7220		R	Impact tooth remov soft tiss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7230		R	Impact tooth remov part bony	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7240		R	Impact tooth remov comp bony	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7241		R	Impact tooth rem bony w/comp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7250		R	Tooth root removal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7260		R	Oral antral fistula closure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7270		N	Tooth reimplantation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
D7272		N	Tooth transplantation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7280		N	Exposure impact tooth orthod	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7281		N	Exposure tooth aid eruption	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7285		I	Biopsy of oral tissue hard	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7286		I	Biopsy of oral tissue soft	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7290		N	Repositioning of teeth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7291		R	Transseptal fiberotomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7310		I	Alveoplasty w/ extraction	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7320		I	Alveoplasty w/o extraction	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7340		I	Vestibuloplasty ridge extens	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7350		I	Vestibuloplasty exten graft	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7410		I	Rad exc lesion up to 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7420		I	Lesion ≤ 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7430		I	Exc benign tumor to 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7431		I	Benign tumor exc ≤ 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7440		I	Malig tumor exc to 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7441		I	Malig tumor ≤ 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7450		I	Rem odontogen cyst to 1.25cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7451		I	Rem odontogen cyst ≤ 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7460		I	Rem nonodonto cyst to 1.25cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7461		I	Rem nonodonto cyst ≤ 1.25 cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7465		I	Lesion destruction	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7470		D	Rem exostosis maxilla/mandib	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7471		I	Rem exostosis any site	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7480		I	Partial ostectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7490		I	Mandible resection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7510		I	I&d absc intraoral soft tiss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7520		I	I&d abscess extraoral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7530		I	Removal fb skin/areolar tiss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7540		I	Removal of fb reaction	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7550		I	Removal of sloughed off bone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7560		I	Maxillary sinusotomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7610		I	Maxilla open reduct simple	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7620		I	Clsd reduct simpl maxilla fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7630		I	Open red simpl mandible fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7640		I	Clsd red simpl mandible fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7650		I	Open red simp malar/zygom fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7660		I	Clsd red simp malar/zygom fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7670		I	Closd rductn splint alveolus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7680		I	Reduct simple facial bone fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7710		I	Maxilla open reduct compound	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7720		I	Clsd reduct compd maxilla fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7730		I	Open reduct compd mandble fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7740		I	Clsd reduct compd mandble fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7750		I	Open red comp malar/zygma fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7760		I	Clsd red comp malar/zygma fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7770		I	Open reduc compd alveolus fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7780		I	Reduct compnd facial bone fx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7810		I	Tmj open reduct-dislocation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7820		I	Closed tmp manipulation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7830		I	Tmj manipulation under anest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7840		I	Removal of tmj condyle	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7850		I	Tmj meniscectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7852		I	Tmj repair of joint disc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7854		I	Tmj excisn of joint membrane	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7856		I	Tmj cutting of a muscle	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7858		I	Tmj reconstruction	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7860		I	Tmj cutting into joint	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7865		I	Tmj reshaping components	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7870		I	Tmj aspiration joint fluid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7871		N	Lysis + lavage w catheters	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7872		I	Tmj diagnostic arthroscopy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7873		I	Tmj arthroscopy lysis adhesn	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7874		I	Tmj arthroscopy disc reposit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7875		I	Tmj arthroscopy synovectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7876		I	Tmj arthroscopy discectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7877		I	Tmj arthroscopy debridement	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7880		I	Occlusal orthotic appliance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7899		I	Tmj unspecified therapy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7910		I	Dent sutur recent wnd to 5cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7911		I	Dental suture wound to 5 cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7912		I	Suture complicate wnd ≤ 5 cm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7920		I	Dental skin graft	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7940		R	Reshaping bone orthognathic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D7941		I	Bone cutting ramus closed	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7942		D	Bone cutting ramus open	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7943		I	Cutting ramus open w/graft	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7944		I	Bone cutting segmented	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7945		I	Bone cutting body mandible	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7946		I	Reconstruction maxilla total	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7947		I	Reconstruct maxilla segment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7948		I	Reconstruct midface no graft	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
D7949		I	Reconstruct midface w/graft	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7950		I	Mandible graft	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7955		I	Repair maxillofacial defects	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7960		I	Frenulectomy/frenulotomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7970		I	Excision hyperplastic tissue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7971		I	Excision pericoronal gingiva	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7980		I	Sialolithotomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7981		I	Excision of salivary gland	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7982		I	Sialodochoplasty	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7983		I	Closure of salivary fistula	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7990		I	Emergency tracheotomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7991		I	Dental coronoidectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7995		I	Synthetic graft facial bones	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7996		I	Implant mandible for augment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7997		N	Appliance removal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D7999		I	Oral surgery procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8010		N	Limited dental tx primary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8020		N	Limited dental tx transition	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8030		N	Limited dental tx adolescent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8040		N	Limited dental tx adult	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8050		N	Intercep dental tx primary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8060		N	Intercep dental tx transitn	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8070		N	Compre dental tx transition	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8080		N	Compre dental tx adolescent	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8090		N	Compre dental tx adult	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8210		N	Orthodontic rem appliance tx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8220		N	Fixed appliance therapy habt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8660		N	Preorthodontic tx visit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8670		N	Periodic orthodontc tx visit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8680		N	Orthodontic retention	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8690		N	Orthodontic treatment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8691		N	Repair ortho appliance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8692		N	Replacement retainer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D8999		N	Orthodontic procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9110		R	Tx dental pain minor proc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9210		I	Dent anesthesia w/o surgery	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9211		I	Regional block anesthesia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9212		I	Trigeminal block anesthesia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9215		I	Local anesthesia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9220		I	General anesthesia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9221		I	General anesthesia ea ad 15m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9230		R	Analgesia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9240		D	Intravenous sedation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9241		I	Intravenous sedation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9242		I	IV sedation ea ad 30 m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9248		R	Sedation (non-iv)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9310		I	Dental consultation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9410		I	Dental house call	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9420		I	Hospital call	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9430		I	Office visit during hours	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9440		I	Office visit after hours	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9610		I	Dent therapeutic drug inject	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9630		R	Other drugs/medicaments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9910		N	Dent appl desensitizing med	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9911		N	Appl desensitizing resin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9920		N	Behavior management	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9930		R	Treatment of complications	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9940		R	Dental occlusal guard	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9941		N	Fabrication athletic guard	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9950		R	Occlusion analysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9951		R	Limited occlusal adjustment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9952		R	Complete occlusal adjustment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	YYY
D9970		N	Enamel microabrasion	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9971		N	Odontoplasty 1–2 teeth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9972		N	Extrnl bleaching per arch	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9973		N	Extrnl bleaching per tooth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9974		N	Intrnl bleaching per tooth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
D9999		I	Adjunctive procedure	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0001		X	Drawing blood for specimen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0002		A	Temporary urinary catheter	0.50	3.05	2.48	0.16	0.31	0.03	3.58	3.01	0.69	0.84	000
G0004		A	ECG transm phys review & int	0.52	7.53	7.64	NA	NA	0.46	8.51	8.62	NA	NA	XXX
G0005		A	ECG 24 hour recording	0.00	1.25	1.26	NA	NA	0.07	1.32	1.33	NA	NA	XXX
G0006		A	ECG transmission & analysis	0.00	6.08	6.12	NA	NA	0.37	6.45	6.49	NA	NA	XXX
G0007		A	ECG phy review & interpret	0.52	0.20	0.26	0.20	0.26	0.02	0.74	0.80	0.74	0.80	XXX
G0008		X	Admin influenza virus vac	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0009		X	Admin pneumococcal vaccine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0010		X	Admin hepatitis b vaccine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0015		A	Post symptom ECG tracing	0.00	6.08	6.12	NA	NA	0.37	6.45	6.49	NA	NA	XXX
G0016		A	Post symptom ECG md review	0.52	0.26	0.30	0.26	0.30	0.02	0.80	0.84	0.80	0.84	XXX
G0025		A	Collagen skin test kit	0.00	0.00	0.26	0.00	0.26	0.00	0.00	0.26	0.00	0.26	XXX
G0026		X	Fecal leukocyte examination	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0027		X	Semen analysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
G0030		C	PET imaging prev PET single	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0030	26	A	PET imaging prev PET single	1.50	0.52	0.52	0.52	0.52	0.05	2.07	2.07	2.07	2.07	XXX
G0030	TC	C	PET imaging prev PET single	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0031		C	PET imaging prev PET multple	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0031	26	A	PET imaging prev PET multple	1.87	0.70	0.70	0.70	0.70	0.07	2.64	2.64	2.64	2.64	XXX
G0031	TC	C	PET imaging prev PET multple	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0032		C	PET follow SPECT 78464 singl	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0032	26	A	PET follow SPECT 78464 singl	1.50	0.52	0.52	0.52	0.52	0.05	2.07	2.07	2.07	2.07	XXX
G0032	TC	C	PET follow SPECT 78464 singl	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0033		C	PET follow SPECT 78464 mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0033	26	A	PET follow SPECT 78464 mult	1.87	0.70	0.70	0.70	0.70	0.06	2.63	2.63	2.63	2.63	XXX
G0033	TC	C	PET follow SPECT 78464 mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0034		C	PET follow SPECT 76865 singl	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0034	26	A	PET follow SPECT 76865 singl	1.50	0.52	0.52	0.52	0.52	0.05	2.07	2.07	2.07	2.07	XXX
G0034	TC	C	PET follow SPECT 76865 singl	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0035		C	PET follow SPECT 78465 mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0035	26	A	PET follow SPECT 78465 mult	1.87	0.70	0.70	0.70	0.70	0.07	2.64	2.64	2.64	2.64	XXX
G0035	TC	C	PET follow SPECT 78465 mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0036		C	PET follow cornry angio sing	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0036	26	A	PET follow cornry angio sing	1.50	0.52	0.52	0.52	0.52	0.06	2.08	2.08	2.08	2.08	XXX
G0036	TC	C	PET follow cornry angio sing	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0037		C	PET follow cornry angio mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0037	26	A	PET follow cornry angio mult	1.87	0.70	0.70	0.70	0.70	0.07	2.64	2.64	2.64	2.64	XXX
G0037	TC	C	PET follow cornry angio mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0038		C	PET follow myocard perf sing	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0038	26	A	PET follow myocard perf sing	1.50	0.52	0.52	0.52	0.52	0.05	2.07	2.07	2.07	2.07	XXX
G0038	TC	C	PET follow myocard perf sing	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0039		C	PET follow myocard perf mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0039	26	A	PET follow myocard perf mult	1.87	0.70	0.70	0.70	0.70	0.06	2.63	2.63	2.63	2.63	XXX
G0039	TC	C	PET follow myocard perf mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0040		C	PET follow stress echo singl	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0040	26	A	PET follow stress echo singl	1.50	0.52	0.52	0.52	0.52	0.05	2.07	2.07	2.07	2.07	XXX
G0040	TC	C	PET follow stress echo singl	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0041		C	PET follow stress echo mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0041	26	A	PET follow stress echo mult	1.87	0.70	0.70	0.70	0.70	0.06	2.63	2.63	2.63	2.63	XXX
G0041	TC	C	PET follow stress echo mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0042		C	PET follow ventriculogm sing	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0042	26	A	PET follow ventriculogm sing	1.50	0.52	0.52	0.52	0.52	0.05	2.07	2.07	2.07	2.07	XXX
G0042	TC	C	PET follow ventriculogm sing	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0043		C	PET follow ventriculogm mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0043	26	A	PET follow ventriculogm mult	1.87	0.70	0.70	0.70	0.70	0.06	2.63	2.63	2.63	2.63	XXX
G0043	TC	C	PET follow ventriculogm mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0044		C	PET following rest ECG singl	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0044	26	A	PET following rest ECG singl	1.50	0.52	0.52	0.52	0.52	0.05	2.07	2.07	2.07	2.07	XXX
G0044	TC	C	PET following rest ECG singl	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0045		C	PET following rest ECG mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0045	26	A	PET following rest ECG mult	1.87	0.70	0.70	0.70	0.70	0.06	2.63	2.63	2.63	2.63	XXX
G0045	TC	C	PET following rest ECG mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0046		C	PET follow stress ECG singl	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0046	26	A	PET follow stress ECG singl	1.50	0.52	0.52	0.52	0.52	0.05	2.07	2.07	2.07	2.07	XXX
G0046	TC	C	PET follow stress ECG singl	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0047		C	PET follow stress ECG mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0047	26	A	PET follow stress ECG mult	1.87	0.70	0.70	0.70	0.70	0.06	2.63	2.63	2.63	2.63	XXX
G0047	TC	C	PET follow stress ECG mult	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0050		A	Residual urine by ultrasound	0.00	0.86	0.87	NA	NA	0.04	0.90	0.91	NA	NA	XXX
G0101		A	CA screen;pelvic/breast exam	0.45	0.59	0.52	0.17	0.20	0.02	1.06	0.99	0.64	0.67	XXX
G0102		A	Prostate ca screening; dre	0.17	0.54	0.46	0.06	0.10	0.01	0.72	0.64	0.24	0.28	XXX
G0103		X	Psa, total screening	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0104		A	CA screen;flexi sigmoidscope	0.96	1.68	1.59	0.42	0.65	0.07	2.71	2.62	1.45	1.68	000
G0105		A	Colorectal scrn; hi risk ind	3.70	5.39	5.16	1.63	2.34	0.26	9.35	9.12	5.59	6.30	000
G0106		A	Colon CA screen;barium enema	0.99	2.60	2.65	NA	NA	0.15	3.74	3.79	NA	NA	XXX
G0106	26	A	Colon CA screen;barium enema	0.99	0.34	0.38	0.34	0.38	0.04	1.37	1.41	1.37	1.41	XXX
G0106	TC	A	Colon CA screen;barium enema	0.00	2.26	2.27	NA	NA	0.11	2.37	2.38	NA	NA	XXX
G0107		X	CA screen; fecal blood test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0108		A	Diab manage trn per indiv	0.00	1.64	1.64	1.64	1.64	0.01	1.65	1.65	1.65	1.65	XXX
G0109		A	Diab manage trn ind/group	0.00	0.96	0.96	0.96	0.96	0.01	0.97	0.97	0.97	0.97	XXX
G0110		R	Nett pulm-rehab educ; ind	0.90	0.66	0.57	0.36	0.34	0.03	1.59	1.50	1.29	1.27	XXX
G0111		R	Nett pulm-rehab educ; group	0.27	0.27	0.26	0.14	0.16	0.01	0.55	0.54	0.42	0.44	XXX
G0112		R	Nett;nutrition guid, initial	1.72	1.36	1.28	0.68	0.77	0.07	3.15	3.07	2.47	2.56	XXX
G0113		R	Nett;nutrition guid,subseqnt	1.29	0.95	0.92	0.41	0.52	0.05	2.29	2.26	1.75	1.86	XXX
G0114		R	Nett; psychosocial consult	1.20	0.49	0.46	0.37	0.37	0.03	1.72	1.69	1.60	1.60	XXX
G0115		R	Nett; psychological testing	1.20	0.52	0.49	0.48	0.46	0.03	1.75	1.72	1.71	1.69	XXX
G0116		R	Nett; psychosocial counsel	1.11	0.60	0.55	0.33	0.34	0.03	1.74	1.69	1.47	1.48	XXX
G0120		A	Colon ca scrn; barium enema	0.99	2.60	2.65	NA	NA	0.15	3.74	3.79	NA	NA	XXX
G0120	26	A	Colon ca scrn; barium enema	0.99	0.34	0.38	0.34	0.38	0.04	1.37	1.41	1.37	1.41	XXX
G0120	TC	A	Colon ca scrn; barium enema	0.00	2.26	2.27	NA	NA	0.11	2.37	2.38	NA	NA	XXX
G0121		N	Colon ca scrn not hi rsk ind	3.70	6.16	5.74	1.47	2.22	0.13	9.99	9.57	5.30	6.05	XXX
G0122		N	Colon ca scrn; barium enema	0.99	2.65	2.69	NA	NA	0.15	3.79	3.83	NA	NA	XXX
G0122	26	N	Colon ca scrn; barium enema	0.99	0.39	0.42	0.39	0.42	0.04	1.42	1.45	1.42	1.45	XXX
G0122	TC	N	Colon ca scrn; barium enema	0.00	2.26	2.27	NA	NA	0.11	2.37	2.38	NA	NA	XXX
G0123		X	Screen cerv/vag thin layer	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0124		A	Screen c/v thin layer by MD	0.42	0.19	0.23	0.19	0.23	0.01	0.62	0.66	0.62	0.66	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
G0125		A	Lung image (PET)	1.50	56.15	56.15	NA	NA	2.06	59.71	59.71	NA	NA	XXX
G0125	26	A	Lung image (PET)	1.50	0.52	0.52	0.52	0.52	0.05	2.07	2.07	2.07	2.07	XXX
G0125	TC	A	Lung image (PET)	0.00	55.63	55.63	NA	NA	2.01	57.64	57.64	NA	NA	XXX
G0126		A	Lung image (PET) staging	1.87	56.33	56.33	NA	NA	2.07	60.27	60.27	NA	NA	XXX
G0126	26	A	Lung image (PET) staging	1.87	0.70	0.70	0.70	0.70	0.06	2.63	2.63	2.63	2.63	XXX
G0126	TC	A	Lung image (PET) staging	0.00	55.63	55.63	NA	NA	2.01	57.64	57.64	NA	NA	XXX
G0127		R	Trim nail(s)	0.11	0.48	0.43	0.04	0.10	0.01	0.60	0.55	0.16	0.22	000
G0128		R	CORF skilled nursing service	0.08	0.03	0.03	0.03	0.03	0.01	0.12	0.12	0.12	0.12	XXX
G0130		A	Single energy x-ray study	0.22	0.90	0.90	NA	NA	0.05	1.17	1.17	NA	NA	XXX
G0130	26	A	Single energy x-ray study	0.22	0.11	0.11	0.11	0.11	0.01	0.34	0.34	0.34	0.34	XXX
G0130	TC	A	Single energy x-ray study	0.00	0.79	0.79	NA	NA	0.04	0.83	0.83	NA	NA	XXX
G0131		A	CT scan, bone density study	0.25	3.18	3.18	NA	NA	0.14	3.57	3.57	NA	NA	XXX
G0131	26	A	CT scan, bone density study	0.25	0.13	0.13	0.13	0.13	0.01	0.39	0.39	0.39	0.39	XXX
G0131	TC	A	CT scan, bone density study	0.00	3.05	3.05	NA	NA	0.13	3.18	3.18	NA	NA	XXX
G0132		A	CT scan, bone density study	0.22	0.90	0.90	NA	NA	0.05	1.17	1.17	NA	NA	XXX
G0132	26	A	CT scan, bone density study	0.22	0.11	0.11	0.11	0.11	0.01	0.34	0.34	0.34	0.34	XXX
G0132	TC	A	CT scan, bone density study	0.00	0.79	0.79	NA	NA	0.04	0.83	0.83	NA	NA	XXX
G0141		A	Scr c/v cyto,autosys and md	0.42	0.19	0.23	0.19	0.23	0.01	0.62	0.66	0.62	0.66	XXX
G0143		X	Scr c/v cyto,thinlayer,rescr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0144		X	Scr c/v cyto,thinlayer,rescr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0145		X	Scr c/v cyto,thinlayer,rescr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0147		X	Scr c/v cyto, automated sys	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0148		X	Scr c/v cyto, autosys, rescr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0159		C	Perc declot dialysis graft	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0160		C	Cryo. ablation, prostate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	090
G0161		C	Echo guide for cryo probes	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0161	26	C	Echo guide for cryo probes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
G0161	TC	C	Echo guide for cryo probes	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
G0163		A	Pet for rec of colorectal ca	1.50	56.22	56.22	NA	NA	2.06	59.78	59.78	NA	NA	XXX
G0163	26	A	Pet for rec of colorectal ca	1.50	0.59	0.59	0.59	0.59	0.05	2.14	2.14	2.14	2.14	XXX
G0163	TC	A	Pet for rec of colorectal ca	0.00	55.63	55.63	NA	NA	2.01	57.64	57.64	NA	NA	XXX
G0164		A	Pet for lymphoma staging	1.87	56.37	56.37	NA	NA	2.06	60.30	60.30	NA	NA	XXX
G0164	26	A	Pet for lymphoma staging	1.87	0.74	0.74	0.74	0.74	0.05	2.66	2.66	2.66	2.66	XXX
G0164	TC	A	Pet for lymphoma staging	0.00	55.63	55.63	NA	NA	2.01	57.64	57.64	NA	NA	XXX
G0165		A	Pet,rec of melanoma/met ca	1.50	56.22	56.22	NA	NA	2.06	59.78	59.78	NA	NA	XXX
G0165	26	A	Pet,rec of melanoma/met ca	1.50	0.59	0.59	0.59	0.59	0.05	2.14	2.14	2.14	2.14	XXX
G0165	TC	A	Pet,rec of melanoma/met ca	0.00	55.63	55.63	NA	NA	2.01	57.64	57.64	NA	NA	XXX
G0166		A	Extrnl counterpulse, per tx	0.07	4.11	4.11	0.03	0.03	0.01	4.19	4.19	0.11	0.11	XXX
G0167		C	Hyperbaric oz tx;no md reqrd	0.00	NA	NA	0.71	0.72	0.00	NA	NA	0.71	0.72	XXX
G0168		A	Wound closure by adhesive	0.45	1.86	1.86	0.26	0.26	0.02	2.33	2.33	0.73	0.73	010
G0169		A	Removal tissue; no anesthsia	0.50	0.56	0.56	0.56	0.56	0.04	1.10	1.10	1.10	1.10	XXX
G0170		A	Skin biograft	1.50	2.29	2.29	0.99	0.99	0.39	4.18	4.18	2.88	2.88	010
G0171		A	Skin biograft add-on	0.38	0.30	0.30	0.15	0.15	0.39	1.07	1.07	0.92	0.92	ZZZ
Gxxx1		A	Home health care supervision	1.73	1.31	1.12	0.61	0.60	0.06	3.10	2.91	2.40	2.39	XXX
Gxxx2		A	Hospice care supervision	1.73	1.55	1.30	0.58	0.57	0.06	3.34	3.09	2.37	2.36	XXX
Gxxx3		A	Initial cert, home health	0.67	1.10	1.10	0.27	0.27	0.06	1.83	1.83	1.00	1.00	XXX
Gxxx4		A	Recertification, home health	0.45	1.00	1.00	0.18	0.18	0.06	1.51	1.51	0.69	0.69	XXX
Gxxx5		A	Treatment of choroid lesion	13.13	9.93	9.93	9.10	9.10	0.52	23.58	23.58	22.75	22.75	090
Gxxx6		A	Ocular phototherapy, iv incl	0.55	34.59	34.59	0.27	0.27	0.52	35.66	35.66	1.34	1.34	XXX
Gxxx7		A	Ocular phototherapy, iv incl	0.28	0.24	0.24	0.14	0.14	0.52	1.04	1.04	0.94	0.94	ZZZ
J0120		E	Tetracyclin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0130		E	Abciximab injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0150		E	Injection adenosine 6 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0151		E	Adenosine injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0170		E	Adrenalin epinephrin inject	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0190		E	Inj biperiden lactate/5 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0200		E	Alatrofloxacin mesylate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0205		E	Alglucerase injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0207		E	Amifostine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0210		E	Methyldopate hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0256		E	Alpha 1 proteinase inhibitor	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0270		E	Alprostadil for injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0275		E	Alprostadil urethral suppos	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0280		E	Aminophyllin 250 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0285		E	Amphotericin B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0286		E	Amphotericin B lipid complex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0290		E	Ampicillin 500 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0295		E	Ampicillin sodium per 1.5 gm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0300		E	Amobarbital 125 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0330		E	Succinycholine chloride inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0340		E	Nandrolon phenpropionate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0350		E	Injection anistreplase 30 u	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0360		E	Hydralazine hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0380		E	Inj metaraminol bitartrate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0390		E	Chloroquine injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0395		E	Arbutamine HCl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0400		E	Inj trimethaphan camsylate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0456		E	Azithromycin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0460		E	Atropine sulfate injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0470		E	Dimecaprol injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0475		E	Baclofen 10 MG injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0476		E	Baclofen intrathecal trial	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
J0500		E	Dicyclomine injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0510		E	Benzquinamide injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0515		E	Inj benztropine mesylate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0520		E	Bethanechol chloride inject	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0530		E	Penicillin g benzathine inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0540		E	Penicillin g benzathine inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0550		E	Penicillin g benzathine inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0560		E	Penicillin g benzathine inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0570		E	Penicillin g benzathine inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0580		E	Penicillin g benzathine inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0585		E	Botulinum toxin a per unit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0590		E	Ethylnorepinephrine hcl inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0600		E	Edetate calcium disodium inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0610		E	Calcium gluconate injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0620		E	Calcium glycer & lact/10 ML	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0630		E	Calcitonin salmon injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0635		E	Calcitriol injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0640		E	Leucovorin calcium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0670		E	Inj mepivacaine HCL/10 ml	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0690		E	Cefazolin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0694		E	Cefoxitin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0695		E	Cefonocid sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0696		E	Ceftriaxone sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0697		E	Sterile cefuroxime injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0698		E	Cefotaxime sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0702		E	Betamethasone acet&sod phosp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0704		E	Betamethasone sod phosp/4 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0710		E	Cephapirin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0713		E	Inj ceftazidime per 500 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0715		E	Ceftizoxime sodium / 500 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0720		E	Chloramphenicol sodium injec	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0725		E	Chorionic gonadotropin/1000u	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0730		E	Chlorpheniramin maleate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0735		E	Clonidine hydrochloride	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0740		E	Cidofovir injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0743		E	Cilastatin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0745		E	Inj codeine phosphate /30 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0760		E	Colchicine injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0770		E	Colistimethate sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0780		E	Prochlorperazine injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0800		E	Corticotropin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0810		E	Cortisone injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0835		E	Inj cosyntropin per 0.25 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0850		E	Cytomegalovirus imm IV /vial	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0895		E	Deferoxamine mesylate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0900		E	Testosterone enanthate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0945		E	Brompheniramine maleate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J0970		E	Estradiol valerate injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1000		E	Depo-estradiol cypionate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1020		E	Methylprednisolone 20 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1030		E	Methylprednisolone 40 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1040		E	Methylprednisolone 80 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1050		E	Medroxyprogesterone inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1055		N	Medrxyprogester acetate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1060		E	Testosterone cypionate 1 ML	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1070		E	Testosterone cypionat 100 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1080		E	Testosterone cypionat 200 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1090		E	Testosterone cypionate 50 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1095		E	Inj dexamethasone acetate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1100		E	Dexamethasone sodium phos	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1110		E	Inj dihydroergotamine mesylt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1120		E	Acetazolamid sodium injectio	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1160		E	Digoxin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1165		E	Phenytoin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1170		E	Hydromorphone injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1180		E	Dyphylline injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1190		E	Dexrazoxane HCl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1200		E	Diphenhydramine hcl injectio	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1205		E	Chlorothiazide sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1212		E	Dimethyl sulfoxide 50% 50 ML	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1230		E	Methadone injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1240		E	Dimenhydrinate injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1245		E	Dipyridamole injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1250		E	Inj dobutamine HCL/250 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1260		E	Dolasetron mesylate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1320		E	Amitriptyline injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1325		E	Epoprostenol injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1327		E	Eptifibatide injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1330		E	Ergonovine maleate injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1362		E	Erythromycin glucep / 250 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1364		E	Erythro lactobionate /500 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1380		E	Estradiol valerate 10 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
J1390		E	Estradiol valerate 20 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1410		E	Inj estrogen conjugate 25 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1435		E	Injection estrone per 1 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1436		E	Etidronate disodium inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1438		E	Etanercept injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1440		E	Filgrastim 300 mcg injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1441		E	Filgrastim 480 mcg injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1450		E	Fluconazole	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1455		E	Foscarnet sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1460		E	Gamma globulin 1 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1470		E	Gamma globulin 2 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1480		E	Gamma globulin 3 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1490		E	Gamma globulin 4 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1500		E	Gamma globulin 5 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1510		E	Gamma globulin 6 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1520		E	Gamma globulin 7 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1530		E	Gamma globulin 8 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1540		E	Gamma globulin 9 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1550		E	Gamma globulin 10 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1560		E	Gamma globulin ≤ 10 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1561		E	Immune globulin 500 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1562		E	Immune globulin 5 gms	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1565		E	RSV-ivig	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1570		E	Ganciclovir sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1580		E	Garamycin gentamicin inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1600		E	Gold sodium thiomaleate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1610		E	Glucagon hydrochloride/1 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1620		E	Gonadorelin hydroch/ 100 mcg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1626		E	Granisetron HCl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1630		E	Haloperidol injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1631		E	Haloperidol decanoate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1642		E	Inj heparin sodium per 10 u	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1644		E	Inj heparin sodium per 1000u	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1645		E	Dalteparin sodium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1650		E	Inj enoxaparin sodium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1670		E	Tetanus immune globulin inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1690		E	Prednisolone tebutate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1700		E	Hydrocortisone acetate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1710		E	Hydrocortisone sodium ph inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1720		E	Hydrocortisone sodium succ i	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1730		E	Diazoxide injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1739		E	Hydroxyprogesterone cap 125	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1741		E	Hydroxyprogesterone cap 250	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1742		E	Ibutilide fumarate injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1745		E	Infliximab injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1750		E	Iron dextran	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1760		D	Iron dextran 2 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	.00	0.00	0.00	XXX
J1770		D	Iron dextran 5 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1780		D	Iron dextran 10 CC inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1785		E	Injection imiglucerase /unit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1790		E	Droperidol injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1800		E	Propranolol injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1810		E	Droperidol/fentanyl inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1820		E	Insulin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1825		E	Interferon beta-1a	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1830		E	Interferon beta-1b / .25 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1840		E	Kanamycin sulfate 500 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1850		E	Kanamycin sulfate 75 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1885		E	Ketorolac tromethamine inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1890		E	Cephalothin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1910		E	Kutapressin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1930		E	Propiomazine injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1940		E	Furosemide injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1950		E	Leuprolide acetate /3.75 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1955		E	Inj levocarnitine per 1 gm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1956		E	Levofloxacin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1960		E	Levorphanol tartrate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1970		E	Methotrimeprazine injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1980		E	Hyoscyamine sulfate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J1990		E	Chlordiazepoxide injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2000		E	Lidocaine injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2010		E	Lincomycin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2060		E	Lorazepam injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2150		E	Mannitol injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2175		E	Meperidine hydrochl /100 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2180		E	Meperidine/promethazine inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2210		E	Methylergonovin maleate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2240		E	Metocurine iodide injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2250		E	Inj midazolam hydrochloride	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2260		E	Inj milrinone lactate / 5 ML	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2270		E	Morphine sulfate injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2271		E	Morphine so4 injection 100mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
J2275		E	Morphine sulfate injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2300		E	Inj nalbuphine hydrochloride	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2310		E	Inj naloxone hydrochloride	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2320		E	Nandrolone decanoate 50 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2321		E	Nandrolone decanoate 100 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2322		E	Nandrolone decanoate 200 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2330		E	Thiothixene injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2350		E	Niacinamide/niacin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2352		E	Octreotide acetate injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2355		E	Oprelvekin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2360		E	Orphenadrine injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2370		E	Phenylephrine hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2400		E	Chloroprocaine hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2405		E	Ondansetron hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2410		E	Oxymorphone hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2430		E	Pamidronate disodium /30 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2440		E	Papaverin hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2460		E	Oxytetracycline injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2480		E	Hydrochlorides of opium inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2500		E	Paricalcitol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2510		E	Penicillin g procaine inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2512		E	Inj pentagastrin per 2 ML	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2515		E	Pentobarbital sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2540		E	Penicillin g potassium inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2543		E	Piperacillin/tazobactam	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2545		E	Pentamidine isethionte/300mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2550		E	Promethazine hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2560		E	Phenobarbital sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2590		E	Oxytocin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2597		E	Inj desmopressin acetate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2640		E	Prednisolone sodium ph inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2650		E	Prednisolone acetate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2670		E	Totazoline hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2675		E	Inj progesterone per 50 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2680		E	Fluphenazine decanoate 25 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2690		E	Procainamide hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2700		E	Oxacillin sodium injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2710		E	Neostigmine methylslfte inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2720		E	Inj protamine sulfate/10 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2725		E	Inj protirelin per 250 mcg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2730		E	Pralidoxime chloride inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2760		E	Phentolaine mesylate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2765		E	Metoclopramide hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2780		E	Ranitidine hydrochloride inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2790		E	Rho d immune globulin inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2792		E	Rho(D) immune globulin h, sd	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2800		E	Methocarbamol injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2810		E	Inj theophylline per 40 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2820		E	Sargramostim injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2860		E	Secobarbital sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2910		E	Aurothioglucose injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2912		E	Sodium chloride injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2920		E	Methylprednisolone injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2930		E	Methylprednisolone injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2950		E	Promazine hcl injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2970		E	Methicillin sodium injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2994		E	Reteplase double bolus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2995		E	Inj streptokinase /250000 IU	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J2996		E	Alteplase recombinant inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3000		E	Streptomycin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3010		E	Fentanyl citrate injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3030		E	Sumatriptan succinate / 6 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3070		E	Pentazocine hcl injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3080		E	Chlorprothixene injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3105		E	Terbutaline sulfate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3120		E	Testosterone enanthate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3130		E	Testosterone enanthate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3140		E	Testosterone suspension inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3150		E	Testosteron propionate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3230		E	Chlorpromazine hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3240		E	Thyrotropin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3245		E	Tirofiban hydrochloride	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3250		E	Trimethobenzamide hcl inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3260		E	Tobramycin sulfate injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3265		E	Injection torsemide 10 mg/ml	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3270		E	Imipramine hcl injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3280		E	Thiethylperazine maleate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3301		E	Triamcinolone acetonide inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3302		E	Triamcinolone diacetate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3303		E	Triamcinolone hexacetonl inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3305		E	Inj trimetrexate glucoronate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3310		E	Perphenazine injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
J3320		E	Spectinomycn di-hcl inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3350		E	Urea injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3360		E	Diazepam injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3364		E	Urokinase 5000 IU injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3365		E	Urokinase 250,000 IU inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3370		R	Vancomycin hcl injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3390		E	Methoxamine injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3400		E	Triflupromazine hcl inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3410		E	Hydroxyzine hcl injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3420		E	Vitamin b12 injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3430		E	Vitamin k phytonadione inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3450		E	Mephentermine sulfate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3470		E	Hyaluronidase injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3475		E	Inj magnesium sulfate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3480		E	Inj potassium chloride	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3490		E	Drugs unclassified injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3520		N	Edetate disodium per 150 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3530		E	Nasal vaccine inhalation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3535		N	Metered dose inhaler drug	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J3570		N	Laetrile amygdalin vit B17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7030		E	Normal saline solution infus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7040		E	Normal saline solution infus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7042		E	5% dextrose/normal saline	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7050		E	Normal saline solution infus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7051		E	Sterile saline/water	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7060		E	5% dextrose/water	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7070		E	D5w infusion	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7100		E	Dextran 40 infusion	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7110		E	Dextran 75 infusion	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7120		E	Ringers lactate infusion	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7130		E	Hypertonic saline solution	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7190		X	Factor viii	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7191		X	Factor VIII (porcine)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7192		X	Factor viii recombinant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7194		X	Factor ix complex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7196		D	Othr hemophilia clot factors	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7197		X	Antithrombin iii injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7198		E	Anti-inhibitor	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7199		E	Hemophilia clot factor noc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7300		N	Intraut copper contraceptive	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7310		E	Ganciclovir long act implant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7315		E	Sodium hyaluronate injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7320		E	Hylan G–F 20 injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7500		X	Azathioprine oral 50mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7501		X	Azathioprine parenteral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7502		E	Cyclosporine oral 100 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7503		D	Cyclosporine parenteral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7504		X	Lymphocyte immune globulin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7505		X	Monoclonal antibodies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7506		X	Prednisone oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7507		E	Tacrolimus oral per 1 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7508		E	Tacrolimus oral per 5 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7509		X	Methylprednisolone oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7510		X	Prednisolone oral per 5 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7513		E	Daclizumab, parenteral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7515		E	Cyclosporine oral 25 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7516		E	Cyclosporin parenteral 250mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7517		E	Mycophenolate mofetil oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7599		X	Immunosuppressive drug noc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7608		E	Acetylcysteine inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7610		E	Acetylcysteine 10% injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7615		E	Acetylcysteine 20% injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7618		E	Albuterol inh sol con	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7619		E	Albuterol inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7620		E	Albuterol sulfate .083%/ml	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7625		E	Albuterol sulfate .5% inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7627		E	Bitolterolmesylate inhal sol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7628		E	Bitolterol mes inhal sol con	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7629		E	Bitolterol mes inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7630		E	Cromolyn sodium injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7631		E	Cromolyn sodium inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7635		E	Atropine inhal sol con	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7636		E	Atropine inhal sol unit dose	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7637		E	Dexamethasone inhal sol con	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7638		E	Dexamethasone inhal sol u d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7639		E	Dornase alpha inhal sol u d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7640		E	Epinephrine injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7642		E	Glycopyrrolate inhal sol con	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7643		E	Glycopyrrolate inhal sol u d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7644		E	Ipratropium brom inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7645		E	Ipratropium bromide .02%/ml	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7648		E	Isoetharine hcl inh sol con	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
J7649		E	Isoetharine hcl inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7650		E	Isoetharine hcl .1% inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7651		E	Isoetharine hcl .125% inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7652		E	Isoetharine hcl .167% inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7653		E	Isoetharine hcl .2%/ inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7654		E	Isoetharine hcl .25% inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7655		E	Isoetharine hcl 1% inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7658		E	Isoproterenolhcl inh sol con	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7659		E	Isoproterenol hcl inh sol ud	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7660		E	Isoproterenol hcl .5% inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7665		E	Isoproterenol hcl 1% inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7668		E	Metaproterenol inh sol con	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7669		E	Metaproterenol inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7670		E	Metaproterenol sulfate .4%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7672		E	Metaproterenol sulfate .6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7675		E	Metaproterenol sulfate 5%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7680		E	Terbutaline so4 inh sol con	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7681		E	Terbutaline so4 inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7682		E	Tobramycin inhalation sol	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7683		E	Triamcinolone inh sol con	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7684		E	Triamcinolone inh sol u d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7699		E	Inhalation solution for DME	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J7799		E	Non-inhalation drug for DME	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8499		N	Oral prescrip drug non chemo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8510		E	Oral busulfan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8520		E	Capecitabine, oral, 150 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8521		E	Capecitabine, oral, 500 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8530		E	Cyclophosphamide oral 25 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8560		E	Etoposide oral 50 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8600		E	Melphalan oral 2 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8610		E	Methotrexate oral 2.5 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J8999		E	Oral prescription drug chemo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9000		E	Doxorubic hcl 10 MG vl chemo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9001		E	Doxorubicin hcl liposome inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9015		E	Aldesleukin/single use vial	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9020		E	Asparaginase injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9031		E	Bcg live intravesical vac	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9040		E	Bleomycin sulfate injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9045		E	Carboplatin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9050		E	Carmus bischl nitro inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9060		E	Cisplatin 10 MG injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9062		E	Cisplatin 50 MG injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9065		E	Inj cladribine per 1 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9070		E	Cyclophosphamide 100 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9080		E	Cyclophosphamide 200 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9090		E	Cyclophosphamide 500 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9091		E	Cyclophosphamide 1.0 grm inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9092		E	Cyclophosphamide 2.0 grm inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9093		E	Cyclophosphamide lyophilized	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9094		E	Cyclophosphamide lyophilized	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9095		E	Cyclophosphamide lyophilized	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9096		E	Cyclophosphamide lyophilized	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9097		E	Cyclophosphamide lyophilized	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9100		E	Cytarabine hcl 100 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9110		E	Cytarabine hcl 500 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9120		E	Dactinomycin actinomycin d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9130		E	Dacarbazine 10 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9140		E	Dacarbazine 200 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9150		E	Daunorubicin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9151		E	Daunorubicin citrate liposom	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9165		E	Diethylstilbestrol injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9170		E	Docetaxel	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9181		E	Etoposide 10 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9182		E	Etoposide 100 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9185		E	Fludarabine phosphate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9190		E	Fluorouracil injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9200		E	Floxuridine injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9201		E	Gemcitabine HCl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9202		E	Goserelin acetate implant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9206		E	Irinotecan injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9208		E	Ifosfomide injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9209		E	Mesna injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9211		E	Idarubicin hcl injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9212		E	Interferon alfacon-1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9213		E	Interferon alfa-2a inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9214		E	Interferon alfa-2b inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9215		E	Interferon alfa-n3 inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9216		E	Interferon gamma 1-b inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9217		E	Leuprolide acetate suspnsion	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9218		E	Leuprolide acetate injeciton	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9230		E	Mechlorethamine hcl inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9245		E	Inj melphalan hydrochl 50 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
J9250		E	Methotrexate sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9260		E	Methotrexate sodium inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9265		E	Paclitaxel injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9266		E	Pegaspargase/singl dose vial	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9268		E	Pentostatin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9270		E	Plicamycin (mithramycin) inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9280		E	Mitomycin 5 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9290		E	Mitomycin 20 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9291		E	Mitomycin 40 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9293		E	Mitoxantrone hydrochl / 5 MG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9310		E	Rituximab cancer treatment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9320		E	Streptozocin injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9340		E	Thiotepa injection	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9350		E	Topotecan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9355		E	Trastuzumab	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9357		E	Valrubicin, 200 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9360		E	Vinblastine sulfate inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9370		E	Vincristine sulfate 1 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9375		E	Vincristine sulfate 2 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9380		E	Vincristine sulfate 5 MG inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9390		E	Vinorelbine tartrate/10 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9600		E	Porfimer sodium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
J9999		E	Chemotherapy drug	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0064		A	Visit for drug monitoring	0.37	0.24	0.23	0.12	0.14	0.01	0.62	0.61	0.50	0.52	XXX
M0075		N	Cellular therapy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0076		N	Prolotherapy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0100		N	Intragastric hypothermia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0300		N	IV chelationtherapy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0301		N	Fabric wrapping of aneurysm	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
M0302	TC	A	Assessment of cardiac output	0.00	0.81	0.81	NA	NA	0.02	0.83	0.83	NA	NA	XXX
P2028		X	Cephalin floculation test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P2029		X	Congo red blood test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P2031		N	Hair analysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P2033		X	Blood thymol turbidity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P2038		X	Blood mucoprotein	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P3000		X	Screen pap by tech w md supv	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P3001		A	Screening pap smear by phys	0.42	0.19	0.23	0.19	0.23	0.01	0.62	0.66	0.62	0.66	XXX
P7001		I	Culture bacterial urine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9010		E	Whole blood for transfusion	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9011		E	Blood split unit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9012		E	Cryoprecipitate each unit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9013		E	Unit/s blood fibrinogen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9016		E	Leukocyte poor blood, unit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9017		E	One donor fresh frozn plasma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9018		E	Plasma protein fract, unit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9019		E	Platelet concentrate unit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9020		E	Plaelet rich plasma unit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9021		E	Red blood cells unit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9022		E	Washed red blood cells unit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9023		X	Frozen plasma, pooled, sd	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9603		X	One-way allow prorated miles	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9604		X	One-way allow prorated trip	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9612		X	Catheterize for urine spec	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
P9615		X	Urine specimen collect mult	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0034		X	Admin of influenza vaccine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0035		A	Cardiokymography	0.17	0.46	0.48	NA	NA	0.03	0.66	0.68	NA	NA	XXX
Q0035	26	A	Cardiokymography	0.17	0.07	0.09	0.07	0.09	0.01	0.25	0.27	0.25	0.27	XXX
Q0035	TC	A	Cardiokymography	0.00	0.39	0.39	NA	NA	0.02	0.41	0.41	NA	NA	XXX
Q0068		D	Extracorpeal plasmapheresis	1.67	4.42	3.66	0.98	1.08	0.11	6.20	5.44	2.76	2.86	000
Q0091		A	Obtaining screen pap smear	0.37	0.54	0.48	0.14	0.18	0.01	0.92	0.86	0.52	0.56	XXX
Q0092		A	Set up port xray equipment	0.00	0.32	0.32	NA	NA	0.01	0.33	0.33	NA	NA	XXX
Q0111		X	Wet mounts/ w preparations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0112		X	Potassium hydroxide preps	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0113		X	Pinworm examinations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0114		X	Fern test	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0115		X	Post-coital mucous exam	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0132		D	Dispensing fee DME neb drug	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0136		X	Non esrd epoetin alpha inj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0144		N	Azithromycin dihydrate, oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0156		X	Human albumin 5%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0157		X	Human albumin 25%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0160		X	Factor IX non-recombinant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0161		X	Factor IX recombinant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0163		X	Diphenhydramine HCl 50mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0164		X	Prochlorperazine maleate 5mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0165		X	Prochlorperazine maleate10mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0166		X	Granisetron HCl 1 mg oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0167		X	Dronabinol 2.5mg oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0168		X	Dronabinol 5mg oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0169		X	Promethazine HCl 12.5mg oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0170		X	Promethazine HCl 25 mg oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0171		X	Chlorpromazine HCl 10mg oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
Q0172		X	Chlorpromazine HCl 25mg oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0173		X	Trimethobenzamide HCl 250mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0174		X	Thiethylperazine maleate10mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0175		X	Perphenazine 4mg oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0176		X	Perphenazine 8mg oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0177		X	Hydroxyzine pamoate 25mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0178		X	Hydroxyzine pamoate 50mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0179		X	Ondansetron HCl 8mg oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0180		X	Dolasetron mesylate oral	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0181		X	Unspecified oral anti-emetic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0183		X	Nonmetabolic active tissue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0184		X	Metabolically active tissue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0185		X	Metabolic active D/E tissue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0186		X	Paramedic intercept, rural	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q0187		E	Factor viia recombinant	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q1001		X	Ntiol category 1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q1002		X	Ntiol category 2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q1003		X	Ntiol category 3	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q1004		X	Ntiol category 4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q1005		X	Ntiol category 5	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9920		E	Epoetin with hct <= 20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9921		E	Epoetin with hct = 21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9922		E	Epoetin with hct = 22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9923		E	Epoetin with hct = 23	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9924		E	Epoetin with hct = 24	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9925		E	Epoetin with hct = 25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9926		E	Epoetin with hct = 26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9927		E	Epoetin with hct = 27	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9928		E	Epoetin with hct = 28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9929		E	Epoetin with hct = 29	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9930		E	Epoetin with hct = 30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9931		E	Epoetin with hct = 31	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9932		E	Epoetin with hct = 32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9933		E	Epoetin with hct = 33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9934		E	Epoetin with hct = 34	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9935		E	Epoetin with hct = 35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9936		E	Epoetin with hct = 36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9937		E	Epoetin with hct = 37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9938		E	Epoetin with hct = 38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9939		E	Epoetin with hct = 39	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
Q9940		E	Epoetin with hct >= 40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
R0070		C	Transport portable x-ray	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
R0075		C	Transport port x-ray multipl	0.00	0.00	0.00	NA	NA	0.00	0.00	0.00	NA	NA	XXX
R0076		B	Transport portable EKG	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0009		I	Injection, butorphanol tartr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0010		I	Injection, somatrem, 5 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0011		I	Injection, somatropin, 5 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0012		I	Butorphanol tartrate, nasal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0014		I	Tacrine hydrochloride, 10 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0016		I	Injection, amikacin sulfate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0017		I	Injection, aminocaproic acid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0020		I	Injection, bupivicaine hydro	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0021		I	Injection, ceftoperazone sod	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0023		I	Injection, cimetidine hydroc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0024		I	Injection, ciprofloxacin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0028		I	Injection, famotidine, 20 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0029		I	Injection, fluconazole	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0030		I	Injection, metronidazole	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0032		I	Injection, nafcillin sodium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0034		I	Injection, ofloxacin, 400 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0039		I	Injection, sulfamethoxazole	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0040		I	Injection, ticarcillin disod	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0071		I	Injection, acyclovir sodium	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0072		I	Injection, amikacin sulfate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0073		I	Injection, aztreonam, 500 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0074		I	Injection, cefotetan disodiu	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0077		I	Injection, clindamycin phosp	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0078		I	Injection, fosphenytoin sodi	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0080		I	Injection, pentamidine iseth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0081		I	Injection, piperacillin sodi	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0090		I	Sildenafil citrate, 25 mg	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0096		I	Injection, itraconazole, 200	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0097		I	Injection, ibutilide fumarat	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0098		I	Injection, sodium ferric glu	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0601		I	Screening proctoscopy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0605		I	Digital rectal examination,	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0610		I	Annual gynecological examina	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0612		I	Annual gynecological examina	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0620		I	Routine ophthalmological exa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0621		I	Routine ophthalmological exa	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0800		I	Laser in situ keratomileusis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S0810		I	Photorefractive keratectomy	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
S2050		I	Donor enterectomy, with prep	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2052		I	Transplantation of small int	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2053		I	Transplantation of small int	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2054		I	Transplantation of multivisc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2055		I	Harvesting of donor multivis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2109		I	Autologous chondrocyte trans	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2190		I	Subcutaneous implantation of	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2204		I	Transmyocardial laser revasc	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2205		I	Minimally invasive direct co	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2206		I	Minimally invasive direct co	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2207		I	Minimally invasive direct co	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2208		I	Minimally invasive direct co	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2209		I	Minimally invasive direct co	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2210		I	Cryosurgical ablation (in si	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2300		I	Arthroscopy, shoulder, surgi	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2350		I	Diskectomy, anterior, with d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S2351		I	Diskectomy, anterior, with d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S3645		I	HIV–1 antibody testing of or	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S3650		I	Saliva test, hormone level;	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S3652		I	Saliva test, hormone level;	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8035		I	Magnetic source imaging	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8040		I	Topographic brain mapping	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8048		I	Isolated limb perfusion	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8049		I	Intraoperative radiation the	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8060		I	Supply of contrast material	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8092		I	Electron beam computed tomog	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8095		I	Wig (for medically-induced h	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8096		I	Portable peak flow meter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8110		I	Peak expiratory flow rate (p	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8200		I	Chest compression vest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8205		I	Chest compression system gen	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8260		I	Oral orthotic for treatment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8300		I	Sacral nerve stimulation tes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S8950		I	Complex lymphedema therapy,	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9001		I	Home uterine monitor with or	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9022		I	Digital subtraction angiogra	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9023		I	Xenon regional cerebral bloo	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9024		I	Paranasal sinus ultrasound	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9033		I	Gait analysis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9055		I	Procuren or other growth fac	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9056		I	Coma stimulation per diem	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9075		I	Smoking cessation treatment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9085		I	Meniscal allograft transplan	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9090		I	Vertebral axial decompressio	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9122		I	Home health aide or certifie	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9123		I	Nursing care, in the home; b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9124		I	Nursing care, in the home; b	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9125		I	Respite care, in the home, p	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9126		I	Hospice care, in the home, p	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9127		I	Social work visit, in the ho	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9128		I	Speech therapy, in the home,	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9129		I	Occupational therapy, in the	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9140		I	Diabetic Management Program,	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9141		I	Diabetic Management Program,	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9455		I	Diabetic Management Program,	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9460		I	Diabetic Management Program,	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9465		I	Diabetic Management Program,	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9470		I	Nutritional counseling, diet	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9472		I	Cardiac rehabilitation progr	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9473		I	Pulmonary rehabilitation pro	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9474		I	Enterostomal therapy by a re	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9475		I	Ambulatory setting substance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9480		I	Intensive outpatient psychia	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9485		I	Crisis intervention mental h	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9524		I	Nursing services related to	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9527		I	Insertion of a peripherally	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9528		I	Insertion of midline central	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9543		I	Administration of medication	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9990		I	Services provided as part of	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9991		I	Services provided as part of	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9992		I	Transportation costs to and	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9994		I	Lodging costs (e.g. hotel ch	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9996		I	Meals for clinical trial par	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
S9999		I	Sales tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2020		X	Vision svcs frames purchases	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2025		N	Eyeglasses delux frames	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2100		X	Lens spher single plano 4.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2101		X	Single visn sphere 4.12–7.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2102		X	Singl visn sphere 7.12–20.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2103		X	Spherocylindr 4.00d/12–2.00d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2104		X	Spherocylindr 4.00d/2.12–4d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2105		X	Spherocylinder 4.00d/4.25–6d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
V2106		X	Spherocylinder 4.00d/≤6.00d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2107		X	Spherocylinder 4.25d/12–2d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2108		X	Spherocylinder 4.25d/2.12–4d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2109		X	Spherocylinder 4.25d/4.25–6d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2110		X	Spherocylinder 4.25d/over 6d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2111		X	Spherocylindr 7.25d/.25–2.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2112		X	Spherocylindr 7.25d/2.25–4d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2113		X	Spherocylindr 7.25d/4.25–6d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2114		X	Spherocylinder over 12.00d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2115		X	Lens lenticular bifocal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2116		X	Nonaspheric lens bifocal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2117		X	Aspheric lens bifocal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2118		X	Lens aniseikonic single	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2199		X	Lens single vision not oth c	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2200		X	Lens spher bifoc plano 4.00d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2201		X	Lens sphere bifocal 4.12–7.0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2202		X	Lens sphere bifocal 7.12–20.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2203		X	Lens sphcyl bifocal 4.00d/.1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2204		X	Lens sphcy bifocal 4.00d/2.1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2205		X	Lens sphcy bifocal 4.00d/4.2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2206		X	Lens sphcy bifocal 4.00d/ove	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2207		X	Lens sphcy bifocal 4.25–7d/.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2208		X	Lens sphcy bifocal 4.25–7/2.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2209		X	Lens sphcy bifocal 4.25–7/4.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2210		X	Lens sphcy bifocal 4.25–7/ov	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2211		X	Lens sphcy bifo 7.25–12/.25–	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2212		X	Lens sphcyl bifo 7.25–12/2.2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2213		X	Lens sphcyl bifo 7.25–12/4.2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2214		X	Lens sphcyl bifocal over 12.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2215		X	Lens lenticular bifocal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2216		X	Lens lenticular nonaspheric	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2217		X	Lens lenticular aspheric bif	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2218		X	Lens aniseikonic bifocal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2219		X	Lens bifocal seg width over	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2220		X	Lens bifocal add over 3.25d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2299		X	Lens bifocal speciality	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2300		X	Lens sphere trifocal 4.00d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2301		X	Lens sphere trifocal 4.12–7.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2302		X	Lens sphere trifocal 7.12–20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2303		X	Lens sphcy trifocal 4.0/.12–	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2304		X	Lens sphcy trifocal 4.0/2.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2305		X	Lens sphcy trifocal 4.0/4.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2306		X	Lens sphcyl trifocal 4.00/≤6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2307		X	Lens sphcy trifocal 4.25–7/.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2308		X	Lens sphc trifocal 4.25–7/2.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2309		X	Lens sphc trifocal 4.25–7/4.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2310		X	Lens sphc trifocal 4.25–7/≤6	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2311		X	Lens sphc trifo 7.25–12/.25–	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2312		X	Lens sphc trifo 7.25–12/2.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2313		X	Lens sphc trifo 7.25–12/4.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2314		X	Lens sphcyl trifocal over 12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2315		X	Lens lenticular trifocal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2316		X	Lens lenticular nonaspheric	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2317		X	Lens lenticular aspheric tri	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2318		X	Lens aniseikonic trifocal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2319		X	Lens trifocal seg width ≤ 28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2320		X	Lens trifocal add over 3.25d	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2399		X	Lens trifocal speciality	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2410		X	Lens variab asphericity sing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2430		X	Lens variable asphericity bi	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2499		X	Variable asphericity lens	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2500		X	Contact lens pmma spherical	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2501		X	Cntct lens pmma-toric/prism	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2502		X	Contact lens pmma bifocal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2503		X	Cntct lens pmma color vision	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2510		X	Cntct gas permeable sphericl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2511		X	Cntct toric prism ballast	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2512		X	Cntct lens gas permbl bifocl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2513		X	Contact lens extended wear	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2520		P	Contact lens hydrophilic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2521		X	Cntct lens hydrophilic toric	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2522		X	Cntct lens hydrophil bifocl	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2523		X	Cntct lens hydrophil extend	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2530		X	Contact lens gas impermeable	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2531		X	Contact lens gas permeable	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2599		X	Contact lens/es other type	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2600		X	Hand held low vision aids	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2610		X	Single lens spectacle mount	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2615		X	Telescop/othr compound lens	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2623		X	Plastic eye prosth custom	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2624		X	Polishing artifical eye	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2625		X	Enlargemnt of eye prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

[1] CPT codes and descriptions only are copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
[2] Copyright 1994 American Dental Association. All rights reserved.
[3] PE RVUs = Practice Expense Relative Value Units.

CPT RVUs: Copyright 1999 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Apply.

ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—Continued

CPT [1]/ HCPCS [2]	Mod	Status	Description	Physician work RVUs	Fully implemented non-facility PE RVUs	Year 2001 transitional non-facility PE RVUs	Fully implemented facility PE RVUs	Year 2001 transitional facility PE RVUs	Malpractice RVUs	Fully implemented non-facility total	Year 2001 transitional non-facility total	Fully implemented facility total	Year 2001 transitional facility total	Global
V2626		X	Reduction of eye prosthesis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2627		X	Scleral cover shell	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2628		X	Fabrication & fitting	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2629		X	Prosthetic eye other type	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2630		X	Anter chamber intraocul lens	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2631		X	Iris support intraoclr lens	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2632		X	Post chmbr intraocular lens	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2700		X	Balance lens	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2710		X	Glass/plastic slab off prism	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2715		X	Prism lens/es	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2718		X	Fresnell prism press-on lens	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2730		X	Special base curve	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2740		X	Rose tint plastic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2741		X	Non-rose tint plastic	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2742		X	Rose tint glass	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2743		X	Non-rose tint glass	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2744		X	Tint photochromatic lens/es	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2750		X	Anti-reflective coating	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2755		X	UV lens/es	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2760		X	Scratch resistant coating	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2770		X	Occluder lens/es	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2780		X	Oversize lens/es	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2781		X	Progressive lens per lens	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2785		X	Corneal tissue processing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V2799		X	Miscellaneous vision service	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5008		N	Hearing screening	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5010		N	Assessment for hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5011		N	Hearing aid fitting/checking	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5014		N	Hearing aid repair/modifying	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5020		N	Conformity evaluation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5030		N	Body-worn hearing aid air	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5040		N	Body-worn hearing aid bone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5050		N	Body-worn hearing aid in ear	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5060		N	Behind ear hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5070		N	Glasses air conduction	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5080		N	Glasses bone conduction	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5090		N	Hearing aid dispensing fee	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5100		N	Body-worn bilat hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5110		N	Hearing aid dispensing fee	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5120		N	Body-worn binaur hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5130		N	In ear binaural hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5140		N	Behind ear binaur hearing ai	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5150		N	Glasses binaural hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5160		N	Dispensing fee binaural	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5170		N	Within ear cros hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5180		N	Behind ear cros hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5190		N	Glasses cros hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5200		N	Cros hearing aid dispens fee	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5210		N	In ear bicros hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5220		N	Behind ear bicros hearing ai	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5230		N	Glasses bicros hearing aid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5240		N	Dispensing fee bicros	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5299		R	Hearing service	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5336		N	Repair communication device	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5362		R	Speech screening	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5363		R	Language screening	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX
V5364		R	Dysphagia screening	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	XXX

ADDENDUM C.—CLINICAL STAFF TIMES FOR SELECTED CODES

Procedure code	Type of staff	Additional time included (minutes)	Procedure code	Type of staff	Additional time included (minutes)
11000	RN/LPN/MA/Tech	3	29085	RN	15
11011	RN/MA	3	29085	RN/LPN	3
11012	RN/MA	3	29105	RN	15
11040	RN/LPN/MA/Tech	3	29105	RN/LPN	3
11041	RN/LPN/MA/Tech	3	29125	RN	15
11042	RN/LPN/MA/Tech	3	29125	RN/LPN	3
11055	RN/LPN/MA/Tech	3	29126	RN	15
11056	RN/LPN/MA/Tech	3	29130	RN	15
11057	RN/LPN/MA/Tech	3	29130	RN/LPN	3
11305	RN/MA	3	29131	RN	15
11740	RN/LPN/MA/Tech	2	29200	RN	15
11921	RN/MA	2	29200	RN/LPN	3
11950	RN/MA	2	29220	RN	15
15775	RN/MA	2	29220	RN/LPN	3
15851	RN/MA	3	29240	RN	15
15852	RN/MA	3	29240	RN/LPN	3
16000	RN/LPN/MA/Tech	3	29260	RN	15
16010	RN/LPN/MA/Tech	3	29260	RN/LPN	3
16015	RN/LPN/MA/Tech	3	29280	RN	15
16020	RN/LPN/MA/Tech	3	29280	RN/LPN	3
16025	RN/LPN/MA/Tech	3	29305	RN	15
16030	RN/MA	10	29325	RN	15
17250	RN/LPN/MA/Tech	3	29345	RN	15
20200	RN/MA	3	29345	RN/LPN	3
20205	RN/MA	3	29355	RN	15
20220	RN	25	29355	RN/LPN	3
20225	RN	25	29358	RN	15
20610	RN	20	29365	RN	15
20660	RN	15	29365	RN/LPN	3
20950	RN	25	29405	RN	15
29000	RN	15	29405	RN/LPN	3
29010	RN	15	29425	RN	15
29015	RN	15	29425	RN/LPN	3
29020	RN	15	29435	RN	15
29025	RN	15	29440	RN	15
29035	RN	15	29440	RN/LPN	3
29040	RN	15	29445	RN	15
29044	RN	15	29450	RN	15
29046	RN	15	29505	RN	15
29049	RN	15	29515	RN	15
29055	RN	15	29520	RN	15
29058	RN	15	29520	RN/LPN	3
29065	RN	15	29530	RN	15
29065	RN/LPN	3	29530	RN/LPN	3
29075	RN	15	29540	RN	15
29075	RN/LPN	3	29540	RN/LPN	3
29550	RN	15	31561	RN/LPN/MA	10
29550	RN/LPN	3	31570	RN/LPN/MA	10
29580	RN	15	31571	RN/LPN/MA	10
29580	RN/LPN	3	31575	RN/LPN/MA	5
29590	RN	15	31612	RN	5
29700	RN	15	31615	RN	20
29700	RN/LPN	3	31622	RN	20
29705	RN	15	31623	RN	20
29705	RN/LPN	3	31624	RN	20
29710	RN	15	31625	RN	20
29715	RN	15	31628	RN	20
29720	RN	15	31629	RN	20
29730	RN	15	31630	RN	30
29730	RN/LPN	3	31631	RN	30
29740	RN	15	31635	RN	30
29740	RN/LPN	3	31640	RN	30
29750	RN	15	31641	RN	30
30901	RN/LPN/MA	10	31643	RN	20
30903	RN/LPN/MA	10	31645	RN	20
30905	RN/LPN/MA	10	31646	RN	20
30906	RN/LPN/MA	10	31656	RN	20
31240	RN/LPN/MA	10	31700	RN	20
31254	RN/LPN/MA	10	31708	RN/LPN/MA	10
31255	RN/LPN/MA	10	31710	RN	20

ADDENDUM C.—CLINICAL STAFF TIMES FOR SELECTED CODES—Continued

Procedure code	Type of staff	Additional time included (minutes)	Procedure code	Type of staff	Additional time included (minutes)
31256	RN/LPN/MA	10	31715	RN	20
31267	RN/LPN/MA	10	31717	RN	20
31276	RN/LPN/MA	10	31730	RN	10
31287	RN/LPN/MA	10	32002	RN	10
31288	RN/LPN/MA	10	32005	RN	10
31500	RN/LPN/MA	10	32020	RN	10
31505	RN/LPN/MA	10	32420	RN	10
31513	RN/LPN/MA	10	32960	RN	10
31515	RN/LPN/MA	10	33010	RN	10
31520	RN/LPN/MA	10	33011	RN	10
31525	RN/LPN/MA	10	36481	RN	25
31526	RN/LPN/MA	10	36488	RN	25
31527	RN/LPN/MA	10	36489	RN	25
31528	RN/LPN/MA	10	36490	RN	25
31529	RN/LPN/MA	10	36491	RN	25
31530	RN/LPN/MA	10	36493	RN	25
31531	RN/LPN/MA	10	36510	RN	25
31535	RN/LPN/MA	10	36520	RN	25
31536	RN/LPN/MA	10	36521	RN	25
31540	RN/LPN/MA	10	36522	RN	25
31541	RN/LPN/MA	10	36680	RN	10
31560	RN/LPN/MA	10	40806	RN/LPN/MA	10
42660	RN/LPN/MA	10	43761	RN/LPN/MA	10
43200	RN/LPN/MA	45	44100	RN/LPN/MA	45
43202	RN/LPN/MA	45	44360	RN/LPN/MA	55
43204	RN/LPN/MA	40	44361	RN/LPN/MA	55
43205	RN/LPN/MA	40	44363	RN/LPN/MA	55
43215	RN/LPN/MA	25	44364	RN/LPN/MA	55
43216	RN/LPN/MA	40	44365	RN/LPN/MA	55
43217	RN/LPN/MA	40	44366	RN/LPN/MA	55
43219	RN/LPN/MA	40	44369	RN/LPN/MA	55
43220	RN/LPN/MA	40	44372	RN/LPN/MA	55
43226	RN/LPN/MA	40	44373	RN/LPN/MA	55
43227	RN/LPN/MA	40	44376	RN/LPN/MA	55
43228	RN/LPN/MA	40	44377	RN/LPN/MA	55
43234	RN/LPN/MA	45	44378	RN/LPN/MA	55
43235	RN/LPN/MA	45	44380	RN/LPN/MA	55
43239	RN/LPN/MA	45	44382	RN/LPN/MA	55
43241	RN/LPN/MA	40	44385	RN/LPN/MA	55
43243	RN/LPN/MA	40	44386	RN/LPN/MA	55
43244	RN/LPN/MA	40	44388	RN/LPN/MA	55
43245	RN/LPN/MA	40	44389	RN/LPN/MA	55
43246	RN/LPN/MA	33	44390	RN/LPN/MA	55
43247	RN/LPN/MA	40	44391	RN/LPN/MA	25
43248	RN/LPN/MA	40	44392	RN/LPN/MA	55
43249	RN/LPN/MA	40	44393	RN/LPN/MA	55
43250	RN/LPN/MA	40	44394	RN/LPN/MA	55
43251	RN/LPN/MA	40	44500	RN/LPN/MA	15
43255	RN/LPN/MA	25	45300	RN/LPN/MA	15
43258	RN/LPN/MA	40	45303	RN/LPN/MA	15
43259	RN/LPN/MA	55	45305	RN/LPN/MA	15
43260	RN/LPN/MA	38	45307	RN/LPN/MA	15
43261	RN/LPN/MA	38	45308	RN/LPN/MA	15
43262	RN/LPN/MA	38	45309	RN/LPN/MA	15
43263	RN/LPN/MA	38	45315	RN/LPN/MA	15
43264	RN/LPN/MA	38	45317	RN/LPN/MA	15
43265	RN/LPN/MA	38	45320	RN/LPN/MA	15
43267	RN/LPN/MA	38	45321	RN/LPN/MA	15
43268	RN/LPN/MA	38	45330	RN/LPN/MA	15
43269	RN/LPN/MA	38	45331	RN/LPN/MA	15
43271	RN/LPN/MA	38	45332	RN/LPN/MA	15
43272	RN/LPN/MA	38	45333	RN/LPN/MA	15
43450	RN/LPN/MA	15	45334	RN/LPN/MA	15
43453	RN/LPN/MA	15	45337	RN/LPN/MA	15
43456	RN/LPN/MA	15	45338	RN/LPN/MA	15
43458	RN/LPN/MA	15	45339	RN/LPN/MA	15
43600	RN/LPN/MA	45	45378	RN/LPN/MA	55
43760	RN/LPN/MA	10	45379	RN/LPN/MA	55
45380	RN/LPN/MA	55	57100	RN/MA	5
45382	RN/LPN/MA	25	57400	RN/MA	5

ADDENDUM C.—CLINICAL STAFF TIMES FOR SELECTED CODES—Continued

Procedure code	Type of staff	Additional time included (minutes)
45383	RN/LPN/MA	55
45384	RN/LPN/MA	55
45385	RN/LPN/MA	55
47552	RN/LPN/MA	38
47553	RN/LPN/MA	38
47554	RN/LPN/MA	38
47555	RN/LPN/MA	38
47556	RN/LPN/MA	38
47561	RN	18
49080	RN	10
49081	RN	10
49400	RN	10
49423	RN	10
49424	RN	10
49427	RN	10
50021	RN	60
50396	RN	10
50686	RN	10
51700	RN	5
51726	RN	10
51772	RN	15
51784	RN	15
51785	RN	15
51792	RN	10
51795	RN	10
51797	RN	15
53020	RN	10
53025	RN	10
53200	RN	10
53600	RN	15
53601	RN	15
53660	RN	15
53670	RN	5
54100	RN	15
54220	RN	30
54231	RN	15
54240	RN	15
54250	RN	15
54450	RN	15
55300	RN	30
55870	RN	15
56605	RN/MA	5
56720	RN/MA	5
57020	RN/MA	5
91010	RN/LPN/MA	15
91011	RN/LPN/MA	15
91012	RN/LPN/MA	15
91020	RN/LPN/MA	15
91030	RN/LPN/MA	15
91032	RN/LPN/MA	15
91033	RN/LPN/MA	15
91052	RN/LPN/MA	15
91055	RN/LPN/MA	15
91060	RN/LPN/MA	15
91065	RN/LPN/MA	15
91100	RN/LPN/MA	15
91105	RN/LPN/MA	10
92950	RN/LPN	12
92953	RN/LPN	12
92971	RN/LPN	12
96440	RN/OCN	10
96445	RN/OCN	10
96450	RN/OCN	10
G0104	RN/LPN/MA	15
G0105	RN/LPN/MA	55
Q0068	RN	25
57410	RN/MA	5
57500	RN/MA	5
57800	RN/MA	5
58555	RN/MA	13
58558	RN/MA	13
58559	RN/MA	13
58560	RN/MA	13
58561	RN/MA	13
58562	RN/MA	13
58563	RN/MA	13
58970	Medical Assistant	10
58970	RN	30
59012	RN	25
59030	RN	25
59300	RN/MA	5
59320	RN/MA	5
59325	RN/MA	5
59350	RN/MA	10
59871	RN/MA	3
61000	RN/LPN/MA	16
61001	RN/LPN/MA	14
61020	RN/LPN/MA	13
61026	RN/LPN/MA	14
61050	RN/LPN/MA	20
61055	RN/LPN/MA	20
61070	RN/LPN/MA	10
61107	RN/LPN/MA	20
61210	RN/LPN/MA	20
62268	RN/LPN/MA	20
62270	RN	5
62272	RN	5
62273	RN/LPN/MA	12
62284	RN/LPN/MA	20
62290	RN/LPN/MA	20
62291	RN/LPN/MA	20
63610	RN/LPN/MA	20
90870	RN	40
90871	RN	40
90935	RN	45
90937	RN	45
90945	RN	45
90947	RN	45
90997	RN	45
91000	RN/LPN/MA	15

ADDENDUM D.—COMPARISON OF 1999 AND PROPOSED 2002 OFFICE RENT INDEX BY FEE SCHEDULE AREA

[In descending order of difference]

Carrier	Locality	Fee schedule area	Office rent index		Difference	Percentage difference
			2000	2002		
31140	05	SAN FRANCISCO, CA	1.629	2.174	0.545	33.5
31140	06	SAN MATEO, CA	1.629	2.174	0.545	33.5
31140	09	SANTA CLARA, CA	1.548	1.949	0.401	25.9
31140	03	MARIN/NAPA/SOLANO, CA	1.346	1.647	0.301	22.4
00900	11	DALLAS, TX	1.005	1.196	0.191	19.0
00910	09	UTAH	0.827	0.978	0.151	18.3
31143	99	REST OF MASSACHUSETTS	1.170	1.308	0.138	11.8
00824	01	COLORADO	0.956	1.066	0.110	11.5
00835	01	PORTLAND, OR	1.006	1.120	0.114	11.3
00740	02	METROPOLITAN KANSAS CITY, MO.	828	0.916	0.088	10.6
00511	01	ATLANTA, GA	1.034	1.136	0.102	9.9
31143	01	METROPOLITAN BOSTON	1.369	1.504	0.135	9.9
31140	07	OAKLAND/BERKLEY, CA	1.339	1.470	0.131	9.8
00953	01	DETROIT, MI	0.971	1.045	0.074	7.6
05535	00	NORTH CAROLINA	0.817	0.869	0.052	6.4
16360	00	OHIO	0.812	0.863	0.051	6.3
00655	00	NEBRASKA	0.770	0.817	0.047	6.1
00900	28	FORT WORTH, TX	0.921	0.977	0.056	6.1
00836	02	SEATTLE (KING CNTY), WA	1.162	1.232	0.070	6.0
05440	35	TENNESSEE	0.758	0.800	0.042	5.5
00820	02	SOUTH DAKOTA	0.809	0.853	0.044	5.4
00952	99	REST OF ILLINOIS	0.756	0.797	0.041	5.4
00820	01	NORTH DAKOTA	0.761	0.800	0.039	5.1
00630	00	INDIANA	0.806	0.847	0.041	5.1
10240	00	MINNESOTA	0.896	0.940	0.044	4.9
00832	00	ARIZONA	0.955	1.000	0.045	4.7
00805	99	REST OF NEW JERSEY	1.261	1.312	0.051	4.0
16510	16	WEST VIRGINIA	0.659	0.685	0.026	3.9
00825	21	WYOMING	0.769	0.799	0.030	3.9
00880	01	SOUTH CAROLINA	0.795	0.825	0.030	3.8
00902	01	DELAWARE	1.013	1.051	0.038	3.8
00751	01	MONTANA	0.766	0.794	0.028	3.7
00834	00	NEVADA	1.078	1.117	0.039	3.6
00510	00	ALABAMA	0.713	0.738	0.025	3.5
00650	00	KANSAS*	0.772	0.793	0.021	2.7
00740	04	KANSAS*	0.772	0.793	0.021	2.7
00803	02	NYC SUBURBS/LONG I., NY	1.535	1.573	0.038	2.5
31145	50	VERMONT	0.980	1.004	0.024	2.4
00953	99	REST OF MICHIGAN	0.829	0.848	0.019	2.3
00865	99	REST OF PENNSYLVANIA	0.826	0.844	0.018	2.2
00900	09	BRAZORIA, TX	1.001	1.018	0.017	1.7
00740	99	REST OF MISSOURI*	0.651	0.662	0.011	1.7
00523	99	REST OF MISSOURI*	0.651	0.662	0.011	1.7
00522	00	OKLAHOMA	0.713	0.725	0.012	1.7
00900	18	HOUSTON, TX	0.972	0.988	0.016	1.6
00590	99	REST OF FLORIDA	0.936	0.951	0.015	1.6
00900	15	GALVESTON, TX	0.910	0.924	0.014	1.5
00951	00	WISCONSIN	0.854	0.866	0.012	1.4
00865	01	METROPOLITAN PHILADELPHIA, PA	1.162	1.178	0.016	1.4
10490	00	VIRGINIA	0.881	0.892	0.011	1.2
00826	00	IOWA	0.778	0.785	0.007	0.9
00523	01	METROPOLITAN ST. LOUIS, MO	0.807	0.814	0.007	0.9
00520	13	ARKANSAS	0.698	0.704	0.006	0.9
00511	99	REST OF GEORGIA	0.765	0.771	0.006	0.8
00952	16	CHICAGO, IL	1.207	1.216	0.009	0.7
00952	15	SUBURBAN CHICAGO, IL	1.207	1.216	0.009	0.7
00528	01	NEW ORLEANS, LA	0.826	0.832	0.006	0.7
00952	12	EAST ST. LOUIS, IL	0.787	0.792	0.005	0.6
00835	99	REST OF OREGON	0.896	0.901	0.005	0.6
00900	99	REST OF TEXAS	0.791	0.795	0.004	0.5
00903	01	DC + MD/VA SUBURBS	1.335	1.341	0.006	0.4
00660	00	KENTUCKY	0.719	0.721	0.002	0.3
00836	99	REST OF WASHINGTON	0.957	0.958	0.001	0.1
00900	20	BEAUMONT, TX	0.758	0.758	.....	0.0
10250	00	MISSISSIPPI	0.690	0.690	.....	0.0
00901	01	BALTIMORE/SURR. CNTYS, MD	1.027	1.026	(0.001)	−0.1
31144	40	NEW HAMPSHIRE	1.091	1.089	(0.002)	−0.2
00900	31	AUSTIN, TX	1.118	1.111	(0.007)	−0.6
00521	05	NEW MEXICO	0.844	0.837	(0.007)	−0.8

ADDENDUM D.—COMPARISON OF 1999 AND PROPOSED 2002 OFFICE RENT INDEX BY FEE SCHEDULE AREA—Continued

[In descending order of difference]

Carrier	Locality	Fee schedule area	Office rent index		Difference	Percentage difference
			2000	2002		
00528	99	REST OF LOUISIANA	0.721	0.715	(0.006)	−0.8
00805	01	NORTHERN NJ	1.415	1.399	(0.016)	−1.1
00870	01	RHODE ISLAND	1.111	1.098	(0.013)	−1.2
05130	00	IDAHO	0.801	0.791	(0.010)	−1.2
00831	01	ALASKA	1.265	1.249	(0.016)	−1.3
02050	99	REST OF CALIFORNIA*	1.068	1.050	(0.018)	−1.7
31140	99	REST OF CALIFORNIA*	1.068	1.050	(0.018)	−1.7
00590	03	FORT LAUDERDALE, FL	1.114	1.090	(0.024)	−2.2
00901	99	REST OF MARYLAND	1.020	0.995	(0.025)	−2.5
02050	17	VENTURA, CA	1.329	1.294	(0.035)	−2.6
31142	99	REST OF MAINE	0.827	0.801	(0.026)	−3.1
02050	26	ANAHEIM/SANTA ANA, CA	1.474	1.422	(0.052)	−3.5
00803	01	MANHATTAN, NY	1.808	1.744	(0.064)	−3.5
14330	04	QUEENS, NY	1.466	1.414	(0.052)	−3.5
00801	99	REST OF NEW YORK	0.909	0.875	(0.034)	−3.7
00973	50	VIRGIN ISLANDS	1.309	1.260	(0.049)	−3.7
00973	20	PUERTO RICO	0.715	0.688	(0.027)	−3.8
00803	03	POUGHKPSIE/N NYC SUBURBS, NY	1.305	1.254	(0.051)	−3.9
10230	00	CONNECTICUT	1.283	1.215	(0.068)	−5.3
00590	04	MIAMI, FL	1.232	1.139	(0.093)	−7.5
31142	03	SOUTHERN MAINE	1.119	1.009	(0.110)	−9.8
00833	01	HAWAII/GUAM	1.639	1.389	(0.250)	−15.3
02050	18	LOS ANGELES, CA	1.466	1.223	(0.243)	−16.6

Notes:
*—Indicates multiple carriers for this Fee Schedule Area.
Neither Office Rent Index reflects budget neutrality adjusting.

ADDENDUM E.—COMPARISON OF 1999 AND PROPOSED 2002 MALPRACTICE GPCIS BY FEE SCHEDULE AREA

[Sorted by percentage difference]

Carrier	Locality	Fee schedule area	2000	2002	Difference	Percentage difference
00825	21	WYOMING	0.705	1.003	0.298	42.27
00521	05	NEW MEXICO	0.716	0.900	0.184	25.70
16510	16	WEST VIRGINIA	1.106	1.375	0.269	24.32
00865	99	REST OF PENNSYLVANIA	0.637	0.772	0.135	21.19
00834	00	NEVADA	0.997	1.206	0.209	20.96
00952	15	SUBURBAN CHICAGO, IL	1.365	1.641	0.276	20.22
05535	00	NORTH CAROLINA	0.497	0.594	0.097	19.52
00630	00	INDIANA	0.408	0.480	0.072	17.65
00865	01	METROPOLITAN PHILADELPHIA, PA	1.207	1.410	0.203	16.82
00952	99	REST OF ILLINOIS	0.990	1.155	0.165	16.67
00952	12	EAST ST. LOUIS, IL	1.487	1.687	0.200	13.45
02050	26	ANAHEIM/SANTA ANA, CA	0.846	0.953	0.107	12.65
02050	18	LOS ANGELES, CA	0.846	0.953	0.107	12.65
00951	00	WISCONSIN	0.841	0.937	0.096	11.41
00528	01	NEW ORLEANS, LA	1.153	1.280	0.127	11.01
31143	01	METROPOLITAN BOSTON	0.713	0.782	0.069	9.68
31143	99	REST OF MASSACHUSETTS	0.713	0.782	0.069	9.68
00900	99	REST OF TEXAS	0.871	0.954	0.083	9.53
02050	17	VENTURA, CA	0.717	0.781	0.064	8.93
00660	00	KENTUCKY	0.807	0.875	0.068	8.43
00910	09	UTAH	0.594	0.643	0.049	8.25
00805	01	NORTHERN NJ	0.795	0.858	0.063	7.92
00805	99	REST OF NEW JERSEY	0.795	0.858	0.063	7.92
10250	00	MISSISSIPPI	0.721	0.777	0.056	7.77
00590	04	MIAMI, FL	2.350	2.523	0.173	7.36
05440	35	TENNESSEE	0.552	0.591	0.039	7.07
02050	99	REST OF CALIFORNIA*	0.698	0.746	0.048	6.88
31140	99	REST OF CALIFORNIA*	0.698	0.746	0.048	6.88
00836	99	REST OF WASHINGTON	0.742	0.786	0.044	5.93
00836	02	SEATTLE (KING CNTY), WA	0.742	0.786	0.044	5.93
00952	16	CHICAGO, IL	1.693	1.793	0.100	5.91
00824	01	COLORADO	0.795	0.838	0.043	5.41
00590	03	FORT LAUDERDALE, FL	1.783	1.873	0.090	5.05
00528	99	REST OF LOUISIANA	1.031	1.071	0.040	3.88
31140	03	MARIN/NAPA/SOLANO, CA	0.667	0.686	0.019	2.85

ADDENDUM E.—COMPARISON OF 1999 AND PROPOSED 2002 MALPRACTICE GPCIS BY FEE SCHEDULE AREA—Continued

[Sorted by percentage difference]

Carrier	Locality	Fee schedule area	2000	2002	Difference	Percentage difference
31140	07	OAKLAND/BERKLEY, CA	0.667	0.686	0.019	2.85
31140	05	SAN FRANCISCO, CA	0.667	0.686	0.019	2.85
31140	06	SAN MATEO, CA	0.667	0.686	0.019	2.85
14330	04	QUEENS, NY	1.839	1.867	0.028	1.52
00900	31	AUSTIN, TX	0.849	0.857	0.008	0.94
00803	02	NYC SUBURBS/LONG I., NY	1.932	1.948	0.016	0.83
00803	01	MANHATTAN, NY	1.654	1.664	0.010	0.60
00820	01	NORTH DAKOTA	0.656	0.656	.....	0.00
00900	11	DALLAS, TX	0.930	0.929	(0.001)	−0.11
00900	28	FORT WORTH, TX	0.930	0.929	(0.001)	−0.11
00880	01	SOUTH CAROLINA	0.280	0.278	(0.002)	−0.71
00751	01	MONTANA	0.732	0.725	(0.007)	−0.96
00522	00	OKLAHOMA	0.451	0.443	(0.008)	−1.77
31145	50	VERMONT	0.548	0.538	(0.010)	−1.82
00511	01	ATLANTA, GA	0.951	0.933	(0.018)	−1.89
00511	99	REST OF GEORGIA	0.951	0.933	(0.018)	−1.89
00973	50	VIRGIN ISLANDS	1.032	1.000	(0.032)	−3.10
00655	00	NEBRASKA	0.443	0.429	(0.014)	−3.16
00900	20	BEAUMONT, TX	1.386	1.335	(0.051)	−3.68
00900	09	BRAZORIA, TX	1.386	1.335	(0.051)	−3.68
00900	15	GALVESTON, TX	1.386	1.335	(0.051)	−3.68
00801	99	REST OF NEW YORK	0.793	0.762	(0.031)	−3.91
00803	03	POUGHKPSIE/N NYC SUBURBS, NY	1.326	1.272	(0.054)	−4.07
31140	09	SANTA CLARA, CA	0.667	0.638	(0.029)	−4.35
00590	99	REST OF FLORIDA	1.327	1.262	(0.065)	−4.90
00900	18	HOUSTON, TX	1.418	1.333	(0.085)	−5.99
31142	99	REST OF MAINE	0.708	0.665	(0.043)	−6.07
31142	03	SOUTHERN MAINE	0.708	0.665	(0.043)	−6.07
00832	00	ARIZONA	1.189	1.109	(0.080)	−6.73
00820	02	SOUTH DAKOTA	0.435	0.405	(0.030)	−6.90
00510	00	ALABAMA	0.876	0.805	(0.071)	−8.11
00826	00	IOWA	0.648	0.595	(0.053)	−8.18
10230	00	CONNECTICUT	1.052	0.964	(0.088)	−8.37
10490	00	VIRGINIA	0.557	0.499	(0.058)	−10.41
00901	99	REST OF MARYLAND	0.866	0.772	(0.094)	−10.85
00953	01	DETROIT, MI	3.069	2.732	(0.337)	−10.98
10240	00	MINNESOTA	0.507	0.451	(0.056)	−11.05
16360	00	OHIO	1.074	0.955	(0.119)	−11.08
00903	01	DC + MD/VA SUBURBS	1.032	0.907	(0.125)	−12.11
05130	00	IDAHO	0.566	0.496	(0.070)	−12.37
00833	01	HAWAII/GUAM	0.954	0.832	(0.122)	−12.79
00953	99	REST OF MICHIGAN	1.828	1.568	(0.260)	−14.22
00650	00	KANSAS *	0.890	0.754	(0.136)	−15.28
00740	04	KANSAS *	0.890	0.754	(0.136)	−15.28
00520	13	ARKANSAS	0.403	0.339	(0.064)	−15.88
00901	01	BALTIMORE/SURR. CNTYS, MD	1.098	0.914	(0.184)	−16.76
00902	01	DELAWARE	0.860	0.710	(0.150)	−17.44
31144	40	NEW HAMPSHIRE	1.013	0.823	(0.190)	−18.76
00831	01	ALASKA	1.533	1.220	(0.313)	−20.42
00973	20	PUERTO RICO	0.359	0.274	(0.085)	−23.68
00835	01	PORTLAND, OR	0.587	0.435	(0.152)	−25.89
00835	99	REST OF OREGON	0.587	0.435	(0.152)	−25.89
00870	01	RHODE ISLAND	1.189	0.881	(0.308)	−25.90
00740	02	METROPOLITAN KANSAS CITY, MO	1.196	0.844	(0.352)	−29.43
00523	01	METROPOLITAN ST. LOUIS, MO	1.198	0.844	(0.354)	−29.55
00740	99	REST OF MISSOURI *	1.165	0.791	(0.374)	−32.10
00523	99	REST OF MISSOURI *	1.165	0.791	(0.374)	−32.10

Notes:
*—Indicates multiple carriers for this Fee Schedule Area.
1999 Malpractice GPCIs have been budget neutrality adjusted.
The 2002 MGPCIs have NOT been budget neutrality adjusted.

ADDENDUM F.—2002 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY

Carrier No.	Locality No.	Locality name	Work	Practice expense	Malpractice
00510	00	ALABAMA	0.978	0.870	0.807
00831	01	ALASKA	1.064	1.172	1.223

ADDENDUM F.—2002 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY—Continued

Carrier No.	Locality No.	Locality name	Work	Practice expense	Malpractice
00832	00	ARIZONA	0.994	0.978	1.111
00520	13	ARKANSAS	0.953	0.847	0.340
02050	26	ANAHEIM/SANTA ANA, CA	1.037	1.184	0.955
02050	18	LOS ANGELES, CA	1.056	1.139	0.955
31140	03	MARIN/NAPA/SOLANO, CA	1.015	1.248	0.687
31140	07	OAKLAND/BERKELEY, CA	1.041	1.235	0.687
31140	05	SAN FRANCISCO, CA	1.068	1.458	0.687
31140	06	SAN MATEO, CA	1.048	1.432	0.687
31140	09	SANTA CLARA, CA	1.063	1.380	0.639
02050	17	VENTURA, CA	1.028	1.125	0.783
02050	99	REST OF CALIFORNIA*	1.007	1.034	0.748
31140	99	REST OF CALIFORNIA*	1.007	1.034	0.748
00824	01	COLORADO	0.985	0.992	0.840
10230	00	CONNECTICUT	1.050	1.156	0.966
00902	01	DELAWARE	1.019	1.035	0.712
00903	01	DC + MD/VA SUBURBS	1.050	1.166	0.909
00590	03	FORT LAUDERDALE, FL	0.996	1.018	1.877
00590	04	MIAMI, FL	1.015	1.052	2.528
00590	99	REST OF FLORIDA	0.975	0.946	1.265
00511	01	ATLANTA, GA	1.006	1.059	0.935
00511	99	REST OF GEORGIA	0.970	0.892	0.935
00833	01	HAWAII/GUAM	0.997	1.124	0.834
05130	00	IDAHO	0.960	0.881	0.497
00952	16	CHICAGO, IL	1.028	1.092	1.797
00952	12	EAST ST. LOUIS, IL	0.988	0.924	1.691
00952	15	SUBURBAN CHICAGO, IL	1.006	1.071	1.645
00952	99	REST OF ILLINOIS	0.964	0.889	1.157
00630	00	INDIANA	0.981	0.922	0.481
00826	00	IOWA	0.959	0.876	0.596
00650	00	KANSAS*	0.963	0.895	0.756
00740	04	KANSAS*	0.963	0.895	0.749
00660	00	KENTUCKY	0.970	0.866	0.877
00528	01	NEW ORLEANS, LA	0.998	0.945	1.283
00528	99	REST OF LOUISIANA	0.968	0.870	1.073
31142	03	SOUTHERN MAINE	0.979	0.999	0.666
31142	99	REST OF MAINE	0.961	0.910	0.666
00901	01	BALTIMORE/SURR. CNTYS, MD	1.021	1.038	0.916
00901	99	REST OF MARYLAND	0.984	0.972	0.774
31143	01	METROPOLITAN BOSTON	1.041	1.239	0.784
31143	99	REST OF MASSACHUSETTS	1.010	1.129	0.784
00953	01	DETROIT, MI	1.043	1.038	2.738
00953	99	REST OF MICHIGAN	0.997	0.938	1.571
10240	00	MINNESOTA	0.990	0.974	0.452
10250	00	MISSISSIPPI	0.957	0.837	0.779
00740	02	METROPOLITAN KANSAS CITY, MO	0.988	0.967	0.846
00523	01	METROPOLITAN ST. LOUIS, MO	0.994	0.938	0.846
00740	99	REST OF MISSOURI*	0.946	0.825	0.793
00523	99	REST OF MISSOURI*	0.946	0.825	0.793
00751	01	MONTANA	0.950	0.876	0.727
00655	00	NEBRASKA	0.948	0.877	0.430
00834	00	NEVADA	1.005	1.039	1.209
31144	40	NEW HAMPSHIRE	0.986	1.030	0.825
00805	01	NORTHERN NJ	1.058	1.193	0.860
00805	99	REST OF NEW JERSEY	1.029	1.110	0.860
00521	05	NEW MEXICO	0.973	0.900	0.902
00803	01	MANHATTAN, NY	1.094	1.351	1.668
00803	02	NYC SUBURBS/LONG I., NY	1.068	1.251	1.952
00803	03	POUGHKPSIE/N NYC SUBURBS, NY	1.011	1.075	1.275
14330	04	QUEENS, NY	1.058	1.228	1.871
00801	99	REST OF NEW YORK	0.998	0.944	0.764
05535	00	NORTH CAROLINA	0.970	0.931	0.595
00820	01	NORTH DAKOTA	0.950	0.880	0.657
16360	00	OHIO	0.988	0.944	0.957
00522	00	OKLAHOMA	0.968	0.876	0.444
00835	01	PORTLAND, OR	0.996	1.049	0.436
00835	99	REST OF OREGON	0.961	0.933	0.436
00865	01	METROPOLITAN PHILADELPHIA, PA	1.023	1.092	1.413
00865	99	REST OF PENNSYLVANIA	0.989	0.929	0.774
00973	20	PUERTO RICO	0.881	0.712	0.275
00870	01	RHODE ISLAND	1.017	1.065	0.883
00880	01	SOUTH CAROLINA	0.974	0.904	0.279

ADDENDUM F.—2002 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY—Continued

Carrier No.	Locality No.	Locality name	Work	Practice expense	Malpractice
00820	02	SOUTH DAKOTA	0.935	0.878	0.406
05440	35	TENNESSEE	0.975	0.900	0.592
00900	31	AUSTIN, TX	0.986	0.996	0.859
00900	20	BEAUMONT, TX	0.992	0.890	1.338
00900	09	BRAZORIA, TX	0.992	0.978	1.338
00900	11	DALLAS, TX	1.010	1.065	0.931
00900	28	FORT WORTH, TX	0.987	0.981	0.931
00900	15	GALVESTON, TX	0.988	0.969	1.338
00900	18	HOUSTON, TX	1.020	1.007	1.336
00900	99	REST OF TEXAS	0.966	0.880	0.956
00910	09	UTAH	0.976	0.941	0.644
31145	50	VERMONT	0.973	0.986	0.539
00973	50	VIRGIN ISLANDS	0.965	1.023	1.002
10490	00	VIRGINIA	0.984	0.938	0.500
00836	02	SEATTLE (KING CNTY), WA	1.005	1.100	0.788
00836	99	REST OF WASHINGTON	0.981	0.972	0.788
16510	16	WEST VIRGINIA	0.963	0.850	1.378
00951	00	WISCONSIN	0.981	0.929	0.939
00825	21	WYOMING	0.967	0.895	1.005

* Payment locality is serviced by two carriers.

Note: Work GPCI is the ¼ work GPCI required by Section 1848(e)(1)(A)(iii) of the Social Security Act. GPCIs rescaled by the following factors for budget netrality: Work = 0.99699; Practice Expense = 0.99235; Malpractice Expense = 1.00215.

ADDENDUM G.—2001 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY

Carrier No.	Locality No.	Locality name	Work	Practice expense	Malpractice
00510	00	ALABAMA	0.978	0.871	0.841
00831	01	ALASKA	1.063	1.172	1.378
00832	00	ARIZONA	0.994	0.975	1.150
00520	13	ARKANSAS	0.953	0.851	0.371
02050	26	ANAHEIM/SANTA ANA, CA	1.036	1.187	0.901
02050	18	LOS ANGELES, CA	1.055	1.169	0.901
31140	03	MARIN/NAPA/SOLANO, CA	1.014	1.205	0.677
31140	07	OAKLAND/BERKELEY, CA	1.040	1.216	0.677
31140	05	SAN FRANCISCO, CA	1.067	1.378	0.677
31140	06	SAN MATEO, CA	1.047	1.353	0.677
31140	09	SANTA CLARA, CA	1.062	1.321	0.653
02050	17	VENTURA, CA	1.027	1.128	0.750
02050	99	REST OF CALIFORNIA*	1.007	1.039	0.723
31140	99	REST OF CALIFORNIA*	1.007	1.039	0.723
00824	01	COLORADO	0.986	0.981	0.817
10230	00	CONNECTICUT	1.049	1.164	1.009
00902	01	DELAWARE	1.019	1.032	0.786
00903	01	DC + MD/VA SUBURBS	1.050	1.164	0.970
00590	03	FORT LAUDERDALE, FL	0.996	1.022	1.830
00590	04	MIAMI, FL	1.015	1.064	2.439
00590	99	REST OF FLORIDA	0.975	0.947	1.296
00511	01	ATLANTA, GA	1.006	1.046	0.943
00511	99	REST OF GEORGIA	0.970	0.896	0.943
00833	01	HAWAII/GUAM	0.997	1.154	0.894
05130	00	IDAHO	0.960	0.887	0.532
00952	16	CHICAGO, IL	1.027	1.090	1.745
00952	12	EAST ST. LOUIS, IL	0.988	0.927	1.589
00952	15	SUBURBAN CHICAGO, IL	1.006	1.069	1.505
00952	99	REST OF ILLINOIS	0.964	0.888	1.074
00630	00	INDIANA	0.981	0.919	0.445
00826	00	IOWA	0.959	0.879	0.622
00650	00	KANSAS*	0.963	0.897	0.823
00740	04	KANSAS*	0.963	0.897	0.819
00660	00	KENTUCKY	0.970	0.870	0.842
00528	01	NEW ORLEANS, LA	0.998	0.947	1.218
00528	99	REST OF LOUISIANA	0.969	0.876	1.052
31142	03	SOUTHERN MAINE	0.979	1.015	0.687
31142	99	REST OF MAINE	0.961	0.917	0.687
00901	01	BALTIMORE/SURR. CNTYS, MD	1.020	1.038	1.007
00901	99	REST OF MARYLAND	0.985	0.979	0.820
31143	01	METROPOLITAN BOSTON	1.040	1.218	0.748
31143	99	REST OF MASSACHUSETTS	1.010	1.111	0.748

ADDENDUM G.—2001 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY—Continued

Carrier No.	Locality No.	Locality name	Work	Practice expense	Malpractice
00953	01	DETROIT, MI	1.042	1.030	2.903
00953	99	REST OF MICHIGAN	0.996	0.938	1.700
10240	00	MINNESOTA	0.990	0.971	0.479
10250	00	MISSISSIPPI	0.957	0.841	0.750
00740	02	METROPOLITAN KANSAS CITY, MO	0.988	0.958	1.021
00523	01	METROPOLITAN ST. LOUIS, MO	0.994	0.940	1.022
00740	99	REST OF MISSOURI*	0.946	0.826	0.979
00523	99	REST OF MISSOURI*	0.946	0.826	0.979
00751	01	MONTANA	0.951	0.877	0.729
00655	00	NEBRASKA	0.949	0.875	0.436
00834	00	NEVADA	1.005	1.035	1.103
31144	40	NEW HAMPSHIRE	0.987	1.032	0.919
00805	01	NORTHERN NJ	1.057	1.192	0.827
00805	99	REST OF NEW JERSEY	1.028	1.102	0.827
00521	05	NEW MEXICO	0.973	0.905	0.809
00803	01	MANHATTAN, NY	1.093	1.352	1.661
00803	02	NYC SUBURBS/LONG I., NY	1.067	1.242	1.942
00803	03	POUGHKPSIE/N NYC SUBURBS, NY	1.010	1.079	1.300
14330	04	QUEENS, NY	1.057	1.231	1.855
00801	99	REST OF NEW YORK	0.998	0.951	0.778
05535	00	NORTH CAROLINA	0.970	0.927	0.546
00820	01	NORTH DAKOTA	0.950	0.879	0.657
16360	00	OHIO	0.989	0.941	1.016
00522	00	OKLAHOMA	0.969	0.879	0.447
00835	01	PORTLAND, OR	0.996	1.035	0.511
00835	99	REST OF OREGON	0.961	0.935	0.511
00865	01	METROPOLITAN PHILADELPHIA, PA	1.023	1.090	1.310
00865	99	REST OF PENNSYLVANIA	0.989	0.930	0.705
00973	20	PUERTO RICO	0.882	0.720	0.317
00870	01	RHODE ISLAND	1.017	1.067	1.036
00880	01	SOUTH CAROLINA	0.975	0.905	0.279
00820	02	SOUTH DAKOTA	0.935	0.876	0.420
05440	35	TENNESSEE	0.975	0.900	0.572
00900	31	AUSTIN, TX	0.986	0.998	0.854
00900	20	BEAUMONT, TX	0.992	0.895	1.362
00900	09	BRAZORIA, TX	0.992	0.978	1.362
00900	11	DALLAS, TX	1.010	1.040	0.930
00900	28	FORT WORTH, TX	0.987	0.976	0.930
00900	15	GALVESTON, TX	0.988	0.969	1.362
00900	18	HOUSTON, TX	1.020	1.007	1.377
00900	99	REST OF TEXAS	0.966	0.884	0.914
00910	09	UTAH	0.977	0.925	0.619
31145	50	VERMONT	0.973	0.985	0.544
00973	50	VIRGIN ISLANDS	0.965	1.029	1.017
10490	00	VIRGINIA	0.985	0.939	0.529
00836	02	SEATTLE (KING CNTY), WA	1.005	1.090	0.765
00836	99	REST OF WASHINGTON	0.982	0.974	0.765
16510	16	WEST VIRGINIA	0.963	0.852	1.242
00951	00	WISCONSIN	0.981	0.931	0.890
00825	21	WYOMING	0.967	0.895	0.855

*Payment locality is serviced by two carriers.

Note: Work GPCI is the 1/4 work GPCI required by Section 1848(e)(1)(A)(iii) of the Social Security Act. GPCIs rescaled by the following factors for budget neutrality: Work = 0.99699; Practice Expense = 0.99235; Malpractice Expense = 1.00215.

ADDENDUM H.—PROPOSED 2002 VERSUS 1999 GEOGRAPHIC ADJUSTMENT FACTORS (GAF)

[In descending order of difference]

Locality	1999 GAF	2002 GAF	Difference	Percent difference
SAN MATEO, CA	1.122	1.199	0.077	6.89
SAN FRANCISCO, CA	1.143	1.221	0.078	6.84
SANTA CLARA, CA	1.125	1.184	0.059	5.28
MARIN/NAPA/SOLANO, CA	1.058	1.104	0.046	4.33
METROPOLITAN BOSTON	1.088	1.117	0.029	2.64
OAKLAND/BERKELEY, CA	1.086	1.113	0.027	2.46
REST OF MASSACHUSETTS	1.030	1.053	0.023	2.24
DALLAS, TX	1.009	1.031	0.022	2.19
UTAH	0.931	0.951	0.020	2.10
SEATTLE (KING CNTY), WA	1.023	1.038	0.015	1.48

ADDENDUM H.—PROPOSED 2002 VERSUS 1999 GEOGRAPHIC ADJUSTMENT FACTORS (GAF)—Continued

[In descending order of difference]

Locality	1999 GAF	2002 GAF	Difference	Percent difference
INDIANA	0.927	0.941	0.014	1.46
NORTH CAROLINA	0.928	0.942	0.014	1.46
WYOMING	0.925	0.938	0.013	1.36
PORTLAND, OR	0.987	1.000	0.013	1.35
REST OF NEW JERSEY	1.044	1.058	0.014	1.34
COLORADO	0.971	0.983	0.012	1.27
ATLANTA, GA	1.015	1.026	0.011	1.10
SOUTH CAROLINA	0.913	0.923	0.010	1.06
NEVADA	1.016	1.026	0.010	1.00
SOUTH DAKOTA	0.886	0.895	0.009	0.99
MINNESOTA	0.957	0.966	0.009	0.99
REST OF PENNSYLVANIA	0.948	0.956	0.008	0.89
NORTHERN NJ	1.099	1.109	0.010	0.89
VERMONT	0.957	0.965	0.008	0.88
NEBRASKA	0.894	0.902	0.008	0.87
TENNESSEE	0.924	0.932	0.008	0.82
VENTURA, CA	1.055	1.062	0.007	0.66
NORTH DAKOTA	0.906	0.912	0.006	0.63
ANAHEIM/SANTA ANA, CA	1.090	1.097	0.007	0.63
REST OF ILLINOIS	0.933	0.939	0.006	0.60
SUBURBAN CHICAGO, IL	1.048	1.054	0.006	0.57
METROPOLITAN PHILADELPHIA, PA	1.059	1.065	0.006	0.56
FORT WORTH, TX	0.978	0.983	0.005	0.55
OKLAHOMA	0.908	0.913	0.005	0.52
NEW MEXICO	0.935	0.940	0.005	0.49
WEST VIRGINIA	0.925	0.929	0.004	0.39
VIRGINIA	0.946	0.950	0.004	0.37
REST OF WASHINGTON	0.968	0.971	0.003	0.35
REST OF CALIFORNIA	1.007	1.010	0.003	0.32
ARKANSAS	0.886	0.889	0.003	0.32
WISCONSIN	0.955	0.957	0.002	0.26
MONTANA	0.910	0.912	0.002	0.19
AUSTIN, TX	0.985	0.986	0.001	0.14
DELAWARE	1.015	1.016	0.001	0.12
MISSISSIPPI	0.900	0.901	0.001	0.08
IOWA	0.912	0.913	0.001	0.08
KENTUCKY	0.923	0.924	0.001	0.07
REST OF TEXAS	0.929	0.930	0.001	0.07
DC + MD/VA SUBURBS	1.095	1.095	−0.000	−0.02
IDAHO	0.913	0.912	−0.001	−0.14
REST OF OREGON	0.934	0.933	−0.001	−0.15
NEW ORLEANS, LA	0.986	0.984	−0.002	−0.17
ARIZONA	0.994	0.991	−0.003	−0.27
NYC SUBURBS/LONG I., NY	1.177	1.173	−0.004	−0.30
ALABAMA	0.930	0.927	−0.003	−0.36
REST OF MAINE	0.934	0.931	−0.003	−0.36
CHICAGO, IL	1.084	1.080	−0.004	−0.38
OHIO	0.973	0.968	−0.005	−0.47
MANHATTAN, NY	1.227	1.221	−0.006	−0.47
REST OF GEORGIA	0.940	0.936	−0.004	−0.47
PUERTO RICO	0.794	0.790	−0.004	−0.47
BALTIMORE/SURR. CNTYS, MD	1.031	1.025	−0.006	−0.57
VIRGIN ISLANDS	0.997	0.991	−0.006	−0.57
EAST ST. LOUIS, IL	0.989	0.983	−0.006	−0.57
REST OF NEW YORK	0.973	0.967	−0.006	−0.57
KANSAS	0.933	0.928	−0.005	−0.58
CONNECTICUT	1.100	1.093	−0.007	−0.65
REST OF LOUISIANA	0.936	0.930	−0.006	−0.68
BRAZORIA, TX	1.005	0.997	−0.008	−0.77
METROPOLITAN KANSAS CITY, MO	0.982	0.974	−0.008	−0.77
REST OF MARYLAND	0.980	0.972	−0.008	−0.77
HOUSTON, TX	1.034	1.025	−0.009	−0.86
NEW HAMPSHIRE	1.008	0.999	−0.009	−0.86
GALVESTON, TX	1.000	0.991	−0.009	−0.87
REST OF FLORIDA	0.981	0.972	−0.009	−0.88
POUGHKPSIE/N NYC SUBURBS, NY	1.056	1.046	−0.010	−0.94
SOUTHERN MAINE	0.987	0.977	−0.010	−0.97
QUEENS, NY	1.167	1.156	−0.011	−0.98
FORT LAUDERDALE, FL	1.046	1.033	−0.013	−1.23
RHODE ISLAND	1.047	1.033	−0.014	−1.33

ADDENDUM H.—PROPOSED 2002 VERSUS 1999 GEOGRAPHIC ADJUSTMENT FACTORS (GAF)—Continued

[In descending order of difference]

Locality	1999 GAF	2002 GAF	Difference	Percent difference
BEAUMONT, TX	0.973	0.959	−0.014	−1.39
ALASKA	1.131	1.115	−0.016	−1.44
LOS ANGELES, CA	1.104	1.088	−0.016	−1.46
METROPOLITAN ST. LOUIS, MO	0.983	0.965	−0.018	−1.79
REST OF MISSOURI	0.908	0.890	−0.018	−2.00
REST OF MICHIGAN	1.013	0.990	−0.023	−2.24
MIAMI, FL	1.105	1.079	−0.026	−2.36
HAWAII/GUAM	1.072	1.046	−0.026	−2.42
DETROIT, MI	1.131	1.095	−0.036	−3.20

[FR Doc. 00–17830 Filed 7–14–00; 8:45 am]

BILLING CODE 4120–01–P

Federal Register

Monday,
July 17, 2000

Part IV

Nuclear Regulatory Commission

10 CFR Part 71

Major Revision to 10 CFR Part 71: Compatibility With ST–1—The IAEA Transportation Safety Standards—And Other Transportation Safety Issues, Issues Paper, and Notice of Public Meetings; Proposed Rule

NUCLEAR REGULATORY COMMISSION

10 CFR Part 71

Major Revision to 10 CFR Part 71: Compatibility With ST–1—The IAEA Transportation Safety Standards—and Other Transportation Safety Issues, Issues Paper, and Notice of Public Meetings

AGENCY: Nuclear Regulatory Commission.

ACTION: Request for comment on issues paper, and notice of plans for public meetings.

SUMMARY: The Nuclear Regulatory Commission (NRC) is considering a rulemaking that would revise the Commission's regulations on packaging and transporting radioactive material to make it compatible with the International Atomic Energy Agency (IAEA) transportation safety standards as well as codify other requirements. The NRC is seeking early public input on the major issues associated with such a rulemaking. To aid in that process, the NRC is requesting comments on the issues paper included in this notice. Specifically, the NRC is interested in public and industry comments related to: Quantitative information on the costs and benefits resulting from consideration of the factors described in the issues paper, operational data on radiation exposures (increased or reduced) that might result from implementing the contemplated changes; whether the presented factors are appropriate; and whether other factors should be considered, including providing quantitative information for these factors. The Commission believes that the stakeholders' comments will help to quantify the potential impact of these changes and will assist the NRC, as the proposed rule is developed, in developing a risk-informed alternative as its preferred option. NRC also intends to conduct three public meetings in August and September of this year to discuss those issues and solicit public comments.

DATES: Submit comments at the public meetings, or in writing by September 30, 2000. Comments received after this date will be considered if it is practicable to do so, but the Commission is able to assure consideration only for comments received on or before this date.

In addition to providing opportunity for written (and electronic) comments, public meetings on the paper will be held as follows :

August 10, 2000 NRC Headquarters, Washington, DC, 8:30 am–5pm

September 20, 2000 Atlanta, Georgia, J.W. Marriott, 3300 Lenox Road Northeast, Atlanta, GA 30326, 6–10 pm

September 26, 2000 Oakland, California, Oakland Federal Building, Edward R. Roybal Auditorium and Conference Center, 1301 Clay Street, Oakland, CA 94612, 6–10 pm

ADDRESSES: Submit comments to: Secretary, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555. Attention: Rulemaking and Adjudications staff.

Deliver comments to 11555 Rockville Pike, Rockville, Maryland, between 7:30 a.m. and 4:15 p.m. on Federal workdays.

You may also provide comments via the NRC's interactive rulemaking website at http://ruleforum.llnl.gov). This site provides the capability to upload comments as files (any format), if your web browser supports that function. For information about the interactive rulemaking website, contact Ms. Carol Gallagher, (301) 415–5095 (e-mail:CAG@nrc.gov).

Copies of any comments received and documents related to this action may be examined at the NRC Public Document Room, 2120 L Street NW (Lower Level), Washington, DC Documents created or received at the NRC after November 1, 1999 are also available electronically at the NRC's Public Electronic Reading Room on the Internet at *http://www.nrc.gov/NRC/ADAMS/index.html.* From this site, the public can gain entry into the NRC's Agencywide Documents Access and Management System (ADAMS), which provides text and image files of NRC's public documents. For more information, contact the NRC Public Document Room (PDR) Reference staff at 1–800–397–4209, 202–634–3273 or email to *pdr@nrc.gov.*

FOR FURTHER INFORMATION CONTACT: Naiem S. Tanious, telephone: (301) 415–6103; e-mail: nst@nrc.gov, Office of Nuclear Material Safety and Safeguards, USNRC, Washington, DC 20555–0001. Specific comments on the public meeting process should be directed to Francis X. Cameron; e-mail fxc@nrc.gov, telephone: (301) 415–1642; Office of the General Counsel, USNRC, Washington, DC 20555–0001.

SUPPLEMENTARY INFORMATION:

I. Background

By international agreement and through Commission direction, the NRC staff is preparing an overall rulemaking effort that addresses the need to make 10 CFR Part 71 regulations, ''Packaging and Transportation of Radioactive Material'' compatible with the most current revision of the IAEA Safety Standards Series No. ST–1. Part 71 is based, in general, on the safety standards developed by the IAEA. The IAEA has been revising its transportation standards on approximately a 10-year cycle, with the last edition, ST–1, published in December 1996. Further, several additional issues related to other changes to 10 CFR Part 71 are being considered by NRC. These issues include the fissile material exemptions, general license provisions, and the current requirements for double containment of plutonium.

The NRC is supplementing its standard rulemaking process by conducting enhanced public participatory activities including facilitated public meetings before the start of any formal rulemaking process to solicit early and active public input on major issues with revision of 10 CFR Part 71. The NRC will also utilize its rulemaking website to make the issues paper available to the public and to solicit public comments. To facilitate discussion and public comments, the NRC has prepared an issues paper that describes 18 rulemaking issues (IAEA and Non-IAEA-related) to be addressed in revisions to Part 71. These issues are described in more detail in Section III of this notice.

II. Request for Written and Electronic Comments and Plans for Public Meetings

The NRC is soliciting comments on the items presented in the issues paper in Section III of this notice. Comments may be submitted either in writing or electronically as indicated under the **ADDRESSES** heading. In addition to providing an opportunity for written comments, the NRC is holding facilitated public meetings at three different geographical locations on the issues discussed in Section III (see the DATES heading of this notice for the dates and locations of these meetings). In addition to the NRC staff, a representative from the Department of Transportation (DOT) will be available to answer any questions related to their concurrent rulemaking efforts.

In addition to inviting public comments on the issues presented in Section III, NRC is soliciting specific comments related to: (1) Quantitative information on the costs and benefits resulting from consideration of the factors described in the issues paper, (2) operational data on radiation exposures (increased or reduced) that might result from implementing the Part 71 changes; (3) whether the presented factors are appropriate; and (4) whether other factors should be considered, including

providing quantitative information for these factors. The Commission believes that the stakeholders' comments will help to quantify the potential impact of these changes and will assist the NRC, as the proposed rule is developed, in developing a risk-informed alternative as its preferred option.

Based on the comments received in written or electronic form, and at the public meetings, the Commission will then be in a better position to evaluate options for Part 71 rulemaking, to decide on the preferred options, and to proceed with development of a proposed rule.

III. Issues Paper on Major Revision to 10 CFR Part 71: Compatibility with ST–1—the IAEA Transportation Safety Standards—and Other Transportation Safety Issues

A. Introduction

1. Background

In 1969, the International Atomic Energy Agency (IAEA), recognizing that its international regulations for the safe transportation of radioactive material should be revised from time to time because of scientific and technical advances, and accumulated experience, invited Member States (the U.S. is a Member State) to submit comments and suggest changes to its standards. As a result of this initiative, the IAEA issued revised standards in 1973 (Regulations for the Safe Transport of Radioactive Material, 1973 Edition, Safety Series (SS) No. 6). The IAEA has periodically reviewed its transportation regulations (about every ten years) to ensure that the regulations are kept current. Thus, a review of IAEA regulations was initiated in 1979 and resulted in the publication of revised regulations in 1985 (1985 Edition, SS No. 6).

The U.S. Nuclear Regulatory Commission (NRC) also periodically revises its regulations to make them compatible, to the extent appropriate, with those of the IAEA. On August 5, 1983 (48 FR 35600), the NRC published, in the **Federal Register**, a final revision to 10 CFR Part 71, ''Packaging and Transportation of Radioactive Material.'' That revision, in combination with a parallel revision of the hazardous materials transportation regulations of the U.S. Department of Transportation (DOT), brought U.S. domestic transport regulations into general accord with the 1973 edition of SS No. 6. The next IAEA revision of the transportation standards in SS No. 6 resulted in a revision to Part 71 that was published on September 28, 1995 (60 FR 50248), to make Part 71 compatible with the 1985 edition of SS No. 6. DOT published its corresponding revision to Title 49 of the Code of Federal Regulations on the same date.

In each case, the NRC coordinated its Part 71 revisions with the DOT. DOT is the U.S. Competent Authority for transportation of hazardous materials. ''Radioactive Materials Regulations'' is a subset of ''Hazardous Materials Regulations'' in Title 49. The DOT and the NRC co-regulate transport of radioactive material in the United States and have a Memorandum of Understanding to that effect.

The last revision to the IAEA SS No. 6 was titled Safety Standards Series No. ST–1, referred to hereafter as ST–1, and was published in December 1996.

2. Scope of Part 71 Rulemaking

The Commission has directed the NRC staff to begin rulemaking to revise Part 71 for compatibility with ST–1. The NRC staff compared ST–1 to SS No. 6 to identify changes made in ST–1, and then identified affected sections of Part 71. Based on this comparison, the NRC staff identified eleven Part 71 IAEA-compatibility issues to be addressed through the rulemaking process. These eleven issues (identified as issues 1 through 11) are discussed in greater detail in Section B. Seven additional issues were identified (issues 12 thru 18) for incorporation in the rulemaking process, through NRC staff identification and through Commission direction, and are also discussed in further detail in Section B.

The Part 71 rulemaking and this issues paper are being coordinated with DOT to ensure that consistent regulatory standards are maintained between NRC and DOT radioactive material transportation regulations, and to ensure coordinated publication of the final rules by each agency. Note that on December 28, 1999 (64 FR 72633), DOT published an Advance Notice of Proposed Rule regarding adoption of ST–1 in its regulations, and plans to proceed to develop a proposed rule for public comments and subsequently a final rule. In order to develop a final rule concurrent with the timing of the DOT final rule, the NRC staff developed the following schedule: (1) the NRC staff will submit to the Commission for approval, a proposed rule to revise Part 71 by March 1, 2001, (2) the proposed rule is expected to be published for public comment in April 2001, (3) the NRC staff is planning to hold public meetings during the public comment period, and (4) after the end of the public comment period, the staff will revise the rule and submit it for approval as a final rule by June 2002.

The NRC proposed rule will include a cost-benefit (regulatory analysis). Contrary to the NRC's rulemaking process under the Administrative Procedure Act, development of the IAEA ST–1 did not directly involve the public or include a cost-benefit analysis, to our knowledge. In contrast, NRC is bound to consider costs and benefits in its regulatory analysis, and is prepared to differ from the ST–1 standards, at least for domestic purposes, to the extent the standards cannot be justified from a cost-benefit perspective.

B. Issues Format

The following format is used in the presentation of the issues that follow. Each issue is assigned a tracking number with a short title, and includes an issue description paragraph and a listing of factors for consideration. The factors for consideration in this document are not meant to be a complete or final listing, but are included to help prompt consideration and discussion of the issue. In August and September 2000, through a series of public meetings and a summary workshop, the public and industry will be requested to (1) comment on and recommend additions, deletions, or modifications to the factors for consideration; (2) propose implementation options for each issue; and (3) provide estimated implementation cost information. Other venues for feedback will be made available through mailings and by internet through the NRC web site. This public feedback will then be used in developing implementation options for Commission consideration as the Part 71 rulemaking process proceeds. Comments received that are outside the scope of this rulemaking may be addressed in future rulemaking if warranted.

Factors for consideration that are common to most of the issues are stated here, rather than repeated in each issue. These include: (1) How should risk considerations (*i.e.,* what can happen, how likely is it, what are the consequences) be factored into rulemaking on applicable issues, (2) costs (*i.e.,* administrative, training, testing) to industry and/or Government agencies in adopting ST–1 requirements (issues 1–11) or the NRC-initiated changes (issues 12–18), and (3) potential problems that may occur as a result of adopting ST–1 requirements, or problems that may occur from partial or non-adoption of the ST–1 requirements resulting in dual standards between domestic (10 CFR 71) and international (ST–1) requirements. For issues 1–11, the ''factors for consideration'' noted under each issue are generally written

in the context of adopting the ST–1 requirements into Part 71.

In the case of the eleven IAEA-compatibility issues, portions of the Safety Standards Series ST–1 are referenced by the corresponding paragraph number from the original IAEA document. The full text of the ST–1 references can be found in Appendix A of this issues paper.

Issue 1. Changing Part 71 to SI Units Only

Description

ST–1, Annex II, page 199 states: ''This edition of the Regulations for the Safe Transport of Radioactive Material uses the International System of Units (SI).'' The change to SI units exclusively is evident throughout ST–1. ST–1 also requires that activity values contained in shipping papers and displayed on package labels be expressed only in SI units (paragraphs 543 and 549). SS No. 6, 1985 Edition, used SI units as the primary controlling units, with subsidiary units in parentheses; either units were permissible on labels and shipping papers.

The ST–1 requirement regarding only the use of SI units conflicts with the NRC Metrication Policy issued on June 19, 1996 (61 FR 31169). This policy allows a dual-unit system to be used; SI units with English units in parentheses. According to the NRC's metrication policy, the following documents should be published in dual units: New regulations, major amendments to existing regulations, regulatory guides, NUREG-series documents, policy statements, information notices, generic letters, bulletins, and all written communications directed to the public. Documents specific to a licensee, such as inspection reports and docketed material dealing with a particular licensee, will be issued in the system of units employed by the licensee. Currently, Part 71 utilizes the dual unit scheme in accordance with the NRC Metrication Policy.

Factors for Consideration

- What changes would licensees and Certificate of Compliance holders have to make to relevant documents if NRC revised 10 CFR Part 71 to require SI units only?
- What risks and safety impacts might occur in shipments because of possible confusion or erroneous conversion between the currently utilized English units and SI units?
- What sort of transition period would be needed to allow for the conversion to exclusive use of SI units?
- What other conforming changes would have to be made to Title 10?

Issue 2. Radionuclide Exemption Values

Description

Exempt materials are those which are of such low potential hazard that they may not be required to be shipped in accordance with specific transportation regulations. In ST–1, the IAEA adopted a new approach to specifying these materials by developing radionuclide-specific activity concentration values for exempt materials and activity limits for exempt consignments. These new values are found in ST–1, Tables I and II, and Section IV. Related information is provided in paragraphs 401 through 406 of ST–1. Exempt materials are those that fall below the listed activity concentration values. Exempt consignments are packages or loads that have a total activity less than the listed activity values.

The exempt materials activity concentration values range from 0.1 to 1,000,000 Bq/g, with most radionuclides in the 1 to 100 Bq/g range. This IAEA requirement does not currently exist in Part 71. Appendix A to Part 71—Determination of A_1 and A_2, does not contain exemption values for each radionuclide because the exemption for low-level radioactive material as contained in 10 CFR 71.10(a) is 70 Bq/g (2000 picoCuries per gram) or less.

Some materials, such as ores containing naturally occurring radionuclides, would be brought into the scope of the regulations for the first time; however, provisions are included in ST–1 that reduce the potential impact on natural materials containing radionuclides at these low levels. The provisions continue to exempt natural material and ores containing naturally occurring radionuclides, that are not intended to be processed for the use of these radionuclides, provided the activity concentration of the material does not exceed 10 times the values [ST–1 paragraph 107(e)]. Additionally, for materials that may appear in the scope of the regulations for the first time, but which have activity concentrations not exceeding 30 times the exempt activity concentrations, provisions exist in ST–1 to allow them to be transported as LSA–I materials that may be transported unpackaged (in bulk). However, there may be unintended consequences in implementing the ST–1 concentration values where applied to non-transportation activities. The DOT current exempt material standard of 70 Bq/g (2000 picoCuries per gram), based on previous IAEA transportation standards, has application by cross reference outside the domain of transportation.

Factors for Consideration

- In some cases, would shippers have to expend resources to: (1) Identify the radionuclides in a material; (2) measure the activity concentration of each radionuclide; and, (3) apply the method for mixtures of radionuclides when determining the basic radionuclide values for exempt material?
- Should the exemption values apply to domestic as well as export shipments?
- If the exemption values only applied to export shipments, would the resulting standard be practical to implement?
- If DOT specifies the exemption values in its regulations (49 CFR 173), should the NRC incorporate those same exemption values in Part 71, or simply make reference to the exemption values in the DOT regulations?
- There may be unintended consequences to adoption of specific exemption values as the current exemption value is used for non-transportation related activities. To what extent and in what manner would a change to specific exemption values affect entities whose non-transportation activities are linked to the current exemption value?

Issue 3. Revision of A_1 and A_2

Description

The A_1 and A_2 values specified in Part 71, Appendix A, are basic dose-based values used in several areas of the regulations, including determining the type of package that must be used for transporting radioactive material. For example, the A_1 values are the maximum activity of special-form materials allowed in a Type A package, and the A_2 values are the maximum activity of non-special-form material allowed in a Type A package. The A_1 and A_2 values are also used for several other quantitative limits including Type B-package activity release limits, low-specific activity material specifications, and excepted package content limits.

The ST–1 revised A_1 and A_2 values are primarily based on dosimetric models that use the IAEA's Q system for dose determination. The Q system includes consideration of a broad range of specific exposure pathways consisting of: External photon dose, external beta dose, inhalation dose, skin and ingestion dose because of contamination, and dose from submersion in gaseous isotopes. The main changes in the Q system resulted from making the dosimetric models

consistent with those used in International Commission on Radiation Protection (ICRP) Publication 61. The lung model and dose conversion factors were updated to the latest ICRP models and the radionuclide values were recalculated. The Q system reference doses and exposure pathways were not changed.

Factors for Consideration

- Is there a practical alternative to adoption of the A_1 and A_2 values?
- Are there specific values that should be modified for domestic use only? What would be the justification for doing so?
- To what extent should the US partial adoption of ICRP 61 be considered for revising the A_1 and A_2 values?

Issue 4. Uranium Hexafluoride Package Requirements

Description

ST–1 introduces detailed requirements for uranium hexaflouride (UF_6) packages designed for more than 0.1 kg UF_6. NRC certifies Type B and fissile (*i.e.,* enriched uranium) UF_6 packages under 10 CFR Part 71. Although most of these issues are under DOT in 49 CFR Part 173, the new ST–1 provisions relevant to 10 CFR Part 71 are summarized as follows (see Appendix A for a listing of the specific ST–1 provisions):

Para 629: Packages shall be packaged and transported in accordance with an international standard, ISO 7195, ''Packaging of Uranium Hexafluoride (UF_6) for Transport.'' ST–1 also allows [para 632(a)] for use of equivalent national standards (*e.g.,* ANSI N14.1); provided that approval by all countries involved in the shipment is obtained (*i.e.,* multilateral approval).

Para 630: ST–1 requires that packages must withstand: (a) A minimum internal pressure test to 2.8 MPa (1.4 MPa for multilateral approval), (b) the ''normal conditions of transport'' drop test, and (c) the hypothetical accident condition thermal test (except that packages containing grater than 9000 kg are exempt from this test if given multilateral approval).

Para 631: ST–1 prohibits packages from utilizing pressure relief devices.

Para 677(b): ST–1 includes an exception that allows UF_6 packages to be evaluated for criticality without considering the in-leakage of water into the containment system. This provision means that a single fissile UF_6 package does not have to be subcritical assuming that water leaks into the containment system. This provision only applies when there is no physical contact of the cylinder valve to any other component of the packaging after the hypothetical accident tests, the valve remains leak-tight, and when there is a high degree of quality control in the manufacture, maintenance, and repair of packaging coupled with tests to demonstrate closure of each package before each shipment.

Factors for Consideration

- NRC practice has been to certify fissile UF_6 packages (including the cylinder which is the containment vessel and a protective overpack) that are shown to be leaktight when subject to the hypothetical accident tests and to specify that the cylinder meets ANSI N14.1 (ANSI N14.1 has the domestic pressure test requirement in 630(a), not the regulations). For this reason, it is believed that NRC-certified UF_6 packages already comply with the above package performance requirements (para 630 and 677(b)). However, these changes appear to have significant ramifications for non-fissile UF_6 packaging that are under the purview of DOT.
- NRC practice has been to reference the ANSI N14.1 standard in the certification, but not to reference the standard in the rule. Although the ISO–7195–2000 standard (in draft) has been drafted taking into account ANSI N14.1, a detailed confirmation of the compatibility of the two standards has not been performed. NRC has representation on the ANSI N14.1 revision panel.

Issue 5. Introduction of Criticality Safety Index (CSI) Requirements

Description

For fissile material packages, ST–1 defines a new term, ''criticality safety index'' (CSI) (paragraph 218), that applies in addition to the traditional package transport index (TI). In current domestic regulations and in the previous IAEA regulations, the overall package TI was determined based upon the more limiting of a ''TI based upon criticality considerations'' and a ''TI based on package radiation levels.'' Both NRC and DOT regulations define and rely on the TI to determine appropriate safety requirements.

The CSI is determined in the same manner as the current TI ''based upon criticality considerations,'' but it now must be displayed on shipments of fissile material (paras 544–545) using a new ''fissile material'' label. A package TI is still determined in the same way as the ''TI based on package radiation levels'' and continues to be displayed on the traditional ''radioactive material'' label.

Factors for Consideration

- Under the new approach, it is believed that some shipments of fissile material packages might be made more efficiently (equivalent safety but more packages allowed in a single shipment), due to avoiding the situation where separation distance requirements (radiological safety) restrict package accumulation (criticality safety), or vice versa.
- Are any issues envisioned in the use of two TI values for shipments?

Issue 6. Type C Packages and Low Dispersible Material

Description

IAEA has adopted the concept of a new category of package, the Type C package (paragraphs 230, 667–670, 730, 734–737) that could withstand severe accident conditions in air transport without loss of containment or significant increase in external radiation levels. At the same time, ST–1 introduced a new category of material, Low Dispersible Material (LDM), which due to its limited radiation hazard and low dispersibility could continue to be transported by aircraft in Type B packages. U.S. regulations have no Type C package or LDM category, but do have specific requirements for the air transport of plutonium. These specific NRC requirements for the air transportation of plutonium (10 CFR 71.64 and 71.74) continue to apply, and will not be addressed in this rulemaking.

The Type C requirements apply to packages destined for air transport that contain a total activity above the following thresholds: for special form material—3,000 A_1 or 100,000 A_2, whichever is lesser, and for all other radioactive material—3,000 A_2. Below these thresholds, Type B packages would be permitted to be used in air transport.

The Type C package performance requirements are significantly more stringent than those for Type B packages. For example, a 90 m/s impact test is required instead of the 9 m-drop test. A 60-minute fire test is required instead of the 30-minute Type B requirement. Other additional tests, such as a puncture/tearing test are also imposed. These tests are more stringent and are expected to result in package designs that will survive more severe aircraft accidents than Type B package designs.

The LDM specification was added to account for materials (package contents)

that have inherently limited dispersibility, solubility, and external radiation levels. The test requirements for LDM are a subset of the Type C package requirements (90 m/s impact and 60 minute thermal test) with an added solubility test, and must be performed on the material without packaging. Specific acceptance criteria are established for evaluating the performance of the material during and after the tests (less than 100 A_2 in gaseous or particulate form of less than 100 micrometer aerodynamic equivalent diameter and less than 100 A_2 in solution). These stringent performance and acceptance requirements are intended to ensure that these materials can continue to be transported safely in Type B packages aboard aircraft.

Factors for Consideration

- What would be the impact on air transport of currently certified Type B packages if the activity content is limited to the activity content thresholds specified above?
- What tests and analyses would be a practical method for demonstrating compliance with the type C package standards?

Issue 7. Deep Immersion Test

Description

The IAEA performance requirement for deep water immersion contained in ST–1 (para. 657 and 730) is an expansion of the requirement contained in SS No. 6. Previously, the deep immersion test was only required for packages of irradiated fuel exceeding 37 PBq (1,000,000 Ci). The ST–1 requirements apply to all Type B(U) and B(M) packages containing more than 10^5A_2 and to Type C packages.

10 CFR 71.61 requires a deep immersion test for packages of irradiated nuclear fuel with activity greater than 10^6 Ci. Currently, 10 CFR 71.61 is more conservative than SS No. 6, with respect to irradiated fuel package design requirements because it requires that a package for irradiated nuclear fuel must be designed such that its undamaged containment system can withstand an external water pressure of 2 MPa for a period of not less than one hour without collapse, buckling, or in leakage of water. The conservatism lies in the test criteria of no collapse, buckling, or in leakage as compared to the ''no rupture'' criteria found in SS No. 6 and ST–1.

To be consistent with ST–1, the NRC would have to revise 10 CFR Part 71.61 to apply to all packages with activity greater than 10^5A_2 and adopt the ST–1 test criteria.

Factors for Consideration

- How should the differences in the acceptance standards be addressed?
- What would be the impact on availability of packages and shipping costs if all packages with an activity greater than 10^5A_2 are required to pass the immersion test requirements?
- Would US origin package designs have to be specially reviewed and certified before shippers could export them in accordance with international regulations if ST–1 requirements were not adopted?

Issue 8. Grandfathering Previously Approved Packages

Description

Historically, IAEA, DOT, and NRC regulations have included transitional arrangements or ''grandfathering'' provisions whenever the regulations have undergone major revision. The purpose of grandfathering is to minimize the costs and impacts of implementing changes in the regulations. Package designs and packagings compliant with the existing regulations do not become ''unsafe'' when the regulations are amended (unless a significant safety issue is corrected in the revision).

Grandfathering typically includes provisions that allow for: (1) Continued use of existing package designs and packagings already fabricated, although some additional requirements may be imposed, (2) completion of packagings in the process of being fabricated or that may be fabricated within a given time period after the regulatory change; and (3) limited modifications to package designs and packagings without the need to demonstrate full compliance with the revised regulations, provided that the modifications do not significantly affect the safety of the package.

A major change in ST–1 is that ''grandfathering'' should be limited to only those package designs that have been certified under the last two major revisions of the regulations. Packages approved under an earlier revision would either be removed from service or be required to be re-certified under the revised regulations that result from this rulemaking.

As revised in 1996, IAEA regulations in ST–1 only recognize the ''grandfathering'' of package designs certified under the 1973 and 1985 editions of IAEA regulations (SS No. 6). Package designs approved under the 1967 edition of SS No. 6 would be required to be re-certified, removed from service, or shipped via exemption (*i.e.,* special arrangement). If this approach to ''grandfathering'' is adopted in DOT and NRC regulations, package designs approved to earlier versions of DOT and NRC regulations (*i.e.,* those based on 1967 IAEA regulations) would be required to be re-certified, removed from service, or shipped via exemption.

Factors for Consideration

- Should the ''grandfathering '' of previously approved packages be limited to those approved under the last two major revisions of the regulations? If not, on what basis should the ''grandfathering '' of previously approved packages be allowed?
- How long should ''grandfathered'' packages be allowed to be fabricated or used?
- What type and magnitude of package design changes should be allowed for ''grandfathered'' packages, before re-certification to the current set of regulations is required?
- IAEA has initiated a process to review and update ST–1 on a two-year frequency and does this new process raise any issues on the grandfathering limitations to the last two major revisions?

Issue 9. Changes to Various Definitions

Description

The NRC is contemplating changes to various definitions in Part 71 to provide internal consistency and improve correlation with ST–1. 10 CFR 71.4 includes defined terms used throughout Part 71. These terms require clear definition so that they can be used to accurately communicate requirements to licensees. The NRC would add the following definitions from ST–1: (1) Confinement system (paragraph 209), (2) Criticality safety index (paragraph 218; reference issue 5), (3) Low dispersible radioactive material (paragraph 225; reference issue 6), and (4) Quality assurance (paragraph 232). Additionally, the NRC would propose to revise the definition of ''package'' in 10 CFR 71.4 to be consistent with ST–1. For reference, the ST–1 definitions are contained in Appendix A and provided below.

Para. 209. ''Confinement System shall mean the assembly of fissile material and packaging components specified by the designer and agreed to by the competent authority as intended to preserve criticality safety.''

Para. 218. ''Criticality safety index (CSI) assigned to a package, overpack or freight container containing fissile material shall mean a number which is used to provide control over the accumulation of packages, overpacks or freight containers containing material.''

Para. 225. ''Low dispersible radioactive material shall mean either a solid radioactive material or a solid radioactive material in a sealed capsule, that has limited dispersibility and is not in powdered form.''

Para. 232. ''Quality assurance shall mean a systematic programme of controls qand inspections applied by an organization or body involved in the transport of radioactive material which is aimed at providing adequate confidence that the standard of safety prescribed in these Regulations is achieved in practice.''

Factors for Consideration

- Do the definitions conflict with existing programs, or introduce other issues or concerns?
- Are there other definitions of terms that are recommended for incorporation in Part 71?

Issue 10. Crush Test for Fissile Material Package Design

Description

Under requirements for packages containing fissile material, ST–1 682(b) requires tests specified in paragraphs 719–724 followed by whichever of the following is the more limiting: the drop test onto a bar as identified in paragraph 727(b) and, either the crush test listed in paragraph 727(c) for packages having a mass not greater than 500 kg and an overall density not greater than 1000 kg/m^3 based on external dimensions, or the nine meter drop test listed in paragraph 727(a) for all other packages; or the water immersion test of paragraph 729.

SS No.6 and Part 71 presently require the crush test for fissile material packages having a mass not greater than 500 kg and an overall density not greater than 1000 kg/m^3 based on external dimensions, and radioactive contents greater than 1000 A_2 not as special form radioactive material. Under ST–1, the crush test is no longer limited to fissile material packages containing an activity greater than 1000 A_2 because ST–1 has extended the crush test requirement to include fissile material package designs regardless of the activity of the contents. This was done in recognition that the crush environment was a potential accident force that should be protected against for both radiological safety purposes (packages containing more than 1000 A_2 in normal form) and criticality safety purposes (fissile material package designs).

To be consistent with ST–1, the NRC would have to revise 10 CFR Part 71 wording to recognize removal of the 1000 A_2 activity limit with respect to the crush test requirement for fissile material package designs. However, full compliance with ST–1 requirements for fissile material packages would also require changes to the hypothetical accident conditions test sequencing of 10 CFR 71.73 and would require performance of the nine-meter free drop test or the crush test, but not both as presently required by § 71.73.

Factors for Consideration

- How should the differences in the test sequencing and required tests be addressed? Would the test sequencing requirements be applied to Type B packages as well?
- What would be the impact on availability of packages and shipping costs due to elimination of the 1000 A_2 activity limit for fissile material packages having a mass not greater than 500 kg and an overall density not greater than 1000 kg/m^3 based on external dimensions?
- If Part 71 is changed to only eliminate the 1000 A_2 activity limit for fissile material packages, but all other tests and the testing sequence remains unchanged, what implications would this have for US origin packages for export?

Issue 11. Fissile Material Package Design for Transport by Aircraft

Issue Description

For shipment of fissile material by air, ST–1 requires that packages with quantities greater than excepted amounts (that would include all the NRC certified packages) require an additional criticality evaluation. Specifically, the requirements are:

Para 680(a): Packages must remain subcritical, assuming 20 centimeters water reflection but not inleakage (*i.e.,* moderation) when subjected to the tests for Type C packages (see Issue 6). The specification of no water ingress is given as the objective of this requirement is protection from criticality events resulting from mechanical or physical rearrangement of the geometry of the package (*i.e.,* fast criticality).

Para 680(b) This provision states that if a package takes credit for ''special features,'' this package can only be presented for air transport if it is shown that these features remain effective even under the Type C test conditions followed by a water immersion test. ''Special features'' are specified in ST–1 Para 677, and include features that provide moderator exclusion.

The application of the paragraph 680 requirement to fissile-by-air packages is in addition to the normal condition tests (and possibly accident tests) that the package already must meet. Thus:

- A Type IF or AF package by air must: 1) Withstand incident-free conditions of transport with respect to release, shielding, and maintaining subcriticality (single package and array of packages), (2) withstand accident condition tests with respect to maintaining subcriticality (single package and array of packages), and (3) comply with para 680 with respect to maintaining subcriticality (single package).
- A Type BF package by air must: (1) Withstand incident-free conditions of transport *and* Type B tests with respect to release, shielding, and maintaining subcriticality (single package and array of packages); and (2) comply with para 680 with respect to maintaining subcriticality (single package).
- A Type C fissile material package must withstand: incident-free conditions of transport (single package and array of packages), Type B tests (single package and array of packages), and Type C tests (single package) with respect to release, shielding, and maintaining subcriticality.

Factors for Consideration

- Certain factors need to be considered in determining the practical impacts of domestic adoption of ST–1 paragraph 680. First, all uranium can be shipped in non-Type C package (IF, AF) due to its A_1 and A_2 values. The paragraph 680(a) requirements appear to be readily satisfied by low-enriched uranium, because low enriched uranium (less than approximately 5% enrichment) would typically require moderation (*e.g.,* by water) to achieve nuclear criticality, but the test specifies no water ingress. Secondly, there are statutory restrictions on air transport of plutonium in the U.S. Finally, packaging for air transportation may follow International Civil Aviation Organization Technical Instructions that are also being revised for compatibility with ST–1.

Issue 12: Special Package Approvals

Description

The transport of large objects that are too large for certified packagings and cannot satisfy the packaging requirements was not considered in the development of Part 71. However, as decommissioning activities increase, the need to transport large objects is rising. For example, in 1997, Portland General Electric Company (PGE) requested approval of the Trojan Reactor Vessel Package (TRVP) (including internals) for transport to the disposal facility

operated by US Ecology on the Hanford Nuclear Reservation near Richland, Washington. The TRVP contained approximately 74 petabequerels (2 million curies) in the form of activated metal and 5.7 terabequerels (155 curies) in the form of internal surface contamination; was filled with low-density concrete; and weighed approximately 900 metric tons (1000 tons).

The Commission approved the Trojan shipment under exemptions issued through 10 CFR Part 71.8. Also, the U.S. Department of Transportation's (DOT's) regulations that govern radioactive material shipments do not recognize packages approved via NRC exemption, so DOT also had to consider and issue an exemption for the Trojan shipment.

Because it is the Commission's policy to avoid the use of exemptions for recurring licensing actions, the NRC staff is considering adding regulatory provisions to Part 71 to address special package approvals. If adopted, these provisions would provide a mechanism for review of special packages under the regulations without the need for exemptions.

Factors for Consideration

- Should Part 71 be revised to address reactor vessels specifically or to address large objects in general?
- Should NRC consider adopting an analogue of IAEA's special arrangement provision modified to address packaging?
- What (additional) determinations should be included in an application for a special package approval?
- Should the risk-informed basis used specifically for the Trojan approval be adopted for other special package approvals?

Issue 13. Expansion of Part 71 Quality Assurance Requirements to Holders of, and Applicants for, a Certificate of Compliance

Description

The NRC has observed problems with the performance of 10 CFR Part 72 Certificate of Compliance (CoC) holders in implementing the Part 72 quality assurance (QA) requirements. Problems have occurred in design, design control, fabrication, and corrective action areas. Although CoCs are legally binding documents, certificate holders or applicants for a CoC and their contractors and subcontractors have not clearly been brought within the scope of Part 72 requirements. Therefore, because the terms ''certificate holder'' and ''applicant for a certificate of compliance'' do not appear in the Part 72, Subpart G regulations, the NRC has not had a clear basis to cite these persons for violations of Part 72 requirements in the same way it treats licensees.

The NRC Enforcement Policy [1] and its implementing program were established to support the NRC's overall safety mission in protecting public health and safety and the environment. Consistent with this purpose, enforcement actions are used as a deterrent to emphasize the importance of compliance with requirements and to encourage prompt identification and comprehensive correction of the violations. Enforcement sanctions consist of Notices of Violation (NOVs), civil penalties, and orders of various types. In addition to formal enforcement actions, the NRC also uses related administrative actions such as Notices of Nonconformance (NONs), Confirmatory Action Letters, and Demands for Information to supplement its enforcement program. The NRC expects licensees, certificate holders, and applicants for a CoC to adhere to any obligations and commitments that result from these actions and will not hesitate to issue appropriate orders to ensure that these obligations and commitments are met. The nature and extent of the enforcement action are intended to reflect the seriousness of the violation involved. An NOV is a written notice setting forth one or more violations of a legally binding requirement.

However, when the NRC has identified a failure to comply with Part 72 QA requirements by certificate holders or applicants for a CoC, it has issued an NON rather than an NOV. Although an NON and an NOV appear to be similar, the Commission prefers the issuance of an NOV because: (1) The issuance of an NOV effectively conveys to both the person violating the requirement and the public that a violation of a legally binding requirement has occurred; (2) the use of graduated severity levels associated with an NOV allows the NRC to effectively convey to both the person violating the requirement and the public a clearer perspective on the safety and regulatory significance of the violation; and (3) violation of a regulation reflects the NRC's conclusion that potential risk to public health and safety could exist. Therefore, the NRC believed that limiting the available enforcement sanctions to administrative actions was insufficient to address the performance problems observed in industry.

In response to this problem, the NRC staff submitted a rulemaking plan to revise Part 72 to the Commission in SECY–97–214.[2] In a Staff Requirements Memorandum (SRM) to SECY–97–214, the Commission approved the staff's rulemaking plan and directed the staff to also consider whether conforming changes to the quality assurance (QA) regulations in Part 71 would be necessary, because of dual purpose cask designs. Dual purpose cask designs are intended for both the storage of spent fuel under Part 72 and the transportation of spent fuel under Part 71. In a memorandum from the EDO to the Commission, dated December 3, 1997, the NRC staff indicated that expansion of the Part 71 QA provisions to include certificate holders and applicants for a Certificate of Compliance (CoC) would be made as part of the rulemaking to conform Part 71 to IAEA standard ST–1.

The Commission recently issued a final rule expanding QA regulations in Part 72, Subpart G, to specifically include certificate holders and applicants for a CoC. Consequently, the NRC is now considering similarly expanding the QA regulations in Part 71, Subpart H, to specifically include certificate holders and applicants for a CoC. The NRC believes that this change is necessary to ensure consistency between the QA provisions of Parts 71 and 72, particularly in light of NRC approval of dual purpose cask designs. As with the Part 72 final rule, this issue would provide explicit notice to certificate holders and applicants for a CoC of their QA responsibilities; and would provide the NRC staff with additional enforcement sanction—should violations of the Part 71 QA requirements occur.

Factors for Consideration

- Should consistency be maintained between the QA provisions of Parts 71 and 72, in light of the existence of dual purpose cask designs?

Issue 14. Adoption of ASME Code

Description

The NRC staff proposes that the ASME (American Society of Mechanical Engineers) Code, Section III, Division 3, be incorporated by reference in 10 CFR Part 71 via rulemaking. This rule will ensure implementation of the ASME

[1] NUREG–1600, ''General Statement of Policy and Procedures for NRC Enforcement Actions,'' May 2000.

[2] SECY–97–214, ''Changes to 10 CFR Part 72, Expand Applicability to Include Certificate Holders and Applicants and Their Contractors and Subcontractors,'' dated September 24, 1997. This rulemaking plan expanded the applicability of the QA provision of Part 72, Subpart G, to specifically include Part 72 certificate holders and applicants for a Certificate of Compliance.

Code in cask fabrication, including all QA aspects of the code, such as the presence of an authorized nuclear inspector (ANI) during the fabrication to ensure that the code requirements are met, and stamping of components after fabrication is complete. This approach would be similar to how the ASME Code is endorsed for power reactors under 10 CFR 50.55(a) and would make the fabrication process for transportation cask containments commensurate with that used for nuclear power plant components.

NRC inspections of vendors'/fabricators' shops (for fabrication of spent fuel storage canisters and transportation casks) have identified, over the past several years, quality control (QC) and quality assurance (QA) problems in these fabricated systems. A major reason for these problems is that these fabricators/vendors do not fully use a code for QA in the fabrication process of these systems. These QA problems have in some instances continued in spite of repeated adverse NRC and licensee findings.

The NRC staff intends to incorporate two recent developments. First, ASME issued a consensus code in May 1997 entitled: ''Containment Systems and Transport Packages for Spent Fuel and High Level Radioactive Waste,'' ASME B&PV Code Section III, Division 3, that would require stamping of components constructed to it (*i.e.,* the transportation cask's containment). Second, Public Law 104–113 ''National Technology Transfer and Advancement Act'' was enacted in 1996 to require that Federal agencies use consensus standards (*e.g.,* the ASME B&PV Code), except when there are justified reasons for not doing so. These two developments support efforts to initiate rulemaking in this area.

Factors for Consideration

- Can other regulatory vehicles for NRC endorsement of Code be used or should this only be done by rulemaking?
- Are there other voluntary consensus standards that should be considered in addition to, or in lieu of, ASME code?

Issue 15. Adoption of Changes, Tests, and Experiments Authority

Description

The Commission recently approved a final rule to expand the provisions of 10 CFR 72.48, ''Changes, Tests, and Experiments,'' to include Part 72 certificate holders (October 4, 1999; 64 FR 53582). 10 CFR Part 72 Certificate holders are allowed to make changes to a spent fuel storage cask design or conduct tests and experiments, without prior NRC review and approval, if certain requirements are met. However, Part 71 contains no similar provisions to permit a certificate holder to change the design of a Part 71 transportation package. The NRC has issued Certificates of Compliance (CoC) under Parts 71 and 72 for dual purpose casks [packages] (*i.e.,* containers intended for both the storage and transportation of spent fuel). This has created the situation where a 10 CFR Part 72 certificate holder is authorized to change a storage design feature of a dual-purpose storage/transportation cask without obtaining NRC prior approval; however, the 10 CFR Part 71 certificate holder is not authorized to modify transportation package design without obtaining NRC prior approval, even when the same physical component and change is involved.

In SECY–99–130 [3] and SECY–99–054.[4] the staff indicated that comments had been received on the proposed rule that requested that authority similar to 10 CFR 72.48 be created in Part 71, particularly with respect to dual purpose casks. Staff indicated that this issue would be addressed in the subsequent rulemaking to conform Part 71 with IAEA standard ST–1. The Commission adopted the staff's recommendations in a Staff Requirements Memorandum (SRM) dated June 22, 1999.

In SECY–99–054 staff recommended that a similar authority to 10 CFR 72.48 be created for spent fuel transportation packages intended for domestic use only. Staff also recommended that this authority be limited to Part 50 and 72 licensees shipping spent fuel and the Part 71 certificate holder. Furthermore, other supporting changes to Part 71 would be required to ensure consistency with the process contained in 10 CFR 72.48. These changes would include using common terminology such as ''changes to the cask design, as described in the final safety analysis report'' (FSAR) and a process for requesting amendments to a CoC. Requirements for periodically updating a transportation package FSAR would also be required to ensure an accurate ''licensing'' basis is available for evaluating future proposed changes, and requirements for package users to have a copy of the FSAR, and the updated FSAR.

The current IAEA standard ST–1 does not contain any equivalent provisions for changing a transportation package's design, without prior review by the competent authority.

Factors for Consideration

- Should this change authority apply to spent fuel packages involved in domestic commerce only?
- Should this change authority be expanded to include all types of transportation packages, licensees, or users?
- Should the change authority apply to all domestic transportation packages?
- Should the change authority apply to dual purpose spent fuel packages?

Issue 16. Fissile Material Exemptions and General License Provisions

Discussion

The NRC published an emergency final rule on February 10, 1997 (62 FR 5907), amending Part 71 regulations that deal with shipments of exempt quantities of fissile material and shipments of fissile material under a general license. An NRC licensee had identified that a shipment of waste material (beryllium oxide containing a low concentration of high-enriched uranium) that met the fissile exemption provisions of 10 CFR 71.53 had the potential for an accidental criticality in certain specific circumstances. Packages shipped under the provisions of 10 CFR 71.53 were considered inherently safe for criticality-safety purposes. These regulations assumed that only ordinary water (H_2O) could be present as a moderating material. The regulations did not contemplate the presence of special moderating materials (*e.g.*, beryllium, graphite, or deuterium). Because of this criticality safety issue, the NRC published a rule that was immediately effective with no opportunity for pre-promulgation public comment. The NRC did solicit comments after the rule was effective. All public comments supported the need for the emergency final rule when the shipments contained special moderators (moderators other than water); however, the commenters stated that the rule had gone too far for water moderated shipments, that it was excessively restrictive and costly to licensees, and that further rulemaking was necessary.

Based on these comments, NRC staff contracted with Oak Ridge National Laboratory (ORNL) to thoroughly review fissile material exemptions and general license provisions. ORNL performed

[3] SECY–99–130, ''Final Rule—Revisions to Requirements of 10 CFR Parts 50 and 72 Concerning Changes, Tests, and Experiments,'' dated May 12, 1999.

[4] SECY–99–054, ''Plans for Final Rule—Revisions to Requirements of 10 CFR Parts 50, 52, and 72 Concerning Changes, Tests, and Experiments,'' dated February 22, 1999.

computer model calculations of k_{eff} (k-effective) for various combinations of fissile material and moderating material—including beryllium, carbon, deuterium, silicon-dioxide, and water—to verify the accuracy of minimum critical mass values. These minimum critical mass values were then applied to the regulatory structure contained in Part 71, and revised mass limits for both the general license and exemption provisions to Part 71 were determined. Also, ORNL researched the historical bases for the fissile material exemption and general license regulations in Part 71 and discussed the impact of the emergency final rule's restrictions on NRC licensees. The ORNL study was issued as NUREG/CR–5342 in July 1998 (available via the following NRC website: http://www.nrc.gov/NRC/NUREGS/CR5342/index.html). The ORNL study confirmed that the emergency rule was needed to provide safe transportation of packages with special moderators that are shipped under the general license and fissile material exemptions, but may be excessive for water-moderated shipments.

NUREG/CR–5342 identified 16 recommended actions for additional rulemaking. Additionally, the Commission's SRM on SECY–96–268 approving the emergency final rule directed the staff to issue guidance for instances where fissile materials may be mixed in the same shipping container with different moderators. The staff indicated that this issue would be addressed in a forthcoming rulemaking (memorandum from the EDO to the Commission, dated September 8, 1998). On October 27, 1999, the NRC published **Federal Register** Notice 64 FR 57769 responding to public comments on the emergency final rule, and also requesting information on the cost impact of the final rule from the public, industry, and the DOE, because the NRC staff had not been successful in obtaining this information. The requirements for the fissile material general licenses are provided in 10 CFR 71.18, 71.20, 71.22, and 71.24, and the fissile material exemptions are provided in 71.53.

IAEA standard ST–1 contains language on fissile exemptions and restrictions on the use of special moderators. However, ST–1 does not presently contain provisions on general licenses for shipment of fissile material; previous version did contain general license conditions.

Factors for Consideration

- Should all, or only some, of the 16 sub-issues (*i.e.*, the recommendations contained in NUREG/CR–5342) be included in this rulemaking on this issue?
- Should additional issues or alternative approaches on the fissile exemptions or general license provisions be included in this rulemaking?
- Is there available cost data that may help to understand the cost impact of the implemented emergency rule; or help to better understand the possible cost impact of the ORNL recommendations?

Issue 17. Double Containment of Plutonium (PRM–71–12)

Description

The NRC received a Petition for Rulemaking from International Energy Consultants, Inc. (IEC), dated September 25, 1997. The petition was docketed as PRM–71–12 and was published for public comment on February 19, 1998. The comment period was extended to July 31, 1998. The petitioner requested that regulations in 10 CFR 71.63 be eliminated. The petitioner argued that the double containment requirement in 71.63(b) was not consistent with the basis for other packaging standards (*i.e.*, the Q-value system for identifying the A_1 and A_2 values for each nuclide). The petitioner also argued that the use of double containment for shipments of plutonium imposed unnecessary costs (*i.e.*, fabrication of shipping packages and a weight penalty). As an option, the petitioner requested that 71.63 be entirely eliminated.

In 1974, the Atomic Energy Commission (AEC) issued 10 CFR 71.63 which imposed special requirements on the shipment of plutonium in excess of 0.74 terabecquerels (20 curies). These requirements specify that plutonium must be in solid form (71.63(a)) and that packages used to ship plutonium must provide a separate inner containment (*i.e.*, the ''double containment'' requirement) (71.63(b)). In adopting these requirements, the AEC specifically excluded plutonium in the form of reactor fuel elements, metal or metal alloys, and other plutonium-bearing solids that the Commission determines, on a case-by-case basis, do not require double containment. These regulations have remained essentially unchanged since 1974, except for the addition in 1998 of vitrified high-level waste in sealed canisters to the list of exempt forms of plutonium. Double containment is in addition to Type B packaging standards and is not required for any other nuclides that are listed in Part 71. Additionally, IAEA standard ST–1 does not contain a double containment requirement for any nuclide.

The AEC issued this regulation at a time when wide-spread reprocessing of commercial spent fuel was anticipated. The AEC expected increases in the quantities of plutonium to be shipped and the number of shipments of plutonium. In addition, the specific activity of the plutonium was expected to increase with increased burnup, resulting in higher gamma and neutron radiation levels, greater heat generation, and greater pressure generation potential from plutonium nitrate solutions in shipping containers. Because of these expected changes and because of the susceptibility of liquids to leakage, the AEC believed that safety would be significantly enhanced if the basic form for shipments of plutonium were changed from liquid to solid, and if the solid form of plutonium were required to be shipped in a package providing double containment of the contents.

The AEC indicated that ''The arguments for requiring a solid form of plutonium for shipment are largely subjective, in that there is no hard evidence on which to base statistical probabilities or to assess quantitatively the incremental increase in safety which is expected.'' [5] The AEC also indicated that the double containment provision compensates for the fact that the plutonium may not be in a ''nonrespirable'' form. Notwithstanding these rationales, some of the underlying assumptions for this rule were altered in 1979 when the U.S. government decided that reprocessing of civilian spent fuel and reuse of plutonium was not desirable. Consequently, the expected plutonium reprocessing economy and wide-spread shipments never materialized.

With respect to PRM–71–12, eight public comments were received on the petition; of those, three supported the petition and five opposed the petition. The supporting comments essentially stated that the IAEA's Q-System accurately reflects the dangers of nuclides, including plutonium, and that elimination of 10 CFR 71.63(a) and (b) would make the regulations more performance based, reduce costs and personnel exposures, and be consistent with the IAEA standards.

The five opposing comments essentially stated that plutonium is very dangerous, especially in liquid form, and therefore additional regulatory requirements are warranted, that existing regulations are not overly burdensome, especially in light of the

[5] SECY–R–74–5, dated July 6, 1973.

total expected transportation cost, that TRUPACT–II package meets 71.63(b) requirement, that a commenter (i.e., the Western Governors Association) has worked for over 10 years to ensure a safe transportation system for WIPP, including educating the public about the TRUPACT–II package, and that any change now would erode public confidence and be detrimental to the entire transportation system for WIPP shipments, and that additional personnel exposure due to double containment is insignificant.

Factors for Consideration

- Should NRC change any of the special requirements for the transportation of plutonium?
- Should the double containment requirement in 71.63(b) be eliminated?
- Should both the solid form and the double containment requirements of 71.63(a) and (b) be eliminated?
- Is consistency with IAEA standard ST–1 important on this issue?

Issue 18. Contamination Limits as Applied to Spent Fuel and High Level Waste (HLW) Packages

Description

As part of the NRC's upcoming public meetings on proposed changes to 10 CFR Part 71, the Commission will consider the issue of removable package contamination limits for transportation (*i.e.,* radioactive material that can be removed from the surface of a package prior to shipment). This issue involves contamination limits for all transportation packages, including spent fuel and HLW packages, contained in DOT regulations which are based on the international transportation standards for contamination limits. The NRC staff requests public and stakeholder views on whether different contamination limits should be considered for spent fuel and HLW packages, and recommendations for future interactions that NRC has with DOT and IAEA on this issue. NRC staff is aware that the IAEA is starting a review of contamination models and limits, and this review will be conducted over the next few years.

The removable contamination limit of 4 Becquerels per square centimeter (4Bq/cm2) is contained in IAEA Safety Series 6, in ST–1, in U.S. DOT regulations (49 CFR 173.443), and by reference to DOT's regulations in NRC's 10 CFR Part 71. The limit applies to the transportation of all packages, regardless of size. Thus, the 4 Bq/cm2 contamination limit applies to shipment of spent fuel and HLW packages, even though the unique aspects of these packages were not explicitly considered in the modeling assumptions used in developing the contamination limit. Specifically, the contamination limit was designed to reduce delivery worker exposure from external contamination on small packages during frequent manual handling of these packages in freight facilities; however, unlike small packages moved by delivery workers, handling of spent fuel and HLW packages is done by cranes and other manipulation equipment, due to the large weights involved, and does not involve extensive personnel contact, thereby reducing worker exposure from external package contamination.

Irrespective of remote handling, workers must obtain contamination readings on a spent fuel or HLW package's external surfaces to ensure compliance with the 4 Bq/cm2 limit prior to release for shipment. Due to the large surface areas involved in the contamination checks, and the prolonged time that workers are in the vicinity of a loaded package while performing these checks, they receive exposure from radiation emanating through the package walls. Further, should the contamination checks reveal contamination above 4 Bq/cm2, then additional worker exposure occurs during decontamination activities and subsequent checks of contamination levels to achieve the 4 Bq/cm2 limit. It should be noted that if the contamination limit for spent fuel and HLW packages was changed, workers would still be required to check the packages for contamination (under the changed limit) and thus receive exposure while performing this activity and any required decontamination activities.

Factors for Consideration

- Should the 4 Bq/cm2 limit continue to apply to spent fuel and HLW packages or should an alternative limit be developed? Is there an alternate contamination limit or alternative approach that will result in lowered exposure to workers, yet ensure that the rail and truck workers as well as the public are adequately protected from external package contamination?
- If alternative contamination limits are established for spent fuel and HLW packages, is there any concern with the possible resulting difference in US domestic regulations and international standards?

Appendix A—Paragraphs Referenced from IAEA ST–1

Appendix A contains the full text of specific paragraphs from ST–1 referenced in the eleven IAEA-compatibility issues. Paragraphs are listed numerically in ascending order, with the corresponding issue identified in bold text at the end of the reference.

107. The Regulations do not apply to:

(e) natural material and ores containing naturally occurring radionuclides which are not intended to be processed for use of these radionuclides provided the activity concentration of the material does not exceed 10 times the values specified in paras 401–406. (Issue 2)

209. Confinement system shall mean the assembly of fissile material and packaging components specified by the designer and agreed to by the competent authority as intended to preserve criticality safety. (Issue 9)

218. Criticality safety index (CSI) assigned to a package, overpack or freight container containing fissile material shall mean a number which is used to provide control over the accumulation of packages, overpacks or freight containers containing fissile material. (Issue 9)

225. Low dispersible radioactive material shall mean either a solid radioactive material or a solid radioactive material in a sealed capsule, that has limited dispersibility and is not in powder form. (Issue 9)

230. Package shall mean the packaging with its radioactive contents as presented for transport. The types of packages covered by these Regulations, which are subject to the activity limits and material restrictions of Section IV and meet the corresponding requirements, are:

(a) Excepted package;
(b) Industrial package Type 1 (Type IP–1);
(c) Industrial package Type 2 (Type IP–2);
(d) Industrial package Type 3 (Type IP–3);
(e) Type A package;
(f) Type B(U) package;
(g) Type B(M) package;
(h) Type C package.

Packages containing fissile material or uranium hexafluoride are subject to additional requirements. (Issue 6)

232. Quality assurance shall mean a systematic programme of controls and inspections applied by any organization or body involved in the transport of radioactive material which is aimed at providing adequate confidence that the standard of safety prescribed in these Regulations is achieved in practice. (Issue 9)

401. The following basic values for individual radionuclides are given in Table I:

(a) A_1 and A_2 in TBq;
(b) activity concentration for exempt material in Bq/g; and
(c) activity limits for exempt consignments in Bq. (Issue 2)

402. For individual radionuclides which are not listed in Table I the determination of the basic radionuclide values referred to in para. 401 shall require competent authority approval or, for international transport, multilateral approval. Where the chemical form of each radionuclide is known, it is permissible to use the A_2 value related to its solubility class as recommended by the International Commission on Radiological Protection, if the chemical forms under both normal and accident conditions of transport

are taken into consideration. Alternatively, the radionuclide values in Table II may be used without obtaining competent authority approval. (Issue 2)

403. In the calculations of A_1 and A_2 for a radionuclide not in Table I, a single radioactive decay chain in which the radionuclides are present in their naturally occurring proportions, and in which no daughter nuclide has a half-life either longer than 10 days or longer than that of the parent nuclide, shall be considered as a single radionuclide; and the activity to be taken into account and the A_1 or A_2 value to be applied shall be those corresponding to the parent nuclide of that chain. In the case of radioactive decay chains in which any daughter nuclide has a half-life either longer than 10 days or greater than that of the parent nuclide, the parent and such daughter nuclides shall be considered as mixtures of different nuclides. (Issue 2)

404. For mixtures of radionuclides, the determination of the basic radionuclide values referred to in para. 401 may be determined as follows:

$$X_m = \frac{1}{\sum_i \frac{f(i)}{X(i)}}$$

Text Continued After Table I

BILLING CODE 7590–01–P

Table I. BASIC RADIONUCLIDE VALUES

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Actinium (89)				
Ac-225 (a)	8×10^{-1}	6×10^{-3}	1×10^{1}	1×10^{4}
Ac-227 (a)	9×10^{-1}	9×10^{-5}	1×10^{-1}	1×10^{3}
Ac-228	6×10^{-1}	5×10^{-1}	1×10^{1}	1×10^{6}
Silver (47)				
Ag-105	2×10^{0}	2×10^{0}	1×10^{2}	1×10^{6}
Ag-108m (a)	7×10^{-1}	7×10^{-1}	1×10^{1} (b)	1×10^{6} (b)
Ag-110m (a)	4×10^{-1}	4×10^{-1}	1×10^{1}	1×10^{6}
Ag-111	2×10^{0}	6×10^{-1}	1×10^{3}	1×10^{6}
Aluminium (13)				
Al-26	1×10^{-1}	1×10^{-1}	1×10^{1}	1×10^{5}
Americium (95)				
Am-241	1×10^{1}	1×10^{-3}	1×10^{0}	1×10^{4}
Am-242m (a)	1×10^{1}	1×10^{-3}	1×10^{0} (b)	1×10^{4} (b)
Am-243 (a)	5×10^{0}	1×10^{-3}	1×10^{0} (b)	1×10^{3} (b)
Argon (18)				
Ar-37	4×10^{1}	4×10^{1}	1×10^{6}	1×10^{8}
Ar-39	2×10^{1}	4×10^{1}	1×10^{7}	1×10^{4}
Ar-41	3×10^{-1}	3×10^{-1}	1×10^{2}	1×10^{9}
Arsenic (33)				
As-72	3×10^{-1}	3×10^{-1}	1×10^{1}	1×10^{5}
As-73	4×10^{1}	4×10^{1}	1×10^{3}	1×10^{7}
As-74	1×10^{0}	9×10^{-1}	1×10^{1}	1×10^{6}
As-76	3×10^{-1}	3×10^{-1}	1×10^{2}	1×10^{5}
As-77	2×10^{1}	7×10^{-1}	1×10^{3}	1×10^{6}
Astatine (85)				
At-211 (a)	2×10^{1}	5×10^{-1}	1×10^{3}	1×10^{7}
Gold (79)				
Au-193	7×10^{0}	2×10^{0}	1×10^{2}	1×10^{7}

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Au-194	1×10^0	1×10^0	1×10^1	1×10^6
Au-195	1×10^1	6×10^0	1×10^2	1×10^7
Au-198	1×10^0	6×10^{-1}	1×10^2	1×10^6
Au-199	1×10^1	6×10^{-1}	1×10^2	1×10^6
Barium (56)				
Ba-131 (a)	2×10^0	2×10^0	1×10^2	1×10^6
Ba-133	3×10^0	3×10^0	1×10^2	1×10^6
Ba-133m	2×10^1	6×10^{-1}	1×10^2	1×10^6
Ba-140 (a)	5×10^{-1}	3×10^{-1}	1×10^1 (b)	1×10^5 (b)
Beryllium (4)				
Be-7	2×10^1	2×10^1	1×10^3	1×10^7
Be-10	4×10^1	6×10^{-1}	1×10^4	1×10^6
Bismuth (83)				
Bi-205	7×10^{-1}	7×10^{-1}	1×10^1	1×10^6
Bi-206	3×10^{-1}	3×10^{-1}	1×10^1	1×10^5
Bi-207	7×10^{-1}	7×10^{-1}	1×10^1	1×10^6
Bi-210	1×10^0	6×10^{-1}	1×10^3	1×10^6
Bi-210m (a)	6×10^{-1}	2×10^{-2}	1×10^1	1×10^5
Bi-212 (a)	7×10^{-1}	6×10^{-1}	1×10^1 (b)	1×10^5 (b)
Berkelium (97)				
Bk-247	8×10^0	8×10^{-4}	1×10^0	1×10^4
Bk-249 (a)	4×10^1	3×10^{-1}	1×10^3	1×10^6
Bromine (35)				

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Br-76	4×10^{-1}	4×10^{-1}	1×10^{1}	1×10^{5}
Br-77	3×10^{0}	3×10^{0}	1×10^{2}	1×10^{6}
Br-82	4×10^{-1}	4×10^{-1}	1×10^{1}	1×10^{6}
Carbon (6)				
C-11	1×10^{0}	6×10^{-1}	1×10^{1}	1×10^{6}
C-14	4×10^{1}	3×10^{0}	1×10^{4}	1×10^{7}
Calcium (20)				
Ca-41	Unlimited	Unlimited	1×10^{5}	1×10^{7}
Ca-45	4×10^{1}	1×10^{0}	1×10^{4}	1×10^{7}
Ca-47 (a)	3×10^{0}	3×10^{-1}	1×10^{1}	1×10^{6}
Cadmium (48)				
Cd-109	3×10^{1}	2×10^{0}	1×10^{4}	1×10^{6}
Cd-113m	4×10^{1}	5×10^{-1}	1×10^{3}	1×10^{6}
Cd-115 (a)	3×10^{0}	4×10^{-1}	1×10^{2}	1×10^{6}
Cd-115m	5×10^{-1}	5×10^{-1}	1×10^{3}	1×10^{6}
Cerium (58)				
Ce-139	7×10^{0}	2×10^{0}	1×10^{2}	1×10^{6}
Ce-141	2×10^{1}	6×10^{-1}	1×10^{2}	1×10^{7}
Ce-143	9×10^{-1}	6×10^{-1}	1×10^{2}	1×10^{6}
Ce-144 (a)	2×10^{-1}	2×10^{-1}	1×10^{2} (b)	1×10^{5} (b)
Californium (98)				
Cf-248	4×10^{1}	6×10^{-3}	1×10^{1}	1×10^{4}
Cf-249	3×10^{0}	8×10^{-4}	1×10^{0}	1×10^{3}
Cf-250	2×10^{1}	2×10^{-3}	1×10^{1}	1×10^{4}

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Cf-251	7×10^{0}	7×10^{-4}	1×10^{0}	1×10^{3}
Cf-252	5×10^{-2}	3×10^{-3}	1×10^{1}	1×10^{4}
Cf-253 (a)	4×10^{1}	4×10^{-2}	1×10^{2}	1×10^{5}
Cf-254	1×10^{-3}	1×10^{-3}	1×10^{0}	1×10^{3}
Chlorine (17)				
Cl-36	1×10^{1}	6×10^{-1}	1×10^{4}	1×10^{6}
Cl-38	2×10^{-1}	2×10^{-1}	1×10^{1}	1×10^{5}
Curium (96)				
Cm-240	4×10^{1}	2×10^{-2}	1×10^{2}	1×10^{5}
Cm-241	2×10^{0}	1×10^{0}	1×10^{2}	1×10^{6}
Cm-242	4×10^{1}	1×10^{-2}	1×10^{2}	1×10^{5}
Cm-243	9×10^{0}	1×10^{-3}	1×10^{0}	1×10^{4}
Cm-244	2×10^{1}	2×10^{-3}	1×10^{1}	1×10^{4}
Cm-245	9×10^{0}	9×10^{-4}	1×10^{0}	1×10^{3}
Cm-246	9×10^{0}	9×10^{-4}	1×10^{0}	1×10^{3}
Cm-247 (a)	3×10^{0}	1×10^{-3}	1×10^{0}	1×10^{4}
Cm-248	2×10^{-2}	3×10^{-4}	1×10^{0}	1×10^{3}
Cobalt (27)				
Co-55	5×10^{-1}	5×10^{-1}	1×10^{1}	1×10^{6}
Co-56	3×10^{-1}	3×10^{-1}	1×10^{1}	1×10^{5}
Co-57	1×10^{1}	1×10^{1}	1×10^{2}	1×10^{6}
Co-58	1×10^{0}	1×10^{0}	1×10^{1}	1×10^{6}
Co-58m	4×10^{1}	4×10^{1}	1×10^{4}	1×10^{7}
Co-60	4×10^{-1}	4×10^{-1}	1×10^{1}	1×10^{5}

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Chromium (24)				
Cr-51	3×10^1	3×10^1	1×10^3	1×10^7
Caesium (55)				
Cs-129	4×10^0	4×10^0	1×10^2	1×10^5
Cs-131	3×10^1	3×10^1	1×10^3	1×10^6
Cs-132	1×10^0	1×10^0	1×10^1	1×10^5
Cs-134	7×10^{-1}	7×10^{-1}	1×10^1	1×10^4
Cs-134m	4×10^1	6×10^{-1}	1×10^3	1×10^5
Cs-135	4×10^1	1×10^0	1×10^4	1×10^7
Cs-136	5×10^{-1}	5×10^{-1}	1×10^1	1×10^5
Cs-137 (a)	2×10^0	6×10^{-1}	1×10^1 (b)	1×10^4 (b)
Copper (29)				
Cu-64	6×10^0	1×10^0	1×10^2	1×10^6
Cu-67	1×10^1	7×10^{-1}	1×10^2	1×10^6
Dysprosium (66)				
Dy-159	2×10^1	2×10^1	1×10^3	1×10^7
Dy-165	9×10^{-1}	6×10^{-1}	1×10^3	1×10^6
Dy-166 (a)	9×10^{-1}	3×10^{-1}	1×10^3	1×10^6
Erbium (68)				
Er-169	4×10^1	1×10^0	1×10^4	1×10^7
Er-171	8×10^{-1}	5×10^{-1}	1×10^2	1×10^6
Europium (63)				
Eu-147	2×10^0	2×10^0	1×10^2	1×10^6
Eu-148	5×10^{-1}	5×10^{-1}	1×10^1	1×10^6

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Eu-149	2×10^{1}	2×10^{1}	1×10^{2}	1×10^{7}
Eu-150(short lived)	2×10^{0}	7×10^{-1}	1×10^{3}	1×10^{6}
Eu-150(long lived)	7×10^{-1}	7×10^{-1}	1×10^{1}	1×10^{6}
Eu-152	1×10^{0}	1×10^{0}	1×10^{1}	1×10^{6}
Eu-152m	8×10^{-1}	8×10^{-1}	1×10^{2}	1×10^{6}
Eu-154	9×10^{-1}	6×10^{-1}	1×10^{1}	1×10^{6}
Eu-155	2×10^{1}	3×10^{0}	1×10^{2}	1×10^{7}
Eu-156	7×10^{-1}	7×10^{-1}	1×10^{1}	1×10^{6}
Fluorine (9)				
F-18	1×10^{0}	6×10^{-1}	1×10^{1}	1×10^{6}
Iron (26)				
Fe-52 (a)	3×10^{-1}	3×10^{-1}	1×10^{1}	1×10^{6}
Fe-55	4×10^{1}	4×10^{1}	1×10^{4}	1×10^{6}
Fe-59	9×10^{-1}	9×10^{-1}	1×10^{1}	1×10^{6}
Fe-60 (a)	4×10^{1}	2×10^{-1}	1×10^{2}	1×10^{5}
Gallium (31)				
Ga-67	7×10^{0}	3×10^{0}	1×10^{2}	1×10^{6}
Ga-68	5×10^{-1}	5×10^{-1}	1×10^{1}	1×10^{5}
Ga-72	4×10^{-1}	4×10^{-1}	1×10^{1}	1×10^{5}
Gadolinium (64)				
Gd-146 (a)	5×10^{-1}	5×10^{-1}	1×10^{1}	1×10^{6}
Gd-148	2×10^{1}	2×10^{-3}	1×10^{1}	1×10^{4}
Gd-153	1×10^{1}	9×10^{0}	1×10^{2}	1×10^{7}
Gd-159	3×10^{0}	6×10^{-1}	1×10^{3}	1×10^{6}

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Germanium (32)				
Ge-68 (a)	5×10^{-1}	5×10^{-1}	1×10^{1}	1×10^{5}
Ge-71	4×10^{1}	4×10^{1}	1×10^{4}	1×10^{8}
Ge-77	3×10^{-1}	3×10^{-1}	1×10^{1}	1×10^{5}
Hafnium (72)				
Hf-172 (a)	6×10^{-1}	6×10^{-1}	1×10^{1}	1×10^{6}
Hf-175	3×10^{0}	3×10^{0}	1×10^{2}	1×10^{6}
Hf-181	2×10^{0}	5×10^{-1}	1×10^{1}	1×10^{6}
Hf-182	Unlimited	Unlimited	1×10^{2}	1×10^{6}
Mercury (80)				
Hg-194 (a)	1×10^{0}	1×10^{0}	1×10^{1}	1×10^{6}
Hg-195m (a)	3×10^{0}	7×10^{-1}	1×10^{2}	1×10^{6}
Hg-197	2×10^{1}	1×10^{1}	1×10^{2}	1×10^{7}
Hg-197m	1×10^{1}	4×10^{-1}	1×10^{2}	1×10^{6}
Hg-203	5×10^{0}	1×10^{0}	1×10^{2}	1×10^{5}
Holmium (67)				
Ho-166	4×10^{-1}	4×10^{-1}	1×10^{3}	1×10^{5}
Ho-166m	6×10^{-1}	5×10^{-1}	1×10^{1}	1×10^{6}
Iodine (53)				
I-123	6×10^{0}	3×10^{0}	1×10^{2}	1×10^{7}
I-124	1×10^{0}	1×10^{0}	1×10^{1}	1×10^{6}
I-125	2×10^{1}	3×10^{0}	1×10^{3}	1×10^{6}
I-126	2×10^{0}	1×10^{0}	1×10^{2}	1×10^{6}
I-129	Unlimited	Unlimited	1×10^{2}	1×10^{5}

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
I-131	3×10^{0}	7×10^{-1}	1×10^{2}	1×10^{6}
I-132	4×10^{-1}	4×10^{-1}	1×10^{1}	1×10^{5}
I-133	7×10^{-1}	6×10^{-1}	1×10^{1}	1×10^{6}
I-134	3×10^{-1}	3×10^{-1}	1×10^{1}	1×10^{5}
I-135 (a)	6×10^{-1}	6×10^{-1}	1×10^{1}	1×10^{6}
Indium (49)				
In-111	3×10^{0}	3×10^{0}	1×10^{2}	1×10^{6}
In-113m	4×10^{0}	2×10^{0}	1×10^{2}	1×10^{6}
In-114m (a)	1×10^{1}	5×10^{-1}	1×10^{2}	1×10^{6}
In-115m	7×10^{0}	1×10^{0}	1×10^{2}	1×10^{6}
Iridium (77)				
Ir-189 (a)	1×10^{1}	1×10^{1}	1×10^{2}	1×10^{7}
Ir-190	7×10^{-1}	7×10^{-1}	1×10^{1}	1×10^{6}
Ir-192	1×10^{0}(c)	6×10^{-1}	1×10^{1}	1×10^{4}
Ir-194	3×10^{-1}	3×10^{-1}	1×10^{2}	1×10^{5}
Potassium (19)				
K-40	9×10^{-1}	9×10^{-1}	1×10^{2}	1×10^{6}
K-42	2×10^{-1}	2×10^{-1}	1×10^{2}	1×10^{6}
K-43	7×10^{-1}	6×10^{-1}	1×10^{1}	1×10^{6}
Krypton (36)				
Kr-81	4×10^{1}	4×10^{1}	1×10^{4}	1×10^{7}
Kr-85	1×10^{1}	1×10^{1}	1×10^{5}	1×10^{4}
Kr-85m	8×10^{0}	3×10^{0}	1×10^{3}	1×10^{10}
Kr-87	2×10^{-1}	2×10^{-1}	1×10^{2}	1×10^{9}

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Lanthanum (57)				
La-137	3×10^{1}	6×10^{0}	1×10^{3}	1×10^{7}
La-140	4×10^{-1}	4×10^{-1}	1×10^{1}	1×10^{5}
Lutetium (71)				
Lu-172	6×10^{-1}	6×10^{-1}	1×10^{1}	1×10^{6}
Lu-173	8×10^{0}	8×10^{0}	1×10^{2}	1×10^{7}
Lu-174	9×10^{0}	9×10^{0}	1×10^{2}	1×10^{7}
Lu-174m	2×10^{1}	1×10^{1}	1×10^{2}	1×10^{7}
Lu-177	3×10^{1}	7×10^{-1}	1×10^{3}	1×10^{7}
Magnesium (12)				
Mg-28 (a)	3×10^{-1}	3×10^{-1}	1×10^{1}	1×10^{5}
Manganese (25)				
Mn-52	3×10^{-1}	3×10^{-1}	1×10^{1}	1×10^{5}
Mn-53	Unlimited	Unlimited	1×10^{4}	1×10^{9}
Mn-54	1×10^{0}	1×10^{0}	1×10^{1}	1×10^{6}
Mn-56	3×10^{-1}	3×10^{-1}	1×10^{1}	1×10^{5}
Molybdenum (42)				
Mo-93	4×10^{1}	2×10^{1}	1×10^{3}	1×10^{8}
Mo-99 (a)	1×10^{0}	6×10^{-1}	1×10^{2}	1×10^{6}
Nitrogen (7)				
N-13	9×10^{-1}	6×10^{-1}	1×10^{2}	1×10^{9}
Sodium (11)				
Na-22	5×10^{-1}	5×10^{-1}	1×10^{1}	1×10^{6}
Na-24	2×10^{-1}	2×10^{-1}	1×10^{1}	1×10^{5}

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Niobium (41)				
Nb-93m	4×10^1	3×10^1	1×10^4	1×10^7
Nb-94	7×10^{-1}	7×10^{-1}	1×10^1	1×10^6
Nb-95	1×10^0	1×10^0	1×10^1	1×10^6
Nb-97	9×10^{-1}	6×10^{-1}	1×10^1	1×10^6
Neodymium (60)				
Nd-147	6×10^0	6×10^{-1}	1×10^2	1×10^6
Nd-149	6×10^{-1}	5×10^{-1}	1×10^2	1×10^6
Nickel (28)				
Ni-59	Unlimited	Unlimited	1×10^4	1×10^8
Ni-63	4×10^1	3×10^1	1×10^5	1×10^8
Ni-65	4×10^{-1}	4×10^{-1}	1×10^1	1×10^6
Neptunium (93)				
Np-235	4×10^1	4×10^1	1×10^3	1×10^7
Np-236(short-lived)	2×10^1	2×10^0	1×10^3	1×10^7
Np-236(long-lived)	9×10^0	2×10^{-2}	1×10^2	1×10^5
Np-237	2×10^1	2×10^{-3}	1×10^0 (b)	1×10^3 (b)
Np-239	7×10^0	4×10^{-1}	1×10^2	1×10^7
Osmium (76)				
Os-185	1×10^0	1×10^0	1×10^1	1×10^6
Os-191	1×10^1	2×10^0	1×10^2	1×10^7
Os-191m	4×10^1	3×10^1	1×10^3	1×10^7
Os-193	2×10^0	6×10^{-1}	1×10^2	1×10^6
Os-194 (a)	3×10^{-1}	3×10^{-1}	1×10^2	1×10^5

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Phosphorus (15)				
P-32	5×10^{-1}	5×10^{-1}	1×10^{3}	1×10^{5}
P-33	4×10^{1}	1×10^{0}	1×10^{5}	1×10^{8}
Protactinium (91)				
Pa-230 (a)	2×10^{0}	7×10^{-2}	1×10^{1}	1×10^{6}
Pa-231	4×10^{0}	4×10^{-4}	1×10^{0}	1×10^{3}
Pa-233	5×10^{0}	7×10^{-1}	1×10^{2}	1×10^{7}
Lead (82)				
Pb-201	1×10^{0}	1×10^{0}	1×10^{1}	1×10^{6}
Pb-202	4×10^{1}	2×10^{1}	1×10^{3}	1×10^{6}
Pb-203	4×10^{0}	3×10^{0}	1×10^{2}	1×10^{6}
Pb-205	Unlimited	Unlimited	1×10^{4}	1×10^{7}
Pb-210 (a)	1×10^{0}	5×10^{-2}	1×10^{1} (b)	1×10^{4} (b)
Pb-212 (a)	7×10^{-1}	2×10^{-1}	1×10^{1} (b)	1×10^{5} (b)
Palladium (46)				
Pd-103 (a)	4×10^{1}	4×10^{1}	1×10^{3}	1×10^{8}
Pd-107	Unlimited	Unlimited	1×10^{5}	1×10^{8}
Pd-109	2×10^{0}	5×10^{-1}	1×10^{3}	1×10^{6}
Promethium (61)				
Pm-143	3×10^{0}	3×10^{0}	1×10^{2}	1×10^{6}
Pm-144	7×10^{-1}	7×10^{-1}	1×10^{1}	1×10^{6}
Pm-145	3×10^{1}	1×10^{1}	1×10^{3}	1×10^{7}
Pm-147	4×10^{1}	2×10^{0}	1×10^{4}	1×10^{7}

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Pm-148m (a)	8×10^{-1}	7×10^{-1}	1×10^{1}	1×10^{6}
Pm-149	2×10^{0}	6×10^{-1}	1×10^{3}	1×10^{6}
Pm-151	2×10^{0}	6×10^{-1}	1×10^{2}	1×10^{6}
Polonium (84)				
Po-210	4×10^{1}	2×10^{-2}	1×10^{1}	1×10^{4}
Praseodymium (59)				
Pr-142	4×10^{-1}	4×10^{-1}	1×10^{2}	1×10^{5}
Pr-143	3×10^{0}	6×10^{-1}	1×10^{4}	1×10^{6}
Platinum (78)				
Pt-188 (a)	1×10^{0}	8×10^{-1}	1×10^{1}	1×10^{6}
Pt-191	4×10^{0}	3×10^{0}	1×10^{2}	1×10^{6}
Pt-193	4×10^{1}	4×10^{1}	1×10^{4}	1×10^{7}
Pt-193m	4×10^{1}	5×10^{-1}	1×10^{3}	1×10^{7}
Pt-195m	1×10^{1}	5×10^{-1}	1×10^{2}	1×10^{6}
Pt-197	2×10^{1}	6×10^{-1}	1×10^{3}	1×10^{6}
Pt-197m	1×10^{1}	6×10^{-1}	1×10^{2}	1×10^{6}
Plutonium (94)				
Pu-236	3×10^{1}	3×10^{-3}	1×10^{1}	1×10^{4}
Pu-237	2×10^{1}	2×10^{1}	1×10^{3}	1×10^{7}
Pu-238	1×10^{1}	1×10^{-3}	1×10^{0}	1×10^{4}
Pu-239	1×10^{1}	1×10^{-3}	1×10^{0}	1×10^{4}
Pu-240	1×10^{1}	1×10^{-3}	1×10^{0}	1×10^{3}
Pu-241 (a)	4×10^{1}	6×10^{-2}	1×10^{2}	1×10^{5}
Pu-242	1×10^{1}	1×10^{-3}	1×10^{0}	1×10^{4}

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Pu-244 (a)	4×10^{-1}	1×10^{-3}	1×10^{0}	1×10^{4}
Radium (88)				
Ra-223 (a)	4×10^{-1}	7×10^{-3}	1×10^{2} (b)	1×10^{5} (b)
Ra-224 (a)	4×10^{-1}	2×10^{-2}	1×10^{1} (b)	1×10^{5} (b)
Ra-225 (a)	2×10^{-1}	4×10^{-3}	1×10^{2}	1×10^{5}
Ra-226 (a)	2×10^{-1}	3×10^{-3}	1×10^{1} (b)	1×10^{4} (b)
Ra-228 (a)	6×10^{-1}	2×10^{-2}	1×10^{1} (b)	1×10^{5} (b)
Rubidium (37)				
Rb-81	2×10^{0}	8×10^{-1}	1×10^{1}	1×10^{6}
Rb-83 (a)	2×10^{0}	2×10^{0}	1×10^{2}	1×10^{6}
Rb-84	1×10^{0}	1×10^{0}	1×10^{1}	1×10^{6}
Rb-86	5×10^{-1}	5×10^{-1}	1×10^{2}	1×10^{5}
Rb-87	Unlimited	Unlimited	1×10^{4}	1×10^{7}
Rb(nat)	Unlimited	Unlimited	1×10^{4}	1×10^{7}
Rhenium (75)				
Re-184	1×10^{0}	1×10^{0}	1×10^{1}	1×10^{6}
Re-184m	3×10^{0}	1×10^{0}	1×10^{2}	1×10^{6}
Re-186	2×10^{0}	6×10^{-1}	1×10^{3}	1×10^{6}
Re-187	Unlimited	Unlimited	1×10^{6}	1×10^{9}
Re-188	4×10^{-1}	4×10^{-1}	1×10^{2}	1×10^{5}
Re-189 (a)	3×10^{0}	6×10^{-1}	1×10^{2}	1×10^{6}
Re(nat)	Unlimited	Unlimited	1×10^{6}	1×10^{9}

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Rhodium (45)				
Rh-99	2×10^0	2×10^0	1×10^1	1×10^6
Rh-101	4×10^0	3×10^0	1×10^2	1×10^7
Rh-102	5×10^{-1}	5×10^{-1}	1×10^1	1×10^6
Rh-102m	2×10^0	2×10^0	1×10^2	1×10^6
Rh-103m	4×10^1	4×10^1	1×10^4	1×10^8
Rh-105	1×10^1	8×10^{-1}	1×10^2	1×10^7
Radon (86)				
Rn-222 (a)	3×10^{-1}	4×10^{-3}	1×10^1 (b)	1×10^8 (b)
Ruthenium (44)				
Ru-97	5×10^0	5×10^0	1×10^2	1×10^7
Ru-103 (a)	2×10^0	2×10^0	1×10^2	1×10^6
Ru-105	1×10^0	6×10^{-1}	1×10^1	1×10^6
Ru-106 (a)	2×10^{-1}	2×10^{-1}	1×10^2 (b)	1×10^5 (b)
Sulphur (16)				
S-35	4×10^1	3×10^0	1×10^5	1×10^8
Antimony (51)				
Sb-122	4×10^{-1}	4×10^{-1}	1×10^2	1×10^4
Sb-124	6×10^{-1}	6×10^{-1}	1×10^1	1×10^6
Sb-125	2×10^0	1×10^0	1×10^2	1×10^6
Sb-126	4×10^{-1}	4×10^{-1}	1×10^1	1×10^5
Scandium (21)				
Sc-44	5×10^{-1}	5×10^{-1}	1×10^1	1×10^5

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Sc-46	5×10^{-1}	5×10^{-1}	1×10^{1}	1×10^{6}
Sc-47	1×10^{1}	7×10^{-1}	1×10^{2}	1×10^{6}
Sc-48	3×10^{-1}	3×10^{-1}	1×10^{1}	1×10^{5}
Selenium (34)				
Se-75	3×10^{0}	3×10^{0}	1×10^{2}	1×10^{6}
Se-79	4×10^{1}	2×10^{0}	1×10^{4}	1×10^{7}
Silicon (14)				
Si-31	6×10^{-1}	6×10^{-1}	1×10^{3}	1×10^{6}
Si-32	4×10^{1}	5×10^{-1}	1×10^{3}	1×10^{6}
Samarium (62)				
Sm-145	1×10^{1}	1×10^{1}	1×10^{2}	1×10^{7}
Sm-147	Unlimited	Unlimited	1×10^{1}	1×10^{4}
Sm-151	4×10^{1}	1×10^{1}	1×10^{4}	1×10^{8}
Sm-153	9×10^{0}	6×10^{-1}	1×10^{2}	1×10^{6}
Tin (50)				
Sn-113 (a)	4×10^{0}	2×10^{0}	1×10^{3}	1×10^{7}
Sn-117m	7×10^{0}	4×10^{-1}	1×10^{2}	1×10^{6}
Sn-119m	4×10^{1}	3×10^{1}	1×10^{3}	1×10^{7}
Sn-121m (a)	4×10^{1}	9×10^{-1}	1×10^{3}	1×10^{7}
Sn-123	8×10^{-1}	6×10^{-1}	1×10^{3}	1×10^{6}
Sn-125	4×10^{-1}	4×10^{-1}	1×10^{2}	1×10^{5}
Sn-126 (a)	6×10^{-1}	4×10^{-1}	1×10^{1}	1×10^{5}
Strontium (38)				
Sr-82 (a)	2×10^{-1}	2×10^{-1}	1×10^{1}	1×10^{5}

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Sr-85	2×10^0	2×10^0	1×10^2	1×10^6
Sr-85m	5×10^0	5×10^0	1×10^2	1×10^7
Sr-87m	3×10^0	3×10^0	1×10^2	1×10^6
Sr-89	6×10^{-1}	6×10^{-1}	1×10^3	1×10^6
Sr-90 (a)	3×10^{-1}	3×10^{-1}	1×10^2 (b)	1×10^4 (b)
Sr-91 (a)	3×10^{-1}	3×10^{-1}	1×10^1	1×10^5
Sr-92 (a)	1×10^0	3×10^{-1}	1×10^1	1×10^6
Tritium (1)				
T(H-3)	4×10^1	4×10^1	1×10^6	1×10^9
Tantalum (73)				
Ta-178(long-lived)	1×10^0	8×10^{-1}	1×10^1	1×10^6
Ta-179	3×10^1	3×10^1	1×10^3	1×10^7
Ta-182	9×10^{-1}	5×10^{-1}	1×10^1	1×10^4
Terbium (65)				
Tb-157	4×10^1	4×10^1	1×10^4	1×10^7
Tb-158	1×10^0	1×10^0	1×10^1	1×10^6
Tb-160	1×10^0	6×10^{-1}	1×10^1	1×10^6
Technetium (43)				
Tc-95m (a)	2×10^0	2×10^0	1×10^1	1×10^6
Tc-96	4×10^{-1}	4×10^{-1}	1×10^1	1×10^6
Tc-96m (a)	4×10^{-1}	4×10^{-1}	1×10^3	1×10^7
Tc-97	Unlimited	Unlimited	1×10^3	1×10^8
Tc-97m	4×10^1	1×10^0	1×10^3	1×10^7
Tc-98	8×10^{-1}	7×10^{-1}	1×10^1	1×10^6

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Tc-99	4×10^{1}	9×10^{-1}	1×10^{4}	1×10^{7}
Tc-99m	1×10^{1}	4×10^{0}	1×10^{2}	1×10^{7}
Tellurium (52)				
Te-121	2×10^{0}	2×10^{0}	1×10^{1}	1×10^{6}
Te-121m	5×10^{0}	3×10^{0}	1×10^{2}	1×10^{5}
Te-123m	8×10^{0}	1×10^{0}	1×10^{2}	1×10^{7}
Te-125m	2×10^{1}	9×10^{-1}	1×10^{3}	1×10^{7}
Te-127	2×10^{1}	7×10^{-1}	1×10^{3}	1×10^{6}
Te-127m (a)	2×10^{1}	5×10^{-1}	1×10^{3}	1×10^{7}
Te-129	7×10^{-1}	6×10^{-1}	1×10^{2}	1×10^{6}
Te-129m (a)	8×10^{-1}	4×10^{-1}	1×10^{3}	1×10^{6}
Te-131m (a)	7×10^{-1}	5×10^{-1}	1×10^{1}	1×10^{6}
Te-132 (a)	5×10^{-1}	4×10^{-1}	1×10^{2}	1×10^{7}
Thorium (90)				
Th-227	1×10^{1}	5×10^{-3}	1×10^{1}	1×10^{4}
Th-228 (a)	5×10^{-1}	1×10^{-3}	1×10^{0} (b)	1×10^{4} (b)
Th-229	5×10^{0}	5×10^{-4}	1×10^{0} (b)	1×10^{3} (b)
Th-230	1×10^{1}	1×10^{-3}	1×10^{0}	1×10^{4}
Th-231	4×10^{1}	2×10^{-2}	1×10^{3}	1×10^{7}
Th-232	Unlimited	Unlimited	1×10^{1}	1×10^{4}
Th-234 (a)	3×10^{-1}	3×10^{-1}	1×10^{3} (b)	1×10^{5} (b)
Th(nat)	Unlimited	Unlimited	1×10^{0} (b)	1×10^{3} (b)

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Titanium (22)				
Ti-44 (a)	5×10^{-1}	4×10^{-1}	1×10^{1}	1×10^{5}
Thallium (81)				
Tl-200	9×10^{-1}	9×10^{-1}	1×10^{1}	1×10^{6}
Tl-201	1×10^{1}	4×10^{0}	1×10^{2}	1×10^{6}
Tl-202	2×10^{0}	2×10^{0}	1×10^{2}	1×10^{6}
Tl-204	1×10^{1}	7×10^{-1}	1×10^{4}	1×10^{4}
Thulium (69)				
Tm-167	7×10^{0}	8×10^{-1}	1×10^{2}	1×10^{6}
Tm-170	3×10^{0}	6×10^{-1}	1×10^{3}	1×10^{6}
Tm-171	4×10^{1}	4×10^{1}	1×10^{4}	1×10^{8}
Uranium (92)				
U-230 (fast lung absorption)(a)(d)	4×10^{1}	1×10^{-1}	1×10^{1} (b)	1×10^{5} (b)
U-230 (medium lung absorption)(a)(e)	4×10^{1}	4×10^{-3}	1×10^{1}	1×10^{4}
U-230 (slow lung absorption)(a)(f)	3×10^{1}	3×10^{-3}	1×10^{1}	1×10^{4}
U-232 (fast lung absorption)(d)	4×10^{1}	1×10^{-2}	1×10^{0} (b)	1×10^{3} (b)
U-232 (medium lung absorption)(e)	4×10^{1}	7×10^{-3}	1×10^{1}	1×10^{4}
U-232 (slow lung absorption)(f)	1×10^{1}	1×10^{-3}	1×10^{1}	1×10^{4}
U-233 (fast lung absorption)(d)	4×10^{1}	9×10^{-2}	1×10^{1}	1×10^{4}
U-233 (medium lung absorption)(e)	4×10^{1}	2×10^{-2}	1×10^{2}	1×10^{5}
U-233 (slow lung absorption)(f)	4×10^{1}	6×10^{-3}	1×10^{1}	1×10^{5}
U-234 (fast lung absorption)(d)	4×10^{1}	9×10^{-2}	1×10^{1}	1×10^{4}
U-234 (medium lung absorption)(e)	4×10^{1}	2×10^{-2}	1×10^{2}	1×10^{5}

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
U-234 (slow lung absorption)(f)	4×10^1	6×10^{-3}	1×10^1	1×10^5
U-235 (all lung absorption types)(a),(d),(e),(f)	Unlimited	Unlimited	1×10^1 (b)	1×10^4 (b)
U-236 (fast lung absorption)(d)	Unlimited	Unlimited	1×10^1	1×10^4
U-236 (medium lung absorption)(e)	4×10^1	2×10^{-2}	1×10^2	1×10^5
U-236 (slow lung absorption)(f)	4×10^1	6×10^{-3}	1×10^1	1×10^4
U-238 (all lung absorption types)(d),(e),(f)	Unlimited	Unlimited	1×10^1 (b)	1×10^4 (b)
U (nat)	Unlimited	Unlimited	1×10^0 (b)	1×10^3 (b)
U (enriched to 20% or less)(g)	Unlimited	Unlimited	1×10^0	1×10^3
U (dep)	Unlimited	Unlimited	1×10^0	1×10^3
Vanadium (23)				
V-48	4×10^{-1}	4×10^{-1}	1×10^1	1×10^5
V-49	4×10^1	4×10^1	1×10^4	1×10^7
Tungsten (74)				
W-178 (a)	9×10^0	5×10^0	1×10^1	1×10^6
W-181	3×10^1	3×10^1	1×10^3	1×10^7
W-185	4×10^1	8×10^{-1}	1×10^4	1×10^7
W-187	2×10^0	6×10^{-1}	1×10^2	1×10^6
W-188 (a)	4×10^{-1}	3×10^{-1}	1×10^2	1×10^5
Xenon (54)				
Xe-122 (a)	4×10^{-1}	4×10^{-1}	1×10^2	1×10^9
Xe-123	2×10^0	7×10^{-1}	1×10^2	1×10^9
Xe-127	4×10^0	2×10^0	1×10^3	1×10^5
Xe-131m	4×10^1	4×10^1	1×10^4	1×10^4

Radionuclide (atomic number)	A_1	A_2	Activity concentration for exempt material	Activity limit for an exempt consignment
	(TBq)	(TBq)	(Bq/g)	(Bq)
Xe-133	2×10^1	1×10^1	1×10^3	1×10^4
Xe-135	3×10^0	2×10^0	1×10^3	1×10^{10}
Yttrium (39)				
Y-87 (a)	1×10^0	1×10^0	1×10^1	1×10^6
Y-88	4×10^{-1}	4×10^{-1}	1×10^1	1×10^6
Y-90	3×10^{-1}	3×10^{-1}	1×10^3	1×10^5
Y-91	6×10^{-1}	6×10^{-1}	1×10^3	1×10^6
Y-91m	2×10^0	2×10^0	1×10^2	1×10^6
Y-92	2×10^{-1}	2×10^{-1}	1×10^2	1×10^5
Y-93	3×10^{-1}	3×10^{-1}	1×10^2	1×10^5
Ytterbium (79)				
Yb-169	4×10^0	1×10^0	1×10^2	1×10^7
Yb-175	3×10^1	9×10^{-1}	1×10^3	1×10^7
Zinc (30)				
Zn-65	2×10^0	2×10^0	1×10^1	1×10^6
Zn-69	3×10^0	6×10^{-1}	1×10^4	1×10^6
Zn-69m (a)	3×10^0	6×10^{-1}	1×10^2	1×10^6
Zirconium (40)				
Zr-88	3×10^0	3×10^0	1×10^2	1×10^6
Zr-93	Unlimited	Unlimited	1×10^3 (b)	1×10^7 (b)
Zr-95 (a)	2×10^0	8×10^{-1}	1×10^1	1×10^6
Zr-97 (a)	4×10^{-1}	4×10^{-1}	1×10^1 (b)	1×10^5 (b)

(a) A_1 and/or A_2 values include contributions from daughter nuclides with half-lives less than 10 days

(b) Parent nuclides and their progeny included in secular equilibrium are listed in the following:

Sr-90	Y-90
Zr-93	Nb-93m
Zr-97	Nb-97
Ru-106	Rh-106
Cs-137	Ba-137m
Ce-134	La-134
Ce-144	Pr-144
Ba-140	La-140
Bi-212	Tl-208 (0.36), Po-212 (0.64)
Pb-210	Bi-210, Po-210
Pb-212	Bi-212, Tl-208 (0.36), Po-212 (0.64)
Rn-220	Po-216
Rn-222	Po-218, Pb-214, Bi-214, Po-214
Ra-223	Rn-219, Po-215, Pb-211, Bi-211, Tl-207
Ra-224	Rn-220, Po-216, Pb-212, Bi-212, Tl-208 (0.36), Po-212 (0.64)
Ra-226	Rn-222, Po-218, Pb-214, Bi-214, Po-214, Pb-210, Bi-210, Po-210
Ra-228	Ac-228
Th-226	Ra-222, Rn-218, Po-214
Th-228	Ra-224, Rn-220, Po-216, Pb212, Bi-212, Tl208 (0.36), Po-212 (0.64)
Th-229	Ra-225, Ac-225, Fr-221, At-217, Bi-213, Po-213, Pb-209
Th-nat	Ra-228, Ac-228, Th-228, Ra-224, Rn-220, Po-216, Pb-212, Bi-212, Tl-208 (0.36), Po-212 (0.64)
Th-234	Pa-234m
U-230	Th-226, Ra-222, Rn-218, Po-214
U-232	Th-228, Ra-224, Rn-220, Po-216, Pb-212, Bi-212, Tl-208 (0.36), Po-212 (0.64)
U-235	Th-231
U-238	Th-234, Pa-234m
U-nat	Th-234, Pa-234m, U-234, Th-230, Ra-226, Rn-222, Po-218, Pb-214, Bi-214, Po-214, Pb-210, Bi-210, Po-210
U-240	Np-240m
Np-237	Pa-233
Am-242m	Am-242
Am-243	Np-239

(c) The quantity may be determined from a measurement of the rate of decay or a measurement of the radiation level at a prescribed distance from the source.

(d) These values apply only to compounds of uranium that take the chemical form of UF_6, UO_2F_2 and $UO_2(NO_3)_2$ in both normal and accident conditions of transport.

(e) These values apply only to compounds of uranium that take the chemical form of UO_3, UF_4, UCl_4 and hexavalent compounds in both normal and accident conditions of transport.

(f) These values apply to all compounds of uranium other than those specified in (d) and (e) above.

(g) These values apply to *unirradiated uranium* only.

where,

f(i) is the fraction of activity or activity concentration of radionuclide i in the mixture;

Table II. BASIC RADIONUCLIDE VALUES FOR UNKNOWN RADIONUCLIDES OR MIXTURES

Radioactive contents	A_1	A_2	Activity concentration for exempt material	Activity limits for exempt consignments
	TBq	TBq	Bq/g	Bq
Only beta or gamma emitting nuclides are known to be present	0.1	0.02	1×10^{1}	1×10^{4}
Only alpha emitting nuclides are known to be present	0.2	9×10^{-5}	1×10^{-1}	1×10^{3}
No relevant data are available	0.001	9×10^{-5}	1×10^{-1}	1×10^{3}

X(i) is the appropriate value of A_1 or A_2, or the activity concentration for exempt material or the activity limit for an exempt consignment as appropriate for the radionuclide i; and X_m is the derived value of A_1 or A_2, or the activity concentration for exempt material or the activity limit for an exempt consignment in the case of a mixture. **(Issue 2)**


5 mm
4 mm
RADIOACTIVE
CONTENTS
ACTIVITY
MINIMUM DIMENSION
100 mm
MINIMUM DIMENSION
100 mm
7


5 mm
4 mm
RADIOACTIVE
CONTENTS
ACTIVITY
TRANSPORT
INDEX
7
MINIMUM DIMENSION
100 mm
MINIMUM DIMENSION
100 mm



BILLING CODE 7590–01–C

FIG. 4. Category III–YELLOW label. The background colour of the upper half of the label shall be yellow and the lower half white, the colour of the trefoil and the printing shall be black, and the clour of the category bars shall be red.

(a) Contents:

(i) Except for LSA–I material, the name(s) of the radionuclide(s) as taken from Table I, using the symbols prescribed therein. For mixtures of radionuclides, the most restrictive nuclides must be listed to the extent the space on the line permits. The group of LSA or SCO shall be shown following the name(s) of the radionuclide(s). The terms ''LSA–II'',''LSA–III'', ''SCO–I'' and ''SCO–II'' shall be used for this purpose.

(ii) For LSA–I material, the term ''LSA–I'' is all that is necessary; the name of the radionuclide is not necessary.

(b) Activity: The maximum activity of the radioactive contents during transport expressed in units of becquerels (Bq) with the appropriate SI prefix (see Annex II). For fissile material, the mass of fissile material in units of grams (g), or multiples thereof, may be used in place of activity.

(c) For overpacks and freight containers the ''contents'' and ''activity'' entries on the label shall bear the information required in subparas 543(a) and 543(b), respectively, totalled together for the entire contents of the overpack or freight container except that on labels for overpacks or freight containers containing mixed loads of packages containing different radionuclides, such entries may read ''See Transport Documents''.

(d) Transport index: See paras 526 and 527. (No transport index entry is required for category I–WHITE.) (Issue 1)

544. Each label conforming to the model in Fig. 5 shall be completed with the criticality safety index (CSI) as stated in the certificate of approval for special arrangement or the certificate of approval for the package design issued by the competent authority. (Issue 5)

545. For overpacks and freight containers, the criticality safety index (CSI) on the label shall bear the information required in para. 544 totalled together for the fissile contents of the overpack or freight container. (Issue 5)

549. The consignor shall include in the transport documents with each consignment the following information, as applicable in the order given:

(a) The proper shipping name, as specified in Table VIII;

(b) The United Nations Class number ''7'';

(c) The United Nations number assigned to the material as specified in Table VIII, preceded by the letters ''UN'';

(d) The name or symbol of each radionuclide or, for mixtures of radionuclides, an appropriate general description or a list of the most restrictive nuclides;

(e) A description of the physical and chemical form of the material, or a notation that the material is special form radioactive material or low dispersible radioactive material. A generic chemical description is acceptable for chemical form;

(f) The maximum activity of the radioactive contents during transport expressed in units

of becquerels (Bq) with an appropriate SI prefix (see Annex II). For fissile material, the mass of fissile material in units of grams (g), or appropriate multiples thereof, may be used in place of activity.

(g) The category of the package, *i.e.* I–WHITE, II–YELLOW, III–YELLOW;

(h) The transport index (categories II–YELLOW and III–YELLOW only);

(i) For consignments including fissile material other than consignments excepted under para. 672, the criticality safety index;

(j) The identification mark for each competent authority approval certificate (special form radioactive material, low dispersible radioactive material, special arrangement, package design, or shipment) applicable to the consignment;

(k) For consignments of packages in an overpack or freight container, a detailed statement of the contents of each package within the overpack or freight container and, where appropriate, of each overpack or freight container in the consignment. If packages are to be removed from the overpack or freight container at a point of intermediate unloading, appropriate transport documents shall be made available;

(l) Where a consignment is required to be shipped under exclusive use, the statement ''EXCLUSIVE USE SHIPMENT''; and

(m) For LSA–II, LSA–III, SCO–I and SCO–II, the total activity of the consignment as a multiple of A_2. (Issue 1)

629. Except as allowed in para. 632, uranium hexafluoride shall be packaged and transported in accordance with the provisions of the International Organization for Standardization document ISO 7195:, ''Packaging of uranium hexafluoride (UF_6) for transport'' [1], and the requirements of paras 630–631. The package shall also meet the requirements prescribed elsewhere in these Regulations which pertain to the radioactive and fissile properties of the material. (Issue 4)

630. Each package designed to contain 0.1 kg or more of uranium hexafluoride shall be designed so that it would meet the following requirements:

(a) withstand without leakage and without unacceptable stress, as specified in the International Organization for Standardization document ISO 7195[10], the structural test as specified in para. 718;

(b) withstand without loss or dispersal of the uranium hexafluoride the test specified in para. 722; and

(c) withstand without rupture of the containment system the test specified in para. 728. (Issue 4)

631. Packages designed to contain 0.1 kg or more of uranium hexafluoride shall not be provided with pressure relief devices. (Issue 4)

632. Subject to the approval of the competent authority, packages designed to contain 0.1 kg or more of uranium hexafluoride may be transported if:

(a) the packages are designed to requirements other than those given in ISO 7195[10] and paras 630–631 but, notwithstanding, the requirements of paras 630–631 are met as far as practicable. (Issue 4)

657. A package for radioactive contents with activity greater than 10^5 A_2 shall be so designed that if it were subjected to the enhanced water immersion test specified in para. 730, there would be no rupture of the containment system. (Issue 7)

667. Type C packages shall be designed to meet the requirements specified in paras 606–619, and of paras 634–647, except as specified in para. 646(a), and of the requirements specified in paras 651–654, paras 658–664, and, in addition, of paras 668–670. (Issue 6)

668. A package shall be capable of meeting the assessment criteria prescribed for tests in paras 656(b) and 660 after burial in an environment defined by a thermal conductivity of 0.33 W/m.K and a temperature of 38°C in the steady state. Initial conditions for the assessment shall assume that any thermal insulation of the package remains intact, the package is at the maximum normal operating pressure and the ambient temperature is 38°C. (Issue 6)

669. A package shall be so designed that, if it were at the maximum normal operating pressure and subjected to:

(a) the tests specified in paras 719–724, it would restrict the loss of radioactive contents to not more than 10^{-6} A_2 per hour; and

(b) the test sequences in para. 734, it would meet the following requirements:

(i) retain sufficient shielding to ensure that the radiation level at 1 m from the surface of the package would not exceed 10 mSv/h with the maximum radioactive contents which the package is designed to contain; and

(ii) restrict the accumulated loss of radioactive contents in a period of 1 week to not more than 10 A_2 for krypton-85 and not more than A_2 for all other radionuclides.

Where mixtures of different radionuclides are present, the provisions of paras 404–406 shall apply except that for krypton-85 an effective A_2(i) value equal to 10 A_2 may be used. For case (a) above, the assessment shall take into account the external contamination limits of para. 508. (Issue 6)

670. A package shall be so designed that there will be no rupture of the containment system following performance of the enhanced water immersion test specified in para. 730. (Issue 6)

677. For a package in isolation, it shall be assumed that water can leak into or out of all void spaces of the package, including those within the containment system. However, if the design incorporates special features to prevent such leakage of water into or out of certain void spaces, even as a result of error, absence of leakage may be assumed in respect of those void spaces. Special features shall include the following:

(a) Multiple high standard water barriers, each of which would remain watertight if the package were subject to the tests prescribed in para. 682(b), a high degree of quality control in the manufacture, maintenance and repair of packagings and tests to demonstrate the closure of each package before each shipment; or

(b) For packages containing uranium hexafluoride only:

(i) packages where, following the tests prescribed in para. 682(b), there is no physical contact between the valve and any other component of the packaging other than at its original point of attachment and where, in addition, following the test prescribed in para. 728 the valves remain leaktight; and

(ii) a high degree of quality control in the manufacture, maintenance and repair of packagings coupled with tests to demonstrate closure of each package before each shipment. (Issue 4 and issue 11)

680. For packages to be transported by air:

(a) the package shall be subcritical under conditions consistent with the tests prescribed in para. 734 assuming reflection by at least 20cm of water but no water inleakage; and

(b) allowance shall not be made for special features of para. 677 unless, following the tests specified in para. 734 and, subsequently, para. 733, leakage of water into or out of the void spaces is prevented. (Issue 11)

682. A number ''N'' shall be derived, such that two times ''N'' shall be subcritical for the arrangement and package conditions that provide the maximum neutron multiplication consistent with the following:

(a) Hydrogenous moderation between packages, and the package arrangement reflected on all sides by at least 20 cm of water; and

(b) The tests specified in paras 719–724 followed by whichever of the following is the more limiting:

(i) the tests specified in para. 727(b) and, either para. 727(c) for packages having a mass not greater than 500 kg and an overall density not greater than 1000 kg/m3 based on the external dimensions, or para. 727(a) for all other packages; followed by the test specified in para. 728 and completed by the tests specified in paras 731–733; or

(ii) the test specified in para. 729; and

(c) Where any part of the fissile material escapes from the containment system following the tests specified in para. 682(b), it shall be assumed that fissile material escapes from each package in the array and all of the fissile material shall be arranged in the configuration and moderation that results in the maximum neutron multiplication with close reflection by at least 20 cm of water. (Issue 10)

719. The tests are: the water spray test, the free drop test, the stacking test and the penetration test. Specimens of the package shall be subjected to the free drop test, the stacking test and the penetration test, preceded in each case by the water spray test. One specimen may be used for all the tests, provided that the requirements of para. 720 are fulfilled. (Issue 10)

720. The time interval between the conclusion of the water spray test and the succeeding test shall be such that the water has soaked in to the maximum extent, without appreciable drying of the exterior of the specimen. In the absence of any evidence to the contrary, this interval shall be taken to be two hours if the water spray is applied from four directions simultaneously. No time interval shall elapse, however, if the water spray is applied from each of the four directions consecutively. (Issue 10)

721. Water spray test: The specimen shall be subjected to a water spray test that simulates exposure to rainfall of approximately 5 cm per hour for at least one hour. (Issue 10).

722. Free drop test: The specimen shall drop onto the target so as to suffer maximum damage in respect of the safety features to be tested.

(a) The height of drop measured from the lowest point of the specimen to the upper surface of the target shall be not less than the distance specified in Table XIII for the applicable mass. The target shall be as defined in para. 717.

(b) For rectangular fibreboard or wood packages not exceeding a mass of 50 kg, a separate specimen shall be subjected to a free drop onto each corner from a height of 0.3 m.

(c) For cylindrical fibreboard packages not exceeding a mass of 100 kg, a separate specimen shall be subjected to a free drop onto each of the quarters of each rim from a height of 0.3 m. (Issue 10)

723. Stacking test: Unless the shape of the packaging effectively prevents stacking, the specimen shall be subjected, for a period of 24 h, to a compressive load equal to the greater of the following:

(a) The equivalent of 5 times the mass of the actual package; and

(b) The equivalent of 13 kPa multiplied by the vertically projected area of the package.

The load shall be applied uniformly to two opposite sides of the specimen, one of which shall be the base on which the package would typically rest. (Issue 10)

724. Penetration test: The specimen shall be placed on a rigid, flat, horizontal surface which will not move significantly while the test is being carried out.

(a) A bar of 3.2 cm in diameter with a hemispherical end and a mass of 6 kg shall be dropped and directed to fall, with its longitudinal axis vertical, onto the centre of the weakest part of the specimen, so that, if it penetrates sufficiently far, it will hit the containment system. The bar shall not be significantly deformed by the test performance.

(b) The height of drop of the bar measured from its lower end to the intended point of impact on the upper surface of the specimen shall be 1 m. (Issue 10)

727. Mechanical test: The mechanical test consists of three different drop tests. Each specimen shall be subjected to the applicable drops as specified in para. 656 or para. 682. The order in which the specimen is subjected to the drops shall be such that, on completion of the mechanical test, the specimen shall have suffered such damage as will lead to the maximum damage in the thermal test which follows.

(a) For drop I, the specimen shall drop onto the target so as to suffer the maximum damage, and the height of the drop measured from the lowest point of the specimen to the upper surface of the target shall be 9 m. The target shall be as defined in para. 717.

(b) For drop II, the specimen shall drop so as to suffer the maximum damage onto a bar rigidly mounted perpendicularly on the target. The height of the drop measured from the intended point of impact of the specimen to the upper surface of the bar shall be 1 m. The bar shall be of solid mild steel of circular section, (15.0 ± 0.5) cm in diameter and 20 cm long unless a longer bar would cause greater damage, in which case a bar of sufficient length to cause maximum damage shall be used. The upper end of the bar shall be flat and horizontal with its edges rounded off to a radius of not more than 6 mm. The target on which the bar is mounted shall be as described in para. 717.

(c) For drop III, the specimen shall be subjected to a dynamic crush test by positioning the specimen on the target so as to suffer maximum damage by the drop of a 500 kg mass from 9 m onto the specimen. The mass shall consist of a solid mild steel plate 1 m by 1 m and shall fall in a horizontal attitude. The height of the drop shall be measured from the underside of the plate to the highest point of the specimen. The target on which the specimen rests shall be as defined in para. 717. (Issue 10)

729. Water immersion test: The specimen shall be immersed under a head of water of at least 15 m for a period of not less than eight hours in the attitude which will lead to maximum damage. For demonstration purposes, an external gauge pressure of at least 150 kPa shall be considered to meet these conditions. (Issue 10)

730. Enhanced water immersion test: The specimen shall be immersed under a head of water of at least 200 m for a period of not less than one hour. For demonstration purposes, an external gauge pressure of at least 2 MPa shall be considered to meet these conditions. (Issue 7)

734. Specimens shall be subjected to the effects of each of the following test sequences in the orders specified:

(a) the tests specified in paras 727(a), 727(c), 735 and 736; and

(b) the test specified in para. 737.

Separate specimens are allowed to be used for each of the sequences (a) and (b). (Issue 6)

735. Puncture/tearing test: The specimen shall be subjected to the damaging effects of a solid probe made of mild steel. The orientation of the probe to the surface of the specimen shall be as to cause maximum damage at the conclusion of the test sequence specified in para. 734(a).

(a) The specimen, representing a package having a mass less than 250 kg, shall be placed on a target and subjected to a probe having a mass of 250 kg falling from a height of 3 m above the intended impact point. For this test the probe shall be a 20 cm diameter cylindrical bar with the striking end forming a frustum of a right circular cone with the following dimensions: 30 cm height and 2.5 cm in diameter at the top. The target on which the specimen is placed shall be as specified in para. 717.

(b) For packages having a mass of 250 kg or more, the base of the probe shall be placed on a target and the specimen dropped onto the probe. The height of the drop , measured from the point of impact with the specimen to the upper surface of the probe shall be 3 m. For this test the probe shall have the same properties and dimensions as specified in (a) above, except that the length and mass of the probe shall be such as to incur maximum damage to the specimen. The target on which the base of the probe is placed shall be as specified in para. 717. (Issue 6)

736. Enhanced thermal test: The conditions for this test shall be as specified in para. 728, except that the exposure to the thermal environment shall be for a period of 60 minutes. (Issue 6)

737. Impact test: The specimen shall be subject to an impact on a target at a velocity of not less than 90 m/s, at such an orientation as to suffer maximum damage. The target shall be as defined in para. 717. (Issue 6)

Dated at Rockville, Maryland, this 11th day of July, 2000.

For the Nuclear Regulatory Commission.

William F. Kane,

Director, Office of Nuclear Material Safety and Safeguards.

[FR Doc. 00–18029 Filed 7–14–00; 8:45 am]

BILLING CODE 7590–01–P

Federal Register

Monday,
July 17, 2000

Part V

Department of Justice

Bureau of Prisons

28 CFR Parts 540 and 544

Postsecondary Education Programs and Occupational Education Programs; Proposed Rules

DEPARTMENT OF JUSTICE

Bureau of Prisons

28 CFR Part 544

[BOP–1019–P]

RIN 1120–AA25

Postsecondary Education Programs

AGENCY: Bureau of Prisons, Justice.

ACTION: Proposed rule.

SUMMARY: In this document, the Bureau of Prisons is proposing to amend its regulations on postsecondary education programs to exclude courses which are offered as part of an occupational education program. Courses which are offered as part of an occupational education program are to be covered by separate Bureau regulations. Consequently, the inmate is to be responsible for paying postsecondary education tuition costs either through personal funds, community resources, or scholarships available to the inmate. This amendment is intended to simplify the organization of the Bureau's regulations and to conform with the usual community standards of government-funded educational opportunities available to the general public.

DATES: Comments due by September 15, 2000.

ADDRESSES: Rules Unit, Office of General Counsel, Bureau of Prisons, HOLC Room 754, 320 First Street, NW., Washington, DC 20534.

FOR FURTHER INFORMATION CONTACT: Roy Nanovic, Office of General Counsel, Bureau of Prisons, phone (202) 514–6655.

SUPPLEMENTARY INFORMATION: The Bureau of Prisons is proposing to amend its regulations on postsecondary education programs (28 CFR part 544, subpart C). Current regulations on this subject were published in the **Federal Register** on May 7, 1997 (62 FR 25100).

Why Is the Bureau Revising Its Regulations on Postsecondary Education Programs?

The current regulations on postsecondary education programs generally require the inmate to pay for tuition. If resources allow, however, the institution may pay the tuition if all of the following apply: The inmate is unable to pay; the course is directly related to preparation for a specific occupation/vocation; and the course is part of a one year certificate or a two year Associate Arts degree program. The Bureau is reorganizing and revising its regulations in order to cover occupational education courses separately (see the Bureau's proposed rule on Occupational Education Programs published elsewhere in today's **Federal Register**). Consequently, there is no need to make any determinations under the postsecondary education program as to the responsibility for payment. The inmate is to be responsible for postsecondary education tuition costs either through personal funds, community resources, or available scholarships. This conforms to the usual community standards for government-funded educational opportunities available to the general public. Under the usual community standards, the local government funds public elementary and secondary school systems. The individual is responsible for paying tuition for postsecondary education. In revising the regulations on postsecondary education programs, the Bureau is also eliminating unnecessary definitions and is restating eligibility criteria in plainer language.

Who Is Affected by the Changes Being Made to the Regulations?

The regulations are applicable to all Federal inmates. The actual effect of the changes on inmates is likely to be minimal. Postsecondary education courses pertinent to the vocational education needs of inmates can be funded by the institution when offered through a Bureau-approved occupational education program. An inmate who has the financial resources to pay for tuition costs may continue to take postsecondary courses provided that the courses are appropriate for the institution's need for discipline, security, and good order. Most postsecondary education courses do not pose problems to institution discipline, security, and good order. However, a course in waste treatment management, for example, which requires the unsupervised use of particular tools may pose problems for institution security. Such a course would likely not be approved.

The combined effect of the proposed revisions to the Bureau's regulations on Postsecondary Education and Occupational Education Programs is to ensure that Bureau funding of occupational education courses occurs as part of a comprehensive occupational education program designed to address the general occupational education needs of the greatest number of inmates as is practicable.

Interested persons may participate in this proposed rulemaking by submitting data, views, or arguments in writing to the Rules Unit, Office of General Counsel, Bureau of Prisons, 320 First Street, NW., HOLC Room 754, Washington, DC 20534. Comments received during the comment period will be considered before final action is taken. Comments received after the expiration of the comment period will be considered to the extent practicable. All comments received remain on file for public inspection at the above address. The proposed rule may be changed in light of the comments received. No oral hearings are contemplated.

Executive Order 12866

This rule falls within a category of actions that the Office of Management and Budget (OMB) has determined not to constitute ''significant regulatory actions'' under section 3(f) of Executive Order 12866 and, accordingly, it was not reviewed by OMB.

Executive Order 13132

This regulation will not have substantial direct effects on the States, on the relationship between the national government and the States, or on distribution of power and responsibilities among the various levels of government. Therefore, in accordance with Executive Order 13132, it is determined that this rule does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

Regulatory Flexibility Act

The Director of the Bureau of Prisons, in accordance with the Regulatory Flexibility Act (5 U.S.C. 605(b)), has reviewed this regulation and by approving it certifies that this regulation will not have a significant economic impact upon a substantial number of small entities for the following reasons: This rule pertains to the correctional management of offenders committed to the custody of the Attorney General or the Director of the Bureau of Prisons, and its economic impact is limited to the Bureau's appropriated funds.

Unfunded Mandates Reform Act of 1995

This rule will not result in the expenditure by State, local and tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more in any one year, and it will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.

Small Business Regulatory Enforcement Fairness Act of 1996

This rule is not a major rule as defined by § 804 of the Small Business Regulatory Enforcement Fairness Act of 1996. This rule will not result in an annual effect on the economy of $100,000,000 or more; a major increase in costs or prices; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic and export markets.

Plain Language Instructions

We try to write clearly. If you can suggest how to improve the clarity of these regulations, call or write Roy Nanovic at the address listed above.

List of Subjects in 28 CFR Part 544

Prisoners.

Kathleen Hawk Sawyer,

Director, Bureau of Prisons.

Accordingly, pursuant to the rulemaking authority vested in the Attorney General in 5 U.S.C. 552(a) and delegated to the Director, Bureau of Prisons in 28 CFR 0.96(o), part 544 in subchapter C of 28 CFR, chapter V is proposed to be amended as set forth below.

SUBCHAPTER C—INSTITUTIONAL MANAGEMENT

PART 544—EDUCATION

1. The authority citation for 28 CFR part 544 continues to read as follows:

Authority: 5 U.S.C. 301; 18 U.S.C. 3621, 3622, 3624, 4001, 4042, 4081, 4082 (Repealed in part as to offenses committed on or after November 1, 1987), 5006–5024 (Repealed October 12, 1984 as to offenses committed after that date), 5039; 28 U.S.C. 509, 510; 28 CFR 0.95–0.99.

2. Subpart C is revised to read as follows:

Subpart C—Postsecondary Education Programs for Inmates

Sec.
544.20 Purpose and scope.
544.21 Procedures.

Subpart C—Postsecondary Education Programs for Inmates

§ 544.20 Purpose and scope.

The Bureau of Prisons offers inmates the opportunity under its postsecondary education program to participate in postsecondary education courses (courses for college credit other than those courses which pertain to occupational education programs) which have been determined to be appropriate in light of the institution's need for discipline, security, and good order. Participation in postsecondary education courses which are part of occupational education programs is governed by the provisions of the Bureau's occupational education program (see subpart F of this part).

§ 544.21 Procedures.

(a) The Warden or designee must appoint a postsecondary education coordinator (ordinarily an education staff member) for the institution. The postsecondary education coordinator is responsible for coordinating the institution's postsecondary education program.

(b) An inmate who wishes to participate in a postsecondary education course must apply through the postsecondary education coordinator. If the postsecondary education coordinator determines that the course is appropriate in light of the institution's need for discipline, security, and good order, the inmate may enroll provided that:

(1) The inmate meets eligibility requirements for the course which have been set by the course provider, and

(2) The inmate is responsible for payment of any tuition either through personal funds, community resources, or scholarships available to the inmate.

(3) The unit team determines that the course is appropriate for the inmate's apparent needs.

[FR Doc. 00–18050 Filed 7–14–00; 8:45 am]

BILLING CODE 4410–05–P

DEPARTMENT OF JUSTICE

Bureau of Prisons

28 CFR Part 540

[BOP–1096–P]

RIN 1120–AA92

Occupational Education Programs

AGENCY: Bureau of Prisons, Justice.

ACTION: Proposed rule.

SUMMARY: In this document, the Bureau of Prisons is proposing to amend its regulations on occupational education programs in order to exclude, with certain exceptions, inmates currently under an order of deportation, exclusion, or removal, and to remove obsolete or redundant provisions. This amendment is intended to help ensure that available educational opportunities for occupational training ordinarily will be allocated to inmates who will be returning to the community within, rather than outside, the United States upon release.

DATES: Comments due by September 15, 2000.

ADDRESSES: Rules Unit, Office of General Counsel, Bureau of Prisons, HOLC Room 754, 320 First Street, NW., Washington, DC 20534.

FOR FURTHER INFORMATION CONTACT: Roy Nanovic, Office of General Counsel, Bureau of Prisons, phone (202) 514–6655.

SUPPLEMENTARY INFORMATION: The Bureau of Prisons is proposing to amend its regulations on occupational education programs (28 CFR part 544, subpart F). Current regulations on this subject were published in the **Federal Register** on March 29, 1988 (53 FR 10204).

The Bureau's occupational education programs are designed to enhance post-release employment opportunities for inmates with occupational training needs. The Bureau is revising its regulations on occupational education programs in order to exclude, with certain exceptions, inmates currently under an order of deportation, exclusion, or removal, and to remove obsolete or redundant provisions. An inmate or detainee who is currently under an order of deportation, exclusion, or removal may be considered for placement in an occupational education program if the Attorney General has determined that the inmate or detainee cannot be removed from the United States because the designated country of removal will not accept his/her return. Under internal agency procedures, the Immigration and Naturalization Service is responsible for informing the Bureau when an inmate/detainee's designated country of removal will not accept his/her return. In restricting other inmates under an order of deportation, removal, or exclusion from consideration, the Bureau intends to help ensure that available educational opportunities for occupational training ordinarily will be allocated to inmates who will be returning to the community within, rather than outside, the United States upon release.

In revising the regulations, the Bureau has included procedures for making application similar to revised procedures for postsecondary education programs (see the Bureau's proposed rule published elsewhere in today's **Federal Register**) and has reorganized the provisions in order to remove obsolete or redundant provisions and to improve general clarity.

Interested persons may participate in this proposed rulemaking by submitting

data, views, or arguments in writing to the Rules Unit, Office of General Counsel, Bureau of Prisons, 320 First Street, NW., HOLC Room 754, Washington, DC 20534. Comments received during the comment period will be considered before final action is taken. Comments received after the expiration of the comment period will be considered to the extent practicable. All comments received remain on file for public inspection at the above address. The proposed rule may be changed in light of the comments received. No oral hearings are contemplated.

Executive Order 12866

This rule falls within a category of actions that the Office of Management and Budget (OMB) has determined not to constitute ''significant regulatory actions'' under section 3(f) of Executive Order 12866 and, accordingly, it was not reviewed by OMB.

Executive Order 13132

This regulation will not have substantial direct effects on the States, on the relationship between the national government and the States, or on distribution of power and responsibilities among the various levels of government. Therefore, in accordance with Executive Order 13132, it is determined that this rule does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

Regulatory Flexibility Act

The Director of the Bureau of Prisons, in accordance with the Regulatory Flexibility Act (5 U.S.C. 605(b)), has reviewed this regulation and by approving it certifies that this regulation will not have a significant economic impact upon a substantial number of small entities for the following reasons: This rule pertains to the correctional management of offenders committed to the custody of the Attorney General or the Director of the Bureau of Prisons, and its economic impact is limited to the Bureau's appropriated funds.

Unfunded Mandates Reform Act of 1995

This rule will not result in the expenditure by State, local and tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more in any one year, and it will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.

Small Business Regulatory Enforcement Fairness Act of 1996

This rule is not a major rule as defined by section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996. This rule will not result in an annual effect on the economy of $100,000,000 or more; a major increase in costs or prices; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic and export markets.

Plain Language Instructions

We try to write clearly. If you can suggest how to improve the clarity of these regulations, call or write Roy Nanovic at the address listed above.

List of Subjects in 28 CFR Part 544

Prisoners.

Kathleen Hawk Sawyer,

Director, Bureau of Prisons.

Accordingly, pursuant to the rulemaking authority vested in the Attorney General in 5 U.S.C. 552(a) and delegated to the Director, Bureau of Prisons in 28 CFR 0.96(o), part 544 in subchapter C of 28 CFR, chapter V is proposed to be amended as set forth below.

SUBCHAPTER C—INSTITUTIONAL MANAGEMENT

PART 544—EDUCATION

1. The authority citation for 28 CFR part 544 continues to read as follows:

Authority: 5 U.S.C. 301; 18 U.S.C. 3621, 3622, 3624, 4001, 4042, 4081, 4082 (Repealed in part as to offenses committed on or after November 1, 1987), 5006–5024 (Repealed October 12, 1984 as to offenses committed after that date), 5039; 28 U.S.C. 509, 510; 28 CFR 0.95–0.99.

2. Subpart F is revised to read as follows:

Subpart F—Occupational Education Programs

Sec.
544.50 Purpose and scope.
544.51 Procedures.
544.52 Levels of Occupational Education Programs.

Subpart F—Occupational Education Programs

§ 544.50 Purpose and scope.

The Bureau of Prisons offers eligible inmates the opportunity under its occupational education programs to participate in occupational education courses for the purpose of obtaining marketable skills designed to enhance post-release employment opportunities.

§ 544.51 Procedures.

(a) An inmate is eligible to participate in an institution's occupational education program unless the inmate is currently under an order of deportation, exclusion, or removal. However, an inmate or detainee who is currently under an order of deportation, exclusion, or removal may be considered for placement in an occupational education program if the Attorney General has determined that the inmate or detainee cannot be removed from the United States because the designated country of removal will not accept his/her return.

(b) An eligible inmate must apply through the inmate's unit team for placement consideration. The unit team is responsible for determining that the occupational education course is appropriate for the inmate's apparent needs.

§ 544.52 Levels of Occupational Education Programs.

Occupational education programs are offered at the certificate level and the classroom level. Each level may include the following types of training:

(a) *Exploratory Training.* Exploratory training is a study of occupations and industries for the purpose of providing the student with a general knowledge of the occupation and the world of work, rather than specific skill development.

(b) *Marketable Training.* Marketable training provides specific entry-level or advanced job skills. Marketable training may include ''live work'', that is, the training would result in a product or service produced by the inmate for actual use by the institution, FPI, another federal agency, or community service project.

(c) *Apprentice Training.* Apprentice training provides an inmate the opportunity to participate in training which prepares the inmate for employment in various trades through structured apprenticeship programs approved at the state and national levels by the Bureau of Apprenticeship and Training, U.S. Department of Labor.

[FR Doc. 00–18049 Filed 7–14–00; 8:45 am]

BILLING CODE 4410–05–P

Reader Aids

Federal Register

Vol. 65, No. 137

Monday, July 17, 2000

CUSTOMER SERVICE AND INFORMATION

Federal Register/Code of Federal Regulations

General Information, indexes and other finding aids	**202–523–5227**
Laws	**523–5227**
Presidential Documents	
Executive orders and proclamations	**523–5227**
The United States Government Manual	**523–5227**
Other Services	
Electronic and on-line services (voice)	**523–4534**
Privacy Act Compilation	**523–3187**
Public Laws Update Service (numbers, dates, etc.)	**523–6641**
TTY for the deaf-and-hard-of-hearing	**523–5229**

ELECTRONIC RESEARCH

World Wide Web

Full text of the daily Federal Register, CFR and other publications:

http://www.access.gpo.gov/nara

Federal Register information and research tools, including Public Inspection List, indexes, and links to GPO Access:

http://www.nara.gov/fedreg

E-mail

PENS (Public Law Electronic Notification Service) is an E-mail service for notification of recently enacted Public Laws. To subscribe, send E-mail to

listserv@www.gsa.gov

with the text message:

subscribe PUBLAWS-L your name

Use listserv@www.gsa.gov only to subscribe or unsubscribe to PENS. We cannot respond to specific inquiries.

Reference questions. Send questions and comments about the Federal Register system to:

info@fedreg.nara.gov

The Federal Register staff cannot interpret specific documents or regulations.

FEDERAL REGISTER PAGES AND DATE, JULY

40967–41320 3
41321–41550 5
41551–41864 6
41865–42272 7
42273–42596 10
42597–42854 11
42855–43212 12
43213–43676 13
43677–43960 14
43961–44402 17

CFR PARTS AFFECTED DURING JULY

At the end of each month, the Office of the Federal Register publishes separately a List of CFR Sections Affected (LSA), which lists parts and sections affected by documents published since the revision date of each title.

3 CFR

Proclamations:
7325 41313
7326 41547
7327 41865
7328 42595
7329 43673

Executive Orders:
13129 (See Notice of June 30, 2000) 41549
13161 41543
13162 43211

Administrative Orders:
Memorandums
July 5, 2000 43213
Notices:
June 30, 2000 41549
Presidential Determinations:
No. 2000-25 of June 29, 2000 42273

5 CFR

3 41867
178 40967
213 41867
315 41867
532 ..... 42597, 43215
550 41868
591 ..... 44099, 44100

7 CFR

272 ..... 41321, 41752
273 ..... 41321, 41752
274 41321
723 41551
929 42598
931 41557
947 42275
958 40967
982 40970
985 40973
989 40975
1218 43961
1230 43498
1464 41551
1735 42615

Proposed Rules:
205 43259
905 ..... 41608, 42642
927 41018

8 CFR

103 43528
214 43528
236 43677
274a 43677
299 43677

Proposed Rules:
103 43527
214 43527
248 43527
264 43527

9 CFR

94 ..... 43680, 43682

Proposed Rules:
1 42304
2 42304

10 CFR

Proposed Rules:
54 42305
55 41021
71 44360
72 42647

11 CFR

104 42619

12 CFR

5 41559
563b 43088
575 43088
900 43969
915 41560
925 40979
940 43969
950 ..... 40979, 43969
955 43969
956 43969
966 43969

Proposed Rules:
226 42092
563b 43092
575 43088
917 43408
925 43408
930 43408
931 43408
932 43408
933 43408
956 43408
960 43408

13 CFR

120 42624

Proposed Rules:
123 43261

14 CFR

35 42278
39 ..... 40981, 40983, 40985, 40988, 41326, 41869, 41871, 42281, 42855, 43215, 43217, 43219, 43221, 43223, 43228, 43406
71 ..... 40990, 40991, 41328, 41329, 41330, 41576, 42856, 42858, 42859, 42860, 43406, 43683, 43684, 43686
95 41578
97 ..... 43230, 43232

Proposed Rules:
Ch. 1 43265

13 41528
21 42796
36 42796
39 ....41381, 41385, 41884, 42306, 43265, 43720, 44013
71 ....41387, 41388, 43406, 43722

15 CFR

30 42556
732 42556
740 ....42556, 43130
743 42556
748 42556
750 42556
752 42556
758 42556
762 42556
772 ....42556, 43130
774 ....42556, 43130, 43406
902 43687

17 CFR

211 40992
Proposed Rules:
210 43148
240 43148

18 CFR

284 ....41581, 41873, 43688
Proposed Rules:
284 41885

19 CFR

Ch. I 42634
132 43689
163 43689
Proposed Rules:
4 42893
19 42893
122 42893
123 42893
127 42893
141 42893
142 42893

20 CFR

404 ....42283, 42772
416 ....42283, 42772
655 43539
Proposed Rules:
655 43547

21 CFR

73 ....41581, 41584
178 41874
314 43233
524 41587
556 41588
558 ....41589, 41876
821 43690
895 43690
884 41330
900 43690
1308 43690
Proposed Rules:
20 43269
58 43269
101 41029
170 43269
171 43269
174 43269
179 43269

23 CFR

Proposed Rules:
450 41891
771 41892
1410 41891
1420 41892
1430 41892

24 CFR

960 42518
964 42512
982 42508
Proposed Rules:
15 42578
27 41538
290 41538
990 42488

25 CFR

Proposed Rules:
15 43874
84 43874
114 43874
115 43874
162 43874
166 43874

26 CFR

1 ....40993, 41332
Proposed Rules:
1 ....41610, 42900, 43723

28 CFR

Proposed Rules:
540 44400
544 44400

29 CFR

4022 43694
4044 43694
Proposed Rules:
4022 41610
4044 41610

30 CFR

3 42769
250 41000
Proposed Rules:
70 42122
72 42068
75 42122
90 42122
250 41892
934 44015
946 43723

31 CFR

501 41334
598 41334

32 CFR

199 41002

33 CFR

100 41003
165 ....41004, 41005, 41007, 41009, 41010, 41342, 41590, 42287, 42289, 43236, 43244, 43695, 43697

34 CFR

99 41852

36 CFR

Proposed Rules:
800 42834

37 CFR

Proposed Rules:
1 42309
102 41903
201 41612

38 CFR

3 43699

39 CFR

111 41877
775 41011

40 CFR

9 ....43586, 43840
52 ....41344, 41346, 41350, 41352, 41355, 41592, 42290, 42861, 43700, 43986, 43994
60 42292
62 43702
63 ....41594, 42292
112 43840
122 ....43586, 43840
123 ....43586, 43840
124 ....43586, 43840
130 ....43586, 43840
180 ....41365, 41594, 41601, 42863, 43704
261 42292
270 42292
271 ....42871, 43246
300 41369
712 41371
Proposed Rules:
52 ....41389, 41390, 41391, 42312, 42649, 42900, 42907, 42913, 42919, 43726, 43727
62 43730
63 43730
80 42920
81 42312
82 42653
125 42936
131 41216
136 41391
141 41031
142 41031
146 42248
260 42937
261 42937
268 42937
271 ....42937, 42960, 43284
300 41392
434 41613

42 CFR

59 41268
409 41128
410 41128
411 41128
413 41128
424 41128
484 41128
Proposed Rules:
410 444176
414 444176

45 CFR

1635 41879

47 CFR

0 43713
1 43995
2 43995
15 43995
27 42879
52 43251
64 43251
73 ....41012, 41013, 41375, 41376, 41377, 44010, 44011
80 43713
90 ....43713, 43716, 43995
95 43995
101 41603
Proposed Rules:
1 41613
2 41032
24 41034
27 42960
73 ....41035, 41036, 41037, 41393, 41401, 41620, 41621, 44017, 44018
74 41401
87 41032

48 CFR

501 41377
511 41377
512 41377
525 41377
532 41377
537 41377
552 41377
1804 43717
1852 43717
Proposed Rules:
2 42852
3 42852
8 41264
14 42852
15 ....41264, 42852
28 42852
35 42852
44 41264
52 ....41264, 42852
225 41037
242 41038
252 41038
1837 43730

49 CFR

1 41282
209 42529
211 42529
215 41282
220 41282
238 41282
260 41838
821 42637
Proposed Rules:
613 41891
621 41891
622 41892
623 41892

50 CFR

223 ....42422, 42481
622 ....41015, 41016, 41379
635 42883
648 ....41017, 43687
679 ....41380, 41883, 42302, 42641, 42888, 44011
Proposed Rules:
17 ....41404, 41405, 41782, 41812, 41917, 42316, 42662, 42962, 42973, 43450, 43730
25 42318
32 42318
600 41622
622 ....41041, 42978
648 42979
660 ....41424, 41426
679 ....41044, 44018

REMINDERS

The items in this list were editorially compiled as an aid to Federal Register users. Inclusion or exclusion from this list has no legal significance.

RULES GOING INTO EFFECT JULY 17, 2000

ENVIRONMENTAL PROTECTION AGENCY

Air quality implementation plans; approval and promulgation; various States:

Alabama; published 7-17-00

California; published 5-16-00

FEDERAL COMMUNICATIONS COMMISSION

Common carrier services:

Numbering resource optimization; published 6-16-00

Effective date; published 7-13-00

Radio stations; table of assignments:

Colorado; published 6-16-00

Florida; published 6-16-00

FEDERAL HOUSING FINANCE BOARD

Federal home loan bank system:

Acquired member assets, core mission activities, and investments and advances; published 7-17-00

HEALTH AND HUMAN SERVICES DEPARTMENT

Food and Drug Administration

Human cellular and tissue-based product donors; suitability determinations; published 4-18-00

INTERIOR DEPARTMENT

Assistance programs; administrative and audit requirements and cost principles:

On-the-job seat belt use; published 6-16-00

Correction; published 6-28-00

PERSONNEL MANAGEMENT OFFICE

Allowances and differentials:

Cost-of-living allowances (nonforeign areas)—

Guam and Northern Mariana Islands; published 7-17-00

SMALL BUSINESS ADMINISTRATION

Small business size standards:

General building contractors, heavy construction, dredging and surface cleanup, special trade contractors, garbage and refuse collection, and refuse systems; published 6-16-00

TRANSPORTATION DEPARTMENT

Federal Aviation Administration

Airworthiness directives:

Pilatus Aircraft Ltd.; published 6-2-00

COMMENTS DUE NEXT WEEK

AGRICULTURE DEPARTMENT

Animal and Plant Health Inspection Service

Irradiation phytosanitary treatment of imported fruits and vegetables; comments due by 7-25-00; published 5-26-00

AGRICULTURE DEPARTMENT

Rural Utilities Service

Seismic safety; comments due by 7-25-00; published 5-26-00

COMMERCE DEPARTMENT

National Oceanic and Atmospheric Administration

Fishery conservation and management:

Alaska; fisheries of Exclusive Economic Zone—

Pacific halibut and red king crab; comments due by 7-27-00; published 6-27-00

ENVIRONMENTAL PROTECTION AGENCY

Air pollutants, hazardous; national emission standards:

Vegetable oil production; solvent extraction; comments due by 7-25-00; published 5-26-00

Air pollution control:

State operating permits programs—

North Carolina; comments due by 7-24-00; published 6-22-00

North Carolina; comments due by 7-24-00; published 6-22-00

Air programs:

Ambient air quality standards, national—

Northern Ada County/Boise, ID; PM-10 standards nonapplicability finding rescinded; comments due by 7-26-00; published 6-26-00

Air programs; approval and promulgation; State plans for designated facilities and pollutants:

Arizona; comments due by 7-24-00; published 6-22-00

Various States; comments due by 7-24-00; published 6-22-00

Air quality implementation plans; approval and promulgation; various States:

Arizona; comments due by 7-28-00; published 7-14-00

Solid wastes:

Municipal solid waste landfill permit programs; adequacy determinations—

Virgin Islands; comments due by 7-24-00; published 5-8-00

Superfund program:

National oil and hazardous substances contingency plan—

National priorities list update; comments due by 7-24-00; published 6-22-00

National priorities list update; comments due by 7-24-00; published 6-22-00

FEDERAL COMMUNICATIONS COMMISSION

Digital television stations; table of assignments:

Alaska; comments due by 7-27-00; published 6-12-00

Georgia; comments due by 7-27-00; published 6-12-00

Texas; comments due by 7-27-00; published 6-12-00

Virginia; comments due by 7-27-00; published 6-12-00

Radio services, special:

Maritime communications; rules consolidation, revision, and streamlining; comments due by 7-24-00; published 4-24-00

Radio stations; table of assignments:

Florida; comments due by 7-24-00; published 6-16-00

Georgia; comments due by 7-24-00; published 6-16-00

Virgin Islands; comments due by 7-24-00; published 6-16-00

GENERAL SERVICES ADMINISTRATION

Acquisition regulations:

Tax adjustment; comments due by 7-24-00; published 5-25-00

HEALTH AND HUMAN SERVICES DEPARTMENT

Food and Drug Administration

Medical devices:

Device tracking; comments due by 7-24-00; published 4-25-00

National Environmental Policy Act; implementation:

Food contact substance notification system; comments due by 7-25-00; published 5-11-00

HOUSING AND URBAN DEVELOPMENT DEPARTMENT

Federal Housing Enterprise Oversight Office

Freedom of Information Act; implementation:

Releasing information; comments due by 7-24-00; published 5-25-00

INTERIOR DEPARTMENT

Fish and Wildlife Service

Endangered and threatened species:

Critical habitat designations—

Alameda whipsnake; comments due by 7-24-00; published 6-23-00

Tidewater goby; comments due by 7-28-00; published 6-28-00

Dusky gopher frog; Mississippi gopher frog distinct population segment; comments due by 7-24-00; published 5-23-00

Preble's meadow jumping mouse; comments due by 7-24-00; published 6-23-00

INTERIOR DEPARTMENT

Surface Mining Reclamation and Enforcement Office

Permanent program and abandoned mine land reclamation plan submissions:

Kentucky; comments due by 7-26-00; published 6-26-00

NATIONAL TRANSPORTATION SAFETY BOARD

Practice and procedures:

Air safety enforcement proceedings; emergency

determinations; comments due by 7-26-00; published 7-11-00

NUCLEAR REGULATORY COMMISSION

Rulemaking petitions:

Epstein, Eric Joesph; comments due by 7-26-00; published 5-12-00

United Plant Guard Workers of America; comments due by 7-24-00; published 5-10-00

Spent nuclear fuel and high-level radioactive waste; independent storage; licensing requirements:

Approved spent fuel storage casks; list additions; comments due by 7-24-00; published 6-22-00

Spent nuclear fuel and high-level radioactive waste; independent storage; lic ensing requirements:

Approved spent fuel storage casks; list additions; comments due by 7-24-00; published 6-22-00

Spent nuclear fuel and high-level radioactive waste; independent storage; licensing requirements:

Approved spent fuel storage casks; list additions; comments due by 7-24-00; published 6-22-00

PERSONNEL MANAGEMENT OFFICE

Pay administration:

Grade and pay retention; discretionary authority by agencies; comments due by 7-24-00; published 5-25-00

TRANSPORTATION DEPARTMENT

Coast Guard

Ports and waterways safety:

Lower Mississippi River; Vessel Traffic Service; comments due by 7-25-00; published 4-26-00

United Nations Headquarters, East River, NY; dignitary arrival/departure and UN meetings; permanent security zones; comments due by 7-24-00; published 6-8-00

TRANSPORTATION DEPARTMENT

Federal Aviation Administration

Airworthiness directives:

Air Tractor Inc.; comments due by 7-28-00; published 6-2-00

Airbus; comments due by 7-28-00; published 6-28-00

Boeing; comments due by 7-24-00; published 5-24-00

British Aerospace; comments due by 7-28-00; published 6-28-00

Commander Aircraft Co.; comments due by 7-28-00; published 6-1-00

Empresa Brasileira de Aeronautica S.A.; comments due by 7-27-00; published 6-27-00

Empresa Brasileira de Aeronautica S.A.; correction; comments due by 7-27-00; published 7-13-00

Learjet; comments due by 7-24-00; published 6-8-00

REVO, Inc.; comments due by 7-28-00; published 5-26-00

Class D airspace; comments due by 7-24-00; published 6-23-00

Class D airspace; correction; comments due by 7-24-00; published 7-13-00

Class E airspace; comments due by 7-24-00; published 6-16-00

Federal airways; comments due by 7-28-00; published 6-12-00

TREASURY DEPARTMENT

Customs Service

Merchandise, special classes:

Softwood lumber shipments from Canada; comments due by 7-24-00; published 5-23-00

LIST OF PUBLIC LAWS

This is a continuing list of public bills from the current session of Congress which have become Federal laws. It may be used in conjunction with ''P L U S'' (Public Laws Update Service) on 202–523–6641. This list is also available online at http://www.nara.gov/fedreg.

The text of laws is not published in the **Federal Register** but may be ordered in ''slip law'' (individual pamphlet) form from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 (phone, 202–512–1808). The text will also be made available on the Internet from GPO Access at http://www.access.gpo.gov/nara/index.html. Some laws may not yet be available.

H.R. 4425/P.L. 106–246

Making appropriations for military construction, family housing, and base realignment and closure for the Department of Defense for the fiscal year ending September 30, 2001, and for other purposes. (July 13, 2000; 114 Stat. 511)

Last List July 12, 2000

Public Laws Electronic Notification Service (PENS)

PENS is a free electronic mail notification service of newly enacted public laws. To subscribe, go to www.gsa.gov/archives/publaws-l.html or send E-mail to **listserv@www.gsa.gov** with the following text message:

SUBSCRIBE PUBLAWS-L Your Name.

Note: This service is strictly for E-mail notification of new laws. The text of laws is not available through this service. **PENS** cannot respond to specific inquiries sent to this address.

CFR CHECKLIST

This checklist, prepared by the Office of the Federal Register, is published weekly. It is arranged in the order of CFR titles, stock numbers, prices, and revision dates.

An asterisk (*) precedes each entry that has been issued since last week and which is now available for sale at the Government Printing Office.

A checklist of current CFR volumes comprising a complete CFR set, also appears in the latest issue of the LSA (List of CFR Sections Affected), which is revised monthly.

The CFR is available free on-line through the Government Printing Office's GPO Access Service at http://www.access.gpo.gov/nara/cfr/index.html. For information about GPO Access call the GPO User Support Team at 1-888-293-6498 (toll free) or 202-512-1530.

The annual rate for subscription to all revised paper volumes is $951.00 domestic, $237.75 additional for foreign mailing.

Mail orders to the Superintendent of Documents, Attn: New Orders, P.O. Box 371954, Pittsburgh, PA 15250–7954. All orders must be accompanied by remittance (check, money order, GPO Deposit Account, VISA, Master Card, or Discover). Charge orders may be telephoned to the GPO Order Desk, Monday through Friday, at **(202) 512–1800** from 8:00 a.m. to 4:00 p.m. eastern time, or FAX your charge orders to **(202) 512-2250**.

Title	Stock Number	Price	Revision Date
1, 2 (2 Reserved)	(869–038–00001–3)	6.50	Apr. 1, 2000
3 (1997 Compilation and Parts 100 and 101)	(869–042–00002–1)	22.00	[1] Jan. 1, 2000
4	(869–042–00003–0)	8.50	Jan. 1, 2000
5 Parts:			
1–699	(869–042–00004–8)	43.00	Jan. 1, 2000
700–1199	(869–042–00005–6)	31.00	Jan. 1, 2000
1200–End, 6 (6 Reserved)	(869–042–00006–4)	48.00	Jan. 1, 2000
7 Parts:			
1–26	(869–042–00007–2)	28.00	Jan. 1, 2000
27–52	(869–042–00008–1)	35.00	Jan. 1, 2000
53–209	(869–042–00009–9)	22.00	Jan. 1, 2000
210–299	(869–042–00010–2)	54.00	Jan. 1, 2000
300–399	(869–042–00011–1)	29.00	Jan. 1, 2000
400–699	(869–042–00012–9)	41.00	Jan. 1, 2000
700–899	(869–042–00013–7)	37.00	Jan. 1, 2000
900–999	(869–042–00014–5)	46.00	Jan. 1, 2000
1000–1199	(869–042–00015–3)	18.00	Jan. 1, 2000
1200–1599	(869–042–00016–1)	44.00	Jan. 1, 2000
1600–1899	(869–042–00017–0)	61.00	Jan. 1, 2000
1900–1939	(869–042–00018–8)	21.00	Jan. 1, 2000
1940–1949	(869–042–00019–6)	37.00	Jan. 1, 2000
1950–1999	(869–042–00020–0)	38.00	Jan. 1, 2000
2000–End	(869–042–00021–8)	31.00	Jan. 1, 2000
8	(869–042–00022–6)	41.00	Jan. 1, 2000
9 Parts:			
1–199	(869–042–00023–4)	46.00	Jan. 1, 2000
200–End	(869–042–00024–2)	44.00	Jan. 1, 2000
10 Parts:			
1–50	(869–042–00025–1)	46.00	Jan. 1, 2000
51–199	(869–042–00026–9)	38.00	Jan. 1, 2000
200–499	(869–042–00027–7)	38.00	Jan. 1, 2000
500–End	(869–042–00028–5)	48.00	Jan. 1, 2000
11	(869–042–00029–3)	23.00	Jan. 1, 2000
12 Parts:			
1–199	(869–042–00030–7)	18.00	Jan. 1, 2000
200–219	(869–042–00031–5)	22.00	Jan. 1, 2000
220–299	(869–042–00032–3)	45.00	Jan. 1, 2000
300–499	(869–042–00033–1)	29.00	Jan. 1, 2000
500–599	(869–042–00034–0)	26.00	Jan. 1, 2000
600–End	(869–042–00035–8)	53.00	Jan. 1, 2000
13	(869–042–00036–6)	35.00	Jan. 1, 2000
14 Parts:			
1–59	(869–042–00037–4)	58.00	Jan. 1, 2000
60–139	(869–042–00038–2)	46.00	Jan. 1, 2000
140–199	(869–038–00039–1)	17.00	[4] Jan. 1, 2000
200–1199	(869–042–00040–4)	29.00	Jan. 1, 2000
1200–End	(869–042–00041–2)	25.00	Jan. 1, 2000
15 Parts:			
0–299	(869–042–00042–1)	28.00	Jan. 1, 2000
300–799	(869–042–00043–9)	45.00	Jan. 1, 2000
800–End	(869–042–00044–7)	26.00	Jan. 1, 2000
16 Parts:			
0–999	(869–042–00045–5)	33.00	Jan. 1, 2000
1000–End	(869–042–00046–3)	43.00	Jan. 1, 2000
17 Parts:			
1–199	(869–042–00048–0)	32.00	Apr. 1, 2000
200–239	(869–042–00049–8)	38.00	Apr. 1, 2000
240–End	(869–038–00050–4)	44.00	Apr. 1, 1999
18 Parts:			
1–399	(869–042–00051–0)	54.00	Apr. 1, 2000
400–End	(869–042–00052–8)	15.00	Apr. 1, 2000
19 Parts:			
1–140	(869–042–00053–6)	40.00	Apr. 1, 2000
141–199	(869–038–00054–7)	36.00	Apr. 1, 1999
200–End	(869–038–00055–5)	18.00	Apr. 1, 1999
20 Parts:			
1–399	(869–038–00056–3)	30.00	Apr. 1, 1999
400–499	(869–038–00057–1)	51.00	Apr. 1, 1999
*500–End	(869–042–00058–7)	58.00	[7] Apr. 1, 2000
21 Parts:			
1–99	(869–042–00059–5)	26.00	Apr. 1, 2000
100–169	(869–042–00060–9)	30.00	Apr. 1, 2000
170–199	(869–042–00061–7)	29.00	Apr. 1, 2000
*200–299	(869–042–00062–5)	13.00	Apr. 1, 2000
300–499	(869–038–00063–6)	18.00	Apr. 1, 1999
500–599	(869–042–00064–1)	31.00	Apr. 1, 2000
600–799	(869–038–00065–2)	9.00	Apr. 1, 1999
*800–1299	(869–042–00066–8)	38.00	Apr. 1, 2000
1300–End	(869–042–00067–6)	15.00	Apr. 1, 2000
22 Parts:			
1–299	(869–038–00068–7)	44.00	Apr. 1, 1999
300–End	(869–042–00069–2)	31.00	Apr. 1, 2000
***23**	(869–042–00070–6)	29.00	Apr. 1, 2000
24 Parts:			
0–199	(869–038–00071–7)	34.00	Apr. 1, 1999
200–499	(869–038–00072–5)	32.00	Apr. 1, 1999
500–699	(869–042–00073–1)	20.00	Apr. 1, 2000
700–1699	(869–038–00074–1)	40.00	Apr. 1, 1999
1700–End	(869–042–00075–7)	18.00	[5] Apr. 1, 2000
25	(869–042–00076–5)	52.00	Apr. 1, 2000
26 Parts:			
§§ 1.0-1–1.60	(869–042–00077–3)	31.00	Apr. 1, 2000
§§ 1.61–1.169	(869–042–00078–1)	56.00	Apr. 1, 2000
§§ 1.170–1.300	(869–038–00079–2)	34.00	Apr. 1, 1999
§§ 1.301–1.400	(869–042–00080–3)	29.00	Apr. 1, 2000
§§ 1.401–1.440	(869–042–00081–1)	47.00	Apr. 1, 2000
§§ 1.441-1.500	(869-042-00082-0)	36.00	Apr. 1, 2000
§§ 1.501–1.640	(869–038–00083–1)	27.00	[6] Apr. 1, 1999
§§ 1.641–1.850	(869–042–00084–6)	41.00	Apr. 1, 2000
§§ 1.851–1.907	(869–042–00085–4)	43.00	Apr. 1, 2000
*§§ 1.908–1.1000	(869–042–00086–2)	41.00	Apr. 1, 2000
*§§ 1.1001–1.1400	(869–042–00087–1)	45.00	Apr. 1, 2000
§§ 1.1401–End	(869–038–00088–1)	55.00	Apr. 1, 1999
2–29	(869–038–00089–0)	39.00	Apr. 1, 1999
30–39	(869–042–00090–1)	31.00	Apr. 1, 2000
40–49	(869–042–00091–9)	18.00	Apr. 1, 2000
50–299	(869–042–00092–7)	23.00	Apr. 1, 2000
300–499	(869–038–00093–8)	37.00	Apr. 1, 1999
500–599	(869–042–00094–3)	12.00	Apr. 1, 2000
600–End	(869–042–00095–1)	12.00	Apr. 1, 2000
27 Parts:			
1–199	(869–042–00096–0)	59.00	Apr. 1, 2000

Title	Stock Number	Price	Revision Date
200–End	(869–038–00097–1)	17.00	Apr. 1, 1999
28 Parts:			
0-42	(869–038–00098–9)	39.00	July 1, 1999
43-end	(869-038-00099-7)	32.00	July 1, 1999
29 Parts:			
0–99	(869–038–00100–4)	28.00	July 1, 1999
100–499	(869–038–00101–2)	13.00	July 1, 1999
500–899	(869–038–00102–1)	40.00	[7] July 1, 1999
900–1899	(869–038–00103–9)	21.00	July 1, 1999
1900–1910 (§§ 1900 to 1910.999)	(869–038–00104–7)	46.00	July 1, 1999
1910 (§§ 1910.1000 to end)	(869–038–00105–5)	28.00	July 1, 1999
1911–1925	(869–038–00106–3)	18.00	July 1, 1999
1926	(869–038–00107–1)	30.00	July 1, 1999
1927–End	(869–038–00108–0)	43.00	July 1, 1999
30 Parts:			
1–199	(869–038–00109–8)	35.00	July 1, 1999
200–699	(869–038–00110–1)	30.00	July 1, 1999
700–End	(869–038–00111–0)	35.00	July 1, 1999
31 Parts:			
0–199	(869–038–00112–8)	21.00	July 1, 1999
200–End	(869–038–00113–6)	48.00	July 1, 1999
32 Parts:			
1–39, Vol. I		15.00	[2] July 1, 1984
1–39, Vol. II		19.00	[2] July 1, 1984
1–39, Vol. III		18.00	[2] July 1, 1984
1–190	(869–038–00114–4)	46.00	July 1, 1999
191–399	(869–038–00115–2)	55.00	July 1, 1999
400–629	(869–038–00116–1)	32.00	July 1, 1999
630–699	(869–038–00117–9)	23.00	July 1, 1999
700–799	(869–038–00118–7)	27.00	July 1, 1999
800–End	(869–038–00119–5)	27.00	July 1, 1999
33 Parts:			
1–124	(869–038–00120–9)	32.00	July 1, 1999
125–199	(869–038–00121–7)	41.00	July 1, 1999
200–End	(869–038–00122–5)	33.00	July 1, 1999
34 Parts:			
1–299	(869–038–00123–3)	28.00	July 1, 1999
300–399	(869–038–00124–1)	25.00	July 1, 1999
400–End	(869–038–00125–0)	46.00	July 1, 1999
35	(869–038–00126–8)	14.00	[7] July 1, 1999
36 Parts			
1–199	(869–038–00127–6)	21.00	July 1, 1999
200–299	(869–038–00128–4)	23.00	July 1, 1999
300–End	(869–038–00129–2)	38.00	July 1, 1999
37	(869–038–00130–6)	29.00	July 1, 1999
38 Parts:			
0–17	(869–038–00131–4)	37.00	July 1, 1999
18–End	(869–038–00132–2)	41.00	July 1, 1999
39	(869–038–00133–1)	24.00	July 1, 1999
40 Parts:			
1–49	(869–038–00134–9)	33.00	July 1, 1999
50–51	(869–038–00135–7)	25.00	July 1, 1999
52 (52.01–52.1018)	(869–038–00136–5)	33.00	July 1, 1999
52 (52.1019–End)	(869–038–00137–3)	37.00	July 1, 1999
53–59	(869–038–00138–1)	19.00	July 1, 1999
60	(869–038–00139–0)	59.00	July 1, 1999
61–62	(869–038–00140–3)	19.00	July 1, 1999
63 (63.1–63.1119)	(869–038–00141–1)	58.00	July 1, 1999
63 (63.1200–End)	(869–038–00142–0)	36.00	July 1, 1999
64–71	(869–038–00143–8)	11.00	July 1, 1999
72–80	(869–038–00144–6)	41.00	July 1, 1999
81–85	(869–038–00145–4)	33.00	July 1, 1999
86	(869–038–00146–2)	59.00	July 1, 1999
87-135	(869–038–00146–1)	53.00	July 1, 1999
136–149	(869–038–00148–9)	40.00	July 1, 1999
150–189	(869–038–00149–7)	35.00	July 1, 1999
190–259	(869–038–00150–1)	23.00	July 1, 1999
260–265	(869–038–00151–9)	32.00	July 1, 1999
266–299	(869–038–00152–7)	33.00	July 1, 1999
300–399	(869–038–00153–5)	26.00	July 1, 1999
400–424	(869–038–00154–3)	34.00	July 1, 1999
425–699	(869–038–00155–1)	44.00	July 1, 1999
700–789	(869–038–00156–0)	42.00	July 1, 1999
790–End	(869–038–00157–8)	23.00	July 1, 1999
41 Chapters:			
1, 1–1 to 1–10		13.00	[3] July 1, 1984
1, 1–11 to Appendix, 2 (2 Reserved)		13.00	[3] July 1, 1984
3–6		14.00	[3] July 1, 1984
7		6.00	[3] July 1, 1984
8		4.50	[3] July 1, 1984
9		13.00	[3] July 1, 1984
10–17		9.50	[3] July 1, 1984
18, Vol. I, Parts 1–5		13.00	[3] July 1, 1984
18, Vol. II, Parts 6–19		13.00	[3] July 1, 1984
18, Vol. III, Parts 20–52		13.00	[3] July 1, 1984
19–100		13.00	[3] July 1, 1984
1–100	(869–038–00158–6)	14.00	July 1, 1999
101	(869–038–00159–4)	39.00	July 1, 1999
102–200	(869–038–00160–8)	16.00	July 1, 1999
201–End	(869–038–00161–6)	15.00	July 1, 1999
42 Parts:			
1–399	(869–038–00162–4)	36.00	Oct. 1, 1999
400–429	(869–038–00163–2)	44.00	Oct. 1, 1999
430–End	(869–038–00164–1)	54.00	Oct. 1, 1999
43 Parts:			
1–999	(869–038–00165–9)	32.00	Oct. 1, 1999
1000–end	(869–038–00166–7)	47.00	Oct. 1, 1999
44	(869–038–00167–5)	28.00	Oct. 1, 1999
45 Parts:			
1–199	(869–038–00168–3)	33.00	Oct. 1, 1999
200–499	(869–038–00169–1)	16.00	Oct. 1, 1999
500–1199	(869–038–00170–5)	30.00	Oct. 1, 1999
1200–End	(869–038–00171–3)	40.00	Oct. 1, 1999
46 Parts:			
1–40	(869–038–00172–1)	27.00	Oct. 1, 1999
41–69	(869–038–00173–0)	23.00	Oct. 1, 1999
70–89	(869–038–00174–8)	8.00	Oct. 1, 1999
90–139	(869–038–00175–6)	26.00	Oct. 1, 1999
140–155	(869–038–00176–4)	15.00	Oct. 1, 1999
156–165	(869–038–00177–2)	21.00	Oct. 1, 1999
166–199	(869–038–00178–1)	27.00	Oct. 1, 1999
200–499	(869–038–00179–9)	23.00	Oct. 1, 1999
500–End	(869–038–00180–2)	15.00	Oct. 1, 1999
47 Parts:			
0–19	(869–038–00181–1)	39.00	Oct. 1, 1999
20–39	(869–038–00182–9)	26.00	Oct. 1, 1999
40–69	(869–038–00183–7)	26.00	Oct. 1, 1999
70–79	(869–038–00184–5)	39.00	Oct. 1, 1999
80–End	(869–038–00185–3)	40.00	Oct. 1, 1999
48 Chapters:			
1 (Parts 1–51)	(869–038–00186–1)	55.00	Oct. 1, 1999
1 (Parts 52–99)	(869–038–00187–0)	30.00	Oct. 1, 1999
2 (Parts 201–299)	(869–038–00188–8)	36.00	Oct. 1, 1999
3–6	(869–038–00189–6)	27.00	Oct. 1, 1999
7–14	(869–038–00190–0)	35.00	Oct. 1, 1999
15–28	(869–038–00191–8)	36.00	Oct. 1, 1999
29–End	(869–038–00192–6)	25.00	Oct. 1, 1999
49 Parts:			
1–99	(869–038–00193–4)	34.00	Oct. 1, 1999
100–185	(869–038–00194–2)	53.00	Oct. 1, 1999
186–199	(869–038–00195–1)	13.00	Oct. 1, 1999
200–399	(869–038–00196–9)	53.00	Oct. 1, 1999
400–999	(869–038–00197–7)	57.00	Oct. 1, 1999
1000–1199	(869–038–00198–5)	17.00	Oct. 1, 1999
1200–End	(869–038–00199–3)	14.00	Oct. 1, 1999
50 Parts:			
1–199	(869–038–00200–1)	43.00	Oct. 1, 1999
200–599	(869–038–00201–9)	22.00	Oct. 1, 1999

Title	Stock Number	Price	Revision Date
600–End	(869–038–00202–7)	37.00	Oct. 1, 1999
CFR Index and Findings Aids	(869–042–00047–1)	53.00	Jan. 1, 2000
Complete 1999 CFR set		951.00	1999
Microfiche CFR Edition:			
Subscription (mailed as issued)		290.00	1999
Individual copies		1.00	1999
Complete set (one-time mailing)		247.00	1997
Complete set (one-time mailing)		264.00	1996

[1] Because Title 3 is an annual compilation, this volume and all previous volumes should be retained as a permanent reference source.

[2] The July 1, 1985 edition of 32 CFR Parts 1–189 contains a note only for Parts 1–39 inclusive. For the full text of the Defense Acquisition Regulations in Parts 1–39, consult the three CFR volumes issued as of July 1, 1984, containing those parts.

[3] The July 1, 1985 edition of 41 CFR Chapters 1–100 contains a note only for Chapters 1 to 49 inclusive. For the full text of procurement regulations in Chapters 1 to 49, consult the eleven CFR volumes issued as of July 1, 1984 containing those chapters.

[4] No amendments to this volume were promulgated during the period January 1, 1999, through January 1, 2000. The CFR volume issued as of January 1, 1999 should be retained.

[5] No amendments to this volume were promulgated during the period April 1, 1999, through April 1, 2000. The CFR volume issued as of April 1, 1999 should be retained.

[6] No amendments to this volume were promulgated during the period April 1, 1998, through April 1, 1999. The CFR volume issued as of April 1, 1998, should be retained.

[7] No amendments to this volume were promulgated during the period July 1, 1998, through July 1, 1999. The CFR volume issued as of July 1, 1998, should be retained.